{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# ArxivLoader\n",
    "\n",
    "[arXiv](https://arxiv.org/) is an open-access archive for 2 million scholarly articles in the fields of physics, mathematics, computer science, quantitative biology, quantitative finance, statistics, electrical engineering and systems science, and economics."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup\n",
    "\n",
    "To access Arxiv document loader you'll need to install the `arxiv`, `PyMuPDF` and `langchain-community` integration packages. PyMuPDF transforms PDF files downloaded from the arxiv.org site into the text format."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install -qU langchain-community arxiv pymupdf"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Instantiation\n",
    "\n",
    "Now we can instantiate our model object and load documents:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import ArxivLoader\n",
    "\n",
    "# Supports all arguments of `ArxivAPIWrapper`\n",
    "arxiv_loader = ArxivLoader(\n",
    "    query=\"Diabetes\",\n",
    "    top_k_results=300,\n",
    "    load_max_docs=300,\n",
    "    # doc_content_chars_max=1000,\n",
    "    load_all_available_meta=True,\n",
    "    # ...\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## get summaries as docs\n",
    "\n",
    "Directly access the arXiv PDF links via the metadata from get_summaries_as_docs().\n",
    "\n",
    "Let's run through a basic example of how to use the `ArxivLoader` searching for papers of reasoning:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "arxiv_docs = arxiv_loader.get_summaries_as_docs()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'Entry ID': 'http://arxiv.org/abs/2202.11216v1', 'Published': datetime.date(2022, 2, 22), 'Title': 'Early Stage Diabetes Prediction via Extreme Learning Machine', 'Authors': 'Nelly Elsayed, Zag ElSayed, Murat Ozer'}, page_content=\"Diabetes is one of the chronic diseases that has been discovered for decades.\\nHowever, several cases are diagnosed in their late stages. Every one in eleven\\nof the world's adult population has diabetes. Forty-six percent of people with\\ndiabetes have not been diagnosed. Diabetes can develop several other severe\\ndiseases that can lead to patient death. Developing and rural areas suffer the\\nmost due to the limited medical providers and financial situations. This paper\\nproposed a novel approach based on an extreme learning machine for diabetes\\nprediction based on a data questionnaire that can early alert the users to seek\\nmedical assistance and prevent late diagnoses and severe illness development.\")"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "arxiv_docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "300"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(arxiv_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://arxiv.org/pdf/2202.11216v1.pdf\n",
      "https://arxiv.org/pdf/1005.5221v1.pdf\n",
      "https://arxiv.org/pdf/1510.02196v1.pdf\n",
      "https://arxiv.org/pdf/2012.15025v1.pdf\n",
      "https://arxiv.org/pdf/1909.09853v1.pdf\n",
      "https://arxiv.org/pdf/2105.09379v1.pdf\n",
      "https://arxiv.org/pdf/2307.16417v1.pdf\n",
      "https://arxiv.org/pdf/2307.16622v1.pdf\n",
      "https://arxiv.org/pdf/2406.17090v1.pdf\n",
      "https://arxiv.org/pdf/2406.00297v1.pdf\n",
      "https://arxiv.org/pdf/2412.14736v1.pdf\n",
      "https://arxiv.org/pdf/2409.13191v2.pdf\n",
      "https://arxiv.org/pdf/1904.08764v1.pdf\n",
      "https://arxiv.org/pdf/2008.11153v1.pdf\n",
      "https://arxiv.org/pdf/2003.02261v1.pdf\n",
      "https://arxiv.org/pdf/2011.02286v1.pdf\n",
      "https://arxiv.org/pdf/1809.05814v1.pdf\n",
      "https://arxiv.org/pdf/2101.03203v1.pdf\n",
      "https://arxiv.org/pdf/2102.12984v1.pdf\n",
      "https://arxiv.org/pdf/2301.10450v1.pdf\n",
      "https://arxiv.org/pdf/2402.10153v2.pdf\n",
      "https://arxiv.org/pdf/2410.03188v1.pdf\n",
      "https://arxiv.org/pdf/2004.03408v1.pdf\n",
      "https://arxiv.org/pdf/2011.08068v1.pdf\n",
      "https://arxiv.org/pdf/2409.07315v1.pdf\n",
      "https://arxiv.org/pdf/2007.07922v1.pdf\n",
      "https://arxiv.org/pdf/1501.02402v1.pdf\n",
      "https://arxiv.org/pdf/2205.02900v2.pdf\n",
      "https://arxiv.org/pdf/2308.01930v1.pdf\n",
      "https://arxiv.org/pdf/2404.13260v1.pdf\n",
      "https://arxiv.org/pdf/1904.09884v1.pdf\n",
      "https://arxiv.org/pdf/2011.06962v1.pdf\n",
      "https://arxiv.org/pdf/2103.08186v1.pdf\n",
      "https://arxiv.org/pdf/2108.09953v1.pdf\n",
      "https://arxiv.org/pdf/1505.00476v1.pdf\n",
      "https://arxiv.org/pdf/2001.01953v1.pdf\n",
      "https://arxiv.org/pdf/2201.07884v1.pdf\n",
      "https://arxiv.org/pdf/2301.03093v1.pdf\n",
      "https://arxiv.org/pdf/2310.02351v1.pdf\n",
      "https://arxiv.org/pdf/2403.07483v2.pdf\n",
      "https://arxiv.org/pdf/2011.11732v1.pdf\n",
      "https://arxiv.org/pdf/1707.02110v1.pdf\n",
      "https://arxiv.org/pdf/1902.04151v1.pdf\n",
      "https://arxiv.org/pdf/2004.06334v1.pdf\n",
      "https://arxiv.org/pdf/2208.06354v1.pdf\n",
      "https://arxiv.org/pdf/2211.07643v2.pdf\n",
      "https://arxiv.org/pdf/2310.11063v1.pdf\n",
      "https://arxiv.org/pdf/2311.10731v1.pdf\n",
      "https://arxiv.org/pdf/2406.00993v1.pdf\n",
      "https://arxiv.org/pdf/2406.05189v2.pdf\n",
      "https://arxiv.org/pdf/2412.03961v1.pdf\n",
      "https://arxiv.org/pdf/1910.09356v1.pdf\n",
      "https://arxiv.org/pdf/2104.03735v2.pdf\n",
      "https://arxiv.org/pdf/2412.09727v2.pdf\n",
      "https://arxiv.org/pdf/1602.04257v1.pdf\n",
      "https://arxiv.org/pdf/1707.08386v1.pdf\n",
      "https://arxiv.org/pdf/1902.10028v1.pdf\n",
      "https://arxiv.org/pdf/1706.07679v1.pdf\n",
      "https://arxiv.org/pdf/1910.11437v1.pdf\n",
      "https://arxiv.org/pdf/2003.05104v1.pdf\n",
      "https://arxiv.org/pdf/2011.02287v1.pdf\n",
      "https://arxiv.org/pdf/2104.07820v2.pdf\n",
      "https://arxiv.org/pdf/2109.01863v1.pdf\n",
      "https://arxiv.org/pdf/2001.05835v1.pdf\n",
      "https://arxiv.org/pdf/2304.06506v1.pdf\n",
      "https://arxiv.org/pdf/2308.00525v1.pdf\n",
      "https://arxiv.org/pdf/2404.12605v1.pdf\n",
      "https://arxiv.org/pdf/2411.00858v1.pdf\n",
      "https://arxiv.org/pdf/2412.02265v1.pdf\n",
      "https://arxiv.org/pdf/1708.07480v1.pdf\n",
      "https://arxiv.org/pdf/1709.09586v3.pdf\n",
      "https://arxiv.org/pdf/1204.1576v1.pdf\n",
      "https://arxiv.org/pdf/2108.03760v1.pdf\n",
      "https://arxiv.org/pdf/2101.02557v1.pdf\n",
      "https://arxiv.org/pdf/2304.12001v1.pdf\n",
      "https://arxiv.org/pdf/2408.10333v1.pdf\n",
      "https://arxiv.org/pdf/2410.01413v1.pdf\n",
      "https://arxiv.org/pdf/1310.7505v1.pdf\n",
      "https://arxiv.org/pdf/1901.10530v1.pdf\n",
      "https://arxiv.org/pdf/1411.2514v2.pdf\n",
      "https://arxiv.org/pdf/1803.03792v1.pdf\n",
      "https://arxiv.org/pdf/1908.06086v1.pdf\n",
      "https://arxiv.org/pdf/2111.10376v1.pdf\n",
      "https://arxiv.org/pdf/2101.00435v1.pdf\n",
      "https://arxiv.org/pdf/2101.07350v1.pdf\n",
      "https://arxiv.org/pdf/2112.00065v1.pdf\n",
      "https://arxiv.org/pdf/2201.05963v1.pdf\n",
      "https://arxiv.org/pdf/2209.07313v1.pdf\n",
      "https://arxiv.org/pdf/2304.00003v1.pdf\n",
      "https://arxiv.org/pdf/2308.09945v2.pdf\n",
      "https://arxiv.org/pdf/2403.14327v1.pdf\n",
      "https://arxiv.org/pdf/2409.16721v2.pdf\n",
      "https://arxiv.org/pdf/2501.12892v1.pdf\n",
      "https://arxiv.org/pdf/1111.3664v1.pdf\n",
      "https://arxiv.org/pdf/1710.02628v1.pdf\n",
      "https://arxiv.org/pdf/2010.13276v1.pdf\n",
      "https://arxiv.org/pdf/2309.16742v4.pdf\n",
      "https://arxiv.org/pdf/2504.21464v2.pdf\n",
      "https://arxiv.org/pdf/1205.5921v2.pdf\n",
      "https://arxiv.org/pdf/1612.03961v1.pdf\n",
      "https://arxiv.org/pdf/1902.03122v1.pdf\n",
      "https://arxiv.org/pdf/1909.07881v1.pdf\n",
      "https://arxiv.org/pdf/2006.04947v1.pdf\n",
      "https://arxiv.org/pdf/2008.03550v1.pdf\n",
      "https://arxiv.org/pdf/1503.07795v1.pdf\n",
      "https://arxiv.org/pdf/1804.04500v1.pdf\n",
      "https://arxiv.org/pdf/2005.08701v1.pdf\n",
      "https://arxiv.org/pdf/2005.14308v1.pdf\n",
      "https://arxiv.org/pdf/2110.02222v1.pdf\n",
      "https://arxiv.org/pdf/2204.00624v1.pdf\n",
      "https://arxiv.org/pdf/2007.13838v1.pdf\n",
      "https://arxiv.org/pdf/2101.06788v1.pdf\n",
      "https://arxiv.org/pdf/2105.09490v1.pdf\n",
      "https://arxiv.org/pdf/2112.07780v1.pdf\n",
      "https://arxiv.org/pdf/2112.10024v1.pdf\n",
      "https://arxiv.org/pdf/2208.01810v1.pdf\n",
      "https://arxiv.org/pdf/2208.02408v1.pdf\n",
      "https://arxiv.org/pdf/2209.09880v1.pdf\n",
      "https://arxiv.org/pdf/2305.10353v1.pdf\n",
      "https://arxiv.org/pdf/2307.04109v1.pdf\n",
      "https://arxiv.org/pdf/2308.05178v1.pdf\n",
      "https://arxiv.org/pdf/2309.15493v1.pdf\n",
      "https://arxiv.org/pdf/2403.19752v2.pdf\n",
      "https://arxiv.org/pdf/2403.19905v1.pdf\n",
      "https://arxiv.org/pdf/2404.14970v1.pdf\n",
      "https://arxiv.org/pdf/2408.12029v1.pdf\n",
      "https://arxiv.org/pdf/2409.04486v1.pdf\n",
      "https://arxiv.org/pdf/2409.12854v1.pdf\n",
      "https://arxiv.org/pdf/2501.07931v1.pdf\n",
      "https://arxiv.org/pdf/2501.18071v2.pdf\n",
      "https://arxiv.org/pdf/2503.03557v1.pdf\n",
      "https://arxiv.org/pdf/2503.04137v1.pdf\n",
      "https://arxiv.org/pdf/1810.03044v3.pdf\n",
      "https://arxiv.org/pdf/1709.07916v1.pdf\n",
      "https://arxiv.org/pdf/2108.07107v1.pdf\n",
      "https://arxiv.org/pdf/2111.01225v4.pdf\n",
      "https://arxiv.org/pdf/2201.08224v2.pdf\n",
      "https://arxiv.org/pdf/1403.0638v1.pdf\n",
      "https://arxiv.org/pdf/1404.3993v1.pdf\n",
      "https://arxiv.org/pdf/1605.04070v1.pdf\n",
      "https://arxiv.org/pdf/1710.01711v3.pdf\n",
      "https://arxiv.org/pdf/1812.02852v1.pdf\n",
      "https://arxiv.org/pdf/1812.10595v1.pdf\n",
      "https://arxiv.org/pdf/1902.06548v1.pdf\n",
      "https://arxiv.org/pdf/2002.04066v1.pdf\n",
      "https://arxiv.org/pdf/1711.10448v2.pdf\n",
      "https://arxiv.org/pdf/1811.09350v2.pdf\n",
      "https://arxiv.org/pdf/1911.08588v1.pdf\n",
      "https://arxiv.org/pdf/2108.09711v2.pdf\n",
      "https://arxiv.org/pdf/2110.01795v1.pdf\n",
      "https://arxiv.org/pdf/2203.14629v1.pdf\n",
      "https://arxiv.org/pdf/2212.06265v1.pdf\n",
      "https://arxiv.org/pdf/2302.02939v1.pdf\n",
      "https://arxiv.org/pdf/2303.11340v2.pdf\n",
      "https://arxiv.org/pdf/2304.12987v1.pdf\n",
      "https://arxiv.org/pdf/2305.04724v1.pdf\n",
      "https://arxiv.org/pdf/2309.13049v1.pdf\n",
      "https://arxiv.org/pdf/2312.00510v1.pdf\n",
      "https://arxiv.org/pdf/2312.00529v1.pdf\n",
      "https://arxiv.org/pdf/2402.02188v1.pdf\n",
      "https://arxiv.org/pdf/2403.18069v1.pdf\n",
      "https://arxiv.org/pdf/2405.01734v1.pdf\n",
      "https://arxiv.org/pdf/2407.04676v1.pdf\n",
      "https://arxiv.org/pdf/2409.14154v1.pdf\n",
      "https://arxiv.org/pdf/2501.05826v2.pdf\n",
      "https://arxiv.org/pdf/2502.00065v1.pdf\n",
      "https://arxiv.org/pdf/2504.12417v1.pdf\n",
      "https://arxiv.org/pdf/2504.15883v1.pdf\n",
      "https://arxiv.org/pdf/2505.07036v1.pdf\n",
      "https://arxiv.org/pdf/2505.22554v1.pdf\n",
      "https://arxiv.org/pdf/0409018v1.pdf\n",
      "https://arxiv.org/pdf/1508.05764v4.pdf\n",
      "https://arxiv.org/pdf/2006.02322v3.pdf\n",
      "https://arxiv.org/pdf/1910.04925v1.pdf\n",
      "https://arxiv.org/pdf/1803.06740v1.pdf\n",
      "https://arxiv.org/pdf/2103.09031v1.pdf\n",
      "https://arxiv.org/pdf/2106.12979v1.pdf\n",
      "https://arxiv.org/pdf/1303.1442v1.pdf\n",
      "https://arxiv.org/pdf/1906.08586v1.pdf\n",
      "https://arxiv.org/pdf/2107.03651v2.pdf\n",
      "https://arxiv.org/pdf/2003.06541v1.pdf\n",
      "https://arxiv.org/pdf/2003.09208v2.pdf\n",
      "https://arxiv.org/pdf/2111.07455v1.pdf\n",
      "https://arxiv.org/pdf/1505.04424v2.pdf\n",
      "https://arxiv.org/pdf/2007.11880v1.pdf\n",
      "https://arxiv.org/pdf/2101.02409v1.pdf\n",
      "https://arxiv.org/pdf/2301.00109v1.pdf\n",
      "https://arxiv.org/pdf/2405.00323v1.pdf\n",
      "https://arxiv.org/pdf/2409.04137v1.pdf\n",
      "https://arxiv.org/pdf/2505.05683v1.pdf\n",
      "https://arxiv.org/pdf/1802.08761v1.pdf\n",
      "https://arxiv.org/pdf/1806.09692v1.pdf\n",
      "https://arxiv.org/pdf/1810.08290v1.pdf\n",
      "https://arxiv.org/pdf/1904.04137v1.pdf\n",
      "https://arxiv.org/pdf/1910.12444v1.pdf\n",
      "https://arxiv.org/pdf/2008.00148v1.pdf\n",
      "https://arxiv.org/pdf/1804.02850v1.pdf\n",
      "https://arxiv.org/pdf/1911.01376v1.pdf\n",
      "https://arxiv.org/pdf/2011.04052v2.pdf\n",
      "https://arxiv.org/pdf/2012.06990v1.pdf\n",
      "https://arxiv.org/pdf/2103.06708v1.pdf\n",
      "https://arxiv.org/pdf/2104.10108v1.pdf\n",
      "https://arxiv.org/pdf/2108.04358v1.pdf\n",
      "https://arxiv.org/pdf/2108.06763v1.pdf\n",
      "https://arxiv.org/pdf/1905.02552v1.pdf\n",
      "https://arxiv.org/pdf/2206.03584v1.pdf\n",
      "https://arxiv.org/pdf/2208.01168v1.pdf\n",
      "https://arxiv.org/pdf/2211.11509v1.pdf\n",
      "https://arxiv.org/pdf/2212.13486v2.pdf\n",
      "https://arxiv.org/pdf/2212.14840v1.pdf\n",
      "https://arxiv.org/pdf/2301.04844v2.pdf\n",
      "https://arxiv.org/pdf/2307.04378v3.pdf\n",
      "https://arxiv.org/pdf/2308.02985v1.pdf\n",
      "https://arxiv.org/pdf/2310.17255v2.pdf\n",
      "https://arxiv.org/pdf/2401.02759v1.pdf\n",
      "https://arxiv.org/pdf/2402.10999v1.pdf\n",
      "https://arxiv.org/pdf/2402.18600v1.pdf\n",
      "https://arxiv.org/pdf/2406.19980v1.pdf\n",
      "https://arxiv.org/pdf/2407.04068v1.pdf\n",
      "https://arxiv.org/pdf/2407.21272v1.pdf\n",
      "https://arxiv.org/pdf/2409.13743v1.pdf\n",
      "https://arxiv.org/pdf/2411.01251v2.pdf\n",
      "https://arxiv.org/pdf/2411.10843v2.pdf\n",
      "https://arxiv.org/pdf/2411.12812v1.pdf\n",
      "https://arxiv.org/pdf/2411.19204v1.pdf\n",
      "https://arxiv.org/pdf/2502.03269v1.pdf\n",
      "https://arxiv.org/pdf/2502.15762v1.pdf\n",
      "https://arxiv.org/pdf/2504.01624v1.pdf\n",
      "https://arxiv.org/pdf/2504.03439v1.pdf\n",
      "https://arxiv.org/pdf/2504.19362v1.pdf\n",
      "https://arxiv.org/pdf/2505.07702v1.pdf\n",
      "https://arxiv.org/pdf/2505.21824v2.pdf\n",
      "https://arxiv.org/pdf/1201.2173v1.pdf\n",
      "https://arxiv.org/pdf/1312.0804v1.pdf\n",
      "https://arxiv.org/pdf/1404.4482v1.pdf\n",
      "https://arxiv.org/pdf/1502.03774v1.pdf\n",
      "https://arxiv.org/pdf/1806.02411v1.pdf\n",
      "https://arxiv.org/pdf/1808.01946v1.pdf\n",
      "https://arxiv.org/pdf/1808.03656v1.pdf\n",
      "https://arxiv.org/pdf/1808.08375v1.pdf\n",
      "https://arxiv.org/pdf/1808.09517v1.pdf\n",
      "https://arxiv.org/pdf/1906.00042v2.pdf\n",
      "https://arxiv.org/pdf/2002.11215v1.pdf\n",
      "https://arxiv.org/pdf/1704.01264v1.pdf\n",
      "https://arxiv.org/pdf/1706.04372v1.pdf\n",
      "https://arxiv.org/pdf/1709.07915v1.pdf\n",
      "https://arxiv.org/pdf/1711.09002v1.pdf\n",
      "https://arxiv.org/pdf/2004.05334v3.pdf\n",
      "https://arxiv.org/pdf/2107.13157v1.pdf\n",
      "https://arxiv.org/pdf/1103.0087v1.pdf\n",
      "https://arxiv.org/pdf/1405.0549v1.pdf\n",
      "https://arxiv.org/pdf/1503.06316v1.pdf\n",
      "https://arxiv.org/pdf/2011.04802v2.pdf\n",
      "https://arxiv.org/pdf/2103.08501v4.pdf\n",
      "https://arxiv.org/pdf/2108.03026v1.pdf\n",
      "https://arxiv.org/pdf/2110.07745v1.pdf\n",
      "https://arxiv.org/pdf/2111.09939v1.pdf\n",
      "https://arxiv.org/pdf/1603.04327v1.pdf\n",
      "https://arxiv.org/pdf/1807.09232v1.pdf\n",
      "https://arxiv.org/pdf/2001.06125v1.pdf\n",
      "https://arxiv.org/pdf/2007.02026v1.pdf\n",
      "https://arxiv.org/pdf/2007.11700v3.pdf\n",
      "https://arxiv.org/pdf/2007.13854v1.pdf\n",
      "https://arxiv.org/pdf/2007.14994v1.pdf\n",
      "https://arxiv.org/pdf/2009.04524v1.pdf\n",
      "https://arxiv.org/pdf/2010.06266v1.pdf\n",
      "https://arxiv.org/pdf/2010.15344v1.pdf\n",
      "https://arxiv.org/pdf/2101.06680v1.pdf\n",
      "https://arxiv.org/pdf/2105.07763v1.pdf\n",
      "https://arxiv.org/pdf/2105.15033v2.pdf\n",
      "https://arxiv.org/pdf/2201.00163v1.pdf\n",
      "https://arxiv.org/pdf/2201.09042v2.pdf\n",
      "https://arxiv.org/pdf/2206.14436v1.pdf\n",
      "https://arxiv.org/pdf/2207.04345v1.pdf\n",
      "https://arxiv.org/pdf/2208.06917v2.pdf\n",
      "https://arxiv.org/pdf/2210.00515v1.pdf\n",
      "https://arxiv.org/pdf/2210.09558v1.pdf\n",
      "https://arxiv.org/pdf/2210.16053v3.pdf\n",
      "https://arxiv.org/pdf/2211.03148v2.pdf\n",
      "https://arxiv.org/pdf/2211.16348v1.pdf\n",
      "https://arxiv.org/pdf/2301.00973v2.pdf\n",
      "https://arxiv.org/pdf/2302.01400v1.pdf\n",
      "https://arxiv.org/pdf/2302.06374v2.pdf\n",
      "https://arxiv.org/pdf/2305.00294v1.pdf\n",
      "https://arxiv.org/pdf/2307.05372v1.pdf\n",
      "https://arxiv.org/pdf/2307.12296v1.pdf\n",
      "https://arxiv.org/pdf/2309.15216v3.pdf\n",
      "https://arxiv.org/pdf/2310.10806v1.pdf\n",
      "https://arxiv.org/pdf/2312.08193v1.pdf\n",
      "https://arxiv.org/pdf/2312.10122v1.pdf\n",
      "https://arxiv.org/pdf/2312.11226v1.pdf\n",
      "https://arxiv.org/pdf/2402.04258v1.pdf\n",
      "https://arxiv.org/pdf/2403.10514v1.pdf\n",
      "https://arxiv.org/pdf/2403.19057v1.pdf\n",
      "https://arxiv.org/pdf/2404.09716v2.pdf\n",
      "https://arxiv.org/pdf/2404.10901v1.pdf\n",
      "https://arxiv.org/pdf/2404.11924v1.pdf\n",
      "https://arxiv.org/pdf/2404.14915v1.pdf\n",
      "https://arxiv.org/pdf/2408.06784v1.pdf\n",
      "https://arxiv.org/pdf/2410.09444v1.pdf\n"
     ]
    }
   ],
   "source": [
    "# Extract PDF URLs from metadata\n",
    "arxiv_pdf_urls = []\n",
    "for doc in arxiv_docs:\n",
    "    entry_id = doc.metadata.get(\"Entry ID\")  # e.g., http://arxiv.org/abs/2402.03268v2\n",
    "    Title  = doc.metadata.get(\"Title\")\n",
    "    if entry_id:\n",
    "        arxiv_id = entry_id.split(\"/\")[-1]\n",
    "        pdf_url = f\"https://arxiv.org/pdf/{arxiv_id}.pdf\"\n",
    "        arxiv_pdf_urls.append(pdf_url)\n",
    "\n",
    "# Example usage\n",
    "for url in arxiv_pdf_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Read PDF from URL"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from io import BytesIO\n",
    "import requests\n",
    "import fitz  # pymupdf\n",
    "\n",
    "pdf_url = arxiv_pdf_urls[0]\n",
    "response = requests.get(pdf_url)\n",
    "if response.status_code != 200:\n",
    "    raise ValueError(f\"Failed to download PDF. Status code: {response.status_code}\")\n",
    "\n",
    "pdf_stream = BytesIO(response.content)\n",
    "pdf = fitz.open(stream=pdf_stream, filetype=\"pdf\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# PubMed Loader\n",
    "\n",
    "https://python.langchain.com/docs/integrations/document_loaders/pubmed/\n",
    "\n",
    "https://github.com/langchain-ai/langchain-community/blob/main/libs/community/langchain_community/document_loaders/pubmed.py\n",
    "\n",
    "\n",
    "\n",
    ">[PubMed®](https://pubmed.ncbi.nlm.nih.gov/) by `The National Center for Biotechnology Information, National Library of Medicine` comprises more than 35 million citations for biomedical literature from `MEDLINE`, life science journals, and online books. Citations may include links to full text content from `PubMed Central` and publisher web sites."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PubMedLoader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "pubmed_loader = PubMedLoader(\n",
    "    query=\"Diabetes\",\n",
    "    #top_k_results=300,\n",
    "    load_max_docs=300,\n",
    "    # doc_content_chars_max=1000,\n",
    "    #load_all_available_meta=True,\n",
    "    # ...\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "pubmed_docs = pubmed_loader.load()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'uid': '40498532', 'Title': 'Caring for the Caregiver: Investigating the Relationship Between Caregiving, Gender, and Diabetes Risk in MIDUS II.', 'Published': '2025-06-11', 'Copyright Information': ''}, page_content='This study examines whether caregiving presents an equal risk for diabetes among gender. This study uses data from the second wave of the Midlife in the United States Survey, which included biological markers. We tested the relationship between caregiving and risk of diabetes across various models, controlling for demographics, confounders, and mechanisms that can explain the relationship. Cross-sectional analysis of the Homeostatic Model Assessment of Insulin Resistance (HOMO-IR) determined that (1)men had a higher risk of diabetes than women overall; (2)male caregivers demonstrated a lower risk of diabetes compared to non-caregiving men; (3)female caregivers exhibited a non-significant elevation in diabetes risk compared with non-caregiving females. Findings establish the basis for future studies which identify cardiometabolic disease risks between genders. Our study also provides foundation for future studies to expand and identify differences in psychosocial resources among male and female caregivers which may mitigate cardiometabolic disease risk.')"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "300"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(pubmed_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'uid': '40498198',\n",
       " 'Title': 'Protocol to Use Mouse Hepatocyte Cell Line AML12 to Study Hepatic Metabolism In Vitro.',\n",
       " 'Published': '--',\n",
       " 'Copyright Information': '© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.'}"
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_docs[10].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 172,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting pubmed2pdf\n",
      "  Downloading pubmed2pdf-0.0.7.tar.gz (7.4 kB)\n",
      "  Preparing metadata (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25hRequirement already satisfied: click>=7.0 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed2pdf) (8.1.7)\n",
      "Requirement already satisfied: requests>=2.22.0 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed2pdf) (2.32.3)\n",
      "Requirement already satisfied: beautifulsoup4>=4.7.1 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed2pdf) (4.13.4)\n",
      "Requirement already satisfied: lxml in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed2pdf) (5.4.0)\n",
      "Collecting biopython (from pubmed2pdf)\n",
      "  Downloading biopython-1.85-cp312-cp312-macosx_11_0_arm64.whl.metadata (13 kB)\n",
      "Requirement already satisfied: soupsieve>1.2 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from beautifulsoup4>=4.7.1->pubmed2pdf) (2.6)\n",
      "Requirement already satisfied: typing-extensions>=4.0.0 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from beautifulsoup4>=4.7.1->pubmed2pdf) (4.12.2)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests>=2.22.0->pubmed2pdf) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests>=2.22.0->pubmed2pdf) (3.8)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests>=2.22.0->pubmed2pdf) (1.26.20)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests>=2.22.0->pubmed2pdf) (2024.8.30)\n",
      "Requirement already satisfied: numpy in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from biopython->pubmed2pdf) (1.26.4)\n",
      "Downloading biopython-1.85-cp312-cp312-macosx_11_0_arm64.whl (2.8 MB)\n",
      "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.8/2.8 MB\u001b[0m \u001b[31m2.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0ma \u001b[36m0:00:01\u001b[0m\n",
      "\u001b[?25hBuilding wheels for collected packages: pubmed2pdf\n",
      "  Building wheel for pubmed2pdf (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for pubmed2pdf: filename=pubmed2pdf-0.0.7-py3-none-any.whl size=7801 sha256=e4da29c2df272a1cda4bf653f6a3a387d1262b453cfbc3cdbba868018ffdea63\n",
      "  Stored in directory: /Users/tubakaraca/Library/Caches/pip/wheels/6c/f8/50/159e46c278dd07df8d5aa665b2285220d0670a63d155d4542c\n",
      "Successfully built pubmed2pdf\n",
      "Installing collected packages: biopython, pubmed2pdf\n",
      "Successfully installed biopython-1.85 pubmed2pdf-0.0.7\n",
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "!pip install pubmed2pdf\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting pubmed_download\n",
      "  Downloading pubmed_download-0.2.1-py3-none-any.whl.metadata (976 bytes)\n",
      "Requirement already satisfied: setuptools in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed_download) (75.6.0)\n",
      "Requirement already satisfied: pandas in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed_download) (2.2.3)\n",
      "Requirement already satisfied: lxml in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed_download) (5.4.0)\n",
      "Requirement already satisfied: requests in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pubmed_download) (2.32.3)\n",
      "Collecting PyPDF2 (from pubmed_download)\n",
      "  Downloading pypdf2-3.0.1-py3-none-any.whl.metadata (6.8 kB)\n",
      "Collecting bs4 (from pubmed_download)\n",
      "  Downloading bs4-0.0.2-py2.py3-none-any.whl.metadata (411 bytes)\n",
      "Requirement already satisfied: beautifulsoup4 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from bs4->pubmed_download) (4.13.4)\n",
      "Requirement already satisfied: numpy>=1.26.0 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pandas->pubmed_download) (1.26.4)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pandas->pubmed_download) (2.8.2)\n",
      "Requirement already satisfied: pytz>=2020.1 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pandas->pubmed_download) (2024.2)\n",
      "Requirement already satisfied: tzdata>=2022.7 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from pandas->pubmed_download) (2024.2)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests->pubmed_download) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests->pubmed_download) (3.8)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests->pubmed_download) (1.26.20)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from requests->pubmed_download) (2024.8.30)\n",
      "Requirement already satisfied: six>=1.5 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from python-dateutil>=2.8.2->pandas->pubmed_download) (1.16.0)\n",
      "Requirement already satisfied: soupsieve>1.2 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from beautifulsoup4->bs4->pubmed_download) (2.6)\n",
      "Requirement already satisfied: typing-extensions>=4.0.0 in /Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages (from beautifulsoup4->bs4->pubmed_download) (4.12.2)\n",
      "Downloading pubmed_download-0.2.1-py3-none-any.whl (9.1 kB)\n",
      "Downloading bs4-0.0.2-py2.py3-none-any.whl (1.2 kB)\n",
      "Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
      "Installing collected packages: PyPDF2, bs4, pubmed_download\n",
      "Successfully installed PyPDF2-3.0.1 bs4-0.0.2 pubmed_download-0.2.1\n",
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "!pip install pubmed_download"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 178,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'uid': '40498412',\n",
       " 'Title': 'miR-320-3p regulates apelin and TGF-β/SMAD3 signaling in hypobaric hypoxia exposed rats to induce skeletal muscle atrophy.',\n",
       " 'Published': '2025-06-11',\n",
       " 'Copyright Information': '© 2025. The Author(s) under exclusive licence to University of Navarra.'}"
      ]
     },
     "execution_count": 178,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_docs[4].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {},
   "outputs": [],
   "source": [
    "uids = ['40498412']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[2025-06-13 21:11:12] [pubmed] [ INFO  ] [ 86 ] [start download.....]\n",
      "[2025-06-13 21:11:12] [pubmed] [ INFO  ] [ 89 ] [start download 40498412, 0/1]\n",
      "[2025-06-13 21:11:13] [pubmed] [ INFO  ] [122 ] [search by doi: 40498412, 10.1007/s13105-025-01100-y]\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/site-packages/pubmed_download/pubmed_download.py\", line 131, in search_by_doi\n",
      "    content = ub.urlopen(temp_url).read().decode('utf-8')\n",
      "              ^^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 215, in urlopen\n",
      "    return opener.open(url, data, timeout)\n",
      "           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 521, in open\n",
      "    response = meth(req, response)\n",
      "               ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 630, in http_response\n",
      "    response = self.parent.error(\n",
      "               ^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 559, in error\n",
      "    return self._call_chain(*args)\n",
      "           ^^^^^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 492, in _call_chain\n",
      "    result = func(*args)\n",
      "             ^^^^^^^^^^^\n",
      "  File \"/Users/tubakaraca/.pyenv/versions/3.12.0/lib/python3.12/urllib/request.py\", line 639, in http_error_default\n",
      "    raise HTTPError(req.full_url, code, msg, hdrs, fp)\n",
      "urllib.error.HTTPError: HTTP Error 404: Not Found\n",
      "[2025-06-13 21:11:13] [pubmed] [ ERROR ] [141 ] [search sci-hub by doi error: None]\n",
      "[2025-06-13 21:11:13] [pubmed] [ INFO  ] [160 ] [try by doi: https://sci-hub.wf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:14] [pubmed] [ INFO  ] [ 59 ] [40498412 https://sci-hub.wf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:14] [pubmed] [ ERROR ] [ 73 ] [40498412, cannot download, [Errno 2] No such file or directory: './pubmed_downloads/40498412.pdf']\n",
      "[2025-06-13 21:11:14] [pubmed] [ INFO  ] [160 ] [try by doi: https://sci/bban/top/10.1007/s13105-025-01100-y.pdf#view=FitH]\n",
      "[2025-06-13 21:11:14] [pubmed] [ ERROR ] [ 73 ] [40498412, cannot download, HTTPSConnectionPool(host='sci', port=443): Max retries exceeded with url: /bban/top/10.1007/s13105-025-01100-y.pdf (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x17add8170>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))]\n",
      "[2025-06-13 21:11:14] [pubmed] [ INFO  ] [160 ] [try by doi: https://www.spandidos-publications.com/10.1007/s13105-025-01100-y/download]\n",
      "[2025-06-13 21:11:14] [pubmed] [ INFO  ] [160 ] [try by doi: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:14] [pubmed] [ INFO  ] [160 ] [try by doi: https://jeccr.biomedcentral.com/track/pdf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:15] [pubmed] [ ERROR ] [ 73 ] [40498412, cannot download, HTTPSConnectionPool(host='13105.springer.com', port=443): Max retries exceeded with url: /track/pdf/10.1007/s13105-025-01100-y.pdf (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x17adda930>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))]\n",
      "[2025-06-13 21:11:15] [pubmed] [ INFO  ] [160 ] [try by doi: https://www.frontiersin.org/articles/10.1007/s13105-025-01100-y/pdf]\n",
      "[2025-06-13 21:11:15] [pubmed] [ INFO  ] [160 ] [try by doi: https://journals.plos.org/plosone/article/file?id=10.1007/s13105-025-01100-y&type=printable]\n",
      "[2025-06-13 21:11:15] [pubmed] [ INFO  ] [160 ] [try by doi: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:15] [pubmed] [ INFO  ] [160 ] [try by doi: https://www.tandfonline.com/doi/pdf/10.1007/s13105-025-01100-y?needAccess=true]\n",
      "[2025-06-13 21:11:16] [pubmed] [ INFO  ] [160 ] [try by doi: https://immunityageing.biomedcentral.com/track/pdf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:16] [pubmed] [ ERROR ] [ 73 ] [40498412, cannot download, HTTPSConnectionPool(host='13105.springer.com', port=443): Max retries exceeded with url: /track/pdf/10.1007/s13105-025-01100-y.pdf (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x17addb770>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))]\n",
      "[2025-06-13 21:11:16] [pubmed] [ INFO  ] [160 ] [try by doi: https://pubs.acs.org/doi/pdf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:16] [pubmed] [ INFO  ] [160 ] [try by doi: https://journals.sagepub.com/doi/pdf/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:16] [pubmed] [ INFO  ] [160 ] [try by doi: https://www.futuremedicine.com/doi/epub/10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:18] [pubmed] [ INFO  ] [164 ] [download by doi:False]\n",
      "[2025-06-13 21:11:18] [pubmed] [ INFO  ] [169 ] [search by pii, 40498412, 10.1007/s13105-025-01100-y...]\n",
      "[2025-06-13 21:11:18] [pubmed] [ INFO  ] [178 ] [try by pii: https://www.jto.org/action/showPdf?pii=10.1007/s13105-025-01100-y]\n",
      "[2025-06-13 21:11:18] [pubmed] [ INFO  ] [178 ] [try by pii: https://www.jto.org/article/10.1007/s13105-025-01100-y/pdf]\n",
      "[2025-06-13 21:11:18] [pubmed] [ INFO  ] [178 ] [try by pii: https://www.oncotarget.com/article/10.1007/s13105-025-01100-y/pdf/]\n",
      "[2025-06-13 21:11:19] [pubmed] [ INFO  ] [182 ] [download by pii: False]\n",
      "[2025-06-13 21:11:19] [pubmed] [ INFO  ] [112 ] [download failed: 40498412]\n",
      "[2025-06-13 21:11:19] [pubmed] [ INFO  ] [117 ] [download file done:0/1]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 190,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pubmed_download import DownloadPdf\n",
    "\n",
    "download_path = r\"./pubmed_downloads\"\n",
    "DownloadPdf(download_path, uids).run()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [],
   "source": [
    "import subprocess\n",
    "\n",
    "def download_pubmed_pdfs(uids, out_dir=\"./pubmed_downloads\"):\n",
    "    cmd = [\n",
    "        \"python3\", \"-m\", \"pubmed2pdf\", \"pdf\",\n",
    "        \"--pmids\", \",\".join(uids),\n",
    "        \"--out\", out_dir,\n",
    "        \"--save\"\n",
    "    ]\n",
    "    subprocess.run(cmd, check=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Usage: python -m pubmed2pdf pdf [OPTIONS]\n",
      "Try 'python -m pubmed2pdf pdf --help' for help.\n",
      "\n",
      "Error: No such option: --outpath Did you mean --out?\n"
     ]
    },
    {
     "ename": "CalledProcessError",
     "evalue": "Command '['python3', '-m', 'pubmed2pdf', 'pdf', '--pmids', '40498412', '--outpath', './pubmed_downloads', '--save']' returned non-zero exit status 2.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mCalledProcessError\u001b[0m                        Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[188], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mdownload_pubmed_pdfs\u001b[49m\u001b[43m(\u001b[49m\u001b[43muids\u001b[49m\u001b[43m)\u001b[49m\n",
      "Cell \u001b[0;32mIn[187], line 10\u001b[0m, in \u001b[0;36mdownload_pubmed_pdfs\u001b[0;34m(uids, out_dir)\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mdownload_pubmed_pdfs\u001b[39m(uids, out_dir\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m./pubmed_downloads\u001b[39m\u001b[38;5;124m\"\u001b[39m):\n\u001b[1;32m      4\u001b[0m     cmd \u001b[38;5;241m=\u001b[39m [\n\u001b[1;32m      5\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpython3\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m-m\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpubmed2pdf\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpdf\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[1;32m      6\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m--pmids\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m,\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;241m.\u001b[39mjoin(uids),\n\u001b[1;32m      7\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m--outpath\u001b[39m\u001b[38;5;124m\"\u001b[39m, out_dir,\n\u001b[1;32m      8\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m--save\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m      9\u001b[0m     ]\n\u001b[0;32m---> 10\u001b[0m     \u001b[43msubprocess\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcmd\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcheck\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/subprocess.py:571\u001b[0m, in \u001b[0;36mrun\u001b[0;34m(input, capture_output, timeout, check, *popenargs, **kwargs)\u001b[0m\n\u001b[1;32m    569\u001b[0m     retcode \u001b[38;5;241m=\u001b[39m process\u001b[38;5;241m.\u001b[39mpoll()\n\u001b[1;32m    570\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m check \u001b[38;5;129;01mand\u001b[39;00m retcode:\n\u001b[0;32m--> 571\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m CalledProcessError(retcode, process\u001b[38;5;241m.\u001b[39margs,\n\u001b[1;32m    572\u001b[0m                                  output\u001b[38;5;241m=\u001b[39mstdout, stderr\u001b[38;5;241m=\u001b[39mstderr)\n\u001b[1;32m    573\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m CompletedProcess(process\u001b[38;5;241m.\u001b[39margs, retcode, stdout, stderr)\n",
      "\u001b[0;31mCalledProcessError\u001b[0m: Command '['python3', '-m', 'pubmed2pdf', 'pdf', '--pmids', '40498412', '--outpath', './pubmed_downloads', '--save']' returned non-zero exit status 2."
     ]
    }
   ],
   "source": [
    "download_pubmed_pdfs(uids)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pubmed2pdf import pubmed2pdf\n",
    "\n",
    "for doc in pubmed_docs:\n",
    "    uid = doc.metadata.get(\"uid\")\n",
    "    if uid:\n",
    "        pdf_path = pubmed2pdf(\n",
    "        uid=uid,\n",
    "        out_dir=\"./downloads\",  # directory to save the PDF\n",
    "        save=True,              # save the PDF\n",
    "        return_path=True        # return the path to the saved PDF\n",
    "        )\n",
    "        url = f\"https://pubmed.ncbi.nlm.nih.gov/{uid}/\"\n",
    "        pubmed_pdf_urls.append(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://pubmed.ncbi.nlm.nih.gov/40498532/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498486/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498480/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498478/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498412/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498369/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498355/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498290/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498287/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498212/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498198/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498168/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498128/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498074/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498052/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498015/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497986/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497970/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497936/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497934/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497928/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497767/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497659/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497571/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497566/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497539/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497520/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497515/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497501/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497454/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497427/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497406/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497377/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497366/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497353/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497345/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497343/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497340/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497336/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497333/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497316/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497287/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497281/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497273/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497223/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497222/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497218/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497202/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497127/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497126/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497041/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496911/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496898/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496897/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496896/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496876/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496842/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496819/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496818/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496754/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496740/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496729/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496728/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496674/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496672/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496649/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496635/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496572/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496570/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496569/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496563/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496562/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496556/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496525/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496517/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496473/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496442/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496432/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496420/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496419/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496405/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496391/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496369/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496367/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496349/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496242/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496236/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496217/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496073/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496070/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496050/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496048/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496040/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40496001/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495979/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495965/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495947/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495943/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495890/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495843/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495832/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495820/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495716/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495703/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495656/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495643/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495635/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495591/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495570/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495558/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495505/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495492/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495485/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495438/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495433/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495415/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495414/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495402/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495360/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495344/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495317/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495301/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495273/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495246/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495231/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495121/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495045/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495031/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40495021/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494867/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494849/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494834/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494801/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494796/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494792/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494789/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494783/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494751/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494747/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494715/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494660/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494612/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494587/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494575/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494540/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494504/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494442/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494433/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494432/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494429/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494410/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494391/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494346/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494338/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494329/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494169/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494165/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494157/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494156/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494023/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494022/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494021/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40494011/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493980/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493966/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493913/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493870/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493832/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493824/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493797/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493766/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493690/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493665/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493636/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493627/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493603/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493602/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493559/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493527/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493506/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493413/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493410/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493405/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493381/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493329/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493295/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493280/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493266/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493262/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493245/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493225/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493192/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493166/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493165/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493162/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493151/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493144/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493135/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493110/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493108/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493103/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493097/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493069/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40493055/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492931/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492908/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492903/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492893/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492891/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492875/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492872/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492780/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492760/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492727/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492668/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492660/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492646/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492643/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492638/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492628/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492602/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492583/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492563/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492525/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492515/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492483/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492481/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492477/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492436/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492420/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492314/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492308/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492301/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492240/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492185/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492180/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492113/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492077/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492074/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492070/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492061/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40492034/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491979/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491952/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491938/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491900/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491812/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491780/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491747/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491732/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491728/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491723/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491720/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491693/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491692/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491691/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491672/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491663/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491653/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491648/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491642/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491639/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491630/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491599/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491592/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491591/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491590/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491573/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491561/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491560/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491524/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491488/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491338/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491309/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491298/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491292/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491247/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491243/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491239/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491217/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491209/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491035/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40491001/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490976/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490942/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490912/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490835/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490808/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490778/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490774/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490769/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490764/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490758/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490754/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490745/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490741/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490726/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490694/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490690/\n",
      "https://pubmed.ncbi.nlm.nih.gov/40490670/\n"
     ]
    }
   ],
   "source": [
    "pubmed_pdf_urls = []\n",
    "for doc in pubmed_docs:\n",
    "    uid = doc.metadata.get(\"uid\")\n",
    "    if uid:\n",
    "        url = f\"https://pubmed.ncbi.nlm.nih.gov/{uid}/\"\n",
    "        pubmed_pdf_urls.append(url)\n",
    "\n",
    "for url in pubmed_pdf_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import xml.etree.ElementTree as ET"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_article_metadata(uid):\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
    "    params = {\n",
    "        \"db\": \"pubmed\",\n",
    "        \"id\": uid,\n",
    "        \"retmode\": \"xml\"\n",
    "    }\n",
    "    r = requests.get(url, params=params)\n",
    "    if r.status_code != 200:\n",
    "        print(f\"Failed to fetch metadata for UID {uid}\")\n",
    "        return None\n",
    "\n",
    "    root = ET.fromstring(r.text)\n",
    "    \n",
    "    # Find DOI\n",
    "    doi = None\n",
    "    for article_id in root.findall(\".//ArticleId\"):\n",
    "        if article_id.attrib.get(\"IdType\") == \"doi\":\n",
    "            doi = article_id.text\n",
    "    \n",
    "    # Find PMCID\n",
    "    pmcid = None\n",
    "    for article_id in root.findall(\".//ArticleId\"):\n",
    "        if article_id.attrib.get(\"IdType\") == \"pmc\":\n",
    "            pmcid = article_id.text\n",
    "    \n",
    "    return {\"doi\": doi, \"pmcid\": pmcid}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_pdf_url_from_metadata(metadata):\n",
    "    pmcid = metadata.get(\"pmcid\")\n",
    "    if pmcid:\n",
    "        return f\"https://www.ncbi.nlm.nih.gov/pmc/articles/{pmcid}/pdf/\"\n",
    "    return None"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_pmc_pdf_url(pmcid):\n",
    "    \"\"\"Return the direct PDF URL for a PMC article if it exists.\"\"\"\n",
    "    if not pmcid.startswith(\"PMC\"):\n",
    "        pmcid = \"PMC\" + pmcid\n",
    "    pdf_url = f\"https://www.ncbi.nlm.nih.gov/pmc/articles/{pmcid}/pdf/\"\n",
    "    # Quick HEAD request to check if PDF exists\n",
    "    r = requests.head(pdf_url)\n",
    "    if r.status_code == 200:\n",
    "        return pdf_url\n",
    "    return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "\n",
    "def get_pmcid_from_pubmed_page(uid):\n",
    "    url = f\"https://pubmed.ncbi.nlm.nih.gov/{uid}/\"\n",
    "    r = requests.get(url)\n",
    "    if r.status_code != 200:\n",
    "        print(f\"Failed to fetch PubMed page for UID {uid}\")\n",
    "        return None\n",
    "\n",
    "    soup = BeautifulSoup(r.text, \"html.parser\")\n",
    "    # Find all anchor tags\n",
    "    links = soup.find_all(\"a\", href=True)\n",
    "    for link in links:\n",
    "        href = link['href']\n",
    "        # Check if href contains the PMC article path\n",
    "        if \"/pmc/articles/PMC\" in href:\n",
    "            # Extract PMCID from href\n",
    "            pmcid = href.strip(\"/\").split(\"/\")[-1]\n",
    "            return pmcid\n",
    "    return None\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_pdf_url_from_pubmed_uid(uid):\n",
    "    \"\"\"Try to get direct PDF URL for a PubMed article UID.\"\"\"\n",
    "    pmcid = get_pmcid_from_pubmed_page(uid)\n",
    "    if pmcid:\n",
    "        pdf_url = get_pmc_pdf_url(pmcid)\n",
    "        if pdf_url:\n",
    "            return pdf_url\n",
    "    print(f\"No direct PDF found for PubMed UID {uid}\")\n",
    "    return None\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 149,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'doi': '10.1177/07334648251343924', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498532\n",
      "{'doi': '10.1001/jamanetworkopen.2025.14631', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498486\n",
      "{'doi': '10.1001/jamadermatol.2025.1565', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498480\n",
      "{'doi': '10.1001/jamacardio.2025.1714', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498478\n",
      "{'doi': '10.3390/jcm11010263', 'pmcid': '8746094'}\n",
      "PDF URL for PubMed UID 40498412: https://www.ncbi.nlm.nih.gov/pmc/articles/8746094/pdf/\n",
      "{'doi': '10.1002/eji.202451176', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498369\n",
      "{'doi': '10.1080/07391102.2025.2507817', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498355\n",
      "{'doi': '10.1136/spcare-2024-004984', 'pmcid': '5817484'}\n",
      "PDF URL for PubMed UID 40498290: https://www.ncbi.nlm.nih.gov/pmc/articles/5817484/pdf/\n",
      "{'doi': '10.1016/S0168-8278(97)80288-7', 'pmcid': '1421079'}\n",
      "PDF URL for PubMed UID 40498287: https://www.ncbi.nlm.nih.gov/pmc/articles/1421079/pdf/\n",
      "{'doi': '10.3389/fncel.2024.1422130', 'pmcid': '11402763'}\n",
      "PDF URL for PubMed UID 40498212: https://www.ncbi.nlm.nih.gov/pmc/articles/11402763/pdf/\n",
      "{'doi': '10.1073/pnas.91.2.674', 'pmcid': '43011'}\n",
      "PDF URL for PubMed UID 40498198: https://www.ncbi.nlm.nih.gov/pmc/articles/43011/pdf/\n",
      "{'doi': '10.1038/s41598-021-92712-z', 'pmcid': '8238964'}\n",
      "PDF URL for PubMed UID 40498168: https://www.ncbi.nlm.nih.gov/pmc/articles/8238964/pdf/\n",
      "{'doi': '10.7759/cureus.46741', 'pmcid': '10631563'}\n",
      "PDF URL for PubMed UID 40498128: https://www.ncbi.nlm.nih.gov/pmc/articles/10631563/pdf/\n",
      "{'doi': '10.1093/emboj/17.19.5822', 'pmcid': 'PMC1170910'}\n",
      "PDF URL for PubMed UID 40498074: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1170910/pdf/\n",
      "{'doi': '10.14309/ajg.0000000000003594', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40498052\n",
      "{'doi': '10.1007/978-1-4939-8597-5_18', 'pmcid': 'PMC9240731'}\n",
      "PDF URL for PubMed UID 40498015: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240731/pdf/\n",
      "{'doi': '10.1152/ajpregu.00216.2006', 'pmcid': 'PMC11593555'}\n",
      "PDF URL for PubMed UID 40497986: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593555/pdf/\n",
      "{'doi': '10.4103/ijot.ijot_37_23', 'pmcid': 'PMC3944043'}\n",
      "PDF URL for PubMed UID 40497970: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944043/pdf/\n",
      "{'doi': '10.3389/fphys.2018.00828', 'pmcid': 'PMC6048272'}\n",
      "PDF URL for PubMed UID 40497936: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048272/pdf/\n",
      "{'doi': '10.1126/sciadv.adh8689', 'pmcid': 'PMC10901469'}\n",
      "PDF URL for PubMed UID 40497934: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10901469/pdf/\n",
      "{'doi': '10.4081/dr.2024.9866', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497928\n",
      "{'doi': '10.3290/j.cjdr.b6260628', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497767\n",
      "{'doi': '10.1093/jbmr/zjaf080', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497659\n",
      "{'doi': '10.1002/ijgo.70267', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497571\n",
      "{'doi': '10.1002/ijgo.70259', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497566\n",
      "{'doi': '10.1097/QCO.0000000000001121', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497539\n",
      "{'doi': '10.1002/jmv.70438', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497520\n",
      "{'doi': '10.1161/JAHA.124.039663', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497515\n",
      "{'doi': '10.4081/monaldi.2024.2815', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497501\n",
      "{'doi': '10.1210/clinem/dgaf350', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497454\n",
      "{'doi': '10.1111/apha.70072', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497427\n",
      "{'doi': '10.1096/fj.202501267R', 'pmcid': 'PMC2678592'}\n",
      "PDF URL for PubMed UID 40497406: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678592/pdf/\n",
      "{'doi': '10.5603/pjnns.103406', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497377\n",
      "{'doi': '10.1111/hiv.70060', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497366\n",
      "{'doi': '10.1111/dom.16502', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497353\n",
      "{'doi': '10.1111/dom.16497', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497345\n",
      "{'doi': '10.1111/dom.16533', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497343\n",
      "{'doi': '10.1111/cpr.70077', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497340\n",
      "{'doi': '10.1111/dom.16528', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497336\n",
      "{'doi': '10.1111/dom.16512', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497333\n",
      "{'doi': '10.1111/dom.15703', 'pmcid': 'PMC11182795'}\n",
      "PDF URL for PubMed UID 40497316: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182795/pdf/\n",
      "{'doi': '10.1177/00045632251350505', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40497287\n",
      "{'doi': '10.1016/j.jhsg.2025.03.004', 'pmcid': 'PMC10749585'}\n",
      "PDF URL for PubMed UID 40497281: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749585/pdf/\n",
      "{'doi': '10.1016/j.jhsg.2025.100746', 'pmcid': 'PMC2903966'}\n",
      "PDF URL for PubMed UID 40497273: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903966/pdf/\n",
      "{'doi': '10.7759/cureus.83903', 'pmcid': 'PMC9542252'}\n",
      "PDF URL for PubMed UID 40497223: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/pdf/\n",
      "{'doi': '10.7759/cureus.83845', 'pmcid': 'PMC9927962'}\n",
      "PDF URL for PubMed UID 40497222: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927962/pdf/\n",
      "{'doi': '10.7759/cureus.83900', 'pmcid': 'PMC3319353'}\n",
      "PDF URL for PubMed UID 40497218: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319353/pdf/\n",
      "{'doi': '10.7759/cureus.83897', 'pmcid': 'PMC2518801'}\n",
      "PDF URL for PubMed UID 40497202: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518801/pdf/\n",
      "{'doi': '10.1253/circrep.CR-25-0021', 'pmcid': 'PMC4689591'}\n",
      "PDF URL for PubMed UID 40497127: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689591/pdf/\n",
      "{'doi': '10.1253/circrep.CR-25-0041', 'pmcid': 'PMC10111968'}\n",
      "PDF URL for PubMed UID 40497126: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111968/pdf/\n",
      "{'doi': '10.1007/s10616-025-00779-7', 'pmcid': 'PMC6838321'}\n",
      "PDF URL for PubMed UID 40497041: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838321/pdf/\n",
      "{'doi': '10.1097/OI9.0000000000000410', 'pmcid': 'PMC9425924'}\n",
      "PDF URL for PubMed UID 40496911: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425924/pdf/\n",
      "{'doi': '10.1210/jendso/bvaf074', 'pmcid': 'PMC4794640'}\n",
      "PDF URL for PubMed UID 40496898: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794640/pdf/\n",
      "{'doi': '10.1210/jendso/bvaf095', 'pmcid': 'PMC9928893'}\n",
      "PDF URL for PubMed UID 40496897: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928893/pdf/\n",
      "{'doi': '10.1210/jendso/bvaf073', 'pmcid': 'PMC10300517'}\n",
      "PDF URL for PubMed UID 40496896: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300517/pdf/\n",
      "{'doi': '10.1186/1472-6882-12-S1-P180', 'pmcid': 'PMC8798588'}\n",
      "PDF URL for PubMed UID 40496876: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798588/pdf/\n",
      "{'doi': '10.1016/j.rmcr.2025.102232', 'pmcid': 'PMC8420631'}\n",
      "PDF URL for PubMed UID 40496842: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420631/pdf/\n",
      "{'doi': '10.2337/dc21-0496', 'pmcid': 'PMC8753766'}\n",
      "PDF URL for PubMed UID 40496819: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753766/pdf/\n",
      "{'doi': '10.2337/dc19-0831', 'pmcid': 'PMC6971783'}\n",
      "PDF URL for PubMed UID 40496818: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971783/pdf/\n",
      "{'doi': '10.1093/cid/ciz1008', 'pmcid': 'PMC7486838'}\n",
      "PDF URL for PubMed UID 40496754: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486838/pdf/\n",
      "{'doi': '10.1093/nar/gkw569', 'pmcid': 'PMC5001611'}\n",
      "PDF URL for PubMed UID 40496740: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001611/pdf/\n",
      "{'doi': '10.1186/s12951-025-03333-x', 'pmcid': 'PMC11998224'}\n",
      "PDF URL for PubMed UID 40496729: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998224/pdf/\n",
      "{'doi': '10.1016/j.bioactmat.2022.12.009', 'pmcid': 'PMC9772805'}\n",
      "PDF URL for PubMed UID 40496728: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772805/pdf/\n",
      "{'doi': '10.1016/j.tips.2023.10.003', 'pmcid': 'PMC10657387'}\n",
      "PDF URL for PubMed UID 40496674: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657387/pdf/\n",
      "{'doi': '10.1093/braincomms/fcaf203', 'pmcid': 'PMC4792330'}\n",
      "PDF URL for PubMed UID 40496672: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792330/pdf/\n",
      "{'doi': '10.1377/hlthaff.2015.1364', 'pmcid': 'PMC5554943'}\n",
      "PDF URL for PubMed UID 40496649: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554943/pdf/\n",
      "{'doi': '10.1186/s13098-024-01329-5', 'pmcid': 'PMC11005231'}\n",
      "PDF URL for PubMed UID 40496635: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005231/pdf/\n",
      "{'doi': '10.1016/j.jtha.2025.02.025', 'pmcid': 'PMC8841437'}\n",
      "PDF URL for PubMed UID 40496572: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841437/pdf/\n",
      "{'doi': '10.1016/j.transproceed.2018.03.087', 'pmcid': 'PMC7066580'}\n",
      "PDF URL for PubMed UID 40496570: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066580/pdf/\n",
      "{'doi': '10.1590/s2237-96222024v33e2024170.especial.en', 'pmcid': 'PMC11654390'}\n",
      "PDF URL for PubMed UID 40496569: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654390/pdf/\n",
      "{'doi': '10.3390/jcm9092816', 'pmcid': 'PMC7563792'}\n",
      "PDF URL for PubMed UID 40496563: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563792/pdf/\n",
      "{'doi': '10.1002/ardp.202100130', 'pmcid': 'PMC2192941'}\n",
      "PDF URL for PubMed UID 40496562: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192941/pdf/\n",
      "{'doi': '10.1093/ndt/gfy021', 'pmcid': 'PMC11101251'}\n",
      "PDF URL for PubMed UID 40496556: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101251/pdf/\n",
      "{'doi': '10.4236/jdm.2020.102007', 'pmcid': 'PMC10769059'}\n",
      "PDF URL for PubMed UID 40496525: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769059/pdf/\n",
      "{'doi': '10.1002/puh2.217', 'pmcid': 'PMC5036809'}\n",
      "PDF URL for PubMed UID 40496517: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036809/pdf/\n",
      "{'doi': '10.1210/jcemcr/luaf132', 'pmcid': 'PMC6150434'}\n",
      "PDF URL for PubMed UID 40496473: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150434/pdf/\n",
      "{'doi': '10.1016/j.jhepr.2025.101388', 'pmcid': 'PMC8273632'}\n",
      "PDF URL for PubMed UID 40496442: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273632/pdf/\n",
      "{'doi': '10.1186/s12986-021-00626-4', 'pmcid': 'PMC2972490'}\n",
      "PDF URL for PubMed UID 40496432: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972490/pdf/\n",
      "{'doi': '10.1016/j.ijmedinf.2024.105550', 'pmcid': 'PMC9943005'}\n",
      "PDF URL for PubMed UID 40496420: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943005/pdf/\n",
      "{'doi': '10.1016/j.jhsg.2025.01.016', 'pmcid': 'PMC3116486'}\n",
      "PDF URL for PubMed UID 40496419: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116486/pdf/\n",
      "{'doi': '10.2106/JBJS.24.00379', 'pmcid': 'PMC11162066'}\n",
      "PDF URL for PubMed UID 40496405: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11162066/pdf/\n",
      "{'doi': '10.4330/wjc.v17.i5.105822', 'pmcid': 'PMC11969339'}\n",
      "PDF URL for PubMed UID 40496391: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969339/pdf/\n",
      "{'doi': '10.1016/j.maturitas.2021.08.002', 'pmcid': 'PMC9276667'}\n",
      "PDF URL for PubMed UID 40496369: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276667/pdf/\n",
      "{'doi': '10.3748/wjg.v31.i18.104525', 'pmcid': 'PMC8338825'}\n",
      "PDF URL for PubMed UID 40496367: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338825/pdf/\n",
      "{'doi': '10.1242/dev.044529', 'pmcid': 'PMC3552560'}\n",
      "PDF URL for PubMed UID 40496349: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552560/pdf/\n",
      "{'doi': '10.3389/fnut.2023.1146916', 'pmcid': 'PMC10062204'}\n",
      "PDF URL for PubMed UID 40496242: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062204/pdf/\n",
      "{'doi': '10.1016/j.mjafi.2024.04.023', 'pmcid': 'PMC6772083'}\n",
      "PDF URL for PubMed UID 40496236: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772083/pdf/\n",
      "{'doi': '10.1007/s00417-024-06695-4', 'pmcid': 'PMC6972781'}\n",
      "PDF URL for PubMed UID 40496217: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972781/pdf/\n",
      "{'doi': '10.3748/wjg.15.6004', 'pmcid': 'PMC3015298'}\n",
      "PDF URL for PubMed UID 40496073: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015298/pdf/\n",
      "{'doi': '10.1016/j.jpha.2024.101130', 'pmcid': 'PMC5480053'}\n",
      "PDF URL for PubMed UID 40496070: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480053/pdf/\n",
      "{'doi': '10.4162/nrp.2025.19.3.425', 'pmcid': 'PMC4890267'}\n",
      "PDF URL for PubMed UID 40496050: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890267/pdf/\n",
      "{'doi': '10.1101/2023.06.14.23291406', 'pmcid': 'PMC5898168'}\n",
      "PDF URL for PubMed UID 40496048: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898168/pdf/\n",
      "{'doi': '10.1159/000506810', 'pmcid': 'PMC8317059'}\n",
      "PDF URL for PubMed UID 40496040: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317059/pdf/\n",
      "{'doi': '10.1038/s41587-020-0430-6', 'pmcid': 'PMC7274216'}\n",
      "PDF URL for PubMed UID 40496001: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274216/pdf/\n",
      "{'doi': '10.1016/j.ijnsa.2025.100353', 'pmcid': 'PMC7379170'}\n",
      "PDF URL for PubMed UID 40495979: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379170/pdf/\n",
      "{'doi': '10.1186/s40842-024-00194-5', 'pmcid': 'PMC11515346'}\n",
      "PDF URL for PubMed UID 40495965: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515346/pdf/\n",
      "{'doi': '10.3748/wjg.v31.i20.105346', 'pmcid': 'PMC11599550'}\n",
      "PDF URL for PubMed UID 40495947: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599550/pdf/\n",
      "{'doi': '10.3748/wjg.v31.i20.105269', 'pmcid': 'PMC436321'}\n",
      "PDF URL for PubMed UID 40495943: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC436321/pdf/\n",
      "{'doi': '10.1186/s12882-022-02716-8', 'pmcid': 'PMC8895563'}\n",
      "PDF URL for PubMed UID 40495890: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895563/pdf/\n",
      "{'doi': '10.5498/wjp.v15.i5.102540', 'pmcid': 'PMC7532110'}\n",
      "PDF URL for PubMed UID 40495843: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532110/pdf/\n",
      "{'doi': '10.5498/wjp.v15.i5.104766', 'pmcid': 'PMC8141681'}\n",
      "PDF URL for PubMed UID 40495832: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141681/pdf/\n",
      "{'doi': '10.1002/cam4.70426', 'pmcid': 'PMC11621967'}\n",
      "PDF URL for PubMed UID 40495820: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621967/pdf/\n",
      "{'doi': '10.1242/bio.061941', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495716\n",
      "{'doi': '10.1177/10781552251348662', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495703\n",
      "{'doi': '10.1021/acs.jcim.5c00869', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495656\n",
      "{'doi': '10.1177/10781552251348222', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495643\n",
      "{'doi': '10.1080/17581869.2025.2515010', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495635\n",
      "{'doi': '10.3760/cma.j.cn112137-20250212-00319', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495591\n",
      "{'doi': '10.1111/dom.16498', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495570\n",
      "{'doi': '10.1111/cen.15292', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495558\n",
      "{'doi': '10.56434/j.arch.esp.urol.20257804.63', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495505\n",
      "{'doi': '10.1002/dmrr.2436', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495492\n",
      "{'doi': None, 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495485\n",
      "{'doi': '10.24171/j.phrp.2024.0310', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495438\n",
      "{'doi': '10.1111/hdi.13271', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495433\n",
      "{'doi': '10.4103/aam.aam_40_25', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495415\n",
      "{'doi': '10.4103/aam.aam_20_25', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495414\n",
      "{'doi': '10.1111/obr.13963', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495402\n",
      "{'doi': '10.1002/jia2.26525', 'pmcid': 'PMC5516957'}\n",
      "PDF URL for PubMed UID 40495360: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516957/pdf/\n",
      "{'doi': '10.1093/rheumatology/keaf320', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495344\n",
      "{'doi': '10.1111/dme.70085', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495317\n",
      "{'doi': '10.5588/ijtld.24.0592', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40495301\n",
      "{'doi': '10.1007/s10067-014-2707-y', 'pmcid': 'PMC4782794'}\n",
      "PDF URL for PubMed UID 40495273: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782794/pdf/\n",
      "{'doi': '10.1186/s13098-025-01739-z', 'pmcid': 'PMC8080329'}\n",
      "PDF URL for PubMed UID 40495246: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080329/pdf/\n",
      "{'doi': '10.1186/s42466-025-00393-0', 'pmcid': 'PMC10770823'}\n",
      "PDF URL for PubMed UID 40495231: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770823/pdf/\n",
      "{'doi': '10.1186/s10020-025-01282-7', 'pmcid': 'PMC8429074'}\n",
      "PDF URL for PubMed UID 40495121: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429074/pdf/\n",
      "{'doi': '10.1186/s12891-015-0819-4', 'pmcid': '6658091'}\n",
      "PDF URL for PubMed UID 40495045: https://www.ncbi.nlm.nih.gov/pmc/articles/6658091/pdf/\n",
      "{'doi': '10.1172/jci.insight.84969', 'pmcid': '4782154'}\n",
      "PDF URL for PubMed UID 40495031: https://www.ncbi.nlm.nih.gov/pmc/articles/4782154/pdf/\n",
      "{'doi': '10.1016/s0022-2836(02)01044-6', 'pmcid': '10491969'}\n",
      "PDF URL for PubMed UID 40495021: https://www.ncbi.nlm.nih.gov/pmc/articles/10491969/pdf/\n",
      "{'doi': '10.4239/wjd.v6.i8.1024', 'pmcid': '3340592'}\n",
      "PDF URL for PubMed UID 40494867: https://www.ncbi.nlm.nih.gov/pmc/articles/3340592/pdf/\n",
      "{'doi': '10.1038/s41387-025-00383-w', 'pmcid': 'PMC5507830'}\n",
      "PDF URL for PubMed UID 40494849: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507830/pdf/\n",
      "{'doi': '10.1021/jacs.5c08198', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494834\n",
      "{'doi': '10.3760/cma.j.cn112338-20240924-00595', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494801\n",
      "{'doi': '10.3760/cma.j.cn112338-20240904-00549', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494796\n",
      "{'doi': '10.3760/cma.j.cn112338-20240909-0056', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494792\n",
      "{'doi': '10.3760/cma.j.cn112338-20241204-00771', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494789\n",
      "{'doi': '10.3760/cma.j.cn112338-20250115-00040', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494783\n",
      "{'doi': '10.1016/j.pcd.2025.05.010', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494751\n",
      "{'doi': '10.1016/j.clinthera.2025.05.002', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494747\n",
      "{'doi': '10.1016/j.jacl.2025.03.015', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494715\n",
      "{'doi': '10.1136/bmjdrc-2020-001529', 'pmcid': 'PMC7678236'}\n",
      "PDF URL for PubMed UID 40494660: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678236/pdf/\n",
      "{'doi': '10.1136/bmj.r1175', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494612\n",
      "{'doi': '10.5853/jos.2024.05057', 'pmcid': 'PMC5852439'}\n",
      "PDF URL for PubMed UID 40494587: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852439/pdf/\n",
      "{'doi': '10.5853/jos.2024.04623', 'pmcid': 'PMC11554860'}\n",
      "PDF URL for PubMed UID 40494575: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554860/pdf/\n",
      "{'doi': '10.1055/a-2500-1026', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494540\n",
      "{'doi': '10.1016/j.bbi.2025.06.014', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494504\n",
      "{'doi': '10.1016/j.metabol.2025.156323', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494442\n",
      "{'doi': '10.1016/j.lfs.2025.123803', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494433\n",
      "{'doi': '10.1016/j.ejphar.2025.177826', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494432\n",
      "{'doi': '10.1016/j.ejps.2025.107161', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494429\n",
      "{'doi': '10.1016/j.neuroscience.2025.06.009', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494410\n",
      "{'doi': '10.5397/cise.2024.00969', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494391\n",
      "{'doi': '10.1016/j.cell.2025.05.012', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494346\n",
      "{'doi': '10.1159/000545587', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494338\n",
      "{'doi': '10.4269/ajtmh.24-0550', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494329\n",
      "{'doi': '10.1016/j.compbiomed.2025.110542', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494169\n",
      "{'doi': '10.1016/j.sbi.2025.103075', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494165\n",
      "{'doi': '10.1016/j.aprim.2025.103301', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494157\n",
      "{'doi': '10.1016/j.preghy.2025.101226', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494156\n",
      "{'doi': '10.1016/j.biomaterials.2025.123489', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494023\n",
      "{'doi': '10.1016/j.biomaterials.2025.123462', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494022\n",
      "{'doi': '10.1016/j.biomaterials.2025.123463', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494021\n",
      "{'doi': '10.1016/j.jchf.2025.03.042', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40494011\n",
      "{'doi': '10.1016/j.transci.2025.104172', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493980\n",
      "{'doi': '10.1177/00912174251350817', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493966\n",
      "{'doi': '10.2196/68915', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493913\n",
      "{'doi': '10.1200/OP-24-01032', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493870\n",
      "{'doi': '10.7705/biomedica.7638', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493832\n",
      "{'doi': '10.7705/biomedica.7486', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493824\n",
      "{'doi': '10.1097/ACO.0000000000001522', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493797\n",
      "{'doi': '10.1093/labmed/lmaf021', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493766\n",
      "{'doi': '10.3109/09638288.2015.1130178', 'pmcid': 'PMC8024127'}\n",
      "PDF URL for PubMed UID 40493690: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024127/pdf/\n",
      "{'doi': '10.2196/62876', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493665\n",
      "{'doi': '10.1519/JSC.0000000000005164', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493636\n",
      "{'doi': '10.1016/j.cca.2019.10.015', 'pmcid': 'PMC5397986'}\n",
      "PDF URL for PubMed UID 40493627: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397986/pdf/\n",
      "{'doi': '10.1016/j.kint.2015.12.043', 'pmcid': 'PMC4800337'}\n",
      "PDF URL for PubMed UID 40493603: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800337/pdf/\n",
      "{'doi': '10.1007/s10792-021-01914-x', 'pmcid': 'PMC5693005'}\n",
      "PDF URL for PubMed UID 40493602: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693005/pdf/\n",
      "{'doi': '10.1177/0962280211419832', 'pmcid': 'PMC5308803'}\n",
      "PDF URL for PubMed UID 40493559: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308803/pdf/\n",
      "{'doi': '10.1093/eurpub/ckaf079', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493527\n",
      "{'doi': '10.2196/64051', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493506\n",
      "{'doi': '10.1172/JCI188584', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493413\n",
      "{'doi': '10.1056/NEJMoa1306033', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493410\n",
      "{'doi': '10.1172/jci.insight.181298', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493405\n",
      "{'doi': '10.1080/03007995.2025.2517697', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493381\n",
      "{'doi': '10.1016/j.lfs.2019.116776', 'pmcid': '11458150'}\n",
      "PDF URL for PubMed UID 40493329: https://www.ncbi.nlm.nih.gov/pmc/articles/11458150/pdf/\n",
      "{'doi': '10.1007/s13300-024-01584-9', 'pmcid': '11211310'}\n",
      "PDF URL for PubMed UID 40493295: https://www.ncbi.nlm.nih.gov/pmc/articles/11211310/pdf/\n",
      "{'doi': '10.1038/sj.ki.5002481', 'pmcid': '3879360'}\n",
      "PDF URL for PubMed UID 40493280: https://www.ncbi.nlm.nih.gov/pmc/articles/3879360/pdf/\n",
      "{'doi': '10.1080/1062936X.2025.2514061', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493266\n",
      "{'doi': '10.1210/clinem/dgad223', 'pmcid': '5024687'}\n",
      "PDF URL for PubMed UID 40493262: https://www.ncbi.nlm.nih.gov/pmc/articles/5024687/pdf/\n",
      "{'doi': '10.1136/practneurol-2019-002335', 'pmcid': '1711284'}\n",
      "PDF URL for PubMed UID 40493245: https://www.ncbi.nlm.nih.gov/pmc/articles/1711284/pdf/\n",
      "{'doi': '10.1136/jech-2022-219267', 'pmcid': '4912021'}\n",
      "PDF URL for PubMed UID 40493225: https://www.ncbi.nlm.nih.gov/pmc/articles/4912021/pdf/\n",
      "{'doi': '10.1073/pnas.2506321122', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493192\n",
      "{'doi': '10.1007/s00198-015-3318-4', 'pmcid': '7556442'}\n",
      "PDF URL for PubMed UID 40493166: https://www.ncbi.nlm.nih.gov/pmc/articles/7556442/pdf/\n",
      "{'doi': '10.1056/NEJMoa2314051', 'pmcid': '9992115'}\n",
      "PDF URL for PubMed UID 40493165: https://www.ncbi.nlm.nih.gov/pmc/articles/9992115/pdf/\n",
      "{'doi': '10.1016/j.exer.2018.10.009', 'pmcid': '11592768'}\n",
      "PDF URL for PubMed UID 40493162: https://www.ncbi.nlm.nih.gov/pmc/articles/11592768/pdf/\n",
      "{'doi': '10.1086/321856', 'pmcid': '4832051'}\n",
      "PDF URL for PubMed UID 40493151: https://www.ncbi.nlm.nih.gov/pmc/articles/4832051/pdf/\n",
      "{'doi': '10.1177/15394492231172933', 'pmcid': '7098706'}\n",
      "PDF URL for PubMed UID 40493144: https://www.ncbi.nlm.nih.gov/pmc/articles/7098706/pdf/\n",
      "{'doi': '10.1038/s41401-021-00635-2', 'pmcid': '8721251'}\n",
      "PDF URL for PubMed UID 40493135: https://www.ncbi.nlm.nih.gov/pmc/articles/8721251/pdf/\n",
      "{'doi': '10.1111/myc.13762', 'pmcid': '5105268'}\n",
      "PDF URL for PubMed UID 40493110: https://www.ncbi.nlm.nih.gov/pmc/articles/5105268/pdf/\n",
      "{'doi': '10.1007/s40123-025-01173-4', 'pmcid': '7759936'}\n",
      "PDF URL for PubMed UID 40493108: https://www.ncbi.nlm.nih.gov/pmc/articles/7759936/pdf/\n",
      "{'doi': '10.1097/IAE.0000000000001280', 'pmcid': '6233839'}\n",
      "PDF URL for PubMed UID 40493103: https://www.ncbi.nlm.nih.gov/pmc/articles/6233839/pdf/\n",
      "{'doi': '10.2147/PPA.S118396', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493097\n",
      "{'doi': '10.3389/fendo.2018.00431', 'pmcid': '11090168'}\n",
      "PDF URL for PubMed UID 40493069: https://www.ncbi.nlm.nih.gov/pmc/articles/11090168/pdf/\n",
      "{'doi': '10.1007/s00048-025-00419-3', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40493055\n",
      "{'doi': '10.1111/jdi.70077', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492931\n",
      "{'doi': '10.1111/jdi.70095', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492908\n",
      "{'doi': '10.1002/adhm.202500688', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492903\n",
      "{'doi': '10.1111/jep.70132', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492893\n",
      "{'doi': '10.1002/adma.202504829', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492891\n",
      "{'doi': '10.1021/acs.analchem.5c00973', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492875\n",
      "{'doi': '10.1186/s12948-018-0094-7', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492872\n",
      "{'doi': '10.1128/mra.00362-25', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492780\n",
      "{'doi': '10.1128/spectrum.00892-25', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492760\n",
      "{'doi': '10.1128/msystems.00369-25', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492727\n",
      "{'doi': '10.1111/ans.70213', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492668\n",
      "{'doi': '10.1111/birt.12923', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492660\n",
      "{'doi': '10.1111/nep.70064', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492646\n",
      "{'doi': '10.1111/adj.13082', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492643\n",
      "{'doi': '10.1097/PRS.0000000000012246', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492638\n",
      "{'doi': '10.1097/XCS.0000000000001479', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492628\n",
      "{'doi': '10.1177/10497323251334543', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492602\n",
      "{'doi': '10.1021/acschemneuro.5c00278', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492583\n",
      "{'doi': '10.1093/ije/dyaf057', 'pmcid': 'PMC5338341'}\n",
      "PDF URL for PubMed UID 40492563: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338341/pdf/\n",
      "{'doi': '10.1111/aos.17535', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492525\n",
      "{'doi': '10.1002/advs.202500141', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492515\n",
      "{'doi': '10.1177/03000605251347414', 'pmcid': 'PMC11037091'}\n",
      "PDF URL for PubMed UID 40492483: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037091/pdf/\n",
      "{'doi': '10.1111/1753-0407.70109', 'pmcid': 'PMC8967557'}\n",
      "PDF URL for PubMed UID 40492481: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967557/pdf/\n",
      "{'doi': '10.1097/BRS.0000000000005420', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492477\n",
      "{'doi': '10.1111/jdi.70094', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492436\n",
      "{'doi': '10.12968/bjon.2025.34.Sup12a.S1', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492420\n",
      "{'doi': '10.1177/19322968221139514', 'pmcid': 'PMC10012354'}\n",
      "PDF URL for PubMed UID 40492314: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012354/pdf/\n",
      "{'doi': '10.1161/CIRCRESAHA.125.326303', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40492308\n",
      "{'doi': '10.2337/dsi21-0017', 'pmcid': 'PMC8914588'}\n",
      "PDF URL for PubMed UID 40492301: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914588/pdf/\n",
      "{'doi': '10.1056/NEJMoa2107038', 'pmcid': 'PMC5072433'}\n",
      "PDF URL for PubMed UID 40492240: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072433/pdf/\n",
      "{'doi': '10.12997/jla.2025.14.2.190', 'pmcid': 'PMC10917854'}\n",
      "PDF URL for PubMed UID 40492185: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917854/pdf/\n",
      "{'doi': '10.12997/jla.2025.14.2.200', 'pmcid': 'PMC10708148'}\n",
      "PDF URL for PubMed UID 40492180: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10708148/pdf/\n",
      "{'doi': '10.1002/brb3.3508', 'pmcid': 'PMC11061203'}\n",
      "PDF URL for PubMed UID 40492113: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061203/pdf/\n",
      "{'doi': '10.1101/2025.05.29.25328357', 'pmcid': 'PMC12148259'}\n",
      "PDF URL for PubMed UID 40492077: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148259/pdf/\n",
      "{'doi': '10.1101/2025.05.12.25327446', 'pmcid': 'PMC12148068'}\n",
      "PDF URL for PubMed UID 40492074: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148068/pdf/\n",
      "{'doi': '10.1101/2025.05.28.25328527', 'pmcid': 'PMC12148267'}\n",
      "PDF URL for PubMed UID 40492070: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148267/pdf/\n",
      "{'doi': '10.1101/2025.05.26.25328184', 'pmcid': 'PMC12148286'}\n",
      "PDF URL for PubMed UID 40492061: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148286/pdf/\n",
      "{'doi': '10.1007/s10068-024-01775-x', 'pmcid': 'PMC9179970'}\n",
      "PDF URL for PubMed UID 40492034: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179970/pdf/\n",
      "{'doi': '10.1016/J.FOODCHEM.2023.137683', 'pmcid': 'PMC11499762'}\n",
      "PDF URL for PubMed UID 40491979: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499762/pdf/\n",
      "{'doi': '10.1016/j.oret.2019.09.012', 'pmcid': 'PMC7812781'}\n",
      "PDF URL for PubMed UID 40491952: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812781/pdf/\n",
      "{'doi': '10.1097/BOR.0b013e32834ff2fd', 'pmcid': 'PMC11268070'}\n",
      "PDF URL for PubMed UID 40491938: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268070/pdf/\n",
      "{'doi': '10.1016/j.vhri.2019.06.003', 'pmcid': 'PMC11759368'}\n",
      "PDF URL for PubMed UID 40491900: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759368/pdf/\n",
      "{'doi': '10.1016/j.mmcr.2025.100707', 'pmcid': 'PMC10057210'}\n",
      "PDF URL for PubMed UID 40491812: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057210/pdf/\n",
      "{'doi': '10.1177/16094069231168485', 'pmcid': 'PMC3398063'}\n",
      "PDF URL for PubMed UID 40491780: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398063/pdf/\n",
      "{'doi': '10.1093/rap/rkaf050', 'pmcid': 'PMC8313211'}\n",
      "PDF URL for PubMed UID 40491747: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313211/pdf/\n",
      "{'doi': '10.5409/wjcp.v14.i2.103442', 'pmcid': 'PMC11572618'}\n",
      "PDF URL for PubMed UID 40491732: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572618/pdf/\n",
      "{'doi': '10.5409/wjcp.v14.i2.102922', 'pmcid': 'PMC10985863'}\n",
      "PDF URL for PubMed UID 40491728: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985863/pdf/\n",
      "{'doi': '10.2337/dc07-1183', 'pmcid': 'PMC6019415'}\n",
      "PDF URL for PubMed UID 40491723: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019415/pdf/\n",
      "{'doi': '10.1016/j.jid.2024.02.015', 'pmcid': 'PMC11602385'}\n",
      "PDF URL for PubMed UID 40491720: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602385/pdf/\n",
      "{'doi': '10.1007/s40200-025-01659-9', 'pmcid': 'PMC5674029'}\n",
      "PDF URL for PubMed UID 40491693: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674029/pdf/\n",
      "{'doi': '10.1007/s40200-025-01649-x', 'pmcid': 'PMC3561609'}\n",
      "PDF URL for PubMed UID 40491692: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561609/pdf/\n",
      "{'doi': '10.1007/s40200-025-01660-2', 'pmcid': 'PMC9575088'}\n",
      "PDF URL for PubMed UID 40491691: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575088/pdf/\n",
      "{'doi': '10.1016/j.metop.2025.100370', 'pmcid': 'PMC11272983'}\n",
      "PDF URL for PubMed UID 40491672: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272983/pdf/\n",
      "{'doi': '10.1037/qup0000196', 'pmcid': 'PMC1615849'}\n",
      "PDF URL for PubMed UID 40491663: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1615849/pdf/\n",
      "{'doi': '10.7759/cureus.83766', 'pmcid': 'PMC6089731'}\n",
      "PDF URL for PubMed UID 40491653: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089731/pdf/\n",
      "{'doi': '10.7759/cureus.83820', 'pmcid': 'PMC7388696'}\n",
      "PDF URL for PubMed UID 40491648: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388696/pdf/\n",
      "{'doi': '10.7759/cureus.83849', 'pmcid': 'PMC11550460'}\n",
      "PDF URL for PubMed UID 40491642: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550460/pdf/\n",
      "{'doi': '10.7759/cureus.83764', 'pmcid': 'PMC7139151'}\n",
      "PDF URL for PubMed UID 40491639: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139151/pdf/\n",
      "{'doi': '10.7759/cureus.83843', 'pmcid': 'PMC11674702'}\n",
      "PDF URL for PubMed UID 40491630: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674702/pdf/\n",
      "{'doi': '10.1016/j.cgh.2023.06.004', 'pmcid': 'PMC10253495'}\n",
      "PDF URL for PubMed UID 40491599: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253495/pdf/\n",
      "{'doi': '10.3389/fendo.2023.1260623', 'pmcid': 'PMC10665905'}\n",
      "PDF URL for PubMed UID 40491592: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665905/pdf/\n",
      "{'doi': '10.1002/hep.510310320', 'pmcid': 'PMC8902381'}\n",
      "PDF URL for PubMed UID 40491591: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902381/pdf/\n",
      "{'doi': '10.1093/ajcn/86.2.353', 'pmcid': 'PMC3138470'}\n",
      "PDF URL for PubMed UID 40491590: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138470/pdf/\n",
      "{'doi': '10.3389/fendo.2019.00056', 'pmcid': 'PMC6439528'}\n",
      "PDF URL for PubMed UID 40491573: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439528/pdf/\n",
      "{'doi': '10.1016/j.reth.2025.05.002', 'pmcid': 'PMC8102863'}\n",
      "PDF URL for PubMed UID 40491561: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102863/pdf/\n",
      "{'doi': '10.1016/j.reth.2025.04.020', 'pmcid': 'PMC8151502'}\n",
      "PDF URL for PubMed UID 40491560: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151502/pdf/\n",
      "{'doi': '10.1038/s41598-023-36334-7', 'pmcid': 'PMC10241780'}\n",
      "PDF URL for PubMed UID 40491524: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241780/pdf/\n",
      "{'doi': '10.1093/ibd/izy022', 'pmcid': 'PMC6939601'}\n",
      "PDF URL for PubMed UID 40491488: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939601/pdf/\n",
      "{'doi': '10.1177/02601060251348690', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491338\n",
      "{'doi': '10.1177/08258597251348106', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491309\n",
      "{'doi': '10.1177/10781552251340330', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491298\n",
      "{'doi': '10.1111/gtc.70032', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491292\n",
      "{'doi': '10.1002/jpn3.70098', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491247\n",
      "{'doi': '10.1002/jsfa.14430', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491243\n",
      "{'doi': '10.1002/oby.24331', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491239\n",
      "{'doi': '10.1111/ceo.14560', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491217\n",
      "{'doi': '10.1093/stmcls/sxaf036', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491209\n",
      "{'doi': '10.12659/AOT.948531', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491035\n",
      "{'doi': '10.1111/jsr.70106', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40491001\n",
      "{'doi': '10.1002/biot.70046', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40490976\n",
      "{'doi': '10.1080/17441692.2025.2516700', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40490942\n",
      "{'doi': '10.1002/ccd.31678', 'pmcid': None}\n",
      "No PDF URL found for PubMed UID 40490912\n",
      "{'doi': '10.1186/s13098-025-01794-6', 'pmcid': 'PMC4686952'}\n",
      "PDF URL for PubMed UID 40490835: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686952/pdf/\n",
      "{'doi': '10.27438/d.cnki.gyadu.2023.001025', 'pmcid': 'PMC11102959'}\n",
      "PDF URL for PubMed UID 40490808: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102959/pdf/\n",
      "{'doi': '10.1186/s13098-025-01787-5', 'pmcid': 'PMC11593722'}\n",
      "PDF URL for PubMed UID 40490778: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593722/pdf/\n",
      "{'doi': '10.1186/s13098-025-01738-0', 'pmcid': 'PMC7363031'}\n",
      "PDF URL for PubMed UID 40490774: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363031/pdf/\n",
      "{'doi': '10.1186/s12944-025-02615-5', 'pmcid': 'PMC11836863'}\n",
      "PDF URL for PubMed UID 40490769: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836863/pdf/\n",
      "{'doi': '10.1186/s12913-025-12949-6', 'pmcid': 'PMC10748758'}\n",
      "PDF URL for PubMed UID 40490764: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10748758/pdf/\n",
      "{'doi': '10.1186/s12906-021-03334-x', 'pmcid': 'PMC7773103'}\n",
      "PDF URL for PubMed UID 40490758: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773103/pdf/\n",
      "{'doi': '10.1186/s12913-025-12944-x', 'pmcid': 'PMC7745163'}\n",
      "PDF URL for PubMed UID 40490754: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745163/pdf/\n",
      "{'doi': '10.1186/s12933-025-02786-6', 'pmcid': 'PMC6520497'}\n",
      "PDF URL for PubMed UID 40490745: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520497/pdf/\n",
      "{'doi': '10.1186/s12875-025-02903-0', 'pmcid': 'PMC11443976'}\n",
      "PDF URL for PubMed UID 40490741: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443976/pdf/\n",
      "{'doi': '10.1186/s12902-025-01908-1', 'pmcid': 'PMC4258676'}\n",
      "PDF URL for PubMed UID 40490726: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258676/pdf/\n",
      "{'doi': '10.1186/s12902-025-01970-9', 'pmcid': 'PMC4688585'}\n",
      "PDF URL for PubMed UID 40490694: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688585/pdf/\n",
      "{'doi': '10.1186/s12902-025-01964-7', 'pmcid': 'PMC4967355'}\n",
      "PDF URL for PubMed UID 40490690: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967355/pdf/\n",
      "{'doi': '10.1159/000437305', 'pmcid': '6161418'}\n",
      "PDF URL for PubMed UID 40490670: https://www.ncbi.nlm.nih.gov/pmc/articles/6161418/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/8746094/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/5817484/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/1421079/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/11402763/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/43011/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/8238964/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/10631563/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1170910/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240731/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593555/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944043/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048272/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10901469/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678592/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182795/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749585/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903966/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927962/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319353/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518801/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689591/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111968/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838321/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425924/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794640/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928893/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300517/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798588/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420631/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753766/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971783/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486838/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001611/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998224/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772805/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657387/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792330/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554943/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005231/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841437/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066580/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654390/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563792/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192941/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101251/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769059/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036809/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150434/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273632/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972490/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943005/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116486/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11162066/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969339/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276667/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338825/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552560/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062204/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772083/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972781/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015298/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480053/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890267/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898168/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317059/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274216/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379170/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515346/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599550/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC436321/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895563/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532110/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141681/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621967/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516957/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782794/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080329/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770823/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429074/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/6658091/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/4782154/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/10491969/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/3340592/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507830/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678236/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852439/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554860/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024127/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397986/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800337/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693005/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308803/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/11458150/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/11211310/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/3879360/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/5024687/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/1711284/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/4912021/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/7556442/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/9992115/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/11592768/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/4832051/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/7098706/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/8721251/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/5105268/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/7759936/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/6233839/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/11090168/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338341/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037091/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967557/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012354/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914588/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072433/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917854/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10708148/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061203/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148259/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148068/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148267/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148286/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179970/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499762/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812781/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268070/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759368/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057210/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398063/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313211/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572618/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985863/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019415/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602385/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674029/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561609/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575088/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272983/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1615849/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089731/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388696/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550460/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139151/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674702/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253495/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665905/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902381/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138470/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439528/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102863/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151502/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241780/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939601/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686952/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102959/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593722/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363031/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836863/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10748758/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773103/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745163/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520497/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443976/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258676/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688585/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967355/pdf/\n",
      "https://www.ncbi.nlm.nih.gov/pmc/articles/6161418/pdf/\n"
     ]
    }
   ],
   "source": [
    "pubmed_pmc_pdf_urls = []\n",
    "for doc in pubmed_docs:\n",
    "    uid = doc.metadata.get(\"uid\")\n",
    "    if uid:\n",
    "        metadata= fetch_article_metadata(uid)\n",
    "        print(metadata)\n",
    "        pdf_url = get_pdf_url_from_metadata(metadata)\n",
    "        if pdf_url:\n",
    "            print(f\"PDF URL for PubMed UID {uid}: {pdf_url}\")\n",
    "            pubmed_pmc_pdf_urls.append(pdf_url)\n",
    "        else:\n",
    "            print(f\"No PDF URL found for PubMed UID {uid}\")\n",
    "        time.sleep(1)  \n",
    "        \n",
    "\n",
    "for url in pubmed_pmc_pdf_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "167"
      ]
     },
     "execution_count": 150,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(pubmed_pmc_pdf_urls)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://pubmed.ncbi.nlm.nih.gov/40498532/'"
      ]
     },
     "execution_count": 152,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_pdf_urls[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "pubmed_pmc_pdf_urls = []\n",
    "for doc in pubmed_docs:\n",
    "    uid = doc.metadata.get(\"uid\")\n",
    "    if uid:\n",
    "        metadata= fetch_article_metadata(uid)\n",
    "        print(metadata)\n",
    "        pdf_url = get_pdf_url_from_metadata(metadata)\n",
    "        if pdf_url:\n",
    "            print(f\"PDF URL for PubMed UID {uid}: {pdf_url}\")\n",
    "            pubmed_pmc_pdf_urls.append(pdf_url)\n",
    "        else:\n",
    "            print(f\"No PDF URL found for PubMed UID {uid}\")\n",
    "        time.sleep(1)  \n",
    "        \n",
    "\n",
    "for url in pubmed_pmc_pdf_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Read PDF from URL"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 160,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://www.ncbi.nlm.nih.gov/pmc/articles/8746094/pdf/'"
      ]
     },
     "execution_count": 160,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_pmc_pdf_urls[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 164,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Status Code: 200\n",
      "Content-Type: text/html; charset=utf-8\n",
      "Content-Length: 1285\n",
      "b'\\n\\n\\n\\n<html>\\n  <head>\\n    <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\\n    <title>Preparing to download ...</title>\\n    <style type=\"text/css\">\\n      body{font-size:1rem;line-h'\n"
     ]
    },
    {
     "ename": "ValueError",
     "evalue": "Not a valid PDF file, got HTML instead.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[164], line 18\u001b[0m\n\u001b[1;32m     16\u001b[0m \u001b[38;5;28mprint\u001b[39m(response\u001b[38;5;241m.\u001b[39mcontent[:\u001b[38;5;241m200\u001b[39m])  \u001b[38;5;66;03m# Peek at start of file\u001b[39;00m\n\u001b[1;32m     17\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m response\u001b[38;5;241m.\u001b[39mheaders\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mContent-Type\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m)\u001b[38;5;241m.\u001b[39mstartswith(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mapplication/pdf\u001b[39m\u001b[38;5;124m\"\u001b[39m):\n\u001b[0;32m---> 18\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mNot a valid PDF file, got HTML instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m     19\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m response\u001b[38;5;241m.\u001b[39mstatus_code \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m200\u001b[39m:\n\u001b[1;32m     20\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mFailed to download PDF. Status code: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mresponse\u001b[38;5;241m.\u001b[39mstatus_code\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n",
      "\u001b[0;31mValueError\u001b[0m: Not a valid PDF file, got HTML instead."
     ]
    }
   ],
   "source": [
    "from io import BytesIO\n",
    "import requests\n",
    "import fitz  # pymupdf\n",
    "\n",
    "pdf_url = pubmed_pmc_pdf_urls[0]\n",
    "headers = {\n",
    "    \"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64)\",\n",
    "    \"Referer\": \"https://www.ncbi.nlm.nih.gov/\"\n",
    "}\n",
    "session = requests.Session()\n",
    "response = session.get(url, headers=headers, allow_redirects=True)\n",
    "\n",
    "print(\"Status Code:\", response.status_code)\n",
    "print(\"Content-Type:\", response.headers.get(\"Content-Type\"))\n",
    "print(\"Content-Length:\", len(response.content))\n",
    "print(response.content[:200])  # Peek at start of file\n",
    "if not response.headers.get(\"Content-Type\", \"\").startswith(\"application/pdf\"):\n",
    "    raise ValueError(\"Not a valid PDF file, got HTML instead.\")\n",
    "if response.status_code != 200:\n",
    "    raise ValueError(f\"Failed to download PDF. Status code: {response.status_code}\")\n",
    "\n",
    "pdf_stream = BytesIO(response.content)\n",
    "pdf = fitz.open(stream=pdf_stream, filetype=\"pdf\")\n",
    "print(\"✅ PDF loaded successfully. Page count:\", pdf.page_count)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 163,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Content-Type: text/html; charset=utf-8\n",
      "Content-Length: 1285\n"
     ]
    }
   ],
   "source": [
    "content_type = response.headers.get(\"Content-Type\", \"\")\n",
    "content_length = len(response.content)\n",
    "print(\"Content-Type:\", content_type)\n",
    "print(\"Content-Length:\", content_length)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 162,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document('None', <memory, doc# 322>)"
      ]
     },
     "execution_count": 162,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://pubmed.ncbi.nlm.nih.gov/40498532/\n",
      "Document('None', <memory, doc# 285>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498486/\n",
      "Document('None', <memory, doc# 286>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498480/\n",
      "Document('None', <memory, doc# 287>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498478/\n",
      "Document('None', <memory, doc# 288>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498412/\n",
      "Document('None', <memory, doc# 289>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498369/\n",
      "Document('None', <memory, doc# 290>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498355/\n",
      "Document('None', <memory, doc# 291>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498290/\n",
      "Document('None', <memory, doc# 292>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498287/\n",
      "Document('None', <memory, doc# 293>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498212/\n",
      "Document('None', <memory, doc# 294>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498198/\n",
      "Document('None', <memory, doc# 295>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498168/\n",
      "Document('None', <memory, doc# 296>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498128/\n",
      "Document('None', <memory, doc# 297>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498074/\n",
      "Document('None', <memory, doc# 298>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498052/\n",
      "Document('None', <memory, doc# 299>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40498015/\n",
      "Document('None', <memory, doc# 300>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497986/\n",
      "Document('None', <memory, doc# 301>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497970/\n",
      "Document('None', <memory, doc# 302>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497936/\n",
      "Document('None', <memory, doc# 303>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497934/\n",
      "Document('None', <memory, doc# 304>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497928/\n",
      "Document('None', <memory, doc# 305>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497767/\n",
      "Document('None', <memory, doc# 306>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497659/\n",
      "Document('None', <memory, doc# 307>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497571/\n",
      "Document('None', <memory, doc# 308>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497566/\n",
      "Document('None', <memory, doc# 309>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497539/\n",
      "Document('None', <memory, doc# 310>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497520/\n",
      "Document('None', <memory, doc# 311>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497515/\n",
      "Document('None', <memory, doc# 312>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497501/\n",
      "Document('None', <memory, doc# 313>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497454/\n",
      "Document('None', <memory, doc# 314>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497427/\n",
      "Document('None', <memory, doc# 315>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497406/\n",
      "Document('None', <memory, doc# 316>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497377/\n",
      "Document('None', <memory, doc# 317>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497366/\n",
      "Document('None', <memory, doc# 318>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497353/\n",
      "Document('None', <memory, doc# 319>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497345/\n",
      "Document('None', <memory, doc# 320>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497343/\n",
      "Document('None', <memory, doc# 321>)\n",
      "https://pubmed.ncbi.nlm.nih.gov/40497340/\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[158], line 3\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m pdf_url \u001b[38;5;129;01min\u001b[39;00m pubmed_pdf_urls:\n\u001b[1;32m      2\u001b[0m     \u001b[38;5;28mprint\u001b[39m(pdf_url)\n\u001b[0;32m----> 3\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mrequests\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[43mpdf_url\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m      4\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m response\u001b[38;5;241m.\u001b[39mstatus_code \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m200\u001b[39m:\n\u001b[1;32m      5\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mFailed to download PDF. Status code: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mresponse\u001b[38;5;241m.\u001b[39mstatus_code\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/requests/api.py:73\u001b[0m, in \u001b[0;36mget\u001b[0;34m(url, params, **kwargs)\u001b[0m\n\u001b[1;32m     62\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mget\u001b[39m(url, params\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m     63\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124mr\u001b[39m\u001b[38;5;124;03m\"\"\"Sends a GET request.\u001b[39;00m\n\u001b[1;32m     64\u001b[0m \n\u001b[1;32m     65\u001b[0m \u001b[38;5;124;03m    :param url: URL for the new :class:`Request` object.\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m     70\u001b[0m \u001b[38;5;124;03m    :rtype: requests.Response\u001b[39;00m\n\u001b[1;32m     71\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[0;32m---> 73\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mget\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mparams\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mparams\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/requests/api.py:59\u001b[0m, in \u001b[0;36mrequest\u001b[0;34m(method, url, **kwargs)\u001b[0m\n\u001b[1;32m     55\u001b[0m \u001b[38;5;66;03m# By using the 'with' statement we are sure the session is closed, thus we\u001b[39;00m\n\u001b[1;32m     56\u001b[0m \u001b[38;5;66;03m# avoid leaving sockets open which can trigger a ResourceWarning in some\u001b[39;00m\n\u001b[1;32m     57\u001b[0m \u001b[38;5;66;03m# cases, and look like a memory leak in others.\u001b[39;00m\n\u001b[1;32m     58\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m sessions\u001b[38;5;241m.\u001b[39mSession() \u001b[38;5;28;01mas\u001b[39;00m session:\n\u001b[0;32m---> 59\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43msession\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmethod\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43murl\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/requests/sessions.py:589\u001b[0m, in \u001b[0;36mSession.request\u001b[0;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[1;32m    584\u001b[0m send_kwargs \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m    585\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtimeout\u001b[39m\u001b[38;5;124m\"\u001b[39m: timeout,\n\u001b[1;32m    586\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mallow_redirects\u001b[39m\u001b[38;5;124m\"\u001b[39m: allow_redirects,\n\u001b[1;32m    587\u001b[0m }\n\u001b[1;32m    588\u001b[0m send_kwargs\u001b[38;5;241m.\u001b[39mupdate(settings)\n\u001b[0;32m--> 589\u001b[0m resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mprep\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43msend_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    591\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m resp\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/requests/sessions.py:703\u001b[0m, in \u001b[0;36mSession.send\u001b[0;34m(self, request, **kwargs)\u001b[0m\n\u001b[1;32m    700\u001b[0m start \u001b[38;5;241m=\u001b[39m preferred_clock()\n\u001b[1;32m    702\u001b[0m \u001b[38;5;66;03m# Send the request\u001b[39;00m\n\u001b[0;32m--> 703\u001b[0m r \u001b[38;5;241m=\u001b[39m \u001b[43madapter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    705\u001b[0m \u001b[38;5;66;03m# Total elapsed time of the request (approximately)\u001b[39;00m\n\u001b[1;32m    706\u001b[0m elapsed \u001b[38;5;241m=\u001b[39m preferred_clock() \u001b[38;5;241m-\u001b[39m start\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/requests/adapters.py:667\u001b[0m, in \u001b[0;36mHTTPAdapter.send\u001b[0;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[1;32m    664\u001b[0m     timeout \u001b[38;5;241m=\u001b[39m TimeoutSauce(connect\u001b[38;5;241m=\u001b[39mtimeout, read\u001b[38;5;241m=\u001b[39mtimeout)\n\u001b[1;32m    666\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 667\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[43mconn\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43murlopen\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    668\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmethod\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    669\u001b[0m \u001b[43m        \u001b[49m\u001b[43murl\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    670\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    671\u001b[0m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    672\u001b[0m \u001b[43m        \u001b[49m\u001b[43mredirect\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    673\u001b[0m \u001b[43m        \u001b[49m\u001b[43massert_same_host\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    674\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpreload_content\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    675\u001b[0m \u001b[43m        \u001b[49m\u001b[43mdecode_content\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    676\u001b[0m \u001b[43m        \u001b[49m\u001b[43mretries\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmax_retries\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    677\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    678\u001b[0m \u001b[43m        \u001b[49m\u001b[43mchunked\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mchunked\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    679\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    681\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m (ProtocolError, \u001b[38;5;167;01mOSError\u001b[39;00m) \u001b[38;5;28;01mas\u001b[39;00m err:\n\u001b[1;32m    682\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mConnectionError\u001b[39;00m(err, request\u001b[38;5;241m=\u001b[39mrequest)\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/urllib3/connectionpool.py:716\u001b[0m, in \u001b[0;36mHTTPConnectionPool.urlopen\u001b[0;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, **response_kw)\u001b[0m\n\u001b[1;32m    713\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_prepare_proxy(conn)\n\u001b[1;32m    715\u001b[0m \u001b[38;5;66;03m# Make the request on the httplib connection object.\u001b[39;00m\n\u001b[0;32m--> 716\u001b[0m httplib_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_make_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    717\u001b[0m \u001b[43m    \u001b[49m\u001b[43mconn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    718\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    719\u001b[0m \u001b[43m    \u001b[49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    720\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout_obj\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    721\u001b[0m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    722\u001b[0m \u001b[43m    \u001b[49m\u001b[43mheaders\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    723\u001b[0m \u001b[43m    \u001b[49m\u001b[43mchunked\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mchunked\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    724\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    726\u001b[0m \u001b[38;5;66;03m# If we're going to release the connection in ``finally:``, then\u001b[39;00m\n\u001b[1;32m    727\u001b[0m \u001b[38;5;66;03m# the response doesn't need to know about the connection. Otherwise\u001b[39;00m\n\u001b[1;32m    728\u001b[0m \u001b[38;5;66;03m# it will also try to release it and we'll have a double-release\u001b[39;00m\n\u001b[1;32m    729\u001b[0m \u001b[38;5;66;03m# mess.\u001b[39;00m\n\u001b[1;32m    730\u001b[0m response_conn \u001b[38;5;241m=\u001b[39m conn \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m release_conn \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/urllib3/connectionpool.py:468\u001b[0m, in \u001b[0;36mHTTPConnectionPool._make_request\u001b[0;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[1;32m    463\u001b[0m             httplib_response \u001b[38;5;241m=\u001b[39m conn\u001b[38;5;241m.\u001b[39mgetresponse()\n\u001b[1;32m    464\u001b[0m         \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m    465\u001b[0m             \u001b[38;5;66;03m# Remove the TypeError from the exception chain in\u001b[39;00m\n\u001b[1;32m    466\u001b[0m             \u001b[38;5;66;03m# Python 3 (including for exceptions like SystemExit).\u001b[39;00m\n\u001b[1;32m    467\u001b[0m             \u001b[38;5;66;03m# Otherwise it looks like a bug in the code.\u001b[39;00m\n\u001b[0;32m--> 468\u001b[0m             \u001b[43msix\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mraise_from\u001b[49m\u001b[43m(\u001b[49m\u001b[43me\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m)\u001b[49m\n\u001b[1;32m    469\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m (SocketTimeout, BaseSSLError, SocketError) \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m    470\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_raise_timeout(err\u001b[38;5;241m=\u001b[39me, url\u001b[38;5;241m=\u001b[39murl, timeout_value\u001b[38;5;241m=\u001b[39mread_timeout)\n",
      "File \u001b[0;32m<string>:3\u001b[0m, in \u001b[0;36mraise_from\u001b[0;34m(value, from_value)\u001b[0m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/urllib3/connectionpool.py:463\u001b[0m, in \u001b[0;36mHTTPConnectionPool._make_request\u001b[0;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[1;32m    460\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m:\n\u001b[1;32m    461\u001b[0m     \u001b[38;5;66;03m# Python 3\u001b[39;00m\n\u001b[1;32m    462\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 463\u001b[0m         httplib_response \u001b[38;5;241m=\u001b[39m \u001b[43mconn\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetresponse\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    464\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[1;32m    465\u001b[0m         \u001b[38;5;66;03m# Remove the TypeError from the exception chain in\u001b[39;00m\n\u001b[1;32m    466\u001b[0m         \u001b[38;5;66;03m# Python 3 (including for exceptions like SystemExit).\u001b[39;00m\n\u001b[1;32m    467\u001b[0m         \u001b[38;5;66;03m# Otherwise it looks like a bug in the code.\u001b[39;00m\n\u001b[1;32m    468\u001b[0m         six\u001b[38;5;241m.\u001b[39mraise_from(e, \u001b[38;5;28;01mNone\u001b[39;00m)\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/http/client.py:1411\u001b[0m, in \u001b[0;36mHTTPConnection.getresponse\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1409\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m   1410\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m-> 1411\u001b[0m         \u001b[43mresponse\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mbegin\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1412\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mConnectionError\u001b[39;00m:\n\u001b[1;32m   1413\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mclose()\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/http/client.py:324\u001b[0m, in \u001b[0;36mHTTPResponse.begin\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    322\u001b[0m \u001b[38;5;66;03m# read until we get a non-100 response\u001b[39;00m\n\u001b[1;32m    323\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 324\u001b[0m     version, status, reason \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_read_status\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    325\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m status \u001b[38;5;241m!=\u001b[39m CONTINUE:\n\u001b[1;32m    326\u001b[0m         \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/http/client.py:285\u001b[0m, in \u001b[0;36mHTTPResponse._read_status\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    284\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_read_status\u001b[39m(\u001b[38;5;28mself\u001b[39m):\n\u001b[0;32m--> 285\u001b[0m     line \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mstr\u001b[39m(\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfp\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mreadline\u001b[49m\u001b[43m(\u001b[49m\u001b[43m_MAXLINE\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m)\u001b[49m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124miso-8859-1\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m    286\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(line) \u001b[38;5;241m>\u001b[39m _MAXLINE:\n\u001b[1;32m    287\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m LineTooLong(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstatus line\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/socket.py:707\u001b[0m, in \u001b[0;36mSocketIO.readinto\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    705\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[1;32m    706\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 707\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrecv_into\u001b[49m\u001b[43m(\u001b[49m\u001b[43mb\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    708\u001b[0m     \u001b[38;5;28;01mexcept\u001b[39;00m timeout:\n\u001b[1;32m    709\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_timeout_occurred \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/ssl.py:1249\u001b[0m, in \u001b[0;36mSSLSocket.recv_into\u001b[0;34m(self, buffer, nbytes, flags)\u001b[0m\n\u001b[1;32m   1245\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m flags \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[1;32m   1246\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m   1247\u001b[0m           \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mnon-zero flags not allowed in calls to recv_into() on \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m%\u001b[39m\n\u001b[1;32m   1248\u001b[0m           \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m)\n\u001b[0;32m-> 1249\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[43mnbytes\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbuffer\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1250\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1251\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28msuper\u001b[39m()\u001b[38;5;241m.\u001b[39mrecv_into(buffer, nbytes, flags)\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/ssl.py:1105\u001b[0m, in \u001b[0;36mSSLSocket.read\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m   1103\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m   1104\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m buffer \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m-> 1105\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sslobj\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mlen\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbuffer\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1106\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1107\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sslobj\u001b[38;5;241m.\u001b[39mread(\u001b[38;5;28mlen\u001b[39m)\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "for pdf_url in pubmed_pdf_urls:\n",
    "    print(pdf_url)\n",
    "    response = requests.get(pdf_url)\n",
    "    if response.status_code != 200:\n",
    "        raise ValueError(f\"Failed to download PDF. Status code: {response.status_code}\")\n",
    "\n",
    "    pdf_stream = BytesIO(response.content)\n",
    "    pdf = fitz.open(stream=pdf_stream, filetype=\"pdf\")\n",
    "    print(pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 167,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['12162178', '12162169', '12162160', '12162155', '12162150']\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "query = \"diabetes\"\n",
    "url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi\"\n",
    "params = {\n",
    "    \"db\": \"pmc\",\n",
    "    \"term\": query,\n",
    "    \"retmax\": 5,\n",
    "    \"retmode\": \"json\"\n",
    "}\n",
    "response = requests.get(url, params=params)\n",
    "uids = response.json()[\"esearchresult\"][\"idlist\"]\n",
    "print(uids)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_article_metadata(pmcid):\n",
    "    summary_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi\"\n",
    "    params = {\n",
    "        \"db\": \"pmc\",\n",
    "        \"id\": pmcid,\n",
    "        \"retmode\": \"json\"\n",
    "    }\n",
    "    r = requests.get(summary_url, params=params)\n",
    "    return r.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 169,
   "metadata": {},
   "outputs": [],
   "source": [
    "from io import BytesIO\n",
    "import fitz  # PyMuPDF\n",
    "\n",
    "def download_pmc_pdf(pmcid):\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC{pmcid}/pdf/\"\n",
    "    headers = {\n",
    "        \"User-Agent\": \"Mozilla/5.0\",\n",
    "        \"Referer\": \"https://www.ncbi.nlm.nih.gov/\"\n",
    "    }\n",
    "    r = requests.get(url, headers=headers, allow_redirects=True)\n",
    "\n",
    "    if r.status_code == 200 and r.headers.get(\"Content-Type\", \"\").startswith(\"application/pdf\"):\n",
    "        pdf_stream = BytesIO(r.content)\n",
    "        pdf = fitz.open(stream=pdf_stream, filetype=\"pdf\")\n",
    "        print(f\"Successfully downloaded and opened PDF for PMC{pmcid}\")\n",
    "        return pdf\n",
    "    else:\n",
    "        print(f\"Failed to download PDF for PMC{pmcid}. Content-Type: {r.headers.get('Content-Type')}\")\n",
    "        return None\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 170,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Failed to download PDF for PMC8746094. Content-Type: text/html; charset=utf-8\n",
      "Failed to download PDF for PMC8901234. Content-Type: text/html; charset=utf-8\n"
     ]
    }
   ],
   "source": [
    "uids = ['8746094', '8901234']\n",
    "for uid in uids:\n",
    "    pdf = download_pmc_pdf(uid)\n",
    "    if pdf:\n",
    "        print(f\"Title: {pdf.metadata.get('title')}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_pdf_link(pmcid):\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC{pmcid}/\"\n",
    "    r = requests.get(url)\n",
    "    soup = BeautifulSoup(r.text, \"html.parser\")\n",
    "    pdf_link = soup.find(\"a\", string=\"PDF\")\n",
    "    if pdf_link:\n",
    "        return \"https://www.ncbi.nlm.nih.gov\" + pdf_link.get(\"href\")\n",
    "    return None"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# TavilySearchAPIRetriever\n",
    "https://python.langchain.com/docs/integrations/retrievers/tavily/\n",
    "\n",
    ">[Tavily's Search API](https://tavily.com) is a search engine built specifically for AI agents (LLMs), delivering real-time, accurate, and factual results at speed.\n",
    "\n",
    "We can use this as a [retriever](/docs/how_to#retrievers). It will show functionality specific to this integration. After going through, it may be useful to explore [relevant use-case pages](/docs/how_to#qa-with-rag) to learn how to use this vectorstore as part of a larger chain.\n",
    "\n",
    "### Integration details\n",
    "\n",
    "import {ItemTable} from \"@theme/FeatureTables\";\n",
    "\n",
    "<ItemTable category=\"external_retrievers\" item=\"TavilySearchAPIRetriever\" />\n",
    "\n",
    "## Setup\n",
    "\n",
    "If you want to get automated tracing from individual queries, you can also set your [LangSmith](https://docs.smith.langchain.com/) API key by uncommenting below:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# os.environ[\"LANGSMITH_API_KEY\"] = getpass.getpass(\"Enter your LangSmith API key: \")\n",
    "# os.environ[\"LANGSMITH_TRACING\"] = \"true\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Installation\n",
    "\n",
    "The integration lives in the `langchain-community` package. We also need to install the `tavily-python` package itself."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install -qU langchain-community tavily-python"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [],
   "source": [
    "#import getpass\n",
    "import os\n",
    "\n",
    "#os.environ[\"TAVILY_API_KEY\"] = getpass.getpass()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"TAVILY_API_KEY\"] = \"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\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Instantiation\n",
    "\n",
    "Now we can instantiate our retriever:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.retrievers import TavilySearchAPIRetriever\n",
    "\n",
    "tavily_retriever = TavilySearchAPIRetriever(k=100,\n",
    "                                            include_raw_content = True,                                            \n",
    "                                            search_depth = \"advanced\",\n",
    "                                            include_domains=[\n",
    "                                            \"clinicaltrials.gov\", \"pubmed.ncbi.nlm.nih.gov\", \"arxiv.org\",\n",
    "                                            \"biorxiv.org\", \"medrxiv.org\", \"diabetes.org\", \"cdc.gov\", \"who.int\",\n",
    "                                            \"fda.gov\", \"ema.europa.eu\", \"nejm.org\", \"thelancet.com\", \"jamanetwork.com\",\n",
    "                                            \"nature.com\", \"sciencedirect.com\", \"springer.com\", \"cell.com\", \"biomedcentral.com\"\n",
    "                                            ]\n",
    "                                            )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "tavily_docs = tavily_retriever.invoke(\"Diabetes\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "38"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "len(tavily_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'title': 'diabetes and hearing loss-cross sectional study.docx',\n",
       " 'source': 'https://cdn.clinicaltrials.gov/large-docs/38/NCT06190938/Prot_SAP_000.pdf',\n",
       " 'score': 0.6533265,\n",
       " 'images': ['https://static.vecteezy.com/system/resources/previews/001/436/750/large_2x/diabetes-symptoms-information-infographic-free-vector.jpg',\n",
       "  'http://thumbs.dreamstime.com/z/types-diabetes-type-type-mellitus-insulin-dependent-mellitus-non-insulin-dependent-mellitus-39731814.jpg',\n",
       "  'https://thumbs.dreamstime.com/z/types-diabetes-simple-medical-vector-illustration-scheme-health-care-information-diagram-types-diabetes-simple-medical-115835865.jpg',\n",
       "  'https://lirp.cdn-website.com/69c0b277/dms3rep/multi/opt/Types+of+Diabetes-1920w.jpg',\n",
       "  'https://detsutah.com/wp-content/uploads/2023/05/DETS-Diabetes-Mellitus.jpg']}"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "tavily_docs[0].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'title': 'diabetes and hearing loss-cross sectional study.docx', 'source': 'https://cdn.clinicaltrials.gov/large-docs/38/NCT06190938/Prot_SAP_000.pdf', 'score': 0.6533265, 'images': ['https://static.vecteezy.com/system/resources/previews/001/436/750/large_2x/diabetes-symptoms-information-infographic-free-vector.jpg', 'http://thumbs.dreamstime.com/z/types-diabetes-type-type-mellitus-insulin-dependent-mellitus-non-insulin-dependent-mellitus-39731814.jpg', 'https://thumbs.dreamstime.com/z/types-diabetes-simple-medical-vector-illustration-scheme-health-care-information-diagram-types-diabetes-simple-medical-115835865.jpg', 'https://lirp.cdn-website.com/69c0b277/dms3rep/multi/opt/Types+of+Diabetes-1920w.jpg', 'https://detsutah.com/wp-content/uploads/2023/05/DETS-Diabetes-Mellitus.jpg']}, page_content='')"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "tavily_docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "import time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Latest breakthroughs in diabetes treatment 2024\n",
      "Novel approaches to curing type 1 and type 2 diabetes\n",
      "Recent advances in beta cell regeneration for diabetes\n",
      "New drug targets for insulin resistance and diabetes cure\n",
      "Gene editing and CRISPR therapies for diabetes\n",
      "Immunotherapy approaches to treat or cure type 1 diabetes\n",
      "Ongoing clinical trials for diabetes reversal\n",
      "Use of AI and machine learning in discovering diabetes treatments\n",
      "Recent trials on diabetes AND site:clinicaltrials.gov\n",
      "Pathophysiology of insulin resistance in type 2 diabetes\n",
      "Prevalence of diabetes in Europe 2024 statistics\n",
      "FDA-approved drugs for type 2 diabetes and their mechanisms\n",
      "Latest ADA clinical guidelines for diabetes management\n"
     ]
    }
   ],
   "source": [
    "tavily_queries = [\n",
    "    \"Latest breakthroughs in diabetes treatment 2024\",\n",
    "    \"Novel approaches to curing type 1 and type 2 diabetes\",\n",
    "    \"Recent advances in beta cell regeneration for diabetes\",\n",
    "    \"New drug targets for insulin resistance and diabetes cure\",\n",
    "    \"Gene editing and CRISPR therapies for diabetes\",\n",
    "    \"Immunotherapy approaches to treat or cure type 1 diabetes\",\n",
    "    \"Ongoing clinical trials for diabetes reversal\",\n",
    "    \"Use of AI and machine learning in discovering diabetes treatments\",\n",
    "    \"Recent trials on diabetes AND site:clinicaltrials.gov\",\n",
    "    \"Pathophysiology of insulin resistance in type 2 diabetes\", #mechanistic, scientific explanations — helpful for AI models focusing on mechanistic reasoning\n",
    "    \"Prevalence of diabetes in Europe 2024 statistics\", #public health datasets, WHO data, etc.\n",
    "    \"FDA-approved drugs for type 2 diabetes and their mechanisms\", #Useful for drug discovery, pharmacological studies, or treatment plans,\n",
    "    \"Latest ADA clinical guidelines for diabetes management\"#Targets specific trusted content like ADA (American Diabetes Association) guidelines.\n",
    "\n",
    "\n",
    "\n",
    "]\n",
    "\n",
    "all_docs = []\n",
    "\n",
    "for query in tavily_queries:\n",
    "    print(query)\n",
    "    try:\n",
    "        docs = tavily_retriever.invoke(query)\n",
    "        all_docs.extend(docs)\n",
    "    except TimeoutError:\n",
    "        print(f\"Timeout on query: {query}\")\n",
    "    time.sleep(3)  # Add delay between requests\n",
    "\n",
    "# Optional: Deduplicate based on document content\n",
    "tavily_docs = list({doc.page_content: doc for doc in all_docs}.values())\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'title': 'Clinical Update Conference On-Demand Registration ...',\n",
       " 'source': 'https://professional.diabetes.org/clinical-update-conference/clinical-update-conference-2025-registration-information',\n",
       " 'score': 0.038311254,\n",
       " 'images': []}"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tavily_docs[0].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'title': 'Clinical Update Conference On-Demand Registration ...', 'source': 'https://professional.diabetes.org/clinical-update-conference/clinical-update-conference-2025-registration-information', 'score': 0.038311254, 'images': []}, page_content='')"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tavily_docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "139"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(tavily_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'title': 'The New England Journal of Medicine | Research & Review Articles on ...',\n",
       " 'source': 'https://www.nejm.org/',\n",
       " 'score': 0.05570498,\n",
       " 'images': []}"
      ]
     },
     "execution_count": 121,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tavily_docs[-1].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Title: Exploring pancreatic beta-cell restoration's potential and challenges\n",
      "Score: 0.8908\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39494103/\n",
      "\n",
      "Title: The promise of CRISPR/Cas9 technology in diabetes mellitus therapy\n",
      "Score: 0.8868\n",
      "Source: https://www.sciencedirect.com/science/article/pii/S1056872723001228\n",
      "\n",
      "Title: The American Diabetes Association Releases ...\n",
      "Score: 0.8830\n",
      "Source: https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024\n",
      "\n",
      "Title: Leveraging artificial intelligence and machine learning to ...\n",
      "Score: 0.8639\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39694914/\n",
      "\n",
      "Title: Innovative immunotherapies and emerging treatments in type 1 ...\n",
      "Score: 0.8580\n",
      "Source: https://www.sciencedirect.com/science/article/pii/S2666970624000519\n",
      "\n",
      "Title: From islet transplantation to beta-cell regeneration - PubMed\n",
      "Score: 0.8519\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38693782/\n",
      "\n",
      "Title: Pancreatic β Cell Regeneration as a Possible Therapy for Diabetes\n",
      "Score: 0.8309\n",
      "Source: https://www.sciencedirect.com/science/article/pii/S1550413117304928\n",
      "\n",
      "Title: The promise of CRISPR/Cas9 technology in diabetes mellitus ... - PubMed\n",
      "Score: 0.8283\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/37295292/\n",
      "\n",
      "Title: Immunotherapy in type 1 diabetes: Novel pathway to the future ahead\n",
      "Score: 0.8283\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39493558/\n",
      "\n",
      "Title: The American Diabetes Association Releases Standards of Care in ...\n",
      "Score: 0.8229\n",
      "Source: https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025\n",
      "\n",
      "Title: Advances in β cell replacement and regeneration strategies for ...\n",
      "Score: 0.8188\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/27694741/\n",
      "\n",
      "Title: The opportunities and challenges of the disease-modifying ...\n",
      "Score: 0.8152\n",
      "Source: https://www.sciencedirect.com/science/article/pii/S1043661824001014\n",
      "\n",
      "Title: Harnessing beta cell regeneration biology for diabetes therapy\n",
      "Score: 0.8070\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38644094/\n",
      "\n",
      "Title: The immunology of type 1 diabetes - Nature\n",
      "Score: 0.8063\n",
      "Source: https://www.nature.com/articles/s41577-023-00985-4\n",
      "\n",
      "Title: Type 1 diabetes mellitus as a disease of the β-cell (do not ... - Nature\n",
      "Score: 0.8033\n",
      "Source: https://www.nature.com/articles/s41574-020-00443-4\n",
      "\n",
      "Title: American Diabetes Association\n",
      "Score: 0.8013\n",
      "Source: http://journal.diabetes.org/diabetesspectrum/00v13n4/page234.asp\n",
      "\n",
      "Title: American Diabetes Association Releases 2023 Standards ...\n",
      "Score: 0.7996\n",
      "Source: https://diabetes.org/newsroom/american-diabetes-association-2023-standards-care-diabetes-guide-for-prevention-diagnosis-treatment-people-living-with-diabetes\n",
      "\n",
      "Title: The American Diabetes Association Releases the Standards of Care in ...\n",
      "Score: 0.7975\n",
      "Source: https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024\n",
      "\n",
      "Title: Insulin Resistance: From Mechanisms to Therapeutic Strategies\n",
      "Score: 0.7960\n",
      "Source: https://www.medrxiv.org/lookup/external-ref?access_num=10.4093/dmj.2021.0280&link_type=DOI\n",
      "\n",
      "Title: The Up-to-date Treatment for Diabetes and Prevention of ...\n",
      "Score: 0.7941\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39840001/\n",
      "\n",
      "Title: The American Diabetes Association Kicks Off the 84th ...\n",
      "Score: 0.7831\n",
      "Source: https://diabetes.org/sites/default/files/2024-06/24.06.06-%20%20Sci%20Sessions%20curtain%20raiser_FINAL%20%281%29.pdf\n",
      "\n",
      "Title: New drug targets for type 2 diabetes and the metabolic syndrome\n",
      "Score: 0.7769\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/11742415/\n",
      "\n",
      "Title: Machine learning and deep learning predictive models for type 2 ...\n",
      "Score: 0.7730\n",
      "Source: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-021-00767-9\n",
      "\n",
      "Title: Artificial intelligence for diabetes: Enhancing prevention, ...\n",
      "Score: 0.7678\n",
      "Source: https://www.sciencedirect.com/science/article/pii/S2666990024000089\n",
      "\n",
      "Title: Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes\n",
      "Score: 0.7452\n",
      "Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2308743\n",
      "\n",
      "Title: Practice Guidelines Resources | American Diabetes Association\n",
      "Score: 0.7423\n",
      "Source: https://professional.diabetes.org/standards-of-care/practice-guidelines-resources\n",
      "\n",
      "Title: The importance of insulin resistance in the pathogenesis of type 2 ...\n",
      "Score: 0.7403\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/10764845/\n",
      "\n",
      "Title: Summary of Revisions: Standards of Care in Diabetes-2024\n",
      "Score: 0.7346\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38078579/\n",
      "\n",
      "Title: 9. Pharmacologic Approaches to Glycemic Treatment: Standards ... - PubMed\n",
      "Score: 0.7316\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39651989/\n",
      "\n",
      "Title: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in ...\n",
      "Score: 0.7235\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38078590/\n",
      "\n",
      "Title: Standards of Care in Diabetes-2023 - PubMed\n",
      "Score: 0.7202\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/36714254/\n",
      "\n",
      "Title: Oral & Injectable Medications for Type 2 Diabetes\n",
      "Score: 0.7190\n",
      "Source: https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications\n",
      "\n",
      "Title: Type 2 diabetes reversal with digital twin technology-enabled precision ...\n",
      "Score: 0.7102\n",
      "Source: https://clindiabetesendo.biomedcentral.com/articles/10.1186/s40842-021-00134-7\n",
      "\n",
      "Title: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings ...\n",
      "Score: 0.7082\n",
      "Source: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious\n",
      "\n",
      "Title: PDF\n",
      "Score: 0.6985\n",
      "Source: https://professional.diabetes.org/sites/dpro/files/2025-02/ADA_2024_ResearchReport_final-reduced.pdf\n",
      "\n",
      "Title: Treatment of type 2 diabetes: challenges, hopes, and anticipated ...\n",
      "Score: 0.6900\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/34181914/\n",
      "\n",
      "Title: Diabetes mellitus-Progress and opportunities in the evolving ... - PubMed\n",
      "Score: 0.6727\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39059357/\n",
      "\n",
      "Title: 2. Diagnosis and Classification of Diabetes: Standards of Care in ...\n",
      "Score: 0.6649\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38078589/\n",
      "\n",
      "Title: New discoveries in therapeutic targets and drug development ...\n",
      "Score: 0.6644\n",
      "Source: https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-025-02682-5\n",
      "\n",
      "Title: Artificial intelligence: The next frontier in diabetes therapy - Nature\n",
      "Score: 0.6636\n",
      "Source: https://www.nature.com/articles/d42473-021-00265-6\n",
      "\n",
      "Title: Urgent action needed as global diabetes cases increase four-fold over ...\n",
      "Score: 0.6591\n",
      "Source: https://www.who.int/news/item/13-11-2024-urgent-action-needed-as-global-diabetes-cases-increase-four-fold-over-past-decades\n",
      "\n",
      "Title: 6. Glycemic Goals and Hypoglycemia: Standards of Care in ...\n",
      "Score: 0.6523\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39651981/\n",
      "\n",
      "Title: FDA Approves New Class of Medicines to Treat Pediatric Type 2 ...\n",
      "Score: 0.6507\n",
      "Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-class-medicines-treat-pediatric-type-2-diabetes\n",
      "\n",
      "Title: Recent advances in the treatment and delivery system ...\n",
      "Score: 0.6485\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/38425757/\n",
      "\n",
      "Title: Recent applications of machine learning and deep learning models in the ...\n",
      "Score: 0.6372\n",
      "Source: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00969-9\n",
      "\n",
      "Title: Worldwide trends in diabetes prevalence and treatment from ... - PubMed\n",
      "Score: 0.6370\n",
      "Source: https://pubmed.ncbi.nlm.nih.gov/39549716/\n",
      "\n",
      "Title: Metformin: update on mechanisms of action and repurposing ... - Nature\n",
      "Score: 0.6058\n",
      "Source: https://www.nature.com/articles/s41574-023-00833-4\n",
      "\n"
     ]
    }
   ],
   "source": [
    "high_score_docs = [doc for doc in tavily_docs if doc.metadata.get(\"score\", 0) > 0.6]\n",
    "\n",
    "# Optional: sort\n",
    "high_score_docs = sorted(high_score_docs, key=lambda d: d.metadata[\"score\"], reverse=True)\n",
    "\n",
    "for doc in high_score_docs:\n",
    "    print(f\"Title: {doc.metadata.get('title')}\")\n",
    "    print(f\"Score: {doc.metadata.get('score'):.4f}\")\n",
    "    print(f\"Source: {doc.metadata.get('source')}\")\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "47"
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(high_score_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 165,
   "metadata": {},
   "outputs": [],
   "source": [
    "tavily_pdf_urls = [doc.metadata.get(\"source\") for doc in high_score_docs if doc.metadata.get(\"source\", \"\").endswith(\".pdf\")]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 166,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://diabetes.org/sites/default/files/2024-06/24.06.06-%20%20Sci%20Sessions%20curtain%20raiser_FINAL%20%281%29.pdf\n",
      "https://professional.diabetes.org/sites/dpro/files/2025-02/ADA_2024_ResearchReport_final-reduced.pdf\n"
     ]
    }
   ],
   "source": [
    "for url in tavily_pdf_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [],
   "source": [
    "from io import BytesIO\n",
    "import requests\n",
    "import fitz  # PyMuPDF\n",
    "\n",
    "pdf_url = tavily_pdf_urls[0]  # or whichever URL you want\n",
    "\n",
    "response = requests.get(pdf_url)\n",
    "response.raise_for_status()  # better error handling\n",
    "\n",
    "pdf_stream = BytesIO(response.content)\n",
    "pdf = fitz.open(stream=pdf_stream, filetype=\"pdf\")\n",
    "\n",
    "# Now you can work with 'pdf' object as needed\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document('None', <memory, doc# 13>)"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "page_content='Guidelines Your visual guide to the guidelines InSIGHT Starting FDA-Approved Weight Management Medications This infographic is based on recommendations from the ADA’s Standards of Care in Diabetes—2024 Supported in part by Treat Obesity, Help Prevent Diabetes Initiative. American Diabetes Association® (ADA) Professional version Learn more at professional.diabetes.org | 1-800-DIABETES (800-342-2383) Medications Lifestyle Recommendations in Conjunction with Interventions for Weight Management MINIMIZE SIDE EFFECTS INCRETIN-BASED GLP-1 RA AND DUAL GIP/GLP-1 RA THERAPIES • Liraglutide (Approved for ages 12 and older) • Semaglutide (Approved for ages 12 and older) • Tirzepatide (Approved for ages 18 and older) ORLISTAT (Approved for ages 12 and older) NALTREXONE/ BUPROPION (Approved for ages 18 and older) PHENTERMINE/ TOPIRAMATE (Approved for ages 12 and older) Mimics gut hormone to lower hunger and slow stomach emptying.\n",
      "Reduces appetite by influencing central appetite centers.\n",
      "Reduces cravings by influencing brain's reward system.\n",
      "Acts locally in the intestines to prevent fat absorption.\n",
      "Start with lowest dose and increase gradually as tolerated, daily or weekly injections.\n",
      "Start with lowest dose and increase gradually as tolerated, take in the morning with breakfast. Start with lowest dose and increase gradually as tolerated, start in the morning, then twice daily as dose is increased.\n",
      "Take with meals containing fat, up to three times daily.\n",
      "Paresthesia, dizziness, taste changes, insomnia, dry mouth, tachycardia, constipation. Nausea, vomiting, diarrhea, constipation, pancreatitis.\n",
      "Nausea, vomiting, headache, sleep disturbances, dizziness, dry mouth, constipation.\n",
      "Oily stools, diarrhea, bloating, flatulence, fecal urgency.\n",
      "Abdominal pain, persistent vomiting, pregnancy.\n",
      "Worsening anxiety, chest pain, high blood pressure, blurry vision.\n",
      "Wean off if ineffective or intolerable; avoid sudden stoppage.\n",
      "Yellowing of eyes/skin, itching, stomach pain, dark urine.\n",
      "• Liraglutide: ~6.2 kg/year • Semaglutide: ~15.3 kg/year • Tirzepatide: ~20.9 kg after 72 weeks HOW IT WORKS: INSTRUCTIONS: SIDE EFFECTS: WHEN TO STOP: AVERAGE WEIGHT LOSS (OBESITY ONLY): ~3.4 kg/year ~5 kg/year ~8.9 kg/year MITIGATE MUSCLE LOSS ADDITIONAL BENEFITS: • Liraglutide & Semaglutide: Lower cardiovascular risk in type 2 diabetes.\n",
      "• Semaglutide: Improves symptoms in heart failure, and kidney outcomes in diabetic kidney disease.\n",
      "• Tirzepatide: Reduces liver fat, improves metabolic dysfunction, and reduces sleep apnea severity.\n",
      "Start low, increase dose gradually.\n",
      "Eat small, frequent meals; avoid greasy, sugary foods and strong odors.\n",
      "Stay hydrated; use anti-nausea medication if needed.1 Engage in 15–20 minutes of resistance activities 20 or more times a week in addition to aerobic exercises to prevent loss of muscle mass.\n",
      "Consume at least 30g of protein per meal, focus on plant-based sources.\n",
      "Monitor nutrition status including fat and water-soluble vitamins and replace if necessary.\n",
      "GLP-1 RA: glucagon-like peptide receptor agonist; GIP/GLP-1 RA, dual glucose-dependent insulinotropic polypeptide 1 Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med 2022;12:[ePub ahead of print].' metadata={'title': 'PDF', 'source': 'https://professional.diabetes.org/sites/dpro/files/2024-08/startingfdaapprovedweightmanagementmedications.pdf', 'score': 0.41805586, 'images': []}\n"
     ]
    }
   ],
   "source": [
    "print(tavily_docs[10])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'title': 'PDF', 'source': 'https://professional.diabetes.org/sites/dpro/files/2024-08/startingfdaapprovedweightmanagementmedications.pdf', 'score': 0.41805586, 'images': []}, page_content=\"Guidelines Your visual guide to the guidelines InSIGHT Starting FDA-Approved Weight Management Medications This infographic is based on recommendations from the ADA’s Standards of Care in Diabetes—2024 Supported in part by Treat Obesity, Help Prevent Diabetes Initiative. American Diabetes Association® (ADA) Professional version Learn more at professional.diabetes.org | 1-800-DIABETES (800-342-2383) Medications Lifestyle Recommendations in Conjunction with Interventions for Weight Management MINIMIZE SIDE EFFECTS INCRETIN-BASED GLP-1 RA AND DUAL GIP/GLP-1 RA THERAPIES • Liraglutide (Approved for ages 12 and older) • Semaglutide (Approved for ages 12 and older) • Tirzepatide (Approved for ages 18 and older) ORLISTAT (Approved for ages 12 and older) NALTREXONE/ BUPROPION (Approved for ages 18 and older) PHENTERMINE/ TOPIRAMATE (Approved for ages 12 and older) Mimics gut hormone to lower hunger and slow stomach emptying.\\nReduces appetite by influencing central appetite centers.\\nReduces cravings by influencing brain's reward system.\\nActs locally in the intestines to prevent fat absorption.\\nStart with lowest dose and increase gradually as tolerated, daily or weekly injections.\\nStart with lowest dose and increase gradually as tolerated, take in the morning with breakfast. Start with lowest dose and increase gradually as tolerated, start in the morning, then twice daily as dose is increased.\\nTake with meals containing fat, up to three times daily.\\nParesthesia, dizziness, taste changes, insomnia, dry mouth, tachycardia, constipation. Nausea, vomiting, diarrhea, constipation, pancreatitis.\\nNausea, vomiting, headache, sleep disturbances, dizziness, dry mouth, constipation.\\nOily stools, diarrhea, bloating, flatulence, fecal urgency.\\nAbdominal pain, persistent vomiting, pregnancy.\\nWorsening anxiety, chest pain, high blood pressure, blurry vision.\\nWean off if ineffective or intolerable; avoid sudden stoppage.\\nYellowing of eyes/skin, itching, stomach pain, dark urine.\\n• Liraglutide: ~6.2 kg/year • Semaglutide: ~15.3 kg/year • Tirzepatide: ~20.9 kg after 72 weeks HOW IT WORKS: INSTRUCTIONS: SIDE EFFECTS: WHEN TO STOP: AVERAGE WEIGHT LOSS (OBESITY ONLY): ~3.4 kg/year ~5 kg/year ~8.9 kg/year MITIGATE MUSCLE LOSS ADDITIONAL BENEFITS: • Liraglutide & Semaglutide: Lower cardiovascular risk in type 2 diabetes.\\n• Semaglutide: Improves symptoms in heart failure, and kidney outcomes in diabetic kidney disease.\\n• Tirzepatide: Reduces liver fat, improves metabolic dysfunction, and reduces sleep apnea severity.\\nStart low, increase dose gradually.\\nEat small, frequent meals; avoid greasy, sugary foods and strong odors.\\nStay hydrated; use anti-nausea medication if needed.1 Engage in 15–20 minutes of resistance activities 20 or more times a week in addition to aerobic exercises to prevent loss of muscle mass.\\nConsume at least 30g of protein per meal, focus on plant-based sources.\\nMonitor nutrition status including fat and water-soluble vitamins and replace if necessary.\\nGLP-1 RA: glucagon-like peptide receptor agonist; GIP/GLP-1 RA, dual glucose-dependent insulinotropic polypeptide 1 Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med 2022;12:[ePub ahead of print].\")"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tavily_docs[10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'pdf_urls' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[113], line 5\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mrequests\u001b[39;00m\n\u001b[1;32m      3\u001b[0m \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mfitz\u001b[39;00m  \u001b[38;5;66;03m# PyMuPDF\u001b[39;00m\n\u001b[0;32m----> 5\u001b[0m pdf_url \u001b[38;5;241m=\u001b[39m \u001b[43mpdf_urls\u001b[49m[\u001b[38;5;241m0\u001b[39m]  \u001b[38;5;66;03m# or whichever URL you want\u001b[39;00m\n\u001b[1;32m      7\u001b[0m response \u001b[38;5;241m=\u001b[39m requests\u001b[38;5;241m.\u001b[39mget(pdf_url)\n\u001b[1;32m      8\u001b[0m response\u001b[38;5;241m.\u001b[39mraise_for_status()  \u001b[38;5;66;03m# better error handling\u001b[39;00m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'pdf_urls' is not defined"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Tavily Search\n",
    "https://python.langchain.com/docs/integrations/tools/tavily_search/\n",
    "\n",
    "https://github.com/langchain-ai/langchain-community/blob/main/libs/community/langchain_community/tools/tavily_search/tool.py"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "[Tavily's Search API](https://tavily.com) is a search engine built specifically for AI agents (LLMs), delivering real-time, accurate, and factual results at speed.\n",
    "\n",
    "## Overview\n",
    "\n",
    "### Integration details\n",
    "| Class                                                         | Package                                                        | Serializable | [JS support](https://js.langchain.com/docs/integrations/tools/tavily_search) |  Package latest |\n",
    "|:--------------------------------------------------------------|:---------------------------------------------------------------| :---: | :---: | :---: |\n",
    "| [TavilySearch](https://github.com/tavily-ai/langchain-tavily) | [langchain-tavily](https://pypi.org/project/langchain-tavily/) | ✅ | ✅  |  ![PyPI - Version](https://img.shields.io/pypi/v/langchain-tavily?style=flat-square&label=%20) |\n",
    "\n",
    "### Tool features\n",
    "| [Returns artifact](/docs/how_to/tool_artifacts/) | Native async |                       Return data                        | Pricing |\n",
    "| :---: | :---: |:--------------------------------------------------------:| :---: |\n",
    "| ❌ | ✅ | title, URL, content snippet, raw_content, answer, images | 1,000 free searches / month |\n",
    "\n",
    "\n",
    "## Setup\n",
    "\n",
    "The integration lives in the `langchain-tavily` package."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[31mERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.\n",
      "llama-index-legacy 0.9.48.post4 requires tenacity<9.0.0,>=8.2.0, but you have tenacity 9.1.2 which is incompatible.\n",
      "llama-index-core 0.11.22 requires tenacity!=8.4.0,<9.0.0,>=8.2.0, but you have tenacity 9.1.2 which is incompatible.\u001b[0m\u001b[31m\n",
      "\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install -qU langchain-tavily"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Credentials\n",
    "\n",
    "We also need to set our Tavily API key. You can get an API key by visiting [this site](https://app.tavily.com/sign-in) and creating an account."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "import getpass\n",
    "import os\n",
    "\n",
    "#if not os.environ.get(\"TAVILY_API_KEY\"):\n",
    "#    os.environ[\"TAVILY_API_KEY\"] = getpass.getpass(\"Tavily API key:\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"TAVILY_API_KEY\"] = \"\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Instantiation\n",
    "\n",
    "Here we show how to instantiate an instance of the Tavily search tool. The tool accepts various parameters to customize the search. After instantiation we invoke the tool with a simple query. This tool allows you to complete search queries using Tavily's Search API endpoint.\n",
    "\n",
    "Instantiation\n",
    "The tool accepts various parameters during instantiation:\n",
    "\n",
    "- max_results (optional, int): Maximum number of search results to return. Default is 5.\n",
    "- topic (optional, str): Category of the search. Can be \"general\", \"news\", or \"finance\". Default is \"general\".\n",
    "- include_answer (optional, bool): Include an answer to original query in results. Default is False.\n",
    "- include_raw_content (optional, bool): Include cleaned and parsed HTML of each search result. Default is False.\n",
    "- include_images (optional, bool): Include a list of query related images in the response. Default is False.\n",
    "- include_image_descriptions (optional, bool): Include descriptive text for each image. Default is False.\n",
    "- search_depth (optional, str): Depth of the search, either \"basic\" or \"advanced\". Default is \"basic\".\n",
    "- time_range (optional, str): The time range back from the current date to filter results - \"day\", \"week\", \"month\", or \"year\". Default is None.\n",
    "- include_domains (optional, List[str]): List of domains to specifically include. Default is None.\n",
    "- exclude_domains (optional, List[str]): List of domains to specifically exclude. Default is None.\n",
    "\n",
    "For a comprehensive overview of the available parameters, refer to the [Tavily Search API documentation](https://docs.tavily.com/documentation/api-reference/endpoint/search)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_tavily import TavilySearch\n",
    "\n",
    "tavily_tool = TavilySearch(\n",
    "    k=100,\n",
    "    max_results=100,\n",
    "    topic=\"general\",\n",
    "    include_answer=True,\n",
    "    include_raw_content=True,\n",
    "    # include_images=False,\n",
    "    # include_image_descriptions=False,\n",
    "    search_depth=\"advanced\",\n",
    "    # time_range=\"day\",\n",
    "    include_domains=[\n",
    "                    \"clinicaltrials.gov\", \"pubmed.ncbi.nlm.nih.gov\", \"arxiv.org\",\n",
    "                    \"biorxiv.org\", \"medrxiv.org\", \"diabetes.org\", \"cdc.gov\", \"who.int\",\n",
    "                    \"fda.gov\", \"ema.europa.eu\", \"nejm.org\", \"thelancet.com\", \"jamanetwork.com\",\n",
    "                    \"nature.com\", \"sciencedirect.com\", \"springer.com\", \"cell.com\", \"biomedcentral.com\"\n",
    "                    ]\n",
    "    # exclude_domains=None\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Invocation\n",
    "\n",
    "### [Invoke directly with args](/docs/concepts/tools)\n",
    "\n",
    "The Tavily search tool accepts the following arguments during invocation:\n",
    "- `query` (required): A natural language search query\n",
    "- The following arguments can also be set during invocation : `include_images`, `search_depth` , `time_range`, `include_domains`, `exclude_domains`, `include_images`\n",
    "- For reliability and performance reasons, certain parameters that affect response size cannot be modified during invocation: `include_answer` and `include_raw_content`. These limitations prevent unexpected context window issues and ensure consistent results.\n",
    "\n",
    "\n",
    "NOTE: The optional arguments are available for agents to dynamically set, if you set an argument during instantiation and then invoke the tool with a different value, the tool will use the value you passed during invocation."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "tavily_docs = tavily_tool.run({\"query\": \"Diabetes\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6"
      ]
     },
     "execution_count": 103,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(tavily_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'query': 'Diabetes',\n",
       " 'follow_up_questions': None,\n",
       " 'answer': 'Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. It has two main types: Type 1 and Type 2. Management includes lifestyle changes and medication.',\n",
       " 'images': [],\n",
       " 'results': [{'title': 'Diabetes Research and Clinical Practice - ScienceDirect',\n",
       "   'url': 'https://www.sciencedirect.com/journal/diabetes-research-and-clinical-practice',\n",
       "   'content': 'Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas.. The role Diabetes Research and Clinical Practice is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical',\n",
       "   'score': 0.6854659,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Diabetes - Latest research and news - Nature',\n",
       "   'url': 'https://www.nature.com/subjects/diabetes',\n",
       "   'content': 'Diabetes - Latest research and news | Nature We also use optional cookies for advertising, personalisation of content, usage analysis, and social media. See our privacy policy for more information on the use of your personal data. Image 2: Nature 1.   nature 3.   diabetes Diabetes articles from across Nature Portfolio Type 1 diabetes Type 2 diabetes Research Open Access 05 Jun 2025Nature Medicine Research Open Access 04 Jun 2025Nature Medicine Research Highlights 02 Jun 2025Nature Reviews Endocrinology Research Highlights 23 May 2025Nature Reviews Endocrinology News 21 May 2025Nature News 20 May 2025Nature Research Highlights 16 May 2025Nature Reviews Endocrinology Nature.com ### About Nature Portfolio Nature Index Nature portfolio policies Nature Masterclasses Nature Africa Nature China Nature India Your privacy choices/Manage cookies ',\n",
       "   'score': 0.59344494,\n",
       "   'raw_content': 'Diabetes - Latest research and news | Nature\\n\\n===============\\n\\nYour privacy, your choice\\n-------------------------\\n\\nWe use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.\\n\\nBy accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.\\n\\nSee our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data.\\n\\nManage preferences for further information and to change your choices.\\n\\nAccept all cookies\\n\\n[Skip to main content](https://www.nature.com/subjects/diabetes#content)\\n\\nThank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.\\n\\nAdvertisement\\n\\n[![Image 2: Nature](https://www.nature.com/static/images/product-logos/naturecom-secondary-5cd474411f.svg)](https://www.nature.com/)\\n\\n*   [View all journals](https://www.nature.com/siteindex)\\n*   [Search](javascript:;)\\n\\nSearch\\n------\\n\\nSearch articles by subject, keyword or author  Show results from  Search   [Advanced search](https://www.nature.com/search/advanced) \\n### Quick links\\n\\n    *   [Explore articles by subject](https://www.nature.com/subjects)\\n    *   [Find a job](https://www.nature.com/naturecareers)\\n    *   [Guide to authors](https://www.nature.com/authors/index.html)\\n    *   [Editorial policies](https://www.nature.com/authors/editorial_policies/)\\n\\n*   [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/subjects/diabetes)\\n\\n1.   [nature](https://www.nature.com/)\\n2.   [subjects](https://www.nature.com/subjects)\\n3.   diabetes\\n\\nDiabetes articles from across Nature Portfolio\\n==============================================\\n\\n*   [Atom](https://www.nature.com/subjects/diabetes.atom)\\n*   [RSS Feed](https://www.nature.com/subjects/diabetes.rss)\\n\\nDefinition\\nDiabetes describes a group of metabolic diseases characterized by high blood sugar levels. Diabetes can be caused by the pancreas not producing insulin (type 1 diabetes) or by insulin resistance (cells do not respond to insulin; type 2 diabetes).\\n\\nRelated Subjects\\n----------------\\n\\n*   [Diabetes complications](https://www.nature.com/subjects/diabetes-complications)\\n*   [Diabetes insipidus](https://www.nature.com/subjects/diabetes-insipidus)\\n*   [Gestational diabetes](https://www.nature.com/subjects/gestational-diabetes)\\n*   [Type 1 diabetes](https://www.nature.com/subjects/type-1-diabetes-mellitus)\\n*   [Type 2 diabetes](https://www.nature.com/subjects/type-2-diabetes-mellitus)\\n\\nLatest Research and Reviews\\n---------------------------\\n\\n*   \\n![Image 3](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04471-w/MediaObjects/41598_2025_4471_Fig1_HTML.png) \\n\\n### [Islet delta-cell architecture is remodelled in the human pancreas during type 1 diabetes](https://www.nature.com/articles/s41598-025-04471-w)\\n\\n    *   Angie Tegehall\\n    *   Olle Korsgren\\n    *   Marcus Lundberg\\n\\nResearch Open Access 05 Jun 2025[Scientific Reports](https://www.nature.com/srep)\\n\\nVolume: 15, P: 19776\\n\\n*   \\n![Image 4](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-03382-0/MediaObjects/41598_2025_3382_Fig1_HTML.png) \\n\\n### [Variability and misclassification of albuminuria in patients with type 2 diabetes mellitus](https://www.nature.com/articles/s41598-025-03382-0)\\n\\n    *   Lukas Buchwinkler\\n    *   Felix Keller\\n    *   Gert Mayer\\n\\nResearch Open Access 05 Jun 2025[Scientific Reports](https://www.nature.com/srep)\\n\\nVolume: 15, P: 19785\\n\\n*   \\n![Image 5](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41366-025-01812-7/MediaObjects/41366_2025_1812_Fig1_HTML.png) \\n\\n### [Association between plasma proteomic dynamic changes and metabolic outcomes in patients undergoing bariatric surgery](https://www.nature.com/articles/s41366-025-01812-7)\\n\\n    *   Candela Diaz-Canestro\\n    *   Wah Yang\\n    *   Aimin Xu\\n\\nResearch 05 Jun 2025[International Journal of Obesity](https://www.nature.com/ijo)\\n\\nP: 1-10\\n\\n*   \\n![Image 6](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41591-025-03730-7/MediaObjects/41591_2025_3730_Fig1_HTML.png) \\n\\n### [A microRNA-based dynamic risk score for type 1 diabetes](https://www.nature.com/articles/s41591-025-03730-7)\\n\\nA 50 microRNA-based dynamic risk score for stratifying individuals with and without type 1 diabetes was developed using samples obtained from multicenter and multiethnic cohorts. \\n    *   Mugdha V. Joglekar\\n    *   Wilson K. M. Wong\\n    *   Noha Lim\\n\\nResearch Open Access 05 Jun 2025[Nature Medicine](https://www.nature.com/nm)\\n\\nP: 1-10\\n\\n*   \\n![Image 7](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41574-025-01129-5/MediaObjects/41574_2025_1129_Fig1_HTML.png) \\n\\n### [Diabetes mellitus and the key role of endoplasmic reticulum stress in pancreatic β cells](https://www.nature.com/articles/s41574-025-01129-5)\\n\\nGenetic mutations and environmental exposures cause severe endoplasmic reticulum (ER) stress in pancreatic β cells, which can culminate in diabetes mellitus. Lytrivi et al. describe the causes and consequences of ER stress for β cell development, function and survival, and debate emerging therapeutic approaches. \\n    *   Maria Lytrivi\\n    *   Yue Tong\\n    *   Miriam Cnop\\n\\nReviews 04 Jun 2025[Nature Reviews Endocrinology](https://www.nature.com/nrendo)\\n\\nP: 1-18\\n\\n*   \\n![Image 8](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41591-025-03719-2/MediaObjects/41591_2025_3719_Fig1_HTML.png) \\n\\n### [Individual variations in glycemic responses to carbohydrates and underlying metabolic physiology](https://www.nature.com/articles/s41591-025-03719-2)\\n\\nDeep phenotyping of responses to carbohydrate meals and mitigators revealed interindividual differences in postprandial glycemic responses that reflect underlying metabolic physiology, such as insulin resistance and beta cell dysfunction. \\n    *   Yue Wu\\n    *   Ben Ehlert\\n    *   Michael P. Snyder\\n\\nResearch Open Access 04 Jun 2025[Nature Medicine](https://www.nature.com/nm)\\n\\nP: 1-12\\n\\n[All Research & Reviews](https://www.nature.com/search?article_type=protocols,research,reviews&subject=diabetes)\\n\\nNews and Comment\\n----------------\\n\\n*   \\n![Image 10](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41574-025-01137-5/MediaObjects/41574_2025_1137_Figa_HTML.png) \\n\\n### [Hyperglycaemia increases anxiety in mice by boosting neuronal CCL2](https://www.nature.com/articles/s41574-025-01137-5)\\n\\n    *   Senegal Carty\\n\\nResearch Highlights 02 Jun 2025[Nature Reviews Endocrinology](https://www.nature.com/nrendo)\\n\\nP: 1\\n\\n*   \\n![Image 11](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41574-025-01136-6/MediaObjects/41574_2025_1136_Figa_HTML.png) \\n\\n### [Hypoglycaemia exacerbates diabetic retinopathy via HIF accumulation](https://www.nature.com/articles/s41574-025-01136-6)\\n\\n    *   Olivia Tysoe\\n\\nResearch Highlights 23 May 2025[Nature Reviews Endocrinology](https://www.nature.com/nrendo)\\n\\nP: 1\\n\\n*   \\n![Image 12](https://media.springernature.com/w290h158/magazine-assets/d41586-025-01598-8/d41586-025-01598-8_50993886.jpg) \\n\\n### [AI listens for health conditions](https://www.nature.com/articles/d41586-025-01598-8)\\n\\nVoice recordings, examined by artificial intelligence, might provide new biomarkers for conditions such as heart disease and Alzheimer’s. \\n    *   Neil Savage\\n\\nComments & Opinion 22 May 2025[Nature](https://www.nature.com/nature)\\n\\n*   \\n![Image 13](https://media.springernature.com/w290h158/magazine-assets/d41586-025-01597-9/d41586-025-01597-9_51000576.jpg) \\n\\n### [Mice lacking this amino acid lost 30% of their body weight](https://www.nature.com/articles/d41586-025-01597-9)\\n\\nBut eliminating cysteine, which is found in high-protein foods, from human diets would be challenging. \\n    *   Rachel Fieldhouse\\n\\nNews 21 May 2025[Nature](https://www.nature.com/nature)\\n\\n*   \\n![Image 14](https://media.springernature.com/w290h158/magazine-assets/d41586-025-01600-3/d41586-025-01600-3_51000588.jpg) \\n\\n### [How much ultra-processed food do you eat? Blood and urine record it](https://www.nature.com/articles/d41586-025-01600-3)\\n\\nSamples could provide an objective measure of diets and help to unravel their contribution to disease. \\n    *   Smriti Mallapaty\\n\\nNews 20 May 2025[Nature](https://www.nature.com/nature)\\n\\n*   \\n### [The inflammatory spark: how TNF rewrote the insulin resistance narrative](https://www.nature.com/articles/s41574-025-01133-9)\\n\\n    *   Subhajit Dutta\\n\\nResearch Highlights 16 May 2025[Nature Reviews Endocrinology](https://www.nature.com/nrendo)\\n\\nP: 1\\n\\n[All News & Comment](https://www.nature.com/search?article_type=news,editorial,comments-and-opinion,correspondence,news-and-views,research-highlights&subject=diabetes)\\n\\nNature.com\\n\\nnature.com sitemap\\n------------------\\n\\n### About Nature Portfolio\\n\\n*   [About us](https://www.nature.com/npg_/company_info/index.html)\\n*   [Press releases](https://www.nature.com/npg_/press_room/press_releases.html)\\n*   [Press office](https://press.nature.com/)\\n*   [Contact us](https://support.nature.com/support/home)\\n\\n### Discover content\\n\\n*   [Journals A-Z](https://www.nature.com/siteindex)\\n*   [Articles by subject](https://www.nature.com/subjects)\\n*   [protocols.io](https://www.protocols.io/)\\n*   [Nature Index](https://www.natureindex.com/)\\n\\n### Publishing policies\\n\\n*   [Nature portfolio policies](https://www.nature.com/authors/editorial_policies)\\n*   [Open access](https://www.nature.com/nature-research/open-access)\\n\\n### Author & Researcher services\\n\\n*   [Reprints & permissions](https://www.nature.com/reprints)\\n*   [Research data](https://www.springernature.com/gp/authors/research-data)\\n*   [Language editing](https://authorservices.springernature.com/language-editing/)\\n*   [Scientific editing](https://authorservices.springernature.com/scientific-editing/)\\n*   [Nature Masterclasses](https://masterclasses.nature.com/)\\n*   [Research Solutions](https://solutions.springernature.com/)\\n\\n### Libraries & institutions\\n\\n*   [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services)\\n*   [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal)\\n*   [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions)\\n*   [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library)\\n\\n### Advertising & partnerships\\n\\n*   [Advertising](https://partnerships.nature.com/product/digital-advertising/)\\n*   [Partnerships & Services](https://partnerships.nature.com/)\\n*   [Media kits](https://partnerships.nature.com/media-kits/)\\n*   [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/)\\n\\n### Professional development\\n\\n*   [Nature Careers](https://www.nature.com/naturecareers/)\\n*   [Nature Conferences](https://conferences.nature.com/)\\n\\n### Regional websites\\n\\n*   [Nature Africa](https://www.nature.com/natafrica)\\n*   [Nature China](http://www.naturechina.com/)\\n*   [Nature India](https://www.nature.com/nindia)\\n*   [Nature Italy](https://www.nature.com/natitaly)\\n*   [Nature Japan](https://www.natureasia.com/ja-jp)\\n*   [Nature Middle East](https://www.nature.com/nmiddleeast)\\n\\n*   [Privacy Policy](https://www.nature.com/info/privacy)\\n*   [Use of cookies](https://www.nature.com/info/cookies)\\n*   Your privacy choices/Manage cookies \\n*   [Legal notice](https://www.nature.com/info/legal-notice)\\n*   [Accessibility statement](https://www.nature.com/info/accessibility-statement)\\n*   [Terms & Conditions](https://www.nature.com/info/terms-and-conditions)\\n*   [Your US state privacy rights](https://www.springernature.com/ccpa)\\n\\n[![Image 15: Springer Nature](https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg)](https://www.springernature.com/)\\n© 2025 Springer Nature Limited\\n'},\n",
       "  {'title': 'International Journal of Diabetes Mellitus - ScienceDirect',\n",
       "   'url': 'https://www.sciencedirect.com/journal/international-journal-of-diabetes-mellitus',\n",
       "   'content': \"Read the latest articles of International Journal of Diabetes Mellitus at ScienceDirect.com, Elsevier's leading platform of peer-reviewed scholarly literature\",\n",
       "   'score': 0.5550741,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Diagnosis and Management of Type 2 Diabetes - World Health Organization',\n",
       "   'url': 'https://iris.who.int/bitstream/handle/10665/331710/WHO-UCN-NCD-20.1-eng.pdf;sequence=1',\n",
       "   'content': 'Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabetes include retinopathy,',\n",
       "   'score': 0.5065188,\n",
       "   'raw_content': 'Diagnosis and Management of Type 2 Diabetes Diagnosis and Management of Type 2 Diabetes WHO/UCN/NCD/20.1 © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0\\xa0IGO licence (CC\\xa0BY-NC-SA\\xa03.0\\xa0IGO; https://creativecommons.\\norg/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.\\nSuggested citation. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva]: World Health Organization; 2020 (WHO/UCN/NCD/20.1). Licence: CC\\xa0BY-NC-SA\\xa03.0\\xa0IGO.\\nCataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.\\nSales, rights and licensing. To purchase WHO publications, see http://apps.who.int/ bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.\\nGeneral disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.\\nThe mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\\nAll reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Design and layout by Myriad Editions.\\nPrinted in Switzerland. Contents Acknowledgements 7 Abbreviations 7 Diagnosis and management of type 2 diabetes 8 Introduction 9 Definition of diabetes 9 Epidemiology and global burden of diabetes 9 Aetio-pathology of diabetes 9 Most common types of diabetes and their risk factors 9 Classification of diabetes 10 1 Clinical manifestations of diabetes and diagnostic criteria 12 Clinical manifestations 12 Diagnostic criteria for diabetes 13 Diagnostic tests 13 2 Management of diabetes 14 Blood glucose management protocol 14 Monitoring of glycaemic control 17 3 Prevention and management of complications of diabetes 18 Acute complications of diabetes 18 Screening and management of chronic complications of diabetes 20 4 Criteria for referral to higher levels of care 26 5 Monitoring of processes and outcomes 27 6 Resources 28 Annex 1: Protocol for treatment of type 2 diabetes mellitus with insulin 29 Annex 2: Prevention, assessment and management of diabetic foot 30 Resources 35 Tables Table 1 Classification of diabetes 11 Table 2 Symptoms and signs of diabetes 12 Table 3 Diagnostic criteria for diabetes 13 Table 4 Symptoms and signs of hypoglycaemia 18 Table 5 Biochemical characteristics of DKA and HHS measurable in primary care facilities 19 Table 6 Categories of albuminuria (measured by ACR) 22 Table 7 Assessment of effectiveness of diabetes services 27 Table 8 Stratification of level of risk of developing diabetic foot problems or the need for an amputation 33 Figures Fig. 1 Protocol for control of blood glucose in type 2 diabetes* 16 Fig. 2 Type 2 diabetes management protocol derived from WHO-PEN 25 Fig. 3 Examples of foot ulcers 30 Fig. 4 Areas of foot at highest risk for ulceration 30 Fig. 5 Dorsal pedis palpation 31 Fig. 6 Posterior tibial artery palpation 31 Fig. 7 Sites to be tested for loss of protective sensation 32 Fig. 8 Pressure perception test using Semmes-Weinstein 10 g monofilament 32 Fig. 9 Application of tuning fork in vibration perception test 32 Fig. 10 The proper way to cut toenails 34 Fig. 11 Appropriate shoe shape and size 35 Acknowledgements WHO expresses special appreciation to US Centers for Disease Control and Prevention for financial support through grant No 5 NU2GGH001235-05-00 of the WHO-CDC Cooperative Agreement.\\nWHO also wishes to thank the International Diabetes Federation, RESOLVE to Save Lives, and external experts Bianca Hemmingsen, Baridalyne Nongkynrih, Sylvia Kehlenbrink Oh and Vijay Viswanathan for their technical input and advice. Abbreviations ACE angiotensin-converting enzyme ACR albumin-to-creatinine ratio CVD cardiovascular disease eGFR estimated glomerular filtration rate FPG fasting plasma glucose GAD glutamic acid decarboxylase GFR glomerular filtration rate HbA1c glycated haemoglobin HHS hyperosmolar hyperglycaemic state PAD peripheral artery disease LOPS loss of protective sensation NPH neutral protamine Hagedorn PCR protein-to-creatinine ratio RPG random plasma glucose T2DM type 2 diabetes mellitus Diagnosis and management of type 2 diabetes Part of the HEARTS technical package for cardiovascular disease management in primary health care Diagnosis and management of type 2 diabetes is based on WHO guidance on diagnosis, classification and management of diabetes. It is aligned with the WHO Package of Essential Noncommunicable Disease Interventions in Primary Health Care (WHO-PEN). It can be used independently or in conjunction with the HEARTS technical package developed to improve cardiovascular health.\\nTarget users may vary, based on context, existing health systems and national priorities.\\nThe people who will find the modules most useful are: • • National level – Ministry of Health NCD policymakers responsible for: o o developing strategies, policies and plans related to service delivery of diabetes o o setting national targets on diabetes, monitoring progress and reporting • • Subnational level – Health/NCD programme managers responsible for: o o planning, training, implementing and monitoring service delivery • • Primary care level – Facility managers and primary health care staff and trainers responsible for: o o assigning tasks, organising training and ensuring the facility is running smoothly o o clinical management of people with type 2 diabetes o o collecting facility-level data on indicators of progress towards diabetes targets.\\n8 HEARTS – D Diagnosis and management of Type 2 diabetes Introduction Definition of diabetes Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabetes include retinopathy, nephropathy, and neuropathy. People with diabetes are also at increased risk of other diseases, including cardiac, peripheral arterial and cerebrovascular disease, cataracts, erectile dysfunction, and nonalcoholic fatty liver disease. They are also at an increased risk of some infectious diseases such as tuberculosis, and are likely to experience poorer outcomes.\\nEpidemiology and global burden of diabetes Diabetes is found in every population in the world and in all regions, including rural parts of low- and middle-income countries. WHO estimates there were 422 million adults with diabetes worldwide in 2014. The age-adjusted prevalence in adults rose from 4.7% in 1980 to 8.5% in 2014, with the greatest increase in low- and middle-income countries.\\nAetio-pathology of diabetes The underlying characteristic common to all forms of diabetes is the dysfunction or destruction of pancreatic beta-cells. These cells are not replaced, as the human pancreas seems incapable of renewing beta-cells after the age of 30 years. Many mechanisms can lead to a decline in function or the complete destruction of beta-cells. These mechanisms include genetic predisposition and abnormalities, epigenetic processes, insulin resistance, auto-immunity, concurrent illnesses, inflammation, and environmental factors. Most common types of diabetes and their risk factors Risk factors for type 2 diabetes • • overweight/obesity • • physical inactivity • • age • • diabetes in first degree relatives • • history of gestational diabetes • • cardiovascular disease and its risk factors • • ethnicity (South Asian, Afro-Caribbean, Hispanic) The most common type of diabetes mellitus is type 2 diabetes (T2DM). The majority of people with T2DM are overweight or obese, which either causes or aggravates 9 HEARTS – D Diagnosis and management of Type 2 diabetes insulin resistance. Many of those who are not obese by BMI criteria have a higher proportion of body fat distributed predominantly in the abdominal region, indicating visceral adiposity, compared to people without diabetes. However, in some populations, such as Asians, beta-cell dysfunction appears to be a more prominent feature than in populations of European descent. This is also observed in thinner people from low- and middle-income countries such as India, and among people of Indian descent living in high-income countries. Risk factors for type 1 diabetes • • certain genetic haplotypes • • unknown environmental factors Type 1 diabetes is much less common, the risk being highest in populations of European origin. This module is specifically for management of type 2 diabetes, as type 1 is usually not managed in primary care facilities.\\nClassification of diabetes The WHO classification of diabetes is presented in Table 1. It prioritizes clinical care and guides health professionals in choosing appropriate treatments at the time of diabetes diagnosis, providing practical guidance to clinicians in assigning a type of diabetes to individuals at the time of diagnosis. 10 HEARTS – D Diagnosis and management of Type 2 diabetes Table 1 Classification of diabetes Type of diabetes Description Type 1 diabetes Beta-cell destruction (mostly immune-mediated) and absolute insulin deficiency; onset most common in childhood and early adulthood.\\nType 2 diabetes Most common type, various degrees of beta-cell dysfunction and insulin resistance; commonly associated with overweight and obesity.\\nHybrid forms of diabetes Slowly evolving, immune-mediated diabetes of adults Similar to slowly evolving type 1 in adults but more often has features of the metabolic syndrome, a single GAD autoantibody, and retains greater beta-cell function.\\nKetosis-prone type 2 diabetes Presents with ketosis and insulin deficiency but later does not require insulin; common episodes of ketosis, not immune-mediated.\\nOther specific types Monogenic diabetes: a) Monogenic defects of beta-cell function b) Monogenic defects in insulin action Caused by specific gene mutations. Has several clinical manifestations requiring different treatment, some occurring in the neonatal period, others by early adulthood. Caused by specific gene mutations. Has features of severe insulin resistance without obesity; diabetes develops when beta-cells do not compensate for insulin resistance.\\nDiseases of the exocrine pancreas Various conditions that affect the pancreas can result in hyperglycaemia (trauma, tumour, inflammation, etc.).\\nEndocrine disorders Occurs in diseases with excess secretion of hormones that are insulin antagonists.\\nDrug- or chemical-induced Some medicines and chemicals impair insulin secretion or action, some can destroy beta-cells. Infection-related diabetes Some viruses have been associated with direct beta-cell destruction. Uncommon specific forms of immune-mediated diabetes Associated with rare immune-mediated diseases.\\nOther genetic syndromes sometimes associated with diabetes Many genetic disorders and chromosomal abnormalities increase the risk of diabetes Unclassified diabetes Used to describe diabetes that does not clearly fit into other categories. This category should be used temporarily, when there is no clear diagnostic category, close to the time of diagnosis, in particular.\\nHyperglycaemia first detected during pregnancy Diabetes mellitus in pregnancy Type 1 or type 2 diabetes first diagnosed during pregnancy.\\nGestational diabetes mellitus Hyperglycaemia below diagnostic thresholds for diabetes in pregnancy.\\n11 HEARTS – D Diagnosis and management of Type 2 diabetes 1 Clinical manifestations of diabetes and diagnostic criteria Clinical manifestations Diabetes may present with characteristic symptoms and signs (Table 2). It is estimated that a significant percentage of cases of type 2 diabetes (T2DM) (30% to 80%, depending on the country) are undiagnosed. The most severe clinical manifestations are ketoacidosis or a non-ketotic hyperosmolar state that may lead to dehydration, coma and, in the absence of effective treatment, death. However, symptoms in T2DM are often not severe, or may be absent, owing to the slow pace at which the hyperglycaemia is worsening. As a result, in the absence of biochemical testing, hyperglycaemia sufficient to cause pathological and functional changes may be present for a long time before a diagnosis is made, resulting in the presence of complications at diagnosis. Type 1 diabetes is more likely to present with symptoms and its onset is typically in children and young adults. However, the type of diabetes cannot always be determined at diagnosis, and initial treatment decisions should be based on clinical presentation and plasma glucose values.\\nTable 2 Symptoms and signs of diabetes Symptoms of diabetes • • thirst • • frequent urination • • blurring of vision • • fatigue Signs of diabetes • • unintentional weight loss • • signs of acute metabolic deterioration (signs of severe dehydration, Kussmaul’s respiration, vomiting, altered level of consciousness) • • clinical signs of chronic complications (acute coronary disease, stroke, kidney disease, vision loss, diabetic foot) 12 HEARTS – D Diagnosis and management of Type 2 diabetes Diagnostic criteria for diabetes Diagnosis of diabetes is based on values of plasma glucose or glycated haemoglobin (HbA1c). Diagnostic cut-off values are presented in Table 3. Table 3 Diagnostic criteria for diabetes Measurement Diagnostic cut-off value Comment Fasting venous or capillary** plasma glucose ≥7.0 mmol/L (126 mg/dL) Least costly but difficulties with ensuring a fasting state 2-hour post-load venous plasma glucose ≥11.1 mmol/L (200 mg/dL) Cumbersome and costly, difficulties with ensuring a fasting state 2-hour post-load capillary** plasma glucose ≥12.2 mmol/L (220 mg/dL) Cumbersome and costly, difficulties with ensuring a fasting state Random plasma glucose ≥11.1 mmol/L (200 mg/dL) To be used only in the presence of symptoms HbA1c*** 6.5% (48 mmol/mol) • • Less intra-individual variability than plasma glucose • • Does not require the fasting state but substantially more costly than glucose measurements • • Is an indirect method • • Can be inaccurate in some conditions (haemoglobinopathies, renal failure, some anaemias, conditions with rapid red blood cell turnover) * Overnight fast of 8–14 hours. ** If laboratory measurement is not available, point of care, (“finger stick”) devices can be used (they report glucose values in capillary plasma). *** Plasma glucose is preferred in people with symptoms who are suspected of having type 1 diabetes.\\nDiagnostic tests Venous plasma glucose is the standard method for measuring and reporting. However, in recognition of the widespread use of capillary sampling, especially in low-resource settings, values for capillary plasma glucose are provided for post-load glucose values. Fasting values for venous and capillary plasma glucose are identical. Glucose should be measured immediately after collection, otherwise the blood sample should be collected into a container with glycolytic inhibitors, immediately centrifuged to separate the plasma, and frozen until analysis.\\n• • In asymptomatic people, repeat the test to confirm the diagnosis, preferably with the same test, as soon as practicable on a subsequent day.\\n• • If plasma glucose ≥18 mmol/L (325 mg/dL), or symptoms are present, measure urine ketones to assess degree of metabolic disturbance. • • If plasma glucose measurement is not possible, urine glucose testing can be used to confirm suspicion of diabetes in people with symptoms. A negative urine test does not exclude diabetes, but it excludes severe hyperglycaemia.\\n13 HEARTS – D Diagnosis and management of Type 2 diabetes 2 Management of diabetes Type 2 diabetes is a progressive illness, with insulin secretion decreasing over time. Introduction of oral hypoglycaemic agents (OHA) will often be necessary in patients treated with diet and physical activity only, and further intensification with insulin might be needed as the illness progresses and OHAs are not sufficient to control glycaemia. Blood glucose management protocol The blood glucose management protocol is recommended for patients with established or newly diagnosed type 2 diabetes (see Fig. 1). A simplified blood glucose management protocol and key actions on complications are presented in Fig.2. Non-pharmacological management A healthy diet to achieve or maintain normal body weight and regular physical activity are the mainstay of diabetes management. • • People with diabetes should be advised to eat a healthy balanced diet that is applicable to the general population.\\n• • Overweight patients should be advised to reduce weight by reducing their food (calorie) intake.\\n• • All patients should be advised to practise regular daily physical activity appropriate for their physical capabilities (e.g walking). Most adults should engage in at least 150 minutes of moderate or vigorous-intensity aerobic activity per week, spread over at least 3 days.\\n• • All patients should be advised on avoidance of tobacco use and harmful use of alcohol.\\nPharmacological management Control of blood glucose levels (glycaemia) Initial treatment: • • Metformin does not cause weight gain or hypoglycaemia and is the recommended initial treatment for people who do not achieve the desired glycaemic control with diet and physical activity. Increase the dosage gradually according to the diabetes protocol.\\n• • A second-generation sulfonylurea (preferably gliclazide) can be used as initial (first-line) treatment when metformin is contraindicated or not tolerated. Sulfonylureas may cause weight gain or hypoglycemia.\\n• • Other pharmacological agents have not been shown to be superior to metformin or sulfonylurea for glycaemic control and long-term outcomes as initial treatment. 14 HEARTS – D Diagnosis and management of Type 2 diabetes Metformin Metformin is contraindicated in: • • people with chronic kidney disease (estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73m2) • • people with severe reduced liver function • • people with acute cardiac insufficiency • • people with respiratory insufficiency • • people who abuse alcohol • • people with history of lactic acidosis Intensification of treatment when metformin alone fails to control glycaemia: • • Add a second-generation sulfonylurea (preferably gliclazide) to metformin in patients with inadequately controlled glycaemia on metformin, along with diet and physical activity. • • In hyperglycaemic patients with symptoms, give a sulfonylurea or refer for insulin treatment. • • Hypoglycaemia is a possible side-effect of sulfonylurea, more frequent with glibenclamide than with gliclazide. Glibenclamide Glibenclamide is not recommended in: • • people aged 60 years or older • • people with severe liver disease • • in patients for whom hypoglycaemia is a concern (people who are at risk of falls, who have impaired awareness of hypoglycaemia, who live alone) • • people who drive or operate machinery as part of their job.\\nIntensification of treatment when metformin and sulfonylurea fail to control glycaemia: • • Refer for insulin treatment or add human insulin1 to oral medication (Annex 1). • • If insulin is unsuitable 2, a DPP-4 inhibitor, SGLT-2 inhibitor or a thiazolidinedione (TZD) may be added, but these are not recommended for routine use due to high cost and, with the exception of SGLT-2 inhibitors, uncertain benefit. 1 Insulin analogues are not recommended for routine use as they are substantially more costly than human insulin and there is considerable uncertainty over their benefits, especially in people with type 2 diabetes.\\n2 Insulin treatment could be unsuitable when it is more costly than oral agents, or when circumstances make its use difficult (e.g. persons who live alone and are dependent on others to inject them with insulin).\\n15 Fig. 1 Protocol for control of blood glucose in type 2 diabetes* TEST ADULTS who have symptoms of diabetes with fasting or random plasma glucose (FPG or RPG) TEST ASYMPTOMATIC ADULTS who are 40+ years old and BMI ≥25 (FPG) REVIEW in 3–5 days REVIEW in 2–3 months TEST urine ketones IF goal NOT achieved No improvement Improvement CONTINUE treatment Urine ketones ≥2+ Urine ketones <2+ FPG ≥7 mmol/L and <18 mmol/L or RPG ≥11.1 mmol/L IF ASYMPTOMATIC repeat test on subsequent day Counsel on diet and physical activity and adherence to medicines at all visits IF goal not achieved BEGIN METFORMIN 500 mg daily IF SYMPTOMATIC and FPG ≥15 mmol/L IF goal not achieved INCREASE METFORMIN to 1000 mg 1 x daily IF SYMPTOMATIC and FPG ≥15 mmol/L IF goal not achieved INCREASE METFORMIN to 1000 mg 2 x daily IF SYMPTOMATIC and FPG ≥15 mmol/L IF goal not achieved ADD gliclazide 80 mg 1 x daily IF SYMPTOMATIC and FPG ≥15 mmol/L FPG ≥15 mmol/L and SYMPTOMATIC or FPG/RPG >18 mmol/L, regardless of symptoms GIVE METFORMIN 1000 mg 2 x daily and GLICLAZIDE 80 g 2 x daily Counsel on diet, physical activity and adherence to medication IF goal achieved or frequent hypoglycaemia, consider reducing or stopping gliclazide in people who were on 2000 mg metformin and 160 mg gliclazide from diagnosis REVIEW IN 1 MONTH REFER to higher level of care REFER to higher level of care REFER to higher level of care REVIEW IN 3 MONTHS (or immediately if symptoms appear) REVIEW IN 1 MONTH (or immediately if symptoms appear) REVIEW IN 3 MONTHS (or immediately if symptoms appear) REVIEW IN 3 MONTHS (or immediately if symptoms appear) REVIEW IN 3 MONTHS (or immediately if symptoms appear) IF goal not achieved ADD gliclazide 80 mg 2 x daily IF SYMPTOMATIC and FPG ≥15 mmol/L REVIEW IN 3 MONTHS (or immediately if symptoms appear) IF goal not achieved despite adherence to medication and diet and physical activity, REFER to higher level of care or BEGIN INSULIN (see insulin protocol) * Derived from WHO-PEN 2013 16 HEARTS – D Diagnosis and management of Type 2 diabetes Control of blood pressure and blood lipids Blood pressure should be measured at every visit.\\nHypertension treatment is indicated in people with diabetes when systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg. Statins are recommended for all people with type 2 diabetes 40 years old or older, but only if this does not negatively impact access to glucose-lowering and blood pressure-lowering medication.\\nReferral criteria Criteria for referral to higher levels of care are presented in Section 4.\\nMonitoring of glycaemic control Glycated haemoglobin (HbA1c) is commonly used in clinical practice to monitor glycaemic control, as it provides a measure of average plasma glucose over the preceding 8 to 12 weeks. If HbA1c is not available: • • Fasting plasma glucose (FPG) values can be used to assess glycaemic control and inform treatment. • • More informative is a combination of FPG and postprandial plasma glucose (2 hours after breakfast). • • Most informative is a glucose profile with several pre- and postprandial measurements throughout the day.\\n• • The least informative is random plasma glucose (RPG).\\nTargets for glycaemic control Blood glucose values closer to normal substantially reduce the risk of microvascular complications. The downside of tight blood glucose control is a potentially dangerous side-effect of the treatment (hypoglycaemia). It is recognized that an individualized approach is preferred when setting treatment targets. Patients with a short life expectancy and those with advanced complications or serious co-morbidities are unlikely to benefit from efforts to achieve near-normal glycaemia.\\n• • The majority of patients can be expected to aim for an HbA1c of 7.0% (53 mmol/mol).\\n• • The HbA1c target can be relaxed (e.g. to <8% or <64 mmol/mol) in people with frequent severe hypoglycaemia, advanced complications or low life-expectancy.\\n• • Patients treated with diet, physical activity and metformin (very low risk of hypoglycaemia) should be encouraged to achieve a lower HbA1c target. • • If HbA1c measurement is not available or there is concern over its validity, an FPG value of ≤7.0 mmol/L (126mg/dL) and a postprandial PG value of ≤9.0 mmol/L (160 mg/dL) can serve as surrogates.\\n17 HEARTS – D Diagnosis and management of Type 2 diabetes 3 Prevention and management of complications of diabetes Acute complications of diabetes Two important acute complications are hypoglycaemia and hyperglycaemic emergencies.\\nHypoglycaemia Hypoglycaemia (abnormally low blood glucose) is a frequent iatrogenic complication in diabetic patients, occurring particularly in patients receiving sulfonylurea or insulin. It can cause loss of consciousness and coma and is potentially life-threatening. Severe hypoglycaemia is defined as hypoglycaemia, during which the patient is unable to self-treat by ingestion of carbohydrates.\\nThere is no universally agreed plasma glucose cut-off point for hypoglycaemia, as symptoms and signs can occur at different thresholds. It is most frequently defined at plasma glucose of ≤3.9 mmol/L (70 mg/dL), when it should be managed even if there are no symptoms and signs. Table 4 Symptoms and signs of hypoglycaemia Symptoms of hypoglycaemia • • headache • • hunger • • irritability, anxiety • • paraesthesias • • palpitations Signs of hypoglycaemia • • sweating • • trembling • • difficulty in speaking • • confusion • • ataxia • • stupor • • pallor • • seizures • • coma 18 HEARTS – D Diagnosis and management of Type 2 diabetes Management of hypoglycaemia Hypoglycaemia is managed by ingestion of carbohydrate if the patient is able to swallow, or by i.v. administration of hypertonic glucose.1 • • If the patient is able to ingest food or drink, they should ingest 15–20 g of glucose. If glucose is not available, give oral carbohydrate that contains 15–20 g of rapidly absorbing forms of glucose (e.g. sugar-sweetened soft drink, 1–2 teaspoons of sugar, 5–6 hard candies, cup of milk). Plasma glucose levels typically increase by 2.8 mmol/l (50 mg/dL) within ~15 minutes; repeat the treatment if hypoglycaemia persists.\\n• • If rapidly absorbing glucose is not available, it can be substituted by any foods containing carbohydrate (e.g. bread, rice, potato).\\n• • Follow by a small meal with complex carbohydrate. • • Unconscious patients, those with plasma glucose ≤2.8 mmol/L (50 mg/dL) and those unable to to ingest drink should be given hypertonic glucose (dextrose) intravenously (20–50 mL of 50% glucose over 1–3 minutes). If this concentration is not available, substitute with any hypertonic glucose solution.\\n• • Food should be provided as soon as the patient is able to ingest food safely.\\n• • Discuss hypoglycaemia risk factors with the patient (skipping meals, physical activity more intense than usual, alcohol ingestion) and adjust medication if necessary.\\nHyperglycaemic emergencies Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) are life-threatening conditions with somewhat different biochemical features (Table 5). Although uncommon, DKA can occur in people with type 2 diabetes.\\nSymptoms and signs of DKA and HHS: • • Frequent symptoms and signs of DKA are nausea, vomiting and abdominal pain.\\n• • Severe cases of DKA can present with Kussmaul’s breathing.\\n• • Changes in sensorium in DKA range from alertness to stupor or coma, depending on the severity.\\n• • Patients with HHS typically present with altered consciousness (stupor or coma).\\nTable 5 Biochemical characteristics of DKA and HHS measurable in primary care facilities DKA HHS Plasma glucose level ≥13.9 mmol/L (250 mg/dL), occasionally lower ≥33.3 mmol/L (600 mg/dL) Urine ketones Positive Negative (or weakly positive) 1 Intramuscular injection of glucagon can also resolve hypoglycaemia, but it is rarely available in primary care.\\n19 HEARTS – D Diagnosis and management of Type 2 diabetes Management of hyperglycaemic emergencies Hyperglycaemic emergencies should be managed in hospital by correction of dehydration and electrolyte disbalance and administration of insulin.\\n• • Refer to hospital all patients with suspected DKA or HHS. (DKA or HHS should be suspected in every ill patient with hyperglycaemia.) • • Correction of dehydration is the critical first step for transport. Hyperglycaemia slows gastric emptying, and oral rehydration might not be effective even in patients who are not vomiting.\\n• • Infuse isotonic saline (0.9% NaCl) at a rate of 1000 mL in the first 2 hours. Continue with 1000 mL every 4 hours until reaching a hospital.\\nScreening and management of chronic complications of diabetes Microvascular complications Longstanding diabetes with uncontrolled blood glucose levels can lead to multiple organ damage, leading to diabetic retinopathy, nephropathy, neuropathy, and diabetic foot complications. These complications are typically clinically “silent” until far advanced.\\nDiabetic eye disease • • Diabetic retinopathy is a highly specific microvascular complication of diabetes. It is among the leading causes of blindness. • • Diabetes is also associated with an increased risk of other vision-threatening conditions, such as cataract and glaucoma.\\nDiagnosis of diabetic retinopathy Signs and symptoms of diabetic retinopathy: • • Vision-threatening retinopathy and macular changes may be asymptomatic. • • Vision loss occurs at advanced stages. Diabetic retinopathy can be diagnosed through the presence of specific retinal abnormalities on examination of the fundus after pupil dilation (microaneurysms, haemorrhages, venous beading, hard exudates, cotton-wool spots and neovascularization) and/or macular oedema (retinal thickening). Retinal examination can be performed through ophthalmoscopy (direct or indirect), slit lamp biomicroscopy, or retinal fundus photography.\\nDiagnosis of diabetic macular oedema requires a three-dimensional assessment that is best performed by a dilated examination using slit-lamp biomicroscopy and/ or stereo fundus photography.\\nRisk factors for diabetic retinopathy • • duration of diabetes • • poor glycaemic control • • hypertension • • diabetic kidney disease • • dyslipidaemia 20 HEARTS – D Diagnosis and management of Type 2 diabetes Screening for and management of diabetic retinopathy People with type 2 diabetes should be screened for retinopathy by a trained person upon diagnosis, and biennially thereafter, or as recommended by an ophthalmologist, for: • • visual acuity • • direct or indirect ophthalmoscopy (dilated pupils) or retinal fundus photography.\\nPatients reporting vision loss at any visit and those who have not had a retinal examination in the past two years should be referred to an ophthalmologist.\\nGood control of glycaemia as well as blood pressure and dyslipidaemia can slow the progression of diabetic retinopathy and macular oedema. Timely treatment of retinopathy with laser photocoagulation can reduce the risk of vision loss. In advanced proliferative retinopathy, some recovery of visual acuity can be achieved by vitrectomy. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) can prevent some visual loss in diabetic macular oedema.\\nDiabetic kidney disease Diabetic kidney disease is a microvascular complication of diabetes, with a characteristic histopathology. If untreated, it is characterized by a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure, and high risk of CVD and death. If left untreated, once the stage of proteinuria is reached it often ends in renal failure in about 5 to 7 years. Diabetic kidney disease is defined by albuminuria and/or a decreased estimated glomerular filtration rate (eGFR). Diagnosis of diabetic kidney disease Symptoms and signs of diabetic kidney disease: • • The earliest clinical signs are elevated blood pressure and moderately increased urine\\xa0albumin\\xa0excretion (Table 6). • • Peripheral oedema occurs at a very late stage.\\n• • The first symptoms are those of uraemia (nausea, itching, anorexia). The diagnosis of diabetic kidney disease is made in patients diagnosed with diabetes upon: • • Estimated glomerular filtration rate (eGFR)1 of <60 mL/min per 1.73 m2 on at least two occasions, 1 to 3 months apart, and/or • • Presence of albuminuria in at least two urine samples, 1 to 3 months apart. 1 eGFR is calculated from serum creatinine, using an equation that has been validated for that population. Otherwise, the most commonly used equation, developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). It is based on serum creatinine, age, sex and race. Risk factors for diabetic kidney disease • • poor glycaemic control • • elevated blood pressure • • genetic susceptibility 21 HEARTS – D Diagnosis and management of Type 2 diabetes Urinary albumin excretion can be estimated in a spot urine sample using several tests (from most preferred to least preferred): • • urine albumin-to-creatinine ratio (ACR) • • urine protein-to-creatinine ratio (PCR) • • reagent strip (“dipstick”) urine analysis for albumin or total protein with automated reading • • reagent strip (“dipstick”) urine analysis for albumin or total protein with manual reading. Table 6 Categories of albuminuria (measured by ACR) Category mg/g mg/mmol dipstick normal to mildly increased <30 <3 – moderately increased 30–300 3–30 Trace/1+ severely increased >300 >30 1+/2+ Screening for and management of diabetic kidney disease People with type 2 diabetes should be screened once a year with either the albumin/creatinine ratio in a spot urine sample or with eGFR using serum creatinine (preferably both tests, for better prognostic ability). Patients with moderately and severely increased albuminuria and those with GFR <60 ml/min/1.73 m2 if combined with albuminuria should be referred for specialist assessment (see Section 4).\\nTo delay onset and slow the progression of diabetic kidney disease: • • Aim for good glycaemic control but adjust for hypoglycaemia risk.\\n• • Maintain blood pressure levels at <130/80 mmHg with an angiotensin-converting enzyme (ACE) inhibitor and add thiazide diuretic if required. • • Modify other major CVD risk factors (dyslipidaemia, smoking).\\nEnd-stage renal disease requires renal replacement therapy (haemodialysis, peritoneal dialysis, renal transplant).\\nDiabetic neuropathy Nerve damage in diabetes is a group of disorders with diverse clinical manifestations. The most common forms are distal symmetrical peripheral neuropathy, which is predominantly sensory, and autonomic neuropathy, which affects the autonomic nervous system. Loss of protective sensation in peripheral neuropathy is a predisposing condition in the pathway leading to foot ulcer and amputation.\\nRisk factors for diabetic neuropathy • • duration of diabetes • • poor glycaemic control • • age 22 HEARTS – D Diagnosis and management of Type 2 diabetes Diagnosis of diabetic neuropathy Symptoms and signs of diabetic neuropathy: • • Peripheral neuropathy: o o sensory loss o o unsteadiness o o sensory symptoms (pain, unpleasant sensation of burning, tingling or numbness). • • Autonomic neuropathy: o o lack of awareness of hypoglycaemia o o orthostatic hypotension and resting tachycardia o o diarrhoea, constipation and fecal incontinence o o erectile dysfunction, urinary incontinence and bladder dysfunction.\\nNeuropathy can be present without symptoms.\\nPeripheral neuropathy is considered probable if there is a combination of two or more of the following: sensory symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes. (See Annex 2 for details.) The diagnosis of autonomic neuropathy requires tests that are not usually performed in primary care facilities.\\nManagement of diabetic neuropathy Specific treatment for the underlying nerve damage is not available. There are several treatment options for pain control, with adjuvant benefits or side effects to consider.\\n• • Exclude causes of peripheral neuropathy other than diabetes (alcohol, chemotherapy, vitamin B12 deficiency, hypothyroidism, renal disease, malignancies, HIV infection).\\n• • Refer patients with painful peripheral neuropathy to specialized care for pharmacological management of pain.\\n• • Refer patients with suspected autonomic neuropathy to specialized care. • • Improve glycaemic control.\\nFoot problems in diabetes Diabetes dramatically increases the risk of lower extremity amputation. Diabetic foot lesions often result from simultaneous presence of several risk factors, with peripheral diabetic neuropathy playing a central role. It leads to an insensitive and sometimes deformed foot, which can cause an abnormal walking pattern and abnormal biomechanical loading of the foot. The resulting high pressure in some areas of the foot leads to the formation of calluses, further increase in abnormal loading and eventually ulceration. A diabetic foot ulcer is a localized injury to the skin and/or underlying tissue below the ankle. People with diabetes often have peripheral artery disease as a result of accelerated atherosclerosis. Consequent ischemia impairs wound healing. Many diabetic foot ulcers occur in patients with combined neuropathy and ischaemia and are most often caused by trauma from inappropriate footwear and/or walking barefoot with insensitive feet. Disruption of protective skin allows for colonization 23 HEARTS – D Diagnosis and management of Type 2 diabetes of subcutaneous tissues by microbes and in many cases the wound becomes clinically infected, requiring antimicrobial treatment and often some form of surgical intervention.\\nAnnex 2 provides details on prevention, assessment and management of diabetic foot. Macrovascular complications Coronary heart disease, cerebrovascular disease and peripheral vascular disease are a major cause of morbidity and mortality in people with diabetes. Blood pressure control Blood pressure lowering in people with diabetes reduces the risk of microvascular and macrovascular complications. Control of blood pressure in people with diabetes often requires more than one medication. Thiazide diuretics and ACE inhibitors are recommended to achieve a target blood pressure of <130/80 mmHg. If this is not achievable, refer to a higher level of care. Other protocols from HEARTS-E are also an option.\\nControl of blood lipids Some improvement in lipid profile can be achieved with a healthy diet and physical activity. Statins can reduce the risk of CVD events in people with diabetes. Statins are recommended for all patients of 40 years of age and older with diabetes. If this is not feasible, use statins in patients at highest risk of CVD events (e.g. patients with CVD, patients with nephropathy and/or patients with a high risk on a CVD risk prediction chart).\\nAntiplatelet treatment Use of antiplatelet treatment is recommended only for secondary prevention of CVD events, even among patients with diabetes. The recommendation is for 75–100 mg of acetylsalicylic acid daily to be prescribed to all people with diabetes who have survived a CVD event and have no history of major bleeding.\\nRisk factors for CVD • • age • • family history of CVD • • overweight and obesity • • chronic kidney disease • • hypertension • • dyslipidaemia • • smoking • • prior CVD event 24 HEARTS – D Diagnosis and management of Type 2 diabetes FPG/RPG >18 mmol/l ( 325 mg/dl) TEST urine ketones if ketones ≥2+ if ketones <2+ REVIEW in 3–5 days REVIEW in 2–3 months No improvement Improvement BEGIN gliclazide 80 mg bid & counsel on diet modifcation, physical activity and adherence to medicines REVIEW IN 3 MONTHS If goal not achieved BEGIN METFORMIN 500 mg once daily. Counsel on diet and physical activity and adherence at ALL visits REVIEW IN 3 MONTHS If goal not achieved increase dose to 1000 mg 1x daily REVIEW IN 3 MONTHS If goal not achieved increase dose to 1000 mg 2x daily REVIEW IN 3 MONTHS If goal not achieved, ADD gliclazide 80 mg 1x daily. Counsel on hypoglycaemia at all subsequent visits REVIEW IN 3 MONTHS If goal not achieved, despite adherence to medication, healthy diet and physical activity, REFER to higher-level health care facility for starting insulin* REVIEW IN 3 MONTHS If goal not achieved increase dose to 80 mg 2x daily FPG ≥7 mmol/l and <18 mmol/l or RPG ≥11.1 mmol/l and <18 mmol/l # Counsel on diet and physical activity REFER to higher level of care REFER to higher level of care CONTINUE gliclazide and diet and physical activity If goal not achieved REFER to higher level of care TEST ADULTS who have symptoms of diabetes with fasting or random plasma glucose (FPG or RPG), Test adults who are 40+ years old with BMI >25 with FPG • Measure blood pressure at every scheduled visit, review medication as per hypertension protocol • REFER for dilated-pupil retinal exam upon diagnosis, and every two years thereafter, or as per ophthalmologist recommendation • Examine feet for ulcers at every visit. REFER to higher level of care if ulcer present • Assess risk of lower limb amputation annually (foot pulses, sensory neuropathy by monoflament, presence of healed or open ulcers, calluses). REFER to higher level of care if ulcer present or pulse absent • Test for proteinuria annually. REFER to higher level of care if positive.\\nMANAGEMENT OF ACUTE COMPLICATIONS Severe hypoglycaemia (plasma glucose <50 mg/dl or 2.8 mmol/l) or signs: • If conscious, give a sugar-sweetened drink • If unconscious, give 20–50 mI of 50% glucose (dextrose) IV over 1–3 minutes.\\nSevere hyperglycaemia (plasma glucose >18 mmol/l (325 mg/dl) and urine ketone 2+) or signs and symptoms of severe hyperglycaemia: • Set up intravenous drip 0.9% NaCI 1 litre in 2 hours; continue at 1 litre every 4 hours, REFER to hospital.\\nGoal for glycaemic control Plasma glucose** Fasting ≤7.0 mmol/l (126mg/dl)† # refer to table on diagnostic values for other tests which can be used to diagnose diabetes.\\n* If they are more afordable than insulin, DPP4-inhibitors, SGLT2-inhibitors or pioglitazone can be used before insulin in cases of treatment failure with metformin and gliclazide. Introduce and titrate insulin treatment according to local practices.\\n** HbA1c should be used where available.\\n† Consider less stringent glycaemic control in patients with frequent severe hypoglycaemia, advanced complications, serious comorbidities and/or Iimited life expectancy.\\nSCREENING FOR CHRONIC COMPLICATIONS 19 February 2018 Fig. 2 Type 2 diabetes management protocol derived from WHO-PEN 25 HEARTS – D Diagnosis and management of Type 2 diabetes 4 Criteria for referral to higher levels of care Urgent (same day) referral should occur if one of the following is detected: • • urine ketones >2+, or no improvement in glycaemia ≥18 mmol/L after management with metformin and/or gliclazide • • suspicion of ketoacidosis or HHS (see page 19) • • hypoglycaemia unresolved by treatment (see page 19) • • clinical suspicion of type 1 diabetes in newly diagnosed patient • • symptoms/signs of coronary heart disease and stroke • • recent deterioration of vision • • blood pressure >200/>110 mmHg • • blood pressure >180/>110 mmHg with headache, shortness of breath, blurred vision, changed mental state, nausea, vomiting, reduced urine output • • infected foot ulcer with or without symptoms of systemic infection; gangrene • • critical limb ischaemia • • anuria or eGFR <30 mL/min/1.73 m2.\\nNon-emergency referral should occur if one of the following is detected: • • glycaemia treatment goal is not achieved despite compliance to treatment with oral medication (and insulin) • • eGFR 30–59 mL/min/1.73 m2 • • moderately and severely increased albuminuria • • symptoms and signs of peripheral vascular disease • • blood pressure >130/80 mmHg despite treatment with two medications • • total cholesterol >8 mmol/L (310 mg/dL). 26 HEARTS – D Diagnosis and management of Type 2 diabetes 5 Monitoring of processes and outcomes A monitoring system to assess the effectiveness of diabetes management should include regular monitoring of biochemical parameters and occurrence of complications due to diabetes. Biochemical parameters: • • Glycated haemoglobin (HbA1c) provides a measure of average plasma glucose over the preceding 8 to 12 weeks. The majority of patients can be expected to aim for a HbA1c of ≤7.0% (53 mmol/mol) • • If HbA1c measurement is not available or there is concern over its validity, an FPG value of ≤7.0 mmol/L (126mg/dL) and a postprandial PG value of ≤9.0 mmol/L (160 mg/dL) can serve as surrogates.\\nTable 7 Assessment of effectiveness of diabetes services Indicator Description Number of patients being treated for diabetes Number of patients and number of new patients with diabetes Frequency of reporting: monthly Control rate among people treated for diabetes Numerator: number of patients with diabetes with good glycaemic control at the last clinical visit in the last 6 months (HbA1c <7.0% (53 mmol/mol), or FPG <7.0 mmol/L (126mg/dL) and (if available) a postprandial PG value <9.0 mmol/L (160 mg/dL) Denominator: number of patients with diabetes in the facility during the last 6 months Frequency of reporting: every 6 months Complications due to diabetes: • • diabetic foot • • nephropathy • • retinopathy • • neuropathy • • cardiovascular diseases Numerator: number of new diabetes complications in the past year Denominator: number of patients with diabetes in the past year Frequency of reporting: annually 27 HEARTS – D Diagnosis and management of Type 2 diabetes 6\\tResources For more detail on the topics discussed here, see the following publications.\\nClassification of diabetes mellitus. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.\\nDefinition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva: World Health Organization; 2006. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Geneva: World Health Organization; 2018. Licence: CC BY-NCSA 3.0 IGO.\\nGlobal report on diabetes. Geneva: World Health Organization; 2016.\\nHEARTS Technical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols. Geneva: World Health Organization; 2018 (WHO/NMH/NVI/18.2). Licence: CC BY-NC-SA 3.0 IGO.\\nImplementation tools: package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization; 2013.\\nThe selection and use of essential medicines 2019. Report of the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines, 1 – 5 April 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.\\nLevey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612. 28 HEARTS – D Diagnosis and management of Type 2 diabetes Annex 1: Protocol for treatment of type 2 diabetes mellitus with insulin START with 10 units intermediate-acting insulin (NPH) at bedtime Continue metformin and sulfonylurea Counsel patient on hypoglycaemia Counsel patient on symptoms of hyperglycaemia CONTINUE INCREASING DOSAGE by 1–2 units at 3-day intervals until FBG = 4–7 mmol/L Do not increase insulin if nocturnal hypoglycaemia occurs REVIEW in 3 days REVIEW in 3 days IF FBG <4mmol/L or if nocturnal hypoglycaemia occurs REDUCE INSULIN by 1–2 units IF FBG 4–7 mmol/L and daytime hypoglycaemia occurs REDUCE morning gliclazide by 40 mg STOP morning gliclazide if daytime hypoglycaemia continues IF FBG >7mmol/L AND nocturnal hypoglycaemia occurs, REFER to higher level of care IF HbA1c >7.5% REFER to higher level of care for intensifcation IF FBG >7 mmol/L INCREASE INSULIN dosage by 1–2 units IF stabilized REVIEW with HbA1c in 3 months 29 HEARTS – D Diagnosis and management of Type 2 diabetes Annex 2: Prevention, assessment and management of diabetic foot What are diabetic foot problems?\\nFig. 3 Examples of foot ulcers Diabetic foot problems are amongst the most common, costly and severe complications of diabetes. The term “diabetic foot complications” encompasses the conditions of diabetic foot ulcer (i.e., a full-thickness epithelial defect below/distal to the ankle) and diabetic foot infections (i.e., any soft-tissue or bone infection occurring in the diabetic foot, including osteomyelitis). A diabetic foot ulcer is a localised injury to the skin and/or underlying tissue below the ankle. Disruption of protective skin allows for colonization of subcutaneous tissues by microbes and in many cases the wound becomes clinically infected, requiring antimicrobial treatment and often some form of surgical intervention. Diabetic foot ulcers frequently result from a person with diabetes simultaneously having two or more risk factors, with diabetic peripheral neuropathy and peripheral artery disease usually playing a central role. Fig. 4 Areas of foot at highest risk for ulceration The neuropathy leads to an insensitive and sometimes deformed foot, often causing abnormal loading of the foot. In people with neuropathy, minor trauma (e.g., from ill-fitting shoes, or an acute mechanical or thermal injury) can precipitate ulceration of the foot. Loss of protective sensation, foot deformities, and limited joint mobility can result in abnormal biomechanical loading of the foot. This produces high mechanical stress in some areas, the response to which is usually thickened skin (callus). The callus then leads to a further increase in the loading of the foot, often with subcutaneous haemorrhage and eventually skin ulceration. Whatever the primary cause of ulceration, continued walking on the insensitive foot impairs healing of the ulcer. Peripheral artery disease (PAD), generally caused by atherosclerosis, is present in up to 50% of patients with a diabetic foot ulcer. PAD is an important risk factor for impaired wound healing and lower extremity amputation. A small percentage of foot ulcers in patients with severe PAD are purely ischaemic; these are usually painful and may follow minor trauma.\\n30 HEARTS – D Diagnosis and management of Type 2 diabetes Common risk factors for the development of foot ulcers in people with diabetes • • peripheral vascular disease • • neuropathy • • poor glycaemic control • • cigarette smoking • • diabetic nephropathy • • previous foot ulcerations/amputations Symptoms Patients can present with symptoms of peripheral neuropathy and or peripheral artery occlusion, such as: • • pain in the legs or cramping in the thighs or calves during physical activity • • tingling, burning, or pain in the feet • • loss of sense of touch or ability to feel heat or cold very well • • a change in the shape of feet over time • • dry, cracked skin on the feet • • a change in the color and temperature of the feet • • thickened, yellow toenails • • fungal infections between the toes • • a blister, sore, ulcer, infected corn, or ingrown toenail.\\nHowever, the absence of symptoms does not exclude diabetic foot problems. Assessment and management of diabetic foot problems Examination of the feet Remove the patient’s shoes, socks, dressings, and bandages and carry out the following examination procedures: Palpation of arteries Fig. 5 Dorsal pedis palpation Dorsal pedis: Feel in the middle of the dorsum of the foot just lateral to the tendon of extensor halluces longus (extensor tendon of the great toe).\\nFig. 6 Posterior tibial artery palpation Posterior tibial artery: Feel midway between medial malleolus and tendon calcaneus.\\n31 HEARTS – D Diagnosis and management of Type 2 diabetes Assessing loss of protective sensation (LOPS) Assessment of LOPS is done with one of the following techniques: a) Pressure perception: Semmes-Weinstein 10 g monofilament (if monofilament is not available, see “method c” below). Sensory examination should be carried out in a quiet and relaxed setting.\\no o First, apply the monofilament on the patient’s hands (or elbow or forehead) so that she or he knows what to expect. The patient must not be able to see whether or where the examiner applies the filament. o o Conduct the test on three sites on both feet (Fig. 6 and Fig. 7).\\no o The total duration – skin contact and removal of the filament should be approximately 2 secs.\\no o Apply the filament along the perimeter of, not on, an ulcer site callus or necrotic tissue. o o Do not allow the filament to slide across the skin or make repetitive contact at the test site.\\no o Apply the monofilament perpendicular to the skin surface. Apply sufficient force to cause the filament to bend or buckle. o o Press the filament to the skin and ask the patient whether they feel the pressure applied (Yes/No). o o Next, ask where they feel the pressure (right foot/left foot). o o Repeat this application twice at the same site but alternate this with one “mock” application in which no filament is applied.\\nFig. 7 Sites to be tested for loss of protective sensation b) Vibration perception: 128 Hz tuning fork. The proper method for using a 128 Hz tuning fork to check for vibratory sensation is as follows: o o First, apply the tuning fork on the patient’s wrist (or elbow or clavicle) to demonstrate what the sensation feels like.\\no o Ensure the patient cannot see whether or where the examiner applies the tuning fork.\\no o Apply the tuning fork to a bony part on the dorsal side of the distal phalanx of the first toe (or another toe if the hallux is absent).\\no o Apply the tuning fork perpendicularly, with constant pressure (Fig. 8).\\no o Repeat this application twice, but alternate this with at least one “mock” Fig. 8 Pressure perception test using Semmes-Weinstein 10 g monofilament Fig. 9 Application of tuning fork in vibration perception test 32 HEARTS – D Diagnosis and management of Type 2 diabetes application in which the tuning fork is not vibrating.\\no o The test is positive if the patient correctly answers at least two out of three applications, and negative if two out of three answers are incorrect.\\no o If the patient is unable to sense the vibrations on the toe, repeat the test more proximally (e.g., malleolus, tibial tuberosity).\\nc) When monofilament or tuning fork are not available, test tactile sensation with the light touch test. This simple test (also called the Ipswich Touch Test) can be used to screen for loss of protective sensation (LOPS), when the 10 g monofilament or 128 HZ tuning fork is not available. The test has reasonable agreement with these tests to determine LOPS, but its accuracy in predicting foot ulcers has not been established.\\no o Instruct the subject to close their eyes and to say “yes” when they feel the touch.\\no o The examiner lightly sequentially touches with the tip of her/his index finger the tips of the first, third, and fifth toes of both feet for 1–2 seconds. When touching, do not push, tap, or poke.\\no o LOPS is likely when light touch is not sensed in ≥2 sites.\\nStratification and management of risk Table 8 Stratification of level of risk of developing diabetic foot problems or the need for an amputation Risk level Low risk Moderate risk High risk Active foot problem Features No risk factor except callus alone Any of: • • deformity • • neuropathy • • non-critical limb ischaemia Any of: • • previous ulcer • • previous amputation • • neuropathy with non-critical limb ischaemia • • neuropathy with callus and/or deformity • • non-critical limb ischaemia with callus and/or deformity Any of: • • ulcer • • spreading infections • • critical limb iscaemia • • gangrene • • suspicion of acute Charcot arthropathy • • unexplained red swollen foot Action Assess annually Assess every 3–6 months Assess every 1–3 months Urgent referral Patients with diabetes should receive counselling on avoidance of foot complications (see below).\\n• • Patients at low risk can be assessed annually, those at moderate risk every 3–6 months, and those at high risk every 1–3 months.\\n• • Pre-ulcerative lesions need to be treated by a trained professional by: o o removal of callus o o protection or draining of blisters o o treatment of ingrown and thickened nails o o antifungal treatment for fungal infections.\\n33 HEARTS – D Diagnosis and management of Type 2 diabetes Management of active diabetic foot problems Active foot problems require referral to a higher level of care. Best results in prevention of amputations have been achieved in settings where multidisciplinary facilities are available. When to refer Patients with a foot ulcer should be referred to a more specialized level for further evaluation if management by a trained professional and the necessary equipment and consumables are not available at the primary care level. Patients with gross foot deformities and/or absent peripheral pulses, and patients with suspected lower limb ischaemia will need to be referred to a higher level of care. Urgent referral to acute services is recommended for patients with any of the following: • • infected ulcer • • spreading infection • • critical limb ischaemia • • gangrene • • suspicion of acute Charcot arthropathy • • unexplained red swollen foot.\\nCounselling patients on foot care To avoid serious foot problems that could result in losing a toe, foot or leg: • • Inspect your feet daily. Check for cuts, blisters, redness, swelling, or nail problems. Use a magnifying hand mirror to look at the bottom of your feet. • • Bathe feet in lukewarm, never hot, water. Keep your feet clean by washing them daily. Use only lukewarm water – the temperature you would use on a newborn baby.\\n• • Be gentle when bathing your feet. Wash them using a soft washcloth or sponge. Dry by blotting or patting, and dry carefully between the toes.\\n• • Moisturize your feet but not between your toes. Use a moisturizer daily to keep dry skin from itching or cracking. But don’t moisturize between the toes – that could encourage a fungal infection.\\n• • Cut nails carefully. Cut them straight across and file the edges. Don’t cut nails too short, as this could lead to ingrown toenails. If you have concerns about your nails, consult your doctor.\\n• • Never treat corns or calluses yourself. No “bathroom surgery” or medicated pads. Visit your doctor for appropriate treatment.\\n• • Shake out your shoes and feel the inside before wearing. Remember, your feet may not be able to feel a pebble or other foreign object, so always inspect your shoes before putting them on.\\nFig. 10 The proper way to cut toenails 34 HEARTS – D Diagnosis and management of Type 2 diabetes • • Wear socks and appropriate footwear. The inside length of the shoe should be 1–2 cm longer than your foot, and should be neither too tight nor too loose.\\n• • Keep your feet warm and dry. • • Never walk barefoot, not even at home. Always wear shoes or slippers. You could step on something and get a scratch or cut.\\n• • Take care of your diabetes. Keep your blood glucose levels under control.\\n• • Do not smoke. Smoking restricts blood flow in your feet.\\n• • Get your feet examined regularly. Resources For further information on care of diabetic foot see the following publications: International Working Group on Diabetic Foot. Practical guidelines on the prevention and management of diabetic foot disease. (https://iwgdfguidelines.org/ wp-content/uploads/2019/05/01-IWGDF-practical-guidelines-2019.pdf) American College of Foot and Ankle Surgeons (ACFAS). Foot health facts.\\nNICE guideline [NG19]: Diabetic foot problems: prevention and management. August 2015. Last updated October 2019.\\nDiabetes and your feet. (https://www.cdc.gov/features/diabetesfoothealth/index.html) Fig. 11 Appropriate shoe shape and size 35 HEARTS – D Diagnosis and management of Type 2 diabetes'},\n",
       "  {'title': 'Diabetes & Metabolism | Journal | ScienceDirect.com by Elsevier',\n",
       "   'url': 'https://www.sciencedirect.com/journal/diabetes-and-metabolism',\n",
       "   'content': 'Diabetes & Metabolism is a subscription journal (with optional open access), which allows you to publish your research without any cost to you (unless you proactively chose the open access option). Your article will be available to all researchers around the globe whose institution has a subscription to the journal.',\n",
       "   'score': 0.44680908,\n",
       "   'raw_content': None},\n",
       "  {'title': 'The burden and risks of emerging complications of diabetes mellitus',\n",
       "   'url': 'https://www.nature.com/articles/s41574-022-00690-7',\n",
       "   'content': 'However, advances in the management of diabetes mellitus and, consequently, longer life expectancies, have resulted in the emergence of evidence of the existence of a different set of lesser-acknowledged diabetes mellitus complications. This Review summarizes information from systematic reviews and major cohort studies regarding emerging complications of type 1 and type 2 diabetes mellitus to identify and quantify associations, highlight gaps and discrepancies in the evidence, and consider implications for the future management of diabetes mellitus. Key points With advances in the management of diabetes mellitus, evidence is emerging of an increased risk and burden of a different set of lesser-known complications of diabetes mellitus. As new complications of diabetes mellitus continue to emerge, the management of this disorder should be viewed holistically, and screening guidelines should consider conditions such as cancer, liver disease and depression.',\n",
       "   'score': 0.4295017,\n",
       "   'raw_content': 'The burden and risks of emerging complications of diabetes mellitus | Nature Reviews Endocrinology\\n===============\\n\\nYour privacy, your choice\\n-------------------------\\n\\nWe use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.\\n\\nBy accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.\\n\\nSee our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data.\\n\\nManage preferences for further information and to change your choices.\\n\\nAccept all cookies\\n\\n[Skip to main content](https://www.nature.com/articles/s41574-022-00690-7#content)\\n\\nThank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.\\n\\nAdvertisement\\n\\n [![Image 1: Nature Reviews Endocrinology](https://media.springernature.com/full/nature-cms/uploads/product/nrendo/header-f259bdb75880389772e0b358a4c006e2.svg)](https://www.nature.com/nrendo)\\n\\n*   [View all journals](https://www.nature.com/siteindex)\\n*   [Search](javascript:;)\\n    \\n    Search\\n    ------\\n    \\n    Search articles by subject, keyword or author\\n    \\n    Show results from \\n    \\n    Search\\n    \\n    [Advanced search](https://www.nature.com/search/advanced)\\n    \\n    ### Quick links\\n    \\n    *   [Explore articles by subject](https://www.nature.com/subjects)\\n    *   [Find a job](https://www.nature.com/naturecareers)\\n    *   [Guide to authors](https://www.nature.com/authors/index.html)\\n    *   [Editorial policies](https://www.nature.com/authors/editorial_policies/)\\n    \\n*   [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41574-022-00690-7)\\n\\n*   [Explore content](javascript:;)\\n    \\n    Explore content\\n    ---------------\\n    \\n    *   [Research articles](https://www.nature.com/nrendo/research-articles)\\n    *   [Reviews & Analysis](https://www.nature.com/nrendo/reviews-and-analysis)\\n    *   [News & Comment](https://www.nature.com/nrendo/news-and-comment)\\n    *   [Current issue](https://www.nature.com/nrendo/current-issue)\\n    *   [Collections](https://www.nature.com/nrendo/collections)\\n    \\n    *   [Follow us on Facebook](https://www.facebook.com/NatureReviews)\\n    *   [Follow us on Twitter](https://twitter.com/NatureRevEndo)\\n    *   [Sign up for alerts](https://www.nature.com/my-account/alerts/subscribe-journal?list-id=112)\\n    *   [RSS feed](https://www.nature.com/nrendo.rss)\\n    \\n*   [About the journal](javascript:;)\\n    \\n    About the journal\\n    -----------------\\n    \\n    *   [Aims & Scope](https://www.nature.com/nrendo/aims)\\n    *   [Journal Information](https://www.nature.com/nrendo/journal-information)\\n    *   [Editorial policies](https://www.nature.com/nrendo/editorial-policies)\\n    *   [About the Editors](https://www.nature.com/nrendo/editors)\\n    *   [Reviews Cross-Journal Editorial Team](https://www.nature.com/nrendo/reviews-cross-journal-editorial-team)\\n    *   [Journal Credits](https://www.nature.com/nrendo/journal-credits)\\n    *   [Editorial input and checks](https://www.nature.com/nrendo/editorial-input-and-checks)\\n    *   [Editorial Values Statement](https://www.nature.com/nrendo/editorial-values-statement)\\n    *   [Journal Metrics](https://www.nature.com/nrendo/journal-impact)\\n    *   [Publishing model](https://www.nature.com/nrendo/publishing-model)\\n    *   [Conferences](https://www.nature.com/nrendo/conferences)\\n    *   [Posters](https://www.nature.com/nrendo/posters)\\n    *   [Web Feeds](https://www.nature.com/nrendo/web-feeds)\\n    *   [Contact](https://www.nature.com/nrendo/contact)\\n    \\n*   [Publish with us](javascript:;)\\n    \\n    Publish with us\\n    ---------------\\n    \\n    *   [For Authors](https://www.nature.com/nrendo/for-authors)\\n    *   [For Referees](https://www.nature.com/nrendo/for-referees)\\n    *   [Submit manuscript](https://mts-nrendo.nature.com/cgi-bin/main.plex)\\n    \\n\\n*   [Sign up for alerts](https://idp.nature.com/auth/personal/springernature?redirect_uri=https%3A%2F%2Fwww.nature.com%2Fmy-account%2Falerts%2Fsubscribe-journal%3Flist-id%3D112%26journal-link%3Dhttps%253A%252F%252Fwww.nature.com%252Fnrendo%252F)\\n*   [RSS feed](https://www.nature.com/nrendo.rss)\\n\\n1.  [nature](https://www.nature.com/)\\n2.  [nature reviews endocrinology](https://www.nature.com/nrendo)\\n3.  [review articles](https://www.nature.com/nrendo/articles?type=review-article)\\n4.  article\\n\\nThe burden and risks of emerging complications of diabetes mellitus\\n\\n[Download PDF](https://www.nature.com/articles/s41574-022-00690-7.pdf)\\n\\n[Download PDF](https://www.nature.com/articles/s41574-022-00690-7.pdf)\\n\\n*   Review Article\\n*   Published: 06 June 2022\\n\\nThe burden and risks of emerging complications of diabetes mellitus\\n===================================================================\\n\\n*   [Dunya Tomic](https://www.nature.com/articles/s41574-022-00690-7#auth-Dunya-Tomic-Aff1-Aff2)\\xa0 [ORCID: orcid.org/0000-0003-2471-2523](http://orcid.org/0000-0003-2471-2523)[1](https://www.nature.com/articles/s41574-022-00690-7#Aff1),[2](https://www.nature.com/articles/s41574-022-00690-7#Aff2),\\n*   [Jonathan E. Shaw](https://www.nature.com/articles/s41574-022-00690-7#auth-Jonathan_E_-Shaw-Aff1-Aff2)\\xa0 [ORCID: orcid.org/0000-0002-6187-2203](http://orcid.org/0000-0002-6187-2203)[1](https://www.nature.com/articles/s41574-022-00690-7#Aff1),[2](https://www.nature.com/articles/s41574-022-00690-7#Aff2)\\xa0[na1](https://www.nature.com/articles/s41574-022-00690-7#na1) &\\n*   [Dianna J. Magliano](https://www.nature.com/articles/s41574-022-00690-7#auth-Dianna_J_-Magliano-Aff1-Aff2)\\xa0 [ORCID: orcid.org/0000-0002-9507-6096](http://orcid.org/0000-0002-9507-6096)[1](https://www.nature.com/articles/s41574-022-00690-7#Aff1),[2](https://www.nature.com/articles/s41574-022-00690-7#Aff2)\\xa0[na1](https://www.nature.com/articles/s41574-022-00690-7#na1)\\xa0\\n\\n[_Nature Reviews Endocrinology_](https://www.nature.com/nrendo) **volume\\xa018**,\\xa0pages 525–539 (2022)[Cite this article](https://www.nature.com/articles/s41574-022-00690-7#citeas)\\n\\n*   80k Accesses\\n    \\n*   499 Citations\\n    \\n*   55 Altmetric\\n    \\n*   [Metrics details](https://www.nature.com/articles/s41574-022-00690-7/metrics)\\n    \\n\\nAbstract\\n--------\\n\\nThe traditional complications of diabetes mellitus are well known and continue to pose a considerable burden on millions of people living with diabetes mellitus. However, advances in the management of diabetes mellitus and, consequently, longer life expectancies, have resulted in the emergence of evidence of the existence of a different set of lesser-acknowledged diabetes mellitus complications. With declining mortality from vascular disease, which once accounted for more than 50% of deaths amongst people with diabetes mellitus, cancer and dementia now comprise the leading causes of death in people with diabetes mellitus in some countries or regions. Additionally, studies have demonstrated notable links between diabetes mellitus and a broad range of comorbidities, including cognitive decline, functional disability, affective disorders, obstructive sleep apnoea and liver disease, and have refined our understanding of the association between diabetes mellitus and infection. However, no published review currently synthesizes this evidence to provide an in-depth discussion of the burden and risks of these emerging complications. This Review summarizes information from systematic reviews and major cohort studies regarding emerging complications of type 1 and type 2 diabetes mellitus to identify and quantify associations, highlight gaps and discrepancies in the evidence, and consider implications for the future management of diabetes mellitus.\\n\\nKey points\\n----------\\n\\n*   With advances in the management of diabetes mellitus, evidence is emerging of an increased risk and burden of a different set of lesser-known complications of diabetes mellitus.\\n    \\n*   As mortality from vascular diseases has declined, cancer and dementia have become leading causes of death amongst people with diabetes mellitus.\\n    \\n*   Diabetes mellitus is associated with an increased risk of various cancers, especially gastrointestinal cancers and female-specific cancers.\\n    \\n*   Hospitalization and mortality from various infections, including COVID-19, pneumonia, foot and kidney infections, are increased in people with diabetes mellitus.\\n    \\n*   Cognitive and functional disability, nonalcoholic fatty liver disease, obstructive sleep apnoea and depression are also common in people with diabetes mellitus.\\n    \\n*   As new complications of diabetes mellitus continue to emerge, the management of this disorder should be viewed holistically, and screening guidelines should consider conditions such as cancer, liver disease and depression.\\n    \\n\\n### Similar content being viewed by others\\n\\n![Image 2](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41574-021-00512-2/MediaObjects/41574_2021_512_Fig1_HTML.png)\\n\\n### [Type 2 diabetes mellitus in older adults: clinical considerations and management](https://www.nature.com/articles/s41574-021-00512-2?fromPaywallRec=false)\\n\\nArticle 25 June 2021\\n\\n![Image 3](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-020-71908-9/MediaObjects/41598_2020_71908_Fig1_HTML.png)\\n\\n### [Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025](https://www.nature.com/articles/s41598-020-71908-9?fromPaywallRec=false)\\n\\nArticle Open access 08 September 2020\\n\\n![Image 4](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41433-022-02033-2/MediaObjects/41433_2022_2033_Fig1_HTML.png)\\n\\n### [The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis](https://www.nature.com/articles/s41433-022-02033-2?fromPaywallRec=false)\\n\\nArticle 02 May 2022\\n\\nIntroduction\\n------------\\n\\nDiabetes mellitus is a common, albeit potentially devastating, medical condition that has increased in prevalence over the past few decades to constitute a major public health challenge of the twenty-first century[1](https://www.nature.com/articles/s41574-022-00690-7#ref-CR1 \"Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782–787 (2001).\"). Complications that have traditionally been associated with diabetes mellitus include macrovascular conditions, such as coronary heart disease, stroke and peripheral arterial disease, and microvascular conditions, including diabetic kidney disease, retinopathy and peripheral neuropathy[2](https://www.nature.com/articles/s41574-022-00690-7#ref-CR2 \"Fowler, M. J. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 26, 77–82 (2008).\") (Fig.\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Fig1)). Heart failure is also a common initial manifestation of cardiovascular disease in patients with type 2 diabetes mellitus (T2DM)[3](https://www.nature.com/articles/s41574-022-00690-7#ref-CR3 \"Shah, A. D. et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 3, 105–113 (2015).\") and confers a high risk of mortality in those with T1DM or T2DM[4](https://www.nature.com/articles/s41574-022-00690-7#ref-CR4 \"Bertoni, A. G. et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27, 699–703 (2004).\"). Although a great burden of disease associated with these traditional complications of diabetes mellitus still exists, rates of these conditions are declining with improvements in the management of diabetes mellitus[5](https://www.nature.com/articles/s41574-022-00690-7#ref-CR5 \"Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).\"). Instead, as people with diabetes mellitus are living longer, they are becoming susceptible to a different set of complications[6](https://www.nature.com/articles/s41574-022-00690-7#ref-CR6 \"Gregg, E. W., Sattar, N. & Ali, M. K. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 4, 537–547 (2016).\"). Population-based studies[7](https://www.nature.com/articles/s41574-022-00690-7#ref-CR7 \"Gregg, E. W. et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet 391, 2430–2440 (2018).\"),[8](https://www.nature.com/articles/s41574-022-00690-7#ref-CR8 \"Harding, J. L., Shaw, J. E., Peeters, A., Davidson, S. & Magliano, D. J. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care 39, 1018–1026 (2016).\"),[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\") show that vascular disease no longer accounts for most deaths among people with diabetes mellitus, as was previously the case[10](https://www.nature.com/articles/s41574-022-00690-7#ref-CR10 \"Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 17, 83 (2018).\"). Cancer is now the leading cause of death in people with diabetes mellitus in some countries or regions (hereafter ‘countries/regions’)[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\"), and the proportion of deaths due to dementia has risen since the turn of the century[11](https://www.nature.com/articles/s41574-022-00690-7#ref-CR11 \"Pearson-Stuttard, J., Buckley, J., Cicek, M. & Gregg, E. W. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol. Metab. Clin. North Am. 50, 357–368 (2021).\"). In England, traditional complications accounted for more than 50% of hospitalizations in people with diabetes mellitus in 2003, but for only 30% in 2018, highlighting the shift in the nature of complications of this disorder over this corresponding period[12](https://www.nature.com/articles/s41574-022-00690-7#ref-CR12 \"Pearson-Stuttard, J. et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 10, 46–57 (2022).\").\\n\\n**Fig. 1: Major traditional complications and emerging complications of diabetes mellitus.**\\n\\n[![Image 5: figure 1](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41574-022-00690-7/MediaObjects/41574_2022_690_Fig1_HTML.png)](https://www.nature.com/articles/s41574-022-00690-7/figures/1)\\n\\nThe traditional complications of diabetes mellitus include stroke, coronary heart disease and heart failure, peripheral neuropathy, retinopathy, diabetic kidney disease and peripheral vascular disease, as represented on the left-hand side of the diagram. With advances in the management of diabetes mellitus, associations between diabetes mellitus and cancer, infections, functional and cognitive disability, liver disease and affective disorders are instead emerging, as depicted in the right-hand side of the diagram. This is not an exhaustive list of complications associated with diabetes mellitus.\\n\\n[Full size image](https://www.nature.com/articles/s41574-022-00690-7/figures/1)\\n\\nCohort studies have reported associations of diabetes mellitus with various cancers, functional and cognitive disability, liver disease, affective disorders and sleep disturbance, and have provided new insights into infection-related complications of diabetes mellitus[13](https://www.nature.com/articles/s41574-022-00690-7#ref-CR13 \"Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D. G. & Critchley, J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 4, 148–158 (2016).\"),[14](https://www.nature.com/articles/s41574-022-00690-7#ref-CR14 \"Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734–743 (2007).\"),[15](https://www.nature.com/articles/s41574-022-00690-7#ref-CR15 \"Chatterjee, S. et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 39, 300–307 (2016).\"),[16](https://www.nature.com/articles/s41574-022-00690-7#ref-CR16 \"Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607 (2015).\"),[17](https://www.nature.com/articles/s41574-022-00690-7#ref-CR17 \"Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).\"). Although emerging complications have been briefly acknowledged in reviews of diabetes mellitus morbidity and mortality[11](https://www.nature.com/articles/s41574-022-00690-7#ref-CR11 \"Pearson-Stuttard, J., Buckley, J., Cicek, M. & Gregg, E. W. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol. Metab. Clin. North Am. 50, 357–368 (2021).\"),[17](https://www.nature.com/articles/s41574-022-00690-7#ref-CR17 \"Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).\"), no comprehensive review currently specifically provides an analysis of the evidence for the association of these complications with diabetes mellitus. In this Review, we synthesize information published since the year 2000 on the risks and burden of emerging complications associated with T1DM and T2DM.\\n\\nDiabetes mellitus and cancer\\n----------------------------\\n\\n### The burden of cancer mortality\\n\\nWith the rates of cardiovascular mortality declining amongst people with diabetes mellitus, cancer deaths now constitute a larger proportion of deaths among this population in some countries/regions[8](https://www.nature.com/articles/s41574-022-00690-7#ref-CR8 \"Harding, J. L., Shaw, J. E., Peeters, A., Davidson, S. & Magliano, D. J. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care 39, 1018–1026 (2016).\"),[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\"). Although the proportion of deaths due to cancer appears to be stable, at around 16–20%, in the population with diabetes mellitus in the USA[7](https://www.nature.com/articles/s41574-022-00690-7#ref-CR7 \"Gregg, E. W. et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet 391, 2430–2440 (2018).\"), in England it increased from 22% to 28% between 2001 and 2018 (ref.[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\")), with a similar increase reported in Australia[8](https://www.nature.com/articles/s41574-022-00690-7#ref-CR8 \"Harding, J. L., Shaw, J. E., Peeters, A., Davidson, S. & Magliano, D. J. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care 39, 1018–1026 (2016).\"). Notably, in England, cancer has overtaken vascular disease as the leading cause of death in people with diabetes mellitus and it is the leading contributor to excess mortality in those with diabetes mellitus compared with those without[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\"). These findings are likely to be due to a substantial decline in the proportion of deaths from vascular diseases, from 44% to 24% between 2001 and 2018, which is thought to reflect the targeting of prevention measures in people with diabetes mellitus[18](https://www.nature.com/articles/s41574-022-00690-7#ref-CR18 \"Unal, B., Critchley, J. A. & Capewell, S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109, 1101–1107 (2004).\"). Over the same time period, cancer mortality rates fell by much less in the population with diabetes mellitus than in that without diabetes[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\"), suggesting that clinical approaches for diabetes mellitus might focus too narrowly on vascular complications and might require revision[19](https://www.nature.com/articles/s41574-022-00690-7#ref-CR19 \"Pearson-Stuttard, J., Ezzati, M. & Gregg, E. W. Multimorbidity — a defining challenge for health systems. Lancet Public. Health 4, e599–e600 (2019).\"). In addition, several studies have reported that female patients with diabetes mellitus receive less-aggressive treatment for breast cancer compared with patients without diabetes mellitus, particularly with regard to chemotherapy[20](https://www.nature.com/articles/s41574-022-00690-7#ref-CR20 \"Lee, L., Cheung, W. Y., Atkinson, E. & Krzyzanowska, M. K. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J. Clin. Oncol. 29, 106–117 (2011).\"),[21](https://www.nature.com/articles/s41574-022-00690-7#ref-CR21 \"Srokowski, T. P., Fang, S., Hortobagyi, G. N. & Giordano, S. H. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J. Clin. Oncol. 27, 2170–2176 (2009).\"),[22](https://www.nature.com/articles/s41574-022-00690-7#ref-CR22 \"Gross, C. P., McAvay, G. J., Guo, Z. & Tinetti, M. E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109, 2410–2419 (2007).\"), suggesting that this treatment approach might result in increased cancer mortality rates in women with diabetes mellitus compared with those without diabetes mellitus. Although substantial investigation of cancer mortality in people with diabetes mellitus has been undertaken in high-income countries/regions, there is a paucity of evidence from low-income and middle-income countries/regions. It is important to understand the potential effect of diabetes mellitus on cancer mortality in these countries/regions owing to the reduced capacity of health-care systems in these countries/regions to cope with the combination of a rising prevalence of diabetes mellitus and rising cancer mortality rates in those with diabetes mellitus. One study in Mauritius showed a significantly increased risk of all-cause cancer mortality in patients with T2DM[23](https://www.nature.com/articles/s41574-022-00690-7#ref-CR23 \"Harding, J. L. et al. All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. Int. J. Cancer 131, 2385–2393 (2012).\"), but this study has yet to be replicated in other low-income and middle-income countries/regions.\\n\\n### Gastrointestinal cancers\\n\\nOf the reported associations between diabetes mellitus and cancer (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)), some of the strongest have been demonstrated for gastrointestinal cancers.\\n\\n**Table 1 Summary of major systematic reviews and original studies reporting a cancer risk associated with diabetes mellitus**\\n\\n[Full size table](https://www.nature.com/articles/s41574-022-00690-7/tables/1)\\n\\n#### Hepatocellular carcinoma\\n\\nIn the case of hepatocellular carcinoma, the most rigorous systematic review on the topic — comprising 18 cohort studies with a combined total of more than 3.5 million individuals — reported a summary relative risk (SRR) of 2.01 (95% confidence interval (CI) 1.61–2.51) for an association with diabetes mellitus[24](https://www.nature.com/articles/s41574-022-00690-7#ref-CR24 \"Wang, C. et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int. J. Cancer 130, 1639–1648 (2012).\"). This increased risk of hepatocellular carcinoma with diabetes mellitus is supported by the results of another systematic review that included case–control studies[25](https://www.nature.com/articles/s41574-022-00690-7#ref-CR25 \"El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369–380 (2006).\"). Another review also found that diabetes mellitus independently increased the risk of hepatocellular carcinoma in the setting of hepatitis C virus infection[26](https://www.nature.com/articles/s41574-022-00690-7#ref-CR26 \"Desbois, A. C. & Cacoub, P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J. Gastroenterol. 23, 1697–1711 (2017).\").\\n\\n#### Pancreatic cancer\\n\\nThe risk of pancreatic cancer appears to be approximately doubled in patients with T2DM compared with patients without T2DM. A meta-analysis of 36 studies found an adjusted odds ratio (OR) of 1.82 (95% CI 1.66–1.89) for pancreatic cancer among people with T2DM compared with patients without T2DM[27](https://www.nature.com/articles/s41574-022-00690-7#ref-CR27 \"Huxley, R., Ansary-Moghaddam, A., Berrington De González, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92, 2076–2083 (2005).\") (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)). However, it is possible that these findings are influenced by reverse causality — in this scenario, diabetes mellitus is triggered by undiagnosed pancreatic cancer[28](https://www.nature.com/articles/s41574-022-00690-7#ref-CR28 \"Gullo, L. et al. Diabetes and the risk of pancreatic cancer. N. Engl. J. Med. 331, 81–84 (1994).\"), with pancreatic cancer subsequently being clinically diagnosed only after the diagnosis of diabetes mellitus. Nevertheless, although the greatest risk (OR 2.05, 95% CI 1.87–2.25) of pancreatic cancer was seen in people diagnosed with T2DM 1–4 years previously compared with people without T2DM, those with a diagnosis of T2DM of more than 10 years remained at increased risk of pancreatic cancer (OR 1.51, 95% CI 1.16–1.96)[27](https://www.nature.com/articles/s41574-022-00690-7#ref-CR27 \"Huxley, R., Ansary-Moghaddam, A., Berrington De González, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92, 2076–2083 (2005).\"), suggesting that reverse causality can explain only part of the association between T2DM and pancreatic cancer. Although T2DM accounts for ~90% of all cases of diabetes mellitus[29](https://www.nature.com/articles/s41574-022-00690-7#ref-CR29 \"Gershell, L. Type 2 diabetes market. Nat. Rev. Drug Discov. 4, 367–368 (2005).\"), a study incorporating data from five nationwide diabetes registries also reported an increased risk of pancreatic cancer amongst both male patients (HR 1.53, 95% CI 1.30–1.79) and female patients (HR 1.25, 95% CI 1.02–1.53) with T1DM[30](https://www.nature.com/articles/s41574-022-00690-7#ref-CR30 \"Carstensen, B. et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59, 980–988 (2016).\").\\n\\n#### Colorectal cancer\\n\\nFor colorectal cancer, three systematic reviews have shown a consistent 20–30% increased risk associated with diabetes mellitus[31](https://www.nature.com/articles/s41574-022-00690-7#ref-CR31 \"Jiang, Y. et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur. J. Epidemiol. 26, 863–876 (2011).\"),[32](https://www.nature.com/articles/s41574-022-00690-7#ref-CR32 \"De Bruijn, K. M. J. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 100, 1421–1429 (2013).\"),[33](https://www.nature.com/articles/s41574-022-00690-7#ref-CR33 \"Deng, L., Gui, Z., Zhao, L., Wang, J. & Shen, L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig. Dis. Sci. 57, 1576–1585 (2012).\"). One systematic review, which included more than eight million people across 30 cohort studies, reported an incidence SRR of 1.27 (95% CI 1.21–1.34) of colorectal cancer[31](https://www.nature.com/articles/s41574-022-00690-7#ref-CR31 \"Jiang, Y. et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur. J. Epidemiol. 26, 863–876 (2011).\"), independent of sex and family history (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)). Similar increases in colorectal cancer incidence in patients with diabetes mellitus were reported in a meta-analysis of randomized controlled trials (RCTs) and cohort studies[32](https://www.nature.com/articles/s41574-022-00690-7#ref-CR32 \"De Bruijn, K. M. J. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 100, 1421–1429 (2013).\") and in a systematic review that included cross-sectional studies[33](https://www.nature.com/articles/s41574-022-00690-7#ref-CR33 \"Deng, L., Gui, Z., Zhao, L., Wang, J. & Shen, L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig. Dis. Sci. 57, 1576–1585 (2012).\").\\n\\n### Female-specific cancers\\n\\nEndometrial, breast and ovarian cancers all occur more frequently in women with diabetes mellitus than in women without diabetes mellitus.\\n\\n#### Endometrial cancer\\n\\nFor endometrial cancer, one systematic review of 29 cohort studies and a combined total of 5,302,259 women reported a SRR of 1.89 (95% CI 1.46–2.45) and summary incidence rate ratio (IRR) of 1.61 (95% CI 1.51–1.71)[34](https://www.nature.com/articles/s41574-022-00690-7#ref-CR34 \"Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D. & Zeidan, A. M. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol. Oncol. 135, 163–171 (2014).\") (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)). Similar increased risks were found in two systematic reviews incorporating cross-sectional studies[35](https://www.nature.com/articles/s41574-022-00690-7#ref-CR35 \"Saed, L. et al. The effect of diabetes on the risk of endometrial cancer: an updated a systematic review and meta-analysis. BMC Cancer 19, 527 (2019).\"),[36](https://www.nature.com/articles/s41574-022-00690-7#ref-CR36 \"Friberg, E., Orsini, N., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia 50, 1365–1374 (2007).\"), one of which found a particularly strong association of T1DM (relative risk (RR) 3.15, 95% CI 1.07–9.29) with endometrial cancer.\\n\\n#### Breast cancer\\n\\nThe best evidence for a link between diabetes mellitus and breast cancer comes from a systematic review of six prospective cohort studies and more than 150,000 women, in which the hazard ratio (HR) for the incidence of breast cancer in women with diabetes mellitus compared with women without diabetes mellitus was 1.23 (95% CI 1.12–1.34)[32](https://www.nature.com/articles/s41574-022-00690-7#ref-CR32 \"De Bruijn, K. M. J. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 100, 1421–1429 (2013).\") (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)). Two further systematic reviews have also shown this increased association[37](https://www.nature.com/articles/s41574-022-00690-7#ref-CR37 \"Anothaisintawee, T. et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia-Pac. J. Public Health 25, 368–387 (2013).\"),[38](https://www.nature.com/articles/s41574-022-00690-7#ref-CR38 \"Larsson, S. C., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121, 856–862 (2007).\").\\n\\nThe association of diabetes mellitus with breast cancer appears to vary according to menopausal status. In a meta-analysis of studies of premenopausal women with diabetes mellitus, no significant association with breast cancer was found[39](https://www.nature.com/articles/s41574-022-00690-7#ref-CR39 \"Boyle, P. et al. Diabetes and breast cancer risk: a meta-analysis. Br. J. Cancer 107, 1608–1617 (2012).\"), whereas in 11 studies that included only postmenopausal women, the SRR was 1.15 (95% CI 1.07–1.24). The difference in breast cancer risk between premenopausal and postmenopausal women with diabetes mellitus was statistically significant. The increased risk of breast cancer after menopause in women with diabetes mellitus compared with women without diabetes mellitus might result from the elevated concentrations and increased bioavailability of oestrogen that are associated with adiposity[40](https://www.nature.com/articles/s41574-022-00690-7#ref-CR40 \"Rinaldi, S. et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int. J. Cancer 118, 2832–2839 (2006).\"), which is a common comorbidity in those with T2DM; oestrogen synthesis occurs in adipose tissue in postmenopausal women, while it is primarily gonadal in premenopausal women[41](https://www.nature.com/articles/s41574-022-00690-7#ref-CR41 \"Michels, K. B. et al. Type 2 diabetes and subsequent incidence of breast cancer in the nurses’ health study. Diabetes Care 26, 1752–1758 (2003).\"). Notably, however, there is evidence that hormone-receptor-negative breast cancers, which typically carry a poor prognosis, occur more frequently in women with breast cancer and diabetes mellitus than in women with breast cancer and no diabetes mellitus[42](https://www.nature.com/articles/s41574-022-00690-7#ref-CR42 \"Bronsveld, H. K. et al. Diabetes and breast cancer subtypes. PLoS ONE 12, e0170084 (2017).\"), indicating that non-hormonal mechanisms also occur.\\n\\n#### Ovarian cancer\\n\\nDiabetes mellitus also appears to increase the risk of ovarian cancer, with consistent results from across four systematic reviews. A pooled RR of 1.32 (95% CI 1.14–1.52) was reported across 15 cohort studies and a total of more than 2.3 million women[43](https://www.nature.com/articles/s41574-022-00690-7#ref-CR43 \"Zhang, D., Li, N., Xi, Y., Zhao, Y. & Wang, T. Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies. Diabetes Res. Clin. Pract. 130, 43–52 (2017).\") (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)). A SRR of 1.19 (95% CI 1.06–1.34) was found across 14 cohort studies and 3,708,313 women[44](https://www.nature.com/articles/s41574-022-00690-7#ref-CR44 \"Weng, L., Wang, L., Zhang, J., Wang, B. & Liu, H. Association between diabetes mellitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. Medicine 96, e6396 (2017).\"). Similar risks were reported in meta-analyses that included cross-sectional studies[45](https://www.nature.com/articles/s41574-022-00690-7#ref-CR45 \"Wang, L., Zhong, L., Xu, B., Chen, M. & Huang, H. Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies. BMJ Open 10, e040137 (2020).\"),[46](https://www.nature.com/articles/s41574-022-00690-7#ref-CR46 \"Lee, J. Y. et al. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int. J. Gynecol. Cancer 23, 402–412 (2013).\").\\n\\n### Male-specific cancers: prostate cancer\\n\\nAn inverse association between diabetes mellitus and prostate cancer has been observed in a systematic review (RR 0.91, 95% CI 0.86–0.96)[47](https://www.nature.com/articles/s41574-022-00690-7#ref-CR47 \"Bonovas, S., Filioussi, K. & Tsantes, A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47, 1071–1078 (2004).\"), and is probably due to reduced testosterone levels that occur secondary to the low levels of sex hormone-binding globulin that are commonly seen in men with T2DM and obesity[48](https://www.nature.com/articles/s41574-022-00690-7#ref-CR48 \"Shikata, K., Ninomiya, T. & Kiyohara, Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 104, 9–14 (2013).\"). Notably, however, the systematic review that showed the inverse association involved mostly white men (Table\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Tab1)), whereas a systematic review of more than 1.7 million men from Taiwan, Japan, South Korea and India found that diabetes mellitus increased prostate cancer risk[49](https://www.nature.com/articles/s41574-022-00690-7#ref-CR49 \"Long, X. J., Lin, S., Sun, Y. N. & Zheng, Z. F. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac. J. Cancer Preven. 13, 4097–4100 (2012).\"), suggesting that ethnicity might be an effect modifier of the diabetes mellitus–prostate cancer relationship. The mechanisms behind this increased risk in men in regions of Asia such as Taiwan and Japan, where most study participants came from, remain unclear. Perhaps, as Asian men develop diabetes mellitus at lower levels of total adiposity than do white men[50](https://www.nature.com/articles/s41574-022-00690-7#ref-CR50 \"Rhee, E. J. Diabetes in Asians. Endocrinol. Metab. 30, 263–269 (2015).\"), the adiposity associated with diabetes mellitus in Asian men might have a lesser impact on sex hormone-binding globulin and testosterone than it does in white men. Despite the reported inverse association between diabetes mellitus and prostate cancer in white men, however, evidence suggests that prostate cancers that do develop in men with T2DM are typically more aggressive, conferring higher rates of disease-specific mortality than prostate cancers in men without diabetes mellitus[51](https://www.nature.com/articles/s41574-022-00690-7#ref-CR51 \"Bensimon, L., Yin, H., Suissa, S., Pollak, M. N. & Azoulay, L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control. 25, 329–338 (2014).\").\\n\\n### An assessment of cancer associations\\n\\nAs outlined above, a wealth of data has shown that diabetes mellitus is associated with an increased risk of various cancers. It has been argued, however, that some of these associations could be due to detection bias resulting from increased surveillance of people with diabetes mellitus in the immediate period after diagnosis[52](https://www.nature.com/articles/s41574-022-00690-7#ref-CR52 \"Johnson, J. A., Bowker, S. L., Richardson, K. & Marra, C. A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54, 2263–2271 (2011).\"), or reverse causality, particularly in the case of pancreatic cancer[53](https://www.nature.com/articles/s41574-022-00690-7#ref-CR53 \"Johnson, J. A. et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55, 1607–1618 (2012).\"). However, neither phenomenon can account for the excess risks seen in the longer term. An Australian study exploring detection bias and reverse causality found that standardized mortality ratios (SMRs) for several cancer types in people with diabetes mellitus compared with the general population fell over time, but remained elevated beyond 2 years for pancreatic and liver cancers[54](https://www.nature.com/articles/s41574-022-00690-7#ref-CR54 \"Harding, J. L., Shaw, J. E., Peeters, A., Cartensen, B. & Magliano, D. J. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 38, 264–270 (2015).\"), suggesting that diabetes mellitus is a genuine risk factor for these cancer types.\\n\\nA limitation of the evidence that surrounds diabetes mellitus and cancer risk is high clinical and methodological heterogeneity across several of the large systematic reviews, which makes it difficult to be certain of the effect size in different demographic groups. Additionally, many of the studies exploring a potential association between diabetes mellitus and cancer were unable to adjust for BMI, which is a major confounder. However, a modelling study that accounted for BMI found that although 2.1% of cancers worldwide in 2012 were attributable to diabetes mellitus as an independent risk factor, twice as many cancers were attributable to high BMI[55](https://www.nature.com/articles/s41574-022-00690-7#ref-CR55 \"Pearson-Stuttard, J. et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 6, e6–e15 (2018).\"), so it is likely that effect sizes for cancer risk associated with diabetes mellitus would be attenuated after adjustment for BMI. Notably, however, low-income and middle-income countries/regions had the largest increase in the numbers of cases of cancer attributable to diabetes mellitus both alone and in combination with BMI[55](https://www.nature.com/articles/s41574-022-00690-7#ref-CR55 \"Pearson-Stuttard, J. et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 6, e6–e15 (2018).\"), highlighting the need for public health intervention, given that these countries/regions are less equipped than high-income countries/regions to manage a growing burden of cancer.\\n\\nAs well as the cancer types outlined above, diabetes mellitus has also been linked to various other types of cancer, including kidney cancer[56](https://www.nature.com/articles/s41574-022-00690-7#ref-CR56 \"Larsson, S. C. & Wolk, A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54, 1013–1018 (2011).\"), bladder cancer[57](https://www.nature.com/articles/s41574-022-00690-7#ref-CR57 \"Xu, X. et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 8, e58079 (2013).\") and haematological malignancies; however, the evidence for these associations is not as strong as for the cancers discussed above[58](https://www.nature.com/articles/s41574-022-00690-7#ref-CR58 \"Gong, I. Y. et al. Association between diabetes and haematological malignancies: a population-based study. Diabetologia 64, 540–551 (2021).\"). Diabetes mellitus might also be associated with other cancer types such as small intestine cancer, but the rarity of some of these types makes it difficult to obtain sufficient statistical power in analyses of any potential association.\\n\\n### Potential aetiological mechanisms\\n\\nSeveral aetiological mechanisms that might be involved in linking diabetes mellitus to cancer have been proposed, including hyperinsulinaemia, hyperglycaemia, inflammation and cellular signalling mechanisms.\\n\\n#### Hyperinsulinaemia\\n\\nMost cancer cells express insulin receptors, through which hyperinsulinaemia is thought to stimulate cancer cell proliferation and metastasis[59](https://www.nature.com/articles/s41574-022-00690-7#ref-CR59 \"Giovannucci, E. et al. Diabetes and cancer: a consensus report. Diabetes Care 33, 1674–1685 (2010).\"). Hyperinsulinaemia might also promote carcinogenesis through increased local levels of insulin-like growth factor 1 (IGF1), which has potent mitogenic and anti-apoptotic activities[60](https://www.nature.com/articles/s41574-022-00690-7#ref-CR60 \"Weinstein, D., Simon, M., Yehezkel, E., Laron, Z. & Werner, H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab. Res. Rev. 25, 41–49 (2009).\"), owing to decreased levels of insulin-like growth factor binding proteins. As outlined above, people with diabetes mellitus show a strong risk of pancreatic and liver cancers; this increased risk might occur because insulin is produced by pancreatic β-cells and transported to the liver via the portal vein[61](https://www.nature.com/articles/s41574-022-00690-7#ref-CR61 \"Najjar, S. M. & Perdomo, G. Hepatic insulin clearance: mechanism and physiology. Physiology 34, 198–215 (2019).\"), thereby exposing the liver and pancreas to high levels of endogenous insulin[59](https://www.nature.com/articles/s41574-022-00690-7#ref-CR59 \"Giovannucci, E. et al. Diabetes and cancer: a consensus report. Diabetes Care 33, 1674–1685 (2010).\").\\n\\n#### Hyperglycaemia and inflammation\\n\\nHyperglycaemia can induce DNA damage[62](https://www.nature.com/articles/s41574-022-00690-7#ref-CR62 \"Lorenzi, M., Montisano, D. F., Toledo, S. & Barrieux, A. High glucose induces DNA damage in cultured human endothelial cells. J. Clin. Invest. 77, 322–325 (1986).\"), increase the generation of reactive oxygen species[63](https://www.nature.com/articles/s41574-022-00690-7#ref-CR63 \"Robertson, R., Zhou, H., Zhang, T. & Harmon, J. S. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Cell Biochem. Biophys. 48, 139–146 (2007).\") and downregulate antioxidant expression[64](https://www.nature.com/articles/s41574-022-00690-7#ref-CR64 \"Turturro, F., Friday, E. & Welbourne, T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 7, 96 (2007).\"), all of which are associated with cancer development. Inflammatory markers, including cytokines such as IL-6, appear to have an important role in the association between diabetes and cancer[65](https://www.nature.com/articles/s41574-022-00690-7#ref-CR65 \"Wu, Y., Liu, Y., Dong, Y. & Vadgama, J. Diabetes-associated dysregulated cytokines and cancer. Integr. Cancer Sci. Ther. 3, 370–378 (2016).\").\\n\\n#### Cellular signalling mechanisms\\n\\nSeveral cellular signalling components are common to the pathogenesis of T2DM and cancer. These include the mechanistic target of rapamycin (mTOR), a central controller of cell growth and proliferation; AMP-activated protein kinase, a cellular energy sensor and signal transducer[66](https://www.nature.com/articles/s41574-022-00690-7#ref-CR66 \"Inoki, K., Kim, J. & Guan, K. L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52, 381–400 (2012).\"); and the phosphatidylinositol 3-kinase (PI3K)–AKT pathway, which transduces growth factor signals during organismal growth, glucose homeostasis and cell proliferation[67](https://www.nature.com/articles/s41574-022-00690-7#ref-CR67 \"Huang, X., Liu, G., Guo, J. & Su, Z. Q. The PI3K/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci. 14, 1483–1496 (2018).\"). Dysregulation of any of these cellular signalling components or pathways could contribute to the development of cancer and metabolic disorders, including T2DM, and glucose-lowering drugs such as metformin have been associated with a reduction in cancer cell proliferation through effective inhibition of some of these components[68](https://www.nature.com/articles/s41574-022-00690-7#ref-CR68 \"Zhao, Y. et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. Gynecol. Endocrinol. 34, 428–432 (2018).\").\\n\\nDiabetes mellitus and infections\\n--------------------------------\\n\\n### Infection-related complications\\n\\nAlthough infection has long been recognized as a complication of diabetes mellitus, an association between diabetes mellitus and infection has not been well documented in epidemiological studies[69](https://www.nature.com/articles/s41574-022-00690-7#ref-CR69 \"Knapp, S. Diabetes and infection: is there a link?-A mini-review. Gerontology 59, 99–104 (2013).\"). Only in the past decade have major studies quantified the burden of infection-related complications in people with diabetes mellitus and explored the specific infections accounting for this burden. In a US cohort of 12,379 participants, diabetes mellitus conferred a significant risk of infection-related hospitalization, with an adjusted HR of 1.67 (95% CI 1.52–1.83) compared with people without diabetes mellitus[70](https://www.nature.com/articles/s41574-022-00690-7#ref-CR70 \"Fang, M. et al. Diabetes and the risk of hospitalisation for infection: the atherosclerosis risk in communities (ARIC) study. Diabetologia 64, 2458–2465 (2021).\") (Table\\xa0[2](https://www.nature.com/articles/s41574-022-00690-7#Tab2)). The association was most pronounced for foot infections (HR 5.99, 95% CI 4.38–8.19), with significant associations also observed for respiratory infection, urinary tract infection, sepsis and post-operative infection, but not for gastrointestinal infection, a category that included appendicitis and gastrointestinal abscesses but not viral or bacterial gastroenteritis. Interestingly, a report from Taiwan demonstrated an association between the use of metformin and a lower risk of appendicitis[71](https://www.nature.com/articles/s41574-022-00690-7#ref-CR71 \"Tseng, C.-H. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus. Sci. Rep. 11, 12400 (2021).\").\\n\\n**Table 2 Summary of major systematic reviews and original studies reporting an infection risk associated with diabetes mellitus**\\n\\n[Full size table](https://www.nature.com/articles/s41574-022-00690-7/tables/2)\\n\\nIn an analysis of the entire Hong Kong population over the period 2001–2016, rates of hospitalization for all types of infection remained consistently higher in people with diabetes mellitus than in those without diabetes mellitus[72](https://www.nature.com/articles/s41574-022-00690-7#ref-CR72 \"Luk, A. O. Y. et al. Temporal trends in rates of infection-related hospitalisations in Hong Kong people with and without diabetes, 2001–2016: a retrospective study. Diabetologia 64, 109–118 (2021).\"). The strongest association was seen for hospitalization due to kidney infections, for which the adjusted RR was 4.9 (95% CI 3.9–6.2) in men and 3.2 (95% CI 2.8–3.7) in women with diabetes mellitus compared with those without diabetes mellitus in 2016 (Table\\xa0[2](https://www.nature.com/articles/s41574-022-00690-7#Tab2)). Diabetes mellitus roughly doubled the risk of hospitalization from tuberculosis or sepsis. The most common cause of infection-related hospitalization was pneumonia, which accounted for 39% of infections across the study period, while no other single cause accounted for more than 25% of infections across the same period. Pneumonia-related hospitalization rates increased substantially from 2001 to 2005, probably as a result of the 2003 severe acute respiratory syndrome (SARS) epidemic and the decreased threshold for pneumonia hospitalization in the immediate post-epidemic period. Rates for hospitalization for influenza increased from 2002 to 2016, possibly because of changes in the virus and increased testing for influenza. Declining rates of hospitalization for tuberculosis, urinary tract infections, foot infections and sepsis could be due to improvements in the management of diabetes mellitus.\\n\\nInfection-related mortality rates were found to be significantly elevated among 1,108,982 Australians with diabetes mellitus studied over the period 2000–2010 compared with rates in people without diabetes mellitus[73](https://www.nature.com/articles/s41574-022-00690-7#ref-CR73 \"Magliano, D. J. et al. Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes. Diabetes Care 38, 1274–1280 (2015).\"). For overall infection-related mortality, SMRs were 4.42 (95% CI 3.68–5.34) for T1DM and 1.47 (95% CI 1.42–1.53) for people with T2DM compared with those without diabetes mellitus (Table\\xa0[2](https://www.nature.com/articles/s41574-022-00690-7#Tab2)). Substantially higher infection-related mortality rates were seen in people with T1DM compared with those with T2DM for all infection types, even after accounting for age. Hyperglycaemia is thought to be a driver of infection amongst people with diabetes mellitus (see below)[73](https://www.nature.com/articles/s41574-022-00690-7#ref-CR73 \"Magliano, D. J. et al. Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes. Diabetes Care 38, 1274–1280 (2015).\"), which might explain the higher SMRs amongst people with T1DM, in whom hyperglycaemia is typically more severe, than in those with T2DM. The highest SMRs were seen for osteomyelitis, and SMRs for septicaemia and pneumonia were also greater than 1.0 for both types of diabetes mellitus compared with those without diabetes mellitus.\\n\\n### Post-operative infection\\n\\nPost-operative infection is also an important complication of diabetes mellitus. In a meta-analysis, diabetes mellitus was found to be associated with an OR of 1.77 (95% CI 1.13–2.78) for surgical site infection across studies that adjusted for confounding factors[74](https://www.nature.com/articles/s41574-022-00690-7#ref-CR74 \"Martin, E. T. et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect. Control. Hosp. Epidemiol. 37, 88–99 (2016).\") (Table\\xa0[2](https://www.nature.com/articles/s41574-022-00690-7#Tab2)). The effect size appears to be greatest after cardiac procedures, and one US study of patients undergoing coronary artery bypass grafting found diabetes mellitus to be an independent predictor of surgical site infection, with an OR of 4.71 (95% CI 2.39–9.28) compared with those without diabetes mellitus[75](https://www.nature.com/articles/s41574-022-00690-7#ref-CR75 \"Trussell, J. et al. Impact of a patient care pathway protocol on surgical site infection rates in cardiothoracic surgery patients. Am. J. Surg. 196, 883–889 (2008).\"). Risks of infection of more than threefold were reported in some studies of gynaecological[76](https://www.nature.com/articles/s41574-022-00690-7#ref-CR76 \"Coleman, J. S. et al. Surgical site infections after hysterectomy among HIV-infected women in the HAART era: a single institution’s experience from 1999–2012. Am. J. Obstet. Gynecol. 210, 117.e111–117.e117 (2014).\") and spinal surgery[77](https://www.nature.com/articles/s41574-022-00690-7#ref-CR77 \"Friedman, N. D., Sexton, D. J., Connelly, S. M. & Kaye, K. S. Risk factors for surgical site infection complicating laminectomy. Infect. Control. Hosp. Epidemiol. 28, 1060–1065 (2007).\") in people with diabetes mellitus compared with those without diabetes mellitus. Increased risks of infection among people with diabetes mellitus were also observed in studies of colorectal and breast surgery and arthroplasty, suggesting that the association between diabetes mellitus and post-operative infection is present across a wide range of types of surgery[74](https://www.nature.com/articles/s41574-022-00690-7#ref-CR74 \"Martin, E. T. et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect. Control. Hosp. Epidemiol. 37, 88–99 (2016).\").\\n\\n### Respiratory infections\\n\\nThe incidence of hospitalizations due to respiratory infections among people with diabetes mellitus was increasing substantially even before the onset of the coronavirus disease 2019 (COVID-19) pandemic, probably owing to increased life expectancy in these patients as well as an increased likelihood of them being hospitalized for conditions such as respiratory infections, which occur mostly in older age[12](https://www.nature.com/articles/s41574-022-00690-7#ref-CR12 \"Pearson-Stuttard, J. et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 10, 46–57 (2022).\"). This rising burden of respiratory infection, in combination with the rising prevalence of diabetes mellitus, highlights the importance of addressing the emerging complications of diabetes mellitus to minimize impacts on health-care systems in current and future global epidemics.\\n\\n#### COVID-19\\n\\nAlthough diabetes mellitus does not appear to increase the risk of becoming infected with COVID-19 (ref.[78](https://www.nature.com/articles/s41574-022-00690-7#ref-CR78 \"Apicella, M. et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 8, 782–792 (2020).\")), various population-based studies have reported increased risks of COVID-19 complications among people with diabetes mellitus. In a study of the total Scottish population, people with diabetes mellitus were found to have an increased risk of fatal or critical care unit-treated COVID-19, with an adjusted OR of 1.40 (95% CI 1.30–1.50) compared with those without diabetes mellitus[79](https://www.nature.com/articles/s41574-022-00690-7#ref-CR79 \"McGurnaghan, S. J. et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82–93 (2021).\") (Table\\xa0[2](https://www.nature.com/articles/s41574-022-00690-7#Tab2)). The risk was particularly high for those with T1DM (OR 2.40, 95% CI 1.82–3.16)[79](https://www.nature.com/articles/s41574-022-00690-7#ref-CR79 \"McGurnaghan, S. J. et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82–93 (2021).\"). Both T1DM and T2DM have been linked to a more than twofold increased risk of hospitalization with COVID-19 in a large Swedish cohort study[80](https://www.nature.com/articles/s41574-022-00690-7#ref-CR80 \"Rawshani, A. et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. Lancet Reg. Health Eur. 4, 100105 (2021).\"). In South Korean studies, T2DM was linked to intensive care unit admission among patients with COVID-19 infection[81](https://www.nature.com/articles/s41574-022-00690-7#ref-CR81 \"You, J. H. et al. Clinical outcomes of COVID-19 patients with type 2 diabetes: a population-based study in Korea. Endocrinol. Metab. 35, 901–908 (2020).\"), and diabetes mellitus (either T1DM or T2DM) was linked to a requirement for ventilation and oxygen therapy[82](https://www.nature.com/articles/s41574-022-00690-7#ref-CR82 \"Moon, S. J. et al. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. Diabetes Metab. J. 44, 737–746 (2020).\") in patients with COVID-19. Diabetes mellitus appears to be the primary predisposing factor for opportunistic infection with mucormycosis in individuals with COVID-19 (ref.[83](https://www.nature.com/articles/s41574-022-00690-7#ref-CR83 \"Aranjani, J. M., Manuel, A., Razack, H. I. A. & Mathew, S. T. Covid-19–associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS. Negl. Trop. Dis. 15, e0009921 (2021).\")). The evidence for diabetes mellitus as a risk factor for post-COVID-19 syndrome is inconclusive[84](https://www.nature.com/articles/s41574-022-00690-7#ref-CR84 \"Crankson, S., Pokhrel, S. & Anokye, N. K. Determinants of COVID-19-related length of hospital stays and long COVID in Ghana: a cross-sectional analysis. Int. J. Environ. Res. Public Health 19, 527 (2022).\"),[85](https://www.nature.com/articles/s41574-022-00690-7#ref-CR85 \"Bellan, M. et al. Respiratory and psychophysical sequelae among patients with covid-19 four months after hospital discharge. JAMA Netw. Open 4, e2036142 (2021).\"). Interestingly, an increase in the incidence of T1DM during the COVID-19 pandemic has been reported in several countries/regions[86](https://www.nature.com/articles/s41574-022-00690-7#ref-CR86 \"Gottesman, B. L., Yu, J., Tanaka, C., Longhurst, C. A. & Kim, J. J. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. JAMA Pediatr. 176, 414–415 (2022).\"), and some data suggest an increased risk of T1DM after COVID-19 infection[87](https://www.nature.com/articles/s41574-022-00690-7#ref-CR87 \"Barrett, C. E. et al. Risk for newly diagnosed diabetes <30 days after SARS-CoV-2 infection among persons aged >18 years-United States, March 1, 2020-June 28, 2021. Morb. Mortal. Wkly. Rep. 71, 59–65 (2022).\"), but the evidence regarding a causal effect is inconclusive.\\n\\n#### Pneumonia, MERS, SARS and H1N1 influenza\\n\\nThe data regarding diabetes mellitus and COVID-19 are consistent with the published literature regarding other respiratory infections, such as pneumonia, for which diabetes mellitus has been shown to increase the risk of hospitalization[88](https://www.nature.com/articles/s41574-022-00690-7#ref-CR88 \"Kornum, J. B. et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31, 1541–1545 (2008).\") and mortality[88](https://www.nature.com/articles/s41574-022-00690-7#ref-CR88 \"Kornum, J. B. et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31, 1541–1545 (2008).\"), with similar effect sizes to those seen for COVID-19, compared with no diabetes mellitus. Diabetes mellitus has also been also linked to adverse outcomes in people with Middle East respiratory syndrome (MERS), SARS and H1N1 influenza[89](https://www.nature.com/articles/s41574-022-00690-7#ref-CR89 \"Matsuyama, R., Nishiura, H., Kutsuna, S., Hayakawa, K. & Ohmagari, N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health 16, 1203 (2016).\"),[90](https://www.nature.com/articles/s41574-022-00690-7#ref-CR90 \"Badawi, A. & Ryoo, S. G. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int. J. Infect. Dis. 49, 129–133 (2016).\"),[91](https://www.nature.com/articles/s41574-022-00690-7#ref-CR91 \"Badawi, A. & Ryoo, S. G. Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis. J. Public. Health Res. 5, 130–138 (2016).\"),[92](https://www.nature.com/articles/s41574-022-00690-7#ref-CR92 \"Yang, J. K. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 23, 623–628 (2006).\"), suggesting that mechanisms specific to COVID-19 are unlikely to be responsible for the relationship between diabetes mellitus and COVID-19. Unlike the case for COVID-19, there is evidence that people with diabetes mellitus are at increased risk of developing certain other respiratory infections, namely pneumonia[93](https://www.nature.com/articles/s41574-022-00690-7#ref-CR93 \"Ehrlich, S. F., Quesenberry, C. P. Jr, Van Den Eeden, S. K., Shan, J. & Ferrara, A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33, 55–60 (2010).\") and possibly also MERS[94](https://www.nature.com/articles/s41574-022-00690-7#ref-CR94 \"Alraddadi, B. M. et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg. Infect. Dis. 22, 49–55 (2016).\").\\n\\n### Potential aetiological mechanisms\\n\\nThe mechanisms that might link diabetes mellitus and infection include a reduced T cell response, reduced neutrophil function and disorders of humoral immunity.\\n\\nMononuclear cells and monocytes of individuals with diabetes mellitus secrete less IL-1 and IL-6 than the same cells from people without diabetes mellitus[95](https://www.nature.com/articles/s41574-022-00690-7#ref-CR95 \"Geerlings, S. E. & Hoepelman, A. I. M. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol. Med. Microbiol. 26, 259–265 (1999).\"). The release of IL-1 and IL-6 by T cells and other cell types in response to infection has been implicated in the response to several viral infections[96](https://www.nature.com/articles/s41574-022-00690-7#ref-CR96 \"Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The role of interleukin 6 during viral infections. Front. Microbiol. 10, 1057 (2019).\"). Thus, the reduced secretion of these cytokines in patients with diabetes mellitus might be associated with the poorer responses to infection observed among these patients compared with people without diabetes mellitus.\\n\\nIn the context of neutrophil function, hyperglycaemic states might give rise to reductions in the mobilization of polymorphonuclear leukocytes, phagocytic activity and chemotaxis[97](https://www.nature.com/articles/s41574-022-00690-7#ref-CR97 \"Joshi, N., Caputo, G. M., Weitekamp, M. R. & Karchmer, A. W. Infections in patients with diabetes mellitus. N. Engl. J. Med. 341, 1906–1912 (1999).\"), resulting in a decreased immune response to infection. Additionally, increased levels of glucose in monocytes isolated from patients with obesity and/or diabetes mellitus have been found to promote viral replication in these cells, as well as to enhance the expression of several cytokines, including pro-inflammatory cytokines that are associated with the COVID-19 ‘cytokine storm’; furthermore, glycolysis was found to sustain the SARS coronavirus 2 (SARS-CoV-2)-induced monocyte response and viral replication[98](https://www.nature.com/articles/s41574-022-00690-7#ref-CR98 \"Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-dependent axis. Cell Metab. 32, 437–446.e435 (2020).\").\\n\\nElevated glucose levels in people with diabetes mellitus are also associated with an increase in glycation, which, by promoting a change in the structure and/or function of several proteins and lipids, is responsible for many of the complications of diabetes mellitus[99](https://www.nature.com/articles/s41574-022-00690-7#ref-CR99 \"Miyazawa, T., Nakagawa, K., Shimasaki, S. & Nagai, R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids 42, 1163–1170 (2012).\"). In people with diabetes mellitus, antibodies can become glycated, a process that is thought to impair their biological function[100](https://www.nature.com/articles/s41574-022-00690-7#ref-CR100 \"Peleg, A. Y., Weerarathna, T., McCarthy, J. S. & Davis, T. M. E. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab. Res. Rev. 23, 3–13 (2007).\"). Although the clinical relevance of this impairment is not clear, it could potentially explain the results of an Israeli study that reported reduced COVID-19 vaccine effectiveness among people with T2DM compared with those without T2DM[101](https://www.nature.com/articles/s41574-022-00690-7#ref-CR101 \"Barda, N., Dagan, N. & Balicer, R. D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. reply. N. Engl. J. Med. 384, 1970 (2021).\").\\n\\nDiabetes mellitus and liver disease\\n-----------------------------------\\n\\n### Nonalcoholic fatty liver disease\\n\\nThe consequences of nonalcoholic fatty liver disease (NAFLD) make it important to recognize the burden of this disease among people with diabetes mellitus. NAFLD and nonalcoholic steatohepatitis (NASH; an advanced form of NAFLD) are major causes of liver transplantation in the general population. In the USA, NASH accounted for 19% of liver transplantations in 2016 — second only to alcoholic liver disease, which was the cause of 24% of transplantations[102](https://www.nature.com/articles/s41574-022-00690-7#ref-CR102 \"Cholankeril, G. & Ahmed, A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin. Gastroenterol. Hepatol. 16, 1356–1358 (2018).\"). In Australia and New Zealand, NAFLD was the primary diagnosis in 9% of liver transplant recipients in 2019, only slightly below the figure for alcoholic cirrhosis of 13%[103](https://www.nature.com/articles/s41574-022-00690-7#ref-CR103 \"Fink, M. & Byrne, M. Australia and New Zealand Liver and Intestinal Transplant Registry Annual Report 2019 (Melbourne, Victoria, Australia, 2019).\"). In Europe, NASH increased as the reason for transplantations from 1% in 2002 to more than 8% in 2016, in parallel with the rising prevalence of diabetes mellitus[104](https://www.nature.com/articles/s41574-022-00690-7#ref-CR104 \"Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J. Hepatol. 71, 313–322 (2019).\").\\n\\nNAFLD is highly prevalent among people with T2DM. In a systematic review of 80 studies across 20 countries/regions, the prevalence of NAFLD among 49,419 people with T2DM was 56%[105](https://www.nature.com/articles/s41574-022-00690-7#ref-CR105 \"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).\"), while the global prevalence of NAFLD in the general population is estimated to be 25%[106](https://www.nature.com/articles/s41574-022-00690-7#ref-CR106 \"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).\"). In a Chinese cohort study of 512,891 adults, diabetes mellitus was associated with an adjusted HR of 1.76 (95% CI 1.47–2.16) for NAFLD compared with no diabetes mellitus[107](https://www.nature.com/articles/s41574-022-00690-7#ref-CR107 \"Pang, Y. et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology 68, 1308–1318 (2018).\") (Table\\xa0[3](https://www.nature.com/articles/s41574-022-00690-7#Tab3)). Another smaller longitudinal Chinese study also reported an increased risk of developing NAFLD among those with T2DM compared with those without T2DM[108](https://www.nature.com/articles/s41574-022-00690-7#ref-CR108 \"Li, Y. et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS ONE 12, e0174291 (2017).\"). However, most evidence regarding the association between NAFLD and diabetes mellitus is from cross-sectional studies[109](https://www.nature.com/articles/s41574-022-00690-7#ref-CR109 \"Mansour-Ghanaei, F. et al. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran. Diabetes Metab. Syndr. 13, 1591–1596 (2019).\"),[110](https://www.nature.com/articles/s41574-022-00690-7#ref-CR110 \"Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29, 113–119 (2009).\"),[111](https://www.nature.com/articles/s41574-022-00690-7#ref-CR111 \"Singh, S. P. et al. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study. J. Clin. Exp. Hepatol. 5, 295–302 (2015).\").\\n\\n**Table 3 Summary of original studies reporting risk of liver disease associated with diabetes mellitus**\\n\\n[Full size table](https://www.nature.com/articles/s41574-022-00690-7/tables/3)\\n\\n### NASH and fibrosis\\n\\nDiabetes mellitus appears to enhance the risk of NAFLD complications, including NASH and fibrosis. An analysis of 892 people with NAFLD and T2DM across 10 studies showed that the prevalence of NASH was 37% (ref.[105](https://www.nature.com/articles/s41574-022-00690-7#ref-CR105 \"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).\")); figures for the prevalence of NASH in the general population with NAFLD vary greatly across different study populations, ranging from 16% to 68%[112](https://www.nature.com/articles/s41574-022-00690-7#ref-CR112 \"Dufour, J.-F. et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–a targeted literature review. Endocr. Metab. Sci. 3, 100089 (2021).\"). Amongst 439 people with T2DM and NAFLD in seven studies, 17% had advanced fibrosis[105](https://www.nature.com/articles/s41574-022-00690-7#ref-CR105 \"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).\"). An analysis of 1,069 people with NAFLD in a US study found that diabetes mellitus was an independent predictor for NASH (OR 1.93, 95% CI 1.37–2.73) and fibrosis (3.31, 95% CI 2.26–4.85)[113](https://www.nature.com/articles/s41574-022-00690-7#ref-CR113 \"Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).\").\\n\\n#### Bidirectional relationship between diabetes mellitus and liver disease\\n\\nThe relationship between diabetes mellitus and NAFLD is bidirectional, as NAFLD is associated with an increased risk of developing T2DM[114](https://www.nature.com/articles/s41574-022-00690-7#ref-CR114 \"Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).\"). There is also a notable bidirectional relationship between diabetes mellitus and liver cirrhosis. The prevalence of diabetes mellitus in people with liver cirrhosis has been reported as 20–63%, depending on the severity of liver damage, aetiology and diagnostic criteria[115](https://www.nature.com/articles/s41574-022-00690-7#ref-CR115 \"Holstein, A., Hinze, S., Thießen, E., Plaschke, A. & Egberts, E. H. Clinical implications of hepatogenous diabetes in liver cirrhosis. J. Gastroenterol. Hepatol. 17, 677–681 (2002).\"). In an Italian study of 401 participants with cirrhosis, 63% of those with decompensated liver disease had diabetes mellitus compared with 10% of those with well-compensated liver disease[116](https://www.nature.com/articles/s41574-022-00690-7#ref-CR116 \"Del Vecchio Blanco, C., Gentile, S., Marmo, R., Carbone, L. & Coltorti, M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res. Clin. Pract. 8, 29–36 (1990).\"), suggesting that diabetes mellitus is more common in severe cases of liver damage. The association between diabetes mellitus and cirrhosis also varies according to the cause of liver disease. In a US study of 204 people with cirrhosis, the prevalence of diabetes mellitus was 25% among those with cirrhosis caused by hepatitis C virus, 19% among those with cirrhosis from alcoholic liver disease and only 1% among those with cirrhosis due to cholestatic liver disease[117](https://www.nature.com/articles/s41574-022-00690-7#ref-CR117 \"Zein, N. N., Abdulkarim, A. S., Wiesner, R. H., Egan, K. S. & Persing, D. H. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J. Hepatol. 32, 209–217 (2000).\"). Among the causes of cirrhosis, haemochromatosis has the strongest association with diabetes mellitus, with diabetes mellitus mainly resulting from the iron deposition that is characteristic of haemochromatosis[118](https://www.nature.com/articles/s41574-022-00690-7#ref-CR118 \"Niederau, C. et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 313, 1256–1262 (1985).\").\\n\\n### Potential aetiological mechanisms\\n\\nSeveral factors have been implicated in the aetiology of liver disease in people with diabetes mellitus, with insulin resistance being the most notable[119](https://www.nature.com/articles/s41574-022-00690-7#ref-CR119 \"Larter, C. Z. & Farrell, G. C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J. Hepatol. 44, 253–261 (2006).\").\\n\\n#### Insulin resistance\\n\\nInsulin resistance causes lipolysis, thereby increasing the circulating levels of free fatty acids, which are then taken up by the liver as an energy source[120](https://www.nature.com/articles/s41574-022-00690-7#ref-CR120 \"Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).\"). These fatty acids overload the mitochondrial β-oxidation system in the liver, resulting in the accumulation of fatty acids and, consequently, NAFLD[121](https://www.nature.com/articles/s41574-022-00690-7#ref-CR121 \"Angulo, P. Medical progress: nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).\"). Of those individuals with NAFLD, 2–3% develop hepatic inflammation, necrosis and fibrosis, which are the hallmarks of NASH[122](https://www.nature.com/articles/s41574-022-00690-7#ref-CR122 \"Porepa, L., Ray, J. G., Sanchez-Romeu, P. & Booth, G. L. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 182, E526–E531 (2010).\"). The exact mechanisms leading to steatohepatitis are unclear, although dysregulated peripheral lipid metabolism appears to be important[14](https://www.nature.com/articles/s41574-022-00690-7#ref-CR14 \"Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734–743 (2007).\").\\n\\n#### Ectopic adipose deposition\\n\\nExcessive or ectopic deposition of adipose tissue around the viscera and in the liver might be an important mechanism underlying both T2DM and liver disease, particularly NAFLD[123](https://www.nature.com/articles/s41574-022-00690-7#ref-CR123 \"Stefan, N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 8, 616–627 (2020).\"). Dysfunction of long-term adipose storage in white adipose tissue is known to lead to ectopic adipose deposition in the liver. In this state, increased levels of fatty acyl-coenzyme As, the activated form of fatty acids, might lead to organ dysfunction, including NAFLD[124](https://www.nature.com/articles/s41574-022-00690-7#ref-CR124 \"Stefan, N., Häring, H. U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 7, 313–324 (2019).\"). Ectopic adipose deposition leading to organ-specific insulin resistance has emerged as a major hypothesis for the pathophysiological basis of T2DM, and ectopic adipose in the pancreas could contribute to β-cell dysfunction and, thus, the development of T2DM[125](https://www.nature.com/articles/s41574-022-00690-7#ref-CR125 \"Sattar, N. & Gill, J. M. R. Type 2 diabetes as a disease of ectopic fat? BMC Med. 12, 123 (2014).\").\\n\\nDiabetes mellitus and affective disorders\\n-----------------------------------------\\n\\n### Depression\\n\\nThe prevalence of depression appears to be high among people with diabetes mellitus. The strongest evidence for an association comes from a systematic review of 147 studies among people with T2DM, which revealed a mean prevalence of depression of 28%[126](https://www.nature.com/articles/s41574-022-00690-7#ref-CR126 \"Harding, K. A. et al. Depression prevalence in type 2 diabetes is not related to diabetes–depression symptom overlap but is related to symptom dimensions within patient self-report measures: a meta-analysis. Diabet. Med. 36, 1600–1611 (2019).\"), while the global prevalence of depression in the general population is estimated at around 13%[127](https://www.nature.com/articles/s41574-022-00690-7#ref-CR127 \"Lim, G. Y. et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci. Rep. 8, 2861 (2018).\"). For T1DM, a systematic review reported a pooled prevalence of depression of 12% compared with only 3% in those without T1DM[128](https://www.nature.com/articles/s41574-022-00690-7#ref-CR128 \"Roy, T. & Lloyd, C. E. Epidemiology of depression and diabetes: a systematic review. J. Affect. Disord. 142, S8–S21 (2012).\"). The risk of depression among people with diabetes mellitus appears to be roughly 25% greater than the risk in the general population, with consistent findings across several meta-analyses (Table\\xa0[4](https://www.nature.com/articles/s41574-022-00690-7#Tab4)). A 2013 study found an adjusted RR of 1.25 (95% CI 1.10–1.44) for incident depression among people with diabetes mellitus compared with those without diabetes mellitus[129](https://www.nature.com/articles/s41574-022-00690-7#ref-CR129 \"Rotella, F. & Mannucci, E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res. Clin. Pract. 99, 98–104 (2013).\"). Another systematic review of people with T2DM reported a near identical effect size[130](https://www.nature.com/articles/s41574-022-00690-7#ref-CR130 \"Nouwen, A. et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 53, 2480–2486 (2010).\").\\n\\n**Table 4 Summary of major systematic reviews reporting risk of affective disorders, cognitive disability and functional disability associated with diabetes mellitus**\\n\\n[Full size table](https://www.nature.com/articles/s41574-022-00690-7/tables/4)\\n\\n### Anxiety and eating disorders\\n\\nEvidence exists for an association of diabetes mellitus with anxiety, and of T1DM with eating disorders. In a systematic review involving 2,584 individuals with diabetes mellitus, a prevalence of 14% was found for generalized anxiety disorder and 40% for anxiety symptoms, whereas the prevalence of generalized anxiety disorder in the general population is estimated as only 3–4%[131](https://www.nature.com/articles/s41574-022-00690-7#ref-CR131 \"Grigsby, A. B., Anderson, R. J., Freedland, K. E., Clouse, R. E. & Lustman, P. J. Prevalence of anxiety in adults with diabetes a systematic review. J. Psychosom. Res. 53, 1053–1060 (2002).\"). People with diabetes mellitus had an increased risk of anxiety disorders (OR 1.20, 95% CI 1.10–1.31) and anxiety symptoms (OR 1.48, 95% CI 1.02–1.93) compared with those without diabetes mellitus in a meta-analysis[132](https://www.nature.com/articles/s41574-022-00690-7#ref-CR132 \"Smith, K. J. et al. Association of diabetes with anxiety: a systematic review and meta-analysis. J. Psychosom. Res. 74, 89–99 (2013).\") (Table\\xa0[4](https://www.nature.com/articles/s41574-022-00690-7#Tab4)), although these findings were based on cross-sectional data. Across 13 studies, 7% of adolescents with T1DM were found to have eating disorders, compared with 3% of peers without diabetes mellitus[133](https://www.nature.com/articles/s41574-022-00690-7#ref-CR133 \"Young, V. et al. Eating problems in adolescents with type1 diabetes: a systematic review with meta-analysis. Diabet. Med. 30, 189–198 (2013).\").\\n\\n### Broader psychological impacts\\n\\nThere is a substantial literature on a broad range of psychological impacts of diabetes mellitus. Social stigma[134](https://www.nature.com/articles/s41574-022-00690-7#ref-CR134 \"Schabert, J., Browne, J. L., Mosely, K. & Speight, J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient 6, 1–10 (2013).\") can have profound impacts on the quality of life of not only people with diabetes mellitus, but their families and carers, too[135](https://www.nature.com/articles/s41574-022-00690-7#ref-CR135 \"Barnard, K. D., Speight, J. & Skinner, T. C. Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents. Pract. Diabetes Int. 25, 278–283 (2008).\"). In a systematic review, diabetes mellitus distress was found to affect around one-third of adolescents with T1DM, which was consistent with the results of studies of adults with diabetes mellitus[136](https://www.nature.com/articles/s41574-022-00690-7#ref-CR136 \"Hagger, V., Hendrieckx, C., Sturt, J., Skinner, T. C. & Speight, J. Diabetes distress among adolescents with type 1 diabetes: a systematic review. Curr. Diabetes Rep. 16, 1–14 (2016).\"). Diabetes mellitus burnout appears to be a distinct concept, and is characterized by exhaustion and detachment, accompanied by the experience of a loss of control over diabetes mellitus[137](https://www.nature.com/articles/s41574-022-00690-7#ref-CR137 \"Abdoli, S. et al. New insights into diabetes burnout and its distinction from diabetes distress and depressive symptoms: a qualitative study. Diabetes Res. Clin. Pract. 169, 108446 (2020).\").\\n\\n### Potential aetiological mechanisms\\n\\nDiabetes mellitus and depression appear to have common biological origins. Activation of the innate immune system and acute-phase inflammation contribute to the pathogenesis of T2DM — increased levels of inflammatory cytokines predict the onset of T2DM[138](https://www.nature.com/articles/s41574-022-00690-7#ref-CR138 \"Pickup, J. C. & Crook, M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241–1248 (1998).\") — and there is growing evidence implicating cytokine-mediated inflammation in people with depression in the absence of diabetes mellitus[139](https://www.nature.com/articles/s41574-022-00690-7#ref-CR139 \"Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).\"). Dysregulation of the hypothalamic–pituitary–adrenal axis is another potential biological mechanism linking depression and diabetes mellitus[140](https://www.nature.com/articles/s41574-022-00690-7#ref-CR140 \"Prestele, S., Aldenhoff, J. & Reiff, J. [The HPA-axis as a possible link between depression, diabetes mellitus and cognitive dysfunction]. Fortschr. Neurol. Psychiatr. 71, 24–36 (2003).\"). There have been numerous reports of hippocampal atrophy, which might contribute to chronic activation of the hypothalamic–pituitary–adrenal axis, in individuals with T2DM as well as those with depression[141](https://www.nature.com/articles/s41574-022-00690-7#ref-CR141 \"Cole, J., Costafreda, S. G., McGuffin, P. & Fu, C. H. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. J. Affect. Disord. 134, 483–487 (2011).\"),[142](https://www.nature.com/articles/s41574-022-00690-7#ref-CR142 \"Gold, S. M. et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 50, 711–719 (2007).\"). A meta-analysis found that, although hypertension modified global cerebral atrophy in those with T2DM, it had no effect on hippocampal atrophy[143](https://www.nature.com/articles/s41574-022-00690-7#ref-CR143 \"Moulton, C. D., Costafreda, S. G., Horton, P., Ismail, K. & Fu, C. H. Y. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. Brain Imaging Behav. 9, 651–662 (2015).\"). This suggests that, although global cerebral atrophy in individuals with T2DM might be driven by atherosclerotic disease, hippocampal atrophy is an independent effect that provides a common neuropathological aetiology for the comorbidity of T2DM with depression. There is a lack of relevant information regarding the potential aetiological mechanisms that link diabetes to other affective disorders.\\n\\nDiabetes mellitus and sleep disturbance\\n---------------------------------------\\n\\n### Obstructive sleep apnoea\\n\\nObstructive sleep apnoea (OSA) is highly prevalent among people with diabetes mellitus. In a systematic review of 41 studies of adults with diabetes mellitus, the prevalence of OSA was found to be 60%[144](https://www.nature.com/articles/s41574-022-00690-7#ref-CR144 \"Khalil, M., Power, N., Graham, E., Deschênes, S. S. & Schmitz, N. The association between sleep and diabetes outcomes – systematic review. Diabetes Res. Clin. Pract. 161, 108035 (2020).\"), whereas reports for OSA prevalence in the general population range from 9% to 38%[145](https://www.nature.com/articles/s41574-022-00690-7#ref-CR145 \"Senaratna, C. V. et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep. Med. Rev. 34, 70–81 (2017).\"). In a UK study of 1,656,739 participants, T2DM was associated with an IRR for OSA of 1.48 (95% CI 1.42–1.55) compared with no T2DM[146](https://www.nature.com/articles/s41574-022-00690-7#ref-CR146 \"Subramanian, A. et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care 42, 954–963 (2019).\"). A population-based US study reported a HR of 1.53 (95% CI 1.32–1.77) for OSA in people with T2DM compared with those without diabetes mellitus[147](https://www.nature.com/articles/s41574-022-00690-7#ref-CR147 \"Huang, T. et al. A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective U.S. Cohorts. Diabetes Care 41, 2111–2119 (2018).\"). However, the association in this latter report was attenuated after adjustment for BMI and waist circumference (1.08, 95% CI 1.00–1.16), suggesting that the excess risk of OSA among people with diabetes mellitus might be mainly explained by the comorbidity of obesity. Although most studies on OSA have focused on T2DM, a meta-analysis of people with T1DM revealed a similar prevalence of 52%[148](https://www.nature.com/articles/s41574-022-00690-7#ref-CR148 \"Reutrakul, S. et al. Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. Sleep. Med. 23, 26–45 (2016).\"); however, this meta-analysis was limited to small studies. The association between T2DM and OSA is bidirectional: the severity of OSA was shown to be positively associated with the incidence of T2DM, independent of adiposity, in a large US cohort study[149](https://www.nature.com/articles/s41574-022-00690-7#ref-CR149 \"Nagayoshi, M. et al. Obstructive sleep apnea and incident type 2 diabetes. Sleep. Med. 25, 156–161 (2016).\").\\n\\n### Potential aetiological mechanisms\\n\\nThe mechanism by which T2DM might increase the risk of developing OSA is thought to involve dysregulation of the autonomic nervous system leading to sleep-disordered breathing[150](https://www.nature.com/articles/s41574-022-00690-7#ref-CR150 \"Ficker, J. H. et al. Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. Eur. Respir. J. 11, 14–19 (1998).\"). Conversely, the specific mechanism behind OSA as a causative factor for T2DM remains poorly understood. It has been suggested that OSA is able to induce insulin resistance[151](https://www.nature.com/articles/s41574-022-00690-7#ref-CR151 \"Young, T., Peppard, P. E. & Taheri, S. Excess weight and sleep-disordered breathing. J. Appl. Physiol. 99, 1592–1599 (2005).\"),[152](https://www.nature.com/articles/s41574-022-00690-7#ref-CR152 \"Ip, M. S. M. et al. Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respir. Crit. Care Med. 165, 670–676 (2002).\") and is a risk factor for the development of glucose intolerance[152](https://www.nature.com/articles/s41574-022-00690-7#ref-CR152 \"Ip, M. S. M. et al. Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respir. Crit. Care Med. 165, 670–676 (2002).\"). However, once T2DM has developed, there is no clear evidence that OSA worsens glycaemic control, as an RCT of people with T2DM found that treating OSA had no effect on glycaemic control[153](https://www.nature.com/articles/s41574-022-00690-7#ref-CR153 \"Shaw, J. E. et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am. J. Respir. Crit. Care Med. 194, 486–492 (2016).\").\\n\\nDiabetes mellitus and cognitive disability\\n------------------------------------------\\n\\n### Dementia and cognitive impairment\\n\\nDementia is emerging as a major cause of mortality in both individuals with diabetes mellitus and the general population, and is now the leading cause of death in some countries/regions[9](https://www.nature.com/articles/s41574-022-00690-7#ref-CR9 \"Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 9, 165–173 (2021).\"). However, compared with the general population, diabetes mellitus increases the risk of dementia, particularly vascular dementia. The association is supported by several systematic reviews, including one of eight population-based studies with more than 23,000 people, which found SRRs of 2.38 (95% CI 1.79–3.18) for vascular dementia and 1.39 (95% CI 1.16–1.66) for Alzheimer disease comparing people with diabetes mellitus with those without diabetes mellitus[154](https://www.nature.com/articles/s41574-022-00690-7#ref-CR154 \"Lu, F. P., Lin, K. P. & Kuo, H. K. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. PLoS ONE 4, e4144 (2009).\") (Table\\xa0[4](https://www.nature.com/articles/s41574-022-00690-7#Tab4)). Similar results, as well as a RR of 1.21 (95% CI 1.02–1.45) for mild cognitive impairment (MCI), were reported across 19 population-based studies of 44,714 people, 6,184 of whom had diabetes mellitus[155](https://www.nature.com/articles/s41574-022-00690-7#ref-CR155 \"Cheng, G., Huang, C., Deng, H. & Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 42, 484–491 (2012).\"). Two meta-analyses of prospective cohort studies have shown increased risks of all-cause dementia in people with diabetes mellitus compared with those without diabetes mellitus[156](https://www.nature.com/articles/s41574-022-00690-7#ref-CR156 \"Li, X. Y. et al. Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. Curr. Alzheimer Res. 16, 1254–1268 (2019).\"),[157](https://www.nature.com/articles/s41574-022-00690-7#ref-CR157 \"Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res. Rev. 55, 100944 (2019).\"), and T2DM has been shown to increase progression to dementia in people with MCI[158](https://www.nature.com/articles/s41574-022-00690-7#ref-CR158 \"Pal, K., Mukadam, N., Petersen, I. & Cooper, C. Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. Soc. Psychiatry Psychiatr. Epidemiol. 53, 1149–1160 (2018).\").\\n\\nThe boundaries between Alzheimer disease and vascular dementia remain controversial, and these conditions are often difficult to differentiate clinically[159](https://www.nature.com/articles/s41574-022-00690-7#ref-CR159 \"Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C. & Scheltens, P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64–74 (2006).\"). Consequently, vascular dementia might have been misdiagnosed as Alzheimer disease in some studies investigating diabetes mellitus and dementia, resulting in an overestimation of the effect size of the association between diabetes mellitus and Alzheimer disease. Although a cohort study found a significant association between diabetes mellitus and Alzheimer disease using imaging[160](https://www.nature.com/articles/s41574-022-00690-7#ref-CR160 \"Peila, R., Rodriguez, B. L. & Launer, L. J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 51, 1256–1262 (2002).\"), autopsy studies have failed to uncover an association between diabetes mellitus and Alzheimer disease pathology[161](https://www.nature.com/articles/s41574-022-00690-7#ref-CR161 \"Abner, E. L. et al. Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. Alzheimer’s Dement. 12, 882–889 (2016).\"),[162](https://www.nature.com/articles/s41574-022-00690-7#ref-CR162 \"Matioli, M. N. P. S. et al. Association between diabetes and causes of dementia: evidence from a clinicopathological study. Dement. Neuropsychol. 11, 406–412 (2017).\"), suggesting that vascular mechanisms are the key driver of cognitive decline in people with diabetes mellitus.\\n\\nAnother important finding is a 45% prevalence of MCI among people with T2DM in a meta-analysis, compared with a prevalence of 3–22% reported for the general population[163](https://www.nature.com/articles/s41574-022-00690-7#ref-CR163 \"You, Y. et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Acta Diabetol. 58, 671–685 (2021).\"). Notably, however, the prevalence of MCI in individuals with T2DM was similar in people younger than 60 years (46%) and those older than 60 years (44%), which is at odds with previous research suggesting that MCI is most common in older people, particularly those aged more than 65 years[164](https://www.nature.com/articles/s41574-022-00690-7#ref-CR164 \"Langa, K. M. & Levine, D. A. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 312, 2551–2561 (2014).\") However, another meta-analysis found cognitive decline in people with T2DM who are younger than 65 years[165](https://www.nature.com/articles/s41574-022-00690-7#ref-CR165 \"Pelimanni, E. & Jehkonen, M. Type 2 diabetes and cognitive functions in middle age: a meta-analysis. J. Int. Neuropsychol. Soc. 25, 215–229 (2019).\"), suggesting that a burden of cognitive disease exists among younger people with diabetes mellitus.\\n\\n### Potential aetiological mechanisms\\n\\nAlthough there is solid evidence that links diabetes mellitus to cognitive disability, our understanding of the underlying mechanisms is incomplete. Mouse models suggest a strong association between hyperglycaemia, the advanced glycation end products glyoxal and methylglyoxal, enhanced blood–brain barrier (BBB) permeability and cognitive dysfunction in both T1DM and T2DM[166](https://www.nature.com/articles/s41574-022-00690-7#ref-CR166 \"Rom, S. et al. Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles. Sci. Rep. 10, 7274 (2020).\"). The BBB reduces the access of neurotoxic compounds and pathogens to the brain and sustains brain homeostasis, so disruption to the BBB can result in cognitive dysfunction through dysregulation of transport of molecules between the peripheral circulation and the brain[167](https://www.nature.com/articles/s41574-022-00690-7#ref-CR167 \"Hussain, B., Fang, C. & Chang, J. Blood–brain barrier breakdown: an emerging biomarker of cognitive impairment in normal aging and dementia. Front. Neurosci. 15, 688090 (2021).\"). There appears to be a continuous relationship between glycaemia and cognition, with associations found between even high-normal blood levels of glucose and cognitive decline[168](https://www.nature.com/articles/s41574-022-00690-7#ref-CR168 \"Anstey, K. J., Sargent-Cox, K., Eramudugolla, R., Magliano, D. J. & Shaw, J. E. Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study. Alzheimers Res. Ther. 7, 48 (2015).\"). Another hypothetical mechanism involves a key role for impaired insulin signalling in the pathogenesis of Alzheimer disease. Brain tissue obtained post mortem from individuals with Alzheimer disease showed extensive abnormalities in insulin and insulin-like growth factor signalling mechanisms compared with control brain tissue[169](https://www.nature.com/articles/s41574-022-00690-7#ref-CR169 \"Steen, E. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease - Is this type 3 diabetes? J. Alzheimer’s Dis. 7, 63–80 (2005).\"). Although the synthesis of insulin-like growth factors occurred normally in people with Alzheimer disease, their expression levels were markedly reduced, which led to the subsequent proposal of the term ‘type 3 diabetes’ to characterize Alzheimer disease.\\n\\nDiabetes mellitus and disability\\n--------------------------------\\n\\n### Functional disability\\n\\nDisability (defined as a difficulty in functioning in one or more life domains as experienced by an individual with a health condition in interaction with contextual factors)[170](https://www.nature.com/articles/s41574-022-00690-7#ref-CR170 \"Leonardi, M., Bickenbach, J., Ustun, T. B., Kostanjsek, N. & Chatterji, S. The definition of disability: what is in a name? Lancet 368, 1219–1221 (2006).\") is highly prevalent in people with diabetes mellitus. In a systematic review, lower-body functional limitation was found to be the most prevalent disability (47–84%) among people with diabetes mellitus[171](https://www.nature.com/articles/s41574-022-00690-7#ref-CR171 \"Lisy, K., Campbell, J. M., Tufanaru, C., Moola, S. & Lockwood, C. The prevalence of disability among people with cancer, cardiovascular disease, chronic respiratory disease and/or diabetes: a systematic review. Int. J. Evid. Based Healthc. 16, 154–166 (2018).\") The prevalence of difficulties with [activities of daily living](https://www.nature.com/articles/s41574-022-00690-7#Glos1) among people with diabetes mellitus ranged from 12% to 55%, although most studies were conducted exclusively in individuals aged 60 years and above, so the results are not generalizable to younger age groups. A systematic review showed a significant association between diabetes mellitus and falls in adults aged 60 years and above[172](https://www.nature.com/articles/s41574-022-00690-7#ref-CR172 \"Yang, Y., Hu, X., Zhang, Q. & Zou, R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. Age Ageing 45, 761–767 (2016).\"). A 2013 meta-analysis[173](https://www.nature.com/articles/s41574-022-00690-7#ref-CR173 \"Wong, E. et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 1, 106–114 (2013).\") showed an increased risk of mobility disability, activities of daily living disability and [independent activities of daily living](https://www.nature.com/articles/s41574-022-00690-7#Glos2) disability among people with diabetes mellitus compared with those without diabetes mellitus (Table\\xa0[4](https://www.nature.com/articles/s41574-022-00690-7#Tab4)). Although this analysis included cross-sectional data, results were consistent across longitudinal and cross-sectional studies, suggesting little effect of reverse causality. However, people with functional disabilities that limit mobility (for example, people with osteoarthritis or who have had a stroke) might be more prone to developing diabetes mellitus owing to physical inactivity[174](https://www.nature.com/articles/s41574-022-00690-7#ref-CR174 \"Havercamp, S. M., Scandlin, D. & Roth, M. Health disparities among adults with developmental disabilities, adults with other disabilities, and adults not reporting disability in North Carolina. Public. Health Rep. 119, 418–426 (2004).\").\\n\\n#### Workplace productivity\\n\\nDecreased productivity while at work, increased time off work and early dropout from the workforce[175](https://www.nature.com/articles/s41574-022-00690-7#ref-CR175 \"Herquelot, E., Guéguen, A., Bonenfant, S. & Dray-Spira, R. Impact of diabetes on work cessation: data from the GAZEL cohort study. Diabetes Care 34, 1344–1349 (2011).\") are all associated with diabetes mellitus, probably partly due to functional disability, and possibly also to comorbidities such as obesity and physical inactivity[176](https://www.nature.com/articles/s41574-022-00690-7#ref-CR176 \"Virtanen, M. et al. Work disability among employees with diabetes: latent class analysis of risk factors in three prospective cohort studies. PLoS ONE 10, e0143184 (2015).\"). Given that young-onset diabetes is becoming more common, and most people with diabetes mellitus in middle-income countries/regions are less than 65 years old[177](https://www.nature.com/articles/s41574-022-00690-7#ref-CR177 \"Cho, N. H. et al. IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271–281 (2018).\"), a pandemic of diabetes mellitus-related work disability among a middle-aged population does not bode well for the economies of these regions.\\n\\n### Potential aetiological mechanisms\\n\\nThe mechanisms by which diabetes mellitus leads to functional disability remain unclear. One suggestion is that hyperglycaemia leads to systemic inflammation, which is one component of a multifactorial process that results in disability[154](https://www.nature.com/articles/s41574-022-00690-7#ref-CR154 \"Lu, F. P., Lin, K. P. & Kuo, H. K. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. PLoS ONE 4, e4144 (2009).\"). The rapid loss of skeletal muscle strength and quality seen among people with diabetes mellitus might be another cause of functional disability[178](https://www.nature.com/articles/s41574-022-00690-7#ref-CR178 \"Seok, W. P. et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 30, 1507–1512 (2007).\") (Box\\xa0[1](https://www.nature.com/articles/s41574-022-00690-7#Sec47)). In addition, complications of diabetes mellitus, including stroke, peripheral neuropathy and cardiac dysfunction, can obviously directly cause disability[179](https://www.nature.com/articles/s41574-022-00690-7#ref-CR179 \"Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321, 405–412 (2000).\").\\n\\n### Box 1 Diabetes mellitus and skeletal muscle atrophy\\n\\n*   Individuals with diabetes mellitus exhibit skeletal muscle atrophy that is typically mild in middle age and becomes more substantial with increasing age.\\n    \\n*   This muscle loss leads to reduced strength and functional capacity and, ultimately, increased mortality.\\n    \\n*   Skeletal muscle atrophy results from a negative balance between the rate of synthesis and degradation of contractile proteins, which occurs in response to disuse, ageing and chronic diseases such as diabetes mellitus.\\n    \\n*   Degradation of muscle proteins is more rapid in diabetes mellitus, and muscle protein synthesis has also been reported to be decreased.\\n    \\n*   Proposed mechanisms underlying skeletal muscle atrophy include systemic inflammation (affecting both protein synthesis and degradation), dysregulation of muscle protein anabolism and lipotoxicity.\\n    \\n*   Mouse models have also revealed a key role for the WWP1/KLF15 pathway, mediated by hyperglycaemia, in the pathogenesis of muscle atrophy.\\n    \\n\\nSee refs[195](https://www.nature.com/articles/s41574-022-00690-7#ref-CR195 \"Perry, B. D. et al. Muscle atrophy in patients with Type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. Exerc. Immunol. Rev. 22, 94–109 (2016).\"),[196](https://www.nature.com/articles/s41574-022-00690-7#ref-CR196 \"Hirata, Y. et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight 4, e124952 (2019).\"),[197](https://www.nature.com/articles/s41574-022-00690-7#ref-CR197 \"Bassil, M. S. & Gougeon, R. Muscle protein anabolism in type 2 diabetes. Curr. Opin. Clin. Nutr. Metab. Care 16, 83–88 (2013).\"),[198](https://www.nature.com/articles/s41574-022-00690-7#ref-CR198 \"Meex, R. C. R., Blaak, E. E. & van Loon, L. J. C. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes. Rev. 20, 1205–1217 (2019).\").\\n\\nShow more\\n\\nDiabetes management and control\\n-------------------------------\\n\\nAlthough a detailed discussion of the impacts of anti-diabetes mellitus medications and glucose control on emerging complications is beyond the scope of this Review, their potential effect on these complications must be acknowledged.\\n\\n### Medications\\n\\n#### Anti-diabetes mellitus medications and cancer\\n\\nIn the case of cancer as an emerging complication, the use of medications for diabetes mellitus was not controlled for in most studies of diabetes mellitus and cancer and might therefore be a confounding factor. People taking metformin have a lower cancer risk than those not taking metformin[180](https://www.nature.com/articles/s41574-022-00690-7#ref-CR180 \"DeCensi, A. et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. 3, 1451–1461 (2010).\"). However, this association is mainly accounted for by other factors. For example, metformin is less likely to be administered to people with diabetes mellitus who have kidney disease[181](https://www.nature.com/articles/s41574-022-00690-7#ref-CR181 \"Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J. & McGuire, D. K. Metformin in patientswith type 2 diabetes and kidney disease a systematic review. JAMA 312, 2668–2675 (2014).\"), who typically have longer duration diabetes mellitus, which increases cancer risk. A review of observational studies into the association between metformin and cancer found that many studies reporting significant reductions in cancer incidence or mortality associated with metformin were affected by [immortal time bias](https://www.nature.com/articles/s41574-022-00690-7#Glos3) and other time-related biases, casting doubt on the ability of metformin to reduce cancer mortality[182](https://www.nature.com/articles/s41574-022-00690-7#ref-CR182 \"Suissa, S. & Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35, 2665–2673 (2012).\"). Notably, the use of insulin was associated with an increased risk of several cancers in a meta-analysis[183](https://www.nature.com/articles/s41574-022-00690-7#ref-CR183 \"Karlstad, Ø. et al. Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies. Curr. Drug. Saf. 8, 333–348 (2013).\"). However, in an RCT of more than 12,000 people with dysglycaemia, randomization to insulin glargine (compared with standard care) did not increase cancer incidence[184](https://www.nature.com/articles/s41574-022-00690-7#ref-CR184 \"Bordeleau, L. et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 37, 1360–1366 (2014).\"). Furthermore, cancer rates in people with T1DM and T2DM do not appear to vary greatly, despite substantial differences in insulin use between people with these types of diabetes mellitus.\\n\\n#### Anti-diabetes mellitus medications and other emerging complications\\n\\nAnti-diabetes medications appear to affect the onset and development of some other emerging complications of diabetes mellitus. Results from RCTs suggest that metformin might confer therapeutic effects against depression[185](https://www.nature.com/articles/s41574-022-00690-7#ref-CR185 \"Guo, M. et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 41, 650–656 (2014).\"), and its use was associated with reduced dementia incidence in a systematic review[186](https://www.nature.com/articles/s41574-022-00690-7#ref-CR186 \"Campbell, J. M. et al. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J. Alzheimer’s Dis. 65, 1225–1236 (2018).\"). In an RCT investigating a potential association between metformin and NAFLD, no improvement in NAFLD histology was found among people using metformin compared with those given placebo[187](https://www.nature.com/articles/s41574-022-00690-7#ref-CR187 \"Haukeland, J. W. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol. 44, 853–860 (2009).\"). An RCT reported benefits of treatment with the glucagon-like peptide 1 receptor agonist dulaglutide on cognitive function in a post hoc analysis[188](https://www.nature.com/articles/s41574-022-00690-7#ref-CR188 \"Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582–590 (2020).\"), suggesting that trials designed specifically to test the effects of dulaglutide on cognitive function should be undertaken.\\n\\n### Glucose control\\n\\nAnother important consideration is glycaemic control, which appears to have variable effects on emerging complications. A meta-analysis found no association of glycaemic control with cancer risk among those with diabetes mellitus[189](https://www.nature.com/articles/s41574-022-00690-7#ref-CR189 \"Johnson, J. A. & Bowker, S. L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25–31 (2011).\"), and an RCT found no effect of intensive glucose lowering on cognitive function in people with T2DM[190](https://www.nature.com/articles/s41574-022-00690-7#ref-CR190 \"Launer, L. J. et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 10, 969–977 (2011).\"). However, glycaemic control has been associated with improved physical function[191](https://www.nature.com/articles/s41574-022-00690-7#ref-CR191 \"Jia, Y. et al. Associations of the glycaemic control of diabetes with dementia and physical function in rural-dwelling older Chinese adults: a population-based study. Clin. Interv. Aging 16, 1503–1513 (2021).\"), decreased COVID-19 mortality[192](https://www.nature.com/articles/s41574-022-00690-7#ref-CR192 \"Lesniak, C. et al. Inpatient glycemic control and outcome of COVID-19 patients: a retrospective cohort. SAGE Open. Med. 9, 20503121211039105 (2021).\") and a decreased risk of NAFLD[193](https://www.nature.com/articles/s41574-022-00690-7#ref-CR193 \"Afolabi, B. I. et al. The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients. J. Natl Med. Assoc. 110, 256–264 (2018).\") in observational studies of patients with diabetes mellitus; notably, no RCTs have yet confirmed these associations.\\n\\nConclusions\\n-----------\\n\\nWith advances in the management of diabetes mellitus and associated increased life expectancy, the face of diabetes mellitus complications is changing. As the management of glycaemia and traditional complications of diabetes mellitus is optimized, we are beginning instead to see deleterious effects of diabetes mellitus on the liver, brain and other organs. Given the substantial burden and risk of these emerging complications, future clinical and public health strategies should be updated accordingly. There is a need to increase the awareness of emerging complications among primary care physicians at the frontline of diabetes mellitus care, and a place for screening for conditions such as depression, liver disease and cancers in diabetes mellitus guidelines should be considered. Clinical care for older people with diabetes mellitus should target physical activity, particularly strength-based activity, to reduce the risk of functional disability in ageing populations. Ongoing high-quality surveillance of diabetes mellitus outcomes is imperative to ensure we know where the main burdens lie. Given the growing burden of these emerging complications, the traditional management of diabetes mellitus might need to broaden its horizons.\\n\\nReferences\\n----------\\n\\n1.  Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. _Nature_ **414**, 782–787 (2001).\\n    \\n    [Article](https://doi.org/10.1038%2F414782a)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xhtlymtg%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11742409)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20and%20societal%20implications%20of%20the%20diabetes%20epidemic&journal=Nature&doi=10.1038%2F414782a&volume=414&pages=782-787&publication_year=2001&author=Zimmet%2CP&author=Alberti%2CKGMM&author=Shaw%2CJ)\\n    \\n2.  Fowler, M. J. Microvascular and macrovascular complications of diabetes. _Clin. Diabetes_ **26**, 77–82 (2008).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiaclin.26.2.77)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Microvascular%20and%20macrovascular%20complications%20of%20diabetes&journal=Clin.%20Diabetes&doi=10.2337%2Fdiaclin.26.2.77&volume=26&pages=77-82&publication_year=2008&author=Fowler%2CMJ)\\n    \\n3.  Shah, A. D. et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. _Lancet Diabetes Endocrinol._ **3**, 105–113 (2015).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2814%2970219-0)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25466521)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303913)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20incidence%20of%20cardiovascular%20diseases%3A%20a%20cohort%20study%20in%201%C2%B79%20million%20people&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2814%2970219-0&volume=3&pages=105-113&publication_year=2015&author=Shah%2CAD)\\n    \\n4.  Bertoni, A. G. et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. _Diabetes Care_ **27**, 699–703 (2004).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiacare.27.3.699)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14988288)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Heart%20failure%20prevalence%2C%20incidence%2C%20and%20mortality%20in%20the%20elderly%20with%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdiacare.27.3.699&volume=27&pages=699-703&publication_year=2004&author=Bertoni%2CAG)\\n    \\n5.  Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. _N. Engl. J. Med._ **370**, 1514–1523 (2014).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJMoa1310799)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXmvFShtb4%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24738668)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Changes%20in%20diabetes-related%20complications%20in%20the%20United%20States%2C%201990%E2%80%932010&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1310799&volume=370&pages=1514-1523&publication_year=2014&author=Gregg%2CEW)\\n    \\n6.  Gregg, E. W., Sattar, N. & Ali, M. K. The changing face of diabetes complications. _Lancet Diabetes Endocrinol._ **4**, 537–547 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2816%2930010-9)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27156051)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20changing%20face%20of%20diabetes%20complications&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2816%2930010-9&volume=4&pages=537-547&publication_year=2016&author=Gregg%2CEW&author=Sattar%2CN&author=Ali%2CMK)\\n    \\n7.  Gregg, E. W. et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. _Lancet_ **391**, 2430–2440 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2FS0140-6736%2818%2930314-3)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29784146)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20cause-specific%20mortality%20among%20adults%20with%20and%20without%20diagnosed%20diabetes%20in%20the%20USA%3A%20an%20epidemiological%20analysis%20of%20linked%20national%20survey%20and%20vital%20statistics%20data&journal=Lancet&doi=10.1016%2FS0140-6736%2818%2930314-3&volume=391&pages=2430-2440&publication_year=2018&author=Gregg%2CEW)\\n    \\n8.  Harding, J. L., Shaw, J. E., Peeters, A., Davidson, S. & Magliano, D. J. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. _Diabetes Care_ **39**, 1018–1026 (2016).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc15-2308)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27208325)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Age-specific%20trends%20from%202000%E2%80%932011%20in%20all-cause%20and%20cause-specific%20mortality%20in%20type%201%20and%20type%202%20diabetes%3A%20a%20cohort%20study%20of%20more%20than%20one%20million%20people&journal=Diabetes%20Care&doi=10.2337%2Fdc15-2308&volume=39&pages=1018-1026&publication_year=2016&author=Harding%2CJL&author=Shaw%2CJE&author=Peeters%2CA&author=Davidson%2CS&author=Magliano%2CDJ)\\n    \\n9.  Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. _Lancet Diabetes Endocrinol._ **9**, 165–173 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930431-9)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33549162)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886654)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20predominant%20causes%20of%20death%20in%20individuals%20with%20and%20without%20diabetes%20in%20England%20from%202001%20to%202018%3A%20an%20epidemiological%20analysis%20of%20linked%20primary%20care%20records&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930431-9&volume=9&pages=165-173&publication_year=2021&author=Pearson-Stuttard%2CJ)\\n    \\n10.  Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. _Cardiovasc. Diabetol._ **17**, 83 (2018).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12933-018-0728-6)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29884191)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994068)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20cardiovascular%20disease%20in%20type%202%20diabetes%3A%20a%20systematic%20literature%20review%20of%20scientific%20evidence%20from%20across%20the%20world%20in%202007%E2%80%932017&journal=Cardiovasc.%20Diabetol.&doi=10.1186%2Fs12933-018-0728-6&volume=17&publication_year=2018&author=Einarson%2CTR&author=Acs%2CA&author=Ludwig%2CC&author=Panton%2CUH)\\n    \\n11.  Pearson-Stuttard, J., Buckley, J., Cicek, M. & Gregg, E. W. The changing nature of mortality and morbidity in patients with diabetes. _Endocrinol. Metab. Clin. North Am._ **50**, 357–368 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ecl.2021.05.001)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34399950)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20changing%20nature%20of%20mortality%20and%20morbidity%20in%20patients%20with%20diabetes&journal=Endocrinol.%20Metab.%20Clin.%20North%20Am.&doi=10.1016%2Fj.ecl.2021.05.001&volume=50&pages=357-368&publication_year=2021&author=Pearson-Stuttard%2CJ&author=Buckley%2CJ&author=Cicek%2CM&author=Gregg%2CEW)\\n    \\n12.  Pearson-Stuttard, J. et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. _Lancet Diabetes Endocrinol._ **10**, 46–57 (2022).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2821%2900288-6)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34861153)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672063)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20leading%20causes%20of%20hospitalisation%20of%20adults%20with%20diabetes%20in%20England%20from%202003%20to%202018%3A%20an%20epidemiological%20analysis%20of%20linked%20primary%20care%20records&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2821%2900288-6&volume=10&pages=46-57&publication_year=2022&author=Pearson-Stuttard%2CJ)\\n    \\n13.  Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D. G. & Critchley, J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. _Lancet Diabetes Endocrinol._ **4**, 148–158 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2815%2900379-4)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26656292)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20infection%3A%20assessing%20the%20association%20with%20glycaemic%20control%20in%20population-based%20studies&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2815%2900379-4&volume=4&pages=148-158&publication_year=2016&author=Pearson-Stuttard%2CJ&author=Blundell%2CS&author=Harris%2CT&author=Cook%2CDG&author=Critchley%2CJ)\\n    \\n14.  Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. _Diabetes Care_ **30**, 734–743 (2007).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc06-1539)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXjs1Grurk%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17327353)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Spectrum%20of%20liver%20disease%20in%20type%202%20diabetes%20and%20management%20of%20patients%20with%20diabetes%20and%20liver%20disease&journal=Diabetes%20Care&doi=10.2337%2Fdc06-1539&volume=30&pages=734-743&publication_year=2007&author=Tolman%2CKG&author=Fonseca%2CV&author=Dalpiaz%2CA&author=Tan%2CMH)\\n    \\n15.  Chatterjee, S. et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. _Diabetes Care_ **39**, 300–307 (2016).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc15-1588)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XitVKis7nO)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26681727)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20as%20a%20risk%20factor%20for%20dementia%20in%20women%20compared%20with%20men%3A%20a%20pooled%20analysis%20of%202.3%20million%20people%20comprising%20more%20than%20100%2C000%20cases%20of%20dementia&journal=Diabetes%20Care&doi=10.2337%2Fdc15-1588&volume=39&pages=300-307&publication_year=2016&author=Chatterjee%2CS)\\n    \\n16.  Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. _BMJ_ **350**, g7607 (2015).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmj.g7607)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25555821)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20cancer%3A%20umbrella%20review%20of%20meta-analyses%20of%20observational%20studies&journal=BMJ&doi=10.1136%2Fbmj.g7607&volume=350&publication_year=2015&author=Tsilidis%2CKK&author=Kasimis%2CJC&author=Lopez%2CDS&author=Ntzani%2CEE&author=Ioannidis%2CJP)\\n    \\n17.  Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. _Diabetologia_ **62**, 3–16 (2019).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-018-4711-2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30171279)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20trends%20in%20diabetes%20complications%3A%20a%20review%20of%20current%20evidence&journal=Diabetologia&doi=10.1007%2Fs00125-018-4711-2&volume=62&pages=3-16&publication_year=2019&author=Harding%2CJL&author=Pavkov%2CME&author=Magliano%2CDJ&author=Shaw%2CJE&author=Gregg%2CEW)\\n    \\n18.  Unal, B., Critchley, J. A. & Capewell, S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. _Circulation_ **109**, 1101–1107 (2004).\\n    \\n    [Article](https://doi.org/10.1161%2F01.CIR.0000118498.35499.B2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14993137)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Explaining%20the%20decline%20in%20coronary%20heart%20disease%20mortality%20in%20England%20and%20Wales%20between%201981%20and%202000&journal=Circulation&doi=10.1161%2F01.CIR.0000118498.35499.B2&volume=109&pages=1101-1107&publication_year=2004&author=Unal%2CB&author=Critchley%2CJA&author=Capewell%2CS)\\n    \\n19.  Pearson-Stuttard, J., Ezzati, M. & Gregg, E. W. Multimorbidity — a defining challenge for health systems. _Lancet Public. Health_ **4**, e599–e600 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2FS2468-2667%2819%2930222-1)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31812234)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multimorbidity%20%E2%80%94%20a%20defining%20challenge%20for%20health%20systems&journal=Lancet%20Public.%20Health&doi=10.1016%2FS2468-2667%2819%2930222-1&volume=4&pages=e599-e600&publication_year=2019&author=Pearson-Stuttard%2CJ&author=Ezzati%2CM&author=Gregg%2CEW)\\n    \\n20.  Lee, L., Cheung, W. Y., Atkinson, E. & Krzyzanowska, M. K. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. _J. Clin. Oncol._ **29**, 106–117 (2011).\\n    \\n    [Article](https://doi.org/10.1200%2FJCO.2010.31.3049)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21098314)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20comorbidity%20on%20chemotherapy%20use%20and%20outcomes%20in%20solid%20tumors%3A%20a%20systematic%20review&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2010.31.3049&volume=29&pages=106-117&publication_year=2011&author=Lee%2CL&author=Cheung%2CWY&author=Atkinson%2CE&author=Krzyzanowska%2CMK)\\n    \\n21.  Srokowski, T. P., Fang, S., Hortobagyi, G. N. & Giordano, S. H. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. _J. Clin. Oncol._ **27**, 2170–2176 (2009).\\n    \\n    [Article](https://doi.org/10.1200%2FJCO.2008.17.5935)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19307509)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674004)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20diabetes%20mellitus%20on%20complications%20and%20outcomes%20of%20adjuvant%20chemotherapy%20in%20older%20patients%20with%20breast%20cancer&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2008.17.5935&volume=27&pages=2170-2176&publication_year=2009&author=Srokowski%2CTP&author=Fang%2CS&author=Hortobagyi%2CGN&author=Giordano%2CSH)\\n    \\n22.  Gross, C. P., McAvay, G. J., Guo, Z. & Tinetti, M. E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. _Cancer_ **109**, 2410–2419 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fcncr.22726)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17510973)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20impact%20of%20chronic%20illnesses%20on%20the%20use%20and%20effectiveness%20of%20adjuvant%20chemotherapy%20for%20colon%20cancer&journal=Cancer&doi=10.1002%2Fcncr.22726&volume=109&pages=2410-2419&publication_year=2007&author=Gross%2CCP&author=McAvay%2CGJ&author=Guo%2CZ&author=Tinetti%2CME)\\n    \\n23.  Harding, J. L. et al. All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. _Int. J. Cancer_ **131**, 2385–2393 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.27503)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XksFCktLk%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22362309)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=All-cause%20cancer%20mortality%20over%2015%20years%20in%20multi-ethnic%20Mauritius%3A%20the%20impact%20of%20diabetes%20and%20intermediate%20forms%20of%20glucose%20tolerance&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.27503&volume=131&pages=2385-2393&publication_year=2012&author=Harding%2CJL)\\n    \\n24.  Wang, C. et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. _Int. J. Cancer_ **130**, 1639–1648 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.26165)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xhtl2gsbc%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21544812)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Increased%20risk%20of%20hepatocellular%20carcinoma%20in%20patients%20with%20diabetes%20mellitus%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.26165&volume=130&pages=1639-1648&publication_year=2012&author=Wang%2CC)\\n    \\n25.  El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. _Clin. Gastroenterol. Hepatol._ **4**, 369–380 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cgh.2005.12.007)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16527702)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20diabetes%20and%20hepatocellular%20carcinoma%3A%20a%20systematic%20review%20of%20epidemiologic%20evidence&journal=Clin.%20Gastroenterol.%20Hepatol.&doi=10.1016%2Fj.cgh.2005.12.007&volume=4&pages=369-380&publication_year=2006&author=El-Serag%2CHB&author=Hampel%2CH&author=Javadi%2CF)\\n    \\n26.  Desbois, A. C. & Cacoub, P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. _World J. Gastroenterol._ **23**, 1697–1711 (2017).\\n    \\n    [Article](https://doi.org/10.3748%2Fwjg.v23.i9.1697)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjs12itb4%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28321170)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340821)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%2C%20insulin%20resistance%20and%20hepatitis%20C%20virus%20infection%3A%20a%20contemporary%20review&journal=World%20J.%20Gastroenterol.&doi=10.3748%2Fwjg.v23.i9.1697&volume=23&pages=1697-1711&publication_year=2017&author=Desbois%2CAC&author=Cacoub%2CP)\\n    \\n27.  Huxley, R., Ansary-Moghaddam, A., Berrington De González, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. _Br. J. Cancer_ **92**, 2076–2083 (2005).\\n    \\n    [Article](https://doi.org/10.1038%2Fsj.bjc.6602619)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2M3ot1Kjug%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15886696)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361795)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type-II%20diabetes%20and%20pancreatic%20cancer%3A%20a%20meta-analysis%20of%2036%20studies&journal=Br.%20J.%20Cancer&doi=10.1038%2Fsj.bjc.6602619&volume=92&pages=2076-2083&publication_year=2005&author=Huxley%2CR&author=Ansary-Moghaddam%2CA&author=Berrington%20De%20Gonz%C3%A1lez%2CA&author=Barzi%2CF&author=Woodward%2CM)\\n    \\n28.  Gullo, L. et al. Diabetes and the risk of pancreatic cancer. _N. Engl. J. Med._ **331**, 81–84 (1994).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM199407143310203)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK2c3mvVGhug%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8208269)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20pancreatic%20cancer&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM199407143310203&volume=331&pages=81-84&publication_year=1994&author=Gullo%2CL)\\n    \\n29.  Gershell, L. Type 2 diabetes market. _Nat. Rev. Drug Discov._ **4**, 367–368 (2005).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrd1723)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXjs1OktLg%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15902771)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20market&journal=Nat.%20Rev.%20Drug%20Discov.&doi=10.1038%2Fnrd1723&volume=4&pages=367-368&publication_year=2005&author=Gershell%2CL)\\n    \\n30.  Carstensen, B. et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. _Diabetologia_ **59**, 980–988 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-016-3884-9)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xjs1altbw%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26924393)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826427)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer%20incidence%20in%20persons%20with%20type%201%20diabetes%3A%20a%20five-country%20study%20of%209%2C000%20cancers%20in%20type%201%20diabetic%20individuals&journal=Diabetologia&doi=10.1007%2Fs00125-016-3884-9&volume=59&pages=980-988&publication_year=2016&author=Carstensen%2CB)\\n    \\n31.  Jiang, Y. et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. _Eur. J. Epidemiol._ **26**, 863–876 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10654-011-9617-y)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21938478)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20incidence%20and%20mortality%20of%20colorectal%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Eur.%20J.%20Epidemiol.&doi=10.1007%2Fs10654-011-9617-y&volume=26&pages=863-876&publication_year=2011&author=Jiang%2CY)\\n    \\n32.  De Bruijn, K. M. J. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. _Br. J. Surg._ **100**, 1421–1429 (2013).\\n    \\n    [Article](https://doi.org/10.1002%2Fbjs.9229)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24037561)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Systematic%20review%20and%20meta-analysis%20of%20the%20association%20between%20diabetes%20mellitus%20and%20incidence%20and%20mortality%20in%20breast%20and%20colorectal%20cancer&journal=Br.%20J.%20Surg.&doi=10.1002%2Fbjs.9229&volume=100&pages=1421-1429&publication_year=2013&author=Bruijn%2CKMJ)\\n    \\n33.  Deng, L., Gui, Z., Zhao, L., Wang, J. & Shen, L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. _Dig. Dis. Sci._ **57**, 1576–1585 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10620-012-2055-1)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xns1Sjsrg%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22350783)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20the%20incidence%20of%20colorectal%20cancer%3A%20an%20updated%20systematic%20review%20and%20meta-analysis&journal=Dig.%20Dis.%20Sci.&doi=10.1007%2Fs10620-012-2055-1&volume=57&pages=1576-1585&publication_year=2012&author=Deng%2CL&author=Gui%2CZ&author=Zhao%2CL&author=Wang%2CJ&author=Shen%2CL)\\n    \\n34.  Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D. & Zeidan, A. M. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. _Gynecol. Oncol._ **135**, 163–171 (2014).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ygyno.2014.07.095)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25072931)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404750)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Is%20diabetes%20mellitus%20associated%20with%20increased%20incidence%20and%20disease-specific%20mortality%20in%20endometrial%20cancer%3F%20A%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Gynecol.%20Oncol.&doi=10.1016%2Fj.ygyno.2014.07.095&volume=135&pages=163-171&publication_year=2014&author=Liao%2CC&author=Zhang%2CD&author=Mungo%2CC&author=Andrew%20Tompkins%2CD&author=Zeidan%2CAM)\\n    \\n35.  Saed, L. et al. The effect of diabetes on the risk of endometrial cancer: an updated a systematic review and meta-analysis. _BMC Cancer_ **19**, 527 (2019).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12885-019-5748-4)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31151429)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544993)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20diabetes%20on%20the%20risk%20of%20endometrial%20cancer%3A%20an%20updated%20a%20systematic%20review%20and%20meta-analysis&journal=BMC%20Cancer&doi=10.1186%2Fs12885-019-5748-4&volume=19&publication_year=2019&author=Saed%2CL)\\n    \\n36.  Friberg, E., Orsini, N., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. _Diabetologia_ **50**, 1365–1374 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-007-0681-5)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2szjslCjsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17476474)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20endometrial%20cancer%3A%20A%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-007-0681-5&volume=50&pages=1365-1374&publication_year=2007&author=Friberg%2CE&author=Orsini%2CN&author=Mantzoros%2CCS&author=Wolk%2CA)\\n    \\n37.  Anothaisintawee, T. et al. Risk factors of breast cancer: a systematic review and meta-analysis. _Asia-Pac. J. Public Health_ **25**, 368–387 (2013).\\n    \\n    [Article](https://doi.org/10.1177%2F1010539513488795)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23709491)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20of%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Asia-Pac.%20J.%20Public%20Health&doi=10.1177%2F1010539513488795&volume=25&pages=368-387&publication_year=2013&author=Anothaisintawee%2CT)\\n    \\n38.  Larsson, S. C., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. _Int. J. Cancer_ **121**, 856–862 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.22717)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXotlequ7w%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17397032)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20breast%20cancer%3A%20a%20meta-analysis&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.22717&volume=121&pages=856-862&publication_year=2007&author=Larsson%2CSC&author=Mantzoros%2CCS&author=Wolk%2CA)\\n    \\n39.  Boyle, P. et al. Diabetes and breast cancer risk: a meta-analysis. _Br. J. Cancer_ **107**, 1608–1617 (2012).\\n    \\n    [Article](https://doi.org/10.1038%2Fbjc.2012.414)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38bosl2gsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22996614)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493760)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20breast%20cancer%20risk%3A%20a%20meta-analysis&journal=Br.%20J.%20Cancer&doi=10.1038%2Fbjc.2012.414&volume=107&pages=1608-1617&publication_year=2012&author=Boyle%2CP)\\n    \\n40.  Rinaldi, S. et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. _Int. J. Cancer_ **118**, 2832–2839 (2006).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.21730)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xks1Sisb4%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16385576)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Anthropometric%20measures%2C%20endogenous%20sex%20steroids%20and%20breast%20cancer%20risk%20in%20postmenopausal%20women%3A%20a%20study%20within%20the%20EPIC%20cohort&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.21730&volume=118&pages=2832-2839&publication_year=2006&author=Rinaldi%2CS)\\n    \\n41.  Michels, K. B. et al. Type 2 diabetes and subsequent incidence of breast cancer in the nurses’ health study. _Diabetes Care_ **26**, 1752–1758 (2003).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiacare.26.6.1752)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12766105)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20subsequent%20incidence%20of%20breast%20cancer%20in%20the%20nurses%E2%80%99%20health%20study&journal=Diabetes%20Care&doi=10.2337%2Fdiacare.26.6.1752&volume=26&pages=1752-1758&publication_year=2003&author=Michels%2CKB)\\n    \\n42.  Bronsveld, H. K. et al. Diabetes and breast cancer subtypes. _PLoS ONE_ **12**, e0170084 (2017).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0170084)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28076434)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226802)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXnslGku74%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20breast%20cancer%20subtypes&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0170084&volume=12&publication_year=2017&author=Bronsveld%2CHK)\\n    \\n43.  Zhang, D., Li, N., Xi, Y., Zhao, Y. & Wang, T. Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies. _Diabetes Res. Clin. Pract._ **130**, 43–52 (2017).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2017.04.005)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28554142)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20ovarian%20cancer.%20A%20systematic%20review%20and%20meta-analysis%20of%2015%20cohort%20studies&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2017.04.005&volume=130&pages=43-52&publication_year=2017&author=Zhang%2CD&author=Li%2CN&author=Xi%2CY&author=Zhao%2CY&author=Wang%2CT)\\n    \\n44.  Weng, L., Wang, L., Zhang, J., Wang, B. & Liu, H. Association between diabetes mellitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. _Medicine_ **96**, e6396 (2017).\\n    \\n    [Article](https://doi.org/10.1097%2FMD.0000000000006396)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20mellitus%20and%20subsequent%20ovarian%20cancer%20in%20women%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Medicine&doi=10.1097%2FMD.0000000000006396&volume=96&publication_year=2017&author=Weng%2CL&author=Wang%2CL&author=Zhang%2CJ&author=Wang%2CB&author=Liu%2CH)\\n    \\n45.  Wang, L., Zhong, L., Xu, B., Chen, M. & Huang, H. Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies. _BMJ Open_ **10**, e040137 (2020).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmjopen-2020-040137)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33376163)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778773)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20the%20risk%20of%20ovarian%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20and%20case-control%20studies&journal=BMJ%20Open&doi=10.1136%2Fbmjopen-2020-040137&volume=10&publication_year=2020&author=Wang%2CL&author=Zhong%2CL&author=Xu%2CB&author=Chen%2CM&author=Huang%2CH)\\n    \\n46.  Lee, J. Y. et al. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. _Int. J. Gynecol. Cancer_ **23**, 402–412 (2013).\\n    \\n    [Article](https://doi.org/10.1097%2FIGC.0b013e31828189b2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23354371)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20ovarian%20cancer%20risk%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20observational%20studies&journal=Int.%20J.%20Gynecol.%20Cancer&doi=10.1097%2FIGC.0b013e31828189b2&volume=23&pages=402-412&publication_year=2013&author=Lee%2CJY)\\n    \\n47.  Bonovas, S., Filioussi, K. & Tsantes, A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. _Diabetologia_ **47**, 1071–1078 (2004).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-004-1415-6)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2czhvVCksg%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15164171)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20prostate%20cancer%3A%20a%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-004-1415-6&volume=47&pages=1071-1078&publication_year=2004&author=Bonovas%2CS&author=Filioussi%2CK&author=Tsantes%2CA)\\n    \\n48.  Shikata, K., Ninomiya, T. & Kiyohara, Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. _Cancer Sci._ **104**, 9–14 (2013).\\n    \\n    [Article](https://doi.org/10.1111%2Fcas.12043)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXls1Gmtw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23066889)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20cancer%20risk%3A%20review%20of%20the%20epidemiological%20evidence&journal=Cancer%20Sci.&doi=10.1111%2Fcas.12043&volume=104&pages=9-14&publication_year=2013&author=Shikata%2CK&author=Ninomiya%2CT&author=Kiyohara%2CY)\\n    \\n49.  Long, X. J., Lin, S., Sun, Y. N. & Zheng, Z. F. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. _Asian Pac. J. Cancer Preven._ **13**, 4097–4100 (2012).\\n    \\n    [Article](https://doi.org/10.7314%2FAPJCP.2012.13.8.4097)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20prostate%20cancer%20risk%20in%20Asian%20countries%3A%20a%20meta-analysis&journal=Asian%20Pac.%20J.%20Cancer%20Preven.&doi=10.7314%2FAPJCP.2012.13.8.4097&volume=13&pages=4097-4100&publication_year=2012&author=Long%2CXJ&author=Lin%2CS&author=Sun%2CYN&author=Zheng%2CZF)\\n    \\n50.  Rhee, E. J. Diabetes in Asians. _Endocrinol. Metab._ **30**, 263–269 (2015).\\n    \\n    [Article](https://doi.org/10.3803%2FEnM.2015.30.3.263)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFSgur4%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20in%20Asians&journal=Endocrinol.%20Metab.&doi=10.3803%2FEnM.2015.30.3.263&volume=30&pages=263-269&publication_year=2015&author=Rhee%2CEJ)\\n    \\n51.  Bensimon, L., Yin, H., Suissa, S., Pollak, M. N. & Azoulay, L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. _Cancer Causes Control._ **25**, 329–338 (2014).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10552-013-0334-6)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24384808)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20the%20risk%20of%20mortality%20among%20patients%20with%20prostate%20cancer&journal=Cancer%20Causes%20Control.&doi=10.1007%2Fs10552-013-0334-6&volume=25&pages=329-338&publication_year=2014&author=Bensimon%2CL&author=Yin%2CH&author=Suissa%2CS&author=Pollak%2CMN&author=Azoulay%2CL)\\n    \\n52.  Johnson, J. A., Bowker, S. L., Richardson, K. & Marra, C. A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. _Diabetologia_ **54**, 2263–2271 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-011-2242-1)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3MjjsFamug%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21748485)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Time-varying%20incidence%20of%20cancer%20after%20the%20onset%20of%20type%202%20diabetes%3A%20evidence%20of%20potential%20detection%20bias&journal=Diabetologia&doi=10.1007%2Fs00125-011-2242-1&volume=54&pages=2263-2271&publication_year=2011&author=Johnson%2CJA&author=Bowker%2CSL&author=Richardson%2CK&author=Marra%2CCA)\\n    \\n53.  Johnson, J. A. et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. _Diabetologia_ **55**, 1607–1618 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-012-2525-1)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xms1yqtb4%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22476947)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20cancer%20%281%29%3A%20evaluating%20the%20temporal%20relationship%20between%20type%202%20diabetes%20and%20cancer%20incidence&journal=Diabetologia&doi=10.1007%2Fs00125-012-2525-1&volume=55&pages=1607-1618&publication_year=2012&author=Johnson%2CJA)\\n    \\n54.  Harding, J. L., Shaw, J. E., Peeters, A., Cartensen, B. & Magliano, D. J. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. _Diabetes Care_ **38**, 264–270 (2015).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc14-1996)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488912)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer%20risk%20among%20people%20with%20type%201%20and%20type%202%20diabetes%3A%20disentangling%20true%20associations%2C%20detection%20bias%2C%20and%20reverse%20causation&journal=Diabetes%20Care&doi=10.2337%2Fdc14-1996&volume=38&pages=264-270&publication_year=2015&author=Harding%2CJL&author=Shaw%2CJE&author=Peeters%2CA&author=Cartensen%2CB&author=Magliano%2CDJ)\\n    \\n55.  Pearson-Stuttard, J. et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. _Lancet Diabetes Endocrinol._ **6**, e6–e15 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2818%2930150-5)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29803268)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982644)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Worldwide%20burden%20of%20cancer%20attributable%20to%20diabetes%20and%20high%20body-mass%20index%3A%20a%20comparative%20risk%20assessment&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2818%2930150-5&volume=6&pages=e6-e15&publication_year=2018&author=Pearson-Stuttard%2CJ)\\n    \\n56.  Larsson, S. C. & Wolk, A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. _Diabetologia_ **54**, 1013–1018 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-011-2051-6)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3MvhtlGrtg%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21274512)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20incidence%20of%20kidney%20cancer%3A%20a%20meta-analysis%20of%20cohort%20studies&journal=Diabetologia&doi=10.1007%2Fs00125-011-2051-6&volume=54&pages=1013-1018&publication_year=2011&author=Larsson%2CSC&author=Wolk%2CA)\\n    \\n57.  Xu, X. et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. _PLoS ONE_ **8**, e58079 (2013).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0058079)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23472134)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589481)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20bladder%20cancer%3A%20a%20meta-analysis%20of%20cohort%20studies&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0058079&volume=8&publication_year=2013&author=Xu%2CX)\\n    \\n58.  Gong, I. Y. et al. Association between diabetes and haematological malignancies: a population-based study. _Diabetologia_ **64**, 540–551 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-020-05338-7)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFGntLw%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33409570)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20and%20haematological%20malignancies%3A%20a%20population-based%20study&journal=Diabetologia&doi=10.1007%2Fs00125-020-05338-7&volume=64&pages=540-551&publication_year=2021&author=Gong%2CIY)\\n    \\n59.  Giovannucci, E. et al. Diabetes and cancer: a consensus report. _Diabetes Care_ **33**, 1674–1685 (2010).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc10-0666)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20587728)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890380)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20cancer%3A%20a%20consensus%20report&journal=Diabetes%20Care&doi=10.2337%2Fdc10-0666&volume=33&pages=1674-1685&publication_year=2010&author=Giovannucci%2CE)\\n    \\n60.  Weinstein, D., Simon, M., Yehezkel, E., Laron, Z. & Werner, H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. _Diabetes Metab. Res. Rev._ **25**, 41–49 (2009).\\n    \\n    [Article](https://doi.org/10.1002%2Fdmrr.912)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXivFWjurg%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19145584)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Insulin%20analogues%20display%20IGF-I-like%20mitogenic%20and%20anti-apoptotic%20activities%20in%20cultured%20cancer%20cells&journal=Diabetes%20Metab.%20Res.%20Rev.&doi=10.1002%2Fdmrr.912&volume=25&pages=41-49&publication_year=2009&author=Weinstein%2CD&author=Simon%2CM&author=Yehezkel%2CE&author=Laron%2CZ&author=Werner%2CH)\\n    \\n61.  Najjar, S. M. & Perdomo, G. Hepatic insulin clearance: mechanism and physiology. _Physiology_ **34**, 198–215 (2019).\\n    \\n    [Article](https://doi.org/10.1152%2Fphysiol.00048.2018)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslKrs7vF)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30968756)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734066)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hepatic%20insulin%20clearance%3A%20mechanism%20and%20physiology&journal=Physiology&doi=10.1152%2Fphysiol.00048.2018&volume=34&pages=198-215&publication_year=2019&author=Najjar%2CSM&author=Perdomo%2CG)\\n    \\n62.  Lorenzi, M., Montisano, D. F., Toledo, S. & Barrieux, A. High glucose induces DNA damage in cultured human endothelial cells. _J. Clin. Invest._ **77**, 322–325 (1986).\\n    \\n    [Article](https://doi.org/10.1172%2FJCI112295)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaL28XhtVOht70%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3944257)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC423344)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=High%20glucose%20induces%20DNA%20damage%20in%20cultured%20human%20endothelial%20cells&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI112295&volume=77&pages=322-325&publication_year=1986&author=Lorenzi%2CM&author=Montisano%2CDF&author=Toledo%2CS&author=Barrieux%2CA)\\n    \\n63.  Robertson, R., Zhou, H., Zhang, T. & Harmon, J. S. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. _Cell Biochem. Biophys._ **48**, 139–146 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s12013-007-0026-5)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXosV2gtrc%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17709883)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Chronic%20oxidative%20stress%20as%20a%20mechanism%20for%20glucose%20toxicity%20of%20the%20beta%20cell%20in%20type%202%20diabetes&journal=Cell%20Biochem.%20Biophys.&doi=10.1007%2Fs12013-007-0026-5&volume=48&pages=139-146&publication_year=2007&author=Robertson%2CR&author=Zhou%2CH&author=Zhang%2CT&author=Harmon%2CJS)\\n    \\n64.  Turturro, F., Friday, E. & Welbourne, T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. _BMC Cancer_ **7**, 96 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/1471-2407-7-96)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17555594)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906826)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXnslCku7g%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20regulates%20thioredoxin-ROS%20activity%20through%20induction%20of%20thioredoxin-interacting%20protein%20%28TXNIP%29%20in%20metastatic%20breast%20cancer-derived%20cells%20MDA-MB-231&journal=BMC%20Cancer&doi=10.1186%2F1471-2407-7-96&volume=7&publication_year=2007&author=Turturro%2CF&author=Friday%2CE&author=Welbourne%2CT)\\n    \\n65.  Wu, Y., Liu, Y., Dong, Y. & Vadgama, J. Diabetes-associated dysregulated cytokines and cancer. _Integr. Cancer Sci. Ther._ **3**, 370–378 (2016).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29930868)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007890)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes-associated%20dysregulated%20cytokines%20and%20cancer&journal=Integr.%20Cancer%20Sci.%20Ther.&volume=3&pages=370-378&publication_year=2016&author=Wu%2CY&author=Liu%2CY&author=Dong%2CY&author=Vadgama%2CJ)\\n    \\n66.  Inoki, K., Kim, J. & Guan, K. L. AMPK and mTOR in cellular energy homeostasis and drug targets. _Annu. Rev. Pharmacol. Toxicol._ **52**, 381–400 (2012).\\n    \\n    [Article](https://doi.org/10.1146%2Fannurev-pharmtox-010611-134537)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjsV2nt7c%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22017684)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=AMPK%20and%20mTOR%20in%20cellular%20energy%20homeostasis%20and%20drug%20targets&journal=Annu.%20Rev.%20Pharmacol.%20Toxicol.&doi=10.1146%2Fannurev-pharmtox-010611-134537&volume=52&pages=381-400&publication_year=2012&author=Inoki%2CK&author=Kim%2CJ&author=Guan%2CKL)\\n    \\n67.  Huang, X., Liu, G., Guo, J. & Su, Z. Q. The PI3K/AKT pathway in obesity and type 2 diabetes. _Int. J. Biol. Sci._ **14**, 1483–1496 (2018).\\n    \\n    [Article](https://doi.org/10.7150%2Fijbs.27173)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVyqsbbJ)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30263000)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158718)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20PI3K%2FAKT%20pathway%20in%20obesity%20and%20type%202%20diabetes&journal=Int.%20J.%20Biol.%20Sci.&doi=10.7150%2Fijbs.27173&volume=14&pages=1483-1496&publication_year=2018&author=Huang%2CX&author=Liu%2CG&author=Guo%2CJ&author=Su%2CZQ)\\n    \\n68.  Zhao, Y. et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. _Gynecol. Endocrinol._ **34**, 428–432 (2018).\\n    \\n    [Article](https://doi.org/10.1080%2F09513590.2017.1409714)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFaht7jN)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29182407)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20is%20associated%20with%20reduced%20cell%20proliferation%20in%20human%20endometrial%20cancer%20by%20inbibiting%20PI3K%2FAKT%2FmTOR%20signaling&journal=Gynecol.%20Endocrinol.&doi=10.1080%2F09513590.2017.1409714&volume=34&pages=428-432&publication_year=2018&author=Zhao%2CY)\\n    \\n69.  Knapp, S. Diabetes and infection: is there a link?-A mini-review. _Gerontology_ **59**, 99–104 (2013).\\n    \\n    [Article](https://doi.org/10.1159%2F000345107)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXjslOhur8%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23182884)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20infection%3A%20is%20there%20a%20link%3F-A%20mini-review&journal=Gerontology&doi=10.1159%2F000345107&volume=59&pages=99-104&publication_year=2013&author=Knapp%2CS)\\n    \\n70.  Fang, M. et al. Diabetes and the risk of hospitalisation for infection: the atherosclerosis risk in communities (ARIC) study. _Diabetologia_ **64**, 2458–2465 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-021-05522-3)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitVSktrjO)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34345973)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331324)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20hospitalisation%20for%20infection%3A%20the%20atherosclerosis%20risk%20in%20communities%20%28ARIC%29%20study&journal=Diabetologia&doi=10.1007%2Fs00125-021-05522-3&volume=64&pages=2458-2465&publication_year=2021&author=Fang%2CM)\\n    \\n71.  Tseng, C.-H. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus. _Sci. Rep._ **11**, 12400 (2021).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-021-91902-z)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34117321)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195989)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsF2it7jN)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20use%20is%20associated%20with%20a%20reduced%20risk%20of%20acute%20appendicitis%20in%20Taiwanese%20patients%20with%20type%202%20diabetes%20mellitus&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-021-91902-z&volume=11&publication_year=2021&author=Tseng%2CC-H)\\n    \\n72.  Luk, A. O. Y. et al. Temporal trends in rates of infection-related hospitalisations in Hong Kong people with and without diabetes, 2001–2016: a retrospective study. _Diabetologia_ **64**, 109–118 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-020-05286-2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32986145)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Temporal%20trends%20in%20rates%20of%20infection-related%20hospitalisations%20in%20Hong%20Kong%20people%20with%20and%20without%20diabetes%2C%202001%E2%80%932016%3A%20a%20retrospective%20study&journal=Diabetologia&doi=10.1007%2Fs00125-020-05286-2&volume=64&pages=109-118&publication_year=2021&author=Luk%2CAOY)\\n    \\n73.  Magliano, D. J. et al. Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes. _Diabetes Care_ **38**, 1274–1280 (2015).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc14-2820)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26070592)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Excess%20risk%20of%20dying%20from%20infectious%20causes%20in%20those%20with%20type%201%20and%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc14-2820&volume=38&pages=1274-1280&publication_year=2015&author=Magliano%2CDJ)\\n    \\n74.  Martin, E. T. et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. _Infect. Control. Hosp. Epidemiol._ **37**, 88–99 (2016).\\n    \\n    [Article](https://doi.org/10.1017%2Fice.2015.249)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26503187)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20risk%20of%20surgical%20site%20infection%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Infect.%20Control.%20Hosp.%20Epidemiol.&doi=10.1017%2Fice.2015.249&volume=37&pages=88-99&publication_year=2016&author=Martin%2CET)\\n    \\n75.  Trussell, J. et al. Impact of a patient care pathway protocol on surgical site infection rates in cardiothoracic surgery patients. _Am. J. Surg._ **196**, 883–889 (2008).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.amjsurg.2008.07.024)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19095104)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20a%20patient%20care%20pathway%20protocol%20on%20surgical%20site%20infection%20rates%20in%20cardiothoracic%20surgery%20patients&journal=Am.%20J.%20Surg.&doi=10.1016%2Fj.amjsurg.2008.07.024&volume=196&pages=883-889&publication_year=2008&author=Trussell%2CJ)\\n    \\n76.  Coleman, J. S. et al. Surgical site infections after hysterectomy among HIV-infected women in the HAART era: a single institution’s experience from 1999–2012. _Am. J. Obstet. Gynecol._ **210**, 117.e111–117.e117 (2014).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ajog.2013.08.037)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Surgical%20site%20infections%20after%20hysterectomy%20among%20HIV-infected%20women%20in%20the%20HAART%20era%3A%20a%20single%20institution%E2%80%99s%20experience%20from%201999%E2%80%932012&journal=Am.%20J.%20Obstet.%20Gynecol.&doi=10.1016%2Fj.ajog.2013.08.037&volume=210&pages=117.e111-117.e117&publication_year=2014&author=Coleman%2CJS)\\n    \\n77.  Friedman, N. D., Sexton, D. J., Connelly, S. M. & Kaye, K. S. Risk factors for surgical site infection complicating laminectomy. _Infect. Control. Hosp. Epidemiol._ **28**, 1060–1065 (2007).\\n    \\n    [Article](https://doi.org/10.1086%2F519864)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17932827)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20for%20surgical%20site%20infection%20complicating%20laminectomy&journal=Infect.%20Control.%20Hosp.%20Epidemiol.&doi=10.1086%2F519864&volume=28&pages=1060-1065&publication_year=2007&author=Friedman%2CND&author=Sexton%2CDJ&author=Connelly%2CSM&author=Kaye%2CKS)\\n    \\n78.  Apicella, M. et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. _Lancet Diabetes Endocrinol._ **8**, 782–792 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930238-2)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWgs7jM)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32687793)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367664)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=COVID-19%20in%20people%20with%20diabetes%3A%20understanding%20the%20reasons%20for%20worse%20outcomes&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930238-2&volume=8&pages=782-792&publication_year=2020&author=Apicella%2CM)\\n    \\n79.  McGurnaghan, S. J. et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. _Lancet Diabetes Endocrinol._ **9**, 82–93 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930405-8)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXks1aqsA%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33357491)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risks%20of%20and%20risk%20factors%20for%20COVID-19%20disease%20in%20people%20with%20diabetes%3A%20a%20cohort%20study%20of%20the%20total%20population%20of%20Scotland&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930405-8&volume=9&pages=82-93&publication_year=2021&author=McGurnaghan%2CSJ)\\n    \\n80.  Rawshani, A. et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. _Lancet Reg. Health Eur._ **4**, 100105 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.lanepe.2021.100105)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33969336)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086507)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Severe%20COVID-19%20in%20people%20with%20type%201%20and%20type%202%20diabetes%20in%20Sweden%3A%20a%20nationwide%20retrospective%20cohort%20study&journal=Lancet%20Reg.%20Health%20Eur.&doi=10.1016%2Fj.lanepe.2021.100105&volume=4&publication_year=2021&author=Rawshani%2CA)\\n    \\n81.  You, J. H. et al. Clinical outcomes of COVID-19 patients with type 2 diabetes: a population-based study in Korea. _Endocrinol. Metab._ **35**, 901–908 (2020).\\n    \\n    [Article](https://doi.org/10.3803%2FEnM.2020.787)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFKrsLc%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20outcomes%20of%20COVID-19%20patients%20with%20type%202%20diabetes%3A%20a%20population-based%20study%20in%20Korea&journal=Endocrinol.%20Metab.&doi=10.3803%2FEnM.2020.787&volume=35&pages=901-908&publication_year=2020&author=You%2CJH)\\n    \\n82.  Moon, S. J. et al. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. _Diabetes Metab. J._ **44**, 737–746 (2020).\\n    \\n    [Article](https://doi.org/10.4093%2Fdmj.2020.0141)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33115212)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643598)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Independent%20impact%20of%20diabetes%20on%20the%20severity%20of%20coronavirus%20disease%202019%20in%205%2C307%20patients%20in%20South%20Korea%3A%20a%20nationwide%20cohort%20study&journal=Diabetes%20Metab.%20J.&doi=10.4093%2Fdmj.2020.0141&volume=44&pages=737-746&publication_year=2020&author=Moon%2CSJ)\\n    \\n83.  Aranjani, J. M., Manuel, A., Razack, H. I. A. & Mathew, S. T. Covid-19–associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. _PLoS. Negl. Trop. Dis._ **15**, e0009921 (2021).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pntd.0009921)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1yks7bL)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34793455)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601521)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Covid-19%E2%80%93associated%20mucormycosis%3A%20evidence-based%20critical%20review%20of%20an%20emerging%20infection%20burden%20during%20the%20pandemic%E2%80%99s%20second%20wave%20in%20India&journal=PLoS.%20Negl.%20Trop.%20Dis.&doi=10.1371%2Fjournal.pntd.0009921&volume=15&publication_year=2021&author=Aranjani%2CJM&author=Manuel%2CA&author=Razack%2CHIA&author=Mathew%2CST)\\n    \\n84.  Crankson, S., Pokhrel, S. & Anokye, N. K. Determinants of COVID-19-related length of hospital stays and long COVID in Ghana: a cross-sectional analysis. _Int. J. Environ. Res. Public Health_ **19**, 527 (2022).\\n    \\n    [Article](https://doi.org/10.3390%2Fijerph19010527)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVeksrg%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35010786)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744866)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Determinants%20of%20COVID-19-related%20length%20of%20hospital%20stays%20and%20long%20COVID%20in%20Ghana%3A%20a%20cross-sectional%20analysis&journal=Int.%20J.%20Environ.%20Res.%20Public%20Health&doi=10.3390%2Fijerph19010527&volume=19&publication_year=2022&author=Crankson%2CS&author=Pokhrel%2CS&author=Anokye%2CNK)\\n    \\n85.  Bellan, M. et al. Respiratory and psychophysical sequelae among patients with covid-19 four months after hospital discharge. _JAMA Netw. Open_ **4**, e2036142 (2021).\\n    \\n    [Article](https://doi.org/10.1001%2Fjamanetworkopen.2020.36142)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33502487)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841464)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Respiratory%20and%20psychophysical%20sequelae%20among%20patients%20with%20covid-19%20four%20months%20after%20hospital%20discharge&journal=JAMA%20Netw.%20Open&doi=10.1001%2Fjamanetworkopen.2020.36142&volume=4&publication_year=2021&author=Bellan%2CM)\\n    \\n86.  Gottesman, B. L., Yu, J., Tanaka, C., Longhurst, C. A. & Kim, J. J. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. _JAMA Pediatr._ **176**, 414–415 (2022).\\n    \\n    [Article](https://doi.org/10.1001%2Fjamapediatrics.2021.5801)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35072727)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Incidence%20of%20new-onset%20type%201%20diabetes%20among%20US%20children%20during%20the%20COVID-19%20global%20pandemic&journal=JAMA%20Pediatr.&doi=10.1001%2Fjamapediatrics.2021.5801&volume=176&pages=414-415&publication_year=2022&author=Gottesman%2CBL&author=Yu%2CJ&author=Tanaka%2CC&author=Longhurst%2CCA&author=Kim%2CJJ)\\n    \\n87.  Barrett, C. E. et al. Risk for newly diagnosed diabetes <30 days after SARS-CoV-2 infection among persons aged \\\\>18 years-United States, March 1, 2020-June 28, 2021. _Morb. Mortal. Wkly. Rep._ **71**, 59–65 (2022).\\n    \\n    [Article](https://doi.org/10.15585%2Fmmwr.mm7102e2)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xjt1yntLc%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20for%20newly%20diagnosed%20diabetes%20%3C30%20days%20after%20SARS-CoV-2%20infection%20among%20persons%20aged%20%3E18%20years-United%20States%2C%20March%201%2C%202020-June%2028%2C%202021&journal=Morb.%20Mortal.%20Wkly.%20Rep.&doi=10.15585%2Fmmwr.mm7102e2&volume=71&pages=59-65&publication_year=2022&author=Barrett%2CCE)\\n    \\n88.  Kornum, J. B. et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. _Diabetes Care_ **31**, 1541–1545 (2008).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc08-0138)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18487479)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494631)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%2C%20glycemic%20control%2C%20and%20risk%20of%20hospitalization%20with%20pneumonia%3A%20a%20population-based%20case-control%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc08-0138&volume=31&pages=1541-1545&publication_year=2008&author=Kornum%2CJB)\\n    \\n89.  Matsuyama, R., Nishiura, H., Kutsuna, S., Hayakawa, K. & Ohmagari, N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. _BMC Public Health_ **16**, 1203 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12889-016-3881-4)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27899100)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129628)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20determinants%20of%20the%20severity%20of%20Middle%20East%20respiratory%20syndrome%20%28MERS%29%3A%20a%20systematic%20review%20and%20meta-analysis&journal=BMC%20Public%20Health&doi=10.1186%2Fs12889-016-3881-4&volume=16&publication_year=2016&author=Matsuyama%2CR&author=Nishiura%2CH&author=Kutsuna%2CS&author=Hayakawa%2CK&author=Ohmagari%2CN)\\n    \\n90.  Badawi, A. & Ryoo, S. G. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. _Int. J. Infect. Dis._ **49**, 129–133 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ijid.2016.06.015)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27352628)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110556)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20comorbidities%20in%20the%20Middle%20East%20respiratory%20syndrome%20coronavirus%20%28MERS-CoV%29%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Int.%20J.%20Infect.%20Dis.&doi=10.1016%2Fj.ijid.2016.06.015&volume=49&pages=129-133&publication_year=2016&author=Badawi%2CA&author=Ryoo%2CSG)\\n    \\n91.  Badawi, A. & Ryoo, S. G. Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis. _J. Public. Health Res._ **5**, 130–138 (2016).\\n    \\n    [Article](https://doi.org/10.4081%2Fjphr.2016.733)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20diabetes%20in%20the%202009%20influenza%20A%20%28H1N1%29%20and%20the%20middle%20east%20respiratory%20syndrome%20coronavirus%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Public.%20Health%20Res.&doi=10.4081%2Fjphr.2016.733&volume=5&pages=130-138&publication_year=2016&author=Badawi%2CA&author=Ryoo%2CSG)\\n    \\n92.  Yang, J. K. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. _Diabet. Med._ **23**, 623–628 (2006).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1464-5491.2006.01861.x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xnt1Ciu7Y%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16759303)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Plasma%20glucose%20levels%20and%20diabetes%20are%20independent%20predictors%20for%20mortality%20and%20morbidity%20in%20patients%20with%20SARS&journal=Diabet.%20Med.&doi=10.1111%2Fj.1464-5491.2006.01861.x&volume=23&pages=623-628&publication_year=2006&author=Yang%2CJK)\\n    \\n93.  Ehrlich, S. F., Quesenberry, C. P. Jr, Van Den Eeden, S. K., Shan, J. & Ferrara, A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. _Diabetes Care_ **33**, 55–60 (2010).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc09-0880)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19808918)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Patients%20diagnosed%20with%20diabetes%20are%20at%20increased%20risk%20for%20asthma%2C%20chronic%20obstructive%20pulmonary%20disease%2C%20pulmonary%20fibrosis%2C%20and%20pneumonia%20but%20not%20lung%20cancer&journal=Diabetes%20Care&doi=10.2337%2Fdc09-0880&volume=33&pages=55-60&publication_year=2010&author=Ehrlich%2CSF&author=Quesenberry%2CCP&author=Eeden%2CSK&author=Shan%2CJ&author=Ferrara%2CA)\\n    \\n94.  Alraddadi, B. M. et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. _Emerg. Infect. Dis._ **22**, 49–55 (2016).\\n    \\n    [Article](https://doi.org/10.3201%2Feid2201.151340)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXmvFWgsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26692185)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696714)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20for%20primary%20middle%20east%20respiratory%20syndrome%20coronavirus%20illness%20in%20humans%2C%20Saudi%20Arabia%2C%202014&journal=Emerg.%20Infect.%20Dis.&doi=10.3201%2Feid2201.151340&volume=22&pages=49-55&publication_year=2016&author=Alraddadi%2CBM)\\n    \\n95.  Geerlings, S. E. & Hoepelman, A. I. M. Immune dysfunction in patients with diabetes mellitus (DM). _FEMS Immunol. Med. Microbiol._ **26**, 259–265 (1999).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1574-695X.1999.tb01397.x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXnsVKntLc%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10575137)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Immune%20dysfunction%20in%20patients%20with%20diabetes%20mellitus%20%28DM%29&journal=FEMS%20Immunol.%20Med.%20Microbiol.&doi=10.1111%2Fj.1574-695X.1999.tb01397.x&volume=26&pages=259-265&publication_year=1999&author=Geerlings%2CSE&author=Hoepelman%2CAIM)\\n    \\n96.  Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The role of interleukin 6 during viral infections. _Front. Microbiol._ **10**, 1057 (2019).\\n    \\n    [Article](https://doi.org/10.3389%2Ffmicb.2019.01057)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31134045)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524401)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20interleukin%206%20during%20viral%20infections&journal=Front.%20Microbiol.&doi=10.3389%2Ffmicb.2019.01057&volume=10&publication_year=2019&author=Velazquez-Salinas%2CL&author=Verdugo-Rodriguez%2CA&author=Rodriguez%2CLL&author=Borca%2CMV)\\n    \\n97.  Joshi, N., Caputo, G. M., Weitekamp, M. R. & Karchmer, A. W. Infections in patients with diabetes mellitus. _N. Engl. J. Med._ **341**, 1906–1912 (1999).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM199912163412507)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3c%2Fks1Gksw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10601511)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Infections%20in%20patients%20with%20diabetes%20mellitus&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM199912163412507&volume=341&pages=1906-1912&publication_year=1999&author=Joshi%2CN&author=Caputo%2CGM&author=Weitekamp%2CMR&author=Karchmer%2CAW)\\n    \\n98.  Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-dependent axis. _Cell Metab._ **32**, 437–446.e435 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cmet.2020.07.007)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWgs77O)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32697943)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367032)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Elevated%20glucose%20levels%20favor%20SARS-CoV-2%20infection%20and%20monocyte%20response%20through%20a%20HIF-1%CE%B1%2FGlycolysis-dependent%20axis&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2020.07.007&volume=32&pages=437-446.e435&publication_year=2020&author=Codo%2CAC)\\n    \\n99.  Miyazawa, T., Nakagawa, K., Shimasaki, S. & Nagai, R. Lipid glycation and protein glycation in diabetes and atherosclerosis. _Amino Acids_ **42**, 1163–1170 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00726-010-0772-3)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjsVWhsrg%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20957396)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipid%20glycation%20and%20protein%20glycation%20in%20diabetes%20and%20atherosclerosis&journal=Amino%20Acids&doi=10.1007%2Fs00726-010-0772-3&volume=42&pages=1163-1170&publication_year=2012&author=Miyazawa%2CT&author=Nakagawa%2CK&author=Shimasaki%2CS&author=Nagai%2CR)\\n    \\n100.  Peleg, A. Y., Weerarathna, T., McCarthy, J. S. & Davis, T. M. E. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. _Diabetes Metab. Res. Rev._ **23**, 3–13 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fdmrr.682)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXitFSmsLY%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16960917)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Common%20infections%20in%20diabetes%3A%20pathogenesis%2C%20management%20and%20relationship%20to%20glycaemic%20control&journal=Diabetes%20Metab.%20Res.%20Rev.&doi=10.1002%2Fdmrr.682&volume=23&pages=3-13&publication_year=2007&author=Peleg%2CAY&author=Weerarathna%2CT&author=McCarthy%2CJS&author=Davis%2CTME)\\n    \\n101.  Barda, N., Dagan, N. & Balicer, R. D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. reply. _N. Engl. J. Med._ **384**, 1970 (2021).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33882227)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=BNT162b2%20mRNA%20Covid-19%20vaccine%20in%20a%20nationwide%20mass%20vaccination%20setting.%20reply&journal=N.%20Engl.%20J.%20Med.&volume=384&publication_year=2021&author=Barda%2CN&author=Dagan%2CN&author=Balicer%2CRD)\\n    \\n102.  Cholankeril, G. & Ahmed, A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. _Clin. Gastroenterol. Hepatol._ **16**, 1356–1358 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cgh.2017.11.045)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29199144)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alcoholic%20liver%20disease%20replaces%20hepatitis%20C%20virus%20infection%20as%20the%20leading%20indication%20for%20liver%20transplantation%20in%20the%20United%20States&journal=Clin.%20Gastroenterol.%20Hepatol.&doi=10.1016%2Fj.cgh.2017.11.045&volume=16&pages=1356-1358&publication_year=2018&author=Cholankeril%2CG&author=Ahmed%2CA)\\n    \\n103.  Fink, M. & Byrne, M. Australia and New Zealand Liver and Intestinal Transplant Registry Annual Report 2019 (Melbourne, Victoria, Australia, 2019).\\n    \\n104.  Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. _J. Hepatol._ **71**, 313–322 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2019.04.011)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31071367)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656693)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Outcomes%20of%20liver%20transplantation%20for%20non-alcoholic%20steatohepatitis%3A%20a%20European%20liver%20transplant%20registry%20study&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2019.04.011&volume=71&pages=313-322&publication_year=2019&author=Haldar%2CD)\\n    \\n105.  Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. _J. Hepatol._ **71**, 793–801 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2019.06.021)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31279902)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20global%20epidemiology%20of%20NAFLD%20and%20NASH%20in%20patients%20with%20type%202%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2019.06.021&volume=71&pages=793-801&publication_year=2019&author=Younossi%2CZM)\\n    \\n106.  Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. _Hepatology_ **64**, 73–84 (2016).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.28431)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26707365)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20epidemiology%20of%20nonalcoholic%20fatty%20liver%20disease-Meta-analytic%20assessment%20of%20prevalence%2C%20incidence%2C%20and%20outcomes&journal=Hepatology&doi=10.1002%2Fhep.28431&volume=64&pages=73-84&publication_year=2016&author=Younossi%2CZM)\\n    \\n107.  Pang, Y. et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. _Hepatology_ **68**, 1308–1318 (2018).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.30083)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVKqt7vL)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29734463)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%2C%20plasma%20glucose%2C%20and%20incidence%20of%20fatty%20liver%2C%20cirrhosis%2C%20and%20liver%20cancer%3A%20a%20prospective%20study%20of%200.5%20million%20people&journal=Hepatology&doi=10.1002%2Fhep.30083&volume=68&pages=1308-1318&publication_year=2018&author=Pang%2CY)\\n    \\n108.  Li, Y. et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. _PLoS ONE_ **12**, e0174291 (2017).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0174291)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28350839)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369778)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXovVSh)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Bidirectional%20association%20between%20nonalcoholic%20fatty%20liver%20disease%20and%20type%202%20diabetes%20in%20Chinese%20population%3A%20evidence%20from%20the%20Dongfeng-Tongji%20cohort%20study&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0174291&volume=12&publication_year=2017&author=Li%2CY)\\n    \\n109.  Mansour-Ghanaei, F. et al. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran. _Diabetes Metab. Syndr._ **13**, 1591–1596 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.dsx.2019.03.009)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31336526)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20non-alcoholic%20fatty%20liver%20disease%20in%20patients%20with%20diabetes%20mellitus%2C%20hyperlipidemia%2C%20obesity%20and%20polycystic%20ovary%20syndrome%3A%20a%20cross-sectional%20study%20in%20north%20of%20Iran&journal=Diabetes%20Metab.%20Syndr.&doi=10.1016%2Fj.dsx.2019.03.009&volume=13&pages=1591-1596&publication_year=2019&author=Mansour-Ghanaei%2CF)\\n    \\n110.  Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. _Liver Int._ **29**, 113–119 (2009).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1478-3231.2008.01718.x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhvVGmtLk%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18384521)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20and%20associated%20factors%20of%20non-alcoholic%20fatty%20liver%20disease%20in%20patients%20with%20type-2%20diabetes%20mellitus&journal=Liver%20Int.&doi=10.1111%2Fj.1478-3231.2008.01718.x&volume=29&pages=113-119&publication_year=2009&author=Leite%2CNC&author=Salles%2CGF&author=Araujo%2CAL&author=Villela-Nogueira%2CCA&author=Cardoso%2CCR)\\n    \\n111.  Singh, S. P. et al. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study. _J. Clin. Exp. Hepatol._ **5**, 295–302 (2015).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jceh.2015.09.001)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26900270)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723647)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20associated%20with%20non-alcoholic%20fatty%20liver%20disease%20in%20Indians%3A%20a%20case-control%20study&journal=J.%20Clin.%20Exp.%20Hepatol.&doi=10.1016%2Fj.jceh.2015.09.001&volume=5&pages=295-302&publication_year=2015&author=Singh%2CSP)\\n    \\n112.  Dufour, J.-F. et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–a targeted literature review. _Endocr. Metab. Sci._ **3**, 100089 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.endmts.2021.100089)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xht12nt7nM)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20global%20epidemiology%20of%20nonalcoholic%20steatohepatitis%20%28NASH%29%20and%20associated%20risk%20factors%E2%80%93a%20targeted%20literature%20review&journal=Endocr.%20Metab.%20Sci.&doi=10.1016%2Fj.endmts.2021.100089&volume=3&publication_year=2021&author=Dufour%2CJ-F)\\n    \\n113.  Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. _Hepatology_ **56**, 943–951 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.25772)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22505194)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%2C%20family%20history%20of%20diabetes%2C%20and%20risk%20of%20nonalcoholic%20steatohepatitis%20and%20fibrosis&journal=Hepatology&doi=10.1002%2Fhep.25772&volume=56&pages=943-951&publication_year=2012&author=Loomba%2CR)\\n    \\n114.  Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. _Nat. Rev. Gastroenterol. Hepatol._ **10**, 330–344 (2013).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrgastro.2013.41)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXptVOlsrs%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23507799)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Progression%20of%20NAFLD%20to%20diabetes%20mellitus%2C%20cardiovascular%20disease%20or%20cirrhosis&journal=Nat.%20Rev.%20Gastroenterol.%20Hepatol.&doi=10.1038%2Fnrgastro.2013.41&volume=10&pages=330-344&publication_year=2013&author=Anstee%2CQM&author=Targher%2CG&author=Day%2CCP)\\n    \\n115.  Holstein, A., Hinze, S., Thießen, E., Plaschke, A. & Egberts, E. H. Clinical implications of hepatogenous diabetes in liver cirrhosis. _J. Gastroenterol. Hepatol._ **17**, 677–681 (2002).\\n    \\n    [Article](https://doi.org/10.1046%2Fj.1440-1746.2002.02755.x)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12100613)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20implications%20of%20hepatogenous%20diabetes%20in%20liver%20cirrhosis&journal=J.%20Gastroenterol.%20Hepatol.&doi=10.1046%2Fj.1440-1746.2002.02755.x&volume=17&pages=677-681&publication_year=2002&author=Holstein%2CA&author=Hinze%2CS&author=Thie%C3%9Fen%2CE&author=Plaschke%2CA&author=Egberts%2CEH)\\n    \\n116.  Del Vecchio Blanco, C., Gentile, S., Marmo, R., Carbone, L. & Coltorti, M. Alterations of glucose metabolism in chronic liver disease. _Diabetes Res. Clin. Pract._ **8**, 29–36 (1990).\\n    \\n    [Article](https://doi.org/10.1016%2F0168-8227%2890%2990093-9)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2153513)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alterations%20of%20glucose%20metabolism%20in%20chronic%20liver%20disease&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2F0168-8227%2890%2990093-9&volume=8&pages=29-36&publication_year=1990&author=Vecchio%20Blanco%2CC&author=Gentile%2CS&author=Marmo%2CR&author=Carbone%2CL&author=Coltorti%2CM)\\n    \\n117.  Zein, N. N., Abdulkarim, A. S., Wiesner, R. H., Egan, K. S. & Persing, D. H. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. _J. Hepatol._ **32**, 209–217 (2000).\\n    \\n    [Article](https://doi.org/10.1016%2FS0168-8278%2800%2980065-3)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3c7ntVWgsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10707860)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20diabetes%20mellitus%20in%20patients%20with%20end-stage%20liver%20cirrhosis%20due%20to%20hepatitis%20C%2C%20alcohol%2C%20or%20cholestatic%20disease&journal=J.%20Hepatol.&doi=10.1016%2FS0168-8278%2800%2980065-3&volume=32&pages=209-217&publication_year=2000&author=Zein%2CNN&author=Abdulkarim%2CAS&author=Wiesner%2CRH&author=Egan%2CKS&author=Persing%2CDH)\\n    \\n118.  Niederau, C. et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. _N. Engl. J. Med._ **313**, 1256–1262 (1985).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM198511143132004)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL28%2FktVansw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=4058506)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Survival%20and%20causes%20of%20death%20in%20cirrhotic%20and%20in%20noncirrhotic%20patients%20with%20primary%20hemochromatosis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM198511143132004&volume=313&pages=1256-1262&publication_year=1985&author=Niederau%2CC)\\n    \\n119.  Larter, C. Z. & Farrell, G. C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? _J. Hepatol._ **44**, 253–261 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2005.11.030)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16364488)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Insulin%20resistance%2C%20adiponectin%2C%20cytokines%20in%20NASH%3A%20which%20is%20the%20best%20target%20to%20treat%3F&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2005.11.030&volume=44&pages=253-261&publication_year=2006&author=Larter%2CCZ&author=Farrell%2CGC)\\n    \\n120.  Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. _Am. J. Med._ **107**, 450–455 (1999).\\n    \\n    [Article](https://doi.org/10.1016%2FS0002-9343%2899%2900271-5)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXnvFymurc%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10569299)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20nonalcoholic%20fatty%20liver%20disease%20with%20insulin%20resistance&journal=Am.%20J.%20Med.&doi=10.1016%2FS0002-9343%2899%2900271-5&volume=107&pages=450-455&publication_year=1999&author=Marchesini%2CG)\\n    \\n121.  Angulo, P. Medical progress: nonalcoholic fatty liver disease. _N. Engl. J. Med._ **346**, 1221–1231 (2002).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJMra011775)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XivVOmsrY%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11961152)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Medical%20progress%3A%20nonalcoholic%20fatty%20liver%20disease&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMra011775&volume=346&pages=1221-1231&publication_year=2002&author=Angulo%2CP)\\n    \\n122.  Porepa, L., Ray, J. G., Sanchez-Romeu, P. & Booth, G. L. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. _CMAJ_ **182**, E526–E531 (2010).\\n    \\n    [Article](https://doi.org/10.1503%2Fcmaj.092144)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20566726)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917963)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Newly%20diagnosed%20diabetes%20mellitus%20as%20a%20risk%20factor%20for%20serious%20liver%20disease&journal=CMAJ&doi=10.1503%2Fcmaj.092144&volume=182&pages=E526-E531&publication_year=2010&author=Porepa%2CL&author=Ray%2CJG&author=Sanchez-Romeu%2CP&author=Booth%2CGL)\\n    \\n123.  Stefan, N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. _Lancet Diabetes Endocrinol._ **8**, 616–627 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930110-8)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32559477)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Causes%2C%20consequences%2C%20and%20treatment%20of%20metabolically%20unhealthy%20fat%20distribution&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930110-8&volume=8&pages=616-627&publication_year=2020&author=Stefan%2CN)\\n    \\n124.  Stefan, N., Häring, H. U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. _Lancet Diabetes Endocrinol._ **7**, 313–324 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2818%2930154-2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30174213)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Non-alcoholic%20fatty%20liver%20disease%3A%20causes%2C%20diagnosis%2C%20cardiometabolic%20consequences%2C%20and%20treatment%20strategies&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2818%2930154-2&volume=7&pages=313-324&publication_year=2019&author=Stefan%2CN&author=H%C3%A4ring%2CHU&author=Cusi%2CK)\\n    \\n125.  Sattar, N. & Gill, J. M. R. Type 2 diabetes as a disease of ectopic fat? _BMC Med._ **12**, 123 (2014).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12916-014-0123-4)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25159817)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143560)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20as%20a%20disease%20of%20ectopic%20fat%3F&journal=BMC%20Med.&doi=10.1186%2Fs12916-014-0123-4&volume=12&publication_year=2014&author=Sattar%2CN&author=Gill%2CJMR)\\n    \\n126.  Harding, K. A. et al. Depression prevalence in type 2 diabetes is not related to diabetes–depression symptom overlap but is related to symptom dimensions within patient self-report measures: a meta-analysis. _Diabet. Med._ **36**, 1600–1611 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fdme.14139)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXit1Oju73O)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31532013)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Depression%20prevalence%20in%20type%202%20diabetes%20is%20not%20related%20to%20diabetes%E2%80%93depression%20symptom%20overlap%20but%20is%20related%20to%20symptom%20dimensions%20within%20patient%20self-report%20measures%3A%20a%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fdme.14139&volume=36&pages=1600-1611&publication_year=2019&author=Harding%2CKA)\\n    \\n127.  Lim, G. Y. et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. _Sci. Rep._ **8**, 2861 (2018).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-018-21243-x)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29434331)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809481)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhs1CltbnO)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20depression%20in%20the%20community%20from%2030%20countries%20between%201994%20and%202014&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-018-21243-x&volume=8&publication_year=2018&author=Lim%2CGY)\\n    \\n128.  Roy, T. & Lloyd, C. E. Epidemiology of depression and diabetes: a systematic review. _J. Affect. Disord._ **142**, S8–S21 (2012).\\n    \\n    [Article](https://doi.org/10.1016%2FS0165-0327%2812%2970004-6)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23062861)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Epidemiology%20of%20depression%20and%20diabetes%3A%20a%20systematic%20review&journal=J.%20Affect.%20Disord.&doi=10.1016%2FS0165-0327%2812%2970004-6&volume=142&pages=S8-S21&publication_year=2012&author=Roy%2CT&author=Lloyd%2CCE)\\n    \\n129.  Rotella, F. & Mannucci, E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. _Diabetes Res. Clin. Pract._ **99**, 98–104 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2012.11.022)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3s3ksVejtA%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23265924)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20as%20a%20risk%20factor%20for%20depression.%20A%20meta-analysis%20of%20longitudinal%20studies&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2012.11.022&volume=99&pages=98-104&publication_year=2013&author=Rotella%2CF&author=Mannucci%2CE)\\n    \\n130.  Nouwen, A. et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. _Diabetologia_ **53**, 2480–2486 (2010).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-010-1874-x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3cbnsVWmsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20711716)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974923)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20mellitus%20as%20a%20risk%20factor%20for%20the%20onset%20of%20depression%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-010-1874-x&volume=53&pages=2480-2486&publication_year=2010&author=Nouwen%2CA)\\n    \\n131.  Grigsby, A. B., Anderson, R. J., Freedland, K. E., Clouse, R. E. & Lustman, P. J. Prevalence of anxiety in adults with diabetes a systematic review. _J. Psychosom. Res._ **53**, 1053–1060 (2002).\\n    \\n    [Article](https://doi.org/10.1016%2FS0022-3999%2802%2900417-8)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12479986)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20anxiety%20in%20adults%20with%20diabetes%20a%20systematic%20review&journal=J.%20Psychosom.%20Res.&doi=10.1016%2FS0022-3999%2802%2900417-8&volume=53&pages=1053-1060&publication_year=2002&author=Grigsby%2CAB&author=Anderson%2CRJ&author=Freedland%2CKE&author=Clouse%2CRE&author=Lustman%2CPJ)\\n    \\n132.  Smith, K. J. et al. Association of diabetes with anxiety: a systematic review and meta-analysis. _J. Psychosom. Res._ **74**, 89–99 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jpsychores.2012.11.013)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23332522)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20diabetes%20with%20anxiety%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Psychosom.%20Res.&doi=10.1016%2Fj.jpsychores.2012.11.013&volume=74&pages=89-99&publication_year=2013&author=Smith%2CKJ)\\n    \\n133.  Young, V. et al. Eating problems in adolescents with type1 diabetes: a systematic review with meta-analysis. _Diabet. Med._ **30**, 189–198 (2013).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1464-5491.2012.03771.x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38bgsVWktQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22913589)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Eating%20problems%20in%20adolescents%20with%20type1%20diabetes%3A%20a%20systematic%20review%20with%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fj.1464-5491.2012.03771.x&volume=30&pages=189-198&publication_year=2013&author=Young%2CV)\\n    \\n134.  Schabert, J., Browne, J. L., Mosely, K. & Speight, J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. _Patient_ **6**, 1–10 (2013).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s40271-012-0001-0)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23322536)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Social%20stigma%20in%20diabetes%3A%20a%20framework%20to%20understand%20a%20growing%20problem%20for%20an%20increasing%20epidemic&journal=Patient&doi=10.1007%2Fs40271-012-0001-0&volume=6&pages=1-10&publication_year=2013&author=Schabert%2CJ&author=Browne%2CJL&author=Mosely%2CK&author=Speight%2CJ)\\n    \\n135.  Barnard, K. D., Speight, J. & Skinner, T. C. Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents. _Pract. Diabetes Int._ **25**, 278–283 (2008).\\n    \\n    [Article](https://doi.org/10.1002%2Fpdi.1280)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Quality%20of%20life%20and%20impact%20of%20continuous%20subcutaneous%20insulin%20infusion%20for%20children%20and%20their%20parents&journal=Pract.%20Diabetes%20Int.&doi=10.1002%2Fpdi.1280&volume=25&pages=278-283&publication_year=2008&author=Barnard%2CKD&author=Speight%2CJ&author=Skinner%2CTC)\\n    \\n136.  Hagger, V., Hendrieckx, C., Sturt, J., Skinner, T. C. & Speight, J. Diabetes distress among adolescents with type 1 diabetes: a systematic review. _Curr. Diabetes Rep._ **16**, 1–14 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s11892-015-0694-2)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20distress%20among%20adolescents%20with%20type%201%20diabetes%3A%20a%20systematic%20review&journal=Curr.%20Diabetes%20Rep.&doi=10.1007%2Fs11892-015-0694-2&volume=16&pages=1-14&publication_year=2016&author=Hagger%2CV&author=Hendrieckx%2CC&author=Sturt%2CJ&author=Skinner%2CTC&author=Speight%2CJ)\\n    \\n137.  Abdoli, S. et al. New insights into diabetes burnout and its distinction from diabetes distress and depressive symptoms: a qualitative study. _Diabetes Res. Clin. Pract._ **169**, 108446 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2020.108446)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32946853)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20insights%20into%20diabetes%20burnout%20and%20its%20distinction%20from%20diabetes%20distress%20and%20depressive%20symptoms%3A%20a%20qualitative%20study&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2020.108446&volume=169&publication_year=2020&author=Abdoli%2CS)\\n    \\n138.  Pickup, J. C. & Crook, M. A. Is type II diabetes mellitus a disease of the innate immune system? _Diabetologia_ **41**, 1241–1248 (1998).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s001250051058)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1cXmtlais70%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9794114)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Is%20type%20II%20diabetes%20mellitus%20a%20disease%20of%20the%20innate%20immune%20system%3F&journal=Diabetologia&doi=10.1007%2Fs001250051058&volume=41&pages=1241-1248&publication_year=1998&author=Pickup%2CJC&author=Crook%2CMA)\\n    \\n139.  Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. _Nat. Rev. Neurosci._ **9**, 46–56 (2008).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrn2297)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhsVGjsbfJ)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18073775)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919277)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=From%20inflammation%20to%20sickness%20and%20depression%3A%20when%20the%20immune%20system%20subjugates%20the%20brain&journal=Nat.%20Rev.%20Neurosci.&doi=10.1038%2Fnrn2297&volume=9&pages=46-56&publication_year=2008&author=Dantzer%2CR&author=O%E2%80%99Connor%2CJC&author=Freund%2CGG&author=Johnson%2CRW&author=Kelley%2CKW)\\n    \\n140.  Prestele, S., Aldenhoff, J. & Reiff, J. \\\\[The HPA-axis as a possible link between depression, diabetes mellitus and cognitive dysfunction\\\\]. _Fortschr. Neurol. Psychiatr._ **71**, 24–36 (2003).\\n    \\n    [Article](https://doi.org/10.1055%2Fs-2003-36684)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3s%2Fit1Oqtw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12529832)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=%5BThe%20HPA-axis%20as%20a%20possible%20link%20between%20depression%2C%20diabetes%20mellitus%20and%20cognitive%20dysfunction%5D&journal=Fortschr.%20Neurol.%20Psychiatr.&doi=10.1055%2Fs-2003-36684&volume=71&pages=24-36&publication_year=2003&author=Prestele%2CS&author=Aldenhoff%2CJ&author=Reiff%2CJ)\\n    \\n141.  Cole, J., Costafreda, S. G., McGuffin, P. & Fu, C. H. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. _J. Affect. Disord._ **134**, 483–487 (2011).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jad.2011.05.057)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21745692)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hippocampal%20atrophy%20in%20first%20episode%20depression%3A%20a%20meta-analysis%20of%20magnetic%20resonance%20imaging%20studies&journal=J.%20Affect.%20Disord.&doi=10.1016%2Fj.jad.2011.05.057&volume=134&pages=483-487&publication_year=2011&author=Cole%2CJ&author=Costafreda%2CSG&author=McGuffin%2CP&author=Fu%2CCH)\\n    \\n142.  Gold, S. M. et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. _Diabetologia_ **50**, 711–719 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-007-0602-7)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2s7js1Wjuw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17334649)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hippocampal%20damage%20and%20memory%20impairments%20as%20possible%20early%20brain%20complications%20of%20type%202%20diabetes&journal=Diabetologia&doi=10.1007%2Fs00125-007-0602-7&volume=50&pages=711-719&publication_year=2007&author=Gold%2CSM)\\n    \\n143.  Moulton, C. D., Costafreda, S. G., Horton, P., Ismail, K. & Fu, C. H. Y. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. _Brain Imaging Behav._ **9**, 651–662 (2015).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s11682-014-9348-2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25563229)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Meta-analyses%20of%20structural%20regional%20cerebral%20effects%20in%20type%201%20and%20type%202%20diabetes&journal=Brain%20Imaging%20Behav.&doi=10.1007%2Fs11682-014-9348-2&volume=9&pages=651-662&publication_year=2015&author=Moulton%2CCD&author=Costafreda%2CSG&author=Horton%2CP&author=Ismail%2CK&author=Fu%2CCHY)\\n    \\n144.  Khalil, M., Power, N., Graham, E., Deschênes, S. S. & Schmitz, N. The association between sleep and diabetes outcomes – systematic review. _Diabetes Res. Clin. Pract._ **161**, 108035 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2020.108035)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32006640)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20sleep%20and%20diabetes%20outcomes%20%E2%80%93%20systematic%20review&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2020.108035&volume=161&publication_year=2020&author=Khalil%2CM&author=Power%2CN&author=Graham%2CE&author=Desch%C3%AAnes%2CSS&author=Schmitz%2CN)\\n    \\n145.  Senaratna, C. V. et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. _Sleep. Med. Rev._ **34**, 70–81 (2017).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.smrv.2016.07.002)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27568340)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20obstructive%20sleep%20apnea%20in%20the%20general%20population%3A%20a%20systematic%20review&journal=Sleep.%20Med.%20Rev.&doi=10.1016%2Fj.smrv.2016.07.002&volume=34&pages=70-81&publication_year=2017&author=Senaratna%2CCV)\\n    \\n146.  Subramanian, A. et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. _Diabetes Care_ **42**, 954–963 (2019).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc18-2004)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1KitrfP)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30862657)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20of%20incident%20obstructive%20sleep%20apnea%20among%20patients%20with%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc18-2004&volume=42&pages=954-963&publication_year=2019&author=Subramanian%2CA)\\n    \\n147.  Huang, T. et al. A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective U.S. Cohorts. _Diabetes Care_ **41**, 2111–2119 (2018).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc18-0675)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXjslyls7s%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30072403)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150434)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20population-based%20study%20of%20the%20bidirectional%20association%20between%20obstructive%20sleep%20apnea%20and%20type%202%20diabetes%20in%20three%20prospective%20U.S.%20Cohorts&journal=Diabetes%20Care&doi=10.2337%2Fdc18-0675&volume=41&pages=2111-2119&publication_year=2018&author=Huang%2CT)\\n    \\n148.  Reutrakul, S. et al. Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. _Sleep. Med._ **23**, 26–45 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.sleep.2016.03.019)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27692274)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sleep%20characteristics%20in%20type%201%20diabetes%20and%20associations%20with%20glycemic%20control%3A%20systematic%20review%20and%20meta-analysis&journal=Sleep.%20Med.&doi=10.1016%2Fj.sleep.2016.03.019&volume=23&pages=26-45&publication_year=2016&author=Reutrakul%2CS)\\n    \\n149.  Nagayoshi, M. et al. Obstructive sleep apnea and incident type 2 diabetes. _Sleep. Med._ **25**, 156–161 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.sleep.2016.05.009)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27810258)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102826)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnea%20and%20incident%20type%202%20diabetes&journal=Sleep.%20Med.&doi=10.1016%2Fj.sleep.2016.05.009&volume=25&pages=156-161&publication_year=2016&author=Nagayoshi%2CM)\\n    \\n150.  Ficker, J. H. et al. Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. _Eur. Respir. J._ **11**, 14–19 (1998).\\n    \\n    [Article](https://doi.org/10.1183%2F09031936.98.11010014)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK1c3gt1altw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9543264)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnoea%20and%20diabetes%20mellitus%3A%20the%20role%20of%20cardiovascular%20autonomic%20neuropathy&journal=Eur.%20Respir.%20J.&doi=10.1183%2F09031936.98.11010014&volume=11&pages=14-19&publication_year=1998&author=Ficker%2CJH)\\n    \\n151.  Young, T., Peppard, P. E. & Taheri, S. Excess weight and sleep-disordered breathing. _J. Appl. Physiol._ **99**, 1592–1599 (2005).\\n    \\n    [Article](https://doi.org/10.1152%2Fjapplphysiol.00587.2005)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16160020)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Excess%20weight%20and%20sleep-disordered%20breathing&journal=J.%20Appl.%20Physiol.&doi=10.1152%2Fjapplphysiol.00587.2005&volume=99&pages=1592-1599&publication_year=2005&author=Young%2CT&author=Peppard%2CPE&author=Taheri%2CS)\\n    \\n152.  Ip, M. S. M. et al. Obstructive sleep apnea is independently associated with insulin resistance. _Am. J. Respir. Crit. Care Med._ **165**, 670–676 (2002).\\n    \\n    [Article](https://doi.org/10.1164%2Fajrccm.165.5.2103001)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11874812)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnea%20is%20independently%20associated%20with%20insulin%20resistance&journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&doi=10.1164%2Fajrccm.165.5.2103001&volume=165&pages=670-676&publication_year=2002&author=Ip%2CMSM)\\n    \\n153.  Shaw, J. E. et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. _Am. J. Respir. Crit. Care Med._ **194**, 486–492 (2016).\\n    \\n    [Article](https://doi.org/10.1164%2Frccm.201511-2260OC)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslaiu7%2FL)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26926656)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20treatment%20of%20obstructive%20sleep%20apnea%20on%20glycemic%20control%20in%20type%202%20diabetes&journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&doi=10.1164%2Frccm.201511-2260OC&volume=194&pages=486-492&publication_year=2016&author=Shaw%2CJE)\\n    \\n154.  Lu, F. P., Lin, K. P. & Kuo, H. K. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. _PLoS ONE_ **4**, e4144 (2009).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0004144)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19127292)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607544)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsF2msLs%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20multi-system%20aging%20phenotypes%3A%20A%20systematic%20review%20and%20meta-analysis&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0004144&volume=4&publication_year=2009&author=Lu%2CFP&author=Lin%2CKP&author=Kuo%2CHK)\\n    \\n155.  Cheng, G., Huang, C., Deng, H. & Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. _Intern. Med. J._ **42**, 484–491 (2012).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1445-5994.2012.02758.x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38vksFOltQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22372522)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20as%20a%20risk%20factor%20for%20dementia%20and%20mild%20cognitive%20impairment%3A%20a%20meta-analysis%20of%20longitudinal%20studies&journal=Intern.%20Med.%20J.&doi=10.1111%2Fj.1445-5994.2012.02758.x&volume=42&pages=484-491&publication_year=2012&author=Cheng%2CG&author=Huang%2CC&author=Deng%2CH&author=Wang%2CH)\\n    \\n156.  Li, X. Y. et al. Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. _Curr. Alzheimer Res._ **16**, 1254–1268 (2019).\\n    \\n    [Article](https://doi.org/10.2174%2F1567205017666200103111253)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31902364)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVamtbw%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Midlife%20modifiable%20risk%20factors%20for%20dementia%3A%20a%20systematic%20review%20and%20meta-analysis%20of%2034%20prospective%20cohort%20studies&journal=Curr.%20Alzheimer%20Res.&doi=10.2174%2F1567205017666200103111253&volume=16&pages=1254-1268&publication_year=2019&author=Li%2CXY)\\n    \\n157.  Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. _Ageing Res. Rev._ **55**, 100944 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.arr.2019.100944)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslSisLjM)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31430566)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risks%20of%20cognitive%20impairment%20and%20dementia%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20144%20prospective%20studies&journal=Ageing%20Res.%20Rev.&doi=10.1016%2Fj.arr.2019.100944&volume=55&publication_year=2019&author=Xue%2CM)\\n    \\n158.  Pal, K., Mukadam, N., Petersen, I. & Cooper, C. Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. _Soc. Psychiatry Psychiatr. Epidemiol._ **53**, 1149–1160 (2018).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00127-018-1581-3)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30182156)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208946)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mild%20cognitive%20impairment%20and%20progression%20to%20dementia%20in%20people%20with%20diabetes%2C%20prediabetes%20and%20metabolic%20syndrome%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Soc.%20Psychiatry%20Psychiatr.%20Epidemiol.&doi=10.1007%2Fs00127-018-1581-3&volume=53&pages=1149-1160&publication_year=2018&author=Pal%2CK&author=Mukadam%2CN&author=Petersen%2CI&author=Cooper%2CC)\\n    \\n159.  Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C. & Scheltens, P. Risk of dementia in diabetes mellitus: a systematic review. _Lancet Neurol._ **5**, 64–74 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2805%2970284-2)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16361024)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20of%20dementia%20in%20diabetes%20mellitus%3A%20a%20systematic%20review&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2805%2970284-2&volume=5&pages=64-74&publication_year=2006&author=Biessels%2CGJ&author=Staekenborg%2CS&author=Brunner%2CE&author=Brayne%2CC&author=Scheltens%2CP)\\n    \\n160.  Peila, R., Rodriguez, B. L. & Launer, L. J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. _Diabetes_ **51**, 1256–1262 (2002).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiabetes.51.4.1256)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xis1Ois7Y%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11916953)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%2C%20APOE%20gene%2C%20and%20the%20risk%20for%20dementia%20and%20related%20pathologies%3A%20the%20Honolulu-Asia%20aging%20study&journal=Diabetes&doi=10.2337%2Fdiabetes.51.4.1256&volume=51&pages=1256-1262&publication_year=2002&author=Peila%2CR&author=Rodriguez%2CBL&author=Launer%2CLJ)\\n    \\n161.  Abner, E. L. et al. Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. _Alzheimer’s Dement._ **12**, 882–889 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jalz.2015.12.006)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20is%20associated%20with%20cerebrovascular%20but%20not%20Alzheimer%E2%80%99s%20disease%20neuropathology&journal=Alzheimer%E2%80%99s%20Dement.&doi=10.1016%2Fj.jalz.2015.12.006&volume=12&pages=882-889&publication_year=2016&author=Abner%2CEL)\\n    \\n162.  Matioli, M. N. P. S. et al. Association between diabetes and causes of dementia: evidence from a clinicopathological study. _Dement. Neuropsychol._ **11**, 406–412 (2017).\\n    \\n    [Article](https://doi.org/10.1590%2F1980-57642016dn11-040010)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29354221)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769999)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20and%20causes%20of%20dementia%3A%20evidence%20from%20a%20clinicopathological%20study&journal=Dement.%20Neuropsychol.&doi=10.1590%2F1980-57642016dn11-040010&volume=11&pages=406-412&publication_year=2017&author=Matioli%2CMNPS)\\n    \\n163.  You, Y. et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. _Acta Diabetol._ **58**, 671–685 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00592-020-01648-9)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33417039)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%20of%20mild%20cognitive%20impairment%20in%20type%202%20diabetes%20mellitus%20patients%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Acta%20Diabetol.&doi=10.1007%2Fs00592-020-01648-9&volume=58&pages=671-685&publication_year=2021&author=You%2CY)\\n    \\n164.  Langa, K. M. & Levine, D. A. The diagnosis and management of mild cognitive impairment: a clinical review. _JAMA_ **312**, 2551–2561 (2014).\\n    \\n    [Article](https://doi.org/10.1001%2Fjama.2014.13806)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXit1Ogt7Y%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25514304)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269302)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20diagnosis%20and%20management%20of%20mild%20cognitive%20impairment%3A%20a%20clinical%20review&journal=JAMA&doi=10.1001%2Fjama.2014.13806&volume=312&pages=2551-2561&publication_year=2014&author=Langa%2CKM&author=Levine%2CDA)\\n    \\n165.  Pelimanni, E. & Jehkonen, M. Type 2 diabetes and cognitive functions in middle age: a meta-analysis. _J. Int. Neuropsychol. Soc._ **25**, 215–229 (2019).\\n    \\n    [Article](https://doi.org/10.1017%2FS1355617718001042)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30575498)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20cognitive%20functions%20in%20middle%20age%3A%20a%20meta-analysis&journal=J.%20Int.%20Neuropsychol.%20Soc.&doi=10.1017%2FS1355617718001042&volume=25&pages=215-229&publication_year=2019&author=Pelimanni%2CE&author=Jehkonen%2CM)\\n    \\n166.  Rom, S. et al. Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles. _Sci. Rep._ **10**, 7274 (2020).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-020-64349-x)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXosVOksL4%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32350344)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190636)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20and%20advanced%20glycation%20end%20products%20disrupt%20BBB%20and%20promote%20occludin%20and%20claudin-5%20protein%20secretion%20on%20extracellular%20microvesicles&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-020-64349-x&volume=10&publication_year=2020&author=Rom%2CS)\\n    \\n167.  Hussain, B., Fang, C. & Chang, J. Blood–brain barrier breakdown: an emerging biomarker of cognitive impairment in normal aging and dementia. _Front. Neurosci._ **15**, 688090 (2021).\\n    \\n    [Article](https://doi.org/10.3389%2Ffnins.2021.688090)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34489623)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418300)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Blood%E2%80%93brain%20barrier%20breakdown%3A%20an%20emerging%20biomarker%20of%20cognitive%20impairment%20in%20normal%20aging%20and%20dementia&journal=Front.%20Neurosci.&doi=10.3389%2Ffnins.2021.688090&volume=15&publication_year=2021&author=Hussain%2CB&author=Fang%2CC&author=Chang%2CJ)\\n    \\n168.  Anstey, K. J., Sargent-Cox, K., Eramudugolla, R., Magliano, D. J. & Shaw, J. E. Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study. _Alzheimers Res. Ther._ **7**, 48 (2015).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s13195-015-0131-4)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26167206)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499451)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVGjsbjL)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20cognitive%20function%20with%20glucose%20tolerance%20and%20trajectories%20of%20glucose%20tolerance%20over%2012%20years%20in%20the%20AusDiab%20study&journal=Alzheimers%20Res.%20Ther.&doi=10.1186%2Fs13195-015-0131-4&volume=7&publication_year=2015&author=Anstey%2CKJ&author=Sargent-Cox%2CK&author=Eramudugolla%2CR&author=Magliano%2CDJ&author=Shaw%2CJE)\\n    \\n169.  Steen, E. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease - Is this type 3 diabetes? _J. Alzheimer’s Dis._ **7**, 63–80 (2005).\\n    \\n    [Article](https://doi.org/10.3233%2FJAD-2005-7107)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhvVSrtL8%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impaired%20insulin%20and%20insulin-like%20growth%20factor%20expression%20and%20signaling%20mechanisms%20in%20Alzheimer%E2%80%99s%20disease%20-%20Is%20this%20type%203%20diabetes%3F&journal=J.%20Alzheimer%E2%80%99s%20Dis.&doi=10.3233%2FJAD-2005-7107&volume=7&pages=63-80&publication_year=2005&author=Steen%2CE)\\n    \\n170.  Leonardi, M., Bickenbach, J., Ustun, T. B., Kostanjsek, N. & Chatterji, S. The definition of disability: what is in a name? _Lancet_ **368**, 1219–1221 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2FS0140-6736%2806%2969498-1)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17027711)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20definition%20of%20disability%3A%20what%20is%20in%20a%20name%3F&journal=Lancet&doi=10.1016%2FS0140-6736%2806%2969498-1&volume=368&pages=1219-1221&publication_year=2006&author=Leonardi%2CM&author=Bickenbach%2CJ&author=Ustun%2CTB&author=Kostanjsek%2CN&author=Chatterji%2CS)\\n    \\n171.  Lisy, K., Campbell, J. M., Tufanaru, C., Moola, S. & Lockwood, C. The prevalence of disability among people with cancer, cardiovascular disease, chronic respiratory disease and/or diabetes: a systematic review. _Int. J. Evid. Based Healthc._ **16**, 154–166 (2018).\\n    \\n    [Article](https://doi.org/10.1097%2FXEB.0000000000000138)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29608458)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%20of%20disability%20among%20people%20with%20cancer%2C%20cardiovascular%20disease%2C%20chronic%20respiratory%20disease%20and%2For%20diabetes%3A%20a%20systematic%20review&journal=Int.%20J.%20Evid.%20Based%20Healthc.&doi=10.1097%2FXEB.0000000000000138&volume=16&pages=154-166&publication_year=2018&author=Lisy%2CK&author=Campbell%2CJM&author=Tufanaru%2CC&author=Moola%2CS&author=Lockwood%2CC)\\n    \\n172.  Yang, Y., Hu, X., Zhang, Q. & Zou, R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. _Age Ageing_ **45**, 761–767 (2016).\\n    \\n    [Article](https://doi.org/10.1093%2Fageing%2Fafw140)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27515679)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20falls%20in%20older%20adults%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Age%20Ageing&doi=10.1093%2Fageing%2Fafw140&volume=45&pages=761-767&publication_year=2016&author=Yang%2CY&author=Hu%2CX&author=Zhang%2CQ&author=Zou%2CR)\\n    \\n173.  Wong, E. et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. _Lancet Diabetes Endocrinol._ **1**, 106–114 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2813%2970046-9)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24622316)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20risk%20of%20physical%20disability%20in%20adults%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2813%2970046-9&volume=1&pages=106-114&publication_year=2013&author=Wong%2CE)\\n    \\n174.  Havercamp, S. M., Scandlin, D. & Roth, M. Health disparities among adults with developmental disabilities, adults with other disabilities, and adults not reporting disability in North Carolina. _Public. Health Rep._ **119**, 418–426 (2004).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.phr.2004.05.006)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15219799)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1497651)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Health%20disparities%20among%20adults%20with%20developmental%20disabilities%2C%20adults%20with%20other%20disabilities%2C%20and%20adults%20not%20reporting%20disability%20in%20North%20Carolina&journal=Public.%20Health%20Rep.&doi=10.1016%2Fj.phr.2004.05.006&volume=119&pages=418-426&publication_year=2004&author=Havercamp%2CSM&author=Scandlin%2CD&author=Roth%2CM)\\n    \\n175.  Herquelot, E., Guéguen, A., Bonenfant, S. & Dray-Spira, R. Impact of diabetes on work cessation: data from the GAZEL cohort study. _Diabetes Care_ **34**, 1344–1349 (2011).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc10-2225)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21562323)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114330)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20diabetes%20on%20work%20cessation%3A%20data%20from%20the%20GAZEL%20cohort%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc10-2225&volume=34&pages=1344-1349&publication_year=2011&author=Herquelot%2CE&author=Gu%C3%A9guen%2CA&author=Bonenfant%2CS&author=Dray-Spira%2CR)\\n    \\n176.  Virtanen, M. et al. Work disability among employees with diabetes: latent class analysis of risk factors in three prospective cohort studies. _PLoS ONE_ **10**, e0143184 (2015).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0143184)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26569491)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646666)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVSms7rM)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Work%20disability%20among%20employees%20with%20diabetes%3A%20latent%20class%20analysis%20of%20risk%20factors%20in%20three%20prospective%20cohort%20studies&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0143184&volume=10&publication_year=2015&author=Virtanen%2CM)\\n    \\n177.  Cho, N. H. et al. IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. _Diabetes Res. Clin. Pract._ **138**, 271–281 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2018.02.023)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1MrmvVOlsw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29496507)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=IDF%20Diabetes%20atlas%3A%20global%20estimates%20of%20diabetes%20prevalence%20for%202017%20and%20projections%20for%202045&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2018.02.023&volume=138&pages=271-281&publication_year=2018&author=Cho%2CNH)\\n    \\n178.  Seok, W. P. et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. _Diabetes Care_ **30**, 1507–1512 (2007).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc06-2537)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Accelerated%20loss%20of%20skeletal%20muscle%20strength%20in%20older%20adults%20with%20type%202%20diabetes%3A%20the%20health%2C%20aging%2C%20and%20body%20composition%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc06-2537&volume=30&pages=1507-1512&publication_year=2007&author=Seok%2CWP)\\n    \\n179.  Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. _Br. Med. J._ **321**, 405–412 (2000).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmj.321.7258.405)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3cvisFWnsg%3D%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20glycaemia%20with%20macrovascular%20and%20microvascular%20complications%20of%20type%202%20diabetes%20%28UKPDS%2035%29%3A%20prospective%20observational%20study&journal=Br.%20Med.%20J.&doi=10.1136%2Fbmj.321.7258.405&volume=321&pages=405-412&publication_year=2000&author=Stratton%2CIM)\\n    \\n180.  DeCensi, A. et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. _Cancer Prev. Res._ **3**, 1451–1461 (2010).\\n    \\n    [Article](https://doi.org/10.1158%2F1940-6207.CAPR-10-0157)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhs1Wrsr7J)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20and%20cancer%20risk%20in%20diabetic%20patients%3A%20A%20systematic%20review%20and%20meta-analysis&journal=Cancer%20Prev.%20Res.&doi=10.1158%2F1940-6207.CAPR-10-0157&volume=3&pages=1451-1461&publication_year=2010&author=DeCensi%2CA)\\n    \\n181.  Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J. & McGuire, D. K. Metformin in patientswith type 2 diabetes and kidney disease a systematic review. _JAMA_ **312**, 2668–2675 (2014).\\n    \\n    [Article](https://doi.org/10.1001%2Fjama.2014.15298)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25536258)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427053)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVKrs7Y%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20in%20patientswith%20type%202%20diabetes%20and%20kidney%20disease%20a%20systematic%20review&journal=JAMA&doi=10.1001%2Fjama.2014.15298&volume=312&pages=2668-2675&publication_year=2014&author=Inzucchi%2CSE&author=Lipska%2CKJ&author=Mayo%2CH&author=Bailey%2CCJ&author=McGuire%2CDK)\\n    \\n182.  Suissa, S. & Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. _Diabetes Care_ **35**, 2665–2673 (2012).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc12-0788)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvFShsrnN)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23173135)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507580)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20and%20the%20risk%20of%20cancer%3A%20time-related%20biases%20in%20observational%20studies&journal=Diabetes%20Care&doi=10.2337%2Fdc12-0788&volume=35&pages=2665-2673&publication_year=2012&author=Suissa%2CS&author=Azoulay%2CL)\\n    \\n183.  Karlstad, Ø. et al. Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies. _Curr. Drug. Saf._ **8**, 333–348 (2013).\\n    \\n    [Article](https://doi.org/10.2174%2F15680266113136660067)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitlahsQ%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24215311)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Use%20of%20insulin%20and%20insulin%20analogs%20and%20risk%20of%20cancer-systematic%20review%20and%20meta-analysis%20of%20observational%20studies&journal=Curr.%20Drug.%20Saf.&doi=10.2174%2F15680266113136660067&volume=8&pages=333-348&publication_year=2013&author=Karlstad%2C%C3%98)\\n    \\n184.  Bordeleau, L. et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. _Diabetes Care_ **37**, 1360–1366 (2014).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc13-1468)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXpt12qt7w%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24574355)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20of%20basal%20insulin%20glargine%20and%2For%20n-3%20fatty%20acids%20with%20incident%20cancers%20in%20patients%20with%20dysglycemia&journal=Diabetes%20Care&doi=10.2337%2Fdc13-1468&volume=37&pages=1360-1366&publication_year=2014&author=Bordeleau%2CL)\\n    \\n185.  Guo, M. et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. _Clin. Exp. Pharmacol. Physiol._ **41**, 650–656 (2014).\\n    \\n    [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhvVSjsbzI)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24862430)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20may%20produce%20antidepressant%20effects%20through%20improvement%20of%20cognitive%20function%20among%20depressed%20patients%20with%20diabetes%20mellitus&journal=Clin.%20Exp.%20Pharmacol.%20Physiol.&volume=41&pages=650-656&publication_year=2014&author=Guo%2CM)\\n    \\n186.  Campbell, J. M. et al. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. _J. Alzheimer’s Dis._ **65**, 1225–1236 (2018).\\n    \\n    [Article](https://doi.org/10.3233%2FJAD-180263)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20use%20associated%20with%20reduced%20risk%20of%20dementia%20in%20patients%20with%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Alzheimer%E2%80%99s%20Dis.&doi=10.3233%2FJAD-180263&volume=65&pages=1225-1236&publication_year=2018&author=Campbell%2CJM)\\n    \\n187.  Haukeland, J. W. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. _Scand. J. Gastroenterol._ **44**, 853–860 (2009).\\n    \\n    [Article](https://doi.org/10.1080%2F00365520902845268)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtVWjt7nP)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19811343)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20disease%3A%20a%20randomized%2C%20controlled%20trial&journal=Scand.%20J.%20Gastroenterol.&doi=10.1080%2F00365520902845268&volume=44&pages=853-860&publication_year=2009&author=Haukeland%2CJW)\\n    \\n188.  Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. _Lancet Neurol._ **19**, 582–590 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2820%2930173-3)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXht1WmtbrO)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32562683)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20dulaglutide%20on%20cognitive%20impairment%20in%20type%202%20diabetes%3A%20an%20exploratory%20analysis%20of%20the%20REWIND%20trial&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2820%2930173-3&volume=19&pages=582-590&publication_year=2020&author=Cukierman-Yaffe%2CT)\\n    \\n189.  Johnson, J. A. & Bowker, S. L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. _Diabetologia_ **54**, 25–31 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-010-1933-3)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFWqtLfI)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20959956)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intensive%20glycaemic%20control%20and%20cancer%20risk%20in%20type%202%20diabetes%3A%20a%20meta-analysis%20of%20major%20trials&journal=Diabetologia&doi=10.1007%2Fs00125-010-1933-3&volume=54&pages=25-31&publication_year=2011&author=Johnson%2CJA&author=Bowker%2CSL)\\n    \\n190.  Launer, L. J. et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. _Lancet Neurol._ **10**, 969–977 (2011).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2811%2970188-0)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21958949)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333485)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20intensive%20glucose%20lowering%20on%20brain%20structure%20and%20function%20in%20people%20with%20type%202%20diabetes%20%28ACCORD%20MIND%29%3A%20a%20randomised%20open-label%20substudy&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2811%2970188-0&volume=10&pages=969-977&publication_year=2011&author=Launer%2CLJ)\\n    \\n191.  Jia, Y. et al. Associations of the glycaemic control of diabetes with dementia and physical function in rural-dwelling older Chinese adults: a population-based study. _Clin. Interv. Aging_ **16**, 1503–1513 (2021).\\n    \\n    [Article](https://doi.org/10.2147%2FCIA.S319633)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34413638)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370580)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Associations%20of%20the%20glycaemic%20control%20of%20diabetes%20with%20dementia%20and%20physical%20function%20in%20rural-dwelling%20older%20Chinese%20adults%3A%20a%20population-based%20study&journal=Clin.%20Interv.%20Aging&doi=10.2147%2FCIA.S319633&volume=16&pages=1503-1513&publication_year=2021&author=Jia%2CY)\\n    \\n192.  Lesniak, C. et al. Inpatient glycemic control and outcome of COVID-19 patients: a retrospective cohort. _SAGE Open. Med._ **9**, 20503121211039105 (2021).\\n    \\n    [Article](https://doi.org/10.1177%2F20503121211039105)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34422272)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375327)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inpatient%20glycemic%20control%20and%20outcome%20of%20COVID-19%20patients%3A%20a%20retrospective%20cohort&journal=SAGE%20Open.%20Med.&doi=10.1177%2F20503121211039105&volume=9&publication_year=2021&author=Lesniak%2CC)\\n    \\n193.  Afolabi, B. I. et al. The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients. _J. Natl Med. Assoc._ **110**, 256–264 (2018).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29778128)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20relationship%20between%20glycaemic%20control%20and%20non-alcoholic%20fatty%20liver%20disease%20in%20Nigerian%20type%202%20diabetic%20patients&journal=J.%20Natl%20Med.%20Assoc.&volume=110&pages=256-264&publication_year=2018&author=Afolabi%2CBI)\\n    \\n194.  Nouwen, A. et al. Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. _Diabet. Med._ **36**, 1562–1572 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fdme.14054)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3M3otlegsw%3D%3D)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31215077)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Longitudinal%20associations%20between%20depression%20and%20diabetes%20complications%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fdme.14054&volume=36&pages=1562-1572&publication_year=2019&author=Nouwen%2CA)\\n    \\n195.  Perry, B. D. et al. Muscle atrophy in patients with Type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. _Exerc. Immunol. Rev._ **22**, 94–109 (2016).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26859514)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545118)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Muscle%20atrophy%20in%20patients%20with%20Type%202%20diabetes%20mellitus%3A%20roles%20of%20inflammatory%20pathways%2C%20physical%20activity%20and%20exercise&journal=Exerc.%20Immunol.%20Rev.&volume=22&pages=94-109&publication_year=2016&author=Perry%2CBD)\\n    \\n196.  Hirata, Y. et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. _JCI Insight_ **4**, e124952 (2019).\\n    \\n    [Article](https://doi.org/10.1172%2Fjci.insight.124952)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478420)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20induces%20skeletal%20muscle%20atrophy%20via%20a%20WWP1%2FKLF15%20axis&journal=JCI%20Insight&doi=10.1172%2Fjci.insight.124952&volume=4&publication_year=2019&author=Hirata%2CY)\\n    \\n197.  Bassil, M. S. & Gougeon, R. Muscle protein anabolism in type 2 diabetes. _Curr. Opin. Clin. Nutr. Metab. Care_ **16**, 83–88 (2013).\\n    \\n    [Article](https://doi.org/10.1097%2FMCO.0b013e32835a88ee)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvVWhtL7O)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23196814)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Muscle%20protein%20anabolism%20in%20type%202%20diabetes&journal=Curr.%20Opin.%20Clin.%20Nutr.%20Metab.%20Care&doi=10.1097%2FMCO.0b013e32835a88ee&volume=16&pages=83-88&publication_year=2013&author=Bassil%2CMS&author=Gougeon%2CR)\\n    \\n198.  Meex, R. C. R., Blaak, E. E. & van Loon, L. J. C. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. _Obes. Rev._ **20**, 1205–1217 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fobr.12862)\\xa0 [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFyhsrbN)\\xa0 [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31240819)\\xa0 [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852205)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipotoxicity%20plays%20a%20key%20role%20in%20the%20development%20of%20both%20insulin%20resistance%20and%20muscle%20atrophy%20in%20patients%20with%20type%202%20diabetes&journal=Obes.%20Rev.&doi=10.1111%2Fobr.12862&volume=20&pages=1205-1217&publication_year=2019&author=Meex%2CRCR&author=Blaak%2CEE&author=Loon%2CLJC)\\n    \\n\\n[Download references](https://citation-needed.springer.com/v2/references/10.1038/s41574-022-00690-7?format=refman&flavour=references)\\n\\nAcknowledgements\\n----------------\\n\\nD.T. is supported by an Australian Government Research Training Program (RTP) Scholarship and Monash Graduate Excellence Scholarship. J.E.S. is supported by a National Health and Medical Research Council Investigator Grant. D.J.M. is supported by a National Health and Medical Research Council Senior Research Fellowship.\\n\\nAuthor information\\n------------------\\n\\nAuthor notes\\n\\n1.  These authors jointly supervised this work: Jonathan E. Shaw and Dianna J. Magliano.\\n    \\n\\n### Authors and Affiliations\\n\\n1.  Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia\\n    \\n    Dunya Tomic,\\xa0Jonathan E. Shaw\\xa0&\\xa0Dianna J. Magliano\\n    \\n2.  School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia\\n    \\n    Dunya Tomic,\\xa0Jonathan E. Shaw\\xa0&\\xa0Dianna J. Magliano\\n    \\n\\nAuthors\\n\\n1.  Dunya Tomic\\n    \\n    [View author publications](https://www.nature.com/search?author=Dunya%20Tomic)\\n    \\n    You can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dunya%20Tomic)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dunya%20Tomic%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n    \\n2.  Jonathan E. Shaw\\n    \\n    [View author publications](https://www.nature.com/search?author=Jonathan%20E.%20Shaw)\\n    \\n    You can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jonathan%20E.%20Shaw)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jonathan%20E.%20Shaw%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n    \\n3.  Dianna J. Magliano\\n    \\n    [View author publications](https://www.nature.com/search?author=Dianna%20J.%20Magliano)\\n    \\n    You can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dianna%20J.%20Magliano)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dianna%20J.%20Magliano%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n    \\n\\n### Contributions\\n\\nD.T. researched data for the article and wrote the article. J.E.S and D.J.M. contributed substantially to discussion of the content. D.T., J.E.S. and D.J.M reviewed and/or edited the manuscript before submission.\\n\\n### Corresponding author\\n\\nCorrespondence to [Dianna J. Magliano](mailto:Dianna.Magliano@baker.edu.au).\\n\\nEthics declarations\\n-------------------\\n\\n### Competing interests\\n\\nThe authors declare no competing interests.\\n\\nPeer review\\n-----------\\n\\n### Peer review information\\n\\n_Nature Reviews Endocrinology_ thanks Emily Gallagher, Norbert Stefan and Assaad Eid for their contribution to the peer review of this work.\\n\\nAdditional information\\n----------------------\\n\\n### Publisher’s note\\n\\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\\n\\nGlossary\\n--------\\n\\nActivities of daily living\\n\\nFundamental skills required to independently care for oneself such as eating, bathing and mobility.\\n\\nIndependent activities of daily living\\n\\nActivities that allow an individual to live independently in a community.\\n\\nImmortal time bias\\n\\nThe error in estimating the association between an exposure and an outcome that results from misclassification or exclusion of time intervals.\\n\\nRights and permissions\\n----------------------\\n\\n[Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=The%20burden%20and%20risks%20of%20emerging%20complications%20of%20diabetes%20mellitus&author=Dunya%20Tomic%20et%20al&contentID=10.1038%2Fs41574-022-00690-7&copyright=Springer%20Nature%20Limited&publication=1759-5029&publicationDate=2022-06-06&publisherName=SpringerNature&orderBeanReset=true)\\n\\nAbout this article\\n------------------\\n\\n[![Image 6: Check for updates. Verify currency and authenticity via CrossMark](blob:http://localhost/df43c82f6cb6dcd2a87db38f317bf9f2)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41574-022-00690-7)\\n\\n### Cite this article\\n\\nTomic, D., Shaw, J.E. & Magliano, D.J. The burden and risks of emerging complications of diabetes mellitus. _Nat Rev Endocrinol_ **18**, 525–539 (2022). https://doi.org/10.1038/s41574-022-00690-7\\n\\n[Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41574-022-00690-7?format=refman&flavour=citation)\\n\\n*   Accepted: 06 May 2022\\n    \\n*   Published: 06 June 2022\\n    \\n*   Issue Date: September 2022\\n    \\n*   DOI: https://doi.org/10.1038/s41574-022-00690-7\\n    \\n\\n### Share this article\\n\\nAnyone you share the following link with will be able to read this content:\\n\\nGet shareable link\\n\\nSorry, a shareable link is not currently available for this article.\\n\\nCopy to clipboard\\n\\nProvided by the Springer Nature SharedIt content-sharing initiative\\n\\n### Subjects\\n\\n*   [Diabetes complications](https://www.nature.com/subjects/diabetes-complications)\\n*   [Type 1 diabetes](https://www.nature.com/subjects/type-1-diabetes-mellitus)\\n*   [Type 2 diabetes](https://www.nature.com/subjects/type-2-diabetes-mellitus)\\n\\nThis article is cited by\\n------------------------\\n\\n*   ### [Green sanctuaries: residential green and garden space and the natural environment mitigate mental disorders risk of diabetic patients](https://doi.org/10.1186/s12916-025-03864-y)\\n    \\n    *   Erxu Xue\\n    *   Jianhui Zhao\\n    *   Zhihong Ye\\n    \\n    _BMC Medicine_ (2025)\\n    \\n*   ### [Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study](https://doi.org/10.1186/s12933-025-02626-7)\\n    \\n    *   Ying Sun\\n    *   Yuefeng Yu\\n    *   Ningjian Wang\\n    \\n    _Cardiovascular Diabetology_ (2025)\\n    \\n*   ### [Immunomodulation effects of collagen hydrogel encapsulating extracellular vesicles derived from calcium silicate stimulated-adipose mesenchymal stem cells for diabetic healing](https://doi.org/10.1186/s12951-025-03097-4)\\n    \\n    *   Yen-Hong Lin\\n    *   Yeh Chen\\n    *   Ming-You Shie\\n    \\n    _Journal of Nanobiotechnology_ (2025)\\n    \\n*   ### [The association between type 2 diabetes and asthma incidence: a longitudinal analysis considering genetic susceptibility](https://doi.org/10.1186/s12889-024-21266-2)\\n    \\n    *   Fei Chen\\n    *   Ying Yang\\n    *   Bo Zhang\\n    \\n    _BMC Public Health_ (2025)\\n    \\n*   ### [Design, synthesis, and investigation of novel 5-arylpyrazole-glucose hybrids as α-glucosidase inhibitors](https://doi.org/10.1038/s41598-025-92706-1)\\n    \\n    *   Roshanak Hariri\\n    *   Mina Saeedi\\n    *   Tahmineh Akbarzadeh\\n    \\n    _Scientific Reports_ (2025)\\n    \\n\\n[Download PDF](https://www.nature.com/articles/s41574-022-00690-7.pdf)\\n\\n*   Sections\\n*   Figures\\n*   References\\n\\n*   [Abstract](https://www.nature.com/articles/s41574-022-00690-7#Abs1)\\n*   [Key points](https://www.nature.com/articles/s41574-022-00690-7#Abs3)\\n*   [Introduction](https://www.nature.com/articles/s41574-022-00690-7#Sec1)\\n*   [Diabetes mellitus and cancer](https://www.nature.com/articles/s41574-022-00690-7#Sec2)\\n*   [Diabetes mellitus and infections](https://www.nature.com/articles/s41574-022-00690-7#Sec18)\\n*   [Diabetes mellitus and liver disease](https://www.nature.com/articles/s41574-022-00690-7#Sec25)\\n*   [Diabetes mellitus and affective disorders](https://www.nature.com/articles/s41574-022-00690-7#Sec32)\\n*   [Diabetes mellitus and sleep disturbance](https://www.nature.com/articles/s41574-022-00690-7#Sec37)\\n*   [Diabetes mellitus and cognitive disability](https://www.nature.com/articles/s41574-022-00690-7#Sec40)\\n*   [Diabetes mellitus and disability](https://www.nature.com/articles/s41574-022-00690-7#Sec43)\\n*   [Diabetes management and control](https://www.nature.com/articles/s41574-022-00690-7#Sec48)\\n*   [Conclusions](https://www.nature.com/articles/s41574-022-00690-7#Sec53)\\n*   [References](https://www.nature.com/articles/s41574-022-00690-7#Bib1)\\n*   [Acknowledgements](https://www.nature.com/articles/s41574-022-00690-7#Ack1)\\n*   [Author information](https://www.nature.com/articles/s41574-022-00690-7#author-information)\\n*   [Ethics declarations](https://www.nature.com/articles/s41574-022-00690-7#ethics)\\n*   [Peer review](https://www.nature.com/articles/s41574-022-00690-7#peer-review)\\n*   [Additional information](https://www.nature.com/articles/s41574-022-00690-7#additional-information)\\n*   [Glossary](https://www.nature.com/articles/s41574-022-00690-7#glossary)\\n*   [Rights and permissions](https://www.nature.com/articles/s41574-022-00690-7#rightslink)\\n*   [About this article](https://www.nature.com/articles/s41574-022-00690-7#article-info)\\n*   [This article is cited by](https://www.nature.com/articles/s41574-022-00690-7#further-reading)\\n\\nAdvertisement\\n\\n*   **Fig. 1: Major traditional complications and emerging complications of diabetes mellitus.**\\n    \\n    ![Image 8: figure 1](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41574-022-00690-7/MediaObjects/41574_2022_690_Fig1_HTML.png)[View in article](https://www.nature.com/articles/s41574-022-00690-7#Fig1)[Full size image](https://www.nature.com/articles/s41574-022-00690-7/figures/1)\\n    \\n\\n1.  Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. _Nature_ **414**, 782–787 (2001).\\n    \\n    [Article](https://doi.org/10.1038%2F414782a)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xhtlymtg%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11742409)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20and%20societal%20implications%20of%20the%20diabetes%20epidemic&journal=Nature&doi=10.1038%2F414782a&volume=414&pages=782-787&publication_year=2001&author=Zimmet%2CP&author=Alberti%2CKGMM&author=Shaw%2CJ)\\n    \\n2.  Fowler, M. J. Microvascular and macrovascular complications of diabetes. _Clin. Diabetes_ **26**, 77–82 (2008).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiaclin.26.2.77)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Microvascular%20and%20macrovascular%20complications%20of%20diabetes&journal=Clin.%20Diabetes&doi=10.2337%2Fdiaclin.26.2.77&volume=26&pages=77-82&publication_year=2008&author=Fowler%2CMJ)\\n    \\n3.  Shah, A. D. et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. _Lancet Diabetes Endocrinol._ **3**, 105–113 (2015).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2814%2970219-0)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25466521)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303913)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20incidence%20of%20cardiovascular%20diseases%3A%20a%20cohort%20study%20in%201%C2%B79%20million%20people&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2814%2970219-0&volume=3&pages=105-113&publication_year=2015&author=Shah%2CAD)\\n    \\n4.  Bertoni, A. G. et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. _Diabetes Care_ **27**, 699–703 (2004).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiacare.27.3.699)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14988288)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Heart%20failure%20prevalence%2C%20incidence%2C%20and%20mortality%20in%20the%20elderly%20with%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdiacare.27.3.699&volume=27&pages=699-703&publication_year=2004&author=Bertoni%2CAG)\\n    \\n5.  Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. _N. Engl. J. Med._ **370**, 1514–1523 (2014).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJMoa1310799)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXmvFShtb4%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24738668)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Changes%20in%20diabetes-related%20complications%20in%20the%20United%20States%2C%201990%E2%80%932010&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1310799&volume=370&pages=1514-1523&publication_year=2014&author=Gregg%2CEW)\\n    \\n6.  Gregg, E. W., Sattar, N. & Ali, M. K. The changing face of diabetes complications. _Lancet Diabetes Endocrinol._ **4**, 537–547 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2816%2930010-9)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27156051)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20changing%20face%20of%20diabetes%20complications&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2816%2930010-9&volume=4&pages=537-547&publication_year=2016&author=Gregg%2CEW&author=Sattar%2CN&author=Ali%2CMK)\\n    \\n7.  Gregg, E. W. et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. _Lancet_ **391**, 2430–2440 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2FS0140-6736%2818%2930314-3)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29784146)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20cause-specific%20mortality%20among%20adults%20with%20and%20without%20diagnosed%20diabetes%20in%20the%20USA%3A%20an%20epidemiological%20analysis%20of%20linked%20national%20survey%20and%20vital%20statistics%20data&journal=Lancet&doi=10.1016%2FS0140-6736%2818%2930314-3&volume=391&pages=2430-2440&publication_year=2018&author=Gregg%2CEW)\\n    \\n8.  Harding, J. L., Shaw, J. E., Peeters, A., Davidson, S. & Magliano, D. J. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. _Diabetes Care_ **39**, 1018–1026 (2016).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc15-2308)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27208325)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Age-specific%20trends%20from%202000%E2%80%932011%20in%20all-cause%20and%20cause-specific%20mortality%20in%20type%201%20and%20type%202%20diabetes%3A%20a%20cohort%20study%20of%20more%20than%20one%20million%20people&journal=Diabetes%20Care&doi=10.2337%2Fdc15-2308&volume=39&pages=1018-1026&publication_year=2016&author=Harding%2CJL&author=Shaw%2CJE&author=Peeters%2CA&author=Davidson%2CS&author=Magliano%2CDJ)\\n    \\n9.  Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. _Lancet Diabetes Endocrinol._ **9**, 165–173 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930431-9)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33549162)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886654)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20predominant%20causes%20of%20death%20in%20individuals%20with%20and%20without%20diabetes%20in%20England%20from%202001%20to%202018%3A%20an%20epidemiological%20analysis%20of%20linked%20primary%20care%20records&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930431-9&volume=9&pages=165-173&publication_year=2021&author=Pearson-Stuttard%2CJ)\\n    \\n10.  Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. _Cardiovasc. Diabetol._ **17**, 83 (2018).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12933-018-0728-6)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29884191)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994068)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20cardiovascular%20disease%20in%20type%202%20diabetes%3A%20a%20systematic%20literature%20review%20of%20scientific%20evidence%20from%20across%20the%20world%20in%202007%E2%80%932017&journal=Cardiovasc.%20Diabetol.&doi=10.1186%2Fs12933-018-0728-6&volume=17&publication_year=2018&author=Einarson%2CTR&author=Acs%2CA&author=Ludwig%2CC&author=Panton%2CUH)\\n    \\n11.  Pearson-Stuttard, J., Buckley, J., Cicek, M. & Gregg, E. W. The changing nature of mortality and morbidity in patients with diabetes. _Endocrinol. Metab. Clin. North Am._ **50**, 357–368 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ecl.2021.05.001)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34399950)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20changing%20nature%20of%20mortality%20and%20morbidity%20in%20patients%20with%20diabetes&journal=Endocrinol.%20Metab.%20Clin.%20North%20Am.&doi=10.1016%2Fj.ecl.2021.05.001&volume=50&pages=357-368&publication_year=2021&author=Pearson-Stuttard%2CJ&author=Buckley%2CJ&author=Cicek%2CM&author=Gregg%2CEW)\\n    \\n12.  Pearson-Stuttard, J. et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. _Lancet Diabetes Endocrinol._ **10**, 46–57 (2022).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2821%2900288-6)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34861153)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672063)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20leading%20causes%20of%20hospitalisation%20of%20adults%20with%20diabetes%20in%20England%20from%202003%20to%202018%3A%20an%20epidemiological%20analysis%20of%20linked%20primary%20care%20records&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2821%2900288-6&volume=10&pages=46-57&publication_year=2022&author=Pearson-Stuttard%2CJ)\\n    \\n13.  Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D. G. & Critchley, J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. _Lancet Diabetes Endocrinol._ **4**, 148–158 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2815%2900379-4)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26656292)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20infection%3A%20assessing%20the%20association%20with%20glycaemic%20control%20in%20population-based%20studies&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2815%2900379-4&volume=4&pages=148-158&publication_year=2016&author=Pearson-Stuttard%2CJ&author=Blundell%2CS&author=Harris%2CT&author=Cook%2CDG&author=Critchley%2CJ)\\n    \\n14.  Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. _Diabetes Care_ **30**, 734–743 (2007).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc06-1539)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXjs1Grurk%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17327353)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Spectrum%20of%20liver%20disease%20in%20type%202%20diabetes%20and%20management%20of%20patients%20with%20diabetes%20and%20liver%20disease&journal=Diabetes%20Care&doi=10.2337%2Fdc06-1539&volume=30&pages=734-743&publication_year=2007&author=Tolman%2CKG&author=Fonseca%2CV&author=Dalpiaz%2CA&author=Tan%2CMH)\\n    \\n15.  Chatterjee, S. et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. _Diabetes Care_ **39**, 300–307 (2016).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc15-1588)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XitVKis7nO)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26681727)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20as%20a%20risk%20factor%20for%20dementia%20in%20women%20compared%20with%20men%3A%20a%20pooled%20analysis%20of%202.3%20million%20people%20comprising%20more%20than%20100%2C000%20cases%20of%20dementia&journal=Diabetes%20Care&doi=10.2337%2Fdc15-1588&volume=39&pages=300-307&publication_year=2016&author=Chatterjee%2CS)\\n    \\n16.  Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. _BMJ_ **350**, g7607 (2015).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmj.g7607)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25555821)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20cancer%3A%20umbrella%20review%20of%20meta-analyses%20of%20observational%20studies&journal=BMJ&doi=10.1136%2Fbmj.g7607&volume=350&publication_year=2015&author=Tsilidis%2CKK&author=Kasimis%2CJC&author=Lopez%2CDS&author=Ntzani%2CEE&author=Ioannidis%2CJP)\\n    \\n17.  Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. _Diabetologia_ **62**, 3–16 (2019).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-018-4711-2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30171279)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20trends%20in%20diabetes%20complications%3A%20a%20review%20of%20current%20evidence&journal=Diabetologia&doi=10.1007%2Fs00125-018-4711-2&volume=62&pages=3-16&publication_year=2019&author=Harding%2CJL&author=Pavkov%2CME&author=Magliano%2CDJ&author=Shaw%2CJE&author=Gregg%2CEW)\\n    \\n18.  Unal, B., Critchley, J. A. & Capewell, S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. _Circulation_ **109**, 1101–1107 (2004).\\n    \\n    [Article](https://doi.org/10.1161%2F01.CIR.0000118498.35499.B2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14993137)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Explaining%20the%20decline%20in%20coronary%20heart%20disease%20mortality%20in%20England%20and%20Wales%20between%201981%20and%202000&journal=Circulation&doi=10.1161%2F01.CIR.0000118498.35499.B2&volume=109&pages=1101-1107&publication_year=2004&author=Unal%2CB&author=Critchley%2CJA&author=Capewell%2CS)\\n    \\n19.  Pearson-Stuttard, J., Ezzati, M. & Gregg, E. W. Multimorbidity — a defining challenge for health systems. _Lancet Public. Health_ **4**, e599–e600 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2FS2468-2667%2819%2930222-1)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31812234)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multimorbidity%20%E2%80%94%20a%20defining%20challenge%20for%20health%20systems&journal=Lancet%20Public.%20Health&doi=10.1016%2FS2468-2667%2819%2930222-1&volume=4&pages=e599-e600&publication_year=2019&author=Pearson-Stuttard%2CJ&author=Ezzati%2CM&author=Gregg%2CEW)\\n    \\n20.  Lee, L., Cheung, W. Y., Atkinson, E. & Krzyzanowska, M. K. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. _J. Clin. Oncol._ **29**, 106–117 (2011).\\n    \\n    [Article](https://doi.org/10.1200%2FJCO.2010.31.3049)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21098314)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20comorbidity%20on%20chemotherapy%20use%20and%20outcomes%20in%20solid%20tumors%3A%20a%20systematic%20review&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2010.31.3049&volume=29&pages=106-117&publication_year=2011&author=Lee%2CL&author=Cheung%2CWY&author=Atkinson%2CE&author=Krzyzanowska%2CMK)\\n    \\n21.  Srokowski, T. P., Fang, S., Hortobagyi, G. N. & Giordano, S. H. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. _J. Clin. Oncol._ **27**, 2170–2176 (2009).\\n    \\n    [Article](https://doi.org/10.1200%2FJCO.2008.17.5935)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19307509)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674004)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20diabetes%20mellitus%20on%20complications%20and%20outcomes%20of%20adjuvant%20chemotherapy%20in%20older%20patients%20with%20breast%20cancer&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2008.17.5935&volume=27&pages=2170-2176&publication_year=2009&author=Srokowski%2CTP&author=Fang%2CS&author=Hortobagyi%2CGN&author=Giordano%2CSH)\\n    \\n22.  Gross, C. P., McAvay, G. J., Guo, Z. & Tinetti, M. E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. _Cancer_ **109**, 2410–2419 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fcncr.22726)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17510973)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20impact%20of%20chronic%20illnesses%20on%20the%20use%20and%20effectiveness%20of%20adjuvant%20chemotherapy%20for%20colon%20cancer&journal=Cancer&doi=10.1002%2Fcncr.22726&volume=109&pages=2410-2419&publication_year=2007&author=Gross%2CCP&author=McAvay%2CGJ&author=Guo%2CZ&author=Tinetti%2CME)\\n    \\n23.  Harding, J. L. et al. All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. _Int. J. Cancer_ **131**, 2385–2393 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.27503)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XksFCktLk%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22362309)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=All-cause%20cancer%20mortality%20over%2015%20years%20in%20multi-ethnic%20Mauritius%3A%20the%20impact%20of%20diabetes%20and%20intermediate%20forms%20of%20glucose%20tolerance&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.27503&volume=131&pages=2385-2393&publication_year=2012&author=Harding%2CJL)\\n    \\n24.  Wang, C. et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. _Int. J. Cancer_ **130**, 1639–1648 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.26165)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xhtl2gsbc%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21544812)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Increased%20risk%20of%20hepatocellular%20carcinoma%20in%20patients%20with%20diabetes%20mellitus%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.26165&volume=130&pages=1639-1648&publication_year=2012&author=Wang%2CC)\\n    \\n25.  El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. _Clin. Gastroenterol. Hepatol._ **4**, 369–380 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cgh.2005.12.007)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16527702)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20diabetes%20and%20hepatocellular%20carcinoma%3A%20a%20systematic%20review%20of%20epidemiologic%20evidence&journal=Clin.%20Gastroenterol.%20Hepatol.&doi=10.1016%2Fj.cgh.2005.12.007&volume=4&pages=369-380&publication_year=2006&author=El-Serag%2CHB&author=Hampel%2CH&author=Javadi%2CF)\\n    \\n26.  Desbois, A. C. & Cacoub, P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. _World J. Gastroenterol._ **23**, 1697–1711 (2017).\\n    \\n    [Article](https://doi.org/10.3748%2Fwjg.v23.i9.1697)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXjs12itb4%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28321170)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340821)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%2C%20insulin%20resistance%20and%20hepatitis%20C%20virus%20infection%3A%20a%20contemporary%20review&journal=World%20J.%20Gastroenterol.&doi=10.3748%2Fwjg.v23.i9.1697&volume=23&pages=1697-1711&publication_year=2017&author=Desbois%2CAC&author=Cacoub%2CP)\\n    \\n27.  Huxley, R., Ansary-Moghaddam, A., Berrington De González, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. _Br. J. Cancer_ **92**, 2076–2083 (2005).\\n    \\n    [Article](https://doi.org/10.1038%2Fsj.bjc.6602619)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2M3ot1Kjug%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15886696)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361795)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type-II%20diabetes%20and%20pancreatic%20cancer%3A%20a%20meta-analysis%20of%2036%20studies&journal=Br.%20J.%20Cancer&doi=10.1038%2Fsj.bjc.6602619&volume=92&pages=2076-2083&publication_year=2005&author=Huxley%2CR&author=Ansary-Moghaddam%2CA&author=Berrington%20De%20Gonz%C3%A1lez%2CA&author=Barzi%2CF&author=Woodward%2CM)\\n    \\n28.  Gullo, L. et al. Diabetes and the risk of pancreatic cancer. _N. Engl. J. Med._ **331**, 81–84 (1994).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM199407143310203)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK2c3mvVGhug%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8208269)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20pancreatic%20cancer&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM199407143310203&volume=331&pages=81-84&publication_year=1994&author=Gullo%2CL)\\n    \\n29.  Gershell, L. Type 2 diabetes market. _Nat. Rev. Drug Discov._ **4**, 367–368 (2005).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrd1723)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXjs1OktLg%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15902771)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20market&journal=Nat.%20Rev.%20Drug%20Discov.&doi=10.1038%2Fnrd1723&volume=4&pages=367-368&publication_year=2005&author=Gershell%2CL)\\n    \\n30.  Carstensen, B. et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. _Diabetologia_ **59**, 980–988 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-016-3884-9)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xjs1altbw%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26924393)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826427)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer%20incidence%20in%20persons%20with%20type%201%20diabetes%3A%20a%20five-country%20study%20of%209%2C000%20cancers%20in%20type%201%20diabetic%20individuals&journal=Diabetologia&doi=10.1007%2Fs00125-016-3884-9&volume=59&pages=980-988&publication_year=2016&author=Carstensen%2CB)\\n    \\n31.  Jiang, Y. et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. _Eur. J. Epidemiol._ **26**, 863–876 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10654-011-9617-y)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21938478)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20incidence%20and%20mortality%20of%20colorectal%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Eur.%20J.%20Epidemiol.&doi=10.1007%2Fs10654-011-9617-y&volume=26&pages=863-876&publication_year=2011&author=Jiang%2CY)\\n    \\n32.  De Bruijn, K. M. J. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. _Br. J. Surg._ **100**, 1421–1429 (2013).\\n    \\n    [Article](https://doi.org/10.1002%2Fbjs.9229)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24037561)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Systematic%20review%20and%20meta-analysis%20of%20the%20association%20between%20diabetes%20mellitus%20and%20incidence%20and%20mortality%20in%20breast%20and%20colorectal%20cancer&journal=Br.%20J.%20Surg.&doi=10.1002%2Fbjs.9229&volume=100&pages=1421-1429&publication_year=2013&author=Bruijn%2CKMJ)\\n    \\n33.  Deng, L., Gui, Z., Zhao, L., Wang, J. & Shen, L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. _Dig. Dis. Sci._ **57**, 1576–1585 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10620-012-2055-1)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xns1Sjsrg%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22350783)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20the%20incidence%20of%20colorectal%20cancer%3A%20an%20updated%20systematic%20review%20and%20meta-analysis&journal=Dig.%20Dis.%20Sci.&doi=10.1007%2Fs10620-012-2055-1&volume=57&pages=1576-1585&publication_year=2012&author=Deng%2CL&author=Gui%2CZ&author=Zhao%2CL&author=Wang%2CJ&author=Shen%2CL)\\n    \\n34.  Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D. & Zeidan, A. M. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. _Gynecol. Oncol._ **135**, 163–171 (2014).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ygyno.2014.07.095)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25072931)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404750)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Is%20diabetes%20mellitus%20associated%20with%20increased%20incidence%20and%20disease-specific%20mortality%20in%20endometrial%20cancer%3F%20A%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Gynecol.%20Oncol.&doi=10.1016%2Fj.ygyno.2014.07.095&volume=135&pages=163-171&publication_year=2014&author=Liao%2CC&author=Zhang%2CD&author=Mungo%2CC&author=Andrew%20Tompkins%2CD&author=Zeidan%2CAM)\\n    \\n35.  Saed, L. et al. The effect of diabetes on the risk of endometrial cancer: an updated a systematic review and meta-analysis. _BMC Cancer_ **19**, 527 (2019).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12885-019-5748-4)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31151429)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544993)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20diabetes%20on%20the%20risk%20of%20endometrial%20cancer%3A%20an%20updated%20a%20systematic%20review%20and%20meta-analysis&journal=BMC%20Cancer&doi=10.1186%2Fs12885-019-5748-4&volume=19&publication_year=2019&author=Saed%2CL)\\n    \\n36.  Friberg, E., Orsini, N., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. _Diabetologia_ **50**, 1365–1374 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-007-0681-5)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2szjslCjsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17476474)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20endometrial%20cancer%3A%20A%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-007-0681-5&volume=50&pages=1365-1374&publication_year=2007&author=Friberg%2CE&author=Orsini%2CN&author=Mantzoros%2CCS&author=Wolk%2CA)\\n    \\n37.  Anothaisintawee, T. et al. Risk factors of breast cancer: a systematic review and meta-analysis. _Asia-Pac. J. Public Health_ **25**, 368–387 (2013).\\n    \\n    [Article](https://doi.org/10.1177%2F1010539513488795)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23709491)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20of%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Asia-Pac.%20J.%20Public%20Health&doi=10.1177%2F1010539513488795&volume=25&pages=368-387&publication_year=2013&author=Anothaisintawee%2CT)\\n    \\n38.  Larsson, S. C., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. _Int. J. Cancer_ **121**, 856–862 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.22717)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXotlequ7w%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17397032)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20breast%20cancer%3A%20a%20meta-analysis&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.22717&volume=121&pages=856-862&publication_year=2007&author=Larsson%2CSC&author=Mantzoros%2CCS&author=Wolk%2CA)\\n    \\n39.  Boyle, P. et al. Diabetes and breast cancer risk: a meta-analysis. _Br. J. Cancer_ **107**, 1608–1617 (2012).\\n    \\n    [Article](https://doi.org/10.1038%2Fbjc.2012.414)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38bosl2gsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22996614)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493760)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20breast%20cancer%20risk%3A%20a%20meta-analysis&journal=Br.%20J.%20Cancer&doi=10.1038%2Fbjc.2012.414&volume=107&pages=1608-1617&publication_year=2012&author=Boyle%2CP)\\n    \\n40.  Rinaldi, S. et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. _Int. J. Cancer_ **118**, 2832–2839 (2006).\\n    \\n    [Article](https://doi.org/10.1002%2Fijc.21730)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xks1Sisb4%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16385576)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Anthropometric%20measures%2C%20endogenous%20sex%20steroids%20and%20breast%20cancer%20risk%20in%20postmenopausal%20women%3A%20a%20study%20within%20the%20EPIC%20cohort&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.21730&volume=118&pages=2832-2839&publication_year=2006&author=Rinaldi%2CS)\\n    \\n41.  Michels, K. B. et al. Type 2 diabetes and subsequent incidence of breast cancer in the nurses’ health study. _Diabetes Care_ **26**, 1752–1758 (2003).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiacare.26.6.1752)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12766105)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20subsequent%20incidence%20of%20breast%20cancer%20in%20the%20nurses%E2%80%99%20health%20study&journal=Diabetes%20Care&doi=10.2337%2Fdiacare.26.6.1752&volume=26&pages=1752-1758&publication_year=2003&author=Michels%2CKB)\\n    \\n42.  Bronsveld, H. K. et al. Diabetes and breast cancer subtypes. _PLoS ONE_ **12**, e0170084 (2017).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0170084)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28076434)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226802)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXnslGku74%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20breast%20cancer%20subtypes&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0170084&volume=12&publication_year=2017&author=Bronsveld%2CHK)\\n    \\n43.  Zhang, D., Li, N., Xi, Y., Zhao, Y. & Wang, T. Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies. _Diabetes Res. Clin. Pract._ **130**, 43–52 (2017).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2017.04.005)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28554142)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20ovarian%20cancer.%20A%20systematic%20review%20and%20meta-analysis%20of%2015%20cohort%20studies&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2017.04.005&volume=130&pages=43-52&publication_year=2017&author=Zhang%2CD&author=Li%2CN&author=Xi%2CY&author=Zhao%2CY&author=Wang%2CT)\\n    \\n44.  Weng, L., Wang, L., Zhang, J., Wang, B. & Liu, H. Association between diabetes mellitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. _Medicine_ **96**, e6396 (2017).\\n    \\n    [Article](https://doi.org/10.1097%2FMD.0000000000006396)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20mellitus%20and%20subsequent%20ovarian%20cancer%20in%20women%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20studies&journal=Medicine&doi=10.1097%2FMD.0000000000006396&volume=96&publication_year=2017&author=Weng%2CL&author=Wang%2CL&author=Zhang%2CJ&author=Wang%2CB&author=Liu%2CH)\\n    \\n45.  Wang, L., Zhong, L., Xu, B., Chen, M. & Huang, H. Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies. _BMJ Open_ **10**, e040137 (2020).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmjopen-2020-040137)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33376163)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778773)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20the%20risk%20of%20ovarian%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cohort%20and%20case-control%20studies&journal=BMJ%20Open&doi=10.1136%2Fbmjopen-2020-040137&volume=10&publication_year=2020&author=Wang%2CL&author=Zhong%2CL&author=Xu%2CB&author=Chen%2CM&author=Huang%2CH)\\n    \\n46.  Lee, J. Y. et al. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. _Int. J. Gynecol. Cancer_ **23**, 402–412 (2013).\\n    \\n    [Article](https://doi.org/10.1097%2FIGC.0b013e31828189b2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23354371)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20ovarian%20cancer%20risk%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20observational%20studies&journal=Int.%20J.%20Gynecol.%20Cancer&doi=10.1097%2FIGC.0b013e31828189b2&volume=23&pages=402-412&publication_year=2013&author=Lee%2CJY)\\n    \\n47.  Bonovas, S., Filioussi, K. & Tsantes, A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. _Diabetologia_ **47**, 1071–1078 (2004).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-004-1415-6)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2czhvVCksg%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15164171)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20prostate%20cancer%3A%20a%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-004-1415-6&volume=47&pages=1071-1078&publication_year=2004&author=Bonovas%2CS&author=Filioussi%2CK&author=Tsantes%2CA)\\n    \\n48.  Shikata, K., Ninomiya, T. & Kiyohara, Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. _Cancer Sci._ **104**, 9–14 (2013).\\n    \\n    [Article](https://doi.org/10.1111%2Fcas.12043)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXls1Gmtw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23066889)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20cancer%20risk%3A%20review%20of%20the%20epidemiological%20evidence&journal=Cancer%20Sci.&doi=10.1111%2Fcas.12043&volume=104&pages=9-14&publication_year=2013&author=Shikata%2CK&author=Ninomiya%2CT&author=Kiyohara%2CY)\\n    \\n49.  Long, X. J., Lin, S., Sun, Y. N. & Zheng, Z. F. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. _Asian Pac. J. Cancer Preven._ **13**, 4097–4100 (2012).\\n    \\n    [Article](https://doi.org/10.7314%2FAPJCP.2012.13.8.4097)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20prostate%20cancer%20risk%20in%20Asian%20countries%3A%20a%20meta-analysis&journal=Asian%20Pac.%20J.%20Cancer%20Preven.&doi=10.7314%2FAPJCP.2012.13.8.4097&volume=13&pages=4097-4100&publication_year=2012&author=Long%2CXJ&author=Lin%2CS&author=Sun%2CYN&author=Zheng%2CZF)\\n    \\n50.  Rhee, E. J. Diabetes in Asians. _Endocrinol. Metab._ **30**, 263–269 (2015).\\n    \\n    [Article](https://doi.org/10.3803%2FEnM.2015.30.3.263)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsFSgur4%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20in%20Asians&journal=Endocrinol.%20Metab.&doi=10.3803%2FEnM.2015.30.3.263&volume=30&pages=263-269&publication_year=2015&author=Rhee%2CEJ)\\n    \\n51.  Bensimon, L., Yin, H., Suissa, S., Pollak, M. N. & Azoulay, L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. _Cancer Causes Control._ **25**, 329–338 (2014).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s10552-013-0334-6)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24384808)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20the%20risk%20of%20mortality%20among%20patients%20with%20prostate%20cancer&journal=Cancer%20Causes%20Control.&doi=10.1007%2Fs10552-013-0334-6&volume=25&pages=329-338&publication_year=2014&author=Bensimon%2CL&author=Yin%2CH&author=Suissa%2CS&author=Pollak%2CMN&author=Azoulay%2CL)\\n    \\n52.  Johnson, J. A., Bowker, S. L., Richardson, K. & Marra, C. A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. _Diabetologia_ **54**, 2263–2271 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-011-2242-1)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3MjjsFamug%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21748485)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Time-varying%20incidence%20of%20cancer%20after%20the%20onset%20of%20type%202%20diabetes%3A%20evidence%20of%20potential%20detection%20bias&journal=Diabetologia&doi=10.1007%2Fs00125-011-2242-1&volume=54&pages=2263-2271&publication_year=2011&author=Johnson%2CJA&author=Bowker%2CSL&author=Richardson%2CK&author=Marra%2CCA)\\n    \\n53.  Johnson, J. A. et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. _Diabetologia_ **55**, 1607–1618 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-012-2525-1)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xms1yqtb4%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22476947)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20cancer%20%281%29%3A%20evaluating%20the%20temporal%20relationship%20between%20type%202%20diabetes%20and%20cancer%20incidence&journal=Diabetologia&doi=10.1007%2Fs00125-012-2525-1&volume=55&pages=1607-1618&publication_year=2012&author=Johnson%2CJA)\\n    \\n54.  Harding, J. L., Shaw, J. E., Peeters, A., Cartensen, B. & Magliano, D. J. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. _Diabetes Care_ **38**, 264–270 (2015).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc14-1996)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488912)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer%20risk%20among%20people%20with%20type%201%20and%20type%202%20diabetes%3A%20disentangling%20true%20associations%2C%20detection%20bias%2C%20and%20reverse%20causation&journal=Diabetes%20Care&doi=10.2337%2Fdc14-1996&volume=38&pages=264-270&publication_year=2015&author=Harding%2CJL&author=Shaw%2CJE&author=Peeters%2CA&author=Cartensen%2CB&author=Magliano%2CDJ)\\n    \\n55.  Pearson-Stuttard, J. et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. _Lancet Diabetes Endocrinol._ **6**, e6–e15 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2818%2930150-5)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29803268)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982644)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Worldwide%20burden%20of%20cancer%20attributable%20to%20diabetes%20and%20high%20body-mass%20index%3A%20a%20comparative%20risk%20assessment&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2818%2930150-5&volume=6&pages=e6-e15&publication_year=2018&author=Pearson-Stuttard%2CJ)\\n    \\n56.  Larsson, S. C. & Wolk, A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. _Diabetologia_ **54**, 1013–1018 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-011-2051-6)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3MvhtlGrtg%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21274512)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20incidence%20of%20kidney%20cancer%3A%20a%20meta-analysis%20of%20cohort%20studies&journal=Diabetologia&doi=10.1007%2Fs00125-011-2051-6&volume=54&pages=1013-1018&publication_year=2011&author=Larsson%2CSC&author=Wolk%2CA)\\n    \\n57.  Xu, X. et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. _PLoS ONE_ **8**, e58079 (2013).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0058079)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23472134)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589481)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20bladder%20cancer%3A%20a%20meta-analysis%20of%20cohort%20studies&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0058079&volume=8&publication_year=2013&author=Xu%2CX)\\n    \\n58.  Gong, I. Y. et al. Association between diabetes and haematological malignancies: a population-based study. _Diabetologia_ **64**, 540–551 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-020-05338-7)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFGntLw%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33409570)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20and%20haematological%20malignancies%3A%20a%20population-based%20study&journal=Diabetologia&doi=10.1007%2Fs00125-020-05338-7&volume=64&pages=540-551&publication_year=2021&author=Gong%2CIY)\\n    \\n59.  Giovannucci, E. et al. Diabetes and cancer: a consensus report. _Diabetes Care_ **33**, 1674–1685 (2010).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc10-0666)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20587728)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890380)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20cancer%3A%20a%20consensus%20report&journal=Diabetes%20Care&doi=10.2337%2Fdc10-0666&volume=33&pages=1674-1685&publication_year=2010&author=Giovannucci%2CE)\\n    \\n60.  Weinstein, D., Simon, M., Yehezkel, E., Laron, Z. & Werner, H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. _Diabetes Metab. Res. Rev._ **25**, 41–49 (2009).\\n    \\n    [Article](https://doi.org/10.1002%2Fdmrr.912)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXivFWjurg%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19145584)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Insulin%20analogues%20display%20IGF-I-like%20mitogenic%20and%20anti-apoptotic%20activities%20in%20cultured%20cancer%20cells&journal=Diabetes%20Metab.%20Res.%20Rev.&doi=10.1002%2Fdmrr.912&volume=25&pages=41-49&publication_year=2009&author=Weinstein%2CD&author=Simon%2CM&author=Yehezkel%2CE&author=Laron%2CZ&author=Werner%2CH)\\n    \\n61.  Najjar, S. M. & Perdomo, G. Hepatic insulin clearance: mechanism and physiology. _Physiology_ **34**, 198–215 (2019).\\n    \\n    [Article](https://doi.org/10.1152%2Fphysiol.00048.2018)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslKrs7vF)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30968756)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734066)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hepatic%20insulin%20clearance%3A%20mechanism%20and%20physiology&journal=Physiology&doi=10.1152%2Fphysiol.00048.2018&volume=34&pages=198-215&publication_year=2019&author=Najjar%2CSM&author=Perdomo%2CG)\\n    \\n62.  Lorenzi, M., Montisano, D. F., Toledo, S. & Barrieux, A. High glucose induces DNA damage in cultured human endothelial cells. _J. Clin. Invest._ **77**, 322–325 (1986).\\n    \\n    [Article](https://doi.org/10.1172%2FJCI112295)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaL28XhtVOht70%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3944257)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC423344)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=High%20glucose%20induces%20DNA%20damage%20in%20cultured%20human%20endothelial%20cells&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI112295&volume=77&pages=322-325&publication_year=1986&author=Lorenzi%2CM&author=Montisano%2CDF&author=Toledo%2CS&author=Barrieux%2CA)\\n    \\n63.  Robertson, R., Zhou, H., Zhang, T. & Harmon, J. S. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. _Cell Biochem. Biophys._ **48**, 139–146 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s12013-007-0026-5)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXosV2gtrc%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17709883)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Chronic%20oxidative%20stress%20as%20a%20mechanism%20for%20glucose%20toxicity%20of%20the%20beta%20cell%20in%20type%202%20diabetes&journal=Cell%20Biochem.%20Biophys.&doi=10.1007%2Fs12013-007-0026-5&volume=48&pages=139-146&publication_year=2007&author=Robertson%2CR&author=Zhou%2CH&author=Zhang%2CT&author=Harmon%2CJS)\\n    \\n64.  Turturro, F., Friday, E. & Welbourne, T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. _BMC Cancer_ **7**, 96 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/1471-2407-7-96)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17555594)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906826)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXnslCku7g%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20regulates%20thioredoxin-ROS%20activity%20through%20induction%20of%20thioredoxin-interacting%20protein%20%28TXNIP%29%20in%20metastatic%20breast%20cancer-derived%20cells%20MDA-MB-231&journal=BMC%20Cancer&doi=10.1186%2F1471-2407-7-96&volume=7&publication_year=2007&author=Turturro%2CF&author=Friday%2CE&author=Welbourne%2CT)\\n    \\n65.  Wu, Y., Liu, Y., Dong, Y. & Vadgama, J. Diabetes-associated dysregulated cytokines and cancer. _Integr. Cancer Sci. Ther._ **3**, 370–378 (2016).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29930868)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007890)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes-associated%20dysregulated%20cytokines%20and%20cancer&journal=Integr.%20Cancer%20Sci.%20Ther.&volume=3&pages=370-378&publication_year=2016&author=Wu%2CY&author=Liu%2CY&author=Dong%2CY&author=Vadgama%2CJ)\\n    \\n66.  Inoki, K., Kim, J. & Guan, K. L. AMPK and mTOR in cellular energy homeostasis and drug targets. _Annu. Rev. Pharmacol. Toxicol._ **52**, 381–400 (2012).\\n    \\n    [Article](https://doi.org/10.1146%2Fannurev-pharmtox-010611-134537)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjsV2nt7c%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22017684)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=AMPK%20and%20mTOR%20in%20cellular%20energy%20homeostasis%20and%20drug%20targets&journal=Annu.%20Rev.%20Pharmacol.%20Toxicol.&doi=10.1146%2Fannurev-pharmtox-010611-134537&volume=52&pages=381-400&publication_year=2012&author=Inoki%2CK&author=Kim%2CJ&author=Guan%2CKL)\\n    \\n67.  Huang, X., Liu, G., Guo, J. & Su, Z. Q. The PI3K/AKT pathway in obesity and type 2 diabetes. _Int. J. Biol. Sci._ **14**, 1483–1496 (2018).\\n    \\n    [Article](https://doi.org/10.7150%2Fijbs.27173)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVyqsbbJ)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30263000)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158718)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20PI3K%2FAKT%20pathway%20in%20obesity%20and%20type%202%20diabetes&journal=Int.%20J.%20Biol.%20Sci.&doi=10.7150%2Fijbs.27173&volume=14&pages=1483-1496&publication_year=2018&author=Huang%2CX&author=Liu%2CG&author=Guo%2CJ&author=Su%2CZQ)\\n    \\n68.  Zhao, Y. et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. _Gynecol. Endocrinol._ **34**, 428–432 (2018).\\n    \\n    [Article](https://doi.org/10.1080%2F09513590.2017.1409714)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFaht7jN)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29182407)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20is%20associated%20with%20reduced%20cell%20proliferation%20in%20human%20endometrial%20cancer%20by%20inbibiting%20PI3K%2FAKT%2FmTOR%20signaling&journal=Gynecol.%20Endocrinol.&doi=10.1080%2F09513590.2017.1409714&volume=34&pages=428-432&publication_year=2018&author=Zhao%2CY)\\n    \\n69.  Knapp, S. Diabetes and infection: is there a link?-A mini-review. _Gerontology_ **59**, 99–104 (2013).\\n    \\n    [Article](https://doi.org/10.1159%2F000345107)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXjslOhur8%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23182884)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20infection%3A%20is%20there%20a%20link%3F-A%20mini-review&journal=Gerontology&doi=10.1159%2F000345107&volume=59&pages=99-104&publication_year=2013&author=Knapp%2CS)\\n    \\n70.  Fang, M. et al. Diabetes and the risk of hospitalisation for infection: the atherosclerosis risk in communities (ARIC) study. _Diabetologia_ **64**, 2458–2465 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-021-05522-3)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitVSktrjO)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34345973)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331324)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20hospitalisation%20for%20infection%3A%20the%20atherosclerosis%20risk%20in%20communities%20%28ARIC%29%20study&journal=Diabetologia&doi=10.1007%2Fs00125-021-05522-3&volume=64&pages=2458-2465&publication_year=2021&author=Fang%2CM)\\n    \\n71.  Tseng, C.-H. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus. _Sci. Rep._ **11**, 12400 (2021).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-021-91902-z)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34117321)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195989)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsF2it7jN)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20use%20is%20associated%20with%20a%20reduced%20risk%20of%20acute%20appendicitis%20in%20Taiwanese%20patients%20with%20type%202%20diabetes%20mellitus&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-021-91902-z&volume=11&publication_year=2021&author=Tseng%2CC-H)\\n    \\n72.  Luk, A. O. Y. et al. Temporal trends in rates of infection-related hospitalisations in Hong Kong people with and without diabetes, 2001–2016: a retrospective study. _Diabetologia_ **64**, 109–118 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-020-05286-2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32986145)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Temporal%20trends%20in%20rates%20of%20infection-related%20hospitalisations%20in%20Hong%20Kong%20people%20with%20and%20without%20diabetes%2C%202001%E2%80%932016%3A%20a%20retrospective%20study&journal=Diabetologia&doi=10.1007%2Fs00125-020-05286-2&volume=64&pages=109-118&publication_year=2021&author=Luk%2CAOY)\\n    \\n73.  Magliano, D. J. et al. Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes. _Diabetes Care_ **38**, 1274–1280 (2015).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc14-2820)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26070592)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Excess%20risk%20of%20dying%20from%20infectious%20causes%20in%20those%20with%20type%201%20and%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc14-2820&volume=38&pages=1274-1280&publication_year=2015&author=Magliano%2CDJ)\\n    \\n74.  Martin, E. T. et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. _Infect. Control. Hosp. Epidemiol._ **37**, 88–99 (2016).\\n    \\n    [Article](https://doi.org/10.1017%2Fice.2015.249)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26503187)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20risk%20of%20surgical%20site%20infection%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Infect.%20Control.%20Hosp.%20Epidemiol.&doi=10.1017%2Fice.2015.249&volume=37&pages=88-99&publication_year=2016&author=Martin%2CET)\\n    \\n75.  Trussell, J. et al. Impact of a patient care pathway protocol on surgical site infection rates in cardiothoracic surgery patients. _Am. J. Surg._ **196**, 883–889 (2008).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.amjsurg.2008.07.024)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19095104)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20a%20patient%20care%20pathway%20protocol%20on%20surgical%20site%20infection%20rates%20in%20cardiothoracic%20surgery%20patients&journal=Am.%20J.%20Surg.&doi=10.1016%2Fj.amjsurg.2008.07.024&volume=196&pages=883-889&publication_year=2008&author=Trussell%2CJ)\\n    \\n76.  Coleman, J. S. et al. Surgical site infections after hysterectomy among HIV-infected women in the HAART era: a single institution’s experience from 1999–2012. _Am. J. Obstet. Gynecol._ **210**, 117.e111–117.e117 (2014).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ajog.2013.08.037)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Surgical%20site%20infections%20after%20hysterectomy%20among%20HIV-infected%20women%20in%20the%20HAART%20era%3A%20a%20single%20institution%E2%80%99s%20experience%20from%201999%E2%80%932012&journal=Am.%20J.%20Obstet.%20Gynecol.&doi=10.1016%2Fj.ajog.2013.08.037&volume=210&pages=117.e111-117.e117&publication_year=2014&author=Coleman%2CJS)\\n    \\n77.  Friedman, N. D., Sexton, D. J., Connelly, S. M. & Kaye, K. S. Risk factors for surgical site infection complicating laminectomy. _Infect. Control. Hosp. Epidemiol._ **28**, 1060–1065 (2007).\\n    \\n    [Article](https://doi.org/10.1086%2F519864)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17932827)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20for%20surgical%20site%20infection%20complicating%20laminectomy&journal=Infect.%20Control.%20Hosp.%20Epidemiol.&doi=10.1086%2F519864&volume=28&pages=1060-1065&publication_year=2007&author=Friedman%2CND&author=Sexton%2CDJ&author=Connelly%2CSM&author=Kaye%2CKS)\\n    \\n78.  Apicella, M. et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. _Lancet Diabetes Endocrinol._ **8**, 782–792 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930238-2)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWgs7jM)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32687793)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367664)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=COVID-19%20in%20people%20with%20diabetes%3A%20understanding%20the%20reasons%20for%20worse%20outcomes&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930238-2&volume=8&pages=782-792&publication_year=2020&author=Apicella%2CM)\\n    \\n79.  McGurnaghan, S. J. et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. _Lancet Diabetes Endocrinol._ **9**, 82–93 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930405-8)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXks1aqsA%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33357491)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risks%20of%20and%20risk%20factors%20for%20COVID-19%20disease%20in%20people%20with%20diabetes%3A%20a%20cohort%20study%20of%20the%20total%20population%20of%20Scotland&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930405-8&volume=9&pages=82-93&publication_year=2021&author=McGurnaghan%2CSJ)\\n    \\n80.  Rawshani, A. et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. _Lancet Reg. Health Eur._ **4**, 100105 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.lanepe.2021.100105)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33969336)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086507)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Severe%20COVID-19%20in%20people%20with%20type%201%20and%20type%202%20diabetes%20in%20Sweden%3A%20a%20nationwide%20retrospective%20cohort%20study&journal=Lancet%20Reg.%20Health%20Eur.&doi=10.1016%2Fj.lanepe.2021.100105&volume=4&publication_year=2021&author=Rawshani%2CA)\\n    \\n81.  You, J. H. et al. Clinical outcomes of COVID-19 patients with type 2 diabetes: a population-based study in Korea. _Endocrinol. Metab._ **35**, 901–908 (2020).\\n    \\n    [Article](https://doi.org/10.3803%2FEnM.2020.787)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvFKrsLc%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20outcomes%20of%20COVID-19%20patients%20with%20type%202%20diabetes%3A%20a%20population-based%20study%20in%20Korea&journal=Endocrinol.%20Metab.&doi=10.3803%2FEnM.2020.787&volume=35&pages=901-908&publication_year=2020&author=You%2CJH)\\n    \\n82.  Moon, S. J. et al. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. _Diabetes Metab. J._ **44**, 737–746 (2020).\\n    \\n    [Article](https://doi.org/10.4093%2Fdmj.2020.0141)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33115212)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643598)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Independent%20impact%20of%20diabetes%20on%20the%20severity%20of%20coronavirus%20disease%202019%20in%205%2C307%20patients%20in%20South%20Korea%3A%20a%20nationwide%20cohort%20study&journal=Diabetes%20Metab.%20J.&doi=10.4093%2Fdmj.2020.0141&volume=44&pages=737-746&publication_year=2020&author=Moon%2CSJ)\\n    \\n83.  Aranjani, J. M., Manuel, A., Razack, H. I. A. & Mathew, S. T. Covid-19–associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. _PLoS. Negl. Trop. Dis._ **15**, e0009921 (2021).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pntd.0009921)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1yks7bL)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34793455)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601521)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Covid-19%E2%80%93associated%20mucormycosis%3A%20evidence-based%20critical%20review%20of%20an%20emerging%20infection%20burden%20during%20the%20pandemic%E2%80%99s%20second%20wave%20in%20India&journal=PLoS.%20Negl.%20Trop.%20Dis.&doi=10.1371%2Fjournal.pntd.0009921&volume=15&publication_year=2021&author=Aranjani%2CJM&author=Manuel%2CA&author=Razack%2CHIA&author=Mathew%2CST)\\n    \\n84.  Crankson, S., Pokhrel, S. & Anokye, N. K. Determinants of COVID-19-related length of hospital stays and long COVID in Ghana: a cross-sectional analysis. _Int. J. Environ. Res. Public Health_ **19**, 527 (2022).\\n    \\n    [Article](https://doi.org/10.3390%2Fijerph19010527)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVeksrg%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35010786)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744866)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Determinants%20of%20COVID-19-related%20length%20of%20hospital%20stays%20and%20long%20COVID%20in%20Ghana%3A%20a%20cross-sectional%20analysis&journal=Int.%20J.%20Environ.%20Res.%20Public%20Health&doi=10.3390%2Fijerph19010527&volume=19&publication_year=2022&author=Crankson%2CS&author=Pokhrel%2CS&author=Anokye%2CNK)\\n    \\n85.  Bellan, M. et al. Respiratory and psychophysical sequelae among patients with covid-19 four months after hospital discharge. _JAMA Netw. Open_ **4**, e2036142 (2021).\\n    \\n    [Article](https://doi.org/10.1001%2Fjamanetworkopen.2020.36142)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33502487)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841464)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Respiratory%20and%20psychophysical%20sequelae%20among%20patients%20with%20covid-19%20four%20months%20after%20hospital%20discharge&journal=JAMA%20Netw.%20Open&doi=10.1001%2Fjamanetworkopen.2020.36142&volume=4&publication_year=2021&author=Bellan%2CM)\\n    \\n86.  Gottesman, B. L., Yu, J., Tanaka, C., Longhurst, C. A. & Kim, J. J. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. _JAMA Pediatr._ **176**, 414–415 (2022).\\n    \\n    [Article](https://doi.org/10.1001%2Fjamapediatrics.2021.5801)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35072727)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Incidence%20of%20new-onset%20type%201%20diabetes%20among%20US%20children%20during%20the%20COVID-19%20global%20pandemic&journal=JAMA%20Pediatr.&doi=10.1001%2Fjamapediatrics.2021.5801&volume=176&pages=414-415&publication_year=2022&author=Gottesman%2CBL&author=Yu%2CJ&author=Tanaka%2CC&author=Longhurst%2CCA&author=Kim%2CJJ)\\n    \\n87.  Barrett, C. E. et al. Risk for newly diagnosed diabetes <30 days after SARS-CoV-2 infection among persons aged \\\\>18 years-United States, March 1, 2020-June 28, 2021. _Morb. Mortal. Wkly. Rep._ **71**, 59–65 (2022).\\n    \\n    [Article](https://doi.org/10.15585%2Fmmwr.mm7102e2)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xjt1yntLc%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20for%20newly%20diagnosed%20diabetes%20%3C30%20days%20after%20SARS-CoV-2%20infection%20among%20persons%20aged%20%3E18%20years-United%20States%2C%20March%201%2C%202020-June%2028%2C%202021&journal=Morb.%20Mortal.%20Wkly.%20Rep.&doi=10.15585%2Fmmwr.mm7102e2&volume=71&pages=59-65&publication_year=2022&author=Barrett%2CCE)\\n    \\n88.  Kornum, J. B. et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. _Diabetes Care_ **31**, 1541–1545 (2008).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc08-0138)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18487479)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494631)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%2C%20glycemic%20control%2C%20and%20risk%20of%20hospitalization%20with%20pneumonia%3A%20a%20population-based%20case-control%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc08-0138&volume=31&pages=1541-1545&publication_year=2008&author=Kornum%2CJB)\\n    \\n89.  Matsuyama, R., Nishiura, H., Kutsuna, S., Hayakawa, K. & Ohmagari, N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. _BMC Public Health_ **16**, 1203 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12889-016-3881-4)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27899100)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129628)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20determinants%20of%20the%20severity%20of%20Middle%20East%20respiratory%20syndrome%20%28MERS%29%3A%20a%20systematic%20review%20and%20meta-analysis&journal=BMC%20Public%20Health&doi=10.1186%2Fs12889-016-3881-4&volume=16&publication_year=2016&author=Matsuyama%2CR&author=Nishiura%2CH&author=Kutsuna%2CS&author=Hayakawa%2CK&author=Ohmagari%2CN)\\n    \\n90.  Badawi, A. & Ryoo, S. G. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. _Int. J. Infect. Dis._ **49**, 129–133 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.ijid.2016.06.015)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27352628)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110556)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20comorbidities%20in%20the%20Middle%20East%20respiratory%20syndrome%20coronavirus%20%28MERS-CoV%29%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Int.%20J.%20Infect.%20Dis.&doi=10.1016%2Fj.ijid.2016.06.015&volume=49&pages=129-133&publication_year=2016&author=Badawi%2CA&author=Ryoo%2CSG)\\n    \\n91.  Badawi, A. & Ryoo, S. G. Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis. _J. Public. Health Res._ **5**, 130–138 (2016).\\n    \\n    [Article](https://doi.org/10.4081%2Fjphr.2016.733)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20diabetes%20in%20the%202009%20influenza%20A%20%28H1N1%29%20and%20the%20middle%20east%20respiratory%20syndrome%20coronavirus%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Public.%20Health%20Res.&doi=10.4081%2Fjphr.2016.733&volume=5&pages=130-138&publication_year=2016&author=Badawi%2CA&author=Ryoo%2CSG)\\n    \\n92.  Yang, J. K. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. _Diabet. Med._ **23**, 623–628 (2006).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1464-5491.2006.01861.x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xnt1Ciu7Y%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16759303)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Plasma%20glucose%20levels%20and%20diabetes%20are%20independent%20predictors%20for%20mortality%20and%20morbidity%20in%20patients%20with%20SARS&journal=Diabet.%20Med.&doi=10.1111%2Fj.1464-5491.2006.01861.x&volume=23&pages=623-628&publication_year=2006&author=Yang%2CJK)\\n    \\n93.  Ehrlich, S. F., Quesenberry, C. P. Jr, Van Den Eeden, S. K., Shan, J. & Ferrara, A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. _Diabetes Care_ **33**, 55–60 (2010).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc09-0880)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19808918)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Patients%20diagnosed%20with%20diabetes%20are%20at%20increased%20risk%20for%20asthma%2C%20chronic%20obstructive%20pulmonary%20disease%2C%20pulmonary%20fibrosis%2C%20and%20pneumonia%20but%20not%20lung%20cancer&journal=Diabetes%20Care&doi=10.2337%2Fdc09-0880&volume=33&pages=55-60&publication_year=2010&author=Ehrlich%2CSF&author=Quesenberry%2CCP&author=Eeden%2CSK&author=Shan%2CJ&author=Ferrara%2CA)\\n    \\n94.  Alraddadi, B. M. et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. _Emerg. Infect. Dis._ **22**, 49–55 (2016).\\n    \\n    [Article](https://doi.org/10.3201%2Feid2201.151340)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXmvFWgsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26692185)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696714)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20for%20primary%20middle%20east%20respiratory%20syndrome%20coronavirus%20illness%20in%20humans%2C%20Saudi%20Arabia%2C%202014&journal=Emerg.%20Infect.%20Dis.&doi=10.3201%2Feid2201.151340&volume=22&pages=49-55&publication_year=2016&author=Alraddadi%2CBM)\\n    \\n95.  Geerlings, S. E. & Hoepelman, A. I. M. Immune dysfunction in patients with diabetes mellitus (DM). _FEMS Immunol. Med. Microbiol._ **26**, 259–265 (1999).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1574-695X.1999.tb01397.x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXnsVKntLc%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10575137)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Immune%20dysfunction%20in%20patients%20with%20diabetes%20mellitus%20%28DM%29&journal=FEMS%20Immunol.%20Med.%20Microbiol.&doi=10.1111%2Fj.1574-695X.1999.tb01397.x&volume=26&pages=259-265&publication_year=1999&author=Geerlings%2CSE&author=Hoepelman%2CAIM)\\n    \\n96.  Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The role of interleukin 6 during viral infections. _Front. Microbiol._ **10**, 1057 (2019).\\n    \\n    [Article](https://doi.org/10.3389%2Ffmicb.2019.01057)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31134045)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524401)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20interleukin%206%20during%20viral%20infections&journal=Front.%20Microbiol.&doi=10.3389%2Ffmicb.2019.01057&volume=10&publication_year=2019&author=Velazquez-Salinas%2CL&author=Verdugo-Rodriguez%2CA&author=Rodriguez%2CLL&author=Borca%2CMV)\\n    \\n97.  Joshi, N., Caputo, G. M., Weitekamp, M. R. & Karchmer, A. W. Infections in patients with diabetes mellitus. _N. Engl. J. Med._ **341**, 1906–1912 (1999).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM199912163412507)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3c%2Fks1Gksw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10601511)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Infections%20in%20patients%20with%20diabetes%20mellitus&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM199912163412507&volume=341&pages=1906-1912&publication_year=1999&author=Joshi%2CN&author=Caputo%2CGM&author=Weitekamp%2CMR&author=Karchmer%2CAW)\\n    \\n98.  Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-dependent axis. _Cell Metab._ **32**, 437–446.e435 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cmet.2020.07.007)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWgs77O)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32697943)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367032)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Elevated%20glucose%20levels%20favor%20SARS-CoV-2%20infection%20and%20monocyte%20response%20through%20a%20HIF-1%CE%B1%2FGlycolysis-dependent%20axis&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2020.07.007&volume=32&pages=437-446.e435&publication_year=2020&author=Codo%2CAC)\\n    \\n99.  Miyazawa, T., Nakagawa, K., Shimasaki, S. & Nagai, R. Lipid glycation and protein glycation in diabetes and atherosclerosis. _Amino Acids_ **42**, 1163–1170 (2012).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00726-010-0772-3)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjsVWhsrg%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20957396)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipid%20glycation%20and%20protein%20glycation%20in%20diabetes%20and%20atherosclerosis&journal=Amino%20Acids&doi=10.1007%2Fs00726-010-0772-3&volume=42&pages=1163-1170&publication_year=2012&author=Miyazawa%2CT&author=Nakagawa%2CK&author=Shimasaki%2CS&author=Nagai%2CR)\\n    \\n100.  Peleg, A. Y., Weerarathna, T., McCarthy, J. S. & Davis, T. M. E. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. _Diabetes Metab. Res. Rev._ **23**, 3–13 (2007).\\n    \\n    [Article](https://doi.org/10.1002%2Fdmrr.682)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXitFSmsLY%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16960917)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Common%20infections%20in%20diabetes%3A%20pathogenesis%2C%20management%20and%20relationship%20to%20glycaemic%20control&journal=Diabetes%20Metab.%20Res.%20Rev.&doi=10.1002%2Fdmrr.682&volume=23&pages=3-13&publication_year=2007&author=Peleg%2CAY&author=Weerarathna%2CT&author=McCarthy%2CJS&author=Davis%2CTME)\\n    \\n101.  Barda, N., Dagan, N. & Balicer, R. D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. reply. _N. Engl. J. Med._ **384**, 1970 (2021).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33882227)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=BNT162b2%20mRNA%20Covid-19%20vaccine%20in%20a%20nationwide%20mass%20vaccination%20setting.%20reply&journal=N.%20Engl.%20J.%20Med.&volume=384&publication_year=2021&author=Barda%2CN&author=Dagan%2CN&author=Balicer%2CRD)\\n    \\n102.  Cholankeril, G. & Ahmed, A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. _Clin. Gastroenterol. Hepatol._ **16**, 1356–1358 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.cgh.2017.11.045)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29199144)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alcoholic%20liver%20disease%20replaces%20hepatitis%20C%20virus%20infection%20as%20the%20leading%20indication%20for%20liver%20transplantation%20in%20the%20United%20States&journal=Clin.%20Gastroenterol.%20Hepatol.&doi=10.1016%2Fj.cgh.2017.11.045&volume=16&pages=1356-1358&publication_year=2018&author=Cholankeril%2CG&author=Ahmed%2CA)\\n    \\n103.  Fink, M. & Byrne, M. Australia and New Zealand Liver and Intestinal Transplant Registry Annual Report 2019 (Melbourne, Victoria, Australia, 2019).\\n    \\n104.  Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. _J. Hepatol._ **71**, 313–322 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2019.04.011)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31071367)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656693)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Outcomes%20of%20liver%20transplantation%20for%20non-alcoholic%20steatohepatitis%3A%20a%20European%20liver%20transplant%20registry%20study&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2019.04.011&volume=71&pages=313-322&publication_year=2019&author=Haldar%2CD)\\n    \\n105.  Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. _J. Hepatol._ **71**, 793–801 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2019.06.021)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31279902)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20global%20epidemiology%20of%20NAFLD%20and%20NASH%20in%20patients%20with%20type%202%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2019.06.021&volume=71&pages=793-801&publication_year=2019&author=Younossi%2CZM)\\n    \\n106.  Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. _Hepatology_ **64**, 73–84 (2016).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.28431)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26707365)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20epidemiology%20of%20nonalcoholic%20fatty%20liver%20disease-Meta-analytic%20assessment%20of%20prevalence%2C%20incidence%2C%20and%20outcomes&journal=Hepatology&doi=10.1002%2Fhep.28431&volume=64&pages=73-84&publication_year=2016&author=Younossi%2CZM)\\n    \\n107.  Pang, Y. et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. _Hepatology_ **68**, 1308–1318 (2018).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.30083)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVKqt7vL)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29734463)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%2C%20plasma%20glucose%2C%20and%20incidence%20of%20fatty%20liver%2C%20cirrhosis%2C%20and%20liver%20cancer%3A%20a%20prospective%20study%20of%200.5%20million%20people&journal=Hepatology&doi=10.1002%2Fhep.30083&volume=68&pages=1308-1318&publication_year=2018&author=Pang%2CY)\\n    \\n108.  Li, Y. et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. _PLoS ONE_ **12**, e0174291 (2017).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0174291)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28350839)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369778)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXovVSh)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Bidirectional%20association%20between%20nonalcoholic%20fatty%20liver%20disease%20and%20type%202%20diabetes%20in%20Chinese%20population%3A%20evidence%20from%20the%20Dongfeng-Tongji%20cohort%20study&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0174291&volume=12&publication_year=2017&author=Li%2CY)\\n    \\n109.  Mansour-Ghanaei, F. et al. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran. _Diabetes Metab. Syndr._ **13**, 1591–1596 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.dsx.2019.03.009)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31336526)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20non-alcoholic%20fatty%20liver%20disease%20in%20patients%20with%20diabetes%20mellitus%2C%20hyperlipidemia%2C%20obesity%20and%20polycystic%20ovary%20syndrome%3A%20a%20cross-sectional%20study%20in%20north%20of%20Iran&journal=Diabetes%20Metab.%20Syndr.&doi=10.1016%2Fj.dsx.2019.03.009&volume=13&pages=1591-1596&publication_year=2019&author=Mansour-Ghanaei%2CF)\\n    \\n110.  Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. _Liver Int._ **29**, 113–119 (2009).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1478-3231.2008.01718.x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhvVGmtLk%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18384521)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20and%20associated%20factors%20of%20non-alcoholic%20fatty%20liver%20disease%20in%20patients%20with%20type-2%20diabetes%20mellitus&journal=Liver%20Int.&doi=10.1111%2Fj.1478-3231.2008.01718.x&volume=29&pages=113-119&publication_year=2009&author=Leite%2CNC&author=Salles%2CGF&author=Araujo%2CAL&author=Villela-Nogueira%2CCA&author=Cardoso%2CCR)\\n    \\n111.  Singh, S. P. et al. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study. _J. Clin. Exp. Hepatol._ **5**, 295–302 (2015).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jceh.2015.09.001)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26900270)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723647)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20associated%20with%20non-alcoholic%20fatty%20liver%20disease%20in%20Indians%3A%20a%20case-control%20study&journal=J.%20Clin.%20Exp.%20Hepatol.&doi=10.1016%2Fj.jceh.2015.09.001&volume=5&pages=295-302&publication_year=2015&author=Singh%2CSP)\\n    \\n112.  Dufour, J.-F. et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–a targeted literature review. _Endocr. Metab. Sci._ **3**, 100089 (2021).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.endmts.2021.100089)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xht12nt7nM)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20global%20epidemiology%20of%20nonalcoholic%20steatohepatitis%20%28NASH%29%20and%20associated%20risk%20factors%E2%80%93a%20targeted%20literature%20review&journal=Endocr.%20Metab.%20Sci.&doi=10.1016%2Fj.endmts.2021.100089&volume=3&publication_year=2021&author=Dufour%2CJ-F)\\n    \\n113.  Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. _Hepatology_ **56**, 943–951 (2012).\\n    \\n    [Article](https://doi.org/10.1002%2Fhep.25772)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22505194)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%2C%20family%20history%20of%20diabetes%2C%20and%20risk%20of%20nonalcoholic%20steatohepatitis%20and%20fibrosis&journal=Hepatology&doi=10.1002%2Fhep.25772&volume=56&pages=943-951&publication_year=2012&author=Loomba%2CR)\\n    \\n114.  Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. _Nat. Rev. Gastroenterol. Hepatol._ **10**, 330–344 (2013).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrgastro.2013.41)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXptVOlsrs%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23507799)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Progression%20of%20NAFLD%20to%20diabetes%20mellitus%2C%20cardiovascular%20disease%20or%20cirrhosis&journal=Nat.%20Rev.%20Gastroenterol.%20Hepatol.&doi=10.1038%2Fnrgastro.2013.41&volume=10&pages=330-344&publication_year=2013&author=Anstee%2CQM&author=Targher%2CG&author=Day%2CCP)\\n    \\n115.  Holstein, A., Hinze, S., Thießen, E., Plaschke, A. & Egberts, E. H. Clinical implications of hepatogenous diabetes in liver cirrhosis. _J. Gastroenterol. Hepatol._ **17**, 677–681 (2002).\\n    \\n    [Article](https://doi.org/10.1046%2Fj.1440-1746.2002.02755.x)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12100613)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20implications%20of%20hepatogenous%20diabetes%20in%20liver%20cirrhosis&journal=J.%20Gastroenterol.%20Hepatol.&doi=10.1046%2Fj.1440-1746.2002.02755.x&volume=17&pages=677-681&publication_year=2002&author=Holstein%2CA&author=Hinze%2CS&author=Thie%C3%9Fen%2CE&author=Plaschke%2CA&author=Egberts%2CEH)\\n    \\n116.  Del Vecchio Blanco, C., Gentile, S., Marmo, R., Carbone, L. & Coltorti, M. Alterations of glucose metabolism in chronic liver disease. _Diabetes Res. Clin. Pract._ **8**, 29–36 (1990).\\n    \\n    [Article](https://doi.org/10.1016%2F0168-8227%2890%2990093-9)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2153513)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alterations%20of%20glucose%20metabolism%20in%20chronic%20liver%20disease&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2F0168-8227%2890%2990093-9&volume=8&pages=29-36&publication_year=1990&author=Vecchio%20Blanco%2CC&author=Gentile%2CS&author=Marmo%2CR&author=Carbone%2CL&author=Coltorti%2CM)\\n    \\n117.  Zein, N. N., Abdulkarim, A. S., Wiesner, R. H., Egan, K. S. & Persing, D. H. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. _J. Hepatol._ **32**, 209–217 (2000).\\n    \\n    [Article](https://doi.org/10.1016%2FS0168-8278%2800%2980065-3)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3c7ntVWgsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10707860)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20diabetes%20mellitus%20in%20patients%20with%20end-stage%20liver%20cirrhosis%20due%20to%20hepatitis%20C%2C%20alcohol%2C%20or%20cholestatic%20disease&journal=J.%20Hepatol.&doi=10.1016%2FS0168-8278%2800%2980065-3&volume=32&pages=209-217&publication_year=2000&author=Zein%2CNN&author=Abdulkarim%2CAS&author=Wiesner%2CRH&author=Egan%2CKS&author=Persing%2CDH)\\n    \\n118.  Niederau, C. et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. _N. Engl. J. Med._ **313**, 1256–1262 (1985).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJM198511143132004)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL28%2FktVansw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=4058506)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Survival%20and%20causes%20of%20death%20in%20cirrhotic%20and%20in%20noncirrhotic%20patients%20with%20primary%20hemochromatosis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM198511143132004&volume=313&pages=1256-1262&publication_year=1985&author=Niederau%2CC)\\n    \\n119.  Larter, C. Z. & Farrell, G. C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? _J. Hepatol._ **44**, 253–261 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jhep.2005.11.030)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16364488)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Insulin%20resistance%2C%20adiponectin%2C%20cytokines%20in%20NASH%3A%20which%20is%20the%20best%20target%20to%20treat%3F&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2005.11.030&volume=44&pages=253-261&publication_year=2006&author=Larter%2CCZ&author=Farrell%2CGC)\\n    \\n120.  Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. _Am. J. Med._ **107**, 450–455 (1999).\\n    \\n    [Article](https://doi.org/10.1016%2FS0002-9343%2899%2900271-5)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1MXnvFymurc%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10569299)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20nonalcoholic%20fatty%20liver%20disease%20with%20insulin%20resistance&journal=Am.%20J.%20Med.&doi=10.1016%2FS0002-9343%2899%2900271-5&volume=107&pages=450-455&publication_year=1999&author=Marchesini%2CG)\\n    \\n121.  Angulo, P. Medical progress: nonalcoholic fatty liver disease. _N. Engl. J. Med._ **346**, 1221–1231 (2002).\\n    \\n    [Article](https://doi.org/10.1056%2FNEJMra011775)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XivVOmsrY%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11961152)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Medical%20progress%3A%20nonalcoholic%20fatty%20liver%20disease&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMra011775&volume=346&pages=1221-1231&publication_year=2002&author=Angulo%2CP)\\n    \\n122.  Porepa, L., Ray, J. G., Sanchez-Romeu, P. & Booth, G. L. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. _CMAJ_ **182**, E526–E531 (2010).\\n    \\n    [Article](https://doi.org/10.1503%2Fcmaj.092144)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20566726)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917963)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Newly%20diagnosed%20diabetes%20mellitus%20as%20a%20risk%20factor%20for%20serious%20liver%20disease&journal=CMAJ&doi=10.1503%2Fcmaj.092144&volume=182&pages=E526-E531&publication_year=2010&author=Porepa%2CL&author=Ray%2CJG&author=Sanchez-Romeu%2CP&author=Booth%2CGL)\\n    \\n123.  Stefan, N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. _Lancet Diabetes Endocrinol._ **8**, 616–627 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2820%2930110-8)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32559477)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Causes%2C%20consequences%2C%20and%20treatment%20of%20metabolically%20unhealthy%20fat%20distribution&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2820%2930110-8&volume=8&pages=616-627&publication_year=2020&author=Stefan%2CN)\\n    \\n124.  Stefan, N., Häring, H. U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. _Lancet Diabetes Endocrinol._ **7**, 313–324 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2818%2930154-2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30174213)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Non-alcoholic%20fatty%20liver%20disease%3A%20causes%2C%20diagnosis%2C%20cardiometabolic%20consequences%2C%20and%20treatment%20strategies&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2818%2930154-2&volume=7&pages=313-324&publication_year=2019&author=Stefan%2CN&author=H%C3%A4ring%2CHU&author=Cusi%2CK)\\n    \\n125.  Sattar, N. & Gill, J. M. R. Type 2 diabetes as a disease of ectopic fat? _BMC Med._ **12**, 123 (2014).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s12916-014-0123-4)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25159817)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143560)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20as%20a%20disease%20of%20ectopic%20fat%3F&journal=BMC%20Med.&doi=10.1186%2Fs12916-014-0123-4&volume=12&publication_year=2014&author=Sattar%2CN&author=Gill%2CJMR)\\n    \\n126.  Harding, K. A. et al. Depression prevalence in type 2 diabetes is not related to diabetes–depression symptom overlap but is related to symptom dimensions within patient self-report measures: a meta-analysis. _Diabet. Med._ **36**, 1600–1611 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fdme.14139)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXit1Oju73O)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31532013)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Depression%20prevalence%20in%20type%202%20diabetes%20is%20not%20related%20to%20diabetes%E2%80%93depression%20symptom%20overlap%20but%20is%20related%20to%20symptom%20dimensions%20within%20patient%20self-report%20measures%3A%20a%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fdme.14139&volume=36&pages=1600-1611&publication_year=2019&author=Harding%2CKA)\\n    \\n127.  Lim, G. Y. et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. _Sci. Rep._ **8**, 2861 (2018).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-018-21243-x)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29434331)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809481)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhs1CltbnO)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20depression%20in%20the%20community%20from%2030%20countries%20between%201994%20and%202014&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-018-21243-x&volume=8&publication_year=2018&author=Lim%2CGY)\\n    \\n128.  Roy, T. & Lloyd, C. E. Epidemiology of depression and diabetes: a systematic review. _J. Affect. Disord._ **142**, S8–S21 (2012).\\n    \\n    [Article](https://doi.org/10.1016%2FS0165-0327%2812%2970004-6)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23062861)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Epidemiology%20of%20depression%20and%20diabetes%3A%20a%20systematic%20review&journal=J.%20Affect.%20Disord.&doi=10.1016%2FS0165-0327%2812%2970004-6&volume=142&pages=S8-S21&publication_year=2012&author=Roy%2CT&author=Lloyd%2CCE)\\n    \\n129.  Rotella, F. & Mannucci, E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. _Diabetes Res. Clin. Pract._ **99**, 98–104 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2012.11.022)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3s3ksVejtA%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23265924)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20as%20a%20risk%20factor%20for%20depression.%20A%20meta-analysis%20of%20longitudinal%20studies&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2012.11.022&volume=99&pages=98-104&publication_year=2013&author=Rotella%2CF&author=Mannucci%2CE)\\n    \\n130.  Nouwen, A. et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. _Diabetologia_ **53**, 2480–2486 (2010).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-010-1874-x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3cbnsVWmsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20711716)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974923)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20mellitus%20as%20a%20risk%20factor%20for%20the%20onset%20of%20depression%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Diabetologia&doi=10.1007%2Fs00125-010-1874-x&volume=53&pages=2480-2486&publication_year=2010&author=Nouwen%2CA)\\n    \\n131.  Grigsby, A. B., Anderson, R. J., Freedland, K. E., Clouse, R. E. & Lustman, P. J. Prevalence of anxiety in adults with diabetes a systematic review. _J. Psychosom. Res._ **53**, 1053–1060 (2002).\\n    \\n    [Article](https://doi.org/10.1016%2FS0022-3999%2802%2900417-8)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12479986)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20anxiety%20in%20adults%20with%20diabetes%20a%20systematic%20review&journal=J.%20Psychosom.%20Res.&doi=10.1016%2FS0022-3999%2802%2900417-8&volume=53&pages=1053-1060&publication_year=2002&author=Grigsby%2CAB&author=Anderson%2CRJ&author=Freedland%2CKE&author=Clouse%2CRE&author=Lustman%2CPJ)\\n    \\n132.  Smith, K. J. et al. Association of diabetes with anxiety: a systematic review and meta-analysis. _J. Psychosom. Res._ **74**, 89–99 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jpsychores.2012.11.013)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23332522)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20diabetes%20with%20anxiety%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Psychosom.%20Res.&doi=10.1016%2Fj.jpsychores.2012.11.013&volume=74&pages=89-99&publication_year=2013&author=Smith%2CKJ)\\n    \\n133.  Young, V. et al. Eating problems in adolescents with type1 diabetes: a systematic review with meta-analysis. _Diabet. Med._ **30**, 189–198 (2013).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1464-5491.2012.03771.x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38bgsVWktQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22913589)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Eating%20problems%20in%20adolescents%20with%20type1%20diabetes%3A%20a%20systematic%20review%20with%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fj.1464-5491.2012.03771.x&volume=30&pages=189-198&publication_year=2013&author=Young%2CV)\\n    \\n134.  Schabert, J., Browne, J. L., Mosely, K. & Speight, J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. _Patient_ **6**, 1–10 (2013).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s40271-012-0001-0)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23322536)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Social%20stigma%20in%20diabetes%3A%20a%20framework%20to%20understand%20a%20growing%20problem%20for%20an%20increasing%20epidemic&journal=Patient&doi=10.1007%2Fs40271-012-0001-0&volume=6&pages=1-10&publication_year=2013&author=Schabert%2CJ&author=Browne%2CJL&author=Mosely%2CK&author=Speight%2CJ)\\n    \\n135.  Barnard, K. D., Speight, J. & Skinner, T. C. Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents. _Pract. Diabetes Int._ **25**, 278–283 (2008).\\n    \\n    [Article](https://doi.org/10.1002%2Fpdi.1280)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Quality%20of%20life%20and%20impact%20of%20continuous%20subcutaneous%20insulin%20infusion%20for%20children%20and%20their%20parents&journal=Pract.%20Diabetes%20Int.&doi=10.1002%2Fpdi.1280&volume=25&pages=278-283&publication_year=2008&author=Barnard%2CKD&author=Speight%2CJ&author=Skinner%2CTC)\\n    \\n136.  Hagger, V., Hendrieckx, C., Sturt, J., Skinner, T. C. & Speight, J. Diabetes distress among adolescents with type 1 diabetes: a systematic review. _Curr. Diabetes Rep._ **16**, 1–14 (2016).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s11892-015-0694-2)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20distress%20among%20adolescents%20with%20type%201%20diabetes%3A%20a%20systematic%20review&journal=Curr.%20Diabetes%20Rep.&doi=10.1007%2Fs11892-015-0694-2&volume=16&pages=1-14&publication_year=2016&author=Hagger%2CV&author=Hendrieckx%2CC&author=Sturt%2CJ&author=Skinner%2CTC&author=Speight%2CJ)\\n    \\n137.  Abdoli, S. et al. New insights into diabetes burnout and its distinction from diabetes distress and depressive symptoms: a qualitative study. _Diabetes Res. Clin. Pract._ **169**, 108446 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2020.108446)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32946853)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20insights%20into%20diabetes%20burnout%20and%20its%20distinction%20from%20diabetes%20distress%20and%20depressive%20symptoms%3A%20a%20qualitative%20study&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2020.108446&volume=169&publication_year=2020&author=Abdoli%2CS)\\n    \\n138.  Pickup, J. C. & Crook, M. A. Is type II diabetes mellitus a disease of the innate immune system? _Diabetologia_ **41**, 1241–1248 (1998).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s001250051058)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK1cXmtlais70%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9794114)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Is%20type%20II%20diabetes%20mellitus%20a%20disease%20of%20the%20innate%20immune%20system%3F&journal=Diabetologia&doi=10.1007%2Fs001250051058&volume=41&pages=1241-1248&publication_year=1998&author=Pickup%2CJC&author=Crook%2CMA)\\n    \\n139.  Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. _Nat. Rev. Neurosci._ **9**, 46–56 (2008).\\n    \\n    [Article](https://doi.org/10.1038%2Fnrn2297)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhsVGjsbfJ)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18073775)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919277)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=From%20inflammation%20to%20sickness%20and%20depression%3A%20when%20the%20immune%20system%20subjugates%20the%20brain&journal=Nat.%20Rev.%20Neurosci.&doi=10.1038%2Fnrn2297&volume=9&pages=46-56&publication_year=2008&author=Dantzer%2CR&author=O%E2%80%99Connor%2CJC&author=Freund%2CGG&author=Johnson%2CRW&author=Kelley%2CKW)\\n    \\n140.  Prestele, S., Aldenhoff, J. & Reiff, J. \\\\[The HPA-axis as a possible link between depression, diabetes mellitus and cognitive dysfunction\\\\]. _Fortschr. Neurol. Psychiatr._ **71**, 24–36 (2003).\\n    \\n    [Article](https://doi.org/10.1055%2Fs-2003-36684)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3s%2Fit1Oqtw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12529832)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=%5BThe%20HPA-axis%20as%20a%20possible%20link%20between%20depression%2C%20diabetes%20mellitus%20and%20cognitive%20dysfunction%5D&journal=Fortschr.%20Neurol.%20Psychiatr.&doi=10.1055%2Fs-2003-36684&volume=71&pages=24-36&publication_year=2003&author=Prestele%2CS&author=Aldenhoff%2CJ&author=Reiff%2CJ)\\n    \\n141.  Cole, J., Costafreda, S. G., McGuffin, P. & Fu, C. H. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. _J. Affect. Disord._ **134**, 483–487 (2011).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jad.2011.05.057)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21745692)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hippocampal%20atrophy%20in%20first%20episode%20depression%3A%20a%20meta-analysis%20of%20magnetic%20resonance%20imaging%20studies&journal=J.%20Affect.%20Disord.&doi=10.1016%2Fj.jad.2011.05.057&volume=134&pages=483-487&publication_year=2011&author=Cole%2CJ&author=Costafreda%2CSG&author=McGuffin%2CP&author=Fu%2CCH)\\n    \\n142.  Gold, S. M. et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. _Diabetologia_ **50**, 711–719 (2007).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-007-0602-7)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD2s7js1Wjuw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17334649)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hippocampal%20damage%20and%20memory%20impairments%20as%20possible%20early%20brain%20complications%20of%20type%202%20diabetes&journal=Diabetologia&doi=10.1007%2Fs00125-007-0602-7&volume=50&pages=711-719&publication_year=2007&author=Gold%2CSM)\\n    \\n143.  Moulton, C. D., Costafreda, S. G., Horton, P., Ismail, K. & Fu, C. H. Y. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. _Brain Imaging Behav._ **9**, 651–662 (2015).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s11682-014-9348-2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25563229)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Meta-analyses%20of%20structural%20regional%20cerebral%20effects%20in%20type%201%20and%20type%202%20diabetes&journal=Brain%20Imaging%20Behav.&doi=10.1007%2Fs11682-014-9348-2&volume=9&pages=651-662&publication_year=2015&author=Moulton%2CCD&author=Costafreda%2CSG&author=Horton%2CP&author=Ismail%2CK&author=Fu%2CCHY)\\n    \\n144.  Khalil, M., Power, N., Graham, E., Deschênes, S. S. & Schmitz, N. The association between sleep and diabetes outcomes – systematic review. _Diabetes Res. Clin. Pract._ **161**, 108035 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2020.108035)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32006640)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20sleep%20and%20diabetes%20outcomes%20%E2%80%93%20systematic%20review&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2020.108035&volume=161&publication_year=2020&author=Khalil%2CM&author=Power%2CN&author=Graham%2CE&author=Desch%C3%AAnes%2CSS&author=Schmitz%2CN)\\n    \\n145.  Senaratna, C. V. et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. _Sleep. Med. Rev._ **34**, 70–81 (2017).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.smrv.2016.07.002)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27568340)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20obstructive%20sleep%20apnea%20in%20the%20general%20population%3A%20a%20systematic%20review&journal=Sleep.%20Med.%20Rev.&doi=10.1016%2Fj.smrv.2016.07.002&volume=34&pages=70-81&publication_year=2017&author=Senaratna%2CCV)\\n    \\n146.  Subramanian, A. et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. _Diabetes Care_ **42**, 954–963 (2019).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc18-2004)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1KitrfP)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30862657)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20of%20incident%20obstructive%20sleep%20apnea%20among%20patients%20with%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc18-2004&volume=42&pages=954-963&publication_year=2019&author=Subramanian%2CA)\\n    \\n147.  Huang, T. et al. A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective U.S. Cohorts. _Diabetes Care_ **41**, 2111–2119 (2018).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc18-0675)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXjslyls7s%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30072403)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150434)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20population-based%20study%20of%20the%20bidirectional%20association%20between%20obstructive%20sleep%20apnea%20and%20type%202%20diabetes%20in%20three%20prospective%20U.S.%20Cohorts&journal=Diabetes%20Care&doi=10.2337%2Fdc18-0675&volume=41&pages=2111-2119&publication_year=2018&author=Huang%2CT)\\n    \\n148.  Reutrakul, S. et al. Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. _Sleep. Med._ **23**, 26–45 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.sleep.2016.03.019)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27692274)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sleep%20characteristics%20in%20type%201%20diabetes%20and%20associations%20with%20glycemic%20control%3A%20systematic%20review%20and%20meta-analysis&journal=Sleep.%20Med.&doi=10.1016%2Fj.sleep.2016.03.019&volume=23&pages=26-45&publication_year=2016&author=Reutrakul%2CS)\\n    \\n149.  Nagayoshi, M. et al. Obstructive sleep apnea and incident type 2 diabetes. _Sleep. Med._ **25**, 156–161 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.sleep.2016.05.009)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27810258)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102826)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnea%20and%20incident%20type%202%20diabetes&journal=Sleep.%20Med.&doi=10.1016%2Fj.sleep.2016.05.009&volume=25&pages=156-161&publication_year=2016&author=Nagayoshi%2CM)\\n    \\n150.  Ficker, J. H. et al. Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. _Eur. Respir. J._ **11**, 14–19 (1998).\\n    \\n    [Article](https://doi.org/10.1183%2F09031936.98.11010014)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DyaK1c3gt1altw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9543264)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnoea%20and%20diabetes%20mellitus%3A%20the%20role%20of%20cardiovascular%20autonomic%20neuropathy&journal=Eur.%20Respir.%20J.&doi=10.1183%2F09031936.98.11010014&volume=11&pages=14-19&publication_year=1998&author=Ficker%2CJH)\\n    \\n151.  Young, T., Peppard, P. E. & Taheri, S. Excess weight and sleep-disordered breathing. _J. Appl. Physiol._ **99**, 1592–1599 (2005).\\n    \\n    [Article](https://doi.org/10.1152%2Fjapplphysiol.00587.2005)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16160020)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Excess%20weight%20and%20sleep-disordered%20breathing&journal=J.%20Appl.%20Physiol.&doi=10.1152%2Fjapplphysiol.00587.2005&volume=99&pages=1592-1599&publication_year=2005&author=Young%2CT&author=Peppard%2CPE&author=Taheri%2CS)\\n    \\n152.  Ip, M. S. M. et al. Obstructive sleep apnea is independently associated with insulin resistance. _Am. J. Respir. Crit. Care Med._ **165**, 670–676 (2002).\\n    \\n    [Article](https://doi.org/10.1164%2Fajrccm.165.5.2103001)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11874812)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obstructive%20sleep%20apnea%20is%20independently%20associated%20with%20insulin%20resistance&journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&doi=10.1164%2Fajrccm.165.5.2103001&volume=165&pages=670-676&publication_year=2002&author=Ip%2CMSM)\\n    \\n153.  Shaw, J. E. et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. _Am. J. Respir. Crit. Care Med._ **194**, 486–492 (2016).\\n    \\n    [Article](https://doi.org/10.1164%2Frccm.201511-2260OC)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslaiu7%2FL)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26926656)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20treatment%20of%20obstructive%20sleep%20apnea%20on%20glycemic%20control%20in%20type%202%20diabetes&journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&doi=10.1164%2Frccm.201511-2260OC&volume=194&pages=486-492&publication_year=2016&author=Shaw%2CJE)\\n    \\n154.  Lu, F. P., Lin, K. P. & Kuo, H. K. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. _PLoS ONE_ **4**, e4144 (2009).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0004144)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19127292)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607544)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsF2msLs%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20the%20risk%20of%20multi-system%20aging%20phenotypes%3A%20A%20systematic%20review%20and%20meta-analysis&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0004144&volume=4&publication_year=2009&author=Lu%2CFP&author=Lin%2CKP&author=Kuo%2CHK)\\n    \\n155.  Cheng, G., Huang, C., Deng, H. & Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. _Intern. Med. J._ **42**, 484–491 (2012).\\n    \\n    [Article](https://doi.org/10.1111%2Fj.1445-5994.2012.02758.x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC38vksFOltQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22372522)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20as%20a%20risk%20factor%20for%20dementia%20and%20mild%20cognitive%20impairment%3A%20a%20meta-analysis%20of%20longitudinal%20studies&journal=Intern.%20Med.%20J.&doi=10.1111%2Fj.1445-5994.2012.02758.x&volume=42&pages=484-491&publication_year=2012&author=Cheng%2CG&author=Huang%2CC&author=Deng%2CH&author=Wang%2CH)\\n    \\n156.  Li, X. Y. et al. Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. _Curr. Alzheimer Res._ **16**, 1254–1268 (2019).\\n    \\n    [Article](https://doi.org/10.2174%2F1567205017666200103111253)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31902364)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVamtbw%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Midlife%20modifiable%20risk%20factors%20for%20dementia%3A%20a%20systematic%20review%20and%20meta-analysis%20of%2034%20prospective%20cohort%20studies&journal=Curr.%20Alzheimer%20Res.&doi=10.2174%2F1567205017666200103111253&volume=16&pages=1254-1268&publication_year=2019&author=Li%2CXY)\\n    \\n157.  Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. _Ageing Res. Rev._ **55**, 100944 (2019).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.arr.2019.100944)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslSisLjM)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31430566)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risks%20of%20cognitive%20impairment%20and%20dementia%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20144%20prospective%20studies&journal=Ageing%20Res.%20Rev.&doi=10.1016%2Fj.arr.2019.100944&volume=55&publication_year=2019&author=Xue%2CM)\\n    \\n158.  Pal, K., Mukadam, N., Petersen, I. & Cooper, C. Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. _Soc. Psychiatry Psychiatr. Epidemiol._ **53**, 1149–1160 (2018).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00127-018-1581-3)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30182156)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208946)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mild%20cognitive%20impairment%20and%20progression%20to%20dementia%20in%20people%20with%20diabetes%2C%20prediabetes%20and%20metabolic%20syndrome%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Soc.%20Psychiatry%20Psychiatr.%20Epidemiol.&doi=10.1007%2Fs00127-018-1581-3&volume=53&pages=1149-1160&publication_year=2018&author=Pal%2CK&author=Mukadam%2CN&author=Petersen%2CI&author=Cooper%2CC)\\n    \\n159.  Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C. & Scheltens, P. Risk of dementia in diabetes mellitus: a systematic review. _Lancet Neurol._ **5**, 64–74 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2805%2970284-2)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16361024)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20of%20dementia%20in%20diabetes%20mellitus%3A%20a%20systematic%20review&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2805%2970284-2&volume=5&pages=64-74&publication_year=2006&author=Biessels%2CGJ&author=Staekenborg%2CS&author=Brunner%2CE&author=Brayne%2CC&author=Scheltens%2CP)\\n    \\n160.  Peila, R., Rodriguez, B. L. & Launer, L. J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. _Diabetes_ **51**, 1256–1262 (2002).\\n    \\n    [Article](https://doi.org/10.2337%2Fdiabetes.51.4.1256)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38Xis1Ois7Y%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11916953)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%2C%20APOE%20gene%2C%20and%20the%20risk%20for%20dementia%20and%20related%20pathologies%3A%20the%20Honolulu-Asia%20aging%20study&journal=Diabetes&doi=10.2337%2Fdiabetes.51.4.1256&volume=51&pages=1256-1262&publication_year=2002&author=Peila%2CR&author=Rodriguez%2CBL&author=Launer%2CLJ)\\n    \\n161.  Abner, E. L. et al. Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. _Alzheimer’s Dement._ **12**, 882–889 (2016).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.jalz.2015.12.006)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20is%20associated%20with%20cerebrovascular%20but%20not%20Alzheimer%E2%80%99s%20disease%20neuropathology&journal=Alzheimer%E2%80%99s%20Dement.&doi=10.1016%2Fj.jalz.2015.12.006&volume=12&pages=882-889&publication_year=2016&author=Abner%2CEL)\\n    \\n162.  Matioli, M. N. P. S. et al. Association between diabetes and causes of dementia: evidence from a clinicopathological study. _Dement. Neuropsychol._ **11**, 406–412 (2017).\\n    \\n    [Article](https://doi.org/10.1590%2F1980-57642016dn11-040010)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29354221)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769999)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20between%20diabetes%20and%20causes%20of%20dementia%3A%20evidence%20from%20a%20clinicopathological%20study&journal=Dement.%20Neuropsychol.&doi=10.1590%2F1980-57642016dn11-040010&volume=11&pages=406-412&publication_year=2017&author=Matioli%2CMNPS)\\n    \\n163.  You, Y. et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. _Acta Diabetol._ **58**, 671–685 (2021).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00592-020-01648-9)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33417039)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%20of%20mild%20cognitive%20impairment%20in%20type%202%20diabetes%20mellitus%20patients%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Acta%20Diabetol.&doi=10.1007%2Fs00592-020-01648-9&volume=58&pages=671-685&publication_year=2021&author=You%2CY)\\n    \\n164.  Langa, K. M. & Levine, D. A. The diagnosis and management of mild cognitive impairment: a clinical review. _JAMA_ **312**, 2551–2561 (2014).\\n    \\n    [Article](https://doi.org/10.1001%2Fjama.2014.13806)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXit1Ogt7Y%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25514304)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269302)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20diagnosis%20and%20management%20of%20mild%20cognitive%20impairment%3A%20a%20clinical%20review&journal=JAMA&doi=10.1001%2Fjama.2014.13806&volume=312&pages=2551-2561&publication_year=2014&author=Langa%2CKM&author=Levine%2CDA)\\n    \\n165.  Pelimanni, E. & Jehkonen, M. Type 2 diabetes and cognitive functions in middle age: a meta-analysis. _J. Int. Neuropsychol. Soc._ **25**, 215–229 (2019).\\n    \\n    [Article](https://doi.org/10.1017%2FS1355617718001042)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30575498)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20and%20cognitive%20functions%20in%20middle%20age%3A%20a%20meta-analysis&journal=J.%20Int.%20Neuropsychol.%20Soc.&doi=10.1017%2FS1355617718001042&volume=25&pages=215-229&publication_year=2019&author=Pelimanni%2CE&author=Jehkonen%2CM)\\n    \\n166.  Rom, S. et al. Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles. _Sci. Rep._ **10**, 7274 (2020).\\n    \\n    [Article](https://doi.org/10.1038%2Fs41598-020-64349-x)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXosVOksL4%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32350344)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190636)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20and%20advanced%20glycation%20end%20products%20disrupt%20BBB%20and%20promote%20occludin%20and%20claudin-5%20protein%20secretion%20on%20extracellular%20microvesicles&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-020-64349-x&volume=10&publication_year=2020&author=Rom%2CS)\\n    \\n167.  Hussain, B., Fang, C. & Chang, J. Blood–brain barrier breakdown: an emerging biomarker of cognitive impairment in normal aging and dementia. _Front. Neurosci._ **15**, 688090 (2021).\\n    \\n    [Article](https://doi.org/10.3389%2Ffnins.2021.688090)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34489623)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418300)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Blood%E2%80%93brain%20barrier%20breakdown%3A%20an%20emerging%20biomarker%20of%20cognitive%20impairment%20in%20normal%20aging%20and%20dementia&journal=Front.%20Neurosci.&doi=10.3389%2Ffnins.2021.688090&volume=15&publication_year=2021&author=Hussain%2CB&author=Fang%2CC&author=Chang%2CJ)\\n    \\n168.  Anstey, K. J., Sargent-Cox, K., Eramudugolla, R., Magliano, D. J. & Shaw, J. E. Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study. _Alzheimers Res. Ther._ **7**, 48 (2015).\\n    \\n    [Article](https://link.springer.com/doi/10.1186/s13195-015-0131-4)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26167206)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499451)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVGjsbjL)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20cognitive%20function%20with%20glucose%20tolerance%20and%20trajectories%20of%20glucose%20tolerance%20over%2012%20years%20in%20the%20AusDiab%20study&journal=Alzheimers%20Res.%20Ther.&doi=10.1186%2Fs13195-015-0131-4&volume=7&publication_year=2015&author=Anstey%2CKJ&author=Sargent-Cox%2CK&author=Eramudugolla%2CR&author=Magliano%2CDJ&author=Shaw%2CJE)\\n    \\n169.  Steen, E. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease - Is this type 3 diabetes? _J. Alzheimer’s Dis._ **7**, 63–80 (2005).\\n    \\n    [Article](https://doi.org/10.3233%2FJAD-2005-7107)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhvVSrtL8%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impaired%20insulin%20and%20insulin-like%20growth%20factor%20expression%20and%20signaling%20mechanisms%20in%20Alzheimer%E2%80%99s%20disease%20-%20Is%20this%20type%203%20diabetes%3F&journal=J.%20Alzheimer%E2%80%99s%20Dis.&doi=10.3233%2FJAD-2005-7107&volume=7&pages=63-80&publication_year=2005&author=Steen%2CE)\\n    \\n170.  Leonardi, M., Bickenbach, J., Ustun, T. B., Kostanjsek, N. & Chatterji, S. The definition of disability: what is in a name? _Lancet_ **368**, 1219–1221 (2006).\\n    \\n    [Article](https://doi.org/10.1016%2FS0140-6736%2806%2969498-1)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17027711)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20definition%20of%20disability%3A%20what%20is%20in%20a%20name%3F&journal=Lancet&doi=10.1016%2FS0140-6736%2806%2969498-1&volume=368&pages=1219-1221&publication_year=2006&author=Leonardi%2CM&author=Bickenbach%2CJ&author=Ustun%2CTB&author=Kostanjsek%2CN&author=Chatterji%2CS)\\n    \\n171.  Lisy, K., Campbell, J. M., Tufanaru, C., Moola, S. & Lockwood, C. The prevalence of disability among people with cancer, cardiovascular disease, chronic respiratory disease and/or diabetes: a systematic review. _Int. J. Evid. Based Healthc._ **16**, 154–166 (2018).\\n    \\n    [Article](https://doi.org/10.1097%2FXEB.0000000000000138)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29608458)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%20of%20disability%20among%20people%20with%20cancer%2C%20cardiovascular%20disease%2C%20chronic%20respiratory%20disease%20and%2For%20diabetes%3A%20a%20systematic%20review&journal=Int.%20J.%20Evid.%20Based%20Healthc.&doi=10.1097%2FXEB.0000000000000138&volume=16&pages=154-166&publication_year=2018&author=Lisy%2CK&author=Campbell%2CJM&author=Tufanaru%2CC&author=Moola%2CS&author=Lockwood%2CC)\\n    \\n172.  Yang, Y., Hu, X., Zhang, Q. & Zou, R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. _Age Ageing_ **45**, 761–767 (2016).\\n    \\n    [Article](https://doi.org/10.1093%2Fageing%2Fafw140)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27515679)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%20and%20risk%20of%20falls%20in%20older%20adults%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Age%20Ageing&doi=10.1093%2Fageing%2Fafw140&volume=45&pages=761-767&publication_year=2016&author=Yang%2CY&author=Hu%2CX&author=Zhang%2CQ&author=Zou%2CR)\\n    \\n173.  Wong, E. et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. _Lancet Diabetes Endocrinol._ **1**, 106–114 (2013).\\n    \\n    [Article](https://doi.org/10.1016%2FS2213-8587%2813%2970046-9)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24622316)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20and%20risk%20of%20physical%20disability%20in%20adults%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2813%2970046-9&volume=1&pages=106-114&publication_year=2013&author=Wong%2CE)\\n    \\n174.  Havercamp, S. M., Scandlin, D. & Roth, M. Health disparities among adults with developmental disabilities, adults with other disabilities, and adults not reporting disability in North Carolina. _Public. Health Rep._ **119**, 418–426 (2004).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.phr.2004.05.006)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15219799)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1497651)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Health%20disparities%20among%20adults%20with%20developmental%20disabilities%2C%20adults%20with%20other%20disabilities%2C%20and%20adults%20not%20reporting%20disability%20in%20North%20Carolina&journal=Public.%20Health%20Rep.&doi=10.1016%2Fj.phr.2004.05.006&volume=119&pages=418-426&publication_year=2004&author=Havercamp%2CSM&author=Scandlin%2CD&author=Roth%2CM)\\n    \\n175.  Herquelot, E., Guéguen, A., Bonenfant, S. & Dray-Spira, R. Impact of diabetes on work cessation: data from the GAZEL cohort study. _Diabetes Care_ **34**, 1344–1349 (2011).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc10-2225)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21562323)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114330)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20diabetes%20on%20work%20cessation%3A%20data%20from%20the%20GAZEL%20cohort%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc10-2225&volume=34&pages=1344-1349&publication_year=2011&author=Herquelot%2CE&author=Gu%C3%A9guen%2CA&author=Bonenfant%2CS&author=Dray-Spira%2CR)\\n    \\n176.  Virtanen, M. et al. Work disability among employees with diabetes: latent class analysis of risk factors in three prospective cohort studies. _PLoS ONE_ **10**, e0143184 (2015).\\n    \\n    [Article](https://doi.org/10.1371%2Fjournal.pone.0143184)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26569491)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646666)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVSms7rM)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Work%20disability%20among%20employees%20with%20diabetes%3A%20latent%20class%20analysis%20of%20risk%20factors%20in%20three%20prospective%20cohort%20studies&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0143184&volume=10&publication_year=2015&author=Virtanen%2CM)\\n    \\n177.  Cho, N. H. et al. IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. _Diabetes Res. Clin. Pract._ **138**, 271–281 (2018).\\n    \\n    [Article](https://doi.org/10.1016%2Fj.diabres.2018.02.023)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1MrmvVOlsw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29496507)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=IDF%20Diabetes%20atlas%3A%20global%20estimates%20of%20diabetes%20prevalence%20for%202017%20and%20projections%20for%202045&journal=Diabetes%20Res.%20Clin.%20Pract.&doi=10.1016%2Fj.diabres.2018.02.023&volume=138&pages=271-281&publication_year=2018&author=Cho%2CNH)\\n    \\n178.  Seok, W. P. et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. _Diabetes Care_ **30**, 1507–1512 (2007).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc06-2537)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Accelerated%20loss%20of%20skeletal%20muscle%20strength%20in%20older%20adults%20with%20type%202%20diabetes%3A%20the%20health%2C%20aging%2C%20and%20body%20composition%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc06-2537&volume=30&pages=1507-1512&publication_year=2007&author=Seok%2CWP)\\n    \\n179.  Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. _Br. Med. J._ **321**, 405–412 (2000).\\n    \\n    [Article](https://doi.org/10.1136%2Fbmj.321.7258.405)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD3cvisFWnsg%3D%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20glycaemia%20with%20macrovascular%20and%20microvascular%20complications%20of%20type%202%20diabetes%20%28UKPDS%2035%29%3A%20prospective%20observational%20study&journal=Br.%20Med.%20J.&doi=10.1136%2Fbmj.321.7258.405&volume=321&pages=405-412&publication_year=2000&author=Stratton%2CIM)\\n    \\n180.  DeCensi, A. et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. _Cancer Prev. Res._ **3**, 1451–1461 (2010).\\n    \\n    [Article](https://doi.org/10.1158%2F1940-6207.CAPR-10-0157)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhs1Wrsr7J)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20and%20cancer%20risk%20in%20diabetic%20patients%3A%20A%20systematic%20review%20and%20meta-analysis&journal=Cancer%20Prev.%20Res.&doi=10.1158%2F1940-6207.CAPR-10-0157&volume=3&pages=1451-1461&publication_year=2010&author=DeCensi%2CA)\\n    \\n181.  Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J. & McGuire, D. K. Metformin in patientswith type 2 diabetes and kidney disease a systematic review. _JAMA_ **312**, 2668–2675 (2014).\\n    \\n    [Article](https://doi.org/10.1001%2Fjama.2014.15298)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25536258)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427053)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVKrs7Y%3D)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20in%20patientswith%20type%202%20diabetes%20and%20kidney%20disease%20a%20systematic%20review&journal=JAMA&doi=10.1001%2Fjama.2014.15298&volume=312&pages=2668-2675&publication_year=2014&author=Inzucchi%2CSE&author=Lipska%2CKJ&author=Mayo%2CH&author=Bailey%2CCJ&author=McGuire%2CDK)\\n    \\n182.  Suissa, S. & Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. _Diabetes Care_ **35**, 2665–2673 (2012).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc12-0788)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvFShsrnN)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23173135)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507580)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20and%20the%20risk%20of%20cancer%3A%20time-related%20biases%20in%20observational%20studies&journal=Diabetes%20Care&doi=10.2337%2Fdc12-0788&volume=35&pages=2665-2673&publication_year=2012&author=Suissa%2CS&author=Azoulay%2CL)\\n    \\n183.  Karlstad, Ø. et al. Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies. _Curr. Drug. Saf._ **8**, 333–348 (2013).\\n    \\n    [Article](https://doi.org/10.2174%2F15680266113136660067)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitlahsQ%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24215311)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Use%20of%20insulin%20and%20insulin%20analogs%20and%20risk%20of%20cancer-systematic%20review%20and%20meta-analysis%20of%20observational%20studies&journal=Curr.%20Drug.%20Saf.&doi=10.2174%2F15680266113136660067&volume=8&pages=333-348&publication_year=2013&author=Karlstad%2C%C3%98)\\n    \\n184.  Bordeleau, L. et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. _Diabetes Care_ **37**, 1360–1366 (2014).\\n    \\n    [Article](https://doi.org/10.2337%2Fdc13-1468)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXpt12qt7w%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24574355)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20association%20of%20basal%20insulin%20glargine%20and%2For%20n-3%20fatty%20acids%20with%20incident%20cancers%20in%20patients%20with%20dysglycemia&journal=Diabetes%20Care&doi=10.2337%2Fdc13-1468&volume=37&pages=1360-1366&publication_year=2014&author=Bordeleau%2CL)\\n    \\n185.  Guo, M. et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. _Clin. Exp. Pharmacol. Physiol._ **41**, 650–656 (2014).\\n    \\n    [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhvVSjsbzI)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24862430)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20may%20produce%20antidepressant%20effects%20through%20improvement%20of%20cognitive%20function%20among%20depressed%20patients%20with%20diabetes%20mellitus&journal=Clin.%20Exp.%20Pharmacol.%20Physiol.&volume=41&pages=650-656&publication_year=2014&author=Guo%2CM)\\n    \\n186.  Campbell, J. M. et al. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. _J. Alzheimer’s Dis._ **65**, 1225–1236 (2018).\\n    \\n    [Article](https://doi.org/10.3233%2FJAD-180263)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20use%20associated%20with%20reduced%20risk%20of%20dementia%20in%20patients%20with%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Alzheimer%E2%80%99s%20Dis.&doi=10.3233%2FJAD-180263&volume=65&pages=1225-1236&publication_year=2018&author=Campbell%2CJM)\\n    \\n187.  Haukeland, J. W. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. _Scand. J. Gastroenterol._ **44**, 853–860 (2009).\\n    \\n    [Article](https://doi.org/10.1080%2F00365520902845268)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtVWjt7nP)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19811343)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20disease%3A%20a%20randomized%2C%20controlled%20trial&journal=Scand.%20J.%20Gastroenterol.&doi=10.1080%2F00365520902845268&volume=44&pages=853-860&publication_year=2009&author=Haukeland%2CJW)\\n    \\n188.  Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. _Lancet Neurol._ **19**, 582–590 (2020).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2820%2930173-3)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXht1WmtbrO)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32562683)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20dulaglutide%20on%20cognitive%20impairment%20in%20type%202%20diabetes%3A%20an%20exploratory%20analysis%20of%20the%20REWIND%20trial&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2820%2930173-3&volume=19&pages=582-590&publication_year=2020&author=Cukierman-Yaffe%2CT)\\n    \\n189.  Johnson, J. A. & Bowker, S. L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. _Diabetologia_ **54**, 25–31 (2011).\\n    \\n    [Article](https://link.springer.com/doi/10.1007/s00125-010-1933-3)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFWqtLfI)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20959956)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intensive%20glycaemic%20control%20and%20cancer%20risk%20in%20type%202%20diabetes%3A%20a%20meta-analysis%20of%20major%20trials&journal=Diabetologia&doi=10.1007%2Fs00125-010-1933-3&volume=54&pages=25-31&publication_year=2011&author=Johnson%2CJA&author=Bowker%2CSL)\\n    \\n190.  Launer, L. J. et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. _Lancet Neurol._ **10**, 969–977 (2011).\\n    \\n    [Article](https://doi.org/10.1016%2FS1474-4422%2811%2970188-0)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21958949)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333485)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20intensive%20glucose%20lowering%20on%20brain%20structure%20and%20function%20in%20people%20with%20type%202%20diabetes%20%28ACCORD%20MIND%29%3A%20a%20randomised%20open-label%20substudy&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2811%2970188-0&volume=10&pages=969-977&publication_year=2011&author=Launer%2CLJ)\\n    \\n191.  Jia, Y. et al. Associations of the glycaemic control of diabetes with dementia and physical function in rural-dwelling older Chinese adults: a population-based study. _Clin. Interv. Aging_ **16**, 1503–1513 (2021).\\n    \\n    [Article](https://doi.org/10.2147%2FCIA.S319633)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34413638)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370580)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Associations%20of%20the%20glycaemic%20control%20of%20diabetes%20with%20dementia%20and%20physical%20function%20in%20rural-dwelling%20older%20Chinese%20adults%3A%20a%20population-based%20study&journal=Clin.%20Interv.%20Aging&doi=10.2147%2FCIA.S319633&volume=16&pages=1503-1513&publication_year=2021&author=Jia%2CY)\\n    \\n192.  Lesniak, C. et al. Inpatient glycemic control and outcome of COVID-19 patients: a retrospective cohort. _SAGE Open. Med._ **9**, 20503121211039105 (2021).\\n    \\n    [Article](https://doi.org/10.1177%2F20503121211039105)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34422272)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375327)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inpatient%20glycemic%20control%20and%20outcome%20of%20COVID-19%20patients%3A%20a%20retrospective%20cohort&journal=SAGE%20Open.%20Med.&doi=10.1177%2F20503121211039105&volume=9&publication_year=2021&author=Lesniak%2CC)\\n    \\n193.  Afolabi, B. I. et al. The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients. _J. Natl Med. Assoc._ **110**, 256–264 (2018).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29778128)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20relationship%20between%20glycaemic%20control%20and%20non-alcoholic%20fatty%20liver%20disease%20in%20Nigerian%20type%202%20diabetic%20patients&journal=J.%20Natl%20Med.%20Assoc.&volume=110&pages=256-264&publication_year=2018&author=Afolabi%2CBI)\\n    \\n194.  Nouwen, A. et al. Longitudinal associations between depression and diabetes complications: a systematic review and meta-analysis. _Diabet. Med._ **36**, 1562–1572 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fdme.14054)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3M3otlegsw%3D%3D)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31215077)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Longitudinal%20associations%20between%20depression%20and%20diabetes%20complications%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Diabet.%20Med.&doi=10.1111%2Fdme.14054&volume=36&pages=1562-1572&publication_year=2019&author=Nouwen%2CA)\\n    \\n195.  Perry, B. D. et al. Muscle atrophy in patients with Type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. _Exerc. Immunol. Rev._ **22**, 94–109 (2016).\\n    \\n    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26859514)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545118)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Muscle%20atrophy%20in%20patients%20with%20Type%202%20diabetes%20mellitus%3A%20roles%20of%20inflammatory%20pathways%2C%20physical%20activity%20and%20exercise&journal=Exerc.%20Immunol.%20Rev.&volume=22&pages=94-109&publication_year=2016&author=Perry%2CBD)\\n    \\n196.  Hirata, Y. et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. _JCI Insight_ **4**, e124952 (2019).\\n    \\n    [Article](https://doi.org/10.1172%2Fjci.insight.124952)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478420)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperglycemia%20induces%20skeletal%20muscle%20atrophy%20via%20a%20WWP1%2FKLF15%20axis&journal=JCI%20Insight&doi=10.1172%2Fjci.insight.124952&volume=4&publication_year=2019&author=Hirata%2CY)\\n    \\n197.  Bassil, M. S. & Gougeon, R. Muscle protein anabolism in type 2 diabetes. _Curr. Opin. Clin. Nutr. Metab. Care_ **16**, 83–88 (2013).\\n    \\n    [Article](https://doi.org/10.1097%2FMCO.0b013e32835a88ee)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvVWhtL7O)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23196814)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Muscle%20protein%20anabolism%20in%20type%202%20diabetes&journal=Curr.%20Opin.%20Clin.%20Nutr.%20Metab.%20Care&doi=10.1097%2FMCO.0b013e32835a88ee&volume=16&pages=83-88&publication_year=2013&author=Bassil%2CMS&author=Gougeon%2CR)\\n    \\n198.  Meex, R. C. R., Blaak, E. E. & van Loon, L. J. C. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. _Obes. Rev._ **20**, 1205–1217 (2019).\\n    \\n    [Article](https://doi.org/10.1111%2Fobr.12862)\\xa0[CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFyhsrbN)\\xa0[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31240819)\\xa0[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852205)\\xa0 [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipotoxicity%20plays%20a%20key%20role%20in%20the%20development%20of%20both%20insulin%20resistance%20and%20muscle%20atrophy%20in%20patients%20with%20type%202%20diabetes&journal=Obes.%20Rev.&doi=10.1111%2Fobr.12862&volume=20&pages=1205-1217&publication_year=2019&author=Meex%2CRCR&author=Blaak%2CEE&author=Loon%2CLJC)\\n    \\n\\nNature Reviews Endocrinology (_Nat Rev Endocrinol_) ISSN 1759-5037 (online) ISSN 1759-5029 (print)\\n\\nnature.com sitemap\\n------------------\\n\\n### About Nature Portfolio\\n\\n*   [About us](https://www.nature.com/npg_/company_info/index.html)\\n*   [Press releases](https://www.nature.com/npg_/press_room/press_releases.html)\\n*   [Press office](https://press.nature.com/)\\n*   [Contact us](https://support.nature.com/support/home)\\n\\n### Discover content\\n\\n*   [Journals A-Z](https://www.nature.com/siteindex)\\n*   [Articles by subject](https://www.nature.com/subjects)\\n*   [protocols.io](https://www.protocols.io/)\\n*   [Nature Index](https://www.natureindex.com/)\\n\\n### Publishing policies\\n\\n*   [Nature portfolio policies](https://www.nature.com/authors/editorial_policies)\\n*   [Open access](https://www.nature.com/nature-research/open-access)\\n\\n### Author & Researcher services\\n\\n*   [Reprints & permissions](https://www.nature.com/reprints)\\n*   [Research data](https://www.springernature.com/gp/authors/research-data)\\n*   [Language editing](https://authorservices.springernature.com/language-editing/)\\n*   [Scientific editing](https://authorservices.springernature.com/scientific-editing/)\\n*   [Nature Masterclasses](https://masterclasses.nature.com/)\\n*   [Research Solutions](https://solutions.springernature.com/)\\n\\n### Libraries & institutions\\n\\n*   [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services)\\n*   [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal)\\n*   [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions)\\n*   [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library)\\n\\n### Advertising & partnerships\\n\\n*   [Advertising](https://partnerships.nature.com/product/digital-advertising/)\\n*   [Partnerships & Services](https://partnerships.nature.com/)\\n*   [Media kits](https://partnerships.nature.com/media-kits/)\\n*   [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/)\\n\\n### Professional development\\n\\n*   [Nature Careers](https://www.nature.com/naturecareers/)\\n*   [Nature Conferences](https://conferences.nature.com/)\\n\\n### Regional websites\\n\\n*   [Nature Africa](https://www.nature.com/natafrica)\\n*   [Nature China](http://www.naturechina.com/)\\n*   [Nature India](https://www.nature.com/nindia)\\n*   [Nature Italy](https://www.nature.com/natitaly)\\n*   [Nature Japan](https://www.natureasia.com/ja-jp)\\n*   [Nature Middle East](https://www.nature.com/nmiddleeast)\\n\\n*   [Privacy Policy](https://www.nature.com/info/privacy)\\n*   [Use of cookies](https://www.nature.com/info/cookies)\\n*   Your privacy choices/Manage cookies\\n*   [Legal notice](https://www.nature.com/info/legal-notice)\\n*   [Accessibility statement](https://www.nature.com/info/accessibility-statement)\\n*   [Terms & Conditions](https://www.nature.com/info/terms-and-conditions)\\n*   [Your US state privacy rights](https://www.springernature.com/ccpa)\\n\\n[![Image 9: Springer Nature](https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg)](https://www.springernature.com/)© 2025 Springer Nature Limited\\n\\n Close\\n\\n![Image 10: Nature Briefing](https://www.nature.com/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg)Sign up for the _Nature Briefing_ newsletter — what matters in science, free to your inbox daily.\\n\\n      Email address\\n\\n  Sign up\\n\\n I agree my information will be processed in accordance with the _Nature_ and Springer Nature Limited [Privacy Policy](https://www.nature.com/info/privacy).\\n\\n Close\\n\\nGet the most important science stories of the day, free in your inbox. [Sign up for Nature Briefing](https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner)\\n'},\n",
       "  {'title': 'Type 2 diabetes mellitus in adults: pathogenesis, prevention and ...',\n",
       "   'url': 'https://www.nature.com/articles/s41392-024-01951-9',\n",
       "   'content': 'Type 2 diabetes (T2D) is a disease characterized by heterogeneously progressive loss of islet β cell insulin secretion usually occurring after the presence of insulin resistance (IR) and it is one component of metabolic syndrome (MS), and we named it metabolic dysfunction syndrome (MDS). MDS-related TOD including macrovascular diseases and microvascular complications, such as chronic kidney disease (CKD), retinopathy, neuropathy, along with diabetic foot ulcerations (DFU), are responsible for much of the burden associated with diabetes.8.\") CKD, which has been recognized as primary factors contributing to elevated mortality and DALYs among diabetic patients,9.\") occurs in 20–40% diabetic patients and it’s still rising.',\n",
       "   'score': 0.36398646,\n",
       "   'raw_content': 'Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain\\nthe best experience, we recommend you use a more up to date browser (or turn off compatibility mode in\\nInternet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles\\nand JavaScript.\\n\\nAdvertisement\\n\\n![Advertisement](//pubads.g.doubleclick.net/gampad/ad?iu=/285/sigtrans.nature.com/article&sz=728x90&c=-78771496&t=pos%3Dtop%26type%3Darticle%26artid%3Ds41392-024-01951-9%26doi%3D10.1038/s41392-024-01951-9%26subjmeta%3D163,2743,317,565,692,699,700%26kwrd%3DEndocrine+system+and+metabolic+diseases,Metabolic+disorders,Therapeutics)\\n![Signal Transduction and Targeted Therapy](https://media.springernature.com/full/nature-cms/uploads/product/sigtrans/header-0db8944b73efe3a9d2686bcbbb5b2aa8.svg)\\n\\n# Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy\\n\\n[*Signal Transduction and Targeted Therapy*](/sigtrans)\\n**volume\\xa09**, Article\\xa0number:\\xa0262 (2024)\\n[Cite this article](#citeas)\\n\\n60k Accesses\\n\\n56 Citations\\n\\n98 Altmetric\\n\\n[Metrics details](/articles/s41392-024-01951-9/metrics)\\n\\n### Subjects\\n\\n## Abstract\\n\\nType 2 diabetes (T2D) is a disease characterized by heterogeneously progressive loss of islet β cell insulin secretion usually occurring after the presence of insulin resistance (IR) and it is one component of metabolic syndrome (MS), and we named it metabolic dysfunction syndrome (MDS). The pathogenesis of T2D is not fully understood, with IR and β cell dysfunction playing central roles in its pathophysiology. Dyslipidemia, hyperglycemia, along with other metabolic disorders, results in IR and/or islet β cell dysfunction via some shared pathways, such as inflammation, endoplasmic reticulum stress (ERS), oxidative stress, and ectopic lipid deposition. There is currently no cure for T2D, but it can be prevented or in remission by lifestyle intervention and/or some medication. If prevention fails, holistic and personalized management should be taken as soon as possible through timely detection and diagnosis, considering target organ protection, comorbidities, treatment goals, and other factors in reality. T2D is often accompanied by other components of MDS, such as preobesity/obesity, metabolic dysfunction associated steatotic liver disease, dyslipidemia, which usually occurs before it, and they are considered as the upstream diseases of T2D. It is more appropriate to call “diabetic complications” as “MDS-related target organ damage (TOD)”, since their development involves not only hyperglycemia but also other metabolic disorders of MDS, promoting an up-to-date management philosophy. In this review, we aim to summarize the underlying mechanism, screening, diagnosis, prevention, and treatment of T2D, especially regarding the personalized selection of hypoglycemic agents and holistic management based on the concept of “MDS-related TOD”.\\n\\n### Similar content being viewed by others\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41574-021-00489-y/MediaObjects/41574_2021_489_Fig1_HTML.png)\\n\\n### [Novel therapies with precision mechanisms for type 2 diabetes mellitus](https://www.nature.com/articles/s41574-021-00489-y?fromPaywallRec=false)\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41392-022-01073-0/MediaObjects/41392_2022_1073_Fig1_HTML.png)\\n\\n### [Trends in insulin resistance: insights into mechanisms and therapeutic strategy](https://www.nature.com/articles/s41392-022-01073-0?fromPaywallRec=false)\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-022-13084-6/MediaObjects/41598_2022_13084_Fig1_HTML.png)\\n\\n### [Differences in complication patterns in subgroups of type 2 diabetes according to insulin resistance and beta-cell function](https://www.nature.com/articles/s41598-022-13084-6?fromPaywallRec=false)\\n\\n## Introduction\\n\\nDiabetes is a heterogeneous syndrome characterized by defined hyperglycemia which is classified as type 1 diabetes (T1D), type 2 diabetes (T2D), specific types of diabetes and gestational diabetes mellitus.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") T2D is a disease characterized by a nonautoimmune heterogeneously progressive loss of adequate islet β cell insulin secretion frequently in the presence of insulin resistance (IR) and metabolic syndrome (MS). We think that “metabolic” or “metabolism” is a description of physiological phenomena which are not able to indicate normal or abnormal phenomena, so we adopt the proper term “metabolic dysfunction syndrome (MDS)” to replace MS. T2D accounts for 96% of diabetes and is one of the important noncommunicable chronic diseases that seriously threaten human health, without totally clear cognition on pathogenesis.\\n\\nThe continuous hyperglycemia can induce target organ damage (TOD) by increasing the risk of panvascular disease, including microvascular disease (such as diabetic retinopathy, nephropathy and neuropathy), and atherosclerotic macrovascular disease (cardiovascular, cerebrovascular, and other peripheral vascular diseases). Unlike classical T1D with almost only hyperglycemia, T2D is just one component of MDS, and is often accompanied by other components of MDS, such as overweight/obesity (preobesity might be a more appropriate term instead of “overweight” since obesity is not determined only by weight), metabolic dysfunction associated steatotic liver disease (MASLD), dyslipidemia. They are usually considered as the upstream diseases of T2D. Among them, preobesity/obesity, MASLD and some coexisting hypertension, closely related to poor lifestyle, are independent risk factors for the development of cardiovascular-kidney-metabolic syndrome and T2D,[2](/articles/s41392-024-01951-9#ref-CR2 \"Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence. J. Hepatol. 68, 335–352 (2018).\") indicating their preventable characteristic.\\n\\nThe realization of T2D as downstream disease of MDS suggests that “metabolic complications or “MDS-related TOD” may be more reasonable instead of so-called “chronic diabetic complications”. This updated philosophy is crucial for the management of T2D, emphasizing that TOD is not only caused by hyperglycemia. The used term “chronic diabetic complications” is misleading for both doctors and patients, leading to the blood glucose-focused management, while ignoring the development of TOD related to other metabolic disorders in the MDS. Based on this concept, the treatment should be holistic management to protect the target organs of MDS.\\n\\nThis review provides an overview of the epidemiology, diagnosis, screening, and prevention of T2D, with an emphasis on T2D pathophysiology and molecular mechanisms, as well as holistic management for T2D based on the concept of “MDS-related TOD”.\\n\\n## Epidemiology\\n\\nDiabetes has become a worldwide health burden due to its high incidence, disability and mortality, which is estimated to be the eighth leading cause of death combined disability.[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\"),[4](/articles/s41392-024-01951-9#ref-CR4 \"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).\") It is estimated that the annual global health care spending on diabetes among people aged 20–79 was US$ 966 billion in 2021, and is estimated to reach more than $1054 billion by 2045.[5](/articles/s41392-024-01951-9#ref-CR5 \"Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 183, 109119 (2022).\") In 2021, there were 529 million people of all ages in worldwide living with diabetes, and the global age-standardized prevalence is 6.1%, which increased by 90.5% from 3.2% in 1990, and is expected to reach 9.8%, affecting 13.1 billion people. It is noteworthy that T2D accounts for more than 96% of all.[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\") T2D is a complex multifactorial polygenetic disease that can attribute to many risk factors. Preobesity/obesity are major risk factors for T2D. In 2021, high BMI contribute more than 50% of global T2D disability-adjusted life year (DALY).[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\") Mounting evidence show association between T2D and gender difference.[6](/articles/s41392-024-01951-9#ref-CR6 \"Kautzky-Willer, A., Harreiter, J. & Pacini, G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr. Rev. 37, 278–316 (2016).\") The global age-standardized diabetes prevalence was higher in males than in females in 2021, with a male-to-female ratio of 1.14 despite it varied from regions.[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\") Age is also an important risk factor for T2D. The global diabetes prevalence peaked in group aged 75–79 years, at 24.4% while less than 1% in group age under 20 years.[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\") Other factors such as dietary risks, environmental or occupational risks, tobacco use, low physical activity alcohol use all account for part of the risk of T2D.[3](/articles/s41392-024-01951-9#ref-CR3 \"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023).\") In addition, genetics also play a modest but true role in T2D risk. Studies showed that the estimates of the heritability of T2D range from 30% to 70%, depending on the age of diabetes onset and the glycemic status of cases.[7](/articles/s41392-024-01951-9#ref-CR7 \"Bonnefond, A. & Froguel, P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metab. 21, 357–368 (2015).\") For now, more than 100 T2D-susceptibility genes have been mapped in human including TCF7L2, GCK, KCNJ11, PPARG.[7](/articles/s41392-024-01951-9#ref-CR7 \"Bonnefond, A. & Froguel, P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metab. 21, 357–368 (2015).\")\\n\\nMDS-related TOD including macrovascular diseases and microvascular complications, such as chronic kidney disease (CKD), retinopathy, neuropathy, along with diabetic foot ulcerations (DFU), are responsible for much of the burden associated with diabetes.[8](/articles/s41392-024-01951-9#ref-CR8 \"Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. Diabetologia 62, 3–16 (2019).\") CKD, which has been recognized as primary factors contributing to elevated mortality and DALYs among diabetic patients,[9](/articles/s41392-024-01951-9#ref-CR9 \"Liu, W. et al. Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: an age-period-cohort analysis. Diabetes Obes. Metab. 26, 602–610 (2024).\") occurs in 20–40% diabetic patients and it’s still rising. It is estimated approximately 50% and 34% of patients with diabetes will be affected by diabetic neuropathy (DN) and DFU over the course of their lifetime, respectively.[10](/articles/s41392-024-01951-9#ref-CR10 \"Armstrong, D. G., Tan, T.-W., Boulton, A. J. M. & Bus, S. A. Diabetic foot ulcers: a review. JAMA 330, 62–75 (2023).\"),[11](/articles/s41392-024-01951-9#ref-CR11 \"Hicks, C. W. & Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab Rep. 19, 86 (2019).\") About 20% of people with a DFU will undergo a lower extremity amputation and the 5-year mortality rate for them is greater than 70%.[10](/articles/s41392-024-01951-9#ref-CR10 \"Armstrong, D. G., Tan, T.-W., Boulton, A. J. M. & Bus, S. A. Diabetic foot ulcers: a review. JAMA 330, 62–75 (2023).\") Diabetic retinopathy (DR), occurred in 22% of diabetes patients and 6% suffer from vision threatening DR which might lead to irreversible vision impairment even blindness.[12](/articles/s41392-024-01951-9#ref-CR12 \"Teo, Z. L. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128, 1580–1591 (2021).\")\\n\\n## Pathophysiology and signaling pathways involved\\n\\nT2D, usually accompanied by other manifestations of MDS, is a complex metabolic disease with multiple underlying mechanisms not fully understood, while IR and β cell dysfunction are two core pathophysiological mechanisms[13](/articles/s41392-024-01951-9#ref-CR13 \"Mulder, H. Transcribing β-cell mitochondria in health and disease. Mol. Metab. 6, 1040–1051 (2017).\"),[14](/articles/s41392-024-01951-9#ref-CR14 \"Festa, A. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42–47 (2000).\") (Fig. [1](/articles/s41392-024-01951-9#Fig1)). Inflammation, ectopic lipid deposition, endoplasmic reticulum stress (ERS), and oxidative stress are involved in the onset and progression of T2D and TOD by impairing insulin sensitivity and/or β cell dysfunction, reciprocal with metabolic disorders.\\n\\n![figure 1](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01951-9/MediaObjects/41392_2024_1951_Fig1_HTML.png)\\n\\nVicious cycle of hyperglycemia. Poor lifestyle and/or metabolic dysfunction syndrome leads to elevated triglycerides, non-esterified fatty acids (**a**). Excessive lipids is deposited in non-adipose tissue, blocking the insulin signaling pathways, then resulting in insulin resistance, especially in the liver which increase the liver’s glucose production and weakens uptake of glucose, thereby increasing blood glucose and basal insulin levels, and the elevated insulin promotes lipid deposition, further aggravating insulin resistance and forming a vicious circle; elevated glucose and lipids produce hyperglucolipotoxicity to islet β cells and lipid deposition in islets, damaging the secretion function and number of pancreatic β cells, and further increasing blood glucose (**b**). MDS metabolic dysfunction syndrome, MASLD metabolic associated steatotic liver disease, TG triglycerides, NEFAs non-esterified fatty acids, GSIS glucose-stimulated insulin secretion\\n\\n### IR and insulin signaling pathways\\n\\nIR is defined as the loss of the ability of target tissues to respond to insulin signals, resulting in hyperinsulinemia and associated with many metabolic disorders in MDS, such as obesity, MASLD and hypertension. It often presents before T2D occurs and is thus considered as a risk factor.\\n\\nThe occurrence of IR varies by sex and ethnicity. Women demonstrate lower prevalence of T2D and prediabetes in younger ages as well as decreased mortality due to diabetes compared to males despite higher BMI in women.[15](/articles/s41392-024-01951-9#ref-CR15 \"Gado, M., Tsaousidou, E., Bornstein, S. R. & Perakakis, N. Sex-based differences in insulin resistance. J. Endocrinol. 261, e230245 (2024).\") The incidence of IR in Asian-Indians is approximately 2 to 3 times greater than that in other races,[16](/articles/s41392-024-01951-9#ref-CR16 \"Petersen, K. F. et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl Acad. Sci. USA 103, 18273–18277 (2006).\") possibly related to their phenotypes of high fat mass and low lean mass, indicating higher insulin levels.[17](/articles/s41392-024-01951-9#ref-CR17 \"Lear, S. A., Kohli, S., Bondy, G. P., Tchernof, A. & Sniderman, A. D. Ethnic variation in fat and lean body mass and the association with insulin resistance. J. Clin. Endocrinol. Metab. 94, 4696–4702 (2009).\")\\n\\nSome genetic factors are also found to be involved. For example, individuals with defects in genes mediating glucose transporter (GLUT)4 translocation have a genetic susceptibility to IR for the aberrant glucose uptake,[18](/articles/s41392-024-01951-9#ref-CR18 \"Sylow, L., Tokarz, V. L., Richter, E. A. & Klip, A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 33, 758–780 (2021).\") while GLUT4 expression in adipocyte is reduced in T2D and prediabetes.[19](/articles/s41392-024-01951-9#ref-CR19 \"Smith, U. & Kahn, B. B. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J. Intern Med. 280, 465–475 (2016).\") Gene expression differences involved in O-GlcNAcylation and hexosamine biosynthesis pathway have also been detected between diabetic and nondiabetic individuals,[20](/articles/s41392-024-01951-9#ref-CR20 \"Xie, Z., Xie, T., Liu, J., Zhang, Q. & Xiao, X. Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD. Int. J. Mol. Sci. 24, 2142 (2023).\") probably because multiple molecules in insulin signaling pathways can be modified by glycosylation which in turn reduces phosphorylation, leading to inhibition of insulin signaling.[20](/articles/s41392-024-01951-9#ref-CR20 \"Xie, Z., Xie, T., Liu, J., Zhang, Q. & Xiao, X. Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD. Int. J. Mol. Sci. 24, 2142 (2023).\"),[21](/articles/s41392-024-01951-9#ref-CR21 \"Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825–858 (2011).\") Pregestational diabetes exposes oocytes to hyperglycemia. It downregulates ten-eleven-translocation protein 3 (TET3) and impairs the DNA demethylation at the paternal alleles of several insulin secretion genes such as glucokinase (GCK), thus making the offspring susceptible to impaired glucose tolerance and diabetes.[22](/articles/s41392-024-01951-9#ref-CR22 \"Chen, B. et al. Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency. Nature 605, 761–766 (2022).\")\\n\\n#### Insulin signaling pathways\\n\\nPhysiologically, insulin binds to the extracellular α subunit of insulin receptor, a receptor tyrosine kinase which recruits and phosphorates insulin receptor substrate (IRS)-1, thus activating phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling and diverse downstream pathways to maintain the glucose homeostasis.[23](/articles/s41392-024-01951-9#ref-CR23 \"Epstein, F. H., Moller, D. E. & Flier, J. S. Insulin resistance—mechanisms, syndromes, and implications. N. Engl. J. Med. 325, 938–948 (1991).\") Firstly, activated Akt induces the translocation of GLUT4 vesicle from cytoplasm to membrane, promoting glucose uptake.[24](/articles/s41392-024-01951-9#ref-CR24 \"Jaldin-Fincati, J. R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P. J. & Klip, A. Update on GLUT4 vesicle traffic: a cornerstone of insulin action. Trends Endocrinol. Metab. 28, 597–611 (2017).\") Secondly, activated Akt phosphorylates forkhead box O1 (FOXO1), a transcription factor upregulating gluconeogenesis rate-limiting enzyme such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and translocate it from nucleus to cytoplasm, which inactivate its transcriptional activity, thus inhibiting gluconeogenesis.[25](/articles/s41392-024-01951-9#ref-CR25 \"He, L. Alterations of gut microbiota by overnutrition impact gluconeogenic gene expression and insulin signaling. Int J. Mol. Sci. 22, 2121 (2021).\") Thirdly, activated Akt directly phosphorylates and inactivates glycogen synthase kinase 3 (GSK3), thus promoting glycogen synthesis. In addition, activated Akt can relinquish the inhibition of mammalian target of rapamycin (mTOR) signaling pathways and promote proteins synthesis (Fig. [2a](/articles/s41392-024-01951-9#Fig2)).\\n\\n![figure 2](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01951-9/MediaObjects/41392_2024_1951_Fig2_HTML.png)\\n\\nSignaling pathways involved in T2D. In T2D, insulin signaling pathways (**a**) and insulin synthesis and secretion pathways (**b**) are affected by inflammatory pathways (**c**), ERS (**d**), and other pathways such as mTOR and notch pathways (**e**), AMPK pathway (**f**), Wnt pathway (**g**), HIF pathway (**h**), Hippo/YAP pathway (**i**)\\n\\n#### Overview of IR\\n\\nThe metabolites of chronic overnutrition, such as high glucose and non-esterified fatty acids (NEFAs), interfere with the activation of insulin receptor and its subsequent IRS-1/PI3K/Akt2 pathways, leading to the development of chronic inflammation in adipose tissue and ectopic lipid deposition in the liver and muscles, along with ERS and oxidative stress, etc. These alterations in target organs interact with each other to aggravate metabolic disorders, ultimately leading to IR. Many of the pathophysiology and the signaling pathways involved in this process are also shared by the development of MDS-related TOD.\\n\\nIn the early stage of IR, β cells work overload to increase insulin secretion to maintain blood glucose stability, with the compensatory capacity more genetically determined.[26](/articles/s41392-024-01951-9#ref-CR26 \"Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr. Rev. 29, 351–366 (2008).\") As the disease progresses, β cells are no longer able to secrete enough insulin to compensate for the abnormally high blood glucose, leading to progression to prediabetes or T2D.[27](/articles/s41392-024-01951-9#ref-CR27 \"Weir, G. C. & Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53, S16–S21 (2004).\")\\n\\n#### Inflammation\\n\\nObesity associated with overnutrition induces macrophage infiltration and chronic hypoxia, causing low-grade inflammation in the adipose tissue[28](/articles/s41392-024-01951-9#ref-CR28 \"Shaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. Nat. Rev. Endocrinol. 20, 136–148 (2024).\") and the release of proinflammatory factors such as interleukin (IL)-1β and tumor necrosis factor α (TNF-α),[29](/articles/s41392-024-01951-9#ref-CR29 \"Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).\"),[30](/articles/s41392-024-01951-9#ref-CR30 \"Bays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89, 463–478 (2004).\") thus impairing insulin signaling pathway in a number of ways.\\n\\nFirstly, they downregulate the level of insulin signaling molecules at the transcriptional level. Secondly, they activate multiple signaling pathways associated with inflammation (e.g. NF-κB, JAK/STAT and JNK), leading to impaired activation of the molecules. Thirdly, they also accelerate ceramide synthesis, aggravating ectopic lipid deposition.[31](/articles/s41392-024-01951-9#ref-CR31 \"Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645 (2012).\"),[32](/articles/s41392-024-01951-9#ref-CR32 \"Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).\")\\n\\nIn diabetic peripheral neuropathy (DPN), macrophages infiltrate to initiate repairment on nerve injury, with more cytokine and chemokine released.[33](/articles/s41392-024-01951-9#ref-CR33 \"Liu, P. et al. Role of macrophages in peripheral nerve injury and repair. Neural Regen. Res 14, 1335–1342 (2019).\") This highly inflammatory environment intensifies existing oxidative stress, further aggravating nerve damage.[34](/articles/s41392-024-01951-9#ref-CR34 \"El, F., Ka, N., Ts, J. & Dlh, B. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 93, 1296–1313 (2017).\")\\n\\n### NF-κB signaling pathway\\n\\nNuclear factor-kappa B (NF-κB) transcription factors are critical regulators of immunity, stress responses, apoptosis and differentiation.[35](/articles/s41392-024-01951-9#ref-CR35 \"Oeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-κB signaling pathways. Nat. Immunol. 12, 695–708 (2011).\") In T2D, the NF-κB pathway can be activated directly by excess metabolites and multiple inflammatory factors.[36](/articles/s41392-024-01951-9#ref-CR36 \"Kracht, M., Müller-Ladner, U. & Schmitz, M. L. Mutual regulation of metabolic processes and proinflammatory NF-κB signaling. J. Allergy Clin. Immunol. 146, 694–705 (2020).\") Those stimuli phosphorylate IκB kinase (IKK) complex,[37](/articles/s41392-024-01951-9#ref-CR37 \"Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol. Asp. Med. 66, 49–61 (2019).\") and induce degradation of IκB, thus releasing NF-κB to translocate to nucleus. NF-κB then promotes the expression of inducible nitric oxide synthase (iNOS) and the production of nitric oxide (NO), and finally inhibits the activation of IRS-1. It also upregulates the transcription of IL-1β, IL-18, and TNF-α, forming positive feedback.\\n\\nBesides, activation of IKKβ, a component of IKK complex, can also directly phosphorylate IRS-1 serine to interfere its activation. What’s more, the NOD-like receptor family pyrin domain-containing 3 (NLRP3), also upregulated by the activation of NF-κB,[38](/articles/s41392-024-01951-9#ref-CR38 \"Prasad, M. K., Mohandas, S. & Ramkumar, K. M. Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic β-cells in diabetes. Apoptosis 28, 958–976 (2023).\") forms inflammasome and activates protein kinase C epsilon (PKCε),[39](/articles/s41392-024-01951-9#ref-CR39 \"Qin, W. & Weng, J. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis. Sci. Bull. (Beijing) 68, 1413–1429 (2023).\") thus imparting IRS-1[40](/articles/s41392-024-01951-9#ref-CR40 \"Petersen, K. F. et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104, 12587–12594 (2007).\") (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\nNF-κB activation also participated in the MDS-related TOD. Firstly, activated NF-κB and NLRP3 inflammasome in DN promotes inflammation and increases fibronectin and collagen deposition in kidney,[41](/articles/s41392-024-01951-9#ref-CR41 \"Bhat, O. M. et al. Interleukin-18-induced cell adhesion molecule expression is associated with feedback regulation by PPAR-γ and NF-κB in Apo E-/- mice. Mol. Cell Biochem. 428, 119–128 (2017).\"),[42](/articles/s41392-024-01951-9#ref-CR42 \"Fu, Y., Wu, N. & Zhao, D. Function of NLRP3 in the Pathogenesis and Development of Diabetic Nephropathy. Med Sci. Monit. 23, 3878–3884 (2017).\") leading to thickening glomerular basement membrane, glomerular sclerosis, podocyte damage, and ultimately kidney fibrosis.[43](/articles/s41392-024-01951-9#ref-CR43 \"Matoba, K. et al. Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. Int J. Mol. Sci. 20, 3393 (2019).\") Secondly, Activation of NF-κB also leads to wound inflammation and promotes apoptosis of human endothelial cells by enhancing caspase-3 activity, thus delaying wound healing in DFU.[44](/articles/s41392-024-01951-9#ref-CR44 \"Sheu, M. L. et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler. Thromb. Vasc. Biol. 25, 539–545 (2005).\") Thirdly, retinal NF-κB in diabetes is activated at the beginning of retinopathy, initiating proapoptotic procedures,[45](/articles/s41392-024-01951-9#ref-CR45 \"Romeo, G., Liu, W.-H., Asnaghi, V., Kern, T. S. & Lorenzi, M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51, 2241–2248 (2002).\") and stay energetic while interacts with reactive oxygen species (ROS) even if the apoptotic process of retinal capillary cells speeds up.[46](/articles/s41392-024-01951-9#ref-CR46 \"Kowluru, R. A., Koppolu, P., Chakrabarti, S. & Chen, S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res. 37, 1169–1180 (2003).\"),[47](/articles/s41392-024-01951-9#ref-CR47 \"Wu, M.-Y., Yiang, G.-T., Lai, T.-T. & Li, C.-J. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid. Med. Cell Longev. 2018, 3420187 (2018).\") Elevated NLRP3 and IL-1β in the retina of proliferative diabetic retinopathy (PDR) patients are involved in the formation of late pathological neointima and lead to apoptosis of pericytes in the retina.[48](/articles/s41392-024-01951-9#ref-CR48 \"Chaurasia, S. S. et al. The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci. Rep. 8, 2847 (2018).\")\\n\\n### JAK/STAT signaling pathway\\n\\nThe janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway is involved in cell proliferation, differentiation, apoptosis, and inflammation response. It serves as an important downstream mediator for various cytokines, hormones, and growth factors. When they bind to their receptors, JAK proteins are recruited intracellularly, dimerized and activated through autophosphorylation. These activated JAKs then phosphorylate STAT proteins, which then translocate to the nucleus where they regulate a set of gene transcription.[49](/articles/s41392-024-01951-9#ref-CR49 \"Dodington, D. W., Desai, H. R. & Woo, M. JAK/STAT—emerging players in metabolism. Trends Endocrinol. Metab. 29, 55–65 (2018).\")\\n\\nElevated inflammatory factors in T2D such as IL-6 and interferon-γ (IFN-γ) cand bind to their receptors, activate JAK2/STAT3, subsequently upregulates the expression of suppressor of cytokine signaling 3 (SOCS3), which inhibit IRS-1 cascade.[50](/articles/s41392-024-01951-9#ref-CR50 \"Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).\"),[51](/articles/s41392-024-01951-9#ref-CR51 \"Bako, H. Y., Ibrahim, M. A., Isah, M. S. & Ibrahim, S. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. Life Sci. 239, 117045 (2019).\") JAK/STAT3 is also found to promote NF-κB cascade[50](/articles/s41392-024-01951-9#ref-CR50 \"Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).\") (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\nJAK/STAT3 activation also relates to the MDS-related TOD. During DN, the increased expression of JAK in glomerular podocytes aggravates the persistent inflammatory response of the kidney by activating the STAT3/NF-κB pathway.[52](/articles/s41392-024-01951-9#ref-CR52 \"Zhang, H. et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int. 92, 909–921 (2017).\"),[53](/articles/s41392-024-01951-9#ref-CR53 \"Liu, Z. et al. Nobiletin suppresses high-glucose-induced inflammation and ECM accumulation in human mesangial cells through STAT3/NF-κB pathway. J. Cell Biochem. 120, 3467–3473 (2019).\") In DFU, the increasing expression of IL-6 results in a sharp increase in phosphorylated STAT3 levels,[54](/articles/s41392-024-01951-9#ref-CR54 \"Eg, L. et al. Interleukin 6 function in the skin and isolated keratinocytes is modulated by hyperglycemia. J. Immunol. Res. 2019, 5087847 (2019).\") which mediates impaired immune cell activation, recruitment, and survival, resulting in delayed wound healing.[55](/articles/s41392-024-01951-9#ref-CR55 \"Ap, S. et al. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. Nat. Commun. 11, 4678 (2020).\")\\n\\n### JNK signaling pathway\\n\\nJNK, a subgroup of the mitogen-activated protein kinase (MAPK) family, can be activated by the inflammatory factors, metabolites and the crosstalk between other signaling pathways.[25](/articles/s41392-024-01951-9#ref-CR25 \"He, L. Alterations of gut microbiota by overnutrition impact gluconeogenic gene expression and insulin signaling. Int J. Mol. Sci. 22, 2121 (2021).\"),[56](/articles/s41392-024-01951-9#ref-CR56 \"Yung, J. H. M. & Giacca, A. Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. Cells 9, 706 (2020).\"),[57](/articles/s41392-024-01951-9#ref-CR57 \"Kitamura, T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 9, 615–623 (2013).\")\\n\\nActivated JNK not only phosphorylates IRS-1 serine to block its proper activation, but also causes phosphorylation and translocation of FOXO1 directly (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\n#### ERS\\n\\nERS in insulin target organs has been considered as a major pathogenesis of IR. ERS activating unfolded protein reaction (UPR) pathways is recognized by 3 sensors in endoplasmic reticulum (ER) membrane: protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring protein 1α (IRE1α), and cyclic AMP-dependent transcription factor 6α (ATF6α). They promote downstream signaling for alleviating cell survival, or induced apoptosis pathway under sustained UPR.\\n\\nPERK phosphorylates the eukaryotic translation initiator factor 2 (eIF2), which increase the translation of transcription factor-4 (ATF4) and subsequently upregulating the expression of C/EBP homologous protein (CHOP) and tribbles homolog 3 (TRIB3).[37](/articles/s41392-024-01951-9#ref-CR37 \"Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol. Asp. Med. 66, 49–61 (2019).\") Among them, CHOP inhibits the expression of anti-apoptosis proteins B-cell lymphoma-2 (BCL-2) and B-cell lymphoma-extra-large (BCL-XL), inducing cell apoptosis, while TRIB3 inhibits Akt activity, promoting IR in insulin-target organs. IRE1α binding with tumor necrosis factor receptor-associated factor 2 (TRAF2) activates IKKβ and JNK1, thus promoting chronic inflammation in IR[37](/articles/s41392-024-01951-9#ref-CR37 \"Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol. Asp. Med. 66, 49–61 (2019).\"),[58](/articles/s41392-024-01951-9#ref-CR58 \"Back, S. H. & Kaufman, R. J. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev. Biochem. 81, 767–793 (2012).\"),[59](/articles/s41392-024-01951-9#ref-CR59 \"Gorman, A. M., Healy, S. J. M., Jäger, R. & Samali, A. Stress management at the ER: Regulators of ER stress-induced apoptosis. Pharm. Thers 134, 306–316 (2012).\") (Fig. [2d](/articles/s41392-024-01951-9#Fig2)).\\n\\nThe ERS in the MDS-related TOD promotes the development of the diseases. The X-box-binding protein-1 (XBP1), spliced and activated by IRE1α, is downregulated in glomerular mesangial cells, weakening the inhibitory effect on the phosphatase and tensin homolog (PTEN)/Akt pathway, thereby aggravating kidney damage.[60](/articles/s41392-024-01951-9#ref-CR60 \"Wang, Y., He, Z., Yang, Q. & Zhou, G. XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy. FEBS Open Bio 9, 1249–1258 (2019).\") ERS also contributes to DPN and DR, with increased IRE1 in the neurons,[61](/articles/s41392-024-01951-9#ref-CR61 \"Yao, W. et al. IRE1α siRNA relieves endoplasmic reticulum stress-induced apoptosis and alleviates diabetic peripheral neuropathy in vivo and in vitro. Sci. Rep. 8, 2579 (2018).\") and upregulated CHOP, caspase 12, and phosphorylated JNK in diabetic retina.[62](/articles/s41392-024-01951-9#ref-CR62 \"Yang, L. et al. Role of endoplasmic reticulum stress in the loss of retinal ganglion cells in diabetic retinopathy. Neural Regen. Res. 8, 3148–3158 (2013).\")\\n\\n#### Oxidative stress\\n\\nOxidative stress is a condition that results in the production of ROS or reactive nitrogen species (RNS) that cannot be adequately addressed by normal antioxidant mechanisms.[63](/articles/s41392-024-01951-9#ref-CR63 \"Gupta, D., Kono, T. & Evans-Molina, C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes. Metab. 12, 1036–1047 (2010).\") Prolonged skeletal muscle inactivity promotes mitochondrial dysfunction, resulting in increase in mitochondrial ROS production and leading to protracted oxidative stress and disturbed redox signaling,[64](/articles/s41392-024-01951-9#ref-CR64 \"Powers, S. K. & Schrager, M. Redox signaling regulates skeletal muscle remodeling in response to exercise and prolonged inactivity. Redox Biol. 54, 102374 (2022).\") which can exacerbate IR through multiple pathways such as JNK and NF-κB pathways (Fig. [2c](/articles/s41392-024-01951-9#Fig2)). However, it does not appear to directly lead to an increase in fasting blood glucose; rather, it converts the carbohydrates into increased liver fat and plasma very-low-density lipoprotein (VLDL) due to hyperinsulinemia.[40](/articles/s41392-024-01951-9#ref-CR40 \"Petersen, K. F. et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104, 12587–12594 (2007).\"),[65](/articles/s41392-024-01951-9#ref-CR65 \"Petersen, K. F. et al. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proc. Natl Acad. Sci. USA 109, 8236–8240 (2012).\")\\n\\nOxidative stress is also widespread in MDS-related TOD and is broadly associated with other pathophysiological processes. Firstly, excessive accumulation of ROS within mesangial cells under chronic hyperglycemia can lead to cell death by activating mTOR,[66](/articles/s41392-024-01951-9#ref-CR66 \"Lu, Q. et al. The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy. Mol. Cell Endocrinol. 473, 31–43 (2018).\") sirtuin1,[67](/articles/s41392-024-01951-9#ref-CR67 \"Samadi, M., Aziz, S. G.-G. & Naderi, R. The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats. Cell Stress Chaperones 26, 217–227 (2021).\") and XBP1,[60](/articles/s41392-024-01951-9#ref-CR60 \"Wang, Y., He, Z., Yang, Q. & Zhou, G. XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy. FEBS Open Bio 9, 1249–1258 (2019).\") resulting in renal dysfunction. Secondly, the ROS attack accelerates apoptosis of retinal tissues and cells and aggravates DR,[68](/articles/s41392-024-01951-9#ref-CR68 \"Domingueti, C. P. et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes Complications 30, 738–745 (2016).\") with the activated polyol pathway, hexosamine pathway, and PKC pathway, as well as advanced glycation end products (AGEs) accumulation involved in the process.[69](/articles/s41392-024-01951-9#ref-CR69 \"Kang, Q. & Yang, C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 37, 101799 (2020).\") Thirdly, during the DPN, excess saturated fatty acids (SFAs) and hyperglycemia depolarize mitochondrial membranes and generate ROS,[70](/articles/s41392-024-01951-9#ref-CR70 \"Eid, S. A. et al. New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023).\") which eventually produce mitochondrial dysfunction and Schwann cells (SCs) apoptosis.[71](/articles/s41392-024-01951-9#ref-CR71 \"Eid, S. A. et al. Targeting the NADPH oxidase-4 and liver X receptor pathway preserves Schwann cell integrity in diabetic mice. Diabetes 69, 448–464 (2020).\") ROS can also activate downstream effectors like PKCε[72](/articles/s41392-024-01951-9#ref-CR72 \"Xu, J. et al. Oxidative stress induced by NOX2 contributes to neuropathic pain via plasma membrane translocation of PKCε in rat dorsal root ganglion neurons. J. Neuroinflammation 18, 106 (2021).\") and JNK,[73](/articles/s41392-024-01951-9#ref-CR73 \"Jiao, Y. et al. MicroRNA-7a-5p ameliorates diabetic peripheral neuropathy by regulating VDAC1/JNK/c-JUN pathway. Diabet. Med. 40, e14890 (2023).\") which are independently associated with DPN pathology.\\n\\n#### Ectopic lipid deposition\\n\\nIR in the liver and muscle is associated with fat mass.[74](/articles/s41392-024-01951-9#ref-CR74 \"Taylor, R. Type 2 diabetes. Diabetes Care 36, 1047–1055 (2013).\") Chronic overnutrition, a sedentary lifestyle and IR in adipose tissue can directly lead to the production and accumulation of excess toxic lipid products (such as diacylglycerol, ceramides, and NEFAs), and the metabolites can aggravate the ectopic lipid deposition through some signaling pathways (such as mTOR and notch). Among them, diacylglycerol activates PKCε and impairs IRS-1 activation, while ceramides activate protein kinase C zeta (PKCζ) and protein phosphatase 2A (PP2A), resulting in dephosphorylation of Akt,[31](/articles/s41392-024-01951-9#ref-CR31 \"Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645 (2012).\"),[32](/articles/s41392-024-01951-9#ref-CR32 \"Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).\") and promoting gluconeogenesis.[74](/articles/s41392-024-01951-9#ref-CR74 \"Taylor, R. Type 2 diabetes. Diabetes Care 36, 1047–1055 (2013).\"),[75](/articles/s41392-024-01951-9#ref-CR75 \"Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277 (2010).\")\\n\\nWD40 repeat-containing protein 6 (WDR6) is up-regulated in liver with IR. It phosphorylates upstream stimulatory factor 1 (USF1) and then upregulate fatty acid synthase (FASN), which promotes de novo lipogenesis (DNL) in liver and aggravates hepatic fat deposition.[76](/articles/s41392-024-01951-9#ref-CR76 \"Yao, Z. et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat. Metab. 5, 1706–1725 (2023).\") The altered membrane potential of hepatocytes after adipose deposition causes γ-aminobutyric acid (GABA) release and inhibits the vagus nerve, which is also involved in hyperinsulinemia.[77](/articles/s41392-024-01951-9#ref-CR77 \"Geisler, C. E. et al. Hepatocyte membrane potential regulates serum insulin and insulin sensitivity by altering hepatic GABA release. Cell Rep. 35, 109298 (2021).\") In turn, hyperinsulinemia due to IR in the liver and other target tissues can promote the production of liver fat, resulting in a vicious cycle.\\n\\n### mTOR signaling pathway\\n\\nmTOR, a member of the PI3K-related kinase family, is the core component of two structurally and functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).[78](/articles/s41392-024-01951-9#ref-CR78 \"Das, A. & Reis, F. mTOR signaling: new insights into cancer, cardiovascular diseases, diabetes and aging. Int J. Mol. Sci. 24, 13628 (2023).\") mTORC1 participates in protein, glucose and lipid metabolism mainly through phosphorylation and activation of p70S6 kinase 1 (S6K1), while mTORC2, an effector of PI3K, contributes to the activation of Akt.[79](/articles/s41392-024-01951-9#ref-CR79 \"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).\")\\n\\nChronic exposure to excessive glucose and lipids continuously activates mTOR signaling pathways in liver and muscle, contributing to the development of IR. Firstly, mTORC1/S6K1 activates transcription factor sterol-regulatory element binding proteins (SREBP), promoting fat synthesis. Meanwhile, mTORC1/S6K1 can also phosphorylate IRS-1 serine, thus block its activation[80](/articles/s41392-024-01951-9#ref-CR80 \"Leibowitz, G., Cerasi, E. & Ketzinel-Gilad, M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes. Metab. 10, 157–169 (2008).\") (Fig. [2e](/articles/s41392-024-01951-9#Fig2)).\\n\\nmTOR pathways are also associated with TOD. Firstly, activated mTOR reduces the antioxidant activity of mesangial cells in the glomerulus, promoting the production of ROS.[66](/articles/s41392-024-01951-9#ref-CR66 \"Lu, Q. et al. The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy. Mol. Cell Endocrinol. 473, 31–43 (2018).\") It also inhibits the activation of nuclear factor erythroid 2-related factor 2 (NRF2), exacerbating oxidative stress injury to the kidneys.[81](/articles/s41392-024-01951-9#ref-CR81 \"Qiao, S. et al. Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR/β-TrcP/Nrf2 pathway. Free Radic. Biol. Med. 145, 118–135 (2019).\") Secondly, IR blunted mTORC1 signaling in SCs.[70](/articles/s41392-024-01951-9#ref-CR70 \"Eid, S. A. et al. New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023).\") It impairs lactate, as a source of energy, shuttling to axons via monocarboxylate transporters,[82](/articles/s41392-024-01951-9#ref-CR82 \"Bouçanova, F. et al. Disrupted function of lactate transporter MCT1, but not MCT4, in Schwann cells affects the maintenance of motor end-plate innervation. Glia 69, 124–136 (2021).\") thus contributing to the nerve damage. Thirdly, activated mTOR enhances wound healing in DFU by upregulating the expression of multiple growth factors,[83](/articles/s41392-024-01951-9#ref-CR83 \"Yang, H.-L., Tsai, Y.-C., Korivi, M., Chang, C.-T. & Hseu, Y.-C. Lucidone promotes the cutaneous wound healing process via activation of the PI3K/AKT, Wnt/β-catenin and NF-κB signaling pathways. Biochim. Biophys. Acta Mol. Cell Res. 1864, 151–168 (2017).\") regulating the accumulation of lipids in endothelial cells and fibroblasts,[84](/articles/s41392-024-01951-9#ref-CR84 \"Wei, F. et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/Akt/mTOR pathway. Aging (Albany NY) 12, 12002–12018 (2020).\") inducing epithelial-mesenchymal transition,[85](/articles/s41392-024-01951-9#ref-CR85 \"Jere, S. W., Houreld, N. N. & Abrahamse, H. Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing. Cytokine Growth Factor Rev. 50, 52–59 (2019).\") and promoting the proliferation and differentiation of fibroblasts.[86](/articles/s41392-024-01951-9#ref-CR86 \"Zhang, E., Gao, B., Yang, L., Wu, X. & Wang, Z. Notoginsenoside Ft1 promotes fibroblast proliferation via PI3K/Akt/mTOR signaling pathway and benefits wound healing in genetically diabetic mice. J. Pharm. Exp. Ther. 356, 324–332 (2016).\")\\n\\n### Notch signaling pathway\\n\\nNotch signaling, intimately involved in embryonic development and maintenance of multicellular organisms in adults, is activated by ligand-receptor interaction between adjacent cells, which leads to successive proteolytic cleavages and releases the notch intracellular domain (NICD). NICD binds to intracellular effector molecules (CSL) to form NICD/CSL transcription complex, activating the notch target genes.[87](/articles/s41392-024-01951-9#ref-CR87 \"Kim, W., Shin, Y.-K., Kim, B.-J. & Egan, J. M. Notch signaling in pancreatic endocrine cell and diabetes. Biochem. Biophys. Res. Commun. 392, 247–251 (2010).\")\\n\\nAbnormality of notch signaling is strongly associated with metabolic disorders. Increased notch activity in T2D induces expression of SREBP1 in liver through constitutive activation of mTORC1, promoting fat deposition, and increases expression of G6Pase and PEPCK in liver in a FOXO1-dependent manner, promoting glucogenesis, and ultimately exacerbating IR.[50](/articles/s41392-024-01951-9#ref-CR50 \"Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).\"),[88](/articles/s41392-024-01951-9#ref-CR88 \"Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat. Med. 19, 1054–1060 (2013).\"),[89](/articles/s41392-024-01951-9#ref-CR89 \"Pajvani, U. B. et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat. Med. 17, 961–967 (2011).\") Inhibition of notch signaling can promote glucose uptake in muscle thus improving glucose tolerance[90](/articles/s41392-024-01951-9#ref-CR90 \"Hasan, S. S. et al. Endothelial Notch signaling controls insulin transport in muscle. EMBO Mol. Med. 12, e09271 (2020).\") (Fig. [2e](/articles/s41392-024-01951-9#Fig2)).\\n\\nIn DFU, notch pathway dysfunction can lead to inhibition of cell differentiation, proliferation disorders, and reduced angiogenesis, all of which interfere with diabetic wound healing.[91](/articles/s41392-024-01951-9#ref-CR91 \"Siebel, C. & Lendahl, U. Notch signaling in development, tissue homeostasis, and disease. Physiol. Rev. 97, 1235–1294 (2017).\")\\n\\n#### Decreased adiponectin and AMPK pathway\\n\\nChronic inflammation in adipose tissue leads to a decrease in adiponectin, an insulin-sensitized adipokine released by adipose tissues, which perform physical function through the adenosine 5’-monophosphate-activated protein kinase (AMPK) signaling pathway.[92](/articles/s41392-024-01951-9#ref-CR92 \"Stumvoll, M., Goldstein, B. J. & Van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333–1346 (2005).\") Phosphorylation and activation of AMPK is in response to nutrients and AMP/ATP ratio through the upstream kinases serine/threonine kinase (LKB1) and calcium/calmodulin-dependent protein kinase β (CaMKKβ).[50](/articles/s41392-024-01951-9#ref-CR50 \"Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).\") Activated AMPK then promotes glucose uptake through the translocation of GLUT4, suppresses gluconeogenesis by inhibiting G6Pase and PEPCK, and improves lipid metabolism by inhibiting fatty acid synthesis and promoting its oxidation.[93](/articles/s41392-024-01951-9#ref-CR93 \"Townsend, L. K. & Steinberg, G. R. AMPK and the endocrine control of metabolism. Endocr. Rev. 44, 910–933 (2023).\"),[94](/articles/s41392-024-01951-9#ref-CR94 \"Steinberg, G. R. & Hardie, D. G. New insights into activation and function of the AMPK. Nat. Rev. Mol. Cell Biol. 24, 255–272 (2023).\")\\n\\nIn T2D, AMPK activity is decreased from several ways. Firstly, less adiponectin from adipose tissue reduces the activation of CaMKKβ due to the downregulation of nicotinamide phosphoribosyl transferase (NAMPT),[74](/articles/s41392-024-01951-9#ref-CR74 \"Taylor, R. Type 2 diabetes. Diabetes Care 36, 1047–1055 (2013).\"),[95](/articles/s41392-024-01951-9#ref-CR95 \"Stromsdorfer, K. L. et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16, 1851–1860 (2016).\") leading to a weaker AMPK activity, which can be observed long before the onset of diabetes.[96](/articles/s41392-024-01951-9#ref-CR96 \"Tabák, A. G. et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care 35, 2540–2547 (2012).\") Meanwhile, high glucose and inflammation block LKB1 recruitment, activate PP2A/C, and induce degradation of AMPK catalytic subunits through the E3 ubiquitin ligase. AMPK downstream effects are blunted in T2D patients, exacerbating hyperglycemia and hyperlipidemia (Fig. [2f](/articles/s41392-024-01951-9#Fig2)).\\n\\nAMPK is closely related to mitochondrial autophagy,[97](/articles/s41392-024-01951-9#ref-CR97 \"Yc, H. et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis. 12, 925 (2021).\") which maintains mitochondrial function under stress by timely clearing of damaged mitochondria. Hyperglycemia reduces instantaneous calcium intake, and increases NADPH production, thus inhibiting AMPK.[98](/articles/s41392-024-01951-9#ref-CR98 \"Xu, J., Liu, L.-Q., Xu, L.-L., Xing, Y. & Ye, S. Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis. Clin. Exp. Pharm. Physiol. 47, 599–608 (2020).\") It leads to the weakening of the ability of renal cells to clear damaged proteins and organelles, thus promoting renal fibrosis in DR.[99](/articles/s41392-024-01951-9#ref-CR99 \"Ren, H. et al. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. Mol. Cell Endocrinol. 500, 110628 (2020).\")\\n\\n#### The gut microbiota\\n\\nEmerging studies have shown that the intestinal microbiota composition of obese people has changed compared with that of lean people, even though the reported changes are inconsistent or even contradictory. An altered composition of the microbiota increases plasma bacterial lipopolysaccharide (LPS) levels, resulting in metabolic endotoxemia.[100](/articles/s41392-024-01951-9#ref-CR100 \"Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590 (2020).\")\\n\\nIn addition, a high-fat diet and short-chain fatty acids (the metabolites of the gut microbiota) can alter intestinal permeability, which is a characteristic of human T2D.[100](/articles/s41392-024-01951-9#ref-CR100 \"Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590 (2020).\") Increased permeability exacerbates metabolic endotoxemia, thus triggering immune response and IR through toll-like receptor 4 (TLR4), CD14,[101](/articles/s41392-024-01951-9#ref-CR101 \"Cox, A. J., West, N. P. & Cripps, A. W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 3, 207–215 (2015).\") and G protein-coupled receptor (GPR) 41/43.[101](/articles/s41392-024-01951-9#ref-CR101 \"Cox, A. J., West, N. P. & Cripps, A. W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 3, 207–215 (2015).\")\\n\\n#### Other signaling pathways with controversial effects\\n\\n### Wnt signaling pathway\\n\\nWnt signaling pathways is associated with adipogenesis. The canonical Wnt pathway can be activated by the binding of Wnt ligands (secreted glycoproteins) and their receptors, and keep the β-catenin from degradation through altering a range of downstream molecules. Stabilized β-catenin translocates to the nucleus and binds to transcription factors such as T cell factor and lymphoid enhancing factor (TCF/LEF), thus leading to the activation of target genes.[102](/articles/s41392-024-01951-9#ref-CR102 \"Wang, H. et al. The Wnt signaling pathway in diabetic nephropathy. Front. Cell Dev. Biol. 9, 701547 (2022).\") Some non-classical Wnt ligands can activate non-canonical pathways such as Wnt/planar cell polarity (PCP) and Wnt/Ca+ pathways, playing different roles.\\n\\nWnt signaling pathways are upregulated in IR with controversial effects. Wnt5a activats Wnt/PCP pathway, upregulating Ras-related C3 botulinum toxin substrate 1(Rac), which can activate JNK, thus aggravating IR in adipose tissue.[103](/articles/s41392-024-01951-9#ref-CR103 \"Zuriaga, M. A. et al. Activation of non-canonical WNT signaling in human visceral adipose tissue contributes to local and systemic inflammation. Sci. Rep. 7, 17326 (2017).\") However, Wnt3a is reported to be capable of activating transcriptional coactivator with PDZ-binding motif (TAZ), which can directly upregulate IRS-1, indicating its potential ability of increasing insulin sensitivity in muscle.[104](/articles/s41392-024-01951-9#ref-CR104 \"Nie, X., Wei, X., Ma, H., Fan, L. & Chen, W.-D. The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. J. Cell Mol. Med. 25, 6479–6495 (2021).\") Wnt3a is also found to play a resistance role in the differentiation of preadipocytes into adipocytes[104](/articles/s41392-024-01951-9#ref-CR104 \"Nie, X., Wei, X., Ma, H., Fan, L. & Chen, W.-D. The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. J. Cell Mol. Med. 25, 6479–6495 (2021).\") (Fig. [2g](/articles/s41392-024-01951-9#Fig2)).\\n\\nThe Wnt/β-catenin pathway is downregulated in DFU.[105](/articles/s41392-024-01951-9#ref-CR105 \"Zhang, H. et al. Regulatory mechanisms of the Wnt/β-catenin pathway in diabetic cutaneous ulcers. Front. Pharmacol. 9, 1114 (2018).\") It suppresses the biological activity of skin cells and the expression of cytokines, resulting in immune dysfunction of the wound, dysplasia of granulation tissue, and reepithelialization disorders, thus delaying wound healing.[106](/articles/s41392-024-01951-9#ref-CR106 \"Yamaguchi, Y. et al. Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. FASEB J. 22, 1009–1020 (2008).\")\\n\\n### HIF signaling pathway\\n\\nHypoxia-inducible factors (HIFs), consisting of an oxygen-sensitive α subunit and a constitutively expressed HIF-1β subunit, are major regulators of adaptive responses to hypoxia and directly activate the expression of multiple target genes to maintain cellular oxygen homeostasis.[107](/articles/s41392-024-01951-9#ref-CR107 \"Catrina, S.-B. & Zheng, X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 64, 709–716 (2021).\") In the presence of oxygen, HIF-1α is hydroxylated, followed by a ubiquitination reaction, leading to the proteolysis of HIF‐1α through the ubiquitin‐proteasome system; Upon hypoxia, HIF-1α is stabilized and translocates to the nucleus, where it dimerizes with HIF-1β, binds to target genes, and activates gene transcription.[108](/articles/s41392-024-01951-9#ref-CR108 \"Koyasu, S., Kobayashi, M., Goto, Y., Hiraoka, M. & Harada, H. Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge. Cancer Sci. 109, 560–571 (2018).\")\\n\\nThe role of HIF in IR is controversial. In adipose tissue, HIF activation can improve IR by stimulating the thermogenic function of brown adipose tissue (BAT) by regulating mitochondrial biogenesis and glycolysis. However, HIF activates the transcription of SOCS3 which inhibits JAK/STAT3 signaling and thus inhibits the expression of adiponectin (Fig. [2h](/articles/s41392-024-01951-9#Fig2)).\\n\\nThe TRIB3 is induced in DR under ERS, leading to overexpression of HIF1α. In turn, HIF1α regulates GLUT1 expression and, together with TRIB3, increases the influx of glucose in the retina,[109](/articles/s41392-024-01951-9#ref-CR109 \"Pitale, P. M. & Gorbatyuk, M. S. Diabetic retinopathy: from animal models to cellular signaling. Int J. Mol. Sci. 23, 1487 (2022).\") aggravating metabolism disorder. In addition, it increases the expression of vascular endothelial growth factor (VEGF) and promotes the formation of retinal blood vessels.[110](/articles/s41392-024-01951-9#ref-CR110 \"Zhang, D., Lv, F.-L. & Wang, G.-H. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur. Rev. Med. Pharm. Sci. 22, 5071–5076 (2018).\")\\n\\n### Hippo/YAP signaling pathway\\n\\nHippo/YAP signaling plays a central role in the cellular proliferation and differentiation. Hippo signaling regulates YAP primarily through large tumor suppressor kinases 1 and 2 (LATS 1/2), which are activated through phosphorylation by mammalian sterile 20-like protein kinases 1/2 (MST1/2). Phosphorylation of YAP results in cytoplasmic localization and degradation, while dephosphorylated YAP proteins translocate to nucleus and induce gene expression through interactions with TEA domain (TEAD) transcription factors.[111](/articles/s41392-024-01951-9#ref-CR111 \"Ibar, C. & Irvine, K. D. Integration of Hippo-YAP signaling with metabolism. Dev. Cell 54, 256–267 (2020).\")\\n\\nYAP signaling is involved in glucose and lipid metabolism through crosstalk with other signaling pathway. It promotes glucose uptake by directly upregulating GLUT1/3, promotes glycolysis by upregulating hexokinase 2 (HK2), and promotes lipogenesis by directly interacting with SREBP.[111](/articles/s41392-024-01951-9#ref-CR111 \"Ibar, C. & Irvine, K. D. Integration of Hippo-YAP signaling with metabolism. Dev. Cell 54, 256–267 (2020).\") Therefore, abnormal Hippo/YAP pathways may be the potential pathogenesis of IR and other metabolic disease (Fig. [2i](/articles/s41392-024-01951-9#Fig2)).\\n\\n### β cell dysfunction and pathways involved\\n\\nIslet β cell dysfunction plays a key role in the progression of T2D, which includes impaired insulin synthesis and secretion, and a reduced mass of β cells. It occurs before the diagnosis of T2D, by when the β cells have been lost approximately 50% compared with that of nondiabetic individuals.[112](/articles/s41392-024-01951-9#ref-CR112 \"Taylor, R., Al-Mrabeh, A. & Sattar, N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 7, 726–736 (2019).\")\\n\\nIslet β cells shift from a compensatory increase to reduced function and decreased β cell mass.[27](/articles/s41392-024-01951-9#ref-CR27 \"Weir, G. C. & Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53, S16–S21 (2004).\") In the early stage of T2D, impaired insulin synthesis and secretion plays a major role, with the stimuli reducing glucose-stimulated insulin secretion (GSIS), the basic function of β cells.[74](/articles/s41392-024-01951-9#ref-CR74 \"Taylor, R. Type 2 diabetes. Diabetes Care 36, 1047–1055 (2013).\") Progressively, chronic exposure to high glucose and lipids affects the survival of islet β cells, and the loss of mass gradually exacerbates with the prolongation of T2D and becomes the main factor involved in insufficient secretion of insulin.\\n\\nApoptosis due to inflammation, ERS, and oxidative stress has long been thought to be the main cause of β cell dysfunction. However, in recent years, dedifferentiation, senescence and other forms of cell death, such as autophagy, pyroptosis and ferroptosis, have been found to be involved in the loss of β cells.[113](#ref-CR113 \"Sun, T. & Han, X. Death versus dedifferentiation: the molecular bases of beta cell mass reduction in type 2 diabetes. Semin Cell Dev. Biol. 103, 76–82 (2020).\"),[114](#ref-CR114 \"Cinti, F. et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 1044–1054 (2016).\"),[115](#ref-CR115 \"Spijker, H. S. et al. Conversion of mature human β-cells into glucagon-producing α-cells. Diabetes 62, 2471–2480 (2013).\"),[116](#ref-CR116 \"Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150, 1223–1234 (2012).\"),[117](/articles/s41392-024-01951-9#ref-CR117 \"Aguayo-Mazzucato, C. et al. Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes. Cell Metab. 30, 129–142.e4 (2019).\") The Aldehyde dehydrogenase 1 isoform A3 (ALDH1A3), normally not expressed in mature islets, is activated in diabetic patients, which damages characterization of β cells, leads to dedifferentiation and impairs secretory function.[118](/articles/s41392-024-01951-9#ref-CR118 \"Son, J. et al. Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure. Nat. Commun. 14, 558 (2023).\")\\n\\n#### Insulin synthesis and secretion pathways\\n\\nThe insulin gene is transcribed to mRNA with the aid of various transcription factors such as MAF bZIP transcription factor A (MAFA),[119](/articles/s41392-024-01951-9#ref-CR119 \"Liang, J., Chirikjian, M., Pajvani, U. B. & Bartolomé, A. MafA regulation in β-cells: from transcriptional to post-translational mechanisms. Biomolecules 12, 535 (2022).\") and pancreatic duodenal homeobox 1 (PDX1).[120](/articles/s41392-024-01951-9#ref-CR120 \"Ebrahim, N., Shakirova, K. & Dashinimaev, E. PDX1 is the cornerstone of pancreatic β-cell functions and identity. Front. Mol. Biosci. 9, 1091757 (2022).\") Subsequently, the preproinsulin is translated at the cytosolic surface of the ER and then translocated into it. Within the ER, the signal peptide is cleaved, disulfide bonds form, and the peptide is folded. Proinsulin moves into the Golgi body where it is sorted and packed into secretory vesicles. Within these vesicles, the C-peptide is cleaved off, forming mature insulin.[121](/articles/s41392-024-01951-9#ref-CR121 \"Ataie-Ashtiani, S. & Forbes, B. A review of the biosynthesis and structural implications of insulin gene mutations linked to human disease. Cells 12, 1008 (2023).\") In general, most nutrients that stimulate insulin secretion also increase proinsulin biosynthesis, with glucose the most physiologically relevant one.[122](/articles/s41392-024-01951-9#ref-CR122 \"Uchizono, Y., Alarcón, C., Wicksteed, B. L., Marsh, B. J. & Rhodes, C. J. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead. Diabetes Obes. Metab. 9, 56–66 (2007).\")\\n\\nIn the classical theory of GSIS, the glucose is transported into islet β cell through GLUT2, and generates pyruvate, entering tricarboxylic acid cycle (TCA) to produce ATP. Increased ATP/ADP ratio induces the closure of ATP-sensitive potassium (KATP) channels, leading to membrane depolarization followed by activation of voltage-gated Ca2+ channels (VGCC) and Ca2+ influx. The increase in Ca2+ ultimately activates insulin granular docking and releasing from the “ready releasable” pool[123](/articles/s41392-024-01951-9#ref-CR123 \"Cui, D. et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. Chin. Med. J. (Engl.) 137, 791 (2024).\") (Fig. [2b](/articles/s41392-024-01951-9#Fig2)).\\n\\n#### Hyperglucotoxicity and lipotoxicity\\n\\nPersistent hyperglycemia and excess fatty acids in the circulation due to overnutrition and IR have widespread and significant effects on β cell function and mass. In addition to involving several shared pathways (e.g., inflammation, ERS, and oxidative stress), they have several individual effects.\\n\\nHigh glucose stimulates the continuous secretion of insulin. This process does not involve changes in gene expression at first, but results in secretion failure due to physical consumption. As exposure progresses, the expression of the insulin synthesis transcription factors such as PDX1 and MAFA decreases, disrupting the insulin synthesis. What’s worse, patients with T2D were observed a decreased expression of GLUT1/2, which reduce intracellular transportation of glucose, thus producing less ATP and impaired insulin releasing. In addition, MYC, a transcription factor that improves sensitivity to apoptosis stimulation, is upregulated, along with the activation of other apoptotic pathways,[26](/articles/s41392-024-01951-9#ref-CR26 \"Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr. Rev. 29, 351–366 (2008).\"),[124](/articles/s41392-024-01951-9#ref-CR124 \"Pascal, S. M. A., Guiot, Y., Pelengaris, S., Khan, M. & Jonas, J.-C. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets. Am. J. Physiol. Endocrinol. Metab. 295, E92–E102 (2008).\"),[125](/articles/s41392-024-01951-9#ref-CR125 \"Bensellam, M., Laybutt, D. R. & Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. Mol. Cell Endocrinol. 364, 1–27 (2012).\") causing irreversible damage or even death of β cells. It is called glucotoxicity previously,[126](/articles/s41392-024-01951-9#ref-CR126 \"Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y. & Takahashi, H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52, 581–587 (2003).\") however, we may call this phenomenon hyperglucotoxicity, as a normal glucose level is not toxic to islet β cells.\\n\\nLipotoxicity is the effect of abnormal lipid metabolism on islet β cells. Excess NEFAs, which stimulate the secretion of insulin, disrupt the function of β cells by increasing basal insulin levels but inhibit GSIS.[127](/articles/s41392-024-01951-9#ref-CR127 \"Lee, Y. et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl Acad. Sci. USA 91, 10878–10882 (1994).\") SFAs, such as palmitic acid, can increase the production of ceramide and NO, leading to impaired insulin synthesis, and the apoptosis of β cells through inflammation, ERS, and oxidative stress, which can be blocked by unsaturated fatty acids.[127](/articles/s41392-024-01951-9#ref-CR127 \"Lee, Y. et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl Acad. Sci. USA 91, 10878–10882 (1994).\"),[128](/articles/s41392-024-01951-9#ref-CR128 \"Maedler, K., Oberholzer, J., Bucher, P., Spinas, G. A. & Donath, M. Y. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52, 726–733 (2003).\")\\n\\nLipoproteins and cholesterol have also been found to impact β cell function and mass. Low-density lipoprotein (LDL) can promote apoptosis, while high-density lipoprotein (HDL) can block it.[129](/articles/s41392-024-01951-9#ref-CR129 \"Brunham, L. R., Kruit, J. K., Verchere, C. B. & Hayden, M. R. Cholesterol in islet dysfunction and type 2 diabetes. J. Clin. Invest. 118, 403–408 (2008).\") In addition, the cholesterol homeostasis of β cells is essential for the insulin secretion, as accumulated cholesterol in the plasma membrane resulting in impaired secretion via exocytosis, and reduced cholesterol in insulin granules making them enlarged, also resulting in secretory dysfunction.[130](/articles/s41392-024-01951-9#ref-CR130 \"Brunham, L. R. et al. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340–347 (2007).\"),[131](/articles/s41392-024-01951-9#ref-CR131 \"Sturek, J. M. et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells. J. Clin. Invest. 120, 2575 (2010).\") Many polymorphisms and mutations in the genes involved in cholesterol homeostasis of β cells are associated with T2D in multiple ethnic populations.[129](/articles/s41392-024-01951-9#ref-CR129 \"Brunham, L. R., Kruit, J. K., Verchere, C. B. & Hayden, M. R. Cholesterol in islet dysfunction and type 2 diabetes. J. Clin. Invest. 118, 403–408 (2008).\")\\n\\n#### Inflammation\\n\\nThe inflammatory response in islets can be secondary to a variety of factors, such as metabolites, ROS,[132](/articles/s41392-024-01951-9#ref-CR132 \"Maedler, K. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851–860 (2002).\"),[133](/articles/s41392-024-01951-9#ref-CR133 \"Kim, E.-K. et al. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J. Biochem Cell Biol. 39, 1260–1275 (2007).\") and proinflammatory factors released by adipose tissue with low-grade chronic inflammation.[30](/articles/s41392-024-01951-9#ref-CR30 \"Bays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89, 463–478 (2004).\"),[31](/articles/s41392-024-01951-9#ref-CR31 \"Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645 (2012).\") These compounds induce an increase in cytokines such as IL-1β, activating NF-κB signaling,[134](/articles/s41392-024-01951-9#ref-CR134 \"Kaneto, H. et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44, 733–738 (1995).\") leading to IL-1β-mediated β cell dysfunction and apoptosis.[134](/articles/s41392-024-01951-9#ref-CR134 \"Kaneto, H. et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44, 733–738 (1995).\") The NLRP3 is also upregulated resulting from activated NF-κB, and activates caspase 1 which induces β cell pyroptosis, a type of programmed cell death characterized by the formation of pores in the plasma membrane, leading to the release of proinflammatory cytokines and subsequent cell lysis[38](/articles/s41392-024-01951-9#ref-CR38 \"Prasad, M. K., Mohandas, S. & Ramkumar, K. M. Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic β-cells in diabetes. Apoptosis 28, 958–976 (2023).\"),[135](/articles/s41392-024-01951-9#ref-CR135 \"Li, X., Xiao, G.-Y., Guo, T., Song, Y.-J. & Li, Q.-M. Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications. Front. Endocrinol. (Lausanne) 13, 986565 (2022).\") (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\nIn addition, increasing STAT3 from activated JAK/STAT signaling pathway might be involved in the apoptosis of β cell through PTEN, which inhibits Akt cascade, resulting in exacerbated hyperglycemia[136](/articles/s41392-024-01951-9#ref-CR136 \"Weng, Q. et al. STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. Cell Death Differ. 27, 130–145 (2020).\") (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\nImmune cells in islets also contribute to the loss of β cells. Macrophages induce the expression of the neutrophil chemokine (C-X-C motif) ligand 8a (Cxcl8a) in β cells under ERS, recruit neutrophils into islets thus promoting the loss of β cells.[137](/articles/s41392-024-01951-9#ref-CR137 \"Yang, B. et al. Macrophages and neutrophils are necessary for ER stress-induced β cell loss. Cell Rep. 40, 111255 (2022).\"),[138](/articles/s41392-024-01951-9#ref-CR138 \"Yang, B. et al. RIPK3-mediated inflammation is a conserved β cell response to ER stress. Sci. Adv. 6, eabd7272 (2020).\")\\n\\n#### ERS\\n\\nContinuous insulin production and secretion in β cells under chronic hyperglycemia and IR result in the overload of protein folding machinery and the accumulation of excessive misfolded or unfolded proteins in the ER, therefore triggering UPR and the ERS. In addition, many metabolites and also ROS are capable of activating ERS networks directly.[139](/articles/s41392-024-01951-9#ref-CR139 \"Chung, S. S. et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. Am. J. Physiol. Endocrinol. Metab. 301, E912–E921 (2011).\"),[140](/articles/s41392-024-01951-9#ref-CR140 \"Tang, C. et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia 55, 1366–1379 (2012).\")\\n\\nThe UPR relieves cellular load by reshaping the capacity for ER synthesis. However, sustained activation of the UPR can trigger the apoptotic pathway, leading to apoptosis of β cells.[141](/articles/s41392-024-01951-9#ref-CR141 \"Hetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421–438 (2020).\"),[142](/articles/s41392-024-01951-9#ref-CR142 \"Sharma, R. B., Landa-Galván, H. V. & Alonso, L. C. Living dangerously: protective and harmful ER stress responses in pancreatic β-cells. Diabetes 70, 2431–2443 (2021).\") ERS-induced apoptosis in β cells is largely dependent on increasing CHOP and decreasing BCL-2, while activation of IKKβ and JNK1 by IRE1α binding with TRAF2 also promotes mitochondria-mediated apoptosis in β cells[37](/articles/s41392-024-01951-9#ref-CR37 \"Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol. Asp. Med. 66, 49–61 (2019).\"),[58](/articles/s41392-024-01951-9#ref-CR58 \"Back, S. H. & Kaufman, R. J. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev. Biochem. 81, 767–793 (2012).\"),[59](/articles/s41392-024-01951-9#ref-CR59 \"Gorman, A. M., Healy, S. J. M., Jäger, R. & Samali, A. Stress management at the ER: Regulators of ER stress-induced apoptosis. Pharm. Thers 134, 306–316 (2012).\") (Fig. [2d](/articles/s41392-024-01951-9#Fig2)).\\n\\nHyperglucotoxicity and lipotoxicity increase the expression of islet THADA. Firstly, it reduces ER calcium storage by reducing calcium reuptake and increasing calcium leakage. Secondly, the decreasing insulin 1/2 (INS1/2) transcription and the smaller insulin-secreting vesicles are observed after the upregulation of THADA, together leading to the impaired insulin secretion. In addition, THADA can cause apoptosis in β cells by activating the death receptor 5 (DR5)/Fas-associated death domain (FADD)/caspase 8 pathway under ERS.[143](/articles/s41392-024-01951-9#ref-CR143 \"Zhang, Y. et al. THADA inhibition in mice protects against type 2 diabetes mellitus by improving pancreatic β-cell function and preserving β-cell mass. Nat. Commun. 14, 1020 (2023).\")\\n\\n#### Oxidative stress\\n\\nROS are byproducts of mitochondrial oxidative phosphorylation and are scavenged by antioxidant systems.[125](/articles/s41392-024-01951-9#ref-CR125 \"Bensellam, M., Laybutt, D. R. & Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. Mol. Cell Endocrinol. 364, 1–27 (2012).\") The expression of the antioxidant enzymes in islet β cells is low, leading to a greater tendency for them to be affected by oxidative stress.[125](/articles/s41392-024-01951-9#ref-CR125 \"Bensellam, M., Laybutt, D. R. & Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. Mol. Cell Endocrinol. 364, 1–27 (2012).\"),[139](/articles/s41392-024-01951-9#ref-CR139 \"Chung, S. S. et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. Am. J. Physiol. Endocrinol. Metab. 301, E912–E921 (2011).\")\\n\\nUnder chronic hyperglycemia, glycolysis becomes saturated, and excessive ROS are produced by alternative metabolic pathways to induce oxidative stress, causing mitochondrial and DNA damage. The impaired mitochondrial fails to produced sufficient ATP in a short time to activate VGCC, leading to impaired release of insulin granular,[123](/articles/s41392-024-01951-9#ref-CR123 \"Cui, D. et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. Chin. Med. J. (Engl.) 137, 791 (2024).\") while the downregulation of PDX1 and MAFA results in reduced transcription of insulin.\\n\\nIn addition, excessive NEFAs lead to increasing lipid esterification and ceramide production, causing oxidative stress, and promoting the production of NO. It also downregulates PDX1 and MAFA,[26](/articles/s41392-024-01951-9#ref-CR26 \"Poitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr. Rev. 29, 351–366 (2008).\") thus resulting in impaired insulin synthesis[63](/articles/s41392-024-01951-9#ref-CR63 \"Gupta, D., Kono, T. & Evans-Molina, C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes. Metab. 12, 1036–1047 (2010).\"),[139](/articles/s41392-024-01951-9#ref-CR139 \"Chung, S. S. et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. Am. J. Physiol. Endocrinol. Metab. 301, E912–E921 (2011).\") (Fig. [2c](/articles/s41392-024-01951-9#Fig2)).\\n\\nFurthermore, JNK activated by ROS under chronic hyperglycemia also leads to mitochondrial-induced apoptosis via multiple genes regulating cell proliferation and survival such as BCL-XL and BCL-2[80](/articles/s41392-024-01951-9#ref-CR80 \"Leibowitz, G., Cerasi, E. & Ketzinel-Gilad, M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes. Metab. 10, 157–169 (2008).\") (Fig. [2d](/articles/s41392-024-01951-9#Fig2)). MST1 in the hippo pathways is also strongly activated in T2D, inducing β cell apoptosis through activation of JNK and impairing β cell function through destabilizing PDX1[144](/articles/s41392-024-01951-9#ref-CR144 \"Ardestani, A. et al. MST1 is a novel regulator of apoptosis in pancreatic beta-cells. Nat. Med. 20, 385–397 (2014).\") (Fig. [2i](/articles/s41392-024-01951-9#Fig2)). Mature islet β cells lack the expression of YAP, while overexpression of YAP in islets is associated with proliferative and antiapoptotic effects.[145](/articles/s41392-024-01951-9#ref-CR145 \"Yuan, T. et al. Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells. JCI Insight 1, e86326 (2016).\")\\n\\n#### Ectopic lipid deposition in islet\\n\\nNonalcoholic fatty pancreas disease (NAFPD) is defined as fat accumulation in the pancreas associated with obesity and the MDS.[146](/articles/s41392-024-01951-9#ref-CR146 \"Filippatos, T. D., Alexakis, K., Mavrikaki, V. & Mikhailidis, D. P. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, ‘prediabetes,’ diabetes and atherosclerosis. Dig. Dis. Sci. 67, 26–41 (2022).\") A 10-year prospective cohort study showed an independent association between fatty pancreas and subsequent T2D development.[147](/articles/s41392-024-01951-9#ref-CR147 \"Tt, C. et al. Fatty pancreas is independently associated with subsequent diabetes mellitus development: a 10-year prospective cohort study. Clin. Gastroenterol. Hepatol. 20, 2013–2022 (2022).\")\\n\\nObesity and IR lead to an increased delivery of NEFAs from adipose tissue to the liver and pancreas. However, unlike in hepatic tissue, fat deposition in pancreatic tissue occurs not intracellularly but rather intercellularly via adipocyte infiltration of the intralobular region, in both acinar and islet cells.[148](/articles/s41392-024-01951-9#ref-CR148 \"Pinnick, K. E. et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obes. (Silver Spring) 16, 522–530 (2008).\") The increased LDL, lipocalin-2, and hepatokine fetuin, as well as reduced adiponectin, may promote fat accumulation in the pancreas, which might be enhanced by inflammation and oxidative stress through the serine/threonine protein kinase 25 pathway.[146](/articles/s41392-024-01951-9#ref-CR146 \"Filippatos, T. D., Alexakis, K., Mavrikaki, V. & Mikhailidis, D. P. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, ‘prediabetes,’ diabetes and atherosclerosis. Dig. Dis. Sci. 67, 26–41 (2022).\")\\n\\nAlthough lack of exhaustive research on mechanism, fat accumulation in the pancreas is associated with β cell lipotoxicity, which may be enhanced from local paracrine pathways.[149](/articles/s41392-024-01951-9#ref-CR149 \"Gerst, F. et al. What role do fat cells play in pancreatic tissue? Mol. Metab. 25, 1–10 (2019).\") It results in β cell dysfunction,[150](/articles/s41392-024-01951-9#ref-CR150 \"Yu, T.-Y. & Wang, C.-Y. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J. Diabetes Investig. 8, 735–747 (2017).\") leading to the initiation of a vicious cycle that further aggravates metabolic diseases and NAFPD.\\n\\n#### Islet amyloid polypeptide (IAPP)\\n\\nIAPP, a protein that is coexpressed and cosecreted with insulin by β cells, forms membrane-permeable toxic oligomers and accumulates in the ER under continuous demand for insulin.[151](/articles/s41392-024-01951-9#ref-CR151 \"Haataja, L., Gurlo, T., Huang, C. J. & Butler, P. C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29, 303–316 (2008).\"),[152](/articles/s41392-024-01951-9#ref-CR152 \"Huang, C. et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56, 2016–2027 (2007).\") The mechanism of IAPP-induced cell death may also include inflammation and oxidative stress.[153](/articles/s41392-024-01951-9#ref-CR153 \"Montane, J., Klimek-Abercrombie, A., Potter, K. J., Westwell-Roper, C. & Bruce Verchere, C. Metabolic stress, IAPP and islet amyloid. Diabetes Obes. Metab. 14, 68–77 (2012).\")\\n\\nAs a compensatory mechanism, IAPP may activate HIF-1α/6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) to protect against oligomer toxicity, thus delaying the loss of β cells but at the cost of impairing β cell function.[154](/articles/s41392-024-01951-9#ref-CR154 \"Montemurro, C. et al. IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nat. Commun. 10, 2679 (2019).\") However, HIF-1α in islets is decreased in T2D, by hyperglycemia through inhibiting the HIF-1α-HIF-1β dimer formation, and by NEFAs through increasing the proteolysis, leading to inability to initiate hypoxic adaptive responses.[155](/articles/s41392-024-01951-9#ref-CR155 \"Gunton, J. E. Hypoxia-inducible factors and diabetes. J. Clin. Invest. 130, 5063–5073 (2020).\") Depletion of HIF-1α shows impaired GSIS, due to the decreased basal and glucose-stimulated ATP concentration[155](/articles/s41392-024-01951-9#ref-CR155 \"Gunton, J. E. Hypoxia-inducible factors and diabetes. J. Clin. Invest. 130, 5063–5073 (2020).\"),[156](/articles/s41392-024-01951-9#ref-CR156 \"Gonzalez, F. J., Xie, C. & Jiang, C. The role of hypoxia-inducible factors in metabolic diseases. Nat. Rev. Endocrinol. 15, 21–32 (2018).\") (Fig. [2h](/articles/s41392-024-01951-9#Fig2)).\\n\\n#### Other signaling pathways involved in β cell dysfunction\\n\\nmTOR can phosphorylate AGC family of protein kinases, regulating cell survival and proliferation.[79](/articles/s41392-024-01951-9#ref-CR79 \"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).\") Chronic hyperglycemia activates mTORC1 and reduces mTORC2 activity[157](/articles/s41392-024-01951-9#ref-CR157 \"Yuan, T. et al. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. Diabetologia 60, 668–678 (2017).\") in islet β cells, which leads to the translocation of FOXO1 to nucleus and less nuclear PDX1, resulting in reduced insulin synthesis and secretion and impaired β cell mass[80](/articles/s41392-024-01951-9#ref-CR80 \"Leibowitz, G., Cerasi, E. & Ketzinel-Gilad, M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. Diabetes Obes. Metab. 10, 157–169 (2008).\"),[158](/articles/s41392-024-01951-9#ref-CR158 \"Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G. & Maedler, K. mTORC1 signaling: a double-edged sword in diabetic β cells. Cell Metab. 27, 314–331 (2018).\") (Fig. [2e](/articles/s41392-024-01951-9#Fig2)).\\n\\nGenerally, canonical Wnt cascades such as Wnt3a can stimulate insulin secretion and enhance the proliferation of β cell by activating β-catenin/TCF/LEF-mediated Cyclin D1 transcription.[50](/articles/s41392-024-01951-9#ref-CR50 \"Tian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. Crit. Rev. Food Sci. Nutr. 64, 5039–5056 (2022).\") However, in T2D, most non-classical Wnt ligands such as Wnt4 and Wnt2a are highly upregulated,[159](/articles/s41392-024-01951-9#ref-CR159 \"Chen, J. et al. Role of Wnt signaling pathways in type 2 diabetes mellitus. Mol. Cell Biochem. 476, 2219–2232 (2021).\") inhibiting Wnt3a and promoting β cell dysfunction.[160](/articles/s41392-024-01951-9#ref-CR160 \"Bowen, A., Kos, K., Whatmore, J., Richardson, S. & Welters, H. J. Wnt4 antagonises Wnt3a mediated increases in growth and glucose stimulated insulin secretion in the pancreatic beta-cell line, INS-1. Biochem. Biophys. Res. Commun. 479, 793–799 (2016).\") In addition, Wnt2b and TCF7L2, encoding an important transcription factor TCF4, are associated with the susceptibility of T2D among individuals with impaired glucose tolerance[161](/articles/s41392-024-01951-9#ref-CR161 \"Florez, J. C. et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241–250 (2006).\") (Fig. [2g](/articles/s41392-024-01951-9#Fig2))\\n\\nNotch signaling is also critical for pancreas development and endocrine specification. Hyperglycemia increases notch activity in vitro and vivo, and consistent activation of notch results in impaired GSIS and blocks maturation of β cells, which may be a result of degradation of MAFA due to the blockage of its binding to kat2b.[162](/articles/s41392-024-01951-9#ref-CR162 \"Bartolome, A., Zhu, C., Sussel, L. & Pajvani, U. B. Notch signaling dynamically regulates adult β cell proliferation and maturity. J. Clin. Invest. 129, 268–280 (2019).\") In addition, activated notch may affect islet architecture through Ephrin A5 (EFNA5) which is increased in T2D[163](/articles/s41392-024-01951-9#ref-CR163 \"Bartolomé, A. et al. Notch-mediated Ephrin signaling disrupts islet architecture and β cell function. JCI Insight 7, e157694 (2022).\") (Fig. [2e](/articles/s41392-024-01951-9#Fig2))\\n\\nSince the diagnosis of T2D relies primarily on exclusion, the clinical phenotype varies widely. However, IR and secondary β cell dysfunction leading to increasing blood glucose accounts for the majority of cases. Elevated blood glucose triggers hyperglucotoxicity, leading to aggravation of IR and deterioration of β cell function, creating a vicious cycle that leads to further elevation of blood glucose to diabetic levels and even hyperglycemic crises.[164](/articles/s41392-024-01951-9#ref-CR164 \"Li, M. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct. Target Ther. 7, 216 (2022).\") In addition, hyperglycemia and other metabolic disorders such as dyslipidemia, inflammatory factors, excess IAPP and alterations in the gut microbiota, combine to contribute to IR and/or β cell dysfunction through the common pathways of inflammation, ERS and oxidative stress (Fig. [3](/articles/s41392-024-01951-9#Fig3)).\\n\\n![figure 3](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01951-9/MediaObjects/41392_2024_1951_Fig3_HTML.png)\\n\\nA sketch of pathogenesis of T2D. Briefly, Under the stimulation of SFAs, hypoxia in adipocytes due to enhanced SFAs metabolism, and the release of inflammatory factors from macrophage infiltration cause chronic inflammation in adipose tissues, leading to adipocyte IR and increased lipolysis. NEFAs and glycerol from lipolysis causes increased lipid synthesis, gluconeogenesis, and ectopic fat deposition in the liver, which affects IRS-1/PI3K/Akt2 phosphorylation on the one hand, and increases hepatic release of glucose on the other. At the same time, ectopic fat deposition also occurs in the muscle and leads to elevated circulating VLDL, further exacerbating lipid metabolism disorders and IR in the liver. Persistent hyperglycemia and excess fatty acids in the circulation due to overnutrition and IR further damage β-cell function and mass by some shared pathways, involving inflammation, ERS, and oxidative stress. IR insulin resistance, SFAs saturated fatty acid, NEFAs non-esterified fatty acids, TNF-α tumor necrosis factor α, IL-1β interleukin-1β, JNK c-Jun N-terminal kinase, FASN fatty acid synthase, DAG diacylglycerol, FA-CoA Fatty acyl-coenzyme A, ANT-2 adenine nucleotide translocase 2, HIF-1α hypoxia-inducible factor 1 alpha, NLRP3 NOD-like receptor family pyrin domain-containing 3, GABA γ-aminobutyric acid, PP2A protein phosphatase 2A, PKC protein kinase C, AMPK adenosine 5’-monophosphate-activated protein kinase, VLDL very-low-density lipoprotein, ROS reactive oxygen species, NF-κB nuclear factor-kappa B, Cxcl8a neutrophil chemokine (C-X-C motif) ligand 8a, ERS endoplasmic reticulum stress, CHOP C/EBP homologous protein, PDX1 pancreatic and duodenal homeobox factor-1, MAFA MAF bZIP transcription factor A\\n\\n## Diagnosis and screening\\n\\nThe diagnostic criteria for diabetes are internationally consistent. Both the ADA and the World Health Organization (WHO) have adopted fasting blood glucose (FBG), 2-hour postprandial blood glucose (2-h PG), and random blood glucose levels as diagnostic criteria for diabetes mellitus; later, HbA1c was included in the diagnostic criteria for expanded screening. The diagnostic cutoff points are shown in Table [1](/articles/s41392-024-01951-9#Tab1). And recently, International Diabetes Federation (IDF) state that people with 1-hour postprandial glucose (1-h PG)\\u2009≥8.6\\u2009mmol/L are considered to be have prediabetes while ≥11.6\\u2009mmol/L to have diabetes.[165](/articles/s41392-024-01951-9#ref-CR165 \"Bergman, M. & Tuomilehto, J. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res. Clin. Pr. 210, 111636 (2024).\") However, for prediabetes, which is defined as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), the diagnostic scope of the WHO and ADA for FBG and HbA1c are not completely consistent. In addition, the WHO divides individuals with prediabetes into two groups (IFG or IGT) without distinguishing between those with both IFG and IGT (IGF\\u2009+\\u2009IGT), while the ADA divides those individuals into three groups (IFG, IGT, IGF\\u2009+\\u2009IGT). Our meta-analysis revealed that patients with prediabetes and IGF\\u2009+\\u2009IGT have a greater risk of T2D, suggesting that it is more reasonable to classify prediabetes into three subtypes, as ADA does.[166](/articles/s41392-024-01951-9#ref-CR166 \"Liu, Y. et al. Evidence from a systematic review and meta-analysis: classical impaired glucose tolerance should be divided into subgroups of isolated impaired glucose tolerance and impaired glucose tolerance combined with impaired fasting glucose, according to the risk of progression to diabetes. Front. Endocrinol. (Lausanne) 13, 835460 (2022).\") T2D has long been found mostly in adults, but it is increasingly common in adolescents and children due to the increase in obesity in these individuals.[167](/articles/s41392-024-01951-9#ref-CR167 \"Twig, G. et al. Adolescent obesity and early-onset type 2 diabetes. Diabetes Care 43, 1487–1495 (2020).\") It is important to note that we set absolute blood glucose cutoff points, but blood glucose abnormalities and the risk of developing T2D are continuous processes. A meta-analysis of 16 studies showed that for people with HbA1c between 5.5–6%, the 5-year risk of developing diabetes is 9–25%, while for people with HbA1c between 6–6.5%, the 5-year risk increases to 25–50%.[168](/articles/s41392-024-01951-9#ref-CR168 \"Zhang, X. et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 33, 1665–1673 (2010).\") The Whitehall II cohort study showed a linear trend in glycemic trajectories during the natural onset of T2D, with a sharp increase in blood glucose 2 years before T2D.[169](/articles/s41392-024-01951-9#ref-CR169 \"Tabák, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009).\") Baseline characteristics at diagnosis of T2D might be used to predict early glycemic deterioration followed by more aggressive interventions. A study revealed that baseline characteristics such as younger age (<58 years), higher HbA1c, fasting glucose, and TG levels were associated with subsequent glycemic control, and patients with younger age and higher HbA1c at baseline were more likely to fail to maintain HbA1c\\u2009<7%,[170](/articles/s41392-024-01951-9#ref-CR170 \"Garvey, W. T. et al. Association of baseline factors with glycemic outcomes in GRADE: a comparative effectiveness randomized clinical trial. Diabetes Care 47, 562–570 (2024).\") which indicates the crucial in early diagnosis.\\n\\nIn 2021, it is estimated that almost one in two adults with diabetes were unaware of their diabetes status, with nearly one-quarter of those with diabetes diagnosed in North America and the Caribbean, 52.8% in the Western Pacific, 51.3% in Southeast Asia and 53.6% in Africa remaining undiagnosed.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[171](/articles/s41392-024-01951-9#ref-CR171 \"Ogurtsova, K. et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res. Clin. Pr. 183, 109118 (2022).\") Because it is asymptomatic, patients usually cannot notice. However, the risk of diabetes still exists, and the duration of glycemic burden is a strong predictor of adverse outcomes.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Therefore, screening for diabetes is necessary and crucial, especially for patients with high-risk factors, and early diagnosis and treatment can effectively improve patient prognosis. Age, preobese/obese status and prediabetes are the major risk factors for diabetes. The risk of diabetes increases significantly with age, and it is recommended by the ADA that all people ≥35 years old be screened for diabetes since the positive detection rate of diabetes is greatly increased.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Preobesity/obesity is defined by body mass index (BMI), which is considered preobesity if the BMI is ≥25\\u2009kg/m2 (≥23\\u2009kg/m2 in Asia) or obese if the BMI is ≥30\\u2009kg/m2 (≥27.5\\u2009kg/m2 in Asia). Additionally, preobesity/obesity can cause hypertension, IR and lipid disorders, which all contribute to T2D and are used for T2D screening.[172](/articles/s41392-024-01951-9#ref-CR172 \"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163 (2004).\") However, BMI cannot be used as a proxy for the amount of body fat since people with the same BMI may have different fat contents and distributions, which represent different risks of diabetes.[173](/articles/s41392-024-01951-9#ref-CR173 \"Prillaman, M. Why BMI is flawed—and how to redefine obesity. Nature 622, 232–233 (2023).\") Several indicators have been proposed to redefine obesity rather than BMI. The waist-to-height ratio (WHtR), defined by waist circumference (cm)/height (cm), has been proposed as a surrogate indicator of BMI. A meta-analysis consisting of 72 prospective studies showed that central adiposity, defined as the accumulation of excess fat in the abdominal area, was positively associated with all-cause mortality, and the WHtR had the highest hazard ratio (1.24), suggesting that central adiposity measurements, such as the waist-to-hip ratio, the WHtR, and waist circumference, can be used as supplements for determining BMI.[174](/articles/s41392-024-01951-9#ref-CR174 \"Jayedi, A., Soltani, S., Zargar, M. S., Khan, T. A. & Shab-Bidar, S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 370, m3324 (2020).\") According to the guidelines of the National Institute for Health and Care Excellence (NICE), adults with a BMI\\u2009<35\\u2009kg/m2 are also recommended for whom the WHtR is measured to assess central adiposity and central adiposity and to use these data to help assess and predict health risks.[175](/articles/s41392-024-01951-9#ref-CR175 \"National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management (NICE, 2023).\") The International Society of Hypertension (ISH) also recommends that body weight be managed by maintaining the WHtR below 0.5, which is suggested to be the cutoff point by the NICE.[176](/articles/s41392-024-01951-9#ref-CR176 \"Charchar, F. J. et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J. Hypertens. 42, 23–49 (2024).\") In addition to risk factors, the practical way to screen for diabetes is to perform fasting blood glucose and HbA1c tests at the same time as annual physical examination, which can detect the vast majority of diabetic patients in time. Our study revealed that a point-of-care test (POCT) of FBG\\u2009≥5.3\\u2009mmol/L is a more cost-effective method for screening those with undiagnosed diabetes, suggesting that patients with a POCT of FBG\\u2009≥5.3\\u2009mmol/L should perform confirm test of diabetes. We believe that this method is feasible and inexpensive for detecting diabetes and is worth recommending because POCT is convenient and readily available.[177](/articles/s41392-024-01951-9#ref-CR177 \"Xu, S. et al. Evaluation of the value of diabetes risk scores in screening for undiagnosed diabetes and prediabetes: a community-based study in southwestern China. Postgrad. Med. 132, 737–745 (2020).\")\\n\\nFor many years, venous blood glucose and laboratory-based HbA1c have been used as standard biomarkers and technologies for diagnosing and screening of diabetes. Meanwhile, novel potential biomarkers are still being sought.\\n\\nSome of the clinically validated biomarkers such as glycated albumin (GA), fructosamine (FA), 1,5-anhydroxybergamottinol (1,5-AHG) showed high specificity and sensitivity in diagnosis and can be used for alternative markers when HbA1c cannot be measured in specific situations.[178](/articles/s41392-024-01951-9#ref-CR178 \"Ortiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr. Diabetes Rep. 22, 95–115 (2022).\") In addition, there are a number of novel markers such as fetuin-A, branched-chain amino acids (BCAAs), adipokines, linoleoylglyglycerophosphocholine (L-GPC), lysophosphatidylcholine (LysoPC) which are discovered by metabolomics showed strong relationship with HbA1c or blood glucose, indicating their future potential in diagnosis and screening.[178](/articles/s41392-024-01951-9#ref-CR178 \"Ortiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr. Diabetes Rep. 22, 95–115 (2022).\"),[179](/articles/s41392-024-01951-9#ref-CR179 \"Laakso, M. Biomarkers for type 2 diabetes. Mol. Metab. 27S, S139–S146 (2019).\") More than 30 genetic factors are associated with increased risk for T2D. However, the risk alleles in these loci all have relatively small effects and do not significantly enhance our ability to predict the risk of T2D.[180](/articles/s41392-024-01951-9#ref-CR180 \"Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 69, 808–868 (2023).\")\\n\\nUnconventional body fluid glucose testing will be a new direction for future development, but further studies are still needed to support its clinical application. There have been reports that glucose in sweat, tears, and saliva for diagnosis and screening of diabetes.[181](#ref-CR181 \"Caixeta, D. C. et al. Salivary molecular spectroscopy: a sustainable, rapid and non-invasive monitoring tool for diabetes mellitus during insulin treatment. PLoS ONE 15, e0223461 (2020).\"),[182](#ref-CR182 \"Ascaso, F. J. & Huerva, V. Noninvasive continuous monitoring of tear glucose using glucose-sensing contact lenses. Optom. Vis. Sci. 93, 426–434 (2016).\"),[183](/articles/s41392-024-01951-9#ref-CR183 \"Lee, H. et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. Sci. Adv. 3, e1601314 (2017).\") Study showed that glucose levels in saliva are highly significantly correlated with serum glucose levels, but there is a lack of validated methods to detect salivary glucose nor have critical reference values been established, and the relationship between glucose in tears and sweat and serum glucose is inconclusive.[178](/articles/s41392-024-01951-9#ref-CR178 \"Ortiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr. Diabetes Rep. 22, 95–115 (2022).\"),[180](/articles/s41392-024-01951-9#ref-CR180 \"Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 69, 808–868 (2023).\") In addition, urine glucose is advocated by the IDF as a screening test for undiagnosed diabetes in a low-resource setting without other procedures.[178](/articles/s41392-024-01951-9#ref-CR178 \"Ortiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Curr. Diabetes Rep. 22, 95–115 (2022).\"),[180](/articles/s41392-024-01951-9#ref-CR180 \"Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 69, 808–868 (2023).\")\\n\\nPortable blood glucose testing and continuous glucose monitoring (CGM) are also commonly used as blood glucose testing devices. Current evidence is insufficient to support their use for diagnostic purposes, however, there have been results showed its potential. 40% and 3% patients who would have been considered to have normal FBG based on the first FBG measurement could been reclassified as having glucose in the prediabetes and diabetes ranges, respectively, based on sequential measurements throughout the study.[184](/articles/s41392-024-01951-9#ref-CR184 \"Shilo, S. et al. Continuous glucose monitoring and intrapersonal variability in fasting glucose. Nat. Med. 30, 1424–1431 (2024).\") CGM detect higher blood glucose levels in pregnant women with gestational diabetes mellitus (GDM) prior to the OGTT, suggesting a potential future role in the early diagnosis of GDM.[185](/articles/s41392-024-01951-9#ref-CR185 \"Durnwald, C. et al. Continuous Glucose Monitoring Profiles in Pregnancies With and Without Gestational Diabetes Mellitus. Diabetes Care \\n                  https://doi.org/10.2337/dc23-2149\\n                  \\n                \")\\n\\nPOCT devices are convenient and fast, and POCT HbA1c have been allowed for diabetes screening and diagnosis but should be restricted to U.S. Food and Drug Administration (FDA)-approved devices at CLIA-certified laboratories that perform testing of moderate complexity or higher. Noninvasive glucose sensing is also a promising technique but FDA hasn’t approved any noninvasive device for clinical measurement due to the lack of the ability to produce stable calibration functions required for practical clinical operation.[180](/articles/s41392-024-01951-9#ref-CR180 \"Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 69, 808–868 (2023).\")\\n\\n## Prevention\\n\\nThe Whitehall II study showed that people with prediabetes are already at a steep end of the glycemia trajectory,[169](/articles/s41392-024-01951-9#ref-CR169 \"Tabák, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009).\") which means that blood glucose is likely to increase at an accelerated rate and progress to T2D. In addition, people with prediabetes already exhibit a loss of islet β cells and impairment of target tissues. Approximately 30–50% of islet β cell function is lost in individuals with prediabetes,[186](/articles/s41392-024-01951-9#ref-CR186 \"Ferrannini, E. et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 90, 493–500 (2005).\") and approximately 10% of people with prediabetes develop DR or polyneuropathy.[187](/articles/s41392-024-01951-9#ref-CR187 \"Ziegler, D. et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31, 464–469 (2008).\"),[188](/articles/s41392-024-01951-9#ref-CR188 \"Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 24, 137–144 (2007).\") Therefore, aggressive actions are necessary and important for preventing T2D in people at high risk (such as those with an HbA1c\\u2009>6%).\\n\\n### Lifestyle intervention\\n\\nSeveral major trials have shown some effective interventions to prevent the occurrence of T2D and even reduce the risk of TOD. Intensive lifestyle interventions, including physical activities and individualized medical nutrition treatment (MNT), have been proven to be highly effective at preventing diabetes. Exercise, diet or a combination of both can reduce T2D risk by 30–60% according to large-scale RCT trials (the IDPP, DPP, FDPS, and Da Qing trials), and the variation in the reduction rate may be due to differences in the population in those trials, while people with a greater BMI and older age had a greater reduction in T2D risk.[189](#ref-CR189 \"Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537–544 (1997).\"),[190](#ref-CR190 \"Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).\"),[191](#ref-CR191 \"Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).\"),[192](/articles/s41392-024-01951-9#ref-CR192 \"Ramachandran, A. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49, 289–297 (2006).\") Weight loss is an important factor in intensive lifestyle intervention since both the DPP and FDPS trials set a goal for weight loss achieved by physical activities and a calorie-reduced diet. As shown in the DPP, for every kilogram of weight loss, the risk of T2D was reduced by 16%.[193](/articles/s41392-024-01951-9#ref-CR193 \"Hamman, R. F. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29, 2102–2107 (2006).\") There is also evidence that physical activity and nutrition have preventive effects and metabolic improvement independent of body weight. In the Da Qing trial, analysis of the relatively lean subgroup (BMI\\u2009<25\\u2009kg/m2) showed that even with weight gain, lifestyle intervention still significantly reduced the risk of T2D.[189](/articles/s41392-024-01951-9#ref-CR189 \"Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537–544 (1997).\") In the long-term follow-up, both physical activity and nutritional treatment showed sustained benefits for T2D prevention, which still significantly reduced the risk of progression to T2D by 45% and 39%, respectively, after 23 and 30 years of follow-up in the Da Qing trial; by 43% after a 7-year follow-up in the FDPS; and by 27% after a 15-year follow-up.[194](#ref-CR194 \"Gong, Q. et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 7, 452–461 (2019).\"),[195](#ref-CR195 \"Li, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474–480 (2014).\"),[196](#ref-CR196 \"Lindström, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673–1679 (2006).\"),[197](/articles/s41392-024-01951-9#ref-CR197 \"Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3, 866–875 (2015).\") Da Qing trials also showed significant cardiovascular benefits, which included a reduced incidence of cardiovascular events and cardiovascular and all-cause mortality; however, follow-up with DPP did not reveal improvements in microvascular or cardiovascular mortality.[194](/articles/s41392-024-01951-9#ref-CR194 \"Gong, Q. et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 7, 452–461 (2019).\"),[195](/articles/s41392-024-01951-9#ref-CR195 \"Li, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474–480 (2014).\"),[197](/articles/s41392-024-01951-9#ref-CR197 \"Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3, 866–875 (2015).\"),[198](/articles/s41392-024-01951-9#ref-CR198 \"Lee, C. G. et al. Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 44, 2775–2782 (2021).\")\\n\\n### Medications\\n\\nThere are no medications have been proven for a specific indication of T2D prevention by FDA; however, several hypoglycemic agents metformin, α-glucosidase inhibitors (AGIs), thiazolidinediones (TZDs), sodium-glucose cotransporter inhibitors (SGLT-is, classified into two categories: SGLT-2i and SGLT-1 and SGLT-2 dual inhibitors, SGLT-1/2i), and glucagon-like peptide-1 (GLP-1) (we refer to this name, because its active ingredient is GLP-1, which includes human GLP-1 analogues, animal-origin GLP-1 or derivatives of exantine-4, while GLP-1 receptor agonists, which are now usually called, is the action target instead of active ingredients, and does not conform to the traditional classification by chemical name.) have been shown to prevent T2D in studies. Metformin was the first hypoglycemic agent studied for its ability to reduce T2D risk and it reduced the T2D risk by 31% and 26.5% in the DPP and IDPP trials, respectively. Acarbose reduced the risk of T2D by 25% in the STOP-NIDDM trial.[199](/articles/s41392-024-01951-9#ref-CR199 \"Chiasson, J.-L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077 (2002).\") Neither metformin nor acarbose has any cardiovascular benefits. TZDs reduced the risk of T2D by 60% and 72% in the DREAM and ACT NOW trials, respectively.[200](/articles/s41392-024-01951-9#ref-CR200 \"DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096–1105 (2006).\"),[201](/articles/s41392-024-01951-9#ref-CR201 \"DeFronzo, R. A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104–1115 (2011).\") The IRIS trial randomized nondiabetic patients with a history of recent ischemic stroke or transient ischemic attack and IR to pioglitazone or placebo; the results showed that pioglitazone reduced the risk of T2D by 52% and reduced the risk of any stroke or ischemic infarction by 24%.[202](/articles/s41392-024-01951-9#ref-CR202 \"Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331 (2016).\"),[203](/articles/s41392-024-01951-9#ref-CR203 \"Yaghi, S. et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation 137, 455–463 (2018).\") Those trials suggest that TZDs are comparable or even superior to lifestyle interventions. Pioglitazone not only is effective at preventing diabetes but is also the first hypoglycemic agent shown to have an anti-atherosclerotic effect on cardiovascular disease (secondary prevention) in nondiabetic patients. Liraglutide 3\\u2009mg per day significantly reduces the risk of T2D by 80% in individuals with prediabetes and preobesity or obesity.[204](/articles/s41392-024-01951-9#ref-CR204 \"le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017).\") Another two GLP-1 agents, semaglutide and tirzepatide, significantly convert abnormal glycemia in individuals with prediabetes with preobesity or obesity to normoglycemia.[205](/articles/s41392-024-01951-9#ref-CR205 \"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).\"),[206](/articles/s41392-024-01951-9#ref-CR206 \"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).\") Furthermore, 2.4\\u2009mg of semaglutide per week has been shown to reduce the risk of the composite outcome of cardiovascular death, nonfatal myocardial infarction (MI) and stroke (i.e., major adverse cardiovascular events [MACE] by 20%, and the risk of diabetes by 73% in nondiabetic patients with established atherosclerotic cardiovascular disease (ASCVD) and obesity, suggesting cardiovascular benefits (secondary prevention) of semaglutide in nondiabetic people and prevention of T2D.[207](/articles/s41392-024-01951-9#ref-CR207 \"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).\") However, GLP-1 has been demonstrated in only a specific population with preobesity or obesity, and further evaluation of the prevention of T2D in the general population is needed. The SGLT-2i dapagliflozin demonstrated a 33% reduction in the risk of T2D in a pooled analysis of the DAPA-CKD and DAPA-HF trials.[208](/articles/s41392-024-01951-9#ref-CR208 \"Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022).\") In the DAPA-MI trial, which enrolled nondiabetic patients with acute MI, dapagliflozin also significantly reduced the risk of diabetes.[209](/articles/s41392-024-01951-9#ref-CR209 \"James, S. et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 3, EVIDoa2300286 (2024).\")\\n\\nMetformin is well studied and has the longest history of safety for the prevention of diabetes and is recommended by ADA for patients at high risk of T2D; however, in terms of the chances of reducing the risk of diabetes, it is not as effective as liraglutide, semaglutide or TZDs, although there are no head-to-head studies. In addition, there is no evidence that metformin reduces the risk of ASCVD as pioglitazone or semaglutide did. Therefore, we do not consider metformin to be a reasonable choice for the prevention of T2D in terms of its cardiovascular effect and preventative effect diabetes. For patients without severe osteoporosis and heart failure (HF), particularly for ASCVD patients with IR, pioglitazone is a reasonable choice for the prevention of T2D. For preobese or obese people, especially those with ASCVD, semaglutide and liraglutide are reasonable choices. Dapagliflozin may be a reasonable choice for patients with HF and/or CKD.\\n\\n## Treatment\\n\\nPatients with T2D often exhibit a variety of comorbidities, such as dyslipidemia, preobesity/obesity, CKD and cardiovascular disease (CVD), and suffer from TOD caused by MDS. Therefore, T2D treatment usually includes holistic management of MDS, such as MASLD, hyperglycemia, dyslipidemia, hypertension, and preobesity/obesity, which are all risk factors for CVD and CKD by lifestyle intervention and necessary medication to reduce TOD, improve cardiovascular and renal outcomes, span life expectancy and improve quality of life. Notably, due to the diabetes stigma in media and society, for example, attributing diabetes simply to a personal unhealthy diet and ignoring genetic, regional, economic, and social factors, diabetic patients do not get support they deserve and may suffer from psychologically and socially negative impacts. Therefore, mounting voices have called for society to reduce diabetes stigma and patients to strengthen awareness of diabetes to avoid self-stigma.[210](/articles/s41392-024-01951-9#ref-CR210 \"Speight, J. et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 12, 61–82 (2024).\")\\n\\nSince the development of hypoglycemic agents, there have been various drugs that act via different mechanisms, ranging from the older agents metformin, insulin secretagogues, AGIs, TZDs, and insulin to new ones, such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and GLP-1; SGLT-is, which includes SGLT-2i, such as dapagliflozin and empagliflozin; and SGLT-1/2i, such as sotagliflozin and canagliflozin. How to choose the appropriate hypoglycemic regimen for patients has become an increasingly prominent need. It is reasonable to stratify treatment regimens according to glycemic targets and current blood glucose levels and based on this, personalized treatment considering target organ protection, comorbidities, treatment goals, costs, access to medication and patient preferences can be administered.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Stratified glycemic targets\\n\\nSubstantial studies have shown that good glycemic control can reduce TOD and cardiovascular risk. The glycemic targets should be specialized according to individual characteristics (duration of diabetes, risk of hypoglycemia, advanced age, microvascular disease and comorbidities such as CVD, life expectancy, and social factors). For people with diabetes, in general, it is appropriate for most nonpregnant adults to have their glycemic target controlled at less than 7%. For young or middle-aged patients without organ lesions, the HbA1c level should be reduced to normal or <5.7% to minimize vascular lesions due to a long life expectancy.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Patients with diabetes who have a relatively long enough life expectancy to achieve macro- or microvascular benefits of tighter glycemic control and few microvascular diseases and comorbidities can pursue more stringent glycemic control (<6–6.5%[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")) without increasing hypoglycemic risk. For those with advanced age, short life expectancy, frequent hypoglycemia and severe comorbidities, more relaxed targets should be taken (<8% recommended by the ADA[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") and 8.5% recommended by the European Society of Cardiology (ESC)[212](/articles/s41392-024-01951-9#ref-CR212 \"Marx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 39, 4043–4140 (2023).\")) because the risks associated with intensive glycemic control may outweigh the benefits. Several key trials suggest that although intensive glycemic control may reduce the incidence of macrovascular and microvascular complications,[213](/articles/s41392-024-01951-9#ref-CR213 \"ADVANCE Collaborative Group. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).\"),[214](/articles/s41392-024-01951-9#ref-CR214 \"Lachin, J. M. & Nathan, D. M. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 44, 2216–2224 (2021).\") it is not significant for patients with longer durations of diabetes, advanced age and established or at high risk of CVD,[215](/articles/s41392-024-01951-9#ref-CR215 \"Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Circulation 119, 351–357 (2009).\") and even showed increased mortalities as ACCORD trial was halted early because of increased mortality rate.[216](/articles/s41392-024-01951-9#ref-CR216 \"Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010).\")\\n\\n### Baseline HbA1c stratification\\n\\nTreatment regimens need to be stratified based on current HbA1c and target HbA1c, as summarized in Table [2](/articles/s41392-024-01951-9#Tab2). For those T2D patients with a present HbA1c level ≤ the target of HbA1c\\u2009+\\u20090.5%, lifestyle interventions alone can be reasonable,[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\") and due to the closer proximity to the glycemic target, lifestyle interventions are sufficient to maintain the target without additional pharmacotherapy. For those with a present HbA1c level > target HbA1c\\u2009+\\u20090.5% but ≤target HbA1c\\u2009+\\u20091.5%, lifestyle intervention plus treatment with one type of antidiabetic medication should be considered. For those with a present HbA1c > target HbA1c\\u2009+\\u20091.5% but ≤10%, lifestyle intervention plus treatment with two types of antidiabetic medications can be considered to achieve glycemic targets more rapidly. When the HbA1c level is >10% or there are symptoms of hyperglycemia or ketonemia, intensive therapy with insulin should be considered to minimize the risk of hyperglycemic crisis.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Lifestyle intervention\\n\\nLifestyle interventions, including physical activity, MNT, and weight management, are the foundation of T2D management. Many studies have shown that lifestyle interventions, such as physical activities and MNT, can reduce HbA1c levels by 0.3–2% and even achieve remission of diabetes, defined as an HbA1c\\u2009<\\u20096.5%, in the absence of pharmacological intervention.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\"),[217](/articles/s41392-024-01951-9#ref-CR217 \"Goldenberg, J. Z. et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 372, m4743 (2021).\"),[218](/articles/s41392-024-01951-9#ref-CR218 \"Riddle, M. C. et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 44, 2438–2444 (2021).\") Physical activities have been shown to effectively lower blood glucose levels, improve insulin sensitivity and cardiopulmonary function and reduce the risk of cardiovascular events.[219](#ref-CR219 \"Bonekamp, N. E. et al. Leisure-time and occupational physical activity and health outcomes in cardiovascular disease. Heart 109, 686–694 (2023).\"),[220](#ref-CR220 \"Uusitupa, M. et al. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients 11, 2611 (2019).\"),[221](/articles/s41392-024-01951-9#ref-CR221 \"Kirkpatrick, C. F., Liday, C. & Maki, K. C. The effects of carbohydrate-restricted dietary patterns and physical activity on body weight and glycemic control. Curr. Atheroscler. Rep. 22, 20 (2020).\") And there have been results demonstrated that physical activity significantly improve time in range (TIR) and reduce glycemic excursion with no increased risk of hypoglycemia[222](/articles/s41392-024-01951-9#ref-CR222 \"Zhu, X. et al. The effect of physical activity on glycemic variability in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. (Lausanne) 12, 767152 (2021).\") and reduced the risk of progress to CKD in T2D with preobesity/obesity.[223](/articles/s41392-024-01951-9#ref-CR223 \"Liu, M. et al. Association of accelerometer-measured physical activity and its change with progression to chronic kidney disease in adults with type 2 diabetes and overweight/obesity. Br. J. Sports Med. 58, 313–319 (2024).\") Various types of physical activities, including aerobic exercise, resistance exercise training and even brief standing, walking, or other light physical activities during leisure time, help with glycemia management. At least 150\\u2009min of moderate-intensity exercise per week is recommended for adults with T2D, and this exercise should be applied for at least 3 days per week, with no more than 2 consecutive days without activity.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") In addition, Moderate to vigorous physical activity in the evening showed the lowest risk of mortality, CVD, and microvascular disease in compared to the morning and afternoon in preobese or obese patients, especially those with T2D.[224](/articles/s41392-024-01951-9#ref-CR224 \"Sabag, A. et al. Timing of moderate to vigorous physical activity, mortality, cardiovascular disease, and microvascular disease in adults with obesity. Diabetes Care 47, 890–897 (2024).\"),[225](/articles/s41392-024-01951-9#ref-CR225 \"Clavero-Jimeno, A. et al. Impact of lifestyle moderate-to-vigorous physical activity timing on glycemic control in sedentary adults with overweight/obesity and metabolic impairments. Obesity (Silver Spring) 32,1465–1473.\") Currently, most guidelines recommend time-based physical activities. A study showed step- and time-based physical activity, are comparable in the association with all-cause mortality and CVD, suggesting a future consideration for step-based physical activity for personalized choice.[226](/articles/s41392-024-01951-9#ref-CR226 \"Hamaya, R. et al. Time- vs step-based physical activity metrics for health. JAMA Intern. Med. 184, 718–725 (2024).\")\\n\\nBy improving dietary structure and energy intake, MNT can improve blood glucose and metabolic parameters and delay or prevent MDS-related TOD. There is no one-size-fits-all dietary pattern for patients with T2D, and it should be individualized based on their metabolic goals and dietary preferences (traditional, religious, cultural, etc.). Several dietary patterns, such as a continuous energy-restricted diet, a Mediterranean diet, a low-carbohydrate or very low-carbohydrate diet, intermittent fasting and time-restricted eating, have been shown to lead to glycemic reduction and metabolic benefits in patients with T2D.[217](/articles/s41392-024-01951-9#ref-CR217 \"Goldenberg, J. Z. et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 372, m4743 (2021).\"),[227](#ref-CR227 \"Pavlou, V. et al. Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. JAMA Netw. Open 6, e2339337 (2023).\"),[228](#ref-CR228 \"Delgado-Lista, J. et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399, 1876–1885 (2022).\"),[229](#ref-CR229 \"Cienfuegos, S. et al. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. Cell Metab. 32, 366–378.e3 (2020).\"),[230](#ref-CR230 \"Horne, B. D., Grajower, M. M. & Anderson, J. L. Limited evidence for the health effects and safety of intermittent fasting among patients with type 2 diabetes. JAMA 324, 341–342 (2020).\"),[231](#ref-CR231 \"Wilkinson, M. J. et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 31, 92–104.e5 (2020).\"),[232](/articles/s41392-024-01951-9#ref-CR232 \"Carter, S., Clifton, P. M. & Keogh, J. B. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw. Open 1, e180756 (2018).\") Recently, a 5:2 intermittent fasting diet showed even better glycemic control in newly diagnosed diabetic patients compared with metformin or empagliflozin.[233](/articles/s41392-024-01951-9#ref-CR233 \"Guo, L. et al. A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the early randomized clinical trial. JAMA Netw. Open 7, e2416786 (2024).\") And high-fiber diet enriches the proportion of beneficial gut microbiota and improved glucose hemostasis, inflammation and emotional mood.[234](/articles/s41392-024-01951-9#ref-CR234 \"Chen, L. et al. High-fiber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients. Front. Cell Infect. Microbiol. 13, 1069954 (2023).\")\\n\\nAlthough there is no single best diet pattern, the key nutritional principles among the variable patterns should be emphasized, including nonstarchy vegetables, whole fruits, legumes, whole grains, nuts/seeds, and low-fat dairy products, as well as minimizing the consumption of meat, sweets, refined grains, and ultra-processed foods in people with prediabetes and diabetes.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\nLifestyle interventions are long-term behaviors, and digital apps available on prescription (DiGA) and telemedicine may help with long-term monitoring and improve adherence, and reduce HbA1c by 0.3-0.5% according to a systematic review.[235](/articles/s41392-024-01951-9#ref-CR235 \"Wang, Y. et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. JMIR Mhealth Uhealth 8, e15400 (2020).\")\\n\\n### Choice of pharmacologic therapy\\n\\nThe selection of hypoglycemic agents should consider the three goals of hypoglycemic efficacy, weight management and cardiorenal risk reduction. For patients without established CVD, CKD or multiple high-risk factors, priority can be given to metformin or other hypoglycemic agents that have sufficient glucose-lowering effects to achieve and maintain treatment goals. GLP-1 (4.5\\u2009mg dulaglutide, 2.0\\u2009mg semaglutide), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist (GLP-1/GIP RA) tirzepatide, insulin and combination therapy have been proven to have very high efficacy, while other GLP-1s, metformin, SGLT-is and TZDs have high efficacy, and DPP-4is have intermediate efficacy. For patients without established CVD, CKD or multiple high-risk factors but with weight loss demand, the selection of hypoglycemic agents should consider both glucose-lowering efficacy and weight loss efficacy. Semaglutide and tirzepatide have been proven to be highly effective at decreasing weight. For those with CVD or CKD or with high cardiorenal risk, hypoglycemic agents with additional cardiorenal benefits are recommended in addition to comprehensive cardiovascular risk management. For patients with established ASCVD or at high risk of ASCVD, GLP-1 and SGLT-is agents with proven ASCVD benefits are recommended as the first choice, and TZD is considered a complementary agent when glycemia is still above the target HbA1c after the combination of GLP-1 and SGLT-is. For patients with HF, SGLT-is agents with proven HF benefits are recommended. For patients with CKD, SGLT-is therapy with proven renal benefit is recommended, and GLP-1 could be the choice if SGLT-is is unavailable. A combination of these two agents with proven greater glucose-lowering efficacy is considered to achieve the target glycemic targets.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n#### Classification according to the characteristics of hypoglycemic agents\\n\\nAt present, the most commonly used classification for hypoglycemic drugs is based on the drug structure, but this classification lacks clinical practicality. Our team classified hypoglycemic agents in detail based on their hypoglycemic mechanisms[236](/articles/s41392-024-01951-9#ref-CR236 \"DeMarsilis, A. et al. Pharmacotherapy of type 2 diabetes: an update and future directions. Metabolism 137, 155332 (2022).\")(Table [3](/articles/s41392-024-01951-9#Tab3)) and organ protective effects, which is helpful for drug selection and personalized treatment in clinical practice, as Table [4](/articles/s41392-024-01951-9#Tab4) shows.\\n\\n#### Initial selection of hypoglycemic drugs for newly diagnosed patients with different characteristics\\n\\n### Hypoglycemic agents for T2D patients with preobesity/obesity\\n\\nWeight loss is an important component of glycemic management and can significantly reduce blood glucose levels and the risk of TOD, and a 5–10% weight loss in T2D patients may decrease the HbA1c by 0.6-1.0% and improve metabolic status and cardiovascular risk factors.[237](/articles/s41392-024-01951-9#ref-CR237 \"Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481–1486 (2011).\"),[238](/articles/s41392-024-01951-9#ref-CR238 \"Elmaleh-Sachs, A. et al. Obesity management in adults: a review. JAMA 330, 2000–2015 (2023).\") Currently, there are voices suggesting that weight loss be a primary target treatment rather than just a strategy for lowering HbA1c since weight loss has cardiovascular benefits independent of blood glucose.[239](/articles/s41392-024-01951-9#ref-CR239 \"Lingvay, I., Sumithran, P., Cohen, R. V. & le Roux, C. W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399, 394–405 (2022).\"),[240](/articles/s41392-024-01951-9#ref-CR240 \"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753–2786 (2022).\") The effect of hypoglycemic agents on body weight should be considered, and it is reasonable to use drugs with weight-loss effect in T2D patients with preobesity/obesity as an adjunct to lifestyle interventions. The newer drugs GLP-1/GIP RA and GLP-1 have shown substantial and clinical reductions in body weight in key trials. In the STEP-2 and SCALE trials, semaglutide 2.4\\u2009mg and liraglutide 3.0\\u2009mg reduced body weight by 9.6% and 6%, respectively, in preobese and obese T2D patients.[241](/articles/s41392-024-01951-9#ref-CR241 \"Davies, M. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397, 971–984 (2021).\"),[242](/articles/s41392-024-01951-9#ref-CR242 \"Davies, M. J. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 314, 687–699 (2015).\") Besides, in STEP-HFpEF DM trial, compared with placebo, T2D patients with obesity-related HF received semaglutide 2.4\\u2009mg showed a 6.4% reduced mean weight and 7.3 points increase of Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) which mean improved HF-related symptoms, physical function, quality of life, and social function.[243](/articles/s41392-024-01951-9#ref-CR243 \"Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394–1407 (2024).\") In the SURMOUNT-2 trial, GIP/GLP-1 RA tirzepatide demonstrated a greater weight loss of 14.7%; however, semaglutide and tirzepatide were both approximately 5% less effective in preobesity and obese people with T2D than in those without diabetes. This might suggest that weight loss is more difficult in people with diabetes.[205](/articles/s41392-024-01951-9#ref-CR205 \"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).\"),[206](/articles/s41392-024-01951-9#ref-CR206 \"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).\"),[244](/articles/s41392-024-01951-9#ref-CR244 \"Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402, 613–626 (2023).\") Substantial evidence that GLP-1 weight loss is due in large part to reduced food intake.[245](/articles/s41392-024-01951-9#ref-CR245 \"Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).\") Mountains of evidence suggests that multiple sites in the brain are more likely to dominate the effects of GLP-1 in inhibiting intake and reducing body weight, such as increasing preingestive satiation via dorsomedial GLP-1 receptors (GLP-1R) in hypothalamus-NPY/AgRP in arcuate neural circuit and reduce food intake by GLP-1R-mediated suppression of AMPK in hindbrain neurons.[246](/articles/s41392-024-01951-9#ref-CR246 \"Kim, K. S. et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science \\n                  https://doi.org/10.1126/science.adj2537\\n                  \\n                 (2024).\") In addition, GLP-1 delays gastric emptying and reduces food intake via vagal GLP-1R.[247](/articles/s41392-024-01951-9#ref-CR247 \"Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2021).\")\\n\\nRecently there has been inconsistency regarding the management of GLP-1 in the perioperative period, with evidence suggesting that GLP-1 use increases gastric residue rates and increases the risk of incomplete procedures and aspiration,[248](/articles/s41392-024-01951-9#ref-CR248 \"Silveira, S. Q. et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J. Clin. Anesth. 87, 111091 (2023).\"),[249](/articles/s41392-024-01951-9#ref-CR249 \"Garza, K. et al. Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study. Am. J. Gastroenterol. 119, 1081–1088 (2024).\") but there is also evidence suggesting that this does not increase the risk of postoperative complications such as postoperative pneumonia.[249](/articles/s41392-024-01951-9#ref-CR249 \"Garza, K. et al. Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study. Am. J. Gastroenterol. 119, 1081–1088 (2024).\"),[250](/articles/s41392-024-01951-9#ref-CR250 \"Welk, B. et al. No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery. Diabetes Obes. Metab. \\n                  https://doi.org/10.1111/dom.15711\\n                  \\n                 (2024).\") And gastric emptying delay of 36\\u2009min due to GLP-1 is of limited magnitude relative to standard periprocedural fasting periods.[251](/articles/s41392-024-01951-9#ref-CR251 \"Hiramoto, B. et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am. J. Gastroenterol. 119, 1126–1140 (2024).\")\\n\\n### Hypoglycemic agents for T2D patients with MASLD\\n\\nNonalcoholic fatty liver disease (NAFLD) is a histologic spectrum of hepatic disorders ranging from steatosis and steatohepatitis to advanced fibrosis, cirrhosis and even increased risk of hepatocellular carcinoma (HCC) and liver-related mortality. NAFLD has been replaced by the term “metabolic dysfunction associated steatotic liver disease (MASLD)” to enhance awareness, understanding of the disease and drug/biomarker development.[252](/articles/s41392-024-01951-9#ref-CR252 \"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).\"),[253](/articles/s41392-024-01951-9#ref-CR253 \"Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 29, 101133 (2024).\") MASLD and T2D are generally considered to have strong bidirectional relationships both epidemically and pathologically and share a common mechanism, IR.[254](/articles/s41392-024-01951-9#ref-CR254 \"Lee, B.-W. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab. J. 44, 382–401 (2020).\") A large meta-analysis estimated that approximately 56% of T2D patients in the global population have MASLD.[255](/articles/s41392-024-01951-9#ref-CR255 \"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).\") Two meta-analyses suggested that patients with MASLD have a two-fold increased risk of developing diabetes.[256](/articles/s41392-024-01951-9#ref-CR256 \"Ballestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 936–944 (2016).\"),[257](/articles/s41392-024-01951-9#ref-CR257 \"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70, 962–969 (2021).\") A recent cohort study showed that regression of MASLD reduced the risk of diabetes; however, the benefits are evident only in patients with low MASLD fibrosis scores, suggesting early intervention for MASLD.[258](/articles/s41392-024-01951-9#ref-CR258 \"Sinn, D. H. et al. Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: a longitudinal cohort study. PLoS One 18, e0288820 (2023).\")\\n\\n*TZDs*. TZDs, which improve insulin sensitivity, have been tested for their effect on MASLD. In the first RCT to prove the effect of TZDs on MASLD, 55 prediabetic patients or T2D patients with metabolic dysfunction-associated steatohepatitis (MASH) were randomized to pioglitazone or placebo groups for 6 months. The results showed that pioglitazone significantly improved the histologic features of steatohepatitis compared with placebo, and fibrosis scores significantly improved in the pioglitazone group before and after treatment; however, the change from baseline did not significantly differ from that in the placebo group.[259](/articles/s41392-024-01951-9#ref-CR259 \"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297–2307 (2006).\") Aithal et al. randomized 74 nondiabetic patients with MASH to pioglitazone or placebo groups for 12 months. The results showed that pioglitazone significantly reduced hepatocyte injury and fibrosis scores compared with those of the placebo.[260](/articles/s41392-024-01951-9#ref-CR260 \"Aithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176–1184 (2008).\") The FLIRT[261](/articles/s41392-024-01951-9#ref-CR261 \"Ratziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100–110 (2008).\") trial tested another TZD, rosiglitazone, and 63 patients with MASH were randomized to the rosiglitazone or placebo group for 12 months. The results showed that the mean reduction in steatosis and the proportion of patients reaching a >30% reduction in steatosis in the rosiglitazone group were both significantly greater than those in the placebo group. However, there was no difference in fibrosis score between the groups. A multicenter RCT, the PIVENS[262](/articles/s41392-024-01951-9#ref-CR262 \"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).\") trial, randomized 247 nondiabetic patients treated with MASH into the pioglitazone, vitamin E, and placebo groups for 96 weeks. Compared with placebo, pioglitazone significantly reduced the histologic feature scores, and a greater proportion of subjects in the pioglitazone group achieved resolution of MASH. More patients had improved fibrosis and reduced fibrosis scores, but these changes were not significant. In 2016, an 18-month RCT conducted by Cusi et al. included 101 prediabetic T2D patients with MASH and randomized them to pioglitazone or placebo groups. At the end of the treatment, more patients in the pioglitazone groups achieved the primary outcome and resolution of MASH than did those in the placebo group, and pioglitazone significantly reduced the fibrosis scores.[263](/articles/s41392-024-01951-9#ref-CR263 \"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern Med. 165, 305–315 (2016).\") A similar study conducted by Bril et al. randomized 105 T2D patients with MASH to pioglitazone plus vitamin E, vitamin E, or placebo groups for 18 months. The results showed that more patients in the combination group achieved the primary outcome and resolution of MASH than did those in the placebo group, while there was no significant difference between the vitamin and placebo groups, suggesting the beneficial effect of pioglitazone on MASH. However, no significant changes were observed in fibrosis scores, although there was a trend toward more patients in the combination and vitamin E groups having improved fibrosis stages than in the placebo group.[264](/articles/s41392-024-01951-9#ref-CR264 \"Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 42, 1481–1488 (2019).\") In summary, the beneficial effects of TZDs on the improvement and even the resolution of steatosis and histologic features of MASH were highly consistent, but the effects on liver fibrosis were inconsistent with several studies suggesting no significant improvement in fibrosis with TZDs, possibly because the intervention time was not long enough to produce significant improvement in fibrosis or because of the differences in baseline fibrosis stage between studies. Two meta-analyses suggested that pioglitazone reverses or delays the progression of fibrosis, including advanced-stage fibrosis, which is an independent predictor of liver-related adverse events and mortality in MASLD/MASH patients.[265](#ref-CR265 \"Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 177, 633–640 (2017).\"),[266](#ref-CR266 \"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).\"),[267](#ref-CR267 \"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).\"),[268](/articles/s41392-024-01951-9#ref-CR268 \"Xie, Q. et al. Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review. Chin. Med. J. (Engl.) 136, 2014–2016 (2023).\") Interestingly, Pepa et al. showed that even a low dose of pioglitazone still significantly improved liver steatosis and inflammation.[269](/articles/s41392-024-01951-9#ref-CR269 \"Della Pepa, G. et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res. Clin. Pr. 178, 108984 (2021).\") The benefits of TZDs in MASLD and fibrosis may be the increased adiponectin levels and the adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism[270](/articles/s41392-024-01951-9#ref-CR270 \"Lutchman, G. et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 4, 1048–1052 (2006).\") and the downregulated fibrogenic factors and related pathways, inflammatory pathways like JAK/STAT and NF-κB signaling pathways.[271](#ref-CR271 \"Alatas, F. S., Matsuura, T., Pudjiadi, A. H., Wijaya, S. & Taguchi, T. Peroxisome proliferator-activated receptor gamma agonist attenuates liver fibrosis by several fibrogenic pathways in an animal model of cholestatic fibrosis. Pediatr. Gastroenterol. Hepatol. Nutr. 23, 346–355 (2020).\"),[272](#ref-CR272 \"Wang, S. et al. PPARγ regulates macrophage polarization by inhibiting the JAK/STAT pathway and attenuates myocardial ischemia/reperfusion injury in vivo. Cell Biochem. Biophys. 81, 349–358 (2023).\"),[273](/articles/s41392-024-01951-9#ref-CR273 \"Liu, X., Zhang, P., Song, X., Cui, H. & Shen, W. PPARγ mediates protective effect against hepatic ischemia/reperfusion injury via NF-κB pathway. J. Invest. Surg. 35, 1648–1659 (2022).\")\\n\\n*GLP-1*. LEAN trial randomized 52 patients with MASH to the liraglutide or placebo group. The results showed that more patients treated with liraglutide achieved resolution of MASH than did those treated with placebo, but there was no significant difference in fibrosis improvement.[274](/articles/s41392-024-01951-9#ref-CR274 \"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).\") A phase 2 study testing semaglutide enrolled 320 patients with MASH and fibrosis and randomized them to 0.1, 0.2, or 0.4\\u2009mg semaglutide group or the placebo group. The results showed that 0.4\\u2009mg semaglutide once daily was associated with a significantly greater incidence of MASH resolution without worsening of fibrosis than placebo. However, the improvement in fibrosis between the groups did not significantly differ.[275](/articles/s41392-024-01951-9#ref-CR275 \"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2021).\") Another smaller phase 2 study enrolled 71 patients with MASH-related cirrhosis testing 2.4\\u2009mg semaglutide once weekly did not reveal significant changes in either the resolution of MASH or improvement in fibrosis despite some improvement of noninvasive markers of disease activity.[276](/articles/s41392-024-01951-9#ref-CR276 \"Loomba, R. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 511–522 (2023).\") Tirzepatide is associated with significantly greater proportion of achieving MASH remission with no worsening of fibrosis compared with placebo[277](/articles/s41392-024-01951-9#ref-CR277 \"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. \\n                  https://doi.org/10.1056/NEJMoa2401943\\n                  \\n                 (2024).\") in a phase 2 trial, and another phase 2 trial for dual agonism of glucagon receptor and GLP-1R (GCGR/GLP-1RA) survodutide demonstrated similar improvements in MASH.[278](/articles/s41392-024-01951-9#ref-CR278 \"Sanyal, A. J. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N. Engl. J. Med. \\n                  https://doi.org/10.1056/NEJMoa2401755\\n                  \\n                 (2024).\") The effects of GLP-1 on ameliorating hepatic inflammation, steatosis, and injury are thought to be secondary to weight loss and improved hepatocyte lipid synthesis and oxidation.[245](/articles/s41392-024-01951-9#ref-CR245 \"Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).\"),[279](/articles/s41392-024-01951-9#ref-CR279 \"Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 79, 552–566 (2023).\")\\n\\nIn summary, based on histopathological results, pioglitazone is the most studied agent; it has shown the strongest beneficial effects of hypoglycemic agents and has shown additional hypoglycemic-independent anti-atherosclerotic effects. Although TZDs can increase body weight, weight gain mostly occurs in subcutaneous fat, while visceral fat, which is closely related to metabolic disorders, does not increase or even decreases.[280](#ref-CR280 \"Nesti, L., Tricò, D., Mengozzi, A. & Natali, A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc. Diabetol. 20, 109 (2021).\"),[281](#ref-CR281 \"Smith, S. R. et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54, 24–32 (2005).\"),[282](/articles/s41392-024-01951-9#ref-CR282 \"Miyazaki, Y. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87, 2784–2791 (2002).\") Therefore, pioglitazone has been recommended as the preferred drug.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[283](#ref-CR283 \"Cusi, K. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pr. 28, 528–562 (2022).\"),[284](#ref-CR284 \"Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb. Vasc. Biol. 42, e168–e185 (2022).\"),[285](/articles/s41392-024-01951-9#ref-CR285 \"Chinese Society of Endocrinology & Chinese Diabetes Society. Management of Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease: an expert consensus (in Chinese). Chin. J. Endocrinol. Metab. 37, 589–598 (2021).\") Liraglutide, which has shown some pathological evidence of beneficial effects on liver fibrosis and glucose-independent anti-atherosclerotic effects, as well as weight loss, is also one of the preferred drugs for treating T2D with MASLD. Other current hypoglycemic drugs lack evidence of their effect on liver fibrosis and are not considered drugs for T2D patients with MASLD.\\n\\n### Hypoglycemic agents for T2D patients with established or high risk of CVD\\n\\n*ASCVD*. CVD are the leading cause of patients with T2D. T2D tends to coexist with metabolic disorders such as dyslipidemia and hypertension, which are risk factors for ASCVD. In addition, T2D itself is a potent and independent risk factor for CVD.\\n\\nSpecific GLP-1 agents have been shown to improve cardiovascular outcomes, and liraglutide, semaglutide (subcutaneous and oral), dulaglutide, and albiglutide consistently reduce the risk of MACE in people with T2D with established CVD or a high risk of CVD. However, lixisenatide in the ELIXA trial did not significantly alter the incidence of MACE, and exnatide in the EXSCEL trial lower the risk of MACE with no significant difference.[286](#ref-CR286 \"Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).\"),[287](#ref-CR287 \"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).\"),[288](#ref-CR288 \"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).\"),[289](#ref-CR289 \"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).\"),[290](#ref-CR290 \"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).\"),[291](#ref-CR291 \"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).\"),[292](/articles/s41392-024-01951-9#ref-CR292 \"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).\") Overall, GLP-1 reduced the risk of MACE by 14% according to a meta-analysis comprising these trials.[293](/articles/s41392-024-01951-9#ref-CR293 \"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019).\")\\n\\nSome TZDs have shown cardiovascular-protective benefits, as pioglitazone reduced the risk of ASCVD in some trials. The PROactive[294](/articles/s41392-024-01951-9#ref-CR294 \"Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279–1289 (2005).\") trial showed that pioglitazone, compared with a placebo, reduced the risk of composite outcomes (all-cause mortality, nonfatal MI and stroke) by 16% in diabetic patients with established ASCVD. COSTA.IT[295](/articles/s41392-024-01951-9#ref-CR295 \"Vaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 5, 887–897 (2017).\") trial showed that although pioglitazone had no significant difference in total cardiovascular deaths compared with sulfonylureas in primary ASCVD diabetic patients, it significantly reduced the risk of ischemic cardiovascular events by 33%. The IRIS[203](/articles/s41392-024-01951-9#ref-CR203 \"Yaghi, S. et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation 137, 455–463 (2018).\") trial showed that pioglitazone reduced the incidence of any stroke in nondiabetic patients with IR and stroke, suggesting that pioglitazone has glucose-independent cardiovascular benefits. And the benefits might be partly result from decrease in lectin-like oxidized receptor1 (LOX-1) followed by significant declines in cellular ROS and NF-κB signaling pathways.[296](/articles/s41392-024-01951-9#ref-CR296 \"Ahmadi, A., Panahi, Y., Johnston, T. P. & Sahebkar, A. Antidiabetic drugs and oxidized low-density lipoprotein: a review of anti-atherosclerotic mechanisms. Pharm. Res. 172, 105819 (2021).\")\\n\\nEmerging evidence has proven that SGLT-is can reduce the risk of adverse cardiovascular outcomes. The EMPA-REG and CANVAS trials showed that the SGLT-2i empagliflozin and SGLT-1/2i canagliflozin reduced the risk of MACE in T2D patients with or at high risk of CVD by 14%, while the SGLT-2i dapagliflozin did not significantly reduce the risk of MACE, possibly due to the difference in population (approximately 60% with no established ASCVD) between previous trials and strict exclusion criteria.[297](#ref-CR297 \"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).\"),[298](#ref-CR298 \"Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 2099 (2017).\"),[299](/articles/s41392-024-01951-9#ref-CR299 \"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).\") However, ertugliflozin in the VERTIS trial did not show superiority to the placebo in T2D patients with established ASCVD.[300](/articles/s41392-024-01951-9#ref-CR300 \"Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).\") SGLT-1/2i, sotagliflozin, reduced the risk of MACE by 16% in the SCORED trial in patients with chronic kidney disease and additional cardiovascular risk factors, and it is the only SGLT-i with evidence of a reduced risk of ASCVD-related macrovascular events of MI and stroke.[301](/articles/s41392-024-01951-9#ref-CR301 \"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).\") In addition, SGLT-2i still showed a remarkable cardiovascular benefit in nondiabetic patients, indicating that SGLT-2i had a blood glucose-independent effect on improving cardiovascular outcomes.\\n\\nSeveral GLP-1 and SGLT-is proven cardiovascular benefits are recommended by the ADA to be the first-line hypoglycemic agents for patients with T2D with established ASCVD or at high risk of ASCVD, and combination therapy comprising SGLT-is and GLP-1 may provide additional cardiovascular benefits. Pioglitazone is recommended as a second-line hypoglycemic therapy when HbA1c is still above the target level.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") The ESC also suggests that pioglitazone should be considered for reducing ASCVD risk in patients with T2D with ASCVD based on the data and net benefit-risk assessment.[212](/articles/s41392-024-01951-9#ref-CR212 \"Marx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 39, 4043–4140 (2023).\")\\n\\n*HF*. Patients with diabetes are twice as likely to develop HF, which leads to increased mortality.[302](/articles/s41392-024-01951-9#ref-CR302 \"Kenny, H. C. & Abel, E. D. Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies. Circ. Res. 124, 121–141 (2019).\") SGLT-is showed a more robust and consistent effect on reducing hospitalization for HF. SGLT-is significantly reduce the risk of HF by 30–40% in individuals with T2D with established or high risk of CVD according to previous large-scale RCTs, and the HF benefits exists no matter the ejection fraction is preserved or reduced.[297](#ref-CR297 \"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).\"),[298](#ref-CR298 \"Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 2099 (2017).\"),[299](/articles/s41392-024-01951-9#ref-CR299 \"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).\"),[301](/articles/s41392-024-01951-9#ref-CR301 \"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).\") Subsequent trials in patients with T2D and established HF showed that dapagliflozin and empagliflozin reduced the composite outcomes of worsening HF (defined as hospitalization for HF or an urgent visit for HF) or cardiovascular death by 21–26%.[303](#ref-CR303 \"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).\"),[304](#ref-CR304 \"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).\"),[305](#ref-CR305 \"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).\"),[306](/articles/s41392-024-01951-9#ref-CR306 \"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).\") SGLT-i sotagliflozin in the SOLOIST-WHF trial was associated with a 33% reduction in worsening of HF, which is greater than other SGLT-is.[307](/articles/s41392-024-01951-9#ref-CR307 \"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117–128 (2021).\")\\n\\nMost GLP-1 trials did not significantly reduce the risk of HF in patients with T2D.[286](#ref-CR286 \"Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).\"),[287](#ref-CR287 \"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).\"),[288](#ref-CR288 \"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).\"),[289](#ref-CR289 \"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).\"),[290](#ref-CR290 \"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).\"),[291](#ref-CR291 \"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).\"),[292](/articles/s41392-024-01951-9#ref-CR292 \"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).\") Despite the benefits of ASCVD, pioglitazone may increase the risk of HF. Many RCTs and meta-analyses have shown that TZDs, including pioglitazone, increase the risk of HF; however, it seems that an increased risk of HF does not increase the risk of death or cardiovascular events following HF.[308](#ref-CR308 \"Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006).\"),[309](#ref-CR309 \"Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125–2135 (2009).\"),[310](#ref-CR310 \"Erdmann, E. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30, 2773–2778 (2007).\"),[311](#ref-CR311 \"Lago, R. M., Singh, P. P. & Nesto, R. W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370, 1129–1136 (2007).\"),[312](/articles/s41392-024-01951-9#ref-CR312 \"Lincoff, A. M., Wolski, K., Nicholls, S. J. & Nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180–1188 (2007).\") This may be explained by the fact that an increased risk of HF may be related to fluid retention, which suggests that this change is reversible. Moreover, there is no direct evidence that TZDs damage the structure and function of the heart. Instead, some animal experiments and clinical trials have suggested that TZDs might improve ventricular structure or function.[280](/articles/s41392-024-01951-9#ref-CR280 \"Nesti, L., Tricò, D., Mengozzi, A. & Natali, A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc. Diabetol. 20, 109 (2021).\"),[313](/articles/s41392-024-01951-9#ref-CR313 \"van der Meer, R. W. et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119, 2069–2077 (2009).\"),[314](/articles/s41392-024-01951-9#ref-CR314 \"Dorkhan, M., Dencker, M., Stagmo, M. & Groop, L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 8, 15 (2009).\") SGLT-is have become the first choice of hypoglycemic agent for patients with T2D and HF or for those with multiple risk factors for HF due to its well-proven benefits.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\nMeta-analysis and post hoc analysis demonstrated that the cardiovascular benefits of GLP-1 and SGLT-is are not associated with the use of metformin; therefore, in patients with established CVD or at high risk of CVD, metformin is not the basic therapy.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[315](/articles/s41392-024-01951-9#ref-CR315 \"Ferrannini, G. et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur. Heart J. 42, 2565–2573 (2021).\"),[316](/articles/s41392-024-01951-9#ref-CR316 \"Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G. & Molinero, G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur. J. Prev. Cardiol. 28, 69–75 (2021).\")\\n\\nAlthough there were no head-to-head RCTs comparing GLP-1 and SGLT-is for cardiovascular benefit, a meta-analysis showed no significant difference between them.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Recently, a propensity pair-matched study showed that combination therapy comprising GLP-1 and SGLT-is reduced the risk of all-cause mortality and CVD better than did GLP-1 or SGLT-is alone.[317](/articles/s41392-024-01951-9#ref-CR317 \"Riley, D. R. et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes. Metab. 25, 2897–2909 (2023).\") The mechanism of SGLT-is and GLP-1 on CVD benefits might be that they improve mitochondrial energy metabolism and reduces oxidative stress though activation of AMPK signaling pathways[318](/articles/s41392-024-01951-9#ref-CR318 \"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463–474 (2023).\"); and alleviate inflammation through reduced proinflammatory factors, infiltration of immune cells and downregulated NF-κB and JAK/STAT signal pathways. In addition, the anti-inflammatory effects also gain benefits on skeletal muscle atrophy and retinal vascular permeability.[319](#ref-CR319 \"Zhang, R., Xie, Q., Lu, X., Fan, R. & Tong, N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol. Metab. Syndr. 16, 99 (2024).\"),[320](#ref-CR320 \"Wood, N. et al. Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail 26, 925–935 (2024).\"),[321](#ref-CR321 \"Kasperova, B. J. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc. Diabetol. 23, 223 (2024).\"),[322](/articles/s41392-024-01951-9#ref-CR322 \"Xu, C. et al. Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors. J. Diabetes Complications 38, 108631 (2024).\") SGLT-is can also reshape gut microbiota, reducing uremic toxins on organs such as heart and kidney[323](/articles/s41392-024-01951-9#ref-CR323 \"Billing, A. M. et al. Metabolic communication by SGLT2 inhibition. Circulation 149, 860–884 (2024).\") and upregulating l-tryptophan which promote secretion of GLP-1.[324](/articles/s41392-024-01951-9#ref-CR324 \"Jiang, Y. et al. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. Diabetes 73, 926–940 (2024).\") GLP-1 similarly reduce atherosclerosis by reducing inflammatory factors. In addition, GLP-1 can reduce cardiomyocyte apoptosis and increases left ventricular ejection fraction through AMPK activation and NF-κB downregulation.[318](/articles/s41392-024-01951-9#ref-CR318 \"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463–474 (2023).\")\\n\\n### Hypoglycemic agents for patients with T2D and CKD\\n\\nCKD, diagnosed by a persistent increase in urinary albumin excretion (albuminuria), a low estimated glomerular filtration rate (eGFR), or other manifestations of kidney damage, may be a consequence of DN and nondiabetic nephropathy coincident with T2D.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[325](/articles/s41392-024-01951-9#ref-CR325 \"Anders, H.-J., Huber, T. B., Isermann, B. & Schiffer, M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat. Rev. Nephrol. 14, 361–377 (2018).\") CKD can progress to end-stage renal disease (ESRD), which requires dialysis or kidney transplantation and increases the risk of CVD. SGLT-is have been proven to be beneficial for CKD in many trials. Several trials of SGLT-is in which renal efficiency was set as a secondary outcome have shown that SGLT-is reduces the risk of worsening CKD.[297](/articles/s41392-024-01951-9#ref-CR297 \"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).\"),[298](/articles/s41392-024-01951-9#ref-CR298 \"Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 2099 (2017).\") Additionally, two other key trials of SGLT-is in people with CKD showed that canagliflozin reduced the primary composite outcome of ESRD (dialysis, transplantation, or a sustained estimated eGFR <15\\u2009ml per minute per 1.73 m2), doubled the serum creatinine level, or led to death from renal or cardiovascular causes by 30% in the CREDENCE trial, and dapagliflozin reduced the risk of a composite outcome of a sustained decline in eGFR of at least 50%, ESRD, or death from renal or cardiovascular causes by 39% in the DAPA-CKD trial compared with the placebo. This might due to the ameliorated proximal tubular cells apoptosis through glycine-mediated activation of AMPK/mTOR signaling pathway.[326](/articles/s41392-024-01951-9#ref-CR326 \"Shao, M. et al. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. Diabetologia 67, 738–754 (2024).\")Besides SGLT-is can also inhibit apoptosis in kidney through PI3K/Akt signaling pathways[327](/articles/s41392-024-01951-9#ref-CR327 \"Qiuxiao-Zhu et al. Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury. Transpl. Immunol. 84, 102010 (2024).\") and renal tubular ferroptosis though AMPK/NRF2 signaling pathways.[328](/articles/s41392-024-01951-9#ref-CR328 \"Lu, Q. et al. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway. Free Radic. Biol. Med. 195, 89–102 (2023).\")\\n\\nGLP-1 has also been demonstrated to have renal benefits.[329](/articles/s41392-024-01951-9#ref-CR329 \"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).\"),[330](/articles/s41392-024-01951-9#ref-CR330 \"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).\") The LEADER, SUSTAIN 6 and REWIND trials, which examine cardiovascular outcomes, showed that liraglutide, semaglutide and dulagutide, respectively, reduced the risk of a composite renal outcome by 22%, 36%, and 15%, while ELIXA and EXSCEL trials demonstrated less than a 20% risk reduction, with no significant difference compared with that of the placebo.[287](/articles/s41392-024-01951-9#ref-CR287 \"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).\"),[289](#ref-CR289 \"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).\"),[290](#ref-CR290 \"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).\"),[291](#ref-CR291 \"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).\"),[292](/articles/s41392-024-01951-9#ref-CR292 \"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).\") These results are limited to patients with CVD and cannot be generalized to people with CKD. The FLOW trial firstly demonstrates that semaglutide reduced the risk of major kidney disease events by 24% in the population with T2D and CKD.[331](/articles/s41392-024-01951-9#ref-CR331 \"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).\") Another study reclassified FLOW trial by whether or not SGLT-2 was used, and the analysis found consistent renal benefits of semaglutide with or without SGLT-2i. But further study specifically targeted for verification of combined effect are needed, as the FLOW only has limited test power due to fewer people using SGLT-2i in this trial.[332](/articles/s41392-024-01951-9#ref-CR332 \"Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. \\n                  https://doi.org/10.1038/s41591-024-03133-0\\n                  \\n                 (2024).\") The potential mechanism of renal benefits be reduced oxidative stress through decreased levels of glomerular superoxide and renal NADPH oxidase and reduced inflammation through counteracting angiotensin-II- induced NF-κB activation in glomerular endothelium and mesangial cells. In addition, GLP-1 induced human mesangial cells reduced proliferation and fibrosis.[333](/articles/s41392-024-01951-9#ref-CR333 \"Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).\") For now, SGLT-is are the only recommended first choice for patients with T2D and CKD or with multiple risk factors.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n### Hypoglycemic agents for T2D patients at medium risk of CVD\\n\\nFor diabetic patients at medium risk of CVD, referring to patients without other CVD and CKD risk factors other than diabetes, the choice of hypoglycemic drugs emphasizes the effect of glycemia control and weight management. For preobese/obese patients, a class of hypoglycemic agents with weight loss effects are recommended, with dulaglutide as the first-line therapy. For nonobese or nonobese patients with T2D, if there is no concern about weight loss, the abovementioned recommendation also applies to this population. In patients with weight loss concerns, classes of hypoglycemic agents with neutral effects on body weight or weight gain are recommended, such as DPP-4i, sulfonylureas, and glinides.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Hypoglycemic agents for T2D patients at high hypoglycemic risk\\n\\nHypoglycemia is a rare but serious consequence of T2D, and poor glycemic control, glycemic variability, kidney damage and poor cognitive function are strongly associated with an increased risk of hypoglycemia.[334](/articles/s41392-024-01951-9#ref-CR334 \"Lee, A. K. et al. Risk factors for severe hypoglycemia in black and white adults with diabetes: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 40, 1661–1667 (2017).\") Patients with newly diagnosed T2D without CKD are usually not at high risk of hypoglycemia. T2D patients who are elderly and have renal failure or severely impaired liver function are common high-risk groups for hypoglycemia; therefore, the hypoglycemic risk of drugs should be considered when choosing medications. For T2D patients with renal function or severe liver function impairment will be discussed in a later part. For elderly individuals who are preobese/obese or have a weight loss demand, metformin, AGI, SGLT-is and GLP-1 (liraglutide, dulaglutide, and semaglutide) are recommended because of their low hypoglycemic risk and weight loss benefits. For elderly patients without preobesity/obesity and with weight loss concerns, the use of DPP-4i is recommended because of its neutral effect on body weight.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Hypoglycemic agents for T2D patients with hepatic failure\\n\\nDiabetic patients with severely impaired liver function are prone to fasting hypoglycemia due to impaired liver gluconeogenesis. In patients with severely impaired liver function, the choice of hypoglycemic agents should emphasize the low risk of hypoglycemia and decreased liver impairment associated with hypoglycemic drugs. Therefore, when patients have severe liver function impairment, insulin, linagliptin, lixisenatide, and dulaglutide are recommended.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Hypoglycemic agents for T2D patients with renal failure\\n\\nPeople with diabetes and CKD are at high risk for progression to kidney failure and cardiovascular events, as well as acute hypoglycemia and diabetic ketoacidosis (DKA). The hypoglycemic agents with renal benefits have been described in the section “Hypoglycemic agents for patients with T2D and CKD”. For T2D patients with a moderate or greater renal function decrease (eGFR <45\\u2009ml/min/1.73 m2), hypoglycemic agents should be carefully selected. When renal failure reaches the G3b stage (eGFR 15–29\\u2009ml/min/1.73 m2), DPP-4i and sulfonylureas (gliclazide and glipizide) need to be administered at lower doses, while glibenclamide and glimepiride are not allowed. When renal failure reaches the G4 stage (eGFR 15–29\\u2009ml/min/1.73 m2), metformin, exenatide, lixisenatide, sulfonylureas and AGIs are not recommended, and these medications should be discontinued or not initiated. When renal failure reaches the G5 stage (eGFR <15\\u2009ml/min/1.73 m2), which requires dialysis or transplantation, GLP-1 and TZD should be discontinued, while the DPP-4i linagliptin and insulin might be the preferred choices.[335](/articles/s41392-024-01951-9#ref-CR335 \"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 102, S1–S127 (2022).\")\\n\\nSGLT-is can be initiated in diabetic patients with renal failure at any stage but for different treatment purposes. An eGFR >45\\u2009ml/min/1.73m2 and a urinary-to-creatinine ratio (uACR)\\u2009≥25\\u2009mg/mmol or 20–45\\u2009ml/min/1.73 m2 or established CVD are recommended for diabetic patients because of its high glucose-lowering efficacy and proven cardiorenal benefits. In addition, SGLT-2i is also suggested for patients with an eGFR >45–60\\u2009ml/min/m2 and a uACR <25\\u2009mg/mmol to improve cardiovascular risk and slow the rate of renal function decline but have limited effects on glycemic control. For eGFRs <20\\u2009ml/min/m2, there are some inconsistencies. The guidelines issued by the Kidney Disease Improving Global Outcomes (KDIGO) suggest that SGLT-2i should be discontinued, while the 2023 guidelines issued by the UK Kidney Association (UKKA) suggest initiating SGLT-2i to slow the progression of kidney disease.[335](/articles/s41392-024-01951-9#ref-CR335 \"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 102, S1–S127 (2022).\"),[336](/articles/s41392-024-01951-9#ref-CR336 \"Roddick, A. J. et al. UK Kidney Association Clinical Practice Guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE. BMC Nephrol. 24, 310 (2023).\")\\n\\n### Initial insulin therapy\\n\\nAs the disease progresses, patients with T2D eventually develop an absolute lack of insulin and require insulin therapy. For newly diagnosed T2D patients, insulin therapy should be considered when HbA1c\\u2009>10% is associated with symptoms of hyperglycemia or ketonemia, as indicated in the treatment stratification above. Basal insulin alone is the most convenient initial insulin therapy, but it can also be used in combination with other drugs for glycemic control, which allows for both effective glycemic control and additional benefits according to the patient’s characteristics.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") When diabetic patients are not at risk of DKA, basal insulin plus noninsulin hypoglycemic agents with weight loss effects are recommended for those with preobesity/obesity or without weight loss, and basal insulin/premix insulin plus secretagogues or DPP-4i are recommended for those without preobesity/obesity and with weight loss concerns. When diabetic patients are at risk of DKA, multiple daily injections of insulin are more appropriate. Once DKA develops, emergency actions should be taken immediately, which will not be discussed here.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\")\\n\\n### Combination therapy\\n\\nFor people newly diagnosed with T2D, there are two approaches to pharmacal therapy: stepwise therapy and combination therapy. Stepwise therapy starts with monotherapy followed by stepwise addition of add-on medication to the main glycemic targets; this approach is a conventional therapy and has been well studied.[337](/articles/s41392-024-01951-9#ref-CR337 \"Cersosimo, E., Johnson, E. L., Chovanes, C. & Skolnik, N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes. Metab. 20, 497–507 (2018).\") The choice of hypoglycemic agents for initial monotherapy should be personalized considering the need to reduce MDS-related TOD, such as weight management and comorbidities, as demonstrated above. Initial combination therapy is considered for those with a present HbA1c level > target HbA1c\\u2009+\\u20091.5% but ≤10%, and emerging evidence has shown that combination therapy might offer some potential benefits. Multiple trials have demonstrated that combination therapy with complementary mechanisms reduces HbA1c more quickly and increases with faster achievement of glycemic targets.[338](#ref-CR338 \"Lim, S. et al. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). Diabetes Obes. Metab. 19, 87–97 (2017).\"),[339](#ref-CR339 \"Pratley, R. E., Fleck, P. & Wilson, C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes. Metab. 16, 613–621 (2014).\"),[340](/articles/s41392-024-01951-9#ref-CR340 \"Jabbour, S. A. et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 41, 2136–2146 (2018).\") Results have shown that glucose-dependent organ protection agents (saxagliptin combined with metformin) have beneficial effects only on islet β cells but no protections of target organs has been showed, as the VERIFY[341](/articles/s41392-024-01951-9#ref-CR341 \"Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).\") trial showed that combination therapy comprising DPP-4i and metformin reduced the risk of treatment failure (defined as HbA1c\\u2009>\\u20097% at two consecutive scheduled visits 13 weeks after randomization) by 49% compared with that of stepwise therapy, and it extended the duration of glycemic maintenance by 2 years, which suggested that the initial combination therapy delayed the deterioration of islet β cells. A real-world prospective cohort study including 2.2 million people demonstrated that the combination of SGLT-i and GLP-1 had better effects on all-cause mortality, MI and admission rate than SGLT-i or GLP-1 alone.[317](/articles/s41392-024-01951-9#ref-CR317 \"Riley, D. R. et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes. Metab. 25, 2897–2909 (2023).\") Combination therapy should also be personalized according to patient characteristics as monotherapy does. Fig. [4](/articles/s41392-024-01951-9#Fig4) shows the combinations of different hypoglycemic agents.\\n\\n![figure 4](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01951-9/MediaObjects/41392_2024_1951_Fig4_HTML.png)\\n\\nPersonalized choice of hypoglycemic agents for patients with newly diagnosed T2D. This figure is modified according to Zhang et al.[211](/articles/s41392-024-01951-9#ref-CR211 \"Zhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J. Evid. Based Med. 15, 168–179 (2022).\") T2D type 2 diabetes, MASLD metabolic associated steatotic liver disease, ASCVD atherosclerotic coronary heart disease, HF heart failure, CKD chronic kidney disease, CVD cardiovascular disease, DKA diabetic ketoacidosis, Met metformin, AGI α-glucosidase inhibitors, GLP-1 glucagon-like peptide-1, SGLT-is sodium-glucose cotransporter inhibitors, DPP-4i dipeptidyl peptidase-4 inhibitors, TZD thiazolidinediones. **\\\\***These regimens are considered in patients with affordability and willingness for injection therapy\\n\\nWe summarized the personalized selection of hypoglycemic agents for patients with newly diagnosed T2D according to different clinical scenarios in Fig. [4](/articles/s41392-024-01951-9#Fig4).\\n\\n### Treatment of MDS-related TOD/complications in patient with T2D\\n\\n#### MDS-related chronic kidney disease\\n\\nWe believe that, unlike classical T1D, T2D is a component of MDS and chronic kidney disease in T2D patients is supposed to be TOD/complications of MDS, since any component of MDS can cause the initiation and progression of CKD.[342](/articles/s41392-024-01951-9#ref-CR342 \"Tuttle, K. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 102, 248–260 (2022).\") Moreover, a considerable number of patients with T2D also have hyperuricemia, which is also a cause of CKD.[343](/articles/s41392-024-01951-9#ref-CR343 \"Johnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a Scientific Workshop Organized by the National Kidney Foundation. Am. J. Kidney Dis. 71, 851–865 (2018).\") Therefore, it is not appropriate to use “diabetic kidney disease” in this case and it may be more appropriate to use MDS-related CKD (MDSRCKD) for most T2D patients after excluding other specific causes. The use of this term is conducive to its prevention and control for early intervention with every risk factor of MDSRCKD instead of the conventional glycemic-control-centered management. In addition, the presence of CKD increased cardiovascular risk and mortality in patients with diabetes.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[344](/articles/s41392-024-01951-9#ref-CR344 \"Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302–308 (2013).\")\\n\\n### Holistic management\\n\\nBoth the uACR and eGFR are two common and easily performed markers for early diagnosis and monitoring of CKD progression and should be assessed annually for all patients with T2D, and 1–4 times per year for patients with established CKD to monitor the development of renal function.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Nutrition*. For patients requiring no dialysis, restricting protein intake to 0.8\\u2009g/kg per day is appropriate since this level slows the reduction in eGFR while higher or lower level showed no better or even worse effect. For patients requiring dialysis, protein intake should be elevated to 1.0-1.2\\u2009g/kg per day since they may suffer from malnutrition. Control of dietary potassium and sodium is necessary for the balance of serum potassium and sodium, since patients with reduced eGFR may have a problem with urinary excretion of potassium and sodium. Additionally, dietary potassium and sodium should be controlled according to the comorbidities, medicine use, blood pressure and test results.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Glycemic control*. Evidence from various studies have proved that glucose-lowering can delay the onset and progression of CKD. Moreover, there have been hypoglycemic agents such as SGLT-is have been proven to have direct renal benefits independent of glucose. Non-pharmacological therapies and pharmacologic therapies for patients with CKD have been fully discussed in parts above.\\n\\nWe believe it is unreasonable to recommend metformin for diabetic patients with CKD as we have not found evidence of additional renal benefits from metformin for diabetic patients with CKD. In addition, for those with an eGFR <60\\u2009ml/min/1.73 m2, glycemic target should be relaxed due to the increased risk of hypoglycemia.\\n\\n*Antihypertension therapy*. Hypertension is a strong risk factor for the development and progression of CKD. Antihypertension therapies have been proven to slow the progression of CKD in patients with diabetes and reduce the risk of cardiovascular events, and a blood pressure <130/80\\u2009mmHg is recommended to achieve such benefits. In patients with diabetes and hypertension, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are the preferred first-line agents for treating hypertension for those with an eGFR <60\\u2009ml/min/1.73 m2 and a uACR ≥300\\u2009mg/g creatinine for their proven effect to slow the progression of CKD and reduce the risk of cardiovascular events.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Moreover, other antihypertension agents lacking evidence of renalcardiovascular benefits could be added for personal blood pressure targets.\\n\\n*Mineralocorticoid receptor antagonists (MRAs)*. MRAs have not been well studied in CKD before due to their risk of hyperkalemia. Currently, the novel nonsteroidal MRA finerenone has been demonstrated to delay the progression of CKD and reduce cardiovascular events in patients with T2D and CKD in FIDELIO-DKD trial and FIGARO-DKD trials which primarily focus on renal outcome and cardiovascular outcome, respectively. These two trials demonstrated that compared with placebo, finerenone reduced the worsening of CKD by 23%, and also reduced the risk of cardiovascular events by 14%. However, compared with placebo, finerenone also showed a greater risk of hyperkalemia.[345](/articles/s41392-024-01951-9#ref-CR345 \"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).\"),[346](/articles/s41392-024-01951-9#ref-CR346 \"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).\") In patients with T2D and CKD, finerenone, the only nonsteroidal MRAs with proven renalcardiovascular benefits, was considered for those with an ACR\\u2009≥\\u200930\\u2009mg/g and normal potassium.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Control of other risk factors*. Dyslipidemia is associated with the pathogenesis and progression of CKD. Moreover, as renal function declines, the lipid profile gradually shifts to uremic lipid profile, which is characterized by increased triglycerides, low HDL cholesterol and elevated LDL cholesterol and contributes to atherosclerosis.[347](/articles/s41392-024-01951-9#ref-CR347 \"Ferro, C. J. et al. Lipid management in patients with chronic kidney disease. Nat. Rev. Nephrol. 14, 727–749 (2018).\") Therefore, lipid-loss management is essential for potentially delaying the progression of CKD and reducing the cardiovascular risk. Moderate- or high-intensity statin is recommended for all patients with T2D and CKD. Statin therapy is used for secondary prevention of CVD and for primary prevention in individuals aged >40 with diabetes or with CKD stages 1–4 and kidney transplantation. In addition, aspirin should generally be used for patients with established ASCVD and considered for primary use for those at high risk of ASCVD.[335](/articles/s41392-024-01951-9#ref-CR335 \"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 102, S1–S127 (2022).\")\\n\\n#### DN\\n\\nDN comprises a heterogeneous group of disorders that affect different parts of the nervous system and present with diverse clinical manifestations.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") DN is believed to be associated with neuronal, neuroglial cell and vascular endothelial cell injury caused by uncontrolled hyperglycemia, dyslipidemia and IR through multiple pathways, such as ERS, inflammation, oxidative stress and mitochondrial disorders.[70](/articles/s41392-024-01951-9#ref-CR70 \"Eid, S. A. et al. New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023).\") DPN and diabetic autonomic neuropathy, especially cardiovascular neuropathy (CAN) are the most common and well-studied forms of neuropathy.\\n\\nScreening at the time of diagnosis and annually thereafter is important for detecting DN in a timely manner and preventing further damage to the nervous system. Current treatments are not able to reverse the existing nerve damage but rather delay the onset and progression of DN and relieve symptoms to improve life quality.\\n\\n### Pathology-targeting treatment\\n\\n*Glycemic control*. Several lines of evidence have shown that intensive glycemic control dramatically reduced the risk of DPN and CAN in patients with T1D; however, some studies have demonstrated limited benefits of intensive glycemic control for T2D patients as only modestly prevents or delays the progression of DPN and CAN in patients with T2D, possibly because of undiagnosed hyperglycemia and multiple combined risk factors.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Lipid management*. Emerging evidence has demonstrated that dyslipidemia plays a crucial role in the pathogenesis of DN.[70](/articles/s41392-024-01951-9#ref-CR70 \"Eid, S. A. et al. New perspectives in diabetic neuropathy. Neuron 111, 2623–2641 (2023).\") Various strategies for lowering lipids, such as physical activity, weight loss and bariatric surgery, have been reported to have positive effects, but the use of lipid-lowering medicine does not seem to be effective at slowing the development of DN.[348](/articles/s41392-024-01951-9#ref-CR348 \"Afshinnia, F. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann. Clin. Transl. Neurol. 9, 1392–1404 (2022).\")\\n\\n*Hypertension control*. Many studies have shown that hypertension is also involved in the development of DN. A meta-analysis revealed that hypertension is an independent risk factor for DPN. Additionally, data from ACCORD trial demonstrated that intensive blood pressure management reduced the risk of CAN by 25%.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n### Symptom-alleviating treatment\\n\\n*Neuropathic pain*. Symptoms of DPN vary according to the class of involved sensory fibers, presenting with pain and unpleasant sensations if small fibers are involved and with numbness and loss of protective sensation (LOPS) if large fibers are involved.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Severe neuropathic pain can significantly limit motivation, and impact life quality and contribute to depression and social dysfunction. However, there is insufficient evidence indicating that holistic management of glycemia and other risk factors can alleviate the neuropathic pain. Therefore, agents for treating neuropathic pain are essential to relieving neuropathic pain, improving life quality and mental health. A number of agents can be considered for pain in DPN patients. Gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRIs), sodium channel blockers, and tricyclic antidepressants have been suggested as the first approach for neuropathic pain in patients with DPN, and oral analgesics and lidocaine patches are also considered.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Diabetic autonomic neuropathy*. Diabetic autonomic neuropathy affects autonomic neurons, and the symptoms vary according to the organs or systems of autonomic neuron damage. As with DPN, management targeting pathogenesis is not able to reverse established autonomic neuropathy. Treatment for existing diabetic autonomic neuropathy generally focuses on alleviating the symptoms. For example, CAN often presents with resting tachycardia and orthostatic hypotension, so nonpharmacologic strategies (such as adequate salt intake and physical activities and avoidance of medicine-related hypotension) and pharmacologic strategies (such as midodrine and droxidopa) should be considered to minimize postural symptoms rather than to restore normotension.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") When it affects the gastrointestinal system, patients can exhibit esophageal dysmotility, gastroparesis, constipation, diarrhea, and fecal incontinence.[349](/articles/s41392-024-01951-9#ref-CR349 \"Pop-Busui, R. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 40, 136–154 (2017).\") Dietary modifications and pharmacologic strategies targeting symptoms are considered to improve life quality despite no alterations in the underlying pathology or natural history of this disease.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n#### DFU\\n\\nDFU is the advanced consequence of multiple factors, including uncontrolled hyperglycemia, DPN and peripheral arterial disease (PAD). It is the leading cause of disability and mortality in people with diabetes.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\"),[350](/articles/s41392-024-01951-9#ref-CR350 \"Wang, Y. et al. An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. Biomed. Pharmacother. 133, 110991 (2021).\")\\n\\n### Prevention\\n\\nPreventing the development of foot ulcerations for the first time and after healing plays an essential role in the management of foot ulcerations. Early recognition of risk factors and examinations for foot ulcerations are effective ways to prevent and delay the occurrence of DFU and amputation. DFU are associated with multiple factors including DPN, PAD, foot deformities, history of foot ulcerations or amputations, nephropathy, etc., and are stratified at risk based on these risk factors. A thorough examination of the feet including the evaluation of DPN, PAD, and foot deformities should be performed annually in all people with diabetes, and the interval should be shortened based on the level of risk.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Education*. For all diabetic patients, especially those at risk of foot ulcerations, education on foot care, including disease awareness and self-care strategies, should be provided. However, a systematic review demonstrated that education about foot care improved the awareness and acknowledgement of foot ulcerations and the care, but it failed to achieve a positive impact on self-care behavior and incidence of diabetic foot ulcerations or amputation.[351](/articles/s41392-024-01951-9#ref-CR351 \"Goodall, R. J. et al. A systematic review of the impact of foot care education on self efficacy and self care in patients with diabetes. Eur. J. Vasc. Endovasc. Surg. 60, 282–292 (2020).\")\\n\\n*Foot care*. Foot care for patients with diabetes should be determined by their risk category. Diabetic patients at no or low risk can be managed by education and self-care. Diabetic patients at moderate or high risk require the involvement of a foot care specialist for further examination and surveillance. Treatment should include daily foot inspection, the use of moisturizers, the avoidance of self-care of ingrown nails and calluses, and specialized shoes (such as shoes with customized pressure-relieving orthoses for people with increased plantar pressures; additionally, individuals with deformities such as bunions or hammertoes may require specialized or custom-made footwear for people with deformities). Those who with neuropathy present with a warm, swollen, red foot requires a thorough work up for possible charcot neuroarthropathy, nonweight bearing and urgent referral to a foot care specialist to prevent foot deformities and instability leading to ulcerations and amputations.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n### Treatment of foot ulcerations\\n\\nThere are five basic principles for treating foot ulcerations which includes offloading of plantar ulcerations, debridement of necrotic, nonviable tissue, revascularization of ischemic wounds when necessary, management of infection, and use of physiologic, topical dressings.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Effective off-loading prevents patients with plantar neuropathic ulcers from walking on the lesions and is the key to successful management.[349](/articles/s41392-024-01951-9#ref-CR349 \"Pop-Busui, R. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 40, 136–154 (2017).\") If the ulcers fail to show a ≥50% reduction after 4 weeks of appropriate management via conventional methods, several advanced therapies, including negative-pressure therapy, growth factor therapy, bioengineered tissue, acellular matrix tissue, stem cell therapy, hyperbaric oxygen therapy, and, most recently, topical oxygen therapy, can be considered. However, these robust RCTs for these advanced therapies are lacking, which is challenging. Once the wounds healed, the above prevention program was started.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n#### DR\\n\\nDR is strongly related to the duration of diabetes, the level of glycemic control, nephropathy, hypertension and dyslipidemia and contributes to the disruption of the blood-retinal barrier (BRB), which is mainly caused by VEGF-A and proinflammatory factors.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") DR remains to be the leading cause of visual loss and blindness globally.[352](/articles/s41392-024-01951-9#ref-CR352 \"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).\")\\n\\n### Holistic treatment\\n\\nIt is essential for patients to be screened for DR once diagnosed with T2D and undergo regular eye examination by an ophthalmologist since early diagnose and treatment can efficiently slow the progression of DR and prevent and prevent vision loss. The time interval of examination depends on the presence of risk factors for the onset and worsening of DR such as uncontrolled hyperglycemia and diabetic macular edema.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\nEducation for awareness and health care and control of hyperglycemia, dyslipidemia and hypertension are key strategies for slowing the onset and worsening of DR, similar to other MDS-related complications.\\n\\n### Ophthalmic treatment\\n\\nOphthalmic treatment requires an ophthalmologist with experience in DR treatment. There are two main treatment strategies: photocoagulation surgery and intravitreal drug injection.\\n\\n*Photocoagulation surgery*. Panretinal laser photocoagulation therapy is a common strategy for treating high-risk PDR and some severe nonproliferative diabetic retinopathy (NPDR) since evidence shows that it reduces the risk of severe vision loss from PDR in patients with high-risk PDR and some severe NPDR. The macular laser photocoagulation technique, which is more gentle, was shown to be effective in treating diabetic macular edema.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n*Intravitreal drug injections*. VEGF-A is upregulated due to MDS and partially contributes to the vascular changes in DR by altering the blood vessel permeability and promoting neovascularization.[352](/articles/s41392-024-01951-9#ref-CR352 \"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).\") Intravitreal injection of anti-VEGF agents has provided an effective alternative to panretinal laser photocoagulation therapy for PDR. Evidence has demonstrated that the intravitreal injection of anti-VEGF agents effectively reduces the risk of vision loss. In addition, it is more effective to treat center-involved diabetic macular edema than photocoagulation surgery and has become the first-line therapy for diabetic macular edema.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\") Notably, not all patients respond optimally, indicating that other mechanisms are involved in vascular changes in DR.[352](/articles/s41392-024-01951-9#ref-CR352 \"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).\")\\n\\nA variety of studies suggest that proinflammatory factors such as IL-1β, TNF α, and IL-6 may contribute to DR pathogenesis.[352](/articles/s41392-024-01951-9#ref-CR352 \"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).\") Therefore, intravitreal injection of corticosteroid is an option for patients who are not candidates for anti-VEGF therapy.[1](/articles/s41392-024-01951-9#ref-CR1 \"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. Diabetes Care 47 (2024).\")\\n\\n## Conclusion and perspective\\n\\nIt is hoped that this review and our idea can provide a reference for most newly diagnosed patients with T2D receiving hypoglycemic therapy. The mechanism of T2D is not fully understood, and there is no cure yet. However, as mentioned earlier, T2D and MDS-related TOD are preventable, and effective measures must be taken to prevent the occurrence of diabetes, such as the prevention and treatment of preobesity and obesity and MASLD, which will greatly reduce the occurrence of T2D. If diabetes prevention fails, early detection should be emphasized. Once diabetes is diagnosed, holistic management of organ protection targeting MDS should be provided since most patients with T2D also have MDS. Due to the article layout limitation, we did not specifically address the prevention and treatment of hyperglycemic crises, DKA or the hyperosmolar hyperglycemic state (HHS). Diabetes treatment available for elderly individuals or those with gestational diabetes was not covered in this review. We also did not discuss much about the management of patients with T2D and CVD. We believe that T2D as a disease is simple, but the situation of patients with T2D is more complicated since most of them have MDS, and T2D is only one of the components that usually occurs later than preobesity, obesity and MASLD. Therefore, the term “complications” should not be used arbitrarily in patients with T2D, especially for “DKD” “macrovascular complications”; otherwise, the management of MDS will be mistakenly guided to focus on glycemic management. Only by holistically managing MDS can we achieve our goals of improving the quality of life and prolonging the life expectancy of patients with T2D.\\n\\n## References\\n\\nAmerican Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2024. *Diabetes Care* **47** (2024).\\n\\nLonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence. *J. Hepatol.* **68**, 335–352 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.jhep.2017.09.021)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29122390)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hypertension%2C%20diabetes%2C%20atherosclerosis%20and%20NASH%3A%20Cause%20or%20consequence&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2017.09.021&volume=68&pages=335-352&publication_year=2018&author=Lonardo%2CA&author=Nascimbeni%2CF&author=Mantovani%2CA&author=Targher%2CG)\\n\\nGBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* **402**, 203–234 (2023).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2823%2901301-6)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%2C%20regional%2C%20and%20national%20burden%20of%20diabetes%20from%201990%20to%202021%2C%20with%20projections%20of%20prevalence%20to%202050%3A%20a%20systematic%20analysis%20for%20the%20Global%20Burden%20of%20Disease%20Study%202021&journal=Lancet&doi=10.1016%2FS0140-6736%2823%2901301-6&volume=402&pages=203-234&publication_year=2023)\\n\\nGBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1204–1222 (2020).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2820%2930925-9)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20burden%20of%20369%20diseases%20and%20injuries%20in%20204%20countries%20and%20territories%2C%201990-2019%3A%20a%20systematic%20analysis%20for%20the%20Global%20Burden%20of%20Disease%20Study%202019&journal=Lancet&doi=10.1016%2FS0140-6736%2820%2930925-9&volume=396&pages=1204-1222&publication_year=2020)\\n\\nSun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res. Clin. Pr.* **183**, 109119 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.diabres.2021.109119)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=IDF%20Diabetes%20Atlas%3A%20Global%2C%20regional%20and%20country-level%20diabetes%20prevalence%20estimates%20for%202021%20and%20projections%20for%202045&journal=Diabetes%20Res.%20Clin.%20Pr.&doi=10.1016%2Fj.diabres.2021.109119&volume=183&publication_year=2022&author=Sun%2CH)\\n\\nKautzky-Willer, A., Harreiter, J. & Pacini, G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. *Endocr. Rev.* **37**, 278–316 (2016).\\n\\n[Article](https://doi.org/10.1210%2Fer.2015-1137)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXkt1Oqs7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27159875)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890267)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sex%20and%20gender%20differences%20in%20risk%2C%20pathophysiology%20and%20complications%20of%20type%202%20diabetes%20mellitus&journal=Endocr.%20Rev.&doi=10.1210%2Fer.2015-1137&volume=37&pages=278-316&publication_year=2016&author=Kautzky-Willer%2CA&author=Harreiter%2CJ&author=Pacini%2CG)\\n\\nBonnefond, A. & Froguel, P. Rare and common genetic events in type 2 diabetes: what should biologists know? *Cell Metab.* **21**, 357–368 (2015).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2014.12.020)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVOqtLc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25640731)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rare%20and%20common%20genetic%20events%20in%20type%202%20diabetes%3A%20what%20should%20biologists%20know%3F&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2014.12.020&volume=21&pages=357-368&publication_year=2015&author=Bonnefond%2CA&author=Froguel%2CP)\\n\\nHarding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E. & Gregg, E. W. Global trends in diabetes complications: a review of current evidence. *Diabetologia* **62**, 3–16 (2019).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-018-4711-2)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30171279)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20trends%20in%20diabetes%20complications%3A%20a%20review%20of%20current%20evidence&journal=Diabetologia&doi=10.1007%2Fs00125-018-4711-2&volume=62&pages=3-16&publication_year=2019&author=Harding%2CJL&author=Pavkov%2CME&author=Magliano%2CDJ&author=Shaw%2CJE&author=Gregg%2CEW)\\n\\nLiu, W. et al. Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: an age-period-cohort analysis. *Diabetes Obes. Metab.* **26**, 602–610 (2024).\\n\\n[Article](https://doi.org/10.1111%2Fdom.15349)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXitlahtrvP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37936340)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20trends%20in%20the%20burden%20of%20chronic%20kidney%20disease%20attributable%20to%20type%202%20diabetes%3A%20an%20age-period-cohort%20analysis&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.15349&volume=26&pages=602-610&publication_year=2024&author=Liu%2CW)\\n\\nArmstrong, D. G., Tan, T.-W., Boulton, A. J. M. & Bus, S. A. Diabetic foot ulcers: a review. *JAMA* **330**, 62–75 (2023).\\n\\n[Article](https://doi.org/10.1001%2Fjama.2023.10578)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhsVagtrrN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37395769)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10723802)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetic%20foot%20ulcers%3A%20a%20review&journal=JAMA&doi=10.1001%2Fjama.2023.10578&volume=330&pages=62-75&publication_year=2023&author=Armstrong%2CDG&author=Tan%2CT-W&author=Boulton%2CAJM&author=Bus%2CSA)\\n\\nHicks, C. W. & Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. *Curr. Diab Rep.* **19**, 86 (2019).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11892-019-1212-8)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31456118)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755905)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Epidemiology%20of%20peripheral%20neuropathy%20and%20lower%20extremity%20disease%20in%20diabetes&journal=Curr.%20Diab%20Rep.&doi=10.1007%2Fs11892-019-1212-8&volume=19&publication_year=2019&author=Hicks%2CCW&author=Selvin%2CE)\\n\\nTeo, Z. L. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. *Ophthalmology* **128**, 1580–1591 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.ophtha.2021.04.027)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33940045)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Global%20prevalence%20of%20diabetic%20retinopathy%20and%20projection%20of%20burden%20through%202045%3A%20systematic%20review%20and%20meta-analysis&journal=Ophthalmology&doi=10.1016%2Fj.ophtha.2021.04.027&volume=128&pages=1580-1591&publication_year=2021&author=Teo%2CZL)\\n\\nMulder, H. Transcribing β-cell mitochondria in health and disease. *Mol. Metab.* **6**, 1040–1051 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.molmet.2017.05.014)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXptlSgs7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28951827)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605719)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Transcribing%20%CE%B2-cell%20mitochondria%20in%20health%20and%20disease&journal=Mol.%20Metab.&doi=10.1016%2Fj.molmet.2017.05.014&volume=6&pages=1040-1051&publication_year=2017&author=Mulder%2CH)\\n\\nFesta, A. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* **102**, 42–47 (2000).\\n\\n[Article](https://doi.org/10.1161%2F01.CIR.102.1.42)\\xa0\\n[CAS](/articles/cas-redirect/1:STN:280:DC%2BD3czkt1ymtQ%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10880413)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Chronic%20subclinical%20inflammation%20as%20part%20of%20the%20insulin%20resistance%20syndrome%3A%20the%20Insulin%20Resistance%20Atherosclerosis%20Study%20%28IRAS%29&journal=Circulation&doi=10.1161%2F01.CIR.102.1.42&volume=102&pages=42-47&publication_year=2000&author=Festa%2CA)\\n\\nGado, M., Tsaousidou, E., Bornstein, S. R. & Perakakis, N. Sex-based differences in insulin resistance. *J. Endocrinol.* **261**, e230245 (2024).\\n\\n[Article](https://doi.org/10.1530%2FJOE-23-0245)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38265844)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sex-based%20differences%20in%20insulin%20resistance&journal=J.%20Endocrinol.&doi=10.1530%2FJOE-23-0245&volume=261&publication_year=2024&author=Gado%2CM&author=Tsaousidou%2CE&author=Bornstein%2CSR&author=Perakakis%2CN)\\n\\nPetersen, K. F. et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc. Natl Acad. Sci. USA* **103**, 18273–18277 (2006).\\n\\n[Article](https://doi.org/10.1073%2Fpnas.0608537103)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28XhtlWisrnP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17114290)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693873)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Increased%20prevalence%20of%20insulin%20resistance%20and%20nonalcoholic%20fatty%20liver%20disease%20in%20Asian-Indian%20men&journal=Proc.%20Natl%20Acad.%20Sci.%20USA&doi=10.1073%2Fpnas.0608537103&volume=103&pages=18273-18277&publication_year=2006&author=Petersen%2CKF)\\n\\nLear, S. A., Kohli, S., Bondy, G. P., Tchernof, A. & Sniderman, A. D. Ethnic variation in fat and lean body mass and the association with insulin resistance. *J. Clin. Endocrinol. Metab.* **94**, 4696–4702 (2009).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2009-1030)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsFyltLnL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19820012)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ethnic%20variation%20in%20fat%20and%20lean%20body%20mass%20and%20the%20association%20with%20insulin%20resistance&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2009-1030&volume=94&pages=4696-4702&publication_year=2009&author=Lear%2CSA&author=Kohli%2CS&author=Bondy%2CGP&author=Tchernof%2CA&author=Sniderman%2CAD)\\n\\nSylow, L., Tokarz, V. L., Richter, E. A. & Klip, A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. *Cell Metab.* **33**, 758–780 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2021.03.020)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXosVCmsrs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33826918)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20many%20actions%20of%20insulin%20in%20skeletal%20muscle%2C%20the%20paramount%20tissue%20determining%20glycemia&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2021.03.020&volume=33&pages=758-780&publication_year=2021&author=Sylow%2CL&author=Tokarz%2CVL&author=Richter%2CEA&author=Klip%2CA)\\n\\nSmith, U. & Kahn, B. B. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. *J. Intern Med.* **280**, 465–475 (2016).\\n\\n[Article](https://doi.org/10.1111%2Fjoim.12540)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs12lt73M)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27699898)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218584)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Adipose%20tissue%20regulates%20insulin%20sensitivity%3A%20role%20of%20adipogenesis%2C%20de%20novo%20lipogenesis%20and%20novel%20lipids&journal=J.%20Intern%20Med.&doi=10.1111%2Fjoim.12540&volume=280&pages=465-475&publication_year=2016&author=Smith%2CU&author=Kahn%2CBB)\\n\\nXie, Z., Xie, T., Liu, J., Zhang, Q. & Xiao, X. Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD. *Int. J. Mol. Sci.* **24**, 2142 (2023).\\n\\n[Article](https://doi.org/10.3390%2Fijms24032142)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXjsVSqsr8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36768465)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916810)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Emerging%20role%20of%20protein%20O-GlcNAcylation%20in%20liver%20metabolism%3A%20implications%20for%20diabetes%20and%20NAFLD&journal=Int.%20J.%20Mol.%20Sci.&doi=10.3390%2Fijms24032142&volume=24&publication_year=2023&author=Xie%2CZ&author=Xie%2CT&author=Liu%2CJ&author=Zhang%2CQ&author=Xiao%2CX)\\n\\nHart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. *Annu. Rev. Biochem.* **80**, 825–858 (2011).\\n\\n[Article](https://doi.org/10.1146%2Fannurev-biochem-060608-102511)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXptVCntr4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21391816)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294376)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cross%20talk%20between%20O-GlcNAcylation%20and%20phosphorylation%3A%20roles%20in%20signaling%2C%20transcription%2C%20and%20chronic%20disease&journal=Annu.%20Rev.%20Biochem.&doi=10.1146%2Fannurev-biochem-060608-102511&volume=80&pages=825-858&publication_year=2011&author=Hart%2CGW&author=Slawson%2CC&author=Ramirez-Correa%2CG&author=Lagerlof%2CO)\\n\\nChen, B. et al. Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency. *Nature* **605**, 761–766 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fs41586-022-04756-4)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhtlajtrvL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35585240)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Maternal%20inheritance%20of%20glucose%20intolerance%20via%20oocyte%20TET3%20insufficiency&journal=Nature&doi=10.1038%2Fs41586-022-04756-4&volume=605&pages=761-766&publication_year=2022&author=Chen%2CB)\\n\\nEpstein, F. H., Moller, D. E. & Flier, J. S. Insulin resistance—mechanisms, syndromes, and implications. *N. Engl. J. Med.* **325**, 938–948 (1991).\\n\\n[Article](https://doi.org/10.1056%2FNEJM199109263251307)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Insulin%20resistance%E2%80%94mechanisms%2C%20syndromes%2C%20and%20implications&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM199109263251307&volume=325&pages=938-948&publication_year=1991&author=Epstein%2CFH&author=Moller%2CDE&author=Flier%2CJS)\\n\\nJaldin-Fincati, J. R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P. J. & Klip, A. Update on GLUT4 vesicle traffic: a cornerstone of insulin action. *Trends Endocrinol. Metab.* **28**, 597–611 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.tem.2017.05.002)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXotFynsrg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28602209)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Update%20on%20GLUT4%20vesicle%20traffic%3A%20a%20cornerstone%20of%20insulin%20action&journal=Trends%20Endocrinol.%20Metab.&doi=10.1016%2Fj.tem.2017.05.002&volume=28&pages=597-611&publication_year=2017&author=Jaldin-Fincati%2CJR&author=Pavarotti%2CM&author=Frendo-Cumbo%2CS&author=Bilan%2CPJ&author=Klip%2CA)\\n\\nHe, L. Alterations of gut microbiota by overnutrition impact gluconeogenic gene expression and insulin signaling. *Int J. Mol. Sci.* **22**, 2121 (2021).\\n\\n[Article](https://doi.org/10.3390%2Fijms22042121)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXotVKls7c%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33672754)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924631)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alterations%20of%20gut%20microbiota%20by%20overnutrition%20impact%20gluconeogenic%20gene%20expression%20and%20insulin%20signaling&journal=Int%20J.%20Mol.%20Sci.&doi=10.3390%2Fijms22042121&volume=22&publication_year=2021&author=He%2CL)\\n\\nPoitout, V. & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. *Endocr. Rev.* **29**, 351–366 (2008).\\n\\n[Article](https://doi.org/10.1210%2Fer.2007-0023)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXntV2lsbk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18048763)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucolipotoxicity%3A%20fuel%20excess%20and%20%CE%B2-cell%20dysfunction&journal=Endocr.%20Rev.&doi=10.1210%2Fer.2007-0023&volume=29&pages=351-366&publication_year=2008&author=Poitout%2CV&author=Robertson%2CRP)\\n\\nWeir, G. C. & Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. *Diabetes* **53**, S16–S21 (2004).\\n\\n[Article](https://doi.org/10.2337%2Fdiabetes.53.suppl_3.S16)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2cXhtVOls7zJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15561905)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Five%20stages%20of%20evolving%20beta-cell%20dysfunction%20during%20progression%20to%20diabetes&journal=Diabetes&doi=10.2337%2Fdiabetes.53.suppl_3.S16&volume=53&pages=S16-S21&publication_year=2004&author=Weir%2CGC&author=Bonner-Weir%2CS)\\n\\nShaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. *Nat. Rev. Endocrinol.* **20**, 136–148 (2024).\\n\\n[Article](https://doi.org/10.1038%2Fs41574-023-00932-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXms1GlsQ%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38129700)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Emerging%20mechanisms%20of%20obesity-associated%20immune%20dysfunction&journal=Nat.%20Rev.%20Endocrinol.&doi=10.1038%2Fs41574-023-00932-2&volume=20&pages=136-148&publication_year=2024&author=Shaikh%2CSR&author=Beck%2CMA&author=Alwarawrah%2CY&author=MacIver%2CNJ)\\n\\nWeisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* **112**, 1796–1808 (2003).\\n\\n[Article](https://doi.org/10.1172%2FJCI200319246)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD3sXhtVSmtLvO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14679176)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296995)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obesity%20is%20associated%20with%20macrophage%20accumulation%20in%20adipose%20tissue&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI200319246&volume=112&pages=1796-1808&publication_year=2003&author=Weisberg%2CSP)\\n\\nBays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. *J. Clin. Endocrinol. Metab.* **89**, 463–478 (2004).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2003-030723)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2cXhsFKqu7k%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14764748)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20the%20adipocyte%2C%20free%20fatty%20acids%2C%20and%20ectopic%20fat%20in%20pathogenesis%20of%20type%202%20diabetes%20mellitus%3A%20peroxisomal%20proliferator-activated%20receptor%20agonists%20provide%20a%20rational%20therapeutic%20approach&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2003-030723&volume=89&pages=463-478&publication_year=2004&author=Bays%2CH&author=Mandarino%2CL&author=DeFronzo%2CRA)\\n\\nGlass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell Metab.* **15**, 635–645 (2012).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2012.04.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XmsVCjtLc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22560216)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156155)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inflammation%20and%20lipid%20signaling%20in%20the%20etiology%20of%20insulin%20resistance&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2012.04.001&volume=15&pages=635-645&publication_year=2012&author=Glass%2CCK&author=Olefsky%2CJM)\\n\\nPetersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. *Physiol. Rev.* **98**, 2133–2223 (2018).\\n\\n[Article](https://doi.org/10.1152%2Fphysrev.00063.2017)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXmtleqsbw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30067154)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170977)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20insulin%20action%20and%20insulin%20resistance&journal=Physiol.%20Rev.&doi=10.1152%2Fphysrev.00063.2017&volume=98&pages=2133-2223&publication_year=2018&author=Petersen%2CMC&author=Shulman%2CGI)\\n\\nLiu, P. et al. Role of macrophages in peripheral nerve injury and repair. *Neural Regen. Res* **14**, 1335–1342 (2019).\\n\\n[Article](https://doi.org/10.4103%2F1673-5374.253510)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhvFChsb3N)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30964051)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524518)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20macrophages%20in%20peripheral%20nerve%20injury%20and%20repair&journal=Neural%20Regen.%20Res&doi=10.4103%2F1673-5374.253510&volume=14&pages=1335-1342&publication_year=2019&author=Liu%2CP)\\n\\nEl, F., Ka, N., Ts, J. & Dlh, B. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. *Neuron* **93**, 1296–1313 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.neuron.2017.02.005)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20horizons%20in%20diabetic%20neuropathy%3A%20mechanisms%2C%20bioenergetics%2C%20and%20pain&journal=Neuron&doi=10.1016%2Fj.neuron.2017.02.005&volume=93&pages=1296-1313&publication_year=2017&author=El%2CF&author=Ka%2CN&author=Ts%2CJ&author=Dlh%2CB)\\n\\nOeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-κB signaling pathways. *Nat. Immunol.* **12**, 695–708 (2011).\\n\\n[Article](https://doi.org/10.1038%2Fni.2065)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXptV2it7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21772278)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Crosstalk%20in%20NF-%CE%BAB%20signaling%20pathways&journal=Nat.%20Immunol.&doi=10.1038%2Fni.2065&volume=12&pages=695-708&publication_year=2011&author=Oeckinghaus%2CA&author=Hayden%2CMS&author=Ghosh%2CS)\\n\\nKracht, M., Müller-Ladner, U. & Schmitz, M. L. Mutual regulation of metabolic processes and proinflammatory NF-κB signaling. *J. Allergy Clin. Immunol.* **146**, 694–705 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.jaci.2020.07.027)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1Gqtb%2FL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32771559)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mutual%20regulation%20of%20metabolic%20processes%20and%20proinflammatory%20NF-%CE%BAB%20signaling&journal=J.%20Allergy%20Clin.%20Immunol.&doi=10.1016%2Fj.jaci.2020.07.027&volume=146&pages=694-705&publication_year=2020&author=Kracht%2CM&author=M%C3%BCller-Ladner%2CU&author=Schmitz%2CML)\\n\\nVillalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F. & Sobrevia, L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. *Mol. Asp. Med.* **66**, 49–61 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.mam.2018.11.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlentL3P)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Endoplasmic%20reticulum%20stress%20and%20development%20of%20insulin%20resistance%20in%20adipose%2C%20skeletal%2C%20liver%2C%20and%20foetoplacental%20tissue%20in%20diabesity&journal=Mol.%20Asp.%20Med.&doi=10.1016%2Fj.mam.2018.11.001&volume=66&pages=49-61&publication_year=2019&author=Villalobos-Labra%2CR&author=Subiabre%2CM&author=Toledo%2CF&author=Pardo%2CF&author=Sobrevia%2CL)\\n\\nPrasad, M. K., Mohandas, S. & Ramkumar, K. M. Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic β-cells in diabetes. *Apoptosis* **28**, 958–976 (2023).\\n\\n[Article](https://link.springer.com/doi/10.1007/s10495-023-01854-0)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37273039)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dysfunctions%2C%20molecular%20mechanisms%2C%20and%20therapeutic%20strategies%20of%20pancreatic%20%CE%B2-cells%20in%20diabetes&journal=Apoptosis&doi=10.1007%2Fs10495-023-01854-0&volume=28&pages=958-976&publication_year=2023&author=Prasad%2CMK&author=Mohandas%2CS&author=Ramkumar%2CKM)\\n\\nQin, W. & Weng, J. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis. *Sci. Bull. (Beijing)* **68**, 1413–1429 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.scib.2023.06.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXht12iu7rK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37336688)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hepatocyte%20NLRP3%20interacts%20with%20PKC%CE%B5%20to%20drive%20hepatic%20insulin%20resistance%20and%20steatosis&journal=Sci.%20Bull.%20%28Beijing%29&doi=10.1016%2Fj.scib.2023.06.003&volume=68&pages=1413-1429&publication_year=2023&author=Qin%2CW&author=Weng%2CJ)\\n\\nPetersen, K. F. et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc. Natl Acad. Sci. USA* **104**, 12587–12594 (2007).\\n\\n[Article](https://doi.org/10.1073%2Fpnas.0705408104)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXptVGqt78%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17640906)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924794)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20skeletal%20muscle%20insulin%20resistance%20in%20the%20pathogenesis%20of%20the%20metabolic%20syndrome&journal=Proc.%20Natl%20Acad.%20Sci.%20USA&doi=10.1073%2Fpnas.0705408104&volume=104&pages=12587-12594&publication_year=2007&author=Petersen%2CKF)\\n\\nBhat, O. M. et al. Interleukin-18-induced cell adhesion molecule expression is associated with feedback regulation by PPAR-γ and NF-κB in Apo E-/- mice. *Mol. Cell Biochem.* **428**, 119–128 (2017).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11010-016-2922-8)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXitlKrsb8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28176248)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Interleukin-18-induced%20cell%20adhesion%20molecule%20expression%20is%20associated%20with%20feedback%20regulation%20by%20PPAR-%CE%B3%20and%20NF-%CE%BAB%20in%20Apo%20E-%2F-%20mice&journal=Mol.%20Cell%20Biochem.&doi=10.1007%2Fs11010-016-2922-8&volume=428&pages=119-128&publication_year=2017&author=Bhat%2COM)\\n\\nFu, Y., Wu, N. & Zhao, D. Function of NLRP3 in the Pathogenesis and Development of Diabetic Nephropathy. *Med Sci. Monit.* **23**, 3878–3884 (2017).\\n\\n[Article](https://doi.org/10.12659%2FMSM.903269)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28798291)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565226)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Function%20of%20NLRP3%20in%20the%20Pathogenesis%20and%20Development%20of%20Diabetic%20Nephropathy&journal=Med%20Sci.%20Monit.&doi=10.12659%2FMSM.903269&volume=23&pages=3878-3884&publication_year=2017&author=Fu%2CY&author=Wu%2CN&author=Zhao%2CD)\\n\\nMatoba, K. et al. Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. *Int J. Mol. Sci.* **20**, 3393 (2019).\\n\\n[Article](https://doi.org/10.3390%2Fijms20143393)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVGitr4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31295940)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678414)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Unraveling%20the%20role%20of%20inflammation%20in%20the%20pathogenesis%20of%20diabetic%20kidney%20disease&journal=Int%20J.%20Mol.%20Sci.&doi=10.3390%2Fijms20143393&volume=20&publication_year=2019&author=Matoba%2CK)\\n\\nSheu, M. L. et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. *Arterioscler. Thromb. Vasc. Biol.* **25**, 539–545 (2005).\\n\\n[Article](https://doi.org/10.1161%2F01.ATV.0000155462.24263.e4)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtl2ku7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15653566)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=High%20glucose%20induces%20human%20endothelial%20cell%20apoptosis%20through%20a%20phosphoinositide%203-kinase-regulated%20cyclooxygenase-2%20pathway&journal=Arterioscler.%20Thromb.%20Vasc.%20Biol.&doi=10.1161%2F01.ATV.0000155462.24263.e4&volume=25&pages=539-545&publication_year=2005&author=Sheu%2CML)\\n\\nRomeo, G., Liu, W.-H., Asnaghi, V., Kern, T. S. & Lorenzi, M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. *Diabetes* **51**, 2241–2248 (2002).\\n\\n[Article](https://doi.org/10.2337%2Fdiabetes.51.7.2241)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD38Xlt1Wks78%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12086956)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Activation%20of%20nuclear%20factor-kappaB%20induced%20by%20diabetes%20and%20high%20glucose%20regulates%20a%20proapoptotic%20program%20in%20retinal%20pericytes&journal=Diabetes&doi=10.2337%2Fdiabetes.51.7.2241&volume=51&pages=2241-2248&publication_year=2002&author=Romeo%2CG&author=Liu%2CW-H&author=Asnaghi%2CV&author=Kern%2CTS&author=Lorenzi%2CM)\\n\\nKowluru, R. A., Koppolu, P., Chakrabarti, S. & Chen, S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. *Free Radic. Res.* **37**, 1169–1180 (2003).\\n\\n[Article](https://doi.org/10.1080%2F10715760310001604189)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD3sXoslels7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14703729)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes-induced%20activation%20of%20nuclear%20transcriptional%20factor%20in%20the%20retina%2C%20and%20its%20inhibition%20by%20antioxidants&journal=Free%20Radic.%20Res.&doi=10.1080%2F10715760310001604189&volume=37&pages=1169-1180&publication_year=2003&author=Kowluru%2CRA&author=Koppolu%2CP&author=Chakrabarti%2CS&author=Chen%2CS)\\n\\nWu, M.-Y., Yiang, G.-T., Lai, T.-T. & Li, C.-J. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. *Oxid. Med. Cell Longev.* **2018**, 3420187 (2018).\\n\\n[Article](https://doi.org/10.1155%2F2018%2F3420187)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30254714)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145164)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20oxidative%20stress%20and%20mitochondrial%20dysfunction%20during%20the%20pathogenesis%20of%20diabetic%20retinopathy&journal=Oxid.%20Med.%20Cell%20Longev.&doi=10.1155%2F2018%2F3420187&volume=2018&publication_year=2018&author=Wu%2CM-Y&author=Yiang%2CG-T&author=Lai%2CT-T&author=Li%2CC-J)\\n\\nChaurasia, S. S. et al. The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. *Sci. Rep.* **8**, 2847 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41598-018-21198-z)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29434227)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809448)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20NLRP3%20inflammasome%20may%20contribute%20to%20pathologic%20neovascularization%20in%20the%20advanced%20stages%20of%20diabetic%20retinopathy&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-018-21198-z&volume=8&publication_year=2018&author=Chaurasia%2CSS)\\n\\nDodington, D. W., Desai, H. R. & Woo, M. JAK/STAT—emerging players in metabolism. *Trends Endocrinol. Metab.* **29**, 55–65 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.tem.2017.11.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVegu73E)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29191719)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=JAK%2FSTAT%E2%80%94emerging%20players%20in%20metabolism&journal=Trends%20Endocrinol.%20Metab.&doi=10.1016%2Fj.tem.2017.11.001&volume=29&pages=55-65&publication_year=2018&author=Dodington%2CDW&author=Desai%2CHR&author=Woo%2CM)\\n\\nTian, S., Zhao, H. & Song, H. Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. *Crit. Rev. Food Sci. Nutr.* **64**, 5039–5056 (2022).\\n\\n[Article](https://doi.org/10.1080%2F10408398.2022.2148090)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36397728)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Shared%20signaling%20pathways%20and%20targeted%20therapy%20by%20natural%20bioactive%20compounds%20for%20obesity%20and%20type%202%20diabetes&journal=Crit.%20Rev.%20Food%20Sci.%20Nutr.&doi=10.1080%2F10408398.2022.2148090&volume=64&pages=5039-5056&publication_year=2022&author=Tian%2CS&author=Zhao%2CH&author=Song%2CH)\\n\\nBako, H. Y., Ibrahim, M. A., Isah, M. S. & Ibrahim, S. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. *Life Sci.* **239**, 117045 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.lfs.2019.117045)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXitF2mtb3K)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31730866)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20JAK-STAT%20and%20NF-%CE%BAB%20signalling%20systems%20could%20be%20a%20novel%20therapeutic%20target%20against%20insulin%20resistance%20and%20type%202%20diabetes&journal=Life%20Sci.&doi=10.1016%2Fj.lfs.2019.117045&volume=239&publication_year=2019&author=Bako%2CHY&author=Ibrahim%2CMA&author=Isah%2CMS&author=Ibrahim%2CS)\\n\\nZhang, H. et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. *Kidney Int.* **92**, 909–921 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.kint.2017.03.027)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXosl2qt7c%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28554737)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610635)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Podocyte-specific%20JAK2%20overexpression%20worsens%20diabetic%20kidney%20disease%20in%20mice&journal=Kidney%20Int.&doi=10.1016%2Fj.kint.2017.03.027&volume=92&pages=909-921&publication_year=2017&author=Zhang%2CH)\\n\\nLiu, Z. et al. Nobiletin suppresses high-glucose-induced inflammation and ECM accumulation in human mesangial cells through STAT3/NF-κB pathway. *J. Cell Biochem.* **120**, 3467–3473 (2019).\\n\\n[Article](https://doi.org/10.1002%2Fjcb.27621)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlGgurbK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30499124)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nobiletin%20suppresses%20high-glucose-induced%20inflammation%20and%20ECM%20accumulation%20in%20human%20mesangial%20cells%20through%20STAT3%2FNF-%CE%BAB%20pathway&journal=J.%20Cell%20Biochem.&doi=10.1002%2Fjcb.27621&volume=120&pages=3467-3473&publication_year=2019&author=Liu%2CZ)\\n\\nEg, L. et al. Interleukin 6 function in the skin and isolated keratinocytes is modulated by hyperglycemia. *J. Immunol. Res.* **2019**, 5087847 (2019).\\n\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Interleukin%206%20function%20in%20the%20skin%20and%20isolated%20keratinocytes%20is%20modulated%20by%20hyperglycemia&journal=J.%20Immunol.%20Res.&volume=2019&publication_year=2019&author=Eg%2CL)\\n\\nAp, S. et al. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. *Nat. Commun.* **11**, 4678 (2020).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-020-18276-0)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Deregulated%20immune%20cell%20recruitment%20orchestrated%20by%20FOXM1%20impairs%20human%20diabetic%20wound%20healing&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-020-18276-0&volume=11&publication_year=2020&author=Ap%2CS)\\n\\nYung, J. H. M. & Giacca, A. Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. *Cells* **9**, 706 (2020).\\n\\n[Article](https://doi.org/10.3390%2Fcells9030706)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVShtbfO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32183037)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140703)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20c-Jun%20N-terminal%20kinase%20%28JNK%29%20in%20obesity%20and%20type%202%20diabetes&journal=Cells&doi=10.3390%2Fcells9030706&volume=9&publication_year=2020&author=Yung%2CJHM&author=Giacca%2CA)\\n\\nKitamura, T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. *Nat. Rev. Endocrinol.* **9**, 615–623 (2013).\\n\\n[Article](https://doi.org/10.1038%2Fnrendo.2013.157)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsVCntrfN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23959366)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20FOXO1%20in%20%CE%B2-cell%20failure%20and%20type%202%20diabetes%20mellitus&journal=Nat.%20Rev.%20Endocrinol.&doi=10.1038%2Fnrendo.2013.157&volume=9&pages=615-623&publication_year=2013&author=Kitamura%2CT)\\n\\nBack, S. H. & Kaufman, R. J. Endoplasmic reticulum stress and type 2 diabetes. *Annu Rev. Biochem.* **81**, 767–793 (2012).\\n\\n[Article](https://doi.org/10.1146%2Fannurev-biochem-072909-095555)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVGlsL7K)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22443930)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684428)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Endoplasmic%20reticulum%20stress%20and%20type%202%20diabetes&journal=Annu%20Rev.%20Biochem.&doi=10.1146%2Fannurev-biochem-072909-095555&volume=81&pages=767-793&publication_year=2012&author=Back%2CSH&author=Kaufman%2CRJ)\\n\\nGorman, A. M., Healy, S. J. M., Jäger, R. & Samali, A. Stress management at the ER: Regulators of ER stress-induced apoptosis. *Pharm. Thers* **134**, 306–316 (2012).\\n\\n[Article](https://doi.org/10.1016%2Fj.pharmthera.2012.02.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38Xjs1Gnt7Y%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Stress%20management%20at%20the%20ER%3A%20Regulators%20of%20ER%20stress-induced%20apoptosis&journal=Pharm.%20Thers&doi=10.1016%2Fj.pharmthera.2012.02.003&volume=134&pages=306-316&publication_year=2012&author=Gorman%2CAM&author=Healy%2CSJM&author=J%C3%A4ger%2CR&author=Samali%2CA)\\n\\nWang, Y., He, Z., Yang, Q. & Zhou, G. XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy. *FEBS Open Bio* **9**, 1249–1258 (2019).\\n\\n[Article](https://doi.org/10.1002%2F2211-5463.12655)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVOnsrfF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31077568)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609578)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=XBP1%20inhibits%20mesangial%20cell%20apoptosis%20in%20response%20to%20oxidative%20stress%20via%20the%20PTEN%2FAKT%20pathway%20in%20diabetic%20nephropathy&journal=FEBS%20Open%20Bio&doi=10.1002%2F2211-5463.12655&volume=9&pages=1249-1258&publication_year=2019&author=Wang%2CY&author=He%2CZ&author=Yang%2CQ&author=Zhou%2CG)\\n\\nYao, W. et al. IRE1α siRNA relieves endoplasmic reticulum stress-induced apoptosis and alleviates diabetic peripheral neuropathy in vivo and in vitro. *Sci. Rep.* **8**, 2579 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41598-018-20950-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29416111)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803253)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=IRE1%CE%B1%20siRNA%20relieves%20endoplasmic%20reticulum%20stress-induced%20apoptosis%20and%20alleviates%20diabetic%20peripheral%20neuropathy%20in%20vivo%20and%20in%20vitro&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-018-20950-9&volume=8&publication_year=2018&author=Yao%2CW)\\n\\nYang, L. et al. Role of endoplasmic reticulum stress in the loss of retinal ganglion cells in diabetic retinopathy. *Neural Regen. Res.* **8**, 3148–3158 (2013).\\n\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2cXls1amsb8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25206636)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158709)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20endoplasmic%20reticulum%20stress%20in%20the%20loss%20of%20retinal%20ganglion%20cells%20in%20diabetic%20retinopathy&journal=Neural%20Regen.%20Res.&volume=8&pages=3148-3158&publication_year=2013&author=Yang%2CL)\\n\\nGupta, D., Kono, T. & Evans-Molina, C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. *Diabetes Obes. Metab.* **12**, 1036–1047 (2010).\\n\\n[Article](https://doi.org/10.1111%2Fj.1463-1326.2010.01299.x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXhs1WmsbzM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20977574)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764483)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20peroxisome%20proliferator-activated%20receptor%20%CE%B3%20in%20pancreatic%20%CE%B2%20cell%20function%20and%20survival%3A%20therapeutic%20implications%20for%20the%20treatment%20of%20type%202%20diabetes%20mellitus&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fj.1463-1326.2010.01299.x&volume=12&pages=1036-1047&publication_year=2010&author=Gupta%2CD&author=Kono%2CT&author=Evans-Molina%2CC)\\n\\nPowers, S. K. & Schrager, M. Redox signaling regulates skeletal muscle remodeling in response to exercise and prolonged inactivity. *Redox Biol.* **54**, 102374 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.redox.2022.102374)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFKns7%2FM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35738088)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233275)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Redox%20signaling%20regulates%20skeletal%20muscle%20remodeling%20in%20response%20to%20exercise%20and%20prolonged%20inactivity&journal=Redox%20Biol.&doi=10.1016%2Fj.redox.2022.102374&volume=54&publication_year=2022&author=Powers%2CSK&author=Schrager%2CM)\\n\\nPetersen, K. F. et al. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. *Proc. Natl Acad. Sci. USA* **109**, 8236–8240 (2012).\\n\\n[Article](https://doi.org/10.1073%2Fpnas.1205675109)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XosFaiurY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22547801)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361376)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reversal%20of%20muscle%20insulin%20resistance%20by%20weight%20reduction%20in%20young%2C%20lean%2C%20insulin-resistant%20offspring%20of%20parents%20with%20type%202%20diabetes&journal=Proc.%20Natl%20Acad.%20Sci.%20USA&doi=10.1073%2Fpnas.1205675109&volume=109&pages=8236-8240&publication_year=2012&author=Petersen%2CKF)\\n\\nLu, Q. et al. The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy. *Mol. Cell Endocrinol.* **473**, 31–43 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.mce.2017.12.012)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXitVCktLnI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29277549)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20mTOR%20promotes%20oxidative%20stress-induced%20apoptosis%20of%20mesangial%20cells%20in%20diabetic%20nephropathy&journal=Mol.%20Cell%20Endocrinol.&doi=10.1016%2Fj.mce.2017.12.012&volume=473&pages=31-43&publication_year=2018&author=Lu%2CQ)\\n\\nSamadi, M., Aziz, S. G.-G. & Naderi, R. The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats. *Cell Stress Chaperones* **26**, 217–227 (2021).\\n\\n[Article](https://link.springer.com/doi/10.1007/s12192-020-01170-5)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33047279)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20tropisetron%20on%20oxidative%20stress%2C%20SIRT1%2C%20FOXO3a%2C%20and%20claudin-1%20in%20the%20renal%20tissue%20of%20STZ-induced%20diabetic%20rats&journal=Cell%20Stress%20Chaperones&doi=10.1007%2Fs12192-020-01170-5&volume=26&pages=217-227&publication_year=2021&author=Samadi%2CM&author=Aziz%2CSG-G&author=Naderi%2CR)\\n\\nDomingueti, C. P. et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. *J. Diabetes Complications* **30**, 738–745 (2016).\\n\\n[Article](https://doi.org/10.1016%2Fj.jdiacomp.2015.12.018)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26781070)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetes%20mellitus%3A%20The%20linkage%20between%20oxidative%20stress%2C%20inflammation%2C%20hypercoagulability%20and%20vascular%20complications&journal=J.%20Diabetes%20Complications&doi=10.1016%2Fj.jdiacomp.2015.12.018&volume=30&pages=738-745&publication_year=2016&author=Domingueti%2CCP)\\n\\nKang, Q. & Yang, C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. *Redox Biol.* **37**, 101799 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.redox.2020.101799)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVGitbnO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33248932)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767789)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Oxidative%20stress%20and%20diabetic%20retinopathy%3A%20molecular%20mechanisms%2C%20pathogenetic%20role%20and%20therapeutic%20implications&journal=Redox%20Biol.&doi=10.1016%2Fj.redox.2020.101799&volume=37&publication_year=2020&author=Kang%2CQ&author=Yang%2CC)\\n\\nEid, S. A. et al. New perspectives in diabetic neuropathy. *Neuron* **111**, 2623–2641 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.neuron.2023.05.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtFehurbJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37263266)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525009)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20perspectives%20in%20diabetic%20neuropathy&journal=Neuron&doi=10.1016%2Fj.neuron.2023.05.003&volume=111&pages=2623-2641&publication_year=2023&author=Eid%2CSA)\\n\\nEid, S. A. et al. Targeting the NADPH oxidase-4 and liver X receptor pathway preserves Schwann cell integrity in diabetic mice. *Diabetes* **69**, 448–464 (2020).\\n\\n[Article](https://doi.org/10.2337%2Fdb19-0517)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVSnur0%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31882567)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20NADPH%20oxidase-4%20and%20liver%20X%20receptor%20pathway%20preserves%20Schwann%20cell%20integrity%20in%20diabetic%20mice&journal=Diabetes&doi=10.2337%2Fdb19-0517&volume=69&pages=448-464&publication_year=2020&author=Eid%2CSA)\\n\\nXu, J. et al. Oxidative stress induced by NOX2 contributes to neuropathic pain via plasma membrane translocation of PKCε in rat dorsal root ganglion neurons. *J. Neuroinflammation* **18**, 106 (2021).\\n\\n[Article](https://link.springer.com/doi/10.1186/s12974-021-02155-6)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1SmtrrL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33952299)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101139)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Oxidative%20stress%20induced%20by%20NOX2%20contributes%20to%20neuropathic%20pain%20via%20plasma%20membrane%20translocation%20of%20PKC%CE%B5%20in%20rat%20dorsal%20root%20ganglion%20neurons&journal=J.%20Neuroinflammation&doi=10.1186%2Fs12974-021-02155-6&volume=18&publication_year=2021&author=Xu%2CJ)\\n\\nJiao, Y. et al. MicroRNA-7a-5p ameliorates diabetic peripheral neuropathy by regulating VDAC1/JNK/c-JUN pathway. *Diabet. Med.* **40**, e14890 (2023).\\n\\n[Article](https://doi.org/10.1111%2Fdme.14890)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XitVemtbbJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35616949)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=MicroRNA-7a-5p%20ameliorates%20diabetic%20peripheral%20neuropathy%20by%20regulating%20VDAC1%2FJNK%2Fc-JUN%20pathway&journal=Diabet.%20Med.&doi=10.1111%2Fdme.14890&volume=40&publication_year=2023&author=Jiao%2CY)\\n\\nTaylor, R. Type 2 diabetes. *Diabetes Care* **36**, 1047–1055 (2013).\\n\\n[Article](https://doi.org/10.2337%2Fdc12-1805)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVKltbfO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23520370)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609491)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc12-1805&volume=36&pages=1047-1055&publication_year=2013&author=Taylor%2CR)\\n\\nSamuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. *Lancet* **375**, 2267–2277 (2010).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2810%2960408-4)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXotVagtrk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20609972)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995547)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipid-induced%20insulin%20resistance%3A%20unravelling%20the%20mechanism&journal=Lancet&doi=10.1016%2FS0140-6736%2810%2960408-4&volume=375&pages=2267-2277&publication_year=2010&author=Samuel%2CVT&author=Petersen%2CKF&author=Shulman%2CGI)\\n\\nYao, Z. et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. *Nat. Metab.* **5**, 1706–1725 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs42255-023-00896-7)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhvFOltb7P)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37735236)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590755)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Upregulation%20of%20WDR6%20drives%20hepatic%20de%20novo%20lipogenesis%20in%20insulin%20resistance%20in%20mice&journal=Nat.%20Metab.&doi=10.1038%2Fs42255-023-00896-7&volume=5&pages=1706-1725&publication_year=2023&author=Yao%2CZ)\\n\\nGeisler, C. E. et al. Hepatocyte membrane potential regulates serum insulin and insulin sensitivity by altering hepatic GABA release. *Cell Rep.* **35**, 109298 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.celrep.2021.109298)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsVKlsbbL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34192533)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341405)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hepatocyte%20membrane%20potential%20regulates%20serum%20insulin%20and%20insulin%20sensitivity%20by%20altering%20hepatic%20GABA%20release&journal=Cell%20Rep.&doi=10.1016%2Fj.celrep.2021.109298&volume=35&publication_year=2021&author=Geisler%2CCE)\\n\\nDas, A. & Reis, F. mTOR signaling: new insights into cancer, cardiovascular diseases, diabetes and aging. *Int J. Mol. Sci.* **24**, 13628 (2023).\\n\\n[Article](https://doi.org/10.3390%2Fijms241713628)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37686434)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487471)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=mTOR%20signaling%3A%20new%20insights%20into%20cancer%2C%20cardiovascular%20diseases%2C%20diabetes%20and%20aging&journal=Int%20J.%20Mol.%20Sci.&doi=10.3390%2Fijms241713628&volume=24&publication_year=2023&author=Das%2CA&author=Reis%2CF)\\n\\nSaxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. *Cell* **168**, 960–976 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.cell.2017.02.004)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXkt1Ogtb4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28283069)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394987)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=mTOR%20signaling%20in%20growth%2C%20metabolism%2C%20and%20disease&journal=Cell&doi=10.1016%2Fj.cell.2017.02.004&volume=168&pages=960-976&publication_year=2017&author=Saxton%2CRA&author=Sabatini%2CDM)\\n\\nLeibowitz, G., Cerasi, E. & Ketzinel-Gilad, M. The role of mTOR in the adaptation and failure of β-cells in type 2 diabetes. *Diabetes Obes. Metab.* **10**, 157–169 (2008).\\n\\n[Article](https://doi.org/10.1111%2Fj.1463-1326.2008.00952.x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsVeqsb7I)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18834443)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20mTOR%20in%20the%20adaptation%20and%20failure%20of%20%CE%B2-cells%20in%20type%202%20diabetes&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fj.1463-1326.2008.00952.x&volume=10&pages=157-169&publication_year=2008&author=Leibowitz%2CG&author=Cerasi%2CE&author=Ketzinel-Gilad%2CM)\\n\\nQiao, S. et al. Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR/β-TrcP/Nrf2 pathway. *Free Radic. Biol. Med.* **145**, 118–135 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.freeradbiomed.2019.09.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvVyltrvI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31494242)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Bergenin%20impedes%20the%20generation%20of%20extracellular%20matrix%20in%20glomerular%20mesangial%20cells%20and%20ameliorates%20diabetic%20nephropathy%20in%20mice%20by%20inhibiting%20oxidative%20stress%20via%20the%20mTOR%2F%CE%B2-TrcP%2FNrf2%20pathway&journal=Free%20Radic.%20Biol.%20Med.&doi=10.1016%2Fj.freeradbiomed.2019.09.003&volume=145&pages=118-135&publication_year=2019&author=Qiao%2CS)\\n\\nBouçanova, F. et al. Disrupted function of lactate transporter MCT1, but not MCT4, in Schwann cells affects the maintenance of motor end-plate innervation. *Glia* **69**, 124–136 (2021).\\n\\n[Article](https://doi.org/10.1002%2Fglia.23889)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32686211)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Disrupted%20function%20of%20lactate%20transporter%20MCT1%2C%20but%20not%20MCT4%2C%20in%20Schwann%20cells%20affects%20the%20maintenance%20of%20motor%20end-plate%20innervation&journal=Glia&doi=10.1002%2Fglia.23889&volume=69&pages=124-136&publication_year=2021&author=Bou%C3%A7anova%2CF)\\n\\nYang, H.-L., Tsai, Y.-C., Korivi, M., Chang, C.-T. & Hseu, Y.-C. Lucidone promotes the cutaneous wound healing process via activation of the PI3K/AKT, Wnt/β-catenin and NF-κB signaling pathways. *Biochim. Biophys. Acta Mol. Cell Res.* **1864**, 151–168 (2017).\\n\\n[Article](https://doi.org/10.1016%2Fj.bbamcr.2016.10.021)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28Xhsl2itb%2FM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27816443)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lucidone%20promotes%20the%20cutaneous%20wound%20healing%20process%20via%20activation%20of%20the%20PI3K%2FAKT%2C%20Wnt%2F%CE%B2-catenin%20and%20NF-%CE%BAB%20signaling%20pathways&journal=Biochim.%20Biophys.%20Acta%20Mol.%20Cell%20Res.&doi=10.1016%2Fj.bbamcr.2016.10.021&volume=1864&pages=151-168&publication_year=2017&author=Yang%2CH-L&author=Tsai%2CY-C&author=Korivi%2CM&author=Chang%2CC-T&author=Hseu%2CY-C)\\n\\nWei, F. et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/Akt/mTOR pathway. *Aging (Albany NY)* **12**, 12002–12018 (2020).\\n\\n[Article](https://doi.org/10.18632%2Faging.103366)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFCmtL%2FO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32570219)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Plasma%20endothelial%20cells-derived%20extracellular%20vesicles%20promote%20wound%20healing%20in%20diabetes%20through%20YAP%20and%20the%20PI3K%2FAkt%2FmTOR%20pathway&journal=Aging%20%28Albany%20NY%29&doi=10.18632%2Faging.103366&volume=12&pages=12002-12018&publication_year=2020&author=Wei%2CF)\\n\\nJere, S. W., Houreld, N. N. & Abrahamse, H. Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing. *Cytokine Growth Factor Rev.* **50**, 52–59 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.cytogfr.2019.03.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXltFCrtb8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30890300)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20the%20PI3K%2FAKT%20%28mTOR%20and%20GSK3%CE%B2%29%20signalling%20pathway%20and%20photobiomodulation%20in%20diabetic%20wound%20healing&journal=Cytokine%20Growth%20Factor%20Rev.&doi=10.1016%2Fj.cytogfr.2019.03.001&volume=50&pages=52-59&publication_year=2019&author=Jere%2CSW&author=Houreld%2CNN&author=Abrahamse%2CH)\\n\\nZhang, E., Gao, B., Yang, L., Wu, X. & Wang, Z. Notoginsenoside Ft1 promotes fibroblast proliferation via PI3K/Akt/mTOR signaling pathway and benefits wound healing in genetically diabetic mice. *J. Pharm. Exp. Ther.* **356**, 324–332 (2016).\\n\\n[Article](https://doi.org/10.1124%2Fjpet.115.229369)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XpvVelsbw%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Notoginsenoside%20Ft1%20promotes%20fibroblast%20proliferation%20via%20PI3K%2FAkt%2FmTOR%20signaling%20pathway%20and%20benefits%20wound%20healing%20in%20genetically%20diabetic%20mice&journal=J.%20Pharm.%20Exp.%20Ther.&doi=10.1124%2Fjpet.115.229369&volume=356&pages=324-332&publication_year=2016&author=Zhang%2CE&author=Gao%2CB&author=Yang%2CL&author=Wu%2CX&author=Wang%2CZ)\\n\\nKim, W., Shin, Y.-K., Kim, B.-J. & Egan, J. M. Notch signaling in pancreatic endocrine cell and diabetes. *Biochem. Biophys. Res. Commun.* **392**, 247–251 (2010).\\n\\n[Article](https://doi.org/10.1016%2Fj.bbrc.2009.12.115)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXitVGqtLk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20035712)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Notch%20signaling%20in%20pancreatic%20endocrine%20cell%20and%20diabetes&journal=Biochem.%20Biophys.%20Res.%20Commun.&doi=10.1016%2Fj.bbrc.2009.12.115&volume=392&pages=247-251&publication_year=2010&author=Kim%2CW&author=Shin%2CY-K&author=Kim%2CB-J&author=Egan%2CJM)\\n\\nPajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. *Nat. Med.* **19**, 1054–1060 (2013).\\n\\n[Article](https://doi.org/10.1038%2Fnm.3259)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtVKgsr3L)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23832089)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737382)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20Notch%20uncouples%20Akt%20activation%20from%20hepatic%20lipid%20accumulation%20by%20decreasing%20mTorc1%20stability&journal=Nat.%20Med.&doi=10.1038%2Fnm.3259&volume=19&pages=1054-1060&publication_year=2013&author=Pajvani%2CUB)\\n\\nPajvani, U. B. et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. *Nat. Med.* **17**, 961–967 (2011).\\n\\n[Article](https://doi.org/10.1038%2Fnm.2378)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXpsFOjsLg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21804540)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387563)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20Notch%20signaling%20ameliorates%20insulin%20resistance%20in%20a%20FoxO1-dependent%20manner&journal=Nat.%20Med.&doi=10.1038%2Fnm.2378&volume=17&pages=961-967&publication_year=2011&author=Pajvani%2CUB)\\n\\nHasan, S. S. et al. Endothelial Notch signaling controls insulin transport in muscle. *EMBO Mol. Med.* **12**, e09271 (2020).\\n\\n[Article](https://doi.org/10.15252%2Femmm.201809271)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXltFSqtr8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32187826)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136962)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Endothelial%20Notch%20signaling%20controls%20insulin%20transport%20in%20muscle&journal=EMBO%20Mol.%20Med.&doi=10.15252%2Femmm.201809271&volume=12&publication_year=2020&author=Hasan%2CSS)\\n\\nSiebel, C. & Lendahl, U. Notch signaling in development, tissue homeostasis, and disease. *Physiol. Rev.* **97**, 1235–1294 (2017).\\n\\n[Article](https://doi.org/10.1152%2Fphysrev.00005.2017)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXltlCnsr4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28794168)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Notch%20signaling%20in%20development%2C%20tissue%20homeostasis%2C%20and%20disease&journal=Physiol.%20Rev.&doi=10.1152%2Fphysrev.00005.2017&volume=97&pages=1235-1294&publication_year=2017&author=Siebel%2CC&author=Lendahl%2CU)\\n\\nStumvoll, M., Goldstein, B. J. & Van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet* **365**, 1333–1346 (2005).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2805%2961032-X)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2MXjtF2iu7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15823385)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%3A%20principles%20of%20pathogenesis%20and%20therapy&journal=Lancet&doi=10.1016%2FS0140-6736%2805%2961032-X&volume=365&pages=1333-1346&publication_year=2005&author=Stumvoll%2CM&author=Goldstein%2CBJ&author=Haeften%2CTW)\\n\\nTownsend, L. K. & Steinberg, G. R. AMPK and the endocrine control of metabolism. *Endocr. Rev.* **44**, 910–933 (2023).\\n\\n[Article](https://doi.org/10.1210%2Fendrev%2Fbnad012)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37115289)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=AMPK%20and%20the%20endocrine%20control%20of%20metabolism&journal=Endocr.%20Rev.&doi=10.1210%2Fendrev%2Fbnad012&volume=44&pages=910-933&publication_year=2023&author=Townsend%2CLK&author=Steinberg%2CGR)\\n\\nSteinberg, G. R. & Hardie, D. G. New insights into activation and function of the AMPK. *Nat. Rev. Mol. Cell Biol.* **24**, 255–272 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs41580-022-00547-x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XislOmtrzN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36316383)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20insights%20into%20activation%20and%20function%20of%20the%20AMPK&journal=Nat.%20Rev.%20Mol.%20Cell%20Biol.&doi=10.1038%2Fs41580-022-00547-x&volume=24&pages=255-272&publication_year=2023&author=Steinberg%2CGR&author=Hardie%2CDG)\\n\\nStromsdorfer, K. L. et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. *Cell Rep.* **16**, 1851–1860 (2016).\\n\\n[Article](https://doi.org/10.1016%2Fj.celrep.2016.07.027)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlWjt7nK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27498863)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094180)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=NAMPT-mediated%20NAD%28%2B%29%20biosynthesis%20in%20adipocytes%20regulates%20adipose%20tissue%20function%20and%20multi-organ%20insulin%20sensitivity%20in%20mice&journal=Cell%20Rep.&doi=10.1016%2Fj.celrep.2016.07.027&volume=16&pages=1851-1860&publication_year=2016&author=Stromsdorfer%2CKL)\\n\\nTabák, A. G. et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. *Diabetes Care* **35**, 2540–2547 (2012).\\n\\n[Article](https://doi.org/10.2337%2Fdc11-2263)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22933430)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507593)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Adiponectin%20trajectories%20before%20type%202%20diabetes%20diagnosis%3A%20Whitehall%20II%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc11-2263&volume=35&pages=2540-2547&publication_year=2012&author=Tab%C3%A1k%2CAG)\\n\\nYc, H. et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. *Cell Death Dis.* **12**, 925 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41419-021-04184-8)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=AMPK%20agonist%20alleviate%20renal%20tubulointerstitial%20fibrosis%20via%20activating%20mitophagy%20in%20high%20fat%20and%20streptozotocin%20induced%20diabetic%20mice&journal=Cell%20Death%20Dis.&doi=10.1038%2Fs41419-021-04184-8&volume=12&publication_year=2021&author=Yc%2CH)\\n\\nXu, J., Liu, L.-Q., Xu, L.-L., Xing, Y. & Ye, S. Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis. *Clin. Exp. Pharm. Physiol.* **47**, 599–608 (2020).\\n\\n[Article](https://doi.org/10.1111%2F1440-1681.13226)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVSgurs%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20alleviates%20renal%20injury%20in%20diabetic%20rats%20by%20inducing%20Sirt1%2FFoxO1%20autophagic%20signal%20axis&journal=Clin.%20Exp.%20Pharm.%20Physiol.&doi=10.1111%2F1440-1681.13226&volume=47&pages=599-608&publication_year=2020&author=Xu%2CJ&author=Liu%2CL-Q&author=Xu%2CL-L&author=Xing%2CY&author=Ye%2CS)\\n\\nRen, H. et al. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. *Mol. Cell Endocrinol.* **500**, 110628 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.mce.2019.110628)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFeqsLjE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31647955)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metformin%20alleviates%20oxidative%20stress%20and%20enhances%20autophagy%20in%20diabetic%20kidney%20disease%20via%20AMPK%2FSIRT1-FoxO1%20pathway&journal=Mol.%20Cell%20Endocrinol.&doi=10.1016%2Fj.mce.2019.110628&volume=500&publication_year=2020&author=Ren%2CH)\\n\\nGurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* **51**, 102590 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.ebiom.2019.11.051)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31901868)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948163)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20gut%20microbiota%20in%20type%202%20diabetes%20pathophysiology&journal=EBioMedicine&doi=10.1016%2Fj.ebiom.2019.11.051&volume=51&publication_year=2020&author=Gurung%2CM)\\n\\nCox, A. J., West, N. P. & Cripps, A. W. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* **3**, 207–215 (2015).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2814%2970134-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXpsFeksLo%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25066177)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obesity%2C%20inflammation%2C%20and%20the%20gut%20microbiota&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2814%2970134-2&volume=3&pages=207-215&publication_year=2015&author=Cox%2CAJ&author=West%2CNP&author=Cripps%2CAW)\\n\\nWang, H. et al. The Wnt signaling pathway in diabetic nephropathy. *Front. Cell Dev. Biol.* **9**, 701547 (2022).\\n\\n[Article](https://doi.org/10.3389%2Ffcell.2021.701547)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35059392)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763969)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20Wnt%20signaling%20pathway%20in%20diabetic%20nephropathy&journal=Front.%20Cell%20Dev.%20Biol.&doi=10.3389%2Ffcell.2021.701547&volume=9&publication_year=2022&author=Wang%2CH)\\n\\nZuriaga, M. A. et al. Activation of non-canonical WNT signaling in human visceral adipose tissue contributes to local and systemic inflammation. *Sci. Rep.* **7**, 17326 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fs41598-017-17509-5)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29229927)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725530)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Activation%20of%20non-canonical%20WNT%20signaling%20in%20human%20visceral%20adipose%20tissue%20contributes%20to%20local%20and%20systemic%20inflammation&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-017-17509-5&volume=7&publication_year=2017&author=Zuriaga%2CMA)\\n\\nNie, X., Wei, X., Ma, H., Fan, L. & Chen, W.-D. The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. *J. Cell Mol. Med.* **25**, 6479–6495 (2021).\\n\\n[Article](https://doi.org/10.1111%2Fjcmm.16663)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFaqtbvO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34042263)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278111)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20complex%20role%20of%20Wnt%20ligands%20in%20type%202%20diabetes%20mellitus%20and%20related%20complications&journal=J.%20Cell%20Mol.%20Med.&doi=10.1111%2Fjcmm.16663&volume=25&pages=6479-6495&publication_year=2021&author=Nie%2CX&author=Wei%2CX&author=Ma%2CH&author=Fan%2CL&author=Chen%2CW-D)\\n\\nZhang, H. et al. Regulatory mechanisms of the Wnt/β-catenin pathway in diabetic cutaneous ulcers. *Front. Pharmacol.* **9**, 1114 (2018).\\n\\n[Article](https://doi.org/10.3389%2Ffphar.2018.01114)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXpt1ajt7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30386236)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199358)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Regulatory%20mechanisms%20of%20the%20Wnt%2F%CE%B2-catenin%20pathway%20in%20diabetic%20cutaneous%20ulcers&journal=Front.%20Pharmacol.&doi=10.3389%2Ffphar.2018.01114&volume=9&publication_year=2018&author=Zhang%2CH)\\n\\nYamaguchi, Y. et al. Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. *FASEB J.* **22**, 1009–1020 (2008).\\n\\n[Article](https://doi.org/10.1096%2Ffj.07-9475com)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXktlWnsLY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17984176)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dickkopf%201%20%28DKK1%29%20regulates%20skin%20pigmentation%20and%20thickness%20by%20affecting%20Wnt%2Fbeta-catenin%20signaling%20in%20keratinocytes&journal=FASEB%20J.&doi=10.1096%2Ffj.07-9475com&volume=22&pages=1009-1020&publication_year=2008&author=Yamaguchi%2CY)\\n\\nCatrina, S.-B. & Zheng, X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. *Diabetologia* **64**, 709–716 (2021).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-021-05380-z)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXms1Gmurg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33496820)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940280)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hypoxia%20and%20hypoxia-inducible%20factors%20in%20diabetes%20and%20its%20complications&journal=Diabetologia&doi=10.1007%2Fs00125-021-05380-z&volume=64&pages=709-716&publication_year=2021&author=Catrina%2CS-B&author=Zheng%2CX)\\n\\nKoyasu, S., Kobayashi, M., Goto, Y., Hiraoka, M. & Harada, H. Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge. *Cancer Sci.* **109**, 560–571 (2018).\\n\\n[Article](https://doi.org/10.1111%2Fcas.13483)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVeqtrg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29285833)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834787)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Regulatory%20mechanisms%20of%20hypoxia%E2%80%90inducible%20factor%201%20activity%3A%20Two%20decades%20of%20knowledge&journal=Cancer%20Sci.&doi=10.1111%2Fcas.13483&volume=109&pages=560-571&publication_year=2018&author=Koyasu%2CS&author=Kobayashi%2CM&author=Goto%2CY&author=Hiraoka%2CM&author=Harada%2CH)\\n\\nPitale, P. M. & Gorbatyuk, M. S. Diabetic retinopathy: from animal models to cellular signaling. *Int J. Mol. Sci.* **23**, 1487 (2022).\\n\\n[Article](https://doi.org/10.3390%2Fijms23031487)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XktFWkt7s%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35163410)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835767)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetic%20retinopathy%3A%20from%20animal%20models%20to%20cellular%20signaling&journal=Int%20J.%20Mol.%20Sci.&doi=10.3390%2Fijms23031487&volume=23&publication_year=2022&author=Pitale%2CPM&author=Gorbatyuk%2CMS)\\n\\nZhang, D., Lv, F.-L. & Wang, G.-H. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. *Eur. Rev. Med. Pharm. Sci.* **22**, 5071–5076 (2018).\\n\\n[CAS](/articles/cas-redirect/1:STN:280:DC%2BB3c3ltFymtg%3D%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20HIF-1%CE%B1%20on%20diabetic%20retinopathy%20angiogenesis%20and%20VEGF%20expression&journal=Eur.%20Rev.%20Med.%20Pharm.%20Sci.&volume=22&pages=5071-5076&publication_year=2018&author=Zhang%2CD&author=Lv%2CF-L&author=Wang%2CG-H)\\n\\nIbar, C. & Irvine, K. D. Integration of Hippo-YAP signaling with metabolism. *Dev. Cell* **54**, 256–267 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.devcel.2020.06.025)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVClsrjE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32693058)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373816)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Integration%20of%20Hippo-YAP%20signaling%20with%20metabolism&journal=Dev.%20Cell&doi=10.1016%2Fj.devcel.2020.06.025&volume=54&pages=256-267&publication_year=2020&author=Ibar%2CC&author=Irvine%2CKD)\\n\\nTaylor, R., Al-Mrabeh, A. & Sattar, N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes Endocrinol.* **7**, 726–736 (2019).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2819%2930076-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1Cns7vN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31097391)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Understanding%20the%20mechanisms%20of%20reversal%20of%20type%202%20diabetes&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2819%2930076-2&volume=7&pages=726-736&publication_year=2019&author=Taylor%2CR&author=Al-Mrabeh%2CA&author=Sattar%2CN)\\n\\nSun, T. & Han, X. Death versus dedifferentiation: the molecular bases of beta cell mass reduction in type 2 diabetes. *Semin Cell Dev. Biol.* **103**, 76–82 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.semcdb.2019.12.002)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXitlKhtr7P)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31831356)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Death%20versus%20dedifferentiation%3A%20the%20molecular%20bases%20of%20beta%20cell%20mass%20reduction%20in%20type%202%20diabetes&journal=Semin%20Cell%20Dev.%20Biol.&doi=10.1016%2Fj.semcdb.2019.12.002&volume=103&pages=76-82&publication_year=2020&author=Sun%2CT&author=Han%2CX)\\n\\nCinti, F. et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. *J. Clin. Endocrinol. Metab.* **101**, 1044–1054 (2016).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2015-2860)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVCrtL%2FK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26713822)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Evidence%20of%20%CE%B2-cell%20dedifferentiation%20in%20human%20type%202%20diabetes&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2015-2860&volume=101&pages=1044-1054&publication_year=2016&author=Cinti%2CF)\\n\\nSpijker, H. S. et al. Conversion of mature human β-cells into glucagon-producing α-cells. *Diabetes* **62**, 2471–2480 (2013).\\n\\n[Article](https://doi.org/10.2337%2Fdb12-1001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtFWjsLfK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23569174)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712074)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Conversion%20of%20mature%20human%20%CE%B2-cells%20into%20glucagon-producing%20%CE%B1-cells&journal=Diabetes&doi=10.2337%2Fdb12-1001&volume=62&pages=2471-2480&publication_year=2013&author=Spijker%2CHS)\\n\\nTalchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. *Cell* **150**, 1223–1234 (2012).\\n\\n[Article](https://doi.org/10.1016%2Fj.cell.2012.07.029)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XhtlKrsbzI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22980982)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445031)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pancreatic%20%CE%B2%20cell%20dedifferentiation%20as%20a%20mechanism%20of%20diabetic%20%CE%B2%20cell%20failure&journal=Cell&doi=10.1016%2Fj.cell.2012.07.029&volume=150&pages=1223-1234&publication_year=2012&author=Talchai%2CC&author=Xuan%2CS&author=Lin%2CHV&author=Sussel%2CL&author=Accili%2CD)\\n\\nAguayo-Mazzucato, C. et al. Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes. *Cell Metab.* **30**, 129–142.e4 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2019.05.006)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVyisr7F)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31155496)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610720)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Acceleration%20of%20%CE%B2%20cell%20aging%20determines%20diabetes%20and%20senolysis%20improves%20disease%20outcomes&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2019.05.006&volume=30&pages=129-142.e4&publication_year=2019&author=Aguayo-Mazzucato%2CC)\\n\\nSon, J. et al. Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure. *Nat. Commun.* **14**, 558 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-023-36315-4)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXivFalsLs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36732513)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895451)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genetic%20and%20pharmacologic%20inhibition%20of%20ALDH1A3%20as%20a%20treatment%20of%20%CE%B2-cell%20failure&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-023-36315-4&volume=14&publication_year=2023&author=Son%2CJ)\\n\\nLiang, J., Chirikjian, M., Pajvani, U. B. & Bartolomé, A. MafA regulation in β-cells: from transcriptional to post-translational mechanisms. *Biomolecules* **12**, 535 (2022).\\n\\n[Article](https://doi.org/10.3390%2Fbiom12040535)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFCisb7I)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35454124)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033020)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=MafA%20regulation%20in%20%CE%B2-cells%3A%20from%20transcriptional%20to%20post-translational%20mechanisms&journal=Biomolecules&doi=10.3390%2Fbiom12040535&volume=12&publication_year=2022&author=Liang%2CJ&author=Chirikjian%2CM&author=Pajvani%2CUB&author=Bartolom%C3%A9%2CA)\\n\\nEbrahim, N., Shakirova, K. & Dashinimaev, E. PDX1 is the cornerstone of pancreatic β-cell functions and identity. *Front. Mol. Biosci.* **9**, 1091757 (2022).\\n\\n[Article](https://doi.org/10.3389%2Ffmolb.2022.1091757)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhsFaiu70%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36589234)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798421)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=PDX1%20is%20the%20cornerstone%20of%20pancreatic%20%CE%B2-cell%20functions%20and%20identity&journal=Front.%20Mol.%20Biosci.&doi=10.3389%2Ffmolb.2022.1091757&volume=9&publication_year=2022&author=Ebrahim%2CN&author=Shakirova%2CK&author=Dashinimaev%2CE)\\n\\nAtaie-Ashtiani, S. & Forbes, B. A review of the biosynthesis and structural implications of insulin gene mutations linked to human disease. *Cells* **12**, 1008 (2023).\\n\\n[Article](https://doi.org/10.3390%2Fcells12071008)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXotFOku7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37048081)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093311)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20review%20of%20the%20biosynthesis%20and%20structural%20implications%20of%20insulin%20gene%20mutations%20linked%20to%20human%20disease&journal=Cells&doi=10.3390%2Fcells12071008&volume=12&publication_year=2023&author=Ataie-Ashtiani%2CS&author=Forbes%2CB)\\n\\nUchizono, Y., Alarcón, C., Wicksteed, B. L., Marsh, B. J. & Rhodes, C. J. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead. *Diabetes Obes. Metab.* **9**, 56–66 (2007).\\n\\n[Article](https://doi.org/10.1111%2Fj.1463-1326.2007.00774.x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtlOhsLbJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17919179)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20balance%20between%20proinsulin%20biosynthesis%20and%20insulin%20secretion%3A%20where%20can%20imbalance%20lead&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fj.1463-1326.2007.00774.x&volume=9&pages=56-66&publication_year=2007&author=Uchizono%2CY&author=Alarc%C3%B3n%2CC&author=Wicksteed%2CBL&author=Marsh%2CBJ&author=Rhodes%2CCJ)\\n\\nCui, D. et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. *Chin. Med. J. (Engl.)* **137**, 791 (2024).\\n\\n[Article](https://doi.org/10.1097%2FCM9.0000000000003034)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXhs1CgsL%2FL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38479993)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pancreatic%20%CE%B2-cell%20failure%2C%20clinical%20implications%2C%20and%20therapeutic%20strategies%20in%20type%202%20diabetes&journal=Chin.%20Med.%20J.%20%28Engl.%29&doi=10.1097%2FCM9.0000000000003034&volume=137&publication_year=2024&author=Cui%2CD)\\n\\nPascal, S. M. A., Guiot, Y., Pelengaris, S., Khan, M. & Jonas, J.-C. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets. *Am. J. Physiol. Endocrinol. Metab.* **295**, E92–E102 (2008).\\n\\n[Article](https://doi.org/10.1152%2Fajpendo.90235.2008)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXoslyhtbY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18413670)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20c-MYC%20activation%20on%20glucose%20stimulus-secretion%20coupling%20events%20in%20mouse%20pancreatic%20islets&journal=Am.%20J.%20Physiol.%20Endocrinol.%20Metab.&doi=10.1152%2Fajpendo.90235.2008&volume=295&pages=E92-E102&publication_year=2008&author=Pascal%2CSMA&author=Guiot%2CY&author=Pelengaris%2CS&author=Khan%2CM&author=Jonas%2CJ-C)\\n\\nBensellam, M., Laybutt, D. R. & Jonas, J.-C. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. *Mol. Cell Endocrinol.* **364**, 1–27 (2012).\\n\\n[Article](https://doi.org/10.1016%2Fj.mce.2012.08.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XhtlCjt7fM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22885162)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20molecular%20mechanisms%20of%20pancreatic%20%CE%B2-cell%20glucotoxicity%3A%20recent%20findings%20and%20future%20research%20directions&journal=Mol.%20Cell%20Endocrinol.&doi=10.1016%2Fj.mce.2012.08.003&volume=364&pages=1-27&publication_year=2012&author=Bensellam%2CM&author=Laybutt%2CDR&author=Jonas%2CJ-C)\\n\\nRobertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y. & Takahashi, H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. *Diabetes* **52**, 581–587 (2003).\\n\\n[Article](https://doi.org/10.2337%2Fdiabetes.52.3.581)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD3sXitFajsLc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12606496)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucose%20toxicity%20in%20beta-cells%3A%20type%202%20diabetes%2C%20good%20radicals%20gone%20bad%2C%20and%20the%20glutathione%20connection&journal=Diabetes&doi=10.2337%2Fdiabetes.52.3.581&volume=52&pages=581-587&publication_year=2003&author=Robertson%2CRP&author=Harmon%2CJ&author=Tran%2CPO&author=Tanaka%2CY&author=Takahashi%2CH)\\n\\nLee, Y. et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. *Proc. Natl Acad. Sci. USA* **91**, 10878–10882 (1994).\\n\\n[Article](https://doi.org/10.1073%2Fpnas.91.23.10878)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DyaK2MXitV2ku7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7971976)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45129)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Beta-cell%20lipotoxicity%20in%20the%20pathogenesis%20of%20non-insulin-dependent%20diabetes%20mellitus%20of%20obese%20rats%3A%20impairment%20in%20adipocyte-beta-cell%20relationships&journal=Proc.%20Natl%20Acad.%20Sci.%20USA&doi=10.1073%2Fpnas.91.23.10878&volume=91&pages=10878-10882&publication_year=1994&author=Lee%2CY)\\n\\nMaedler, K., Oberholzer, J., Bucher, P., Spinas, G. A. & Donath, M. Y. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. *Diabetes* **52**, 726–733 (2003).\\n\\n[Article](https://doi.org/10.2337%2Fdiabetes.52.3.726)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD3sXitFajtrk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12606514)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Monounsaturated%20fatty%20acids%20prevent%20the%20deleterious%20effects%20of%20palmitate%20and%20high%20glucose%20on%20human%20pancreatic%20beta-cell%20turnover%20and%20function&journal=Diabetes&doi=10.2337%2Fdiabetes.52.3.726&volume=52&pages=726-733&publication_year=2003&author=Maedler%2CK&author=Oberholzer%2CJ&author=Bucher%2CP&author=Spinas%2CGA&author=Donath%2CMY)\\n\\nBrunham, L. R., Kruit, J. K., Verchere, C. B. & Hayden, M. R. Cholesterol in islet dysfunction and type 2 diabetes. *J. Clin. Invest.* **118**, 403–408 (2008).\\n\\n[Article](https://doi.org/10.1172%2FJCI33296)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsFOnurw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18246189)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214697)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cholesterol%20in%20islet%20dysfunction%20and%20type%202%20diabetes&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI33296&volume=118&pages=403-408&publication_year=2008&author=Brunham%2CLR&author=Kruit%2CJK&author=Verchere%2CCB&author=Hayden%2CMR)\\n\\nBrunham, L. R. et al. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. *Nat. Med.* **13**, 340–347 (2007).\\n\\n[Article](https://doi.org/10.1038%2Fnm1546)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXisVKku74%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17322896)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=%CE%B2-cell%20ABCA1%20influences%20insulin%20secretion%2C%20glucose%20homeostasis%20and%20response%20to%20thiazolidinedione%20treatment&journal=Nat.%20Med.&doi=10.1038%2Fnm1546&volume=13&pages=340-347&publication_year=2007&author=Brunham%2CLR)\\n\\nSturek, J. M. et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells. *J. Clin. Invest.* **120**, 2575 (2010).\\n\\n[Article](https://doi.org/10.1172%2FJCI41280)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXovFart7k%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20530872)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898593)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=An%20intracellular%20role%20for%20ABCG1-mediated%20cholesterol%20transport%20in%20the%20regulated%20secretory%20pathway%20of%20mouse%20pancreatic%20%CE%B2%20cells&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI41280&volume=120&publication_year=2010&author=Sturek%2CJM)\\n\\nMaedler, K. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J. Clin. Invest.* **110**, 851–860 (2002).\\n\\n[Article](https://doi.org/10.1172%2FJCI200215318)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD38Xnt1ehtbY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12235117)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151125)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucose-induced%20beta%20cell%20production%20of%20IL-1beta%20contributes%20to%20glucotoxicity%20in%20human%20pancreatic%20islets&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI200215318&volume=110&pages=851-860&publication_year=2002&author=Maedler%2CK)\\n\\nKim, E.-K. et al. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. *Int J. Biochem Cell Biol.* **39**, 1260–1275 (2007).\\n\\n[Article](https://doi.org/10.1016%2Fj.biocel.2007.04.005)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXmtVejurc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17521952)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Activation%20of%20peroxisome%20proliferator-activated%20receptor-gamma%20protects%20pancreatic%20beta-cells%20from%20cytokine-induced%20cytotoxicity%20via%20NF%20kappaB%20pathway&journal=Int%20J.%20Biochem%20Cell%20Biol.&doi=10.1016%2Fj.biocel.2007.04.005&volume=39&pages=1260-1275&publication_year=2007&author=Kim%2CE-K)\\n\\nKaneto, H. et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. *Diabetes* **44**, 733–738 (1995).\\n\\n[Article](https://doi.org/10.2337%2Fdiab.44.7.733)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DyaK2MXms1Cnu7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7540572)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Apoptotic%20cell%20death%20triggered%20by%20nitric%20oxide%20in%20pancreatic%20beta-cells&journal=Diabetes&doi=10.2337%2Fdiab.44.7.733&volume=44&pages=733-738&publication_year=1995&author=Kaneto%2CH)\\n\\nLi, X., Xiao, G.-Y., Guo, T., Song, Y.-J. & Li, Q.-M. Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications. *Front. Endocrinol. (Lausanne)* **13**, 986565 (2022).\\n\\n[Article](https://doi.org/10.3389%2Ffendo.2022.986565)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36387904)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Potential%20therapeutic%20role%20of%20pyroptosis%20mediated%20by%20the%20NLRP3%20inflammasome%20in%20type%202%20diabetes%20and%20its%20complications&journal=Front.%20Endocrinol.%20%28Lausanne%29&doi=10.3389%2Ffendo.2022.986565&volume=13&publication_year=2022&author=Li%2CX&author=Xiao%2CG-Y&author=Guo%2CT&author=Song%2CY-J&author=Li%2CQ-M)\\n\\nWeng, Q. et al. STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. *Cell Death Differ.* **27**, 130–145 (2020).\\n\\n[Article](https://doi.org/10.1038%2Fs41418-019-0344-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFSmsbvK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31097787)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=STAT3%20dictates%20%CE%B2-cell%20apoptosis%20by%20modulating%20PTEN%20in%20streptozocin-induced%20hyperglycemia&journal=Cell%20Death%20Differ.&doi=10.1038%2Fs41418-019-0344-3&volume=27&pages=130-145&publication_year=2020&author=Weng%2CQ)\\n\\nYang, B. et al. Macrophages and neutrophils are necessary for ER stress-induced β cell loss. *Cell Rep.* **40**, 111255 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.celrep.2022.111255)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1WisrfP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36001973)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444341)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Macrophages%20and%20neutrophils%20are%20necessary%20for%20ER%20stress-induced%20%CE%B2%20cell%20loss&journal=Cell%20Rep.&doi=10.1016%2Fj.celrep.2022.111255&volume=40&publication_year=2022&author=Yang%2CB)\\n\\nYang, B. et al. RIPK3-mediated inflammation is a conserved β cell response to ER stress. *Sci. Adv.* **6**, eabd7272 (2020).\\n\\n[Article](https://doi.org/10.1126%2Fsciadv.abd7272)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXjslyrtrY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33355143)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11206196)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=RIPK3-mediated%20inflammation%20is%20a%20conserved%20%CE%B2%20cell%20response%20to%20ER%20stress&journal=Sci.%20Adv.&doi=10.1126%2Fsciadv.abd7272&volume=6&publication_year=2020&author=Yang%2CB)\\n\\nChung, S. S. et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. *Am. J. Physiol. Endocrinol. Metab.* **301**, E912–E921 (2011).\\n\\n[Article](https://doi.org/10.1152%2Fajpendo.00120.2011)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFaksbjI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21846907)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mechanism%20for%20antioxidative%20effects%20of%20thiazolidinediones%20in%20pancreatic%20%CE%B2-cells&journal=Am.%20J.%20Physiol.%20Endocrinol.%20Metab.&doi=10.1152%2Fajpendo.00120.2011&volume=301&pages=E912-E921&publication_year=2011&author=Chung%2CSS)\\n\\nTang, C. et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. *Diabetologia* **55**, 1366–1379 (2012).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-012-2474-8)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XlvFGmu7o%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22396011)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucose-induced%20beta%20cell%20dysfunction%20in%20vivo%20in%20rats%3A%20link%20between%20oxidative%20stress%20and%20endoplasmic%20reticulum%20stress&journal=Diabetologia&doi=10.1007%2Fs00125-012-2474-8&volume=55&pages=1366-1379&publication_year=2012&author=Tang%2CC)\\n\\nHetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. *Nat. Rev. Mol. Cell Biol.* **21**, 421–438 (2020).\\n\\n[Article](https://doi.org/10.1038%2Fs41580-020-0250-z)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtVWmtLfM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32457508)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867924)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mechanisms%2C%20regulation%20and%20functions%20of%20the%20unfolded%20protein%20response&journal=Nat.%20Rev.%20Mol.%20Cell%20Biol.&doi=10.1038%2Fs41580-020-0250-z&volume=21&pages=421-438&publication_year=2020&author=Hetz%2CC&author=Zhang%2CK&author=Kaufman%2CRJ)\\n\\nSharma, R. B., Landa-Galván, H. V. & Alonso, L. C. Living dangerously: protective and harmful ER stress responses in pancreatic β-cells. *Diabetes* **70**, 2431–2443 (2021).\\n\\n[Article](https://doi.org/10.2337%2Fdbi20-0033)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xls1Gruw%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34711668)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564401)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Living%20dangerously%3A%20protective%20and%20harmful%20ER%20stress%20responses%20in%20pancreatic%20%CE%B2-cells&journal=Diabetes&doi=10.2337%2Fdbi20-0033&volume=70&pages=2431-2443&publication_year=2021&author=Sharma%2CRB&author=Landa-Galv%C3%A1n%2CHV&author=Alonso%2CLC)\\n\\nZhang, Y. et al. THADA inhibition in mice protects against type 2 diabetes mellitus by improving pancreatic β-cell function and preserving β-cell mass. *Nat. Commun.* **14**, 1020 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-023-36680-0)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXjvFequ7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36823211)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950491)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=THADA%20inhibition%20in%20mice%20protects%20against%20type%202%20diabetes%20mellitus%20by%20improving%20pancreatic%20%CE%B2-cell%20function%20and%20preserving%20%CE%B2-cell%20mass&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-023-36680-0&volume=14&publication_year=2023&author=Zhang%2CY)\\n\\nArdestani, A. et al. MST1 is a novel regulator of apoptosis in pancreatic beta-cells. *Nat. Med.* **20**, 385–397 (2014).\\n\\n[Article](https://doi.org/10.1038%2Fnm.3482)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2cXktlCqsLs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24633305)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981675)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=MST1%20is%20a%20novel%20regulator%20of%20apoptosis%20in%20pancreatic%20beta-cells&journal=Nat.%20Med.&doi=10.1038%2Fnm.3482&volume=20&pages=385-397&publication_year=2014&author=Ardestani%2CA)\\n\\nYuan, T. et al. Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells. *JCI Insight* **1**, e86326 (2016).\\n\\n[Article](https://doi.org/10.1172%2Fjci.insight.86326)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27812538)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085606)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Proproliferative%20and%20antiapoptotic%20action%20of%20exogenously%20introduced%20YAP%20in%20pancreatic%20%CE%B2%20cells&journal=JCI%20Insight&doi=10.1172%2Fjci.insight.86326&volume=1&publication_year=2016&author=Yuan%2CT)\\n\\nFilippatos, T. D., Alexakis, K., Mavrikaki, V. & Mikhailidis, D. P. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, ‘prediabetes,’ diabetes and atherosclerosis. *Dig. Dis. Sci.* **67**, 26–41 (2022).\\n\\n[Article](https://link.springer.com/doi/10.1007/s10620-021-06824-7)\\xa0\\n[CAS](/articles/cas-redirect/1:STN:280:DC%2BB3sris1erug%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33469809)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nonalcoholic%20fatty%20pancreas%20disease%3A%20role%20in%20metabolic%20syndrome%2C%20%E2%80%98prediabetes%2C%E2%80%99%20diabetes%20and%20atherosclerosis&journal=Dig.%20Dis.%20Sci.&doi=10.1007%2Fs10620-021-06824-7&volume=67&pages=26-41&publication_year=2022&author=Filippatos%2CTD&author=Alexakis%2CK&author=Mavrikaki%2CV&author=Mikhailidis%2CDP)\\n\\nTt, C. et al. Fatty pancreas is independently associated with subsequent diabetes mellitus development: a 10-year prospective cohort study. *Clin. Gastroenterol. Hepatol.* **20**, 2013–2022 (2022).\\n\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Fatty%20pancreas%20is%20independently%20associated%20with%20subsequent%20diabetes%20mellitus%20development%3A%20a%2010-year%20prospective%20cohort%20study&journal=Clin.%20Gastroenterol.%20Hepatol.&volume=20&pages=2013-2022&publication_year=2022&author=Tt%2CC)\\n\\nPinnick, K. E. et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. *Obes. (Silver Spring)* **16**, 522–530 (2008).\\n\\n[Article](https://doi.org/10.1038%2Foby.2007.110)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXivVOqtLc%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pancreatic%20ectopic%20fat%20is%20characterized%20by%20adipocyte%20infiltration%20and%20altered%20lipid%20composition&journal=Obes.%20%28Silver%20Spring%29&doi=10.1038%2Foby.2007.110&volume=16&pages=522-530&publication_year=2008&author=Pinnick%2CKE)\\n\\nGerst, F. et al. What role do fat cells play in pancreatic tissue? *Mol. Metab.* **25**, 1–10 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.molmet.2019.05.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXpsVyiur4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31113756)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600604)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=What%20role%20do%20fat%20cells%20play%20in%20pancreatic%20tissue%3F&journal=Mol.%20Metab.&doi=10.1016%2Fj.molmet.2019.05.001&volume=25&pages=1-10&publication_year=2019&author=Gerst%2CF)\\n\\nYu, T.-Y. & Wang, C.-Y. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. *J. Diabetes Investig.* **8**, 735–747 (2017).\\n\\n[Article](https://doi.org/10.1111%2Fjdi.12665)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28371475)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668526)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20non-alcoholic%20fatty%20pancreas%20disease%20on%20glucose%20metabolism&journal=J.%20Diabetes%20Investig.&doi=10.1111%2Fjdi.12665&volume=8&pages=735-747&publication_year=2017&author=Yu%2CT-Y&author=Wang%2CC-Y)\\n\\nHaataja, L., Gurlo, T., Huang, C. J. & Butler, P. C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. *Endocr. Rev.* **29**, 303–316 (2008).\\n\\n[Article](https://doi.org/10.1210%2Fer.2007-0037)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXntV2lsbo%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18314421)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528855)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Islet%20amyloid%20in%20type%202%20diabetes%2C%20and%20the%20toxic%20oligomer%20hypothesis&journal=Endocr.%20Rev.&doi=10.1210%2Fer.2007-0037&volume=29&pages=303-316&publication_year=2008&author=Haataja%2CL&author=Gurlo%2CT&author=Huang%2CCJ&author=Butler%2CPC)\\n\\nHuang, C. et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. *Diabetes* **56**, 2016–2027 (2007).\\n\\n[Article](https://doi.org/10.2337%2Fdb07-0197)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXos12qs7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17475933)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=High%20expression%20rates%20of%20human%20islet%20amyloid%20polypeptide%20induce%20endoplasmic%20reticulum%20stress%20mediated%20beta-cell%20apoptosis%2C%20a%20characteristic%20of%20humans%20with%20type%202%20but%20not%20type%201%20diabetes&journal=Diabetes&doi=10.2337%2Fdb07-0197&volume=56&pages=2016-2027&publication_year=2007&author=Huang%2CC)\\n\\nMontane, J., Klimek-Abercrombie, A., Potter, K. J., Westwell-Roper, C. & Bruce Verchere, C. Metabolic stress, IAPP and islet amyloid. *Diabetes Obes. Metab.* **14**, 68–77 (2012).\\n\\n[Article](https://doi.org/10.1111%2Fj.1463-1326.2012.01657.x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XhsFWis7bJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22928566)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metabolic%20stress%2C%20IAPP%20and%20islet%20amyloid&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fj.1463-1326.2012.01657.x&volume=14&pages=68-77&publication_year=2012&author=Montane%2CJ&author=Klimek-Abercrombie%2CA&author=Potter%2CKJ&author=Westwell-Roper%2CC&author=Bruce%20Verchere%2CC)\\n\\nMontemurro, C. et al. IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. *Nat. Commun.* **10**, 2679 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-019-10444-1)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31213603)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581914)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=IAPP%20toxicity%20activates%20HIF1%CE%B1%2FPFKFB3%20signaling%20delaying%20%CE%B2-cell%20loss%20at%20the%20expense%20of%20%CE%B2-cell%20function&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-019-10444-1&volume=10&publication_year=2019&author=Montemurro%2CC)\\n\\nGunton, J. E. Hypoxia-inducible factors and diabetes. *J. Clin. Invest.* **130**, 5063–5073 (2020).\\n\\n[Article](https://doi.org/10.1172%2FJCI137556)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXitF2qs7bM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32809974)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524477)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hypoxia-inducible%20factors%20and%20diabetes&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI137556&volume=130&pages=5063-5073&publication_year=2020&author=Gunton%2CJE)\\n\\nGonzalez, F. J., Xie, C. & Jiang, C. The role of hypoxia-inducible factors in metabolic diseases. *Nat. Rev. Endocrinol.* **15**, 21–32 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41574-018-0096-z)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30275460)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624429)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20hypoxia-inducible%20factors%20in%20metabolic%20diseases&journal=Nat.%20Rev.%20Endocrinol.&doi=10.1038%2Fs41574-018-0096-z&volume=15&pages=21-32&publication_year=2018&author=Gonzalez%2CFJ&author=Xie%2CC&author=Jiang%2CC)\\n\\nYuan, T. et al. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. *Diabetologia* **60**, 668–678 (2017).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-016-4188-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XitFKlsLnN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28004151)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reciprocal%20regulation%20of%20mTOR%20complexes%20in%20pancreatic%20islets%20from%20humans%20with%20type%202%20diabetes&journal=Diabetologia&doi=10.1007%2Fs00125-016-4188-9&volume=60&pages=668-678&publication_year=2017&author=Yuan%2CT)\\n\\nArdestani, A., Lupse, B., Kido, Y., Leibowitz, G. & Maedler, K. mTORC1 signaling: a double-edged sword in diabetic β cells. *Cell Metab.* **27**, 314–331 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2017.11.004)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXitVehtL%2FP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29275961)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=mTORC1%20signaling%3A%20a%20double-edged%20sword%20in%20diabetic%20%CE%B2%20cells&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2017.11.004&volume=27&pages=314-331&publication_year=2018&author=Ardestani%2CA&author=Lupse%2CB&author=Kido%2CY&author=Leibowitz%2CG&author=Maedler%2CK)\\n\\nChen, J. et al. Role of Wnt signaling pathways in type 2 diabetes mellitus. *Mol. Cell Biochem.* **476**, 2219–2232 (2021).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11010-021-04086-5)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXjslKgt7c%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33566231)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20Wnt%20signaling%20pathways%20in%20type%202%20diabetes%20mellitus&journal=Mol.%20Cell%20Biochem.&doi=10.1007%2Fs11010-021-04086-5&volume=476&pages=2219-2232&publication_year=2021&author=Chen%2CJ)\\n\\nBowen, A., Kos, K., Whatmore, J., Richardson, S. & Welters, H. J. Wnt4 antagonises Wnt3a mediated increases in growth and glucose stimulated insulin secretion in the pancreatic beta-cell line, INS-1. *Biochem. Biophys. Res. Commun.* **479**, 793–799 (2016).\\n\\n[Article](https://doi.org/10.1016%2Fj.bbrc.2016.09.130)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1WqurjN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27687546)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Wnt4%20antagonises%20Wnt3a%20mediated%20increases%20in%20growth%20and%20glucose%20stimulated%20insulin%20secretion%20in%20the%20pancreatic%20beta-cell%20line%2C%20INS-1&journal=Biochem.%20Biophys.%20Res.%20Commun.&doi=10.1016%2Fj.bbrc.2016.09.130&volume=479&pages=793-799&publication_year=2016&author=Bowen%2CA&author=Kos%2CK&author=Whatmore%2CJ&author=Richardson%2CS&author=Welters%2CHJ)\\n\\nFlorez, J. C. et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N. Engl. J. Med.* **355**, 241–250 (2006).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa062418)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28XntVWktrw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16855264)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762036)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=TCF7L2%20polymorphisms%20and%20progression%20to%20diabetes%20in%20the%20Diabetes%20Prevention%20Program&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa062418&volume=355&pages=241-250&publication_year=2006&author=Florez%2CJC)\\n\\nBartolome, A., Zhu, C., Sussel, L. & Pajvani, U. B. Notch signaling dynamically regulates adult β cell proliferation and maturity. *J. Clin. Invest.* **129**, 268–280 (2019).\\n\\n[Article](https://doi.org/10.1172%2FJCI98098)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30375986)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Notch%20signaling%20dynamically%20regulates%20adult%20%CE%B2%20cell%20proliferation%20and%20maturity&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI98098&volume=129&pages=268-280&publication_year=2019&author=Bartolome%2CA&author=Zhu%2CC&author=Sussel%2CL&author=Pajvani%2CUB)\\n\\nBartolomé, A. et al. Notch-mediated Ephrin signaling disrupts islet architecture and β cell function. *JCI Insight* **7**, e157694 (2022).\\n\\n[Article](https://doi.org/10.1172%2Fjci.insight.157694)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35167496)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986078)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Notch-mediated%20Ephrin%20signaling%20disrupts%20islet%20architecture%20and%20%CE%B2%20cell%20function&journal=JCI%20Insight&doi=10.1172%2Fjci.insight.157694&volume=7&publication_year=2022&author=Bartolom%C3%A9%2CA)\\n\\nLi, M. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal Transduct. Target Ther.* **7**, 216 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fs41392-022-01073-0)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XitFGmurnF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35794109)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259665)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trends%20in%20insulin%20resistance%3A%20insights%20into%20mechanisms%20and%20therapeutic%20strategy&journal=Signal%20Transduct.%20Target%20Ther.&doi=10.1038%2Fs41392-022-01073-0&volume=7&publication_year=2022&author=Li%2CM)\\n\\nBergman, M. & Tuomilehto, J. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. *Diabetes Res. Clin. Pr.* **210**, 111636 (2024).\\n\\n[Article](https://doi.org/10.1016%2Fj.diabres.2024.111636)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXpvFSjsLs%3D)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=International%20Diabetes%20Federation%20Position%20Statement%20on%20the%201-hour%20post-load%20plasma%20glucose%20for%20the%20diagnosis%20of%20intermediate%20hyperglycaemia%20and%20type%202%20diabetes&journal=Diabetes%20Res.%20Clin.%20Pr.&doi=10.1016%2Fj.diabres.2024.111636&volume=210&publication_year=2024&author=Bergman%2CM&author=Tuomilehto%2CJ)\\n\\nLiu, Y. et al. Evidence from a systematic review and meta-analysis: classical impaired glucose tolerance should be divided into subgroups of isolated impaired glucose tolerance and impaired glucose tolerance combined with impaired fasting glucose, according to the risk of progression to diabetes. *Front. Endocrinol. (Lausanne)* **13**, 835460 (2022).\\n\\n[Article](https://doi.org/10.3389%2Ffendo.2022.835460)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35250886)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Evidence%20from%20a%20systematic%20review%20and%20meta-analysis%3A%20classical%20impaired%20glucose%20tolerance%20should%20be%20divided%20into%20subgroups%20of%20isolated%20impaired%20glucose%20tolerance%20and%20impaired%20glucose%20tolerance%20combined%20with%20impaired%20fasting%20glucose%2C%20according%20to%20the%20risk%20of%20progression%20to%20diabetes&journal=Front.%20Endocrinol.%20%28Lausanne%29&doi=10.3389%2Ffendo.2022.835460&volume=13&publication_year=2022&author=Liu%2CY)\\n\\nTwig, G. et al. Adolescent obesity and early-onset type 2 diabetes. *Diabetes Care* **43**, 1487–1495 (2020).\\n\\n[Article](https://doi.org/10.2337%2Fdc19-1988)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32321731)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Adolescent%20obesity%20and%20early-onset%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc19-1988&volume=43&pages=1487-1495&publication_year=2020&author=Twig%2CG)\\n\\nZhang, X. et al. A1C level and future risk of diabetes: a systematic review. *Diabetes Care* **33**, 1665–1673 (2010).\\n\\n[Article](https://doi.org/10.2337%2Fdc09-1939)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXpslKgs7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20587727)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890379)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A1C%20level%20and%20future%20risk%20of%20diabetes%3A%20a%20systematic%20review&journal=Diabetes%20Care&doi=10.2337%2Fdc09-1939&volume=33&pages=1665-1673&publication_year=2010&author=Zhang%2CX)\\n\\nTabák, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *Lancet* **373**, 2215–2221 (2009).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2809%2960619-X)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19515410)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726723)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trajectories%20of%20glycaemia%2C%20insulin%20sensitivity%2C%20and%20insulin%20secretion%20before%20diagnosis%20of%20type%202%20diabetes%3A%20an%20analysis%20from%20the%20Whitehall%20II%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2960619-X&volume=373&pages=2215-2221&publication_year=2009&author=Tab%C3%A1k%2CAG)\\n\\nGarvey, W. T. et al. Association of baseline factors with glycemic outcomes in GRADE: a comparative effectiveness randomized clinical trial. *Diabetes Care* **47**, 562–570 (2024).\\n\\n[Article](https://doi.org/10.2337%2Fdc23-1782)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXpt1GntLc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38285957)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20baseline%20factors%20with%20glycemic%20outcomes%20in%20GRADE%3A%20a%20comparative%20effectiveness%20randomized%20clinical%20trial&journal=Diabetes%20Care&doi=10.2337%2Fdc23-1782&volume=47&pages=562-570&publication_year=2024&author=Garvey%2CWT)\\n\\nOgurtsova, K. et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. *Diabetes Res. Clin. Pr.* **183**, 109118 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.diabres.2021.109118)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=IDF%20diabetes%20Atlas%3A%20Global%20estimates%20of%20undiagnosed%20diabetes%20in%20adults%20for%202021&journal=Diabetes%20Res.%20Clin.%20Pr.&doi=10.1016%2Fj.diabres.2021.109118&volume=183&publication_year=2022&author=Ogurtsova%2CK)\\n\\nWHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* **363**, 157–163 (2004).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2803%2915268-3)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Appropriate%20body-mass%20index%20for%20Asian%20populations%20and%20its%20implications%20for%20policy%20and%20intervention%20strategies&journal=Lancet&doi=10.1016%2FS0140-6736%2803%2915268-3&volume=363&pages=157-163&publication_year=2004)\\n\\nPrillaman, M. Why BMI is flawed—and how to redefine obesity. *Nature* **622**, 232–233 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fd41586-023-03143-x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXitFWlsLvJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37821595)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Why%20BMI%20is%20flawed%E2%80%94and%20how%20to%20redefine%20obesity&journal=Nature&doi=10.1038%2Fd41586-023-03143-x&volume=622&pages=232-233&publication_year=2023&author=Prillaman%2CM)\\n\\nJayedi, A., Soltani, S., Zargar, M. S., Khan, T. A. & Shab-Bidar, S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. *BMJ* **370**, m3324 (2020).\\n\\n[Article](https://doi.org/10.1136%2Fbmj.m3324)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32967840)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509947)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Central%20fatness%20and%20risk%20of%20all%20cause%20mortality%3A%20systematic%20review%20and%20dose-response%20meta-analysis%20of%2072%20prospective%20cohort%20studies&journal=BMJ&doi=10.1136%2Fbmj.m3324&volume=370&publication_year=2020&author=Jayedi%2CA&author=Soltani%2CS&author=Zargar%2CMS&author=Khan%2CTA&author=Shab-Bidar%2CS)\\n\\nNational Institute for Health and Care Excellence (NICE). *Obesity: Identification, Assessment and Management* (NICE, 2023).\\n\\nCharchar, F. J. et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. *J. Hypertens.* **42**, 23–49 (2024).\\n\\n[Article](https://doi.org/10.1097%2FHJH.0000000000003563)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXisVyjsb3L)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37712135)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lifestyle%20management%20of%20hypertension%3A%20International%20Society%20of%20Hypertension%20position%20paper%20endorsed%20by%20the%20World%20Hypertension%20League%20and%20European%20Society%20of%20Hypertension&journal=J.%20Hypertens.&doi=10.1097%2FHJH.0000000000003563&volume=42&pages=23-49&publication_year=2024&author=Charchar%2CFJ)\\n\\nXu, S. et al. Evaluation of the value of diabetes risk scores in screening for undiagnosed diabetes and prediabetes: a community-based study in southwestern China. *Postgrad. Med.* **132**, 737–745 (2020).\\n\\n[Article](https://doi.org/10.1080%2F00325481.2020.1821234)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhslajtrzL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32990128)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20the%20value%20of%20diabetes%20risk%20scores%20in%20screening%20for%20undiagnosed%20diabetes%20and%20prediabetes%3A%20a%20community-based%20study%20in%20southwestern%20China&journal=Postgrad.%20Med.&doi=10.1080%2F00325481.2020.1821234&volume=132&pages=737-745&publication_year=2020&author=Xu%2CS)\\n\\nOrtiz-Martínez, M. et al. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. *Curr. Diabetes Rep.* **22**, 95–115 (2022).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11892-022-01453-4)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Recent%20developments%20in%20biomarkers%20for%20diagnosis%20and%20screening%20of%20type%202%20diabetes%20mellitus&journal=Curr.%20Diabetes%20Rep.&doi=10.1007%2Fs11892-022-01453-4&volume=22&pages=95-115&publication_year=2022&author=Ortiz-Mart%C3%ADnez%2CM)\\n\\nLaakso, M. Biomarkers for type 2 diabetes. *Mol. Metab.* **27S**, S139–S146 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.molmet.2019.06.016)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31500825)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Biomarkers%20for%20type%202%20diabetes&journal=Mol.%20Metab.&doi=10.1016%2Fj.molmet.2019.06.016&volume=27S&pages=S139-S146&publication_year=2019&author=Laakso%2CM)\\n\\nSacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin. Chem.* **69**, 808–868 (2023).\\n\\n[Article](https://doi.org/10.1093%2Fclinchem%2Fhvad080)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37473453)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Guidelines%20and%20recommendations%20for%20laboratory%20analysis%20in%20the%20diagnosis%20and%20management%20of%20diabetes%20mellitus&journal=Clin.%20Chem.&doi=10.1093%2Fclinchem%2Fhvad080&volume=69&pages=808-868&publication_year=2023&author=Sacks%2CDB)\\n\\nCaixeta, D. C. et al. Salivary molecular spectroscopy: a sustainable, rapid and non-invasive monitoring tool for diabetes mellitus during insulin treatment. *PLoS ONE* **15**, e0223461 (2020).\\n\\n[Article](https://doi.org/10.1371%2Fjournal.pone.0223461)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXmsVCrtLc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32182246)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077825)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Salivary%20molecular%20spectroscopy%3A%20a%20sustainable%2C%20rapid%20and%20non-invasive%20monitoring%20tool%20for%20diabetes%20mellitus%20during%20insulin%20treatment&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0223461&volume=15&publication_year=2020&author=Caixeta%2CDC)\\n\\nAscaso, F. J. & Huerva, V. Noninvasive continuous monitoring of tear glucose using glucose-sensing contact lenses. *Optom. Vis. Sci.* **93**, 426–434 (2016).\\n\\n[Article](https://doi.org/10.1097%2FOPX.0000000000000698)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26390345)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Noninvasive%20continuous%20monitoring%20of%20tear%20glucose%20using%20glucose-sensing%20contact%20lenses&journal=Optom.%20Vis.%20Sci.&doi=10.1097%2FOPX.0000000000000698&volume=93&pages=426-434&publication_year=2016&author=Ascaso%2CFJ&author=Huerva%2CV)\\n\\nLee, H. et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. *Sci. Adv.* **3**, e1601314 (2017).\\n\\n[Article](https://doi.org/10.1126%2Fsciadv.1601314)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28345030)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342654)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Wearable%2Fdisposable%20sweat-based%20glucose%20monitoring%20device%20with%20multistage%20transdermal%20drug%20delivery%20module&journal=Sci.%20Adv.&doi=10.1126%2Fsciadv.1601314&volume=3&publication_year=2017&author=Lee%2CH)\\n\\nShilo, S. et al. Continuous glucose monitoring and intrapersonal variability in fasting glucose. *Nat. Med.* **30**, 1424–1431 (2024).\\n\\n[Article](https://doi.org/10.1038%2Fs41591-024-02908-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXnslyhtbw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38589602)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Continuous%20glucose%20monitoring%20and%20intrapersonal%20variability%20in%20fasting%20glucose&journal=Nat.%20Med.&doi=10.1038%2Fs41591-024-02908-9&volume=30&pages=1424-1431&publication_year=2024&author=Shilo%2CS)\\n\\nDurnwald, C. et al. Continuous Glucose Monitoring Profiles in Pregnancies With and Without Gestational Diabetes Mellitus. *Diabetes Care* <https://doi.org/10.2337/dc23-2149>\\n\\nFerrannini, E. et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *J. Clin. Endocrinol. Metab.* **90**, 493–500 (2005).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2004-1133)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2MXlvFCitA%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15483086)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=beta-Cell%20function%20in%20subjects%20spanning%20the%20range%20from%20normal%20glucose%20tolerance%20to%20overt%20diabetes%3A%20a%20new%20analysis&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2004-1133&volume=90&pages=493-500&publication_year=2005&author=Ferrannini%2CE)\\n\\nZiegler, D. et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. *Diabetes Care* **31**, 464–469 (2008).\\n\\n[Article](https://doi.org/10.2337%2Fdc07-1796)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXktVSnsbg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18039804)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20polyneuropathy%20in%20pre-diabetes%20and%20diabetes%20is%20associated%20with%20abdominal%20obesity%20and%20macroangiopathy%3A%20the%20MONICA%2FKORA%20Augsburg%20Surveys%20S2%20and%20S3&journal=Diabetes%20Care&doi=10.2337%2Fdc07-1796&volume=31&pages=464-469&publication_year=2008&author=Ziegler%2CD)\\n\\nDiabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet. Med.* **24**, 137–144 (2007).\\n\\n[Article](https://doi.org/10.1111%2Fj.1464-5491.2007.02043.x)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267935)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20prevalence%20of%20retinopathy%20in%20impaired%20glucose%20tolerance%20and%20recent-onset%20diabetes%20in%20the%20Diabetes%20Prevention%20Program&journal=Diabet.%20Med.&doi=10.1111%2Fj.1464-5491.2007.02043.x&volume=24&pages=137-144&publication_year=2007)\\n\\nPan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* **20**, 537–544 (1997).\\n\\n[Article](https://doi.org/10.2337%2Fdiacare.20.4.537)\\xa0\\n[CAS](/articles/cas-redirect/1:STN:280:DyaK2s3ltFaqtw%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9096977)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20diet%20and%20exercise%20in%20preventing%20NIDDM%20in%20people%20with%20impaired%20glucose%20tolerance.%20The%20Da%20Qing%20IGT%20and%20Diabetes%20Study&journal=Diabetes%20Care&doi=10.2337%2Fdiacare.20.4.537&volume=20&pages=537-544&publication_year=1997&author=Pan%2CXR)\\n\\nTuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N. Engl. J. Med.* **344**, 1343–1350 (2001).\\n\\n[Article](https://doi.org/10.1056%2FNEJM200105033441801)\\xa0\\n[CAS](/articles/cas-redirect/1:STN:280:DC%2BD3M3kvFejsA%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11333990)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevention%20of%20type%202%20diabetes%20mellitus%20by%20changes%20in%20lifestyle%20among%20subjects%20with%20impaired%20glucose%20tolerance&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJM200105033441801&volume=344&pages=1343-1350&publication_year=2001&author=Tuomilehto%2CJ)\\n\\nKnowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* **346**, 393–403 (2002).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa012512)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD38XhtVWqurc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11832527)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reduction%20in%20the%20incidence%20of%20type%202%20diabetes%20with%20lifestyle%20intervention%20or%20metformin&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa012512&volume=346&pages=393-403&publication_year=2002&author=Knowler%2CWC)\\n\\nRamachandran, A. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* **49**, 289–297 (2006).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-005-0097-z)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28XhtFWnurc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16391903)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20Indian%20Diabetes%20Prevention%20Programme%20shows%20that%20lifestyle%20modification%20and%20metformin%20prevent%20type%202%20diabetes%20in%20Asian%20Indian%20subjects%20with%20impaired%20glucose%20tolerance%20%28IDPP-1%29&journal=Diabetologia&doi=10.1007%2Fs00125-005-0097-z&volume=49&pages=289-297&publication_year=2006&author=Ramachandran%2CA)\\n\\nHamman, R. F. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care* **29**, 2102–2107 (2006).\\n\\n[Article](https://doi.org/10.2337%2Fdc06-0560)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16936160)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20weight%20loss%20with%20lifestyle%20intervention%20on%20risk%20of%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc06-0560&volume=29&pages=2102-2107&publication_year=2006&author=Hamman%2CRF)\\n\\nGong, Q. et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. *Lancet Diabetes Endocrinol.* **7**, 452–461 (2019).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2819%2930093-2)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31036503)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172050)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Morbidity%20and%20mortality%20after%20lifestyle%20intervention%20for%20people%20with%20impaired%20glucose%20tolerance%3A%2030-year%20results%20of%20the%20Da%20Qing%20Diabetes%20Prevention%20Outcome%20Study&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2819%2930093-2&volume=7&pages=452-461&publication_year=2019&author=Gong%2CQ)\\n\\nLi, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. *Lancet Diabetes Endocrinol.* **2**, 474–480 (2014).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2814%2970057-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24731674)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cardiovascular%20mortality%2C%20all-cause%20mortality%2C%20and%20diabetes%20incidence%20after%20lifestyle%20intervention%20for%20people%20with%20impaired%20glucose%20tolerance%20in%20the%20Da%20Qing%20Diabetes%20Prevention%20Study%3A%20a%2023-year%20follow-up%20study&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2814%2970057-9&volume=2&pages=474-480&publication_year=2014&author=Li%2CG)\\n\\nLindström, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet* **368**, 1673–1679 (2006).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2806%2969701-8)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17098085)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sustained%20reduction%20in%20the%20incidence%20of%20type%202%20diabetes%20by%20lifestyle%20intervention%3A%20follow-up%20of%20the%20Finnish%20Diabetes%20Prevention%20Study&journal=Lancet&doi=10.1016%2FS0140-6736%2806%2969701-8&volume=368&pages=1673-1679&publication_year=2006&author=Lindstr%C3%B6m%2CJ)\\n\\nDiabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. *Lancet Diabetes Endocrinol.* **3**, 866–875 (2015).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2815%2900291-0)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623946)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Long-term%20effects%20of%20lifestyle%20intervention%20or%20metformin%20on%20diabetes%20development%20and%20microvascular%20complications%20over%2015-year%20follow-up%3A%20the%20Diabetes%20Prevention%20Program%20Outcomes%20Study&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2815%2900291-0&volume=3&pages=866-875&publication_year=2015)\\n\\nLee, C. G. et al. Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. *Diabetes Care* **44**, 2775–2782 (2021).\\n\\n[Article](https://doi.org/10.2337%2Fdc21-1046)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xhs1KjsLw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34697033)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669534)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20metformin%20and%20lifestyle%20interventions%20on%20mortality%20in%20the%20Diabetes%20Prevention%20Program%20and%20Diabetes%20Prevention%20Program%20Outcomes%20Study&journal=Diabetes%20Care&doi=10.2337%2Fdc21-1046&volume=44&pages=2775-2782&publication_year=2021&author=Lee%2CCG)\\n\\nChiasson, J.-L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* **359**, 2072–2077 (2002).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2802%2908905-5)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD38XkslGhs7g%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12086760)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Acarbose%20for%20prevention%20of%20type%202%20diabetes%20mellitus%3A%20the%20STOP-NIDDM%20randomised%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2802%2908905-5&volume=359&pages=2072-2077&publication_year=2002&author=Chiasson%2CJ-L)\\n\\nDREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* **368**, 1096–1105 (2006).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2806%2969420-8)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20rosiglitazone%20on%20the%20frequency%20of%20diabetes%20in%20patients%20with%20impaired%20glucose%20tolerance%20or%20impaired%20fasting%20glucose%3A%20a%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2806%2969420-8&volume=368&pages=1096-1105&publication_year=2006)\\n\\nDeFronzo, R. A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. *N. Engl. J. Med.* **364**, 1104–1115 (2011).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1010949)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXktVyjsbc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21428766)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20for%20diabetes%20prevention%20in%20impaired%20glucose%20tolerance&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1010949&volume=364&pages=1104-1115&publication_year=2011&author=DeFronzo%2CRA)\\n\\nKernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. *N. Engl. J. Med.* **374**, 1321–1331 (2016).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1506930)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhtFGqsbbI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26886418)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887756)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20after%20ischemic%20stroke%20or%20transient%20ischemic%20attack&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1506930&volume=374&pages=1321-1331&publication_year=2016&author=Kernan%2CWN)\\n\\nYaghi, S. et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). *Circulation* **137**, 455–463 (2018).\\n\\n[Article](https://doi.org/10.1161%2FCIRCULATIONAHA.117.030458)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVekt7c%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29084736)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20prevents%20stroke%20in%20patients%20with%20a%20recent%20transient%20ischemic%20attack%20or%20ischemic%20stroke%3A%20a%20planned%20secondary%20analysis%20of%20the%20IRIS%20Trial%20%28Insulin%20Resistance%20Intervention%20After%20Stroke%29&journal=Circulation&doi=10.1161%2FCIRCULATIONAHA.117.030458&volume=137&pages=455-463&publication_year=2018&author=Yaghi%2CS)\\n\\nle Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet* **389**, 1399–1409 (2017).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2817%2930069-7)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28237263)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=3%20years%20of%20liraglutide%20versus%20placebo%20for%20type%202%20diabetes%20risk%20reduction%20and%20weight%20management%20in%20individuals%20with%20prediabetes%3A%20a%20randomised%2C%20double-blind%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2817%2930069-7&volume=389&pages=1399-1409&publication_year=2017&author=Roux%2CCW)\\n\\nWilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. *N. Engl. J. Med.* **384**, 989–1002 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2032183)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXntVWlur8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33567185)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2032183&volume=384&pages=989-1002&publication_year=2021&author=Wilding%2CJPH)\\n\\nJastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. *N. Engl. J. Med.* **387**, 205–216 (2022).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2206038)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1ersLnP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35658024)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tirzepatide%20once%20weekly%20for%20the%20treatment%20of%20obesity&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2206038&volume=387&pages=205-216&publication_year=2022&author=Jastreboff%2CAM)\\n\\nLincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N. Engl. J. Med.* **389**, 2221–2232 (2023).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2307563)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXis1KqsrvJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37952131)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20obesity%20without%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2307563&volume=389&pages=2221-2232&publication_year=2023&author=Lincoff%2CAM)\\n\\nRossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes Endocrinol.* **10**, 24–34 (2022).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2821%2900295-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XktVGhsrg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34856173)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20and%20new-onset%20type%202%20diabetes%20in%20patients%20with%20chronic%20kidney%20disease%20or%20heart%20failure%3A%20pooled%20analysis%20of%20the%20DAPA-CKD%20and%20DAPA-HF%20trials&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2821%2900295-3&volume=10&pages=24-34&publication_year=2022&author=Rossing%2CP)\\n\\nJames, S. et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. *NEJM Evid.* **3**, EVIDoa2300286 (2024).\\n\\n[Article](https://doi.org/10.1056%2FEVIDoa2300286)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38320489)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20in%20myocardial%20infarction%20without%20diabetes%20or%20heart%20failure&journal=NEJM%20Evid.&doi=10.1056%2FEVIDoa2300286&volume=3&publication_year=2024&author=James%2CS)\\n\\nSpeight, J. et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. *Lancet Diabetes Endocrinol.* **12**, 61–82 (2024).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2823%2900347-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38128969)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Bringing%20an%20end%20to%20diabetes%20stigma%20and%20discrimination%3A%20an%20international%20consensus%20statement%20on%20evidence%20and%20recommendations&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2823%2900347-9&volume=12&pages=61-82&publication_year=2024&author=Speight%2CJ)\\n\\nZhang, F. et al. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. *J. Evid. Based Med.* **15**, 168–179 (2022).\\n\\n[Article](https://doi.org/10.1111%2Fjebm.12474)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35715995)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Expert%20consensus%20on%20personalized%20initiation%20of%20glucose-lowering%20therapy%20in%20adults%20with%20newly%20diagnosed%20type%202%20diabetes%20without%20clinical%20cardiovascular%20disease%20or%20chronic%20kidney%20disease&journal=J.%20Evid.%20Based%20Med.&doi=10.1111%2Fjebm.12474&volume=15&pages=168-179&publication_year=2022&author=Zhang%2CF)\\n\\nMarx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur. Heart J.* **39**, 4043–4140 (2023).\\n\\n[Article](https://doi.org/10.1093%2Feurheartj%2Fehad192)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=2023%20ESC%20Guidelines%20for%20the%20management%20of%20cardiovascular%20disease%20in%20patients%20with%20diabetes&journal=Eur.%20Heart%20J.&doi=10.1093%2Feurheartj%2Fehad192&volume=39&pages=4043-4140&publication_year=2023&author=Marx%2CN)\\n\\nADVANCE Collaborative Group. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* **358**, 2560–2572 (2008).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa0802987)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intensive%20blood%20glucose%20control%20and%20vascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa0802987&volume=358&pages=2560-2572&publication_year=2008)\\n\\nLachin, J. M. & Nathan, D. M. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC). *Diabetes Care* **44**, 2216–2224 (2021).\\n\\n[Article](https://doi.org/10.2337%2Fdc20-3097)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1Gju7vK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34548284)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929187)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Understanding%20metabolic%20memory%3A%20the%20prolonged%20influence%20of%20glycemia%20during%20the%20Diabetes%20Control%20and%20Complications%20Trial%20%28DCCT%29%20on%20future%20risks%20of%20complications%20during%20the%20study%20of%20the%20Epidemiology%20of%20Diabetes%20Interventions%20and%20Complications%20%28EDIC%29&journal=Diabetes%20Care&doi=10.2337%2Fdc20-3097&volume=44&pages=2216-2224&publication_year=2021&author=Lachin%2CJM&author=Nathan%2CDM)\\n\\nSkyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. *Circulation* **119**, 351–357 (2009).\\n\\n[Article](https://doi.org/10.1161%2FCIRCULATIONAHA.108.191305)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19095622)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intensive%20glycemic%20control%20and%20the%20prevention%20of%20cardiovascular%20events%3A%20implications%20of%20the%20ACCORD%2C%20ADVANCE%2C%20and%20VA%20Diabetes%20Trials&journal=Circulation&doi=10.1161%2FCIRCULATIONAHA.108.191305&volume=119&pages=351-357&publication_year=2009&author=Skyler%2CJS)\\n\\nIsmail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* **376**, 419–430 (2010).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2810%2960576-4)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20594588)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123233)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20intensive%20treatment%20of%20hyperglycaemia%20on%20microvascular%20outcomes%20in%20type%202%20diabetes%3A%20an%20analysis%20of%20the%20ACCORD%20randomised%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2810%2960576-4&volume=376&pages=419-430&publication_year=2010&author=Ismail-Beigi%2CF)\\n\\nGoldenberg, J. Z. et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. *BMJ* **372**, m4743 (2021).\\n\\n[Article](https://doi.org/10.1136%2Fbmj.m4743)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33441384)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804828)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20low%20and%20very%20low%20carbohydrate%20diets%20for%20type%202%20diabetes%20remission%3A%20systematic%20review%20and%20meta-analysis%20of%20published%20and%20unpublished%20randomized%20trial%20data&journal=BMJ&doi=10.1136%2Fbmj.m4743&volume=372&publication_year=2021&author=Goldenberg%2CJZ)\\n\\nRiddle, M. C. et al. Consensus report: definition and interpretation of remission in type 2 diabetes. *Diabetes Care* **44**, 2438–2444 (2021).\\n\\n[Article](https://doi.org/10.2337%2Fdci21-0034)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1Gju7rF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34462270)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929179)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Consensus%20report%3A%20definition%20and%20interpretation%20of%20remission%20in%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdci21-0034&volume=44&pages=2438-2444&publication_year=2021&author=Riddle%2CMC)\\n\\nBonekamp, N. E. et al. Leisure-time and occupational physical activity and health outcomes in cardiovascular disease. *Heart* **109**, 686–694 (2023).\\n\\n[Article](https://doi.org/10.1136%2Fheartjnl-2022-321474)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36270785)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Leisure-time%20and%20occupational%20physical%20activity%20and%20health%20outcomes%20in%20cardiovascular%20disease&journal=Heart&doi=10.1136%2Fheartjnl-2022-321474&volume=109&pages=686-694&publication_year=2023&author=Bonekamp%2CNE)\\n\\nUusitupa, M. et al. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. *Nutrients* **11**, 2611 (2019).\\n\\n[Article](https://doi.org/10.3390%2Fnu11112611)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXpt1Smu78%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31683759)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893436)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prevention%20of%20type%202%20diabetes%20by%20lifestyle%20changes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Nutrients&doi=10.3390%2Fnu11112611&volume=11&publication_year=2019&author=Uusitupa%2CM)\\n\\nKirkpatrick, C. F., Liday, C. & Maki, K. C. The effects of carbohydrate-restricted dietary patterns and physical activity on body weight and glycemic control. *Curr. Atheroscler. Rep.* **22**, 20 (2020).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11883-020-00838-8)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtVCrtrzJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32468247)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effects%20of%20carbohydrate-restricted%20dietary%20patterns%20and%20physical%20activity%20on%20body%20weight%20and%20glycemic%20control&journal=Curr.%20Atheroscler.%20Rep.&doi=10.1007%2Fs11883-020-00838-8&volume=22&publication_year=2020&author=Kirkpatrick%2CCF&author=Liday%2CC&author=Maki%2CKC)\\n\\nZhu, X. et al. The effect of physical activity on glycemic variability in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. *Front Endocrinol. (Lausanne)* **12**, 767152 (2021).\\n\\n[Article](https://doi.org/10.3389%2Ffendo.2021.767152)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34867812)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20effect%20of%20physical%20activity%20on%20glycemic%20variability%20in%20patients%20with%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&journal=Front%20Endocrinol.%20%28Lausanne%29&doi=10.3389%2Ffendo.2021.767152&volume=12&publication_year=2021&author=Zhu%2CX)\\n\\nLiu, M. et al. Association of accelerometer-measured physical activity and its change with progression to chronic kidney disease in adults with type 2 diabetes and overweight/obesity. *Br. J. Sports Med.* **58**, 313–319 (2024).\\n\\n[Article](https://doi.org/10.1136%2Fbjsports-2023-107564)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38320851)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20accelerometer-measured%20physical%20activity%20and%20its%20change%20with%20progression%20to%20chronic%20kidney%20disease%20in%20adults%20with%20type%202%20diabetes%20and%20overweight%2Fobesity&journal=Br.%20J.%20Sports%20Med.&doi=10.1136%2Fbjsports-2023-107564&volume=58&pages=313-319&publication_year=2024&author=Liu%2CM)\\n\\nSabag, A. et al. Timing of moderate to vigorous physical activity, mortality, cardiovascular disease, and microvascular disease in adults with obesity. *Diabetes Care* **47**, 890–897 (2024).\\n\\n[Article](https://doi.org/10.2337%2Fdc23-2448)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38592034)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043226)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Timing%20of%20moderate%20to%20vigorous%20physical%20activity%2C%20mortality%2C%20cardiovascular%20disease%2C%20and%20microvascular%20disease%20in%20adults%20with%20obesity&journal=Diabetes%20Care&doi=10.2337%2Fdc23-2448&volume=47&pages=890-897&publication_year=2024&author=Sabag%2CA)\\n\\nClavero-Jimeno, A. et al. Impact of lifestyle moderate-to-vigorous physical activity timing on glycemic control in sedentary adults with overweight/obesity and metabolic impairments. *Obesity (Silver Spring)* **32**,1465–1473.\\n\\nHamaya, R. et al. Time- vs step-based physical activity metrics for health. *JAMA Intern. Med.* **184**, 718–725 (2024).\\n\\n[Article](https://doi.org/10.1001%2Fjamainternmed.2024.0892)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38767892)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Time-%20vs%20step-based%20physical%20activity%20metrics%20for%20health&journal=JAMA%20Intern.%20Med.&doi=10.1001%2Fjamainternmed.2024.0892&volume=184&pages=718-725&publication_year=2024&author=Hamaya%2CR)\\n\\nPavlou, V. et al. Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. *JAMA Netw. Open* **6**, e2339337 (2023).\\n\\n[Article](https://doi.org/10.1001%2Fjamanetworkopen.2023.39337)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37889487)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611992)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20time-restricted%20eating%20on%20weight%20loss%20in%20adults%20with%20type%202%20diabetes%3A%20a%20randomized%20clinical%20trial&journal=JAMA%20Netw.%20Open&doi=10.1001%2Fjamanetworkopen.2023.39337&volume=6&publication_year=2023&author=Pavlou%2CV)\\n\\nDelgado-Lista, J. et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet* **399**, 1876–1885 (2022).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2822%2900122-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVOqsLfE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35525255)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Long-term%20secondary%20prevention%20of%20cardiovascular%20disease%20with%20a%20Mediterranean%20diet%20and%20a%20low-fat%20diet%20%28CORDIOPREV%29%3A%20a%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2822%2900122-2&volume=399&pages=1876-1885&publication_year=2022&author=Delgado-Lista%2CJ)\\n\\nCienfuegos, S. et al. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. *Cell Metab.* **32**, 366–378.e3 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2020.06.018)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWhs7%2FO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32673591)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407646)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%204-%20and%206-h%20Time-Restricted%20Feeding%20on%20Weight%20and%20Cardiometabolic%20Health%3A%20A%20Randomized%20Controlled%20Trial%20in%20Adults%20with%20Obesity&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2020.06.018&volume=32&pages=366-378.e3&publication_year=2020&author=Cienfuegos%2CS)\\n\\nHorne, B. D., Grajower, M. M. & Anderson, J. L. Limited evidence for the health effects and safety of intermittent fasting among patients with type 2 diabetes. *JAMA* **324**, 341–342 (2020).\\n\\n[Article](https://doi.org/10.1001%2Fjama.2020.3908)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32614382)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Limited%20evidence%20for%20the%20health%20effects%20and%20safety%20of%20intermittent%20fasting%20among%20patients%20with%20type%202%20diabetes&journal=JAMA&doi=10.1001%2Fjama.2020.3908&volume=324&pages=341-342&publication_year=2020&author=Horne%2CBD&author=Grajower%2CMM&author=Anderson%2CJL)\\n\\nWilkinson, M. J. et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. *Cell Metab.* **31**, 92–104.e5 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2019.11.004)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXitlGhsL%2FK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31813824)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ten-hour%20time-restricted%20eating%20reduces%20weight%2C%20blood%20pressure%2C%20and%20atherogenic%20lipids%20in%20patients%20with%20metabolic%20syndrome&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2019.11.004&volume=31&pages=92-104.e5&publication_year=2020&author=Wilkinson%2CMJ)\\n\\nCarter, S., Clifton, P. M. & Keogh, J. B. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. *JAMA Netw. Open* **1**, e180756 (2018).\\n\\n[Article](https://doi.org/10.1001%2Fjamanetworkopen.2018.0756)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30646030)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324303)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20intermittent%20compared%20with%20continuous%20energy%20restricted%20diet%20on%20glycemic%20control%20in%20patients%20with%20type%202%20diabetes%3A%20a%20randomized%20noninferiority%20trial&journal=JAMA%20Netw.%20Open&doi=10.1001%2Fjamanetworkopen.2018.0756&volume=1&publication_year=2018&author=Carter%2CS&author=Clifton%2CPM&author=Keogh%2CJB)\\n\\nGuo, L. et al. A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the early randomized clinical trial. *JAMA Netw. Open* **7**, e2416786 (2024).\\n\\n[Article](https://doi.org/10.1001%2Fjamanetworkopen.2024.16786)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38904963)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193124)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%205%3A2%20intermittent%20fasting%20meal%20replacement%20diet%20and%20glycemic%20control%20for%20adults%20with%20diabetes%3A%20the%20early%20randomized%20clinical%20trial&journal=JAMA%20Netw.%20Open&doi=10.1001%2Fjamanetworkopen.2024.16786&volume=7&publication_year=2024&author=Guo%2CL)\\n\\nChen, L. et al. High-fiber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients. *Front. Cell Infect. Microbiol.* **13**, 1069954 (2023).\\n\\n[Article](https://doi.org/10.3389%2Ffcimb.2023.1069954)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtFCqtr3I)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36794003)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922700)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=High-fiber%20diet%20ameliorates%20gut%20microbiota%2C%20serum%20metabolism%20and%20emotional%20mood%20in%20type%202%20diabetes%20patients&journal=Front.%20Cell%20Infect.%20Microbiol.&doi=10.3389%2Ffcimb.2023.1069954&volume=13&publication_year=2023&author=Chen%2CL)\\n\\nWang, Y. et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. *JMIR Mhealth Uhealth* **8**, e15400 (2020).\\n\\n[Article](https://doi.org/10.2196%2F15400)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32343253)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218595)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effectiveness%20of%20mobile%20health%20interventions%20on%20diabetes%20and%20obesity%20treatment%20and%20management%3A%20systematic%20review%20of%20systematic%20reviews&journal=JMIR%20Mhealth%20Uhealth&doi=10.2196%2F15400&volume=8&publication_year=2020&author=Wang%2CY)\\n\\nDeMarsilis, A. et al. Pharmacotherapy of type 2 diabetes: an update and future directions. *Metabolism* **137**, 155332 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.metabol.2022.155332)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xis1ChsbvN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36240884)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pharmacotherapy%20of%20type%202%20diabetes%3A%20an%20update%20and%20future%20directions&journal=Metabolism&doi=10.1016%2Fj.metabol.2022.155332&volume=137&publication_year=2022&author=DeMarsilis%2CA)\\n\\nWing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* **34**, 1481–1486 (2011).\\n\\n[Article](https://doi.org/10.2337%2Fdc10-2415)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFWlsrbJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21593294)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120182)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Benefits%20of%20modest%20weight%20loss%20in%20improving%20cardiovascular%20risk%20factors%20in%20overweight%20and%20obese%20individuals%20with%20type%202%20diabetes&journal=Diabetes%20Care&doi=10.2337%2Fdc10-2415&volume=34&pages=1481-1486&publication_year=2011&author=Wing%2CRR)\\n\\nElmaleh-Sachs, A. et al. Obesity management in adults: a review. *JAMA* **330**, 2000–2015 (2023).\\n\\n[Article](https://doi.org/10.1001%2Fjama.2023.19897)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXisV2gtLvK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38015216)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325826)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obesity%20management%20in%20adults%3A%20a%20review&journal=JAMA&doi=10.1001%2Fjama.2023.19897&volume=330&pages=2000-2015&publication_year=2023&author=Elmaleh-Sachs%2CA)\\n\\nLingvay, I., Sumithran, P., Cohen, R. V. & le Roux, C. W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet* **399**, 394–405 (2022).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2821%2901919-X)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXis1eru7fO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34600604)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Obesity%20management%20as%20a%20primary%20treatment%20goal%20for%20type%202%20diabetes%3A%20time%20to%20reframe%20the%20conversation&journal=Lancet&doi=10.1016%2FS0140-6736%2821%2901919-X&volume=399&pages=394-405&publication_year=2022&author=Lingvay%2CI&author=Sumithran%2CP&author=Cohen%2CRV&author=Roux%2CCW)\\n\\nDavies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* **45**, 2753–2786 (2022).\\n\\n[Article](https://doi.org/10.2337%2Fdci22-0034)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XivFGlsLnJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36148880)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008140)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Management%20of%20hyperglycemia%20in%20type%202%20diabetes%2C%202022.%20a%20consensus%20report%20by%20the%20American%20Diabetes%20Association%20%28ADA%29%20and%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes%20%28EASD%29&journal=Diabetes%20Care&doi=10.2337%2Fdci22-0034&volume=45&pages=2753-2786&publication_year=2022&author=Davies%2CMJ)\\n\\nDavies, M. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet* **397**, 971–984 (2021).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2821%2900213-0)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsVegsL7E)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33667417)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Semaglutide%202%C2%B74%20mg%20once%20a%20week%20in%20adults%20with%20overweight%20or%20obesity%2C%20and%20type%202%20diabetes%20%28STEP%202%29%3A%20a%20randomised%2C%20double-blind%2C%20double-dummy%2C%20placebo-controlled%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2821%2900213-0&volume=397&pages=971-984&publication_year=2021&author=Davies%2CM)\\n\\nDavies, M. J. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. *JAMA* **314**, 687–699 (2015).\\n\\n[Article](https://doi.org/10.1001%2Fjama.2015.9676)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XlsVegtA%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26284720)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20liraglutide%20for%20weight%20loss%20among%20patients%20with%20type%202%20diabetes%3A%20The%20SCALE%20Diabetes%20Randomized%20Clinical%20Trial&journal=JAMA&doi=10.1001%2Fjama.2015.9676&volume=314&pages=687-699&publication_year=2015&author=Davies%2CMJ)\\n\\nKosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. *N. Engl. J. Med.* **390**, 1394–1407 (2024).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2313917)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXptFaltbk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38587233)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Semaglutide%20in%20patients%20with%20obesity-related%20heart%20failure%20and%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2313917&volume=390&pages=1394-1407&publication_year=2024&author=Kosiborod%2CMN)\\n\\nGarvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* **402**, 613–626 (2023).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2823%2901200-X)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtlOqur%2FF)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tirzepatide%20once%20weekly%20for%20the%20treatment%20of%20obesity%20in%20people%20with%20type%202%20diabetes%20%28SURMOUNT-2%29%3A%20a%20double-blind%2C%20randomised%2C%20multicentre%2C%20placebo-controlled%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2823%2901200-X&volume=402&pages=613-626&publication_year=2023&author=Garvey%2CWT)\\n\\nDrucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab.* **27**, 740–756 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.cmet.2018.03.001)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXntVKqs7k%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29617641)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20action%20and%20therapeutic%20application%20of%20glucagon-like%20peptide-1&journal=Cell%20Metab.&doi=10.1016%2Fj.cmet.2018.03.001&volume=27&pages=740-756&publication_year=2018&author=Drucker%2CDJ)\\n\\nKim, K. S. et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. *Science* <https://doi.org/10.1126/science.adj2537> (2024).\\n\\n[Article](https://doi.org/10.1126%2Fscience.adj2537)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39325905)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232486)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=GLP-1%20increases%20preingestive%20satiation%20via%20hypothalamic%20circuits%20in%20mice%20and%20humans&journal=Science&doi=10.1126%2Fscience.adj2537&publication_year=2024&author=Kim%2CKS)\\n\\nDrucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. *Mol. Metab.* **57**, 101351 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.molmet.2021.101351)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34626851)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859548)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=GLP-1%20physiology%20informs%20the%20pharmacotherapy%20of%20obesity&journal=Mol.%20Metab.&doi=10.1016%2Fj.molmet.2021.101351&volume=57&publication_year=2021&author=Drucker%2CDJ)\\n\\nSilveira, S. Q. et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. *J. Clin. Anesth.* **87**, 111091 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.jclinane.2023.111091)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXksVahu7c%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36870274)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Relationship%20between%20perioperative%20semaglutide%20use%20and%20residual%20gastric%20content%3A%20a%20retrospective%20analysis%20of%20patients%20undergoing%20elective%20upper%20endoscopy&journal=J.%20Clin.%20Anesth.&doi=10.1016%2Fj.jclinane.2023.111091&volume=87&publication_year=2023&author=Silveira%2CSQ)\\n\\nGarza, K. et al. Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study. *Am. J. Gastroenterol.* **119**, 1081–1088 (2024).\\n\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXht1WrurvM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38534127)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucagon-like%20peptide-1%20receptor%20agonists%20increase%20solid%20gastric%20residue%20rates%20on%20upper%20endoscopy%20especially%20in%20patients%20with%20complicated%20diabetes%3A%20a%20case-control%20study&journal=Am.%20J.%20Gastroenterol.&volume=119&pages=1081-1088&publication_year=2024&author=Garza%2CK)\\n\\nWelk, B. et al. No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery. *Diabetes Obes. Metab.* <https://doi.org/10.1111/dom.15711> (2024).\\n\\n[Article](https://doi.org/10.1111%2Fdom.15711)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38860419)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=No%20association%20between%20semaglutide%20and%20postoperative%20pneumonia%20in%20people%20with%20diabetes%20undergoing%20elective%20surgery&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.15711&publication_year=2024&author=Welk%2CB)\\n\\nHiramoto, B. et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. *Am. J. Gastroenterol.* **119**, 1126–1140 (2024).\\n\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXht1WrurvJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38634551)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Quantified%20metrics%20of%20gastric%20emptying%20delay%20by%20glucagon-like%20peptide-1%20agonists%3A%20a%20systematic%20review%20and%20meta-analysis%20with%20insights%20for%20periprocedural%20management&journal=Am.%20J.%20Gastroenterol.&volume=119&pages=1126-1140&publication_year=2024&author=Hiramoto%2CB)\\n\\nChalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* **67**, 328–357 (2018).\\n\\n[Article](https://doi.org/10.1002%2Fhep.29367)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28714183)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20diagnosis%20and%20management%20of%20nonalcoholic%20fatty%20liver%20disease%3A%20practice%20guidance%20from%20the%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases&journal=Hepatology&doi=10.1002%2Fhep.29367&volume=67&pages=328-357&publication_year=2018&author=Chalasani%2CN)\\n\\nRinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *J. Hepatol.* **29**, 101133 (2024).\\n\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20multi-society%20Delphi%20consensus%20statement%20on%20new%20fatty%20liver%20disease%20nomenclature&journal=J.%20Hepatol.&volume=29&publication_year=2024&author=Rinella%2CME)\\n\\nLee, B.-W. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. *Diabetes Metab. J.* **44**, 382–401 (2020).\\n\\n[Article](https://doi.org/10.4093%2Fdmj.2020.0010)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32431115)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332334)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Non-alcoholic%20fatty%20liver%20disease%20in%20patients%20with%20type%202%20diabetes%20mellitus%3A%20a%20position%20statement%20of%20the%20Fatty%20Liver%20Research%20Group%20of%20the%20Korean%20Diabetes%20Association&journal=Diabetes%20Metab.%20J.&doi=10.4093%2Fdmj.2020.0010&volume=44&pages=382-401&publication_year=2020&author=Lee%2CB-W)\\n\\nYounossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. *J. Hepatol.* **71**, 793–801 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.jhep.2019.06.021)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31279902)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20global%20epidemiology%20of%20NAFLD%20and%20NASH%20in%20patients%20with%20type%202%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2019.06.021&volume=71&pages=793-801&publication_year=2019&author=Younossi%2CZM)\\n\\nBallestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *J. Gastroenterol. Hepatol.* **31**, 936–944 (2016).\\n\\n[Article](https://doi.org/10.1111%2Fjgh.13264)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XmvVOgsr0%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26667191)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nonalcoholic%20fatty%20liver%20disease%20is%20associated%20with%20an%20almost%20twofold%20increased%20risk%20of%20incident%20type%202%20diabetes%20and%20metabolic%20syndrome.%20Evidence%20from%20a%20systematic%20review%20and%20meta-analysis&journal=J.%20Gastroenterol.%20Hepatol.&doi=10.1111%2Fjgh.13264&volume=31&pages=936-944&publication_year=2016&author=Ballestri%2CS)\\n\\nMantovani, A. et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. *Gut* **70**, 962–969 (2021).\\n\\n[Article](https://doi.org/10.1136%2Fgutjnl-2020-322572)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXht12gurzN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32938692)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Non-alcoholic%20fatty%20liver%20disease%20and%20risk%20of%20incident%20diabetes%20mellitus%3A%20an%20updated%20meta-analysis%20of%20501%20022%20adult%20individuals&journal=Gut&doi=10.1136%2Fgutjnl-2020-322572&volume=70&pages=962-969&publication_year=2021&author=Mantovani%2CA)\\n\\nSinn, D. H. et al. Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: a longitudinal cohort study. *PLoS One* **18**, e0288820 (2023).\\n\\n[Article](https://doi.org/10.1371%2Fjournal.pone.0288820)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhsFKht77M)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37463179)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353790)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Regression%20of%20nonalcoholic%20fatty%20liver%20disease%20is%20associated%20with%20reduced%20risk%20of%20incident%20diabetes%3A%20a%20longitudinal%20cohort%20study&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0288820&volume=18&publication_year=2023&author=Sinn%2CDH)\\n\\nBelfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N. Engl. J. Med.* **355**, 2297–2307 (2006).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa060326)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28Xht1OrtrvI)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17135584)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20placebo-controlled%20trial%20of%20pioglitazone%20in%20subjects%20with%20nonalcoholic%20steatohepatitis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa060326&volume=355&pages=2297-2307&publication_year=2006&author=Belfort%2CR)\\n\\nAithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* **135**, 1176–1184 (2008).\\n\\n[Article](https://doi.org/10.1053%2Fj.gastro.2008.06.047)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXht12lurrN)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Randomized%2C%20placebo-controlled%20trial%20of%20pioglitazone%20in%20nondiabetic%20subjects%20with%20nonalcoholic%20steatohepatitis&journal=Gastroenterology&doi=10.1053%2Fj.gastro.2008.06.047&volume=135&pages=1176-1184&publication_year=2008&author=Aithal%2CGP)\\n\\nRatziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology* **135**, 100–110 (2008).\\n\\n[Article](https://doi.org/10.1053%2Fj.gastro.2008.03.078)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1cXps1Wltrc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18503774)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rosiglitazone%20for%20nonalcoholic%20steatohepatitis%3A%20one-year%20results%20of%20the%20randomized%20placebo-controlled%20Fatty%20Liver%20Improvement%20with%20Rosiglitazone%20Therapy%20%28FLIRT%29%20Trial&journal=Gastroenterology&doi=10.1053%2Fj.gastro.2008.03.078&volume=135&pages=100-110&publication_year=2008&author=Ratziu%2CV)\\n\\nSanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N. Engl. J. Med.* **362**, 1675–1685 (2010).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa0907929)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXls1Oltr4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20427778)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928471)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%2C%20vitamin%20E%2C%20or%20placebo%20for%20nonalcoholic%20steatohepatitis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa0907929&volume=362&pages=1675-1685&publication_year=2010&author=Sanyal%2CAJ)\\n\\nCusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. *Ann. Intern Med.* **165**, 305–315 (2016).\\n\\n[Article](https://doi.org/10.7326%2FM15-1774)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27322798)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Long-term%20pioglitazone%20treatment%20for%20patients%20with%20nonalcoholic%20steatohepatitis%20and%20prediabetes%20or%20type%202%20diabetes%20mellitus%3A%20a%20randomized%20trial&journal=Ann.%20Intern%20Med.&doi=10.7326%2FM15-1774&volume=165&pages=305-315&publication_year=2016&author=Cusi%2CK)\\n\\nBril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. *Diabetes Care* **42**, 1481–1488 (2019).\\n\\n[Article](https://doi.org/10.2337%2Fdc19-0167)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXjs1Ggt7k%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31332029)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20vitamin%20E%20for%20nonalcoholic%20steatohepatitis%20in%20patients%20with%20type%202%20diabetes%3A%20a%20randomized%20controlled%20trial&journal=Diabetes%20Care&doi=10.2337%2Fdc19-0167&volume=42&pages=1481-1488&publication_year=2019&author=Bril%2CF)\\n\\nMusso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. *JAMA Intern Med.* **177**, 633–640 (2017).\\n\\n[Article](https://doi.org/10.1001%2Fjamainternmed.2016.9607)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28241279)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470366)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Thiazolidinediones%20and%20advanced%20liver%20fibrosis%20in%20nonalcoholic%20steatohepatitis%3A%20a%20meta-analysis&journal=JAMA%20Intern%20Med.&doi=10.1001%2Fjamainternmed.2016.9607&volume=177&pages=633-640&publication_year=2017&author=Musso%2CG&author=Cassader%2CM&author=Paschetta%2CE&author=Gambino%2CR)\\n\\nEkstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* **61**, 1547–1554 (2015).\\n\\n[Article](https://doi.org/10.1002%2Fhep.27368)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXmslWlt7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25125077)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Fibrosis%20stage%20is%20the%20strongest%20predictor%20for%20disease-specific%20mortality%20in%20NAFLD%20after%20up%20to%2033%20years%20of%20follow-up&journal=Hepatology&doi=10.1002%2Fhep.27368&volume=61&pages=1547-1554&publication_year=2015&author=Ekstedt%2CM)\\n\\nAngulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* **149**, 389–397.e10 (2015).\\n\\n[Article](https://doi.org/10.1053%2Fj.gastro.2015.04.043)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25935633)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Liver%20fibrosis%2C%20but%20no%20other%20histologic%20features%2C%20is%20associated%20with%20long-term%20outcomes%20of%20patients%20with%20nonalcoholic%20fatty%20liver%20disease&journal=Gastroenterology&doi=10.1053%2Fj.gastro.2015.04.043&volume=149&pages=389-397.e10&publication_year=2015&author=Angulo%2CP)\\n\\nXie, Q. et al. Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review. *Chin. Med. J. (Engl.)* **136**, 2014–2016 (2023).\\n\\n[Article](https://doi.org/10.1097%2FCM9.0000000000002778)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXis1GlsLfL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37464470)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Histological%20analysis%20of%20hypoglycemic%20agents%20on%20liver%20fibrosis%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20disease%3A%20a%20systematic%20review&journal=Chin.%20Med.%20J.%20%28Engl.%29&doi=10.1097%2FCM9.0000000000002778&volume=136&pages=2014-2016&publication_year=2023&author=Xie%2CQ)\\n\\nDella Pepa, G. et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. *Diabetes Res. Clin. Pr.* **178**, 108984 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.diabres.2021.108984)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20even%20at%20low%20dosage%20improves%20NAFLD%20in%20type%202%20diabetes%3A%20clinical%20and%20pathophysiological%20insights%20from%20a%20subgroup%20of%20the%20TOSCA.IT%20randomised%20trial&journal=Diabetes%20Res.%20Clin.%20Pr.&doi=10.1016%2Fj.diabres.2021.108984&volume=178&publication_year=2021&author=Pepa%2CG)\\n\\nLutchman, G. et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. *Clin. Gastroenterol. Hepatol.* **4**, 1048–1052 (2006).\\n\\n[Article](https://doi.org/10.1016%2Fj.cgh.2006.05.005)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28XptFWmt7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16814613)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Changes%20in%20serum%20adipokine%20levels%20during%20pioglitazone%20treatment%20for%20nonalcoholic%20steatohepatitis%3A%20relationship%20to%20histological%20improvement&journal=Clin.%20Gastroenterol.%20Hepatol.&doi=10.1016%2Fj.cgh.2006.05.005&volume=4&pages=1048-1052&publication_year=2006&author=Lutchman%2CG)\\n\\nAlatas, F. S., Matsuura, T., Pudjiadi, A. H., Wijaya, S. & Taguchi, T. Peroxisome proliferator-activated receptor gamma agonist attenuates liver fibrosis by several fibrogenic pathways in an animal model of cholestatic fibrosis. *Pediatr. Gastroenterol. Hepatol. Nutr.* **23**, 346–355 (2020).\\n\\n[Article](https://doi.org/10.5223%2Fpghn.2020.23.4.346)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32704495)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354870)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Peroxisome%20proliferator-activated%20receptor%20gamma%20agonist%20attenuates%20liver%20fibrosis%20by%20several%20fibrogenic%20pathways%20in%20an%20animal%20model%20of%20cholestatic%20fibrosis&journal=Pediatr.%20Gastroenterol.%20Hepatol.%20Nutr.&doi=10.5223%2Fpghn.2020.23.4.346&volume=23&pages=346-355&publication_year=2020&author=Alatas%2CFS&author=Matsuura%2CT&author=Pudjiadi%2CAH&author=Wijaya%2CS&author=Taguchi%2CT)\\n\\nWang, S. et al. PPARγ regulates macrophage polarization by inhibiting the JAK/STAT pathway and attenuates myocardial ischemia/reperfusion injury in vivo. *Cell Biochem. Biophys.* **81**, 349–358 (2023).\\n\\n[Article](https://link.springer.com/doi/10.1007/s12013-023-01137-0)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXptF2nur4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37129843)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=PPAR%CE%B3%20regulates%20macrophage%20polarization%20by%20inhibiting%20the%20JAK%2FSTAT%20pathway%20and%20attenuates%20myocardial%20ischemia%2Freperfusion%20injury%20in%20vivo&journal=Cell%20Biochem.%20Biophys.&doi=10.1007%2Fs12013-023-01137-0&volume=81&pages=349-358&publication_year=2023&author=Wang%2CS)\\n\\nLiu, X., Zhang, P., Song, X., Cui, H. & Shen, W. PPARγ mediates protective effect against hepatic ischemia/reperfusion injury via NF-κB pathway. *J. Invest. Surg.* **35**, 1648–1659 (2022).\\n\\n[Article](https://doi.org/10.1080%2F08941939.2022.2090033)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35732295)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=PPAR%CE%B3%20mediates%20protective%20effect%20against%20hepatic%20ischemia%2Freperfusion%20injury%20via%20NF-%CE%BAB%20pathway&journal=J.%20Invest.%20Surg.&doi=10.1080%2F08941939.2022.2090033&volume=35&pages=1648-1659&publication_year=2022&author=Liu%2CX&author=Zhang%2CP&author=Song%2CX&author=Cui%2CH&author=Shen%2CW)\\n\\nArmstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* **387**, 679–690 (2016).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2815%2900803-X)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvVygsbzK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26608256)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Liraglutide%20safety%20and%20efficacy%20in%20patients%20with%20non-alcoholic%20steatohepatitis%20%28LEAN%29%3A%20a%20multicentre%2C%20double-blind%2C%20randomised%2C%20placebo-controlled%20phase%202%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2815%2900803-X&volume=387&pages=679-690&publication_year=2016&author=Armstrong%2CMJ)\\n\\nNewsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N. Engl. J. Med.* **384**, 1113–1124 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2028395)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXntlaktbc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33185364)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20placebo-controlled%20trial%20of%20subcutaneous%20semaglutide%20in%20nonalcoholic%20steatohepatitis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2028395&volume=384&pages=1113-1124&publication_year=2021&author=Newsome%2CPN)\\n\\nLoomba, R. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. *Lancet Gastroenterol. Hepatol.* **8**, 511–522 (2023).\\n\\n[Article](https://doi.org/10.1016%2FS2468-1253%2823%2900068-7)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36934740)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792518)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Semaglutide%202%C2%B74%20mg%20once%20weekly%20in%20patients%20with%20non-alcoholic%20steatohepatitis-related%20cirrhosis%3A%20a%20randomised%2C%20placebo-controlled%20phase%202%20trial&journal=Lancet%20Gastroenterol.%20Hepatol.&doi=10.1016%2FS2468-1253%2823%2900068-7&volume=8&pages=511-522&publication_year=2023&author=Loomba%2CR)\\n\\nLoomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2401943> (2024).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2401943)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38856224)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tirzepatide%20for%20metabolic%20dysfunction-associated%20steatohepatitis%20with%20liver%20fibrosis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2401943&publication_year=2024&author=Loomba%2CR)\\n\\nSanyal, A. J. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2401755> (2024).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2401755)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38856224)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20Phase%202%20Randomized%20Trial%20of%20Survodutide%20in%20MASH%20and%20Fibrosis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2401755&publication_year=2024&author=Sanyal%2CAJ)\\n\\nTacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. *J. Hepatol.* **79**, 552–566 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.jhep.2023.03.038)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtFGltL3K)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37061196)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=An%20integrated%20view%20of%20anti-inflammatory%20and%20antifibrotic%20targets%20for%20the%20treatment%20of%20NASH&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2023.03.038&volume=79&pages=552-566&publication_year=2023&author=Tacke%2CF&author=Puengel%2CT&author=Loomba%2CR&author=Friedman%2CSL)\\n\\nNesti, L., Tricò, D., Mengozzi, A. & Natali, A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. *Cardiovasc. Diabetol.* **20**, 109 (2021).\\n\\n[Article](https://link.springer.com/doi/10.1186/s12933-021-01294-7)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlegsLvE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34006325)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130304)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rethinking%20pioglitazone%20as%20a%20cardioprotective%20agent%3A%20a%20new%20perspective%20on%20an%20overlooked%20drug&journal=Cardiovasc.%20Diabetol.&doi=10.1186%2Fs12933-021-01294-7&volume=20&publication_year=2021&author=Nesti%2CL&author=Tric%C3%B2%2CD&author=Mengozzi%2CA&author=Natali%2CA)\\n\\nSmith, S. R. et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. *Metabolism* **54**, 24–32 (2005).\\n\\n[Article](https://doi.org/10.1016%2Fj.metabol.2004.07.008)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2cXhtVansb3E)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15562376)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20pioglitazone%20on%20body%20composition%20and%20energy%20expenditure%3A%20a%20randomized%20controlled%20trial&journal=Metabolism&doi=10.1016%2Fj.metabol.2004.07.008&volume=54&pages=24-32&publication_year=2005&author=Smith%2CSR)\\n\\nMiyazaki, Y. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. *J. Clin. Endocrinol. Metab.* **87**, 2784–2791 (2002).\\n\\n[Article](https://doi.org/10.1210%2Fjcem.87.6.8567)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD38XkvFaku74%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12050251)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20pioglitazone%20on%20abdominal%20fat%20distribution%20and%20insulin%20sensitivity%20in%20type%202%20diabetic%20patients&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjcem.87.6.8567&volume=87&pages=2784-2791&publication_year=2002&author=Miyazaki%2CY)\\n\\nCusi, K. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr. Pr.* **28**, 528–562 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.eprac.2022.03.010)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=American%20Association%20of%20Clinical%20Endocrinology%20Clinical%20Practice%20Guideline%20for%20the%20Diagnosis%20and%20Management%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20Primary%20Care%20and%20Endocrinology%20Clinical%20Settings%3A%20co-sponsored%20by%20the%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases%20%28AASLD%29&journal=Endocr.%20Pr.&doi=10.1016%2Fj.eprac.2022.03.010&volume=28&pages=528-562&publication_year=2022&author=Cusi%2CK)\\n\\nDuell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. *Arterioscler Thromb. Vasc. Biol.* **42**, e168–e185 (2022).\\n\\n[Article](https://doi.org/10.1161%2FATV.0000000000000153)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVOmtLbE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35418240)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nonalcoholic%20fatty%20liver%20disease%20and%20cardiovascular%20risk%3A%20a%20scientific%20statement%20from%20the%20American%20Heart%20Association&journal=Arterioscler%20Thromb.%20Vasc.%20Biol.&doi=10.1161%2FATV.0000000000000153&volume=42&pages=e168-e185&publication_year=2022&author=Duell%2CPB)\\n\\nChinese Society of Endocrinology & Chinese Diabetes Society. Management of Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease: an expert consensus (in Chinese). *Chin. J. Endocrinol. Metab.* **37**, 589–598 (2021).\\n\\nHusain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* **381**, 841–851 (2019).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1901118)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1yktbfN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31185157)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Oral%20semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1901118&volume=381&pages=841-851&publication_year=2019&author=Husain%2CM)\\n\\nGerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet* **394**, 121–130 (2019).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2819%2931149-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFGjtb%2FN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31189511)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dulaglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes%20%28REWIND%29%3A%20a%20double-blind%2C%20randomised%20placebo-controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2819%2931149-3&volume=394&pages=121-130&publication_year=2019&author=Gerstein%2CHC)\\n\\nHernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet* **392**, 1519–1529 (2018).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2818%2932261-X)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVeqtL7O)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30291013)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Albiglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes%20and%20cardiovascular%20disease%20%28Harmony%20Outcomes%29%3A%20a%20double-blind%2C%20randomised%20placebo-controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2818%2932261-X&volume=392&pages=1519-1529&publication_year=2018&author=Hernandez%2CAF)\\n\\nHolman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* **377**, 1228–1239 (2017).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1612917)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1agsbfK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28910237)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792409)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20once-weekly%20exenatide%20on%20cardiovascular%20outcomes%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1612917&volume=377&pages=1228-1239&publication_year=2017&author=Holman%2CRR)\\n\\nMarso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* **375**, 1834–1844 (2016).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1607141)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ksrfK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27633186)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1607141&volume=375&pages=1834-1844&publication_year=2016&author=Marso%2CSP)\\n\\nMarso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* **375**, 311–322 (2016).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1603827)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhvF2ks77O)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27295427)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985288)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Liraglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1603827&volume=375&pages=311-322&publication_year=2016&author=Marso%2CSP)\\n\\nPfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N. Engl. J. Med.* **373**, 2247–2257 (2015).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1509225)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XmvFGgtb4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26630143)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lixisenatide%20in%20patients%20with%20type%202%20diabetes%20and%20acute%20coronary%20syndrome&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1509225&volume=373&pages=2247-2257&publication_year=2015&author=Pfeffer%2CMA)\\n\\nKristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol.* **7**, 776–785 (2019).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2819%2930249-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFyqtb3O)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31422062)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cardiovascular%2C%20mortality%2C%20and%20kidney%20outcomes%20with%20GLP-1%20receptor%20agonists%20in%20patients%20with%20type%202%20diabetes%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20cardiovascular%20outcome%20trials&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2819%2930249-9&volume=7&pages=776-785&publication_year=2019&author=Kristensen%2CSL)\\n\\nDormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* **366**, 1279–1289 (2005).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2805%2967528-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtVOlu7fO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16214598)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Secondary%20prevention%20of%20macrovascular%20events%20in%20patients%20with%20type%202%20diabetes%20in%20the%20PROactive%20Study%20%28PROspective%20pioglitAzone%20Clinical%20Trial%20In%20macroVascular%20Events%29%3A%20a%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2805%2967528-9&volume=366&pages=1279-1289&publication_year=2005&author=Dormandy%2CJA)\\n\\nVaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol.* **5**, 887–897 (2017).\\n\\n[Article](https://doi.org/10.1016%2FS2213-8587%2817%2930317-0)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28917544)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20on%20the%20incidence%20of%20cardiovascular%20events%20of%20the%20addition%20of%20pioglitazone%20versus%20sulfonylureas%20in%20patients%20with%20type%202%20diabetes%20inadequately%20controlled%20with%20metformin%20%28TOSCA.IT%29%3A%20a%20randomised%2C%20multicentre%20trial&journal=Lancet%20Diabetes%20Endocrinol.&doi=10.1016%2FS2213-8587%2817%2930317-0&volume=5&pages=887-897&publication_year=2017&author=Vaccaro%2CO)\\n\\nAhmadi, A., Panahi, Y., Johnston, T. P. & Sahebkar, A. Antidiabetic drugs and oxidized low-density lipoprotein: a review of anti-atherosclerotic mechanisms. *Pharm. Res.* **172**, 105819 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.phrs.2021.105819)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXisF2gs7zN)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Antidiabetic%20drugs%20and%20oxidized%20low-density%20lipoprotein%3A%20a%20review%20of%20anti-atherosclerotic%20mechanisms&journal=Pharm.%20Res.&doi=10.1016%2Fj.phrs.2021.105819&volume=172&publication_year=2021&author=Ahmadi%2CA&author=Panahi%2CY&author=Johnston%2CTP&author=Sahebkar%2CA)\\n\\nZinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N. Engl. J. Med.* **373**, 2117–2128 (2015).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1504720)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XntVSkurs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26378978)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Empagliflozin%2C%20cardiovascular%20outcomes%2C%20and%20mortality%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1504720&volume=373&pages=2117-2128&publication_year=2015&author=Zinman%2CB)\\n\\nNeal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N. Engl. J. Med.* **377**, 2099 (2017).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1611925)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29166232)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Canagliflozin%20and%20cardiovascular%20and%20renal%20events%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1611925&volume=377&publication_year=2017&author=Neal%2CB&author=Perkovic%2CV&author=Matthews%2CDR)\\n\\nWiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* **380**, 347–357 (2019).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1812389)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXit12rsLY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30415602)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1812389&volume=380&pages=347-357&publication_year=2019&author=Wiviott%2CSD)\\n\\nCannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N. Engl. J. Med.* **383**, 1425–1435 (2020).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2004967)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVCgsLjJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32966714)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cardiovascular%20outcomes%20with%20ertugliflozin%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2004967&volume=383&pages=1425-1435&publication_year=2020&author=Cannon%2CCP)\\n\\nBhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. *N. Engl. J. Med.* **384**, 129–139 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2030186)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVKiu7k%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33200891)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sotagliflozin%20in%20patients%20with%20diabetes%20and%20chronic%20kidney%20disease&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2030186&volume=384&pages=129-139&publication_year=2021&author=Bhatt%2CDL)\\n\\nKenny, H. C. & Abel, E. D. Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies. *Circ. Res.* **124**, 121–141 (2019).\\n\\n[Article](https://doi.org/10.1161%2FCIRCRESAHA.118.311371)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXivFejsg%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30605420)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447311)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Heart%20failure%20in%20type%202%20diabetes%20mellitus%3A%20impact%20of%20glucose%20lowering%20agents%2C%20heart%20failure%20therapies%20and%20novel%20therapeutic%20strategies&journal=Circ.%20Res.&doi=10.1161%2FCIRCRESAHA.118.311371&volume=124&pages=121-141&publication_year=2019&author=Kenny%2CHC&author=Abel%2CED)\\n\\nSolomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N. Engl. J. Med.* **387**, 1089–1098 (2022).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2206286)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36027570)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20in%20heart%20failure%20with%20mildly%20reduced%20or%20preserved%20ejection%20fraction&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2206286&volume=387&pages=1089-1098&publication_year=2022&author=Solomon%2CSD)\\n\\nMcMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N. Engl. J. Med.* **381**, 1995–2008 (2019).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1911303)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXit1GjsbjF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31535829)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20in%20patients%20with%20heart%20failure%20and%20reduced%20ejection%20fraction&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1911303&volume=381&pages=1995-2008&publication_year=2019&author=McMurray%2CJJV)\\n\\nAnker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. *N. Engl. J. Med.* **385**, 1451–1461 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2107038)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1Crt7jM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34449189)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Empagliflozin%20in%20heart%20failure%20with%20a%20preserved%20ejection%20fraction&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2107038&volume=385&pages=1451-1461&publication_year=2021&author=Anker%2CSD)\\n\\nPacker, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N. Engl. J. Med.* **383**, 1413–1424 (2020).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2022190)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVCgsbvK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32865377)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cardiovascular%20and%20renal%20outcomes%20with%20empagliflozin%20in%20heart%20failure&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2022190&volume=383&pages=1413-1424&publication_year=2020&author=Packer%2CM)\\n\\nBhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N. Engl. J. Med.* **384**, 117–128 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2030183)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVKiu7Y%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33200892)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sotagliflozin%20in%20patients%20with%20diabetes%20and%20recent%20worsening%20heart%20failure&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2030183&volume=384&pages=117-128&publication_year=2021&author=Bhatt%2CDL)\\n\\nKahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N. Engl. J. Med.* **355**, 2427–2443 (2006).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa066224)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD28Xht12ntrzF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17145742)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glycemic%20durability%20of%20rosiglitazone%2C%20metformin%2C%20or%20glyburide%20monotherapy&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa066224&volume=355&pages=2427-2443&publication_year=2006&author=Kahn%2CSE)\\n\\nHome, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* **373**, 2125–2135 (2009).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2809%2960953-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD1MXnsFSis78%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19501900)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rosiglitazone%20evaluated%20for%20cardiovascular%20outcomes%20in%20oral%20agent%20combination%20therapy%20for%20type%202%20diabetes%20%28RECORD%29%3A%20a%20multicentre%2C%20randomised%2C%20open-label%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2960953-3&volume=373&pages=2125-2135&publication_year=2009&author=Home%2CPD)\\n\\nErdmann, E. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care* **30**, 2773–2778 (2007).\\n\\n[Article](https://doi.org/10.2337%2Fdc07-0717)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtlKhs7rJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17666462)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20use%20and%20heart%20failure%20in%20patients%20with%20type%202%20diabetes%20and%20preexisting%20cardiovascular%20disease%3A%20data%20from%20the%20PROactive%20study%20%28PROactive%2008%29&journal=Diabetes%20Care&doi=10.2337%2Fdc07-0717&volume=30&pages=2773-2778&publication_year=2007&author=Erdmann%2CE)\\n\\nLago, R. M., Singh, P. P. & Nesto, R. W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* **370**, 1129–1136 (2007).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2807%2961514-1)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtFSntLzO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17905165)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Congestive%20heart%20failure%20and%20cardiovascular%20death%20in%20patients%20with%20prediabetes%20and%20type%202%20diabetes%20given%20thiazolidinediones%3A%20a%20meta-analysis%20of%20randomised%20clinical%20trials&journal=Lancet&doi=10.1016%2FS0140-6736%2807%2961514-1&volume=370&pages=1129-1136&publication_year=2007&author=Lago%2CRM&author=Singh%2CPP&author=Nesto%2CRW)\\n\\nLincoff, A. M., Wolski, K., Nicholls, S. J. & Nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* **298**, 1180–1188 (2007).\\n\\n[Article](https://doi.org/10.1001%2Fjama.298.10.1180)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BD2sXhtVGmtL3J)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17848652)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20and%20risk%20of%20cardiovascular%20events%20in%20patients%20with%20type%202%20diabetes%20mellitus%3A%20a%20meta-analysis%20of%20randomized%20trials&journal=JAMA&doi=10.1001%2Fjama.298.10.1180&volume=298&pages=1180-1188&publication_year=2007&author=Lincoff%2CAM&author=Wolski%2CK&author=Nicholls%2CSJ&author=Nissen%2CSE)\\n\\nvan der Meer, R. W. et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. *Circulation* **119**, 2069–2077 (2009).\\n\\n[Article](https://doi.org/10.1161%2FCIRCULATIONAHA.108.803916)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19349323)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pioglitazone%20improves%20cardiac%20function%20and%20alters%20myocardial%20substrate%20metabolism%20without%20affecting%20cardiac%20triglyceride%20accumulation%20and%20high-energy%20phosphate%20metabolism%20in%20patients%20with%20well-controlled%20type%202%20diabetes%20mellitus&journal=Circulation&doi=10.1161%2FCIRCULATIONAHA.108.803916&volume=119&pages=2069-2077&publication_year=2009&author=Meer%2CRW)\\n\\nDorkhan, M., Dencker, M., Stagmo, M. & Groop, L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. *Cardiovasc Diabetol.* **8**, 15 (2009).\\n\\n[Article](https://link.springer.com/doi/10.1186/1475-2840-8-15)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19298680)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664795)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20pioglitazone%20versus%20insulin%20glargine%20on%20cardiac%20size%2C%20function%2C%20and%20measures%20of%20fluid%20retention%20in%20patients%20with%20type%202%20diabetes&journal=Cardiovasc%20Diabetol.&doi=10.1186%2F1475-2840-8-15&volume=8&publication_year=2009&author=Dorkhan%2CM&author=Dencker%2CM&author=Stagmo%2CM&author=Groop%2CL)\\n\\nFerrannini, G. et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. *Eur. Heart J.* **42**, 2565–2573 (2021).\\n\\n[Article](https://doi.org/10.1093%2Feurheartj%2Fehaa777)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33197271)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Similar%20cardiovascular%20outcomes%20in%20patients%20with%20diabetes%20and%20established%20or%20high%20risk%20for%20coronary%20vascular%20disease%20treated%20with%20dulaglutide%20with%20and%20without%20baseline%20metformin&journal=Eur.%20Heart%20J.&doi=10.1093%2Feurheartj%2Fehaa777&volume=42&pages=2565-2573&publication_year=2021&author=Ferrannini%2CG)\\n\\nMasson, W., Lavalle-Cobo, A., Lobo, M., Masson, G. & Molinero, G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. *Eur. J. Prev. Cardiol.* **28**, 69–75 (2021).\\n\\n[Article](https://doi.org/10.1093%2Feurjpc%2Fzwaa074)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33606884)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Novel%20antidiabetic%20drugs%20and%20risk%20of%20cardiovascular%20events%20in%20patients%20without%20baseline%20metformin%20use%3A%20a%20meta-analysis&journal=Eur.%20J.%20Prev.%20Cardiol.&doi=10.1093%2Feurjpc%2Fzwaa074&volume=28&pages=69-75&publication_year=2021&author=Masson%2CW&author=Lavalle-Cobo%2CA&author=Lobo%2CM&author=Masson%2CG&author=Molinero%2CG)\\n\\nRiley, D. R. et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. *Diabetes Obes. Metab.* **25**, 2897–2909 (2023).\\n\\n[Article](https://doi.org/10.1111%2Fdom.15185)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhsVehu77P)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37385958)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=All-cause%20mortality%20and%20cardiovascular%20outcomes%20with%20sodium-glucose%20Co-transporter%202%20inhibitors%2C%20glucagon-like%20peptide-1%20receptor%20agonists%20and%20with%20combination%20therapy%20in%20people%20with%20type%202%20diabetes&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.15185&volume=25&pages=2897-2909&publication_year=2023&author=Riley%2CDR)\\n\\nUssher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. *Nat. Rev. Cardiol.* **20**, 463–474 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs41569-023-00849-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXmsVaqurg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36977782)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glucagon-like%20peptide%201%20receptor%20agonists%3A%20cardiovascular%20benefits%20and%20mechanisms%20of%20action&journal=Nat.%20Rev.%20Cardiol.&doi=10.1038%2Fs41569-023-00849-3&volume=20&pages=463-474&publication_year=2023&author=Ussher%2CJR&author=Drucker%2CDJ)\\n\\nZhang, R., Xie, Q., Lu, X., Fan, R. & Tong, N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. *Diabetol. Metab. Syndr.* **16**, 99 (2024).\\n\\n[Article](https://link.springer.com/doi/10.1186/s13098-024-01325-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38735956)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089742)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Research%20advances%20in%20the%20anti-inflammatory%20effects%20of%20SGLT%20inhibitors%20in%20type%202%20diabetes%20mellitus&journal=Diabetol.%20Metab.%20Syndr.&doi=10.1186%2Fs13098-024-01325-9&volume=16&publication_year=2024&author=Zhang%2CR&author=Xie%2CQ&author=Lu%2CX&author=Fan%2CR&author=Tong%2CN)\\n\\nWood, N. et al. Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction. *Eur. J. Heart Fail* **26**, 925–935 (2024).\\n\\n[Article](https://doi.org/10.1002%2Fejhf.3192)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXlsF2qtbs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38468429)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sodium%E2%80%93glucose%20cotransporter%202%20inhibitors%20influence%20skeletal%20muscle%20pathology%20in%20patients%20with%20heart%20failure%20and%20reduced%20ejection%20fraction&journal=Eur.%20J.%20Heart%20Fail&doi=10.1002%2Fejhf.3192&volume=26&pages=925-935&publication_year=2024&author=Wood%2CN)\\n\\nKasperova, B. J. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. *Cardiovasc. Diabetol.* **23**, 223 (2024).\\n\\n[Article](https://link.springer.com/doi/10.1186/s12933-024-02298-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXhsVKjsL%2FK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38943140)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214218)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sodium-glucose%20cotransporter%202%20inhibitors%20induce%20anti-inflammatory%20and%20anti-ferroptotic%20shift%20in%20epicardial%20adipose%20tissue%20of%20subjects%20with%20severe%20heart%20failure&journal=Cardiovasc.%20Diabetol.&doi=10.1186%2Fs12933-024-02298-9&volume=23&publication_year=2024&author=Kasperova%2CBJ)\\n\\nXu, C. et al. Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors. *J. Diabetes Complications* **38**, 108631 (2024).\\n\\n[Article](https://doi.org/10.1016%2Fj.jdiacomp.2023.108631)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXjtlOmu70%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38340519)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20ameliorated%20retinal%20vascular%20permeability%20in%20diabetic%20retinopathy%20rats%20by%20suppressing%20inflammatory%20factors&journal=J.%20Diabetes%20Complications&doi=10.1016%2Fj.jdiacomp.2023.108631&volume=38&publication_year=2024&author=Xu%2CC)\\n\\nBilling, A. M. et al. Metabolic communication by SGLT2 inhibition. *Circulation* **149**, 860–884 (2024).\\n\\n[Article](https://doi.org/10.1161%2FCIRCULATIONAHA.123.065517)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXltlWisr8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38152989)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metabolic%20communication%20by%20SGLT2%20inhibition&journal=Circulation&doi=10.1161%2FCIRCULATIONAHA.123.065517&volume=149&pages=860-884&publication_year=2024&author=Billing%2CAM)\\n\\nJiang, Y. et al. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. *Diabetes* **73**, 926–940 (2024).\\n\\n[Article](https://doi.org/10.2337%2Fdb23-0553)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38471012)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11109800)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Gut%20microbiota-tryptophan%20metabolism-GLP-1%20axis%20participates%20in%20%CE%B2-cell%20regeneration%20induced%20by%20dapagliflozin&journal=Diabetes&doi=10.2337%2Fdb23-0553&volume=73&pages=926-940&publication_year=2024&author=Jiang%2CY)\\n\\nAnders, H.-J., Huber, T. B., Isermann, B. & Schiffer, M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. *Nat. Rev. Nephrol.* **14**, 361–377 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41581-018-0001-y)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXos1KnsLg%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29654297)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=CKD%20in%20diabetes%3A%20diabetic%20kidney%20disease%20versus%20nondiabetic%20kidney%20disease&journal=Nat.%20Rev.%20Nephrol.&doi=10.1038%2Fs41581-018-0001-y&volume=14&pages=361-377&publication_year=2018&author=Anders%2CH-J&author=Huber%2CTB&author=Isermann%2CB&author=Schiffer%2CM)\\n\\nShao, M. et al. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. *Diabetologia* **67**, 738–754 (2024).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-023-06078-0)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXitFKrt74%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38236410)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Canagliflozin%20regulates%20metabolic%20reprogramming%20in%20diabetic%20kidney%20disease%20by%20inducing%20fasting-like%20and%20aestivation-like%20metabolic%20patterns&journal=Diabetologia&doi=10.1007%2Fs00125-023-06078-0&volume=67&pages=738-754&publication_year=2024&author=Shao%2CM)\\n\\nQiuxiao-Zhu et al. Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury. *Transpl. Immunol.* **84**, 102010 (2024).\\n\\n[Article](https://doi.org/10.1016%2Fj.trim.2024.102010)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXmsVWhs7o%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38325526)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Protective%20effects%20and%20mechanisms%20of%20dapagliflozin%20on%20renal%20ischemia%2Freperfusion%20injury&journal=Transpl.%20Immunol.&doi=10.1016%2Fj.trim.2024.102010&volume=84&publication_year=2024&author=Qiuxiao-Zhu%2C)\\n\\nLu, Q. et al. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway. *Free Radic. Biol. Med.* **195**, 89–102 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.freeradbiomed.2022.12.088)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xjt1WisLfM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36581059)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Empagliflozin%20attenuates%20the%20renal%20tubular%20ferroptosis%20in%20diabetic%20kidney%20disease%20through%20AMPK%2FNRF2%20pathway&journal=Free%20Radic.%20Biol.%20Med.&doi=10.1016%2Fj.freeradbiomed.2022.12.088&volume=195&pages=89-102&publication_year=2023&author=Lu%2CQ)\\n\\nPerkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N. Engl. J. Med.* **380**, 2295–2306 (2019).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa1811744)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtF2ru77O)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30990260)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Canagliflozin%20and%20renal%20outcomes%20in%20type%202%20diabetes%20and%20nephropathy&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1811744&volume=380&pages=2295-2306&publication_year=2019&author=Perkovic%2CV)\\n\\nHeerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. *N. Engl. J. Med.* **383**, 1436–1446 (2020).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2024816)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVCgsbvE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32970396)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dapagliflozin%20in%20patients%20with%20chronic%20kidney%20disease&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2024816&volume=383&pages=1436-1446&publication_year=2020&author=Heerspink%2CHJL)\\n\\nPerkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N. Engl. J. Med.* **391**, 109–121 (2024).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2403347)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB2cXhvVaiurzJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38785209)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20semaglutide%20on%20chronic%20kidney%20disease%20in%20patients%20with%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2403347&volume=391&pages=109-121&publication_year=2024&author=Perkovic%2CV)\\n\\nMann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. *Nat. Med.* <https://doi.org/10.1038/s41591-024-03133-0> (2024).\\n\\n[Article](https://doi.org/10.1038%2Fs41591-024-03133-0)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39284953)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271413)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effects%20of%20semaglutide%20with%20and%20without%20concomitant%20SGLT2%20inhibitor%20use%20in%20participants%20with%20type%202%20diabetes%20and%20chronic%20kidney%20disease%20in%20the%20FLOW%20trial&journal=Nat.%20Med.&doi=10.1038%2Fs41591-024-03133-0&publication_year=2024&author=Mann%2CJFE)\\n\\nMuskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. *Nat. Rev. Nephrol.* **13**, 605–628 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fnrneph.2017.123)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVKmu7zM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28869249)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=GLP-1%20and%20the%20kidney%3A%20from%20physiology%20to%20pharmacology%20and%20outcomes%20in%20diabetes&journal=Nat.%20Rev.%20Nephrol.&doi=10.1038%2Fnrneph.2017.123&volume=13&pages=605-628&publication_year=2017&author=Muskiet%2CMHA)\\n\\nLee, A. K. et al. Risk factors for severe hypoglycemia in black and white adults with diabetes: The Atherosclerosis Risk in Communities (ARIC) study. *Diabetes Care* **40**, 1661–1667 (2017).\\n\\n[Article](https://doi.org/10.2337%2Fdc17-0819)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXitFGksL3M)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28928117)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711330)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20for%20severe%20hypoglycemia%20in%20black%20and%20white%20adults%20with%20diabetes%3A%20The%20Atherosclerosis%20Risk%20in%20Communities%20%28ARIC%29%20study&journal=Diabetes%20Care&doi=10.2337%2Fdc17-0819&volume=40&pages=1661-1667&publication_year=2017&author=Lee%2CAK)\\n\\nKidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int.* **102**, S1–S127 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.kint.2022.06.008)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=KDIGO%202022%20Clinical%20Practice%20Guideline%20for%20Diabetes%20Management%20in%20Chronic%20Kidney%20Disease&journal=Kidney%20Int.&doi=10.1016%2Fj.kint.2022.06.008&volume=102&pages=S1-S127&publication_year=2022)\\n\\nRoddick, A. J. et al. UK Kidney Association Clinical Practice Guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE. *BMC Nephrol.* **24**, 310 (2023).\\n\\n[Article](https://link.springer.com/doi/10.1186/s12882-023-03339-3)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37880609)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598949)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=UK%20Kidney%20Association%20Clinical%20Practice%20Guideline%3A%20sodium-glucose%20co-transporter-2%20%28SGLT-2%29%20inhibition%20in%20adults%20with%20kidney%20disease%202023%20UPDATE&journal=BMC%20Nephrol.&doi=10.1186%2Fs12882-023-03339-3&volume=24&publication_year=2023&author=Roddick%2CAJ)\\n\\nCersosimo, E., Johnson, E. L., Chovanes, C. & Skolnik, N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. *Diabetes Obes. Metab.* **20**, 497–507 (2018).\\n\\n[Article](https://doi.org/10.1111%2Fdom.13108)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28862799)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Initiating%20therapy%20in%20patients%20newly%20diagnosed%20with%20type%202%20diabetes%3A%20combination%20therapy%20vs%20a%20stepwise%20approach&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.13108&volume=20&pages=497-507&publication_year=2018&author=Cersosimo%2CE&author=Johnson%2CEL&author=Chovanes%2CC&author=Skolnik%2CN)\\n\\nLim, S. et al. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). *Diabetes Obes. Metab.* **19**, 87–97 (2017).\\n\\n[Article](https://doi.org/10.1111%2Fdom.12787)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XitFGgurjE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27619558)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20initial%20combination%20therapy%20with%20gemigliptin%20and%20metformin%20compared%20with%20monotherapy%20with%20either%20drug%20in%20patients%20with%20type%202%20diabetes%3A%20A%20double-blind%20randomized%20controlled%20trial%20%28INICOM%20study%29&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.12787&volume=19&pages=87-97&publication_year=2017&author=Lim%2CS)\\n\\nPratley, R. E., Fleck, P. & Wilson, C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. *Diabetes Obes. Metab.* **16**, 613–621 (2014).\\n\\n[Article](https://doi.org/10.1111%2Fdom.12258)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVKnsb7N)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24400655)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20initial%20combination%20therapy%20with%20alogliptin%20plus%20metformin%20versus%20either%20as%20monotherapy%20in%20drug-na%C3%AFve%20patients%20with%20type%202%20diabetes%3A%20a%20randomized%2C%20double-blind%2C%206-month%20study&journal=Diabetes%20Obes.%20Metab.&doi=10.1111%2Fdom.12258&volume=16&pages=613-621&publication_year=2014&author=Pratley%2CRE&author=Fleck%2CP&author=Wilson%2CC)\\n\\nJabbour, S. A. et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. *Diabetes Care* **41**, 2136–2146 (2018).\\n\\n[Article](https://doi.org/10.2337%2Fdc18-0680)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXjslylsLs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30082326)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150435)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20exenatide%20once%20weekly%20plus%20dapagliflozin%20once%20daily%20versus%20exenatide%20or%20dapagliflozin%20alone%20in%20patients%20with%20type%202%20diabetes%20inadequately%20controlled%20with%20metformin%20monotherapy%3A%2052-week%20results%20of%20the%20DURATION-8%20randomized%20controlled%20trial&journal=Diabetes%20Care&doi=10.2337%2Fdc18-0680&volume=41&pages=2136-2146&publication_year=2018&author=Jabbour%2CSA)\\n\\nMatthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. *Lancet* **394**, 1519–1529 (2019).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2819%2932131-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvVSnsr%2FF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31542292)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Glycaemic%20durability%20of%20an%20early%20combination%20therapy%20with%20vildagliptin%20and%20metformin%20versus%20sequential%20metformin%20monotherapy%20in%20newly%20diagnosed%20type%202%20diabetes%20%28VERIFY%29%3A%20a%205-year%2C%20multicentre%2C%20randomised%2C%20double-blind%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2819%2932131-2&volume=394&pages=1519-1529&publication_year=2019&author=Matthews%2CDR)\\n\\nTuttle, K. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. *Kidney Int.* **102**, 248–260 (2022).\\n\\n[Article](https://doi.org/10.1016%2Fj.kint.2022.05.012)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XitVynsb%2FK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35661785)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Molecular%20mechanisms%20and%20therapeutic%20targets%20for%20diabetic%20kidney%20disease&journal=Kidney%20Int.&doi=10.1016%2Fj.kint.2022.05.012&volume=102&pages=248-260&publication_year=2022&author=Tuttle%2CKR)\\n\\nJohnson, R. J. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a Scientific Workshop Organized by the National Kidney Foundation. *Am. J. Kidney Dis.* **71**, 851–865 (2018).\\n\\n[Article](https://doi.org/10.1053%2Fj.ajkd.2017.12.009)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29496260)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286363)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperuricemia%2C%20acute%20and%20chronic%20kidney%20disease%2C%20hypertension%2C%20and%20cardiovascular%20disease%3A%20report%20of%20a%20Scientific%20Workshop%20Organized%20by%20the%20National%20Kidney%20Foundation&journal=Am.%20J.%20Kidney%20Dis.&doi=10.1053%2Fj.ajkd.2017.12.009&volume=71&pages=851-865&publication_year=2018&author=Johnson%2CRJ)\\n\\nAfkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. *J. Am. Soc. Nephrol.* **24**, 302–308 (2013).\\n\\n[Article](https://doi.org/10.1681%2FASN.2012070718)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3sXivFejtr4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23362314)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559486)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Kidney%20disease%20and%20increased%20mortality%20risk%20in%20type%202%20diabetes&journal=J.%20Am.%20Soc.%20Nephrol.&doi=10.1681%2FASN.2012070718&volume=24&pages=302-308&publication_year=2013&author=Afkarian%2CM)\\n\\nPitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N. Engl. J. Med.* **385**, 2252–2263 (2021).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2110956)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXislKlsbrL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34449181)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cardiovascular%20events%20with%20finerenone%20in%20kidney%20disease%20and%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2110956&volume=385&pages=2252-2263&publication_year=2021&author=Pitt%2CB)\\n\\nBakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N. Engl. J. Med.* **383**, 2219–2229 (2020).\\n\\n[Article](https://doi.org/10.1056%2FNEJMoa2025845)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFynt7%2FE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33264825)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20finerenone%20on%20chronic%20kidney%20disease%20outcomes%20in%20type%202%20diabetes&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2025845&volume=383&pages=2219-2229&publication_year=2020&author=Bakris%2CGL)\\n\\nFerro, C. J. et al. Lipid management in patients with chronic kidney disease. *Nat. Rev. Nephrol.* **14**, 727–749 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41581-018-0072-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVSltrbO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30361677)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Lipid%20management%20in%20patients%20with%20chronic%20kidney%20disease&journal=Nat.%20Rev.%20Nephrol.&doi=10.1038%2Fs41581-018-0072-9&volume=14&pages=727-749&publication_year=2018&author=Ferro%2CCJ)\\n\\nAfshinnia, F. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. *Ann. Clin. Transl. Neurol.* **9**, 1392–1404 (2022).\\n\\n[Article](https://doi.org/10.1002%2Facn3.51639)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1WrtbbN)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35923113)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463947)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Serum%20lipidomic%20determinants%20of%20human%20diabetic%20neuropathy%20in%20type%202%20diabetes&journal=Ann.%20Clin.%20Transl.%20Neurol.&doi=10.1002%2Facn3.51639&volume=9&pages=1392-1404&publication_year=2022&author=Afshinnia%2CF)\\n\\nPop-Busui, R. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care* **40**, 136–154 (2017).\\n\\n[Article](https://doi.org/10.2337%2Fdc16-2042)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlartb4%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27999003)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Diabetic%20neuropathy%3A%20a%20position%20statement%20by%20the%20American%20Diabetes%20Association&journal=Diabetes%20Care&doi=10.2337%2Fdc16-2042&volume=40&pages=136-154&publication_year=2017&author=Pop-Busui%2CR)\\n\\nWang, Y. et al. An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. *Biomed. Pharmacother.* **133**, 110991 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.biopha.2020.110991)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXjvFahtQ%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33227713)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=An%20update%20on%20potential%20biomarkers%20for%20diagnosing%20diabetic%20foot%20ulcer%20at%20early%20stage&journal=Biomed.%20Pharmacother.&doi=10.1016%2Fj.biopha.2020.110991&volume=133&publication_year=2021&author=Wang%2CY)\\n\\nGoodall, R. J. et al. A systematic review of the impact of foot care education on self efficacy and self care in patients with diabetes. *Eur. J. Vasc. Endovasc. Surg.* **60**, 282–292 (2020).\\n\\n[Article](https://doi.org/10.1016%2Fj.ejvs.2020.03.053)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32660807)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20systematic%20review%20of%20the%20impact%20of%20foot%20care%20education%20on%20self%20efficacy%20and%20self%20care%20in%20patients%20with%20diabetes&journal=Eur.%20J.%20Vasc.%20Endovasc.%20Surg.&doi=10.1016%2Fj.ejvs.2020.03.053&volume=60&pages=282-292&publication_year=2020&author=Goodall%2CRJ)\\n\\nAntonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. *Nat. Rev. Endocrinol.* **17**, 195–206 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41574-020-00451-4)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33469209)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053333)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Current%20understanding%20of%20the%20molecular%20and%20cellular%20pathology%20of%20diabetic%20retinopathy&journal=Nat.%20Rev.%20Endocrinol.&doi=10.1038%2Fs41574-020-00451-4&volume=17&pages=195-206&publication_year=2021&author=Antonetti%2CDA&author=Silva%2CPS&author=Stitt%2CAW)\\n\\nWorld Health Organization. *Classification of Diabetes Mellitus* (World Health Organization, 2019).\\n\\n[Download references](https://citation-needed.springer.com/v2/references/10.1038/s41392-024-01951-9?format=refman&flavour=references)\\n\\n## Acknowledgements\\n\\nThis work was supported by the National Nature Science Foundation of China (82170830), grants from the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYGD 18017), and grants from Nature Science Foundation of Department of Science and Technology of Sichuan Province (China) (2023YFS0078). We acknowledge the contribution of Huang Jishu from East China of Architectural Design & Research Institute in the beautification of the images in this article.\\n\\n## Author information\\n\\nThese authors contributed equally: Xi Lu, Qingxing Xie, Xiaohui Pan\\n\\n### Authors and Affiliations\\n\\nDepartment of Endocrinology and Metabolism, Research Centre for Diabetes and Metabolism, West China Hospital, Sichuan University, Chengdu, China\\n\\nXi Lu,\\xa0Qingxing Xie,\\xa0Xiaohui Pan,\\xa0Ruining Zhang,\\xa0Xinyi Zhang,\\xa0Ge Peng,\\xa0Yuwei Zhang,\\xa0Sumin Shen\\xa0&\\xa0Nanwei Tong\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xi%20Lu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xi%20Lu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Qingxing%20Xie)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Qingxing%20Xie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaohui%20Pan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaohui%20Pan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ruining%20Zhang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ruining%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xinyi%20Zhang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xinyi%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ge%20Peng)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ge%20Peng%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yuwei%20Zhang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yuwei%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sumin%20Shen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sumin%20Shen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nanwei%20Tong)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nanwei%20Tong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\n### Contributions\\n\\nConceptualization, Tong NW and Lu X; methodology, Tong NW, Lu X, Xie QX and Pan XH; writing —original draft preparation, Lu X, Xie QX and Zhang RN; writing—review and editing, Lu X, Xie QX, Pan XH, Zhang XY, Peng G, Zhang YW, Shen SM; supervision, Tong NW. All the authors have read and agreed to the published version of the manuscript.\\n\\n### Corresponding author\\n\\nCorrespondence to\\n[Nanwei Tong](mailto:tongnw@scu.edu.cn).\\n\\n## Ethics declarations\\n\\n### Competing interests\\n\\nThe authors declare no competing interests.\\n\\n## Rights and permissions\\n\\n**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.\\n\\n[Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Type%202%20diabetes%20mellitus%20in%20adults%3A%20pathogenesis%2C%20prevention%20and%20therapy&author=Xi%20Lu%20et%20al&contentID=10.1038%2Fs41392-024-01951-9&copyright=The%20Author%28s%29&publication=2059-3635&publicationDate=2024-10-02&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY)\\n\\n## About this article\\n\\n![Check for updates. Verify currency and authenticity via CrossMark](data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>)\\n\\n### Cite this article\\n\\nLu, X., Xie, Q., Pan, X. *et al.* Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.\\n*Sig Transduct Target Ther* **9**, 262 (2024). https://doi.org/10.1038/s41392-024-01951-9\\n\\n[Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41392-024-01951-9?format=refman&flavour=citation)\\n\\nReceived: 01 June 2023\\n\\nRevised: 21 July 2024\\n\\nAccepted: 06 August 2024\\n\\nPublished: 02 October 2024\\n\\nDOI: https://doi.org/10.1038/s41392-024-01951-9\\n\\n### Share this article\\n\\nAnyone you share the following link with will be able to read this content:\\n\\nSorry, a shareable link is not currently available for this article.\\n\\nProvided by the Springer Nature SharedIt content-sharing initiative\\n\\nAdvertisement\\n\\n![Advertisement](//pubads.g.doubleclick.net/gampad/ad?iu=/285/sigtrans.nature.com/article&sz=300x250&c=-222219073&t=pos%3Dright%26type%3Darticle%26artid%3Ds41392-024-01951-9%26doi%3D10.1038/s41392-024-01951-9%26subjmeta%3D163,2743,317,565,692,699,700%26kwrd%3DEndocrine+system+and+metabolic+diseases,Metabolic+disorders,Therapeutics)\\n\\n## Explore content\\n\\n## About the journal\\n\\n## Publish with us\\n\\n## Search\\n\\n### Quick links\\n\\nSignal Transduction and Targeted Therapy\\n(*Sig Transduct Target Ther*)\\n\\nISSN 2059-3635 (online)\\n\\n## nature.com sitemap\\n\\n### About Nature Portfolio\\n\\n### Discover content\\n\\n### Publishing policies\\n\\n### Author & Researcher services\\n\\n### Libraries & institutions\\n\\n### Advertising & partnerships\\n\\n### Professional development\\n\\n### Regional websites\\n\\n![Springer Nature](/static/images/logos/sn-logo-white-ea63208b81.svg)\\n\\n© 2025 Springer Nature Limited\\n\\n![](https://verify.nature.com/verify/nature.png)'},\n",
       "  {'title': 'Genetic drivers of heterogeneity in type 2 diabetes pathophysiology',\n",
       "   'url': 'https://www.nature.com/articles/s41586-024-07019-6',\n",
       "   'content': 'Diabetes mellitus is a huge public-health burden, with an estimated prevalence of 537 million adults worldwide in 2021, of whom more than 90% are affected by T2D 6.The biological processes through',\n",
       "   'score': 0.34773698,\n",
       "   'raw_content': 'Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain\\nthe best experience, we recommend you use a more up to date browser (or turn off compatibility mode in\\nInternet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles\\nand JavaScript.\\n\\nAdvertisement\\n\\n![Advertisement](//pubads.g.doubleclick.net/gampad/ad?iu=/285/nature.com/article&sz=728x90&c=-1178596502&t=pos%3Dtop%26type%3Darticle%26artid%3Ds41586-024-07019-6%26doi%3D10.1038/s41586-024-07019-6%26techmeta%3D43,45%26subjmeta%3D114,137,205,208,2138,2743,631,692,699,721%26kwrd%3DComputational+biology+and+bioinformatics,Diabetes,Genetic+markers,Genome-wide+association+studies)\\n![Nature](https://media.springernature.com/full/nature-cms/uploads/product/nature/header-86f1267ea01eccd46b530284be10585e.svg)\\n\\n# Genetic drivers of heterogeneity in type 2 diabetes pathophysiology\\n\\n[*Nature*](/)\\n**volume\\xa0627**,\\xa0pages 347–357 (2024)[Cite this article](#citeas)\\n\\n110k Accesses\\n\\n126 Citations\\n\\n806 Altmetric\\n\\n[Metrics details](/articles/s41586-024-07019-6/metrics)\\n\\n### Subjects\\n\\n## Abstract\\n\\nType 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes[1](/articles/s41586-024-07019-6#ref-CR1 \"McCarthy, M. I. Painting a new picture of personalised medicine for diabetes. Diabetologia 60, 793–799 (2017).\"),[2](/articles/s41586-024-07019-6#ref-CR2 \"Pearson, E. R. Type 2 diabetes: a multifaceted disease. Diabetologia 62, 1107–1112 (2019).\") and molecular mechanisms that are often specific to cell type[3](/articles/s41586-024-07019-6#ref-CR3 \"Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat. Genet. 50, 559–571 (2018).\"),[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"). Here, to characterize the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study data from 2,535,601 individuals (39.7% not of European ancestry), including 428,452 cases of T2D. We identify 1,289 independent association signals at genome-wide significance (*P*\\u2009<\\u20095\\u2009×\\u200910−8) that map to 611 loci, of which 145 loci are, to our knowledge, previously unreported. We define eight non-overlapping clusters of T2D signals that are characterized by distinct profiles of cardiometabolic trait associations. These clusters are differentially enriched for cell-type-specific regions of open chromatin, including pancreatic islets, adipocytes, endothelial cells and enteroendocrine cells. We build cluster-specific partitioned polygenic scores[5](/articles/s41586-024-07019-6#ref-CR5 \"Udler, M. S., McCarthy, M. I., Florez, J. C. & Mahajan, A. Genetic risk scores for diabetes diagnosis and precision medicine. Endocr. Rev. 40, 1500–1520 (2019).\") in a further 279,552 individuals of diverse ancestry, including 30,288 cases of T2D, and test their association with T2D-related vascular outcomes. Cluster-specific partitioned polygenic scores are associated with coronary artery disease, peripheral artery disease and end-stage diabetic nephropathy across ancestry groups, highlighting the importance of obesity-related processes in the development of vascular outcomes. Our findings show the value of integrating multi-ancestry genome-wide association study data with single-cell epigenomics to disentangle the aetiological heterogeneity that drives the development and progression of T2D. This might offer a route to optimize global access to genetically informed diabetes care.\\n\\n### Similar content being viewed by others\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-024-02865-3/MediaObjects/41591_2024_2865_Fig1_HTML.png)\\n\\n### [Multi-ancestry polygenic mechanisms of type 2 diabetes](https://www.nature.com/articles/s41591-024-02865-3?fromPaywallRec=false)\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41574-025-01132-w/MediaObjects/41574_2025_1132_Fig1_HTML.png)\\n\\n### [Diabetes mellitus polygenic risk scores: heterogeneity and clinical translation](https://www.nature.com/articles/s41574-025-01132-w?fromPaywallRec=false)\\n\\n![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41588-022-01058-3/MediaObjects/41588_2022_1058_Fig1_HTML.png)\\n\\n### [Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation](https://www.nature.com/articles/s41588-022-01058-3?fromPaywallRec=false)\\n\\n## Main\\n\\nDiabetes mellitus is a huge public-health burden, with an estimated prevalence of 537\\u2009million adults worldwide in 2021, of whom more than 90% are affected by T2D[6](/articles/s41586-024-07019-6#ref-CR6 \"International Diabetes Federation. IDF Diabetes Atlas 10th edn \\n                  https://diabetesatlas.org/\\n                  \\n                 (IDF, 2021).\"). The biological processes through which T2D develops are diverse and include impaired insulin secretion and insulin resistance. This aetiological heterogeneity leads to substantial variability in patient phenotypes, including age of disease onset, manifestation of disease complications and response to management strategies[1](/articles/s41586-024-07019-6#ref-CR1 \"McCarthy, M. I. Painting a new picture of personalised medicine for diabetes. Diabetologia 60, 793–799 (2017).\"),[2](/articles/s41586-024-07019-6#ref-CR2 \"Pearson, E. R. Type 2 diabetes: a multifaceted disease. Diabetologia 62, 1107–1112 (2019).\"). Although environment and lifestyle are well-established risk factors for T2D, heritability has been estimated to be 69% amongst individuals of 35–60 years of age[7](/articles/s41586-024-07019-6#ref-CR7 \"Almgren, P. et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 54, 2811–2819 (2011).\"). Previous genome-wide association studies (GWASs) of T2D have identified more than 500 risk loci[8](/articles/s41586-024-07019-6#ref-CR8 \"Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52, 680–691 (2020).\"),[9](/articles/s41586-024-07019-6#ref-CR9 \"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).\"), which showed variable patterns of association with clinical features mediated by effector genes acting through distinct molecular mechanisms that are often cell-type specific[3](/articles/s41586-024-07019-6#ref-CR3 \"Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat. Genet. 50, 559–571 (2018).\"),[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"). Through the newly established Type 2 Diabetes Global Genomics Initiative, we present findings from a very large meta-analysis of T2D GWAS data, comprising more than 2.5\\u2009million individuals of diverse ancestry—an increase of nearly threefold in the effective sample size compared with previous efforts[8](/articles/s41586-024-07019-6#ref-CR8 \"Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52, 680–691 (2020).\"),[9](/articles/s41586-024-07019-6#ref-CR9 \"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).\"). We take advantage of the power afforded by this increased sample size and combine the GWAS data with emerging single-cell functional genomics data derived from disease-relevant tissues to uncover the aetiological heterogeneity of T2D. Furthermore, we construct partitioned polygenic scores (PSs)[5](/articles/s41586-024-07019-6#ref-CR5 \"Udler, M. S., McCarthy, M. I., Florez, J. C. & Mahajan, A. Genetic risk scores for diabetes diagnosis and precision medicine. Endocr. Rev. 40, 1500–1520 (2019).\") across multiple ancestry groups, and assess their association with T2D-related macrovascular outcomes and progression to microvascular complications.\\n\\n## Study overview\\n\\nWe assembled GWAS data, including 428,452 cases of T2D and 2,107,149 controls (Supplementary Fig. [1](/articles/s41586-024-07019-6#MOESM1) and Supplementary Tables [1](/articles/s41586-024-07019-6#MOESM3) and [2](/articles/s41586-024-07019-6#MOESM3)). We organized these GWASs into six subsets of genetically similar studies, which we refer to as ‘ancestry groups’ (Extended Data Fig. [1](/articles/s41586-024-07019-6#Fig4)). Specifically, we considered: a European ancestry group (EUR, 60.3% of the effective sample size); an East Asian ancestry group (EAS, 19.8%); an admixed African American group with ancestry predominantly from West Africa and Europe (AFA, 10.5%); an admixed Hispanic group with ancestry predominantly from the Americas, West Africa and Europe (HIS, 5.9%); a South Asian ancestry group (SAS, 3.3%); and a South African ancestry group (SAF, 0.2%). Association analyses accounted for study-level population structure and relatedness, and adjusted for age and sex, where appropriate, and additional study-specific covariates (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3) and [Methods](/articles/s41586-024-07019-6#Sec10)).\\n\\n## Discovery of T2D loci\\n\\nWe aggregated association summary statistics across GWASs through multi-ancestry meta-regression, implemented in MR-MEGA (ref. [10](/articles/s41586-024-07019-6#ref-CR10 \"Mägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet. 26, 3639–3650 (2017).\")), which allows for allelic effect heterogeneity that is correlated with ancestry. We included three axes of genetic variation as covariates in the meta-regression model that separated GWASs from different ancestry groups (Extended Data Fig. [1](/articles/s41586-024-07019-6#Fig4) and [Methods](/articles/s41586-024-07019-6#Sec10)), which resulted in lower genomic control inflation than did a fixed-effects meta-analysis (*λ*GC\\u2009=\\u20091.120 and *λ*GC\\u2009=\\u20091.396, respectively).\\n\\nThe DIAMANTE Consortium previously advocated the use of a multi-ancestry genome-wide significance threshold (*P*\\u2009<\\u20095\\u2009×\\u200910−9) to define loci, which takes account of the weaker linkage disequilibrium (LD) between single-nucleotide variants (SNVs) expected after multi-ancestry meta-analysis[9](/articles/s41586-024-07019-6#ref-CR9 \"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).\"). To gain insight into true positive signals meeting conventional genome-wide significance (*P*\\u2009<\\u20095\\u2009×\\u200910−8) that would be overlooked at this more stringent threshold, we considered loci reported by the DIAMANTE Consortium, which contributed 39.5% of the effective sample size of the current study. Of 39 loci with association signals meeting 5\\u2009×\\u200910−9\\u2009≤\\u2009*P*\\u2009<\\u20095\\u2009×\\u200910−8 in the DIAMANTE Consortium analysis, 36 (92.3%) attained multi-ancestry genome-wide significance with the larger sample size available to us in the current study ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1)). We therefore focused our downstream analyses on SNVs that met the conventional genome-wide significance threshold.\\n\\nWe identified a total of 1,289 distinct T2D association signals (*P*\\u2009<\\u20095\\u2009×\\u200910−8) that were represented by independent (*r*2\\u2009<\\u20090.05) index SNVs (Supplementary Fig. [2](/articles/s41586-024-07019-6#MOESM1), Supplementary Table [4](/articles/s41586-024-07019-6#MOESM3) and [Methods](/articles/s41586-024-07019-6#Sec10)). The 1,289 association signals mapped to 611 loci, of which 145 (23.7%) loci\\xa0have not to our knowledge been previously reported in GWASs of T2D. At association signals that mapped to loci not previously reported for T2D, index SNVs were predominantly common (minor allele frequency (MAF) higher than 5% in at least one ancestry group) with odds ratios (ORs) lower than 1.05 (Supplementary Fig. [3](/articles/s41586-024-07019-6#MOESM1)).\\n\\n## Mechanistic clusters of T2D index SNVs\\n\\nTo understand the genetic contribution to phenotypic heterogeneity in T2D, we classified the 1,289 index SNVs according to their profile of associations (aligned to the T2D risk allele) with 37 cardiometabolic phenotypes. These included glycaemic traits, anthropometric measures, body fat and adipose tissue volume, blood pressure, levels of circulating plasma lipids, and biomarkers of liver function and lipid metabolism[11](#ref-CR11 \"Warrington, N. M. et al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nat. Genet. 51, 804–814 (2019).\"),[12](#ref-CR12 \"Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. Nat. Genet. 53, 840–860 (2021).\"),[13](#ref-CR13 \"Liu, Y. et al. Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. eLife 10, e65554 (2021).\"),[14](#ref-CR14 \"Sulc, J. et al. Composite trait Mendelian randomization reveals distinct metabolic and lifestyle consequences of differences in body shape. Commun. Biol. 4, 1064 (2021).\"),[15](#ref-CR15 \"Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021).\"),[16](#ref-CR16 \"Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679 (2021).\"),[17](#ref-CR17 \"Agrawal, S. et al. Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. Nat. Commun. 13, 3771 (2022).\"),[18](#ref-CR18 \"Warren, H. et al. Genome-wide analysis in over 1 million individuals reveals over 2,000 independent genetic signals for blood pressure. Preprint at \\n                  https://doi.org/10.21203/rs.3.rs-1409164/v1\\n                  \\n                 (2022).\"),[19](/articles/s41586-024-07019-6#ref-CR19 \"Broadaway, K. A. et al. Loci for insulin processing and secretion provide insight into type 2 diabetes risk. Am. J .Hum. Genet. 110, 284–299 (2023).\") (Supplementary Table [5](/articles/s41586-024-07019-6#MOESM3)). We applied an unsupervised ‘hard clustering’ approach with imputation of missing phenotype associations, which identified eight non-overlapping but exhaustive subsets of index SNVs with similar cardiometabolic profiles (Fig. [1](/articles/s41586-024-07019-6#Fig1), Table [1](/articles/s41586-024-07019-6#Tab1), Extended Data Fig. [2](/articles/s41586-024-07019-6#Fig5), Supplementary Fig. [4](/articles/s41586-024-07019-6#MOESM1), Supplementary Tables [6](/articles/s41586-024-07019-6#MOESM3) and [7](/articles/s41586-024-07019-6#MOESM3) and [Methods](/articles/s41586-024-07019-6#Sec10)).\\n\\n![figure 1](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_Fig1_HTML.png)\\n\\nEach column corresponds to a cluster. Each row corresponds to a cardiometabolic phenotype. The ‘temperature’ of each cell represents the *z*-score (aligned to the T2D risk allele) of association of the phenotype with index SNVs assigned to the cluster. \\\\*Phenotype is adjusted for body mass index.\\n\\nWe observed that the cardiometabolic features and loci of five of our identified clusters overlapped with those reported in previous efforts[3](/articles/s41586-024-07019-6#ref-CR3 \"Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat. Genet. 50, 559–571 (2018).\"),[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"),[20](/articles/s41586-024-07019-6#ref-CR20 \"Kim, H. et al. High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease. Diabetologia 66, 495–507 (2023).\"),[21](/articles/s41586-024-07019-6#ref-CR21 \"Smith, K. et al. Multi-ancestry polygenic mechanisms of type 2 diabetes elucidate disease processes and clinical heterogeneity. Nat. Med. (in the press).\"), representing beta-cell dysfunction with a positive or negative association with proinsulin (PI), and insulin resistance mediated through obesity, lipodystrophy, and liver and lipid metabolism (Supplementary Table [8](/articles/s41586-024-07019-6#MOESM3)). T2D risk alleles at index SNVs in the two beta-cell-dysfunction clusters are associated with increased fasting glucose, two-hour glucose and glycated haemoglobin, and with decreased fasting insulin. Index SNVs in both clusters are also associated with PI, but with opposite directions of effect for the T2D risk allele. The clusters reflecting mechanisms of insulin resistance mediated through obesity, lipodystrophy, and liver and lipid metabolism include index SNVs that are associated with anthropometric measures and levels of circulating plasma lipids. T2D risk alleles at index SNVs in the obesity cluster are associated with increased body mass index (BMI), waist–hip ratio (WHR), body fat percentage and basal metabolic rate, and with decreased high-density lipoprotein (HDL) cholesterol. The lipodystrophy cluster comprises index SNVs for which T2D risk alleles are associated with increased fasting insulin, WHR, blood pressure and triglycerides, and with decreased body fat percentage, gluteofemoral adipose tissue (GFAT) volume and HDL cholesterol. T2D risk alleles at index SNVs assigned to the liver and lipid metabolism cluster are associated with increased liver fat and liver-related biomarkers, and with decreased low-density lipoprotein (LDL) cholesterol and total cholesterol.\\n\\nBy increasing the number of index SNVs in the clustering by nearly fourfold relative to previous efforts, we provide a more granular view of the biological processes through which T2D associations affect disease, and highlight three previously unreported clusters of signals with cardiometabolic profiles that are representative of metabolic syndrome, body fat and residual glycaemic effects. We observed significantly weaker allelic effects on T2D in these three clusters than in those previously reported (mean OR of 1.028 versus 1.033, *P*\\u2009=\\u20092.2\\u2009×\\u200910−7), but there was no noticeable difference in disparity around the centroid between clusters (Extended Data Fig. [3](/articles/s41586-024-07019-6#Fig6), Supplementary Table [9](/articles/s41586-024-07019-6#MOESM3) and Supplementary Fig. [5](/articles/s41586-024-07019-6#MOESM1)). T2D risk alleles at index SNVs assigned to the metabolic syndrome cluster are associated with increased fasting glucose, WHR, triglycerides and blood pressure, and with decreased HDL cholesterol, which together are used to define metabolic syndrome. T2D risk alleles in this cluster are also associated with increased fasting insulin, with accumulations of unhealthy fat depots (increased visceral adipose tissue (VAT) volume and liver fat) and with decreased GFAT volume. Previous investigations have shown that\\xa0individuals with metabolic syndrome are at increased risk of T2D[22](/articles/s41586-024-07019-6#ref-CR22 \"Ford, E. S., Li, C. & Sattar, N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31, 1898–1904 (2008).\"), although Mendelian randomization studies indicate that a causal effect is driven by increased waist circumference and increased fasting glucose[23](/articles/s41586-024-07019-6#ref-CR23 \"Marott, S. C., Nordestgaard, B. G., Tybjærg-Hansen, A. & Benn, M. Components of the metabolic syndrome and risk of type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 3212–3221 (2016).\"). T2D risk alleles at index SNVs assigned to the body fat cluster are associated with increased abdominal subcutaneous adipose tissue volume, VAT volume and body fat percentage. Although the body fat cluster profile of associations with cardiometabolic phenotypes shares these features in common with obesity-mediated insulin resistance, index SNVs in the body fat cluster are not strongly associated with BMI, lipid levels or basal metabolic rate. Previous investigations have highlighted that body fat percentage is predictive of abnormal blood glucose in individuals with a healthy BMI[24](/articles/s41586-024-07019-6#ref-CR24 \"Jo, A. & Mainous, A. G. 3rd Informational value of percent body fat with body mass index for the risk of abnormal blood glucose: a nationally representative cross-sectional study. BMJ Open 8, e019200 (2018).\"). Finally, T2D risk alleles at index SNVs assigned to the residual glycaemic cluster are most strongly associated with increased fasting glucose and glycated haemoglobin, but, unlike the two beta-cell-dysfunction clusters, are not associated with PI or decreased fasting insulin.\\n\\nClustering provides a framework to better understand the diverse physiological processes through which T2D develops and the shared biological pathways that drive genetic correlations with other insulin-resistance-related disorders, including gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS). T2D risk alleles at index SNVs showed a gradient of effects on insulin-related endophenotypes across clusters ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1), Extended Data Fig. [4](/articles/s41586-024-07019-6#Fig7) and Supplementary Tables [10](/articles/s41586-024-07019-6#MOESM3) and [11](/articles/s41586-024-07019-6#MOESM3)), representing a cline from insulin production and processing in the two beta-cell-dysfunction clusters through to insulin resistance that was most extreme in the lipodystrophy cluster. Index SNVs in the beta cell +PI cluster showed the strongest associations with GDM, whereas those in the obesity cluster were most strongly associated with PCOS ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1), Extended Data Fig. [5](/articles/s41586-024-07019-6#Fig8) and Supplementary Table [12](/articles/s41586-024-07019-6#MOESM3)).\\n\\n## Regulatory processes underlying clusters\\n\\nTo gain insight into tissue-specific regulatory processes underpinning mechanistic clusters, we integrated T2D association signals with assay for transposase-accessible chromatin using sequencing (ATAC-seq) peaks from single-cell atlases of chromatin accessibility (CATLAS and DESCARTES) for 222 cell types derived from 30 human adult and 15 human fetal tissues[25](/articles/s41586-024-07019-6#ref-CR25 \"Domcke, S. et al. A human cell atlas of fetal chromatin accessibility. Science 370, eaba7612 (2020).\"),[26](/articles/s41586-024-07019-6#ref-CR26 \"Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985–6001 (2021).\") and an additional 106 cell types from the human brain[27](/articles/s41586-024-07019-6#ref-CR27 \"Li, Y. E. et al. A comparative atlas of single-cell chromatin accessibility in the human brain. Science 382, eadf7044 (2023).\") (Fig. [2](/articles/s41586-024-07019-6#Fig2), Supplementary Tables [13](/articles/s41586-024-07019-6#MOESM3) and [14](/articles/s41586-024-07019-6#MOESM3) and [Methods](/articles/s41586-024-07019-6#Sec10)).\\n\\n![figure 2](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_Fig2_HTML.png)\\n\\n**a**, Cell types (222 types) from 30 human adult tissues and 15 human fetal tissues. **b**, Cell types (106 types) from the human brain. In each panel, columns represent mechanistic clusters. Each row represents a cell type that was significantly enriched (Bonferroni correction for the number of cell types) for T2D associations in at least one cluster (indicated by an asterisk). The ‘temperature’ of each cell defines the magnitude of the log fold enrichment. The liver and lipid metabolism cluster is not presented because it includes only three T2D association signals and the model parameter estimates were unstable.\\n\\nWe observed significant enrichment for regions of open chromatin in fetal islets and adult neuroendocrine cells in pancreatic islets (alpha, beta, gamma and delta) in the beta cell +PI, beta cell −PI and residual glycaemic clusters. In addition, the residual glycaemic cluster was enriched in fetal and adult pancreatic ductal cells, whereas the beta cell −PI cluster was enriched in adult enterochromaffin cells—a type of enteroendocrine cell that has an essential role in regulating intestinal motility and secretion in the gastrointestinal tract[28](/articles/s41586-024-07019-6#ref-CR28 \"Bertrand, P. P. & Bertrand, R. L. Serotonin release and uptake in the gastrointestinal tract. Auton. Neurosci. 153, 47–57 (2010).\"). Enterochromaffin cells are a major target for glucagon-like peptide 1 (GLP-1) and highly express the GLP-1 receptor, agonists of which are widely used as medications for T2D[29](/articles/s41586-024-07019-6#ref-CR29 \"Lund, M. L. et al. Enterochromaffin 5-HT cells—a major target for GLP-1 and gut microbial metabolites. Mol. Metab. 11, 70–83 (2018).\") ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1)).\\n\\nThe obesity cluster was also significantly enriched for regions of open chromatin in adult pancreatic islets, although not as strongly as were the beta-cell-dysfunction clusters. Enrichment was observed only for alpha, gamma and delta cells, suggesting that there are alternative pathways through which islets affect the development of T2D, other than through the secretion of insulin from beta cells. The obesity cluster was further enriched in fetal adrenal gland cells (chromaffin cells and adrenal neurons), fetal heart cells (ventricular cardiomyocytes) and fetal kidney cells (metanephric cells). Previous studies have reported an enrichment of BMI loci\\xa0or\\xa0heritability for epigenomic annotations in pancreatic islets and adrenal gland[30](/articles/s41586-024-07019-6#ref-CR30 \"Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).\"),[31](/articles/s41586-024-07019-6#ref-CR31 \"Akiyama, M. et al. Genome-wide association study identifies 112 new loci for body mass index in the Japanese population. Nat. Genet. 49, 1458–1467 (2017).\"), consistent with our findings. In the human brain, the obesity cluster was significantly enriched for regions of open chromatin in cell types including intratelencephalic (IT) projecting neurons, somatostatin-positive (SST+) GABAergic inhibitory neurons and D1 medium spiny neurons. SST+ GABAergic neurons exist in the hypothalamus and regulate food intake[32](/articles/s41586-024-07019-6#ref-CR32 \"Suyama, S. & Yada, T. New insight into GABAergic neurons in the hypothalamic feeding regulation. J. Physiol. Sci. 68, 717–722 (2018).\"). D1 medium spiny neurons are a type of GABAergic neuron in the human striatum that expresses D1-type dopamine receptors; these neurons have been implicated in food motivation and the development of diet-induced obesity in mice[33](/articles/s41586-024-07019-6#ref-CR33 \"Matikainen-Ankney, B. A. et al. Nucleus accumbens D1 receptor-expressing spiny projection neurons control food motivation and obesity. Biol. Psychiatry 93, 512–523 (2023).\").\\n\\nThe remaining four clusters (lipodystrophy; metabolic syndrome; body fat; and liver and lipid metabolism) were not significantly enriched for regions of open chromatin in pancreatic islets. The lipodystrophy cluster was enriched only in adult adipocytes, which confirms previous reports in bulk adipose tissue[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"),[20](/articles/s41586-024-07019-6#ref-CR20 \"Kim, H. et al. High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease. Diabetologia 66, 495–507 (2023).\"). Consistent with these results, association signals for WHR, triglycerides and HDL cholesterol, which are strongly affected by index SNVs in the lipodystrophy cluster, have been shown to be enriched in candidate *cis*-regulatory elements in adipocytes[26](/articles/s41586-024-07019-6#ref-CR26 \"Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985–6001 (2021).\"). The metabolic syndrome cluster was enriched in cells that reside in the walls of blood vessels (adult pericytes and fetal endothelial cells), fetal kidney cells (mesangial cells) and fetal fibroblasts. Association signals for systolic and diastolic blood pressure, a key component of metabolic syndrome, have been shown to be enriched in candidate *cis*-regulatory elements in these cell types[26](/articles/s41586-024-07019-6#ref-CR26 \"Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985–6001 (2021).\"). Endothelial dysfunction is not only a consequence of insulin resistance, but also impairs insulin signalling to further reduce insulin sensitivity, thereby providing a pathophysiological mechanism that links the metabolic and cardiovascular components of metabolic syndrome[34](/articles/s41586-024-07019-6#ref-CR34 \"Kim, J. A., Montagnani, M., Koh, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888–1904 (2006).\"). In human brain, the metabolic syndrome cluster was significantly enriched for regions of open chromatin in cell types including IT projecting neurons and SST+ GABAergic inhibitory neurons. IT projecting neurons are a type of glutamatergic excitatory pyramidal neuron in the cerebral cortex, and metabolic syndrome was previously associated with pyramidal neurons and GABAergic neurons in cell-type specificity analyses in a GWAS that examined genetic factors in metabolic syndrome[35](/articles/s41586-024-07019-6#ref-CR35 \"van Walree, E. S. et al. Disentangling genetic risks for metabolic syndrome. Diabetes 71, 2447–2457 (2022).\"). We observed no significant enrichments in the body fat cluster or in the liver and lipid metabolism cluster.\\n\\n## Ancestry-correlated heterogeneity\\n\\nPrevious multi-ancestry GWASs have shown widespread heterogeneity in allelic effects at T2D association signals across ancestry groups[9](/articles/s41586-024-07019-6#ref-CR9 \"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).\"),[36](/articles/s41586-024-07019-6#ref-CR36 \"Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 570, 514–518 (2019).\"). We took advantage of the meta-regression model to partition heterogeneity into an ancestry-correlated component explained by three axes of genetic variation, and a residual component reflecting differences in environmental exposures (that are not correlated with ancestry) and/or study design (Supplementary Table [15](/articles/s41586-024-07019-6#MOESM3)). We observed 127 (9.9%) independent T2D association signals with significant evidence for ancestry-correlated heterogeneity (*P*HET\\u2009<\\u20093.9\\u2009×\\u200910−5, Bonferroni correction for 1,289 signals). We would expect less than one signal to meet this threshold of significance, highlighting that ancestry-correlated heterogeneity is strongly enriched at T2D associations (one-sided binomial test *P*\\u2009<\\u20092.2\\u2009×\\u200910−16). By contrast, we observed significant evidence of residual heterogeneity at only four (0.3%) association signals (one-sided binomial test *P*\\u2009=\\u20090.031). These results therefore suggest that differences in allelic effects at index SNVs are more strongly correlated with genetic ancestry than other factors that vary between GWASs.\\n\\nWe next sought to better understand the impact of genetic diversity on differences in allelic effects between GWASs at the 127 association signals with significant evidence of ancestry-correlated heterogeneity ([Methods](/articles/s41586-024-07019-6#Sec10)). For 118 (92.9%) signals, allelic effect sizes were most strongly associated with the first two axes of genetic variation, which reflect differences between AFA/EUR and EAS GWASs (AFA–EAS axis), and between AFA/EAS and EUR GWASs (AFA–EUR axis), respectively ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1), Extended Data Figs. [1](/articles/s41586-024-07019-6#Fig4) and\\xa0[6](/articles/s41586-024-07019-6#Fig9) and Supplementary Table [16](/articles/s41586-024-07019-6#MOESM3)).\\n\\nWe observed significant differences in mean *z*-scores for association between clusters for both the AFA–EAS axis (*P*\\u2009=\\u20094.1\\u2009×\\u200910−6) and the AFA–EUR axis (*P*\\u2009=\\u20091.5\\u2009×\\u200910−6). Index SNVs in the two beta-cell-dysfunction clusters were most positively associated with the AFR–EAS axis, indicating allelic effects on T2D that were greater in EAS GWASs\\xa0than in AFA and EUR GWASs (Extended Data Fig. [7](/articles/s41586-024-07019-6#Fig10) and Supplementary Table [17](/articles/s41586-024-07019-6#MOESM3)). By contrast, index SNVs in the lipodystrophy and obesity clusters were most positively associated with the AFA–EUR axis, indicating allelic effects on T2D that were greater in EUR GWASs than in EAS and AFA GWASs. These results indicate that ancestry-correlated heterogeneity varies between mechanistic clusters, with allelic effects greatest for EAS GWASs at association signals assigned to clusters acting through beta-cell dysfunction and greatest for EUR GWASs at those assigned to clusters operating through insulin resistance.\\n\\nAncestry-correlated heterogeneity in allelic effects between GWASs is not driven by differences in allele frequency between ancestry groups, but can occur because of interaction between index SNVs and environmental and lifestyle factors, if not accounted for in the association analysis[37](/articles/s41586-024-07019-6#ref-CR37 \"Petersen, R. E. et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. Cell 179, 589–603 (2019).\"). We observed substantial variation in the distribution of study-level mean BMI in T2D cases and controls across ancestry groups (Supplementary Fig. [6](/articles/s41586-024-07019-6#MOESM1)). Such variation could affect ancestry-correlated heterogeneity because, when cases and controls are selected from the extremes of the BMI distribution, the magnitude of allelic effect estimates at T2D signals acting through beta-cell dysfunction can be inflated[38](/articles/s41586-024-07019-6#ref-CR38 \"Perry, J. R. B. et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet. 8, e1002741 (2012).\"). We therefore extended the MR-MEGA meta-regression model to allow for allelic effect heterogeneity at index SNVs due to mean BMI in T2D cases and controls, in addition to axes of genetic variation ([Methods](/articles/s41586-024-07019-6#Sec10)).\\n\\nAfter adjustment for study-level mean BMI in cases of T2D and in controls, only 24 association signals retained significant evidence of ancestry-correlated heterogeneity (*P*\\u2009<\\u20093.9\\u2009×\\u200910−5), compared with 127 signals without adjustment ([Supplementary Text](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [18](/articles/s41586-024-07019-6#MOESM3)). After adjustment for BMI, significant differences in mean *z*-scores for association between clusters for the AFA–EUR axis were maintained (*P*\\u2009=\\u20093.2\\u2009×\\u200910−5 versus *P*\\u2009=\\u20091.5\\u2009×\\u200910−6 without adjustment), whereas those for the AFA–EAS axis were not (*P*\\u2009=\\u20090.18 versus *P*\\u2009=\\u20094.1\\u2009×\\u200910−6 without adjustment). Furthermore, after adjustment for BMI, the two beta-cell-dysfunction clusters were no longer strongly positively associated with the AFA–EAS axis (Extended Data Fig. [7](/articles/s41586-024-07019-6#Fig10) and Supplementary Table [19](/articles/s41586-024-07019-6#MOESM3)). Together, these results suggest that heterogeneity in allelic effects between EAS GWASs and EUR/AFA GWASs, which occur most often at association signals assigned to the beta-cell-dysfunction clusters, can be mostly accounted for by differences in the distributions of mean BMI in T2D cases and in controls between these ancestry groups.\\n\\n## Associations of partitioned PS with outcomes\\n\\nThe major complications in individuals with T2D are macrovascular outcomes including coronary artery disease (CAD), ischaemic stroke and peripheral artery disease, and microvascular outcomes, including end-stage diabetic nephropathy (ESDN) and proliferative diabetic retinopathy. We tested for association of a cluster-specific partitioned PS with these vascular outcomes in up to 279,552 individuals (including 30,288 cases of T2D) across five ancestry groups (AFA, EAS, EUR, HIS and SAS) from the All of Us Research Program, Biobank Japan and the Genes & Health study ([Methods](/articles/s41586-024-07019-6#Sec10)). These individuals were not included in the multi-ancestry meta-analysis, thus avoiding potential inflated type I error rates owing to overlap between the discovery and the testing datasets. To maximize sample size, we tested macrovascular outcomes in all individuals, adjusted for T2D status, and microvascular complications only in individuals with T2D ([Methods](/articles/s41586-024-07019-6#Sec10) and Supplementary Table [20](/articles/s41586-024-07019-6#MOESM3)). To assess the additional information afforded by the partitioned PS over an overall T2D PS, agnostic to cluster membership, we tested for association of each cluster-specific component of the partitioned PS after adjustment for the overall PS. Figure [3](/articles/s41586-024-07019-6#Fig3) provides an overview of the associations of each cluster-specific component of the partitioned PS with the five vascular outcomes across ancestry groups.\\n\\n![figure 3](//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_Fig3_HTML.png)\\n\\nSummaries of the associations of each cluster-specific component of the partitioned PS with CAD, ischaemic stroke (IS), peripheral artery disease (PAD), ESDN and proliferative diabetic retinopathy (PDR). The height of each bar corresponds to the log-odds ratio (beta) per standard deviation of the PS, and the grey bar shows the 95% confidence interval. Analyses of T2D-related macrovascular complications (CAD, PAD and IS) were undertaken in all individuals, with adjustment for T2D status. Analyses of microvascular complications were undertaken in individuals with T2D only. \\\\**P*\\u2009<\\u20090.05, nominal association; \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are provided in Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3).\\n\\nWe observed a significant association (*P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters) of two components of the partitioned PS with CAD: a negative association with the beta cell +PI cluster (OR\\u2009=\\u20090.96 per standard deviation of the PS, *P*\\u2009=\\u20091.3\\u2009×\\u200910−6) and a positive association with the obesity cluster (OR\\u2009=\\u20091.04, *P*\\u2009=\\u20090.00019). There was no evidence of heterogeneity in the effects of these two clusters on CAD across ancestry groups (Supplementary Fig. [7](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3)). Notably, after adjustment for a CAD PS derived from a previously published multi-ancestry meta-analysis of CAD GWASs[39](/articles/s41586-024-07019-6#ref-CR39 \"Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803–1815 (2022).\"), the positive CAD association with both components of the partitioned PS remained significant (Extended Data Fig. [8](/articles/s41586-024-07019-6#Fig11) and Supplementary Table [22](/articles/s41586-024-07019-6#MOESM3)): beta cell +PI cluster (OR\\u2009=\\u20090.96, *P*\\u2009=\\u20094.4\\u2009×\\u200910−5) and obesity cluster (OR\\u2009=\\u20091.04, *P*\\u2009=\\u20090.00065). We also observed a significant positive association of the obesity cluster from the partitioned PS with peripheral artery disease (OR\\u2009=\\u20091.05, *P*\\u2009=\\u20090.00045), with no evidence of heterogeneity in effects across ancestry groups (Supplementary Fig. [8](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3)). Across all three macrovascular outcomes, there was a general trend of negative association with the beta cell +PI cluster and positive association with the obesity cluster, although no cluster-specific components of the partitioned PS attained significance for ischaemic stroke (Supplementary Fig. [9](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3)). There was no strong association of the overall T2D PS with CAD (*P*\\u2009=\\u20090.17), ischaemic stroke (*P*\\u2009=\\u20090.022) or peripheral artery disease (*P*\\u2009=\\u20090.77) after meta-analysis across ancestry groups. Together, these results highlight the advantages of the partitioned PS over an overall T2D PS for detecting associations with macrovascular outcomes, and provide insight into the biological processes that lead to their development.\\n\\nWe observed significant associations of two components of the partitioned PS with ESDN: a negative association with the beta cell +PI cluster (OR\\u2009=\\u20090.83, *P*\\u2009=\\u20090.00024) and a positive association with the obesity cluster (OR\\u2009=\\u20091.19, *P*\\u2009=\\u20090.00050). There was no evidence of heterogeneity in the effects of these two clusters across ancestry groups, (Supplementary Fig. [10](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3)), and the overall PS was not strongly associated with ESDN (*P*\\u2009=\\u20090.048). By contrast, none of the cluster-specific components of the partitioned PS were associated with proliferative diabetic retinopathy. However, there was a strong positive association of the overall PS with this microvascular outcome (OR\\u2009=\\u20091.32, *P*\\u2009=\\u20091.1\\u2009×\\u200910−9), with no evidence of heterogeneity in effects across ancestry groups (Supplementary Fig. [11](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [21](/articles/s41586-024-07019-6#MOESM3)). Together, these results suggest that ESDN is associated with obesity and beta-cell dysfunction with opposite directions of effect, and confirm previous reports that proliferative diabetic retinopathy is driven by hyperglycaemia[40](/articles/s41586-024-07019-6#ref-CR40 \"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).\") and therefore strongly associated with the overall burden of T2D risk variants.\\n\\nFinally, we tested for associations of the cluster-specific components of the partitioned PS and the overall T2D PS with age of onset of T2D (Extended Data Fig. [9](/articles/s41586-024-07019-6#Fig12) and [Methods](/articles/s41586-024-07019-6#Sec10)). The overall PS was strongly associated with an earlier age of onset (1.15 years per standard deviation of the PS, *P*\\u2009=\\u20095.1\\u2009×\\u200910−8), although the effects were highly heterogeneous across ancestry groups (Supplementary Fig. [12](/articles/s41586-024-07019-6#MOESM1) and Supplementary Table [23](/articles/s41586-024-07019-6#MOESM3)). However, even after adjustment for the overall PS, the obesity cluster was significantly associated with an earlier age of onset (0.38 years, *P*\\u2009=\\u20091.4\\u2009×\\u200910−7), with no evidence of heterogeneity across ancestry groups. These findings highlight the importance of obesity-related processes for the onset of T2D, in addition to the development of vascular complications.\\n\\n## Associations with vascular outcomes in clinical trials\\n\\nTo gain insight into the associations of the obesity and beta cell +PI clusters with a broader range of vascular outcomes, we assessed the performance of the partitioned PS (after adjustment for the overall PS) in prospective GWASs in up to 29,827 EUR individuals with T2D from six clinical trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group ([Methods](/articles/s41586-024-07019-6#Sec10) and Supplementary Table [24](/articles/s41586-024-07019-6#MOESM3)). We observed the strongest associations of cluster-specific components of the partitioned PS with risk of hospitalization for heart failure: positive with the obesity cluster (hazard ratio (HR)\\u2009=\\u20091.15 per standard deviation of the PS, *P*\\u2009=\\u20094.8\\u2009×\\u200910−6) and negative with the beta cell +PI cluster (HR\\u2009=\\u20090.90, *P*\\u2009=\\u20090.00092). Amongst macrovascular outcomes, the beta cell +PI cluster was also negatively associated with cardiovascular death (HR\\u2009=\\u20090.90, *P*\\u2009=\\u20090.0020), major cardiovascular events (HR\\u2009=\\u20090.94, *P*\\u2009=\\u20090.0050) and myocardial infarction (HR\\u2009=\\u20090.94, *P*\\u2009=\\u20090.027). For microvascular outcomes, the two clusters showed associations with opposite directions of effect for albuminuria: obesity cluster (HR\\u2009=\\u20091.06, *P*\\u2009=\\u20090.012) and beta cell +PI cluster (HR\\u2009=\\u20090.95, *P*\\u2009=\\u20090.047). Across all outcomes, there was a general trend of positive association with the obesity cluster and negative association with the beta cell +PI cluster (Extended Data Fig. [10](/articles/s41586-024-07019-6#Fig13)), consistent with the associations observed from our analyses of retrospective GWASs across ancestry groups.\\n\\n## Discussion\\n\\nTo better understand the aetiological heterogeneity of T2D across diverse populations, we assembled a large collection of T2D GWASs for six\\xa0ancestry groups through the Type 2 Diabetes Global Genomics Initiative. By increasing the effective sample size by almost threefold compared with previous efforts, we identified a total of 611 loci attaining the conventional threshold of genome-wide significance (*P*\\u2009<\\u20095\\u2009×\\u200910−8), 145 (23.7%) of which have not to our knowledge been previously reported. This conventional threshold is equivalent to a Bonferroni correction for the effective number of independent SNVs in EUR reference data[41](/articles/s41586-024-07019-6#ref-CR41 \"Pe’er, I., Yelensky, R., Altshuler, D. & Daly, M. J. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 32, 381–385 (2008).\"). Using empirical data from the 1000 Genomes Project, the DIAMANTE Consortium and others have advocated more stringent thresholds for multi-ancestry meta-analysis because the structure of LD is broken down across ancestry groups and the effective number of independent SNVs is increased[9](/articles/s41586-024-07019-6#ref-CR9 \"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).\"),[42](/articles/s41586-024-07019-6#ref-CR42 \"Kanai, M., Tanaka, T. & Okada, Y. Empirical estimation of genome-wide significance thresholds based on the 1000 Genomes Project data set. J. Hum. Genet. 61, 861–866 (2016).\"). In fact, our analyses suggest that loci meeting conventional genome-wide significance are unlikely to be false positive association signals, but instead are driven by index SNVs that have modest effects that require larger sample sizes to meet more stringent thresholds. We therefore recommend the use of this conventional threshold but advocate careful review of reported signals to ensure that associations are not driven by single studies or poorly imputed variants to protect against false positives.\\n\\nMulti-ancestry meta-regression maximizes power to detect associations that are shared across ancestry groups by allowing for heterogeneity in allelic effects at index SNVs. MR-MEGA is not restricted to broad continental ancestry labels that can be used to reinforce the concept of fundamental genetic differences between groups[43](/articles/s41586-024-07019-6#ref-CR43 \"Carlson, J., Henn, B. M., Al-Hindi, R. R. & Ramachandran, S. Counter the weaponization of genetics research by extremists. Nature 610, 444–447 (2022).\"), but instead represents ancestry as continuous axes of genetic variation, which better reflect the continuum of human genetic diversity and demographic history[44](/articles/s41586-024-07019-6#ref-CR44 \"Lewis, A. C. F. et al. Getting genetic ancestry right for science and society. Science 376, 250–252 (2022).\"). Still, it is important to emphasize that our meta-analysis does not fully capture global genetic diversity, in particular underrepresented populations across Africa, South and Central America, the Middle East and Oceania. For example, 98.2% of the total effective sample size of individuals with the highest proportion of ancestry from Africa are African Americans. The ancestry of these individuals represents a cline of admixture that is predominantly from West Africa and is therefore not representative of other regions in Africa, where the level of genetic variation is equivalent to the differences observed between other continental groups[43](/articles/s41586-024-07019-6#ref-CR43 \"Carlson, J., Henn, B. M., Al-Hindi, R. R. & Ramachandran, S. Counter the weaponization of genetics research by extremists. Nature 610, 444–447 (2022).\"). Bolstering GWAS collections in these underrepresented populations remains an urgent priority for the human genetics research community and highlights the need for careful interpretation of results that does not generalize findings across ancestry groups that are sensitive to biased representation.\\n\\nWithin the landscape of the genetic architecture of T2D, we identified eight clusters of index SNVs with distinct profiles of associations with 37 cardiometabolic phenotypes, which defined pathophysiology-relevant groupings. The addition of previously unreported T2D signals identified through the multi-ancestry meta-analysis helped define three clusters that were not detected in previous clustering efforts[3](/articles/s41586-024-07019-6#ref-CR3 \"Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat. Genet. 50, 559–571 (2018).\"),[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"),[20](/articles/s41586-024-07019-6#ref-CR20 \"Kim, H. et al. High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease. Diabetologia 66, 495–507 (2023).\"),[21](/articles/s41586-024-07019-6#ref-CR21 \"Smith, K. et al. Multi-ancestry polygenic mechanisms of type 2 diabetes elucidate disease processes and clinical heterogeneity. Nat. Med. (in the press).\"), with cardiometabolic profiles that are consistent with residual glycaemic effects, accumulations of body fat and metabolic syndrome. These previous efforts have implemented ‘soft clustering’ approaches, such as Bayesian non-negative matrix factorization, that generate weights for cluster membership for each index SNV[4](/articles/s41586-024-07019-6#ref-CR4 \"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).\"). The assignment of index SNVs to clusters is then determined given a threshold weight for cluster membership, allowing for the possibility that a T2D association signal affects disease through multiple pathophysiological pathways. However, depending on the threshold for cluster membership, some index SNVs will be unassigned. Bayesian non-negative matrix factorization also considers positive and negative associations with the same phenotype as independent variables, and most clustering methods cannot directly accommodate missing phenotype associations. To address these potential limitations, we implemented methodology that jointly conducts *k*-means clustering of index SNVs with powerful iterative multiple imputation of missing phenotype associations. In this ‘hard clustering’ approach, each index SNV is assigned to exactly one cluster. This has the potential disadvantage, therefore, that index SNVs with outlying or intermediate profiles of trait associations are ‘forced’ into a cluster that does not fit well. However, the previously unreported clusters that we identified in our hard clustering were not noticeably more disparate than the clusters reported previously, suggesting that we have not introduced substantial noise by forcing all SNVs into exactly one cluster. Ultimately, the choice of clustering approach may depend on the objectives of any downstream investigations.\\n\\nOur analyses highlighted a significant excess of T2D association signals with ancestry-correlated heterogeneity, which is driven mainly by differences in allelic effects between AFA, EAS and EUR GWASs. The two beta-cell-dysfunction clusters are most strongly associated with the AFA–EAS axis, in which effects are typically larger in EAS GWASs than in those for other ancestry groups. These two clusters are also most strongly associated with reduced insulin secretion and lower insulin resistance. By contrast, the lipodystrophy and obesity clusters, which are characterized by reduced insulin sensitivity and higher insulin resistance, are most strongly associated with the AFA–EUR axis, in which effects are typically larger in EUR than in other ancestry groups. These observations are consistent with studies reporting differences in the pathogenesis of T2D between ancestry groups, whereby T2D is initiated mainly through increased insulin resistance in EUR individuals, but is characterized by reduced insulin secretion with lower insulin resistance in EAS individuals[45](/articles/s41586-024-07019-6#ref-CR45 \"Moller, J. B. et al. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J. Clin. Endocrinol. Metab. 99, 4273–4280 (2014).\"),[46](/articles/s41586-024-07019-6#ref-CR46 \"Yabe, D., Seino, Y., Fukushima, M. & Seino, S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr. Diab. Rep. 15, 602 (2015).\"). We have shown that most signals with ancestry-correlated heterogeneity can be explained by differences in the distribution of BMI in T2D cases and controls between ancestry groups. Furthermore, after adjustment for study-level mean BMI, we observe no difference in allelic effects between clusters along the AFA–EAS axis. This is consistent with previous studies that reported that body composition is the main determinant of variation in T2D pathogenesis between EAS and EUR individuals, because insulin sensitivity and beta-cell response are similar in the two ancestry groups after accounting for differences in BMI[45](/articles/s41586-024-07019-6#ref-CR45 \"Moller, J. B. et al. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J. Clin. Endocrinol. Metab. 99, 4273–4280 (2014).\"),[47](/articles/s41586-024-07019-6#ref-CR47 \"Moller, J. B. et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 37, 796–804 (2014).\").\\n\\nWe reveal—across multiple ancestry groups—significant associations of vascular outcomes with cluster-specific components of the partitioned PS after adjustment for the overall PS, which suggests that disease trajectories are associated with genetic burden in certain biological pathways that are consistent across diverse populations. Although the effect sizes of the cluster-specific components of the partitioned PS were small, they motivate future work to strengthen these effects through the identification of further T2D associations in larger sample sizes. Through integration with single-cell chromatin accessibility data across diverse cell types, they also enhance understanding of key biological processes driving heterogeneity in the clinical features of T2D phenotypes. For example, the obesity-cluster-specific component of the PS was positively associated with CAD and ESDN, and included index SNVs that were enriched for regions of open chromatin in fetal ventricular cardiomyocytes, fetal adrenal neuron, adult chromaffin cells in the adrenal gland and fetal metanephric cells. These findings are in line with the reported enrichments of CAD association signals for transcriptomic and epigenomic annotations in bulk tissues including the aorta and arteries, the heart and the adrenal gland[39](/articles/s41586-024-07019-6#ref-CR39 \"Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803–1815 (2022).\"),[48](/articles/s41586-024-07019-6#ref-CR48 \"Matsunaga, H. et al. Transethnic meta-analysis of genome-wide association studies identifies three new loci and characterizes population-specific differences for coronary artery disease. Circ. Genom. Precis. Med. 13, e002670 (2020).\"),[49](/articles/s41586-024-07019-6#ref-CR49 \"Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat. Genet. 52, 1169–1177 (2020).\"), and of renal function association signals in kidney-tissue-specific regulatory annotations[50](/articles/s41586-024-07019-6#ref-CR50 \"Morris, A. P. et al. Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies. Nat. Commun. 10, 29 (2019).\"). Together, these findings provide a clear link to shared biological mechanisms that drive the development of T2D and other vascular diseases.\\n\\nIn conclusion, our findings show the value of integrating multi-ancestry GWASs of T2D and cardiometabolic traits with single-cell epigenomics across diverse tissues to disentangle the aetiological heterogeneity driving the development and progression of T2D across population groups. Improved understanding of the varied pathophysiological processes that link T2D to vascular outcomes could offer a route to genetically informed diabetes care and global opportunities for the clinical translation of findings from T2D GWASs.\\n\\n## Methods\\n\\n### Study-level analyses\\n\\nWithin each study, we assigned individuals to ancestry groups using self-report and genetic background (Supplementary Tables [1](/articles/s41586-024-07019-6#MOESM3) and [2](/articles/s41586-024-07019-6#MOESM3)). Any individuals not assigned to an ancestry group were excluded as population outliers. Within each ancestry group-specific GWAS, we conducted quality control of genotype data and imputed up to reference panels from the Trans-Omics for Precision Medicine Program[51](/articles/s41586-024-07019-6#ref-CR51 \"Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290–299 (2021).\"), Haplotype Reference Consortium[52](/articles/s41586-024-07019-6#ref-CR52 \"McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).\"), 1000 Genomes Project (phase 1, March 2012 release; phase 3, October 2014 release)[53](/articles/s41586-024-07019-6#ref-CR53 \"The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).\"),[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\"), or population-specific whole-genome sequencing[55](#ref-CR55 \"Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. Eur. J. Hum. Genet. 25, 869–876 (2017).\"),[56](#ref-CR56 \"Jónsson, H. et al. Whole genome characterization of sequence diversity of 15,220 Icelanders. Sci. Data 4, 170115 (2017).\"),[57](#ref-CR57 \"Moon, S. et al. The Korea Biobank Array: design and identification of coding variants associated with blood biochemical traits. Sci. Rep. 9, 1382 (2019).\"),[58](#ref-CR58 \"Akiyama, M. et al. Characterizing rare and low-frequency height-associated variants in the Japanese population. Nat. Commun. 10, 4393 (2019).\"),[59](#ref-CR59 \"Gurdasani, D. et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 517, 327–332 (2015).\"),[60](#ref-CR60 \"Gurdasani, D. et al. Uganda genome resource enables insights into population history and genomic discovery in Africa. Cell 179, 984–1002 (2019).\"),[61](/articles/s41586-024-07019-6#ref-CR61 \"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508–518 (2023).\") (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3)). Studies imputed to reference panels mapped to GRCh38 (hg38) were lifted back to hg19 using the UCSC LiftOver tool (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>). We excluded SNVs with poor imputation quality and/or minor allele count (MAC)\\u2009<\\u20095 (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3)).\\n\\nWithin each ancestry group-specific GWAS, we tested for association of each SNV with T2D through generalized linear (mixed) modelling, under an additive dosage of the minor allele, with adjustment for age and sex (where appropriate), and additional study-specific covariates (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3)). We used different strategies to account for population stratification and/or kinship: (i) exclude closely related individuals and adjust for principal components derived from a genetic relatedness matrix (GRM) as additional covariates; or (ii) incorporate a random effect for the GRM (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3)). Allelic effects and corresponding standard errors that were estimated from a linear mixed model were converted to the log-odds scale[62](/articles/s41586-024-07019-6#ref-CR62 \"Cook, J. P., Mahajan, A. & Morris, A. P. Guidance for the utility of linear models in meta-analysis of genetic association studies of binary phenotypes. Eur. J. Hum. Genet. 25, 240–245 (2017).\"). We corrected study-level association summary statistics for residual structure by the LD-score regression intercept[63](/articles/s41586-024-07019-6#ref-CR63 \"Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015).\") (Supplementary Table [3](/articles/s41586-024-07019-6#MOESM3)) using an LD reference that we derived from ancestry-matched haplotypes from continental groups in the 1000 Genomes Project (phase 3, October 2014 release)[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\"). We matched AFA GWASs to the ‘African’ continental group and HIS GWASs to the ‘American’ continental group.\\n\\n### Multi-ancestry meta-analyses\\n\\nWe analysed autosomal bi-allelic SNVs that overlap reference panels from the 1000 Genomes Project (phase 3, October 2014 release)[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\") and the Haplotype Reference Consortium[52](/articles/s41586-024-07019-6#ref-CR52 \"McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).\"). We considered SNVs with MAF\\u2009>\\u20090.5% in at least one of the five continental groups in the 1000 Genomes Project (phase 3, October 2014 release)[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\"). We excluded SNVs that differed in allele frequency by more than 20% when comparing reference panels in the same subsets of haplotypes.\\n\\nWe used meta-regression, implemented in MR-MEGA[10](/articles/s41586-024-07019-6#ref-CR10 \"Mägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet. 26, 3639–3650 (2017).\"), to aggregate association summary statistics across GWASs. MR-MEGA models allelic effect heterogeneity that is correlated with genetic ancestry by including axes of genetic variation as covariates in the meta-regression model to capture diversity between GWASs. We used SNVs reported in all studies to construct a distance matrix of differences in mean effect allele frequency between each pair of GWASs. We implemented multi-dimensional scaling of the distance matrix to obtain three principal components that represent axes of genetic variation to separate GWASs across ancestry groups (Extended Data Fig. [1](/articles/s41586-024-07019-6#Fig4)).\\n\\nFor each SNV, we aggregated inverse-variance weighted allelic effects across GWASs through linear regression, including three axes of genetic variation as covariates. We tested for: (i) association with T2D allowing for ancestry-correlated allelic effect heterogeneity between GWASs; (ii) ancestry-correlated allelic effect heterogeneity between GWASs (defined by the axes of genetic variation); and (iii) residual allelic effect heterogeneity between GWASs. MR-MEGA is a meta-regression approach, and therefore does not produce an allelic effect estimate because this is allowed to vary with the axes of genetic variation. Consequently, we also aggregated association summary statistics across GWASs through fixed-effects meta-analysis (inverse-variance weighting of allelic effects) using METAL[64](/articles/s41586-024-07019-6#ref-CR64 \"Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).\"). To assess the extent of residual structure between GWASs, we calculated the genomic control inflation factor[65](/articles/s41586-024-07019-6#ref-CR65 \"Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997–1004 (1999).\") for the multi-ancestry meta-regression and the fixed-effects meta-analysis. We considered only those SNVs reported in at least five GWASs for downstream interrogation.\\n\\n### Defining T2D signals and loci\\n\\nWe identified all SNVs attaining genome-wide significance (*P*\\u2009<\\u20095\\u2009×\\u200910−8) for association with T2D from the multi-ancestry meta-regression. Clumps were formed around index variants, which were selected using a greedy algorithm in PLINK v.1.9 (ref. [66](/articles/s41586-024-07019-6#ref-CR66 \"Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).\")), after ranking SNVs by ascending *P* value. SNVs less than 5\\u2009Mb from an index SNV were assigned to the clump if *r*2\\u2009>\\u20090.05 in at least one of the five continental groups from the 1000 Genomes Project (phase 3, October 2014 release)[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\"). Index SNVs separated by less than 1\\u2009Mb were assigned to the same locus. Each locus was then defined as mapping 500\\u2009kb up- and downstream of index SNVs contained within it. We considered the locus to have been previously reported if it contained variants discovered in published large-scale T2D GWASs at genome-wide significance.\\n\\n### Ancestry-group-specific meta-analyses\\n\\nWe aggregated association summary statistics across GWASs from the same ancestry group through fixed-effects meta-analysis (inverse-variance weighting of allelic effects) using METAL[64](/articles/s41586-024-07019-6#ref-CR64 \"Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).\"). We estimated the mean effect allele frequency across GWASs from each ancestry group, weighted by the effective sample size of the study. We generated forest plots of association summary statistics of index SNVs across ancestry groups using the R package meta (<https://cran.r-project.org/package=meta/>).\\n\\n### Defining clusters of T2D index SNVs with distinct cardiometabolic profiles\\n\\nWe considered cardiometabolic-related quantitative phenotypes that are used to define T2D status and/or are associated with risk of T2D or complications. We excluded phenotypes for which GWAS summary statistics were available only after imputation to reference panels from the International HapMap Project[67](/articles/s41586-024-07019-6#ref-CR67 \"The International HapMap Consortium. The International HapMap Project. Nature 426, 789–796 (2003).\") because they did not provide sufficient coverage of SNVs included in the multi-ancestry meta-analysis. We considered the largest available GWAS meta-analysis (ancestry-specific or multi-ancestry) that provided the following association summary statistics for each SNV: effect allele, other allele, allelic effect and corresponding standard error (Supplementary Table [5](/articles/s41586-024-07019-6#MOESM3)). We re-aligned the effect estimate to the T2D risk allele from the fixed-effects multi-ancestry meta-analysis, denoted *β**ij* for the *j*th index SNV and the *i*th phenotype. We then calculated a sample size corrected *z*-score, given by \\\\({Z}\\\\_{ij}={\\\\beta }\\\\_{ij}/\\\\left(\\\\sqrt{{N}\\\\_{i}}{s}\\\\_{ij}\\\\right)\\\\), where *s**ij* is the standard error of the effect estimate of the *j*th index SNV and the *i*th phenotype, and *N**i* is the maximum sample size reported for the *i*th phenotype. Where association summary statistics were not reported, the *z*-score was set as ‘missing’.\\n\\nWe conducted *k*-means clustering of index SNVs with imputation of missing *z*-scores using the R package ClustImpute (<https://cran.r-project.org/package=ClustImpute>). For a pre-defined number of clusters, ClustImpute replaces missing *z*-scores at random from the marginal distribution for the phenotype in the first iteration and performs *k*-means clustering. In subsequent iterations, missing *z*-scores are updated, conditional on the current cluster assignment, so that correlations between phenotypes are considered. At each iteration, penalizing weights are imposed on imputed values and successively decreased (to zero) as the missing data imputation improves. Finally, we determined the ‘optimal’ number of clusters according to the majority rule across 27 indices of cluster performance[68](/articles/s41586-024-07019-6#ref-CR68 \"Charrad, M., Ghazzali, N., Boiteau, V. & Niknafs, A. NbClust: an R package for determining the relevant number of clusters in a data set. J. Stat. Softw. 61, 1–36 (2014).\"), implemented in the R package NbClust (<https://cran.r-project.org/package=NbClust>).\\n\\nWe tested for association of the *i*th phenotype with index SNVs across clusters in a linear regression model, given by \\\\(E\\\\left({Z}\\\\_{ij}\\\\right)={\\\\sum }\\\\_{k}{\\\\gamma }\\\\_{ik}{C}\\\\_{jk}\\\\), where *C**jk* is an indicator variable that takes the value 1 if the *j*th index SNV was assigned to the *k*th cluster and 0 otherwise. The strength or direction of the association of each phenotype with each cluster was then presented in a heat map, in which the ‘temperature’ was defined by the direction of the regression coefficient *γ**ik* and the corresponding −log10 *P* value. Regression models were fitted using the glm function in R.\\n\\nWe extracted cardiometabolic phenotype *z*-scores from the final imputed dataset from ClustImpute. We calculated the Euclidean distance between the *j*th SNV and *k*th cluster centroid as\\n\\nwhere *Z**ij* and *μ**ik* are the *z*-score of the *j*th SNV and the location of the *k*th cluster centroid for the *i*th cardiometabolic phenotype. To assess cluster disparity, we also performed principal components analysis of cardiometabolic phenotype *z*-scores from the final imputed dataset using the R package factoextra (<https://cran.r-project.org/package=factoextra>).\\n\\n### Cluster-specific associations of index SNVs with T2D\\n\\nWe tested for association of T2D with index SNVs across clusters in a linear regression model, given by \\\\(E\\\\left({\\\\beta }\\\\_{j}\\\\right)={\\\\sum }\\\\_{k}{\\\\gamma }\\\\_{k}{C}\\\\_{jk}\\\\), where *C**jk* is an indicator variable that takes the value 1 if the *j*th index SNV was assigned to the *k*th cluster and 0 otherwise, and weighted by the inverse of the variance of the allelic effect. We tested for heterogeneity in cluster effects on T2D by comparing the deviance of this model with that of \\\\(E\\\\left({\\\\beta }\\\\_{j}\\\\right)={\\\\gamma }\\\\_{0}\\\\), again weighted by the inverse of the variance of the allelic effect. To compare associations between previously reported clusters and previously unreported clusters, we replaced *C**jk* with an indicator variable that takes the value 1 if the *j*th index SNV was assigned to a previously reported cluster and 0 otherwise. Regression models were fitted using the glm function in R.\\n\\n### Enrichment of T2D associations for cell-type-specific regions of open chromatin within clusters\\n\\nFor each T2D association signal, we defined ‘null’ SNVs that mapped within 50\\u2009kb of the index SNV and were not in LD (*r*2\\u2009>\\u20090.05) with the index SNV in any of the five continental groups from the 1000 Genomes Project (phase 3, October 2014 release)[54](/articles/s41586-024-07019-6#ref-CR54 \"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).\"). We defined an indicator variable, *Y**j*, taking the value 1 if the *j*th SNV is an index SNV and 0 if the *j*th SNV is a null SNV. We mapped index SNVs and null SNVs to genic regions defined by the Ensembl Project (release 104)[69](/articles/s41586-024-07019-6#ref-CR69 \"Cunningham, F. et al. Ensembl 2022. Nucleic Acids Res. 50, D988–D995 (2022).\"), including protein-coding exons, and 3′ UTRs and 5′ UTRs. We defined indicator variables, \\\\({G}\\\\_{j}^{{\\\\rm{EXON}}}\\\\), \\\\({G}\\\\_{j}^{3{\\\\rm{UTR}}}\\\\) and \\\\({G}\\\\_{j}^{5{\\\\rm{UTR}}}\\\\), which each take the value 1 if the *j*th SNV mapped to the respective genic annotation and 0 otherwise. We also mapped index SNVs and null SNVs to ATAC-seq peaks from single-cell atlases of chromatin accessibility (CATLAS and DESCARTES) for: 222 cell types derived from 30 human adult and 15 human fetal tissues[25](/articles/s41586-024-07019-6#ref-CR25 \"Domcke, S. et al. A human cell atlas of fetal chromatin accessibility. Science 370, eaba7612 (2020).\"),[26](/articles/s41586-024-07019-6#ref-CR26 \"Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985–6001 (2021).\"); and 106 cell types derived from human brain[27](/articles/s41586-024-07019-6#ref-CR27 \"Li, Y. E. et al. A comparative atlas of single-cell chromatin accessibility in the human brain. Science 382, eadf7044 (2023).\"). We defined an indicator variable, *X**ij*, that takes the value 1 if the *j*th SNV mapped to an ATAC-seq peak for the *i*th cell type and 0 otherwise.\\n\\nWithin each cluster, we modelled enrichment of T2D associations for ATAC-seq peaks in the *i*th cell type, after accounting for genic annotations, in a Firth bias-reduced logistic regression, given by\\n\\nwhere *f* is the logit link function. In this expression, *α*0 is an intercept, *α*EXON, *α*3UTR and *α*5UTR are log fold enrichments of genic annotations, and *θ**i* is the log fold enrichment of ATAC-seq peaks in the *i*th cell type. We conducted a test of enrichment of the *i*th cell type by comparing the deviances of models in which *θ**i*\\u2009*=*\\u20090 and *θ**i* is unconstrained. We identified cell types with significant evidence of enrichment (*P*\\u2009<\\u20090.00023, Bonferroni correction for 222 cell types in adult and fetal tissues; *P*\\u2009<\\u20090.00047, Bonferroni correction for 106 cell types in the brain). All models were fitted using the R package logistf (<https://cran.r-project.org/package=logistf>).\\n\\n### Contribution of each axis of genetic variation to ancestry-correlated heterogeneity\\n\\nFor each index SNV, we calculated a *z*-score (beta/SE) for association with each axis of variation by aligning the effect from the meta-regression model to the T2D risk allele. For each index SNV, we identified the axis of genetic variation with the strongest association (greatest magnitude *z*-score).\\n\\n### Differences in ancestry-correlated heterogeneity between mechanistic clusters\\n\\nWe tested for differences in *z*-scores (beta/SE) for association of index SNVs in each cluster with the *i*th axis of genetic variation by comparing two linear models by ANOVA: (i) \\\\({f}^{-1}\\\\left({Z}\\\\_{ij}\\\\right)={\\\\tau }\\\\_{0i}\\\\); and (ii) \\\\({f}^{-1}\\\\left({Z}\\\\_{ij}\\\\right)={\\\\sum }\\\\_{k}{\\\\tau }\\\\_{ki}{C}\\\\_{jk}\\\\). In these expressions: *f* is the identity link function; *Z**ij* is the *z*-score for the *j*th index SNV; *C**jk* is an indicator variable that takes the value 1 if the *j*th index SNV was assigned to the *k*th cluster and 0 otherwise; and *τ*0*i* and *τ**ki* are regression coefficients. Regression models were fitted using the glm function in R.\\n\\n### Effect of BMI on ancestry-correlated and residual heterogeneity in allelic effects between GWASs\\n\\nFor each index SNV, we aggregated inverse-variance weighted allelic effects across GWASs by linear regression, implemented in MR-MEGA[10](/articles/s41586-024-07019-6#ref-CR10 \"Mägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet. 26, 3639–3650 (2017).\"), including as covariates: (i) three axes of genetic variation; (ii) mean BMI in controls; and (iii) mean BMI in T2D cases. After adjustment for BMI, we tested for: (i) ancestry-correlated allelic effect heterogeneity between GWASs; and (ii) residual allelic effect heterogeneity between GWASs. After adjustment, as outlined above, we re-assessed: (i) the contribution of each axis of genetic variation to ancestry-correlated heterogeneity; and (ii) the difference in ancestry-correlated heterogeneity between mechanistic clusters.\\n\\n### Cluster-specific partitioned PS analyses of vascular outcomes and age of T2D onset\\n\\nWe tested for association of cluster-specific components of the partitioned PS and an overall PS with T2D-related macrovascular outcomes (CAD, ischaemic stroke and peripheral artery disease), microvascular complications (ESDN and proliferative diabetic retinopathy) and age of T2D onset in participants from the All of Us Research Program (AoURP; AFA, EUR and HIS ancestry groups), Biobank Japan (BBJ; EAS ancestry group), and Genes & Health (G&H; SAS ancestry group). Cohort descriptions and details of sequencing and genotyping, quality control and phenotype derivation are provided in the\\xa0[Supplementary Methods](/articles/s41586-024-07019-6#MOESM1).\\n\\nWe conducted analyses separately for each ancestry group in AoURP, BBJ and G&H. For each ancestry, we performed analyses for macrovascular outcomes using all individuals, irrespective of T2D status, and for microvascular complications in individuals with T2D only. For each analysis, we calculated the overall PS and cluster-specific partitioned PS for each individual, with each index SNV weighted by the allelic log-OR from the ancestry-specific meta-analyses. We did not include index SNVs with MAF\\u2009<\\u20091% in the PS. We also excluded index SNVs with poor imputation quality (*r*2\\u2009<\\u20090.7) in BBJ and G&H, and those with extreme deviation from Hardy–Weinberg equilibrium (*P*\\u2009<\\u200910−6) in AoURP. We standardized the overall PS and each cluster-specific component of the partitioned PS to have mean zero and unit variance. We tested for association with each vascular outcome through generalized linear regression and with age of T2D onset through linear regression. For each outcome, we considered a model including the overall PS and then each cluster-specific component the partitioned PS adjusted for the overall PS. All association analyses were conducted using the glm function in R.\\n\\nWe adjusted association analyses with vascular outcomes for age, sex and the first 20 principal components. In BBJ, we also adjusted for recruitment phase and status of the registered common diseases (other than T2D) to account for ascertainment. We further adjusted analyses of macrovascular outcomes for T2D status. We also further adjusted analyses of microvascular complications for duration of T2D. In AoURP, we defined age as age at last hospital visit. In BBJ, we defined age as age at first record. In G&H, we defined age as age at diagnosis for T2D cases and age at last follow-up for controls. For CAD, we also conducted sensitivity analyses by including, as an additional covariate, a CAD PS from the largest published multi-ancestry CAD GWAS[39](/articles/s41586-024-07019-6#ref-CR39 \"Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803–1815 (2022).\"). The PS was constructed from index SNVs for 241 conditionally independent CAD associations, weighted by the multi-ancestry allelic log-OR (ancestry-specific effects were not available), and standardized to have mean zero and unit variance. We adjusted association analyses with age of T2D onset for sex and the first 20 principal components. In BBJ, we also adjusted for recruitment phase and status of the registered common diseases (other than T2D) to account for ascertainment.\\n\\nFor each outcome, we aggregated association summary statistics from each cluster-specific component of the partitioned PS and the overall PS across ancestries through random-effects meta-analyses. All meta-analyses were conducted using the R package meta (<https://cran.r-project.org/package=meta>).\\n\\n### Cluster-specific partitioned PS analyses of clinical outcomes\\n\\nWe tested for association of cardiovascular and kidney-related clinical outcomes in EUR individuals with T2D in prospective GWASs from six clinical trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group (<https://timi.org/>). Trial descriptions and details of genotyping and quality control are provided in the\\xa0[Supplementary Methods](/articles/s41586-024-07019-6#MOESM1).\\n\\nWithin each trial, we calculated the overall PS and cluster-specific components of the partitioned PS for each individual, with each index SNV weighted by the allelic log-OR from the European ancestry-specific meta-analysis. We standardized the overall PS and each cluster-specific component of the partitioned PS to have mean zero and unit variance. Data from the six trials were subsequently pooled, and we considered the following clinical outcomes in patients with T2D only: myocardial infarction, ischaemic stroke, cardiovascular death, hospitalization for heart failure, atrial fibrillation, acute limb ischaemia, peripheral revascularization, end-stage renal disease or renal death and albuminuria. We tested for association of each cluster-specific component of the partitioned PS with each clinical outcome under a Cox proportional hazards model, including age, sex, the first ten principal components and the overall PS as covariates. All association analyses were conducted using the coxph function with Efron ties handling from the R package survival (<https://cran.r-project.org/package=survival>).\\n\\n### Ethics statement\\n\\nStudy-level ethics statements are provided in the\\xa0[Supplementary Note](/articles/s41586-024-07019-6#MOESM1).\\n\\n### Reporting summary\\n\\nFurther information on research design is available in the\\xa0[Nature Portfolio Reporting Summary](/articles/s41586-024-07019-6#MOESM2) linked to this article.\\n\\n## Data availability\\n\\nGenome-wide association summary statistics from the multi-ancestry meta-analysis and ancestry-specific meta-analyses reported in this study are available through the DIAGRAM Consortium website (<http://www.diagram-consortium.org/downloads.html>).\\n\\n## Code availability\\n\\nAnalyses were conducted using publicly available software: the UCSC LiftOver tool (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>), MR-MEGA v.0.2 (<https://genomics.ut.ee/en/tools>), METAL v.2011-03-25 (<https://genome.sph.umich.edu/wiki/METAL>), PLINK v.1.9 (<https://www.cog-genomics.org/plink/1.9/>), Beagle 4.1 (<https://faculty.washington.edu/browning/beagle/b4_1.html>), SNPTEST v.2.5.6 (<https://www.well.ox.ac.uk/~gav/snptest/>), GWAMA v.2.2.2 (<https://genomics.ut.ee/en/tools>), EIGENSOFT v.7.2.1 (<https://www.hsph.harvard.edu/alkes-price/software/>), PLINK v.2.0 (<https://www.cog-genomics.org/plink/2.0/>), SHAPEIT4 (<https://odelaneau.github.io/shapeit4/>), Minimac4 (<https://genome.sph.umich.edu/wiki/Minimac4>), KING v.2.3 (<https://www.kingrelatedness.com/>) and EAGLE v.2.4 (<https://alkesgroup.broadinstitute.org/Eagle/#Xeagle2>). Analyses were also conducted using the following R packages: meta (<https://cran.r-project.org/package=meta>), ClustImpute (<https://cran.r-project.org/package=ClustImpute>), NbClust (<https://cran.r-project.org/package=NbClust>), factoextra (<https://cran.r-project.org/package=factoextra>) and logistf (<https://cran.r-project.org/package=logistf>).\\n\\n## References\\n\\nMcCarthy, M. I. Painting a new picture of personalised medicine for diabetes. *Diabetologia* **60**, 793–799 (2017).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-017-4210-x)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28175964)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518376)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Painting%20a%20new%20picture%20of%20personalised%20medicine%20for%20diabetes&journal=Diabetologia&doi=10.1007%2Fs00125-017-4210-x&volume=60&pages=793-799&publication_year=2017&author=McCarthy%2CMI)\\n\\nPearson, E. R. Type 2 diabetes: a multifaceted disease. *Diabetologia* **62**, 1107–1112 (2019).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-019-4909-y)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31161345)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560016)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%3A%20a%20multifaceted%20disease&journal=Diabetologia&doi=10.1007%2Fs00125-019-4909-y&volume=62&pages=1107-1112&publication_year=2019&author=Pearson%2CER)\\n\\nMahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat. Genet.* **50**, 559–571 (2018).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-018-0084-1)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXnsVGrsbc%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29632382)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898373)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Refining%20the%20accuracy%20of%20validated%20target%20identification%20through%20coding%20variant%20fine-mapping%20in%20type%202%20diabetes&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-018-0084-1&volume=50&pages=559-571&publication_year=2018&author=Mahajan%2CA)\\n\\nUdler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. *PLoS Med.* **15**, e1002654 (2018).\\n\\n[Article](https://doi.org/10.1371%2Fjournal.pmed.1002654)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30240442)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150463)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Type%202%20diabetes%20genetic%20loci%20informed%20by%20multi-trait%20associations%20point%20to%20disease%20mechanisms%20and%20subtypes%3A%20a%20soft%20clustering%20analysis&journal=PLoS%20Med.&doi=10.1371%2Fjournal.pmed.1002654&volume=15&publication_year=2018&author=Udler%2CMS)\\n\\nUdler, M. S., McCarthy, M. I., Florez, J. C. & Mahajan, A. Genetic risk scores for diabetes diagnosis and precision medicine. *Endocr. Rev.* **40**, 1500–1520 (2019).\\n\\n[Article](https://doi.org/10.1210%2Fer.2019-00088)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31322649)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760294)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genetic%20risk%20scores%20for%20diabetes%20diagnosis%20and%20precision%20medicine&journal=Endocr.%20Rev.&doi=10.1210%2Fer.2019-00088&volume=40&pages=1500-1520&publication_year=2019&author=Udler%2CMS&author=McCarthy%2CMI&author=Florez%2CJC&author=Mahajan%2CA)\\n\\nInternational Diabetes Federation. *IDF Diabetes Atlas* 10th edn <https://diabetesatlas.org/> (IDF, 2021).\\n\\nAlmgren, P. et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. *Diabetologia* **54**, 2811–2819 (2011).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-011-2267-5)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3MXht12js7rM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21826484)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Heritability%20and%20familiality%20of%20type%202%20diabetes%20and%20related%20quantitative%20traits%20in%20the%20Botnia%20Study&journal=Diabetologia&doi=10.1007%2Fs00125-011-2267-5&volume=54&pages=2811-2819&publication_year=2011&author=Almgren%2CP)\\n\\nVujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat. Genet.* **52**, 680–691 (2020).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-020-0637-y)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFKgtr%2FO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32541925)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343592)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Discovery%20of%20318%20new%20risk%20loci%20for%20type%202%20diabetes%20and%20related%20vascular%20outcomes%20among%201.4%20million%20participants%20in%20a%20multi-ancestry%20meta-analysis&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-020-0637-y&volume=52&pages=680-691&publication_year=2020&author=Vujkovic%2CM)\\n\\nMahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat. Genet.* **54**, 560–572 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-022-01058-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xht1ynsbvJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35551307)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179018)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multi-ancestry%20genetic%20study%20of%20type%202%20diabetes%20highlights%20the%20power%20of%20diverse%20populations%20for%20discovery%20and%20translation&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-022-01058-3&volume=54&pages=560-572&publication_year=2022&author=Mahajan%2CA)\\n\\nMägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639–3650 (2017).\\n\\n[Article](https://doi.org/10.1093%2Fhmg%2Fddx280)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28911207)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755684)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trans-ethnic%20meta-regression%20of%20genome-wide%20association%20studies%20accounting%20for%20ancestry%20increases%20power%20for%20discovery%20and%20improves%20fine-mapping%20resolution&journal=Hum.%20Mol.%20Genet.&doi=10.1093%2Fhmg%2Fddx280&volume=26&pages=3639-3650&publication_year=2017&author=M%C3%A4gi%2CR)\\n\\nWarrington, N. M. et al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-019-0403-1)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXoslKqtrw%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31043758)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522365)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Maternal%20and%20fetal%20genetic%20effects%20on%20birth%20weight%20and%20their%20relevance%20to%20cardio-metabolic%20risk%20factors&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-019-0403-1&volume=51&pages=804-814&publication_year=2019&author=Warrington%2CNM)\\n\\nChen, J. et al. The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.* **53**, 840–860 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-021-00852-9)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Sksr3P)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34059833)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610958)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20trans-ancestral%20genomic%20architecture%20of%20glycemic%20traits&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-021-00852-9&volume=53&pages=840-860&publication_year=2021&author=Chen%2CJ)\\n\\nLiu, Y. et al. Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. *eLife* **10**, e65554 (2021).\\n\\n[Article](https://doi.org/10.7554%2FeLife.65554)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXislantr3K)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34128465)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205492)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genetic%20architecture%20of%2011%20organ%20traits%20derived%20from%20abdominal%20MRI%20using%20deep%20learning&journal=eLife&doi=10.7554%2FeLife.65554&volume=10&publication_year=2021&author=Liu%2CY)\\n\\nSulc, J. et al. Composite trait Mendelian randomization reveals distinct metabolic and lifestyle consequences of differences in body shape. *Commun. Biol.* **4**, 1064 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs42003-021-02550-y)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXisVGqs7nP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34518635)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438050)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Composite%20trait%20Mendelian%20randomization%20reveals%20distinct%20metabolic%20and%20lifestyle%20consequences%20of%20differences%20in%20body%20shape&journal=Commun.%20Biol.&doi=10.1038%2Fs42003-021-02550-y&volume=4&publication_year=2021&author=Sulc%2CJ)\\n\\nSakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-021-00931-x)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXitFGru7fO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34594039)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20cross-population%20atlas%20of%20genetic%20associations%20for%20220%20human%20phenotypes&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-021-00931-x&volume=53&pages=1415-1424&publication_year=2021&author=Sakaue%2CS)\\n\\nGraham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature* **600**, 675–679 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41586-021-04064-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXislWkt73M)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34887591)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730582)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2021Natur.600..675G)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20power%20of%20genetic%20diversity%20in%20genome-wide%20association%20studies%20of%20lipids&journal=Nature&doi=10.1038%2Fs41586-021-04064-3&volume=600&pages=675-679&publication_year=2021&author=Graham%2CSE)\\n\\nAgrawal, S. et al. Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. *Nat. Commun.* **13**, 3771 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-022-30931-2)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhslajtbbK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35773277)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247093)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2022NatCo..13.3771A)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Inherited%20basis%20of%20visceral%2C%20abdominal%20subcutaneous%20and%20gluteofemoral%20fat%20depots&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-022-30931-2&volume=13&publication_year=2022&author=Agrawal%2CS)\\n\\nWarren, H. et al. Genome-wide analysis in over 1 million individuals reveals over 2,000 independent genetic signals for blood pressure. Preprint at <https://doi.org/10.21203/rs.3.rs-1409164/v1> (2022).\\n\\nBroadaway, K. A. et al. Loci for insulin processing and secretion provide insight into type 2 diabetes risk. *Am. J .Hum. Genet.* **110**, 284–299 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.ajhg.2023.01.002)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhs1ymtbs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36693378)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943750)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Loci%20for%20insulin%20processing%20and%20secretion%20provide%20insight%20into%20type%202%20diabetes%20risk&journal=Am.%20J%20.Hum.%20Genet.&doi=10.1016%2Fj.ajhg.2023.01.002&volume=110&pages=284-299&publication_year=2023&author=Broadaway%2CKA)\\n\\nKim, H. et al. High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease. *Diabetologia* **66**, 495–507 (2023).\\n\\n[Article](https://link.springer.com/doi/10.1007/s00125-022-05848-6)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XjtF2gs7rK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36538063)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=High-throughput%20genetic%20clustering%20of%20type%202%20diabetes%20loci%20reveals%20heterogeneous%20mechanistic%20pathways%20of%20metabolic%20disease&journal=Diabetologia&doi=10.1007%2Fs00125-022-05848-6&volume=66&pages=495-507&publication_year=2023&author=Kim%2CH)\\n\\nSmith, K. et al. Multi-ancestry polygenic mechanisms of type 2 diabetes elucidate disease processes and clinical heterogeneity. *Nat. Med.* (in the press).\\n\\nFord, E. S., Li, C. & Sattar, N. Metabolic syndrome and incident diabetes: current state of the evidence. *Diabetes Care* **31**, 1898–1904 (2008).\\n\\n[Article](https://doi.org/10.2337%2Fdc08-0423)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18591398)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518368)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metabolic%20syndrome%20and%20incident%20diabetes%3A%20current%20state%20of%20the%20evidence&journal=Diabetes%20Care&doi=10.2337%2Fdc08-0423&volume=31&pages=1898-1904&publication_year=2008&author=Ford%2CES&author=Li%2CC&author=Sattar%2CN)\\n\\nMarott, S. C., Nordestgaard, B. G., Tybjærg-Hansen, A. & Benn, M. Components of the metabolic syndrome and risk of type 2 diabetes. *J. Clin. Endocrinol. Metab.* **101**, 3212–3221 (2016).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2015-3777)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhslyqsrzO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27285293)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Components%20of%20the%20metabolic%20syndrome%20and%20risk%20of%20type%202%20diabetes&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2015-3777&volume=101&pages=3212-3221&publication_year=2016&author=Marott%2CSC&author=Nordestgaard%2CBG&author=Tybj%C3%A6rg-Hansen%2CA&author=Benn%2CM)\\n\\nJo, A. & Mainous, A. G. 3rd Informational value of percent body fat with body mass index for the risk of abnormal blood glucose: a nationally representative cross-sectional study. *BMJ Open* **8**, e019200 (2018).\\n\\n[Article](https://doi.org/10.1136%2Fbmjopen-2017-019200)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29654009)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905746)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Informational%20value%20of%20percent%20body%20fat%20with%20body%20mass%20index%20for%20the%20risk%20of%20abnormal%20blood%20glucose%3A%20a%20nationally%20representative%20cross-sectional%20study&journal=BMJ%20Open&doi=10.1136%2Fbmjopen-2017-019200&volume=8&publication_year=2018&author=Jo%2CA&author=Mainous%2CAG)\\n\\nDomcke, S. et al. A human cell atlas of fetal chromatin accessibility. *Science* **370**, eaba7612 (2020).\\n\\n[Article](https://doi.org/10.1126%2Fscience.aba7612)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXitlCmt7nM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33184180)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785298)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20human%20cell%20atlas%20of%20fetal%20chromatin%20accessibility&journal=Science&doi=10.1126%2Fscience.aba7612&volume=370&publication_year=2020&author=Domcke%2CS)\\n\\nZhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. *Cell* **184**, 5985–6001 (2021).\\n\\n[Article](https://doi.org/10.1016%2Fj.cell.2021.10.024)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXisVyjsLfM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34774128)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664161)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20single-cell%20atlas%20of%20chromatin%20accessibility%20in%20the%20human%20genome&journal=Cell&doi=10.1016%2Fj.cell.2021.10.024&volume=184&pages=5985-6001&publication_year=2021&author=Zhang%2CK)\\n\\nLi, Y. E. et al. A comparative atlas of single-cell chromatin accessibility in the human brain. *Science* **382**, eadf7044 (2023).\\n\\n[Article](https://doi.org/10.1126%2Fscience.adf7044)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXitFygur7J)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37824643)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852054)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20comparative%20atlas%20of%20single-cell%20chromatin%20accessibility%20in%20the%20human%20brain&journal=Science&doi=10.1126%2Fscience.adf7044&volume=382&publication_year=2023&author=Li%2CYE)\\n\\nBertrand, P. P. & Bertrand, R. L. Serotonin release and uptake in the gastrointestinal tract. *Auton. Neurosci.* **153**, 47–57 (2010).\\n\\n[Article](https://doi.org/10.1016%2Fj.autneu.2009.08.002)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXnt1Wksg%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19729349)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Serotonin%20release%20and%20uptake%20in%20the%20gastrointestinal%20tract&journal=Auton.%20Neurosci.&doi=10.1016%2Fj.autneu.2009.08.002&volume=153&pages=47-57&publication_year=2010&author=Bertrand%2CPP&author=Bertrand%2CRL)\\n\\nLund, M. L. et al. Enterochromaffin 5-HT cells—a major target for GLP-1 and gut microbial metabolites. *Mol. Metab.* **11**, 70–83 (2018).\\n\\n[Article](https://doi.org/10.1016%2Fj.molmet.2018.03.004)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXks12mt7w%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29576437)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001397)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Enterochromaffin%205-HT%20cells%E2%80%94a%20major%20target%20for%20GLP-1%20and%20gut%20microbial%20metabolites&journal=Mol.%20Metab.&doi=10.1016%2Fj.molmet.2018.03.004&volume=11&pages=70-83&publication_year=2018&author=Lund%2CML)\\n\\nFinucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).\\n\\n[Article](https://doi.org/10.1038%2Fng.3404)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFKqu7rF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26414678)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626285)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Partitioning%20heritability%20by%20functional%20annotation%20using%20genome-wide%20association%20summary%20statistics&journal=Nat.%20Genet.&doi=10.1038%2Fng.3404&volume=47&pages=1228-1235&publication_year=2015&author=Finucane%2CHK)\\n\\nAkiyama, M. et al. Genome-wide association study identifies 112 new loci for body mass index in the Japanese population. *Nat. Genet.* **49**, 1458–1467 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fng.3951)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVKltbjK)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28892062)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genome-wide%20association%20study%20identifies%20112%20new%20loci%20for%20body%20mass%20index%20in%20the%20Japanese%20population&journal=Nat.%20Genet.&doi=10.1038%2Fng.3951&volume=49&pages=1458-1467&publication_year=2017&author=Akiyama%2CM)\\n\\nSuyama, S. & Yada, T. New insight into GABAergic neurons in the hypothalamic feeding regulation. *J. Physiol. Sci.* **68**, 717–722 (2018).\\n\\n[Article](https://link.springer.com/doi/10.1007/s12576-018-0622-8)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtlSqtrfF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30003408)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10717766)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=New%20insight%20into%20GABAergic%20neurons%20in%20the%20hypothalamic%20feeding%20regulation&journal=J.%20Physiol.%20Sci.&doi=10.1007%2Fs12576-018-0622-8&volume=68&pages=717-722&publication_year=2018&author=Suyama%2CS&author=Yada%2CT)\\n\\nMatikainen-Ankney, B. A. et al. Nucleus accumbens D1 receptor-expressing spiny projection neurons control food motivation and obesity. *Biol. Psychiatry* **93**, 512–523 (2023).\\n\\n[Article](https://doi.org/10.1016%2Fj.biopsych.2022.10.003)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XjtVylsLjF)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36494220)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nucleus%20accumbens%20D1%20receptor-expressing%20spiny%20projection%20neurons%20control%20food%20motivation%20and%20obesity&journal=Biol.%20Psychiatry&doi=10.1016%2Fj.biopsych.2022.10.003&volume=93&pages=512-523&publication_year=2023&author=Matikainen-Ankney%2CBA)\\n\\nKim, J. A., Montagnani, M., Koh, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation* **113**, 1888–1904 (2006).\\n\\n[Article](https://doi.org/10.1161%2FCIRCULATIONAHA.105.563213)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16618833)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Reciprocal%20relationships%20between%20insulin%20resistance%20and%20endothelial%20dysfunction%3A%20molecular%20and%20pathophysiological%20mechanisms&journal=Circulation&doi=10.1161%2FCIRCULATIONAHA.105.563213&volume=113&pages=1888-1904&publication_year=2006&author=Kim%2CJA&author=Montagnani%2CM&author=Koh%2CKK&author=Quon%2CMJ)\\n\\nvan Walree, E. S. et al. Disentangling genetic risks for metabolic syndrome. *Diabetes* **71**, 2447–2457 (2022).\\n\\n[Article](https://doi.org/10.2337%2Fdb22-0478)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35983957)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Disentangling%20genetic%20risks%20for%20metabolic%20syndrome&journal=Diabetes&doi=10.2337%2Fdb22-0478&volume=71&pages=2447-2457&publication_year=2022&author=Walree%2CES)\\n\\nWojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. *Nature* **570**, 514–518 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41586-019-1310-4)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1aqtbjJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31217584)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785182)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genetic%20analyses%20of%20diverse%20populations%20improves%20discovery%20for%20complex%20traits&journal=Nature&doi=10.1038%2Fs41586-019-1310-4&volume=570&pages=514-518&publication_year=2019&author=Wojcik%2CGL)\\n\\nPetersen, R. E. et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell* **179**, 589–603 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.cell.2019.08.051)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genome-wide%20association%20studies%20in%20ancestrally%20diverse%20populations%3A%20opportunities%2C%20methods%2C%20pitfalls%2C%20and%20recommendations&journal=Cell&doi=10.1016%2Fj.cell.2019.08.051&volume=179&pages=589-603&publication_year=2019&author=Petersen%2CRE)\\n\\nPerry, J. R. B. et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in *LAMA1* and enrichment for risk variants in lean compared to obese cases. *PLoS Genet.* **8**, e1002741 (2012).\\n\\n[Article](https://doi.org/10.1371%2Fjournal.pgen.1002741)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC38XosVeksLk%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22693455)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364960)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Stratifying%20type%202%20diabetes%20cases%20by%20BMI%20identifies%20genetic%20risk%20variants%20in%20LAMA1%20and%20enrichment%20for%20risk%20variants%20in%20lean%20compared%20to%20obese%20cases&journal=PLoS%20Genet.&doi=10.1371%2Fjournal.pgen.1002741&volume=8&publication_year=2012&author=Perry%2CJRB)\\n\\nAragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-022-01233-6)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XjtVGru7%2FJ)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36474045)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729111)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Discovery%20and%20systematic%20characterization%20of%20risk%20variants%20and%20genes%20for%20coronary%20artery%20disease%20in%20over%20a%20million%20participants&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-022-01233-6&volume=54&pages=1803-1815&publication_year=2022&author=Aragam%2CKG)\\n\\nUK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* **352**, 837–853 (1998).\\n\\n[Article](https://doi.org/10.1016%2FS0140-6736%2898%2907019-6)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intensive%20blood-glucose%20control%20with%20sulphonylureas%20or%20insulin%20compared%20with%20conventional%20treatment%20and%20risk%20of%20complications%20in%20patients%20with%20type%202%20diabetes%20%28UKPDS%2033%29.&journal=Lancet&doi=10.1016%2FS0140-6736%2898%2907019-6&volume=352&pages=837-853&publication_year=1998)\\n\\nPe’er, I., Yelensky, R., Altshuler, D. & Daly, M. J. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet. Epidemiol.* **32**, 381–385 (2008).\\n\\n[Article](https://doi.org/10.1002%2Fgepi.20303)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18348202)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Estimation%20of%20the%20multiple%20testing%20burden%20for%20genomewide%20association%20studies%20of%20nearly%20all%20common%20variants&journal=Genet.%20Epidemiol.&doi=10.1002%2Fgepi.20303&volume=32&pages=381-385&publication_year=2008&author=Pe%E2%80%99er%2CI&author=Yelensky%2CR&author=Altshuler%2CD&author=Daly%2CMJ)\\n\\nKanai, M., Tanaka, T. & Okada, Y. Empirical estimation of genome-wide significance thresholds based on the 1000 Genomes Project data set. *J. Hum. Genet.* **61**, 861–866 (2016).\\n\\n[Article](https://doi.org/10.1038%2Fjhg.2016.72)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28XhslKgtbzE)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27305981)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090169)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Empirical%20estimation%20of%20genome-wide%20significance%20thresholds%20based%20on%20the%201000%20Genomes%20Project%20data%20set&journal=J.%20Hum.%20Genet.&doi=10.1038%2Fjhg.2016.72&volume=61&pages=861-866&publication_year=2016&author=Kanai%2CM&author=Tanaka%2CT&author=Okada%2CY)\\n\\nCarlson, J., Henn, B. M., Al-Hindi, R. R. & Ramachandran, S. Counter the weaponization of genetics research by extremists. *Nature* **610**, 444–447 (2022).\\n\\n[Article](https://doi.org/10.1038%2Fd41586-022-03252-z)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xis1Onu7rL)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36261568)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2022Natur.610..444C)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Counter%20the%20weaponization%20of%20genetics%20research%20by%20extremists&journal=Nature&doi=10.1038%2Fd41586-022-03252-z&volume=610&pages=444-447&publication_year=2022&author=Carlson%2CJ&author=Henn%2CBM&author=Al-Hindi%2CRR&author=Ramachandran%2CS)\\n\\nLewis, A. C. F. et al. Getting genetic ancestry right for science and society. *Science* **376**, 250–252 (2022).\\n\\n[Article](https://doi.org/10.1126%2Fscience.abm7530)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFSgsb7N)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35420968)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135340)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2022Sci...376..250L)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Getting%20genetic%20ancestry%20right%20for%20science%20and%20society&journal=Science&doi=10.1126%2Fscience.abm7530&volume=376&pages=250-252&publication_year=2022&author=Lewis%2CACF)\\n\\nMoller, J. B. et al. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. *J. Clin. Endocrinol. Metab.* **99**, 4273–4280 (2014).\\n\\n[Article](https://doi.org/10.1210%2Fjc.2014-1724)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25119313)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ethnic%20differences%20in%20insulin%20sensitivity%2C%20%CE%B2-cell%20function%2C%20and%20hepatic%20extraction%20between%20Japanese%20and%20Caucasians%3A%20a%20minimal%20model%20analysis&journal=J.%20Clin.%20Endocrinol.%20Metab.&doi=10.1210%2Fjc.2014-1724&volume=99&pages=4273-4280&publication_year=2014&author=Moller%2CJB)\\n\\nYabe, D., Seino, Y., Fukushima, M. & Seino, S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. *Curr. Diab. Rep.* **15**, 602 (2015).\\n\\n[Article](https://link.springer.com/doi/10.1007/s11892-015-0602-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25944304)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=%CE%B2%20cell%20dysfunction%20versus%20insulin%20resistance%20in%20the%20pathogenesis%20of%20type%202%20diabetes%20in%20East%20Asians&journal=Curr.%20Diab.%20Rep.&doi=10.1007%2Fs11892-015-0602-9&volume=15&publication_year=2015&author=Yabe%2CD&author=Seino%2CY&author=Fukushima%2CM&author=Seino%2CS)\\n\\nMoller, J. B. et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. *Diabetes Care* **37**, 796–804 (2014).\\n\\n[Article](https://doi.org/10.2337%2Fdc13-0598)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24130359)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2014ssst.book.....M)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Body%20composition%20is%20the%20main%20determinant%20for%20the%20difference%20in%20type%202%20diabetes%20pathophysiology%20between%20Japanese%20and%20Caucasians&journal=Diabetes%20Care&doi=10.2337%2Fdc13-0598&volume=37&pages=796-804&publication_year=2014&author=Moller%2CJB)\\n\\nMatsunaga, H. et al. Transethnic meta-analysis of genome-wide association studies identifies three new loci and characterizes population-specific differences for coronary artery disease. *Circ. Genom. Precis. Med.* **13**, e002670 (2020).\\n\\n[Article](https://doi.org/10.1161%2FCIRCGEN.119.002670)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVWnurzM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32469254)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Transethnic%20meta-analysis%20of%20genome-wide%20association%20studies%20identifies%20three%20new%20loci%20and%20characterizes%20population-specific%20differences%20for%20coronary%20artery%20disease&journal=Circ.%20Genom.%20Precis.%20Med.&doi=10.1161%2FCIRCGEN.119.002670&volume=13&publication_year=2020&author=Matsunaga%2CH)\\n\\nKoyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* **52**, 1169–1177 (2020).\\n\\n[Article](https://doi.org/10.1038%2Fs41588-020-0705-3)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvF2jtb7N)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33020668)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Population-specific%20and%20trans-ancestry%20genome-wide%20analyses%20identify%20distinct%20and%20shared%20genetic%20risk%20loci%20for%20coronary%20artery%20disease&journal=Nat.%20Genet.&doi=10.1038%2Fs41588-020-0705-3&volume=52&pages=1169-1177&publication_year=2020&author=Koyama%2CS)\\n\\nMorris, A. P. et al. Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies. *Nat. Commun.* **10**, 29 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-018-07867-7)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXmvVCmsbs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30604766)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318312)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2019NatCo..10...29M)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trans-ethnic%20kidney%20function%20association%20study%20reveals%20putative%20causal%20genes%20and%20effects%20on%20kidney-specific%20disease%20aetiologies&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-018-07867-7&volume=10&publication_year=2019&author=Morris%2CAP)\\n\\nTaliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).\\n\\n[Article](https://doi.org/10.1038%2Fs41586-021-03205-y)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3MXjslKnsrY%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33568819)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875770)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2021Natur.590..290T)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sequencing%20of%2053%2C831%20diverse%20genomes%20from%20the%20NHLBI%20TOPMed%20Program&journal=Nature&doi=10.1038%2Fs41586-021-03205-y&volume=590&pages=290-299&publication_year=2021&author=Taliun%2CD)\\n\\nMcCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).\\n\\n[Article](https://doi.org/10.1038%2Fng.3643)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC28Xhtlykt7zO)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27548312)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388176)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20reference%20panel%20of%2064%2C976%20haplotypes%20for%20genotype%20imputation&journal=Nat.%20Genet.&doi=10.1038%2Fng.3643&volume=48&pages=1279-1283&publication_year=2016&author=McCarthy%2CS)\\n\\nThe 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65 (2012).\\n\\n[Article](https://doi.org/10.1038%2Fnature11632)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498066)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=An%20integrated%20map%20of%20genetic%20variation%20from%201%2C092%20human%20genomes&journal=Nature&doi=10.1038%2Fnature11632&volume=491&pages=56-65&publication_year=2012)\\n\\nThe 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).\\n\\n[Article](https://doi.org/10.1038%2Fnature15393)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20global%20reference%20for%20human%20genetic%20variation&journal=Nature&doi=10.1038%2Fnature15393&volume=526&pages=68-74&publication_year=2015)\\n\\nMitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. *Eur. J. Hum. Genet.* **25**, 869–876 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fejhg.2017.51)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28401899)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520064)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Improved%20imputation%20accuracy%20of%20rare%20and%20low-frequency%20variants%20using%20population-specific%20high-coverage%20WGS-based%20imputation%20reference%20panel&journal=Eur.%20J.%20Hum.%20Genet.&doi=10.1038%2Fejhg.2017.51&volume=25&pages=869-876&publication_year=2017&author=Mitt%2CM)\\n\\nJónsson, H. et al. Whole genome characterization of sequence diversity of 15,220 Icelanders. *Sci. Data* **4**, 170115 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fsdata.2017.115)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28933420)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607473)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Whole%20genome%20characterization%20of%20sequence%20diversity%20of%2015%2C220%20Icelanders&journal=Sci.%20Data&doi=10.1038%2Fsdata.2017.115&volume=4&publication_year=2017&author=J%C3%B3nsson%2CH)\\n\\nMoon, S. et al. The Korea Biobank Array: design and identification of coding variants associated with blood biochemical traits. *Sci. Rep.* **9**, 1382 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41598-018-37832-9)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30718733)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361960)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2019NatSR...9.1382M)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20Korea%20Biobank%20Array%3A%20design%20and%20identification%20of%20coding%20variants%20associated%20with%20blood%20biochemical%20traits&journal=Sci.%20Rep.&doi=10.1038%2Fs41598-018-37832-9&volume=9&publication_year=2019&author=Moon%2CS)\\n\\nAkiyama, M. et al. Characterizing rare and low-frequency height-associated variants in the Japanese population. *Nat. Commun.* **10**, 4393 (2019).\\n\\n[Article](https://doi.org/10.1038%2Fs41467-019-12276-5)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvVOlt7rM)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31562340)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764965)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2019NatCo..10.4393A)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Characterizing%20rare%20and%20low-frequency%20height-associated%20variants%20in%20the%20Japanese%20population&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-019-12276-5&volume=10&publication_year=2019&author=Akiyama%2CM)\\n\\nGurdasani, D. et al. The African Genome Variation Project shapes medical genetics in Africa. *Nature* **517**, 327–332 (2015).\\n\\n[Article](https://doi.org/10.1038%2Fnature13997)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7nP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25470054)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2015Natur.517..327G)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20African%20Genome%20Variation%20Project%20shapes%20medical%20genetics%20in%20Africa&journal=Nature&doi=10.1038%2Fnature13997&volume=517&pages=327-332&publication_year=2015&author=Gurdasani%2CD)\\n\\nGurdasani, D. et al. Uganda genome resource enables insights into population history and genomic discovery in Africa. *Cell* **179**, 984–1002 (2019).\\n\\n[Article](https://doi.org/10.1016%2Fj.cell.2019.10.004)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFSjsrrP)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31675503)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202134)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Uganda%20genome%20resource%20enables%20insights%20into%20population%20history%20and%20genomic%20discovery%20in%20Africa&journal=Cell&doi=10.1016%2Fj.cell.2019.10.004&volume=179&pages=984-1002&publication_year=2019&author=Gurdasani%2CD)\\n\\nKurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).\\n\\n[Article](https://doi.org/10.1038%2Fs41586-022-05473-8)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB3sXhslKmtrs%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36653562)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849126)\\xa0\\n[ADS](http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2023Natur.613..508K)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=FinnGen%20provides%20genetic%20insights%20from%20a%20well-phenotyped%20isolated%20population&journal=Nature&doi=10.1038%2Fs41586-022-05473-8&volume=613&pages=508-518&publication_year=2023&author=Kurki%2CMI)\\n\\nCook, J. P., Mahajan, A. & Morris, A. P. Guidance for the utility of linear models in meta-analysis of genetic association studies of binary phenotypes. *Eur. J. Hum. Genet.* **25**, 240–245 (2017).\\n\\n[Article](https://doi.org/10.1038%2Fejhg.2016.150)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27848946)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Guidance%20for%20the%20utility%20of%20linear%20models%20in%20meta-analysis%20of%20genetic%20association%20studies%20of%20binary%20phenotypes&journal=Eur.%20J.%20Hum.%20Genet.&doi=10.1038%2Fejhg.2016.150&volume=25&pages=240-245&publication_year=2017&author=Cook%2CJP&author=Mahajan%2CA&author=Morris%2CAP)\\n\\nBulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).\\n\\n[Article](https://doi.org/10.1038%2Fng.3211)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvFCntb8%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25642630)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495769)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=LD%20Score%20regression%20distinguishes%20confounding%20from%20polygenicity%20in%20genome-wide%20association%20studies&journal=Nat.%20Genet.&doi=10.1038%2Fng.3211&volume=47&pages=291-295&publication_year=2015&author=Bulik-Sullivan%2CBK)\\n\\nWiller, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).\\n\\n[Article](https://doi.org/10.1093%2Fbioinformatics%2Fbtq340)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVGru73F)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20616382)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922887)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=METAL%3A%20fast%20and%20efficient%20meta-analysis%20of%20genomewide%20association%20scans&journal=Bioinformatics&doi=10.1093%2Fbioinformatics%2Fbtq340&volume=26&pages=2190-2191&publication_year=2010&author=Willer%2CCJ&author=Li%2CY&author=Abecasis%2CGR)\\n\\nDevlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).\\n\\n[Article](https://doi.org/10.1111%2Fj.0006-341X.1999.00997.x)\\xa0\\n[CAS](/articles/cas-redirect/1:STN:280:DC%2BD3M3itFSqtA%3D%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11315092)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genomic%20control%20for%20association%20studies&journal=Biometrics&doi=10.1111%2Fj.0006-341X.1999.00997.x&volume=55&pages=997-1004&publication_year=1999&author=Devlin%2CB&author=Roeder%2CK)\\n\\nChang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).\\n\\n[Article](https://link.springer.com/doi/10.1186/s13742-015-0047-8)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25722852)\\xa0\\n[PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342193)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Second-generation%20PLINK%3A%20rising%20to%20the%20challenge%20of%20larger%20and%20richer%20datasets&journal=Gigascience&doi=10.1186%2Fs13742-015-0047-8&volume=4&publication_year=2015&author=Chang%2CCC)\\n\\nThe International HapMap Consortium. The International HapMap Project. *Nature* **426**, 789–796 (2003).\\n\\n[Article](https://doi.org/10.1038%2Fnature02168)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20International%20HapMap%20Project&journal=Nature&doi=10.1038%2Fnature02168&volume=426&pages=789-796&publication_year=2003)\\n\\nCharrad, M., Ghazzali, N., Boiteau, V. & Niknafs, A. NbClust: an R package for determining the relevant number of clusters in a data set. *J. Stat. Softw.* **61**, 1–36 (2014).\\n\\n[Article](https://doi.org/10.18637%2Fjss.v061.i06)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=NbClust%3A%20an%20R%20package%20for%20determining%20the%20relevant%20number%20of%20clusters%20in%20a%20data%20set&journal=J.%20Stat.%20Softw.&doi=10.18637%2Fjss.v061.i06&volume=61&pages=1-36&publication_year=2014&author=Charrad%2CM&author=Ghazzali%2CN&author=Boiteau%2CV&author=Niknafs%2CA)\\n\\nCunningham, F. et al. Ensembl 2022. *Nucleic Acids Res.* **50**, D988–D995 (2022).\\n\\n[Article](https://doi.org/10.1093%2Fnar%2Fgkab1049)\\xa0\\n[CAS](/articles/cas-redirect/1:CAS:528:DC%2BB38Xis1ChtL0%3D)\\xa0\\n[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34791404)\\xa0\\n[Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ensembl%202022&journal=Nucleic%20Acids%20Res.&doi=10.1093%2Fnar%2Fgkab1049&volume=50&pages=D988-D995&publication_year=2022&author=Cunningham%2CF)\\n\\n[Download references](https://citation-needed.springer.com/v2/references/10.1038/s41586-024-07019-6?format=refman&flavour=references)\\n\\n## Acknowledgements\\n\\nCentral analyses were supported by the Japan Agency for Medical Research and Development (JP21km0405213, JP20km0405202 and JP21tm0424218), NHGRI (HG011723), the American Diabetes Association Innovative and a Clinical Translational Award (1-19-ICTS-068), the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101017802 (OPTOMICS), American Heart Association Postdoctoral Fellowships (15POST24470131 and 17POST33650016), the American Diabetes Association (11-22-JDFPM-06), Corporal Michael J Crescenz VA Medical Center Research, NIDDK (DK126194 and DK105535), Versus Arthritis (21754), NIHR Manchester Biomedical Research Centre (NIHR203308) and the MRC (MR/W029626/1). A complete list of acknowledgments and funding appears in the\\xa0[Supplementary Note](/articles/s41586-024-07019-6#MOESM1). We thank the International Consortium of Blood Pressure (ICBP) and the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) for providing pre-publication access to GWAS summary statistics for blood pressure, proinsulin and post-challenge insulin-resistance measures. The views expressed in this article are those of the authors and do not necessarily represent those of: the UK National Health Service, the UK National Institute for Health Research or the UK Department of Health and Social Care; the US National Heart, Lung, and Blood Institute, the US National Institute of Neurological Disorders and Stroke, the US National Institute on Aging, the US National Institutes of Health, the US Department of Health and Human Services, the US Department of Veterans Affairs, the US Food and Drug Administration or the US Government.\\n\\n## Funding\\n\\nOpen access funding provided by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).\\n\\n## Author information\\n\\nAdam E. Locke\\n\\nPresent address: Regeneron Genetics Center, Tarrytown, NY, USA\\n\\nMark I. McCarthy\\xa0&\\xa0Anubha Mahajan\\n\\nPresent address: Genentech, South San Francisco, CA, USA\\n\\nThese authors contributed equally: Ken Suzuki, Konstantinos Hatzikotoulas, Lorraine Southam, Henry J. Taylor, Xianyong Yin, Kim M. Lorenz, Ravi Mandla\\n\\nThese authors jointly supervised this work: Mark I. McCarthy, James B. Meigs, Anubha Mahajan, Cassandra N. Spracklen, Josep M. Mercader, Michael Boehnke, Jerome I. Rotter, Marijana Vujkovic, Benjamin F. Voight, Andrew P. Morris, Eleftheria Zeggini\\n\\nDeceased: Michèle M. Sale\\n\\nA full list of members and their affiliations appears in the Supplementary Information\\n\\n### Authors and Affiliations\\n\\nCentre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, UK\\n\\nKen Suzuki\\xa0&\\xa0Andrew P. Morris\\n\\nDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan\\n\\nKen Suzuki,\\xa0Nobuhiro Shojima,\\xa0Toshimasa Yamauchi\\xa0&\\xa0Takashi Kadowaki\\n\\nDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan\\n\\nKen Suzuki,\\xa0Kyuto Sonehara,\\xa0Shinichi Namba,\\xa0Yukinori Okada\\xa0&\\xa0Kenichi Yamamoto\\n\\nInstitute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany\\n\\nKonstantinos Hatzikotoulas,\\xa0Lorraine Southam,\\xa0Nigel W. Rayner,\\xa0Ozvan Bocher,\\xa0Ana Luiza Arruda,\\xa0Andrew P. Morris\\xa0&\\xa0Eleftheria Zeggini\\n\\nCenter for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA\\n\\nHenry J. Taylor,\\xa0Jacob M. Keaton,\\xa0Huan Mo,\\xa0Tam C. Tran,\\xa0Francis S. Collins\\xa0&\\xa0Joshua C. Denny\\n\\nBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK\\n\\nHenry J. Taylor,\\xa0Adam S. Butterworth\\xa0&\\xa0John Danesh\\n\\nHeart and Lung Research Institute, University of Cambridge, Cambridge, UK\\n\\nHenry J. Taylor,\\xa0Adam S. Butterworth\\xa0&\\xa0John Danesh\\n\\nDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China\\n\\nXianyong Yin\\n\\nDepartment of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA\\n\\nXianyong Yin,\\xa0Brett Vanderwerff,\\xa0Daniel Taliun,\\xa0Snehal Patil,\\xa0Matthew Zawistowski,\\xa0Sebastian Zöllner\\xa0&\\xa0Michael Boehnke\\n\\nCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA\\n\\nKim M. Lorenz,\\xa0Kyong-Mi Chang,\\xa0Marijana Vujkovic\\xa0&\\xa0Benjamin F. Voight\\n\\nDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nKim M. Lorenz\\xa0&\\xa0Benjamin F. Voight\\n\\nDepartment of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nKim M. Lorenz,\\xa0Daniel J. Rader,\\xa0Marylyn D. Ritchie\\xa0&\\xa0Benjamin F. Voight\\n\\nPrograms in Metabolism and Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA\\n\\nRavi Mandla,\\xa0Alicia Huerta-Chagoya,\\xa0Philip Schroeder,\\xa0Miriam S. Udler,\\xa0Jose C. Florez,\\xa0James B. Meigs\\xa0&\\xa0Josep M. Mercader\\n\\nDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA\\n\\nRavi Mandla,\\xa0Philip Schroeder,\\xa0Varinderpal Kaur,\\xa0Miriam S. Udler,\\xa0Jose C. Florez\\xa0&\\xa0Josep M. Mercader\\n\\nTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA\\n\\nGiorgio E. M. Melloni,\\xa0Frederick K. Kamanu,\\xa0Filipe A. Moura,\\xa0Nicholas A. Marston\\xa0&\\xa0Christian T. Ruff\\n\\nWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK\\n\\nStavroula Kanoni,\\xa0Ioanna Ntalla\\xa0&\\xa0Stavroula Kanona\\n\\nGraduate School of Experimental Medicine, Technical University of Munich, Munich, Germany\\n\\nAna Luiza Arruda\\n\\nMunich School for Data Science, Helmholtz Munich, Neuherberg, Germany\\n\\nAna Luiza Arruda\\n\\nDepartment of Genome Informatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan\\n\\nKyuto Sonehara\\xa0&\\xa0Yukinori Okada\\n\\nIntegrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan\\n\\nKyuto Sonehara\\xa0&\\xa0Yukinori Okada\\n\\nLaboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan\\n\\nKyuto Sonehara\\xa0&\\xa0Yukinori Okada\\n\\nCharles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA\\n\\nSimon S. K. Lee,\\xa0Michael H. Preuss\\xa0&\\xa0Ruth J. F. Loos\\n\\nDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA\\n\\nLauren E. Petty,\\xa0Hannah G. Polikowsky\\xa0&\\xa0Jennifer E. Below\\n\\nEstonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia\\n\\nMart Kals,\\xa0Krista Fischer,\\xa0Kristi Läll,\\xa0Andres Metspalu,\\xa0Reedik Mägi\\xa0&\\xa0Andrew P. Morris\\n\\nNuffield Department of Population Health, University of Oxford, Oxford, UK\\n\\nFiona Bragg,\\xa0Kuang Lin,\\xa0Zhengming Chen,\\xa0Iona Y. Millwood\\xa0&\\xa0Robin G. Walters\\n\\nMedical Research Council Population Health Research Unit, University of Oxford, Oxford, UK\\n\\nFiona Bragg,\\xa0Zhengming Chen,\\xa0Iona Y. Millwood\\xa0&\\xa0Robin G. Walters\\n\\nInstitute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA\\n\\nXiuqing Guo,\\xa0Jie Yao,\\xa0Yang Hai,\\xa0Jingyi Tan,\\xa0Katheryn Roll,\\xa0Kevin Sandow,\\xa0Kent D. Taylor,\\xa0Yii-Der Ida Chen\\xa0&\\xa0Jerome I. Rotter\\n\\nDepartment of Epidemiology and Biostatistics, Imperial College London, London, UK\\n\\nWeihua Zhang\\xa0&\\xa0John C. Chambers\\n\\nDepartment of Cardiology, Ealing Hospital, London NorthWest Healthcare NHS Trust, London, UK\\n\\nWeihua Zhang,\\xa0Jaspal S. Kooner\\xa0&\\xa0John C. Chambers\\n\\nDivision of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju-si, South Korea\\n\\nYoung Jin Kim,\\xa0Sanghoon Moon\\xa0&\\xa0Sohee Han\\n\\nDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA\\n\\nMariaelisa Graff,\\xa0Rebecca Rohde\\xa0&\\xa0Kari E. North\\n\\nDepartment of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan\\n\\nFumihiko Takeuchi,\\xa0Masato Isono\\xa0&\\xa0Norihiro Kato\\n\\nInstitute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany\\n\\nJana Nano,\\xa0Christian Gieger,\\xa0Annette Peters,\\xa0Barbara Thorand\\xa0&\\xa0Harald Grallert\\n\\nDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada\\n\\nAmel Lamri,\\xa0Sonia S. Anand,\\xa0Hertzel C. Gerstein\\xa0&\\xa0Salim Yusuf\\n\\nPopulation Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada\\n\\nAmel Lamri,\\xa0Sonia S. Anand,\\xa0Hertzel C. Gerstein,\\xa0Salim Yusuf\\xa0&\\xa0Guillaume Paré\\n\\nPublic Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan\\n\\nMasahiro Nakatochi\\n\\nMRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK\\n\\nRobert A. Scott,\\xa0Alice Williamson,\\xa0Jian’an Luan,\\xa0Eleanor Wheeler,\\xa0Nicholas J. Wareham\\xa0&\\xa0Claudia Langenberg\\n\\nDepartment of Health Data Science, University of Liverpool, Liverpool, UK\\n\\nJames P. Cook\\n\\nDivision of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, USA\\n\\nJung-Jin Lee\\n\\nDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA\\n\\nIan Pan,\\xa0Mengna Huang\\xa0&\\xa0Simin Liu\\n\\nDepartment of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario, Canada\\n\\nEsteban J. Parra\\n\\nSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore\\n\\nJin-Fang Chai,\\xa0Victor J. Y. Lim,\\xa0Rob M. van Dam,\\xa0E-Shyong Tai\\xa0&\\xa0Xueling Sim\\n\\nDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA\\n\\nLawrence F. Bielak,\\xa0Jennifer A. Smith,\\xa0Sharon L. R. Kardia\\xa0&\\xa0Patricia A. Peyser\\n\\nCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan\\n\\nYasuharu Tabara,\\xa0Takahisa Kawaguchi\\xa0&\\xa0Fumihiko Matsuda\\n\\ndeCODE Genetics, Amgen, Reykjavik, Iceland\\n\\nGudmar Thorleifsson,\\xa0Valgerdur Steinthorsdottir,\\xa0Unnur Thorsteinsdottir\\xa0&\\xa0Kari Stefansson\\n\\nNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark\\n\\nNiels Grarup,\\xa0Jette Bork-Jensen,\\xa0Torben Hansen,\\xa0Oluf Pedersen\\xa0&\\xa0Ruth J. F. Loos\\n\\nDepartment of Biostatistics, Harvard University, Boston, MA, USA\\n\\nTamar Sofer\\n\\nDivision of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, USA\\n\\nTamar Sofer,\\xa0Brian E. Cade\\xa0&\\xa0Susan Redline\\n\\nDepartment of Medicine, Harvard University, Boston, MA, USA\\n\\nTamar Sofer\\n\\nInstitute of Genetic Epidemiology, Department of Data Driven Medicine, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany\\n\\nMatthias Wuttke\\xa0&\\xa0Anna Köttgen\\n\\nDepartment of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA\\n\\nChloé Sarnowski\\n\\nGerman Center for Diabetes Research (DZD), Neuherberg, Germany\\n\\nChristian Gieger,\\xa0Christian Herder,\\xa0Annette Peters,\\xa0Michael Roden,\\xa0Barbara Thorand\\xa0&\\xa0Harald Grallert\\n\\nResearch Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany\\n\\nChristian Gieger\\n\\nDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA\\n\\nDarryl Nousome\\xa0&\\xa0Roberta McKean-Cowdin\\n\\nDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands\\n\\nStella Trompet\\xa0&\\xa0J. Wouter Jukema\\n\\nSection of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands\\n\\nStella Trompet\\xa0&\\xa0Raymond Noordam\\n\\nDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea\\n\\nSoo-Heon Kwak\\xa0&\\xa0Kyong-Soo Park\\n\\nDivision of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA\\n\\nJirong Long,\\xa0Edmond Kabagambe,\\xa0Jacob M. Keaton,\\xa0Wei Zheng\\xa0&\\xa0Xiao-Ou Shu\\n\\nNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK\\n\\nMeng Sun\\n\\nInstitute for Population and Precision Health (IPPH), Biological Sciences Division, University of Chicago, Chicago, IL, USA\\n\\nLin Tong,\\xa0Farzana Jasmine,\\xa0Muhammad G. Kibriya,\\xa0Mohammad Shahriar\\xa0&\\xa0Habibul Ahsan\\n\\nDepartment of Public Health Sciences and Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA\\n\\nWei-Min Chen,\\xa0Uma Nayak\\xa0&\\xa0Michèle M. Sale\\n\\nGenomic Research on Complex Diseases (GRC-Group), CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, India\\n\\nSuraj S. Nongmaithem,\\xa0Sohail Rafik Mansuri,\\xa0Alagu Sankareswaran\\xa0&\\xa0Giriraj R. Chandak\\n\\nDepartment of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China\\n\\nClaudia H. T. Tam,\\xa0Juliana C. N. Chan,\\xa0Guozhi Jiang,\\xa0Andrea O. Luk,\\xa0Wing Yee So,\\xa0Brian Tomlinson\\xa0&\\xa0Ronald C. W. Ma\\n\\nChinese University of Hong Kong–Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine, Chinese University of Hong Kong, Hong Kong, China\\n\\nClaudia H. T. Tam,\\xa0Juliana C. N. Chan,\\xa0Guozhi Jiang,\\xa0Andrea O. Luk\\xa0&\\xa0Ronald C. W. Ma\\n\\nSamsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea\\n\\nYoonjung Yoonie Joo\\n\\nDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA\\n\\nYoonjung Yoonie Joo\\xa0&\\xa0Laura J. Rasmussen-Torvik\\n\\nInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan\\n\\nChien-Hsiun Chen,\\xa0Li-Ching Chang,\\xa0Yuan-Tsong Chen\\xa0&\\xa0Jer-Yuarn Wu\\n\\nDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA\\n\\nLaura M. Raffield,\\xa0K. Alaine Broadaway,\\xa0Qing Duan,\\xa0Yun Li\\xa0&\\xa0Karen L. Mohlke\\n\\nDepartment of Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK\\n\\nBram Peter Prins,\\xa0John Danesh\\xa0&\\xa0Sophie Hackinger\\n\\nLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA\\n\\nAude Nicolas\\xa0&\\xa0Michael A. Nalls\\n\\nDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA\\n\\nLisa R. Yanek\\xa0&\\xa0Diane M. Becker\\n\\nCenter for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA\\n\\nGuanjie Chen,\\xa0Adebowale Adeyemo,\\xa0Ayo P. Doumatey\\xa0&\\xa0Charles N. Rotimi\\n\\nCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA\\n\\nJennifer A. Brody,\\xa0James S. Floyd\\xa0&\\xa0Bruce M. Psaty\\n\\nDivision of Academics, Ochsner Health, New Orleans, LA, USA\\n\\nEdmond Kabagambe\\n\\nDivision of Statistical Genomics, Washington University School of Medicine, St Louis, MO, USA\\n\\nPing An\\xa0&\\xa0Michael A. Province\\n\\nDepartment of Research and Evaluation, Division of Biostatistics Research, Kaiser Permanente of Southern California, Pasadena, CA, USA\\n\\nAnny H. Xiang\\n\\nDepartment of Biomedical Science, Hallym University, Chuncheon, South Korea\\n\\nHyeok Sun Choi\\xa0&\\xa0Yoon Shin Cho\\n\\nHarvard Medical School, Boston, MA, USA\\n\\nBrian E. Cade,\\xa0Susan Redline\\xa0&\\xa0Josep M. Mercader\\n\\nMetabolic Research Laboratories, Wellcome Trust–Medical Research Council Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK\\n\\nAlice Williamson\\n\\nDepartment of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands\\n\\nZoha Kamali\\n\\nDepartment of Bioinformatics, Isfahan University of Medical Sciences, Isfahan, Iran\\n\\nZoha Kamali\\n\\nDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA\\n\\nJinrui Cui\\xa0&\\xa0Mark O. Goodarzi\\n\\nLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden\\n\\nManonanthini Thangam,\\xa0Olle Melander,\\xa0Tiinamaija Tuomi\\xa0&\\xa0Emma Ahlqvist\\n\\nDepartment of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA\\n\\nLinda S. Adair,\\xa0Shufa Du\\xa0&\\xa0Penny Gordon-Larsen\\n\\nUnidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico\\n\\nCarlos A. Aguilar-Salinas\\n\\nSteno Diabetes Center Copenhagen, Herlev, Denmark\\n\\nTarunveer S. Ahluwalia\\n\\nBioinformatics Center, Department of Biology, University of Copenhagen, Copenhagen, Denmark\\n\\nTarunveer S. Ahluwalia\\n\\nDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada\\n\\nSonia S. Anand,\\xa0Hertzel C. Gerstein\\xa0&\\xa0Salim Yusuf\\n\\nDepartment of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nAlain Bertoni\\xa0&\\xa0Yongmei Liu\\n\\nInstitute of Regional Health Research, University of Southern Denmark, Odense, Denmark\\n\\nIvan Brandslund\\n\\nDepartment of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark\\n\\nIvan Brandslund\\n\\nDepartment of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of USC, Los Angeles, CA, USA\\n\\nThomas A. Buchanan\\n\\nDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA\\n\\nCharles F. Burant\\n\\nBritish Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK\\n\\nAdam S. Butterworth\\xa0&\\xa0John Danesh\\n\\nHealth Data Research UK Cambridge, Wellcome Genome Campus, University of Cambridge, Hinxton, UK\\n\\nAdam S. Butterworth\\xa0&\\xa0John Danesh\\n\\nNational Institute for Health and Care Research (NIHR) Blood and Transplant Unit (BTRU) in Donor Health and Behaviour, Heart and Lung Research Institute, University of Cambridge, Cambridge, UK\\n\\nAdam S. Butterworth\\xa0&\\xa0John Danesh\\n\\nInserm U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France\\n\\nMickaël Canouil,\\xa0Amélie Bonnefond\\xa0&\\xa0Philippe Froguel\\n\\nUniversity of Lille, Lille, France\\n\\nMickaël Canouil,\\xa0Amélie Bonnefond\\xa0&\\xa0Philippe Froguel\\n\\nLi Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China\\n\\nJuliana C. N. Chan\\xa0&\\xa0Ronald C. W. Ma\\n\\nHong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong, Hong Kong, China\\n\\nJuliana C. N. Chan,\\xa0Wing Yee So\\xa0&\\xa0Ronald C. W. Ma\\n\\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore\\n\\nMiao-Li Chee,\\xa0Charumathi Sabanayagam,\\xa0Liang Zhang,\\xa0Tien-Yin Wong\\xa0&\\xa0Ching-Yu Cheng\\n\\nExeter Centre of Excellence in Diabetes (ExCEeD), Exeter Medical School, University of Exeter, Exeter, UK\\n\\nJi Chen\\n\\nWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK\\n\\nJi Chen\\n\\nDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nShyh-Huei Chen\\n\\nDivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan\\n\\nLee-Ming Chuang\\n\\nInstitute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan\\n\\nLee-Ming Chuang\\n\\nDepartment of Medicine, University of Vermont, Colchester, VT, USA\\n\\nMary Cushman\\n\\nSection of Endocrinology and Metabolism, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nSwapan K. Das\\n\\nDepartment of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka\\n\\nH. Janaka de Silva\\n\\nDepartment of Nutrition and Dietetics, Harokopio University of Athens, Athens, Greece\\n\\nGeorge Dedoussis\\n\\nCenter for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nLatchezar Dimitrov,\\xa0Jacob M. Keaton,\\xa0Donald W. Bowden\\xa0&\\xa0Maggie C. Y. Ng\\n\\nCarolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA\\n\\nShufa Du,\\xa0Penny Gordon-Larsen\\xa0&\\xa0Annie-Green Howard\\n\\nDepartment of Nephrology and Medical Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany\\n\\nKai-Uwe Eckardt\\n\\nDepartment of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany\\n\\nKai-Uwe Eckardt\\n\\nDepartment of Biostatistics, University of Washington, Seattle, WA, USA\\n\\nLeslie S. Emery,\\xa0Tin Louie\\xa0&\\xa0Adrienne M. Stilp\\n\\nCalifornia Pacific Medical Center Research Institute, San Francisco, CA, USA\\n\\nDaniel S. Evans\\n\\nLaboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA\\n\\nMichele K. Evans,\\xa0Botong Shen\\xa0&\\xa0Alan B. Zonderman\\n\\nInstitute of Mathematics and Statistics, University of Tartu, Tartu, Estonia\\n\\nKrista Fischer\\n\\nRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK\\n\\nIan Ford\\n\\nDepartment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands\\n\\nOscar H. Franco,\\xa0Mohammad Arfan Ikram,\\xa0Symen Ligthart\\xa0&\\xa0Mohsen Ghanbari\\n\\nGenetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK\\n\\nTimothy M. Frayling\\n\\nDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nBarry I. Freedman\\n\\nDepartment of Medicine, Division of Endocrinology and Metabolism, Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA\\n\\nPauline Genter\\xa0&\\xa0Eli Ipp\\n\\nDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden\\n\\nVilmantas Giedraitis\\xa0&\\xa0Martin Ingelsson\\n\\nCentro de Estudios en Diabetes, Unidad de Investigacion en Diabetes y Riesgo Cardiovascular, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Mexico City, Mexico\\n\\nClicerio González-Villalpando\\xa0&\\xa0Maria Elena González-Villalpando\\n\\nDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA\\n\\nMyron Gross\\n\\nGenomics and Computational Biology Graduate Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nLindsay A. Guare\\n\\nInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland\\n\\nLiisa Hakaste\\xa0&\\xa0Tiinamaija Tuomi\\n\\nFolkhalsan Research Center, Helsinki, Finland\\n\\nLiisa Hakaste\\xa0&\\xa0Tiinamaija Tuomi\\n\\nUniversity of Exeter Medical School, University of Exeter, Exeter, UK\\n\\nAndrew T. Hattersley\\n\\nInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany\\n\\nChristian Herder\\xa0&\\xa0Michael Roden\\n\\nDepartment of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany\\n\\nChristian Herder\\xa0&\\xa0Michael Roden\\n\\nLaboratory for Genomics of Diabetes and Metabolism, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan\\n\\nMomoko Horikoshi\\xa0&\\xa0Shiro Maeda\\n\\nDepartment of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA\\n\\nAnnie-Green Howard\\n\\nDepartment of Internal Medicine, Diabetes and Metabolism Research Center, Ohio State University Wexner Medical Center, Columbus, OH, USA\\n\\nWilla Hsueh\\n\\nCenter for Global Cardiometabolic Health, Brown University, Providence, RI, USA\\n\\nMengna Huang\\xa0&\\xa0Simin Liu\\n\\nShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China\\n\\nWei Huang\\xa0&\\xa0Jinxiu Shi\\n\\nDivision of Endocrine and Metabolism, Tri-Service General Hospital Songshan Branch, Taipei, Taiwan\\n\\nYi-Jen Hung\\n\\nSchool of Medicine, National Defense Medical Center, Taipei, Taiwan\\n\\nYi-Jen Hung\\xa0&\\xa0Wayne H. H. Sheu\\n\\nDivision of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju-si, Korea\\n\\nMi Yeong Hwang,\\xa0Hye-Mi Jang,\\xa0Dong Mun Shin,\\xa0Kyungheon Yoon,\\xa0Juyoung Lee\\xa0&\\xa0Bong-Jo Kim\\n\\nSection of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan\\n\\nChii-Min Hwu\\n\\nSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan\\n\\nChii-Min Hwu\\xa0&\\xa0Wayne H. H. Sheu\\n\\nDepartment of Environmental and Preventive Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan\\n\\nSahoko Ichihara\\n\\nUniversity of Chicago Research Bangladesh, Dhaka, Bangladesh\\n\\nMd. Tariqul Islam\\n\\nInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland\\n\\nJost B. Jonas\\n\\nCenter for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark\\n\\nTorben Jørgensen\\xa0&\\xa0Allan Linneberg\\n\\nFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark\\n\\nTorben Jørgensen\\n\\nFaculty of Medicine, Aalborg University, Aalborg, Denmark\\n\\nTorben Jørgensen\\n\\nDepartment of Clinical Diabetes, Endocrinology and Metabolism, Department of Translational Research and Cellular Therapeutics, City of Hope, Duarte, CA, USA\\n\\nFouad R. Kandeel\\n\\nDepartment of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka\\n\\nAnuradhani Kasturiratne\\xa0&\\xa0Ananda R. Wickremasinghe\\n\\nDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan\\n\\nTomohiro Katsuya\\n\\nDepartment of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan\\n\\nTomohiro Katsuya\\n\\nDivision of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA\\n\\nAbel N. Kho\\n\\nCenter for Health Information Partnerships, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA\\n\\nAbel N. Kho\\n\\nGenome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore\\n\\nChiea-Chuen Khor\\xa0&\\xa0Jianjun Liu\\n\\nDepartment of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea\\n\\nDuk-Hwan Kim\\n\\nInstitute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria\\n\\nFlorian Kronenberg\\xa0&\\xa0Sebastian Schönherr\\n\\nInstitute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland\\n\\nJohanna Kuusisto,\\xa0Alena Stančáková\\xa0&\\xa0Markku Laakso\\n\\nDepartment of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA\\n\\nLeslie A. Lange\\n\\nVA Salt Lake City Health Care System, Salt Lake City, UT, USA\\n\\nKyung Min Lee\\xa0&\\xa0Julie A. Lynch\\n\\nDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA\\n\\nKyung Min Lee\\xa0&\\xa0Julie A. Lynch\\n\\nSoochunhyang Institute of Medi-bio Science and Division of Endocrinology, Department of Internal Medicine, Soochunhyang University College of Medicine, Cheonan, South Korea\\n\\nMyung-Shik Lee\\n\\nDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea\\n\\nMyung-Shik Lee\\n\\nUSC-Office of Population Studies Foundation, University of San Carlos, Cebu City, Philippines\\n\\nNanette R. Lee\\n\\nDepartment of Medicine, Harvard Medical School, Boston, MA, USA\\n\\nAaron Leong,\\xa0Miriam S. Udler,\\xa0Jose C. Florez\\xa0&\\xa0James B. Meigs\\n\\nDivision of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA\\n\\nAaron Leong,\\xa0Bianca Porneala\\xa0&\\xa0James B. Meigs\\n\\nDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China\\n\\nLiming Li,\\xa0Jun Lv\\xa0&\\xa0Canqing Yu\\n\\nPeking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China\\n\\nLiming Li,\\xa0Jun Lv,\\xa0Pei Pei\\xa0&\\xa0Canqing Yu\\n\\nDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands\\n\\nRuifang Li-Gao\\xa0&\\xa0Dennis O. Mook-Kanamori\\n\\nWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK\\n\\nCecilia M. Lindgren,\\xa0Mark I. McCarthy\\xa0&\\xa0Anubha Mahajan\\n\\nProgram in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA\\n\\nCecilia M. Lindgren\\n\\nBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK\\n\\nCecilia M. Lindgren\\n\\nDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark\\n\\nAllan Linneberg\\n\\nDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA\\n\\nChing-Ti Liu\\xa0&\\xa0Josee Dupuis\\n\\nDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore\\n\\nJianjun Liu,\\xa0Rob M. van Dam\\xa0&\\xa0E-Shyong Tai\\n\\nMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA\\n\\nAdam E. Locke\\n\\nDepartment of Medicine, Division of Genomics and Bioinformatics, Washington University School of Medicine, St Louis, MO, USA\\n\\nAdam E. Locke\\n\\nDepartment of Biostatistics and Data Science, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA\\n\\nXi Luo\\n\\nDepartment of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden\\n\\nValeriya Lyssenko\\n\\nDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, Bergen, Norway\\n\\nValeriya Lyssenko\\n\\nDepartment of Advanced Genomic and Laboratory Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan\\n\\nShiro Maeda\\n\\nDivision of Clinical Laboratory and Blood Transfusion, University of the Ryukyus Hospital, Nishihara, Japan\\n\\nShiro Maeda\\n\\nDromokaiteio Psychiatric Hospital, National and Kapodistrian University of Athens, Athens, Greece\\n\\nVasiliki Mamakou\\n\\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, India\\n\\nSohail Rafik Mansuri\\xa0&\\xa0Alagu Sankareswaran\\n\\nComputational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan\\n\\nKoichi Matsuda\\n\\nInstitute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany\\n\\nThomas Meitinger\\n\\nInstitute of Human Genetics, Technical University Munich, Munich, Germany\\n\\nThomas Meitinger\\n\\nGerman Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany\\n\\nThomas Meitinger\\xa0&\\xa0Annette Peters\\n\\nUsher Institute to the Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK\\n\\nAndrew D. Morris\\n\\nDepartment of Medicine and Pharmacology, New York Medical College, Valhalla, NY, USA\\n\\nJerry L. Nadler\\n\\nData Tecnica International, Glen Echo, MD, USA\\n\\nMichael A. Nalls\\n\\nCenter for Alzheimer’s and Related Dementias, National Institutes of Health, Bethesda, MD, USA\\n\\nMichael A. Nalls\\n\\nLaboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan\\n\\nYukinori Okada\\xa0&\\xa0Kenichi Yamamoto\\n\\nPremium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Japan\\n\\nYukinori Okada\\n\\nInstituto Nacional de Medicina Genómica, Mexico City, Mexico\\n\\nLorena Orozco\\n\\nDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA\\n\\nSanjay R. Patel\\n\\nDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA\\n\\nMark A. Pereira\\xa0&\\xa0James S. Pankow\\n\\nInstitute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany\\n\\nAnnette Peters\\n\\nDepartment of Diabetes and Endocrinology, Nelson R. Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa\\n\\nFraser J. Pirie\\xa0&\\xa0Ayesha A. Motala\\n\\nAcademy of Scientific and Innovative Research, CSIR-Human Resource Development Campus, Ghaziabad, India\\n\\nGauri Prasad\\n\\nGenomics and Molecular Medicine Unit, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India\\n\\nGauri Prasad\\n\\nFred Hutchinson Cancer Research Center, Seattle, WA, USA\\n\\nAlexander P. Reiner\\xa0&\\xa0Charles Kooperberg\\n\\nOphthalmology and Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore\\n\\nCharumathi Sabanayagam,\\xa0Tien-Yin Wong\\xa0&\\xa0Ching-Yu Cheng\\n\\nDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore\\n\\nCharumathi Sabanayagam,\\xa0Tien-Yin Wong\\xa0&\\xa0Ching-Yu Cheng\\n\\nSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK\\n\\nNaveed Sattar\\n\\nSurvey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA\\n\\nJennifer A. Smith\\n\\nInstitute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany\\n\\nKonstantin Strauch\\n\\nInstitute for Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University, Mainz, Germany\\n\\nKonstantin Strauch\\n\\nChair of Genetic Epidemiology, Institute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany\\n\\nKonstantin Strauch\\n\\nFaculty of Medicine, University of Iceland, Reykjavik, Iceland\\n\\nUnnur Thorsteinsdottir\\xa0&\\xa0Kari Stefansson\\n\\nFaculty of Medicine, Macau University of Science and Technology, Macau, China\\n\\nBrian Tomlinson\\n\\nDepartment of Medical Genetics and Medical Research, China Medical University Hospital, Taichung, Taiwan\\n\\nFuu-Jen Tsai\\n\\nPopulation Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland\\n\\nJaakko Tuomilehto\\n\\nNational School of Public Health, Madrid, Spain\\n\\nJaakko Tuomilehto\\n\\nDepartment of Public Health, University of Helsinki, Helsinki, Finland\\n\\nJaakko Tuomilehto\\n\\nDiabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia\\n\\nJaakko Tuomilehto\\n\\nUnidad de Biología Molecular y Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico\\n\\nTeresa Tusie-Luna\\n\\nDepartamento de Medicina Genómica y Toxiología Ambiental, Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico\\n\\nTeresa Tusie-Luna\\n\\nUnidad de Investigacion Medica en Bioquimica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico\\n\\nAdan Valladares-Salgado\\xa0&\\xa0Miguel Cruz\\n\\nEinthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands\\n\\nJan B. van Klinken\\xa0&\\xa0Ko Willems van Dijk\\n\\nDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands\\n\\nJan B. van Klinken\\xa0&\\xa0Ko Willems van Dijk\\n\\nDepartment of Clinical Chemistry, Laboratory of Genetic Metabolic Disease, Amsterdam University Medical Center, Amsterdam, The Netherlands\\n\\nJan B. van Klinken\\n\\nSouthern California Eye Institute, CHA Hollywood Presbyterian Hospital, Los Angeles, CA, USA\\n\\nRohit Varma\\n\\nUnidad de Investigación Médica en Epidemiologia Clinica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico\\n\\nNiels Wacher-Rodarte\\n\\nDepartment of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands\\n\\nKo Willems van Dijk\\n\\nDepartment of Public Health, Aarhus University, Aarhus, Denmark\\n\\nDaniel R. Witte\\n\\nDanish Diabetes Academy, Odense, Denmark\\n\\nDaniel R. Witte\\n\\nDiabetology Research Centre, King Edward Memorial Hospital and Research Centre, Pune, India\\n\\nChittaranjan S. Yajnik\\n\\nDepartment of Medical Biochemistry, Kurume University School of Medicine, Kurume, Japan\\n\\nKen Yamamoto\\n\\nDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan\\n\\nKenichi Yamamoto\\n\\nDivision of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA\\n\\nJian-Min Yuan\\n\\nDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA\\n\\nJian-Min Yuan\\n\\nDepartment of Pediatrics, Division of Genetic and Genomic Medicine, UCI Irvine School of Medicine, Irvine, CA, USA\\n\\nLeslie J. Raffel\\n\\nDepartment of Anti-Aging Medicine, Ehime University Graduate School of Medicine, Touon, Japan\\n\\nMichiya Igase\\n\\nDivision of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA\\n\\nSusan Redline\\n\\nDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden\\n\\nLars Lind\\n\\nInstitute of Molecular Medicine, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA\\n\\nMyriam Fornage\\n\\nHuman Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA\\n\\nCraig L. Hanis\\n\\nDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA\\n\\nErik Ingelsson\\xa0&\\xa0Philip S. Tsao\\n\\nDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden\\n\\nErik Ingelsson\\n\\nDepartment of Epidemiology, University of Washington, Seattle, WA, USA\\n\\nBruce M. Psaty\\n\\nDepartment of Health Systems and Population Health, University of Washington, Seattle, WA, USA\\n\\nBruce M. Psaty\\n\\nBeijing Institute of Ophthalmology, Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing, China\\n\\nYa-Xing Wang\\n\\nDepartment of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA\\n\\nYongmei Liu\\n\\nKurume University School of Medicine, Kurume, Japan\\n\\nMitsuhiro Yokota\\n\\nDepartment of Medicine, McGill University, Montreal, Quebec, Canada\\n\\nJames C. Engert\\n\\nDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada\\n\\nJames C. Engert\\n\\nDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK\\n\\nAmélie Bonnefond\\xa0&\\xa0Philippe Froguel\\n\\nDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA\\n\\nJames G. Wilson\\n\\nDivision of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan\\n\\nWayne H. H. Sheu\\n\\nDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA\\n\\nM. Geoffrey Hayes\\n\\nCenter for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA\\n\\nM. Geoffrey Hayes\\n\\nDepartment of Anthropology, Northwestern University, Evanston, IL, USA\\n\\nM. Geoffrey Hayes\\n\\nDepartment of Endocrinology, Helsinki University Hospital, Helsinki, Finland\\n\\nTiinamaija Tuomi\\n\\nScience and Engineering Research Board (SERB), Department of Science and Technology, Ministry of Science and Technology, Government of India, New Delhi, India\\n\\nGiriraj R. Chandak\\n\\nSystems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India\\n\\nDwaipayan Bharadwaj\\n\\nDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada\\n\\nGuillaume Paré\\n\\nDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea\\n\\nKyong-Soo Park\\n\\nNetherlands Heart Institute, Utrecht, The Netherlands\\n\\nJ. Wouter Jukema\\n\\nCenter for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA\\n\\nStephen S. Rich\\n\\nResearch Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany\\n\\nHarald Grallert\\n\\nDuke-NUS Medical School, Singapore, Singapore\\n\\nE-Shyong Tai\\n\\nDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada\\n\\nJosee Dupuis\\n\\nSingapore Institute for Clinical Sciences, Agency for Science Technology and Research (A\\\\*STAR), Singapore, Singapore\\n\\nWoon-Puay Koh\\n\\nHealthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore\\n\\nWoon-Puay Koh\\n\\nCenter for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nDonald W. Bowden\\n\\nDepartment of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA\\n\\nDonald W. Bowden\\xa0&\\xa0Maggie C. Y. Ng\\n\\nPat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, University of Dundee, Dundee, UK\\n\\nColin N. A. Palmer\\n\\nImperial College Healthcare NHS Trust, Imperial College London, London, UK\\n\\nJaspal S. Kooner\\xa0&\\xa0John C. Chambers\\n\\nMRC-PHE Centre for Environment and Health, Imperial College London, London, UK\\n\\nJaspal S. Kooner\\n\\nNational Heart and Lung Institute, Imperial College London, London, UK\\n\\nJaspal S. Kooner\\n\\nDepartment of Medicine, Brown University Alpert School of Medicine, Providence, RI, USA\\n\\nSimin Liu\\n\\nDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA\\n\\nDanish Saleheen\\n\\nDepartment of Cardiology, Columbia University Irving Medical Center, New York, NY, USA\\n\\nDanish Saleheen\\n\\nCenter for Non-Communicable Diseases, Karachi, Pakistan\\n\\nDanish Saleheen\\n\\nComputational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin, Berlin, Germany\\n\\nClaudia Langenberg\\n\\nPrecision Healthcare University Research Institute, Queen Mary University of London, London, UK\\n\\nClaudia Langenberg\\n\\nDepartment of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA\\n\\nChristopher A. Haiman\\n\\nThe Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA\\n\\nRuth J. F. Loos\\n\\nDivision of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nDaniel J. Rader\\n\\nInstitute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nDaniel J. Rader\\xa0&\\xa0Benjamin F. Voight\\n\\nDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nDaniel J. Rader\\n\\nCenter for Precision Medicine, University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, USA\\n\\nMarylyn D. Ritchie\\n\\nInstitute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nMarylyn D. Ritchie\\n\\nDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USA\\n\\nSebastian Zöllner\\n\\nBlizard Institute, Queen Mary University of London, London, UK\\n\\nDavid A. van Heel\\xa0&\\xa0David A. van Heel\\n\\nInstitute for Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK\\n\\nSarah Finer\\n\\nAll of Us Research Program, National Institutes of Health, Bethesda, MD, USA\\n\\nJoshua C. Denny\\n\\nToranomon Hospital, Tokyo, Japan\\n\\nTakashi Kadowaki\\n\\nLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore\\n\\nJohn C. Chambers\\n\\nVanderbilt Genetics Institute, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA\\n\\nMaggie C. Y. Ng\\n\\nVA Palo Alto Health Care System, Palo Alto, CA, USA\\n\\nPhilip S. Tsao\\n\\nStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA\\n\\nPhilip S. Tsao\\n\\nDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nKyong-Mi Chang\\xa0&\\xa0Marijana Vujkovic\\n\\nOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK\\n\\nMark I. McCarthy\\xa0&\\xa0Anubha Mahajan\\n\\nOxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK\\n\\nMark I. McCarthy\\n\\nDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA\\n\\nCassandra N. Spracklen\\n\\nDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA\\n\\nMarijana Vujkovic\\n\\nTUM School of Medicine and Health, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany\\n\\nEleftheria Zeggini\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ken%20Suzuki)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ken%20Suzuki%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Konstantinos%20Hatzikotoulas)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Konstantinos%20Hatzikotoulas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lorraine%20Southam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lorraine%20Southam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Henry%20J.%20Taylor)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Henry%20J.%20Taylor%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xianyong%20Yin)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xianyong%20Yin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kim%20M.%20Lorenz)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kim%20M.%20Lorenz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ravi%20Mandla)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ravi%20Mandla%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alicia%20Huerta-Chagoya)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alicia%20Huerta-Chagoya%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Giorgio%20E.%20M.%20Melloni)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Giorgio%20E.%20M.%20Melloni%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stavroula%20Kanoni)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stavroula%20Kanoni%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nigel%20W.%20Rayner)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nigel%20W.%20Rayner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ozvan%20Bocher)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ozvan%20Bocher%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ana%20Luiza%20Arruda)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ana%20Luiza%20Arruda%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyuto%20Sonehara)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyuto%20Sonehara%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shinichi%20Namba)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shinichi%20Namba%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Simon%20S.%20K.%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Simon%20S.%20K.%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20H.%20Preuss)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20H.%20Preuss%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lauren%20E.%20Petty)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lauren%20E.%20Petty%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Philip%20Schroeder)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Philip%20Schroeder%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brett%20Vanderwerff)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brett%20Vanderwerff%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mart%20Kals)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mart%20Kals%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fiona%20Bragg)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fiona%20Bragg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kuang%20Lin)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kuang%20Lin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiuqing%20Guo)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiuqing%20Guo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Weihua%20Zhang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Weihua%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jie%20Yao)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jie%20Yao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Young%20Jin%20Kim)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Young%20Jin%20Kim%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mariaelisa%20Graff)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mariaelisa%20Graff%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fumihiko%20Takeuchi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fumihiko%20Takeuchi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jana%20Nano)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jana%20Nano%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Amel%20Lamri)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Amel%20Lamri%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masahiro%20Nakatochi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masahiro%20Nakatochi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sanghoon%20Moon)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sanghoon%20Moon%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20A.%20Scott)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20A.%20Scott%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20P.%20Cook)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20P.%20Cook%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jung-Jin%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jung-Jin%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ian%20Pan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ian%20Pan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20Taliun)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20Taliun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Esteban%20J.%20Parra)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Esteban%20J.%20Parra%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jin-Fang%20Chai)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jin-Fang%20Chai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lawrence%20F.%20Bielak)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lawrence%20F.%20Bielak%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yasuharu%20Tabara)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yasuharu%20Tabara%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yang%20Hai)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yang%20Hai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gudmar%20Thorleifsson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gudmar%20Thorleifsson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Niels%20Grarup)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Niels%20Grarup%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tamar%20Sofer)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tamar%20Sofer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Matthias%20Wuttke)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Matthias%20Wuttke%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chlo%C3%A9%20Sarnowski)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chlo%C3%A9%20Sarnowski%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Christian%20Gieger)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Christian%20Gieger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Darryl%20Nousome)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Darryl%20Nousome%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stella%20Trompet)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stella%20Trompet%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Soo-Heon%20Kwak)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Soo-Heon%20Kwak%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jirong%20Long)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jirong%20Long%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Meng%20Sun)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Meng%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lin%20Tong)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lin%20Tong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wei-Min%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wei-Min%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Suraj%20S.%20Nongmaithem)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Suraj%20S.%20Nongmaithem%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Raymond%20Noordam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Raymond%20Noordam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Victor%20J.%20Y.%20Lim)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Victor%20J.%20Y.%20Lim%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Claudia%20H.%20T.%20Tam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Claudia%20H.%20T.%20Tam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yoonjung%20Yoonie%20Joo)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yoonjung%20Yoonie%20Joo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chien-Hsiun%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chien-Hsiun%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Laura%20M.%20Raffield)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Laura%20M.%20Raffield%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bram%20Peter%20Prins)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bram%20Peter%20Prins%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Aude%20Nicolas)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Aude%20Nicolas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lisa%20R.%20Yanek)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lisa%20R.%20Yanek%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guanjie%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guanjie%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jennifer%20A.%20Brody)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jennifer%20A.%20Brody%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Edmond%20Kabagambe)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Edmond%20Kabagambe%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ping%20An)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ping%20An%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anny%20H.%20Xiang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anny%20H.%20Xiang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hyeok%20Sun%20Choi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hyeok%20Sun%20Choi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brian%20E.%20Cade)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brian%20E.%20Cade%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jingyi%20Tan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jingyi%20Tan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=K.%20Alaine%20Broadaway)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22K.%20Alaine%20Broadaway%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alice%20Williamson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alice%20Williamson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zoha%20Kamali)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zoha%20Kamali%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jinrui%20Cui)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jinrui%20Cui%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Manonanthini%20Thangam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Manonanthini%20Thangam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Linda%20S.%20Adair)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Linda%20S.%20Adair%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adebowale%20Adeyemo)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adebowale%20Adeyemo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carlos%20A.%20Aguilar-Salinas)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carlos%20A.%20Aguilar-Salinas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tarunveer%20S.%20Ahluwalia)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tarunveer%20S.%20Ahluwalia%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sonia%20S.%20Anand)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sonia%20S.%20Anand%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alain%20Bertoni)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alain%20Bertoni%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jette%20Bork-Jensen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jette%20Bork-Jensen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ivan%20Brandslund)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ivan%20Brandslund%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20A.%20Buchanan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20A.%20Buchanan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Charles%20F.%20Burant)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Charles%20F.%20Burant%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adam%20S.%20Butterworth)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adam%20S.%20Butterworth%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Micka%C3%ABl%20Canouil)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Micka%C3%ABl%20Canouil%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Juliana%20C.%20N.%20Chan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Juliana%20C.%20N.%20Chan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Li-Ching%20Chang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Li-Ching%20Chang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Miao-Li%20Chee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Miao-Li%20Chee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ji%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ji%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shyh-Huei%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shyh-Huei%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yuan-Tsong%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yuan-Tsong%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zhengming%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zhengming%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lee-Ming%20Chuang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lee-Ming%20Chuang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mary%20Cushman)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mary%20Cushman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=John%20Danesh)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22John%20Danesh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Swapan%20K.%20Das)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Swapan%20K.%20Das%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=H.%20Janaka%20de%20Silva)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22H.%20Janaka%20de%20Silva%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=George%20Dedoussis)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22George%20Dedoussis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Latchezar%20Dimitrov)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Latchezar%20Dimitrov%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ayo%20P.%20Doumatey)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ayo%20P.%20Doumatey%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shufa%20Du)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shufa%20Du%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Qing%20Duan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Qing%20Duan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kai-Uwe%20Eckardt)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kai-Uwe%20Eckardt%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leslie%20S.%20Emery)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leslie%20S.%20Emery%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20S.%20Evans)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20S.%20Evans%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michele%20K.%20Evans)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michele%20K.%20Evans%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Krista%20Fischer)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Krista%20Fischer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20S.%20Floyd)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20S.%20Floyd%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ian%20Ford)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ian%20Ford%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Oscar%20H.%20Franco)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Oscar%20H.%20Franco%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Timothy%20M.%20Frayling)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Timothy%20M.%20Frayling%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Barry%20I.%20Freedman)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Barry%20I.%20Freedman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Pauline%20Genter)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Pauline%20Genter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hertzel%20C.%20Gerstein)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hertzel%20C.%20Gerstein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Vilmantas%20Giedraitis)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Vilmantas%20Giedraitis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Clicerio%20Gonz%C3%A1lez-Villalpando)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Clicerio%20Gonz%C3%A1lez-Villalpando%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maria%20Elena%20Gonz%C3%A1lez-Villalpando)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maria%20Elena%20Gonz%C3%A1lez-Villalpando%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Penny%20Gordon-Larsen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Penny%20Gordon-Larsen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Myron%20Gross)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Myron%20Gross%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lindsay%20A.%20Guare)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lindsay%20A.%20Guare%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sophie%20Hackinger)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sophie%20Hackinger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Liisa%20Hakaste)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Liisa%20Hakaste%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sohee%20Han)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sohee%20Han%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrew%20T.%20Hattersley)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrew%20T.%20Hattersley%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Christian%20Herder)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Christian%20Herder%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Momoko%20Horikoshi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Momoko%20Horikoshi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Annie-Green%20Howard)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Annie-Green%20Howard%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Willa%20Hsueh)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Willa%20Hsueh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mengna%20Huang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mengna%20Huang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wei%20Huang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wei%20Huang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yi-Jen%20Hung)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yi-Jen%20Hung%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mi%20Yeong%20Hwang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mi%20Yeong%20Hwang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chii-Min%20Hwu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chii-Min%20Hwu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sahoko%20Ichihara)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sahoko%20Ichihara%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mohammad%20Arfan%20Ikram)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mohammad%20Arfan%20Ikram%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Martin%20Ingelsson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Martin%20Ingelsson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Md.%20Tariqul%20Islam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Md.%20Tariqul%20Islam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masato%20Isono)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masato%20Isono%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hye-Mi%20Jang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hye-Mi%20Jang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Farzana%20Jasmine)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Farzana%20Jasmine%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guozhi%20Jiang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guozhi%20Jiang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jost%20B.%20Jonas)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jost%20B.%20Jonas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Torben%20J%C3%B8rgensen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Torben%20J%C3%B8rgensen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Frederick%20K.%20Kamanu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Frederick%20K.%20Kamanu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fouad%20R.%20Kandeel)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fouad%20R.%20Kandeel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anuradhani%20Kasturiratne)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anuradhani%20Kasturiratne%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tomohiro%20Katsuya)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tomohiro%20Katsuya%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Varinderpal%20Kaur)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Varinderpal%20Kaur%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Takahisa%20Kawaguchi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Takahisa%20Kawaguchi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jacob%20M.%20Keaton)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jacob%20M.%20Keaton%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Abel%20N.%20Kho)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Abel%20N.%20Kho%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chiea-Chuen%20Khor)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chiea-Chuen%20Khor%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Muhammad%20G.%20Kibriya)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Muhammad%20G.%20Kibriya%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Duk-Hwan%20Kim)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Duk-Hwan%20Kim%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Florian%20Kronenberg)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Florian%20Kronenberg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Johanna%20Kuusisto)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Johanna%20Kuusisto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kristi%20L%C3%A4ll)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kristi%20L%C3%A4ll%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leslie%20A.%20Lange)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leslie%20A.%20Lange%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyung%20Min%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyung%20Min%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Myung-Shik%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Myung-Shik%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nanette%20R.%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nanette%20R.%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Aaron%20Leong)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Aaron%20Leong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Liming%20Li)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Liming%20Li%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yun%20Li)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yun%20Li%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ruifang%20Li-Gao)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ruifang%20Li-Gao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Symen%20Ligthart)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Symen%20Ligthart%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cecilia%20M.%20Lindgren)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cecilia%20M.%20Lindgren%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Allan%20Linneberg)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Allan%20Linneberg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ching-Ti%20Liu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ching-Ti%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jianjun%20Liu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jianjun%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adam%20E.%20Locke)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adam%20E.%20Locke%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tin%20Louie)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tin%20Louie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jian%E2%80%99an%20Luan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jian%E2%80%99an%20Luan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrea%20O.%20Luk)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrea%20O.%20Luk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xi%20Luo)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xi%20Luo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jun%20Lv)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jun%20Lv%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Julie%20A.%20Lynch)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Julie%20A.%20Lynch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Valeriya%20Lyssenko)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Valeriya%20Lyssenko%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shiro%20Maeda)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shiro%20Maeda%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Vasiliki%20Mamakou)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Vasiliki%20Mamakou%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sohail%20Rafik%20Mansuri)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sohail%20Rafik%20Mansuri%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Koichi%20Matsuda)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Koichi%20Matsuda%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20Meitinger)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20Meitinger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Olle%20Melander)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Olle%20Melander%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andres%20Metspalu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andres%20Metspalu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Huan%20Mo)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Huan%20Mo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrew%20D.%20Morris)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrew%20D.%20Morris%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Filipe%20A.%20Moura)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Filipe%20A.%20Moura%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jerry%20L.%20Nadler)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jerry%20L.%20Nadler%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20A.%20Nalls)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20A.%20Nalls%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Uma%20Nayak)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Uma%20Nayak%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ioanna%20Ntalla)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ioanna%20Ntalla%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yukinori%20Okada)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yukinori%20Okada%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lorena%20Orozco)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lorena%20Orozco%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sanjay%20R.%20Patel)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sanjay%20R.%20Patel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Snehal%20Patil)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Snehal%20Patil%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Pei%20Pei)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Pei%20Pei%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20A.%20Pereira)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20A.%20Pereira%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Annette%20Peters)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Annette%20Peters%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fraser%20J.%20Pirie)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fraser%20J.%20Pirie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hannah%20G.%20Polikowsky)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hannah%20G.%20Polikowsky%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bianca%20Porneala)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bianca%20Porneala%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gauri%20Prasad)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gauri%20Prasad%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Laura%20J.%20Rasmussen-Torvik)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Laura%20J.%20Rasmussen-Torvik%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alexander%20P.%20Reiner)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alexander%20P.%20Reiner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20Roden)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20Roden%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rebecca%20Rohde)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rebecca%20Rohde%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Katheryn%20Roll)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Katheryn%20Roll%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Charumathi%20Sabanayagam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Charumathi%20Sabanayagam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kevin%20Sandow)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kevin%20Sandow%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alagu%20Sankareswaran)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alagu%20Sankareswaran%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Naveed%20Sattar)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Naveed%20Sattar%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sebastian%20Sch%C3%B6nherr)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sebastian%20Sch%C3%B6nherr%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mohammad%20Shahriar)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mohammad%20Shahriar%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Botong%20Shen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Botong%20Shen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jinxiu%20Shi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jinxiu%20Shi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dong%20Mun%20Shin)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dong%20Mun%20Shin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nobuhiro%20Shojima)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nobuhiro%20Shojima%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jennifer%20A.%20Smith)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jennifer%20A.%20Smith%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wing%20Yee%20So)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wing%20Yee%20So%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alena%20Stan%C4%8D%C3%A1kov%C3%A1)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alena%20Stan%C4%8D%C3%A1kov%C3%A1%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Valgerdur%20Steinthorsdottir)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Valgerdur%20Steinthorsdottir%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adrienne%20M.%20Stilp)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adrienne%20M.%20Stilp%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Konstantin%20Strauch)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Konstantin%20Strauch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kent%20D.%20Taylor)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kent%20D.%20Taylor%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Barbara%20Thorand)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Barbara%20Thorand%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Unnur%20Thorsteinsdottir)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Unnur%20Thorsteinsdottir%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brian%20Tomlinson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brian%20Tomlinson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tam%20C.%20Tran)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tam%20C.%20Tran%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fuu-Jen%20Tsai)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fuu-Jen%20Tsai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jaakko%20Tuomilehto)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jaakko%20Tuomilehto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Teresa%20Tusie-Luna)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Teresa%20Tusie-Luna%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Miriam%20S.%20Udler)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Miriam%20S.%20Udler%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adan%20Valladares-Salgado)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adan%20Valladares-Salgado%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rob%20M.%20van%20Dam)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rob%20M.%20van%20Dam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jan%20B.%20van%20Klinken)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jan%20B.%20van%20Klinken%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rohit%20Varma)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rohit%20Varma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Niels%20Wacher-Rodarte)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Niels%20Wacher-Rodarte%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eleanor%20Wheeler)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eleanor%20Wheeler%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ananda%20R.%20Wickremasinghe)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ananda%20R.%20Wickremasinghe%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ko%20Willems%20van%20Dijk)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ko%20Willems%20van%20Dijk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20R.%20Witte)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20R.%20Witte%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chittaranjan%20S.%20Yajnik)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chittaranjan%20S.%20Yajnik%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ken%20Yamamoto)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ken%20Yamamoto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kenichi%20Yamamoto)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kenichi%20Yamamoto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyungheon%20Yoon)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyungheon%20Yoon%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Canqing%20Yu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Canqing%20Yu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jian-Min%20Yuan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jian-Min%20Yuan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Salim%20Yusuf)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Salim%20Yusuf%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Matthew%20Zawistowski)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Matthew%20Zawistowski%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Liang%20Zhang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Liang%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wei%20Zheng)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wei%20Zheng%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leslie%20J.%20Raffel)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leslie%20J.%20Raffel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michiya%20Igase)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michiya%20Igase%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eli%20Ipp)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eli%20Ipp%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Susan%20Redline)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Susan%20Redline%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yoon%20Shin%20Cho)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yoon%20Shin%20Cho%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lars%20Lind)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lars%20Lind%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20A.%20Province)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20A.%20Province%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Myriam%20Fornage)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Myriam%20Fornage%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Craig%20L.%20Hanis)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Craig%20L.%20Hanis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Erik%20Ingelsson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Erik%20Ingelsson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alan%20B.%20Zonderman)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alan%20B.%20Zonderman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bruce%20M.%20Psaty)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bruce%20M.%20Psaty%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ya-Xing%20Wang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ya-Xing%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Charles%20N.%20Rotimi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Charles%20N.%20Rotimi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Diane%20M.%20Becker)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Diane%20M.%20Becker%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fumihiko%20Matsuda)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fumihiko%20Matsuda%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yongmei%20Liu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yongmei%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mitsuhiro%20Yokota)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mitsuhiro%20Yokota%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sharon%20L.%20R.%20Kardia)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sharon%20L.%20R.%20Kardia%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Patricia%20A.%20Peyser)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Patricia%20A.%20Peyser%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20S.%20Pankow)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20S.%20Pankow%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20C.%20Engert)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20C.%20Engert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Am%C3%A9lie%20Bonnefond)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Am%C3%A9lie%20Bonnefond%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Philippe%20Froguel)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Philippe%20Froguel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20G.%20Wilson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20G.%20Wilson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wayne%20H.%20H.%20Sheu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wayne%20H.%20H.%20Sheu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jer-Yuarn%20Wu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jer-Yuarn%20Wu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20Geoffrey%20Hayes)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20Geoffrey%20Hayes%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ronald%20C.%20W.%20Ma)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ronald%20C.%20W.%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tien-Yin%20Wong)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tien-Yin%20Wong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dennis%20O.%20Mook-Kanamori)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dennis%20O.%20Mook-Kanamori%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tiinamaija%20Tuomi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tiinamaija%20Tuomi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Giriraj%20R.%20Chandak)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Giriraj%20R.%20Chandak%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Francis%20S.%20Collins)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Francis%20S.%20Collins%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dwaipayan%20Bharadwaj)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dwaipayan%20Bharadwaj%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guillaume%20Par%C3%A9)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guillaume%20Par%C3%A9%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mich%C3%A8le%20M.%20Sale)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mich%C3%A8le%20M.%20Sale%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Habibul%20Ahsan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Habibul%20Ahsan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ayesha%20A.%20Motala)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ayesha%20A.%20Motala%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiao-Ou%20Shu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiao-Ou%20Shu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyong-Soo%20Park)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyong-Soo%20Park%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20Wouter%20Jukema)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20Wouter%20Jukema%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Miguel%20Cruz)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Miguel%20Cruz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yii-Der%20Ida%20Chen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yii-Der%20Ida%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stephen%20S.%20Rich)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stephen%20S.%20Rich%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Roberta%20McKean-Cowdin)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Roberta%20McKean-Cowdin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Harald%20Grallert)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Harald%20Grallert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ching-Yu%20Cheng)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ching-Yu%20Cheng%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mohsen%20Ghanbari)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mohsen%20Ghanbari%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E-Shyong%20Tai)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E-Shyong%20Tai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Josee%20Dupuis)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Josee%20Dupuis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Norihiro%20Kato)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Norihiro%20Kato%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Markku%20Laakso)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Markku%20Laakso%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anna%20K%C3%B6ttgen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anna%20K%C3%B6ttgen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Woon-Puay%20Koh)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Woon-Puay%20Koh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Donald%20W.%20Bowden)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Donald%20W.%20Bowden%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Colin%20N.%20A.%20Palmer)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Colin%20N.%20A.%20Palmer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jaspal%20S.%20Kooner)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jaspal%20S.%20Kooner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Charles%20Kooperberg)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Charles%20Kooperberg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Simin%20Liu)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Simin%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kari%20E.%20North)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kari%20E.%20North%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Danish%20Saleheen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Danish%20Saleheen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Torben%20Hansen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Torben%20Hansen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Oluf%20Pedersen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Oluf%20Pedersen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nicholas%20J.%20Wareham)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nicholas%20J.%20Wareham%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Juyoung%20Lee)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Juyoung%20Lee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bong-Jo%20Kim)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bong-Jo%20Kim%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Iona%20Y.%20Millwood)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Iona%20Y.%20Millwood%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robin%20G.%20Walters)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robin%20G.%20Walters%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kari%20Stefansson)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kari%20Stefansson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Emma%20Ahlqvist)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Emma%20Ahlqvist%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20O.%20Goodarzi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20O.%20Goodarzi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Karen%20L.%20Mohlke)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Karen%20L.%20Mohlke%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Claudia%20Langenberg)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Claudia%20Langenberg%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Christopher%20A.%20Haiman)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Christopher%20A.%20Haiman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ruth%20J.%20F.%20Loos)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ruth%20J.%20F.%20Loos%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jose%20C.%20Florez)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jose%20C.%20Florez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20J.%20Rader)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20J.%20Rader%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marylyn%20D.%20Ritchie)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marylyn%20D.%20Ritchie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sebastian%20Z%C3%B6llner)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sebastian%20Z%C3%B6llner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Reedik%20M%C3%A4gi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Reedik%20M%C3%A4gi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nicholas%20A.%20Marston)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nicholas%20A.%20Marston%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Christian%20T.%20Ruff)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Christian%20T.%20Ruff%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20A.%20van%20Heel)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20A.%20van%20Heel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sarah%20Finer)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sarah%20Finer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Joshua%20C.%20Denny)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Joshua%20C.%20Denny%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Toshimasa%20Yamauchi)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Toshimasa%20Yamauchi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Takashi%20Kadowaki)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Takashi%20Kadowaki%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=John%20C.%20Chambers)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22John%20C.%20Chambers%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maggie%20C.%20Y.%20Ng)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maggie%20C.%20Y.%20Ng%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xueling%20Sim)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xueling%20Sim%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jennifer%20E.%20Below)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jennifer%20E.%20Below%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Philip%20S.%20Tsao)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Philip%20S.%20Tsao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyong-Mi%20Chang)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyong-Mi%20Chang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20I.%20McCarthy)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20I.%20McCarthy%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=James%20B.%20Meigs)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22James%20B.%20Meigs%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Anubha%20Mahajan)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Anubha%20Mahajan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cassandra%20N.%20Spracklen)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cassandra%20N.%20Spracklen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Josep%20M.%20Mercader)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Josep%20M.%20Mercader%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20Boehnke)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20Boehnke%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jerome%20I.%20Rotter)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jerome%20I.%20Rotter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marijana%20Vujkovic)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marijana%20Vujkovic%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Benjamin%20F.%20Voight)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Benjamin%20F.%20Voight%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrew%20P.%20Morris)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrew%20P.%20Morris%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\nYou can also search for this author in[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eleftheria%20Zeggini)\\xa0[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eleftheria%20Zeggini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\\n\\n### Consortia\\n\\n### VA Million Veteran Program\\n\\n#### AMED GRIFIN Diabetes Initiative Japan\\n\\n#### Biobank Japan Project\\n\\n#### Penn Medicine BioBank\\n\\n#### Regeneron Genetics Center\\n\\n#### Genes & Health Research Team\\n\\n#### eMERGE Consortium\\n\\n#### International Consortium of Blood Pressure (ICBP)\\n\\n#### Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC)\\n\\n### Contributions\\n\\nCentral analysis group: K. Suzuki, K.H., L.S., H.J.T., X.Y., K. M. Lorenz, R. Mandla, A.H.-C., N.W.R., O.B., A.L.A., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. PS analysis: K. Suzuki, K.H., L.S., H.J.T., G.E.M.M., S.K., A.P.M. Study-level primary analysis: K. Suzuki, H.J.T., X.Y., K. M. Lorenz, R. Mandla, A.H.-C., K. Sonehara, S.N., S.S.K.L., M.H.P., L.E.P., P.S., B.V., M.K., F.B., K. Lin, X.G., W. Zhang, J.Y., Y.J.K., M. Graff, F.T., J.N., A. Lamri, M.N., S. Moon, R.A.S., J.P.C., J.-J.L., I.P., D.T., E.J.P., J.-F.C., L.F.B., Y.T., Y.H., G.T., N.G., T.S., M.W., C. Sarnowski, C.G., D.N., S.T., S.-H.K., J. Long, M. Sun, L.T., W.-M.C., S.S.N., R.N., V.J.Y.L., C.H.T.T., Y.Y.J., C.-H.C., L.M.R., B.P.P., A.N., L.R.Y., G.C., J.A.B., E.K., P.A., A.H.X., H.S.C., B.E.C., J. Tan, M.C.Y.N., X.S., A. Mahajan, C.N.S., A.P.M. Study-level sample collection, phenotyping, genotyping, and additional analysis: L.S.A., A.A., C.A.A.-S., T.S.A., S.S.A., A. Bertoni, J.B.-J., I.B., T.A.B., C.F.B., A.S.B., M. Canouil, J.C.N.C., L.-C.C., M.-L.C., J. Chen, S.-H.C., Y.-T.C., Z.C., L.-M.C., M. Cushman, J. Danesh, S.K.D., H.J.d.S., G.D., L.D., A.P.D., S.D., Q.D., K.-U.E., L.S.E., D.S.E., M.K.E., K.F., J.S.F., I.F., O.H.F., T.M.F., B.I.F., P.G., H.C.G., V.G., C.G.-V., M.E.G.-V., P.G.-L., M. Gross, L.A.G., S. Hackinger, S. Han, A.T.H., C.H., M. Horikoshi, A.-G.H., W. Hsueh, M. Huang, W. Huang, Y.-J.H., M.Y.H., C.-M.H., S.I., M.A.I., M. Ingelsson, M.T.I., M. Isono, H.-M.J., F.J., G.J., J.B.J., T.J., F.K.K., F.R.K., A. Kasturiratne, T. Katsuya, V.K., T. Kawaguchi, J.M.K., A.N.K., C.-C.K., M.G.K., D.-H.K., F.K., J.K., K. Läll, L.A.L., K.M. Lee, M.-S.L., N.R.L., A. Leong, L. Li, Y. Liu, R.L.-G., S. Lithgart, C.M.L., A. Linneberg, C.-T.L., J. Liu, A.E.L., T.L., J. Luan, A.O.L., X.L., J.Lv, J.A.L., V.L., S. Maeda, V.M., S.R.M., K.M., T.M., A. Metspalu, H.M., A.D.M., F.A.M., J.L.N., M.A.N., U.N., I.N., Y.O., L.O., S.R.P., S.P., P.P., M.A. Pereira, A.P., F.J.P., H.G.P., B.P., G. Prasad, L.J.R.-T., A.P.R., M.R., R.R., K.R., C. Sabanayagam, K. Sandow, A. Sankareswaran, N. Sattar, S.S., M. Shahriar, B.S., J.S., D.M.S., N. Shojima, J.A.S., W.Y.S., A. Stančáková, V.S., A.M.S., K. Strauch, K.D.T., B. Thorand, U.T., B. Tomlinson, T.C.T., F.-J.T., J. Tuomilehto, T.T.-L., M.S.U., A.V., R.M.v.D., J.B.v.K., R.V., N.W.-R., E.W., A.R.W., K.W.v.D., D.R.W., C.S.Y., Ken Yamamoto, Kenichi Yamamoto, K. Yoon, C.Y., J.-M.Y., S.Y., M.Z., L.Z., W. Zheng, J.S.P., T.-Y.W., F.S.C., M.O.G., K.L.M., J.C.F., J.E.B., M.I.M., M.V. Study-level principal investigator: L.J.R., M. Igase, E. Ipp, S.R., Y.S.C., L. Lind, M. A. Province, M.F., C.L.H., E. Ingelsson, A.B.Z., B.M.P., Y.-X.W., C.N.R., D.M.B., F.M., Y. Liu, M.Y., S.L.R.K., P.A.P., J.S.P., J.C.E., A. Bonnefond, P.F., J.G.W., W.H.H.S., J.-Y.W., M.G.H., R.C.W.M., T.-Y.W., D.O.M.-K., T.T., G.R.C., F.S.C., D.B., G. Paré, M.M.S., H.A., A.A.M., X.-O.S., K.-S.P., J.W.J., M. Cruz, Y.-D.I.C., S.S.R., R.M.-C., H.G., C.-Y.C., M.G., E.-S.T., J. Dupuis, N.K., M.L., A. Köttgen, W.-P.K., D.W.B., C.N.A.P., J.S.K., C.K., S. Liu, K.E.N., D.S., T.H., O.P., N.J.W., J. Lee, B.-J.K., I.Y.M., R.G.W., K. Stefansson, K.L.M., C.L., C.A.H., R.J.F.L., J.C.F., D.J.R., M.D.R., S.Z., R. Mägi, N.A.M., C.T.R., D.A.v.H., S.F., J.C.D., T.Y., T. Kadowaki, J.C.C., J.E.B., P.S.T., K.-M.C., M.I.M., J.B.M., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. MAGIC analysis: K.A.B., A.W., K.L.M., C.L. ICBP analysis: Z.K. GUARDIAN Consortium analysis: J. Cui, M.O.G. GLP-1 GWAS analysis: M.T., L.H., O.M., T.T., E.A. DIAMANTE Consortium ancestry-specific data co-ordination: J.C.C., M.C.Y.N., X.S., J.E.B., A. Mahajan. Manuscript preparation: K. Suzuki, K.H., L.S., H.J.T., X.Y., K. M. Lorenz, R. Mandla, M.I.M., J.B.M., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. T2DGGI steering group: M.I.M., J.B.M., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z.\\n\\n### Corresponding authors\\n\\nCorrespondence to\\n[Konstantinos Hatzikotoulas](mailto:konstantinos.hatzikotoulas@helmholtz-munich.de), [Benjamin F. Voight](mailto:bvoight28@gmail.com), [Andrew P. Morris](mailto:andrew.morris-5@manchester.ac.uk) or [Eleftheria Zeggini](mailto:eleftheria.zeggini@helmholtz-munich.de).\\n\\n## Ethics declarations\\n\\n### Competing interests\\n\\nR.A.S. is now an employee of GlaxoSmithKline. G.T. is an employee of deCODE Genetics (Amgen). A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. J. Danesh serves on scientific advisory boards for AstraZeneca, Novartis and UK Biobank, and has received multiple grants from academic, charitable and industry sources outside of the submitted work. L.S.E. is now an employee of Bristol Myers Squibb. J.S.F. has consulted for Shionogi. T.M.F. has consulted for Sanofi and Boehringer Ingelheim, and has received funding from GlaxoSmithKline. H.C.G. holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care; reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk and Sanofi; reports honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, DKSH, Zuellig, Roche and Sanofi; and reports consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Pfizer, Sanofi, Kowa and Hanmi. M. Ingelsson is a paid consultant to BioArctic AB. R.L.-G. is a part-time consultant for Metabolon. A.E.L. is now an employee of Regeneron Genetics Center and holds shares in Regeneron Pharmaceuticals. M.A.N. currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23. S.R.P. has received grant funding from Bayer Pharmaceuticals, Philips Respironics and Respicardia. N. Sattar has consulted for or been on the speaker bureau for Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, Novartis, Novo Nordisk, Sanofi and Pfizer, and has received grant funding from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. V.S. is now an employee of deCODE Genetics/Amgen Inc. A.M.S. receives funding from Seven Bridges Genomics to develop tools for the NHLBI BioData Catalyst consortium. U.T. is an employee of deCODE Genetics (Amgen). E. Ingelsson is now an employee of GlaxoSmithKline. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. R.C.W.M. reports research funding from AstraZeneca, Bayer, Novo Nordisk, Pfizer, Tricida and Sanofi, and has consulted for or received speaker’s fees from AstraZeneca, Bayer and Boehringer Ingelheim, all of which have been donated to the Chinese University of Hong Kong to support diabetes research. D.O.M.-K. is a part-time clinical research consultant for Metabolon. S. Liu reports consulting payments and honoraria or promises of the same for scientific presentations or reviews at numerous venues, including but not limited to Barilla, By-Health, Ausa Pharmed., Fred Hutchinson Cancer Center, Harvard University, University of Buffalo, Guangdong General Hospital and Academy of Medical Sciences; is a consulting member for Novo Nordisk; is a member of the Data Safety and Monitoring Board for a trial of pulmonary hypertension in patients with diabetes at Massachusetts General Hospital; receives royalties from UpToDate; and receives an honorarium from the American Society for Nutrition for his duties as Associate Editor. K. Stefansson is an employee of deCODE Genetics (Amgen). M.I.M. has served on advisory panels for Pfizer, Novo Nordisk and Zoe Global; has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly; has received research funding from Abbvie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier and Takeda; and is now an employee of Genentech and a holder of Roche stock. J.B.M. is an Academic Associate for Quest Diagnostics R&D. A. Mahajan is an employee of Genentech, and a holder of Roche stock. The TIMI Study Group received institutional research grants through Brigham and Women’s Hospital supported by: Abbott, Abiomed, Inc., Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, Medimmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Inc., Siemens Healthcare Diagnostics, Inc. Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc, and Zora Biosciences.\\xa0The remaining authors declare no competing interests.\\n\\n## Peer review\\n\\n### Peer review information\\n\\n*Nature* thanks Ewan Pearson, Jason Torres and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.\\n\\n## Additional information\\n\\n**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\\n\\n## Extended data figures and tables\\n\\n### [Extended Data Fig. 1 Axes of genetic variation separating GWASs of T2D across ancestry groups.](/articles/s41586-024-07019-6/figures/4)\\n\\nWe used SNVs that were reported in all studies to construct a distance matrix of mean effect allele frequency differences between each pair of GWASs. We implemented multi-dimensional scaling of the distance matrix to principal components that represent axes of genetic variation. The first three axes of genetic variation (PC1, PC2 and PC3) from multi-dimensional scaling of the Euclidean distance matrix between populations are sufficient to separate GWASs from six ancestry groups: African American (AFA), East Asian (EAS), European (EUR), Hispanic (HIS), South African (SAF), and South Asian (SAS). Variance explained by each axis: PC1 90.7%; PC2 6.5%; PC3 1.0%.\\n\\n### [Extended Data Fig. 2 Cluster-specific associations of index SNVs with defining cardiometabolic phenotypes.](/articles/s41586-024-07019-6/figures/5)\\n\\nEach bar presents the −log10 *P* value for association, with effect direction aligned to the T2D risk allele. FG: fasting glucose. FI: fasting insulin. PI: proinsulin. BMI: body mass index. WHR: waist–hip ratio. LDL: low-density lipoprotein cholesterol. HDL: high-density lipoprotein cholesterol. TG: triglycerides. \\\\*Trait adjusted for BMI.\\n\\n### [Extended Data Fig. 3 Cluster-specific associations of index SNVs with T2D.](/articles/s41586-024-07019-6/figures/6)\\n\\nThe height of each bar corresponds to the log-odds ratio (beta), and the grey bar shows the 95% confidence interval. \\\\**P*\\u2009<\\u20090.05, nominal association. \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are presented in Supplementary Table [9](/articles/s41586-024-07019-6#MOESM3).\\n\\n### [Extended Data Fig. 4 Cluster-specific associations of T2D risk alleles at index SNVs with insulin-related endophenotypes.](/articles/s41586-024-07019-6/figures/7)\\n\\nMeasures of insulin secretion and insulin sensitivity were derived from hyperinsulinaemic-euglycaemic clamp assessments and oral glucose tolerance tests in up to 1,316 Mexican American participants without diabetes. Homeostatic model assessment measures of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) were obtained from 36,466 non-diabetic individuals of European ancestry. Each point corresponds to the cluster-specific mean *z*-score for each trait, and grey bars represent 95% confidence intervals. The liver and lipid metabolism cluster has been removed for ease of presentation.\\n\\n### [Extended Data Fig. 5 Cluster-specific associations of T2D risk alleles at index SNVs with insulin-resistance-related disorders.](/articles/s41586-024-07019-6/figures/8)\\n\\nAssociation with gestational diabetes mellitus (GDM) was assessed in 5,485 cases and 347,856 female controls of diverse ancestry. Association with polycystic ovary syndrome (PCOS) was assessed in 10,074 cases and 103,164 female controls of European ancestry. The height of each bar corresponds to the mean *z*-score, and the grey bar shows the 95% confidence interval. The liver and lipid metabolism cluster has been removed for ease of presentation. \\\\**P*\\u2009<\\u20090.05, nominal association. \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are presented in Supplementary Table [12](/articles/s41586-024-07019-6#MOESM3).\\n\\n### [Extended Data Fig. 6 Ancestry-correlated heterogeneity is driven by differences in allelic effect sizes between AFA, EAS and EUR ancestry groups.](/articles/s41586-024-07019-6/figures/9)\\n\\nIn the scatter plot, index SNVs with significant evidence (*P*HET\\u2009<\\u20093.9 × 10−5, Bonferroni correction for 1,289 signals) for ancestry-correlated heterogeneity are plotted according to their association (*z*-score) with the first two axes of genetic variation. The first axis represents differences in allelic effect sizes between AFA/EUR GWASs and EAS GWASs (AFA–EAS axis), whilst the second axis represents differences in effect size between AFA/EAS GWASs\\xa0and EUR GWASs (AFA–EUR axis). The forest plots present examples of ancestry-correlated heterogeneity at index SNVs. In each forest plot, the allelic log-odds ratio (OR) from each ancestry group-specific fixed-effects meta-analysis is given by the black tick mark, the 95% confidence interval is given by the horizontal line, and the weight (inverse-variance) of each ancestry group by the grey box. AFA: African American ancestry group. EAS: East Asian ancestry group. EUR: European ancestry group. HIS: Hispanic ancestry group. SAF: South African ancestry group. SAS: South Asian ancestry group.\\n\\n### [Extended Data Fig. 7 Cluster-specific associations of index SNVs with the first two axes of genetic variation in T2D cases and controls.](/articles/s41586-024-07019-6/figures/10)\\n\\n**a**, Unadjusted for BMI. **b**, Adjusted for study-level mean BMI. Each point corresponds to a cluster, plotted according to the mean *z*-score for association with the first two axes of genetic variation (PC1 and PC2) on the *x* axis and *y* axis, respectively. Grey bars correspond to 95% confidence intervals. The liver and lipid metabolism cluster has been removed for ease of presentation.\\n\\n### [Extended Data Fig. 8 Associations of cluster-specific components of the partitioned PS with CAD in up to 279,552 individuals across diverse ancestry groups.](/articles/s41586-024-07019-6/figures/11)\\n\\nThe panel summarizes the associations of each cluster-specific component of the partitioned PS with CAD, with and without adjustment for a previously published multi-ancestry CAD PS. The height of each bar corresponds to the log-OR (beta) per standard deviation of the PS, and the grey bar shows the 95% confidence interval. Analyses were undertaken in all individuals, with adjustment for T2D status. \\\\**P*\\u2009<\\u20090.05, nominal association. \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are presented in Supplementary Tables [21](/articles/s41586-024-07019-6#MOESM3) and [22](/articles/s41586-024-07019-6#MOESM3).\\n\\n### [Extended Data Fig. 9 Associations of cluster-specific components of the partitioned PS with T2D age of onset in up to 30,288 individuals across diverse ancestry groups.](/articles/s41586-024-07019-6/figures/12)\\n\\nThe panel summarizes the associations of each cluster-specific component of the partitioned PS with age of onset. The height of each bar corresponds to years (beta) per standard deviation of the PS, and the grey bar shows the 95% confidence interval. A negative effect corresponds to earlier age of onset. \\\\**P*\\u2009<\\u20090.05, nominal association. \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are presented in Supplementary Table [23](/articles/s41586-024-07019-6#MOESM3).\\n\\n### [Extended Data Fig. 10 Associations of the beta cell +PI and obesity cluster-specific components of the partitioned PS with vascular outcomes in up to 29,827 EUR individuals with T2D from six clinical trials from the TIMI Study Group.](/articles/s41586-024-07019-6/figures/13)\\n\\nMajor cardiovascular event is defined as myocardial infarction, ischaemic stroke, or cardiovascular death. Major limb event is defined as acute limb ischaemia or peripheral revascularization. The height of each bar corresponds to the log-hazard ratio per standard deviation of the PS, and the grey bar shows the 95% confidence interval. \\\\**P*\\u2009<\\u20090.05, nominal association. \\\\*\\\\**P*\\u2009<\\u20090.0063, Bonferroni correction for eight clusters. Exact *P* values are presented in Supplementary Table [24](/articles/s41586-024-07019-6#MOESM3).\\n\\n## Supplementary information\\n\\n### [Supplementary Information](https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_MOESM1_ESM.pdf)\\n\\nSupplementary Note, including Supplementary Text, Methods, Acknowledgements and Funding, Ethics statements, lists of contributors and consortia members, and Supplementary Figs. 1–13.\\n\\n### [Reporting Summary](https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_MOESM2_ESM.pdf)\\n\\n### [Supplementary Tables](https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-024-07019-6/MediaObjects/41586_2024_7019_MOESM3_ESM.xlsx)\\n\\nThis file contains Supplementary Tables 1–25\\n\\n## Rights and permissions\\n\\n**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.\\n\\n[Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Genetic%20drivers%20of%20heterogeneity%20in%20type%202%20diabetes%20pathophysiology&author=Ken%20Suzuki%20Stavroula%20Kanona%20et%20al&contentID=10.1038%2Fs41586-024-07019-6&copyright=The%20Author%28s%29&publication=0028-0836&publicationDate=2024-02-19&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY)\\n\\n## About this article\\n\\n![Check for updates. Verify currency and authenticity via CrossMark](data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>)\\n\\n### Cite this article\\n\\nSuzuki, K., Hatzikotoulas, K., Southam, L. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.\\n*Nature* **627**, 347–357 (2024). https://doi.org/10.1038/s41586-024-07019-6\\n\\n[Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41586-024-07019-6?format=refman&flavour=citation)\\n\\nReceived: 22 March 2023\\n\\nAccepted: 03 January 2024\\n\\nPublished: 19 February 2024\\n\\nIssue Date: 14 March 2024\\n\\nDOI: https://doi.org/10.1038/s41586-024-07019-6\\n\\n### Share this article\\n\\nAnyone you share the following link with will be able to read this content:\\n\\nSorry, a shareable link is not currently available for this article.\\n\\nProvided by the Springer Nature SharedIt content-sharing initiative\\n\\n## This article is cited by\\n\\n### [Therapeutic potential of GLP-1RAs in sleep apnea with genetic associations to type 2 diabetes](https://doi.org/10.1186/s13098-025-01699-4)\\n\\n*Diabetology & Metabolic Syndrome* (2025)\\n\\n### [Association between stress hyperglycemia ratio and neovascular glaucoma in patients with proliferative diabetic retinopathy](https://doi.org/10.1186/s12886-025-03982-4)\\n\\n*BMC Ophthalmology* (2025)\\n\\n### [Association between CAPN-10 gene variant and diabetes mellitus in Nigeria: a review](https://doi.org/10.1186/s43042-025-00655-1)\\n\\n*Egyptian Journal of Medical Human Genetics* (2025)\\n\\n### [Inflammatory markers link triglyceride-glucose index and obesity indicators with adverse cardiovascular events in patients with hypertension: insights from three cohorts](https://doi.org/10.1186/s12933-024-02571-x)\\n\\n*Cardiovascular Diabetology* (2025)\\n\\n### [Macrophages protect against sensory axon loss in peripheral neuropathy](https://doi.org/10.1038/s41586-024-08535-1)\\n\\n*Nature* (2025)\\n\\n## Associated content\\n\\nSpecial\\n\\n### [All of Us](https://www.nature.com/collections/dbcchccagg)\\n\\n### [Genetic contribution to heterogeneity in type 2 diabetes](https://www.nature.com/articles/s41588-024-01698-7)\\n\\n### [Global genomic diversity for All of Us](https://www.nature.com/articles/s41576-024-00727-9)\\n\\n### [Genetic risk variants lead to type 2 diabetes development through different pathways](https://www.nature.com/articles/d41586-024-00440-x)\\n\\nAdvertisement\\n\\n![Advertisement](//pubads.g.doubleclick.net/gampad/ad?iu=/285/nature.com/article&sz=300x250&c=-1012912167&t=pos%3Dright%26type%3Darticle%26artid%3Ds41586-024-07019-6%26doi%3D10.1038/s41586-024-07019-6%26techmeta%3D43,45%26subjmeta%3D114,137,205,208,2138,2743,631,692,699,721%26kwrd%3DComputational+biology+and+bioinformatics,Diabetes,Genetic+markers,Genome-wide+association+studies)\\n\\n## Explore content\\n\\n## About the journal\\n\\n## Publish with us\\n\\n## Search\\n\\n### Quick links\\n\\nNature\\n(*Nature*)\\n\\nISSN 1476-4687 (online)\\n\\nISSN 0028-0836 (print)\\n\\n## nature.com sitemap\\n\\n### About Nature Portfolio\\n\\n### Discover content\\n\\n### Publishing policies\\n\\n### Author & Researcher services\\n\\n### Libraries & institutions\\n\\n### Advertising & partnerships\\n\\n### Professional development\\n\\n### Regional websites\\n\\n![Springer Nature](/static/images/logos/sn-logo-white-ea63208b81.svg)\\n\\n© 2025 Springer Nature Limited\\n\\n![Nature Briefing](/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg)\\n\\nSign up for the *Nature Briefing* newsletter — what matters in science, free to your inbox daily.\\n\\n![](https://verify.nature.com/verify/nature.png)'},\n",
       "  {'title': 'Diabetes mellitus: From molecular mechanism to pathophysiology and ...',\n",
       "   'url': 'https://www.sciencedirect.com/science/article/pii/S2590093523000425',\n",
       "   'content': 'The pathophysiology of type 2 diabetes mellitus is distinguished by insulin deficiency and insulin resistance, which have been linked to inflammatory cytokines in the plasma and high levels of fatty acids, leading to deficient glucose transport into target cells, elevated breakdown of fat, and increased hepatic glucose production . In the case of type 2 diabetes mellitus, the disease is diagnosed because patients cannot increase insulin secretion to make up for their insulin resistance, thereby causing a high level of glycemic value . Frystyk, J.F. Rehfeld, J.J. Holst, _et al._ Effects of carbohydrate restriction on postprandial glucose metabolism, β-cell function, gut hormone secretion, and satiety in patients with type 2 diabetes  Am. J. Diabetes mellitus is a chronic metabolic disorder characterized by abnormally elevated blood glucose levels due to insulin resistance or insulin deficiency .',\n",
       "   'score': 0.3028759,\n",
       "   'raw_content': 'Diabetes mellitus: From molecular mechanism to pathophysiology and pharmacology - ScienceDirect\\n\\n===============\\n[Skip to main content](https://www.sciencedirect.com/science/article/pii/S2590093523000425#screen-reader-main-content)[Skip to article](https://www.sciencedirect.com/science/article/pii/S2590093523000425#screen-reader-main-title)\\n\\n[![Image 2: Elsevier logo](https://sdfestaticassets-us-east-1.sciencedirectassets.com/shared-assets/24/images/elsevier-non-solus-new-grey.svg)](https://www.sciencedirect.com/)\\n\\n*   [Journals & Books](https://www.sciencedirect.com/browse/journals-and-books)\\n\\n*      \\n*   [](https://www.sciencedirect.com/search \"Search\") \\n\\n[](https://www.sciencedirect.com/user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS2590093523000425&from=globalheader \"My account\")\\n\\n[](https://www.sciencedirect.com/user/institution/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS2590093523000425 \"Sign In\")\\n\\n*   [View**PDF**](https://www.sciencedirect.com/science/article/pii/S2590093523000425/pdfft?md5=80d4d1a0678891462a4d77ef0328fc54&pid=1-s2.0-S2590093523000425-main.pdf)\\n*   Download full issue\\n\\nSearch ScienceDirect \\n\\nOutline\\n-------\\n\\n1.   [Highlights](https://www.sciencedirect.com/science/article/pii/S2590093523000425#abs0020 \"Highlights\")\\n2.   [Abstract](https://www.sciencedirect.com/science/article/pii/S2590093523000425#abs0010 \"Abstract\")\\n3.   [Graphical abstract](https://www.sciencedirect.com/science/article/pii/S2590093523000425#abs0015 \"Graphical abstract\")\\n4.   [Keywords](https://www.sciencedirect.com/science/article/pii/S2590093523000425#kwrds0010 \"Keywords\")\\n5.   [1. Introduction](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec2 \"1. Introduction\")\\n6.   [2. Mechanism](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec3 \"2. Mechanism\")\\n7.   [3. Pathophysiology](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec4 \"3. Pathophysiology\")\\n8.   [4. Pharmacology](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec5 \"4. Pharmacology\")\\n9.   [5. Conclusion and future perspective](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec6 \"5. Conclusion and future perspective\")\\n10.   [Credit author statement](https://www.sciencedirect.com/science/article/pii/S2590093523000425#sec1 \"Credit author statement\")\\n11.   [Declaration of competing interest](https://www.sciencedirect.com/science/article/pii/S2590093523000425#coi0010 \"Declaration of competing interest\")\\n12.   [References](https://www.sciencedirect.com/science/article/pii/S2590093523000425#cebib0010 \"References\")\\n\\nShow full outline\\n\\n[Cited by (26)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#section-cited-by)\\n-----------------------------------------------------------------------------------------------------\\n\\nFigures (11)\\n------------\\n\\n1.   [![Image 3: Unlabelled figure](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-ga1.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#undfig1)\\n2.   [![Image 4: Fig.1. Types of diabetes mellitus](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr1.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig1)\\n3.   [![Image 5: Fig.2. Complications of type 2 diabetes mellitus](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr2.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig2)\\n4.   [![Image 6: Fig.3. Factors affecting type 2 diabetes mellitus](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr3.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig3)\\n5.   [![Image 7: Fig.4. Chart showing the relationship between the processes of glucose metabolism](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr4.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig4)\\n6.   [![Image 8: Fig.5. Activity of Glucose Transporters (GLUTs) in the liver, skeletal muscle, and…](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr5.sml)](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig5)\\n\\nShow 5 more figures\\n\\nTables (1)\\n----------\\n\\n1.   [Table 1](https://www.sciencedirect.com/science/article/pii/S2590093523000425#tbl1 \"Haemoglobin A1c test score adapted from [24].\")\\n\\n[![Image 9: Elsevier](https://sdfestaticassets-us-east-1.sciencedirectassets.com/prod/bbcebc374bd034f2b69007c2d8fa1a7860b68c43/image/elsevier-non-solus.svg)](https://www.sciencedirect.com/journal/medicine-in-novel-technology-and-devices \"Go to Medicine in Novel Technology and Devices on ScienceDirect\")\\n\\n[Medicine in Novel Technology and Devices](https://www.sciencedirect.com/journal/medicine-in-novel-technology-and-devices \"Go to Medicine in Novel Technology and Devices on ScienceDirect\")\\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\\n\\n[Volume 19](https://www.sciencedirect.com/journal/medicine-in-novel-technology-and-devices/vol/19/suppl/C \"Go to table of contents for this volume/issue\"), September 2023, 100247\\n\\n[![Image 10: Medicine in Novel Technology and Devices](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523X00034-cov150h.gif)](https://www.sciencedirect.com/journal/medicine-in-novel-technology-and-devices/vol/19/suppl/C)\\n\\nReview Article\\n\\nDiabetes mellitus: From molecular mechanism to pathophysiology and pharmacology\\n===============================================================================================\\n\\nAuthor links open overlay panel Oluwafemi Adeleke Ojo a, Hannah Sokolayam Ibrahim a, Damilare Emmanuel Rotimi b, Akingbolabo Daniel Ogunlakin a, Adebola Busola Ojo c\\n\\nShow more\\n\\nOutline\\n\\nAdd to Mendeley\\n\\nShare\\n\\nCite\\n\\n[https://doi.org/10.1016/j.medntd.2023.100247](https://doi.org/10.1016/j.medntd.2023.100247 \"Persistent link using digital object identifier\")[Get rights and content](https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&contentID=S2590093523000425&orderBeanReset=true)\\n\\nUnder a Creative Commons [license](http://creativecommons.org/licenses/by-nc-nd/4.0/)\\n\\nOpen access\\n\\nHighlights\\n----------\\n\\n*   •DM is a persistent condition serious complications that affect the quality of life. \\n*   •Oxidative stress has key roles in the [pathophysiology](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pathophysiology \"Learn more about pathophysiology from ScienceDirect\\'s AI-generated Topic Pages\") of insulin resistance and DM. \\n*   •The pathophysiology of the prognosis and diagnosis dictates DM treatment option. \\n\\nAbstract\\n--------\\n\\nDiabetes mellitus is a [metabolic disease](https://www.sciencedirect.com/topics/medicine-and-dentistry/water-electrolyte-imbalance \"Learn more about metabolic disease from ScienceDirect\\'s AI-generated Topic Pages\") characterized by high [blood glucose](https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-glucose \"Learn more about blood glucose from ScienceDirect\\'s AI-generated Topic Pages\") levels and a range of other symptoms that last for a long period of time. It has a rapid prevalence globally, and there is a possibility of the statistic doubling in a few years. This review is aimed at evaluating the mechanism, [pathophysiology](https://www.sciencedirect.com/topics/medicine-and-dentistry/pathophysiology \"Learn more about pathophysiology from ScienceDirect\\'s AI-generated Topic Pages\"), and pharmacology of diabetes mellitus. The data used was sourced through a thorough review of scientific articles published in a variety of databases, including Springer, [Scopus](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/scopus \"Learn more about Scopus from ScienceDirect\\'s AI-generated Topic Pages\"), Elsevier, Google Scholar, Wiley, Web of Science, [PubMed](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/medline \"Learn more about PubMed from ScienceDirect\\'s AI-generated Topic Pages\"), and Taylor & Francis. Furthermore, PhD and MSc theses were also used in compiling data. According to the literature review, diabetes mellitus is a persistent condition with various risk factors and serious complications that affect the [quality of life](https://www.sciencedirect.com/topics/medicine-and-dentistry/quality-of-life \"Learn more about quality of life from ScienceDirect\\'s AI-generated Topic Pages\"). However, research studies have helped in the prognosis, diagnosis, treatment, and management of its different forms.\\n\\nGraphical abstract\\n------------------\\n\\n![Image 11: Image 1](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-ga1.jpg)\\n1.   [Download: Download high-res image (232KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-ga1_lrg.jpg \"Download high-res image (232KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-ga1.jpg \"Download full-size image\")\\n\\n*   [Previous article in issue](https://www.sciencedirect.com/science/article/pii/S2590093523000589)\\n*   [Next article in issue](https://www.sciencedirect.com/science/article/pii/S2590093523000474)\\n\\nKeywords\\n--------\\n\\nMechanism\\n\\nPathophysiology\\n\\nPharmacology\\n\\nDiabetes mellitus\\n\\n1. Introduction\\n---------------\\n\\nDiabetes is a long-term, persistent disease that occurs due to the body\\'s inability to process and regulate [blood glucose](https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-glucose \"Learn more about blood glucose from ScienceDirect\\'s AI-generated Topic Pages\") due to the over-secretion of insulin from the pancreas or the inability of the insulin to regulate the blood [glucose levels](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-level \"Learn more about glucose levels from ScienceDirect\\'s AI-generated Topic Pages\") [[1](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib1)]. Insulin is a [polypeptide hormone](https://www.sciencedirect.com/topics/medicine-and-dentistry/peptide-hormone \"Learn more about polypeptide hormone from ScienceDirect\\'s AI-generated Topic Pages\") secreted by the beta cells of the [islets of Langerhans](https://www.sciencedirect.com/topics/medicine-and-dentistry/pancreatic-islet \"Learn more about islets of Langerhans from ScienceDirect\\'s AI-generated Topic Pages\") of the pancreas, and its functions are the regulation of glucose levels in the blood, the assimilation, and the utilization of glucose [[2](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib2)]. In a diabetic patient, a phenomenon called “insulin resistance” is present. It occurs when the [body\\'s cells](https://www.sciencedirect.com/topics/medicine-and-dentistry/cell-body \"Learn more about body\\'s cells from ScienceDirect\\'s AI-generated Topic Pages\") resist the hormone “insulin”, causing a lack of response to insulin. Insulin resistance is summed up as a decline in sensitivity to the biochemical actions of insulin as well as insulin-mediated glucose disposal. This leads to a buildup of glucose in the bloodstream, eventually leading to [type 2 diabetes](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/non-insulin-dependent-diabetes-mellitus \"Learn more about type 2 diabetes from ScienceDirect\\'s AI-generated Topic Pages\") [[3](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib3)]. There are a range of reasons diabetes can occur, and how it is managed depends on the type. There are various types of diabetes but three main types: [type 1 diabetes](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-dependent-diabetes-mellitus \"Learn more about type 1 diabetes from ScienceDirect\\'s AI-generated Topic Pages\"), type 2 diabetes, and [gestational diabetes](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pregnancy-diabetes-mellitus \"Learn more about gestational diabetes from ScienceDirect\\'s AI-generated Topic Pages\") (pregnancy-induced diabetes) ([Fig.1](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig1)).\\n\\n![Image 12: Fig.\\xa01](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr1.jpg)\\n1.   [Download: Download high-res image (286KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr1_lrg.jpg \"Download high-res image (286KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr1.jpg \"Download full-size image\")\\n\\nFig.1. Types of diabetes mellitus.\\n\\n### 1.1. Type 1 diabetes\\n\\nType 1 diabetes is a persistent autoimmune disease marked by [insulin insufficiency](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-deficiency \"Learn more about insulin insufficiency from ScienceDirect\\'s AI-generated Topic Pages\") and consequent [hyperglycemia](https://www.sciencedirect.com/topics/medicine-and-dentistry/hyperglycemia \"Learn more about hyperglycemia from ScienceDirect\\'s AI-generated Topic Pages\") [[4](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib4)]. It is caused by autoimmune beta-cell destruction in the pancreas, which leads to total insulin deficiency [[5](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib5)]. Type 1 diabetes affects several people globally and needs cautious supervision to avoid grave complications, which include cardiovascular and [renal disease](https://www.sciencedirect.com/topics/medicine-and-dentistry/nephropathy \"Learn more about renal disease from ScienceDirect\\'s AI-generated Topic Pages\"), loss of vision, and stroke. The overall treatment for [type 1 diabetes](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/insulin-dependent-diabetes-mellitus \"Learn more about type 1 diabetes from ScienceDirect\\'s AI-generated Topic Pages\") is [insulin therapy](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-treatment \"Learn more about insulin therapy from ScienceDirect\\'s AI-generated Topic Pages\"), which stems from “exogenic insulin substitution therapy.” Unfortunately, this method is unable to achieve optimal [blood glucose control](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-glucose-monitoring \"Learn more about blood glucose control from ScienceDirect\\'s AI-generated Topic Pages\") in many individuals [[6](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib6)].\\n\\n### 1.2. Type 2 diabetes\\n\\nIt is a common [metabolic disorder](https://www.sciencedirect.com/topics/medicine-and-dentistry/water-electrolyte-imbalance \"Learn more about metabolic disorder from ScienceDirect\\'s AI-generated Topic Pages\") caused by a combination of two main features: deficient [insulin secretion](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-release \"Learn more about insulin secretion from ScienceDirect\\'s AI-generated Topic Pages\") by the β-cells of the pancreas and the inability of tissues to respond properly to insulin [[8](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib8)]. The risk factors for this disorder are high [blood glucose](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-blood-level \"Learn more about blood glucose from ScienceDirect\\'s AI-generated Topic Pages\") levels, obesity, [hypertriglyceridemia](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/hypertriglyceridemia \"Learn more about hypertriglyceridemia from ScienceDirect\\'s AI-generated Topic Pages\"), unhealthy eating habits, lack of exercise, aging, family history, stress, anxiety, and depression [[9](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib9)]. Insulin therapy in conjunction with [metformin](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycon \"Learn more about metformin from ScienceDirect\\'s AI-generated Topic Pages\") and other glucose-lowering agents is required for the treatment and management of type 2 diabetes [[10](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib10)].\\n\\n### 1.3. Gestational diabetes (pregnancy-induced diabetes)\\n\\nIt is a condition in which a pregnant woman has high or elevated blood sugar. It occurs only during [gestation](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/pregnancy \"Learn more about gestation from ScienceDirect\\'s AI-generated Topic Pages\") in some women and can affect both mother and child. It is triggered by a range of factors, such as obesity, family history of diabetes, and [maternal age](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/maternal-age \"Learn more about maternal age from ScienceDirect\\'s AI-generated Topic Pages\"). It is associated with type 2 diabetes and [ischemic heart disease](https://www.sciencedirect.com/topics/medicine-and-dentistry/ischemic-heart-disease \"Learn more about ischemic heart disease from ScienceDirect\\'s AI-generated Topic Pages\") [[11](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib11)]. Gestational diabetes is usually diagnosed in the second or [third trimester](https://www.sciencedirect.com/topics/medicine-and-dentistry/third-trimester-pregnancy \"Learn more about third trimester from ScienceDirect\\'s AI-generated Topic Pages\") of pregnancy in patients with no history of diabetes preceding the period of gestation. It is the most common [complication of pregnancy](https://www.sciencedirect.com/topics/medicine-and-dentistry/complication-of-pregnancy \"Learn more about complication of pregnancy from ScienceDirect\\'s AI-generated Topic Pages\") [[12](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib12)]. This disorder can be managed using two strategies: insulin therapy and lifestyle modification, including nutritional therapy [[13](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib13)]. Globally, diabetes occurrence estimates indicate that over half a billion people live with diabetes, which is over 10.5% of the world’s adult population [[14](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib14)] ([Fig.2](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig2)) (see [Fig.3](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig3)).\\n\\n![Image 13: Fig.\\xa02](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr2.jpg)\\n1.   [Download: Download high-res image (203KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr2_lrg.jpg \"Download high-res image (203KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr2.jpg \"Download full-size image\")\\n\\nFig.2. Complications of type 2 diabetes mellitus.\\n\\n![Image 14: Fig.\\xa03](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr3.jpg)\\n1.   [Download: Download high-res image (339KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr3_lrg.jpg \"Download high-res image (339KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr3.jpg \"Download full-size image\")\\n\\nFig.3. Factors affecting type 2 diabetes mellitus.\\n\\n2. Mechanism\\n------------\\n\\n### 2.1. Glucose metabolism\\n\\nGlucose is the key source of energy and fuel for human cells. It is gotten from the diet consumed, processed within the body, and transferred from the circulation into target cells. The movement of glucose across the plasma membrane is important [[15](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib15)]. [Lipids](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lipid \"Learn more about Lipids from ScienceDirect\\'s AI-generated Topic Pages\"), proteins, and carbohydrates eventually break down to form glucose, which serves as fuel for the metabolic processes of the body. [Glycogenesis](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycogen-synthesis \"Learn more about Glycogenesis from ScienceDirect\\'s AI-generated Topic Pages\"), glycolysis, [gluconeogenesis](https://www.sciencedirect.com/topics/medicine-and-dentistry/gluconeogenesis \"Learn more about gluconeogenesis from ScienceDirect\\'s AI-generated Topic Pages\"), and [glycogenolysis](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glycogenolysis \"Learn more about glycogenolysis from ScienceDirect\\'s AI-generated Topic Pages\") are only a few of the multiple processes that make up glucose metabolism. An enzyme-catalyzed metabolic mechanism called glycolysis promotes [glucose catabolism](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycolysis \"Learn more about glucose catabolism from ScienceDirect\\'s AI-generated Topic Pages\") in cells and the conversion of glucose to [pyruvate](https://www.sciencedirect.com/topics/medicine-and-dentistry/pyruvic-acid \"Learn more about pyruvate from ScienceDirect\\'s AI-generated Topic Pages\") [[16](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib16)]. In order to maintain steady blood sugar and [glucose levels](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-level \"Learn more about glucose levels from ScienceDirect\\'s AI-generated Topic Pages\") during the fasting state, the cytosol and mitochondria of hepatocytes undergo a series of metabolic activities that result in the synthesis of glucose from non-carbohydrate substrates. Insulin, [glucagon](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucagon \"Learn more about glucagon from ScienceDirect\\'s AI-generated Topic Pages\"), and [cortisol](https://www.sciencedirect.com/topics/medicine-and-dentistry/hydrocortisone \"Learn more about cortisol from ScienceDirect\\'s AI-generated Topic Pages\") control it [[17](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib17)]. Furthermore, the pancreas\\'s release of [glucagon](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/glucagon \"Learn more about glucagon from ScienceDirect\\'s AI-generated Topic Pages\") during fasting triggers the start of [glycogenolysis](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycogenolysis \"Learn more about glycogenolysis from ScienceDirect\\'s AI-generated Topic Pages\"). A biological procedure called glycogenolysis involves the breakdown of glycogen to produce glucose and glucose-1-phosphate. The process of synthesising glycogen is known as glycogenesis, and glucose molecules connect the glycogen links for storage ([Fig.4](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig4)).\\n\\n![Image 15: Fig.\\xa04](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr4.jpg)\\n1.   [Download: Download high-res image (299KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr4_lrg.jpg \"Download high-res image (299KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr4.jpg \"Download full-size image\")\\n\\nFig.4. Chart showing the relationship between the processes of [glucose metabolism](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucose-metabolism \"Learn more about glucose metabolism from ScienceDirect\\'s AI-generated Topic Pages\").\\n\\nThe circadian cycle [controls blood glucose](https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-glucose-monitoring \"Learn more about controls blood glucose from ScienceDirect\\'s AI-generated Topic Pages\") levels. In humans, [glucose tolerance](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucose-tolerance \"Learn more about glucose tolerance from ScienceDirect\\'s AI-generated Topic Pages\") for metabolism is at its peak at the beginning of the day. This occurs because pancreatic beta cells are mostly activated in the morning and glycogen storage increases greatly in the evening. Past noon, [adipose tissue](https://www.sciencedirect.com/topics/medicine-and-dentistry/adipose-tissue \"Learn more about adipose tissue from ScienceDirect\\'s AI-generated Topic Pages\") is highly responsive to insulin. The different scheduling of energy utilization during the entire day makes up the glucose metabolism chain [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)]. On average, the fasting blood sugar level with no meal consumption in a period of 3–4\\u200bh is usually between 80 and 90\\u200bmg/dl. Postprandial (after a meal) blood sugar can increase to 120–140\\u200bmg/dL on average, although glucose returns to normal in a period of 2\\u200bh due to the body’s feedback mechanism. In the case of starvation, the process of [gluconeogenesis](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/gluconeogenesis \"Learn more about gluconeogenesis from ScienceDirect\\'s AI-generated Topic Pages\") provides the body with glucose. A surge in [blood glucose](https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-glucose \"Learn more about blood glucose from ScienceDirect\\'s AI-generated Topic Pages\") level (high blood glucose) leads to the secretion of insulin; simultaneously, [blood glucose levels](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-blood-level \"Learn more about blood glucose levels from ScienceDirect\\'s AI-generated Topic Pages\") reduce due to the influx of glucose from the extracellular to the intracellular. Contrarily, [glucagon](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucagon \"Learn more about glucagon from ScienceDirect\\'s AI-generated Topic Pages\") is secreted due to the stimulation caused by the decrease in blood glucose level secretion, thereby raising blood glucose levels. Therefore, the clinical importance is that impaired and insufficient [insulin secretion](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-release \"Learn more about insulin secretion from ScienceDirect\\'s AI-generated Topic Pages\") leads to diabetes mellitus [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)].\\n\\n### 2.2. Glucose transport and defect in transport activity\\n\\n[Glucose transport](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-transport \"Learn more about Glucose transport from ScienceDirect\\'s AI-generated Topic Pages\") is a regulated process conducted by facilitated diffusion with the aid of [carrier proteins](https://www.sciencedirect.com/topics/medicine-and-dentistry/mitochondrial-membrane-transport-protein \"Learn more about carrier proteins from ScienceDirect\\'s AI-generated Topic Pages\") to cross cell membranes. There are different kinds of glucose transporters, but the most important are glucose transporters (GLUT1–5) ([Fig.5](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig5)). These are sensitive to a range of [metabolic stresses](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/metabolic-stress \"Learn more about metabolic stresses from ScienceDirect\\'s AI-generated Topic Pages\"), including growth factors, hypoglycemia, stress hormones, and [hypoxia](https://www.sciencedirect.com/topics/medicine-and-dentistry/hypoxia \"Learn more about hypoxia from ScienceDirect\\'s AI-generated Topic Pages\"). Many [signaling pathways](https://www.sciencedirect.com/topics/medicine-and-dentistry/signal-transduction \"Learn more about signaling pathways from ScienceDirect\\'s AI-generated Topic Pages\") participate in transporter regulation. [Glucose transport](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucose-uptake \"Learn more about Glucose transport from ScienceDirect\\'s AI-generated Topic Pages\") is needed for the supply of energy or fuel to the cells for metabolism. There are instances where [transport proteins](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/translocator-protein \"Learn more about transport proteins from ScienceDirect\\'s AI-generated Topic Pages\") responsible for glucose transport are adjusted in their form, expression, distribution, synthesis, and actions by stress-related factors like hormones, poisons, [kinase signaling](https://www.sciencedirect.com/topics/medicine-and-dentistry/kinase-signaling \"Learn more about kinase signaling from ScienceDirect\\'s AI-generated Topic Pages\"), and inflammation. Some modifications of glucose transport encourage or aggravate diseases like diabetes [[19](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib19)]. Important pathologies leading to [type 2 diabetes](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/non-insulin-dependent-diabetes-mellitus \"Learn more about type 2 diabetes from ScienceDirect\\'s AI-generated Topic Pages\") and [impaired glucose tolerance](https://www.sciencedirect.com/topics/medicine-and-dentistry/impaired-glucose-tolerance \"Learn more about impaired glucose tolerance from ScienceDirect\\'s AI-generated Topic Pages\") are defective and deficient glucose transport and disposal. A proper study of reduced glucose transport and disposal in type 2 diabetes is based on the function of the glucose transporter, [GLUT4](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glut4 \"Learn more about GLUT4 from ScienceDirect\\'s AI-generated Topic Pages\"), which is insulin-dependent. Patients with type 2 diabetes have defective glucose uptake in the brain, visceral adipose tissue, and [skeletal muscles](https://www.sciencedirect.com/topics/medicine-and-dentistry/skeletal-muscle \"Learn more about skeletal muscles from ScienceDirect\\'s AI-generated Topic Pages\"), and these are the most precise indicators of insulin resistance [[20](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib20)].\\n\\n![Image 16: Fig.\\xa05](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr5.jpg)\\n1.   [Download: Download high-res image (303KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr5_lrg.jpg \"Download high-res image (303KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr5.jpg \"Download full-size image\")\\n\\nFig.5. Activity of Glucose Transporters (GLUTs) in the liver, [skeletal muscle](https://www.sciencedirect.com/topics/medicine-and-dentistry/skeletal-muscle \"Learn more about skeletal muscle from ScienceDirect\\'s AI-generated Topic Pages\"), and [adipose tissue](https://www.sciencedirect.com/topics/medicine-and-dentistry/adipose-tissue \"Learn more about adipose tissue from ScienceDirect\\'s AI-generated Topic Pages\") as adapted from Ref.[[21](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib21)].\\n\\n### 2.3. Hormonal regulation for glucose metabolism\\n\\nGlucagon and insulin secreted by the pancreas maintain plasma glucose levels. Glucagon is triggered by hypoglycemia via pancreatic α-cells leading to glycogenolysis, gluconeogenesis, and [lipolysis](https://www.sciencedirect.com/topics/medicine-and-dentistry/lipolysis \"Learn more about lipolysis from ScienceDirect\\'s AI-generated Topic Pages\"), all aiming to restore a normal blood glucose level. Contrarily, insulin is secreted by pancreatic β-cells in response to [hyperglycemia](https://www.sciencedirect.com/topics/medicine-and-dentistry/hyperglycemia \"Learn more about hyperglycemia from ScienceDirect\\'s AI-generated Topic Pages\"), which encourages glucose uptake for metabolism [[22](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib22)]. Reduced [insulin secretion](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-release \"Learn more about insulin secretion from ScienceDirect\\'s AI-generated Topic Pages\") and the failure of the pancreatic β-cells to equal the demand is one of the key forces aggravating [hyperglycemia](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/hyperglycemia \"Learn more about hyperglycemia from ScienceDirect\\'s AI-generated Topic Pages\") in patients with type 2 diabetes mellitus. Continuous β-cell failure is thought to be caused by continuously increased levels of plasma glucose, whereas vigorous [insulin treatment](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-treatment \"Learn more about insulin treatment from ScienceDirect\\'s AI-generated Topic Pages\") has been shown to improve β-cell sensitivity to insulin, glucagon, and glucose [[23](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib23)]. PI3K/Akt signaling cascades are activated when insulin binds to [insulin receptors](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-receptor \"Learn more about insulin receptors from ScienceDirect\\'s AI-generated Topic Pages\"). In adipose tissues and [skeletal muscle cells](https://www.sciencedirect.com/topics/medicine-and-dentistry/skeletal-muscle-cell \"Learn more about skeletal muscle cells from ScienceDirect\\'s AI-generated Topic Pages\"), [insulin signaling](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-signaling \"Learn more about insulin signaling from ScienceDirect\\'s AI-generated Topic Pages\") activates inhibitory [glycogen synthase kinase 3](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycogen-synthase-kinase-3 \"Learn more about glycogen synthase kinase 3 from ScienceDirect\\'s AI-generated Topic Pages\") (GSK3), which allows glycogen synthesis to be inactive and encourages the transfer of vesicles containing GLUT-4 to the cell membrane for absorption of glucose. Insulin signaling in adipocytes blocks hormone-sensitive lipase (HSL), which suppresses [lipolysis](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lipolysis \"Learn more about lipolysis from ScienceDirect\\'s AI-generated Topic Pages\"). Additionally, gluconeogenesis is hindered while [protein synthesis](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/protein-biosynthesis \"Learn more about protein synthesis from ScienceDirect\\'s AI-generated Topic Pages\") and [lipogenesis](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lipogenesis \"Learn more about lipogenesis from ScienceDirect\\'s AI-generated Topic Pages\") are enhanced [[22](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib22)] ([Fig.6](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig6)).\\n\\n![Image 17: Fig.\\xa06](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr6.jpg)\\n1.   [Download: Download high-res image (253KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr6_lrg.jpg \"Download high-res image (253KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr6.jpg \"Download full-size image\")\\n\\nFig.6. [Hormonal regulation](https://www.sciencedirect.com/topics/medicine-and-dentistry/hormonal-regulation \"Learn more about Hormonal regulation from ScienceDirect\\'s AI-generated Topic Pages\") of glucose metabolism.\\n\\n### 2.4. Tests for diabetes\\n\\nDiabetes can be diagnosed using a range of tests listed and discussed below. They are:\\n*   1.Hemoglobin A1C: The HbA1C test is a diagnostic test used to check a patient’s [glycaemic](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycemic \"Learn more about glycaemic from ScienceDirect\\'s AI-generated Topic Pages\") level ([Table 1](https://www.sciencedirect.com/science/article/pii/S2590093523000425#tbl1)). The value shown is a two to three months average of a patient’s glycaemic level. It is useful and effective in evaluating patients with diabetes or at risk of [diabetes complications](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/diabetic-complication \"Learn more about diabetes complications from ScienceDirect\\'s AI-generated Topic Pages\") [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)]. Table 1. [Haemoglobin A1c](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glycosylated-hemoglobin \"Learn more about Haemoglobin A1c from ScienceDirect\\'s AI-generated Topic Pages\") test score adapted from [[24](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib24)].\\n\\n| Empty Cell | HbA1c Test Score | Mean Blood Glucose (mg/dL) | Glucose (mmol/L) |\\n| --- | --- | --- |\\n| Excellent | 4.0 | 50 | 2.6 |\\n| 5.0 | 80 | 4.7 |\\n| 6.0 | 115 | 6.3 |\\n| Good | 7.0 | 150 | 8.2 |\\n| 8.0 | 180 | 10.0 |\\n| Poor | 9.0 | 215 | 11.9 |\\n| 10.0 | 250 | 13.7 |\\n| 11.0 | 280 | 15.6 |\\n| 12.0 | 315 | 17.4 |\\n| 13.0 | 350 | 19.3 |\\n| Empty Cell | 14.0 | 380 | 21.1 |   \\n*   2.Fasting Plasma Glucose: The fasting plasma glucose (FPG) test calculates blood glucose levels simultaneously. For accuracy, the test is administered in the morning after a fasting period of about 8\\u200bh. A value larger than 126\\u200bmg/dL infers diabetes [[25](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib25)]. \\n*   3.Random Plasma Glucose: the blood sample is taken and analysed after food has been ingested. Diabetes is suspected when the value is greater than 200\\u200bmg/dL [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)]. \\n*   4.[Oral Glucose Tolerance Test](https://www.sciencedirect.com/topics/medicine-and-dentistry/oral-glucose-tolerance-test \"Learn more about Oral Glucose Tolerance Test from ScienceDirect\\'s AI-generated Topic Pages\"): it is a medical test conducted when glucose is administered, and the blood sample is analysed to measure how fast glucose has been cleared out. It is used to screen for type 2 diabetes mellitus. \\n*   5.C-Peptide: the beta cell function of the pancreas is measured. The measurement and analysis of urine and serum samples are carried out and the value helps diagnose and treat diabetes [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)]. \\n*   6.Autoantibody: the presence of autoantibodies, such as insulin autoantibody and islet autoantibody anti-glutamic acid decarboxylase (GAD) autoantibodies suggests auto-immune response also noticed in [type 1 diabetes](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-dependent-diabetes-mellitus \"Learn more about type 1 diabetes from ScienceDirect\\'s AI-generated Topic Pages\"). The presence of autoantibodies for diabetes in the blood confirms [type 1 diabetes](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/insulin-dependent-diabetes-mellitus \"Learn more about type 1 diabetes from ScienceDirect\\'s AI-generated Topic Pages\") [[18](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib18)]. \\n\\n3. Pathophysiology\\n------------------\\n\\nThe [pathophysiology of diabetes](https://www.sciencedirect.com/topics/medicine-and-dentistry/pathophysiology-of-diabetes \"Learn more about pathophysiology of diabetes from ScienceDirect\\'s AI-generated Topic Pages\") is largely based on insulin resistance, and many research studies have examined the factors such as environmental and [genetic](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/genetics \"Learn more about genetic from ScienceDirect\\'s AI-generated Topic Pages\") factors that promotetype 2 diabetes mellitus ([Fig.7](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig7)) [[26](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib26)].\\n\\n![Image 18: Fig.\\xa07](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr7.jpg)\\n1.   [Download: Download high-res image (281KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr7_lrg.jpg \"Download high-res image (281KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr7.jpg \"Download full-size image\")\\n\\nFig.7. [Pathophysiology of Diabetes](https://www.sciencedirect.com/topics/medicine-and-dentistry/pathophysiology-of-diabetes \"Learn more about Pathophysiology of Diabetes from ScienceDirect\\'s AI-generated Topic Pages\"). **Source**: Created with [Biorender.com](http://biorender.com/).\\n\\nIt is dependent on the body’s [insulin level](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-level \"Learn more about insulin level from ScienceDirect\\'s AI-generated Topic Pages\") and its utilization. Insulin is absent in type 1 diabetes mellitus, while in type 2 diabetes mellitus, the effect of insulin is resisted by the peripheral tissues. The brain, an organ greatly dependent on the blood glucose concentration for proper functioning, is served by the pancreatic beta cells’ release of insulin in response to elevated blood glucose concentrations. Oral anti-hyperglycemic and insulin are drugs that reverse hyperglycemia [[[27]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib27), [[28]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib28)]. Also, the [plasma concentration](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-level \"Learn more about plasma concentration from ScienceDirect\\'s AI-generated Topic Pages\") of glucose signals the [central nervous system](https://www.sciencedirect.com/topics/medicine-and-dentistry/central-nervous-system \"Learn more about central nervous system from ScienceDirect\\'s AI-generated Topic Pages\") to release energy fuel for utilization. An increase in autonomic activity is caused by low blood glucose concentration. Hypoglycemia is evidence of low blood glucose levels, which aids in the diagnosis of diabetes. A chain of events occurs as a response to hypoglycemia: reduced insulin secretion, increased secretion of [glucagon](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucagon \"Learn more about glucagon from ScienceDirect\\'s AI-generated Topic Pages\") and epinephrine (counter-regulatory hormones of glucose), heightened sympathoadrenal symptoms, and in the worst case, [intellectual disability](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/intellectual-impairment \"Learn more about intellectual disability from ScienceDirect\\'s AI-generated Topic Pages\"), convulsions, stroke, syncope, or coma. The administration of glucose intravenously or orally is a rapid treatment to reverse hypoglycemia and return the blood glucose concentration to normal levels [[28](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib28)].\\n\\nIn type 1 diabetes mellitus, the resulting progression of this disease is dependent on the rate of the autoimmune destruction of the pancreatic β-cells. [Diabetic ketoacidosis](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/diabetic-ketoacidosis \"Learn more about Diabetic ketoacidosis from ScienceDirect\\'s AI-generated Topic Pages\") (DKA) is a [grave syndrome](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/graves-disease \"Learn more about grave syndrome from ScienceDirect\\'s AI-generated Topic Pages\") present in diabetic patients. The body breaks down fat at a faster rate than normal, causing the liver to process the fat into ketones and making the blood acidic. Diabetic [ketoacidosis](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ketoacidosis \"Learn more about ketoacidosis from ScienceDirect\\'s AI-generated Topic Pages\") (DKA) can likely occur in children and young adults because of β-cell destruction, it is usually described as the first manifestation of the illness. The disease progresses at a very slow rate, coupled with a gradual increase in fasting plasma glucose levels. Nevertheless, based on increasing [insulin deficiency](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-deficiency \"Learn more about insulin deficiency from ScienceDirect\\'s AI-generated Topic Pages\"), patients become insulin-dependent together with the presence of severe hyperglycemia and [ketoacidosis](https://www.sciencedirect.com/topics/medicine-and-dentistry/ketoacidosis \"Learn more about ketoacidosis from ScienceDirect\\'s AI-generated Topic Pages\"). Furthermore, due to the severity and progression of type 1 diabetes mellitus, the patient becomes fully dependent on insulin therapy for his or her survival [[7](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib7)].\\n\\nThe pathophysiology of type 2 diabetes mellitus is distinguished by [insulin deficiency](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/insulin-deficiency \"Learn more about insulin deficiency from ScienceDirect\\'s AI-generated Topic Pages\") and insulin resistance, which have been linked to [inflammatory cytokines](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/inflammatory-cytokine \"Learn more about inflammatory cytokines from ScienceDirect\\'s AI-generated Topic Pages\") in the plasma and high levels of fatty acids, leading to deficient [glucose transport](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-transport \"Learn more about glucose transport from ScienceDirect\\'s AI-generated Topic Pages\") into target cells, elevated breakdown of fat, and increased hepatic [glucose production](https://www.sciencedirect.com/topics/medicine-and-dentistry/gluconeogenesis \"Learn more about glucose production from ScienceDirect\\'s AI-generated Topic Pages\") [[29](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib29)]. Consequent hyperglycemia is caused by the over secretion of [glucagon](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/glucagon \"Learn more about glucagon from ScienceDirect\\'s AI-generated Topic Pages\") and a deficiency of insulin by the glucagon-secreting alpha cell and the insulin-secreting beta cell, respectively. In the case of type 2 diabetes mellitus, the disease is diagnosed because patients cannot increase insulin secretion to make up for their insulin resistance, thereby causing a high level of [glycemic](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycemic \"Learn more about glycemic from ScienceDirect\\'s AI-generated Topic Pages\") value [[29](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib29)].\\n\\nType 2 diabetes mellitus may go undiagnosed at the early stage because it progresses rather slowly and asymptomatically, sometimes with mild hyperglycemia. The appearance of other symptoms like [polydipsia](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/polydipsia \"Learn more about polydipsia from ScienceDirect\\'s AI-generated Topic Pages\"), weight loss, blurry vision and growth impairment comes at the late or advanced stage of the disease. The etiology of this form of diabetes involves a combination of genetic and [environmental factors](https://www.sciencedirect.com/topics/medicine-and-dentistry/environmental-factor \"Learn more about environmental factors from ScienceDirect\\'s AI-generated Topic Pages\"). The disease is often related to various lifestyle factors such as poor diet, age, lack of exercise, family history of diabetes, obesity, earlier [gestational diabetes mellitus](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pregnancy-diabetes-mellitus \"Learn more about gestational diabetes mellitus from ScienceDirect\\'s AI-generated Topic Pages\") in women, and pathophysiological conditions like [atherosclerosis](https://www.sciencedirect.com/topics/medicine-and-dentistry/atherosclerosis \"Learn more about atherosclerosis from ScienceDirect\\'s AI-generated Topic Pages\"), [dyslipidemia](https://www.sciencedirect.com/topics/medicine-and-dentistry/dyslipidemia \"Learn more about dyslipidemia from ScienceDirect\\'s AI-generated Topic Pages\"), and hypertension ([Fig.8](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig8)) [[7](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib7)].\\n\\n![Image 19: Fig.\\xa08](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr8.jpg)\\n1.   [Download: Download high-res image (152KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr8_lrg.jpg \"Download high-res image (152KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr8.jpg \"Download full-size image\")\\n\\nFig.8. Risk Factors of type 2 diabetes mellitus.\\n\\nGestational diabetes mellitus is the measure of diabetes or [glucose intolerance](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucose-intolerance \"Learn more about glucose intolerance from ScienceDirect\\'s AI-generated Topic Pages\") confirmed at the second or [third trimester](https://www.sciencedirect.com/topics/medicine-and-dentistry/third-trimester-pregnancy \"Learn more about third trimester from ScienceDirect\\'s AI-generated Topic Pages\") of pregnancy and [gestation](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/pregnancy \"Learn more about gestation from ScienceDirect\\'s AI-generated Topic Pages\"). At the onset of pregnancy, it is noted that fasting and random blood are lower than the normal blood concentration value, and an exponential increase in blood glucose levels in the [third trimester](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/third-trimester-pregnancy \"Learn more about third trimester from ScienceDirect\\'s AI-generated Topic Pages\") confirms [gestational diabetes mellitus](https://www.sciencedirect.com/topics/medicine-and-dentistry/gestational-diabetes \"Learn more about gestational diabetes mellitus from ScienceDirect\\'s AI-generated Topic Pages\") [[7](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib7)].\\n\\n4. Pharmacology\\n---------------\\n\\n### 4.1. Pharmacological agents\\n\\nAlthough lifestyle modifications can aid in the enhancement of [glycemic control](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glycemic-control \"Learn more about glycemic control from ScienceDirect\\'s AI-generated Topic Pages\"), medications will be required in the long run to effectively manage the disease. Inhibitors are classes of oral pharmacological agents used to treat type 2 diabetes mellitus and examples include [bile acid sequestrants](https://www.sciencedirect.com/topics/medicine-and-dentistry/bile-acid-sequestrant \"Learn more about bile acid sequestrants from ScienceDirect\\'s AI-generated Topic Pages\"), [dopamine agonists](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/dopamine-agonist \"Learn more about dopamine agonists from ScienceDirect\\'s AI-generated Topic Pages\"), [sulfonylureas](https://www.sciencedirect.com/topics/medicine-and-dentistry/sulfonylurea \"Learn more about sulfonylureas from ScienceDirect\\'s AI-generated Topic Pages\"), [meglitinides](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/meglitinide \"Learn more about meglitinides from ScienceDirect\\'s AI-generated Topic Pages\"), [metformin](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycon \"Learn more about metformin from ScienceDirect\\'s AI-generated Topic Pages\") (biguanide), [thiazolidinediones](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/thiazolidinedione \"Learn more about thiazolidinediones from ScienceDirect\\'s AI-generated Topic Pages\"), sodium-glucose transport protein 2 (SGLT2) inhibitors, oral glucagon like peptide 1 (GLP-1) receptor, alpha-glucosidase inhibitors, and [dipeptidyl peptidase](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/dipeptidyl-peptidase \"Learn more about dipeptidyl peptidase from ScienceDirect\\'s AI-generated Topic Pages\") IV (DPP-IV) inhibitors [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)].\\n\\n### 4.2. Pharmacological treatment of type 1 diabetes mellitus\\n\\nThe basis of the treatment for type 1 diabetes is insulin therapy. Although, thanks to research, non-insulin supplement treatment is now used in laboratories and [clinical trials](https://www.sciencedirect.com/topics/medicine-and-dentistry/clinical-trial \"Learn more about clinical trials from ScienceDirect\\'s AI-generated Topic Pages\") to find new treatment options for diabetes. Metformin, a [biguanide](https://www.sciencedirect.com/topics/medicine-and-dentistry/biguanide \"Learn more about biguanide from ScienceDirect\\'s AI-generated Topic Pages\"), is the most common drug used to manage diabetes. It is sometimes supplemented with [amylin](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/amylin \"Learn more about amylin from ScienceDirect\\'s AI-generated Topic Pages\") analogues, GLP-1 receptors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. These medications grant good outcomes and management in type 1 diabetes mellitus patients [[31](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib31)].\\n\\n### 4.3. Pharmacological treatment of type 2 diabetes mellitus\\n\\nThe various drugs administered to treat type 2 diabetes mellitus patients have different mechanisms to reverse the effects of hyperglycemia by reducing blood sugar levels ([Fig.9](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig9)) [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)].\\n*   1.**Sulfonylureas** are insulin [secretagogues](https://www.sciencedirect.com/topics/medicine-and-dentistry/secretagogue \"Learn more about secretagogues from ScienceDirect\\'s AI-generated Topic Pages\") that have been used extensively in the treatment of patients with diabetes. They are mostly metabolized in the liver and sometimes excreted by the kidneys [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. Irrespective of blood glucose levels, [sulfonylureas](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/sulfonylurea \"Learn more about sulfonylureas from ScienceDirect\\'s AI-generated Topic Pages\") trigger insulin secretion from the pancreas [[32](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib32)]. Also, [sulfonylureas](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/sulfonylurea \"Learn more about sulfonylureas from ScienceDirect\\'s AI-generated Topic Pages\") inhibit [glucagon secretion](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucagon-release \"Learn more about glucagon secretion from ScienceDirect\\'s AI-generated Topic Pages\"), enhance [insulin sensitivity](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-sensitivity \"Learn more about insulin sensitivity from ScienceDirect\\'s AI-generated Topic Pages\") in peripheral tissues, and reduce hepatic [insulin clearance](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-clearance \"Learn more about insulin clearance from ScienceDirect\\'s AI-generated Topic Pages\") [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   2.**Meglitinides** are drugs that increase insulin secretion from the pancreas, and they are dependent on glucose levels, which reduces the risk of hypoglycemia. It has a short duration of action and can be administered to match the postprandial increase in glucose [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   3.**Metformin (Glucophage**) improves hepatic [insulin sensitivity](https://www.sciencedirect.com/topics/medicine-and-dentistry/insulin-sensitivity \"Learn more about insulin sensitivity from ScienceDirect\\'s AI-generated Topic Pages\") and reduces hepatic glucose production. It also reduces insulin resistance in the peripheral tissues by reducing [free fatty acids](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/free-fatty-acids \"Learn more about free fatty acids from ScienceDirect\\'s AI-generated Topic Pages\"), [triglycerides](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/triglyceride \"Learn more about triglycerides from ScienceDirect\\'s AI-generated Topic Pages\"), and high blood glucose levels [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. It carries out its [antihyperglycemic action](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/antidiabetic-activity \"Learn more about antihyperglycemic action from ScienceDirect\\'s AI-generated Topic Pages\") without influencing insulin secretion [[33](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib33)]. Also, it elevates gut [glucose utilization](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-utilization \"Learn more about glucose utilization from ScienceDirect\\'s AI-generated Topic Pages\") and triggers GLP-1 secretion. Metformin is commonly administered as the first pharmacological agent in the treatment of diabetes because of its affordable price, efficiency, and few [side effects](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/side-effect \"Learn more about side effects from ScienceDirect\\'s AI-generated Topic Pages\") [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   4.**Sodium-glucose transport protein 2 (SGLT2) inhibitors** They are a class of [oral antidiabetic agents](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/oral-antidiabetic-agent \"Learn more about oral antidiabetic agents from ScienceDirect\\'s AI-generated Topic Pages\") administered to lower blood glucose levels in adult patients with type 2 diabetes mellitus. Its action is not affected by insulin resistance or the [insulin levels](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-level \"Learn more about insulin levels from ScienceDirect\\'s AI-generated Topic Pages\") in the body [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   5.**Glucagon-like peptide-1 (GLP-1**) GLP-1 is produced and stored in the L cells of the ileum and colon. Neural and hormonal mechanisms coupled with the presence of food in the [gastrointestinal tract](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/gastrointestinal-tract \"Learn more about gastrointestinal tract from ScienceDirect\\'s AI-generated Topic Pages\") trigger its release. GLP-1 enhances insulin secretion by the beta cells and inhibits [glucagon secretion](https://www.sciencedirect.com/topics/medicine-and-dentistry/glucagon-release \"Learn more about glucagon secretion from ScienceDirect\\'s AI-generated Topic Pages\") by the alpha cells when blood glucose levels are elevated above normal ([Fig.10](https://www.sciencedirect.com/science/article/pii/S2590093523000425#fig10)) [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   6.[Pramlintide](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/pramlintide \"Learn more about Pramlintide from ScienceDirect\\'s AI-generated Topic Pages\") (symlin)[Pramlintide](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pramlintide \"Learn more about Pramlintide from ScienceDirect\\'s AI-generated Topic Pages\") is a synthetic derivative of [amylin](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/amylin \"Learn more about amylin from ScienceDirect\\'s AI-generated Topic Pages\"). It is soluble in nature and administered orally. In response to nutrient stimuli, the pancreas secures Amylin with insulin. It reduces post-prandial stimulated glucagon secretion, slows down gastric emptying, and suppresses appetite [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   7.**Bromocriptine-QR** reduces insulin sensitivity and resistance, leading to a decrease in hepatic glucose production and an increase in glucose disposal. It does not elevate insulin levels, making it effective in patients who produce insulin but are insulin resistant. Bromocriptine-QR improves glycemic levels in patients with type 2 diabetes mellitus when administered as a [monotherapy](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/monotherapy \"Learn more about monotherapy from ScienceDirect\\'s AI-generated Topic Pages\") drug or combined with other antihyperglycemic agents [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n*   8.**Thiazolidinediones** (TZDS) reduce insulin resistance while simultaneously activating the response to insulin. TZDs improve [glycemic control](https://www.sciencedirect.com/topics/medicine-and-dentistry/glycemic-control \"Learn more about glycemic control from ScienceDirect\\'s AI-generated Topic Pages\") and act to reverse certain disease complications like [polycystic ovarian syndrome](https://www.sciencedirect.com/topics/medicine-and-dentistry/polycystic-ovarian-syndrome \"Learn more about polycystic ovarian syndrome from ScienceDirect\\'s AI-generated Topic Pages\"), [atherosclerosis](https://www.sciencedirect.com/topics/medicine-and-dentistry/atherosclerosis \"Learn more about atherosclerosis from ScienceDirect\\'s AI-generated Topic Pages\"), and other cardiovascular diseases in patients with type 2 diabetes mellitus. However, side effects like weight gain and [osteoporosis](https://www.sciencedirect.com/topics/medicine-and-dentistry/osteoporosis \"Learn more about osteoporosis from ScienceDirect\\'s AI-generated Topic Pages\") can be very serious, causing its use to be limited [[30](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bib30)]. \\n\\n![Image 20: Fig.\\xa09](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr9.jpg)\\n1.   [Download: Download high-res image (350KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr9_lrg.jpg \"Download high-res image (350KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr9.jpg \"Download full-size image\")\\n\\nFig.9. Sites of action of the pharmacological agents.\\n\\n![Image 21: Fig.\\xa010](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr10.jpg)\\n1.   [Download: Download high-res image (144KB)](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr10_lrg.jpg \"Download high-res image (144KB)\")\\n2.   [Download: Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S2590093523000425-gr10.jpg \"Download full-size image\")\\n\\nFig.10. Effects of secretion of [incretin hormone](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/incretin \"Learn more about incretin hormone from ScienceDirect\\'s AI-generated Topic Pages\") on pancreas.\\n\\n5. Conclusion and future perspective\\n------------------------------------\\n\\nDiabetes mellitus is a persistent condition with various risk factors and serious complications that affect the [quality of life](https://www.sciencedirect.com/topics/medicine-and-dentistry/quality-of-life \"Learn more about quality of life from ScienceDirect\\'s AI-generated Topic Pages\"). However, research studies have helped in the prognosis, diagnosis, treatment, and management of its different forms. The [pathophysiology](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pathophysiology \"Learn more about pathophysiology from ScienceDirect\\'s AI-generated Topic Pages\") of the prognosis and diagnosis dictates the treatment option to be administered. Although it is important to note that such pharmacological agents have different [side effects](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/side-effect \"Learn more about side effects from ScienceDirect\\'s AI-generated Topic Pages\"), new studies aid in the proper application and combination of the drugs. Eating the right diet, increasing [physical activity](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/physical-activity \"Learn more about physical activity from ScienceDirect\\'s AI-generated Topic Pages\"), and monitoring and maintaining healthy glucose levels are some of the ways individuals can prevent the risk of the disease.\\n\\nIt is vital to highlight that diabetes research and its associated disorders are hotly debated topics. While we attempted to highlight some of the most important features, there are others that ought to be included as well. Some of these include the critical role of [nitric oxide synthase](https://www.sciencedirect.com/topics/medicine-and-dentistry/nitric-oxide-synthase \"Learn more about nitric oxide synthase from ScienceDirect\\'s AI-generated Topic Pages\") and [endothelial function](https://www.sciencedirect.com/topics/medicine-and-dentistry/endothelial-function \"Learn more about endothelial function from ScienceDirect\\'s AI-generated Topic Pages\") in insulin action, regulatory hormones such as [amylin](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/amylin \"Learn more about amylin from ScienceDirect\\'s AI-generated Topic Pages\") and glucagon, gestational diabetes, insulin [gene transcription](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/genetic-transcription \"Learn more about gene transcription from ScienceDirect\\'s AI-generated Topic Pages\"), [insulin degradation](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/insulin-degradation \"Learn more about insulin degradation from ScienceDirect\\'s AI-generated Topic Pages\"), steroid-induced diabetes, and other central regulators other than leptin. Furthermore, we have not covered developments in gene therapy or other potential therapeutic targets that are being investigated, nor have we discussed various [animal models](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/animal-model \"Learn more about animal models from ScienceDirect\\'s AI-generated Topic Pages\") that have defined key lessons about metabolism, [genetics](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/genetics \"Learn more about genetics from ScienceDirect\\'s AI-generated Topic Pages\"), and other complicated interactions. Over the last few years, breakthroughs in understanding the metabolic stages of diabetes have resulted in considerable advances in the treatment regimen for this deadly disease. Indeed, there are currently therapeutic methods available that allow for the treatment of both insulin resistance and secretion. However, it is uncertain if current therapy techniques address the underlying metabolic deficiencies. Improvements in illness treatment or prevention will be dependent on a better knowledge of the underlying [molecular pathophysiology](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/molecular-pathology \"Learn more about molecular pathophysiology from ScienceDirect\\'s AI-generated Topic Pages\"). Indeed, developments in genetics, [signal transduction](https://www.sciencedirect.com/topics/medicine-and-dentistry/signal-transduction \"Learn more about signal transduction from ScienceDirect\\'s AI-generated Topic Pages\"), and the [neurology](https://www.sciencedirect.com/topics/medicine-and-dentistry/neurology \"Learn more about neurology from ScienceDirect\\'s AI-generated Topic Pages\") of [energy intake](https://www.sciencedirect.com/topics/medicine-and-dentistry/caloric-intake \"Learn more about energy intake from ScienceDirect\\'s AI-generated Topic Pages\") and metabolism should allow for a more precise and possibly personalized approach to therapy, allowing us to target the problem where it exists. This alone is cause for celebration.\\n\\nCredit author statement\\n-----------------------\\n\\nO.A.O and D.E.R designed the study. H.S.I. conducted and wrote the manuscript draft. A.D.O., A.B.O., D.E.R. and O.A.O. helped with analysis and literature review and revised the manuscript. All authors read and approved the final version of the manuscript.\\n\\nDeclaration of competing interest\\n---------------------------------\\n\\nThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\\n\\nRecommended articles\\n\\nReferences\\n----------\\n\\n1.   [[1]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib1)Centers for Disease Control and Prevention National Diabetes Statistics Report   (November 11, 2022) [https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf](https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf) [Google Scholar](https://scholar.google.com/scholar?q=Centers%20for%20Disease%20Control%20and%20Prevention.%20National%20Diabetes%20Statistics%20Report.%20Accessed%20November%2011%2C%202022%2C%20from%20https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fpdfs%2Fdata%2Fstatistics%2Fnational-diabetes-statistics-report.pdf) \\n2.   [[2]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib2)S. Thota, A. Akbar Insulin. PubMed  StatPearls Publishing (2020) [https://www.ncbi.nlm.nih.gov/books/NBK560688](https://www.ncbi.nlm.nih.gov/books/NBK560688) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Insulin.%20PubMed&publication_year=2020&author=S.%20Thota&author=A.%20Akbar) \\n3.   [[3]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib3)M.A. Hill, Y. Yang, L. Zhang, Z. Sun, G. Jia, A.R. Parrish, _et al._ Insulin resistance, cardiovascular stiffening and cardiovascular disease  Metabolism, 119 (0026-0495) (2021), Article 154766, [10.1016/j.metabol.2021.154766](https://doi.org/10.1016/j.metabol.2021.154766) [View PDF](https://www.sciencedirect.com/science/article/pii/S0026049521000664/pdfft?md5=7eea039f75e7136554799fe79ab7141e&pid=1-s2.0-S0026049521000664-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/S0026049521000664)[View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85103756714&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Insulin%20resistance%2C%20cardiovascular%20stiffening%20and%20cardiovascular%20disease&publication_year=2021&author=M.A.%20Hill&author=Y.%20Yang&author=L.%20Zhang&author=Z.%20Sun&author=G.%20Jia&author=A.R.%20Parrish) \\n4.   [[4]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib4)L.A. DiMeglio, C. Evans-Molina, R.A. Oram Type 1 diabetes  Lancet, 391 (10138) (2018), pp. 2449-2462 [View PDF](https://www.sciencedirect.com/science/article/pii/S0140673618313205/pdfft?md5=f0fc297afa4b5a910eb1814584f2c5f1&pid=1-s2.0-S0140673618313205-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/S0140673618313205)[View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85048387111&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Type%201%20diabetes&publication_year=2018&author=L.A.%20DiMeglio&author=C.%20Evans-Molina&author=R.A.%20Oram) \\n5.   [[5]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib5)American Diabetes Association Standards of medical care in diabetes—2022 abridged for primary care providers  Clin Diabetes, 40 (1) (2021), [10.2337/cd22-as01](https://doi.org/10.2337/cd22-as01) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Standards%20of%20medical%20care%20in%20diabetes2022%20abridged%20for%20primary%20care%20providers&publication_year=2021&author=American%20Diabetes%20Association) \\n6.   [[6]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib6)A.A.S. Akil, E. Yassin, A. Al-Maraghi, E. Aliyev, K. Al-Malki, K.A. Fakhro Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era  J.Transl. Med., 19 (2021), p. 137, [10.1186/s12967-021-02778-6](https://doi.org/10.1186/s12967-021-02778-6) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85103806532&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Diagnosis%20and%20treatment%20of%20type%201%20diabetes%20at%20the%20dawn%20of%20the%20personalized%20medicine%20era&publication_year=2021&author=A.A.S.%20Akil&author=E.%20Yassin&author=A.%20Al-Maraghi&author=E.%20Aliyev&author=K.%20Al-Malki&author=K.A.%20Fakhro) \\n7.   [[7]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib7)M. Banday, A. Sameer, S. Nissar Pathophysiology of diabetes: an overview  Avicenna J. Med., 10 (4) (2020), pp. 174-188, [10.4103/ajm.ajm_53_20](https://doi.org/10.4103/ajm.ajm_53_20) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85101118078&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Pathophysiology%20of%20diabetes%3A%20an%20overview&publication_year=2020&author=M.%20Banday&author=A.%20Sameer&author=S.%20Nissar) \\n8.   [[8]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib8)U. Galicia-Garcia, A. Benito-Vicente, S. Jebari, A. Larrea-Sebal, H. Siddiqi, K.B. Uribe, _et al._ Pathophysiology of type 2 diabetes mellitus  Int. J. Mol. Sci., 21 (17) (2020), p. 6275, [10.3390/ijms21176275](https://doi.org/10.3390/ijms21176275) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Pathophysiology%20of%20type%202%20diabetes%20mellitus&publication_year=2020&author=U.%20Galicia-Garcia&author=A.%20Benito-Vicente&author=S.%20Jebari&author=A.%20Larrea-Sebal&author=H.%20Siddiqi&author=K.B.%20Uribe) \\n9.   [[9]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib9)I. Kyrou, C. Tsigos, C. Mavrogianni, G. Cardon, V. Van Stappen, J. Latomme, _et al._ Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: a narrative review with emphasis on data from Europe  BMC Endocr. Disord., 20 (S1) (2020), p. 134, [10.1186/s12902-019-0463-3](https://doi.org/10.1186/s12902-019-0463-3) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85081908158&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Sociodemographic%20and%20lifestyle-related%20risk%20factors%20for%20identifying%20vulnerable%20groups%20for%20type%202%20diabetes%3A%20a%20narrative%20review%20with%20emphasis%20on%20data%20from%20Europe&publication_year=2020&author=I.%20Kyrou&author=C.%20Tsigos&author=C.%20Mavrogianni&author=G.%20Cardon&author=V.%20Van%20Stappen&author=J.%20Latomme) \\n10.   [[10]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib10)C.J. Bailey, C. Day Treatment of type 2 diabetes: future approaches  Br. Med. Bull., 126 (1) (2019), pp. 123-137, [10.1093/brimed/ldy013](https://doi.org/10.1093/brimed/ldy013) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85079305781&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Treatment%20of%20type%202%20diabetes%3A%20future%20approaches&publication_year=2019&author=C.J.%20Bailey&author=C.%20Day) \\n11.   [[11]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib11)G. Li, T. Wei, W. Ni, A. Zhang, J. Zhang, Y. Xing, _et al._ Incidence and risk factors of gestational diabetes mellitus: a prospective cohort study in Qingdao, China  Front. Endocrinol., 11 (2020), p. 636, [10.3389/fendo.2020.00636](https://doi.org/10.3389/fendo.2020.00636) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Incidence%20and%20risk%20factors%20of%20gestational%20diabetes%20mellitus%3A%20a%20prospective%20cohort%20study%20in%20Qingdao%2C%20China&publication_year=2020&author=G.%20Li&author=T.%20Wei&author=W.%20Ni&author=A.%20Zhang&author=J.%20Zhang&author=Y.%20Xing) \\n12.   [[12]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib12)P. Šimják, A. Cinkajzlová, K. Anderlová, A. Pařízek, M. Mráz, M. Kršek, _et al._ The role of obesity and adipose tissue dysfunction in gestational diabetes mellitus  J.Endocrinol., 238 (2) (2018), pp. R63-R77, [10.1530/JOE-18-0032](https://doi.org/10.1530/JOE-18-0032) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85049487936&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=The%20role%20of%20obesity%20and%20adipose%20tissue%20dysfunction%20in%20gestational%20diabetes%20mellitus&publication_year=2018&author=P.%20%C5%A0imj%C3%A1k&author=A.%20Cinkajzlov%C3%A1&author=K.%20Anderlov%C3%A1&author=A.%20Pa%C5%99%C3%ADzek&author=M.%20Mr%C3%A1z&author=M.%20Kr%C5%A1ek) \\n13.   [[13]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib13)Z.A. Oskovi-Kaplan, A.S. Ozgu-Erdinc Management of gestational diabetes mellitus  Adv. Exp. Med. Biol., 1307 (2021), pp. 257-272, [10.1007/5584_2020_552](https://doi.org/10.1007/5584_2020_552) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85095861080&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Management%20of%20gestational%20diabetes%20mellitus&publication_year=2021&author=Z.A.%20Oskovi-Kaplan&author=A.S.%20Ozgu-Erdinc) \\n14.   [[14]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib14)H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan, _et al._ IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045  Diabetes Res. Clin. Pract., 183 (2021), Article 109119, [10.1016/j.diabres.2021.109119](https://doi.org/10.1016/j.diabres.2021.109119) [Google Scholar](https://scholar.google.com/scholar_lookup?title=IDF%20diabetes%20Atlas%3A%20global%2C%20regional%20and%20country-level%20diabetes%20prevalence%20estimates%20for%202021%20and%20projections%20for%202045&publication_year=2021&author=H.%20Sun&author=P.%20Saeedi&author=S.%20Karuranga&author=M.%20Pinkepank&author=K.%20Ogurtsova&author=B.B.%20Duncan) \\n15.   [[15]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib15)L. Szablewski Introductory chapter: glucose transporters  Intech (2020), [10.5772/intechopen.82263](https://doi.org/10.5772/intechopen.82263) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Introductory%20chapter%3A%20glucose%20transporters&publication_year=2020&author=L.%20Szablewski) \\n16.   [[16]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib16)R.A. Harris, J.S. Johnson Glycolysis overview. reference module in biomedical sciences  Encyclopedia Biol. Chem. (2013), pp. 443-447, [10.1016/b978-0-12-801238-3.11342-x](https://doi.org/10.1016/b978-0-12-801238-3.11342-x) [View PDF](https://www.sciencedirect.com/science/article/pii/B978012378630200044X/pdfft?md5=ee78fced659a00a6c1feede751eeb949&pid=3-s2.0-B978012378630200044X-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/B978012378630200044X)[View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85042804838&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Glycolysis%20overview.%20reference%20module%20in%20biomedical%20sciences&publication_year=2013&author=R.A.%20Harris&author=J.S.%20Johnson) \\n17.   [[17]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib17)X. Zhang, S. Yang, J. Chen, A. Su Unraveling the regulation of hepatic gluconeogenesis  Front. Endocrinol., 9 (2019), p. 802, [10.3389/fendo.2018.00802](https://doi.org/10.3389/fendo.2018.00802) [View PDF](https://www.sciencedirect.com/science/article/pii/S0960148119305427/pdfft?md5=1bf5a07925e50c281d3f2d4350960478&pid=1-s2.0-S0960148119305427-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/S0960148119305427)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Unraveling%20the%20regulation%20of%20hepatic%20gluconeogenesis&publication_year=2019&author=X.%20Zhang&author=S.%20Yang&author=J.%20Chen&author=A.%20Su) \\n18.   [[18]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib18)M.N. Nakrani, R.H. Wineland, F. Anjum Physiology, glucose metabolism  StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing (2023) [https://www.ncbi.nlm.nih.gov/books/NBK560599/](https://www.ncbi.nlm.nih.gov/books/NBK560599/) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Physiology%2C%20glucose%20metabolism&publication_year=2023&author=M.N.%20Nakrani&author=R.H.%20Wineland&author=F.%20Anjum) \\n19.   [[19]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib19)A.L. McCall Glucose transport  Stress: Physiol. Biochem. Pathol. (2019), pp. 293-307, [10.1016/b978-0-12-813146-6.00022-9](https://doi.org/10.1016/b978-0-12-813146-6.00022-9) [View PDF](https://www.sciencedirect.com/science/article/pii/B9780128131466000229/pdfft?md5=9096a194ed041b3280b5c00c1bee644d&pid=3-s2.0-B9780128131466000229-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/B9780128131466000229)[View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85093476790&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Glucose%20transport&publication_year=2019&author=A.L.%20McCall) \\n20.   [[20]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib20)A.L. Olson, K. Humphries Recent advances in understanding glucose transport and glucose disposal  F1000Res, 9 (2020), p. F1000, [10.12688/f1000research.22237.1](https://doi.org/10.12688/f1000research.22237.1) Faculty Rev-639 [Google Scholar](https://scholar.google.com/scholar_lookup?title=Recent%20advances%20in%20understanding%20glucose%20transport%20and%20glucose%20disposal&publication_year=2020&author=A.L.%20Olson&author=K.%20Humphries) \\n21.   [[21]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib21)A. Chadt, H. Al-Hasani Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease  Pflugers Arch - Eur. J. Physiol., 472 (2020), pp. 1273-1298, [10.1007/s00424-020-02417-x](https://doi.org/10.1007/s00424-020-02417-x) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85087010669&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Glucose%20transporters%20in%20adipose%20tissue%2C%20liver%2C%20and%20skeletal%20muscle%20in%20metabolic%20health%20and%20disease&publication_year=2020&author=A.%20Chadt&author=H.%20Al-Hasani) \\n22.   [[22]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib22)C. Fillebeen, N.H. Lam, S. Chow, A. Botta, G. Sweeney, K. Pantopoulos Regulatory connections between iron and glucose metabolism  Int. J. Mol. Sci., 21 (20) (2020), p. 7773, [10.3390/ijms21207773](https://doi.org/10.3390/ijms21207773) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Regulatory%20connections%20between%20iron%20and%20glucose%20metabolism&publication_year=2020&author=C.%20Fillebeen&author=N.H.%20Lam&author=S.%20Chow&author=A.%20Botta&author=G.%20Sweeney&author=K.%20Pantopoulos) \\n23.   [[23]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib23)M.J. Skytte, A. Samkani, A. Astrup, J. Frystyk, J.F. Rehfeld, J.J. Holst, _et al._ Effects of carbohydrate restriction on postprandial glucose metabolism, β-cell function, gut hormone secretion, and satiety in patients with type 2 diabetes  Am. J. Physiol. Endocrinol. Metab., 320 (1) (2021), [10.1152/ajpendo.00165.2020](https://doi.org/10.1152/ajpendo.00165.2020) E7–E18 [Google Scholar](https://scholar.google.com/scholar_lookup?title=Effects%20of%20carbohydrate%20restriction%20on%20postprandial%20glucose%20metabolism%2C%20-cell%20function%2C%20gut%20hormone%20secretion%2C%20and%20satiety%20in%20patients%20with%20type%202%20diabetes&publication_year=2021&author=M.J.%20Skytte&author=A.%20Samkani&author=A.%20Astrup&author=J.%20Frystyk&author=J.F.%20Rehfeld&author=J.J.%20Holst) \\n24.   [[24]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib24)V. D’Rozario Blood Sugar Chart  Medindia (2022) [https://www.medindia.net/patients/calculators/bloodsugar_chart.asp](https://www.medindia.net/patients/calculators/bloodsugar_chart.asp) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Blood%20Sugar%20Chart&publication_year=2022&author=V.%20D%E2%80%99Rozario) \\n25.   [[25]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib25)NIDDK Diabetes Tests & Diagnosis  National institute of diabetes and digestive and kidney diseases (2019) [https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis](https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Diabetes%20Tests%20%20Diagnosis&publication_year=2019&author=NIDDK) \\n26.   [[26]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib26)F.R. Kosasih, B. Bonavida YY1-mediated regulation of type 2 diabetes via insulin  YY1 in the control of the Pathogenesis and Drug Resistance of Cancer (2021), pp. 271-287 [View PDF](https://www.sciencedirect.com/science/article/pii/B9780128219096000055/pdfft?md5=d467ab6ee97e9682274c564a9f5e6cb7&pid=3-s2.0-B9780128219096000055-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/B9780128219096000055)[Google Scholar](https://scholar.google.com/scholar_lookup?title=YY1-mediated%20regulation%20of%20type%202%20diabetes%20via%20insulin&publication_year=2021&author=F.R.%20Kosasih&author=B.%20Bonavida) \\n27.   [[27]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib27)I. Zahoor, S. Singh, T. Behl, N. Sharma, T. Naved, V. Subramaniyan, _et al._ Emergence of microneedles as a potential therapeutics in diabetes mellitus  Environ. Sci. Pollut. Res., 29 (3) (2021), pp. 3302-3322, [10.1007/s11356-021-17346-0](https://doi.org/10.1007/s11356-021-17346-0) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Emergence%20of%20microneedles%20as%20a%20potential%20therapeutics%20in%20diabetes%20mellitus&publication_year=2021&author=I.%20Zahoor&author=S.%20Singh&author=T.%20Behl&author=N.%20Sharma&author=T.%20Naved&author=V.%20Subramaniyan) \\n28.   [[28]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib28)J. Moini Pathophysiology of diabetes  Epidemiol. Diabetes (2019), pp. 25-43, [10.1016/b978-0-12-816864-6.00003-1](https://doi.org/10.1016/b978-0-12-816864-6.00003-1) [View PDF](https://www.sciencedirect.com/science/article/pii/B9780128168646000031/pdfft?md5=55300b1f4a38ca6bfa56296dc0a1c274&pid=3-s2.0-B9780128168646000031-main.pdf)[View article](https://www.sciencedirect.com/science/article/pii/B9780128168646000031)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Pathophysiology%20of%20diabetes&publication_year=2019&author=J.%20Moini) \\n29.   [[29]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib29)R. Khardori Type 2 Diabetes Mellitus: Practice Essentials, Background, Pathophysiology  EMedicine (2022) [https://emedicine.medscape.com/article/117853-overview#a3](https://emedicine.medscape.com/article/117853-overview#a3) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Type%202%20Diabetes%20Mellitus%3A%20Practice%20Essentials%2C%20Background%2C%20Pathophysiology&publication_year=2022&author=R.%20Khardori) \\n30.   [[30]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib30)K.R. Feingold Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes  K.R. Feingold, B. Anawalt, M.R. Blackman, A. Boyce, G. Chrousos, E. Corpas, _et al._ (Eds.), Endotext [Internet], MDText.com, Inc, South Dartmouth (MA) (2022) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Oral%20and%20injectable%20%20pharmacological%20agents%20for%20the%20treatment%20of%20type%202%20diabetes&publication_year=2022&author=K.R.%20Feingold) \\n31.   [[31]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib31)E. Otto-Buczkowska, N. Jainta Pharmacological treatment in diabetes mellitus type 1-insulin and what else?  Int. J. Endocrinol. Metabol., 16 (1) (2017), Article e13008, [10.5812/ijem.13008](https://doi.org/10.5812/ijem.13008) 2017 [Google Scholar](https://scholar.google.com/scholar_lookup?title=Pharmacological%20treatment%20in%20diabetes%20mellitus%20type%201-insulin%20and%20what%20else&publication_year=2017&author=E.%20Otto-Buczkowska&author=N.%20Jainta) \\n32.   [[32]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib32)R.A. Costello, S. Nicolas, A. Shivkumar Sulfonylureas  StatPearls [Internet], StatPearls Publishing, Treasure Island (FL) (2023) [https://www.ncbi.nlm.nih.gov/books/NBK513225/](https://www.ncbi.nlm.nih.gov/books/NBK513225/) [Google Scholar](https://scholar.google.com/scholar_lookup?title=Sulfonylureas&publication_year=2023&author=R.A.%20Costello&author=S.%20Nicolas&author=A.%20Shivkumar) \\n33.   [[33]](https://www.sciencedirect.com/science/article/pii/S2590093523000425#bbib33)S. Kalra, S. Bahendeka, R. Sahay, S Md F. Ghosh, A. Orabi, K. Ramaiya, _et al._ Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus – international task force  Indian J. Endocrinol. Metab., 22 (1) (2018), pp. 132-157, [10.4103/ijem.IJEM_556_17](https://doi.org/10.4103/ijem.IJEM_556_17) [View in Scopus](https://www.scopus.com/inward/record.url?eid=2-s2.0-85041917179&partnerID=10&rel=R3.0.0)[Google Scholar](https://scholar.google.com/scholar_lookup?title=Consensus%20recommendations%20on%20sulfonylurea%20and%20sulfonylurea%20combinations%20in%20the%20management%20of%20type%202%20diabetes%20mellitus%20%20international%20task%20force&publication_year=2018&author=S.%20Kalra&author=S.%20Bahendeka&author=R.%20Sahay&author=S%20Md%20F.%20Ghosh&author=A.%20Orabi&author=K.%20Ramaiya) \\n\\nCited by (26)\\n-------------\\n\\n*   ### [Natural α-glucosidase inhibitors from Aquilaria sinensis leaf-tea: Targeted bio-affinity screening, identification, and inhibition mechanism](https://www.sciencedirect.com/science/article/pii/S0308814624029790)\\n\\n2025, Food Chemistry Citation Excerpt : \\nDiabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia as the main pathological change (Tanaka et al., 2024). Hyperglycemia, on the other hand, is caused by defective insulin secretion, impaired biological action of insulin, or both, with those suffering from type II diabetes mellitus (T2DM) accounting for about 90 % of cases of diabetes mellitus (Hami et al., 2023; Ojo et al., 2023). Hydrolysis of carbohydrates is an essential source of energy for the body.   Show abstract _Aquilaria sinensis_ leaves have long been consumed as a popular replacement tea for lowering postprandial blood glucose levels, but their specific functional components remain unclear. In this study, _Aquilaria sinensis_ leaf-tea 70% ethanol extract (ALTE) exhibited excellent anti-α-glucosidase activity (IC 50=6.93±1.91 μg/mL) and promoted glucose consumption ability in 3 T3-L1 preadipocyte cells. Subsequently phenolic compositions of ALTE were identified for the first time. After that, five potential _α_-glucosidase inhibitors (α-GIs) including cynaroside-3,5-diglucose, malvidin 3-glucose, epicatechin, epigallocatechin gallate, and dihydromyricetin in ALTE were screened using a targeted bio-affinity ultrafiltration-HPLC/MS method. Moreover, these five _α_-GIs all showed good anti-α-glucosidase effects and glucose consumption-promoting ability. Furthermore, the binding properties and inhibition mechanisms of five α-GIs to α-glucosidase were further analyzed _via_ enzyme inhibition kinetics, molecular docking, and molecular dynamics simulation. This study confirms that _Aquilaria sinensis_ leaf-tea is effective in preventing post-hyperglycemia _in vitro_ models, suggesting potential for future research in human trials.    \\n*   ### [Targeting histone deacetylases: Emerging applications beyond cancer](https://www.sciencedirect.com/science/article/pii/S1359644624002198)\\n\\n2024, Drug Discovery Today Citation Excerpt : \\nDM is a chronic metabolic disorder characterized by persistent hyperglycemia. As the most common endocrine disease (>500 million patients), DM is caused by a deficiency or insensitivity to insulin (e.g., type 1 or type 2 DM).(p39) T1DM is an autoimmune condition involving damage to insulin-producing β-cells resulting in insulin deficiencies, whereas T2DM (90% of all cases) involves insulin resistance and an overall shortage in production.   Show abstract Histone deacetylases (HDACs) are a special class of hydrolase enzymes, which through epigenetic control of cellular acetylation, play regulatory roles in various processes including chromatin packing, cytokine signaling, and gene expression. Widespread influence on cell function has implicated dysregulated HDAC activity in human disease. While traditionally an oncology target, in the past decade, there has been a notable rise in inhibition strategies within several therapeutic areas beyond cancer. This review highlights advances in four of these indications, neurodegenerative disease, metabolic disorders, cardiovascular disease, and viral infections, focusing on the role of deacetylases in disease, small molecule drug discovery, and clinical progress.    \\n*   ### [Ultrasonic-assisted resting of Tartary buckwheat dough: Study on its effect and mechanism](https://www.sciencedirect.com/science/article/pii/S1350417723003681)\\n\\n2023, Ultrasonics Sonochemistry Citation Excerpt : \\nDiabetes mellitus is a chronic metabolic disorder characterized by abnormally elevated blood glucose levels due to insulin resistance or insulin deficiency [1].   Show abstract Utilizing natural hypoglycemic ingredients in staple foods is a safe and effective way to improve diabetes. High Tartary buckwheat noodles have garnered research interest due to their hypoglycemic properties. However, increasing the Tartary buckwheat content poses challenges in noodle processing and affects their edible quality. Effective resting is a critical link to improve the processing performance of noodle and edible quality of noodle. Therefore, research was conducted on ultrasound assisted resting of Tartary buckwheat dough (TBD) to explore its feasibility and mechanism in improving the quality of Tartary buckwheat noodle. The results indicated that ultrasound treatment effectively promoted the migration of weakly-bound water towards strongly-bound water, thereby enhancing the gluten protein network structure and increasing the α-helix and β-sheet contents significantly (p<0.05). Furthermore, Texture analysis indicated decreased hardness and adhesion, and increased elasticity and stretching distance in the final noodles. Ultrasound-assisted maturation pre-treatment shortens TBD\\'s dough\\'s resting time and improves noodle quality, according to this study.    \\n*   ### [Gelatin/PLA-loaded gold nanocomposites synthesis using Syzygium cumini fruit extract and their antioxidant, antibacterial, anti-inflammatory, antidiabetic and anti-Alzheimer’s activities](https://doi.org/10.1038/s41598-024-84098-5)\\n\\n2025, Scientific Reports     \\n*   ### [The antimicrobial and antibiofilm effects of gentamicin, imipenem, and fucoidan combinations against dual-species biofilms of Staphylococcus aureus and Acinetobacter baumannii isolated from diabetic foot ulcers](https://doi.org/10.1186/s12941-024-00760-w)\\n\\n2024, Annals of Clinical Microbiology and Antimicrobials     \\n*   ### [Dual active pyrimidine-based carbocyclic nucleoside derivatives: synthesis, and in silico and in vitro anti-diabetic and anti-microbial studies](https://doi.org/10.1039/d4ra00304g)\\n\\n2024, Rsc Advances     \\n\\n[View all citing articles on Scopus](http://www.scopus.com/scopus/inward/citedby.url?partnerID=10&rel=3.0.0&eid=2-s2.0-85172762034&md5=94b19f6379e4473327a1308f55517295)\\n\\n© 2023 The Authors. Published by Elsevier B.V.\\n\\nRecommended articles\\n--------------------\\n\\n*   ### [Epidemiology of diabetes mellitus](https://www.sciencedirect.com/science/article/pii/B9780128148334000046 \"Epidemiology of diabetes mellitus\")\\n\\nTransplantation, Bioengineering, and Regeneration of the Endocrine Pancreas, 2020, pp. 49-58  Kavya Chitra Mekala, Alain Gerald Bertoni   \\n*   ### [Smart passive gait retraining intervention via pebbles for reducing peak plantar pressure: Short-term results](https://www.sciencedirect.com/science/article/pii/S2590093523000371 \"Smart passive gait retraining intervention via pebbles for reducing peak plantar pressure: Short-term results\")\\n\\nMedicine in Novel Technology and Devices, Volume 19, 2023, Article 100242  Fatemeh Farhadi, …, Shane Johnson  [View PDF](https://www.sciencedirect.com/science/article/pii/S2590093523000371/pdfft?md5=33314c95a3626cfb3051339c0d544f7a&pid=1-s2.0-S2590093523000371-main.pdf) \\n*   ### [Dysregulated autophagy: A key player in the pathophysiology of type 2 diabetes and its complications](https://www.sciencedirect.com/science/article/pii/S0925443923000327 \"Dysregulated autophagy: A key player in the pathophysiology of type 2 diabetes and its complications\")\\n\\nBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Volume 1869, Issue 4, 2023, Article 166666  Abhishek Sehrawat, …, Jasvinder Singh Bhatti  [View PDF](https://www.sciencedirect.com/science/article/pii/S0925443923000327/pdfft?md5=0e582d2146c7a39364b1c41cdec5f648&pid=1-s2.0-S0925443923000327-main.pdf) \\n*   ### [Molecular aspects and biochemical regulation of diabetes mellitus](https://www.sciencedirect.com/science/article/pii/B9780128498866000021 \"Molecular aspects and biochemical regulation of diabetes mellitus\")\\n\\nMolecular Nutrition: Carbohydrates, 2019, pp. 35-57  Daniel Gyamfi, …, Stephen Owusu   \\n*   ### [Diabetes mellitus](https://www.sciencedirect.com/science/article/pii/S0304541220302110 \"Diabetes mellitus\")\\n\\nMedicine - Programa de Formación Médica Continuada Acreditado, Volume 13, Issue 16, 2020, pp. 883-890  P. Gallardo Jiménez, …, E. Lorenzo Hernández   \\n*   ### [Diabetic Kidney Disease](https://www.sciencedirect.com/science/article/pii/B9780323529785000033 \"Diabetic Kidney Disease\")\\n\\nChronic Kidney Disease, Dialysis, and Transplantation, 2019, pp. 42-61.e5  Radica Z.Alicic, …, Katherine R.Tuttle   \\n\\nShow 3 more articles\\n\\nArticle Metrics\\n---------------\\n\\n### Citations\\n\\n*   Citation Indexes 25\\n\\n### Captures\\n\\n*   Mendeley Readers 1053\\n\\n### Mentions\\n\\n*   News Mentions 1\\n\\n### Social Media\\n\\n*   Shares, Likes & Comments 3\\n\\n![Image 22: PlumX Metrics Logo](https://cdn.plu.mx/3ba727faf225e19d2c759f6ebffc511d/plumx-logo.png)[View details](https://plu.mx/plum/a/?doi=10.1016%2Fj.medntd.2023.100247&theme=plum-sciencedirect-theme&hideUsage=true)\\n\\n[![Image 23: Elsevier logo with wordmark](https://sdfestaticassets-us-east-1.sciencedirectassets.com/shared-assets/47/images/elsevier-non-solus-new-with-wordmark.svg)](https://www.elsevier.com/)\\n\\n*   [About ScienceDirect](https://www.elsevier.com/solutions/sciencedirect)\\n*   [Remote access](https://www.sciencedirect.com/user/institution/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS2590093523000425)\\n*   [Advertise](https://www.elsmediakits.com/)\\n*   [Contact and support](https://service.elsevier.com/app/contact/supporthub/sciencedirect/)\\n*   [Terms and conditions](https://www.elsevier.com/legal/elsevier-website-terms-and-conditions)\\n*   [Privacy policy](https://www.elsevier.com/legal/privacy-policy)\\n\\nCookies are used by this site. Cookie Settings\\n\\nAll content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.\\n\\n[![Image 24: RELX group home page](https://sdfestaticassets-us-east-1.sciencedirectassets.com/shared-assets/60/images/logo-relx-tm.svg)](https://www.relx.com/)\\n\\n![Image 25: Company Logo](https://cdn.cookielaw.org/logos/static/ot_company_logo.png)\\n\\nCookie Preference Center\\n------------------------\\n\\nWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our [Cookie Policy](https://www.elsevier.com/legal/cookienotice/_nocache) and the list of [Google Ad-Tech Vendors](https://support.google.com/admanager/answer/9012903). \\n\\n You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer. See the different category headings below to find out more or change your settings. \\n\\nAllow all\\n### Manage Consent Preferences\\n\\n#### Strictly Necessary Cookies\\n\\nAlways active\\n\\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.\\n\\nCookie Details List\\u200e\\n\\n#### Performance Cookies\\n\\n- [x] Performance Cookies \\n\\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.\\n\\nCookie Details List\\u200e\\n\\n#### Targeting Cookies\\n\\n- [x] Targeting Cookies \\n\\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you will experience less targeted advertising.\\n\\nCookie Details List\\u200e\\n\\n### Cookie List\\n\\nClear\\n\\n- [x] checkbox label label\\n\\nApply Cancel\\n\\nConsent Leg.Interest\\n\\n- [x] checkbox label label\\n\\n- [x] checkbox label label\\n\\n- [x] checkbox label label\\n\\nConfirm my choices\\n\\n[![Image 26: Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\\n\\nYour Privacy [`dialog closed`]\\n\\n![Image 27: Feedback](https://pendo-static-5661679399600128.storage.googleapis.com/D_T2uHq_M1r-XQq8htU6Z3GjHfE/guide-media-75af8ddc-3c43-49fd-8836-cfc7e2c3ea60)\\n\\n×\\n\\n![Image 28: Image of ScienceDirect AI search screen](https://pendo-static-5661679399600128.storage.googleapis.com/qhaIperF4_FY8nMWbTR3IUBGVSI/guide-media-fa0f15a8-02df-4cf5-a6ea-e675c21e080f)\\n\\n**From question to evidence in seconds**\\n\\nScienceDirect AI enhances your research, producing cited responses from full-text research literature.\\n\\nTry for free\\n'},\n",
       "  {'title': 'The New England Journal of Medicine | Research & Review Articles on ...',\n",
       "   'url': 'https://www.nejm.org/',\n",
       "   'content': '*   [The New England Journal of Medicine NEJM](https://www.nejm.org/) *   [Clinical Medicine](https://www.nejm.org/browse/specialty/clinical-medicine) *   [Gastroenterology](https://www.nejm.org/browse/specialty/gastroenterology) *   [Images in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/images-in-clinical-medicine) K.L. Jhaveri and Others [![Image 4: Vepdegestrant in Advanced Breast Cancer](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2505725_300x200-1748451168327.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2505725) #### [Vepdegestrant in Advanced Breast Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2505725) [![Image 6: T-DXd or Ramucirumab–Paclitaxel in Gastric Cancer](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2503119_300x200-1748364719277.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2503119) #### [T-DXd or Ramucirumab–Paclitaxel in Gastric Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2503119) #### [Undermining Women’s Health Research](https://www.nejm.org/doi/full/10.1056/NEJMp2503576) D.K. McGuire and Others *   [Clinical Practice](https://www.nejm.org/browse/nejm-article-type/clinical-practice) #### [Cancer of Unknown Primary Site](https://www.nejm.org/doi/full/10.1056/NEJMcp2402691) K. Raghav M. Hunter and Others #### [Cancer of Unknown Primary Site](https://www.nejm.org/doi/full/10.1056/NEJMcp2402691) #### [Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2501006) *   [![Image 28](https://www.nejm.org/cms/asset/e9699072-3a9f-4943-9824-a98617f093fd/nejmdo007997_600x400.jpg)](https://www.nejm.org/do/10.1056/NEJMdo007997/full/) *   [Research](https://www.nejm.org/browse/nejm-article-category/research) *   [Other](https://www.nejm.org/browse/nejm-article-category/other) *   [The New England Journal of Medicine](https://www.nejm.org/) You will need to [sign in](https://www.nejm.org/signin) again using your new password to access site content and features.',\n",
       "   'score': 0.27871838,\n",
       "   'raw_content': 'The New England Journal of Medicine | Research & Review Articles on Disease & Clinical Practice\\n\\n===============\\n\\n[Skip to main content](https://www.nejm.org/#mainContent)\\n\\n*   [The New England Journal of Medicine NEJM](https://www.nejm.org/)\\n*   [NEJM Evidence](https://evidence.nejm.org/)\\n*   [NEJM AI](https://ai.nejm.org/)\\n*   [NEJM Catalyst](https://catalyst.nejm.org/)\\n*   [NEJM Journal Watch](https://www.jwatch.org/)\\n\\n[Sign In](https://www.nejm.org/sign-in?uri=/)|[Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC1)\\n\\n[Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS1)\\n\\n[![Image 1: The New England Journal of Medicine homepage](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg)](https://www.nejm.org/ \"The New England Journal of Medicine homepage\")\\n\\n[Sign In](https://www.nejm.org/sign-in?uri=/)|[Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC1)\\n\\n[Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS1)\\n\\n[![Image 2: The New England Journal of Medicine homepage](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg)](https://www.nejm.org/ \"The New England Journal of Medicine homepage\")\\n\\n*   [current issue](https://www.nejm.org/toc/nejm/current)\\n\\n    *   [VIEW CURRENT ISSUE](https://www.nejm.org/toc/nejm/current)\\n    *   [BROWSE RECENTLY PUBLISHED](https://www.nejm.org/toc/nejm/recently-published)\\n    *   [BROWSE ALL ISSUES](https://www.nejm.org/loi/nejm)\\n\\n*   [SPECIALTIES](https://www.nejm.org/medical-specialties)\\n\\n    *   [Cardiology](https://www.nejm.org/browse/specialty/cardiology)\\n    *   [Clinical Medicine](https://www.nejm.org/browse/specialty/clinical-medicine)\\n    *   [Endocrinology](https://www.nejm.org/browse/specialty/endocrinology)\\n    *   [Gastroenterology](https://www.nejm.org/browse/specialty/gastroenterology)\\n    *   [Hematology/Oncology](https://www.nejm.org/browse/specialty/hematology-oncology)\\n    *   [Infectious Disease](https://www.nejm.org/browse/specialty/infectious-disease)\\n    *   [Nephrology](https://www.nejm.org/browse/specialty/nephrology)\\n    *   [Neurology/Neurosurgery](https://www.nejm.org/browse/specialty/neurology-neurosurgery)\\n    *   [Obstetrics/Gynecology](https://www.nejm.org/browse/specialty/obstetrics-gynecology)\\n    *   [Pediatrics](https://www.nejm.org/browse/specialty/pediatrics)\\n    *   [Pulmonary/Critical Care](https://www.nejm.org/browse/specialty/pulmonary-critical-care)\\n    *   [Surgery](https://www.nejm.org/browse/specialty/surgery)\\n    *   [View All Specialties](https://www.nejm.org/medical-specialties)\\n\\n*   [TOPICS](https://www.nejm.org/topics)\\n\\n    *   [AI in Medicine](https://www.nejm.org/ai-in-medicine)\\n    *   [Climate Change](https://www.nejm.org/browse/specialty/climate-change)\\n    *   [Coronavirus](https://www.nejm.org/coronavirus)\\n    *   [Efforts toward Equity](https://www.nejm.org/equity)\\n    *   [Firearm Injury Prevention](https://www.nejm.org/firearm-injury-prevention)\\n    *   [From the National Academy of Medicine](https://www.nejm.org/nam)\\n    *   [Fundamentals of Medical Ethics](https://www.nejm.org/fundamentals-of-medical-ethics)\\n    *   [Gray Matters](https://www.nejm.org/gray-matters)\\n    *   [Health Policy](https://www.nejm.org/browse/specialty/health-policy)\\n    *   [Medicine and Society](https://www.nejm.org/medicine-and-society)\\n    *   [Nutrition in Medicine](https://www.nejm.org/nutrition-in-medicine)\\n    *   [Outbreaks Center](https://www.nejm.org/outbreaks)\\n    *   [Race and Medicine](https://www.nejm.org/race-and-medicine)\\n    *   [Recognizing Historical Injustices and the Journal](https://www.nejm.org/recognizing-historical-injustices)\\n    *   [Tobacco Use Reduction](https://www.nejm.org/tobacco-use-reduction)\\n    *   [View All Topics](https://www.nejm.org/topics)\\n\\n*   [MULTIMEDIA](https://www.nejm.org/multimedia)\\n\\n    *   [Podcasts](https://www.nejm.org/rss-feed)\\n    *   [Double Takes](https://www.nejm.org/double-take)\\n    *   [Illustrated Glossary](https://illustrated-glossary.nejm.org/)\\n    *   [Image Challenge](https://www.nejm.org/image-challenge)\\n    *   [Images in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/images-in-clinical-medicine)\\n    *   [Interactive Medical Cases](https://www.nejm.org/browse/nejm-media-type/interactive-medical-case)\\n    *   [Plain Language/Research Summaries](https://www.nejm.org/plain-language-research-summaries)\\n    *   [Quick Takes](https://www.nejm.org/multimedia/quick-take-video)\\n    *   [Videos in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/videos-in-clinical-medicine)\\n    *   [View All Multimedia](https://www.nejm.org/multimedia)\\n\\n*   [LEARNING/CME](https://www.nejm.org/learning)\\n\\n    *   [Weekly CME](https://www.nejm.org/continuing-medical-education)\\n    *   [Obesity CME/CE](https://www.nejm.org/cme-ce/obesity)\\n    *   [VIEW ALL LEARNING/CME](https://www.nejm.org/learning)\\n\\n*   [AUTHOR CENTER](https://www.nejm.org/author-center/home)\\n\\n[Sign In](https://www.nejm.org/sign-in?uri=/)|[Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC1)\\n\\n[Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS1)\\n\\n[Advanced Search](https://www.nejm.org/search/advanced)SEARCH\\n\\nSave\\n\\n*   \\n[![Image 3: Inavolisib in <i>PIK3CA</i>-Mutated Breast Cancer](https://www.nejm.org/pb-assets/images/editorial/large/NEJMoa2501796_600x400-1748443695013.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2501796)  \\n\\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 31, 2025\\n\\n##### Meeting of the American Society of Clinical Oncology\\n\\n#### [Inavolisib in _PIK3CA_-Mutated Breast Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2501796)\\n\\nK.L. Jhaveri and Others\\n\\nIn patients with _PIK3CA_-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 31, 2025\\n\\n##### Meeting of the American Society of Clinical Oncology\\n\\n[![Image 4: Vepdegestrant in Advanced Breast Cancer](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2505725_300x200-1748451168327.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2505725)\\n\\n#### [Vepdegestrant in Advanced Breast Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2505725)\\n\\nM. Campone and Others\\n\\nIn advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with _ESR1_ mutations but not in the full patient population.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 31, 2025\\n\\n##### Meeting of the American Society of Clinical Oncology\\n\\n[![Image 5: Adjuvant Cemiplimab in High-Risk Cutaneous SCC](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2502449_300x200-1748539435363.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2502449)\\n\\n#### [Adjuvant Cemiplimab in High-Risk Cutaneous SCC](https://www.nejm.org/doi/full/10.1056/NEJMoa2502449)\\n\\nD. Rischin and Others\\n\\nIn high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab were seen.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 31, 2025\\n\\n##### Meeting of the American Society of Clinical Oncology\\n\\n[![Image 6: T-DXd or Ramucirumab–Paclitaxel in Gastric Cancer](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2503119_300x200-1748364719277.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2503119)\\n\\n#### [T-DXd or Ramucirumab–Paclitaxel in Gastric Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2503119)\\n\\nK. Shitara and Others\\n\\nIn HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 30, 2025\\n\\n##### Meeting of the American Society of Clinical Oncology\\n\\n[![Image 7: Targeted Therapy in <i>BRAF</i> V600E Metastatic Colorectal Cancer](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2501912_300x200-1747927639583.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2501912)\\n\\n#### [Targeted Therapy in _BRAF_ V600E Metastatic Colorectal Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2501912)\\n\\nE. Elez and Others\\n\\nThe addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic _BRAF_ V600E–mutated colorectal cancer.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   Mar 31, 2025\\n    *   CME\\n\\n[![Image 8: Sotatercept in High-Risk Pulmonary Arterial Hypertension](https://www.nejm.org/pb-assets/images/editorial/small/NEJMdo007993_300x200-1747927638927.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2415160)\\n\\n#### [Sotatercept in High-Risk Pulmonary Arterial Hypertension](https://www.nejm.org/doi/full/10.1056/NEJMoa2415160)\\n\\nM. Humbert and Others\\n\\nAmong adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension.\\n\\n[Editorial Sotatercept and the Clinical Transformation of Pulmonary Arterial Hypertension](https://www.nejm.org/doi/full/10.1056/NEJMe2503944)\\n\\n*   \\n    *   [Perspective](https://www.nejm.org/browse/nejm-article-type/perspective)\\n    *   May 28, 2025\\n\\n##### [Double Take](https://www.nejm.org/double-take)\\n\\n[![Image 9: A Burning Question](https://www.nejm.org/pb-assets/images/editorial/small/NEJMdo007828_300x200-1747927638790.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMp2414536)\\n\\n#### [A Burning Question](https://www.nejm.org/doi/full/10.1056/NEJMp2414536)\\n\\nS. Li and Others\\n\\nThis Double Take video explores the differential diagnosis for progressive dyspnea and cough and highlights the importance of taking a thorough history.\\n\\n*   \\n    *   [Perspective](https://www.nejm.org/browse/nejm-article-type/perspective)\\n    *   May 28, 2025\\n\\n#### [Undermining Women’s Health Research](https://www.nejm.org/doi/full/10.1056/NEJMp2503576)\\n\\nA.N. Kallen and Others\\n\\nThe benefits of women’s health research haven’t been limited to women. But actions by the Trump administration threaten to dismantle the hard-won progress in this area.\\n\\n### [Image Challenge](https://www.nejm.org/image-challenge)\\n\\n[![Image 10](https://csvc.nejm.org/ContentServer/images?id=IC20250529&width=150&height=4000)](https://www.nejm.org/image-challenge)\\n\\nWhat is the diagnosis?\\n\\n[Answer](https://www.nejm.org/image-challenge)\\n\\n[![Image 11](https://www.nejm.org/sda/126205/HomePromoTop--NOS_001.jpg)](https://www.nejm.org/action/clickThrough?id=126205&url=https%3A%2F%2Fnot-otherwise-specified-podcast.nejm.org%2F%3Fquery%3Dcm%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dnoss2&loc=%2F&placeholderId=101355&productId=1007)\\n\\nOriginal Research\\n=================\\n\\nSave\\n\\n*   \\n[![Image 12: Oral Semaglutide and Cardiovascular Outcomes](https://www.nejm.org/pb-assets/images/editorial/xxl/NEJMdo007995_1350x800-1748355964343.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2501006)  \\n\\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   Mar 29, 2025\\n\\n#### [Oral Semaglutide and Cardiovascular Outcomes](https://www.nejm.org/doi/full/10.1056/NEJMoa2501006)\\n\\nD.K. McGuire and Others\\n\\nAmong participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.\\n\\n[Editorial Seeking Multiorgan Benefits with Cardiovascular–Kidney–Metabolic Drug Therapy](https://www.nejm.org/doi/full/10.1056/NEJMe2503600)\\n\\nSave\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   Apr 02, 2025\\n    *   CME\\n\\n[![Image 13: Upadacitinib for Giant-Cell Arteritis](https://www.nejm.org/pb-assets/images/editorial/small/NEJMdo007997_300x200-1748450856380.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413449)\\n\\n#### [Upadacitinib for Giant-Cell Arteritis](https://www.nejm.org/doi/full/10.1056/NEJMoa2413449)\\n\\nD. Blockmans and Others\\n\\nIn this randomized, placebo-controlled trial involving patients with giant-cell arteritis, the oral Janus kinase inhibitor upadacitinib (15 mg) significantly improved remission of disease, with less glucocorticoid use.\\n\\n[Editorial Upadacitinib — An Up-and-Comer for Treatment of Giant-Cell Arteritis](https://www.nejm.org/doi/full/10.1056/NEJMe2503584)\\n\\n*   \\n    *   [Correspondence](https://www.nejm.org/browse/nejm-article-type/correspondence)\\n    *   May 28, 2025\\n\\n[![Image 14: Anti-CD38 Agent in Relapsed or Refractory Pediatric ITP](https://www.nejm.org/pb-assets/images/editorial/small/NEJMc2501527_300x200-1747927638237.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMc2501527)\\n\\n#### [Anti-CD38 Agent in Relapsed or Refractory Pediatric ITP](https://www.nejm.org/doi/full/10.1056/NEJMc2501527)\\n\\nT. Sun, Y. Chen, and L. Zhang\\n\\nTwenty children with relapsed or refractory immune thrombocytopenia were treated with daratumumab. Most patients had a response, platelet counts increased quickly, and responses were durable in half the patients.\\n\\n*   \\n    *   [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article)\\n    *   May 24, 2025\\n\\n##### Peking University Diabetes Forum\\n\\n[![Image 15: Mazdutide in Chinese Adults with Obesity or Overweight](https://www.nejm.org/pb-assets/images/editorial/small/NEJMoa2411528_300x200-1747927639333.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMoa2411528)\\n\\n#### [Mazdutide in Chinese Adults with Obesity or Overweight](https://www.nejm.org/doi/full/10.1056/NEJMoa2411528)\\n\\nL. Ji and Others\\n\\nOnce-weekly mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight.\\n\\n[Editorial Overweight and Obesity — Capturing the Whole Picture](https://www.nejm.org/doi/full/10.1056/NEJMe2505819)\\n\\n*   \\n    *   [Special Article](https://www.nejm.org/browse/nejm-article-type/special-article)\\n    *   May 14, 2025\\n\\n[![Image 16: Loss of Subsidized Drug Coverage and Mortality](https://www.nejm.org/pb-assets/images/editorial/small/NEJMsa2414435_300x200-1747927639800.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMsa2414435)\\n\\n#### [Loss of Subsidized Drug Coverage and Mortality](https://www.nejm.org/doi/full/10.1056/NEJMsa2414435)\\n\\nE.T. Roberts and Others\\n\\nDual-eligible Medicare–Medicaid beneficiaries receive the Low-Income Subsidy, which reduces cost sharing for medications. Loss of drug subsidies after Medicaid disenrollment was associated with increased mortality.\\n\\n[![Image 17: CareerCenter](https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif)](https://www.nejmcareercenter.org/?query=fjw)\\n\\nPHYSICIAN JOBS\\n\\nMay 31, 2025\\n\\n Pensacola, Florida\\n\\nInternal Medicine\\n\\n[Internal Medicine Physician - Woodlands Medical Specialists](https://www.nejmcareercenter.org/job/886961/internal-medicine-physician-woodlands-medical-specialists/?query=fjwp&rid=5696)\\n\\n Brooklyn, New York\\n\\nGastroenterology\\n\\n[GENERAL GASTROENTEROLOGIST / ADVANCED GASTROENTEROLOGIST](https://www.nejmcareercenter.org/job/887327/general-gastroenterologist-advanced-gastroenterologist/?query=fjwp&rid=16388)\\n\\n Virginia\\n\\nPediatrics, General\\n\\n[Pediatric Hospitalist](https://www.nejmcareercenter.org/job/876593/pediatric-hospitalist/?query=fjwf&rid=49812)\\n\\n Pennsylvania\\n\\nSurgery, General\\n\\n[Rare Opening for Oral Surgery-One of the nation\\'s premier groups- Northeast](https://www.nejmcareercenter.org/job/883886/rare-opening-for-oral-surgery-one-of-the-nation-s-premier-groups-northeast/?query=fjwf&rid=5263)\\n\\n Stratford, Connecticut\\n\\nFamily Medicine\\n\\n[Physician - Family Medicine Primary Care](https://www.nejmcareercenter.org/job/877473/physician-family-medicine-primary-care/?query=fjwf&rid=36610)\\n\\n Charlottesville, Virginia\\n\\nRadiology\\n\\n[Assistant, Associate or Full Professor of Musculoskeletal Imaging](https://www.nejmcareercenter.org/job/886083/assistant-associate-or-full-professor-of-musculoskeletal-imaging/?query=fjwf&rid=468039)\\n\\n[![Image 18](https://www.nejm.org/sda/128745/rrHomePromo1--notable24_001.jpg)](https://www.nejm.org/action/clickThrough?id=128745&url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQHPNA%26query%3Dcm-hp2%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&loc=%2F&placeholderId=101353&productId=1007)\\n\\n[![Image 19: NEJM One-Year Editorial Fellowship beginning July 2026 - Apply by August 1 2025](https://www.nejm.org/pb-assets/images/editorial/featuredTopics/editorial-fellow/Editorial-Fellowship-Ad-2025-1743522920760.jpg)](https://editorialfellows.nejm.org/)\\n\\nClinical Practice and Review\\n============================\\n\\nSave\\n\\n*   \\n[![Image 20: Cancer of Unknown Primary Site](https://www.nejm.org/pb-assets/images/editorial/xxl/NEJMcp2402691_1350x800-1747927892553.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMcp2402691)  \\n\\n    *   [Clinical Practice](https://www.nejm.org/browse/nejm-article-type/clinical-practice)\\n    *   May 28, 2025\\n    *   CME\\n\\n#### [Cancer of Unknown Primary Site](https://www.nejm.org/doi/full/10.1056/NEJMcp2402691)\\n\\nK. Raghav\\n\\nCancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options.\\n\\nSave\\n\\n*   \\n    *   [Case Records of the Massachusetts General Hospital](https://www.nejm.org/browse/nejm-article-type/case-records-of-the-massachusetts-general-hospital)\\n    *   May 28, 2025\\n    *   CME\\n\\n[![Image 21: A Man with Fever, Nausea, and Respiratory Failure](https://www.nejm.org/pb-assets/images/editorial/small/NEJMcpc2412526_300x200-1747927638690.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMcpc2412526)\\n\\n#### [A Man with Fever, Nausea, and Respiratory Failure](https://www.nejm.org/doi/full/10.1056/NEJMcpc2412526)\\n\\nM. Hunter and Others\\n\\nA 52-year-old man was evaluated in a hospital in Argentina for fever and hypoxemic respiratory failure. Imaging showed pulmonary opacities, and the hematocrit was 56.9%. What is te diagnosis?\\n\\n*   \\n    *   [Images in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/images-in-clinical-medicine)\\n    *   May 28, 2025\\n\\n[![Image 22: Insulin-Derived Amyloidosis](https://www.nejm.org/pb-assets/images/editorial/small/NEJMicm2415719_300x200-1747927639437.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMicm2415719)\\n\\n#### [Insulin-Derived Amyloidosis](https://www.nejm.org/doi/full/10.1056/NEJMicm2415719)\\n\\nD. Connors and P. Chia\\n\\nA 47-year-old man with type 2 diabetes presented with several years of progressive growth of pendulous skin lesions on his lower abdominal wall where he had repeatedly injected insulin.\\n\\n*   \\n    *   [Perspective](https://www.nejm.org/browse/nejm-article-type/perspective)\\n    *   May 24, 2025\\n\\n#### [The Meaning of Goodbye](https://www.nejm.org/doi/full/10.1056/NEJMp2416194)\\n\\nD. Pisetsky\\n\\nWhen a physician’s wife has Alzheimer’s disease — the worst disease for the patient’s partner, according to their doctor — he must grapple with effects more challenging than memory loss.\\n\\n*   \\n    *   [Images in Clinical Medicine](https://www.nejm.org/browse/nejm-media-type/images-in-clinical-medicine)\\n    *   May 24, 2025\\n\\n[![Image 23: Tufted Angioma with Kasabach–Merritt Phenomenon](https://www.nejm.org/pb-assets/images/editorial/small/NEJMicm2414170_300x200-1747927639057.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMicm2414170)\\n\\n#### [Tufted Angioma with Kasabach–Merritt Phenomenon](https://www.nejm.org/doi/full/10.1056/NEJMicm2414170)\\n\\nS. Servattalab and P.-O. Grenier\\n\\nA full-term baby boy was evaluated at a quaternary care hospital for a large, violaceous, firm, hypertrichotic plaque on the right side of the back. Laboratory studies showed thrombocytopenia and low fibrinogen and elevated d-dimer levels.\\n\\n*   \\n    *   [Clinical Implications of Basic Research](https://www.nejm.org/browse/nejm-article-type/clinical-implications-of-basic-research)\\n    *   May 28, 2025\\n\\n[![Image 24: Countering Venom Toxins with AI](https://www.nejm.org/pb-assets/images/editorial/small/NEJMcibr2501084_300x200-1747927638337.jpg)](https://www.nejm.org/doi/full/10.1056/NEJMcibr2501084)\\n\\n#### [Countering Venom Toxins with AI](https://www.nejm.org/doi/full/10.1056/NEJMcibr2501084)\\n\\nJ.M. Gutiérrez\\n\\nThis article describes how machine-learning tools were used to design novel protein inhibitors that proved effective against snake-venom toxins in mice.\\n\\n*   \\n    *   [Perspective](https://www.nejm.org/browse/nejm-article-type/perspective)\\n    *   May 24, 2025\\n\\n#### [The GINA Gap](https://www.nejm.org/doi/full/10.1056/NEJMp2415951)\\n\\nK.Y. Tossas and Others\\n\\nNative Americans who receive care from the Indian Health Service aren’t covered by the federal law that bans discrimination based on genetic makeup, which could perpetuate health disparities.\\n\\n[![Image 25](https://www.nejm.org/sda/126111/N-ad-home-promo-2-Obesity.png)](https://www.nejm.org/action/clickThrough?id=126111&url=https%3A%2F%2Fwww.nejm.org%2Fcme-ce%2Fobesity%3Fpromo%3DONFQCEO7%26query%3Dcm_hp2%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dcme_ce_obesity&loc=%2F&placeholderId=101354&productId=101515)\\n\\n### Trending\\n\\n*   \\n    *    Original Article  |MAY 30, 2025\\n\\n#### [Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer](https://www.nejm.org/doi/full/10.1056/NEJMoa2501912)\\n\\n Elena Elez and others \\n\\n*   \\n    *    Clinical Practice  |MAY 29, 2025\\n\\n#### [Cancer of Unknown Primary Site](https://www.nejm.org/doi/full/10.1056/NEJMcp2402691)\\n\\n Kanwal Raghav \\n\\n*   \\n    *    Original Article  |MAY 11, 2025\\n\\n#### [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2416394)\\n\\n Louis J. Aronne and others \\n\\n*   \\n    *    Original Article  |MAY 29, 2025\\n\\n#### [Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2501006)\\n\\n Darren K. McGuire and others \\n\\n*   \\n    *    Case Records of the Massachusetts General Hospital  |MAY 29, 2025\\n\\n#### [Case 15-2025: A 52-Year-Old Man with Fever, Nausea, and Respiratory Failure](https://www.nejm.org/doi/full/10.1056/NEJMcpc2412526)\\n\\n Martín Hunter and others \\n\\n*   \\n    *    Sounding Board  |MAY 20, 2025\\n\\n#### [An Evidence-Based Approach to Covid-19 Vaccination](https://www.nejm.org/doi/full/10.1056/NEJMsb2506929)\\n\\n Vinay Prasad and others \\n\\n### [Featured Multimedia See all multimedia](https://www.nejm.org/browse/nejm-media-type)\\n\\n*   [![Image 26](https://www.nejm.org/cms/asset/03ddbbdb-0450-4b3f-9749-b018a0aeb9e6/nejmdo007993_600x400.jpg)](https://www.nejm.org/do/10.1056/NEJMdo007993/full/)\\n\\n    *   [Quick Take](https://www.nejm.org/browse/nejm-media-type/quick-take)\\n    *   May 29, 2025\\n\\n#### [Sotatercept in High-Risk Pulmonary Arterial Hypertension](https://www.nejm.org/do/10.1056/NEJMdo007993/full/)\\n\\n*   [![Image 27](https://www.nejm.org/cms/asset/61624f11-d3de-492c-af6d-88ffc097d7b7/nejmdo007995_600x400.jpg)](https://www.nejm.org/do/10.1056/NEJMdo007995/full/)\\n\\n    *   [Quick Take](https://www.nejm.org/browse/nejm-media-type/quick-take)\\n    *   May 29, 2025\\n\\n#### [Oral Semaglutide and Cardiovascular Outcomes](https://www.nejm.org/do/10.1056/NEJMdo007995/full/)\\n\\n*   [![Image 28](https://www.nejm.org/cms/asset/e9699072-3a9f-4943-9824-a98617f093fd/nejmdo007997_600x400.jpg)](https://www.nejm.org/do/10.1056/NEJMdo007997/full/)\\n\\n    *   [Quick Take](https://www.nejm.org/browse/nejm-media-type/quick-take)\\n    *   May 29, 2025\\n\\n#### [Upadacitinib for Giant-Cell Arteritis](https://www.nejm.org/do/10.1056/NEJMdo007997/full/)\\n\\nTap into groundbreaking research and clinically relevant insights\\n\\n*   [Subscribe](https://www.nejm.org/action/clickThrough?id=125732&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252F%26promo%3DONFQAFAZ&loc=%2F&placeholderId=101352&productId=1035)\\n\\nAlready a subscriber? [Sign In](https://www.nejm.org/action/clickThrough?id=125732&url=%2Fsign-in&loc=%2F&placeholderId=101352&productId=1035) or [Renew](https://www.nejm.org/action/clickThrough?id=125732&url=%2Faction%2FstoreProxy%3Faction%3Drenew%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252F%26promo%3DONFQJRAN%26product%3Dnejm&loc=%2F&placeholderId=101352&productId=1035)\\n\\n![Image 29: Devices](https://www.nejm.org/sda/125732/footer-devices-2x.png)\\n\\n#### ARTICLE CATEGORIES\\n\\n*   [Research](https://www.nejm.org/browse/nejm-article-category/research)\\n*   [Reviews](https://www.nejm.org/browse/nejm-article-category/review)\\n*   [Clinical Cases](https://www.nejm.org/browse/nejm-article-category/clinical-cases)\\n*   [Perspective](https://www.nejm.org/browse/nejm-article-category/perspective)\\n*   [Commentary](https://www.nejm.org/browse/nejm-article-category/commentary)\\n*   [Other](https://www.nejm.org/browse/nejm-article-category/other)\\n*   [Browse all Articles](https://www.nejm.org/medical-article-index)\\n*   [Current Issue](https://www.nejm.org/toc/nejm/current)\\n*   [Issue Index](https://www.nejm.org/loi/nejm)\\n\\n#### RESOURCES\\n\\n*   [Authors & Reviewers](https://www.nejm.org/author-center/home)\\n*   [Submit a Manuscript](https://www.nejm.org/author-center/home)\\n*   [Subscribers](https://www.nejm.org/about-nejm/products-and-services)\\n*   [Institutional Administrators](https://tools.ovid.com/ovidtools/nejm.html)\\n*   [Media](https://www.nejm.org/media)\\n*   [Advertisers](https://www.nejm.org/about-nejm/how-to-advertise)\\n*   [Agents](https://www.nejm.org/information-for-subscription-agents)\\n*   [Permissions & Licensing](https://www.nejm.org/about-nejm/permissions)\\n*   [Reprints](https://www.nejm.org/about-nejm/reprints)\\n*   [NEJM CareerCenter](https://www.nejmcareercenter.org/)\\n\\n#### ABOUT US\\n\\n*   [About NEJM](https://www.nejm.org/about-nejm/about-nejm)\\n*   [NEJM Group](https://www.nejmgroup.org/)\\n*   [Products & Services](https://www.nejm.org/about-nejm/products-and-services)\\n*   [Editors & Publishers](https://www.nejm.org/about-nejm/editors-and-publishers)\\n*   [Advertising Policies](https://www.nejm.org/about-nejm/advertising-policies)\\n*   [Contact Us](https://www.nejm.org/contact-nejm)\\n*   [Accessibility](https://www.nejm.org/about-nejm/frequently-asked-questions?#Accessibility)\\n*   [FAQs](https://www.nejm.org/about-nejm/frequently-asked-questions)\\n*   [Help](https://www.nejm.org/about-nejm/help)\\n*   [Site Feedback](mailto:sitefeedback@nejm.org)\\n\\n#### SUBSCRIPTIONS\\n\\n*   [Subscribe](https://www.nejm.org/action/storeProxy?action=subscribe&promo=ONF4NRS3)\\n*   [Renew](https://www.nejm.org/action/storeProxy?action=renew&product=nejm&promo=ONFLNRR3&prc=ONFARN52)\\n*   [Activate Subscription](https://www.nejm.org/action/storeProxy?action=activate&promo=ONFLNAA1)\\n*   [Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC4)\\n*   [Manage Account](https://myaccount.nejm.org/)\\n*   [Pay Bill](https://www.nejm.org/action/storeProxy?action=paybill&product=nejm&promo=BNFLPBA1)\\n*   [Institutional Sales](https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection)\\n*   [Special Content](https://myaccount.nejm.org/special-content)\\n\\n#### STAY CONNECTED\\n\\n*   [Email Alerts](https://myaccount.nejm.org/emails?section=NEJM)\\n*   [Create Account](https://www.nejm.org/action/storeProxy?action=register&promo=ONFLNRC3)\\n*   [Apps](https://www.nejm.org/about-nejm/products-and-services)\\n*   [NEJM CareerCenter](https://www.nejmcareercenter.org/)\\n*   [Podcasts](https://www.nejm.org/rss-feed/)\\n*   [RSS Feed](https://www.nejm.org/rss-feed/)\\n*   [Remote Access](https://www.nejm.org/about-nejm/institutional-access)\\n\\n#### FOLLOW US\\n\\n*   [Facebook](https://www.facebook.com/TheNewEnglandJournalofMedicine)\\n*   [X (formerly Twitter)](https://twitter.com/nejm)\\n*   [Instagram](https://www.instagram.com/nejm/)\\n*   [Youtube](https://www.youtube.com/user/NEJMvideo)\\n*   [LinkedIn](https://www.linkedin.com/company/nejm-group)\\n*   [Bluesky](https://bsky.app/profile/nejm.org)\\n*   [TikTok](https://www.tiktok.com/@nejm.org)\\n\\n#### JOURNALS\\n\\n*   [The New England Journal of Medicine](https://www.nejm.org/)\\n*   [NEJM Catalyst Innovations in Care Delivery](https://catalyst.nejm.org/)\\n*   [NEJM Evidence](https://evidence.nejm.org/)\\n*   [NEJM AI](https://ai.nejm.org/)\\n\\nCopyright © 2025 [**Massachusetts Medical Society**](https://www.massmed.org/). All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.\\n\\n*   [Copyright](https://www.nejmgroup.org/legal/copyright-information.htm)\\n*   [Terms](https://www.nejmgroup.org/legal/terms-of-use.htm)\\n*   [Privacy Policy](https://www.nejmgroup.org/legal/privacy-policy.htm)\\n*   Cookie Preferences\\n\\n[![Image 30: NEJM Group logo](https://www.nejm.org/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg)](https://www.nejmgroup.org/ \"NEJM Group\")\\n\\nBack to top\\n\\nThis site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences. \\n\\nManage Settings Accept\\n\\nSign In\\n=======\\n\\n {* #signInForm *} \\n\\n {* signInEmailAddress *} {* currentPassword *} \\n\\n- [x] Remember Me \\n\\nForgot your password?\\n\\nSign In\\n\\nDon\\'t have an account?\\n\\nCreate Account[Subscribe](https://store.nejm.org/nejm?promo=ONF4NRS1)\\n\\nCreate Account[Subscribe](https://store.nejm.org/nejm?promo=ONF4NRS1)\\n\\n {* /signInForm *} \\n\\nSign In\\n=======\\n\\n {* #signInForm *} \\n\\n {* signInEmailAddress *} {* currentPassword *} \\n\\n- [x] Remember Me \\n\\nForgot your password?\\n\\nSign In\\n\\nDon\\'t have an account?\\n\\nCreate Account[Subscribe](https://store.nejm.org/nejm?promo=ONF4NRS1)\\n\\n {* /signInForm *} \\n\\nForgot Password\\n===============\\n\\nEnter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.\\n\\n {* #forgotPasswordForm *} \\n\\n {* forgotPasswordEmailAddress *} {* captcha *} \\n\\n {* /forgotPasswordForm *} \\n\\nCreate New Password\\n===================\\n\\nWe\\'ve sent an email with instructions to create a new password. Your existing password has not been changed.\\n\\nCLOSE\\n\\nTo reset your password, enter a new password twice and click the \\'Reset Password\\' button.\\n\\n {* #changePasswordFormNoAuth *} {* newPassword *} {* newPasswordConfirm *}  {* /changePasswordFormNoAuth *} \\n\\nYour password has been reset. You will need to [sign in](https://www.nejm.org/signin) again using your new password to access site content and features.\\n\\n {* #resetPasswordForm *} \\n\\nThe link that you followed to reset your password has expired.\\n\\nEnter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.\\n\\n {* signInEmailAddress *} \\n\\n {* /resetPasswordForm *} \\n\\nIf the address matches an existing account, you will receive an email with instructions to reset your password.\\n\\nSign in using your account with\\n\\n*   [AOL](javascript:void(0);)\\n*   [OpenID](javascript:void(0);)\\n\\n*   [Yahoo!](javascript:void(0);)\\n\\n[Social Login by Janrain](http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&utm_medium=Partner&utm_campaign=attribution)\\n'},\n",
       "  {'title': 'Prevention of Cardiovascular Disease in Type 1 Diabetes',\n",
       "   'url': 'https://www.nejm.org/doi/full/10.1056/NEJMra2311526',\n",
       "   'content': 'Type 1 diabetes mellitus is a chronic metabolic disease resulting from autoimmune destruction of pancreatic beta cells. More than half the cases of type 1 diabetes are diagnosed in adulthood; 62%',\n",
       "   'score': 0.27269635,\n",
       "   'raw_content': None},\n",
       "  {'title': 'ICD-10-CM - Centers for Disease Control and Prevention',\n",
       "   'url': 'https://icd10cmtool.cdc.gov/?fy=FY2024',\n",
       "   'content': 'Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People',\n",
       "   'score': 0.26202357,\n",
       "   'raw_content': None},\n",
       "  {'title': 'National Drug Code Directory (NDC) - Food and Drug Administration',\n",
       "   'url': 'https://open.fda.gov/data/ndc/',\n",
       "   'content': '## National Drug Code Directory (NDC) Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. The NDC Directory does not contain all listed drugs. The previous version of the NDC Directory only included listed human prescription drugs and insulin products and excluded many products, including Over The Counter (OTC) products. The new edition of the NDC Directory includes electronically listed human prescription and OTC drugs that have been manufactured, prepared, propagated, compounded, or processed by registered establishments for commercial distribution.',\n",
       "   'score': 0.26045105,\n",
       "   'raw_content': '## National Drug Code Directory (NDC)\\n\\nDrug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs.\\n\\n![]()\\n\\n## About NDC\\n\\nThe Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily.\\n\\nThe information submitted as part of the listing process, the NDC number, and the NDC Directory are used in the implementation and enforcement of the Act.\\n\\nThe NDC Directory does not contain all listed drugs. The new version includes the final marketed drugs which listing information were submitted electronically. It does not include animal drugs, blood products, or human drugs that are not in final marketed form, such as Active Pharmaceutical Ingredients(APIs), drugs for further processing, drugs manufactured exclusively for a private label distributor, or drugs that are marketed solely as part of a kit or combination product or inner layer of a multi-level packaged product not marketed individually. For more information about how certain kits or multi-level packaged drugs are addressed in the new NDC Directory, see the NDC Directory Package File definitions document.\\n\\nEach listed drug product is assigned a unique 10-digit, 3-segment number. This number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. A labeler is any firm that manufactures (including repackers or relabelers), or distributes (under its own name) the drug. The second segment, the product code, identifies a specific strength, dosage form, and formulation of a drug for a particular firm. Different formulations or different strengths of the same formulation should be assigned different product codes. This means even if the same formulations of a drug product ultimately deliver different strengths of the active ingredient to the recipient, they should be assigned different product codes. Also, drug products that share the same formulation but have different product characteristics that clearly distinguish one drug product version from another can not share the same product code under the same labeler code. The third segment, the package code, identifies package sizes and types. Different package codes only differentiate between different quantitative and qualitative attributes of the product packaging. Both the product and package codes are assigned by the firm. The NDC will be in one of the following configurations: 4-4-2, 5-3-2, or 5-4-1.\\n\\nThe previous version of the NDC Directory only included listed human prescription drugs and insulin products and excluded many products, including Over The Counter (OTC) products. The new edition of the NDC Directory includes electronically listed human prescription and OTC drugs that have been manufactured, prepared, propagated, compounded, or processed by registered establishments for commercial distribution.\\n\\n## Learn more\\n\\nGeneral information  \\n[Learn more about NDC Directory](https://www.fda.gov/drugs/informationondrugs/ucm142438.htm)\\n\\nOriginal dataset downloads  \\n[NDC download information](https://www.accessdata.fda.gov/cder/ndctext.zip)\\n\\n### Provider\\n\\n[FDA](http://www.fda.gov/)\\n\\n### License\\n\\n[Public Domain and CC0](http://creativecommons.org/publicdomain/zero/1.0/)'},\n",
       "  {'title': 'Advanced Search Results - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/advanced/',\n",
       "   'content': \"An official website of the United States government Federal government websites often end in .gov or .mil. government site. **The site is secure.** official website and that any information you provide is encrypted NIH NLM Logo pubmed logo ## History and Search Details No History items are available for download. History items expire after 8 hour of inactivity. Click 'Refresh' to clear items from the table, The history table currently contains expired items. No History items are available for deletion. History items expire after 8 hour of inactivity. Click 'Refresh' to clear items from the table, The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Connect with NLM\",\n",
       "   'score': 0.25196552,\n",
       "   'raw_content': \"![U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\\n\\nAn official website of the United States government\\n\\n![Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**\\n  \\nFederal government websites often end in .gov or .mil. Before\\nsharing sensitive information, make sure you’re on a federal\\ngovernment site.\\n\\n![Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**\\n  \\nThe **https://** ensures that you are connecting to the\\nofficial website and that any information you provide is encrypted\\nand transmitted securely.\\n\\n![NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)\\n\\n#### Account\\n\\n# PubMed Advanced Search Builder\\n\\n![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/3a9fa263-60f0-46bd-99dd-5f80dc7a99c0/core/images/pubmed-logo-blue.svg)\\n\\n## Your saved search\\n\\n## History and Search Details\\n\\n\\n\\nNo History items are available for download.\\n\\nHistory items expire after 8 hour of inactivity.\\n\\nClick 'Refresh' to clear items from the table,\\n\\nor click the 'X' to go back to the table.\\n\\nThe history table currently contains expired items.\\n\\nClear expired items and add your new query?\\n\\nNo History items are available for deletion.\\n\\nHistory items expire after 8 hour of inactivity.\\n\\nClick 'Refresh' to clear items from the table,\\n\\nor click the 'X' to go back to the table.\\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/)\\n[PMC](https://www.ncbi.nlm.nih.gov/pmc/)\\n[Bookshelf](https://www.ncbi.nlm.nih.gov/books)\\n[Disclaimer](/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike  \\nBethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\"},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'https://professional.diabetes.org/sites/dpro/files/2023-12/glycemic_targets_1.pdf',\n",
       "   'content': \"diabetes.org | 1-800-DIABETES (1-800-342-2383) Supported in part by Time in Range. TM —a diabetes technology initiative of the American Diabetes Association (ADA) Learn more about . time in range ® Guidelines. Your visual guide to the guidelines . InSIGHT. This infographic is based on recommendations from the ADA's . Standards of Care in\",\n",
       "   'score': 0.22622798,\n",
       "   'raw_content': 'Glycemic Targets Most non-pregnant adults A1C target <7% Preprandial glucose 80–130 mg/dL Peak postprandial glucose <180 mg/dL Preprandial glucose measurement should be made before food Consider less stringent A1C goals (such as <8%) Hypoglycemia/hypoglycemia unawareness Reduced life expectancy Older age Increased risk or frequency of hyperglycemia Established vascular complications Multiple comorbidities Patient preference Lack of resources/support systems 7% 6% 8% A1C Target 1-2 hours Post prandial glucose measurements should be made 1–2 hours after the beginning of a meal before food Learn more at diabetes.org | 1-800-DIABETES (1-800-342-2383) Supported in part by Time in RangeTM—a diabetes technology initiative of the American Diabetes Association (ADA) Learn more about time in range ® Guidelines Your visual guide to the guidelines InSIGHT This infographic is based on recommendations from the ADA’s Standards of Care in Diabetes—2023'},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'http://main.diabetes.org/dforg/pdfs/2019/2019-cg-medications.pdf',\n",
       "   'content': 'Diabetes Forecast GENERIC NAME BRAND NAME MANUFACTURER FORM DELIVERY ONSET PEAK DURATION RAPID-ACTING INSULIN Insulin aspart Fiasp Novo Nordisk Analog Syringe or pen 2.5 min. 50 to 70 min. About 5 hours Insulin aspart NovoLog Novo Nordisk Analog Syringe, pen, or pump 10 to 20 min.',\n",
       "   'score': 0.22146891,\n",
       "   'raw_content': None},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'https://professional.diabetes.org/sites/dpro/files/2023-12/plan_your_plate.pdf',\n",
       "   'content': 'The Diabetes Plate Method is a helpful tool for anyone who wants to eat better and learn about variety and portion sizes, including people with prediabetes. Each section of the plate (based on a nine-inch plate) is for the following three food groups: vegetables, grains, and protein. Off to the side is dairy and fruit.',\n",
       "   'score': 0.21820295,\n",
       "   'raw_content': None},\n",
       "  {'title': 'FDA Purplebook',\n",
       "   'url': 'https://purplebooksearch.fda.gov/',\n",
       "   'content': 'Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS Share sensitive information only on official, secure websites. Purple Book Glossary Contact FDA Products About FDA Database of Licensed Biological Products The Purple Book database contains information on all FDA-licensed (approved) biological products regulated by the Center for Drug Evaluation and Research (CDER), including licensed biosimilar and interchangeable products, and their reference products. The Purple Book also contains information about all FDA-licensed allergenic, cellular and gene therapy, hematologic, and vaccine products regulated by the Center for Biologics Evaluation and Research (CBER). The results page for your selected product will include all biological products that share a core name (i.e., biosimilar, interchangeable, reference, and related biological products). About FDA FDA Homepage',\n",
       "   'score': 0.20919527,\n",
       "   'raw_content': 'FDA Purplebook\\n===============\\n\\n![Image 1: U.S. flag](blob:http://localhost/28ac974dcc54f856173f0c3376bc989e)\\n\\nAn official website of the United States government\\n\\nHere’s how you know\\n\\nHere’s how you know\\n\\n![Image 2: Dot gov](blob:http://localhost/de399488f47cffe744c3d5087e0fd666)\\n\\n**Official websites use .gov**  \\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![Image 3: Https](blob:http://localhost/4abb1844c91ac375f55c33ae5dc4c8ee)\\n\\n**Secure .gov websites use HTTPS**  \\nA **lock** () or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n[U.S. Food and Drug Administration =================================](https://www.fda.gov/home \"FDA Homepage\")\\n\\nPurple Book Glossary\\n\\nGlossary\\n\\nFeatured\\n--------\\n\\n*   [Contact FDA](https://www.fda.gov/about-fda/contact-fda)\\n*   [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents)\\n*   [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts)\\n*   [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements)\\n*   [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\\n*   [Advisory Committees](https://www.fda.gov/advisory-committees)\\n*   [En Espanol](https://www.fda.gov/about-fda/en-espanol)\\n\\nProducts\\n--------\\n\\n*   [Food](https://www.fda.gov/food)\\n*   [Drugs](https://www.fda.gov/drugs)\\n*   [Medical Devices](https://www.fda.gov/medical-devices)\\n*   [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products)\\n*   [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics)\\n*   [Animal and Veterinary](https://www.fda.gov/animal-veterinary)\\n*   [Cosmetics](https://www.fda.gov/cosmetics)\\n*   [Tobacco Products](https://www.fda.gov/tobacco-products)\\n\\nTopics\\n------\\n\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Combination Products](https://www.fda.gov/combination-products)\\n*   [Regulatory Information](https://www.fda.gov/regulatory-information)\\n*   [Safety](https://www.fda.gov/safety)\\n*   [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response)\\n*   [International Programs](https://www.fda.gov/international-programs)\\n*   [News and Events](https://www.fda.gov/news-events)\\n*   [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education)\\n*   [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations)\\n*   [Science and Research](https://www.fda.gov/science-research)\\n\\nInformation For\\n---------------\\n\\n*   [Consumers](https://www.fda.gov/consumers)\\n*   [Patients](https://www.fda.gov/patients)\\n*   [Industry](https://www.fda.gov/industry)\\n*   [Health Professionals](https://www.fda.gov/health-professionals)\\n*   [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials)\\n\\n*   [Purple Book Homepage](https://purplebooksearch.fda.gov/)\\n*   [About Purple Book](https://purplebooksearch.fda.gov/about)\\n*   [User Guide](https://purplebooksearch.fda.gov/userguide)\\n*   [FAQs](https://purplebooksearch.fda.gov/faqs)\\n*   [Patent List](https://purplebooksearch.fda.gov/patent-list)\\n*   [Download Purple Book Data](https://purplebooksearch.fda.gov/downloads)\\n\\nPurple Book  \\nDatabase of Licensed Biological Products\\n======================================================\\n\\n*   [Purple Book Homepage](https://purplebooksearch.fda.gov/)\\n*   [About Purple Book](https://purplebooksearch.fda.gov/about)\\n*   [User Guide](https://purplebooksearch.fda.gov/userguide)\\n*   [FAQs](https://purplebooksearch.fda.gov/faqs)\\n*   [Patent List](https://purplebooksearch.fda.gov/patent-list)\\n*   [Download Purple Book Data](https://purplebooksearch.fda.gov/downloads)\\n\\nThe Purple Book database contains information on all FDA-licensed (approved) biological products regulated by the Center for Drug Evaluation and Research (CDER), including licensed biosimilar and interchangeable products, and their reference products.\\n\\nThe Purple Book also contains information about all FDA-licensed allergenic, cellular and gene therapy, hematologic, and vaccine products regulated by the Center for Biologics Evaluation and Research (CBER).\\n\\n**Enter a product\\'s proprietary (brand) name or the nonproprietary (proper) name to find biological products. As you type, a list of potential results will begin to appear below the search box based on what you are typing. Click on a product from the auto-populated results list below to view the results page. The results page for your selected product will include all biological products that share a core name (_i.e._, biosimilar, interchangeable, reference, and related biological products).**\\n\\nSearch: \\n\\n_[Advanced Search](https://purplebooksearch.fda.gov/advanced-search)_\\n\\n_Database last updated:_\\n\\nFooter Links\\n------------\\n\\n*   [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive)\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility)\\n\\n*   [Visitor Information](https://www.fda.gov/about-fda/white-oak-campus-information/public-meetings-fda-white-oak-campus)\\n*   [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies)\\n*   [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html/)\\n\\n*   [FOIA](https://www.fda.gov/regulatory-information/freedom-information \"Freedom of Information Act\")\\n*   [HHS.gov](https://www.hhs.gov/ \"Health and Human Services\")\\n*   [USA.gov](https://www.usa.gov/)\\n\\n[Contact FDA](https://www.fda.gov/about-fda/contact-fda)[Follow FDA on Facebook](https://www.facebook.com/FDA \"Follow FDA on Facebook\")[Follow FDA on Twitter](https://www.twitter.com/US_FDA \"Follow FDA on Twitter\")[View FDA videos on YouTube](https://www.youtube.com/user/USFoodandDrugAdmin \"View FDA videos on YouTube\")[Subscribe to FDA RSS feeds](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds \"Subscribe to FDA RSS feeds\")\\n\\n[FDA Homepage](https://www.fda.gov/ \"FDA Homepage\")\\n\\nContact Number1-888-INFO-FDA (1-888-463-6332)\\n'},\n",
       "  {'title': 'VAMS-Login - Centers for Disease Control and Prevention',\n",
       "   'url': 'https://vams.cdc.gov/vaccineportal/s/landingpage?language=en_US',\n",
       "   'content': 'Web site created for vams. Oops - we could not find what you are looking for',\n",
       "   'score': 0.20866264,\n",
       "   'raw_content': None},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'https://professional.diabetes.org/sites/default/files/media/ada-factsheet-understandingyoura1ctest.pdf',\n",
       "   'content': 'The A1C is a blood test that tells you what your average blood sugar (blood glucose) levels have been for the past two to three months. It measures how much sugar is attached to your red blood cells. If your blood sugar is frequently high, more will be attached to your blood cells. Because you are always making new red blood cells to replace old ones, your A1C changes over time as your blood sugar levels change. eAG stands for estimated average glucose and is your estimated average blood sugar.',\n",
       "   'score': 0.1997607,\n",
       "   'raw_content': None},\n",
       "  {'title': 'PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed',\n",
       "   'content': 'Citations may include links to full text content from PubMed Central and publisher web sites. PubMed Updates Latest Literature Replaced by PubMed Updates February 28, 2025The Latest Literature section on the PubMed homepage has been removed and replaced with a PubMed Updates section that includes PubMed development updates and other PubMed-related highlights. October 1, 2024The filters interface on the search results page was updated based on user feedback to provide a more intuitive, user-friendly experience. Related Citation Links in Search Results June 13, 2024The four PubMed comment correction types labeled in search results now also include a link to the related citation in the search results summary format display. June 3, 2024PubMed search syntax now supports expanded use of the asterisk (*) wildcard character.',\n",
       "   'score': 0.19933952,\n",
       "   'raw_content': 'PubMed\\n===============                                   \\n\\nClipboard, Search History, and several other advanced features are temporarily unavailable.\\n\\n[Skip to main page content](https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed#home-page)\\n\\n![Image 1: U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)An official website of the United States government\\n\\nHere\\'s how you know\\n\\n![Image 2: Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**  \\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\\n\\n![Image 3: Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**  \\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\n[![Image 4: NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\\n\\n[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F%3FDb%3Dpubmed) Show account info\\n\\nClose\\n\\n#### Account\\n\\nLogged in as:  \\n**username**\\n\\n*   [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)\\n*   [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\\n*   [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)\\n*   [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/%3FDb%3Dpubmed)\\n\\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov/) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed#)\\n\\nHome Page\\n=========\\n\\n[![Image 5: pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/0229fd7c-1ee0-4f97-b054-c03da56bfd78/core/images/pubmed-logo-white.svg)](https://pubmed.ncbi.nlm.nih.gov/)[](https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed# \"Show search bar\")\\n\\nSearch: \\n\\n[](https://pubmed.ncbi.nlm.nih.gov/?Db=pubmed# \"Clear search input\")Search\\n\\n[Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [Clipboard](https://pubmed.ncbi.nlm.nih.gov/clipboard/)\\n\\nPubMed® comprises more than 38 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.\\n\\nLearn\\n-----\\n\\n[About PubMed](https://pubmed.ncbi.nlm.nih.gov/about/)\\n\\n[FAQs & User Guide](https://pubmed.ncbi.nlm.nih.gov/help/)\\n\\n[Finding Full Text](https://support.nlm.nih.gov/knowledgebase/article/KA-03304/en-us/)\\n\\nFind\\n----\\n\\n[Advanced Search](https://pubmed.ncbi.nlm.nih.gov/advanced/)\\n\\n[Clinical Queries](https://pubmed.ncbi.nlm.nih.gov/clinical/)\\n\\n[Single Citation Matcher](https://pubmed.ncbi.nlm.nih.gov/citmatch/)\\n\\nDownload\\n--------\\n\\n[E-utilities API](https://www.ncbi.nlm.nih.gov/books/NBK25497/)\\n\\n[FTP](https://pubmed.ncbi.nlm.nih.gov/download/)\\n\\n[Batch Citation Matcher](https://pubmed.ncbi.nlm.nih.gov/batchcitmatch/)\\n\\nExplore\\n-------\\n\\n[MeSH Database](https://www.ncbi.nlm.nih.gov/mesh/)\\n\\n[Journals](https://www.ncbi.nlm.nih.gov/nlmcatalog/journals/)\\n\\nTrending Articles\\n-----------------\\n\\nPubMed records with recent increases in activity\\n\\n*   [Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.](https://pubmed.ncbi.nlm.nih.gov/12626527/)\\n    \\n    Mahanty S, et al. J Immunol. 2003. PMID: 12626527\\n    \\n*   [Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli.](https://pubmed.ncbi.nlm.nih.gov/16731801/)\\n    \\n    Flück M. J Exp Biol. 2006. PMID: 16731801 Review.\\n    \\n*   [Phosphorylation of auxin signaling repressor IAA8 by heat-responsive MPKs causes defective flower development.](https://pubmed.ncbi.nlm.nih.gov/39240752/)\\n    \\n    Kim SH, et al. Plant Physiol. 2024. PMID: 39240752 Free PMC article.\\n    \\n*   [The transcription factor GhMYB4 represses lipid transfer and sucrose transporter genes and inhibits fiber cell elongation in cotton.](https://pubmed.ncbi.nlm.nih.gov/39607732/)\\n    \\n    Duan Y, et al. Plant Physiol. 2024. PMID: 39607732\\n    \\n*   [Loss-of-function of _MEDIATOR 12_ or _13_ subunits causes the swelling of root hairs in response to sucrose and abscisic acid in Arabidopsis.](https://pubmed.ncbi.nlm.nih.gov/36942634/)\\n    \\n    Raya-González J, et al. Plant Signal Behav. 2023. PMID: 36942634 Free PMC article.\\n    \\n\\nSee more trending articles\\n\\nPubMed Updates\\n--------------\\n\\nFeature updates and other PubMed highlights\\n\\n*   ### [Latest Literature Replaced by PubMed Updates](https://www.nlm.nih.gov/pubs/techbull/jf25/jf25_pubmed_news.html)\\n    \\n    February 28, 2025The Latest Literature section on the PubMed homepage has been removed and replaced with a PubMed Updates section that includes PubMed development updates and other PubMed-related highlights.\\n    \\n*   ### [Filters Interface Improvements](https://www.nlm.nih.gov/pubs/techbull/so24/so24_pubmed_filters_improvements.html)\\n    \\n    October 1, 2024The filters interface on the search results page was updated based on user feedback to provide a more intuitive, user-friendly experience.\\n    \\n*   ### [Related Citation Links in Search Results](https://www.nlm.nih.gov/pubs/techbull/mj24/mj24_pubmed_related_citations.html)\\n    \\n    June 13, 2024The four PubMed comment correction types labeled in search results now also include a link to the related citation in the search results summary format display.\\n    \\n*   ### [Wildcard Search Improvements](https://www.nlm.nih.gov/pubs/techbull/mj24/mj24_pubmed_wildcard.html)\\n    \\n    June 3, 2024PubMed search syntax now supports expanded use of the asterisk (\\\\*) wildcard character.\\n    \\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\nFollow NCBI\\n\\n[](https://twitter.com/ncbi) [](https://www.facebook.com/ncbi.nlm) [](https://www.linkedin.com/company/ncbinlm) [](https://github.com/ncbi) [](https://ncbiinsights.ncbi.nlm.nih.gov/)\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\n*   [](https://twitter.com/NLM_NIH)\\n*   [](https://www.facebook.com/nationallibraryofmedicine)\\n*   [](https://www.youtube.com/user/NLMNIH)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\\n\\n*   [NLM](https://www.nlm.nih.gov/)\\n*   [NIH](https://www.nih.gov/)\\n*   [HHS](https://www.hhs.gov/)\\n*   [USA.gov](https://www.usa.gov/)\\n'},\n",
       "  {'title': 'PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y',\n",
       "   'content': 'Citations may include links to full text content from PubMed Central and publisher web sites. PMID: 40346671 Free PMC article. PubMed Updates Latest Literature Replaced by PubMed Updates February 28, 2025The Latest Literature section on the PubMed homepage has been removed and replaced with a PubMed Updates section that includes PubMed development updates and other PubMed-related highlights. October 1, 2024The filters interface on the search results page was updated based on user feedback to provide a more intuitive, user-friendly experience. Related Citation Links in Search Results June 13, 2024The four PubMed comment correction types labeled in search results now also include a link to the related citation in the search results summary format display.',\n",
       "   'score': 0.17758287,\n",
       "   'raw_content': 'PubMed\\n===============                                   \\n\\nClipboard, Search History, and several other advanced features are temporarily unavailable.\\n\\n[Skip to main page content](https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y#home-page)\\n\\n![Image 1: U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)An official website of the United States government\\n\\nHere\\'s how you know\\n\\n![Image 2: Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**  \\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\\n\\n![Image 3: Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**  \\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\n[![Image 4: NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\\n\\n[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F%3FSUBMIT%3Dy) Show account info\\n\\nClose\\n\\n#### Account\\n\\nLogged in as:  \\n**username**\\n\\n*   [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)\\n*   [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\\n*   [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)\\n*   [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/%3FSUBMIT%3Dy)\\n\\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov/) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y#)\\n\\nHome Page\\n=========\\n\\n[![Image 5: pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/0229fd7c-1ee0-4f97-b054-c03da56bfd78/core/images/pubmed-logo-white.svg)](https://pubmed.ncbi.nlm.nih.gov/)[](https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y# \"Show search bar\")\\n\\nSearch: \\n\\n[](https://pubmed.ncbi.nlm.nih.gov/?SUBMIT=y# \"Clear search input\")Search\\n\\n[Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [Clipboard](https://pubmed.ncbi.nlm.nih.gov/clipboard/)\\n\\nPubMed® comprises more than 38 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.\\n\\nLearn\\n-----\\n\\n[About PubMed](https://pubmed.ncbi.nlm.nih.gov/about/)\\n\\n[FAQs & User Guide](https://pubmed.ncbi.nlm.nih.gov/help/)\\n\\n[Finding Full Text](https://support.nlm.nih.gov/knowledgebase/article/KA-03304/en-us/)\\n\\nFind\\n----\\n\\n[Advanced Search](https://pubmed.ncbi.nlm.nih.gov/advanced/)\\n\\n[Clinical Queries](https://pubmed.ncbi.nlm.nih.gov/clinical/)\\n\\n[Single Citation Matcher](https://pubmed.ncbi.nlm.nih.gov/citmatch/)\\n\\nDownload\\n--------\\n\\n[E-utilities API](https://www.ncbi.nlm.nih.gov/books/NBK25497/)\\n\\n[FTP](https://pubmed.ncbi.nlm.nih.gov/download/)\\n\\n[Batch Citation Matcher](https://pubmed.ncbi.nlm.nih.gov/batchcitmatch/)\\n\\nExplore\\n-------\\n\\n[MeSH Database](https://www.ncbi.nlm.nih.gov/mesh/)\\n\\n[Journals](https://www.ncbi.nlm.nih.gov/nlmcatalog/journals/)\\n\\nTrending Articles\\n-----------------\\n\\nPubMed records with recent increases in activity\\n\\n*   [The foam cell-derived exosomes exacerbate ischemic white matter injury via transmitting metabolic defects to microglia.](https://pubmed.ncbi.nlm.nih.gov/40345179/)\\n    \\n    Zhang H, et al. Cell Metab. 2025. PMID: 40345179\\n    \\n*   [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.](https://pubmed.ncbi.nlm.nih.gov/40353578/)\\n    \\n    Aronne LJ, et al. N Engl J Med. 2025. PMID: 40353578\\n    \\n*   [The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease.](https://pubmed.ncbi.nlm.nih.gov/40346671/)\\n    \\n    Gao X, et al. Cardiovasc Diabetol. 2025. PMID: 40346671 Free PMC article.\\n    \\n*   [Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.](https://pubmed.ncbi.nlm.nih.gov/40345189/)\\n    \\n    Zhu B, et al. Cancer Cell. 2025. PMID: 40345189\\n    \\n*   [Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.](https://pubmed.ncbi.nlm.nih.gov/40339010/)\\n    \\n    Ely ZA, et al. Science. 2025. PMID: 40339010\\n    \\n\\nSee more trending articles\\n\\nPubMed Updates\\n--------------\\n\\nFeature updates and other PubMed highlights\\n\\n*   ### [Latest Literature Replaced by PubMed Updates](https://www.nlm.nih.gov/pubs/techbull/jf25/jf25_pubmed_news.html)\\n    \\n    February 28, 2025The Latest Literature section on the PubMed homepage has been removed and replaced with a PubMed Updates section that includes PubMed development updates and other PubMed-related highlights.\\n    \\n*   ### [Filters Interface Improvements](https://www.nlm.nih.gov/pubs/techbull/so24/so24_pubmed_filters_improvements.html)\\n    \\n    October 1, 2024The filters interface on the search results page was updated based on user feedback to provide a more intuitive, user-friendly experience.\\n    \\n*   ### [Related Citation Links in Search Results](https://www.nlm.nih.gov/pubs/techbull/mj24/mj24_pubmed_related_citations.html)\\n    \\n    June 13, 2024The four PubMed comment correction types labeled in search results now also include a link to the related citation in the search results summary format display.\\n    \\n*   ### [Wildcard Search Improvements](https://www.nlm.nih.gov/pubs/techbull/mj24/mj24_pubmed_wildcard.html)\\n    \\n    June 3, 2024PubMed search syntax now supports expanded use of the asterisk (\\\\*) wildcard character.\\n    \\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\nFollow NCBI\\n\\n[](https://twitter.com/ncbi) [](https://www.facebook.com/ncbi.nlm) [](https://www.linkedin.com/company/ncbinlm) [](https://github.com/ncbi) [](https://ncbiinsights.ncbi.nlm.nih.gov/)\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\n*   [](https://twitter.com/NLM_NIH)\\n*   [](https://www.facebook.com/nationallibraryofmedicine)\\n*   [](https://www.youtube.com/user/NLMNIH)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\\n\\n*   [NLM](https://www.nlm.nih.gov/)\\n*   [NIH](https://www.nih.gov/)\\n*   [HHS](https://www.hhs.gov/)\\n*   [USA.gov](https://www.usa.gov/)\\n'},\n",
       "  {'title': 'Scientific Reports - Nature',\n",
       "   'url': 'https://www.nature.com/srep/',\n",
       "   'content': 'Image 2: Scientific Reports 1.   nature An open access Nature Portfolio journal publishing research from the natural sciences, psychology, medicine, and engineering. ### Physical sciences Image 10  Image 11  Image 12  Image 13  Image 14  #### Subjects within Physical sciences Image 15  Image 16  Image 17  Image 18  Image 19  #### Subjects within Earth and environmental sciences *   Environmental sciences ### Biological sciences Image 20  Image 21  Image 22  Image 23  Image 24  #### Subjects within Biological sciences ### Health sciences Image 25  Image 26  Image 27  Image 28  Image 29  #### Subjects within Health sciences Image 37: Nature Careers ### Science jobs European Molecular Biology Laboratory (EMBL)  Image 40  Top headline image: Springer Nature Image 46: Springer Nature',\n",
       "   'score': 0.17397511,\n",
       "   'raw_content': \"Scientific Reports\\n\\n===============\\n\\n[Skip to main content](https://www.nature.com/srep/#content)\\n\\nThank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.\\n\\nAdvertisement\\n\\n[![Image 2: Scientific Reports](https://media.springernature.com/full/nature-cms/uploads/product/srep/header-d3c533c187c710c1bedbd8e293815d5f.svg)](https://www.nature.com/srep)\\n================================================================================================================================================================================\\n\\n*   [View all journals](https://www.nature.com/siteindex)\\n*   [Search](https://www.nature.com/srep/#search-menu)\\n*   [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/srep/)\\n\\n*   [Explore content](https://www.nature.com/srep/#explore)\\n*   [About the journal](https://www.nature.com/srep/#about-the-journal)\\n*   [Publish with us](https://www.nature.com/srep/#publish-with-us)\\n\\n*   [Sign up for alerts](https://journal-alerts.springernature.com/subscribe?journal_id=41598)\\n*   [RSS feed](https://www.nature.com/srep.rss)\\n\\n1.   [nature](https://www.nature.com/)\\n2.   scientific reports\\n\\n![Image 3: Aerial view of ocean water that blends out into wavy lines of digital art mimicking water](https://media.springernature.com/w735h400/nature-cms/uploads/cms/pages/2103/top_item_image/SciRep_Brand-Campaign_Homepage_Hero-Image_735x400-6f0ee5ab5ac3df1013bed419f185edf8.jpg)\\n\\n[Your hub for global discovery](https://www.nature.com/srep/about)\\n------------------------------------------------------------------\\n\\nAn open access Nature Portfolio journal publishing research from the natural sciences, psychology, medicine, and engineering. We offer authors a trustworthy, highly respected home for their research.\\n\\nAnnouncements\\n-------------\\n\\n*   \\n![Image 4: Icon of metrics.](https://media.springernature.com/w290h158/nature-cms/uploads/mosaic_featured_form_item/2103/announcement-image-f930b32607e002563297d1096468b85d.png) \\n\\n### [Journal Metrics](https://www.nature.com/srep/about)\\n\\n_Scientific Reports_ has a 2-year impact factor of 3.8 (2023), and is the 5th most-cited journal in the world, with more than 734,000 citations in 2023*.     *    *2023 Journal Citation Reports® Science Edition (Clarivate Analytics, 2024).\\n\\n*   \\n![Image 5: Icon of a megaphone, indicating the Call for Papers page.](https://media.springernature.com/w290h158/nature-cms/uploads/mosaic_featured_form_item/2103/announcement-image-8adf30b7b51e7a54cef57827be3ec4c8.png) \\n\\n### [Calls for Papers](https://www.nature.com/srep/guestedited)\\n\\nHighlight your research and enhance its visibility to your field by submitting to one of our Guest Edited Collections, led by our expert Editorial Board Members.    *    The median time from submission to acceptance for papers submitted to our Guest Edited Collections is 102 days.\\n\\n*   \\n![Image 6: Icon of an article with a star icon](https://media.springernature.com/w290h158/nature-cms/uploads/mosaic_featured_form_item/2103/announcement-image-eef57a7124c55018aa51b9576838ebdc.jpg) \\n\\n### [Top 100 Collections](https://www.nature.com/srep/highlights/top-articles)\\n\\nExplore subject area specific Collections of the most downloaded* papers from _Scientific Reports_ in 2024.     *    *Data obtained from SN Insights which is based on Digital Science's Dimensions.\\n\\n*   ![Image 7: Icon of cogs, indicating the Engineering scope expansion announcement.](https://media.springernature.com/w290h158/nature-cms/uploads/mosaic_featured_form_item/2103/announcement-image-b5a3145cbab915b871a9fc1d8bbf21ce.png) ### [Engineering](https://www.nature.com/srep/announcements/engineering)\\n\\nWe are delighted to welcome submissions from all engineering disciplines.   \\n\\nSearch Scientific Reports \\n\\nSubject \\n\\nSearch\\n\\nAdvertisement\\n-------------\\n\\nBrowse articles\\n---------------\\n\\n### [Physical sciences](https://www.nature.com/subjects/physical-sciences/srep)\\n\\n*   \\n![Image 10](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04830-7/MediaObjects/41598_2025_4830_Fig1_HTML.png) \\n\\n### [Inconsistency of AI in intracranial aneurysm detection with varying dose and image reconstruction](https://www.nature.com/articles/s41598-025-04830-7)\\n\\n    *   Leonie Goelz\\n    *   Angelo Laudani\\n    *   Paul Jahnke\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 11](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04637-6/MediaObjects/41598_2025_4637_Fig1_HTML.png) \\n\\n### [Computational insights into wide bandgap lead free perovskite solar cells for silicon based tandem configurations](https://www.nature.com/articles/s41598-025-04637-6)\\n\\n    *   Sofia Tahir\\n    *   Shammas Mushtaq\\n    *   Arslan Ashfaq\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 12](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-03746-6/MediaObjects/41598_2025_3746_Fig1_HTML.png) \\n\\n### [Simultaneous influence of nanoPSS and photonic crystal on light extraction in AlGaN 304nm UVB LEDs](https://www.nature.com/articles/s41598-025-03746-6)\\n\\n    *   M. Ajmal Khan\\n    *   Eriko Matsuura\\n    *   Hideki Hirayama\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 13](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04966-6/MediaObjects/41598_2025_4966_Fig1_HTML.png) \\n\\n### [Fabrication of industrial grade F/g-C 3 N 4 reinforced banana natural Fiber sustainable PCB substrates](https://www.nature.com/articles/s41598-025-04966-6)\\n\\n    *   Dola Sundeep\\n    *   Eswaramoorthy K Varadharaj\\n    *   C. Chandrasekhara Sastry\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 14](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-95080-0/MediaObjects/41598_2025_95080_Fig1_HTML.png) \\n\\n### [Impact of addition of polyvinyl chloride on the properties of clayey soil using experimental approach and optimization for geotechnical engineering applications](https://www.nature.com/articles/s41598-025-95080-0)\\n\\n    *   Ghania Boukhatem\\n    *   Said Berdoudi\\n    *   Krishnaraj Ramaswamy\\n\\nArticle Open Access 06 Jun 2025\\n\\n#### Subjects within Physical sciences\\n\\n*   [Astronomy and planetary science](https://www.nature.com/subjects/astronomy-and-planetary-science/srep)\\n*   [Chemistry](https://www.nature.com/subjects/chemistry/srep)\\n*   [Energy science and technology](https://www.nature.com/subjects/energy-science-and-technology/srep)\\n*   [Engineering](https://www.nature.com/subjects/engineering/srep)\\n*   [Materials science](https://www.nature.com/subjects/materials-science/srep)\\n*   [Mathematics and computing](https://www.nature.com/subjects/mathematics-and-computing/srep)\\n*   [Nanoscience and technology](https://www.nature.com/subjects/nanoscience-and-technology/srep)\\n*   [Optics and photonics](https://www.nature.com/subjects/optics-and-photonics/srep)\\n*   [Physics](https://www.nature.com/subjects/physics/srep)\\n\\n### [Earth and environmental sciences](https://www.nature.com/subjects/earth-and-environmental-sciences/srep)\\n\\n*   \\n![Image 15](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04395-5/MediaObjects/41598_2025_4395_Fig1_HTML.png) \\n\\n### [Calibration-free picosecond LIPS for quantifying heavy metals in soils near Egyptian industrial sites](https://www.nature.com/articles/s41598-025-04395-5)\\n\\n    *   Mohamed El-Saeed\\n    *   Walid Tawfik\\n    *   Mohamed Fikry\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 16](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-03780-4/MediaObjects/41598_2025_3780_Fig1_HTML.png) \\n\\n### [Air quality prediction based on factor analysis combined with Transformer and CNN-BILSTM-ATTENTION models](https://www.nature.com/articles/s41598-025-03780-4)\\n\\n    *   Shuyuan Liu\\n    *   Yang Hu\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 17](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-01726-4/MediaObjects/41598_2025_1726_Fig1_HTML.png) \\n\\n### [Nationwide association between ambient ozone and sudden cardiac arrests in South Korea](https://www.nature.com/articles/s41598-025-01726-4)\\n\\n    *   Cinoo Kang\\n    *   Yejin Kim\\n    *   Whanhee Lee\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 18](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04605-0/MediaObjects/41598_2025_4605_Fig1_HTML.png) \\n\\n### [Investigating the impact of meteorological parameters on daily soil temperature changes using machine learning models](https://www.nature.com/articles/s41598-025-04605-0)\\n\\n    *   Farrokh Asadzadeh\\n    *   Somayeh Emami\\n    *   Ali Salem\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 19](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04895-4/MediaObjects/41598_2025_4895_Fig1_HTML.png) \\n\\n### [Spatiotemporal variations of precipitation and driving forces during wheat maturation season in Henan Province](https://www.nature.com/articles/s41598-025-04895-4)\\n\\n    *   Zezhong Zhang\\n    *   Hengzhi Guo\\n    *   Jian Liu\\n\\nArticle Open Access 06 Jun 2025\\n\\n#### Subjects within Earth and environmental sciences\\n\\n*   [Biogeochemistry](https://www.nature.com/subjects/biogeochemistry/srep)\\n*   [Climate sciences](https://www.nature.com/subjects/climate-sciences/srep)\\n*   [Ecology](https://www.nature.com/subjects/ecology/srep)\\n*   [Environmental sciences](https://www.nature.com/subjects/environmental-sciences/srep)\\n*   [Environmental social sciences](https://www.nature.com/subjects/environmental-social-sciences/srep)\\n*   [Hydrology](https://www.nature.com/subjects/hydrology/srep)\\n*   [Limnology](https://www.nature.com/subjects/limnology/srep)\\n*   [Natural hazards](https://www.nature.com/subjects/natural-hazards/srep)\\n*   [Ocean sciences](https://www.nature.com/subjects/ocean-sciences/srep)\\n*   [Planetary science](https://www.nature.com/subjects/planetary-science/srep)\\n*   [Solid Earth sciences](https://www.nature.com/subjects/solid-earth-sciences/srep)\\n*   [Space physics](https://www.nature.com/subjects/space-physics/srep)\\n\\n### [Biological sciences](https://www.nature.com/subjects/biological-sciences/srep)\\n\\n*   \\n![Image 20](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04408-3/MediaObjects/41598_2025_4408_Fig1_HTML.png) \\n\\n### [Therapeutic efficacy of BSA formulated hydrogels in corneal wound healing and epithelial cell regeneration: an ex vivo study](https://www.nature.com/articles/s41598-025-04408-3)\\n\\n    *   Ramachandran Samivel\\n    *   Mana A. Alanazi\\n    *   Saeed Akhtar\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 21](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-03562-y/MediaObjects/41598_2025_3562_Fig1_HTML.png) \\n\\n### [Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control](https://www.nature.com/articles/s41598-025-03562-y)\\n\\n    *   Panagiotis Sakellariou\\n    *   Katja Walpurgis\\n    *   Mario Thevis\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 22](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04996-0/MediaObjects/41598_2025_4996_Fig1_HTML.png) \\n\\n### [Deferential nephrotoxicity effect of lanthanum oxide nanoparticle responses to concentration and time in _vivo_](https://www.nature.com/articles/s41598-025-04996-0)\\n\\n    *   Nouf M. Alyami\\n    *   Ghufran A. Almuhaini\\n    *   Saud Alarifi\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 23](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-03626-z/MediaObjects/41598_2025_3626_Fig1_HTML.png) \\n\\n### [Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy](https://www.nature.com/articles/s41598-025-03626-z)\\n\\n    *   Gianluca Santini\\n    *   Laura Bonati\\n    *   Stefano Motta\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 24](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-05172-0/MediaObjects/41598_2025_5172_Fig1_HTML.png) \\n\\n### [Dysregulation of the low-level replication stress response in transformed cell lines](https://www.nature.com/articles/s41598-025-05172-0)\\n\\n    *   Sandrine Ragu\\n    *   Elodie Dardillac\\n    *   Bernard S. Lopez\\n\\nArticle Open Access 06 Jun 2025\\n\\n#### Subjects within Biological sciences\\n\\n*   [Biochemistry](https://www.nature.com/subjects/biochemistry/srep)\\n*   [Biological techniques](https://www.nature.com/subjects/biological-techniques/srep)\\n*   [Biophysics](https://www.nature.com/subjects/biophysics/srep)\\n*   [Biotechnology](https://www.nature.com/subjects/biotechnology/srep)\\n*   [Cancer](https://www.nature.com/subjects/cancer/srep)\\n*   [Cell biology](https://www.nature.com/subjects/cell-biology/srep)\\n*   [Chemical biology](https://www.nature.com/subjects/chemical-biology/srep)\\n*   [Computational biology and bioinformatics](https://www.nature.com/subjects/computational-biology-and-bioinformatics/srep)\\n*   [Developmental biology](https://www.nature.com/subjects/developmental-biology/srep)\\n*   [Drug discovery](https://www.nature.com/subjects/drug-discovery/srep)\\n*   [Ecology](https://www.nature.com/subjects/ecology/srep)\\n*   [Evolution](https://www.nature.com/subjects/evolution/srep)\\n*   [Genetics](https://www.nature.com/subjects/genetics/srep)\\n*   [Immunology](https://www.nature.com/subjects/immunology/srep)\\n*   [Microbiology](https://www.nature.com/subjects/microbiology/srep)\\n*   [Molecular biology](https://www.nature.com/subjects/molecular-biology/srep)\\n*   [Neuroscience](https://www.nature.com/subjects/neuroscience/srep)\\n*   [Physiology](https://www.nature.com/subjects/physiology/srep)\\n*   [Plant sciences](https://www.nature.com/subjects/plant-sciences/srep)\\n*   [Psychology](https://www.nature.com/subjects/psychology/srep)\\n*   [Stem cells](https://www.nature.com/subjects/stem-cells/srep)\\n*   [Structural biology](https://www.nature.com/subjects/structural-biology/srep)\\n*   [Systems biology](https://www.nature.com/subjects/systems-biology/srep)\\n*   [Zoology](https://www.nature.com/subjects/zoology/srep)\\n\\n### [Health sciences](https://www.nature.com/subjects/health-sciences/srep)\\n\\n*   \\n![Image 25](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04340-6/MediaObjects/41598_2025_4340_Fig1_HTML.png) \\n\\n### [An explorative study on movement detection using wearable sensors in acute care hospital patients](https://www.nature.com/articles/s41598-025-04340-6)\\n\\n    *   Joris Kirchberger\\n    *   Dominik Kunz\\n    *   Jens Eckstein\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 26](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-96097-1/MediaObjects/41598_2025_96097_Fig1_HTML.png) \\n\\n### [Time to achieve optimal glycemic control and its determinants among diabetes mellitus patients receiving treatment: a retrospective study](https://www.nature.com/articles/s41598-025-96097-1)\\n\\n    *   Maru Zewdu Kassie\\n    *   Chekol Alemu\\n    *   Asaye Alamneh Gebeyehu\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 27](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-05082-1/MediaObjects/41598_2025_5082_Fig1_HTML.png) \\n\\n### [Fluorescence-guided ureteral identification in robotic surgery for advanced endometriosis: a comparison of junior versus senior surgeons](https://www.nature.com/articles/s41598-025-05082-1)\\n\\n    *   Linda A. Alpuing Radilla\\n    *   Qiannan Yang\\n    *   Xiaoming Guan\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 28](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04988-0/MediaObjects/41598_2025_4988_Fig1_HTML.png) \\n\\n### [Analysis of vascular aging phenotypes in a high cardiovascular risk population](https://www.nature.com/articles/s41598-025-04988-0)\\n\\n    *   Dmitrii Usoltsev\\n    *   Ekaterina Moguchaya\\n    *   Mykyta Artomov\\n\\nArticle Open Access 06 Jun 2025\\n\\n*   \\n![Image 29](https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038%2Fs41598-025-04672-3/MediaObjects/41598_2025_4672_Fig1_HTML.png) \\n\\n### [Association between timing of surgery and refracture after initial osteoporotic fractures](https://www.nature.com/articles/s41598-025-04672-3)\\n\\n    *   Zhujie Xu\\n    *   Peng Wang\\n    *   Yi Liu\\n\\nArticle Open Access 06 Jun 2025\\n\\n#### Subjects within Health sciences\\n\\n*   [Anatomy](https://www.nature.com/subjects/anatomy/srep)\\n*   [Biomarkers](https://www.nature.com/subjects/biomarkers/srep)\\n*   [Cardiology](https://www.nature.com/subjects/cardiology/srep)\\n*   [Diseases](https://www.nature.com/subjects/diseases/srep)\\n*   [Endocrinology](https://www.nature.com/subjects/endocrinology/srep)\\n*   [Gastroenterology](https://www.nature.com/subjects/gastroenterology/srep)\\n*   [Health care](https://www.nature.com/subjects/health-care/srep)\\n*   [Health occupations](https://www.nature.com/subjects/health-occupations/srep)\\n*   [Medical research](https://www.nature.com/subjects/medical-research/srep)\\n*   [Molecular medicine](https://www.nature.com/subjects/molecular-medicine/srep)\\n*   [Nephrology](https://www.nature.com/subjects/nephrology/srep)\\n*   [Neurology](https://www.nature.com/subjects/neurology/srep)\\n*   [Oncology](https://www.nature.com/subjects/oncology/srep)\\n*   [Pathogenesis](https://www.nature.com/subjects/pathogenesis/srep)\\n*   [Rheumatology](https://www.nature.com/subjects/rheumatology/srep)\\n*   [Risk factors](https://www.nature.com/subjects/risk-factors/srep)\\n*   [Signs and symptoms](https://www.nature.com/subjects/signs-and-symptoms/srep)\\n*   [Urology](https://www.nature.com/subjects/urology/srep)\\n\\nTrending - Altmetric\\n--------------------\\n\\n*   [![Image 33: Score 660](https://badges.altmetric.com/?size=64&score=660&types=mbtttttf) ### Wolves lead and dogs follow, but they both cooperate with humans](http://dx.doi.org/10.1038/s41598-019-40468-y)\\n*   [![Image 34: Score 590](https://badges.altmetric.com/?size=64&score=590&types=mmmmmbtu) ### Chimpanzees yawn when observing an android yawn](http://dx.doi.org/10.1038/s41598-025-98639-z)\\n*   [![Image 35: Score 390](https://badges.altmetric.com/?size=64&score=390&types=mmvttttf) ### Daily activity in minimal footwear increases foot strength](http://dx.doi.org/10.1038/s41598-021-98070-0)\\n*   [![Image 36: Score 230](https://badges.altmetric.com/?size=64&score=230&types=mmmmmbtu) ### Polarity-tunable dye-sensitized optoelectronic artificial synapses for physical reservoir computing-based machine vision](http://dx.doi.org/10.1038/s41598-025-00693-0)\\n\\n![Image 37: Nature Careers](https://www.nature.com/static/images/logos/nature-careers-logo-f6ff1c1c64.svg)\\n----------------------------------------------------------------------------------------------------------\\n\\n### [Science jobs](https://www.nature.com/naturecareers/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\n*   #### [Gathering the Talents and Writing Our Glorious Chapter](https://www.nature.com/naturecareers/job/12821263/gathering-the-talents-and-writing-our-glorious-chapter/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\nWuxi Medical College of Jiangnan University (Affiliated Hospital) invites you to join us!\\n\\nWuxi, Jiangsu (CN)\\n\\nWuxi Medical College of Jiangnan University (Affiliated Hospital)  ![Image 38](https://www.nature.com/naturecareers/getasset/d88bf191-d3be-4183-8787-a7f28aee11f8/) \\n*   #### [Professorship for Trauma, Hand and Reconstructive Surgery (W3)](https://www.nature.com/naturecareers/job/12840169/professorship-for-trauma-hand-and-reconstructive-surgery-w3-/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\nThe Jena University Hospital (JUH) invites applications for a  Professorship for Trauma, Hand and Reconstructive Surgery (W3)  to be filled at th...\\n\\nJena, Thüringen (DE)\\n\\nFriedrich-Schiller-Universität Jena  ![Image 39](https://www.nature.com/naturecareers/getasset/3a4dd6da-1887-4862-90a1-c2e76794f22e/) \\n*   #### [Group Leader - Molecular Mechanisms of Environmental Adaptation](https://www.nature.com/naturecareers/job/12840224/group-leader-molecular-mechanisms-of-environmental-adaptation/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\nEMBL is seeking a Group Leader to develop an independent research program on molecular mechanisms driving phenotype and environmental response.\\n\\nRome (IT)\\n\\nEuropean Molecular Biology Laboratory (EMBL)  ![Image 40](https://www.nature.com/naturecareers/getasset/252d507f-a235-4695-9e1d-a78cf7bf817d/) \\n*   #### [Faculty and Research Positions, Postdoctoral Recruitment](https://www.nature.com/naturecareers/job/12840215/faculty-and-research-positions-postdoctoral-recruitment/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\nJointly sponsored by the Hangzhou Municipal People's Government and the University of Chinese Academy of Sciences.\\n\\nHangzhou, Zhejiang, China\\n\\nHangzhou Institute of Advanced Study, UCAS  ![Image 41](https://www.nature.com/naturecareers/getasset/655aed52-f292-4bef-ac4f-2f6cd16afe65/) \\n*   #### [Tenure-Track Assistant Professor at the Graduate School of Pharmaceutical Studies, Tohoku University](https://www.nature.com/naturecareers/job/12840113/tenure-track-assistant-professor-at-the-graduate-school-of-pharmaceutical-studies-tohoku-university/?TrackID=62&utm_source=widget&utm_medium=referral&utm_campaign=62)\\n\\nThe Graduate School of Pharmaceutical Studies at Tohoku Universities invites applications for one open tenure-track assistant professor position.\\n\\nJapan (JP)\\n\\nTohoku University  ![Image 42](https://www.nature.com/naturecareers/getasset/2ddfb877-ee6c-4003-9fd0-3f78d5518af1/) \\n\\nAdvertisement\\n\\n*   [![Image 44: Committee on Publication Ethics](https://www.nature.com/static/images/logos/cope-8d92c4b829.png)](http://publicationethics.org/)\\nThis journal is a member of and subscribes to the principles of the Committee on Publication Ethics.\\n\\n*   [![Image 45: Ithenticate Plagiarism Detection](https://www.nature.com/static/images/logos/ithenticate-eabe2377a3.png)](http://www.ithenticate.com/)\\n\\nExplore content\\n---------------\\n\\n*   [Research articles](https://www.nature.com/srep/research-articles)\\n*   [News & Comment](https://www.nature.com/srep/news-and-comment)\\n*   [Collections](https://www.nature.com/srep/collections)\\n*   [Subjects](https://www.nature.com/srep/browse-subjects)\\n\\n*   [Follow us on Facebook](https://www.facebook.com/scientificreports)\\n*   [Follow us on Twitter](https://twitter.com/SciReports)\\n*   [Sign up for alerts](https://www.nature.com/my-account/alerts/subscribe-journal?list-id=288)\\n*   [RSS feed](https://www.nature.com/srep.rss)\\n\\nAbout the journal\\n-----------------\\n\\n*   [About Scientific Reports](https://www.nature.com/srep/about)\\n*   [Contact](https://www.nature.com/srep/contact)\\n*   [Journal policies](https://www.nature.com/srep/journal-policies)\\n*   [Guide to referees](https://www.nature.com/srep/guide-to-referees)\\n*   [Calls for Papers](https://www.nature.com/srep/calls-for-papers)\\n*   [Editor's Choice](https://www.nature.com/srep/editorschoice)\\n*   [Journal highlights](https://www.nature.com/srep/highlights)\\n*   [Open Access Fees and Funding](https://www.nature.com/srep/open-access)\\n\\nPublish with us\\n---------------\\n\\n*   [For authors](https://www.nature.com/srep/author-instructions)\\n*   [Language editing services](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022)\\n*   [Open access funding](https://www.nature.com/srep/open-access-funding)\\n*   [Submit manuscript](https://author-welcome.nature.com/41598)\\n\\nSearch\\n------\\n\\nSearch articles by subject, keyword or author \\n\\nShow results from \\n\\nSearch\\n\\n[Advanced search](https://www.nature.com/search/advanced)\\n\\n### Quick links\\n\\n*   [Explore articles by subject](https://www.nature.com/subjects)\\n*   [Find a job](https://www.nature.com/naturecareers)\\n*   [Guide to authors](https://www.nature.com/authors/index.html)\\n*   [Editorial policies](https://www.nature.com/authors/editorial_policies/)\\n\\nTop headline image: Springer Nature\\n\\nScientific Reports  (_Sci Rep_)\\n\\nISSN 2045-2322 (online)\\n\\nnature.com sitemap\\n------------------\\n\\n### About Nature Portfolio\\n\\n*   [About us](https://www.nature.com/npg_/company_info/index.html)\\n*   [Press releases](https://www.nature.com/npg_/press_room/press_releases.html)\\n*   [Press office](https://press.nature.com/)\\n*   [Contact us](https://support.nature.com/support/home)\\n\\n### Discover content\\n\\n*   [Journals A-Z](https://www.nature.com/siteindex)\\n*   [Articles by subject](https://www.nature.com/subjects)\\n*   [protocols.io](https://www.protocols.io/)\\n*   [Nature Index](https://www.natureindex.com/)\\n\\n### Publishing policies\\n\\n*   [Nature portfolio policies](https://www.nature.com/authors/editorial_policies)\\n*   [Open access](https://www.nature.com/nature-research/open-access)\\n\\n### Author & Researcher services\\n\\n*   [Reprints & permissions](https://www.nature.com/reprints)\\n*   [Research data](https://www.springernature.com/gp/authors/research-data)\\n*   [Language editing](https://authorservices.springernature.com/language-editing/)\\n*   [Scientific editing](https://authorservices.springernature.com/scientific-editing/)\\n*   [Nature Masterclasses](https://masterclasses.nature.com/)\\n*   [Research Solutions](https://solutions.springernature.com/)\\n\\n### Libraries & institutions\\n\\n*   [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services)\\n*   [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal)\\n*   [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions)\\n*   [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library)\\n\\n### Advertising & partnerships\\n\\n*   [Advertising](https://partnerships.nature.com/product/digital-advertising/)\\n*   [Partnerships & Services](https://partnerships.nature.com/)\\n*   [Media kits](https://partnerships.nature.com/media-kits/)\\n*   [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/)\\n\\n### Professional development\\n\\n*   [Nature Careers](https://www.nature.com/naturecareers/)\\n*   [Nature Conferences](https://conferences.nature.com/)\\n\\n### Regional websites\\n\\n*   [Nature Africa](https://www.nature.com/natafrica)\\n*   [Nature China](http://www.naturechina.com/)\\n*   [Nature India](https://www.nature.com/nindia)\\n*   [Nature Italy](https://www.nature.com/natitaly)\\n*   [Nature Japan](https://www.natureasia.com/ja-jp)\\n*   [Nature Middle East](https://www.nature.com/nmiddleeast)\\n\\n*   [Privacy Policy](https://www.nature.com/info/privacy)\\n*   [Use of cookies](https://www.nature.com/info/cookies)\\n*   Your privacy choices/Manage cookies \\n*   [Legal notice](https://www.nature.com/info/legal-notice)\\n*   [Accessibility statement](https://www.nature.com/info/accessibility-statement)\\n*   [Terms & Conditions](https://www.nature.com/info/terms-and-conditions)\\n*   [Your US state privacy rights](https://www.springernature.com/ccpa)\\n\\n[![Image 46: Springer Nature](https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg)](https://www.springernature.com/)\\n© 2025 Springer Nature Limited\\n\"},\n",
       "  {'title': 'Laboratory Search | CDC',\n",
       "   'url': 'https://archive.cdc.gov/www_cdc_gov/clia/LabSearch.html',\n",
       "   'content': 'This page is archived for historical purposes and is no longer being updated.',\n",
       "   'score': 0.1722557,\n",
       "   'raw_content': None},\n",
       "  {'title': '世界卫生组织数据 - datadot',\n",
       "   'url': 'https://data.who.int/zh/',\n",
       "   'content': '世界卫生组织数据 Skip to content 世界卫生组织世衛 数据 世卫组织全球 设置 语言 语言 English العربية 中文 Français Русский Español 指标 关于 Close Menu 全球报告 发布于2024年5月21日 2024年世界卫生统计 查看 下载4.5 Mb 2024\\xa0年世界卫生统计 《世界卫生统计报告》是世界卫生组织（WHO）每年汇编的关于健康和健康相关指标的最新可用数据。 阅读报告（英文） 下载数据（英文） 在线数据应用程序（英文) 三个十亿进展 更健康的人群 全球范围内，预计到2025年，享有更好健康和福祉的额外人数将比2018年增加15亿（12亿–18亿）。 全民健康覆盖 全球范围内，预计到2025年，将有5.85亿（5.261亿–6.395亿）额外人数获得基本服务保障并不遭受经济困难，与2018年相比。 健康紧急情况保护 全球范围内，预计到2025年，将有7.769亿（6.474亿–9.125亿）额外人数受到健康紧急情况的保护，与2018年相比。 第十三个总计划的三个十亿目标为加速实现健康相关的可持续发展目标提供了统一的方法。 了解更多关于三亿计划的信息。 估算值使用90%的不确定性区间（UI）计算，并在平均估算值后用括号表示上下限。 精选指标 五岁以下儿童死亡率（每千名活产儿） 如果遭受特定年份或时期的年龄特定死亡率，指某一特定年份或时期出生的儿童在五岁前死亡的概率。（可持续发展目标3.2.1 访问指标 下载数据 所有指标 世界卫生组织（WHO）地区，每 1000 名活产婴儿的死亡率 设计创新和多样性 通过data.who.int，世界卫生组织继续培育围绕健康数据的社区；促进创意、促进创新，并增强该领域的能力。 data.who.int将为可信赖的健康数据提供多样化且引人入胜的呈现方式；将统计学家和技术负责人与来自世界各地的顶尖数据设计师进行配对。 了解更多信息 世界卫生组织正在data.who.int上建立一个新的健康数据中心。在数据产品和资源迁移期间，您可以在www.who.int/data和全球卫生观察上找到更多信息。 如果您对世界卫生数据中心的工作和data.who.int的发布有更多疑问，请通过whdh@who.int与我们联系。 Datadot 世卫组织网站主页 指标 关于 更多数据 who.int/data 全球卫生估计 健康不平等数据库 COVID-19 数据 了解更多 数据原则 世卫组织数据政策 条款和条件 语言翻译 Datadot 世卫组织网站主页 指标 关于 更多数据 who.int/data 全球卫生估计 健康不平等数据库 COVID-19 数据 了解更多 数据原则 世卫组织数据政策 条款和条件 语言翻译 Privacy legal notice ©2024 WHO',\n",
       "   'score': 0.17079856,\n",
       "   'raw_content': '世界卫生组织数据\\n===============\\n\\n[Skip to content](https://data.who.int/zh/#main)\\n\\n[![Image 1: WHO Logo](https://data.who.int/ResourcePackages/DDIBootstrap5/assets/src/images/icons/navigation/who-logo.svg)](https://data.who.int/)\\n\\n世界卫生组织世衛 数据\\n\\n   \\n\\n*   More from WHO\\n*   [世卫组织全球](https://www.who.int/)\\n\\n*   设置\\n*   语言\\n    *   [语言](https://data.who.int/zh/#void)\\n    *   English\\n    *   العربية\\n    *   中文\\n    *   Français\\n    *   Русский\\n    *   Español\\n\\n*   [指标](https://data.who.int/zh/indicators)\\n*   [关于](https://data.who.int/zh/about)\\n*   Close Menu\\n\\n![Image 2](https://iris.who.int/bitstream/handle/10665/376869/9789240094703-eng.pdf.jpg?sequence=4)\\n\\n**全球报告** 发布于2024年5月21日\\n\\n[2024年世界卫生统计](https://www.who.int/publications/i/item/9789240094703)\\n\\n[查看](https://www.who.int/publications/i/item/9789240094703) [下载4.5 Mb](https://iris.who.int/bitstream/handle/10665/376869/9789240094703-eng.pdf?sequence=1)\\n\\n2024\\xa0年世界卫生统计\\n------------\\n\\n《世界卫生统计报告》是世界卫生组织（WHO）每年汇编的关于健康和健康相关指标的最新可用数据。\\n\\n[阅读报告（英文）](https://www.who.int/publications/i/item/9789240094703)\\n\\n[下载数据（英文）](https://cdn.who.int/media/docs/default-source/gho-documents/world-health-statistic-reports/2024/web_download.xlsx?sfvrsn=4e7bbebd_1)\\n\\n[在线数据应用程序（英文)](https://www.who.int/data/gho/whs-annex/)\\n\\n三个十亿进展\\n------\\n\\n**更健康的人群**\\n\\n![Image 3: HPOP](https://data.who.int/images/librariesprovider22/default-album/hpop.jpg?sfvrsn=97f80407_0)\\n\\n全球范围内，预计到2025年，享有更好健康和福祉的额外人数将比2018年增加15亿（12亿–18亿）。\\n\\n**全民健康覆盖**\\n\\n![Image 4: UHC](https://data.who.int/images/librariesprovider22/default-album/uhc.jpg?sfvrsn=b5907eb2_2)\\n\\n全球范围内，预计到2025年，将有5.85亿（5.261亿–6.395亿）额外人数获得基本服务保障并不遭受经济困难，与2018年相比。\\n\\n**健康紧急情况保护**\\n\\n![Image 5: HEP](https://data.who.int/images/librariesprovider22/default-album/hep.jpg?sfvrsn=1e55a306_2)\\n\\n全球范围内，预计到2025年，将有7.769亿（6.474亿–9.125亿）额外人数受到健康紧急情况的保护，与2018年相比。\\n\\n第十三个总计划的三个十亿目标为加速实现健康相关的可持续发展目标提供了统一的方法。\\n\\n[了解更多关于三亿计划的信息。](https://www.who.int/data/triple-billion-dashboard)\\n\\n* * *\\n\\n估算值使用90%的不确定性区间（UI）计算，并在平均估算值后用括号表示上下限。\\n\\n精选指标\\n----\\n\\n#### 五岁以下儿童死亡率（每千名活产儿）\\n\\n如果遭受特定年份或时期的年龄特定死亡率，指某一特定年份或时期出生的儿童在五岁前死亡的概率。（可持续发展目标3.2.1\\n\\n访问指标\\n\\n[下载数据](https://srhdpeuwpubsa.blob.core.windows.net/whdh/DATADOT/INDICATOR/2322814_ALL_LATEST.csv)\\n\\n[所有指标](https://data.who.int/zh/indicators)\\n\\n![Image 6: under5](https://data.who.int/images/librariesprovider22/default-album/under5.jpg?sfvrsn=71cecbec_2)\\n\\n世界卫生组织（WHO）地区，每 1000 名活产婴儿的死亡率\\n\\n设计创新和多样性\\n--------\\n\\n通过data.who.int，世界卫生组织继续培育围绕健康数据的社区；促进创意、促进创新，并增强该领域的能力。\\n\\ndata.who.int将为可信赖的健康数据提供多样化且引人入胜的呈现方式；将统计学家和技术负责人与来自世界各地的顶尖数据设计师进行配对。\\n\\n[了解更多信息](https://data.who.int/zh/about/datadot/design-innovation-diversity)\\n\\n![Image 7: Poster of Antibiotic Consumption data design sitting on a wooden desk](https://data.who.int/images/librariesprovider22/creators/19e688d/who_datadot_creators_19e688d_a.tmb-549v.jpg?Culture=en&sfvrsn=1f00331d_2)\\n\\n##### 世界卫生组织正在data.who.int上建立一个新的健康数据中心。在数据产品和资源迁移期间，您可以在[www.who.int/data](https://www.who.int/data)和[全球卫生观察](https://www.who.int/data/gho)上找到更多信息。\\n\\n##### 如果您对世界卫生数据中心的工作和data.who.int的发布有更多疑问，请通过[whdh@who.int](mailto:whdh@who.int)与我们联系。\\n\\n        \\n\\n### Datadot\\n\\n*   [世卫组织网站主页](https://data.who.int/zh/redirect-pages/footer/datadot/home)\\n*   [指标](https://data.who.int/zh/redirect-pages/footer/datadot/indicators)\\n*   [关于](https://data.who.int/zh/redirect-pages/footer/datadot/about)\\n\\n### 更多数据\\n\\n*   [who.int/data](https://data.who.int/zh/redirect-pages/footer/more-data/who.int-data)\\n*   [全球卫生估计](https://data.who.int/zh/redirect-pages/footer/more-data/triple-billion-dashboard)\\n*   [健康不平等数据库](https://data.who.int/zh/redirect-pages/footer/more-data/ddi)\\n*   [COVID-19 数据](https://data.who.int/zh/redirect-pages/footer/more-data/covid-19-dashboard)\\n\\n### 了解更多\\n\\n*   [数据原则](https://data.who.int/zh/redirect-pages/footer/learn-more/data-principles)\\n*   [世卫组织数据政策](https://data.who.int/zh/redirect-pages/footer/learn-more/who-data-policy)\\n*   [条款和条件](https://data.who.int/zh/redirect-pages/footer/learn-more/terms-and-conditions)\\n*   [语言翻译](https://data.who.int/zh/redirect-pages/footer/learn-more/language-translations)\\n\\nDatadot\\n\\n*   [世卫组织网站主页](https://data.who.int/zh/redirect-pages/footer/datadot/home)\\n*   [指标](https://data.who.int/zh/redirect-pages/footer/datadot/indicators)\\n*   [关于](https://data.who.int/zh/redirect-pages/footer/datadot/about)\\n\\n更多数据\\n\\n*   [who.int/data](https://data.who.int/zh/redirect-pages/footer/more-data/who.int-data)\\n*   [全球卫生估计](https://data.who.int/zh/redirect-pages/footer/more-data/triple-billion-dashboard)\\n*   [健康不平等数据库](https://data.who.int/zh/redirect-pages/footer/more-data/ddi)\\n*   [COVID-19 数据](https://data.who.int/zh/redirect-pages/footer/more-data/covid-19-dashboard)\\n\\n了解更多\\n\\n*   [数据原则](https://data.who.int/zh/redirect-pages/footer/learn-more/data-principles)\\n*   [世卫组织数据政策](https://data.who.int/zh/redirect-pages/footer/learn-more/who-data-policy)\\n*   [条款和条件](https://data.who.int/zh/redirect-pages/footer/learn-more/terms-and-conditions)\\n*   [语言翻译](https://data.who.int/zh/redirect-pages/footer/learn-more/language-translations)\\n\\n[![Image 8: WHO Logo](https://data.who.int/ResourcePackages/DDIBootstrap5/assets/src/images/icons/navigation/who-logo.svg)](https://data.who.int/)\\n\\n*   [Privacy legal notice](https://data.who.int/)\\n*   ©2024 WHO\\n'},\n",
       "  {'title': 'Standards of Care in Diabetes',\n",
       "   'url': 'https://professional.diabetes.org/standards-of-care',\n",
       "   'content': \"Membership Membership Become a Member Group Membership Member Benefits Interest Groups bold Membership Advisory Group Women's Interprofessional Network ADA Scholars Member FAQs Member Forum Connect with other members Member Directory Find other members Career Center Find open positions and career resources 2025 National Scientific and Health Care Achievement Awards Navigation Diabetes.org Diabetes Food Hub Navigation Conversion Calculator Donate Join ADA Online Store Contact Us Breadcrumb Home Standards of Care In Diabetes main content start Standards of Care Standards of Care in Diabetes The Standards of Care in Diabetes (Standards of Care) includes all of current clinical practice recommendations of the American Diabetes Association (ADA) and is intended to provide clinicians, researchers, policy makers, and other individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The Standards of Care in Diabetes is updated annually, or more frequently online if new evidence or regulatory changes merit immediate incorporation, and is published in Diabetes Care. You are free to use the slides in presentations without further permission as long as the slide content is not altered in any way and appropriate attribution is made to the American Diabetes Association (the ADA name and logo on the slides constitutes appropriate attribution). View Abridged Standards of Care Abridged Standards of Care: Slide Deck Image ! Efforts were made to consistently apply terminology that empowers people with diabetes and recognizes the individual at the center of diabetes care.\",\n",
       "   'score': 0.16898064,\n",
       "   'raw_content': 'Standards of Care in Diabetes | American Diabetes Association\\n===============\\n     ![Image 1](https://polo.feathr.co/v1/analytics/crumb?cb=09e5d755eea8c&a_id=6005e8d9656c9743797c3217&ses_id=6822e893fd4c461f2318b832&flvr=page_view&loc_url=https%3A%2F%2Fprofessional.diabetes.org%2Fstandards-of-care&s_w=800&s_h=600&b_w=1024&b_h=1024&cust_params=e30=)\\n\\n[Skip to Main content](https://professional.diabetes.org/standards-of-care#main-content)\\n\\nNavigation\\n----------\\n\\n*   [Diabetes.org](https://diabetes.org/)\\n*   [Diabetes Food Hub](https://www.diabetesfoodhub.org/ \"(opens in a new window)\")\\n\\nNavigation\\n----------\\n\\n*   [Conversion Calculator](https://professional.diabetes.org/glucose_calc)\\n*   [Donate](https://professional.diabetes.org/standards-of-care?form=FUNERYBBRPU)\\n*   [Join ADA](https://professional.diabetes.org/membership)\\n*   [Online Store](http://shopdiabetes.org/Categories/3-Health-Care-Professional.aspx \"(opens in a new window)\")\\n*   [Contact Us](https://professional.diabetes.org/site/contact)\\n\\n[![Image 2: ADA Logo](https://professional.diabetes.org/themes/custom/diabetespro/apps/drupal/ADA_DPRO_Logo.svg)](https://professional.diabetes.org/ \"ADA Logo\")\\n\\nkeywords\\n\\nSearch\\n\\n \\n\\nurl\\n\\nLeave this field blank\\n\\nOpen main menu\\n\\n* * *\\n\\nNavigation\\n----------\\n\\n*   [Standards of Care](https://professional.diabetes.org/standards-of-care)\\n    \\n    ![Image 3: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Link title here](https://professional.diabetes.org/ \"Link title here\")\\n    \\n    ![Image 4: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Link copy to come here](https://professional.diabetes.org/ \"Link copy to come here\")\\n    \\n    bold\\n    \\n*   [Meetings](https://professional.diabetes.org/meetings)\\n    \\n    *   [Scientific Sessions](https://professional.diabetes.org/scientific-sessions)\\n        \\n        *   [Registration](https://professional.diabetes.org/scientific-sessions/registration-information)\\n            \\n        *   [Agenda](https://professional.diabetes.org/scientific-sessions/program-information)\\n            \\n        *   [Abstracts](https://professional.diabetes.org/scientific-sessions/abstracts)\\n            \\n        *   [2025 Innovation Challenge](https://professional.diabetes.org/scientific-sessions/innovation-challenge)\\n            \\n        *   [FAQs](https://professional.diabetes.org/scientific-sessions/frequently-asked-questions)\\n            \\n        *   [Hotel Information](https://professional.diabetes.org/scientific-sessions/hotel-information)\\n            \\n        \\n        bold\\n        \\n    *   [Clinical Update Conference](https://professional.diabetes.org/clinical-update-conference)\\n        \\n        *   [Get 2026 Meeting Updates](https://professional.diabetes.org/meeting-updates)\\n            \\n        *   [Team-Based Care Spotlight Challenge](https://professional.diabetes.org/clinical-update-conference/team-based-care-spotlight)\\n            \\n        \\n        bold\\n        \\n    \\n    ![Image 5: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Why Attend Scientific Sessions](https://professional.diabetes.org/scientific-sessions/justification-toolkit \"Why Attend Scientific Sessions\")\\n    \\n    Tools to help with planning your attendance\\n    \\n    ![Image 6: Red megaphone in front of desktop computer](https://professional.diabetes.org/sites/dpro/files/2025-04/ada-news-icon-flyout.svg)\\n    \\n    [ADA Meeting News](https://www.adameetingnews.org/?utm_source=professional.diabetes.org&utm_medium=association-website&utm_campaign=ADA-Homepage-sub-nav-link&utm_content=navigation-item \"ADA Meeting News (opens in a new window)\")\\n    \\n    Catch up on the groundbreaking science presented during the Scientific Sessions and the biggest developments in the diabetes community over the past year by visiting the meeting’s official online news source.\\n    \\n    ![Image 7: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [2025 Innovation Challenge](https://professional.diabetes.org/scientific-sessions/innovation-challenge \"2025 Innovation Challenge\")\\n    \\n    Take center stage at the Scientific Sessions to present your pioneering ideas for improving the lives of people with diabetes.\\n    \\n    bold\\n    \\n*   [Clinical Support](https://professional.diabetes.org/clinical-support)\\n    \\n    *   [Clinical Support](https://professional.diabetes.org/clinical-support)\\n        \\n        *   [Patient Education Library](https://professional.diabetes.org/clinical-support/patient-education-library)\\n            \\n            *   [Nutrition & Wellness](https://professional.diabetes.org/clinical-support/nutrition-wellness)\\n                \\n            *   [Vaccinations](https://professional.diabetes.org/clinical-support/vaccinations)\\n                \\n            *   [COVID-19 & Diabetes](https://professional.diabetes.org/clinical-support/covid-19)\\n                \\n            *   [Community Health Workers](https://professional.diabetes.org/clinical-support/resources-community-health-workers)\\n                \\n            \\n        *   [Diabetes INSIDE](https://professional.diabetes.org/clinical-support/diabetes-inside)\\n            \\n            *   [Diabetes Primary Care Alliance](https://professional.diabetes.org/clinical-support/diabetes-primary-care-alliance)\\n                \\n            \\n        *   [Treating Type 1 Diabetes](https://professional.diabetes.org/clinical-support/type-1-diabetes)\\n            \\n        \\n        bold\\n        \\n    *   [Diabetes Prevention Alliance](https://professional.diabetes.org/clinical-support/diabetes-prevention-alliance)\\n        \\n        *   [National Diabetes Prevention Program](https://professional.diabetes.org/clinical-support/nationaldpp)\\n            \\n        *   [DPP Express](https://professional.diabetes.org/clinical-support/national-diabetes-prevention-program/dpp-express)\\n            \\n        \\n        bold\\n        \\n    \\n    ![Image 8: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [National DPP](https://professional.diabetes.org/clinical-support/nationaldpp \"National DPP\")\\n    \\n    Learn about ADA\\'s work with the National Diabetes Prevention Program\\n    \\n    ![Image 9: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Consumer Guide](https://consumerguide.diabetes.org/ \"Consumer Guide\")\\n    \\n    Explore products for diabetes management\\n    \\n    ![Image 10: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Clinical References](https://shopdiabetes.org/collections/clinical-references \"Clinical References (opens in a new window)\")\\n    \\n    Browse the ShopDiabetes store\\n    \\n    bold\\n    \\n*   [Professional Development](https://professional.diabetes.org/professional-development)\\n    \\n    *   [Professional Development](https://professional.diabetes.org/professional-development)\\n        \\n        *   [Institute of Learning](https://professionaleducation.diabetes.org/Catalog/Learning)\\n            \\n        *   [Register for Upcoming Webinars](https://professional.diabetes.org/professional-development/upcoming-professional-webinars)\\n            \\n        *   [Case Study Competition](https://professional.diabetes.org/testyourknowledge)\\n            \\n        *   [Programs and Initiatives](https://professional.diabetes.org/clinical-support/programs-initiatives)\\n            \\n            *   [Time in Range](https://professional.diabetes.org/professional-development/time-range)\\n                \\n            *   [Cardiovascular Disease (CVD)](https://professional.diabetes.org/professional-development/cardiovascular-disease)\\n                \\n            *   [Focus on Eye Health Initiative](https://diabetes.org/health-wellness/eye-health)\\n                \\n            \\n            bold\\n            \\n            spacing\\n            \\n        \\n        bold\\n        \\n    *   [Overcoming Therapeutic Inertia](https://professional.diabetes.org/professional-development/overcoming-therapeutic-inertia)\\n        \\n        *   [Women\\'s Health](https://professional.diabetes.org/professional-development/womens-health)\\n            \\n        *   [Behavioral Health](https://professional.diabetes.org/journals-resources/behavioral-health-resources)\\n            \\n        *   [Nutrition & Technology](https://professional.diabetes.org/professional-development/programs-initiatives/nutrition-technology-resources)\\n            \\n        *   [Meetings](https://professional.diabetes.org/meetings)\\n            \\n            *   [Scientific Sessions](https://professional.diabetes.org/scientific-sessions)\\n                \\n            *   [Clinical Update Conference](https://professional.diabetes.org/clinical-update-conference)\\n                \\n            \\n            bold\\n            \\n            spacing\\n            \\n        \\n    \\n    ![Image 11: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Clinical Update Conference](https://professional.diabetes.org/clinical-update-conference \"Clinical Update Conference\")\\n    \\n    Registration for the 2025 Clinical Update Conference is now open!\\n    \\n    ![Image 12: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Membership](https://professional.diabetes.org/membership \"Membership\")\\n    \\n    Find out how membership can support your career\\n    \\n    ![Image 13: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Professional Books](https://shopdiabetes.org/collections/professional-books \"Professional Books (opens in a new window)\")\\n    \\n    Browse the ShopDiabetes store\\n    \\n    ![Image 14: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [2025 National Scientific and Health Care Achievement Awards](https://professional.diabetes.org/awards/national-scientific-health-care-achievement-awards \"2025 National Scientific and Health Care Achievement Awards\")\\n    \\n    bold\\n    \\n*   [Journals & Resources](https://professional.diabetes.org/journals-resources)\\n    \\n    *   [Journals & Resources](https://professional.diabetes.org/journals-resources)\\n        \\n        *   [Diabetes](https://diabetesjournals.org/diabetes \"(opens in a new window)\")\\n            \\n        *   [Diabetes Care](https://diabetesjournals.org/care \"(opens in a new window)\")\\n            \\n        *   [Clinical Diabetes](https://diabetesjournals.org/clinical \"(opens in a new window)\")\\n            \\n        *   [Diabetes Spectrum](https://diabetesjournals.org/spectrum \"(opens in a new window)\")\\n            \\n        *   [Diabetes Core Update](https://diabetesjournals.org/journals/pages/diabetes-core-update-podcasts \"(opens in a new window)\")\\n            \\n        *   [Institutional Journal Subscriptions](https://diabetesjournals.org/journals/pages/institutional_subscriptions \"(opens in a new window)\")\\n            \\n        \\n        bold\\n        \\n    *   [Podcasts](https://diabetesjournals.org/journals/pages/podcasts \"(opens in a new window)\")\\n        \\n        *   [Books & Materials](https://diabetesjournals.org/books \"(opens in a new window)\")\\n            \\n        *   [Infographics](https://professional.diabetes.org/journals-resources/infographics)\\n            \\n        \\n    \\n    ![Image 15: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Explore our Journals](https://diabetesjournals.org/ \"Explore our Journals (opens in a new window)\")\\n    \\n    Browse all journal content\\n    \\n    ![Image 16: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Clinical Compendia Series](https://professional.diabetes.org/journals-resources/monographs-compendia \"Clinical Compendia Series\")\\n    \\n    Explore topics related to diabetes treatment and prevention\\n    \\n    ![Image 17: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Justice, Equity, Diversity & Inclusion](https://diabetesjournals.org/pages/justice_equity_diversity_inclusion \"Justice, Equity, Diversity & Inclusion (opens in a new window)\")\\n    \\n    Learn about our commitment\\n    \\n    bold\\n    \\n*   [Education Recognition Program](https://professional.diabetes.org/education-recognition-program)\\n    \\n    *   [Education Recognition Program](https://professional.diabetes.org/education-recognition-program)\\n        \\n        *   [ERP First Steps](https://professional.diabetes.org/education-recognition-program/first-steps)\\n            \\n        *   [Recognition Requirements](https://professional.diabetes.org/education-recognition-program/recognition-requirements)\\n            \\n        *   [ERP Announcements](https://professional.diabetes.org/education-recognition-program/erp-announcements-whats-new)\\n            \\n        *   [ERP Networking Community](https://professional.diabetes.org/education-recognition-program/erp-networking-community)\\n            \\n        \\n        bold\\n        \\n    *   [Chronicle Diabetes Platform](https://professional.diabetes.org/education-recognition-program/chronicle-diabetes)\\n        \\n        *   [ERP Portal](https://erp.diabetes.org/)\\n            \\n            *   [DSMES Cycle](https://professional.diabetes.org/erpdsmecycle)\\n                \\n            \\n        \\n    \\n    ![Image 18: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [ERP University](https://professional.diabetes.org/education-recognition-program/erp-university-preparing-services-success \"ERP University\")\\n    \\n    Practical solutions for the National Standards for DSMES\\n    \\n    ![Image 19: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [List of ADA-Recognized Programs](https://professional.diabetes.org/erp_list_zip \"List of ADA-Recognized Programs\")\\n    \\n    Search the list of recognized DSMES programs\\n    \\n    ![Image 20: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Ask the Experts](https://professional.diabetes.org/education-recognition-program/ask-erp-experts-monthly-qa-webinar-schedule-recordings \"Ask the Experts\")\\n    \\n    Learn about the monthly webinars\\n    \\n    bold\\n    \\n*   [Research & Grants](https://professional.diabetes.org/research-grants)\\n    \\n    *   [Research & Grants](https://professional.diabetes.org/research-grants)\\n        \\n        *   [Funding Opportunities](https://professional.diabetes.org/research-grants/current-funding-opportunities)\\n            \\n        *   [Grant Management Portal](https://us.grantrequest.com/Login.aspx?ReturnUrl=/accountmanager.aspx%3FSA%3DAM%26sid%3D320&SA=AM&sid=320 \"(opens in a new window)\")\\n            \\n        *   [Information for Current Grantees](https://professional.diabetes.org/research-grants/information-current-grantees)\\n            \\n        \\n        bold\\n        \\n    *   [Resources for Researchers](https://professional.diabetes.org/research-grants/resources-researchers)\\n        \\n        *   [Contact Us](https://professional.diabetes.org/research-grants/contact-us)\\n            \\n        *   [FAQs](https://professional.diabetes.org/awards/meetings/frequently-asked-questions-general)\\n            \\n        \\n    \\n    ![Image 21: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Funded Research](https://professional.diabetes.org/research-grants/ada-funded-research \"Funded Research\")\\n    \\n    Learn about funded research\\n    \\n    ![Image 22: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Pathway to Stop Diabetes®](https://professional.diabetes.org/research-grants/pathway-stop-diabetes \"Pathway to Stop Diabetes®\")\\n    \\n    Learn about ADA\\'s Pathway to Stop Diabetes initiative\\n    \\n    ![Image 23: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Grant Awardee Resources](https://professional.diabetes.org/research-grants/information-current-grantees \"Grant Awardee Resources\")\\n    \\n    Information for Current Grantees\\n    \\n    ![Image 24: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [The ADA’s Scientific Sessions](https://professional.diabetes.org/scientific-sessions \"The ADA’s Scientific Sessions\")\\n    \\n    Join us at the premier diabetes conference where leading experts and peers will share the latest findings in research, prevention, and care.\\n    \\n*   [Membership](https://professional.diabetes.org/membership)\\n    \\n    *   [Membership](https://professional.diabetes.org/membership)\\n        \\n        *   [Become a Member](https://professional.diabetes.org/membership)\\n            \\n        *   [Group Membership](https://professional.diabetes.org/membership/group-membership)\\n            \\n        *   [Member Benefits](https://professional.diabetes.org/membership/member-benefits)\\n            \\n        *   [Interest Groups](https://professional.diabetes.org/membership/interest-groups)\\n            \\n        \\n        bold\\n        \\n    *   [Membership Advisory Group](https://professional.diabetes.org/membership/membership-advisory-group)\\n        \\n        *   [Women\\'s Interprofessional Network](https://professional.diabetes.org/membership/win-ada)\\n            \\n        *   [ADA Scholars](https://professional.diabetes.org/professional-development/ada-scholars)\\n            \\n        *   [Member FAQs](https://professional.diabetes.org/membership/member-frequently-asked-questions)\\n            \\n        \\n    \\n    ![Image 25: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Member Forum](https://professional.diabetes.org/membership/member-forum \"Member Forum\")\\n    \\n    Connect with other members\\n    \\n    ![Image 26: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Member Directory](https://my.diabetes.org/memberdirectory \"Member Directory\")\\n    \\n    Find other members\\n    \\n    ![Image 27: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [Career Center](https://procareers.diabetes.org/jobseekers/ \"Career Center\")\\n    \\n    Find open positions and career resources\\n    \\n    ![Image 28: red bookmark on red book](https://professional.diabetes.org/sites/dpro/files/2023-12/bookmark-flyout.svg)\\n    \\n    [2025 National Scientific and Health Care Achievement Awards](https://professional.diabetes.org/awards/national-scientific-health-care-achievement-awards \"2025 National Scientific and Health Care Achievement Awards\")\\n    \\n\\nNavigation\\n----------\\n\\n*   [Diabetes.org](https://diabetes.org/)\\n*   [Diabetes Food Hub](https://www.diabetesfoodhub.org/ \"(opens in a new window)\")\\n\\nNavigation\\n----------\\n\\n*   [Conversion Calculator](https://professional.diabetes.org/glucose_calc)\\n*   [Donate](https://professional.diabetes.org/standards-of-care?form=FUNERYBBRPU)\\n*   [Join ADA](https://professional.diabetes.org/membership)\\n*   [Online Store](http://shopdiabetes.org/Categories/3-Health-Care-Professional.aspx \"(opens in a new window)\")\\n*   [Contact Us](https://professional.diabetes.org/site/contact)\\n\\nBreadcrumb\\n----------\\n\\n*   [Home](https://professional.diabetes.org/)\\n*   Standards of Care In Diabetes\\n\\nmain content start\\n\\nStandards of Care\\n\\nStandards of Care in Diabetes\\n=============================\\n\\nThe _Standards of Care in Diabetes_ (_Standards of Care_) includes all of current clinical practice recommendations of the American Diabetes Association (ADA) and is intended to provide clinicians, researchers, policy makers, and other individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.\\n\\n[View the 2025 Standards of Care](https://diabetesjournals.org/care/issue/48/Supplement_1 \"View the 2025 Standards of Care Standards of Care in Diabetes (opens in a new window)\")\\n\\nImage\\n\\n        ![Image 29: Standards of Care Hero Image](https://professional.diabetes.org/sites/dpro/files/styles/hero_banner_with_timer_medium_812_x_500/public/2024-12/standards_care_2025_0.png?h=1821efe8&itok=DObnKKnZ)\\n\\nThe recommendations included in the Standards of Care are based on an extensive review of the clinical diabetes literature, supplemented with input from ADA staff and the medical community at large. The Standards of Care in Diabetes is updated annually, or more frequently online if new evidence or regulatory changes merit immediate incorporation, and is published in [_Diabetes Care_](https://diabetesjournals.org/care \"(opens in a new window)\").\\n\\nGet the Standards of Care App in the [App Store for iOS](https://apps.apple.com/us/app/ada-standards-of-care/id529516990 \"(opens in a new window)\") or [Google Play for Android](https://play.google.com/store/apps/details?id=org.diabetes.american_diabetes_association_standards_of_medical_care \"(opens in a new window)\") for up-to-date recommendations and interactive tables and algorithms.\\n\\n### Standards of Care in Diabetes\\n\\n*   [Introduction and Methodology](https://doi.org/10.2337/dc25-sint \"(opens in a new window)\")\\n*   [Summary of Revisions](https://doi.org/10.2337/dc25-srev \"(opens in a new window)\")\\n*   [Disclosures](https://doi.org/10.2337/dc25-sdis \"(opens in a new window)\")\\xa0\\xa0\\xa0\\n*   [Index](https://doi.org/10.2337/dc25-in01 \"(opens in a new window)\")\\n\\n#### Sections\\n\\n1.  [Improving Care and Promoting Health in Populations](https://doi.org/10.2337/dc25-s001 \"(opens in a new window)\")\\n2.  [Diagnosis and Classification of Diabetes](https://doi.org/10.2337/dc25-s002 \"(opens in a new window)\")\\n3.  [Prevention or Delay of Diabetes and Associated Comorbidities](https://doi.org/10.2337/dc25-s003 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\xa0\\n4.  [Comprehensive Medical Evaluation and Assessment of Comorbidities](https://doi.org/10.2337/dc25-s004 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\xa0\\n5.  [Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes](https://doi.org/10.2337/dc25-s005 \"(opens in a new window)\")\\xa0\\xa0\\n6.  [Glycemic Goals and Hypoglycemia](https://doi.org/10.2337/dc25-s006 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\n7.  [Diabetes Technology](https://doi.org/10.2337/dc25-s007 \"(opens in a new window)\")\\n8.  [Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes](https://doi.org/10.2337/dc25-s008 \"(opens in a new window)\")\\xa0\\n9.  [Pharmacologic Approaches to Glycemic Treatment](https://doi.org/10.2337/dc25-s009 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\n10.  [Cardiovascular Disease and Risk Management](https://doi.org/10.2337/dc25-s010 \"(opens in a new window)\")\\xa0\\xa0\\n11.  [Chronic Kidney Disease and Risk Management](https://doi.org/10.2337/dc25-s011 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\xa0\\n12.  [Retinopathy, Neuropathy, and Foot Care](https://doi.org/10.2337/dc25-s012 \"(opens in a new window)\")\\xa0\\xa0\\n13.  [Older Adults](https://doi.org/10.2337/dc25-S013 \"(opens in a new window)\")\\xa0\\xa0\\n14.  [Children and Adolescents](https://doi.org/10.2337/dc25-s014 \"(opens in a new window)\")\\xa0\\xa0\\xa0\\n15.  [Management of Diabetes in Pregnancy](https://doi.org/10.2337/dc25-s015 \"(opens in a new window)\")\\xa0\\xa0\\n16.  [Diabetes Care in the Hospital](https://doi.org/10.2337/dc25-s016 \"(opens in a new window)\")\\n17.  [Diabetes Advocacy](https://doi.org/10.2337/dc25-s017 \"(opens in a new window)\")\\xa0\\xa0\\n\\nStandards of Care App\\n---------------------\\n\\nGet the Standards of Care App in the App Store for iOS or Google Play for Android for up-to-date recommendations and interactive tables and algorithms.\\n\\n[App Store for iOS](https://apps.apple.com/us/app/ada-standards-of-care/id529516990 \"(opens in a new window)\") [Google Play for Android](https://play.google.com/store/apps/details?id=org.diabetes.american_diabetes_association_standards_of_medical_care \"(opens in a new window)\")\\n\\nImage\\n\\n        ![Image 30: SOS App](https://professional.diabetes.org/sites/dpro/files/styles/featured_image_container_contained_1_1_392_392/public/2023-12/SOC%20Webpage_APP.jpg?h=df4edc08&itok=j3VWEVlj)\\n\\nStandards of Care: Slide Deck\\n-----------------------------\\n\\nThis comprehensive [slide deck of ADA\\'s 2025 Standards of Care](https://professional.diabetes.org/sites/dpro/files/2024-12/2025-ADA-SOC-Slide-Deck-all-recommendations-FINAL-12-9-24.pptx) (.PPTX) contains content created, reviewed, and approved by the ADA. You are free to use the slides in presentations without further permission as long as the slide content is not altered in any way and appropriate attribution is made to the American Diabetes Association (the ADA name and logo on the slides constitutes appropriate attribution).\\n\\nPermission is required from the Association for any commercial use or for reproduction in any print materials [permissions@diabetes.org](mailto:permissions@diabetes.org).\\n\\n[Get the Slide Deck](https://professional.diabetes.org/sites/dpro/files/2024-12/2025-ADA-SOC-Slide-Deck-all-recommendations-FINAL-12-9-24.pptx \"Get the Slide Deck Standards of Care: Slide Deck\")\\n\\nImage\\n\\n        ![Image 31: SOC Webpage_Presentation-Deck](https://professional.diabetes.org/sites/dpro/files/styles/featured_image_container_contained_1_1_392_392/public/2023-12/SOC%20Webpage_Presentation-Deck.jpg?h=df4edc08&itok=uvXIxeF1)\\n\\n2025 Abridged Standards of Care\\n-------------------------------\\n\\nThe ADA’s Primary Care Advisory Group (PCAG) has worked diligently to summarize and condense the 2025 _Standards of Care_ recently published as a supplement to _Diabetes Care_ into a more manageable abridged version that highlights the aspects of this important document that are particularly applicable to primary care practice.\\n\\n[View Abridged Standards of Care](https://diabetesjournals.org/collection/2720/2025-Abridged-Standards-of-Care \"(opens in a new window)\")\\n\\n[Abridged Standards of Care: Slide Deck](https://professional.diabetes.org/sites/dpro/files/2024-04/ASOC_2024.pptx)\\n\\nImage\\n\\n        ![Image 32: Diabetes Care magazine cover for 2025 standards of care abridged version](https://professional.diabetes.org/sites/dpro/files/styles/featured_image_container_contained_1_1_392_392/public/2025-04/Clin_43_02_Cvr_cropped.jpg?h=5f460081&itok=5JxVyLsZ)\\n\\nStandards of Care in Diabetes—2025 Videos\\n-----------------------------------------\\n\\nThe 2025 _Standards of Care in Diabetes_ has continued to incorporate person-first and inclusive language. Efforts were made to consistently apply terminology that empowers people with diabetes and recognizes the individual at the center of diabetes care.\\n\\n![Image 33](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/DWdaOQ9wZteRLfDS3V1GX2IFixQBznFkENof5n0I-uM.jpg?h=2e7c25ba&itok=Ol7qAIjn)\\n\\n![Image 34: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 1\\n\\n![Image 35](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/YLQ1jxs6avel4Pp-HHyT8wOkmSMz2iR7g-wrCm0I-uo.jpg?h=2e7c25ba&itok=fwUDr4T9)\\n\\n![Image 36: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 5\\n\\n![Image 37](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/y8EFmen0devX1Uzsn1Uu5KQs8J3ED7UxADhQ1I2wweI.jpg?h=2e7c25ba&itok=esRWpV6r)\\n\\n![Image 38: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 6\\n\\n![Image 39](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/AB6NzQsS1gL-yAHEErvKhDBvMjH_FYu02TX4P4vNREQ.jpg?h=2e7c25ba&itok=lUNETV18)\\n\\n![Image 40: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 8\\n\\n![Image 41](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/SF4NNVQwCE1lA8ezRsiMKV8uCH6-sfI3DePhZYEY4FM.jpg?h=2e7c25ba&itok=YbbIST9N)\\n\\n![Image 42: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 9\\n\\n![Image 43](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/8yK1HGh39eyV7kLU82OO3DpCD4n22mZjnKJIPwt4e2k.jpg?h=2e7c25ba&itok=Hte9YPN5)\\n\\n![Image 44: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Sections 10 & 11\\n\\n![Image 45](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/v_UEyr7r341yq1rF_FchTDD4dYhw6BuGG5ZWKNhI3Fg.jpg?h=2e7c25ba&itok=eMFk338e)\\n\\n![Image 46: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 13\\n\\n![Image 47](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/4R29ZxdUKCoU_Pv34_9Qwpq6GYvaiLPps-c09m1y2RA.jpg?h=2e7c25ba&itok=6-RSEbe3)\\n\\n![Image 48: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 15\\n\\n![Image 49](https://professional.diabetes.org/sites/dpro/files/styles/video_card_576_331/public/oembed_thumbnails/2025-03/yN-H33YUh5jxoolkkFgyROA2OG1CAm-TDjXZ_zfkmYA.jpg?h=2e7c25ba&itok=MYe2Nmyt)\\n\\n![Image 50: play video](https://professional.diabetes.org/themes/custom/diabetespro/dist/app-drupal/images/play-btn.png)\\n\\nSOC 2025 Updates - Section 16\\n\\nSee More\\n\\nSubmit a Comment\\n\\nThe American Diabetes Association truly welcomes your comments and suggestions regarding the Standards of Care in Diabetes.\\n\\n[Submit Form](https://www.esurveyspro.com/Survey.aspx?id=329bb4f5-04e2-49a0-ac4a-26828506b9ca \"(opens in a new window)\")\\n\\nSubmit a Proposal\\n\\nDownload and complete this form to submit a proposal for an ADA Publication or Conference.\\n\\n[Download Form (.PDF)](https://professional.diabetes.org/sites/default/files/media/document_proposal_form_final1.pdf)\\n\\n[![Image 51: ADA Logo](https://professional.diabetes.org/themes/custom/diabetespro/apps/drupal/ADA_DPRO_Logo.svg)](https://professional.diabetes.org/ \"ADA Logo\")\\n\\nNavigation\\n----------\\n\\n*   [](https://www.facebook.com/DiabetesPro \"Facebook (opens in a new window)\")\\n*   [](https://www.instagram.com/AmDiabetesAssn/ \"Instagram (opens in a new window)\")\\n*   [](https://www.linkedin.com/company/american-diabetes-association/ \"LinkedIn (opens in a new window)\")\\n*   [](https://twitter.com/ada_diabetespro \"Twitter (opens in a new window)\")\\n*   [](https://www.youtube.com/user/AmericanDiabetesAssn \"Youtube (opens in a new window)\")\\n\\nNavigation\\n----------\\n\\n*   Popular Links\\n    \\n    *   [A1C Conversion Calculator](https://professional.diabetes.org/glucose_calc)\\n        \\n    *   [Standards of Care](https://professional.diabetes.org/standards-of-care)\\n        \\n    *   [2025 Scientific Sessions](https://professional.diabetes.org/scientific-sessions)\\n        \\n    *   [2026 Clinical Update Conference](https://professional.diabetes.org/clinical-update-conference)\\n        \\n    *   [Continuing Education](https://professional.diabetes.org/professional-development/continuing-education-meetings)\\n        \\n    *   [Institute of Learning](https://professionaleducation.diabetes.org/Catalog/Learning)\\n        \\n    *   [Grant Management Portal](https://us.grantrequest.com/Login.aspx?ReturnUrl=/accountmanager.aspx%3FSA%3DAM%26sid%3D320&SA=AM&sid=320 \"(opens in a new window)\")\\n        \\n    \\n*   Connect\\n    \\n    *   [Join ADA](https://professional.diabetes.org/membership)\\n        \\n    *   [Login/Register](https://my.diabetes.org/NC__Login)\\n        \\n    *   [Donate](https://professional.diabetes.org/)\\n        \\n    *   [About Us](https://diabetes.org/about-us)\\n        \\n    *   [Awards](https://professional.diabetes.org/awards/national-scientific-health-care-achievement-awards)\\n        \\n    *   [Careers](https://procareers.diabetes.org/jobseekers/)\\n        \\n    *   [For Media](https://diabetes.org/newsroom)\\n        \\n    *   [Contact Us](https://professional.diabetes.org/site/contact)\\n        \\n    \\n*   More From ADA\\n    \\n    *   [DiabetesJournals.org](https://diabetesjournals.org/ \"(opens in a new window)\")\\n        \\n    *   [DiabetesPro SmartBrief](https://www.smartbrief.com/diabetespro \"(opens in a new window)\")\\n        \\n    *   [Diabetes.org](https://diabetes.org/)\\n        \\n    *   [DiabetesFoodHub.org](https://www.diabetesfoodhub.org/ \"(opens in a new window)\")\\n        \\n    *   [ShopDiabetes.org](https://shopdiabetes.org/ \"(opens in a new window)\")\\n        \\n    *   [ADA Meeting News](https://www.adameetingnews.org/?utm_source=professional.diabetes.org&utm_medium=association-website&utm_campaign=ADA-Homepage-footer-link&utm_content=link-text \"(opens in a new window)\")\\n        \\n    *   [ConsumerGuide.Diabetes.org](https://consumerguide.diabetes.org/)\\n        \\n    \\n\\nCharity sponsor logos\\n---------------------\\n\\nImage\\n\\n        ![Image 52: national-health-council](https://professional.diabetes.org/sites/dpro/files/styles/sponsor_logo_288_180_no_crop/public/2023-12/national-health-council.png.png?itok=SOjgumzs)\\n\\nImage\\n\\n        ![Image 53: charity navigator](https://professional.diabetes.org/sites/dpro/files/styles/sponsor_logo_288_180_no_crop/public/2023-12/charity-navigator-g.png_1.png?itok=f9-44yC6)\\n\\nImage\\n\\n        ![Image 54: accredited-charity-seal](https://professional.diabetes.org/sites/dpro/files/styles/sponsor_logo_288_180_no_crop/public/2023-12/accredited-charity-seal.png.png?itok=V7SdhnVW)\\n\\nNavigation\\n----------\\n\\n*   [Sitemap](https://professional.diabetes.org/sitemap.xml)\\n*   [Terms of Use](https://professional.diabetes.org/disclaimer/terms-use)\\n*   [Privacy Policy](https://professional.diabetes.org/disclaimer/privacy-policy)\\n*   [Contact Us](https://professional.diabetes.org/site/contact)\\n*   [Clinical Trials](https://professional.diabetes.org/research-grants/resources-researchers)\\n*   [Careers](https://diabetes.org/careers)\\n\\nCopyright 1995–2025. American Diabetes Association®. All rights reserved.\\n\\npreviousnextstart slideshow\\n\\n    ![Image 59](https://t.co/i/adsct?bci=3&dv=UTC%26en-US%26Google%20Inc.%26Linux%20x86_64%26255%26800%26600%264%2624%26800%26600%260%26na&eci=2&event_id=2c0704d7-acee-44fa-8a59-ca53638abac4&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=44eff7f6-b5a3-4e8f-bb13-2ab1a1ff7091&tw_document_href=https%3A%2F%2Fprofessional.diabetes.org%2Fstandards-of-care&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o161i&type=javascript&version=2.3.33)![Image 60](https://analytics.twitter.com/i/adsct?bci=3&dv=UTC%26en-US%26Google%20Inc.%26Linux%20x86_64%26255%26800%26600%264%2624%26800%26600%260%26na&eci=2&event_id=2c0704d7-acee-44fa-8a59-ca53638abac4&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=44eff7f6-b5a3-4e8f-bb13-2ab1a1ff7091&tw_document_href=https%3A%2F%2Fprofessional.diabetes.org%2Fstandards-of-care&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o161i&type=javascript&version=2.3.33)\\n'},\n",
       "  {'title': 'Careers Home | Careers at CDC | CDC',\n",
       "   'url': 'https://jobs.cdc.gov/',\n",
       "   'content': \"Official websites use .gov Secure .gov websites use HTTPS Share sensitive information only on official, secure websites. Careers at CDC CDC scientists work 24/7 to protect the world from public health threats. Register for recruiting events and CDC webinars! Read the CDC Director's message and review orientation information. Learn about the opportunities at CDC. Professionals in nearly all fields can find a career at CDC. Learn about mission-critical occupations at CDC. Did you know CDC is on Linkedin? Connect with CDC on LinkedIn today! Did you know that 8 out of 10 employees would recommend CDC as an employer of choice? The Pathways Program for students and college graduates can be your ticket to a rewarding public health career with the CDC.\",\n",
       "   'score': 0.1638601,\n",
       "   'raw_content': None},\n",
       "  {'title': 'ClinicalTrials.gov PRS: Login',\n",
       "   'url': 'https://register.clinicaltrials.gov/',\n",
       "   'content': 'ClinicalTrials.gov PRS: Login Welcome to the ClinicalTrials.gov Protocol Registration and Results System (PRS).OMB NO: 0925-0586 EXPIRATION DATE: 03/31/2026 Burden Statement The Modernized PRS is now the primary website for Protocol Registration. The Classic PRS remains available for users who need to access features that have not yet been migrated to the Modernized PRS. Select the PRS version to open after logging in. Modernized PRS  Classic PRS  | Organization: | One-word organization name assigned by PRS (sent via email when account was created) | See How to Apply on ClinicalTrials.gov for information on how to apply for a PRS account. See PRS Guided Tutorials for assistance with entering registration and results information in the PRS. Send email to ClinicalTrials.gov PRS Administration.',\n",
       "   'score': 0.15839584,\n",
       "   'raw_content': 'ClinicalTrials.gov PRS: Login\\n\\n===============\\n\\n[![Image 1: Protocol Registration and Results System (Logo)](https://register.clinicaltrials.gov/prs/html/images/fda-left.gif)](https://register.clinicaltrials.gov/prs/app/template/Home.vm?ts=1&cx=-cnls62)\\n\\n* * *\\n\\n Login \\n\\nWelcome to the [ClinicalTrials.gov](https://clinicaltrials.gov/) Protocol Registration and Results System (PRS).OMB NO: 0925-0586 EXPIRATION DATE: 03/31/2026 [Burden Statement](https://register.clinicaltrials.gov/prs/html/omb-burden-statement.html)\\n\\n NOTICE \\n\\n The Modernized PRS is now the primary website for Protocol Registration. After logging in, you will be directed to the new website. The Classic PRS remains available for users who need to access features that have not yet been migrated to the Modernized PRS. \\n\\n Select the PRS version to open after logging in. \\n\\nModernized PRS \\n\\nClassic PRS \\n\\n| Organization: | One-word organization name assigned by PRS (sent via email when account was created) |\\n| --- |\\n| Username: |  |\\n| Password: | [Forgot password](https://register.clinicaltrials.gov/prs/app/template/ForgotPassword.vm?ts=1&cx=u4l6sl) |\\n\\nSee [How to Apply](https://clinicaltrials.gov/submit-studies/prs-accounts/how-to-apply) on ClinicalTrials.gov for information on how to apply for a PRS account.\\n\\nSee [PRS Guided Tutorials](https://cdn.clinicaltrials.gov/documents/tutorial/content/index.html) for assistance with entering registration and results information in the PRS.\\n\\n[Send email to ClinicalTrials.gov PRS](mailto:register@clinicaltrials.gov) Administration.\\n\\n* * *\\n\\n[U.S. National Library of Medicine](https://www.nlm.nih.gov/ \"U.S. National Library of Medicine\")|[U.S. National Institutes of Health](https://www.nih.gov/ \"U.S. National Institutes of Health\")|[U.S. Department of Health & Human Services](https://www.hhs.gov/ \"U.S. Department of Health & Human Services\")|[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html \"HHS Vulnerability Disclosure\")\\n\\n![Image 2: Working...](https://register.clinicaltrials.gov/prs/html/images/working.gif)\\n'},\n",
       "  {'title': 'What to Do If You Were Exposed to COVID-19 | CDC',\n",
       "   'url': 'https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/your-health/if-you-were-exposed.html',\n",
       "   'content': 'What to Do If You Were Exposed to COVID-19 If you have tested positive or are showing symptoms of COVID-19, isolate immediately. About Being Exposed to COVID-19 A tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19. If you were exposed to the virus that causes COVID-19 or have been told by a healthcare provider or public health authority that you were exposed, here are the steps that you should take, regardless of your vaccination status or if you have had a previous infection. After Being Exposed to COVID-19 If your test result is positive, follow the isolation recommendations. If you already had COVID-19 within the past 90 days, see specific testing recommendations. You can still develop COVID-19 up to 10 days after you have been exposed.',\n",
       "   'score': 0.14074938,\n",
       "   'raw_content': None},\n",
       "  {'title': 'arXiv.org e-Print archive',\n",
       "   'url': 'https://arxiv.org/',\n",
       "   'content': 'arXiv is a free distribution service and an open-access archive for nearly 2.4 million scholarly articles in the fields of physics, mathematics, computer science, quantitative biology, quantitative finance, statistics, electrical engineering and systems science, and economics. *   Condensed Matter (**cond-mat**new, recent, search) Disordered Systems and Neural Networks; Materials Science; Mesoscale and Nanoscale Physics; Other Condensed Matter; Quantum Gases; Soft Condensed Matter; Statistical Mechanics; Strongly Correlated Electrons; Superconductivity *   High Energy Physics - Experiment (**hep-ex**new, recent, search)  *   High Energy Physics - Lattice (**hep-lat**new, recent, search)  *   High Energy Physics - Phenomenology (**hep-ph**new, recent, search)  *   High Energy Physics - Theory (**hep-th**new, recent, search)  *   Mathematical Physics (**math-ph**new, recent, search)  *   Physics (**physics**new, recent, search)  *   Electrical Engineering and Systems Science (**eess**new, recent, search) ',\n",
       "   'score': 0.13551812,\n",
       "   'raw_content': 'arXiv.org e-Print archive\\n\\n===============\\n\\n[Skip to main content](https://arxiv.org/#content)\\n\\n[![Image 1: Cornell University Logo](https://arxiv.org/static/browse/0.3.4/images/icons/cu/cornell-reduced-white-SMALL.svg)](https://www.cornell.edu/)\\n\\nWe gratefully acknowledge support from the Simons Foundation, [member institutions](https://info.arxiv.org/about/ourmembers.html), and all contributors.[Donate](https://info.arxiv.org/about/donate.html)\\n\\n[](https://arxiv.org/IgnoreMe)\\n![Image 2: arxiv logo](https://arxiv.org/static/browse/0.3.4/images/arxiv-logo-one-color-white.svg)\\n===================================================================================================\\n\\n[Login](https://arxiv.org/login)\\n\\n[Help](https://info.arxiv.org/help) | [Advanced Search](https://arxiv.org/search/advanced)\\n\\nSearch\\n\\n[![Image 3: arXiv logo](https://arxiv.org/static/browse/0.3.4/images/arxiv-logomark-small-white.svg)](https://arxiv.org/)\\n\\n[![Image 4: Cornell University Logo](https://arxiv.org/static/browse/0.3.4/images/icons/cu/cornell-reduced-white-SMALL.svg)](https://www.cornell.edu/)\\n\\nGO\\n\\nquick links\\n-----------\\n\\n*   [Login](https://arxiv.org/login)\\n*   [Help Pages](https://info.arxiv.org/help)\\n*   [About](https://info.arxiv.org/about)\\n\\narXiv is a free distribution service and an open-access archive for nearly 2.4 million scholarly articles in the fields of physics, mathematics, computer science, quantitative biology, quantitative finance, statistics, electrical engineering and systems science, and economics. Materials on this site are not peer-reviewed by arXiv.\\n\\nSubject search and browse: \\n\\nPhysics\\n-------\\n\\n*   [Astrophysics](https://arxiv.org/archive/astro-ph) (**astro-ph**[new](https://arxiv.org/list/astro-ph/new), [recent](https://arxiv.org/list/astro-ph/recent), [search](https://arxiv.org/search/astro-ph)) [Astrophysics of Galaxies](https://arxiv.org/list/astro-ph.GA/recent); [Cosmology and Nongalactic Astrophysics](https://arxiv.org/list/astro-ph.CO/recent); [Earth and Planetary Astrophysics](https://arxiv.org/list/astro-ph.EP/recent); [High Energy Astrophysical Phenomena](https://arxiv.org/list/astro-ph.HE/recent); [Instrumentation and Methods for Astrophysics](https://arxiv.org/list/astro-ph.IM/recent); [Solar and Stellar Astrophysics](https://arxiv.org/list/astro-ph.SR/recent)\\n*   [Condensed Matter](https://arxiv.org/archive/cond-mat) (**cond-mat**[new](https://arxiv.org/list/cond-mat/new), [recent](https://arxiv.org/list/cond-mat/recent), [search](https://arxiv.org/search/cond-mat)) [Disordered Systems and Neural Networks](https://arxiv.org/list/cond-mat.dis-nn/recent); [Materials Science](https://arxiv.org/list/cond-mat.mtrl-sci/recent); [Mesoscale and Nanoscale Physics](https://arxiv.org/list/cond-mat.mes-hall/recent); [Other Condensed Matter](https://arxiv.org/list/cond-mat.other/recent); [Quantum Gases](https://arxiv.org/list/cond-mat.quant-gas/recent); [Soft Condensed Matter](https://arxiv.org/list/cond-mat.soft/recent); [Statistical Mechanics](https://arxiv.org/list/cond-mat.stat-mech/recent); [Strongly Correlated Electrons](https://arxiv.org/list/cond-mat.str-el/recent); [Superconductivity](https://arxiv.org/list/cond-mat.supr-con/recent)\\n*   [General Relativity and Quantum Cosmology](https://arxiv.org/archive/gr-qc) (**gr-qc**[new](https://arxiv.org/list/gr-qc/new), [recent](https://arxiv.org/list/gr-qc/recent), [search](https://arxiv.org/search/gr-qc)) \\n*   [High Energy Physics - Experiment](https://arxiv.org/archive/hep-ex) (**hep-ex**[new](https://arxiv.org/list/hep-ex/new), [recent](https://arxiv.org/list/hep-ex/recent), [search](https://arxiv.org/search/hep-ex)) \\n*   [High Energy Physics - Lattice](https://arxiv.org/archive/hep-lat) (**hep-lat**[new](https://arxiv.org/list/hep-lat/new), [recent](https://arxiv.org/list/hep-lat/recent), [search](https://arxiv.org/search/hep-lat)) \\n*   [High Energy Physics - Phenomenology](https://arxiv.org/archive/hep-ph) (**hep-ph**[new](https://arxiv.org/list/hep-ph/new), [recent](https://arxiv.org/list/hep-ph/recent), [search](https://arxiv.org/search/hep-ph)) \\n*   [High Energy Physics - Theory](https://arxiv.org/archive/hep-th) (**hep-th**[new](https://arxiv.org/list/hep-th/new), [recent](https://arxiv.org/list/hep-th/recent), [search](https://arxiv.org/search/hep-th)) \\n*   [Mathematical Physics](https://arxiv.org/archive/math-ph) (**math-ph**[new](https://arxiv.org/list/math-ph/new), [recent](https://arxiv.org/list/math-ph/recent), [search](https://arxiv.org/search/math-ph)) \\n*   [Nonlinear Sciences](https://arxiv.org/archive/nlin) (**nlin**[new](https://arxiv.org/list/nlin/new), [recent](https://arxiv.org/list/nlin/recent), [search](https://arxiv.org/search/nlin)) \\n\\n includes: [Adaptation and Self-Organizing Systems](https://arxiv.org/list/nlin.AO/recent); [Cellular Automata and Lattice Gases](https://arxiv.org/list/nlin.CG/recent); [Chaotic Dynamics](https://arxiv.org/list/nlin.CD/recent); [Exactly Solvable and Integrable Systems](https://arxiv.org/list/nlin.SI/recent); [Pattern Formation and Solitons](https://arxiv.org/list/nlin.PS/recent)\\n*   [Nuclear Experiment](https://arxiv.org/archive/nucl-ex) (**nucl-ex**[new](https://arxiv.org/list/nucl-ex/new), [recent](https://arxiv.org/list/nucl-ex/recent), [search](https://arxiv.org/search/nucl-ex)) \\n*   [Nuclear Theory](https://arxiv.org/archive/nucl-th) (**nucl-th**[new](https://arxiv.org/list/nucl-th/new), [recent](https://arxiv.org/list/nucl-th/recent), [search](https://arxiv.org/search/nucl-th)) \\n*   [Physics](https://arxiv.org/archive/physics) (**physics**[new](https://arxiv.org/list/physics/new), [recent](https://arxiv.org/list/physics/recent), [search](https://arxiv.org/search/physics)) \\n\\n includes: [Accelerator Physics](https://arxiv.org/list/physics.acc-ph/recent); [Applied Physics](https://arxiv.org/list/physics.app-ph/recent); [Atmospheric and Oceanic Physics](https://arxiv.org/list/physics.ao-ph/recent); [Atomic and Molecular Clusters](https://arxiv.org/list/physics.atm-clus/recent); [Atomic Physics](https://arxiv.org/list/physics.atom-ph/recent); [Biological Physics](https://arxiv.org/list/physics.bio-ph/recent); [Chemical Physics](https://arxiv.org/list/physics.chem-ph/recent); [Classical Physics](https://arxiv.org/list/physics.class-ph/recent); [Computational Physics](https://arxiv.org/list/physics.comp-ph/recent); [Data Analysis, Statistics and Probability](https://arxiv.org/list/physics.data-an/recent); [Fluid Dynamics](https://arxiv.org/list/physics.flu-dyn/recent); [General Physics](https://arxiv.org/list/physics.gen-ph/recent); [Geophysics](https://arxiv.org/list/physics.geo-ph/recent); [History and Philosophy of Physics](https://arxiv.org/list/physics.hist-ph/recent); [Instrumentation and Detectors](https://arxiv.org/list/physics.ins-det/recent); [Medical Physics](https://arxiv.org/list/physics.med-ph/recent); [Optics](https://arxiv.org/list/physics.optics/recent); [Physics and Society](https://arxiv.org/list/physics.soc-ph/recent); [Physics Education](https://arxiv.org/list/physics.ed-ph/recent); [Plasma Physics](https://arxiv.org/list/physics.plasm-ph/recent); [Popular Physics](https://arxiv.org/list/physics.pop-ph/recent); [Space Physics](https://arxiv.org/list/physics.space-ph/recent)\\n*   [Quantum Physics](https://arxiv.org/archive/quant-ph) (**quant-ph**[new](https://arxiv.org/list/quant-ph/new), [recent](https://arxiv.org/list/quant-ph/recent), [search](https://arxiv.org/search/quant-ph)) \\n\\nMathematics\\n-----------\\n\\n*   [Mathematics](https://arxiv.org/archive/math) (**math**[new](https://arxiv.org/list/math/new), [recent](https://arxiv.org/list/math/recent), [search](https://arxiv.org/search/math)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/math/index.html)): [Algebraic Geometry](https://arxiv.org/list/math.AG/recent); [Algebraic Topology](https://arxiv.org/list/math.AT/recent); [Analysis of PDEs](https://arxiv.org/list/math.AP/recent); [Category Theory](https://arxiv.org/list/math.CT/recent); [Classical Analysis and ODEs](https://arxiv.org/list/math.CA/recent); [Combinatorics](https://arxiv.org/list/math.CO/recent); [Commutative Algebra](https://arxiv.org/list/math.AC/recent); [Complex Variables](https://arxiv.org/list/math.CV/recent); [Differential Geometry](https://arxiv.org/list/math.DG/recent); [Dynamical Systems](https://arxiv.org/list/math.DS/recent); [Functional Analysis](https://arxiv.org/list/math.FA/recent); [General Mathematics](https://arxiv.org/list/math.GM/recent); [General Topology](https://arxiv.org/list/math.GN/recent); [Geometric Topology](https://arxiv.org/list/math.GT/recent); [Group Theory](https://arxiv.org/list/math.GR/recent); [History and Overview](https://arxiv.org/list/math.HO/recent); [Information Theory](https://arxiv.org/list/math.IT/recent); [K-Theory and Homology](https://arxiv.org/list/math.KT/recent); [Logic](https://arxiv.org/list/math.LO/recent); [Mathematical Physics](https://arxiv.org/list/math.MP/recent); [Metric Geometry](https://arxiv.org/list/math.MG/recent); [Number Theory](https://arxiv.org/list/math.NT/recent); [Numerical Analysis](https://arxiv.org/list/math.NA/recent); [Operator Algebras](https://arxiv.org/list/math.OA/recent); [Optimization and Control](https://arxiv.org/list/math.OC/recent); [Probability](https://arxiv.org/list/math.PR/recent); [Quantum Algebra](https://arxiv.org/list/math.QA/recent); [Representation Theory](https://arxiv.org/list/math.RT/recent); [Rings and Algebras](https://arxiv.org/list/math.RA/recent); [Spectral Theory](https://arxiv.org/list/math.SP/recent); [Statistics Theory](https://arxiv.org/list/math.ST/recent); [Symplectic Geometry](https://arxiv.org/list/math.SG/recent)\\n\\nComputer Science\\n----------------\\n\\n*   [Computing Research Repository](https://info.arxiv.org/help/cs/index.html) (**CoRR**[new](https://arxiv.org/list/cs/new), [recent](https://arxiv.org/list/cs/recent), [search](https://arxiv.org/search/cs)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/cs/index.html)): [Artificial Intelligence](https://arxiv.org/list/cs.AI/recent); [Computation and Language](https://arxiv.org/list/cs.CL/recent); [Computational Complexity](https://arxiv.org/list/cs.CC/recent); [Computational Engineering, Finance, and Science](https://arxiv.org/list/cs.CE/recent); [Computational Geometry](https://arxiv.org/list/cs.CG/recent); [Computer Science and Game Theory](https://arxiv.org/list/cs.GT/recent); [Computer Vision and Pattern Recognition](https://arxiv.org/list/cs.CV/recent); [Computers and Society](https://arxiv.org/list/cs.CY/recent); [Cryptography and Security](https://arxiv.org/list/cs.CR/recent); [Data Structures and Algorithms](https://arxiv.org/list/cs.DS/recent); [Databases](https://arxiv.org/list/cs.DB/recent); [Digital Libraries](https://arxiv.org/list/cs.DL/recent); [Discrete Mathematics](https://arxiv.org/list/cs.DM/recent); [Distributed, Parallel, and Cluster Computing](https://arxiv.org/list/cs.DC/recent); [Emerging Technologies](https://arxiv.org/list/cs.ET/recent); [Formal Languages and Automata Theory](https://arxiv.org/list/cs.FL/recent); [General Literature](https://arxiv.org/list/cs.GL/recent); [Graphics](https://arxiv.org/list/cs.GR/recent); [Hardware Architecture](https://arxiv.org/list/cs.AR/recent); [Human-Computer Interaction](https://arxiv.org/list/cs.HC/recent); [Information Retrieval](https://arxiv.org/list/cs.IR/recent); [Information Theory](https://arxiv.org/list/cs.IT/recent); [Logic in Computer Science](https://arxiv.org/list/cs.LO/recent); [Machine Learning](https://arxiv.org/list/cs.LG/recent); [Mathematical Software](https://arxiv.org/list/cs.MS/recent); [Multiagent Systems](https://arxiv.org/list/cs.MA/recent); [Multimedia](https://arxiv.org/list/cs.MM/recent); [Networking and Internet Architecture](https://arxiv.org/list/cs.NI/recent); [Neural and Evolutionary Computing](https://arxiv.org/list/cs.NE/recent); [Numerical Analysis](https://arxiv.org/list/cs.NA/recent); [Operating Systems](https://arxiv.org/list/cs.OS/recent); [Other Computer Science](https://arxiv.org/list/cs.OH/recent); [Performance](https://arxiv.org/list/cs.PF/recent); [Programming Languages](https://arxiv.org/list/cs.PL/recent); [Robotics](https://arxiv.org/list/cs.RO/recent); [Social and Information Networks](https://arxiv.org/list/cs.SI/recent); [Software Engineering](https://arxiv.org/list/cs.SE/recent); [Sound](https://arxiv.org/list/cs.SD/recent); [Symbolic Computation](https://arxiv.org/list/cs.SC/recent); [Systems and Control](https://arxiv.org/list/cs.SY/recent)\\n\\nQuantitative Biology\\n--------------------\\n\\n*   [Quantitative Biology](https://arxiv.org/archive/q-bio) (**q-bio**[new](https://arxiv.org/list/q-bio/new), [recent](https://arxiv.org/list/q-bio/recent), [search](https://arxiv.org/search/q-bio)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/q-bio/index.html)): [Biomolecules](https://arxiv.org/list/q-bio.BM/recent); [Cell Behavior](https://arxiv.org/list/q-bio.CB/recent); [Genomics](https://arxiv.org/list/q-bio.GN/recent); [Molecular Networks](https://arxiv.org/list/q-bio.MN/recent); [Neurons and Cognition](https://arxiv.org/list/q-bio.NC/recent); [Other Quantitative Biology](https://arxiv.org/list/q-bio.OT/recent); [Populations and Evolution](https://arxiv.org/list/q-bio.PE/recent); [Quantitative Methods](https://arxiv.org/list/q-bio.QM/recent); [Subcellular Processes](https://arxiv.org/list/q-bio.SC/recent); [Tissues and Organs](https://arxiv.org/list/q-bio.TO/recent)\\n\\nQuantitative Finance\\n--------------------\\n\\n*   [Quantitative Finance](https://arxiv.org/archive/q-fin) (**q-fin**[new](https://arxiv.org/list/q-fin/new), [recent](https://arxiv.org/list/q-fin/recent), [search](https://arxiv.org/search/q-fin)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/q-fin/index.html)): [Computational Finance](https://arxiv.org/list/q-fin.CP/recent); [Economics](https://arxiv.org/list/q-fin.EC/recent); [General Finance](https://arxiv.org/list/q-fin.GN/recent); [Mathematical Finance](https://arxiv.org/list/q-fin.MF/recent); [Portfolio Management](https://arxiv.org/list/q-fin.PM/recent); [Pricing of Securities](https://arxiv.org/list/q-fin.PR/recent); [Risk Management](https://arxiv.org/list/q-fin.RM/recent); [Statistical Finance](https://arxiv.org/list/q-fin.ST/recent); [Trading and Market Microstructure](https://arxiv.org/list/q-fin.TR/recent)\\n\\nStatistics\\n----------\\n\\n*   [Statistics](https://arxiv.org/archive/stat) (**stat**[new](https://arxiv.org/list/stat/new), [recent](https://arxiv.org/list/stat/recent), [search](https://arxiv.org/search/stat)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/stat/index.html)): [Applications](https://arxiv.org/list/stat.AP/recent); [Computation](https://arxiv.org/list/stat.CO/recent); [Machine Learning](https://arxiv.org/list/stat.ML/recent); [Methodology](https://arxiv.org/list/stat.ME/recent); [Other Statistics](https://arxiv.org/list/stat.OT/recent); [Statistics Theory](https://arxiv.org/list/stat.TH/recent)\\n\\nElectrical Engineering and Systems Science\\n------------------------------------------\\n\\n*   [Electrical Engineering and Systems Science](https://arxiv.org/archive/eess) (**eess**[new](https://arxiv.org/list/eess/new), [recent](https://arxiv.org/list/eess/recent), [search](https://arxiv.org/search/eess)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/eess/index.html)): [Audio and Speech Processing](https://arxiv.org/list/eess.AS/recent); [Image and Video Processing](https://arxiv.org/list/eess.IV/recent); [Signal Processing](https://arxiv.org/list/eess.SP/recent); [Systems and Control](https://arxiv.org/list/eess.SY/recent)\\n\\nEconomics\\n---------\\n\\n*   [Economics](https://arxiv.org/archive/econ) (**econ**[new](https://arxiv.org/list/econ/new), [recent](https://arxiv.org/list/econ/recent), [search](https://arxiv.org/search/econ)) \\n\\nincludes: (see [detailed description](https://info.arxiv.org/help/econ/index.html)): [Econometrics](https://arxiv.org/list/econ.EM/recent); [General Economics](https://arxiv.org/list/econ.GN/recent); [Theoretical Economics](https://arxiv.org/list/econ.TH/recent)\\n\\n* * *\\n\\nAbout arXiv\\n-----------\\n\\n*   [General information](https://info.arxiv.org/about)\\n*   [How to Submit to arXiv](https://info.arxiv.org/help/submit/index.html)\\n*   [Membership & Giving](https://info.arxiv.org/about/donate.html)\\n*   [Who We Are](https://info.arxiv.org/about/people/index.html)\\n\\n*   [About](https://info.arxiv.org/about)\\n*   [Help](https://info.arxiv.org/help)\\n\\n*   [Contact](https://info.arxiv.org/help/contact.html)\\n*   [Subscribe](https://info.arxiv.org/help/subscribe)\\n\\n*   [Copyright](https://info.arxiv.org/help/license/index.html)\\n*   [Privacy Policy](https://info.arxiv.org/help/policies/privacy_policy.html)\\n\\n*   [Web Accessibility Assistance](https://info.arxiv.org/help/web_accessibility.html)\\n*   [arXiv Operational Status](https://status.arxiv.org/)\\n\\n Get status notifications via [email](https://subscribe.sorryapp.com/24846f03/email/new) or [slack](https://subscribe.sorryapp.com/24846f03/slack/new)\\n'},\n",
       "  {'title': 'Import Trade Auxiliary Communications System - Food and Drug Administration',\n",
       "   'url': 'https://www.access.fda.gov/itacs/',\n",
       "   'content': 'WARNING: This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes all devices/storage media attached to this system. This system is provided for Government-authorized use only. Unauthorized or improper use of this system is prohibited and may result in',\n",
       "   'score': 0.13145196,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Immunization Schedules | Vaccines & Immunizations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html',\n",
       "   'content': 'Immunization Schedules | Vaccines & Immunizations | CDC A .gov website belongs to an official government organization in the United States. Vaccines & Immunizations Vaccines and the Diseases They Prevent Vaccines by Age Vaccine Resources Vaccines By Disease Vaccines Used in the U.S. Immunization Schedules Vaccines and the Diseases They Prevent Vaccines by Age Vaccine Resources Vaccines By Disease Vaccines Used in the U.S. Immunization Schedules View All Vaccines & Immunizations Guide health care providers in determining recommended vaccines for each age group. View and print CDC immunization schedules for adult... Vaccination resources Adult Vaccination Vaccines & Immunizations Vaccines and the Diseases They Prevent Vaccines by Age Vaccine Resources Vaccines By Disease Vaccines Used in the U.S. Immunization Schedules',\n",
       "   'score': 0.13125141,\n",
       "   'raw_content': 'Immunization Schedules | Vaccines & Immunizations | CDC\\n\\n===============\\n\\n[Skip directly to site content](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#content)[Skip directly to search](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#cdc-search)\\n\\n![Image 1: U.S. flag](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/us_flag_small.png)An official website of the United States government\\n\\n[Here\\'s how you know](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#gov-notice)\\n\\n![Image 2](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\n**Official websites use .gov**\\nA .gov website belongs to an official government organization in the United States.\\n\\n![Image 3](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\n**Secure .gov websites use HTTPS**\\nA **lock** (  ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n[![Image 4: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)\\n\\n Explore Topics \\n\\n[Search](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)\\n\\nSearch\\n\\n[For Everyone](https://www.cdc.gov/vaccines/index.html)\\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#gen)\\n\\n[Health Care Providers](https://www.cdc.gov/vaccines/hcp/index.html)\\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html)\\n*   [About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html)\\n*   [What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html)\\n*   [General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html)\\n*   [Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#hcp)\\n\\n[Public Health](https://www.cdc.gov/vaccines/site.html#php)\\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [From Me, To You](https://www.cdc.gov/vaccines/php/from-me-to-you/index.html)\\n*   [Keeps It That Way](https://www.cdc.gov/vaccines/php/keeps-it-that-way/index.html)\\n*   [Perinatal Hep B Prevention](https://www.cdc.gov/vaccines/php/perinatal-hep-b-prevention/index.html)\\n*   [Meetings, Conferences, and Events](https://www.cdc.gov/vaccines/php/events/index.html)\\n*   [Adolescent Immunization Action Week (AIAW)](https://www.cdc.gov/vaccines/php/adolescent-immunization-action-week/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#php)\\n\\n**Related Topics:**\\n\\n[Vaccines for Your Children](https://www.cdc.gov/vaccines-children/index.html)|[Vaccine Information for Adults](https://www.cdc.gov/vaccines-adults/index.html)|[Pregnancy and Vaccination](https://www.cdc.gov/vaccines-pregnancy/index.html)\\n\\n[View All](https://www.cdc.gov/vaccines/site.html)\\n\\n[![Image 5: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[_search_ _close search_](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)\\n\\nsearch\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)[Menu](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)\\n\\nsearch\\n\\n For Everyone \\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#gen)[Home](https://www.cdc.gov/vaccines/index.html)\\n\\n Health Care Providers \\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html)\\n*   [About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html)\\n*   [What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html)\\n*   [General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html)\\n*   [Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#hcp)[Home](https://www.cdc.gov/vaccines/hcp/index.html)\\n\\n Public Health \\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [From Me, To You](https://www.cdc.gov/vaccines/php/from-me-to-you/index.html)\\n*   [Keeps It That Way](https://www.cdc.gov/vaccines/php/keeps-it-that-way/index.html)\\n*   [Perinatal Hep B Prevention](https://www.cdc.gov/vaccines/php/perinatal-hep-b-prevention/index.html)\\n*   [Meetings, Conferences, and Events](https://www.cdc.gov/vaccines/php/events/index.html)\\n*   [Adolescent Immunization Action Week (AIAW)](https://www.cdc.gov/vaccines/php/adolescent-immunization-action-week/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#php)\\n\\nRelated Topics\\n\\n*   [Vaccines for Your Children](https://www.cdc.gov/vaccines-children/index.html)\\n*   [Vaccine Information for Adults](https://www.cdc.gov/vaccines-adults/index.html)\\n*   [Pregnancy and Vaccination](https://www.cdc.gov/vaccines-pregnancy/index.html)\\n\\n[View All Vaccines & Immunizations](https://www.cdc.gov/vaccines/site.html)\\n\\n[Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)[Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)[Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)[Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html)[About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html)[What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html)[General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html)[Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html)[View All](https://www.cdc.gov/vaccines/site.html)\\n\\n November 21, 2024 \\n\\nImmunization Schedules\\n======================\\n\\nThe 2025 Immunization Schedules approved by ACIP and adopted by the CDC Director on October 24, 2024 are now available below.\\n\\nFor healthcare providers\\n------------------------\\n\\n[![Image 6: Child immunization schedule.](https://www.cdc.gov/vaccines/hcp/imz-schedules/images/schedule-child.jpg)](https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html \"Child and Adolescent Immunization Schedule by Age\")\\n\\n[Child and Adolescent Immunization Schedule by Age](https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html)\\n\\nGuide health care providers in determining recommended vaccines for each age group.\\n\\nNov. 21, 2024\\n\\n[![Image 7: Adults immunization schedule.](https://www.cdc.gov/vaccines/hcp/imz-schedules/images/schedule-adults.jpg)](https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html \"Adult Immunization Schedule by Age\")\\n\\n[Adult Immunization Schedule by Age](https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html)\\n\\nStay up-to-date on getting recommended vaccines. View and print CDC immunization schedules for adult...\\n\\nNov. 21, 2024\\n\\nVaccination resources\\n---------------------\\n\\n*   [Adult Vaccination](https://www.cdc.gov/vaccines-adults/index.html)\\n\\n*   [Pregnancy and Vaccination](https://www.cdc.gov/vaccines-pregnancy/index.html)\\n\\n*   [Vaccines for Your Children](https://www.cdc.gov/vaccines-children/index.html)\\n\\n*   [Travel Vaccines](https://wwwnc.cdc.gov/travel/page/travel-vaccines)\\n\\n*   [Mpox Vaccination](https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html)\\n\\n November 20, 2024 \\n\\n[Sources](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#content-sources)[Print](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#print)[Share](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#share)\\n\\n[](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)[](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)[](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)[](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#)\\n\\n[Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.cdc.gov \"Share to Facebook\")[LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.cdc.gov&title=Living%20with%20High%20Blood%20Pressure \"Share to LinkedIn\")[Twitter](https://twitter.com/share?url=https%3A%2F%2Fwww.cdc.gov&text=Living%20with%20High%20Blood%20Pressure \"Share to Twitter\")[Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https://https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html \"Embed this Page\")\\n\\nContent Source:\\n\\n[National Center for Immunization and Respiratory Diseases](https://www.cdc.gov/ncird/index.html)\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)\\n-------------------------------------------------------------------\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n[View All](https://www.cdc.gov/vaccines/site.html)\\n\\n### [For Everyone](https://www.cdc.gov/vaccines/index.html#gen)\\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n\\n### [Health Care Providers](https://www.cdc.gov/vaccines/hcp/index.html#hcp)\\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#hcp)\\n\\n### [Public Health](https://www.cdc.gov/vaccines/site.html#php)\\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#php)\\n\\n[Sign up for Email Updates](https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx#featured)\\n\\n[Contact Us](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#aboutCDC)\\n\\n[About CDC](https://www.cdc.gov/about/)\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n\\n[Policies](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#languages)\\n\\n[Languages](https://wwwn.cdc.gov/pubs/other-languages?Sort=Lang%3A%3Aasc)\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\n[Language Assistance](https://www.cdc.gov/other/language-assistance.html)\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[Contact Us](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#mobile-footer-contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#mobile-footer-aboutCDC)\\n\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n*   [About CDC](https://www.cdc.gov/about/)\\n\\n[Policies](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#mobile-footer-policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#mobile-footer-languages)\\n\\nLanguages\\n\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\nLanguage Assistance\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html#mobile-footer-archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[![Image 8: Centers for Disease Control and Prevention](https://www.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)](https://www.cdc.gov/)\\n\\n[](https://www.facebook.com/CDC)[](https://twitter.com/CDCgov)[](https://www.instagram.com/CDCgov)[](https://www.linkedin.com/company/centers-for-disease-control-and-prevention)\\n\\n[](https://www.youtube.com/cdc)[](https://www.pinterest.com/cdcgov)[](https://www.snapchat.com/add/cdcgov)[](https://www.cdc.gov/rss)\\n\\n[HHS.gov](https://hhs.gov/)[USA.gov](https://usa.gov/)\\n\\n[](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html# \"Go to top\")\\n'},\n",
       "  {'title': 'Recalls, Market Withdrawals, & Safety Alerts | FDA',\n",
       "   'url': 'https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts',\n",
       "   'content': 'Recalls, Market Withdrawals, & Safety Alerts | FDA The list below provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. The Recalls, Market Withdrawals & Safety Alerts are available on FDA’s website for three years before being archived. | 06/04/2025 | Multiple brands | Fresh cucumbers and salsa and salads containing fresh cucumbers | Food & Beverages | Potential to be contaminated with Salmonella | TGD Cuts, LLC. | 05/27/2025 | East Coast Fresh, TOPS, Wellsley Farms, WEIS, AHOLD, Jack and Olive, Created Fresh, Spring and Sprout | Salads, salsas, and other products containing salsa containing fresh cucumbers | Food & Beverages, Foodborne Illness | Potential for Salmonella contamination.',\n",
       "   'score': 0.12186354,\n",
       "   'raw_content': 'Recalls, Market Withdrawals, & Safety Alerts | FDA\\n\\n===============\\n\\n*   [Skip to main content](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#main-content)\\n*   [Skip to FDA Search](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#search-form)\\n*   [Skip to in this section menu](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#section-nav)\\n*   [Skip to footer links](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#footer)\\n\\n![Image 1: U.S. flag](https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png)An official website of the United States government Here’s how you know\\n\\n![Image 2: Dot gov](https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**\\n\\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you\\'re on a federal government site.\\n\\n![Image 3: SSL](https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg)\\n\\n**The site is secure.**\\n\\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\n[![Image 4: Food and Drug Administration Logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg)](https://www.fda.gov/ \"FDA Homepage\")\\n\\n*   Search\\n*   Menu\\n\\nSearch FDA Submit search\\n\\nFeatured\\n--------\\n\\n*   [Report a Product Problem](https://www.safetyreporting.hhs.gov/smarthub#/ \"Report a Problem with an FDA Regulated Product\")\\n*   [Contact FDA](https://www.fda.gov/about-fda/contact-fda)\\n*   [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents)\\n*   [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts)\\n*   [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements)\\n*   [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\\n*   [Advisory Committees](https://www.fda.gov/advisory-committees)\\n*   [En Español](https://www.fda.gov/fda-en-espanol)\\n\\nProducts\\n--------\\n\\n*   [Food](https://www.fda.gov/food)\\n*   [Drugs](https://www.fda.gov/drugs)\\n*   [Medical Devices](https://www.fda.gov/medical-devices)\\n*   [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products)\\n*   [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics)\\n*   [Animal and Veterinary](https://www.fda.gov/animal-veterinary)\\n*   [Cosmetics](https://www.fda.gov/cosmetics)\\n*   [Tobacco Products](https://www.fda.gov/tobacco-products)\\n\\nTopics\\n------\\n\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Combination Products](https://www.fda.gov/combination-products)\\n*   [Regulatory Information](https://www.fda.gov/regulatory-information)\\n*   [Safety](https://www.fda.gov/safety)\\n*   [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response)\\n*   [International Programs](https://www.fda.gov/international-programs)\\n*   [News and Events](https://www.fda.gov/news-events)\\n*   [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education)\\n*   [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations)\\n*   [Science and Research](https://www.fda.gov/science-research)\\n\\nInformation For\\n---------------\\n\\n*   [Consumers](https://www.fda.gov/consumers)\\n*   [Patients](https://www.fda.gov/patients)\\n*   [Industry](https://www.fda.gov/industry)\\n*   [Health Professionals](https://www.fda.gov/health-professionals)\\n*   [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials)\\n\\n[In this section: Safety](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#section-nav)\\n*   [Recalls, Market Withdrawals, & Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts)\\n\\n    *   [Recall Resources](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/recall-resources)\\n\\n    *   [Enforcement Reports](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports)\\n    *   [Industry Guidance For Recalls](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-recalls)\\n    *   [Major Product Recalls](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/major-product-recalls)\\n\\n1.   [Home](https://www.fda.gov/)\\n2.   [Safety](https://www.fda.gov/safety)\\n3.   Recalls, Market Withdrawals, & Safety Alerts\\n\\n1.   [Safety](https://www.fda.gov/safety \"Safety\")\\n\\nRecalls, Market Withdrawals, & Safety Alerts\\n============================================\\n\\n*   [Recalls, Market Withdrawals, & Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts)\\n\\n    *   [Recall Resources](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/recall-resources)\\n\\n    *   [Enforcement Reports](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports)\\n    *   [Industry Guidance For Recalls](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-recalls)\\n    *   [Major Product Recalls](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/major-product-recalls)\\n\\nThe list below provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this page. See [Additional information about recalls](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/additional-information-about-recalls \"Additional Information about Recalls \") for a more complete listing.\\n\\n The Recalls, Market Withdrawals & Safety Alerts are available on FDA’s website for three years before being archived. To search archived content, visit[Search FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive)and input the name of the product and/or company name in the Search terms box as well as the year to get the most inclusive search results. To scroll through archived Recalls, Market Withdrawals & Safety Alerts content by year, see the[Recall and Safety Alerts Archive.](https://wayback.archive-it.org/7993/20201217182838/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/archive-recalls-market-withdrawals-safety-alerts)\\n\\n![Image 5: Email Icon for GovDelivery](https://www.fda.gov/media/70675/download)[Sign up to receive Recalls, Market Withdrawals and Safety Alerts](https://public.govdelivery.com/accounts/USFDA/subscriber/new).\\n\\n_* FDA Employees: Use Chrome to Subscribe until further notice._\\n\\nSearch \\n\\n[Filter by](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts#collapseOne)\\n--------------------------------------------------------------------------------------------\\n\\nProduct Type \\n\\nTerminated Recall \\n\\nA Terminated Recall is a recall where the FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. Recalls that are not indicated as being terminated are either ongoing or completed.\\n\\n| Date | Brand Name(s) | Product Description | Product Type | Recall Reason Description | Company Name | Terminated Recall | Excerpt |\\n| --- | --- | --- | --- | --- | --- | --- | --- |\\n| 06/06/2025 | [Multiple brand names](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/august-egg-company-recalls-shell-eggs-because-possible-health-risk) | Brown cage free and brown certified organic eggs | Food & Beverages | Salmonella | August Egg Company |  |  |\\n| 06/06/2025 | [Zicam® and Orajel™](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/church-dwight-co-inc-issues-voluntary-nationwide-recall-zicamr-cold-remedy-nasal-swabs-zicamr-nasal) | Cold Remedy Nasal Swabs, Nasal AllClear Swabs, Baby Teething Swabs | Drugs | Microbial contamination | Church & Dwight Co., Inc. |  |  |\\n| 06/04/2025 | [Multiple brands](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/tgd-cuts-llc-initiated-voluntary-recall-cucumber-bedner-growers-inc-which-had-potential-be) | Fresh cucumbers and salsa and salads containing fresh cucumbers | Food & Beverages | Potential to be contaminated with Salmonella | TGD Cuts, LLC. |  |  |\\n| 06/04/2025 | [Firehook](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/firehook-virginia-issues-allergy-alert-undeclared-sesame-classic-sea-salt-crackers) | Crackers | Food & Beverages | Undeclared Sesame | Firehook of Virginia |  |  |\\n| 06/04/2025 | [Amneal](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceutical-llc-issues-nationwide-recall-sulfamethoxazole-trimethoprim-tablets-usp-400) | Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg | Drugs | Microbial contamination | Amneal Pharmaceutical LLC |  |  |\\n| 06/03/2025 | [Aldi brand Casa Mamita](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camerican-international-inc-issues-allergy-alert-undeclared-milk-aldi-brand-casa-mamita-churro-bites) | Churro Bites | Food & Beverages, Allergens | Undeclared Milk | Camerican International |  |  |\\n| 05/29/2025 | [Shore Lunch](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/homegrown-family-foods-issues-allergy-alert-undeclared-milk-shore-lunch-oven-style-breader-batter) | Breading and Batter Mix | Food & Beverages | Presence of Undeclared Milk | Homegrown Family Foods |  |  |\\n| 05/29/2025 | [Kings, Isabelle’s Kitchen Inc., Maple Avenue Foods](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/isabelles-kitchen-inc-recalls-refrigerated-deli-salads-containing-fresh-cucumbers-because-possible) | Salads containing fresh cucumbers. | Food & Beverages, Foodborne Illness | Potential to be contaminated with Salmonella | Isabelle’s Kitchen, Inc. |  |  |\\n| 05/28/2025 | [Supreme Produce](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/supreme-service-solutions-llc-voluntarily-recalls-supreme-vegetable-products-because-possible-health-0) | Fresh cucumbers and salad and vegetable trays containing fresh cucumbers. | Food & Beverages, Foodborne Illness, Produce | Due to possible contamination with Salmonella | Supreme Service Solutions, LLC. |  |  |\\n| 05/27/2025 | [East Coast Fresh, TOPS, Wellsley Farms, WEIS, AHOLD, Jack and Olive, Created Fresh, Spring and Sprout](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/coastal-companies-issues-voluntary-recall-items-fresh-start-cucumbers-due-potential-salmonella) | Salads, salsas, and other products containing salsa containing fresh cucumbers | Food & Beverages, Foodborne Illness | Potential for Salmonella contamination. | The Coastal Companies |  |  |\\n\\n[Download XLSX](http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/datatables-data?page&_format=xlsx)\\n\\n*   Content current as of:\\n----------------------\\n\\n06/06/2025 \\n\\n*    \\n\\n*   [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive)\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility)\\n\\n*   [Visitor Information](https://www.fda.gov/about-fda/visitor-information)\\n*   [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies)\\n*   [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n*   [FOIA](https://www.fda.gov/regulatory-information/freedom-information \"Freedom of Information Act\")\\n*   [HHS.gov](https://www.hhs.gov/ \"Health and Human Services\")\\n*   [USA.gov](https://www.usa.gov/)\\n\\n[Contact FDA](https://www.fda.gov/about-fda/contact-fda)[Follow FDA on Facebook](https://www.facebook.com/FDA \"Follow FDA on Facebook\")[Follow FDA on X](https://x.com/US_FDA \"Follow FDA on X\")[Follow FDA on Instagram](https://instagram.com/FDA \"Follow FDA on Instagram\")\\n\\n[Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/ \"Follow FDA on LinkedIn\")[View FDA videos on YouTube](https://youtube.com/@US_FDA \"View FDA videos on YouTube\")[Subscribe to FDA RSS feeds](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds \"Subscribe to FDA RSS feeds\")\\n\\n[![Image 6: Food and Drug Administration Logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg)](https://www.fda.gov/ \"FDA Homepage\")\\n\\nContact Number 1-888-INFO-FDA (1-888-463-6332) \\n\\nBack to Top\\n'},\n",
       "  {'title': 'Cancer statistics, 2024 - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/38230766/',\n",
       "   'content': 'Abstract Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers. Progress is also hampered by wide persistent cancer disparities; compared to White people, mortality rates are two-fold higher for prostate, stomach and uterine corpus cancers in Black people and for liver, stomach, and kidney cancers in Native American people.',\n",
       "   'score': 0.12186354,\n",
       "   'raw_content': 'Cancer statistics, 2024 - PubMed\\n\\n===============\\n\\n Clipboard, Search History, and several other advanced features are temporarily unavailable. \\n\\n[Skip to main page content](https://pubmed.ncbi.nlm.nih.gov/38230766/#article-details)\\n\\n![Image 1: U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\\nAn official website of the United States government\\n\\nHere\\'s how you know\\n\\n![Image 2: Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**\\n\\n Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\\n\\n![Image 3: Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**\\n\\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\n[![Image 4: NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\\n\\n[Log in](https://account.ncbi.nlm.nih.gov/)Show account info\\n\\nClose\\n#### Account\\n\\n Logged in as:\\n\\n**username**\\n\\n*   [Dashboard](https://pubmed.ncbi.nlm.nih.gov/myncbi/)\\n*   [Publications](https://pubmed.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\\n*   [Account settings](https://pubmed.ncbi.nlm.nih.gov/account/settings/)\\n*   [Log out](https://pubmed.ncbi.nlm.nih.gov/account/signout/)\\n\\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys)[NCBI Homepage](https://www.ncbi.nlm.nih.gov/)[MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/)[Main Content](https://pubmed.ncbi.nlm.nih.gov/38230766/#maincontent)[Main Navigation](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n[![Image 5: pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/6b2e50c0-24bf-4bfa-a340-ebc909c34d14/core/images/pubmed-logo-blue.svg)](https://pubmed.ncbi.nlm.nih.gov/)[](https://pubmed.ncbi.nlm.nih.gov/38230766/# \"Show search bar\")\\n\\n Search:  [](https://pubmed.ncbi.nlm.nih.gov/38230766/# \"Clear search input\")Search\\n\\n[Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/)[Clipboard](https://pubmed.ncbi.nlm.nih.gov/clipboard/)\\n\\n[User Guide](https://pubmed.ncbi.nlm.nih.gov/help/)\\n\\n Save  Email \\n\\nSend to\\n\\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38230766%2F%23open-bibliography-panel)\\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38230766%2F%23open-collections-panel)\\n*   [Citation manager](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\nDisplay options\\n\\n Display options \\n\\n Format \\n\\nSave citation to file\\n---------------------\\n\\n Format:  \\n\\n Create file  Cancel \\n\\nEmail citation\\n--------------\\n\\n Subject: 1 selected item: 38230766 - PubMed\\n\\n To:  \\n\\n From:  \\n\\n Format:  \\n\\n- [x] MeSH and other data \\n\\n Send email  Cancel \\n\\n### Add to Collections\\n\\n*   Create a new collection \\n*   Add to an existing collection \\n\\n Name your collection:  \\n\\n Name must be less than 100 characters \\n\\n Choose a collection:  \\n\\n Unable to load your collection due to an error\\n\\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n Add  Cancel \\n\\n### Add to My Bibliography\\n\\n*   My Bibliography \\n\\n Unable to load your delegates due to an error\\n\\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n Add  Cancel \\n\\nYour saved search\\n-----------------\\n\\n Name of saved search:  \\n\\n Search terms:  \\n\\n[Test search terms](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n Would you like email updates of new search results? Saved Search Alert Radio Buttons\\n*   Yes \\n*   No \\n\\n Email:   ([change](https://www.ncbi.nlm.nih.gov/account/settings/))\\n\\n Frequency:  \\n\\n Which day?  \\n\\n Which day?  \\n\\n Report format:  \\n\\n Send at most:  \\n\\n- [x]  Send even when there aren\\'t any new results  \\n\\n Optional text in email:  \\n\\n Save  Cancel \\n\\nCreate a file for external citation management software\\n-------------------------------------------------------\\n\\n Create file  Cancel \\n\\nYour RSS Feed\\n-------------\\n\\n Name of RSS Feed:  \\n\\n Number of items displayed:  \\n\\n Create RSS  Cancel \\n\\nRSS Link  Copy \\n\\n### Full text links\\n\\n[![Image 6: Wiley full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-68-wiley-free-full-text.png) Wiley](https://onlinelibrary.wiley.com/doi/10.3322/caac.21820 \"See full text options at Wiley\")\\n\\n[Full text links](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n### Actions\\n\\nCite\\n\\nCollections\\n\\nAdd to Collections\\n\\n*   Create a new collection \\n*   Add to an existing collection \\n\\n Name your collection:  \\n\\n Name must be less than 100 characters \\n\\n Choose a collection:  \\n\\n Unable to load your collection due to an error\\n\\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n Add  Cancel \\n\\nDisplay options\\n\\n Display options \\n\\n Format \\n\\n### Share\\n\\n*   [](http://twitter.com/intent/tweet?text=Cancer%20statistics%2C%202024%20https%3A//pubmed.ncbi.nlm.nih.gov/38230766/ \"Share article on Twitter\")\\n*   [](http://www.facebook.com/sharer/sharer.php?u=https%3A//pubmed.ncbi.nlm.nih.gov/38230766/ \"Share article on Facebook\")\\n*    Permalink  Copy   \\n\\n### Page navigation\\n\\n*   [Title & authors](https://pubmed.ncbi.nlm.nih.gov/38230766/#heading)\\n*   [Erratum in](https://pubmed.ncbi.nlm.nih.gov/38230766/#linked-correction-forward)\\n*   [Abstract](https://pubmed.ncbi.nlm.nih.gov/38230766/#abstract)\\n*   [Similar articles](https://pubmed.ncbi.nlm.nih.gov/38230766/#similar)\\n*   [Cited by](https://pubmed.ncbi.nlm.nih.gov/38230766/#citedby)\\n*   [References](https://pubmed.ncbi.nlm.nih.gov/38230766/#references)\\n*   [MeSH terms](https://pubmed.ncbi.nlm.nih.gov/38230766/#mesh-terms)\\n*   [Related information](https://pubmed.ncbi.nlm.nih.gov/38230766/#related-links)\\n*   [LinkOut - more resources](https://pubmed.ncbi.nlm.nih.gov/38230766/#linkout)\\n\\n CA Cancer J Clin \\n\\nActions\\n\\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22CA+Cancer+J+Clin%22%5Bjour%5D&sort=date&sort_order=desc)\\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22CA+Cancer+J+Clin%22%5BTitle+Abbreviation%5D)\\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n. 2024 Jan-Feb;74(1):12-49.\\n\\n doi: 10.3322/caac.21820.  Epub 2024 Jan 17. \\n\\nCancer statistics, 2024\\n=======================\\n\\n[Rebecca L Siegel](https://pubmed.ncbi.nlm.nih.gov/?term=Siegel+RL&cauthor_id=38230766)[1](https://pubmed.ncbi.nlm.nih.gov/38230766/#full-view-affiliation-1 \"Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\"),[Angela N Giaquinto](https://pubmed.ncbi.nlm.nih.gov/?term=Giaquinto+AN&cauthor_id=38230766)[1](https://pubmed.ncbi.nlm.nih.gov/38230766/#full-view-affiliation-1 \"Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\"),[Ahmedin Jemal](https://pubmed.ncbi.nlm.nih.gov/?term=Jemal+A&cauthor_id=38230766)[2](https://pubmed.ncbi.nlm.nih.gov/38230766/#full-view-affiliation-2 \"Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.\")\\n\\n Affiliations  Expand \\n\\n### Affiliations\\n\\n*   1 Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\\n*   2 Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.\\n\\n*    PMID: **38230766**\\n*    DOI: [10.3322/caac.21820](https://doi.org/10.3322/caac.21820)\\n\\nFree article\\n\\n Item in Clipboard \\n\\nCancer statistics, 2024\\n=======================\\n\\nRebecca L Siegel et al. CA Cancer J Clin.2024 Jan-Feb.\\n\\nFree article\\n\\nShow details\\n\\nDisplay options\\n\\n Display options \\n\\n Format \\n\\n CA Cancer J Clin \\n\\nActions\\n\\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22CA+Cancer+J+Clin%22%5Bjour%5D&sort=date&sort_order=desc)\\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22CA+Cancer+J+Clin%22%5BTitle+Abbreviation%5D)\\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n. 2024 Jan-Feb;74(1):12-49.\\n\\n doi: 10.3322/caac.21820.  Epub 2024 Jan 17. \\n\\n### Authors\\n\\n[Rebecca L Siegel](https://pubmed.ncbi.nlm.nih.gov/?term=Siegel+RL&cauthor_id=38230766)[1](https://pubmed.ncbi.nlm.nih.gov/38230766/#short-view-affiliation-1 \"Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\"),[Angela N Giaquinto](https://pubmed.ncbi.nlm.nih.gov/?term=Giaquinto+AN&cauthor_id=38230766)[1](https://pubmed.ncbi.nlm.nih.gov/38230766/#short-view-affiliation-1 \"Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\"),[Ahmedin Jemal](https://pubmed.ncbi.nlm.nih.gov/?term=Jemal+A&cauthor_id=38230766)[2](https://pubmed.ncbi.nlm.nih.gov/38230766/#short-view-affiliation-2 \"Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.\")\\n\\n### Affiliations\\n\\n*   1 Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.\\n*   2 Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.\\n\\n*    PMID: **38230766**\\n*    DOI: [10.3322/caac.21820](https://doi.org/10.3322/caac.21820)\\n\\n Item in Clipboard \\n\\n Full text links Cite\\n\\nDisplay options\\n\\n Display options \\n\\n Format \\n\\nErratum in\\n----------\\n\\n*   [Erratum to \"Cancer statistics, 2024\".](https://pubmed.ncbi.nlm.nih.gov/38363123/)[No authors listed][No authors listed]CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. Epub 2024 Feb 16.CA Cancer J Clin. 2024.PMID: 38363123 No abstract available.  \\n\\nAbstract\\n--------\\n\\nEach year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers. Incidence rates increased during 2015-2019 by 0.6%-1% annually for breast, pancreas, and uterine corpus cancers and by 2%-3% annually for prostate, liver (female), kidney, and human papillomavirus-associated oral cancers and for melanoma. Incidence rates also increased by 1%-2% annually for cervical (ages 30-44 years) and colorectal cancers (ages <55 years) in young adults. Colorectal cancer was the fourth-leading cause of cancer death in both men and women younger than 50 years in the late-1990s but is now first in men and second in women. Progress is also hampered by wide persistent cancer disparities; compared to White people, mortality rates are two-fold higher for prostate, stomach and uterine corpus cancers in Black people and for liver, stomach, and kidney cancers in Native American people. Continued national progress will require increased investment in cancer prevention and access to equitable treatment, especially among American Indian and Alaska Native and Black individuals.\\n\\n**Keywords:** cancer cases; cancer statistics; death rates; incidence; mortality.\\n\\n© 2024 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.\\n\\n[PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nSimilar articles\\n----------------\\n\\n*   [Laboratory-Confirmed Influenza-Associated Hospitalizations Among Children and Adults - Influenza Hospitalization Surveillance Network, United States, 2010-2023.](https://pubmed.ncbi.nlm.nih.gov/39471107/)Naquin A, O\\'Halloran A, Ujamaa D, Sundaresan D, Masalovich S, Cummings CN, Noah K, Jain S, Kirley PD, Alden NB, Austin E, Meek J, Yousey-Hindes K, Openo K, Witt L, Monroe ML, Henderson J, Nunez VT, Lynfield R, McMahon M, Shaw YP, McCahon C, Spina N, Engesser K, Tesini BL, Gaitan MA, Shiltz E, Lung K, Sutton M, Hendrick MA, Schaffner W, Talbot HK, George A, Zahid H, Reed C, Garg S, Bozio CH.Naquin A, et al.MMWR Surveill Summ. 2024 Oct 31;73(6):1-18. doi: 10.15585/mmwr.ss7706a1.MMWR Surveill Summ. 2024.PMID: 39471107 Free PMC article.  \\n*   [The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.](https://pubmed.ncbi.nlm.nih.gov/26571284/)Walter H, Sadeque-Iqbal F, Ulysse R, Castillo D, Fitzpatrick A, Singleton J.Walter H, et al.JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.JBI Database System Rev Implement Rep. 2015.PMID: 26571284  \\n*   [Ten Americas: a systematic analysis of life expectancy disparities in the USA.](https://pubmed.ncbi.nlm.nih.gov/39581204/)Dwyer-Lindgren L, Baumann MM, Li Z, Kelly YO, Schmidt C, Searchinger C, La Motte-Kerr W, Bollyky TJ, Mokdad AH, Murray CJ.Dwyer-Lindgren L, et al.Lancet. 2024 Dec 7;404(10469):2299-2313. doi: 10.1016/S0140-6736(24)01495-8. Epub 2024 Nov 21.Lancet. 2024.PMID: 39581204 Free PMC article.  \\n*   [Trends in Surgical and Nonsurgical Aesthetic Procedures: A 14-Year Analysis of the International Society of Aesthetic Plastic Surgery-ISAPS.](https://pubmed.ncbi.nlm.nih.gov/39103642/)Triana L, Palacios Huatuco RM, Campilgio G, Liscano E.Triana L, et al.Aesthetic Plast Surg. 2024 Oct;48(20):4217-4227. doi: 10.1007/s00266-024-04260-2. Epub 2024 Aug 5.Aesthetic Plast Surg. 2024.PMID: 39103642 Review.  \\n*   [Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.](https://pubmed.ncbi.nlm.nih.gov/39119869/)Swierz MJ, Storman D, Mitus JW, Hetnal M, Kukielka A, Szlauer-Stefanska A, Pedziwiatr M, Wolff R, Kleijnen J, Bala MM.Swierz MJ, et al.Cochrane Database Syst Rev. 2024 Aug 9;8(8):CD012757. doi: 10.1002/14651858.CD012757.pub2.Cochrane Database Syst Rev. 2024.PMID: 39119869 Review.  \\n\\nSee all similar articles\\n\\nCited by\\n--------\\n\\n*   [Hydrogels with Essential Oils: Recent Advances in Designs and Applications.](https://pubmed.ncbi.nlm.nih.gov/39451288/)Chelu M.Chelu M.Gels. 2024 Sep 30;10(10):636. doi: 10.3390/gels10100636.Gels. 2024.PMID: 39451288 Free PMC article.Review.  \\n*   [Lymphopenia Induced by Different Neoadjuvant Chemo-Radiotherapy Schedules in Patients with Rectal Cancer: Bone Marrow as an Organ at Risk.](https://pubmed.ncbi.nlm.nih.gov/39451733/)Nanos C, Koukourakis IM, Mulita A, Avgousti R, Kouloulias V, Zygogianni A, Koukourakis MI.Nanos C, et al.Curr Oncol. 2024 Sep 25;31(10):5774-5788. doi: 10.3390/curroncol31100429.Curr Oncol. 2024.PMID: 39451733 Free PMC article.  \\n*   [The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/39497717/)Chen Z, Fu X, Zhu L, Wen X, Zhang S.Chen Z, et al.Front Oncol. 2024 Oct 21;14:1448336. doi: 10.3389/fonc.2024.1448336. eCollection 2024.Front Oncol. 2024.PMID: 39497717 Free PMC article.  \\n*   [Global, reginal, national burden and risk factors in female breast cancer from 1990 to 2021.](https://pubmed.ncbi.nlm.nih.gov/39435147/)Lan T, Lu Y, He J, Zhan C, Wang X, Shao X, Hu Z.Lan T, et al.iScience. 2024 Sep 25;27(10):111045. doi: 10.1016/j.isci.2024.111045. eCollection 2024 Oct 18.iScience. 2024.PMID: 39435147 Free PMC article.  \\n*   [Blestriarene C exerts an inhibitory effect on triple-negative breast cancer through multiple signaling pathways.](https://pubmed.ncbi.nlm.nih.gov/39502536/)An J, Han M, Tang H, Peng C, Huang W, Peng F.An J, et al.Front Pharmacol. 2024 Oct 22;15:1434812. doi: 10.3389/fphar.2024.1434812. eCollection 2024.Front Pharmacol. 2024.PMID: 39502536 Free PMC article.  \\n\\nSee all \"Cited by\" articles\\n\\nReferences\\n----------\\n\\n#### REFERENCES\\n\\n1.       1.    Chen R, Aschmann HE, Chen YH, et al. Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020. JAMA Intern Med. 2022;182(7):776-778. doi:10.1001/jamainternmed.2022.1461 \\n\\n2.       1.    Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess deaths from COVID-19 and other causes in the US, March 1, 2020, to January 2, 2021. JAMA. 2021;325(17):1786. doi:10.1001/jama.2021.5199 \\n\\n3.       1.    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 8 Registries, November 2022 Submission (1975-2020)-Linked To County Attributes-Time Dependent (1990-2021) Income/Rurality, 1969-2021 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2023. \\n\\n4.       1.    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 9 Registries (1975-2018). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021. \\n\\n5.       1.    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Limited-Field Data, 22 Registries (excluding Illinois and Massachusetts), November 2022 Submission (2000-2020)-Linked To County Attributes-Time Dependent (1990-2021) Income/Rurality, 1969-2021 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2023. \\n\\n Show all 153 references \\n\\nMeSH terms\\n----------\\n\\n*   \\n Female \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Female)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Humans \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Humans)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Incidence \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Incidence%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Incidence)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Male \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Male)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Melanoma* \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%22%5BMAJR%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Neoplasms* / epidemiology \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fepidemiology%22%5BMAJR%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Neoplasms* / therapy \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Registries \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Registries%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Registries)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Smoking \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Smoking%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Smoking)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n United States / epidemiology \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22United+States%2Fepidemiology%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=United+States)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n White \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22White%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=White)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n*   \\n Young Adult \\n\\nActions \\n\\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Young+Adult%22%5BMeSH%5D&sort=date&sort_order=desc)\\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Young+Adult)\\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\nRelated information\\n-------------------\\n\\n*   [Cited in Books](https://www.ncbi.nlm.nih.gov/books?linkname=pubmed_books_refs&from_uid=38230766 \"PubMed links associated with Books\")\\n*   [MedGen](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=38230766 \"Related information in MedGen\")\\n\\nLinkOut - more resources\\n------------------------\\n\\n*   ### Full Text Sources\\n\\n    *   [Wiley](https://onlinelibrary.wiley.com/doi/10.3322/caac.21820)\\n\\n*   ### Medical\\n\\n    *   [MedlinePlus Health Information](https://medlineplus.gov/cancer.html)\\n\\n**Full text links**[x]\\n\\n[![Image 7: Wiley full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-68-wiley-free-full-text.png) Wiley](https://onlinelibrary.wiley.com/doi/10.3322/caac.21820 \"See full text options at Wiley\")\\n\\n[x]\\n\\nCite\\n\\n Copy Download .nbib.nbib\\n\\nFormat: \\n\\n**Send To**\\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n*   [Email](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n*   [Save](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38230766%2F%23open-bibliography-panel)\\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38230766%2F%23open-collections-panel)\\n*   [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/38230766/#)\\n\\n[x]\\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/)[PMC](https://www.ncbi.nlm.nih.gov/pmc/)[Bookshelf](https://www.ncbi.nlm.nih.gov/books)[Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\nFollow NCBI\\n\\n[](https://twitter.com/ncbi)[](https://www.facebook.com/ncbi.nlm)[](https://www.linkedin.com/company/ncbinlm)[](https://github.com/ncbi)[](https://ncbiinsights.ncbi.nlm.nih.gov/)\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\n*   [](https://twitter.com/NLM_NIH)\\n*   [](https://www.facebook.com/nationallibraryofmedicine)\\n*   [](https://www.youtube.com/user/NLMNIH)\\n\\nNational Library of Medicine\\n\\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\\n\\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\\n\\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)\\n\\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\\n\\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\\n\\n*   [NLM](https://www.nlm.nih.gov/)\\n*   [NIH](https://www.nih.gov/)\\n*   [HHS](https://www.hhs.gov/)\\n*   [USA.gov](https://www.usa.gov/)\\n'},\n",
       "  {'title': 'Cdc Wonder',\n",
       "   'url': 'https://wonder.cdc.gov/',\n",
       "   'content': 'CDC WONDER Skip directly to page options Skip directly to A-Z link CDC WONDER Centers for Disease Control and Prevention. Home CDC WONDER FAQs Help Contact Us WONDER Search Facebook Twitter LinkedIn Email Syndicate CDC WONDER WONDER online databases utilize a rich ad-hoc query system for the analysis of public health data. Reports and other query systems are also available. WONDER Systems Topics A-Z Index WONDER Online Databases AIDS Public Use Data Births Cancer Statistics Deaths: All Ages: Underlying Cause of Death Multiple Cause of Death (Provisional) Multiple Cause of Death (Final) U.S. - Mexico Border Area Mortality Compressed Mortality Fetal Deaths Infant Deaths Environment: Heat Wave Days May-September Daily Air Temperatures & Heat Index Daily Land Surface Temperatures Daily Fine Particulate Matter Daily Sunlight Daily Precipitation Online Tuberculosis Information System Population: Bridged-Race Population (from NCHS) Single-Race Population (from Census) Population Projections (from Census) Sexually Transmitted Disease Morbidity Vaccine Adverse Event Reporting National Notifiable Conditions NNDSS Annual Summary Data Query NNDSS Annual Tables NNDSS Weekly Tables Other Query Systems Healthy People Denotes numerical data available to query or download Page last reviewed: March 18, 2025 Content source: CDC WONDER WONDER Search Search WONDER Info What is WONDER?',\n",
       "   'score': 0.1208016,\n",
       "   'raw_content': 'CDC WONDER\\n===============\\n\\n[Skip directly to page options](https://wonder.cdc.gov/#share-nav) [Skip directly to A-Z link](https://wonder.cdc.gov/#az-large)\\n\\n[CDC WONDER](https://wonder.cdc.gov/)\\n\\n[Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/)\\n\\nSearch\\n\\nSearch Menu Navigation Menu\\n\\n ×\\n\\nSubmit\\n\\nFor a full list of topics: [A-Z Index](https://www.cdc.gov/az/)\\n\\n  \\n\\n*   [What is WONDER?](https://wonder.cdc.gov/wonder/help/main.html#What%20is%20WONDER)\\n*   [Frequently Asked Questions](https://wonder.cdc.gov/wonder/help/faq.html)\\n*   [Data Use Restrictions](https://wonder.cdc.gov/datause.html)\\n*   [Data Collections](https://wonder.cdc.gov/datasets.html)\\n*   [Citations](https://wonder.cdc.gov/wonder/help/faq.html#8)\\n*   [Republishing WONDER Data](https://wonder.cdc.gov/wonder/help/faq.html#10)\\n*   [What\\'s New?](https://wonder.cdc.gov/whatsnew.html)\\n*   [Home](https://wonder.cdc.gov/)\\n\\n[CDC WONDER](https://wonder.cdc.gov/)\\n\\n[FAQs](https://wonder.cdc.gov/wonder/help/faq.html) [Help](https://wonder.cdc.gov/wonder/help/main.html) [Contact Us](https://wonder.cdc.gov/controller/datarequest?stage=contactus&action=start) [WONDER Search](https://wonder.cdc.gov/controller/datarequest?stage=search&action=current)\\n\\n*   [Facebook](https://www.facebook.com/sharer/sharer.php?u=undefined)\\n*   [Twitter](http://twitter.com/share?url=undefined&text=CDC%20WONDER)\\n*   [LinkedIn](https://www.linkedin.com/shareArticle?url=undefined&title=CDC%20WONDER)\\n*   [Email](https://api.addthis.com/oexchange/0.8/forward/email/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png)\\n*   [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https://wonder.cdc.gov/)\\n\\nCDC WONDER\\n==========\\n\\nWONDER online databases utilize a rich ad-hoc query system for the analysis of public health data. Reports and other query systems are also available.\\n\\n*   WONDER Systems\\n*   [Topics](https://wonder.cdc.gov/welcomet.html \"Health related applications and documentation hosted by various sources, sorted by topic\")\\n*   [A-Z Index](https://wonder.cdc.gov/welcomea.html \"Health related applications and documentation hosted by various sources, sorted alphabetically\")\\n\\nWONDER Online Databases\\n-----------------------\\n\\n*   ![Image 1: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [AIDS Public Use Data](https://wonder.cdc.gov/aidspublic.html \"HIV/AIDS Reporting System case reports for years 1981-2002\")\\n*   ![Image 2: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Births](https://wonder.cdc.gov/natality.html \"Natality:  birth certificate data for years 1995 through last month\")\\n*   ![Image 3: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Cancer Statistics](https://wonder.cdc.gov/cancer.html \"Cancer registry case reports of invasive cancer incidence, and cancer deaths for years 1999-2021\")  \\n    \\n*   ### Deaths:\\n    \\n    *   #### All Ages:\\n        \\n        *   ![Image 4: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Underlying Cause of Death](https://wonder.cdc.gov/deaths-by-underlying-cause.html \"Underlying cause of death from death certificates for years 1999-2022 (final)\")\\n        *   ![Image 5: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Multiple Cause of Death (Provisional)](https://wonder.cdc.gov/mcd.html \"Multiple (underlying and contributing) causes of death from death certificates for years 2018 through last week (provisional)\")\\n        *   ![Image 6: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Multiple Cause of Death (Final)](https://wonder.cdc.gov/mcd.html \"Multiple (underlying and contributing) causes of death from death certificates for years 1999-2022 (final)\")\\n        *   ![Image 7: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [U.S. - Mexico Border Area Mortality](https://wonder.cdc.gov/ucd-border.html \"U.S. - Mexico border area mortality by multiple causes (both underlying and contributing) from death certificates for years 1999-2020 \")\\n        *   ![Image 8: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Compressed Mortality](https://wonder.cdc.gov/mortsql.html \"Underlying cause of death from death certificates for years 1968-2016\")\\n    *   ![Image 9: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Fetal Deaths](https://wonder.cdc.gov/fetal.html \"Fetal Deaths: data for years 2005-2022\")\\n    *   ![Image 10: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Infant Deaths](https://wonder.cdc.gov/lbd.html \"Linked birth and death certificates for years 1995-2022\")\\n*   ### Environment:\\n    \\n    *   ![Image 11: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Heat Wave Days May-September](https://wonder.cdc.gov/nca-heatwavedays-historic.html \"National Climate Assessment - Extreme Heat Events:  Heat Wave Days in May - September for  years 1981-2010\")  \\n        \\n    *   ![Image 12: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Daily Air Temperatures & Heat Index](https://wonder.cdc.gov/nasa-nldas.html \"North America Land Data Assimilation System (NLDAS) Daily Air Temperatures and Heat Index for years 1979-2011\")  \\n        \\n    *   ![Image 13: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Daily Land Surface Temperatures](https://wonder.cdc.gov/nasa-lst.html \"Moderate Resolution Imaging Spectroradiometer (MODIS) Land Surface Temperatures (LST) for years 2003-2008\")  \\n        \\n    *   ![Image 14: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Daily Fine Particulate Matter](https://wonder.cdc.gov/nasa-pm.html \"Outdoor Air Quality - Daily Fine Particulate Matter(PM2.5)(µg/m³) for years 2003-2011\")  \\n        \\n    *   ![Image 15: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Daily Sunlight](https://wonder.cdc.gov/nasa-insolar.html \"North America Land Data Assimilation System (NLDAS) Daily Sunlight (Insolation) for years 1979-2011\")  \\n        \\n    *   ![Image 16: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Daily Precipitation](https://wonder.cdc.gov/nasa-precipitation.html \"North America Land Data Assimilation System (NLDAS) Daily Precipitation (mm) for years 1979-2011\")  \\n        \\n*   ![Image 17: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Online Tuberculosis Information System](https://wonder.cdc.gov/tb.html \"TB case report data for years 1993-2022 in OTIS\")\\n*   ### Population:\\n    \\n    *   ![Image 18: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Bridged-Race Population (from NCHS)](https://wonder.cdc.gov/bridged-race-population.html \"Bridged-race population estimates for years 1990-2020\")\\n    *   ![Image 19: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Single-Race Population (from Census)](https://wonder.cdc.gov/single-race-population.html \"Single-race population estimates for years 2010-2022\")\\n    *   ![Image 20: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Population Projections (from Census)](https://wonder.cdc.gov/population.html \"Population projections: national 2014-2060, state 2004-2030\")\\n*   ![Image 21: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Sexually Transmitted Disease Morbidity](https://wonder.cdc.gov/std.html \"STD case report data for years 1984-2014\")\\n*   ![Image 22: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Vaccine Adverse Event Reporting](https://wonder.cdc.gov/vaers.html \"Adverse event reports after vaccination since 1990, updated monthly\")\\n\\nNational Notifiable Conditions\\n------------------------------\\n\\n*   ![Image 23: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [NNDSS Annual Summary Data Query](https://wonder.cdc.gov/nndss-annual-summary.html \"Annual cases of National Notifiable infectious conditions with interactive queries, maps and charts\")\\n*   ![Image 24: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [NNDSS Annual Tables](https://wonder.cdc.gov/wonder/outside/nndss-tables.html \"Annual cases of National Notifiable infectious conditions in published tables\")\\n*   ![Image 25: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [NNDSS Weekly Tables](https://wonder.cdc.gov/wonder/outside/nndss-tables.html \"Case reports of selected National Notifiable infectious conditions, updated weekly in published tables\")\\n\\nOther Query Systems\\n-------------------\\n\\n*   ![Image 26: numerical data available](https://wonder.cdc.gov/images/tri-right.gif) [Healthy People](https://wonder.cdc.gov/wonder/outside/data2010.html \"Healthy People and Data2010 data for measuring progress towards health goals\")\\n\\n![Image 27](https://wonder.cdc.gov/images/tri-right.gif) Denotes numerical data available to query or download\\n\\nPage last reviewed: March 18, 2025\\n\\nContent source: [CDC WONDER](https://wonder.cdc.gov/)\\n\\nWONDER Search\\n\\n  Search   \\n\\nWONDER Info\\n\\n*   [What is WONDER?](https://wonder.cdc.gov/wonder/help/main.html#What%20is%20WONDER)\\n*   [Frequently Asked Questions](https://wonder.cdc.gov/wonder/help/faq.html)\\n*   [Data Use Restrictions](https://wonder.cdc.gov/datause.html)\\n*   [Data Collections](https://wonder.cdc.gov/datasets.html)\\n*   [Citations](https://wonder.cdc.gov/wonder/help/faq.html#8)\\n*   [Republishing WONDER Data](https://wonder.cdc.gov/wonder/help/faq.html#10)\\n*   [What\\'s New?](https://wonder.cdc.gov/whatsnew.html)\\n\\n**HAVE QUESTIONS?**\\n\\n[Visit CDC-INFO](https://www.cdc.gov/cdc-info/index.html)\\n\\nCall 800-232-4636\\n\\n[Email CDC-INFO](https://wwwn.cdc.gov/dcs/contactus/form)\\n\\n**CDC INFORMATION**\\n\\n*   [About CDC](https://www.cdc.gov/about/default.htm)\\n*   [Jobs](https://jobs.cdc.gov/)\\n*   [Funding](https://www.cdc.gov/funding)\\n*   [Policies](https://www.cdc.gov/Other/policies.html)\\n*   [File Viewers & Players](https://www.cdc.gov/other/plugins/index.html)\\n\\n*   [Privacy](https://www.cdc.gov/Other/policies.html)\\n*   [FOIA](https://www.cdc.gov/od/foia)\\n*   [No Fear Act](https://www.cdc.gov/eeo/nofearact/index.htm)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Accessibility](https://www.cdc.gov/contact/accessibility.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) | [Español](https://www.hhs.gov/es/vulnerability-disclosure-policy/index.html)\\n\\n**CONNECT WITH CDC**  \\n\\n*   [Facebook](https://www.facebook.com/CDC)\\n*   [Twitter](https://twitter.com/CDCgov)\\n*   [Youtube](https://www.youtube.com/user/CDCstreamingHealth)\\n*   [Instagram](https://www.instagram.com/CDCgov/)\\n\\n  \\n\\n*   [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https://wonder.cdc.gov/)\\n*   [CDC TV](https://www.cdc.gov/cdctv)\\n*   [RSS](https://tools.cdc.gov/podcasts/rss.asp)\\n*   [Email](https://wwwn.cdc.gov/dcs/RequestForm.aspx)\\n\\n[U.S. Department of Health & Human Services](https://www.hhs.gov/)\\n\\n[USA.gov](https://www.usa.gov/)\\n\\n[CDC Website Exit Disclaimer](https://www.cdc.gov/Other/disclaimer.html) external icon\\n\\n*   [Facebook](https://www.facebook.com/sharer/sharer.php?u=undefined)\\n*   [Twitter](http://twitter.com/share?url=undefined&text=CDC%20WONDER)\\n*   [LinkedIn](https://www.linkedin.com/shareArticle?url=undefined&title=CDC%20WONDER)\\n*   [Email](https://api.addthis.com/oexchange/0.8/forward/email/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png)\\n\\n#### Exit Notification/Disclaimer Policy\\n\\nClose\\n\\n**Links with this icon indicate that you are leaving the CDC website.**\\n\\n*   The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.\\n*   Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.\\n*   You will be subject to the destination website\\'s privacy policy when you follow the link.\\n*   CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.\\n\\nFor more information on CDC\\'s web notification policies, see [Website Disclaimers](https://www.cdc.gov/Other/disclaimer.html).\\n\\nCancel Continue\\n\\n*   [Facebook](https://www.facebook.com/sharer/sharer.php?u=undefined)\\n*   [Twitter](http://twitter.com/share?url=undefined&text=CDC%20WONDER)\\n*   [LinkedIn](https://www.linkedin.com/shareArticle?url=undefined&title=CDC%20WONDER)\\n*   [Email](https://api.addthis.com/oexchange/0.8/forward/email/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png)\\n'},\n",
       "  {'title': 'NHANES Questionnaires, Datasets, and Related Documentation',\n",
       "   'url': 'https://wwwn.cdc.gov/nchs/nhanes/Default.aspx',\n",
       "   'content': 'Conducted in 2012, the NHANES National Youth Fitness Survey (NNYFS) was a one-time survey to collect data on physical activity and fitness levels in order to provide an evaluation of the health and fitness of children and teens in the U.S. ages 3 to 15 years. Conducted from 1988-1994, the third National Health and Nutrition Examination Survey (NHANES III) focused on oversampling many groups within the U.S. population aged 2 months and over. Conducted from 1976-1980, the second National Health and Nutrition Examination Survey (NHANES II) focused on nutrition and health, but the age of participation started at 6 month. Conducted from 1959-1962, the first National Health Examination Survey (NHES I) focused on chronic disease in the U.S. population aged 18-79.',\n",
       "   'score': 0.1188243,\n",
       "   'raw_content': '![National Health and Nutrition Examination Survey](https://www.cdc.gov/nchs/nhanes/wcms-inc/VP4_935_NHANES.png)\\n\\n# NHANES Questionnaires, Datasets, and Related Documentation\\n\\nPlan & Operations, Sample Design, Estimation & Weighting Procedures, Analytic Guidelines, etc.\\n\\nSimple keyword search for Continuous NHANES (1999 and on) variables\\n\\n### Continuous NHANES\\n\\n### NHANES Ancillary Studies\\n\\nConducted in 2012, the NHANES National Youth Fitness Survey (NNYFS) was a one-time survey to collect data on physical activity and fitness levels in order to provide an evaluation of the health and fitness of children and teens in the U.S. ages 3 to 15 years. The NNYFS collected data on physical activity and fitness levels through interviews and fitness tests.\\n\\nConducted in 1986, 1987, and 1992 , the NHANES I Epidemiologic Follow-up Study (NHEFS) was a national longitudinal study designed to investigate the relationships between clinical, nutritional, and behavioral factors assessed in the NHANES I and subsequent morbidity, mortality, and hospital utilization, as well as changes in risk factors, functional limitation, and institutionalization.\\n\\n### NHANES Prior to 1999\\n\\nConducted from 1988-1994, the third National Health and Nutrition Examination Survey (NHANES III) focused on oversampling many groups within the U.S. population aged 2 months and over. These oversampled groups included children aged 2 months to 5 years, persons over age 60, Mexican-American persons, and non-Hispanic black persons. This survey also concentrated on health and nutrition but additionally began to collect environmental exposure and infectious disease data.\\n\\nConducted from 1976-1980, the second National Health and Nutrition Examination Survey (NHANES II) focused on nutrition and health, but the age of participation started at 6 month. The maximum age remained 74 years.\\n\\nConducted from 1971-1974, the National Health Examination Survey added a nutrition component and was renamed the National Health and Nutrition Examination Survey (NHANES I). The first NHANES focused on the U.S. population aged 1-74. In 1974-1975, there was an augmentation to the survey on an additional national sample. \\xa0This augmentation sample only included adults aged 25-74 and did not oversample any population groups nor include nutrition data.\\n\\nDuring 1982-1984, NHANES temporarily shifted to a population-specific survey. The Hispanic Health and Nutrition Survey (HHANES) focused on health and nutrition, but involved only the 3 largest Hispanic subgroups in the U.S. at the time aged 6 months to 74 years: \\xa0Mexican-American persons residing in the Southwest, Cuban-American persons residing in Dade County Florida, and Puerto Rican persons residing in the New York City metropolitan area.\\n\\nConducted from 1966-1970, the third National Health Examination Survey (NHES III) focused on the growth and development of U.S. adolescents aged 12-17. Approximately 1/3 of the examined adolescents in NHES III were previously examined in NHES II.\\n\\nConducted from 1963-1965, the second National Health Examination Survey (NHES II) focused on the growth and development in U.S. children aged 6-11.\\n\\nConducted from 1959-1962, the first National Health Examination Survey (NHES I) focused on chronic disease in the U.S. population aged 18-79.'},\n",
       "  {'title': 'Drugs@FDA - Food and Drug Administration',\n",
       "   'url': 'https://open.fda.gov/data/drugsfda/',\n",
       "   'content': '## Drugs@FDA Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998. ## About Drugs@FDA Drugs@FDA allows you to search for official information about FDA approved innovator (brand name) and generic drugs and therapeutic biological products. Drugs@FDA contains information about the following FDA-approved products for human use: Prescription brand-name drug products, generic drug products, and many therapeutic biological products Over-the-counter brand-name and generic drugs ## Learn more General information   Learn more about Drugs@FDA Original dataset downloads   Drugs@FDA download information ### Provider FDA ### License Public Domain and CC0',\n",
       "   'score': 0.11585087,\n",
       "   'raw_content': '## Drugs@FDA\\n\\nDrugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998.\\n\\n![]()\\n\\n## About Drugs@FDA\\n\\nDrugs@FDA allows you to search for official information about FDA approved innovator (brand name) and generic drugs and therapeutic biological products.\\n\\nDrugs@FDA contains information about the following FDA-approved products for human use:\\n\\nPrescription brand-name drug products, generic drug products, and many therapeutic biological products\\n\\nOver-the-counter brand-name and generic drugs\\n\\n## Learn more\\n\\nGeneral information  \\n[Learn more about Drugs@FDA](https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda)\\n\\nOriginal dataset downloads  \\n[Drugs@FDA download information](https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)\\n\\n### Provider\\n\\n[FDA](http://www.fda.gov/)\\n\\n### License\\n\\n[Public Domain and CC0](http://creativecommons.org/publicdomain/zero/1.0/)'},\n",
       "  {'title': 'Using reflection in nursing practice to enhance patient care',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/37005865/',\n",
       "   'content': 'Federal government websites often end in .gov or .mil. pubmed logo ## Save citation to file # Using reflection in nursing practice to enhance patient care # Using reflection in nursing practice to enhance patient care The ability to reflect on, and learn from, practice experiences is essential for nurses when seeking to provide effective person-centred care. This article outlines the various types of reflection that nurses can use, such as reflection-in-action and reflection-on-action. The article provides examples of cases and reflective activities to demonstrate how nurses can use reflection in their practice. PubMed Disclaimer The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS).',\n",
       "   'score': 0.1119482,\n",
       "   'raw_content': '![U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\\n\\nAn official website of the United States government\\n\\n![Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**\\n  \\nFederal government websites often end in .gov or .mil. Before\\nsharing sensitive information, make sure you’re on a federal\\ngovernment site.\\n\\n![Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**\\n  \\nThe **https://** ensures that you are connecting to the\\nofficial website and that any information you provide is encrypted\\nand transmitted securely.\\n\\n![NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)\\n\\n#### Account\\n\\n![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/3a9fa263-60f0-46bd-99dd-5f80dc7a99c0/core/images/pubmed-logo-blue.svg)\\n\\n## Save citation to file\\n\\n## Email citation\\n\\n### Add to Collections\\n\\n### Add to My Bibliography\\n\\n## Your saved search\\n\\n## Create a file for external citation management software\\n\\n## Your RSS Feed\\n\\n### Actions\\n\\n### Share\\n\\n### Page navigation\\n\\n# Using reflection in nursing practice to enhance patient care\\n\\n### Affiliation\\n\\n# Using reflection in nursing practice to enhance patient care\\n\\n### Author\\n\\n### Affiliation\\n\\n## Abstract\\n\\nThe ability to reflect on, and learn from, practice experiences is essential for nurses when seeking to provide effective person-centred care. This article outlines the various types of reflection that nurses can use, such as reflection-in-action and reflection-on-action. It also details some of the main models of reflection and explains how nurses might develop their skills in reflection to enhance the quality of patient care. The article provides examples of cases and reflective activities to demonstrate how nurses can use reflection in their practice.\\n\\n**Keywords:**\\ncontinuing professional development; education; nursing models and theories; professional; professional issues; reflection.\\n\\n© 2023 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers.\\n\\n[PubMed Disclaimer](/disclaimer/)\\n\\n## Conflict of interest statement\\n\\nNone declared\\n\\n## Similar articles\\n\\n## Cited by\\n\\n## MeSH terms\\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/)\\n[PMC](https://www.ncbi.nlm.nih.gov/pmc/)\\n[Bookshelf](https://www.ncbi.nlm.nih.gov/books)\\n[Disclaimer](/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike  \\nBethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)'},\n",
       "  {'title': 'Exposure to Tuberculosis | Tuberculosis (TB) | CDC',\n",
       "   'url': 'https://www.cdc.gov/tb/exposure/index.html',\n",
       "   'content': 'Contact investigations can help limit the spread of TB. If you have active TB disease, your health care worker may ask about your contacts (the people you spent time when you were able to spread TB germs). Your health care worker may conduct a contact investigation, also known as contact tracing.. Contact tracing is the process of identifying people who have recently been in contact with',\n",
       "   'score': 0.11044257,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Drug Approvals and Databases | FDA',\n",
       "   'url': 'https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases',\n",
       "   'content': \"On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes. U.S. Food and Drug Administration ================================= Search Menu Search FDA Submit search Featured Report a Product Problem Contact FDA FDA Guidance Documents Recalls, Market Withdrawals and Safety Alerts Press Announcements Warning Letters Advisory Committees En Español Products Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood, and Biologics Animal and Veterinary Cosmetics Tobacco Products Topics About FDA Combination Products Regulatory Information Safety Emergency Preparedness International Programs News and Events Training and Continuing Education Inspections and Compliance Science and Research Information For Consumers Patients Industry Health Professionals Federal, State and Local Officials In this section: Development & Approval Process | Drugs Drug Approvals and Databases Resources for Information | Approved Drugs Home Drugs Development & Approval Process | Drugs Drug Approvals and Databases Development & Approval Process | Drugs Drug Approvals and Databases Acronyms and Abbreviations Search More information Approved Risk Evaluation and Mitigation Strategies (REMS) Bioresearch Monitoring Information System (BMIS) Search More information Dissolution Methods Database Search More information Drug Establishments Current Registration Site Search More information Drug Safety-related Labeling Changes (SrLC) More information Drug Shortages More information Drugs@FDA Search More information FDA Adverse Event Reporting System (FAERS) Quarterly Data Files Downloadable data files. FDA Adverse Event Reporting System (FAERS) Public Dashboard Inactive Ingredient Search for Approved Drug Products Search More information Medication Guides Search More information National Drug Code Directory Search More information Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) Search More information OTC Monographs@FDA Outsourcing Facility Product Report Postmarketing Requirements and Commitments Searchable Database More information President's Emergency Plan for AIDS Relief (PEPFAR) Database More Information Product-Specific Guidances for Generic Drug Development Database More Information Purple Book (database of FDA-licensed (approved) biological products, including biosimilar and interchangeable products) More Information Wholesale Distributor and Third-Party Logistics Providers Reporting More information Resources Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals Novel Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products Drug and Biologic Approval and IND Activity Reports This Week's Drug Approvals Drug Trials Snapshots Oncology (Cancer) / Hematologic Malignancies Approval Notifications FDALabel FDA Online Label Repository FDA’s Labeling Resources for Human Prescription Drugs Content current as of: ---------------------- 08/08/2022 Drug Approvals and Databases Resources for Information | Approved Drugs Footer Links FDA Archive About FDA Accessibility Visitor Information Website Policies / Privacy No FEAR Act Vulnerability Disclosure Policy FOIA HHS.gov USA.gov Contact FDA Follow FDA on Facebook Follow FDA on X Follow FDA on Instagram Follow FDA on LinkedIn View FDA videos on YouTube Subscribe to FDA RSS feeds FDA Homepage Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top\",\n",
       "   'score': 0.10113599,\n",
       "   'raw_content': 'Published Time: Thu, 02/13/2025 - 15:15\\n\\nDrug Approvals and Databases | FDA\\n===============\\n\\n*   [Skip to main content](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#main-content)\\n*   [Skip to FDA Search](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#search-form)\\n*   [Skip to in this section menu](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#section-nav)\\n*   [Skip to footer links](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#footer-heading)\\n\\n![Image 1: U.S. flag](https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png) An official website of the United States government Here’s how you know\\n\\n![Image 2: Dot gov](https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**  \\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you\\'re on a federal government site.\\n\\n![Image 3: SSL](https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg)\\n\\n**The site is secure.**  \\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\nOn Oct. 1, 2024, the FDA began implementing a [reorganization](https://www.fda.gov/about-fda/fda-organization/fda-modernization-efforts-establishing-unified-human-foods-program-new-model-field-operations-and \"FDA Modernization Efforts for Establishing a Unified Human Foods Program, New Model for Field Operations and More\") impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.\\n\\n[U.S. Food and Drug Administration =================================](https://www.fda.gov/ \"FDA Homepage\")\\n\\n*   \\xa0 Search\\n*   \\xa0 [Menu](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#primary-nav)\\n\\nSearch FDA  Submit search\\n\\nFeatured\\n--------\\n\\n*   [Report a Product Problem](https://www.safetyreporting.hhs.gov/smarthub#/ \"Report a Problem with an FDA Regulated Product\")\\n*   [Contact FDA](https://www.fda.gov/about-fda/contact-fda)\\n*   [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents)\\n*   [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts)\\n*   [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements)\\n*   [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\\n*   [Advisory Committees](https://www.fda.gov/advisory-committees)\\n*   [En Español](https://www.fda.gov/fda-en-espanol)\\n\\nProducts\\n--------\\n\\n*   [Food](https://www.fda.gov/food)\\n*   [Drugs](https://www.fda.gov/drugs)\\n*   [Medical Devices](https://www.fda.gov/medical-devices)\\n*   [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products)\\n*   [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics)\\n*   [Animal and Veterinary](https://www.fda.gov/animal-veterinary)\\n*   [Cosmetics](https://www.fda.gov/cosmetics)\\n*   [Tobacco Products](https://www.fda.gov/tobacco-products)\\n\\nTopics\\n------\\n\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Combination Products](https://www.fda.gov/combination-products)\\n*   [Regulatory Information](https://www.fda.gov/regulatory-information)\\n*   [Safety](https://www.fda.gov/safety)\\n*   [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response)\\n*   [International Programs](https://www.fda.gov/international-programs)\\n*   [News and Events](https://www.fda.gov/news-events)\\n*   [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education)\\n*   [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations)\\n*   [Science and Research](https://www.fda.gov/science-research)\\n\\nInformation For\\n---------------\\n\\n*   [Consumers](https://www.fda.gov/consumers)\\n*   [Patients](https://www.fda.gov/patients)\\n*   [Industry](https://www.fda.gov/industry)\\n*   [Health Professionals](https://www.fda.gov/health-professionals)\\n*   [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials)\\n\\n[In this section: Development & Approval Process | Drugs](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases#section-nav)\\n\\n*   [Drug Approvals and Databases](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases)\\n    \\n    *   [Resources for Information | Approved Drugs](https://www.fda.gov/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\\n    \\n\\n1.  [Home](https://www.fda.gov/)\\n2.  [Drugs](https://www.fda.gov/drugs)\\n3.  [Development & Approval Process | Drugs](https://www.fda.gov/drugs/development-approval-process-drugs)\\n4.  Drug Approvals and Databases\\n\\n1.  [Development & Approval Process | Drugs](https://www.fda.gov/drugs/development-approval-process-drugs \"Development & Approval Process | Drugs\")\\n\\nDrug Approvals and Databases\\n============================\\n\\n*   [**Acronyms and Abbreviations Search**](https://www.accessdata.fda.gov/scripts/cder/acronyms/index.cfm)\\xa0  \\n    [More information](https://www.fda.gov/fda-acronyms-abbreviations \"More information\")\\n*   [**Approved Risk Evaluation and Mitigation Strategies (REMS)**](https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm)\\n*   [**Bioresearch Monitoring Information System (BMIS) Search**](https://www.accessdata.fda.gov/scripts/cder/bmis/index.cfm)\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/bioresearch-monitoring-information-system-bmis \"More information\")\\n*   [**Dissolution Methods Database Search**](https://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm)\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/dissolution-methods-database \"More information\")\\n*   [**Drug Establishments Current Registration Site Search**](https://dps.fda.gov/decrs/)\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site \"More information\")\\n*   [**Drug Safety-related Labeling Changes (SrLC)**](https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/)\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-labeling-changes-slc-database \"More information\")\\n*   [**Drug Shortages**](https://dps.fda.gov/drugshortages)\\xa0  \\n    [More information](https://dps.fda.gov/drugshortages/faq)\\n*   [**Drugs@FDA Search**](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm \"Drugs@FDA Search\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-database)\\n*   [**FDA Adverse Event Reporting System (FAERS) Quarterly Data Files**](https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files \"Inactive Ingredient Search for Approved Drug Products Search\")\\xa0  \\n    Downloadable data files.\\n*   [**FDA Adverse Event Reporting System (FAERS) Public Dashboard**](https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard)\\n*   [**Inactive Ingredient Search for Approved Drug Products Search**](https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm \"Inactive Ingredient Search for Approved Drug Products Search\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-search-approved-drug-products-frequently-asked-questions)\\n\\n*   [**Medication Guides Search**](https://dps.fda.gov/medguide/ \"Medication Guides database\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-safety-and-availability/medication-guides)\\n*   [**National Drug Code Directory Search**](https://dps.fda.gov/ndc \"National Drug Code Directory Search\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory)\\n*   [**Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) Search**](https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm \"Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) Search\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book)\\n*   [**OTC Monographs@FDA**](https://dps.fda.gov/omuf/ \"OTC Monographs@FDA\")\\n*   [**Outsourcing Facility Product Report**](https://dps.fda.gov/outsourcingfacility \"Outsourcing Facility Product Report\")\\n*   [**Postmarketing Requirements and Commitments Searchable Database**](https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm \"Postmarket Requirements and Commitments Search\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/postmarketing-requirements-and-commitments-introduction/postmarketing-requirements-and-commitments-searchable-database \"Postmarketing Requirements and Commitments: Searchable Database\")\\n*   [**President\\'s Emergency Plan for AIDS Relief (PEPFAR) Database**](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=pepfar.page)\\xa0  \\n    [More Information](https://www.fda.gov/international-programs/presidents-emergency-plan-aids-relief-pepfar \"President\\'s Emergency Plan for AIDS Relief (PEPFAR)\")\\n*   [**Product-Specific Guidances for Generic Drug Development Database**](https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm)\\xa0  \\n    [More Information](https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development \"Product-Specific Guidances for Generic Drug Development\")\\n*   [**Purple Book** (database of FDA-licensed (approved) biological products, including biosimilar and interchangeable products)](https://purplebooksearch.fda.gov/)\\xa0  \\n    [More Information](https://purplebooksearch.fda.gov/about)\\n*   [**Wholesale Distributor and Third-Party Logistics Providers Reporting**](https://dps.fda.gov/wdd3plreporting \"Wholesale Distributor and Third-Party Logistics Providers Reporting\")\\xa0  \\n    [More information](https://www.fda.gov/drugs/drug-supply-chain-security-act/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers)\\n\\nResources\\n---------\\n\\n*   [Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals](https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals \"Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals\")\\n*   [Novel Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products](https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda \"Novel Drug Approvals at FDA\")\\n*   [Drug and Biologic Approval and IND Activity Reports](https://www.fda.gov/drugs/how-drugs-are-developed-and-approved/drug-and-biologic-approval-and-ind-activity-reports \"Drug and Biologic Approval and IND Activity Reports\")\\n*   [This Week\\'s Drug Approvals](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page)\\n*   [Drug Trials Snapshots](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)\\n*   [Oncology (Cancer) / Hematologic Malignancies Approval Notifications](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications \"Oncology (Cancer)/Hematologic Malignancies Approval Notifications\")\\n*   [FDALabel](https://nctr-crs.fda.gov/fdalabel/ui/search)\\n*   [FDA Online Label Repository](https://labels.fda.gov/)\\n*   [FDA’s Labeling Resources for Human Prescription Drugs](https://www.fda.gov/drugs/laws-acts-and-rules/fdas-labeling-resources-human-prescription-drugs \"FDA’s Labeling Resources for Human Prescription Drugs\")\\n\\n  \\n  \\n\\n*   Content current as of:\\n    ----------------------\\n    \\n    08/08/2022\\n    \\n\\n*   [Drug Approvals and Databases](https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases)\\n    \\n    *   [Resources for Information | Approved Drugs](https://www.fda.gov/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\\n    \\n\\nFooter Links\\n------------\\n\\n*   [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive)\\n*   [About FDA](https://www.fda.gov/about-fda)\\n*   [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility)\\n\\n*   [Visitor Information](https://www.fda.gov/about-fda/visitor-information)\\n*   [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies)\\n*   [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n*   [FOIA](https://www.fda.gov/regulatory-information/freedom-information \"Freedom of Information Act\")\\n*   [HHS.gov](https://www.hhs.gov/ \"Health and Human Services\")\\n*   [USA.gov](https://www.usa.gov/)\\n\\n[Contact FDA](https://www.fda.gov/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA \"Follow FDA on Facebook\") [Follow FDA on X](https://x.com/US_FDA \"Follow FDA on X\") [Follow FDA on Instagram](https://instagram.com/FDA \"Follow FDA on Instagram\")  \\n[Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/ \"Follow FDA on LinkedIn\") [View FDA videos on YouTube](https://youtube.com/@US_FDA \"View FDA videos on YouTube\") [Subscribe to FDA RSS feeds](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds \"Subscribe to FDA RSS feeds\")\\n\\n[FDA Homepage](https://www.fda.gov/ \"FDA Homepage\")\\n\\nContact Number 1-888-INFO-FDA (1-888-463-6332)\\n\\nBack to Top\\n'},\n",
       "  {'title': 'Current VISs | Vaccines & Immunizations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/index.html',\n",
       "   'content': \"Current VISs | Vaccines & Immunizations | CDC Vaccines & Immunizations Vaccines By Disease Vaccines & Immunizations Menu Vaccines By Disease View All Vaccines & Immunizations Vaccines By Disease Vaccines Used in the U.S. Immunization Schedules Current VISs About VISs What's New with VISs General Best Practices for Immunization Storage and Handling View All CDC maintains a current English language VIS for each vaccine. Multi-, Routine-, & Non-Routine-Vaccine VISs Multiple Vaccines (DTaP, Hib, Hepatitis B, PCV, and Polio) interim (7/24/23) This VIS may be used in place of the individual VISs for DTaP, Hib, Hepatitis B, Polio, and PCV13 when two or more of these vaccines are administered during the same visit. Multi-, Routine-, & Non-Routine-Vaccine VISs Vaccines & Immunizations\",\n",
       "   'score': 0.10049857,\n",
       "   'raw_content': 'Current VISs | Vaccines & Immunizations | CDC\\n===============                                     \\n\\n[Skip directly to site content](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#content) [Skip directly to search](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#cdc-search)\\n\\n![Image 1: U.S. flag](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/us_flag_small.png) An official website of the United States government\\n\\n[Here\\'s how you know](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#gov-notice)\\n\\n![Image 2](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\n**Official websites use .gov**A .gov website belongs to an official government organization in the United States.\\n\\n![Image 3](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\n**Secure .gov websites use HTTPS**A **lock** ( ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n[![Image 4: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)\\n\\nExplore Topics\\n\\n[Search](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)\\n\\n Search\\n\\n[For Everyone](https://www.cdc.gov/vaccines/index.html)\\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#gen)\\n\\n[Health Care Providers](https://www.cdc.gov/vaccines/hcp/index.html)\\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html)\\n*   [About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html)\\n*   [What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html)\\n*   [General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html)\\n*   [Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#hcp)\\n\\n[Public Health](https://www.cdc.gov/vaccines/site.html#php)\\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [From Me, To You](https://www.cdc.gov/vaccines/php/from-me-to-you/index.html)\\n*   [Keeps It That Way](https://www.cdc.gov/vaccines/php/keeps-it-that-way/index.html)\\n*   [Perinatal Hep B Prevention](https://www.cdc.gov/vaccines/php/perinatal-hep-b-prevention/index.html)\\n*   [Meetings, Conferences, and Events](https://www.cdc.gov/vaccines/php/events/index.html)\\n*   [Adolescent Immunization Action Week (AIAW)](https://www.cdc.gov/vaccines/php/adolescent-immunization-action-week/index.html)\\n*   [View all](https://www.cdc.gov/vaccines/site.html#php)\\n\\n**Related Topics:**\\n\\n[Vaccines for Your Children](https://www.cdc.gov/vaccines-children/index.html) | [Vaccine Information for Adults](https://www.cdc.gov/vaccines-adults/index.html) | [Pregnancy and Vaccination](https://www.cdc.gov/vaccines-pregnancy/index.html)\\n\\n[View All](https://www.cdc.gov/vaccines/site.html)\\n\\n[![Image 5: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[_search_ _close search_](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)\\n\\nsearch \\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html) [Menu](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)\\n\\nsearch \\n\\nFor Everyone\\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#gen) [Home](https://www.cdc.gov/vaccines/index.html)\\n\\nHealth Care Providers\\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html)\\n*   [About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html)\\n*   [What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html)\\n*   [General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html)\\n*   [Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#hcp) [Home](https://www.cdc.gov/vaccines/hcp/index.html)\\n\\nPublic Health\\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [From Me, To You](https://www.cdc.gov/vaccines/php/from-me-to-you/index.html)\\n*   [Keeps It That Way](https://www.cdc.gov/vaccines/php/keeps-it-that-way/index.html)\\n*   [Perinatal Hep B Prevention](https://www.cdc.gov/vaccines/php/perinatal-hep-b-prevention/index.html)\\n*   [Meetings, Conferences, and Events](https://www.cdc.gov/vaccines/php/events/index.html)\\n*   [Adolescent Immunization Action Week (AIAW)](https://www.cdc.gov/vaccines/php/adolescent-immunization-action-week/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#php)\\n\\nRelated Topics\\n\\n*   [Vaccines for Your Children](https://www.cdc.gov/vaccines-children/index.html)\\n*   [Vaccine Information for Adults](https://www.cdc.gov/vaccines-adults/index.html)\\n*   [Pregnancy and Vaccination](https://www.cdc.gov/vaccines-pregnancy/index.html)\\n\\n[View All Vaccines & Immunizations](https://www.cdc.gov/vaccines/site.html)\\n\\n[Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html) [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html) [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html) [Current VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html) [About VISs](https://www.cdc.gov/vaccines/hcp/about-vis/index.html) [What\\'s New with VISs](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html) [General Best Practices for Immunization](https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html) [Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling/index.html) [View All](https://www.cdc.gov/vaccines/site.html)\\n\\nFebruary 28, 2025\\n\\nCurrent VISs\\n============\\n\\nOverview\\n--------\\n\\n[Download all VISs](https://www.cdc.gov/vaccines/hcp/current-vis/downloads/vis.zip)\\n\\n### COVID-19 Vaccine EUA Fact Sheets\\n\\nCurrently, providers are required by law to provide EUA fact sheets to vaccine recipients or their caregivers for all uses of [Novavax](https://www.fda.gov/media/159897/download) and when [Moderna](https://www.fda.gov/media/167209/download?attachment) or [Pfizer](https://www.fda.gov/media/167212/download?attachment) vaccines are given to children 6 months through 11 years of age. For recipients who are 12 or older receiving Pfizer or Moderna vaccine, a provider may use the COVID-19 Vaccine Information Statement (VIS).\\n\\n[Find more information](https://www.cdc.gov/vaccines/covid-19/hcp/index.html)\\n\\nCDC maintains a current English language VIS for each vaccine. You and your patients can\\n\\n*   View and display the web page\\n    \\n*   Download and print the PDF file\\n    \\n*   Import the RTF (text) file into an electronic system\\n    \\n*   View on a smartphone, tablet or other web-accessible mobile device\\n    \\n\\n### What Do Dates & Interim Mean?\\n\\n*   The date next to each VIS is the most recent version.\\n    \\n*   The Interim version is to be used until the final version is available.\\n    *   See [What\\'s New](https://www.cdc.gov/vaccines/hcp/whats-new-vis/index.html) to learn when the final version should be available.\\n        \\n\\nSee [FAQs](https://www.cdc.gov/vaccines/hcp/about-vis/faq.html#cdc_faqs_cat3-new-and-updated-viss) on when to start using a new VIS.\\n\\nMulti-, Routine-, & Non-Routine-Vaccine VISs\\n--------------------------------------------\\n\\n### Multi\\n\\n*   [Multiple Vaccines (DTaP, Hib, Hepatitis B, PCV, and Polio)](https://www.cdc.gov/vaccines/hcp/current-vis/childs-first.html) interim (7/24/23)\\n    *   This VIS may be used in place of the individual VISs for DTaP, Hib, Hepatitis B, Polio, and PCV13 when two or more of these vaccines are administered during the same visit. It may be used for infants through children receiving their routine 4–6 year vaccines.\\n        \\n\\n### Routine\\n\\n*   [COVID-19](https://www.cdc.gov/vaccines/hcp/current-vis/covid-19.html) (1/31/2025)\\n    \\n*   [Dengue](https://www.cdc.gov/vaccines/hcp/current-vis/dengue.html) (1/31/2025)\\n    \\n*   [DTaP (Diphtheria, Tetanus, Pertussis)](https://www.cdc.gov/vaccines/hcp/current-vis/dtap.html) (8/6/21)\\n    \\n*   [Hepatitis A](https://www.cdc.gov/vaccines/hcp/current-vis/hepatitis-a.html) (1/31/2025)\\n    \\n*   [Hepatitis B](https://www.cdc.gov/vaccines/hcp/current-vis/hepatitis-b.html) (1/31/2025) interim\\n    \\n*   [Hib (_Haemophilus Influenzae_ type b)](https://www.cdc.gov/vaccines/hcp/current-vis/hib.html) (8/6/21)\\n    \\n*   [HPV (Human Papillomavirus)](https://www.cdc.gov/vaccines/hcp/current-vis/hpv.html) (8/6/21)\\n    \\n*   [Influenza - Live, Intranasal](https://www.cdc.gov/vaccines/hcp/current-vis/influenza-live-intranasal.html) (1/31/2025)\\n    \\n*   [Influenza - Inactivated](https://www.cdc.gov/vaccines/hcp/current-vis/influenza-inactivated.html) (1/31/2025)\\n    \\n*   [Measles/Mumps/Rubella (MMR)](https://www.cdc.gov/vaccines/hcp/current-vis/mmr.html) (1/31/2025)\\n    \\n*   [Measles/Mumps/Rubella & Varicella (MMRV)](https://www.cdc.gov/vaccines/hcp/current-vis/mmrv.html) (1/31/2025)\\n    \\n*   [Meningococcal ACWY](https://www.cdc.gov/vaccines/hcp/current-vis/meningococcal-acwy.html) (1/31/2025)\\n    \\n*   [Meningococcal B](https://www.cdc.gov/vaccines/hcp/current-vis/meningococcal-b.html) (1/31/2025)\\n    \\n*   [Pneumococcal Conjugate (PCV)](https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-conjugate.html) (5/12/23) interim\\n    \\n*   [Pneumococcal Polysaccharide (PPSV23)](https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-polysaccharide.html) (10/30/19)\\n    \\n*   [Polio](https://www.cdc.gov/vaccines/hcp/current-vis/polio.html) (1/31/2025)\\n    \\n*   [Rotavirus](https://www.cdc.gov/vaccines/hcp/current-vis/rotavirus.html) (10/15/21)\\n    \\n*   [Respiratory Syncytial Virus (RSV) Vaccine](https://www.cdc.gov/vaccines/hcp/current-vis/rsv.html) (1/31/2025)\\n    *   [RSV Preventive Antibody (nirsevimab) Immunization Information Statement (IIS)](https://www.cdc.gov/vaccines/vpd/rsv/immunization-information-statement.html) (9/25/23)\\n        \\n*   [Tdap (Tetanus, Diphtheria, Pertussis)](https://www.cdc.gov/vaccines/hcp/current-vis/tdap.html) (1/31/2025)\\n    \\n*   [Td (Tetanus, Diphtheria)](https://www.cdc.gov/vaccines/hcp/current-vis/td.html) (8/6/21)\\n    \\n*   [Varicella (Chickenpox)](https://www.cdc.gov/vaccines/hcp/current-vis/varicella.html) (1/31/2025)\\n    \\n*   [Zoster / Shingles (Recombinant)](https://www.cdc.gov/vaccines/hcp/current-vis/shingles.html) (2/4/22)\\n    \\n\\n### Non-Routine\\n\\n*   [Adenovirus](https://www.cdc.gov/vaccines/hcp/current-vis/adenovirus.html) (1/8/20)\\n    *   Note: Adenovirus vaccine is approved for use only among military personnel.\\n        \\n*   [Anthrax](https://www.cdc.gov/vaccines/hcp/current-vis/anthrax.html) (1/8/20)\\n    \\n*   [Cholera](https://www.cdc.gov/vaccines/hcp/current-vis/cholera.html) (1/31/2025)\\n    \\n*   [Ebola](https://www.cdc.gov/vaccines/hcp/current-vis/ebola.html) (1/31/2025)\\n    \\n*   [Japanese Encephalitis](https://www.cdc.gov/vaccines/hcp/current-vis/japanese-encephalitis.html) (8/15/19)\\n    \\n*   [Rabies](https://www.cdc.gov/vaccines/hcp/current-vis/rabies.html) (6/2/22)\\n    \\n*   [Smallpox/Monkeypox (JYNNEOS™)](https://www.cdc.gov/vaccines/hcp/current-vis/smallpox-monkeypox.html) (1/31/2025)\\n    \\n*   Smallpox (ACAM2000®) (12/1/15)\\n    *   [Medical Guide for vaccination with ACAM2000 \\\\[6 pages\\\\]](https://www.fda.gov/media/75800/download) This medication guide replaces the Smallpox VIS. It is to be used before one receives the vaccination. This guide is not available in other languages.\\n        \\n*   [Tick-borne Encephalitis Vaccine](https://www.cdc.gov/vaccines/hcp/current-vis/tbe.html) (12/7/23)\\n    \\n*   [Typhoid](https://www.cdc.gov/vaccines/hcp/current-vis/typhoid.html) (10/30/19)\\n    \\n*   [Yellow Fever](https://www.cdc.gov/vaccines/hcp/current-vis/yellow-fever.html) (4/1/20)\\n    \\n\\nOn This Page\\n------------\\n\\n*   [Overview](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#cdc_listing_intro-overview)\\n*   [Multi-, Routine-, & Non-Routine-Vaccine VISs](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#cdc_listing_res-multi-routine-non-routine-vaccine-viss)\\n\\nFebruary 28, 2025\\n\\n[Sources](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#content-sources) [Print](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#print) [Share](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#share)\\n\\n[](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)[](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)[](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)[](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#)\\n\\n[Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.cdc.gov \"Share to Facebook\") [LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.cdc.gov&title=Living%20with%20High%20Blood%20Pressure \"Share to LinkedIn\") [Twitter](https://twitter.com/share?url=https%3A%2F%2Fwww.cdc.gov&text=Living%20with%20High%20Blood%20Pressure \"Share to Twitter\") [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https://https://www.cdc.gov/vaccines/hcp/current-vis/index.html \"Embed this Page\")\\n\\nContent Source:\\n\\n[National Center for Immunization and Respiratory Diseases](https://www.cdc.gov/ncird/index.html)\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)\\n-------------------------------------------------------------------\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n[View All](https://www.cdc.gov/vaccines/site.html)\\n\\n### [For Everyone](https://www.cdc.gov/vaccines/index.html#gen)\\n\\n*   [Vaccine Basics](https://www.cdc.gov/vaccines/basics/index.html)\\n*   [Vaccines and the Diseases They Prevent](https://www.cdc.gov/vaccines/by-disease/index.html)\\n*   [Vaccines by Age](https://www.cdc.gov/vaccines/by-age/index.html)\\n*   [VaxView Vaccination Coverage](https://www.cdc.gov/vaccines/data-reporting/index.html)\\n*   [Glossary](https://www.cdc.gov/vaccines/glossary/index.html)\\n*   [Vaccine Schedules For You and Your Family](https://www.cdc.gov/vaccines/imz-schedules/index.html)\\n*   [Vaccine Resources](https://www.cdc.gov/vaccines/resources/index.html)\\n\\n### [Health Care Providers](https://www.cdc.gov/vaccines/hcp/index.html#hcp)\\n\\n*   [Vaccines By Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)\\n*   [Vaccines Used in the U.S.](https://www.cdc.gov/vaccines/hcp/vaccines-us/index.html)\\n*   [Immunization Schedules](https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#hcp)\\n\\n### [Public Health](https://www.cdc.gov/vaccines/site.html#php)\\n\\n*   [Immunization Program Resources](https://www.cdc.gov/vaccines/php/imz-program-resources/index.html)\\n*   [Requirements and Laws](https://www.cdc.gov/vaccines/php/requirements-laws/index.html)\\n*   [Let\\'s RISE](https://www.cdc.gov/vaccines/php/rise/index.html)\\n*   [View All](https://www.cdc.gov/vaccines/site.html#php)\\n\\n[Sign up for Email Updates](https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx#featured)\\n\\n[Contact Us](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#aboutCDC)\\n\\n[About CDC](https://www.cdc.gov/about/)\\n\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n\\n[Policies](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#languages)\\n\\n[Languages](https://wwwn.cdc.gov/pubs/other-languages?Sort=Lang%3A%3Aasc)\\n\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\n[Language Assistance](https://www.cdc.gov/other/language-assistance.html)\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[Contact Us](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#mobile-footer-contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#mobile-footer-aboutCDC)\\n\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n*   [About CDC](https://www.cdc.gov/about/)\\n\\n[Policies](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#mobile-footer-policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#mobile-footer-languages)\\n\\nLanguages\\n\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\nLanguage Assistance\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/vaccines/hcp/current-vis/index.html#mobile-footer-archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[![Image 6: Centers for Disease Control and Prevention](https://www.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)](https://www.cdc.gov/)\\n\\n[](https://www.facebook.com/CDC)[](https://twitter.com/CDCgov)[](https://www.instagram.com/CDCgov)[](https://www.linkedin.com/company/centers-for-disease-control-and-prevention)\\n\\n[](https://www.youtube.com/cdc)[](https://www.pinterest.com/cdcgov)[](https://www.snapchat.com/add/cdcgov)[](https://www.cdc.gov/rss)\\n\\n[HHS.gov](https://hhs.gov/) [USA.gov](https://usa.gov/)\\n\\n[](https://www.cdc.gov/vaccines/hcp/current-vis/index.html# \"Go to top\")\\n'},\n",
       "  {'title': 'Symptoms of COVID-19 | COVID-19 | CDC',\n",
       "   'url': 'https://www.cdc.gov/covid/signs-symptoms/index.html',\n",
       "   'content': \"# Symptoms of COVID-19 Stay home and away from others (including people you live with who are not sick) if you have symptoms that aren't better explained by another cause. \\\\This list does not include all possible symptoms. ## Difference between flu and COVID-19 Influenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection with one of the influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because some of the symptoms are the same. ## COVID-19 COVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2.\",\n",
       "   'score': 0.09997013,\n",
       "   'raw_content': \"![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA .gov website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Symptoms of COVID-19\\n\\n## Key points\\n\\n![Health care provider taking a patient's temperature.](/covid/media/images/2024/07/gettyimages-1216034366-612x612-1.jpg)\\n\\n## Signs and Symptoms\\n\\nThe following list does not include all possible symptoms. Symptoms may change with new COVID-19 variants and can vary depending on vaccination status. Possible symptoms include:\\n\\nCDC will continue to update this list as we learn more about COVID-19.\\n\\n### Feeling Sick?\\n\\n[Stay home and away from others](https://www.cdc.gov/respiratory-viruses/prevention/precautions-when-sick.html) (including people you live with who are not sick) if you have symptoms that aren't better explained by another cause.\\n\\nSeek health care promptly for testing and/or treatment if you have [risk factors for severe illness](https://www.cdc.gov/respiratory-viruses/risk-factors/index.html); [treatment](/covid/treatment/index.html) may help lower your risk of severe illness.\\n\\n## When to seek emergency help\\n\\nLook for emergency warning signs\\\\* for COVID 19:\\n\\nIf someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that you are seeking care for someone who has or may have COVID-19.\\n\\n*\\\\*This list does not include all possible symptoms. Please call your medical provider for any other symptoms that are severe or concerning to you.*\\n\\n## Difference between flu and COVID-19\\n\\nInfluenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection with one of the influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because some of the symptoms are the same.\\n\\nSome nucleic acid amplification tests (NAATs), including PCR tests, can differentiate between flu and COVID-19 at the same time. If one of these tests is not available, many [testing locations](/covid/testing/index.html) provide flu and COVID-19 tests separately.\\n\\n## Resources\\n\\n### Videos\\n\\n[Symptoms of Coronavirus Disease 2019 (youtube.com)](https://www.youtube.com/watch?v=F70BzSFAZfw)\\n\\n## On This Page\\n\\n## [COVID-19](/covid/index.html)\\n\\nCOVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2. It can be very contagious and spreads quickly.\\n\\n### [For Everyone](/covid/index.html#gen)\\n\\n### [Health Care Providers](/covid/hcp/index.html#hcp)\\n\\n### [Public Health](/covid/php/index.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)\"},\n",
       "  {'title': 'Vaccination Records - Finding, Interpreting, and Recording | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/admin/immuniz-records.html',\n",
       "   'content': 'Vaccination records (sometimes called immunization records) provide a history of all the vaccines you or your child received. This record may be required for certain jobs, travel abroad, or school registration.',\n",
       "   'score': 0.09954918,\n",
       "   'raw_content': None},\n",
       "  {'title': 'FDA Label Search-Package Code',\n",
       "   'url': 'https://labels.fda.gov/packagecode.cfm',\n",
       "   'content': '(Type the 4 or 5 digit NDC Labeler Code with the hyphen (e.g., 0001-), the 8 or 9 digit NDC Product Code (e.g., 0001-0001) or the 10 digit NDC (0001-0001-01))',\n",
       "   'score': 0.09674864,\n",
       "   'raw_content': '![Decrease font size](/scripts/includes/images/img_fdagov_font_adj_small.png \"Decrease font size\")\\n![Return font size to normal](/scripts/includes/images/img_fdagov_font_adj_medium.png \"Return font size to normal\")\\n![Increase font size](/scripts/includes/images/img_fdagov_font_adj_large.png \"Increase font size\")\\n![U.S. Department of Health and Human Services](/scripts/includes/images/img_fdagov_hhs_masthead_logo_r.png \"U.S. Department of Health and Human Services\")\\n![FDA, U.S. Food and Drug Administration](/scripts/includes/images/gov-fda-new-white.png \"FDA, U.S. Food and Drug Administration\")\\n![Search](/scripts/includes/images/img_fdagov_mast_search_button.png \"Search this site\")\\n\\n# FDA Label Search\\n\\n![Print](/scripts/includes/images/img_fdagov_utility_icon_print.png \"Print this page\")\\n![Share](/scripts/includes/images/img_fdagov_utility_icon_share.png \"Share this page\")\\n![E-mail](/scripts/includes/images/img_fdagov_utility_icon_email.png \"E-mail this page\")\\n\\n**Search by NDC:**\\n\\n(Type the 4 or 5 digit NDC Labeler Code with the hyphen (e.g., 0001-), the 8 or 9 digit NDC Product Code (e.g., 0001-0001) or the 10 digit NDC (0001-0001-01))\\n\\n[Return to the FDA Label Search\\nPage](http://labels.fda.gov/)\\n\\n#### Links on this page:\\n\\nNote: If you need help accessing information in different file formats, see\\n[Instructions for Downloading Viewers and Players](https://www.fda.gov/about-fda/website-policies/viewing-files).\\n  \\nLanguage Assistance Available: [Español](https://www.fda.gov/about-fda/about-website/language-assistance-services#spanish \"Spanish\") | [繁體中文](https://www.fda.gov/about-fda/about-website/language-assistance-services#chinese \"Chinese\") | [Tiếng Việt](https://www.fda.gov/about-fda/about-website/language-assistance-services#vietnamese \"Vietnamese\") | [한국어](https://www.fda.gov/about-fda/about-website/language-assistance-services#korean \"Korean\") | [Tagalog](https://www.fda.gov/about-fda/about-website/language-assistance-services#tagalog \"Tagolog\") | [Русский](https://www.fda.gov/about-fda/about-website/language-assistance-services#russian \"Russian\") | [العربية](https://www.fda.gov/about-fda/about-website/language-assistance-services#arabic \"Arabic\") | [Kreyòl Ayisyen](https://www.fda.gov/about-fda/about-website/language-assistance-services#creole \"Creole\") | [Français](https://www.fda.gov/about-fda/about-website/language-assistance-services#french \"French\") | [Polski](https://www.fda.gov/about-fda/about-website/language-assistance-services#polish \"Polish\") | [Português](https://www.fda.gov/about-fda/about-website/language-assistance-services#portuguese \"Portuguese\") | [Italiano](https://www.fda.gov/about-fda/about-website/language-assistance-services#italian \"Italian\") | [Deutsch](https://www.fda.gov/about-fda/about-website/language-assistance-services#german \"German\") | [日本語](https://www.fda.gov/about-fda/about-website/language-assistance-services#japanese \"Japanese\") | [فارسی](https://www.fda.gov/about-fda/about-website/language-assistance-services#farsi \"Farsi\") | [English](https://www.fda.gov/about-fda/about-website/language-assistance-services#english \"English\")\\n\\n![FDA](/scripts/includes/images/fda-square-white-small.png \"FDA Homepage\")\\n![USA.gov](/scripts/includes/images/img_fdagov_footer_logo_usagov.png \"USA.gov\")\\n![E-mail](/scripts/includes/images/img_fdagov_footer_icon_email.png \"Subscribe to E-mails\")\\n![RSS](/scripts/includes/images/img_fdagov_footer_icon_rss.png \"Subscribe to RSS Feeds\")\\n![Twitter](/scripts/includes/images/img_fdagov_footer_icon_twitter.png \"Follow FDA on Twitter\")\\n![Facebook](/scripts/includes/images/img_fdagov_ftr_icon_facebook.png \"Follow FDA on Facebook\")\\n![YouTube](/scripts/includes/images/img_fdagov_footer_icon_youtube.png \"View FDA Videos\")\\n![Flickr](/scripts/includes/images/img_fdagov_footer_icon_flickr.png \"View FDA Photostream on Flickr\")\\n![U.S. Department of Health & Human Services](/scripts/includes/images/img_fdagov_footer_hhslogo.png \"U.S. Department of Health & Human Services\")\\n\\n#### Links on this page:'},\n",
       "  {'title': 'Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS | Vaccines ...',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/tdap.html',\n",
       "   'content': '# Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS ## Why get vaccinated? Tdap vaccine can prevent tetanus, diphtheria, and pertussis. ## Tdap vaccine Also, adults should receive a booster dose of either Tdap or Td (a different vaccine that protects against tetanus and diphtheria but not pertussis) every 10 years, or after 5 years in the case of a severe or dirty wound or burn. Tdap may be given at the same time as other vaccines. In some cases, your health care provider may decide to postpone Tdap vaccination until a future visit. People who are moderately or severely ill should usually wait until they recover before getting Tdap vaccine. ## More about these vaccines ## Vaccines & Immunizations',\n",
       "   'score': 0.09000516,\n",
       "   'raw_content': '![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n**Related Topics:**\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS\\n\\n## At a glance\\n\\n![Tdap (Tetanus, Diphtheria, Pertussis)](/vaccines/hcp/current-vis/images/vis-tdap.gif \"vis-tdap.gif\")\\n\\n## Why get vaccinated?\\n\\n**Tdap vaccine** can prevent **tetanus**, **diphtheria**, and **pertussis**.\\n\\nDiphtheria and pertussis spread from person to person. Tetanus enters the body through cuts or wounds.\\n\\n## Tdap vaccine\\n\\nTdap is only for children 7 years and older, adolescents, and adults.\\n\\n**Adolescents** should receive a single dose of Tdap, preferably at age 11 or 12 years.\\n\\n**Pregnant women** should get a dose of Tdap during every pregnancy, preferably during the early part of the third trimester, to help protect the newborn from pertussis. Infants are most at risk for severe, life-threatening complications from pertussis.\\n\\n**Adults** who have never received Tdap should get a dose of Tdap.\\n\\nAlso, **adults should receive a booster dose of either Tdap or Td** (a different vaccine that protects against tetanus and diphtheria but not pertussis) **every 10 years**, or after 5 years in the case of a severe or dirty wound or burn.\\n\\nTdap may be given at the same time as other vaccines.\\n\\n## Talk with your health care provider\\n\\nTell your vaccination provider if the person getting the vaccine:\\n\\nIn some cases, your health care provider may decide to postpone Tdap vaccination until a future visit.\\n\\nPeople with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover before getting Tdap vaccine.\\n\\nYour health care provider can give you more information.\\n\\n## Risks of a vaccine reaction\\n\\nPeople sometimes faint after medical procedures, including vaccination. Tell your provider if you feel dizzy or have vision changes or ringing in the ears.\\n\\nAs with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.\\n\\n## What if there is a serious problem?\\n\\nAn allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call **9-1-1** and get the person to the nearest hospital.\\n\\nFor other signs that concern you, call your health care provider.\\n\\nAdverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visit the **[VAERS website](https://www.vaers.hhs.gov/)** or call **1-800-822-7967**. *VAERS is only for reporting reactions, and VAERS staff members do not give medical advice.*\\n\\n## The National Vaccine Injury Compensation Program\\n\\nThe National Vaccine Injury Compensation Program (VICP) is a federal program that was created to compensate people who may have been injured by certain vaccines. Claims regarding alleged injury or death due to vaccination have a time limit for filing, which may be as short as two years. Visit the **[VICP website](https://www.hrsa.gov/vaccinecompensation)** or call **1-800-338-2382** to learn about the program and about filing a claim.\\n\\n## How can I learn more?\\n\\n### Available Languages\\n\\nMany vaccine information statements are available in Spanish and other languages.\\n\\nSee [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\nHojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\n## More about these vaccines\\n\\n![Tdap (tetanus, diphtheria, and pertussis) VIS barcode](/vaccines/hcp/current-vis/images/vis-qr-tdap.gif \"Tdap VIS Barcode\")\\n\\n## On This Page\\n\\n## [Vaccines & Immunizations](/vaccines/index.html)\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n### [For Everyone](/vaccines/index.html#gen)\\n\\n### [Health Care Providers](/vaccines/hcp/index.html#hcp)\\n\\n### [Public Health](/vaccines/site.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)'},\n",
       "  {'title': 'Hepatitis B Vaccine (Interim) VIS | Vaccines & Immunizations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/hepatitis-b.html',\n",
       "   'content': 'Hepatitis B vaccine. Hepatitis B vaccine is usually given as 2, 3, or 4 shots. Infants should get their first dose of hepatitis B vaccine at birth and will usually complete the series at 6-18 months of age.The birth dose of hepatitis B vaccine is an important part of preventing long-term illness in infants and the spread of hepatitis B in the United States.',\n",
       "   'score': 0.08688758,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Routine MMR Vaccination Recommendations: For Providers | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html',\n",
       "   'content': 'Saving Lives, Protecting People Search Submit Vaccines & Immunizations Routine Measles, Mumps, and Rubella Vaccination Print Related Pages The Advisory Committee on Immunization Practices (ACIP) recommends that persons who do not have presumptive evidence of immunity to measles, mumps, and rubella should get vaccinated against these diseases with measles, mumps, rubella (MMR) vaccine or measles, mumps, rubella, varicella (MMRV) vaccine. MeaslesMumpsRubella Presumptive Evidence of Immunity for Measles Presumptive evidence of immunity can be established in any of the following ways: Written documentation of one or more doses of a measles-containing vaccine administered on or after the first birthday for preschool-age children and adults not considered high risk Written documentation of two doses of measles-containing vaccine for school-age children and adults at high risk, including students at post-high school secondary educational institutions, healthcare personnel, and international travelers Laboratory evidence of immunity Laboratory confirmation of disease Birth before 1957 (see below for presumptive evidence of immunity criteria for health care personnel born before 1957) Top of Page Routine Vaccination Recommendations to Protect against Measles Children CDC recommends two doses of measles-containing vaccine routinely for children, starting with the first dose at age 12 through 15 months and the second dose at age 4 through 6 years before school entry. Adults Adults should also be up to date on MMR vaccinations with either 1 or 2 doses (depending on risk factors) unless they have other presumptive evidence of immunity to measles, mumps, and rubella. People with a contraindication for MMR or MMRV vaccine should not receive the vaccine, including anyone who— Had a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Has a known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy or patients with human immunodeficiency virus [HIV] infection who are severely immunocompromised) Is pregnant Precautions A precaution is a condition in a recipient that might increase the chance or severity of a serious adverse reaction, or that might compromise the ability of the vaccine to produce immunity (such as administering MMR or MMRV vaccine to a person with passive immunity to measles from a blood transfusion).',\n",
       "   'score': 0.08477284,\n",
       "   'raw_content': 'Routine MMR Vaccination Recommendations: For Providers | CDC\\n===============                   \\n\\n[Skip directly to site content](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#content) [Skip directly to search](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#headerSearch)\\n\\n[Español](https://www.cdc.gov/spanish/) | [Other Languages](https://wwwn.cdc.gov/pubs/other-languages/)\\n\\n![Image 1: U.S. flag](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png) An official website of the United States government Here\\'s how you know\\n\\n![Image 2: Official icon](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg)\\n\\n**Official websites use .gov**\\n\\nA .gov website belongs to an official government organization in the United States.\\n\\n![Image 3: Lock icon](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg)\\n\\n**Secure .gov websites use HTTPS**\\n\\nA lock ( ) or https:// means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n[Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People ![Image 4: CDC Logo](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg) ![Image 5: CDC Logo](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg)](https://www.cdc.gov/)  \\n\\nSearch\\n\\nSubmit\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/index.html)\\n\\nRoutine Measles, Mumps, and Rubella Vaccination\\n===============================================\\n\\n[Print](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#print)\\n\\n[](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#collapse_1729166bf6914d1cdd)\\n\\nRelated Pages\\n\\nThe Advisory Committee on Immunization Practices (ACIP) recommends that persons who do not have [presumptive evidence of immunity](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#immunity)\\xa0to measles, mumps, and rubella should get vaccinated against these diseases with measles, mumps, rubella (MMR) vaccine or measles, mumps, rubella, varicella (MMRV) vaccine. Only combination MMR and MMRV vaccines are licensed in the United States.\\n\\n[Measles](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#tabs-1-1)[Mumps](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#tabs-1-2)[Rubella](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#tabs-1-3)\\n\\nPresumptive Evidence of Immunity for Measles\\n\\nPresumptive evidence of immunity can be established in any of the following ways:\\n\\n*   Written documentation of **one or more doses** of a measles-containing vaccine administered on or after the first birthday for preschool-age children and adults not considered high risk\\n*   Written documentation of **two doses** of measles-containing vaccine for school-age children and adults at high risk, including students at post-high school secondary educational institutions, healthcare personnel, and international travelers\\n*   Laboratory evidence of immunity\\n*   Laboratory confirmation of disease\\n*   Birth before 1957 (_see below for presumptive evidence of immunity criteria for [health care personnel born before 1957](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#hcp)_)\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nRoutine Vaccination Recommendations to Protect against Measles\\n\\n**Children**\\n\\nCDC recommends two doses of measles-containing vaccine routinely for children, starting with the first dose at age 12 through 15 months and the second dose at age 4 through 6 years before school entry. This can be administered as MMR or MMRV vaccine. Children can receive the second dose of MMR vaccine earlier than 4 through 6 years, as long as it is at least 28 days after the first dose.\\xa0 A second dose of MMRV vaccine can be given 3 months after the first dose up to 12 years of age.\\n\\nCDC recommends that separate [MMR](https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#note-mmr) and varicella vaccines be given for the first dose in children aged 12–47 months; however, MMRV may be used if parents or caregivers express a preference.\\n\\n**Adults**\\n\\nAdults should also be up to date on MMR vaccinations with either 1 or 2 doses ([depending on risk factors](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#risk-factors)) unless they have other presumptive evidence of immunity to measles, mumps, and rubella.\\n\\nOne dose of MMR vaccine, or other [presumptive evidence of immunity](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#immunity), is sufficient for most adults. Providers generally do not need to actively screen adult patients for measles immunity in non-outbreak areas in the U.S. After vaccination, it is also not necessary to test patients for antibodies to confirm immunity. There is no recommendation for a catch-up program among adults for a second dose of MMR (e.g., persons born before 1989 or otherwise).\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nVaccination of Special Populations\\n\\n**Students at post-high school educational institutions**\\n\\nStudents at post-high school educational institutions who do not have [presumptive evidence of immunity](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#immunity)\\xa0should receive two doses of MMR vaccine, each dose separated by at least 28 days.\\n\\n**International travelers**\\n\\nPersons aged 6 months and older who will be traveling internationally to any country outside the United States who do not have presumptive evidence of immunity should be vaccinated with measles-containing vaccine if they are not already protected against measles, mumps, and rubella. Before any international travel—\\n\\n*   Infants 6 through 11 months of age should receive one dose of MMR vaccine. Infants who get one dose of MMR vaccine before their first birthday should get two more doses according to the routinely recommended schedule. (The first dose should be given at 12 through 15 months of age and the second dose at 4 through 6 years of age. The second dose can be administered earlier as long as at least 28 days have elapsed since the first dose).\\n*   Persons 12 months of age and older should receive two doses of measles-containing vaccine, separated by at least 28 days, unless they have other [presumptive evidence of immunity](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#immunity)\\xa0against measles.\\n\\n**Healthcare personnel**\\n\\nHealthcare personnel without presumptive evidence of immunity should get two doses of MMR vaccine, separated by at least 28 days. Although birth before 1957 is considered acceptable evidence of immunity, in routine circumstances, healthcare facilities _should consider_ vaccinating healthcare personnel born before 1957 who lack laboratory evidence of immunity or laboratory confirmation of disease.\\n\\n**Household and close contacts of immunocompromised persons**\\n\\nPeople with compromised immune systems are at high risk for severe complications if infected with measles. All family and other close contacts of people with compromised immune systems 12 months of age and older should receive two doses of MMR vaccine separated by 28 days, unless they have other presumptive evidence of measles immunity.\\n\\n**People with Human Immunodeficiency Virus (HIV) infection**\\n\\nPeople 12 months of age and older with HIV infection who do not have presumptive evidence of measles immunity or evidence of severe immunosuppression should receive two doses of MMR vaccine, separated by 28 days. Severe immunosuppression is defined as CD4 percentages less than 15% for 6 months or longer (for children five years of age or younger) and CD4 percentages less than 15% and CD4 count less than 200 cells/mm3 for 6 months or longer (for persons older than five years).\\n\\n**Adults who know they got the killed (inactivated) measles vaccine**\\n\\nA very small proportion of adults (less than 5%) may have received killed measles vaccine from 1963 through 1967 during childhood.\\xa0 The ACIP recommends re-vaccinating anyone who received measles vaccine of unknown type, inactivated measles vaccine, or further attenuated measles vaccine accompanied by IG or high-titer measles immune globulin (no longer available in the United States) during these years with 1 or 2 doses.\\n\\n**Groups at increased risk for measles because of a measles outbreak**\\n\\nDuring measles outbreaks, health departments may provide additional recommendations to protect their communities. The at-risk population is defined by local and state health departments and depends on the epidemiology of the outbreak (e.g., only specific age groups are affected). In addition to the routine recommendations for MMR vaccine, health departments may recommend a second dose for adults or an earlier second dose for children 1 to 4 years of age who are residing in or visiting the affected areas, with the second dose given at least 28 days after the first dose.\\n\\nIf there is ongoing community-wide transmission affecting young infants, health departments may recommend an early dose for infants 6 to 11 months of age. The decision to vaccinate should be made carefully after weighing the risks of the potential long-term impact of lower immune responses when infants are vaccinated less than 12 months of age (versus greater than or equal to 12 months of age) compared to the benefit of early protection when measles is circulating in the community.\\xa0 Infants who get one dose of MMR vaccine before their first birthday should get two more doses according to the routinely recommended schedule (first dose should be given at 12 through 15 months of age and the second dose at 4 through 6 years of age. The second dose can be administered earlier as long as at least 28 days have elapsed since the first dose).\\n\\nDuring an outbreak of measles in a healthcare facility, or in healthcare facilities serving a measles outbreak area, two doses of MMR vaccine are _recommended_ for healthcare personnel, regardless of birth year, who lack other presumptive evidence of measles immunity\\n\\nThere are no recommendations to receive a third dose of MMR vaccine during measles outbreaks.\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nContraindications and Precautions for MMR Vaccination\\n\\nContraindications and precautions to vaccination generally dictate circumstances when vaccines will not be given. Most contraindications and precautions are temporary, and the vaccine can be given at a later time.\\n\\n**Contraindications**\\n\\nA contraindication is a condition in a recipient that **greatly increases** the chance of a serious adverse reaction (or due to the theoretical risk in the case of pregnant women).\\n\\nPeople with a contraindication for MMR or MMRV vaccine should not receive the vaccine, including anyone who—\\n\\n*   Had a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component\\n*   Has a known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy or patients with human immunodeficiency virus \\\\[HIV\\\\] infection who are severely immunocompromised)\\n*   Is pregnant\\n\\n**Precautions**\\n\\nA precaution is a condition in a recipient that **might increase** the chance or severity of a serious adverse reaction, or that might compromise the ability of the vaccine to produce immunity (such as administering MMR or MMRV vaccine to a person with passive immunity to measles from a blood transfusion).\\n\\nPrecautions for MMR or MMRV vaccine include—\\n\\n*   Moderate or severe acute illness with or without fever\\n*   Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)[7](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html)\\n*   History of thrombocytopenia or thrombocytopenic purpura\\n*   Need for tuberculin skin testing or interferon gamma release assay (IGRA) testing\\n*   Personal or family history of seizures\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nPost-exposure prophylaxis\\n\\n**Measles**\\n\\nPeople exposed to measles who cannot readily show that they have adequate [presumptive evidence of immunity](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#immunity) against measles should be offered post-exposure prophylaxis (PEP). Public health officials can help identify eligible persons, assess any contraindications and weigh benefits. There are two types of PEP for measles:\\n\\n*   **MMR vaccine**, if administered within 72 hours of initial measles exposure, may provide some protection or modify the clinical course of disease.\\n*   **Immunoglobulin (IG)**, if administered within six days of exposure, may also provide some protection or modify the clinical course of disease.\\n\\nFor more information on measles outbreak control and post-exposure prophylaxis, healthcare providers should consult their health department and refer to the [measles chapter](https://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html) of the _Manual for the Surveillance of Vaccine-Preventable Diseases._\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nFor more on routine MMR or MMRV vaccination, please see the [**Measles** tab](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#tabs-1-1).\\xa0 Some special considerations for mumps vaccination are described below.\\n\\nVaccination of Special Populations\\n\\n**Groups at increased risk for mumps because of a mumps outbreak**\\n\\nDuring a mumps outbreak, children 12 months of age to 4 years of age who are unvaccinated should receive one dose of MMR or MMRV. Persons 4 years of age or older who are unvaccinated or have received only one dose of MMR or MMRV should receive MMR (2 doses for unvaccinated, and 1 dose for people who previously received the first dose, administered 28 days apart).\\n\\nDuring mumps outbreaks, public health authorities might also recommend that people who belong to groups at increased risk for getting mumps receive an additional dose of MMR (second dose for persons previously vaccinated with one dose or a third dose for persons previously vaccinated with 2 doses). Public health authorities will communicate to providers which groups are at increased risk and should receive a dose.\\n\\nRelated page: [Strategies for the Control and Investigation of Mumps Outbreaks](https://www.cdc.gov/mumps/health-departments/strategies.html)\\n\\nPost-exposure prophylaxis\\n\\n**Mumps**\\n\\nUnlike with measles, MMR vaccine is not effective at helping protect people who have recently been infected with mumps (post-exposure prophylaxis, or PEP). However, vaccination after exposure is not harmful and may possibly prevent later disease if re-exposed.\\n\\nFor more information on mumps outbreak control and post-exposure prophylaxis, healthcare providers should consult their health department and refer to the [mumps chapter](https://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.html)\\xa0of the _Manual for the Surveillance of Vaccine-Preventable Diseases._\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nFor more on routine MMR or MMRV vaccination, please see the [**Measles** tab](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#tabs-1-1).\\xa0 Some special considerations for rubella vaccination are described below.\\n\\nVaccination of Special Populations\\n\\n**Women of Childbearing Age**\\n\\nAll women of childbearing age, especially those who grew up outside the United States in areas where routine rubella vaccination might not occur, should be vaccinated with one dose of MMR vaccine or have other acceptable presumptive [evidence of rubella immunity](https://www.cdc.gov/rubella/hcp.html#immunity). Only a positive serologic test for rubella antibody or documentation of appropriate vaccination should be accepted as presumptive evidence of immunity for women who may become pregnant.\\n\\nWomen known to be pregnant or attempting to become pregnant should not receive a live virus vaccine, including MMR vaccine. Although there is no evidence that rubella vaccine virus is harmful to the fetus during pregnancy, as a precaution, women should not get pregnant for 4 weeks (28 days) after MMR vaccination.\\n\\nPost-exposure prophylaxis\\n\\n**Rubella**\\n\\nUnlike with measles, MMR vaccine is not effective at helping protect people who have recently been infected with rubella (post-exposure prophylaxis, or PEP). However, vaccination after exposure is not harmful and may possibly prevent later disease if re-exposed.\\n\\nFor more information on rubella outbreak control and post-exposure prophylaxis, healthcare providers should consult their health department and refer to the [rubella chapter](https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html)\\xa0of the _Manual for the Surveillance of Vaccine-Preventable Diseases._\\n\\n[Top of Page](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#)\\n\\nLast Reviewed: January 26, 2021\\n\\nSource: [National Center for Immunization and Respiratory Diseases](https://www.cdc.gov/ncird/index.html)\\n\\n*   [Facebook](https://api.addthis.com/oexchange/0.8/forward/facebook/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png \"Share to Facebook\")\\n*   [Twitter](https://api.addthis.com/oexchange/0.8/forward/twitter/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png \"Share to Twitter\")\\n*   [LinkedIn](https://api.addthis.com/oexchange/0.8/forward/linkedin/offer?url=https%3A%2F%2Fwww.cdc.gov%2Findex.htm&title=CDC%20Works%2024/7&description=As%20the%20nation%27s%20health%20protection%20agency,%20CDC%20saves%20lives%20and%20protects%20people%20from%20health,%20safety,%20and%20security%20threats.&via=CDCgov&ct=0&media=https://www.cdc.gov/homepage/images/centers-for-disease-control-and-prevention.png \"Share to LinkedIn\")\\n*   [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https%3A%2F%2Fwww.cdc.gov%2Findex.htm \"Embed this Page\")\\n\\nhome[Vaccines & Immunizations Home](https://www.cdc.gov/vaccines/index.html)\\n\\n*   [Vaccines by Disease](https://www.cdc.gov/vaccines/hcp/by-disease/index.html)[plus icon](https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html#nav-group-4ad92)\\n    *   [COVID-19](https://www.cdc.gov/vaccines/covid-19/)\\n    *   [Dengue](https://www.cdc.gov/vaccines/vpd/dengue/hcp/index.html)\\n    *   [Diphtheria, Tetanus, and Pertussis](https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/index.html)\\n    *   [Hepatitis A](https://www.cdc.gov/vaccines/vpd/hepa/hcp/index.html)\\n    *   [Hepatitis B](https://www.cdc.gov/vaccines/vpd/hepb/hcp/index.html)\\n    *   [Hib (Haemophilus influenzae type b)](https://www.cdc.gov/vaccines/vpd/hib/hcp/index.html)\\n    *   [HPV (Human Papillomavirus)](https://www.cdc.gov/vaccines/vpd/hpv/hcp/index.html)\\n    *   [Influenza (Flu)](https://www.cdc.gov/vaccines/vpd/flu/hcp/index.html)\\n    *   [Measles, Mumps, and Rubella](https://www.cdc.gov/vaccines/vpd/mmr/hcp/index.html)\\n    *   [Meningococcal](https://www.cdc.gov/vaccines/vpd/mening/hcp/index.html)\\n    *   [Mpox](https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html)\\n    *   [Pneumococcal](https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html)\\n    *   [Polio (Poliomyelitis)](https://www.cdc.gov/vaccines/vpd/polio/hcp/index.html)\\n    *   [Rotavirus](https://www.cdc.gov/vaccines/vpd/rotavirus/hcp/index.html)\\n    *   [RSV (Respiratory Syncytial Virus)](https://www.cdc.gov/vaccines/vpd/rsv/index.html)\\n    *   [Shingles (Herpes Zoster)](https://www.cdc.gov/vaccines/vpd/shingles/hcp/index.html)\\n    *   [Varicella (Chickenpox)](https://www.cdc.gov/vaccines/vpd/varicella/hcp/index.html)\\n    *   [Adenovirus](https://www.cdc.gov/vaccines/hcp/current-vis/adenovirus.html)\\n    *   [Anthrax](https://www.cdc.gov/vaccines/vpd/anthrax/hcp/index.html)\\n    *   [Chikungunya](https://www.cdc.gov/chikungunya/hcp/vaccine/index.html)\\n    *   [Cholera](https://www.cdc.gov/cholera/prevention/cholera-vaccines.html)\\n    *   [Ebola](https://www.cdc.gov/ebola/hcp/vaccines/index.html)\\n    *   [Japanese Encephalitis (JE)](https://www.cdc.gov/vaccines/vpd/j-enceph/hcp/index.html)\\n    *   [Rabies](https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html)\\n    *   [Smallpox](https://www.cdc.gov/vaccines/vpd/smallpox/hcp/index.html)\\n    *   [Tuberculosis](https://www.cdc.gov/vaccines/vpd/tb/hcp/index.html)\\n    *   [Typhoid Fever](https://www.cdc.gov/vaccines/vpd/typhoid/hcp/index.html)\\n    *   [Yellow Fever](https://www.cdc.gov/vaccines/vpd/yf/hcp/index.html)\\n\\nAlso Known As & Abbreviations\\n\\n*   MMR=measles, mumps, and rubella combination vaccine\\n*   MMRV = measles, mumps, rubella, and varicella combination vaccine\\n*   Measles=Rubeola\\n*   Measles = ”10-day,” “hard” and “red” measles\\n*   Rubella = also called “German” or “3-day” measles\\n*   CRS = Congenital Rubella Syndrome\\n\\n*   [About CDC](https://www.cdc.gov/about/)\\n*   [Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n*   [800-232-4636](tel:8002324636)\\n\\n[Facebook](https://www.facebook.com/CDC) [Twitter](https://twitter.com/CDCgov) [Instagram](https://www.instagram.com/CDCgov/) [LinkedIn](https://www.linkedin.com/company/centers-for-disease-control-and-prevention) [Youtube](https://www.youtube.com/c/cdc/) [Pinterest](https://www.pinterest.com/cdcgov/) [Snapchat](https://www.snapchat.com/add/cdcgov) [RSS](https://tools.cdc.gov/medialibrary/index.aspx)\\n\\n*   CONTACT CDC\\n    \\n    [Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n    \\n    Call 800-232-4636\\n    \\n    [Email Us](https://www.cdc.gov/cdc-info/index.html)\\n    \\n*   ABOUT CDC\\n    \\n    *   [About CDC](https://www.cdc.gov/about/)\\n    *   [Jobs](https://jobs.cdc.gov/)\\n    *   [Funding](https://www.cdc.gov/funding)\\n    \\n*   POLICIES\\n    \\n    *   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n    *   [External Links](https://www.cdc.gov/Other/disclaimer.html)\\n    *   [Privacy](https://www.cdc.gov/other/privacy.html)\\n    *   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n    *   [FOIA](https://www.cdc.gov/od/foia)\\n    *   [OIG](https://oig.hhs.gov/)\\n    *   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n    *   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n    *   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n    *   [CDC Archive](https://archive.cdc.gov/)\\n    *   [Public Health Publications](https://stacks.cdc.gov/)\\n    *   [HHS.gov](https://hhs.gov/)\\n    *   [USA.gov](https://www.usa.gov/)\\n    \\n*   CONNECT WITH US\\n    \\n    *   [Facebook](https://www.facebook.com/CDC)\\n    *   [Twitter](https://twitter.com/CDCgov)\\n    *   [Instagram](https://www.instagram.com/CDCgov/)\\n    *   [LinkedIn](https://www.linkedin.com/company/centers-for-disease-control-and-prevention)\\n    \\n    *   [Youtube](https://www.youtube.com/c/cdc/)\\n    *   [Pinterest](https://www.pinterest.com/cdcgov/)\\n    *   [Snapchat](https://www.snapchat.com/add/cdcgov)\\n    *   [Email](https://wwwn.cdc.gov/dcs/RequestForm.aspx)\\n    \\n*   LANGUAGES\\n    \\n    *   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish \"Spanish\")\\n    *   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese \"Chinese\")\\n    *   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese \"Vietnamese\")\\n    *   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean \"Korean\")\\n    *   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog \"Tagalog\")\\n    *   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian \"Russian\")\\n    *   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic \"Arabic\")\\n    *   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian \"Haitian\")\\n    *   [Français](https://www.cdc.gov/other/language-assistance.html#French \"French\")\\n    *   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish \"Polish\")\\n    *   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese \"Portuguese\")\\n    *   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian \"Italian\")\\n    *   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German \"German\")\\n    *   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese \"Japanese\")\\n    *   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi \"Farsi\")\\n    *   [English](https://www.cdc.gov/other/language-assistance.html#English \"English\")\\n    \\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n*   [FOIA](https://www.cdc.gov/od/foia)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n*   [HHS.gov](https://hhs.gov/)\\n*   [USA.gov](https://www.usa.gov/)\\n'},\n",
       "  {'title': 'Catch-up Immunization Schedule for Children and Adolescents',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-catch-up.html',\n",
       "   'content': 'Share sensitive information only on official, secure websites. # Catch-up Immunization Schedule for Children and Adolescents Guide health care providers in determining recommended catch-up schedule for children/adolescents whose vaccination is delayed. To make vaccination recommendations, healthcare providers should: receive email updates when changes are made to this page ### Vaccine Catch-Up Guidance CDC has developed catch-up guidance job aids to assist healthcare providers in interpreting Table 2 in the child and adolescent immunization schedule. ## Children and adolescents age 7 through 18 years Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays. Helpful information ## Vaccines & Immunizations Vaccination is one of the best things you can do to help protect yourself from serious diseases.',\n",
       "   'score': 0.082704924,\n",
       "   'raw_content': \"![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n**Related Topics:**\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Catch-up Immunization Schedule for Children and Adolescents\\n\\n## Purpose\\n\\nGuide health care providers in determining recommended catch-up schedule for children/adolescents whose vaccination is delayed.\\n\\n## How to use the schedule\\n\\nTo make vaccination recommendations, healthcare providers should:\\n\\n![receive email updates when changes are made to this page](https://www2a.cdc.gov/vaccines/iis/iisstandards/includes/mailbox_big.gif)\\n\\n[Get email updates](https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx?topic_id=USCDC_11_2)\\n\\n### Vaccine Catch-Up Guidance\\n\\nCDC has developed [catch-up guidance job aids](/vaccines/hcp/imz-schedules/changes-guidance.html#cdc_generic_section_3-vaccine-catch-up-guidance)\\xa0to assist healthcare providers in interpreting Table 2 in the child and adolescent immunization schedule.\\n\\n### Download the Schedule\\n\\n## Children age 4 months through 6 years\\n\\n| Vaccine | Minimum Age for Dose 1 | Minimum Interval Between Doses | | | |\\n| --- | --- | --- | --- | --- | --- |\\n| Dose 1 to Dose 2 | Dose 2 to Dose 3 | Dose 3 to Dose 4 | Dose 4 to Dose 5 |\\n| [Hepatitis B](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hepb) [more info icon.](/vaccines/vpd/hepb/hcp/index.html) | Birth | **4 weeks** | **8 weeks and at least 16 weeks after first dose.** Minimum age for the final dose is 24 weeks |  |  |\\n| [Rotavirus](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-rotavirus) [more info icon.](/vaccines/vpd/rotavirus/hcp/index.html) | **6 weeks** Maximum age for first dose is 14 weeks, 6 days. | **4 weeks** | **4 weeks** Maximum age for final dose is 8 months, 0 days |  |  |\\n| [Diphtheria, tetanus, and acellular pertussis](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-dtap) [more info icon.](/vaccines/vpd/dtap-tdap-td/hcp/index.html) | 6 weeks | **4 weeks** | **4 weeks** | **6 months** | **6 months**A fifth dose is not necessary if the fourth dose was administered at age 4 years or older ***and*** at least 6 months after dose 3 |\\n| [*Haemophilus influenzae* type b](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hib) [more info icon.](/vaccines/vpd/hib/hcp/index.html) | 6 weeks | **No further doses needed** if first dose was administered at age 15 months or older. **4 weeks** if first dose was administered before the 1st birthday. **8 weeks (as final dose)** if first dose was administered at age 12 through 14 months. | **No further doses needed** if previous dose was administered at age 15 months or older  **4 weeks** If current age is younger than 12 months ***and*** first dose was administered at younger than age 7 months ***and*** at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix), Vaxelis or unknown **8 weeks and age 12 through 59 months (as final dose)** if current age is younger than 12 months ***and*** first dose was administered at age 7 through 11 months; **OR** if current age is 12 through 59 months ***and*** first dose was administered before the 1st birthday, ***and*** second dose was administered at younger than 15 months; **OR** if both doses were PedvaxHIB and were administered before the 1st birthday | **8 weeks (as final dose)**  This dose only necessary for children age 12 through 59 months who received 3 doses before the 1st birthday. |  |\\n| [Pneumococcal conjugate](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-pneumo) [more info icon.](/vaccines/vpd/pneumo/hcp/index.html) | 6 weeks | **No further doses needed** for healthy children if first dose was administered at age 24 months or older  **4 weeks** if first dose was administered before the 1st birthday **8 weeks (as final dose for healthy children)** if first dose was administered at the 1st birthday or after | **No further doses needed** for healthy children if previous dose was administered at age 24 months or older **4 weeks** if current age is younger than 12 months **and** previous dose was administered at <7 months old **8 weeks (as final dose for healthy children)** if previous dose was administered between 7–11 months (wait until at least 12 months old); **OR** if current age is 12 months or older ***and*** at least 1 dose was administered before age 12 months | **8 weeks (as final dose)** This dose is only necessary for children age 12 through 59 months regardless of risk, or age 60 through 71 months with any risk, who received 3 doses before age 12 months. |  |\\n| [Inactivated poliovirus](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-polio) [more info icon.](/vaccines/vpd/polio/hcp/index.html) | 6 weeks | **4 weeks** | **4 weeks** if current age is <4 years **6 months (as final dose)** if current age is 4 years or older | **6 months** **(minimum age 4 years for final dose)** |  |\\n| [Measles, mumps, rubella](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mmr) [more info icon.](/vaccines/vpd/mmr/hcp/index.html) | 12 months | **4 weeks** |  |  |  |\\n| [Varicella](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-varicella) [more info icon.](/vaccines/vpd/varicella/hcp/index.html) | 12 months | **3 months** |  |  |  |\\n| [Hepatitis A](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hepa) [more info icon.](/vaccines/vpd/hepa/hcp/index.html) | 12 months | **6 months** |  |  |  |\\n| [Meningococcal ACWY](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mening) [more info icon.](/vaccines/vpd/mening/hcp/index.html) | 2 months MenACWY-CRM 2 years MenACWY-TT | **8 weeks** | See [Notes](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mening) | See [Notes](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mening) |  |\\n\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n\\n## Children and adolescents age 7 through 18 years\\n\\n| Vaccine | Minimum Age for Dose 1 | Minimum Interval Between Doses | | | |\\n| --- | --- | --- | --- | --- | --- |\\n| Dose 1 to Dose 2 | Dose 2 to Dose 3 | Dose 3 to Dose 4 |\\n| [Meningococcal ACWY](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mening) [more info icon.](/vaccines/vpd/mening/hcp/index.html) | Not Applicable (N/A) | **8 weeks** |  |  |\\n| [Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-tdap) [more info icon.](/vaccines/vpd/dtap-tdap-td/hcp/index.html) | 7 years | **4 weeks** | **4 weeks** if first dose of DTaP/DT was administered before the 1st birthday **6 months (as final dose)** if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday | **6 months**  if first dose of DTaP/DT was administered before the 1st birthday |\\n| [Human papillomavirus](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hpv) [more info icon.](/vaccines/vpd/hpv/hcp/index.html) | 9 years | **Routine dosing intervals are recommended.** | | |\\n| [Hepatitis A](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hepa) [more info icon.](/vaccines/vpd/hepa/hcp/index.html) | N/A | **6 months** |  |  |\\n| [Hepatitis B](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-hepb) [more info icon.](/vaccines/vpd/hepb/hcp/index.html) | N/A | **4 weeks** | **8 weeks *and* at least 16 weeks after first dose.** |  |\\n| [Inactivated poliovirus](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-polio) [more info icon.](/vaccines/vpd/polio/hcp/index.html) | N/A | **4 weeks** | **6 months** A fourth dose is not necessary if the third dose was administered at age 4 years or older ***and*** at least 6 months after the previous dose. | A fourth dose of IPV is indicated if all previous doses were administered at <4 years **OR** if the third dose was administered <6 months after the second dose. |\\n| [Measles, mumps, rubella](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-mmr) [more info icon.](/vaccines/vpd/mmr/hcp/index.html) | N/A | **4 weeks** |  |  |\\n| [Varicella](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-varicella) [more info icon.](/vaccines/vpd/varicella/hcp/index.html) | N/A | **3 months** if younger than age 13 years.  **4 weeks** if age 13 years or older |  |  |\\n| [Dengue](/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-dengue) [more info icon.](/dengue/vaccine/hcp/index.html) | 9 years | **6 months** | 6 months |  |\\n\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n![more info icon.](/vaccines/schedules/images/more-info.jpg)\\n\\n## Additional Information\\n\\n**Report**\\n\\n**Questions or comments**  \\nContact [www.cdc.gov/cdc-info](https://www.cdc.gov/cdc-info/)\\xa0or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.\\n\\n**Helpful information**\\n\\n## On This Page\\n\\n## [Vaccines & Immunizations](/vaccines/index.html)\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n### [For Everyone](/vaccines/index.html#gen)\\n\\n### [Health Care Providers](/vaccines/hcp/index.html#hcp)\\n\\n### [Public Health](/vaccines/site.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)\"},\n",
       "  {'title': 'Measles Symptoms and Complications | Measles (Rubeola) | CDC',\n",
       "   'url': 'https://www.cdc.gov/measles/signs-symptoms/index.html',\n",
       "   'content': \"Measles isn't just a little rash. Measles can be dangerous, especially for babies and young children. 7–14 days after a measles infection: first symptoms show Measles symptoms appear 7 to 14 days after contact with the virus. 3–5 days after symptoms begin: measles rash Measles rash appears 3 to 5 days after the first symptoms. They then spread downward to the neck, trunk, arms, legs, and feet.\",\n",
       "   'score': 0.08261607,\n",
       "   'raw_content': '![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n**Related Topics:**\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Measles Symptoms and Complications\\n\\n## Key points\\n\\n![Sick child laying in bed with an IV](/measles/images/sick-child-iv.jpg \"sick-child-iv\")\\n\\n## Signs and symptoms\\n\\n### Seek care immediately!\\n\\nCall your healthcare provider immediately if you think you or your child have been exposed to measles.\\n\\nMeasles isn\\'t just a little rash. Measles can be dangerous, especially for babies and young children.\\n\\n### 7–14 days after a measles infection: first symptoms show\\n\\nMeasles symptoms appear 7 to 14 days after contact with the virus. Measles typically begins with:\\n\\n### 2–3 days after symptoms begin: Koplik spots\\n\\nTiny white spots (Koplik spots) may appear inside the mouth two to three days after symptoms begin.\\n\\n### 3–5 days after symptoms begin: measles rash\\n\\nMeasles rash appears 3 to 5 days after the first symptoms. It usually begins as flat red spots that appear on the face at the hairline. They then spread downward to the neck, trunk, arms, legs, and feet.\\n\\n## Complications\\n\\nCommon complications from measles are:\\n\\n### Who is at risk\\n\\nMeasles can be serious in all age groups. However, there are several groups that are more likely to suffer from measles complications:\\n\\n### Prevent measles & get vaccinated!\\n\\nTalk to your health provider about the [measles, mumps, and rubella (MMR) vaccine.](https://www.cdc.gov/vaccines/vpd/mmr/public/index.html)\\n\\n### Severe complications in children and adults\\n\\nSome people may suffer from severe complications, such as pneumonia (infection of the lungs) and encephalitis (swelling of the brain). They may need to be hospitalized and could die.\\n\\n### Long-term complications\\n\\nSubacute sclerosing panencephalitis (SSPE) is a very rare, but fatal disease of the central nervous system. It results from a measles virus infection acquired earlier in life.\\n\\n#### About SSPE\\n\\n## Resources\\n\\n## On This Page\\n\\n## [Measles (Rubeola)](/measles/index.html)\\n\\nMeasles is one of the most contagious diseases and can be dangerous in babies and young children. The best protection against measles is the MMR vaccine.\\n\\n### [For Everyone](/measles/index.html#gen)\\n\\n### [Health Care Providers](/measles/site.html#hcp)\\n\\n### [Public Health](/measles/site.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)'},\n",
       "  {'title': 'Establishment Registration & Device Listing - Food and Drug Administration',\n",
       "   'url': 'https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/textsearch.cfm',\n",
       "   'content': 'This database includes: medical device manufacturers registered with FDA and; medical devices listed with FDA; Note: Registration of a device establishment, assignment of a registration number, or listing of a medical device does not in any way denote approval of the establishment or its products by FDA.',\n",
       "   'score': 0.08111866,\n",
       "   'raw_content': '![Decrease font size](/scripts/includes/images/img_fdagov_font_adj_small.png \"Decrease font size\")\\n![Return font size to normal](/scripts/includes/images/img_fdagov_font_adj_medium.png \"Return font size to normal\")\\n![Increase font size](/scripts/includes/images/img_fdagov_font_adj_large.png \"Increase font size\")\\n![U.S. Department of Health and Human Services](/scripts/includes/images/img_fdagov_hhs_masthead_logo_r.png \"U.S. Department of Health and Human Services\")\\n![FDA, U.S. Food and Drug Administration](/scripts/includes/images/gov-fda-new-white.png \"FDA, U.S. Food and Drug Administration\")\\n![Search](/scripts/includes/images/img_fdagov_mast_search_button.png \"Search this site\")\\n\\n# Establishment Registration & Device Listing\\n\\n![Print](/scripts/includes/images/img_fdagov_utility_icon_print.png \"Print this page\")\\n![Share](/scripts/includes/images/img_fdagov_utility_icon_share.png \"Share this page\")\\n![E-mail](/scripts/includes/images/img_fdagov_utility_icon_email.png \"E-mail this page\")\\n\\n|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\\n| |  |  |  | | --- | --- | --- | | |  | | --- | | This database includes:  * medical device manufacturers registered with FDA and * medical devices listed with FDA  *Note: Registration of a device establishment, assignment of a registration number, or listing of a medical device does not in any way denote approval of the establishment or its products by FDA.*  You can enter a premarket submission number, a company name, registration or owner/operator number to search for registration and listing information.  [Learn More...](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/default.htm) | |  | |  |  |       |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | Quick Search | | | |  |  |  | | --- | --- | --- | |  | |  | | |       |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | Search by Company or Device Name | | | |  |  | | --- | --- | | Company Name |  | | Device Name |  | | |  |  |  | | --- | --- | --- | | [Advanced Search](./rl.cfm) | [Clear Form](javascript:doClear();) |  | | | | | | |  |  |  | | --- | --- | --- | | |  | | --- | | Other Databases  * [510(k)s](/scripts/cdrh/cfdocs/cfPMN/pmn.cfm \"Database of new or significantly changed device information submitted by medical device manufacturers prior to commercial distribution.\") * [De Novo](/scripts/cdrh/cfdocs/cfPMN/denovo.cfm \"Database of De Novos.\") * [Medical Device Reports (MAUDE)](/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm \"Reports of adverse events involving medical devices.\") * [CDRH Export Certificate Validation (CECV)](/scripts/cdrh/cfdocs/cfRL/DTLS/rl_cert.cfm \"This searchable database contains valid export certificates submitted electronically via CECATS (CDRH Export Certification Application and Tracking System) and issued by the Center for Devices and Radiological Health.\") * [CDRH FOIA Electronic Reading Room](/scripts/cdrh/devicesatfda/readingroom.cfm \"CDRH FOIA Electronic Reading Room.\") * [CFR Title 21](/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm \"Database of the most recent revision of Title 21 of the Code of Federal Regulations (CFR) from the Government Printing Office (GPO). \") * [CLIA](/scripts/cdrh/cfdocs/cfClia/Search.cfm \"Database of laboratory testing standards that ensure the accuracy, reliability and timeliness of patient tests.\") * [Device Classification](/scripts/cdrh/cfdocs/cfPCD/classification.cfm \"Database containing medical device names and associated information developed by the FDA Center for Devices and Radiological Health (CDRH) in support of its mission.\") * [FDA Guidance Documents](http://www.fda.gov/RegulatoryInformation/Guidances/default.htm \"FDA Guidance Documents. \") * [Humanitarian Device Exemption](/scripts/cdrh/cfdocs/cfHDE/hde.cfm \"Humanitaian Device Exemption (HDE) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. \") * [Medsun Reports](/scripts/cdrh/cfdocs/Medsun/searchReportText.cfm \"The Medical Product Safety Network (MedSun) improves FDA’s understanding of problems with the use of medical devices so that the FDA, healthcare facilities, clinicians, and manufacturers can better address safety concerns.\") * [Premarket Approvals (PMAs)](/scripts/cdrh/cfdocs/cfPMA/pma.cfm \"Database of Class III devices that support or sustain human life or are of substantial importance in preventing impairment of human health.\") * [Post-Approval Studies](/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm \"Database of Post-Approval Studies\") * [Postmarket Surveillance Studies](/scripts/cdrh/cfdocs/cfPMA/pss.cfm \"Database of Postmarket Surveillance Studies\") * [Radiation-Emitting Products](/scripts/cdrh/cfdocs/cfPCD_RH/classification.cfm \"The Radiation-Emitting Electronic Product Codes Database contains names of radiation-emitting electronic products and devices and associated information developed by the Center for Devices and Radiological Health (CDRH) in support of its mission. This database contains product names and their associated product codes. Additionally, the radiation type, definition, and applicable performance standards (21 CFR Parts 1020-1050) are provided.\") * [Radiation-Emitting Electronic Products Corrective Actions](/scripts/cdrh/cfdocs/cfPCD_RH/rh_res.cfm \"Electronic products for which manufacturers are required to perform corrective actions when a radiation safety problem exists that was caused by the design, manufacturing, or assembly of the product.\") * [Recalls](/scripts/cdrh/cfdocs/cfRES/res.cfm \"Database of classified medical device recalls since November 1, 2002.\") * [Registration & Listing](/scripts/cdrh/cfdocs/cfRL/rl.cfm \"Database of devices in commercial distribution in the United States submitted by domestic and foreign manufacturers and medical device establishment information submitted by domestic and foreign establishments.\") * [Standards](/scripts/cdrh/cfdocs/cfStandards/search.cfm \"Database of Recognized Consensus Standards with associated FDA, medical device and standards industry information.\") * [Total Product Life Cycle](/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm \"The Total Product Life Cycle (TPLC) database integrates premarket and postmarket data about medical devices. It includes information pulled from CDRH databases including Premarket Approvals (PMA), Premarket Notifications (510[k]), Adverse Events, and Recalls.\") * [X-Ray Assembler](/scripts/cdrh/cfdocs/cfAssem/assembler.cfm \"Database of locations and identities of certified components of diagnostic x-ray systems for routine compliance testing at user facilities. \") | |  | |  |  | |  |  |     |  |  | | --- | --- | | |  | | --- | | Need to update your information? To modify, add, or delete information, [log onto your FURLS account](https://www.access.fda.gov/oaa/). *Note: Changes will appear when the database is updated (usually every Monday).* | | |\\n\\n|  |  |  |\\n| --- | --- | --- |\\n| |  | | --- | | This database includes:  * medical device manufacturers registered with FDA and * medical devices listed with FDA  *Note: Registration of a device establishment, assignment of a registration number, or listing of a medical device does not in any way denote approval of the establishment or its products by FDA.*  You can enter a premarket submission number, a company name, registration or owner/operator number to search for registration and listing information.  [Learn More...](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/default.htm) | |  |\\n|  |  |\\n\\n|  |\\n| --- |\\n| This database includes:  * medical device manufacturers registered with FDA and * medical devices listed with FDA  *Note: Registration of a device establishment, assignment of a registration number, or listing of a medical device does not in any way denote approval of the establishment or its products by FDA.*  You can enter a premarket submission number, a company name, registration or owner/operator number to search for registration and listing information.  [Learn More...](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/default.htm) |\\n\\n|  |  |  |  |  |  |  |\\n| --- | --- | --- | --- | --- | --- | --- |\\n| |  |  | | --- | --- | | |  | | --- | | Quick Search | | | |  |  |  | | --- | --- | --- | |  | |  | | |\\n\\n|  |  |\\n| --- | --- |\\n| |  | | --- | | Quick Search | |\\n| |  |  |  | | --- | --- | --- | |  | |  | |\\n\\n|  |\\n| --- |\\n| Quick Search |\\n\\n|  |  |  |\\n| --- | --- | --- |\\n|  | |  |\\n\\n|  |  |  |  |  |  |  |  |  |  |  |  |  |\\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\\n| |  |  | | --- | --- | | |  | | --- | | Search by Company or Device Name | | | |  |  | | --- | --- | | Company Name |  | | Device Name |  | | |  |  |  | | --- | --- | --- | | [Advanced Search](./rl.cfm) | [Clear Form](javascript:doClear();) |  | | | | |\\n\\n|  |  |\\n| --- | --- |\\n| |  | | --- | | Search by Company or Device Name | |\\n| |  |  | | --- | --- | | Company Name |  | | Device Name |  | | |  |  |  | | --- | --- | --- | | [Advanced Search](./rl.cfm) | [Clear Form](javascript:doClear();) |  | | | |\\n\\n|  |\\n| --- |\\n| Search by Company or Device Name |\\n\\n|  |  |\\n| --- | --- |\\n| Company Name |  |\\n| Device Name |  |\\n| |  |  |  | | --- | --- | --- | | [Advanced Search](./rl.cfm) | [Clear Form](javascript:doClear();) |  | | |\\n\\n|  |  |  |\\n| --- | --- | --- |\\n| [Advanced Search](./rl.cfm) | [Clear Form](javascript:doClear();) |  |\\n\\n|  |  |  |\\n| --- | --- | --- |\\n| |  | | --- | | Other Databases  * [510(k)s](/scripts/cdrh/cfdocs/cfPMN/pmn.cfm \"Database of new or significantly changed device information submitted by medical device manufacturers prior to commercial distribution.\") * [De Novo](/scripts/cdrh/cfdocs/cfPMN/denovo.cfm \"Database of De Novos.\") * [Medical Device Reports (MAUDE)](/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm \"Reports of adverse events involving medical devices.\") * [CDRH Export Certificate Validation (CECV)](/scripts/cdrh/cfdocs/cfRL/DTLS/rl_cert.cfm \"This searchable database contains valid export certificates submitted electronically via CECATS (CDRH Export Certification Application and Tracking System) and issued by the Center for Devices and Radiological Health.\") * [CDRH FOIA Electronic Reading Room](/scripts/cdrh/devicesatfda/readingroom.cfm \"CDRH FOIA Electronic Reading Room.\") * [CFR Title 21](/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm \"Database of the most recent revision of Title 21 of the Code of Federal Regulations (CFR) from the Government Printing Office (GPO). \") * [CLIA](/scripts/cdrh/cfdocs/cfClia/Search.cfm \"Database of laboratory testing standards that ensure the accuracy, reliability and timeliness of patient tests.\") * [Device Classification](/scripts/cdrh/cfdocs/cfPCD/classification.cfm \"Database containing medical device names and associated information developed by the FDA Center for Devices and Radiological Health (CDRH) in support of its mission.\") * [FDA Guidance Documents](http://www.fda.gov/RegulatoryInformation/Guidances/default.htm \"FDA Guidance Documents. \") * [Humanitarian Device Exemption](/scripts/cdrh/cfdocs/cfHDE/hde.cfm \"Humanitaian Device Exemption (HDE) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. \") * [Medsun Reports](/scripts/cdrh/cfdocs/Medsun/searchReportText.cfm \"The Medical Product Safety Network (MedSun) improves FDA’s understanding of problems with the use of medical devices so that the FDA, healthcare facilities, clinicians, and manufacturers can better address safety concerns.\") * [Premarket Approvals (PMAs)](/scripts/cdrh/cfdocs/cfPMA/pma.cfm \"Database of Class III devices that support or sustain human life or are of substantial importance in preventing impairment of human health.\") * [Post-Approval Studies](/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm \"Database of Post-Approval Studies\") * [Postmarket Surveillance Studies](/scripts/cdrh/cfdocs/cfPMA/pss.cfm \"Database of Postmarket Surveillance Studies\") * [Radiation-Emitting Products](/scripts/cdrh/cfdocs/cfPCD_RH/classification.cfm \"The Radiation-Emitting Electronic Product Codes Database contains names of radiation-emitting electronic products and devices and associated information developed by the Center for Devices and Radiological Health (CDRH) in support of its mission. This database contains product names and their associated product codes. Additionally, the radiation type, definition, and applicable performance standards (21 CFR Parts 1020-1050) are provided.\") * [Radiation-Emitting Electronic Products Corrective Actions](/scripts/cdrh/cfdocs/cfPCD_RH/rh_res.cfm \"Electronic products for which manufacturers are required to perform corrective actions when a radiation safety problem exists that was caused by the design, manufacturing, or assembly of the product.\") * [Recalls](/scripts/cdrh/cfdocs/cfRES/res.cfm \"Database of classified medical device recalls since November 1, 2002.\") * [Registration & Listing](/scripts/cdrh/cfdocs/cfRL/rl.cfm \"Database of devices in commercial distribution in the United States submitted by domestic and foreign manufacturers and medical device establishment information submitted by domestic and foreign establishments.\") * [Standards](/scripts/cdrh/cfdocs/cfStandards/search.cfm \"Database of Recognized Consensus Standards with associated FDA, medical device and standards industry information.\") * [Total Product Life Cycle](/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm \"The Total Product Life Cycle (TPLC) database integrates premarket and postmarket data about medical devices. It includes information pulled from CDRH databases including Premarket Approvals (PMA), Premarket Notifications (510[k]), Adverse Events, and Recalls.\") * [X-Ray Assembler](/scripts/cdrh/cfdocs/cfAssem/assembler.cfm \"Database of locations and identities of certified components of diagnostic x-ray systems for routine compliance testing at user facilities. \") | |  |\\n|  |  |\\n|  |  |\\n\\n|  |\\n| --- |\\n| Other Databases  * [510(k)s](/scripts/cdrh/cfdocs/cfPMN/pmn.cfm \"Database of new or significantly changed device information submitted by medical device manufacturers prior to commercial distribution.\") * [De Novo](/scripts/cdrh/cfdocs/cfPMN/denovo.cfm \"Database of De Novos.\") * [Medical Device Reports (MAUDE)](/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm \"Reports of adverse events involving medical devices.\") * [CDRH Export Certificate Validation (CECV)](/scripts/cdrh/cfdocs/cfRL/DTLS/rl_cert.cfm \"This searchable database contains valid export certificates submitted electronically via CECATS (CDRH Export Certification Application and Tracking System) and issued by the Center for Devices and Radiological Health.\") * [CDRH FOIA Electronic Reading Room](/scripts/cdrh/devicesatfda/readingroom.cfm \"CDRH FOIA Electronic Reading Room.\") * [CFR Title 21](/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm \"Database of the most recent revision of Title 21 of the Code of Federal Regulations (CFR) from the Government Printing Office (GPO). \") * [CLIA](/scripts/cdrh/cfdocs/cfClia/Search.cfm \"Database of laboratory testing standards that ensure the accuracy, reliability and timeliness of patient tests.\") * [Device Classification](/scripts/cdrh/cfdocs/cfPCD/classification.cfm \"Database containing medical device names and associated information developed by the FDA Center for Devices and Radiological Health (CDRH) in support of its mission.\") * [FDA Guidance Documents](http://www.fda.gov/RegulatoryInformation/Guidances/default.htm \"FDA Guidance Documents. \") * [Humanitarian Device Exemption](/scripts/cdrh/cfdocs/cfHDE/hde.cfm \"Humanitaian Device Exemption (HDE) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. \") * [Medsun Reports](/scripts/cdrh/cfdocs/Medsun/searchReportText.cfm \"The Medical Product Safety Network (MedSun) improves FDA’s understanding of problems with the use of medical devices so that the FDA, healthcare facilities, clinicians, and manufacturers can better address safety concerns.\") * [Premarket Approvals (PMAs)](/scripts/cdrh/cfdocs/cfPMA/pma.cfm \"Database of Class III devices that support or sustain human life or are of substantial importance in preventing impairment of human health.\") * [Post-Approval Studies](/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm \"Database of Post-Approval Studies\") * [Postmarket Surveillance Studies](/scripts/cdrh/cfdocs/cfPMA/pss.cfm \"Database of Postmarket Surveillance Studies\") * [Radiation-Emitting Products](/scripts/cdrh/cfdocs/cfPCD_RH/classification.cfm \"The Radiation-Emitting Electronic Product Codes Database contains names of radiation-emitting electronic products and devices and associated information developed by the Center for Devices and Radiological Health (CDRH) in support of its mission. This database contains product names and their associated product codes. Additionally, the radiation type, definition, and applicable performance standards (21 CFR Parts 1020-1050) are provided.\") * [Radiation-Emitting Electronic Products Corrective Actions](/scripts/cdrh/cfdocs/cfPCD_RH/rh_res.cfm \"Electronic products for which manufacturers are required to perform corrective actions when a radiation safety problem exists that was caused by the design, manufacturing, or assembly of the product.\") * [Recalls](/scripts/cdrh/cfdocs/cfRES/res.cfm \"Database of classified medical device recalls since November 1, 2002.\") * [Registration & Listing](/scripts/cdrh/cfdocs/cfRL/rl.cfm \"Database of devices in commercial distribution in the United States submitted by domestic and foreign manufacturers and medical device establishment information submitted by domestic and foreign establishments.\") * [Standards](/scripts/cdrh/cfdocs/cfStandards/search.cfm \"Database of Recognized Consensus Standards with associated FDA, medical device and standards industry information.\") * [Total Product Life Cycle](/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm \"The Total Product Life Cycle (TPLC) database integrates premarket and postmarket data about medical devices. It includes information pulled from CDRH databases including Premarket Approvals (PMA), Premarket Notifications (510[k]), Adverse Events, and Recalls.\") * [X-Ray Assembler](/scripts/cdrh/cfdocs/cfAssem/assembler.cfm \"Database of locations and identities of certified components of diagnostic x-ray systems for routine compliance testing at user facilities. \") |\\n\\n|  |  |\\n| --- | --- |\\n| |  | | --- | | Need to update your information? To modify, add, or delete information, [log onto your FURLS account](https://www.access.fda.gov/oaa/). *Note: Changes will appear when the database is updated (usually every Monday).* | |\\n\\n|  |\\n| --- |\\n| Need to update your information? To modify, add, or delete information, [log onto your FURLS account](https://www.access.fda.gov/oaa/). *Note: Changes will appear when the database is updated (usually every Monday).* |\\n\\n#### Links on this page:\\n\\nPage Last Updated: 06/09/2025\\n\\nNote: If you need help accessing information in different file formats, see\\n[Instructions for Downloading Viewers and Players](https://www.fda.gov/about-fda/website-policies/viewing-files).\\n  \\nLanguage Assistance Available: [Español](https://www.fda.gov/about-fda/about-website/language-assistance-services#spanish \"Spanish\") | [繁體中文](https://www.fda.gov/about-fda/about-website/language-assistance-services#chinese \"Chinese\") | [Tiếng Việt](https://www.fda.gov/about-fda/about-website/language-assistance-services#vietnamese \"Vietnamese\") | [한국어](https://www.fda.gov/about-fda/about-website/language-assistance-services#korean \"Korean\") | [Tagalog](https://www.fda.gov/about-fda/about-website/language-assistance-services#tagalog \"Tagolog\") | [Русский](https://www.fda.gov/about-fda/about-website/language-assistance-services#russian \"Russian\") | [العربية](https://www.fda.gov/about-fda/about-website/language-assistance-services#arabic \"Arabic\") | [Kreyòl Ayisyen](https://www.fda.gov/about-fda/about-website/language-assistance-services#creole \"Creole\") | [Français](https://www.fda.gov/about-fda/about-website/language-assistance-services#french \"French\") | [Polski](https://www.fda.gov/about-fda/about-website/language-assistance-services#polish \"Polish\") | [Português](https://www.fda.gov/about-fda/about-website/language-assistance-services#portuguese \"Portuguese\") | [Italiano](https://www.fda.gov/about-fda/about-website/language-assistance-services#italian \"Italian\") | [Deutsch](https://www.fda.gov/about-fda/about-website/language-assistance-services#german \"German\") | [日本語](https://www.fda.gov/about-fda/about-website/language-assistance-services#japanese \"Japanese\") | [فارسی](https://www.fda.gov/about-fda/about-website/language-assistance-services#farsi \"Farsi\") | [English](https://www.fda.gov/about-fda/about-website/language-assistance-services#english \"English\")\\n\\n![FDA](/scripts/includes/images/fda-square-white-small.png \"FDA Homepage\")\\n![USA.gov](/scripts/includes/images/img_fdagov_footer_logo_usagov.png \"USA.gov\")\\n![E-mail](/scripts/includes/images/img_fdagov_footer_icon_email.png \"Subscribe to E-mails\")\\n![RSS](/scripts/includes/images/img_fdagov_footer_icon_rss.png \"Subscribe to RSS Feeds\")\\n![Twitter](/scripts/includes/images/img_fdagov_footer_icon_twitter.png \"Follow FDA on Twitter\")\\n![Facebook](/scripts/includes/images/img_fdagov_ftr_icon_facebook.png \"Follow FDA on Facebook\")\\n![YouTube](/scripts/includes/images/img_fdagov_footer_icon_youtube.png \"View FDA Videos\")\\n![Flickr](/scripts/includes/images/img_fdagov_footer_icon_flickr.png \"View FDA Photostream on Flickr\")\\n![U.S. Department of Health & Human Services](/scripts/includes/images/img_fdagov_footer_hhslogo.png \"U.S. Department of Health & Human Services\")\\n\\n#### Links on this page:'},\n",
       "  {'title': 'Documenting Vaccinations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/admin/document-vaccines.html',\n",
       "   'content': \"Health care providers are required by law to record certain information in a patient's medical record. This record can be in electronic or paper form. Health care providers who administer vaccines covered by the National Childhood Vaccine Injury Act are required to ensure that the permanent medical record of the recipient indicates:\",\n",
       "   'score': 0.08042261,\n",
       "   'raw_content': None},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'http://main.diabetes.org/dorg/PDFs/awareness-programs/hhm/what_can_i_eat-best_foods-American_Diabetes_Association.pdf',\n",
       "   'content': 'A large part of it is making choices about the foods you eat. But there are also best choices within each food group. A best choice is a food that is better for you than other foods in the same group. Best choices are lower in saturated fat, trans fat, added sugar and sodium than similar foods.',\n",
       "   'score': 0.079560205,\n",
       "   'raw_content': 'Best Foods for You: Healthy Food Choices for People with Diabetes What Can I Eat?\\nMaking Choices Managing diabetes from day to day is up to you. A large part of it is making choices about the foods you eat. Everyone knows that vegetables are healthier than cookies. But there are also best choices within each food group.\\nA best choice is a food that is better for you than other foods in the same group. Best choices are lower in saturated fat, trans fat, added sugar and sodium than similar foods.\\nNonstarchy Vegetables \\uf084 The best choices are fresh, frozen and canned vegetables and vegetable juices without added salt (sodium), fat or sugar such as: •\\tAsparagus •\\tGreen beans •\\tCarrots •\\tCabbage •\\tEggplant •\\tCauliflower •\\tBroccoli •\\tMushrooms •\\tTomatoes •\\tSpinach •\\tOnion •\\tPeppers \\uf084 If using canned veggies, drain and rinse them with water to wash away about 40% of the sodium. Fruit \\uf084 The best choices are fresh, frozen and canned fruits without added sugars such as: • Apple • Blueberries • Orange • Grapefruit • Grapes • Peaches • Pear • Plums • Cherries \\uf084 If you use canned fruit in syrup, drain and rinse the fruit with water to wash away the extra syrup.\\nMilk \\uf084 The best choices are milk and yogurt without added sugars such as: •\\tFat-free or low-fat milk (1%) •\\tUnflavored soy milk •\\tPlain, nonfat yogurt •\\t“light” yogurt Grains and Starchy Vegetables \\uf084 The best choices are whole grain foods, beans, peas and lentils and starchy vegetables without added fats, sugars or sodium.\\nBest Choices of Whole Grain Foods \\uf084 Look for cereals, breads, and grains with these whole grains as the first ingredient: • Whole wheat flour • Whole oats/oatmeal • Whole-grain corn/corn meal • Popcorn • Brown rice • Whole-grain rye • Whole-grain barley • Wild rice • Buckwheat/buckwheat flour • Triticale • Bulgur (cracked wheat) • Millet • Quinoa • Sorghum \\uf084 Choose cereals with at least 3 grams of fiber and less than 6 grams of sugar per serving.\\nBest Choices of Legumes and Lentils • Beans such as black, pinto and kidney • Lentils and dried peas • Fat-free refried beans and vegetarian baked beans .\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\nFor more information visit diabetes.org or call 1-800-DIABETES . 1 .\\n1-800-DIABETES (1-800-342-2383) www.diabetes.org Looking for healthy recipes and food tips?\\nSign up for our FREE online resource, Recipes for Healthy Living at diabetes.org/recipes.\\n© 2015 American Diabetes Association 3/2015 Best Choices of Starchy Vegetables • Acorn squash • Butternut squash • Green peas • Corn • Parsnip • Pumpkin • Sweet potato • Plantain Protein \\uf084 The best choices are plant-based protein foods, fish, chicken, and lean meats such as: • Beans and lentils • Nuts and seeds • Fish and seafood • Eggs and cheese • Chicken, turkey, and duck with-out the skin • Buffalo, rabbit and venison • Lean cuts of beef, lamb, and pork such as chuck, rump roast, round, sirloin, T-bone steak and tender-loin A great protein choice. Dried beans, hummus, lentils, nuts, soy-based “nuggets” and “burgers” are examples of plant based protein foods. Use them in your meals instead of beef, poultry or fish.\\nFats \\uf084 Best choices or “good fats” are unsaturated fats like omega-3, monounsaturated and polyunsatu-rated fats: • Avocado, olives and seeds such as flax, pumpkin or sesame • Nuts such as almonds, brazil, cashews, hazelnuts, peanuts, pine, pecans, pistachios and walnuts • Oils such as olive, canola, corn, flaxseed, safflower, soybean and sunflower • Salad dressings and mayonnaise Omega-3 Fatty acids are good for your Heart. When picking your fat sources, consider these foods: –\\tAlbacore tuna, mackerel, halibut, herring, salmon, sardines and trout –\\tFlaxseeds and English walnuts –\\tOils such as canola, soybean, flaxseed and walnut Go Easy \\uf084 Avoid regular soda, fruit punch, sports drinks, sweet tea, and other sugary drinks. Choose water and calorie free drinks instead.\\n\\uf084 Cut back on high calorie snack foods and desserts such as chips, cookies, cakes and ice cream.\\n\\uf084 Replace “bad” fats from fatty meats, full fat dairy, lard, butter and sour cream with “good” fats.\\n\\uf084 Keep portions small.\\nFoods I Like _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ _________________________ ______________ .\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\n.\\nWhat Can I Eat?\\n. 2 .'},\n",
       "  {'title': 'Tetanus Vaccine Recommendations - CDC',\n",
       "   'url': 'https://www.cdc.gov/tetanus/hcp/vaccine-recommendations/index.html',\n",
       "   'content': 'CDC recommends tetanus vaccines for people across the lifespan, including for wound management. Follow the recommended immunization schedule to ensure that your patients get the tetanus vaccines that they need.',\n",
       "   'score': 0.07879127,\n",
       "   'raw_content': None},\n",
       "  {'title': 'HPV Vaccination Recommendations | CDC - Centers for Disease Control and ...',\n",
       "   'url': 'https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html',\n",
       "   'content': 'Vaccination Recommendations Keep in mind that HPV vaccination prevents new HPV infections but does not treat existing HPV infections or diseases. HPV vaccine works best when given before any exposure to HPV. Most sexually active adults have already been exposed to HPV, although not necessarily all of the HPV types targeted by vaccination. Three doses of HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26 years, and for immunocompromised persons. Vaccine Safety HPV vaccines are very safe.',\n",
       "   'score': 0.07303915,\n",
       "   'raw_content': '![U.S. flag](/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png)\\n![Official icon](/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg)\\n\\n**Official websites use .gov**\\n\\nA .gov website belongs to an official government organization in the United States.\\n\\n![Lock icon](/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg)\\n\\n**Secure .gov websites use HTTPS**\\n\\nA lock (  ) or https:// means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![CDC Logo](/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg)\\n![CDC Logo](/TemplatePackage/4.0/assets/imgs/logo/logo-notext.svg)\\n\\n# HPV Vaccination Recommendations\\n\\nFor the full text of CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations, see the [Human Papillomavirus (HPV) ACIP Vaccine Recommendations](/vaccines/hcp/acip-recs/vacc-specific/hpv.html).\\n\\n## Vaccination Recommendations\\n\\nKeep in mind that HPV vaccination prevents new HPV infections but does not treat existing HPV infections or diseases. HPV vaccine works best when given before any exposure to HPV.\\n\\nMost sexually active adults have already been exposed to HPV, although not necessarily all of the HPV types targeted by vaccination. At any age, having a new sex partner is a risk factor for getting a new HPV infection. People who are in a long-term, mutually monogamous relationship are not likely to get a new HPV infection.\\n\\n[Talking to Parents about HPV Vaccine [1page]](/hpv/hcp/for-hcp-tipsheet-hpv.pdf)\\n\\n![Talking to parents about hpv vaccine, CDC, HPV vaccine is cancer prevention](/vaccines/vpd/images/for-hcp-tipsheet-hpv.jpg?_=56887 \"for-hcp-tipsheet-hpv\")\\n\\n## Dosing Schedules\\n\\nTwo doses of HPV vaccine are recommended for most persons starting the series before their 15th birthday.\\n\\nThree doses of HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26 years, and for immunocompromised persons.\\n\\n## Contraindications and Precautions\\n\\nA severe allergic reaction (e.g., anaphylaxis) to a vaccine component or following a prior dose of HPV vaccine is a contraindication to receipt of HPV vaccine.\\n\\n## Pregnancy\\n\\nHPV vaccine is not recommended for use during pregnancy. Women known to be pregnant should delay initiation of the vaccination series until after the pregnancy. However, pregnancy testing before vaccination is not needed.\\n\\nAlthough HPV vaccines have not been linked to causing adverse pregnancy outcomes or side effects (adverse events) to the developing fetus among pregnant women vaccinated inadvertently, HPV vaccines have not been studied in pregnant women in clinical trials.\\n\\n## Vaccine Safety\\n\\nHPV vaccines are very safe. Scientific research shows the benefits of HPV vaccination far outweigh the potential risks. Like all medical interventions, vaccines can have some side effects.\\n\\nAll vaccines used in the United States, including HPV vaccines, go through extensive safety testing before the U.S. Food and Drug Administration (FDA) licenses them. During clinical trials before the licensure, the 9-valent HPV vaccine Gardasil 9 was studied in more than 15,000 males and females and was found to be safe and effective.\\n\\n## Adverse Reactions\\n\\nSyncope (fainting) can occur after any medical procedure, including vaccination. Adolescents should be seated or lying down during vaccination and remain in that position for 15 minutes after vaccination. This is to prevent any injuries that could occur from a fall during a syncopal event.'},\n",
       "  {'title': 'Father-daughter incest: data from an anonymous computerized survey',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/22452300/',\n",
       "   'content': 'Retrospective data were entered anonymously by 1,521 adult women using computer-assisted self-interview. Nineteen were classified as victims of father-daughter incest, and 241 were classified as victims of sexual abuse by an adult other than their father before reaching 18 years of age. The remainin …',\n",
       "   'score': 0.06917,\n",
       "   'raw_content': '![U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\\n\\nAn official website of the United States government\\n\\n![Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**\\n  \\nFederal government websites often end in .gov or .mil. Before\\nsharing sensitive information, make sure you’re on a federal\\ngovernment site.\\n\\n![Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**\\n  \\nThe **https://** ensures that you are connecting to the\\nofficial website and that any information you provide is encrypted\\nand transmitted securely.\\n\\n![NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)\\n\\n#### Account\\n\\n![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/855489e2-fd04-4caa-9021-74bf9c277210/core/images/pubmed-logo-blue.svg)\\n\\n## Save citation to file\\n\\n## Email citation\\n\\n### Add to Collections\\n\\n### Add to My Bibliography\\n\\n## Your saved search\\n\\n## Create a file for external citation management software\\n\\n## Your RSS Feed\\n\\n### Actions\\n\\n### Share\\n\\n### Page navigation\\n\\n# Father-daughter incest: data from an anonymous computerized survey\\n\\n### Affiliation\\n\\n# Father-daughter incest: data from an anonymous computerized survey\\n\\n### Authors\\n\\n### Affiliation\\n\\n## Abstract\\n\\nRetrospective data were entered anonymously by 1,521 adult women using computer-assisted self-interview. Nineteen were classified as victims of father-daughter incest, and 241 were classified as victims of sexual abuse by an adult other than their father before reaching 18 years of age. The remaining 1,261 served as controls. Incest victims were more likely than controls to endorse feeling damaged, psychologically injured, estranged from one or both parents, and shamed by others when they tried to open up about their experience. They had been eroticized early on by the incest experience, and it interfered with their adult sexuality. Incest victims experienced coitus earlier than controls and after reaching age 18 had more sex partners and were more likely to have casual sex outside their primary relationship and engage in sex for money than controls. They also had worse scores on scales measuring depression, sexual satisfaction, and communication about sex than controls.\\n\\n[PubMed Disclaimer](/disclaimer/)\\n\\n## Similar articles\\n\\n## Cited by\\n\\n## MeSH terms\\n\\n## Related information\\n\\n## LinkOut - more resources\\n\\n### Full Text Sources\\n\\n### Medical\\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/)\\n[PMC](https://www.ncbi.nlm.nih.gov/pmc/)\\n[Bookshelf](https://www.ncbi.nlm.nih.gov/books)\\n[Disclaimer](/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike  \\nBethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)'},\n",
       "  {'title': 'Hepatitis B Vaccine Administration | Hepatitis B | CDC',\n",
       "   'url': 'https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html',\n",
       "   'content': 'Hepatitis B Explore Topics Search Search For Everyone Basics Symptoms Testing Prevention Treatment Vaccination Tools and Resources View all Health Care Providers Clinical Overview Perinatal Provider Clinical Overview Clinical Signs and Symptoms Clinical Screening Clinical Care and Treatment Infection Control Guidance Vaccine Administration Tools and Resources View all Related Topics: Viral Hepatitis|Hepatitis A|Hepatitis C|Viral Hepatitis Surveillance Reports View All search close search search Hepatitis BMenu search For Everyone Basics Symptoms Testing Prevention Treatment Vaccination Tools and Resources View AllHome Health Care Providers Clinical Overview Perinatal Provider Clinical Overview Clinical Signs and Symptoms Clinical Screening Clinical Care and Treatment Infection Control Guidance Vaccine Administration Tools and Resources View All Related Topics Viral Hepatitis Hepatitis A Hepatitis C Viral Hepatitis Surveillance Reports View All Hepatitis B Clinical OverviewPerinatal Provider Clinical OverviewClinical Signs and SymptomsClinical ScreeningClinical Care and TreatmentInfection Control GuidanceVaccine AdministrationTools and ResourcesView All January 31, 2025 Hepatitis B Vaccine Administration What to know The Advisory Committee on Immunization Practices (ACIP) recommends hepatitis B (HepB) vaccination among all infants at birth, unvaccinated children younger than 19 years of age, adults aged 19–59 years, and adults aged 60 years and older with risk factors for hepatitis B or without identified risk factors but seeking protection. Who should be vaccinated ACIP recommends that the following people shouldreceive hepatitis B (HepB) vaccination: All infants. Unvaccinated children younger than 19 years of age. Adults 19–59 years. Adults 60 years and older with risk factors for hepatitis B.',\n",
       "   'score': 0.06708697,\n",
       "   'raw_content': 'Hepatitis B Vaccine Administration | Hepatitis B | CDC\\n===============\\n\\n[Skip directly to site content](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#content)[Skip directly to search](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc-search)[Skip directly to On This Page](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#first-on-this-page)\\n\\n![Image 1: U.S. flag](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/us_flag_small.png)An official website of the United States government\\n\\n[Here\\'s how you know](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#gov-notice)\\n\\n![Image 2](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\n**Official websites use .gov**\\nA .gov website belongs to an official government organization in the United States.\\n\\n![Image 3](https://www.cdc.gov/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\n**Secure .gov websites use HTTPS**\\nA **lock** (  ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n[![Image 4: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[Hepatitis B](https://www.cdc.gov/hepatitis-b/index.html)\\n\\n Explore Topics \\n\\n[Search](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#)\\n\\nSearch\\n\\n[For Everyone](https://www.cdc.gov/hepatitis-b/index.html)\\n\\n*   [Basics](https://www.cdc.gov/hepatitis-b/about/index.html)\\n*   [Symptoms](https://www.cdc.gov/hepatitis-b/signs-symptoms/index.html)\\n*   [Testing](https://www.cdc.gov/hepatitis-b/testing/index.html)\\n*   [Prevention](https://www.cdc.gov/hepatitis-b/prevention/index.html)\\n*   [Treatment](https://www.cdc.gov/hepatitis-b/treatment/index.html)\\n*   [Vaccination](https://www.cdc.gov/hepatitis-b/vaccination/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/public-resources/index.html)\\n*   [View all](https://www.cdc.gov/hepatitis-b/site.html#gen)\\n\\n[Health Care Providers](https://www.cdc.gov/hepatitis-b/site.html#hcp)\\n\\n*   [Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html)\\n*   [Perinatal Provider Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/perinatal-provider-overview/index.html)\\n*   [Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)\\n*   [Clinical Screening](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html)\\n*   [Clinical Care and Treatment](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html)\\n*   [Infection Control Guidance](https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html)\\n*   [Vaccine Administration](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)\\n*   [View all](https://www.cdc.gov/hepatitis-b/site.html#hcp)\\n\\n**Related Topics:**\\n\\n[Viral Hepatitis](https://www.cdc.gov/hepatitis/index.html)|[Hepatitis A](https://www.cdc.gov/hepatitis-a/index.html)|[Hepatitis C](https://www.cdc.gov/hepatitis-c/index.html)|[Viral Hepatitis Surveillance Reports](https://www.cdc.gov/hepatitis/php/statistics-surveillance/index.html)\\n\\n[View All](https://www.cdc.gov/hepatitis-b/site.html)\\n\\n[![Image 5: Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](https://www.cdc.gov/TemplatePackage/5.0/img/logo/logo-notext.svg)](https://www.cdc.gov/)\\n\\n[_search_ _close search_](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#)\\n\\nsearch\\n\\n[Hepatitis B](https://www.cdc.gov/hepatitis-b/index.html)[Menu](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#)\\n\\nsearch\\n\\n For Everyone \\n\\n*   [Basics](https://www.cdc.gov/hepatitis-b/about/index.html)\\n*   [Symptoms](https://www.cdc.gov/hepatitis-b/signs-symptoms/index.html)\\n*   [Testing](https://www.cdc.gov/hepatitis-b/testing/index.html)\\n*   [Prevention](https://www.cdc.gov/hepatitis-b/prevention/index.html)\\n*   [Treatment](https://www.cdc.gov/hepatitis-b/treatment/index.html)\\n*   [Vaccination](https://www.cdc.gov/hepatitis-b/vaccination/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/public-resources/index.html)\\n*   [View All](https://www.cdc.gov/hepatitis-b/site.html#gen)[Home](https://www.cdc.gov/hepatitis-b/index.html)\\n\\n Health Care Providers \\n\\n*   [Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html)\\n*   [Perinatal Provider Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/perinatal-provider-overview/index.html)\\n*   [Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)\\n*   [Clinical Screening](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html)\\n*   [Clinical Care and Treatment](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html)\\n*   [Infection Control Guidance](https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html)\\n*   [Vaccine Administration](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)\\n*   [View All](https://www.cdc.gov/hepatitis-b/site.html#hcp)\\n\\nRelated Topics\\n\\n*   [Viral Hepatitis](https://www.cdc.gov/hepatitis/index.html)\\n*   [Hepatitis A](https://www.cdc.gov/hepatitis-a/index.html)\\n*   [Hepatitis C](https://www.cdc.gov/hepatitis-c/index.html)\\n*   [Viral Hepatitis Surveillance Reports](https://www.cdc.gov/hepatitis/php/statistics-surveillance/index.html)\\n\\n[View All Hepatitis B](https://www.cdc.gov/hepatitis-b/site.html)\\n\\n[Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html)[Perinatal Provider Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/perinatal-provider-overview/index.html)[Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)[Clinical Screening](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html)[Clinical Care and Treatment](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html)[Infection Control Guidance](https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html)[Vaccine Administration](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html)[Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)[View All](https://www.cdc.gov/hepatitis-b/site.html)\\n\\n![Image 6](blob:http://localhost/398a4958f85afc100ea1e12cd9291bd7)\\n\\n January 31, 2025 \\n\\nHepatitis B Vaccine Administration\\n==================================\\n\\nWhat to know\\n------------\\n\\nThe Advisory Committee on Immunization Practices (ACIP) recommends hepatitis B (HepB) vaccination among all infants at birth, unvaccinated children younger than 19 years of age, adults aged 19–59 years, and adults aged 60 years and older with risk factors for hepatitis B or without identified risk factors but seeking protection.\\n\\n![Image 7: A doctor placing a vaccine in a patient\\'s shoulder](https://www.cdc.gov/hepatitis-b/media/images/2024/04/hepatitis-b-vaccination-administration-thumbnail.jpg)\\n\\nWho should be vaccinated\\n------------------------\\n\\nACIP recommends that the following people **should**receive hepatitis B (HepB) vaccination:\\n\\n*   All infants.\\n\\n*   Unvaccinated children younger than 19 years of age.\\n\\n*   Adults 19–59 years.\\n\\n*   Adults 60 years and older with [risk factors](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html) for hepatitis B.\\n\\nThe following groups **may also** receive HepB vaccination:\\n\\n*   Adults 60 years and older without known risk factors for hepatitis B.\\n\\n**See Also:**[Hepatitis B Screening Questionnaire for HCPs from Immunize.org](https://www.immunize.org/wp-content/uploads/catg.d/p2191.pdf)\\n\\n### Recommendations for screening, testing, and vaccination\\n\\nThe table below provides recommendations for screening, testing, and vaccination[1](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdcreference_1) among adults and all persons with risk. Prevaccination testing should not be a barrier to vaccination of susceptible people, especially in populations that have less engagement with or access to health care. In settings where testing is not feasible or is refused by the patient, the clinician should offer vaccination and, at future visits, should offer testing again.\\n\\n**Population**\\n\\n**Screening and testing recommendation**\\n\\n**Vaccination recommend ation**\\n\\nAdults with no known risk factors for hepatitis B\\n\\n*   If never previously screened, test for HBsAg, anti-HBs, and total anti-HBc (triple panel)\\n\\n*   Vaccinate § adults aged 19 – 59 years\\n\\nPeople with [risk factors](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html#cdc_hcp_diagnosis_determining_approach-how-to-make-decisions-on-whether-to-test-or-screen), regardless of age.*\\n\\n*   If never previously screened, test for HBsAg, anti-HBs, and total anti-HBc (triple panel)\\n\\n*       *   Unless less than aged 18 years and completed a vaccine series as an infant\\n\\n*   If previously screened, but still unvaccinated, offer testing to people who have ongoing risk for exposure\\n\\n*   Vaccinate §\\n\\nPeople with additional risk factors, such as:\\n\\n*   Residents and staff of facilities for people with developmental disabilities\\n*   Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids\\n*   People with diabetes at the discretion of the treating clinician\\n*   International travelers to countries with high or intermediate levels of endemic hepatitis B virus infection\\n\\n*   If never previously screened, test for HBsAg, anti-HBs, and total anti-HBc (triple panel)\\n    *   Unless less than aged 18 years and completed a vaccine series as an infant\\n\\n*   Vaccinate† §\\n\\n_*_ For additional considerations for patients on dialysis, see _\\\\_Footnote A\\\\_ ._[A](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdcfootnote_1)\\n\\n† For additional considerations for healthcare personnel see _\\\\_Footnote B\\\\_._[B](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdcfootnote_2)\\n\\n§ Vaccinate susceptible persons without documentation of a completed hepatitis B vaccination series; testing should not be a barrier to vaccination.\\n\\nFor testing recommendations and assistance interpreting B screening results, see [hepatitis B testing guidelines](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html).\\n\\nComposition and dosage\\n----------------------\\n\\nThe United States Food and Drug Administration (FDA) has licensed three single-antigen vaccines (Engerix-B, Heplisav-B, and Recombivax HB), and three combination vaccines (Pediarix, Vaxelis, and Twinrix) to protect against hepatitis B. All vaccines contain yeast protein and aluminum adjuvant or a small synthetic nucleotide immunostimulant (Heplisav-B).\\n\\nNo differences in immunogenicity have been observed when one or 2 doses of hepatitis B vaccine produced by one manufacturer are followed by doses from a different manufacturer. Whenever feasible, the same vaccine should be used for the subsequent doses; however, if a different brand is administered, the dose(s) should be [considered valid](https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm#:~:text=Other%20Immunization%20Management%20Issues) and do not need to be repeated.\\n\\n### Engerix-B\\n\\n**For persons from birth through adulthood**\\n\\nPeople aged 19 years and younger should receive three doses. People aged 20 years and older should receive three doses. Adults on hemodialysis should receive four doses. See package insert for detailed dosage instructions.\\n\\nSee the [Engerix-B package insert](https://www.fda.gov/media/119403/download?attachment).\\n\\n### Heplisav-B\\n\\n**For adults aged 18 years through adulthood**\\n\\nPeople aged 18 years and older should receive two doses. The safety and effectiveness of Heplisav-B has not been established in adults on hemodialysis. See package insert for indications and detailed dosage instructions.\\n\\nSee the [Heplisav-B package insert](https://www.fda.gov/media/108745/download?attachment).\\n\\n### Recombivax HB\\n\\n**For persons from birth through adulthood**\\n\\nPeople aged 19 years and younger should receive three doses. People aged 20 years and older should receive three doses. Adults on dialysis or predialysis should receive three doses of the dialysis formulation. See package insert for indications and detailed dosage instructions.\\n\\nSee the [Recombivax HB package insert](https://www.fda.gov/media/74274/download?attachment).\\n\\n### PreHevbrio\\n\\n### PreHevbrio voluntary nationwide recall\\n\\nAs of November of 2024, the vaccine manufacturer is initiating a voluntary nationwide recall of all remaining PreHevbrio® [Hepatitis B Vaccine (Recombinant); NDC 75052-001-10] due to restructuring of the company and discontinuing operations. Further distribution or use of any remaining PreHevbrio vaccine by healthcare providers or others should cease immediately.\\n\\nVaccination should not be deferred when the manufacturer of previously administered doses is unknown or when the vaccine from the same manufacturer is unavailable. For vaccine series started with PreHevbrio as dose 1 or doses 1 and 2, vaccine from a different manufacturer should adhere to the 3-dose schedule; if PreHevbrio was given as dose 1, another vaccine licensed for adults (i.e., Engerix-B or Recombivax HB) should be given as dose 2 and dose 3 in accordance with the schedule. The 2-dose Heplisav-B vaccine series can also be given as dose 2 and dose 3 to complete a 3-dose vaccine series when the manufacturer of a previously administered dose 1 is unknown, or PreHevbrio was given as dose 1.\\n\\n[Recall Details](https://www.vbivaccines.com/press-releases/vbi-vaccines-issues-voluntary-nationwide-recall-of-all-prehevbrio-vaccine-due-to-discontinuation-of-company-operations/)\\n\\n### Pediarix\\n\\n**For children aged 6 weeks through age 6 years**\\n\\nPeople between 6 weeks and 6 years of age should receive three doses. See package insert for detailed dosage instructions.\\n\\nSee the [Pediarix package insert](https://www.fda.gov/media/79830/download?attachment).\\n\\n### Vaxelis\\n\\n**For children aged 6 weeks through age 4 years**\\n\\nPeople between 6 weeks and 4 years of age should receive three doses. See package insert for detailed dosage instructions.\\n\\nSee the [Vaxelis package insert](https://www.fda.gov/media/119465/download).\\n\\n### Twinrix\\n\\n**For adults aged 18 years through adulthood**\\n\\nPeople aged 18 years and older should receive either three or four doses. See package insert for detailed dosage instructions.\\n\\nSee the [Twinrix package insert](https://www.fda.gov/media/119351/download?attachment).\\n\\nVaccine effectiveness\\n---------------------\\n\\nEach of the HepB vaccines are highly effective in preventing infection. Studies indicate that immunity persists for at least 30 years among healthy people who initiate HepB vaccination at less than 6 months of age.\\n\\n### Hemodialysis\\n\\nProviders should vaccinate adult hemodialysis patients needing HepB vaccination with high-dose (40ug) Engerix-B or Recombivax HB. See package insert for detailed dosage instructions.\\n\\n### Pregnancy\\n\\nProviders should vaccinate pregnant patients needing HepB vaccination with Engerix-B, Heplisav-B, Recombivax HB, or Twinrix.\\n\\nSafety and precautions\\n----------------------\\n\\nScientific evidence overwhelmingly supports the safety of HepB vaccines.\\n\\nAs a precaution, clinicians should ask the person getting the vaccine if they\\'ve previously experienced an allergic reaction to:\\n\\n*   A previous dose of HepB vaccine.\\n\\n*   Any part of HepB vaccine.\\n\\n*   Yeast.\\n\\nPeople who are moderately or severely ill should wait until they recover before getting a HepB vaccine. However, administering the vaccine to people with minor illnesses, such as a cold, is fine. Learn more about [contraindications and precautions](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html).\\n\\nReporting adverse events\\n------------------------\\n\\nThe most frequently reported adverse event associated with HepB vaccination is injection site soreness. Any adverse event suspected to be associated with HepB vaccination should be reported through the [Vaccine Adverse Event Reporting System](https://vaers.hhs.gov/) (VAERS).\\n\\nVAERS is an early warning system, co-managed by CDC and the FDA, that monitors potential vaccine safety problems. Clinicians and vaccine manufacturers are required by law to report certain adverse events following vaccination to VAERS. Patients and caregivers can also submit reports.\\n\\nAdministration\\n--------------\\n\\nClinicians should administer the vaccine intramuscularly into the anterolateral aspect of the thigh or the deltoid muscle of the upper arm, depending on the person’s age. When administering multiple vaccines, Clinicians should use different anatomic sites (e.g., separate limbs).\\n\\n### Concurrent administration of other vaccines\\n\\nClinicians can administer HepB vaccine concurrently with other vaccines to children and adults. There is no evidence that coadministration reduces the vaccine response or effectiveness.\\n\\n### Vaccine schedules\\n\\nHepB vaccine can be given as a stand-alone vaccine or as part of a combination vaccine. For detailed information on HepB vaccine schedules, see immunization schedules from CDC.\\n\\n[![Image 8: Child immunization schedule.](https://www.cdc.gov/vaccines/hcp/imz-schedules/images/schedule-child.jpg)](https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html \"Child and Adolescent Immunization Schedule by Age (Addendum updated April 16, 2025)\")\\n\\n[Child and Adolescent Immunization Schedule by Age (Addendum updated April 16, 2025)](https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html)\\n\\nGuide health care providers in determining recommended vaccines for each age group.\\n\\n[![Image 9: Adults immunization schedule.](https://www.cdc.gov/vaccines/hcp/imz-schedules/images/schedule-adults.jpg)](https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html \"Adult Immunization Schedule by Age\\xa0(Addendum updated April 16, 2025)\")\\n\\n[Adult Immunization Schedule by Age(Addendum updated April 16, 2025)](https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html)\\n\\nStay up-to-date on getting recommended vaccines. View and print CDC immunization schedules for adult\\n\\nResources\\n---------\\n\\n### Scientific guidelines and recommendations\\n\\n[Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024](https://www.cdc.gov/mmwr/volumes/73/wr/mm7348a3.htm?s_cid=mm7348a3_w)\\n\\nMMWR. Morbidity and Mortality Weekly Report / Vol. 73 / No. 48 / P. 1106\\n\\n[Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022](https://www.cdc.gov/mmwr/volumes/71/wr/mm7113a1.htm?s_cid=mm7113a1_w)\\n\\nMMWR. Morbidity and Mortality Weekly Report / Vol. 71 / No. 13 / P. 477–483\\n\\n[Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023](https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w)\\n\\nMMWR. Recommendations and Reports / Vol. 72 / No. 1 / P. 1–25\\n\\n[Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant](https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm)\\n\\nMMWR. Morbidity and Mortality Weekly Report / Vol. 67 / No. 15 / P. 455–458\\n\\n[Hepatitis B Vaccination, Screening, and Linkage to Care](https://www.acpjournals.org/doi/10.7326/M17-1106)\\n\\nBest practice advice from the American College of Physicians and CDC.\\n\\n### Continuing education\\n\\n[Driving Hepatitis B Management: Universal Screening and Vaccination in Primary Care](https://www.medscape.org/viewarticle/992709)\\n\\nFree continuing education credits and hepatitis B screening, testing, and vaccination recommendations from CDC and ACIP.\\n\\n[University of Washington Hepatitis B Online Resource](https://www.hepatitisb.uw.edu/go/prevention-hbv/hbv-immunizations/core-concept/all)\\n\\nFree continuing education credits and more information on HBV immunizations.\\n\\n### Vaccine requirements by state\\n\\n[Hepatitis B Vaccine Requirements for Childcare and School (Kg–Gr 12)](https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-childcare-school/)\\n\\nVaccination requirements for childcare and schools from Immunize.org.\\n\\n[Hepatitis B Vaccine Requirements for Colleges and Universities](https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-college/)\\n\\nVaccination requirements for colleges and universities from Immunize.org.\\n\\n### Standing orders\\n\\n[Use of Standing Orders Programs to Increase Adult Vaccination Rates](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4901a2.htm)\\n\\nMMWR covers the effectiveness of these programs, describes implementation, and recommends initiating these programs to improve immunization coverage.\\n\\n### Vaccine assistance programs\\n\\n[Merck Vaccine Patient Assistance Program](https://www.merckhelps.com/)\\n\\nThis site outlines the Merck Vaccine Patient Assistance Program for people who need help with paying for medications and vaccines.\\n\\n[GSK Patient Assistance Program](https://www.gskforyou.com/)\\n\\nThis site outlines the GSK Patient Assistance Program for people who need help with paying for medications and vaccines.\\n\\n### Specific sites and tools\\n\\n[Vaccine Storage and Handling](https://www.cdc.gov/vaccines/hcp/storage-handling)\\n\\nProper vaccine storage and handling practices for clinicians.\\n\\n[Vaccine Administration](https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html)\\n\\nHealthcare providers, learn proper vaccine administration protocols and access vaccine administratio...\\n\\n[Vaccinating Adults: A Step-by-Step Guide](https://www.immunize.org/about/history/pub-archives/adult-guide/)\\n\\nA step-by-step guide from the Immunization Action Coalition providing information to help implement or enhance adult immunization services in your health care setting.\\n\\n### Related pages\\n\\n[Traveler\\'s Health](https://wwwnc.cdc.gov/travel)\\n\\nClinician resources for traveling patients.\\n\\n[Vaccines & Immunizations](https://www.cdc.gov/vaccines/)\\n\\nLearn more about 2024 immunization schedules for your patients.\\n\\nVaccine Information Statement (VIS)\\n-----------------------------------\\n\\nVaccine Information Statements (VISs) are information sheets produced by CDC that explain both the benefits and risks of a vaccine. View the [VIS for HepB vaccine](https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.pdf).\\n\\nOn This Page\\n------------\\n\\n*   [Who should be vaccinated](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_1-who-should-be-vaccinated)\\n*   [Composition and dosage](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_2-composition-and-dosage)\\n*   [Vaccine effectiveness](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_3-vaccine-effectiveness)\\n*   [Safety and precautions](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_4-safety-and-precautions)\\n*   [Reporting adverse events](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_5-reporting-adverse-events)\\n*   [Administration](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_6-administration)\\n*   [Resources](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_7-resources)\\n*   [Vaccine Information Statement (VIS)](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#cdc_generic_section_8-vaccine-information-statement-vis)\\n\\nRelated Pages\\n-------------\\n\\n*   [Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)\\n*   [Clinical Screening](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html)\\n*   [Clinical Care and Treatment](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html)\\n*   [Infection Control Guidance](https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)\\n\\n[View All Hepatitis B](https://www.cdc.gov/hepatitis-b/index.html)\\n\\n[Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)\\n\\n January 31, 2025 \\n\\n[Sources](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#content-sources)[Print](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#print)[Share](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#share)\\n\\n[](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html)[](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html&title=Hepatitis%20B%20Vaccine%20Administration)[](http://twitter.com/share?url=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html&text=Hepatitis%20B%20Vaccine%20Administration)[](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#)\\n\\n[Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html \"Share to Facebook\")[LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html&title=Hepatitis%20B%20Vaccine%20Administration \"Share to LinkedIn\")[Twitter](http://twitter.com/share?url=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis-b%2Fhcp%2Fvaccine-administration%2Findex.html&text=Hepatitis%20B%20Vaccine%20Administration \"Share to Twitter\")[Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent/https://https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html \"Embed this Page\")\\n\\nContent Source:\\n\\n[Division of Viral Hepatitis](https://www.cdc.gov/nchhstp/divisions/viral-hepatitis.html)\\n\\nFootnotes \\n1.   [Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients | MMWR](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm)\\n2.   [Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices | MMWR](https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm)\\n\\nReferences \\n1.   [Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 | MMWR](https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w)\\n\\nRelated Pages\\n-------------\\n\\n*   [Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)\\n*   [Clinical Screening](https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html)\\n*   [Clinical Care and Treatment](https://www.cdc.gov/hepatitis-b/hcp/clinical-care/index.html)\\n*   [Infection Control Guidance](https://www.cdc.gov/hepatitis-b/hcp/infection-control/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/hcp/provider-resources/index.html)\\n\\n[View All Hepatitis B](https://www.cdc.gov/hepatitis-b/index.html)\\n\\nBack to Top\\n\\n[Hepatitis B](https://www.cdc.gov/hepatitis-b/index.html)\\n---------------------------------------------------------\\n\\nLearn more about hepatitis B, a liver disease caused by the hepatitis B virus (HBV). Find HBV information for the public and health professionals.\\n\\n[View All](https://www.cdc.gov/hepatitis-b/site.html)\\n\\n### [For Everyone](https://www.cdc.gov/hepatitis-b/index.html#gen)\\n\\n*   [Basics](https://www.cdc.gov/hepatitis-b/about/index.html)\\n*   [Symptoms](https://www.cdc.gov/hepatitis-b/signs-symptoms/index.html)\\n*   [Testing](https://www.cdc.gov/hepatitis-b/testing/index.html)\\n*   [Prevention](https://www.cdc.gov/hepatitis-b/prevention/index.html)\\n*   [Treatment](https://www.cdc.gov/hepatitis-b/treatment/index.html)\\n*   [Vaccination](https://www.cdc.gov/hepatitis-b/vaccination/index.html)\\n*   [Tools and Resources](https://www.cdc.gov/hepatitis-b/public-resources/index.html)\\n\\n### [Health Care Providers](https://www.cdc.gov/hepatitis-b/site.html#hcp)\\n\\n*   [Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html)\\n*   [Perinatal Provider Clinical Overview](https://www.cdc.gov/hepatitis-b/hcp/perinatal-provider-overview/index.html)\\n*   [Clinical Signs and Symptoms](https://www.cdc.gov/hepatitis-b/hcp/clinical-signs/index.html)\\n*   [View All](https://www.cdc.gov/hepatitis-b/site.html#hcp)\\n\\n[Sign up for Email Updates](https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx#featured)\\n\\n[Contact Us](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#aboutCDC)\\n\\n[About CDC](https://www.cdc.gov/about/)\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n\\n[Policies](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#languages)\\n\\n[Languages](https://wwwn.cdc.gov/pubs/other-languages?Sort=Lang%3A%3Aasc)\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\n[Language Assistance](https://www.cdc.gov/other/language-assistance.html)\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[Contact Us](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#mobile-footer-contactUs)\\n\\n[Contact Us](https://www.cdc.gov/cdc-info/index.html)\\n*   [Call 800-232-4636](tel:800-232-4636)\\n*   [Contact CDC](https://www.cdc.gov/cdc-info/index.html)\\n\\n[About CDC](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#mobile-footer-aboutCDC)\\n\\n*   [Pressroom](https://www.cdc.gov/media/)\\n*   [Organization](https://www.cdc.gov/about/organization/)\\n*   [Budget & Funding](https://www.cdc.gov/budget/)\\n*   [Careers & Jobs](https://jobs.cdc.gov/index.html)\\n*   [About CDC](https://www.cdc.gov/about/)\\n\\n[Policies](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#mobile-footer-policies)\\n\\n*   [Accessibility](https://www.cdc.gov/other/accessibility.html)\\n*   [External Links](https://www.cdc.gov/Other/disclaimer.html#exit-notification)\\n*   [Privacy](https://www.cdc.gov/other/privacy.html)\\n*   [Web Policies](https://www.cdc.gov/Other/policies.html)\\n\\n*   [FOIA](https://www.cdc.gov/foia/)\\n*   [OIG](https://oig.hhs.gov/)\\n*   [No Fear Act](https://www.cdc.gov/oeeowe/no-fear-act/)\\n*   [Nondiscrimination](https://www.cdc.gov/other/nondiscrimination.html)\\n*   [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Languages](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#mobile-footer-languages)\\n\\nLanguages\\n\\n*   [Español](https://www.cdc.gov/spanish/)\\n\\nLanguage Assistance\\n\\n*   [Español](https://www.cdc.gov/other/language-assistance.html#Spanish)\\n*   [繁體中文](https://www.cdc.gov/other/language-assistance.html#Chinese)\\n*   [Tiếng Việt](https://www.cdc.gov/other/language-assistance.html#Vietnamese)\\n*   [한국어](https://www.cdc.gov/other/language-assistance.html#Korean)\\n*   [Tagalog](https://www.cdc.gov/other/language-assistance.html#Tagalog)\\n*   [Русский](https://www.cdc.gov/other/language-assistance.html#Russian)\\n*   [العربية](https://www.cdc.gov/other/language-assistance.html#Arabic)\\n*   [Kreyòl Ayisyen](https://www.cdc.gov/other/language-assistance.html#Haitian)\\n*   [Français](https://www.cdc.gov/other/language-assistance.html#French)\\n*   [Polski](https://www.cdc.gov/other/language-assistance.html#Polish)\\n*   [Português](https://www.cdc.gov/other/language-assistance.html#Portuguese)\\n*   [Italiano](https://www.cdc.gov/other/language-assistance.html#Italian)\\n*   [Deutsch](https://www.cdc.gov/other/language-assistance.html#German)\\n*   [日本語](https://www.cdc.gov/other/language-assistance.html#Japanese)\\n*   [فارسی](https://www.cdc.gov/other/language-assistance.html#Farsi)\\n*   [English](https://www.cdc.gov/other/language-assistance.html#English)\\n\\n[Archive](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html#mobile-footer-archive)\\n\\n*   [CDC Archive](https://archive.cdc.gov/)\\n*   [Public Health Publications](https://stacks.cdc.gov/)\\n\\n[![Image 10: Centers for Disease Control and Prevention](https://www.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)](https://www.cdc.gov/)\\n\\n[](https://www.facebook.com/CDC)[](https://twitter.com/CDCgov)[](https://www.instagram.com/CDCgov)[](https://www.linkedin.com/company/centers-for-disease-control-and-prevention)\\n\\n[](https://www.youtube.com/cdc)[](https://www.pinterest.com/cdcgov)[](https://www.snapchat.com/add/cdcgov)[](https://www.cdc.gov/rss)\\n\\n[HHS.gov](https://hhs.gov/)[USA.gov](https://usa.gov/)\\n\\n[](https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html# \"Go to top\")\\n'},\n",
       "  {'title': 'Send a submission',\n",
       "   'url': 'https://ccp-aws.fda.gov/',\n",
       "   'content': \"You are logged out of the Customer Collaboration Portal. Didn't mean to log out? Log in. We also log you out automatically if you are inactive for 15 minutes.\",\n",
       "   'score': 0.06449435,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Rabies Vaccine VIS | Vaccines & Immunizations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/rabies.html',\n",
       "   'content': '# Rabies Vaccine VIS Rabies Vaccine ## Rabies vaccine Certain people with a higher risk for rabies exposures, such as those who work with potentially infected animals, are recommended to receive vaccine to help prevent rabies if an exposure happens. Rabies vaccine can prevent rabies if given to a person after an exposure. If your health care provider or local health department recommend vaccination, the vaccine should be given as soon as possible after an exposure but may be effective any time before symptoms begin. In some cases, your health care provider may decide to postpone routine (pre-exposure) rabies vaccination until a future visit. Or your health care provider may perform a blood test before or after rabies vaccines are given to determine your level of immunity against rabies.',\n",
       "   'score': 0.06449435,\n",
       "   'raw_content': '![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you\\'ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n**Related Topics:**\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Rabies Vaccine VIS\\n\\n## At a glance\\n\\n![Rabies Vaccine](/vaccines/hcp/current-vis/images/vis-rabies.gif \"vis-rabies.gif\")\\n\\n## Why get vaccinated?\\n\\n**Rabies vaccine** can prevent **rabies**.\\n\\nRabies is a serious illness that almost always results in death.\\n\\nRabies virus infects the central nervous system. Symptoms may occur from days to years after exposure to the virus and include delirium (confusion), abnormal behavior, hallucinations, hydrophobia (fear of water), and insomnia (difficulty sleeping), which precede coma and death.\\n\\nPeople can get rabies if they have contact with the saliva or neural tissue of an infected animal, for example through a bite or scratch, and do not receive appropriate medical care, including rabies vaccine.\\n\\n## Rabies vaccine\\n\\nCertain **people with a higher risk for rabies exposures, such as those who work with potentially infected animals, are recommended to receive vaccine** to help prevent rabies if an exposure happens. If you are at higher risk of exposure to the rabies virus:\\n\\n**Rabies vaccine can prevent rabies if given to a person after an exposure.** After an exposure or potential exposure to rabies, the wound site should be thoroughly cleaned with soap and water. If your health care provider or local health department recommend vaccination, the vaccine should be given as soon as possible after an exposure but may be effective any time before symptoms begin. Once symptoms begin, rabies vaccine is no longer helpful in preventing rabies.\\n\\nRabies vaccine may be given at the same time as other vaccines.\\n\\n## Talk with your health care provider\\n\\nTell your vaccination provider if the person getting the vaccine:\\n\\nIn some cases, your health care provider may decide to postpone routine (pre-exposure) rabies vaccination until a future visit. Or your health care provider may perform a blood test before or after rabies vaccines are given to determine your level of immunity against rabies.\\n\\nPeople with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover before getting a routine (pre-exposure) dose of rabies vaccine. **If you have been exposed to rabies virus, you should get vaccinated regardless of concurrent illnesses, pregnancy, breastfeeding, or weakened immune system.**\\n\\nYour health care provider can give you more information.\\n\\n## Risks of a vaccine reaction\\n\\nPeople sometimes faint after medical procedures, including vaccination. Tell your provider if you feel dizzy or have vision changes or ringing in the ears.\\n\\nAs with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.\\n\\n## What if there is a serious problem?\\n\\nAn allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call **9-1-1** and get the person to the nearest hospital.\\n\\nFor other signs that concern you, call your health care provider.\\n\\nAdverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visit the [VAERS website](https://www.vaers.hhs.gov/) or call **1-800-822-7967**. *VAERS is only for reporting reactions, and VAERS staff members do not give medical advice.*\\n\\n## How can I learn more?\\n\\n### Available Languages\\n\\nMany vaccine information statements are available in Spanish and other languages. See [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\nHojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\n## More about the vaccine\\n\\n![Rabies VIS barcode](/vaccines/hcp/current-vis/images/vis-qr-rabies.gif \"Rabies VIS Barcode\")\\n\\n## On This Page\\n\\n## [Vaccines & Immunizations](/vaccines/index.html)\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n### [For Everyone](/vaccines/index.html#gen)\\n\\n### [Health Care Providers](/vaccines/hcp/index.html#hcp)\\n\\n### [Public Health](/vaccines/site.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)'},\n",
       "  {'title': '\"Almost Looks Illegal\": Family Dick\\'s Daddy\\'s Little Boy Gay ...',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/34009104/',\n",
       "   'content': \"Family Dick is a commercial gay pornography website that has courted controversy for both its stepfather-son theme and for the youthful stylings of its Daddy's Little Boy series. This article reads viewer commentary (selected from more than 700 comments) of scenes within the series posted to its Pornhub channel.\",\n",
       "   'score': 0.06351153,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Pneumococcal Conjugate Vaccine (Interim) VIS',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-conjugate.html',\n",
       "   'content': '# Pneumococcal Conjugate Vaccine (Interim) VIS Pneumococcal Conjugate Vaccine ## Why get vaccinated? Pneumococcal conjugate vaccine can prevent pneumococcal disease. ## Pneumococcal conjugate vaccine Pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. There are several pneumococcal conjugate vaccines (PCVs). Tell your vaccination provider if the person getting the vaccine: Your health care provider can give you more information. ## Risks of a vaccine reaction As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death. Many vaccine information statements are available in Spanish and other languages. ## More about the vaccine ## Vaccines & Immunizations ### Health Care Providers',\n",
       "   'score': 0.061587647,\n",
       "   'raw_content': \"![U.S. flag](/TemplatePackage/5.0/img/uswds/us_flag_small.png)\\n![](/TemplatePackage/5.0/img/uswds/icon-dot-gov.svg)\\n\\nA **.gov** website belongs to an official government organization in the United States.\\n\\n![](/TemplatePackage/5.0/img/uswds/icon-https.svg)\\n\\nA **lock** (  ) or **https://** means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n**Related Topics:**\\n\\n![Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People](/TemplatePackage/5.0/img/logo/logo-notext.svg)\\n\\n# Pneumococcal Conjugate Vaccine (Interim) VIS\\n\\n## At a glance\\n\\n![Pneumococcal Conjugate Vaccine](/vaccines/hcp/current-vis/images/vis-pcv.jpg)\\n\\n## Why get vaccinated?\\n\\n**Pneumococcal conjugate vaccine** can prevent **pneumococcal disease**.\\n\\n**Pneumococcal disease** refers to any illness caused by pneumococcal bacteria. These bacteria can cause many types of illnesses, including:\\n\\nAnyone can get pneumococcal disease, but young children, older adults, and people with certain risk factors are at the highest risk.\\n\\nMost pneumococcal infections are mild. However, some can result in long-term problems, such as brain damage or hearing loss. Meningitis, bacteremia, and pneumonia caused by pneumococcal disease can lead to death.\\n\\n## Pneumococcal conjugate vaccine\\n\\nPneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. There are several pneumococcal conjugate vaccines (PCVs). The specific PCV and number of doses recommended are based on a person's age, vaccination history, and medical status. Your health care provider can help you determine which type of PCV, and how many doses, should be received.\\n\\n## Talk with your health care provider\\n\\nTell your vaccination provider if the person getting the vaccine:\\n\\nIn some cases, your health care provider may decide to postpone PCV until a future visit.\\n\\nPeople with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover.\\n\\nYour health care provider can give you more information.\\n\\n## Risks of a vaccine reaction\\n\\nYoung children may be at increased risk for seizures caused by fever after a PCV if it is administered at the same time as inactivated influenza vaccine. Ask your health care provider for more information.\\n\\nPeople sometimes faint after medical procedures, including vaccination. Tell your provider if you feel dizzy or have vision changes or ringing in the ears.\\n\\nAs with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.\\n\\n## What if there is a serious problem?\\n\\nAn allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call **9-1-1** and get the person to the nearest hospital.\\n\\nFor other signs that concern you, call your health care provider.\\n\\nAdverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visit the [VAERS website](https://www.vaers.hhs.gov/) or call **1-800-822-7967**. *VAERS is only for reporting reactions, and VAERS staff members do not give medical advice.*\\n\\n## The National Vaccine Injury Compensation Program\\n\\nThe National Vaccine Injury Compensation Program (VICP) is a federal program that was created to compensate people who may have been injured by certain vaccines. Claims regarding alleged injury or death due to vaccination have a time limit for filing, which may be as short as two years. Visit the [VICP](https://www.hrsa.gov/vaccinecompensation) website or call **1-800-338-2382** to learn about the program and about filing a claim.\\n\\n## How can I learn more?\\n\\n### Available Languages\\n\\nMany vaccine information statements are available in Spanish and other languages. See [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\nHojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite [www.immunize.org/vis](https://www.immunize.org/vis).\\n\\n## More about the vaccine\\n\\n![Pneumococcal Conjugate (PCV13) VIS barcode](/vaccines/hcp/current-vis/images/vis-qr-pcv.png)\\n\\n## On This Page\\n\\n## [Vaccines & Immunizations](/vaccines/index.html)\\n\\nVaccination is one of the best things you can do to help protect yourself from serious diseases.\\n\\n### [For Everyone](/vaccines/index.html#gen)\\n\\n### [Health Care Providers](/vaccines/hcp/index.html#hcp)\\n\\n### [Public Health](/vaccines/site.html#php)\\n\\nLanguages\\n\\nLanguage Assistance\\n\\n![Centers for Disease Control and Prevention](/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg)\"},\n",
       "  {'title': 'Typhoid Vaccine VIS | Vaccines & Immunizations | CDC',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/current-vis/typhoid.html',\n",
       "   'content': 'Typhoid Vaccine VIS Why get vaccinated? Typhoid vaccine can prevent typhoid fever. Typhoid vaccine There are two vaccines to prevent typhoid fever. Your health care provider can help you decide which type of typhoid vaccine is best for you. Routine typhoid vaccination is not recommended in the United States, but typhoid vaccine is recommended for: Typhoid vaccine may be given at the same time as other vaccines. In some cases, your health care provider may decide to postpone typhoid vaccination to a future visit. People who are moderately or severely ill should usually wait until they recover before getting typhoid vaccine. Many vaccine information statements are available in Spanish and other languages. More about the vaccine Vaccines & Immunizations',\n",
       "   'score': 0.060313307,\n",
       "   'raw_content': None},\n",
       "  {'title': 'PDF',\n",
       "   'url': 'https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-needle-length.pdf',\n",
       "   'content': 'Title: Vaccine Administration: Needle Gauge and Length Author: CDC/NCIRD Subject: Vaccines must reach the desired tissue to provide an optimal immune response and reduce the likelihood of injection-site reactions.',\n",
       "   'score': 0.060246922,\n",
       "   'raw_content': 'Vaccine Administration: Needle Gauge and Length The following table outlines recommended needle gauges and lengths. In addition, clinical judgment should be used when selecting needles to administer injectable vaccines.\\nRoute Age Needle gauge and length Injection site Subcutaneous injection All ages 23–25-gauge 5/8 inch (16 mm) Thigh for infants younger than 12 months of age1; upper outer triceps area for persons 12\\xa0months of age and older Intramuscular injection Neonate, 28 days and younger 22–25-gauge 5/8 inch (16 mm2) Vastus lateralis muscle of anterolateral thigh Infants, 1–12 months 22–25-gauge 1 inch (25 mm) Vastus lateralis muscle of anterolateral thigh Toddlers, 1–2 years 22–25-gauge 1–1.25 inches (25–32 mm) Vastus lateralis muscle of anterolateral thigh3 22–25-gauge 5/82–1 inch (16–25 mm) Deltoid muscle of arm Children, 3–10 years 22–25-gauge 5/82–1 inch (16–25 mm) Deltoid muscle of arm3 22–25-gauge 1–1.25 inches (25–32 mm) Vastus lateralis muscle of anterolateral thigh Children, 11–18 years 22–25-gauge 5/82–1 inch (16–25 mm) Deltoid muscle of arm3,5 Adults, 19 years and older\\x83 \\x83 130 lbs (60 kg) or less\\x83 \\x83 130–152 lbs (60–70\\xa0kg)\\x83 \\x83 Men, 152–260 lbs (70–118\\xa0kg)\\x83 \\x83 Women, 152–200 lbs (70–90\\xa0kg)\\x83 \\x83 Men, 260 lbs (118\\xa0kg) or more\\x83 \\x83 Women, 200 lbs (90\\xa0kg) or more 22–25-gauge 1 inch (25 mm4) 1 inch (25 mm) 1–1.5 inches (25–38 mm) 1–1.5 inches (25–38 mm) 1.5 inches (38 mm) 1.5 inches (38 mm) Deltoid muscle of arm3,5 1 May be administered into the upper outer triceps area if necessary 2 If the skin is stretched tightly and subcutaneous tissues are not bunched 3 Preferred site 4 Some experts recommend a 5/8-inch needle for men and women weighing less than 60 kg, if used, skin must be stretched tightly and subcutaneous tissues must not be bunched.\\n5 The vastus lateralis muscle in the anterolateral thigh can also be used. Most adolescents and adults will require a 1- to 1.5-inch (25–38 mm) needle to ensure intramuscular administration.\\nVaccines must reach the desired tissue to provide an optimal immune response and reduce the likelihood of injection-site reactions. Needle selection should be based on the:\\x83 \\x83 Route\\x83 \\x83 Age\\x83 \\x83 Sex and weight for adults (19 years and older)\\x83 \\x83 Injection site Reference: \\x07 Advisory Committee on Immunization Practices General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html 08/04/20 U.S. D Heal Cente Cont'},\n",
       "  {'title': 'Young women and anal sex - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/35953092/',\n",
       "   'content': 'Affiliations 1 Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK.; 2 Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK lesley.hunt3@nhs.net.',\n",
       "   'score': 0.059194054,\n",
       "   'raw_content': None},\n",
       "  {'title': \"Adolescent boys' experiences of first sex - PubMed\",\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/22762432/',\n",
       "   'content': 'There are limited contextual data regarding first sexual experiences of younger adolescent men. Yet these data that are needed to inform sexually-transmitted-infection and early-fatherhood-prevention efforts, particularly in lower-income communities. Using qualitative methods, 14 adolescent men (age …',\n",
       "   'score': 0.05835133,\n",
       "   'raw_content': None},\n",
       "  {'title': '\"Cum play\" among gay men - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/23519589/',\n",
       "   'content': 'The exchange of semen, often referred to as \"cum play,\" has featured in gay literature and may be a unique aspect of many gay men\\'s sexual behavior. We investigated the prevalence of \"cum play\" and its context among 1153 HIV-negative and 147 HIV-positive Australian gay men in an online survey. Recep …',\n",
       "   'score': 0.045087047,\n",
       "   'raw_content': None},\n",
       "  {'title': 'NetScaler AAA',\n",
       "   'url': 'https://citgo.cdc.gov/',\n",
       "   'content': 'Under the menu, go to Desktops or Apps, click on Details next to your choice and then select Add to Favorites.',\n",
       "   'score': 0.043597396,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Cancer incidence and mortality in China, 2022 - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/39036382/',\n",
       "   'content': 'Cancer incidence and mortality in China, 2022 - PubMed eCollection 2024 Mar. Cancer incidence and mortality in China, 2022 Cancer incidence and mortality in China, 2022 Methods: There were a total of 700 registries reporting high-quality data on cancer incidence and mortality across China in 2018, of which 106 registries with continuous monitoring from 2010 to 2018 were used to establish an age-period-cohort model to simulate the trend of cancer incidence and mortality and to estimate the incidence and mortality in China in 2022. Trends in age-standardized incidence and mortality rates for selected cancers by sex in China, 2000 to 2018. Cancer incidence and mortality in China, 2016. [Cancer incidence and mortality in China, 2022].',\n",
       "   'score': 0.043353733,\n",
       "   'raw_content': 'Cancer incidence and mortality in China, 2022 - PubMed\\n===============                                                     \\n\\nClipboard, Search History, and several other advanced features are temporarily unavailable.\\n\\n[Skip to main page content](https://pubmed.ncbi.nlm.nih.gov/39036382/#article-details)\\n\\n![Image 1: U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)An official website of the United States government\\n\\nHere\\'s how you know\\n\\n![Image 2: Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\\n\\n**The .gov means it’s official.**  \\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\\n\\n![Image 3: Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\\n\\n**The site is secure.**  \\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\\n\\n[![Image 4: NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\\n\\n[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F39036382%2F) Show account info\\n\\nClose\\n\\n#### Account\\n\\nLogged in as:  \\n**username**\\n\\n*   [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)\\n*   [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\\n*   [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)\\n*   [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/39036382/)\\n\\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov/) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/39036382/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\n[![Image 5: pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/7e7ad262-b370-490b-9751-e68ac1c1c5b4/core/images/pubmed-logo-blue.svg)](https://pubmed.ncbi.nlm.nih.gov/)[](https://pubmed.ncbi.nlm.nih.gov/39036382/# \"Show search bar\")\\n\\nSearch: \\n\\n[](https://pubmed.ncbi.nlm.nih.gov/39036382/# \"Clear search input\")Search\\n\\n[Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [Clipboard](https://pubmed.ncbi.nlm.nih.gov/clipboard/)\\n\\n[User Guide](https://pubmed.ncbi.nlm.nih.gov/help/)\\n\\nSave Email\\n\\nSend to\\n\\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F39036382%2F%23open-bibliography-panel)\\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F39036382%2F%23open-collections-panel)\\n*   [Citation manager](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nDisplay options\\n\\nDisplay options\\n\\nFormat \\n\\nSave citation to file\\n---------------------\\n\\nFormat: \\n\\nCreate file Cancel\\n\\nEmail citation\\n--------------\\n\\nSubject: 1 selected item: 39036382 - PubMed  \\n\\nTo: \\n\\nFrom: \\n\\nFormat: \\n\\n MeSH and other data\\n\\nSend email Cancel\\n\\n \\n\\n### Add to Collections\\n\\n*    Create a new collection\\n*    Add to an existing collection\\n\\nName your collection: \\n\\nName must be less than 100 characters\\n\\nChoose a collection:\\n\\nUnable to load your collection due to an error  \\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nAdd Cancel\\n\\n### Add to My Bibliography\\n\\n*    My Bibliography\\n\\nUnable to load your delegates due to an error  \\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nAdd Cancel\\n\\nYour saved search\\n-----------------\\n\\nName of saved search: \\n\\nSearch terms:\\n\\n[Test search terms](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nWould you like email updates of new search results?\\n\\nSaved Search Alert Radio Buttons\\n\\n*    Yes\\n*    No\\n\\nEmail: ([change](https://www.ncbi.nlm.nih.gov/account/settings/))\\n\\nFrequency: \\n\\nWhich day? \\n\\nWhich day? \\n\\nReport format: \\n\\nSend at most: \\n\\n Send even when there aren\\'t any new results\\n\\nOptional text in email:\\n\\nSave Cancel\\n\\nCreate a file for external citation management software\\n-------------------------------------------------------\\n\\n \\n\\nCreate file Cancel\\n\\nYour RSS Feed\\n-------------\\n\\nName of RSS Feed: \\n\\nNumber of items displayed: \\n\\nCreate RSS Cancel\\n\\nRSS Link  Copy\\n\\n### Full text links\\n\\n [![Image 6: Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-elsevieroa.png) Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S2667-0054(24)00006-1 \"See full text options at Elsevier Science\") [Free PMC article](https://pmc.ncbi.nlm.nih.gov/articles/pmid/39036382/ \"Free full text at PubMed Central\")\\n\\n[Full text links](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\n### Actions\\n\\nCite\\n\\nCollections\\n\\nAdd to Collections\\n\\n*   Create a new collection\\n*   Add to an existing collection\\n\\nName your collection: \\n\\nName must be less than 100 characters\\n\\nChoose a collection:\\n\\nUnable to load your collection due to an error  \\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nAdd Cancel\\n\\nDisplay options\\n\\nDisplay options\\n\\nFormat \\n\\n### Share\\n\\n*   [](http://twitter.com/intent/tweet?text=Cancer%20incidence%20and%20mortality%20in%20China%2C%202022%20https%3A//pubmed.ncbi.nlm.nih.gov/39036382/ \"Share article on Twitter\")\\n*   [](http://www.facebook.com/sharer/sharer.php?u=https%3A//pubmed.ncbi.nlm.nih.gov/39036382/ \"Share article on Facebook\")\\n*   Permalink\\n    \\n    Copy\\n    \\n\\n### Page navigation\\n\\n*   [Title & authors](https://pubmed.ncbi.nlm.nih.gov/39036382/#heading)\\n*   [Abstract](https://pubmed.ncbi.nlm.nih.gov/39036382/#abstract)\\n*   [Conflict of interest statement](https://pubmed.ncbi.nlm.nih.gov/39036382/#conflict-of-interest)\\n*   [Figures](https://pubmed.ncbi.nlm.nih.gov/39036382/#figures)\\n*   [Similar articles](https://pubmed.ncbi.nlm.nih.gov/39036382/#similar)\\n*   [Cited by](https://pubmed.ncbi.nlm.nih.gov/39036382/#citedby)\\n*   [References](https://pubmed.ncbi.nlm.nih.gov/39036382/#references)\\n*   [Related information](https://pubmed.ncbi.nlm.nih.gov/39036382/#related-links)\\n*   [LinkOut - more resources](https://pubmed.ncbi.nlm.nih.gov/39036382/#linkout)\\n\\nJ Natl Cancer Cent\\n\\nActions\\n\\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Natl+Cancer+Cent%22%5Bjour%5D&sort=date&sort_order=desc)\\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Natl+Cancer+Cent%22%5BTitle+Abbreviation%5D)\\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\n. 2024 Feb 2;4(1):47-53.\\n\\ndoi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.\\n\\nCancer incidence and mortality in China, 2022\\n=============================================\\n\\n[Bingfeng Han](https://pubmed.ncbi.nlm.nih.gov/?term=Han+B&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Rongshou Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+R&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Hongmei Zeng](https://pubmed.ncbi.nlm.nih.gov/?term=Zeng+H&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Shaoming Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+S&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Kexin Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+K&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Ru Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+R&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Li Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+L&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Wenqiang Wei](https://pubmed.ncbi.nlm.nih.gov/?term=Wei+W&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Jie He](https://pubmed.ncbi.nlm.nih.gov/?term=He+J&cauthor_id=39036382)\\xa0 [2](https://pubmed.ncbi.nlm.nih.gov/39036382/#full-view-affiliation-2 \"Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\")\\n\\nAffiliations Expand\\n\\n### Affiliations\\n\\n*   1 Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\\n*   2 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\\n\\n*   PMID: **39036382**\\n*   PMCID: [PMC11256708](https://pmc.ncbi.nlm.nih.gov/articles/PMC11256708/)\\n*   DOI: [10.1016/j.jncc.2024.01.006](https://doi.org/10.1016/j.jncc.2024.01.006)\\n\\nItem in Clipboard\\n\\nCancer incidence and mortality in China, 2022\\n=============================================\\n\\nBingfeng Han\\xa0et al. J Natl Cancer Cent. 2024.\\n\\nShow details\\n\\nDisplay options\\n\\nDisplay options\\n\\nFormat \\n\\nJ Natl Cancer Cent\\n\\nActions\\n\\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Natl+Cancer+Cent%22%5Bjour%5D&sort=date&sort_order=desc)\\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Natl+Cancer+Cent%22%5BTitle+Abbreviation%5D)\\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\n. 2024 Feb 2;4(1):47-53.\\n\\ndoi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.\\n\\n### Authors\\n\\n[Bingfeng Han](https://pubmed.ncbi.nlm.nih.gov/?term=Han+B&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Rongshou Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+R&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Hongmei Zeng](https://pubmed.ncbi.nlm.nih.gov/?term=Zeng+H&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Shaoming Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+S&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Kexin Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+K&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Ru Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+R&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Li Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+L&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Wenqiang Wei](https://pubmed.ncbi.nlm.nih.gov/?term=Wei+W&cauthor_id=39036382)\\xa0 [1](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-1 \"Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\") ,\\xa0[Jie He](https://pubmed.ncbi.nlm.nih.gov/?term=He+J&cauthor_id=39036382)\\xa0 [2](https://pubmed.ncbi.nlm.nih.gov/39036382/#short-view-affiliation-2 \"Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\")\\n\\n### Affiliations\\n\\n*   1 Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\\n*   2 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.\\n\\n*   PMID: **39036382**\\n*   PMCID: [PMC11256708](https://pmc.ncbi.nlm.nih.gov/articles/PMC11256708/)\\n*   DOI: [10.1016/j.jncc.2024.01.006](https://doi.org/10.1016/j.jncc.2024.01.006)\\n\\nItem in Clipboard\\n\\nFull text links Cite\\n\\nDisplay options\\n\\nDisplay options\\n\\nFormat \\n\\nAbstract\\n--------\\n\\n**Background:** The National Cancer Center (NCC) of China regularly reports the nationwide statistics on cancer incidence and mortality in China. The International Agency for Research on Cancer (IARC) calculates and publishes the cancer burden of countries around the world every two years. To ensure consistency between the actual surveillance data in China and the data published by IARC, NCC has received approval from the National Health Commission and IARC to simultaneously release the cancer burden data for China in GLOBOCAN 2022.\\n\\n**Methods:** There were a total of 700 registries reporting high-quality data on cancer incidence and mortality across China in 2018, of which 106 registries with continuous monitoring from 2010 to 2018 were used to establish an age-period-cohort model to simulate the trend of cancer incidence and mortality and to estimate the incidence and mortality in China in 2022. In addition, we analyzed the temporal trends of age-standardized cancer incidence and mortality from 2000 to 2018 using data from 22 continuous cancer registries.\\n\\n**Results:** It was estimated about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Cancers of the lung, colon-rectum, thyroid, liver and stomach were the top five cancer types, accounting for 57.42% of new cancer cases. Cancers of the lung, liver, stomach, colon-rectum and esophagus were the five leading causes of cancer deaths, accounting for 67.50% of total cancer deaths. The crude rate and age-standardized incidence rate (ASIR) were 341.75 per 100,000 and 201.61 per 100,000, respectively. The crude mortality rate was 182.34 per 100,000 and the age-standardized mortality rate (ASMR) was 96.47 per 100,000. The ASIR of all cancers combined increased by approximately 1.4% per year during 2000-2018, while the ASMR decreased by approximately 1.3% per year. We observed decreasing trends in ASIR and ASMR for cancers of the esophagus, stomach, and liver, whereas the ASIR increased significantly for cancers of the thyroid, prostate, and cervix.\\n\\n**Conclusions:** Cancer remains a major public health concern in China, with a cancer profile that reflects the coexistence of developed and developing regions. Sustained implementation of prevention and control measures has resulted in significant reductions in the incidence and mortality rates of certain historically high incidence cancers, such as esophageal, stomach and liver cancers. Adherence to the guidelines of the Healthy China Action Plan and the Cancer Prevention and Control Action Plan, along with continued efforts in comprehensive risk factor control, cancer screening, early diagnosis and treatment, and standardization of diagnostic and therapeutic protocols, are key strategies to effectively mitigate the increasing cancer burden by 2030.\\n\\n**Keywords:** Cancer registry; China; Incidence; Mortality; Statistics.\\n\\n© 2024 Chinese National Cancer Center. Published by Elsevier B.V.\\n\\n[PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nConflict of interest statement\\n------------------------------\\n\\nThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\\n\\nFigures\\n-------\\n\\n [![Image 7: Fig 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/83a0b44ddd32/gr1.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/d7450e2f213c/gr1.jpg) \\n\\n**Fig. 1\\n\\n**\\n\\nEstimated age-specific incidence rates for…\\n\\n**Fig. 1\\n\\n**\\n\\nEstimated age-specific incidence rates for all cancers combined in China in 2022.\\n\\n**Fig. 1**\\n\\nEstimated age-specific incidence rates for all cancers combined in China in 2022.\\n\\n [![Image 8: Fig 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/a6fecc443545/gr2.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/83b28fc1b02e/gr2.jpg) \\n\\n**Fig. 2\\n\\n**\\n\\nEstimated age-specific mortality rates for…\\n\\n**Fig. 2\\n\\n**\\n\\nEstimated age-specific mortality rates for all cancers combined in China in 2022.\\n\\n**Fig. 2**\\n\\nEstimated age-specific mortality rates for all cancers combined in China in 2022.\\n\\n [![Image 9: Fig 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/af2136e8934d/gr3.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd5c/11256708/6727c18d53db/gr3.jpg) \\n\\n**Fig. 3\\n\\n**\\n\\nTrends in age-standardized incidence and…\\n\\n**Fig. 3\\n\\n**\\n\\nTrends in age-standardized incidence and mortality rates for selected cancers by sex in…\\n\\n**Fig. 3**\\n\\nTrends in age-standardized incidence and mortality rates for selected cancers by sex in China, 2000 to 2018. (A) Male incidence. (B) Female incidence. (C) Male mortality. (D) Female mortality. CNS, central nervous system.\\n\\n[See this image and copyright information in PMC](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\nSimilar articles\\n----------------\\n\\n*   [Cancer incidence and mortality in China, 2016.](https://pubmed.ncbi.nlm.nih.gov/39035212/)\\n    \\n    Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Zheng R, et al. J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar. J Natl Cancer Cent. 2022. PMID: 39035212 Free PMC article.\\n    \\n*   [Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN).](https://pubmed.ncbi.nlm.nih.gov/39282581/)\\n    \\n    Cao W, Qin K, Li F, Chen W. Cao W, et al. J Natl Cancer Cent. 2024 May 7;4(2):128-134. doi: 10.1016/j.jncc.2024.05.001. eCollection 2024 Jun. J Natl Cancer Cent. 2024. PMID: 39282581 Free PMC article.\\n    \\n*   [\\\\[Cancer incidence and mortality in China, 2022\\\\].](https://pubmed.ncbi.nlm.nih.gov/38468501/)\\n    \\n    Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J. Zheng RS, et al. Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231. doi: 10.3760/cma.j.cn112152-20240119-00035. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 38468501 Chinese.\\n    \\n*   [Epidemiology of gynecologic cancers in China.](https://pubmed.ncbi.nlm.nih.gov/29185265/)\\n    \\n    Jiang X, Tang H, Chen T. Jiang X, et al. J Gynecol Oncol. 2018 Jan;29(1):e7. doi: 10.3802/jgo.2018.29.e7. J Gynecol Oncol. 2018. PMID: 29185265 Free PMC article. Review.\\n    \\n*   [Epidemiological trends in digestive cancers in Romania, 1955-2012, compared to alcohol consumption. Correlation or coincidence?](https://pubmed.ncbi.nlm.nih.gov/30564012/)\\n    \\n    Valean S, Chira R, Dumitrascu D. Valean S, et al. Clujul Med. 2018 Oct;91(4):376-386. doi: 10.15386/cjmed-1067. Epub 2018 Oct 30. Clujul Med. 2018. PMID: 30564012 Free PMC article. Review.\\n    \\n\\nSee all similar articles\\n\\nCited by\\n--------\\n\\n*   [\\\\[Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer\\\\].](https://pubmed.ncbi.nlm.nih.gov/39318252/)\\n    \\n    Wang Y, Zheng J, Zhu Y, Zhou J. Wang Y, et al. Zhongguo Fei Ai Za Zhi. 2024 Aug 20;27(8):593-604. doi: 10.3779/j.issn.1009-3419.2024.101.20. Zhongguo Fei Ai Za Zhi. 2024. PMID: 39318252 Free PMC article. Review. Chinese.\\n    \\n*   [The ratio of lymph node eluate/serum cytokeratin 21-1 is a potential predictor of lymph node metastasis in lung adenocarcinoma.](https://pubmed.ncbi.nlm.nih.gov/39444850/)\\n    \\n    Xu S, Hu T, Zhou C, Wang M, Jiang J, Wang Y, Wang C. Xu S, et al. J Thorac Dis. 2024 Sep 30;16(9):5709-5717. doi: 10.21037/jtd-24-410. Epub 2024 Sep 20. J Thorac Dis. 2024. PMID: 39444850 Free PMC article.\\n    \\n*   [Numerical Simulation of Thermal Therapy for Melanoma in Mice.](https://pubmed.ncbi.nlm.nih.gov/39061776/)\\n    \\n    Zhang Y, Lu M. Zhang Y, et al. Bioengineering (Basel). 2024 Jul 9;11(7):694. doi: 10.3390/bioengineering11070694. Bioengineering (Basel). 2024. PMID: 39061776 Free PMC article.\\n    \\n*   [Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China.](https://pubmed.ncbi.nlm.nih.gov/39210462/)\\n    \\n    Hao S, Wang H, Lin S, Chen H, Xie L, Zheng X. Hao S, et al. BMC Urol. 2024 Aug 29;24(1):185. doi: 10.1186/s12894-024-01563-z. BMC Urol. 2024. PMID: 39210462 Free PMC article.\\n    \\n*   [Novel genetic variants in the NLRP3 inflammasome-related PANX1 and APP genes predict survival of patients with hepatitis B virus-related hepatocellular carcinoma.](https://pubmed.ncbi.nlm.nih.gov/39090420/)\\n    \\n    Liu Y, Fan Y, Gong R, Qiu M, Wei X, Lin Q, Zhou Z, Cao J, Jiang Y, Chen P, Chen B, Yang X, Wei Y, Zhang R, Wen Q, Yu H. Liu Y, et al. Clin Transl Oncol. 2025 Feb;27(2):630-641. doi: 10.1007/s12094-024-03634-x. Epub 2024 Aug 1. Clin Transl Oncol. 2025. PMID: 39090420 Free PMC article.\\n    \\n\\nSee all \"Cited by\" articles\\n\\nReferences\\n----------\\n\\n1.  1.  Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21:e342–e349. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/32615118/)\\n2.  1.  National Cancer Center . People\\'s Medical Publishing House Co., LTD; Beijing, China: 2016. Chinese Guideline for Cancer Registration \\\\[in Chinese\\\\]\\n3.  1.  Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45:747–755. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/19117750/)\\n4.  1.  Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer. 2009;45:756–764. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/19128954/)\\n5.  1.  Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/26808342/)\\n\\nShow all 21 references\\n\\nRelated information\\n-------------------\\n\\n*   [MedGen](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=39036382 \"Related information in MedGen\")\\n\\nLinkOut - more resources\\n------------------------\\n\\n*   ### Full Text Sources\\n    \\n    *   [Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S2667-0054(24)00006-1)\\n    *   [PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/pmid/39036382/)\\n\\n**Full text links** \\\\[x\\\\]\\n\\n [![Image 10: Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-elsevieroa.png) Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S2667-0054(24)00006-1 \"See full text options at Elsevier Science\") [Free PMC article](https://pmc.ncbi.nlm.nih.gov/articles/pmid/39036382/ \"Free full text at PubMed Central\")\\n\\n\\\\[x\\\\]\\n\\nCite\\n\\nCopy\\n\\n Download .nbib .nbib\\n\\nFormat: \\n\\n**Send To**\\n\\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n*   [Email](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n*   [Save](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F39036382%2F%23open-bibliography-panel)\\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F39036382%2F%23open-collections-panel)\\n*   [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/39036382/#)\\n\\n\\\\[x\\\\]\\n\\nNCBI Literature Resources\\n\\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\\n\\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\\n\\nFollow NCBI\\n\\n[](https://twitter.com/ncbi) [](https://www.facebook.com/ncbi.nlm) [](https://www.linkedin.com/company/ncbinlm) [](https://github.com/ncbi) [](https://ncbiinsights.ncbi.nlm.nih.gov/)\\n\\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\\n\\n*   [](https://twitter.com/NLM_NIH)\\n*   [](https://www.facebook.com/nationallibraryofmedicine)\\n*   [](https://www.youtube.com/user/NLMNIH)\\n\\nNational Library of Medicine  \\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\\n\\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\\n\\n[Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE)  \\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\\n\\n*   [NLM](https://www.nlm.nih.gov/)\\n*   [NIH](https://www.nih.gov/)\\n*   [HHS](https://www.hhs.gov/)\\n*   [USA.gov](https://www.usa.gov/)\\n'},\n",
       "  {'title': 'Vaginal opening measurement in prepubertal girls - PubMed',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/2816868/',\n",
       "   'content': 'Normative, age-indexed data regarding the size of the vaginal opening in prepubertal girls have not been previously reported, to our knowledge. Measurement of the apparent transverse diameter of the vaginal opening was done in 273 prepubertal girls as part of their routine health assessment. Vaginal …',\n",
       "   'score': 0.043063056,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Applying transformational leadership in nursing practice',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/31840443/',\n",
       "   'content': 'The updated Nursing and Midwifery Council (NMC) standards of proficiency for nurses emphasise the importance of nurse leadership, while the NHS has also developed models to support leadership development. There are several approaches to leadership that are applicable in nursing practice. Transformat …',\n",
       "   'score': 0.034181003,\n",
       "   'raw_content': None},\n",
       "  {'title': 'Size Matters: Penis Size and Sexual Position in Gay Porn Profiles',\n",
       "   'url': 'https://pubmed.ncbi.nlm.nih.gov/28820665/',\n",
       "   'content': 'This article combines qualitative and quantitative textual approaches to the representation of penis size and sexual position of performers in 10 of the most visited gay pornography Web sites currently in operation. Specifically, in excess of 6,900 performer profiles sourced from 10 commercial Web s …',\n",
       "   'score': 0.022579623,\n",
       "   'raw_content': None}],\n",
       " 'response_time': 1.73}"
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tavily_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [],
   "source": [
    "import time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "tavily_queries = [\n",
    "    \"Latest breakthroughs in diabetes treatment 2024\",\n",
    "    \"Novel approaches to curing type 1 and type 2 diabetes\",\n",
    "    \"Recent advances in beta cell regeneration for diabetes\",\n",
    "    \"New drug targets for insulin resistance and diabetes cure\",\n",
    "    \"Gene editing and CRISPR therapies for diabetes\",\n",
    "    \"Immunotherapy approaches to treat or cure type 1 diabetes\",\n",
    "    \"Ongoing clinical trials for diabetes reversal\",\n",
    "    \"Use of AI and machine learning in discovering diabetes treatments\",\n",
    "    \"Recent trials on diabetes AND site:clinicaltrials.gov\",\n",
    "    \"Pathophysiology of insulin resistance in type 2 diabetes\", #mechanistic, scientific explanations — helpful for AI models focusing on mechanistic reasoning\n",
    "    \"Prevalence of diabetes in Europe 2024 statistics\", #public health datasets, WHO data, etc.\n",
    "    \"FDA-approved drugs for type 2 diabetes and their mechanisms\", #Useful for drug discovery, pharmacological studies, or treatment plans,\n",
    "    \"Latest ADA clinical guidelines for diabetes management\"#Targets specific trusted content like ADA (American Diabetes Association) guidelines.\n",
    "\n",
    "\n",
    "\n",
    "]\n",
    "\n",
    "all_docs = []\n",
    "\n",
    "for query in tavily_queries:\n",
    "    print(query)\n",
    "    try:\n",
    "        docs = tavily_tool.invoke(query)\n",
    "        all_docs.extend(docs)\n",
    "    except TimeoutError:\n",
    "        print(f\"Timeout on query: {query}\")\n",
    "    time.sleep(3)  # Add delay between requests\n",
    "\n",
    "# Optional: Deduplicate based on document content\n",
    "tavily_docs = list({doc.page_content: doc for doc in all_docs}.values())\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Recursive URL\n",
    "\n",
    "https://python.langchain.com/docs/integrations/document_loaders/recursive_url/\n",
    "\n",
    "The `RecursiveUrlLoader` lets you recursively scrape all child links from a root URL and parse them into Documents.\n",
    "\n",
    "## Overview\n",
    "### Integration details\n",
    "\n",
    "| Class | Package | Local | Serializable | [JS support](https://js.langchain.com/docs/integrations/document_loaders/web_loaders/recursive_url_loader/)|\n",
    "| :--- | :--- | :---: | :---: |  :---: |\n",
    "| [RecursiveUrlLoader](https://python.langchain.com/api_reference/community/document_loaders/langchain_community.document_loaders.recursive_url_loader.RecursiveUrlLoader.html) | [langchain_community](https://python.langchain.com/api_reference/community/index.html) | ✅ | ❌ | ✅ | \n",
    "### Loader features\n",
    "| Source | Document Lazy Loading | Native Async Support\n",
    "| :---: | :---: | :---: | \n",
    "| RecursiveUrlLoader | ✅ | ❌ | \n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "To enable automated tracing of your model calls, set your [LangSmith](https://docs.smith.langchain.com/) API key:"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup\n",
    "\n",
    "### Credentials\n",
    "\n",
    "No credentials are required to use the `RecursiveUrlLoader`.\n",
    "\n",
    "### Installation\n",
    "\n",
    "The `RecursiveUrlLoader` lives in the `langchain-community` package. There's no other required packages, though you will get richer default Document metadata if you have ``beautifulsoup4` installed as well."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "# os.environ[\"LANGSMITH_API_KEY\"] = getpass.getpass(\"Enter your LangSmith API key: \")\n",
    "# os.environ[\"LANGSMITH_TRACING\"] = \"true\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Installation\n",
    "\n",
    "Install **langchain_community**.£"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.1.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install -qU langchain-community beautifulsoup4 lxml"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Instantiation\n",
    "\n",
    "Now we can instantiate our document loader object and load Documents:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import RecursiveUrlLoader\n",
    "from bs4 import BeautifulSoup\n",
    "import re\n",
    "\n",
    "# clean HTML content\n",
    "def bs4_extractor(html: str) -> str:\n",
    "    soup = BeautifulSoup(html, \"lxml\")\n",
    "    return re.sub(r\"\\n\\n+\", \"\\n\\n\", soup.text).strip()\n",
    "\n",
    "# Load and extract diabetes-related pages\n",
    "medrxiv_loader = RecursiveUrlLoader(\n",
    "    'https://clinicaltrials.gov/',\n",
    "     max_depth=10,\n",
    "    # use_async=False,\n",
    "    extractor=bs4_extractor,\n",
    "    link_regex=r\".*(diabetes|blood[-_]?sugar|glucose|insulin).*\",  # Filter links by diabetes keywords\n",
    "    # metadata_extractor=None,\n",
    "    # exclude_dirs=(),\n",
    "    # timeout=10,\n",
    "    # check_response_status=True,\n",
    "    continue_on_failure=True,\n",
    "    prevent_outside=True,\n",
    "    # base_url=None,\n",
    "    # ...\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "medrxiv_docs = medrxiv_loader.load()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(medrxiv_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'https://clinicaltrials.gov/', 'content_type': 'text/html', 'title': 'ClinicalTrials.gov', 'description': '', 'language': 'en'}, page_content='ClinicalTrials.gov\\n\\nHide glossary\\n\\nGlossary\\n\\n  Study record managers: refer to the Data Element Definitions if submitting registration or results information.\\n  \\n\\nSearch for terms')]"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "medrxiv_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders.sitemap import SitemapLoader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [],
   "source": [
    "medrxiv_sitemap_loader = SitemapLoader(web_path='https://www.medrxiv.org/sitemap.xml',\n",
    "                               filter_urls = [r\".*(diabetes|blood[-_]?sugar|glucose|insulin).*\"],\n",
    "                               continue_on_failure=True,\n",
    "                               )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Fetching pages: 100%|##########| 1/1 [00:01<00:00,  1.25s/it]\n",
      "Fetching pages: 100%|##########| 1/1 [00:01<00:00,  1.13s/it]\n",
      "Fetching pages: 0it [00:00, ?it/s]\n"
     ]
    }
   ],
   "source": [
    "medrxiv_docs = list(medrxiv_sitemap_loader.lazy_load())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(medrxiv_docs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [],
   "source": [
    "for doc in medrxiv_docs:\n",
    "    print(doc.metadata[\"source\"])\n",
    "    print(doc.page_content[:500])  # show first 500 chars of the content\n",
    "    print(\"=\" * 80)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'CrawlStatusResponse' object has no attribute 'get'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[49], line 13\u001b[0m\n\u001b[1;32m     11\u001b[0m \u001b[38;5;66;03m# Step 3: Filter results for \"diabetes\"\u001b[39;00m\n\u001b[1;32m     12\u001b[0m medrxiv_diabetes_docs \u001b[38;5;241m=\u001b[39m []\n\u001b[0;32m---> 13\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m doc \u001b[38;5;129;01min\u001b[39;00m \u001b[43mmedrxiv_crawl_result\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mget\u001b[49m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdata\u001b[39m\u001b[38;5;124m\"\u001b[39m, []):\n\u001b[1;32m     14\u001b[0m     text \u001b[38;5;241m=\u001b[39m doc\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtext\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m)\u001b[38;5;241m.\u001b[39mlower()\n\u001b[1;32m     15\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdiabetes\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m text:\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/pydantic/main.py:991\u001b[0m, in \u001b[0;36mBaseModel.__getattr__\u001b[0;34m(self, item)\u001b[0m\n\u001b[1;32m    988\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28msuper\u001b[39m()\u001b[38;5;241m.\u001b[39m\u001b[38;5;21m__getattribute__\u001b[39m(item)  \u001b[38;5;66;03m# Raises AttributeError if appropriate\u001b[39;00m\n\u001b[1;32m    989\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    990\u001b[0m     \u001b[38;5;66;03m# this is the current error\u001b[39;00m\n\u001b[0;32m--> 991\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mAttributeError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mtype\u001b[39m(\u001b[38;5;28mself\u001b[39m)\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__name__\u001b[39m\u001b[38;5;132;01m!r}\u001b[39;00m\u001b[38;5;124m object has no attribute \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mitem\u001b[38;5;132;01m!r}\u001b[39;00m\u001b[38;5;124m'\u001b[39m)\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'CrawlStatusResponse' object has no attribute 'get'"
     ]
    }
   ],
   "source": [
    "from firecrawl import FirecrawlApp, ScrapeOptions\n",
    "# Step 1: Initialize Firecrawl client\n",
    "medrxiv_app = FirecrawlApp(api_key=api_key)\n",
    "\n",
    "# Step 2: Crawl medRxiv homepage\n",
    "medrxiv_crawl_result = medrxiv_app.crawl_url(\n",
    "  'https://www.medrxiv.org/',\n",
    "  limit=10, \n",
    "  scrape_options=ScrapeOptions(formats=['markdown', 'html']),\n",
    ")\n",
    "# Step 3: Filter results for \"diabetes\"\n",
    "medrxiv_diabetes_docs = []\n",
    "for doc in medrxiv_crawl_result.get(\"data\", []):\n",
    "    text = doc.get(\"text\", \"\").lower()\n",
    "    if \"diabetes\" in text:\n",
    "        medrxiv_diabetes_docs.append(doc[\"url\"])\n",
    "\n",
    "# Step 4: Show matched URLs\n",
    "print(\"Documents mentioning 'diabetes':\")\n",
    "for url in medrxiv_diabetes_docs:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Step 1: Instantiate the loader with your starting URL\n",
    "medrxiv_loader = FireCrawlLoader(\n",
    "    api_key=\"fc-9a8592bd12ee4afd8f361c1ef69786ec\", url=\"https://www.medrxiv.org/\", mode=\"map\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Step 2: Lazy load documents\n",
    "medrxiv_docs_lazy = medrxiv_loader.lazy_load()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<generator object FireCrawlLoader.lazy_load at 0x12a21b740>"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "medrxiv_docs_lazy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Unsupported parameter(s) for map_url: params. Please refer to the API documentation for the correct parameters.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[47], line 4\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;66;03m# Step 3: Filter docs that mention \"diabetes\" and collect their URLs\u001b[39;00m\n\u001b[1;32m      2\u001b[0m medrxiv_diabetes_urls \u001b[38;5;241m=\u001b[39m []\n\u001b[0;32m----> 4\u001b[0m \u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mdoc\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mmedrxiv_loader\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mlazy_load\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m:\u001b[49m\n\u001b[1;32m      5\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mdoc\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mpage_content\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mlower\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m      6\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdiabetes\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m:\u001b[49m\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/langchain_community/document_loaders/firecrawl.py:289\u001b[0m, in \u001b[0;36mFireCrawlLoader.lazy_load\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    287\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39murl:\n\u001b[1;32m    288\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mURL is required for map mode\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m--> 289\u001b[0m     firecrawl_docs \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfirecrawl\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmap_url\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mparams\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mparams\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    290\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmode \u001b[38;5;241m==\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mextract\u001b[39m\u001b[38;5;124m\"\u001b[39m:\n\u001b[1;32m    291\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39murl:\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/firecrawl/firecrawl.py:1140\u001b[0m, in \u001b[0;36mFirecrawlApp.map_url\u001b[0;34m(self, url, search, ignore_sitemap, include_subdomains, sitemap_only, limit, timeout, use_index, **kwargs)\u001b[0m\n\u001b[1;32m   1117\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   1118\u001b[0m \u001b[38;5;124;03mMap and discover links from a URL.\u001b[39;00m\n\u001b[1;32m   1119\u001b[0m \n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1137\u001b[0m \u001b[38;5;124;03m    Exception: If mapping fails or response cannot be parsed\u001b[39;00m\n\u001b[1;32m   1138\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   1139\u001b[0m \u001b[38;5;66;03m# Validate any additional kwargs\u001b[39;00m\n\u001b[0;32m-> 1140\u001b[0m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_validate_kwargs\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmap_url\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1142\u001b[0m \u001b[38;5;66;03m# Build map parameters\u001b[39;00m\n\u001b[1;32m   1143\u001b[0m map_params \u001b[38;5;241m=\u001b[39m {}\n",
      "File \u001b[0;32m~/.pyenv/versions/3.12.0/lib/python3.12/site-packages/firecrawl/firecrawl.py:2516\u001b[0m, in \u001b[0;36mFirecrawlApp._validate_kwargs\u001b[0;34m(self, kwargs, method_name)\u001b[0m\n\u001b[1;32m   2514\u001b[0m unknown_params \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mset\u001b[39m(kwargs\u001b[38;5;241m.\u001b[39mkeys()) \u001b[38;5;241m-\u001b[39m allowed_params\n\u001b[1;32m   2515\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m unknown_params:\n\u001b[0;32m-> 2516\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mUnsupported parameter(s) for \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mmethod_name\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m, \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;241m.\u001b[39mjoin(unknown_params)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m. Please refer to the API documentation for the correct parameters.\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "\u001b[0;31mValueError\u001b[0m: Unsupported parameter(s) for map_url: params. Please refer to the API documentation for the correct parameters."
     ]
    }
   ],
   "source": [
    "# Step 3: Filter docs that mention \"diabetes\" and collect their URLs\n",
    "medrxiv_diabetes_urls = []\n",
    "\n",
    "for doc in medrxiv_loader.lazy_load():\n",
    "    text = doc.page_content.lower()\n",
    "    if \"diabetes\" in text:\n",
    "        metadata = doc.metadata or {}\n",
    "        url = metadata.get(\"sourceURL\") or metadata.get(\"ogUrl\")\n",
    "        if url:\n",
    "            medrxiv_diabetes_urls.append(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Step 4: Print results\n",
    "for url in medrxiv_diabetes_urls:\n",
    "    print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(medrxiv_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'source': 'https://www.medrxiv.org/search', 'content_type': 'text/html; charset=utf-8', 'title': 'Advanced Search | medRxiv', 'description': 'medRxiv - The Preprint Server for Health Sciences', 'language': 'en'}, page_content='<!DOCTYPE html>\\n<html lang=\"en\" dir=\"ltr\" \\n  xmlns=\"http://www.w3.org/1999/xhtml\"\\n  xmlns:mml=\"http://www.w3.org/1998/Math/MathML\">\\n  <head prefix=\"og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#\" >\\n    <!--[if IE]><![endif]-->\\n<link rel=\"dns-prefetch\" href=\"//cdn.jsdelivr.net\" />\\n<link rel=\"dns-prefetch\" href=\"//d33xdlntwy0kbs.cloudfront.net\" />\\n<link rel=\"dns-prefetch\" href=\"//www.googletagmanager.com\" />\\n<link rel=\"dns-prefetch\" href=\"//rum-static.pingdom.net\" />\\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\\n<link rel=\"shortcut icon\" href=\"https://www.medrxiv.org/sites/default/files/images/favicon.ico\" type=\"image/vnd.microsoft.icon\" />\\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1\" />\\n<meta name=\"description\" content=\"medRxiv - The Preprint Server for Health Sciences\" />\\n<meta name=\"generator\" content=\"Drupal 7 (http://drupal.org)\" />\\n<link rel=\"canonical\" href=\"https://www.medrxiv.org/search\" />\\n<link rel=\"shortlink\" href=\"https://www.medrxiv.org/search\" />\\n    <title>Advanced Search | medRxiv</title>  \\n    <link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__1nts4nYp6FnMelPuLHI1Bv5wOPiLdq5gcTs2KWdxZiM__z-Khrsc5V79ZW7fdx8DhV4DtL0C0u6N5XkPm6FsXH48__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<style type=\"text/css\" media=\"all\">\\n/* <![CDATA[ */\\n.panels-flexible-new .panels-flexible-region{padding:0}.panels-flexible-new .panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-new .panels-flexible-region-inside-first{padding-left:0}.panels-flexible-new .panels-flexible-region-inside-last{padding-right:0}.panels-flexible-new .panels-flexible-column{padding:0}.panels-flexible-new .panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-new .panels-flexible-column-inside-first{padding-left:0}.panels-flexible-new .panels-flexible-column-inside-last{padding-right:0}.panels-flexible-new .panels-flexible-row{padding:0 0 .5em;margin:0}.panels-flexible-new .panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}\\n/* ]]> */\\n</style>\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__PWuQ_RYRTJ4BLEKsbWQeHysPg0gOQ3571ruQa_rXvAo__yLchFjMfV0VsvCb7lQCgu43P-Ik3VpuzyecNEs1b7Fs__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<style type=\"text/css\" media=\"all\">\\n/* <![CDATA[ */\\n#sliding-popup.sliding-popup-bottom,#sliding-popup.sliding-popup-bottom .eu-cookie-withdraw-banner,.eu-cookie-withdraw-tab{background:gray}#sliding-popup.sliding-popup-bottom.eu-cookie-withdraw-wrapper{background:transparent}#sliding-popup .popup-content #popup-text h1,#sliding-popup .popup-content #popup-text h2,#sliding-popup .popup-content #popup-text h3,#sliding-popup .popup-content #popup-text p,.eu-cookie-compliance-secondary-button,.eu-cookie-withdraw-tab{color:#fff !important}.eu-cookie-withdraw-tab{border-color:#fff}.eu-cookie-compliance-more-button{color:#fff !important}\\n/* ]]> */\\n</style>\\n\\n<!--[if lte IE 7]>\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__ElJr3PIJEvw3qLXc1cnYiLj2G4KgDPSXFOfm6Phf8hw__JdWGm15cDWjsK6KrFlQVXQix9YgNeYysf22XZHj-Y-c__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<![endif]-->\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.7.2/css/all.min.css\" media=\"all\" />\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__BuoDuzoWcz2CL9-rYVqiOwZYB0s9mtqPm1bLrGHX4Z4__WNptNuPkTJ2rxI9jvljwIQXeYY9GgnsTxhjOkFT4fEY__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__s1V-L61ii6pBkoqGCH2JLhoBrqzSqqX8kCFGLohzztI__jeunelamyTnLjvpeBpZOu47xSchpdZ607j65qtc748U__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n\\n<!--[if (lt IE 9)&(!IEMobile)]>\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__XH6bpcI0f2dImc-p674DLCZtWBGb-QwxJK1YexVGtno__vUceGprdo5nIhV6DH93X7fI3r8RcTJbChbas9TQXeW4__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<![endif]-->\\n\\n<!--[if gte IE 9]><!-->\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__Mwn7scBl98BD52iLFgc9aoaknCGlubkX7KJ5d5dvBYs__TcUoFcz2Xaeg5ehKqQuuW1quNVzLD_2emI9RqvszpaA__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<!--<![endif]-->\\n\\n<!--[if gte IE 9]><!-->\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__IspEMXhIbAzNb41BpP9szWFQI-Qt4l1913RDS4dPu1c__pgc7J9FVZOIa3oRwp2l7IFRgoebOnE_zfFN5vi7xyTA__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<!--<![endif]-->\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://www.medrxiv.org/sites/default/files/advagg_css/css__W_ItEumqsUyv4uJl9NNkQZWPlxWupCxAMaPa4RZVP0M__hsiFRyI4A0SybrSkkCu9HSGtJ5hlTlGSn5bEIYP8DoI__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.css\" media=\"all\" />\\n<link type=\"text/css\" rel=\"stylesheet\" href=\"https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.css\" media=\"all\" />\\n    <script type=\"text/javascript\" src=\"https://www.medrxiv.org/sites/default/files/advagg_js/js__1kvP_VnMW9Ujv8XNFHQu6p7yMxeRVBhVcI6QPWwEZ10__-Gp85M2glFuEpYkBYIr-q2BAx65WqYL9HiMS_hUHVT0__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.js\"></script>\\n<script type=\"text/javascript\" async=\"async\" src=\"https://www.googletagmanager.com/gtag/js?id=G-0K57TCX5BY\"></script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\n/*!\\n * yepnope1.5.4\\n * (c) WTFPL, GPLv2\\n */\\n(function(a,b,c){function d(a){return\"[object Function]\"==o.call(a)}function e(a){return\"string\"==typeof a}function f(){}function g(a){return!a||\"loaded\"==a||\"complete\"==a||\"uninitialized\"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){(\"c\"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){\"img\"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),\"object\"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height=\"0\",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),\"img\"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||\"j\",e(a)?i(\"c\"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName(\"script\")[0],o={}.toString,p=[],q=0,r=\"MozAppearance\"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&\"[object Opera]\"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?\"object\":l?\"script\":\"img\",v=l?\"script\":u,w=Array.isArray||function(a){return\"[object Array]\"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split(\"!\"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split(\"=\"),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(\".\").pop().split(\"?\").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split(\"/\").pop().split(\"?\")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&\"css\"==i.url.split(\".\").pop().split(\"?\").shift()?\"c\":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i<a.length;i++)j=a[i],e(j)?g(j,0,l,0):w(j)?B(j):Object(j)===j&&h(j,l);else Object(a)===a&&h(a,l)},B.addPrefix=function(a,b){z[a]=b},B.addFilter=function(a){x.push(a)},B.errorTimeout=1e4,null==b.readyState&&b.addEventListener&&(b.readyState=\"loading\",b.addEventListener(\"DOMContentLoaded\",A=function(){b.removeEventListener(\"DOMContentLoaded\",A,0),b.readyState=\"complete\"},0)),a.yepnope=k(),a.yepnope.executeStack=h,a.yepnope.injectJs=function(a,c,d,e,i,j){var k=b.createElement(\"script\"),l,o,e=e||B.errorTimeout;k.src=a;for(o in d)k.setAttribute(o,d[o]);c=j?h:c||f,k.onreadystatechange=k.onload=function(){!l&&g(k.readyState)&&(l=1,c(),k.onload=k.onreadystatechange=null)},m(function(){l||(l=1,c(1))},e),i?k.onload():n.parentNode.insertBefore(k,n)},a.yepnope.injectCss=function(a,c,d,e,g,i){var e=b.createElement(\"link\"),j,c=i?h:c||f;e.href=a,e.rel=\"stylesheet\",e.type=\"text/css\";for(j in d)e.setAttribute(j,d[j]);g||(n.parentNode.insertBefore(e,n),m(c,0))}})(this,document);\\n\\n//--><!]]>\\n</script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\nyepnope({\\n  test: Modernizr.matchmedia,\\n  nope: \\'/sites/all/libraries/media-match/media.match.min.js\\'\\n});\\n//--><!]]>\\n</script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\nvar _prum=[[\\'id\\', \\'52e95df3abe53d2e33000000\\'], [\\'mark\\', \\'firstbyte\\',\\n      (new Date()).getTime()]]; (function() {\\n      var s=document.getElementsByTagName(\\'script\\')[0],\\n      p=document.createElement(\\'script\\');\\n      p.async=\\'async\\'; p.src=\\'//rum-static.pingdom.net/prum.min.js\\';s.parentNode.insertBefore(p,s);})();\\n//--><!]]>\\n</script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\"js\", new Date());gtag(\"set\", \"developer_id.dMDhkMT\", true);gtag(\"config\", \"G-0K57TCX5BY\", {\"groups\":\"default\",\"anonymize_ip\":true});\\n//--><!]]>\\n</script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\njQuery.extend(Drupal.settings,{\"basePath\":\"\\\\/\",\"pathPrefix\":\"\",\"ajaxPageState\":{\"theme\":\"jcore_1\",\"theme_token\":\"uVz0-PrRQZSPJmiKkyor9kOViAPHJl58E80wrM_nwPc\"},\"colorbox\":{\"opacity\":\"0.85\",\"current\":\"{current} of {total}\",\"previous\":\"\\\\u00ab Prev\",\"next\":\"Next \\\\u00bb\",\"close\":\"Close\",\"maxWidth\":\"98%\",\"maxHeight\":\"98%\",\"fixed\":true,\"mobiledetect\":true,\"mobiledevicewidth\":\"480px\"},\"jcarousel\":{\"ajaxPath\":\"\\\\/jcarousel\\\\/ajax\\\\/views\"},\"jquery\":{\"ui\":{\"datepicker\":{\"isRTL\":false,\"firstDay\":0}}},\"datePopup\":{\"edit-limit-from-datepicker-popup-0\":{\"func\":\"datepicker\",\"settings\":{\"changeMonth\":true,\"changeYear\":true,\"autoPopUp\":\"focus\",\"closeAtTop\":false,\"speed\":\"immediate\",\"firstDay\":0,\"dateFormat\":\"yy-mm-dd\",\"yearRange\":\"-50:+3\",\"fromTo\":false,\"defaultDate\":\"0y\"}},\"edit-limit-to-datepicker-popup-0\":{\"func\":\"datepicker\",\"settings\":{\"changeMonth\":true,\"changeYear\":true,\"autoPopUp\":\"focus\",\"closeAtTop\":false,\"speed\":\"immediate\",\"firstDay\":0,\"dateFormat\":\"yy-mm-dd\",\"yearRange\":\"-50:+3\",\"fromTo\":false,\"defaultDate\":\"0y\"}}},\"chosen\":{\"selector\":\"select:visible\",\"minimum_single\":20,\"minimum_multiple\":20,\"minimum_width\":250,\"options\":{\"disable_search\":false,\"disable_search_threshold\":0,\"search_contains\":false,\"placeholder_text_multiple\":\"Choose some options\",\"placeholder_text_single\":\"Choose an option\",\"no_results_text\":\"No results match\",\"inherit_select_classes\":true}},\"urlIsAjaxTrusted\":{\"\\\\/search\":true},\"highwire_list_expand\":{\"is_collapsed\":\"1\"},\"highwireResponsive\":{\"enquire_enabled\":1,\"breakpoints_configured\":1,\"breakpoints\":{\"zero\":\"all and (min-width: 0px)\",\"xsmall\":\"all and (min-width: 380px)\",\"narrow\":\"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)\",\"normal\":\"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)\",\"wide\":\"all and (min-width: 1220px)\"}},\"eu_cookie_compliance\":{\"popup_enabled\":1,\"popup_agreed_enabled\":0,\"popup_hide_agreed\":0,\"popup_clicking_confirmation\":1,\"popup_scrolling_confirmation\":false,\"popup_html_info\":\"\\\\u003Cdiv\\\\u003E\\\\n  \\\\u003Cdiv class=\\\\u0022popup-content info\\\\u0022\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-text\\\\u0022\\\\u003E\\\\n      \\\\u003Cp\\\\u003EWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.\\\\u003C\\\\/p\\\\u003E\\\\n    \\\\u003C\\\\/div\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-buttons\\\\u0022\\\\u003E\\\\n      \\\\u003Cbutton type=\\\\u0022button\\\\u0022 role=\\\\u0022dialog\\\\u0022 aria-labelledby=\\\\u0022Continue\\\\u0022\\\\n        class=\\\\u0022agree-button eu-cookie-compliance-default-button\\\\u0022\\\\u003EContinue\\\\u003C\\\\/button\\\\u003E\\\\n                  \\\\u003Cbutton type=\\\\u0022button\\\\u0022 role=\\\\u0022dialog\\\\u0022 aria-labelledby=\\\\u0022Find out more\\\\u0022\\\\n        class=\\\\u0022find-more-button eu-cookie-compliance-more-button\\\\u0022\\\\u003EFind out more\\\\u003C\\\\/button\\\\u003E\\\\n          \\\\u003C\\\\/div\\\\u003E\\\\n  \\\\u003C\\\\/div\\\\u003E\\\\n\\\\u003C\\\\/div\\\\u003E\",\"use_mobile_message\":false,\"mobile_popup_html_info\":\"\\\\u003Cdiv\\\\u003E\\\\n  \\\\u003Cdiv class=\\\\u0022popup-content info\\\\u0022\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-text\\\\u0022\\\\u003E\\\\n          \\\\u003C\\\\/div\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-buttons\\\\u0022\\\\u003E\\\\n      \\\\u003Cbutton type=\\\\u0022button\\\\u0022 role=\\\\u0022dialog\\\\u0022 aria-labelledby=\\\\u0022Continue\\\\u0022\\\\n        class=\\\\u0022agree-button eu-cookie-compliance-default-button\\\\u0022\\\\u003EContinue\\\\u003C\\\\/button\\\\u003E\\\\n                  \\\\u003Cbutton type=\\\\u0022button\\\\u0022 role=\\\\u0022dialog\\\\u0022 aria-labelledby=\\\\u0022Find out more\\\\u0022\\\\n        class=\\\\u0022find-more-button eu-cookie-compliance-more-button\\\\u0022\\\\u003EFind out more\\\\u003C\\\\/button\\\\u003E\\\\n          \\\\u003C\\\\/div\\\\u003E\\\\n  \\\\u003C\\\\/div\\\\u003E\\\\n\\\\u003C\\\\/div\\\\u003E\",\"mobile_breakpoint\":\"768\",\"popup_html_agreed\":\"\\\\u003Cdiv\\\\u003E\\\\n  \\\\u003Cdiv class=\\\\u0022popup-content agreed\\\\u0022\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-text\\\\u0022\\\\u003E\\\\n      \\\\u003Ch2\\\\u003EThank you for accepting cookies\\\\u003C\\\\/h2\\\\u003E\\\\u003Cp\\\\u003EYou can now hide this message or find out more about cookies.\\\\u003C\\\\/p\\\\u003E    \\\\u003C\\\\/div\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-buttons\\\\u0022\\\\u003E\\\\n      \\\\u003Cbutton type=\\\\u0022button\\\\u0022 class=\\\\u0022hide-popup-button eu-cookie-compliance-hide-button\\\\u0022\\\\u003EHide\\\\u003C\\\\/button\\\\u003E\\\\n              \\\\u003Cbutton type=\\\\u0022button\\\\u0022 class=\\\\u0022find-more-button eu-cookie-compliance-more-button-thank-you\\\\u0022 \\\\u003EMore info\\\\u003C\\\\/button\\\\u003E\\\\n          \\\\u003C\\\\/div\\\\u003E\\\\n  \\\\u003C\\\\/div\\\\u003E\\\\n\\\\u003C\\\\/div\\\\u003E\",\"popup_use_bare_css\":false,\"popup_height\":\"auto\",\"popup_width\":\"100%\",\"popup_delay\":1000,\"popup_link\":\"\\\\/help\\\\/cookie-policy\",\"popup_link_new_window\":1,\"popup_position\":null,\"popup_language\":\"en\",\"store_consent\":false,\"better_support_for_screen_readers\":0,\"reload_page\":0,\"domain\":\"\",\"popup_eu_only_js\":0,\"cookie_lifetime\":\"365\",\"cookie_session\":false,\"disagree_do_not_show_popup\":0,\"method\":\"default\",\"whitelisted_cookies\":\"\",\"withdraw_markup\":\"\\\\u003Cbutton type=\\\\u0022button\\\\u0022 class=\\\\u0022eu-cookie-withdraw-tab\\\\u0022\\\\u003EPrivacy settings\\\\u003C\\\\/button\\\\u003E\\\\n\\\\u003Cdiv class=\\\\u0022eu-cookie-withdraw-banner\\\\u0022\\\\u003E\\\\n  \\\\u003Cdiv class=\\\\u0022popup-content info\\\\u0022\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-text\\\\u0022\\\\u003E\\\\n      \\\\u003Cp\\\\u003E\\\\u0026lt;h2\\\\u0026gt;We use cookies on this site to enhance your user experience\\\\u0026lt;\\\\/h2\\\\u0026gt;\\\\u0026lt;p\\\\u0026gt;You have given your consent for us to set cookies.\\\\u0026lt;\\\\/p\\\\u0026gt;\\\\u003C\\\\/p\\\\u003E\\\\n    \\\\u003C\\\\/div\\\\u003E\\\\n    \\\\u003Cdiv id=\\\\u0022popup-buttons\\\\u0022\\\\u003E\\\\n      \\\\u003Cbutton type=\\\\u0022button\\\\u0022 class=\\\\u0022eu-cookie-withdraw-button\\\\u0022\\\\u003EWithdraw consent\\\\u003C\\\\/button\\\\u003E\\\\n    \\\\u003C\\\\/div\\\\u003E\\\\n  \\\\u003C\\\\/div\\\\u003E\\\\n\\\\u003C\\\\/div\\\\u003E\\\\n\",\"withdraw_enabled\":false},\"googleanalytics\":{\"account\":[\"G-0K57TCX5BY\"],\"trackOutbound\":1,\"trackMailto\":1,\"trackDownload\":1,\"trackDownloadExtensions\":\"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\",\"trackColorbox\":1},\"jnl_biorxiv_styles\":{\"defaultJCode\":\"medrxiv\"},\"omega\":{\"layouts\":{\"primary\":\"normal\",\"order\":[\"narrow\",\"normal\",\"wide\"],\"queries\":{\"narrow\":\"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)\",\"normal\":\"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)\",\"wide\":\"all and (min-width: 1220px)\"}}}});\\n//--><!]]>\\n</script>\\n    <!--[if lt IE 9]><script src=\"http://html5shiv.googlecode.com/svn/trunk/html5.js\"></script><![endif]-->\\n  </head>\\n  <body class=\"html not-front not-logged-in page-search context-search hw-default-jcode-medrxiv\">\\n<!-- Google Tag Manager -->\\n<noscript><iframe src=\"//www.googletagmanager.com/ns.html?id=GTM-P4HH5NV\" height=\"0\" width=\"0\" style=\"display:none;visibility:hidden\"></iframe></noscript>\\n<script type=\"text/javascript\">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({\\'gtm.start\\':new Date().getTime(),event:\\'gtm.js\\'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!=\\'dataLayer\\'?\\'&l=\\'+l:\\'\\';j.src=\\'//www.googletagmanager.com/gtm.js?id=\\'+i+dl;j.type=\\'text/javascript\\';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,\\'script\\',\\'dataLayer\\',\\'GTM-P4HH5NV\\');</script>\\n<!-- End Google Tag Manager -->\\n    <div id=\"skip-link\">\\n      <a href=\"#main-content\" class=\"element-invisible element-focusable\">Skip to main content</a>\\n    </div>\\n        <div class=\"page clearfix page-box-shadows footer-borders panels-page panels-layout-jcore_2col\" id=\"page\">\\n      <header id=\"section-header\" class=\"section section-header\">\\n    \\n  <div id=\"zone-branding\" class=\"zone zone-branding clearfix print-display-block container-30\">\\n    <div class=\"grid-15 prefix-1 region region-branding print-display-block\" id=\"region-branding\">\\n  <div class=\"region-inner region-branding-inner\">\\n        <div class=\"branding-data clearfix\">\\n            <div class=\"logo-img\">\\n        <a href=\"/\" rel=\"home\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\"><img alt=\"medRxiv\" src=\"https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png\" /></a>      </div>\\n                </div>\\n          </div>\\n</div><div class=\"grid-11 suffix-1 region region-branding-second print-hidden\" id=\"region-branding-second\">\\n  <div class=\"region-inner region-branding-second-inner\">\\n    <div class=\"block block-system block-menu block-main-menu block-system-main-menu odd block-without-title\" id=\"block-system-main-menu\">\\n  <div class=\"block-inner clearfix\">\\n                \\n    <div class=\"content clearfix\">\\n      <nav class=\"menubar-nav\"><ul class=\"menu\" role=\"menu\"><li class=\"first leaf\" role=\"menuitem\"><a href=\"/\" title=\"\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Home</a></li>\\n<li class=\"leaf\" role=\"menuitem\"><a href=\"/content/about-medrxiv\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">About</a></li>\\n<li class=\"leaf\" role=\"menuitem\"><a href=\"/submit-a-manuscript\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Submit</a></li>\\n<li class=\"last leaf\" role=\"menuitem\"><a href=\"/content/alertsrss\" title=\"\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">ALERTS / RSS</a></li>\\n</ul></nav>    </div>\\n  </div>\\n</div><div class=\"block block-panels-mini block-biorxiv-search-box block-panels-mini-biorxiv-search-box even block-without-title\" id=\"block-panels-mini-biorxiv-search-box\">\\n  <div class=\"block-inner clearfix\">\\n                \\n    <div class=\"content clearfix\">\\n      <div class=\"panel-display panel-1col clearfix\" id=\"mini-panel-biorxiv_search_box\">\\n  <div class=\"panel-panel panel-col\">\\n    <div><div class=\"panel-pane pane-highwire-seach-quicksearch\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <form class=\"highwire-quicksearch button-style-mini button-style-mini\" action=\"/search\" method=\"post\" id=\"highwire-search-quicksearch-form-0\" accept-charset=\"UTF-8\"><div><div class=\"form-item form-item-label-invisible form-type-textfield form-item-keywords\">\\n  <label class=\"element-invisible\" for=\"search_rightsidebar_keywords_1590740951\">Search for this keyword </label>\\n <input placeholder=\"Search\" type=\"text\" id=\"search_rightsidebar_keywords_1590740951\" name=\"keywords\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n</div>\\n<div class=\"button-wrapper button-mini\"><span class=\"icon-search\"></span><input data-icon-only=\"1\" data-font-icon=\"icon-search\" data-icon-position=\"after\" type=\"submit\" id=\"search_rightsidebar_submit_1960692630\" name=\"op\" value=\"Search\" class=\"form-submit\" /></div><input type=\"hidden\" name=\"form_build_id\" value=\"form-CCS8FloM5HfNBoF66ljTdZ1QvpSLVAgJJTsJr6R4nFc\" />\\n<input type=\"hidden\" name=\"form_id\" value=\"highwire_search_quicksearch_form_0\" />\\n</div></form>  </div>\\n\\n  \\n  </div>\\n<div class=\"panel-separator\"></div><div class=\"panel-pane pane-custom pane-1 advanced-search-link\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <a href=\"/search\">Advanced Search</a>  </div>\\n\\n  \\n  </div>\\n</div>\\n  </div>\\n</div>\\n    </div>\\n  </div>\\n</div>  </div>\\n</div>  </div>\\n  \\n  <div id=\"zone-header\" class=\"zone zone-header clearfix container-30\">\\n  \\t      </div>\\n</header>    \\n      <section id=\"section-content\" class=\"section section-content\">\\n    \\n  <div id=\"zone-content\" class=\"zone zone-content clearfix container-30\">    \\n        \\n    <div class=\"grid-28 suffix-1 prefix-1 region region-content\" id=\"region-content\">\\n  <div class=\"region-inner region-content-inner\">\\n    <a id=\"main-content\"></a>\\n                        <div class=\"block block-system block-main block-system-main odd block-without-title\" id=\"block-system-main\">\\n  <div class=\"block-inner clearfix\">\\n                \\n    <div class=\"content clearfix\">\\n      <div class=\"panel-display panels-960-layout jcore-2col-layout\" >\\n\\t  <div class=\"panel-row-wrapper panel-row-first clearfix\">\\n\\t\\t\\n\\t\\t<div class=\"top-wrapper\">\\n\\t\\t\\t<div class=\"panel-panel panel-region-top\">\\n\\t\\t\\t  <div class=\"inside\"><div class=\"panel-pane pane-page-title\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <h1 id=\"page-title\">Advanced Search</h1>\\n  </div>\\n\\n  \\n  </div>\\n</div>\\n\\t\\t\\t</div>\\n\\t\\t</div>\\n\\t\\n\\t</div> <!-- /.panel-row-wrapper -->\\t\\n\\t  \\n  <div class=\"panel-row-wrapper clearfix\">\\n\\t\\t\\n\\t\\t<div class=\"main-content-wrapper grid-17 suffix-1 alpha\">\\n\\t\\t\\t<div class=\"panel-panel panel-region-content\">\\n\\t\\t\\t  <div class=\"inside\"><div class=\"panel-pane pane-highwire-search-form\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <form class=\"highwire-search-form highwire-advanced-search-form\" action=\"/search\" method=\"post\" id=\"highwire-search-form\" accept-charset=\"UTF-8\"><div><div class=\"form-item form-item-label-before form-type-textfield form-item-txtsimple\">\\n  <label for=\"edit-txtsimple\">Search Terms &amp; Keywords </label>\\n <input type=\"text\" id=\"edit-txtsimple\" name=\"txtsimple\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" /><span class=\"icon-search\"></span>\\n<div class=\"description\">Type a term to search within all articles in this journal: e.g., stem cell</div>\\n</div>\\n<fieldset class=\"collapsible form-wrapper\" id=\"edit-limits\"><legend><span class=\"fieldset-legend\">Limit Results</span></legend><div class=\"fieldset-wrapper\"><span class=\"label filter-by-date-label\">Date of Publication</span><div class=\"filter-by-date clearfix form-wrapper\" id=\"edit-limit-by-date\"><div  class=\"container-inline-date\"><div class=\"form-item form-item-label-before form-type-date-popup form-item-limit-from\">\\n  <label for=\"edit-limit-from\"><span class=\"element-invisible\">From</span> </label>\\n <div id=\"edit-limit-from\"  class=\"date-padding\"><div class=\"form-item form-item-label-invisible form-type-textfield form-item-limit-from-date\">\\n  <label class=\"element-invisible\" for=\"edit-limit-from-datepicker-popup-0\">Date </label>\\n <input type=\"text\" id=\"edit-limit-from-datepicker-popup-0\" name=\"limit_from[date]\" value=\"\" size=\"20\" maxlength=\"30\" class=\"form-text\" />\\n<div class=\"description\"> e.g., 2025-06-12</div>\\n</div>\\n</div>\\n</div>\\n</div><span class=\"date-spacer\"> &mdash; </span><div  class=\"container-inline-date\"><div class=\"form-item form-item-label-before form-type-date-popup form-item-limit-to\">\\n  <label for=\"edit-limit-to\"><span class=\"element-invisible\">Through</span> </label>\\n <div id=\"edit-limit-to\"  class=\"date-padding\"><div class=\"form-item form-item-label-invisible form-type-textfield form-item-limit-to-date\">\\n  <label class=\"element-invisible\" for=\"edit-limit-to-datepicker-popup-0\">Date </label>\\n <input type=\"text\" id=\"edit-limit-to-datepicker-popup-0\" name=\"limit_to[date]\" value=\"\" size=\"20\" maxlength=\"30\" class=\"form-text\" />\\n<div class=\"description\"> e.g., 2025-06-12</div>\\n</div>\\n</div>\\n</div>\\n</div></div><div class=\"form-item form-item-label-before form-type-select form-item-jcode\">\\n  <label for=\"edit-jcode\">Include articles in medRxiv and/or bioRxiv: </label>\\n <select data-placeholder=\"Select\" multiple=\"multiple\" name=\"jcode[]\" class=\"chosen-enable form-select\" id=\"edit-jcode\"><option value=\"medrxiv\" selected=\"selected\">medRxiv</option><option value=\"biorxiv\">bioRxiv</option><option value=\"\">bioRxiv and medRxiv</option></select>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-select form-item-subject-collection-code\">\\n  <label for=\"edit-subject-collection-code\">Include articles in subject area(s) </label>\\n <select data-placeholder=\"Select\" multiple=\"multiple\" name=\"subject_collection_code[]\" class=\"chosen-enable form-select\" id=\"edit-subject-collection-code\"><option value=\"0\">-- All Collections --</option><option value=\"Addiction Medicine\">Addiction Medicine</option><option value=\"Allergy and Immunology\">Allergy and Immunology</option><option value=\"Anesthesia\">Anesthesia</option><option value=\"Cardiovascular Medicine\">Cardiovascular Medicine</option><option value=\"Dentistry and Oral Medicine\">Dentistry and Oral Medicine</option><option value=\"Dermatology\">Dermatology</option><option value=\"Emergency Medicine\">Emergency Medicine</option><option value=\"Endocrinology\">Endocrinology (including Diabetes Mellitus and Metabolic Disease)</option><option value=\"Epidemiology\">Epidemiology</option><option value=\"Forensic Medicine\">Forensic Medicine</option><option value=\"Gastroenterology\">Gastroenterology</option><option value=\"Genetic and Genomic Medicine\">Genetic and Genomic Medicine</option><option value=\"Geriatric Medicine\">Geriatric Medicine</option><option value=\"Health Economics\">Health Economics</option><option value=\"Health Informatics\">Health Informatics</option><option value=\"Health Policy\">Health Policy</option><option value=\"Health Systems and Quality Improvement\">Health Systems and Quality Improvement</option><option value=\"Hematology\">Hematology</option><option value=\"HIV/AIDS\">HIV/AIDS</option><option value=\"Infectious Diseases (except HIV/AIDS)\">Infectious Diseases (except HIV/AIDS)</option><option value=\"Intensive Care and Critical Care Medicine\">Intensive Care and Critical Care Medicine</option><option value=\"Medical Education\">Medical Education</option><option value=\"Medical Ethics\">Medical Ethics</option><option value=\"Nephrology\">Nephrology</option><option value=\"Neurology\">Neurology</option><option value=\"Nursing\">Nursing</option><option value=\"Nutrition\">Nutrition</option><option value=\"Obstetrics and Gynecology\">Obstetrics and Gynecology</option><option value=\"Occupational and Environmental Health\">Occupational and Environmental Health</option><option value=\"Oncology\">Oncology</option><option value=\"Ophthalmology\">Ophthalmology</option><option value=\"Orthopedics\">Orthopedics</option><option value=\"Otolaryngology\">Otolaryngology</option><option value=\"Pain Medicine\">Pain Medicine</option><option value=\"Palliative Medicine\">Palliative Medicine</option><option value=\"Pathology\">Pathology</option><option value=\"Pediatrics\">Pediatrics</option><option value=\"Pharmacology and Therapeutics\">Pharmacology and Therapeutics</option><option value=\"Primary Care Research\">Primary Care Research</option><option value=\"Psychiatry and Clinical Psychology\">Psychiatry and Clinical Psychology</option><option value=\"Public and Global Health\">Public and Global Health</option><option value=\"Radiology and Imaging\">Radiology and Imaging</option><option value=\"Rehabilitation Medicine and Physical Therapy\">Rehabilitation Medicine and Physical Therapy</option><option value=\"Respiratory Medicine\">Respiratory Medicine</option><option value=\"Rheumatology\">Rheumatology</option><option value=\"Sexual and Reproductive Health\">Sexual and Reproductive Health</option><option value=\"Sports Medicine\">Sports Medicine</option><option value=\"Surgery\">Surgery</option><option value=\"Toxicology\">Toxicology</option><option value=\"Transplantation\">Transplantation</option><option value=\"Urology\">Urology</option></select>\\n</div>\\n<div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-select form-item-series\">\\n  <label for=\"edit-series\">Include articles in Series </label>\\n <select data-placeholder=\"Choose Article Series\" class=\"element-hidden chosen-enable form-select\" multiple=\"multiple\" name=\"series[]\" id=\"edit-series\"><option value=\"0\">-- All Series --</option></select>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-checkboxes form-item-flag\">\\n  <label for=\"edit-flag\">Include Only: </label>\\n <div id=\"edit-flag\" class=\"form-checkboxes element-hidden\"><div class=\"form-item form-item-label-after form-type-checkbox form-item-flag-OPENACCESS\">\\n <input aria-labelledby=\"Include Only\" class=\"element-hidden form-checkbox\" type=\"checkbox\" id=\"edit-flag-openaccess\" name=\"flag[OPENACCESS]\" value=\"OPENACCESS\" />  <label class=\"option\" for=\"edit-flag-openaccess\"> Open Access Articles </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-checkbox form-item-flag-HWREVIEW\">\\n <input aria-labelledby=\"Include Only\" class=\"element-hidden form-checkbox\" type=\"checkbox\" id=\"edit-flag-hwreview\" name=\"flag[HWREVIEW]\" value=\"HWREVIEW\" />  <label class=\"option\" for=\"edit-flag-hwreview\"> Review Articles </label>\\n\\n</div>\\n</div>\\n</div>\\n</div></div></fieldset>\\n<fieldset class=\"collapsible form-wrapper\" id=\"edit-keywords\"><legend><span class=\"fieldset-legend\">Authors, Keywords</span></legend><div class=\"fieldset-wrapper\"><div class=\"fieldset-description\">Search for specific authors and/or words and phrases.</div><div class=\"form-item form-item-label-before form-type-textfield form-item-author1\">\\n  <label for=\"edit-author1\">Author </label>\\n <input type=\"text\" id=\"edit-author1\" name=\"author1\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">e.g., Smith, JS</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-textfield form-item-author2\">\\n  <label for=\"edit-author2\">Author </label>\\n <input type=\"text\" id=\"edit-author2\" name=\"author2\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">e.g., Smith, JS</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-textfield form-item-title\">\\n  <label for=\"edit-title\">Title </label>\\n <input type=\"text\" id=\"edit-title\" name=\"title\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">Type any phrase that appears in the article title</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-radios form-item-title-flags\">\\n  <label for=\"edit-title-flags\">words </label>\\n <div id=\"edit-title-flags\" class=\"form-radios\"><div class=\"form-item form-item-label-after form-type-radio form-item-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-title-flags-match-any\" name=\"title_flags\" value=\"match-any\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-title-flags-match-any\">any </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-title-flags-match-all\" name=\"title_flags\" value=\"match-all\" checked=\"checked\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-title-flags-match-all\">all </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-title-flags-match-phrase\" name=\"title_flags\" value=\"match-phrase\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-title-flags-match-phrase\">phrase </label>\\n\\n</div>\\n</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-textfield form-item-abstract-title\">\\n  <label for=\"edit-abstract-title\">Abstract or Title </label>\\n <input type=\"text\" id=\"edit-abstract-title\" name=\"abstract_title\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">Type any phrase that appears within article title or abstract</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-radios form-item-abstract-title-flags\">\\n  <label for=\"edit-abstract-title-flags\">words </label>\\n <div id=\"edit-abstract-title-flags\" class=\"form-radios\"><div class=\"form-item form-item-label-after form-type-radio form-item-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-abstract-title-flags-match-any\" name=\"abstract_title_flags\" value=\"match-any\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-abstract-title-flags-match-any\">any </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-abstract-title-flags-match-all\" name=\"abstract_title_flags\" value=\"match-all\" checked=\"checked\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-abstract-title-flags-match-all\">all </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-abstract-title-flags-match-phrase\" name=\"abstract_title_flags\" value=\"match-phrase\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-abstract-title-flags-match-phrase\">phrase </label>\\n\\n</div>\\n</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-textfield form-item-text-abstract-title\">\\n  <label for=\"edit-text-abstract-title\">Full Text or Abstract or Title </label>\\n <input type=\"text\" id=\"edit-text-abstract-title\" name=\"text_abstract_title\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">Type any phrase that appears within article body, title or abstract</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-radios form-item-text-abstract-title-flags\">\\n  <label for=\"edit-text-abstract-title-flags\">words </label>\\n <div id=\"edit-text-abstract-title-flags\" class=\"form-radios\"><div class=\"form-item form-item-label-after form-type-radio form-item-text-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-text-abstract-title-flags-match-any\" name=\"text_abstract_title_flags\" value=\"match-any\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-text-abstract-title-flags-match-any\">any </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-text-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-text-abstract-title-flags-match-all\" name=\"text_abstract_title_flags\" value=\"match-all\" checked=\"checked\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-text-abstract-title-flags-match-all\">all </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-text-abstract-title-flags\">\\n <input aria-labelledby=\"words\" type=\"radio\" id=\"edit-text-abstract-title-flags-match-phrase\" name=\"text_abstract_title_flags\" value=\"match-phrase\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-text-abstract-title-flags-match-phrase\">phrase </label>\\n\\n</div>\\n</div>\\n</div>\\n<div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-references\">\\n  <label for=\"edit-references\">Bibliography </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-references\" name=\"references\" value=\"\" size=\"60\" maxlength=\"128\" />\\n<div class=\"description\">e.g., Smith, JS</div>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-radios form-item-references-flags\">\\n  <label for=\"edit-references-flags\">words </label>\\n <div id=\"edit-references-flags\" class=\"form-radios element-hidden\"><div class=\"form-item form-item-label-after form-type-radio form-item-references-flags\">\\n <input aria-labelledby=\"words\" class=\"element-hidden form-radio\" type=\"radio\" id=\"edit-references-flags-match-any\" name=\"references_flags\" value=\"match-any\" />  <label class=\"option\" for=\"edit-references-flags-match-any\">any </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-references-flags\">\\n <input aria-labelledby=\"words\" class=\"element-hidden form-radio\" type=\"radio\" id=\"edit-references-flags-match-all\" name=\"references_flags\" value=\"match-all\" checked=\"checked\" />  <label class=\"option\" for=\"edit-references-flags-match-all\">all </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-references-flags\">\\n <input aria-labelledby=\"words\" class=\"element-hidden form-radio\" type=\"radio\" id=\"edit-references-flags-match-phrase\" name=\"references_flags\" value=\"match-phrase\" />  <label class=\"option\" for=\"edit-references-flags-match-phrase\">phrase </label>\\n\\n</div>\\n</div>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-select form-item-publisher\">\\n  <label for=\"edit-publisher\">Publisher </label>\\n <select class=\"element-hidden form-select\" id=\"edit-publisher\" name=\"publisher\"><option value=\"\" selected=\"selected\"> - All Publishers - </option></select>\\n<div class=\"description\">Book publisher name</div>\\n</div>\\n</div></div></fieldset>\\n<fieldset class=\"collapsible form-wrapper\" id=\"edit-citation\"><legend><span class=\"fieldset-legend\">Citation</span></legend><div class=\"fieldset-wrapper\"><div class=\"fieldset-description\">Citation-specific search information</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-pubyear\">\\n  <label for=\"edit-pubyear\">Year </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-pubyear\" name=\"pubyear\" value=\"\" size=\"60\" maxlength=\"128\" />\\n<div class=\"description\">e.g., 2009</div>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-volume\">\\n  <label for=\"edit-volume\">Volume </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-volume\" name=\"volume\" value=\"\" size=\"60\" maxlength=\"128\" />\\n<div class=\"description\">e.g., 20</div>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-issue\">\\n  <label for=\"edit-issue\">Issue </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-issue\" name=\"issue\" value=\"\" size=\"60\" maxlength=\"128\" />\\n<div class=\"description\">e.g., 3</div>\\n</div>\\n</div><div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-firstpage\">\\n  <label for=\"edit-firstpage\">First page </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-firstpage\" name=\"firstpage\" value=\"\" size=\"60\" maxlength=\"128\" />\\n<div class=\"description\">e.g., 29</div>\\n</div>\\n</div><div class=\"form-item form-item-label-before form-type-textfield form-item-doi\">\\n  <label for=\"edit-doi\">DOI </label>\\n <input type=\"text\" id=\"edit-doi\" name=\"doi\" value=\"\" size=\"60\" maxlength=\"128\" class=\"form-text\" />\\n<div class=\"description\">e.g., 10.9999/123XYZ456</div>\\n</div>\\n<div class=\"element-hidden\"><div class=\"form-item form-item-label-before form-type-textfield form-item-isbn\">\\n  <label for=\"edit-isbn\">ISBN </label>\\n <input class=\"element-hidden form-text\" type=\"text\" id=\"edit-isbn\" name=\"isbn\" value=\"\" size=\"60\" maxlength=\"128\" />\\n</div>\\n</div></div></fieldset>\\n<fieldset class=\"collapsible form-wrapper\" id=\"edit-format\"><legend><span class=\"fieldset-legend\">Format Results</span></legend><div class=\"fieldset-wrapper\"><div class=\"form-item form-item-label-before form-type-select form-item-numresults\">\\n  <label for=\"edit-numresults\">Number of results per page </label>\\n <select id=\"edit-numresults\" name=\"numresults\" class=\"form-select\"><option value=\"10\" selected=\"selected\">10</option><option value=\"25\">25</option><option value=\"50\">50</option><option value=\"75\">75</option></select>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-radios form-item-sort\">\\n  <label for=\"edit-sort\">Sort </label>\\n <div id=\"edit-sort\" class=\"form-radios\"><div class=\"form-item form-item-label-after form-type-radio form-item-sort\">\\n <input aria-labelledby=\"Sort\" type=\"radio\" id=\"edit-sort-relevance-rank\" name=\"sort\" value=\"relevance-rank\" checked=\"checked\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-sort-relevance-rank\">Best Match </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-sort\">\\n <input aria-labelledby=\"Sort\" type=\"radio\" id=\"edit-sort-publication-date-ascending\" name=\"sort\" value=\"publication-date-ascending\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-sort-publication-date-ascending\">Oldest First </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-sort\">\\n <input aria-labelledby=\"Sort\" type=\"radio\" id=\"edit-sort-publication-date-descending\" name=\"sort\" value=\"publication-date-descending\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-sort-publication-date-descending\">Newest First </label>\\n\\n</div>\\n</div>\\n</div>\\n<div class=\"form-item form-item-label-before form-type-radios form-item-format-result\">\\n  <label for=\"edit-format-result\">Format Results </label>\\n <div id=\"edit-format-result\" class=\"form-radios\"><div class=\"form-item form-item-label-after form-type-radio form-item-format-result\">\\n <input aria-labelledby=\"Format Results\" type=\"radio\" id=\"edit-format-result-standard\" name=\"format_result\" value=\"standard\" checked=\"checked\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-format-result-standard\">Standard Format </label>\\n\\n</div>\\n<div class=\"form-item form-item-label-after form-type-radio form-item-format-result\">\\n <input aria-labelledby=\"Format Results\" type=\"radio\" id=\"edit-format-result-condensed\" name=\"format_result\" value=\"condensed\" class=\"form-radio\" />  <label class=\"option\" for=\"edit-format-result-condensed\">Condensed Format </label>\\n\\n</div>\\n</div>\\n</div>\\n</div></fieldset>\\n<div class=\"element-hidden\"><div class=\"form-item form-item-label-after form-type-checkbox form-item-exclude-meeting-abstracts\">\\n <input class=\"element-hidden form-checkbox\" type=\"checkbox\" id=\"edit-exclude-meeting-abstracts\" name=\"exclude_meeting_abstracts\" value=\"1\" />  <label class=\"option\" for=\"edit-exclude-meeting-abstracts\">Exclude meeting abstracts </label>\\n\\n</div>\\n</div><input type=\"hidden\" name=\"jcode_option\" value=\"medrxiv biorxiv\" />\\n<input type=\"hidden\" name=\"form_build_id\" value=\"form-hTOBV-5Z7PJ9kJUkl7TmzPp-bhlj11DF5sQ44ADiyJM\" />\\n<input type=\"hidden\" name=\"form_id\" value=\"highwire_search_form\" />\\n<div class=\"form-actions form-wrapper\" id=\"edit-actions\"><input type=\"submit\" id=\"search_rightsidebar_submit_795160795\" name=\"op\" value=\"Search\" class=\"form-submit\" /></div></div></form>  </div>\\n\\n  \\n  </div>\\n</div>\\n\\t\\t\\t</div>\\n\\t\\t</div>\\n\\t\\t\\n\\t\\t<div class=\"sidebar-right-wrapper grid-10 omega\">\\n\\t\\t\\t<div class=\"panel-panel panel-region-sidebar-right\">\\n\\t\\t\\t  <div class=\"inside\"><div class=\"panel-pane pane-panels-mini pane-biorxiv-subject-collections block-style-col2\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <div class=\"panel-flexible panels-flexible-new clearfix\" id=\"mini-panel-biorxiv_subject_collections\">\\n<div class=\"panel-flexible-inside panels-flexible-new-inside\">\\n<div class=\"panels-flexible-region panels-flexible-region-new-center panels-flexible-region-first panels-flexible-region-last\">\\n  <div class=\"inside panels-flexible-region-inside panels-flexible-region-new-center-inside panels-flexible-region-inside-first panels-flexible-region-inside-last\">\\n<div class=\"panel-pane pane-snippet\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <div class=\"snippet biorxiv-subject-areas-table-title\" id=\"biorxiv-subject-areas-table-title\">\\n  \\n      \\n  <div class=\"snippet-content\">\\n    <b>Subject Areas</b>  </div>\\n\\n</div>\\n  </div>\\n\\n  \\n  </div>\\n<div class=\"panel-separator\"></div><div class=\"panel-pane pane-snippet\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <div class=\"snippet biorxiv-subject-areas-view-papers\" id=\"biorxiv-subject-areas-view-papers\">\\n  \\n      \\n  <div class=\"snippet-content\">\\n    <a href=\"/content/early/recent\"><strong>All Articles</strong></a>  </div>\\n\\n</div>\\n  </div>\\n\\n  \\n  </div>\\n<div class=\"panel-separator\"></div><div class=\"panel-pane pane-highwire-subject-collections\" >\\n  \\n      \\n  \\n  <div class=\"pane-content\">\\n    <ul id=\"collection\" class=\"collection highwire-list-expand\"><li class=\"outer collection depth-2  child first\"><div class = \"data-wrapper\"><a href=\"/collection/addiction-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Addiction Medicine</a> <span class = \"article-count\">(439)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/allergy-and-immunology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Allergy and Immunology</a> <span class = \"article-count\">(764)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/anesthesia\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Anesthesia</a> <span class = \"article-count\">(223)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/cardiovascular-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Cardiovascular Medicine</a> <span class = \"article-count\">(3372)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/dentistry-and-oral-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Dentistry and Oral Medicine</a> <span class = \"article-count\">(369)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/dermatology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Dermatology</a> <span class = \"article-count\">(286)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/emergency-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Emergency Medicine</a> <span class = \"article-count\">(485)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Endocrinology (including Diabetes Mellitus and Metabolic Disease)</a> <span class = \"article-count\">(1199)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/epidemiology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Epidemiology</a> <span class = \"article-count\">(13488)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/forensic-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Forensic Medicine</a> <span class = \"article-count\">(20)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/gastroenterology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Gastroenterology</a> <span class = \"article-count\">(910)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/genetic-and-genomic-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Genetic and Genomic Medicine</a> <span class = \"article-count\">(5256)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/geriatric-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Geriatric Medicine</a> <span class = \"article-count\">(495)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/health-economics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Health Economics</a> <span class = \"article-count\">(799)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/health-informatics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Health Informatics</a> <span class = \"article-count\">(3348)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/health-policy\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Health Policy</a> <span class = \"article-count\">(1158)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/health-systems-and-quality-improvement\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Health Systems and Quality Improvement</a> <span class = \"article-count\">(1220)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/hematology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Hematology</a> <span class = \"article-count\">(438)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/hiv-aids\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">HIV/AIDS</a> <span class = \"article-count\">(1035)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/infectious_diseases\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Infectious Diseases (except HIV/AIDS)</a> <span class = \"article-count\">(14742)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/intensive-care-and-critical-care-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Intensive Care and Critical Care Medicine</a> <span class = \"article-count\">(929)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/medical-education\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Medical Education</a> <span class = \"article-count\">(486)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/medical-ethics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Medical Ethics</a> <span class = \"article-count\">(129)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/nephrology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Nephrology</a> <span class = \"article-count\">(536)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/neurology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Neurology</a> <span class = \"article-count\">(5004)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/nursing\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Nursing</a> <span class = \"article-count\">(269)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/nutrition\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Nutrition</a> <span class = \"article-count\">(747)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/obstetrics-and-gynecology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Obstetrics and Gynecology</a> <span class = \"article-count\">(906)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/occupational-and-environmental-health\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Occupational and Environmental Health</a> <span class = \"article-count\">(808)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/oncology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Oncology</a> <span class = \"article-count\">(2563)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/ophthalmology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Ophthalmology</a> <span class = \"article-count\">(737)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/orthopedics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Orthopedics</a> <span class = \"article-count\">(285)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/otolaryngology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Otolaryngology</a> <span class = \"article-count\">(351)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/pain-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Pain Medicine</a> <span class = \"article-count\">(332)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/palliative-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Palliative Medicine</a> <span class = \"article-count\">(91)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/pathology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Pathology</a> <span class = \"article-count\">(553)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/pediatrics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Pediatrics</a> <span class = \"article-count\">(1329)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/pharmacology-and-therapeutics\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Pharmacology and Therapeutics</a> <span class = \"article-count\">(556)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/primary-care-research\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Primary Care Research</a> <span class = \"article-count\">(563)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/psychiatry-and-clinical-psychology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Psychiatry and Clinical Psychology</a> <span class = \"article-count\">(4280)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/public-and-global-health\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Public and Global Health</a> <span class = \"article-count\">(7608)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/radiology-and-imaging\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Radiology and Imaging</a> <span class = \"article-count\">(1738)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/rehabilitation-medicine-and-physical-therapy\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Rehabilitation Medicine and Physical Therapy</a> <span class = \"article-count\">(1042)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/respiratory-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Respiratory Medicine</a> <span class = \"article-count\">(1000)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/rheumatology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Rheumatology</a> <span class = \"article-count\">(485)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/sexual-and-reproductive-health\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Sexual and Reproductive Health</a> <span class = \"article-count\">(508)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/sports-medicine\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Sports Medicine</a> <span class = \"article-count\">(430)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/surgery\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Surgery</a> <span class = \"article-count\">(559)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/toxicology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Toxicology</a> <span class = \"article-count\">(73)</span></div></li>\\n<li class=\"outer collection depth-2  child\"><div class = \"data-wrapper\"><a href=\"/collection/transplantation\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Transplantation</a> <span class = \"article-count\">(239)</span></div></li>\\n<li class=\"outer collection depth-2  child last\"><div class = \"data-wrapper\"><a href=\"/collection/urology\" class=\"\" data-icon-position=\"\" data-hide-link-title=\"0\">Urology</a> <span class = \"article-count\">(207)</span></div></li>\\n</ul>  </div>\\n\\n  \\n  </div>\\n  </div>\\n</div>\\n</div>\\n</div>\\n  </div>\\n\\n  \\n  </div>\\n</div>\\n\\t\\t\\t</div>\\n\\t\\t</div>\\n\\t\\n\\t</div> <!-- /.panel-row-wrapper -->\\t\\n\\t\\n\\t</div>\\n\\n    </div>\\n  </div>\\n</div>      </div>\\n</div>  </div>\\n</section>    \\n  \\n  </div>    <div class=\"region region-page-bottom\" id=\"region-page-bottom\">\\n  <div class=\"region-inner region-page-bottom-inner\">\\n      </div>\\n</div><script type=\"text/javascript\" src=\"https://www.medrxiv.org/sites/default/files/advagg_js/js__bnwyEQSuZLC-kZnFqCi5iE02nOCzM7DjY7zYxcN9nsQ__VBiBT_qq_eHMMO2Q1rXK1u-hHff31XLUkmi9dgjuPeY__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.js\"></script>\\n<script type=\"text/javascript\" src=\"https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.js\"></script>\\n<script type=\"text/javascript\" src=\"https://www.medrxiv.org/sites/default/files/advagg_js/js__BmqjBnkz3MgYCAoc25s1lDRMEjLhC3mEPVonUFIHi08__Unwv5-ZIuHBfFwytsjEx1niBVJ7n1T4lPws7VrkHXM4__CBNCnC0C8nw5gAHXOxzB6uTvyvQjVmgpfwqi97PcxXA.js\"></script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\nfunction euCookieComplianceLoadScripts() {}\\n//--><!]]>\\n</script>\\n<script type=\"text/javascript\">\\n<!--//--><![CDATA[//><!--\\nvar eu_cookie_compliance_cookie_name = \"\";\\n//--><!]]>\\n</script>\\n  </body>\\n</html>\\n')"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "medrxiv_docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
